

GenCore version 5.1.9
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: June 10, 2006, 11:48:47 ; Search time 72.4805 Seconds
(without alignments)
706.511 Million cell updates/sec

Title: US-10-733-563-12

Perfect score: 590

Sequence: 1 DVVMTQSLPLVTLGPAS.....CWQGTHTFPYFGQTRLEIK 112

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2589679 seqs, 457216429 residues

Total number of hits satisfying chosen parameters: 2589679

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_8.*

- 1: Geneseqp1980s.*
- 2: Geneseqp1990s.*
- 3: Geneseqp2000s.*
- 4: Geneseqp2001s.*
- 5: Geneseqp2002s.*
- 6: Geneseqp2003as.*
- 7: Geneseqp2003bs.*
- 8: Geneseqp2004s.*
- 9: Geneseqp2005s.*
- 10: Geneseqp2006s.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Match	Query Length	DB ID	Description
1	590	100.0	112	4	AAE06949 Humanised
2	590	100.0	112	4	AAU09921 Humanised
3	590	100.0	112	5	ABG75530 Humanised
4	590	100.0	112	5	AAO14973 Humanised
5	590	100.0	112	5	ADF98233 Humanised
6	590	100.0	112	8	ADQ99234 Humanised
7	590	100.0	112	9	AEBO9507 Humanised
8	590	100.0	112	9	AEC92165 Humanised
9	590	100.0	112	9	AED43684 Humanised
10	584	99.0	114	4	AAE07035 Humanised
11	584	99.0	114	8	ADQ93328 Humanised
12	584	99.0	114	9	AEBO9601 Humanised
13	577	97.8	112	4	AAE06950 Humanised
14	577	97.8	112	4	AAU09922 Humanised
15	577	97.8	112	5	ABG75531 Humanised
16	577	97.8	112	5	ADF98234 Humanised
17	577	97.8	112	8	ADQ99235 Humanised
18	577	97.8	112	9	AEBO9508 Humanised
19	577	97.8	112	9	AEC92166 Humanised
20	577	97.8	112	9	AED43685 Humanised
21	572	96.9	112	4	AAE07036 Humanised
22	572	96.9	112	4	AAU09925 Humanised
23	572	96.9	112	5	ABG75534 Humanised

24	572	96.9	112	5	ADF98237	Adf98237 Humanised
25	572	96.9	112	8	ADQ99329	Adq99329 Humanised
26	572	96.9	112	9	AEBO9602	Aeb09602 Humanized
27	572	96.9	112	9	AEC92169	Aec92169 Humanized
28	572	96.9	112	9	AED43688	Aed43688 Humanized
29	570	96.6	112	4	AAE06951	Aae06951 Humanised
30	570	96.6	112	4	AAU09923	Aau09923 Humanised
31	570	96.6	112	5	ABG75532	Abg75532 Humanised
32	570	96.6	112	5	ADF98235	Adf98235 Humanised
33	570	96.6	112	8	ADQ99236	Adq99236 Humanised
34	570	96.6	112	9	AEBO9509	Aeb09509 Humanized
35	570	96.6	112	9	AEC92167	Aec92167 Humanized
36	570	96.6	112	9	AED43686	Aed43686 Humanized
37	569	96.4	112	8	ADQ31290	Adq31290 Humanised
38	566	95.9	112	8	ADQ31289	Adq31289 Humanised
39	565	95.8	112	4	AAE06952	Aae06952 Humanised
40	565	95.8	112	4	AAU09924	Aau09924 Humanised
41	565	95.8	112	5	ABG75533	Abg75533 Humanised
42	565	95.8	112	5	AAO14976	Aao14976 Humanised
43	565	95.8	112	5	ADF98236	Adf98236 Humanised
44	565	95.8	112	8	ADQ99237	Adq99237 Humanised
45	565	95.8	112	9	AEBO9510	Aeb09510 Humanized

ALIGNMENTS

RESULT 1					
AAE06949					
ID	AAE06949	standard; protein; 112 AA.			
XX	AAE06949;				
XX					
DT	11-SEP-2003	(revised)			
DT	16-OCT-2001	(first entry)			
XX					
DE	Humanised murine 1D9 antibody kappa light chain variable region, 1D9RKA.				
XX					
KW	Murine; humanised antibody; CC-chemokine receptor 2; CCR2; nephrotropic; neuroprotective; immunosuppressive; human immunodeficiency virus;				
KW	HIV infection; cytostatic; vasotropic; leukocyte trafficking; allergy;				
KW	inflammatory disorder; autoimmune disorder; rheumatoid arthritis; shock;				
KW	multiple sclerosis; atherosclerosis; arteriosclerosis; stenosis; atheroma;				
KW	anaphylaxis; malignancy; inflammation; stenosis; allograft rejection;				
KW	fibrotic disease; angioplasty; acquired immune deficiency syndrome; AIDS;				
KW	inflammatory glomerulopathy; vascular intervention; 1D9 antibody;				
KW	neointimal hyperplasia; VK; kappa light chain variable region; 1D9RKA.				
XX					
OS	Mus sp.				
OS	Homo sapiens.				
OS	Chimeric.				
Key	Location/Qualifiers				
Region	23..39				
FT	/label= CDR1				
FT	/note= "Complementarity determining region 1"				
FT	55..61				
FT	/label= CDR2				
FT	/note= "Complementarity determining region 2"				
FT	94..102				
FT	/label= CDR3				
FT	/note= "Complementarity determining region 3"				
WO200157226-A1.					
09-AUG-2001.					
02-FEB-2001; 2001WO-US000537.					
03-FEB-2000; 2000US-00497625.					
(MILL-) MILLENNIUM PHARM INC.					
XX					

```

PI Larosa GJ, Horvath C, Newman W, Jones ST, O'brien S, O'keefe T;
XX WPI; 2001-48888/53.
XX
XX Humanized immunoglobulin for treating a CC-chemokine receptor 2-mediated
PT disorder in a patient, comprises a binding specificity for CCR2, and a
PT non-human antigen binding region and human immunoglobulin.
PT
XX Claim 61; Fig 11; 183pp; English.
XX
XX The patent discloses a humanised antibody or its antigen-binding
CC fragment, having binding specificity for CC-chemokine receptor 2 (CCR2),
CC comprising an antigen binding region of non-human origin and at least a
CC portion of an immunoglobulin of human origin. The humanised antibodies
CC are useful for inhibiting the interaction of a cell expressing CCR2. They
CC are useful for inhibiting or treating HIV infection. The proteins of the
CC CCR2-mediated disorders such as inflammatory trafficking, for treating
CC disorders such as rheumatoid arthritis and multiple sclerosis.
CC atherogenesis and atherosclerosis, and for inhibiting restenosis. They
CC are useful in therapy or diagnosis, and in the manufacture of a
CC medicament for treating CCR2 mediated disease. They are also useful for
CC treating allergy, anaphylaxis, malignancy, chronic and acute
CC inflammation, histamine and IgE-mediated allergic reaction, shock,
CC stenosis, allograft rejection, fibrotic disease, asthma, inflammatory
CC glomerulopathies, acquired immune deficiency syndrome (AIDS), restenosis
CC associated with vascular intervention, including angioplasty and/or stent
CC placement in a mammal. Humanised antibodies are also useful for
CC inhibiting narrowing of the lumen of a vessel in a mammal, and inhibiting
CC neointimal hyperplasia of a vessel in a mammal, preferably associated
CC with vascular intervention. The present sequence is humanised murine 1D9
CC antibody kappa light chain variable (VK) region, 1D9KA. (Updated on 11-
CC SEP-2003 to standardise OS field)
XX
XX Sequence 112 AA;
SQ
Query Match 100.0%; Score 590; DB 4; Length 112;
Best Local Similarity 100.0%; Pred. No. 2.5e-46;
Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 DVVMTQSPVLSPLVTLCGPASISCKSSQSLDSDGKTFLNWFQRPQSPRRLLIYLSKLD 60
DB 1 DVVMTQSPVLSPLVTLCGPASISCKSSQSLDSDGKTFLNWFQRPQSPRRLLIYLSKLD 60
QY 61 SGVPDRFSGSGGTDFTLKISRVEADVGYYVCWQGTFFPYTQGQTRLEIK 112
DB 61 SGVPDRFSGSGGTDFTLKISRVEADVGYYVCWQGTFFPYTQGQTRLEIK 112
RESULT 2
AAU09921
ID AAU09921 standard; protein; 112 AA.
XX
XX AAU09921;
XX
XX 18-JUN-2002 (first entry)
XX
XX Humanised 1D9 light chain variable region, 1D9KA protein sequence.
XX
XX Human; mouse; 1D9 light chain variable region; vasotropic;
XX antiinflammatory; collagen disease; immunosuppressive; antiasthmatic;
XX insulin-dependent diabetes mellitus; inflammatory bowel disease;
XX ulcerative colitis; HF-21/28; Graft rejection; allergic disease;
XX antipsoriatic; 1D9KA; antiarthritis; nephrotropic; antithyroid;
XX restenosis; dermatological; anaphylaxis; cell adhesion inhibitor;
XX vascular injury; autoimmune disease; immunoglobulin;
XX complementarity determining region; CDR; CD18; CCR2; atherosclerosis;
XX mutant; mutein.
XX
XX Homo sapiens.
OS Mus sp.
OS Synthetic.
OS Chimeric.

```

```

XX Key Location/Qualifiers
FH Region 24..39
FT /note= "Complementarity determining region 1 (CDR1),
FT grafted from mouse mAb 1D9 light chain sequence
FT (AAU09918)"
FT Region 55..61
FT /note= "Complementarity determining region 2 (CDR2),
FT grafted from mouse mAb 1D9 light chain sequence
FT (AAU09918)"
FT Region 94..102
FT /note= "Complementarity determining region 3 (CDR3),
FT grafted from mouse mAb 1D9 light chain sequence
FT (AAU09918)"
FT Misc-difference 112
FT /note= "Addition of Lys residue normally present in mouse
FT mAb 1D9 sequence and absent in human antibody HF-21/28
FT sequence (AAU09920)"
XX WO200170266-A2.
XX
XX 27-SEP-2001.
XX
XX 15-MAR-2001; 2001WO-US008266.
XX
XX 17-MAR-2000; 2000US-00528267.
XX (MILL-) MILLENNIUM PHARM INC.
XX Horvath CJ, Rao PE;
XX WPI; 2001-607511/69.
XX
XX Inhibiting stenosis or restenosis of a blood vessel following vascular
XX injury or angioplasty in a subject by administering agent which inhibits
XX recruitment or adhesion of neutrophils, mononuclear cells to injury site.
XX Claim 32; Fig 17; 108pp; English.
XX
XX The present invention relates to a new method of inhibiting stenosis or
XX restenosis of a blood vessel following vascular injury in a subject. The
XX new method comprises administering to the subject agents which inhibit
XX the adhesion and/or recruitment of neutrophils and mononuclear cells to a
XX site of vascular injury by binding CD18 or CCR2. The method of the
XX invention inhibits stenosis or restenosis of a blood vessel following
XX vascular injury arising from a vascular intervention procedure such as
XX vascular by-pass or transplantation surgery. The method is also useful
XX for treating a subject having an inflammatory disease or condition
XX mediated by neutrophil and mononuclear cell activity e.g. asthma and
XX graft versus host disease. Chronic inflammatory diseases of the lung,
XX collagen diseases, and insulin-dependent diabetes mellitus can also be
XX treated. The method is further useful for treating inflammatory bowel
XX diseases, such as ulcerative colitis. Additional diseases or conditions
XX include inflammatory or allergic diseases and conditions, including
XX systemic anaphylaxis of hypersensitivity responses, drug allergies,
XX psoriasis and inflammatory dermatoses, autoimmune diseases such as
XX arthritis, graft rejection and other diseases including atherosclerosis.
XX The present sequence represents the variable region of one of several
XX humanised 1D9 light chains (AAU0921-AAU0925). These light chains were
XX used in the invention for the production of anti-CCR2 antibody or antigen
XX -binding fragment
XX Sequence 112 AA;
XX
Query Match 100.0%; Score 590; DB 4; Length 112;
Best Local Similarity 100.0%; Pred. No. 2.5e-46;
Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 DVVMTQSPVLSPLVTLCGPASISCKSSQSLDSDGKTFLNWFQRPQSPRRLLIYLSKLD 60
DB 1 DVVMTQSPVLSPLVTLCGPASISCKSSQSLDSDGKTFLNWFQRPQSPRRLLIYLSKLD 60
QY 61 SGVPDRFSGSGGTDFTLKISRVEADVGYYVCWQGTFFPYTQGQTRLEIK 112

```


DB 61 SGVPDRFSGSGGDTFLTKISRVEADVGVYVCQGTFFPTFGQGRLEIK 112

RESULT 3

ABG75530

ID ABG75530 standard; protein; 112 AA.

AC ABG75530;

XX

DT 16-APR-2003 (first entry)

XX

DE Humanised mouse mAb 1D9 light chain variable region, 1D9KAVK.

XX

XX Mouse; stenosis; restenosis; blood vessel; vascular injury; antibody;

KW antigen binding fragment; cellular adhesion molecule; adhesion;

KW recruitment; neutrophil; antagonist; CCR2; mononuclear cell; angioplasty;

KW percutaneous transluminal coronary angioplasty; PTCA; stent;

KW vascular by-pass surgery; vascular grafting; endarterectomy; atherectomy;

KW endovascular stenting; prosthetic valve; transplantation;

KW inflammatory disease; mastitis; vaginitis; cholecystitis;

KW chronic bronchitis; asthma; graft-versus-host disease;

KW chronic inflammatory disease; hypersensitivity pneumonitis;

KW collagen disease; sarcoidosis; idiopathic; pancreatitis; HF-21/28;

KW insulin dependent; diabetes mellitus; inflammatory bowel disease;

KW Crohn's disease; allergic disease; psoriasis; atopic dermatitis; human;

KW allergic rhinitis; autoimmune disease; arthritis; multiple sclerosis;

KW graft rejection; atherosclerosis; myositis; therapy; 1D9; 1D9KAVK;

KW light chain variable region; VK; complementarity determining region; CDR;

KW mutant; mutein.

XX

OS Mus sp.

OS Homo sapiens.

OS Synthetic.

XX

PH Key

FT Region 24..39

FT /note= "Mouse complementarity determining region 1

FT (CDR1)"

FT Region 55..61

FT /note= "Mouse complementarity determining region 2

FT (CDR2)"

FT Region 94..102

FT /note= "Mouse complementarity determining region 3

FT (CDR3)"

FT Misc-difference 112

FT /note= "Lys derived from the mouse 1D9 mAb sequence"

XX

PN US2002106369-A1.

XX

PD 08-AUG-2002.

XX

XX 15-MAR-2001; 2001US-00809739.

XX

XX 17-MAR-2000; 2000US-00528267.

XX

XX (MILL-) MILLENNIUM PHARM INC.

XX

XX Horvath CJ, Rao PB;

XX

XX WPI; 2002-697861/75.

DR

XX

XX Inhibiting (re)stenosis of blood vessel following vascular injury, by

PT administering first and second agents that inhibit adhesion and/or

PT recruitment of neutrophils and mononuclear cells, respectively to site of

PT vascular injury.

XX

XX Claim 32; Fig 17; 59pp; English.

PS

XX

XX The invention discloses a method for inhibiting stenosis or restenosis of

CC a blood vessel following vascular injury in a subject. The method

CC involves administering to the subject a first therapeutic agent, which

CC comprises an antibody or its antigen binding fragment which binds a

CC

CC cellular adhesion molecule, that inhibits the adhesion and/or recruitment

CC of neutrophils to a site of vascular injury and a second therapeutic

CC agent, which comprises an antagonist of CCR2 function, that inhibits

CC adhesion and/or recruitment of mononuclear cells to a site of vascular

CC injury. The vascular injury arises from a vascular intervention procedure

CC such as angioplasty (e.g. percutaneous transluminal coronary angioplasty

CC (PTCA) or angioplasty including placement of a stent), vascular by-pass

CC surgery, vascular grafting, endarterectomy, atherectomy, endovascular

CC stenting, insertion of a prosthetic valve and transplantation of organs,

CC tissues or cells. The method is also useful for treating inflammatory

CC diseases or conditions mediated by early neutrophil activity and later

CC mononuclear cell activity. Preferably, the method is useful for treating

CC a subject having mastitis, vaginitis, cholecystitis, chronic bronchitis,

CC asthma and graft-versus-host disease, chronic inflammatory disease of

CC lung, hypersensitivity pneumonitis, collagen diseases, sarcoidosis and

CC other idiopathic conditions, pancreatitis and insulin dependent diabetes

CC mellitus. The method is also useful for treating inflammatory bowel

CC disease, Crohn's disease, inflammatory or allergic diseases (such as

CC psoriasis, atopic dermatitis and allergic rhinitis), autoimmune diseases

CC (such as arthritis and multiple sclerosis), graft rejection,

CC atherosclerosis and myositis. The method enables simultaneous inhibition

CC of neutrophil and mononuclear cell participation in response to vascular

CC injury or inhibition of neutrophil participation followed by inhibition

CC of mononuclear cell participation, and thus provides superior therapy for

CC inhibiting stenosis or restenosis following vascular injury. The sequence

CC presented is the humanised mouse monoclonal antibody (mAb), 1D9, light

CC chain variable region (VK), 1D9KAVK, which is comprised of the mouse 1D9

CC mAb complementarity determining regions (CDR's) linked by human HF-21/28

CC mAb VK regions with a mouse derived Lys at position 112

XX

SQ Sequence 112 AA;

Query Match 100.0%; Score 590; DB 5; Length 112;

Best Local Similarity 100.0%; Pred. No. 2.5e-46;

Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 DVVMTQSPISLPVTLGQPASISCKSSQSLDSDGKTFLNWFQQRPGQSPRLIYLVSKLD 60

DB 1 DVVMTQSPISLPVTLGQPASISCKSSQSLDSDGKTFLNWFQQRPGQSPRLIYLVSKLD 60

QY 61 SGVPDRFSGSGGDTFLTKISRVEADVGVYVCQGTFFPTFGQGRLEIK 112

DB 61 SGVPDRFSGSGGDTFLTKISRVEADVGVYVCQGTFFPTFGQGRLEIK 112

RESULT 4

AAO14973

ID AAO14973 standard; protein; 112 AA.

XX

AC AAO14973;

XX

DT 05-SEP-2002 (first entry)

XX

DE Humanised murine light chain variable region (1D9Rka VK).

XX

XX Mouse; graft rejection; CC chemokine receptor 2 antagonist; mutant;

KW CCR2 antagonist; anti-CCR2 antibody; kidney transplant; liver transplant;

KW lung transplant; heart-lung transplant; pancreas transplant; mutein;

KW bowel transplant; heart transplant; graft versus host disease;

KW chronic graft rejection; antibody light chain variable region; 1D9Rka VK.

XX

OS Mus musculus.

OS Synthetic.

XX

XX US2002042370-A1.

PN

XX

PD 11-APR-2002.

XX

XX 13-APR-2001; 2001US-00835087.

PF

XX

XX 14-APR-2000; 2000US-00549448.

PR

XX

XX (MILL-) MILLENNIUM PHARM INC.

PA

XX Hancock WW;
 XX WPI; 2002-351265/38.
 XX Inhibiting graft rejection, graft versus host disease or chronic
 PT rejection of a transplanted graft, involves administering a CCR2
 PT antagonist.
 XX Claim 26; Fig 1; 16pp; English.
 XX The invention comprises a method of inhibiting graft rejection, graft
 CC versus host disease or chronic rejection of a transplanted graft. The
 CC method involves administering an antagonist of CC chemokine receptor 2
 CC (CCR2) and optionally an immunosuppressive agent. The CCR2 antagonist may
 CC be an anti-CCR2 antibody (i.e. containing light and heavy chain
 CC complementarity determining regions from various non-human origins). CCR2
 CC is known to be involved in the rejection of transplanted grafts. The
 CC method of the invention is useful for inhibiting graft rejection -
 CC particularly allografts such as kidney, liver, lung, heart-lung,
 CC pancreas, bowel and heart. The method of the invention is also useful for
 CC inhibiting graft versus host disease and for inhibiting chronic rejection
 CC of a transplanted graft. The present amino acid sequence represents a
 CC humanised murine antibody light chain variable region (1D9Rka Vκ)
 XX
 SQ Sequence 112 AA;
 Query Match 100.0%; Score 590; DB 5; Length 112;
 Best Local Similarity 100.0%; Pred. No. 2.5e-46;
 Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 DVVMTOSPLSLPVTLGQPASISCKSSQSLSDSGKTFLNWFQORPGQSPRRLLIYLVSKLD 60
 DB 1 DVVMTOSPLSLPVTLGQPASISCKSSQSLSDSGKTFLNWFQORPGQSPRRLLIYLVSKLD 60
 QY 61 SGVPDRFSGSGGTDFTLKISRVEADVGYYCWOQTTHFPYTFGQGRLEIK 112
 DB 61 SGVPDRFSGSGGTDFTLKISRVEADVGYYCWOQTTHFPYTFGQGRLEIK 112
 RESULT 5
 ADF98233
 ID ADF98233 standard; protein; 112 AA.
 XX
 AC ADF98233;
 DT 26-FEB-2004 (first entry)
 XX
 DE Humanised 1D9 light chain variable region, 1D9RKA V kappa, SEQ ID 3.
 XX
 KW Immunosuppressive; CCR2 function inhibitor; graft rejection;
 KW graft versus host disease; CC chemokine receptor 2; CCR2;
 KW anti-CCR2 antibody.
 XX
 OS Synthetic.
 OS Mus musculus.
 OS Homo sapiens.
 XX
 XX WO200178653-A2.
 XX
 XX 25-OCT-2001.
 XX
 PF 13-APR-2001; 2001WO-US012139.
 XX
 XX 14-APR-2000; 2000US-00549448.
 PR
 PA (WILL-) MILLENNIUM PHARM INC.
 XX
 XX Hancock WW;
 PI
 XX WPI; 2002-017543/02.
 DR
 XX Inhibition of rejection of graft e.g. heart or graft versus host disease
 PT

PT involves use of CC chemokine receptor 2 inhibitor.
 XX
 PS Claim 26; Fig 1; 44pp; English.
 XX
 CC The present invention relates to a method for inhibiting graft rejection
 CC or graft versus host diseases. The method comprises administration of a
 CC CC chemokine receptor 2 (CCR2) function antagonist to a subject or
 CC recipient of a transplanted graft. The CCR2 function antagonist is an
 CC anti-CCR2 antibody or its antigen-binding fragment (ADF98233',
 CC ADF98240-ADF98249). The method is useful for inhibiting rejection,
 CC particularly chronic rejection of a graft, particularly an allograft of
 CC kidney, liver, lung, heart-lung, pancreas, bowel and heart, and for
 CC inhibiting graft versus host disease for a bone marrow graft.
 XX
 SQ Sequence 112 AA;
 Query Match 100.0%; Score 590; DB 5; Length 112;
 Best Local Similarity 100.0%; Pred. No. 2.5e-46;
 Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 DVVMTOSPLSLPVTLGQPASISCKSSQSLSDSGKTFLNWFQORPGQSPRRLLIYLVSKLD 60
 DB 1 DVVMTOSPLSLPVTLGQPASISCKSSQSLSDSGKTFLNWFQORPGQSPRRLLIYLVSKLD 60
 QY 61 SGVPDRFSGSGGTDFTLKISRVEADVGYYCWOQTTHFPYTFGQGRLEIK 112
 DB 61 SGVPDRFSGSGGTDFTLKISRVEADVGYYCWOQTTHFPYTFGQGRLEIK 112
 RESULT 6
 ADF98234
 ID ADF98234 standard; protein; 112 AA.
 XX
 AC ADF98234;
 XX
 DT 21-OCT-2004 (first entry)
 XX
 DE Humanised immunoglobulin protein #1.
 XX
 KW Immunoglobulin; heavy chain; light chain; CC-chemokine receptor 2; CCR2;
 KW inflammatory disease; autoimmune disorder; graft rejection;
 KW HIV infection; atherosclerosis; antiinflammatory; immunosuppressive;
 KW anti-HIV; virucide; antiarteriosclerotic.
 XX
 OS Synthetic.
 XX
 XX US2004151721-A1.
 PN
 XX 05-AUG-2004.
 PD
 XX 10-DEC-2003; 2003US-00733563.
 PF
 XX 19-OCT-2001; 2001US-0350166P.
 PR
 XX 26-JUN-2002; 2002US-0392364P.
 PR
 XX 17-OCT-2002; 2002US-00272899.
 PR
 XX (OKEE/) O'KEEFE T.
 PA (PONA/) PONATH P.
 PA
 XX O'keefe T, Ponath P;
 XX
 XX WPI; 2004-580175/56.
 DR
 XX
 XX New humanized immunoglobulin CC-chemokine receptor 2 (CCR2) antagonists,
 PT useful for diagnosing and/or treating inflammatory or autoimmune
 PT diseases, and HIV infection.
 PT
 XX Claim 5; SEQ ID NO 12; 128pp; English.
 PS
 XX The invention relates to humanised immunoglobulin heavy and light chains
 CC which have specificity for the CC-chemokine receptor 2 (CCR2) and an
 CC immunoglobulin or its antigen binding fragment comprising the chains. The
 CC humanised immunoglobulin or its antigen binding fragment preferably

CC comprises two heavy chains and two light chains. The humanised
 CC immunoglobulin and its heavy and light chains are useful for the
 CC diagnosis, prevention and/or treatment of diseases or conditions
 CC associated with aberrant expression or activity of the CCR2 polypeptide,
 CC such as inflammatory diseases, autoimmune disorders, graft rejection, HIV
 CC infection and atherosclerosis. This sequence represents a humanised
 CC immunoglobulin protein of the invention.

XX SQ Sequence 112 AA;

Query Match 100.0%; Score 590; DB 8; Length 112;
 Best Local Similarity 100.0%; Pred. No. 2.5e-46;
 Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 DVVMTQSPVLSPLPTLGQPASISCKSSQSLDSDGKTFLNWFQQRPGQSPRLIYLVSCLD 60

Db 1 DVVMTQSPVLSPLPTLGQPASISCKSSQSLDSDGKTFLNWFQQRPGQSPRLIYLVSCLD 60

Qy 61 SGVDFRFGSGSGTDFTLKISRVEADVGVYVCWQGTFFPYTFQGQTRLEIK 112

Db 61 SGVDFRFGSGSGTDFTLKISRVEADVGVYVCWQGTFFPYTFQGQTRLEIK 112

RESULT 7
 AEB09507
 ID AEB09507 standard; protein; 112 AA.

XX AC AEB09507;

DT 08-SEP-2005 (first entry)

XX DE Humanized 1D9 kappa light chain variable region SEQ ID NO 12.

XX KW antiinflammatory; immunosuppressive; anti-HIV; antiarteriosclerotic;
 KW antibody engineering; therapeutic; diagnosis; inflammation;
 KW autoimmune disease; immune disorder; graft rejection; HIV infection;
 KW infection; atherosclerosis; cardiovascular disease; metabolic disorder;
 KW light chain variable region.

OS Homo sapiens.
 OS Mus musculus.
 OS Synthetic.

XX PN WO2005060368-A2.

XX PD 07-JUL-2005.

XX PF 10-DEC-2003; 2003WO-US039599.

XX PR 10-DEC-2003; 2003WO-US039599.

XX PA (MILL-) MILLENNIUM PHARM INC.

XX PI Okeefe T, Ponath P;

XX DR WPI; 2005-488561/49.

XX PT New humanized immunoglobulin or its antigen binding portion having
 PT binding specificity for CC-chemokine receptor 2 and having a heavy chain
 PT and light chain, for treating inflammatory diseases, HIV, and autoimmune
 PT diseases.

XX PS Claim 1; SEQ ID NO 12; 192pp; English.

XX CC The invention describes a humanized immunoglobulin (I) or its antigen
 CC binding portion having binding specificity for CC-chemokine receptor 2.
 CC (CCR2) and having a heavy chain and a light chain, where the heavy chain
 CC comprises a fully defined 117 and 330 amino acid (SEQ ID NO: 17 and 110)
 CC sequence, given in specification or its portion, and the light chain
 CC comprises a fully defined 112 amino acid (SEQ ID NO: 12) sequence given
 CC in specification. Also described are: a humanized immunoglobulin heavy
 CC chain, or its antigen binding fragment, having binding specificity for
 CC CCR2 and comprising the amino acid sequence of (SEQ ID NO: 17) and the

CC amino acid of (SEQ ID NO: 110), or its portion; and a humanized
 CC immunoglobulin light chain, or its antigen binding fragment, having
 CC binding specificity for CCR2 and comprising the amino acid sequence of
 CC (SEQ ID NO: 12) and the fully defined 107 amino acid (SEQ ID NO: 112)
 CC sequence, given in specification. The following are disclosed: isolated
 CC nucleic acid molecules comprising nucleic acid sequence encoding (i); a
 CC construct comprising nucleic acid molecule encoding (i); and host cell
 CC comprising the nucleic acid molecule. (i) Is useful as a therapeutic
 CC agent for controlling lymphocyte homing the mucosal lymphoid tissue thus
 CC reducing inflammatory response, for use in the treatment of diseases
 CC associated with leukocyte infiltration of tissue, e.g. in the treatment
 CC of inflammatory diseases, autoimmune diseases, graft rejection, HIV
 CC infection and monocyte-mediated disorders such as atherosclerosis. (i) Is
 CC useful for detecting and/or measuring the level of CCR2 in a sample (e.g.
 CC tissues or body fluids such as inflammatory exudates, blood, serum, bowel
 CC fluid), and for modulating binding function and/or leukocyte trafficking
 CC modulated by CCR2. This is the amino acid sequence of a humanized 1D9
 CC kappa light chain variable region used in the creation of a humanized
 CC anti-CCR2-antibody.

XX SQ Sequence 112 AA;

Query Match 100.0%; Score 590; DB 9; Length 112;

Best Local Similarity 100.0%; Pred. No. 2.5e-46;

Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 DVVMTQSPVLSPLPTLGQPASISCKSSQSLDSDGKTFLNWFQQRPGQSPRLIYLVSCLD 60

Db 1 DVVMTQSPVLSPLPTLGQPASISCKSSQSLDSDGKTFLNWFQQRPGQSPRLIYLVSCLD 60

Qy 61 SGVDFRFGSGSGTDFTLKISRVEADVGVYVCWQGTFFPYTFQGQTRLEIK 112

Db 61 SGVDFRFGSGSGTDFTLKISRVEADVGVYVCWQGTFFPYTFQGQTRLEIK 112

RESULT 8
 AEC92165
 ID AEC92165 standard; protein; 112 AA.

XX AC AEC92165;

XX DT 01-DEC-2005 (first entry)

XX DE Humanized 1D9 mAb light chain variable kappa region protein, 1D9RKA Vκ.

XX KW Therapeutic; restenosis; vasotropic; cardiovascular disease; stenosis;
 KW pulmonary disease; respiratory-gen.; respiratory disease;
 KW inflammatory bowel disease; antiinflammatory; gastrointestinal-gen.;
 KW gastrointestinal disease; inflammation; allergy; antiallergic;
 KW immune disorder; autoimmune disease; immunosuppressive; graft rejection;
 KW inflammation; antiinflammatory; 1D9; monoclonal antibody;
 KW humanized antibody; light chain variable region.

XX OS Mus sp.
 OS Homo sapiens.
 OS Synthetic.

XX PH Key Location/Qualifiers

XX FT Region 24..39 /note= "Complementarity determining region (CDR) 1"

XX FT Region 55..61 /note= "CDR 2"

XX FT Region 94..102 /note= "CDR 3"

XX PN US2005214299-A1.

XX PD 29-SEP-2005.

XX PF 12-SEP-2003; 2003US-00662061.

XX PR 17-MAR-2000; 2000US-00528267.

XX PR 15-MAR-2001; 2001US-00809739.

OS Mus sp.
OS Homo sapiens.
OS Chimeric.
XX WO200157226-A1.
XX 09-AUG-2001.
XX 02-FEB-2001; 2001WO-US003537.
XX 03-FEB-2000; 2000US-00497625.
XX (MILL-) MILLENNIUM PHARM INC.
XX Larosa GJ, Horvath C, Newman W, Jones ST, O'brien S, O'keefe T;
XX WPI; 2001-48888/53.
XX N-PSDB; AAD13180.
XX Humanized immunoglobulin for treating a CC-chemokine receptor 2-mediated
PT disorder in a patient, comprises a binding specificity for CCR2, and a
PT non-human antigen binding region and human immunoglobulin.
XX Disclosure; Fig 24; 183pp; English.
XX The patent discloses a humanised antibody or its antigen-binding
CC fragment, having binding specificity for CC-chemokine receptor 2 (CCR2),
CC comprising an antigen binding region of non-human origin and at least a
CC portion of an immunoglobulin of human origin. The humanised antibodies
CC are useful for inhibiting the interaction of a cell expressing CCR2. They
CC are useful for inhibiting or treating HIV infection. The proteins of the
CC invention are useful for inhibiting leukocyte trafficking, for treating
CC CCR2-mediated disorders such as inflammatory disorder, autoimmune
CC disorders such as rheumatoid arthritis and multiple sclerosis,
CC atherogenesis and atherosclerosis, and for inhibiting restenosis. They
CC are useful in therapy or diagnosis, and in the manufacture of a
CC medicament for treating CCR2 mediated disease. They are also useful for
CC treating allergy, anaphylaxis, malignancy, chronic and acute
CC inflammation, histamine and IgE-mediated allergic reaction, shock,
CC stenosis, allograft rejection, fibrotic disease, asthma, inflammatory
CC glomerulopathies, acquired immune deficiency syndrome (AIDS), restenosis
CC associated with vascular intervention, including angioplasty and/or stent
CC placement in a mammal. Humanised antibodies are also useful for
CC inhibiting narrowing of the lumen of a vessel in a mammal, and inhibiting
CC neointimal hyperplasia of a vessel in a mammal, preferably associated
CC with vascular intervention. The present sequence is humanised murine
CC antibody light chain region, 1D9KA. (Updated on 11-SEP-2003 to
CC standardise OS field)
XX Sequence 114 AA;
SQ
Query Match 99.0%; Score 584; DB 4; Length 114;
Best Local Similarity 100.0%; Pred. No. 9e-46;
Matches 111; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2 VVMTQSLPLPVTLGQPASISCKSSQSLDSDGKTFNLNWFQORPGQSPRLIYLVSCLDS 61
DB 2 VVMTQSLPLPVTLGQPASISCKSSQSLDSDGKTFNLNWFQORPGQSPRLIYLVSCLDS 61
QY 62 GVDPFRSGSGGTDFTLKISRVEAEDVGVYYCWQGTFFPYTFQGTRLEIK 112
DB 62 GVDPFRSGSGGTDFTLKISRVEAEDVGVYYCWQGTFFPYTFQGTRLEIK 112
RESULT 11
ADQ89328
ID ADQ89328 standard; protein; 114 AA.
XX
XX ADQ89328;
XX
XX 21-OCT-2004 (first entry)
XX
XX Humanised immunoglobulin protein #10.
DE

XX Immunoglobulin; heavy chain; light chain; CC-chemokine receptor 2; CCR2;
KW inflammatory disease; autoimmune disorder; graft rejection;
KW HIV infection; atherosclerosis; antiinflammatory; immunosuppressive;
KW anti-HIV; virucide; antiarteriosclerotic.
XX Synthetic.
XX US2004151721-A1.
XX 05-AUG-2004.
XX 10-DEC-2003; 2003US-00733563.
XX 19-OCT-2001; 2001US-0350166P.
XX 26-JUN-2002; 2002US-0392364P.
XX 17-OCT-2002; 2002US-00272899.
XX (OKEE/) O'KEEFE T.
PA (PONA/) PONATH P.
XX O'keefe T, Ponath P;
PI
XX WPI; 2004-580175/56.
DR N-PSDB; ADQ89320.
XX New humanized immunoglobulin CC-chemokine receptor 2 (CCR2) antagonists,
PT useful for diagnosing and/or treating inflammatory or autoimmune
PT diseases, and HIV infection.
XX Disclosure; SEQ ID NO 106; 128pp; English.
XX The invention relates to humanised immunoglobulin heavy and light chains
CC which have specificity for the CC-chemokine receptor 2 (CCR2) and an
CC immunoglobulin or its antigen binding fragment comprising the chains. The
CC humanised immunoglobulin or its antigen binding fragment preferably
CC comprises two heavy chains and two light chains. The humanised
CC immunoglobulin and its heavy and light chains are useful for the
CC diagnosis, prevention and/or treatment of diseases or conditions
CC associated with aberrant expression or activity of the CCR2 polypeptide,
CC such as inflammatory diseases, autoimmune disorders, graft rejection, HIV
CC infection and atherosclerosis. This sequence represents a humanised
CC immunoglobulin protein of the invention.
XX Sequence 114 AA;
SQ
Query Match 99.0%; Score 584; DB 8; Length 114;
Best Local Similarity 100.0%; Pred. No. 9e-46;
Matches 111; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2 VVMTQSLPLPVTLGQPASISCKSSQSLDSDGKTFNLNWFQORPGQSPRLIYLVSCLDS 61
DB 2 VVMTQSLPLPVTLGQPASISCKSSQSLDSDGKTFNLNWFQORPGQSPRLIYLVSCLDS 61
QY 62 GVDPFRSGSGGTDFTLKISRVEAEDVGVYYCWQGTFFPYTFQGTRLEIK 112
DB 62 GVDPFRSGSGGTDFTLKISRVEAEDVGVYYCWQGTFFPYTFQGTRLEIK 112
RESULT 12
AEB09601
ID AEB09601 standard; protein; 114 AA.
XX
XX AEB09601;
XX
XX 08-SEP-2005 (first entry)
XX
XX Humanized light chain 1D9KA.
XX
XX antiinflammatory; immunosuppressive; anti-HIV; antiarteriosclerotic;
KW antibody engineering; therapeutic; diagnosis; inflammation;
KW autoimmune disease; immune disorder; graft rejection; HIV infection;
KW infection; atherosclerosis; cardiovascular disease; metabolic disorder;
KW

KW light chain variable region.
 OS Synthetic.
 XX WO2005060368-A2.
 PN 07-JUL-2005.
 PD
 XX
 XX 10-DEC-2003; 2003WO-US039599.
 PF
 XX 10-DEC-2003; 2003WO-US039599.
 PR
 XX (MILL-) MILLENNIUM PHARM INC.
 PA
 XX O'keefe T, Ponath P;
 PI
 XX WPI; 2005-488561/49.
 XX N-PSDB; AEB09593.
 DR
 XX New humanized immunoglobulin or its antigen binding portion having
 PT binding specificity for CC-chemokine receptor 2 and having a heavy chain
 PT and light chain, for treating inflammatory diseases, HIV, and autoimmune
 PT diseases.
 XX
 XX Disclosure; SEQ ID NO 106; 192pp; English.
 PS
 XX
 XX The invention describes a humanized immunoglobulin (I) or its antigen
 CC binding portion having binding specificity for CC-chemokine receptor 2
 CC (CCR2) and having a heavy chain and a light chain, where the heavy chain
 CC comprises a fully defined 117 and 330 amino acid (SEQ ID NO: 17 and 110)
 CC sequence, given in specification or its portion, and the light chain
 CC comprises a fully defined 112 amino acid (SEQ ID NO: 12) sequence given
 CC in specification. Also described are: a humanized immunoglobulin heavy
 CC chain, or its antigen binding fragment, having binding specificity for
 CC CCR2 and comprising the amino acid sequence of (SEQ ID NO: 17) and the
 CC amino acid of (SEQ ID NO: 110), or its portion; and a humanized
 CC immunoglobulin light chain, or its antigen binding fragment, having
 CC binding specificity for CCR2 and comprising the amino acid sequence of
 CC (SEQ ID NO: 12) and the fully defined 107 amino acid (SEQ ID NO: 112)
 CC sequence, given in specification. The following are disclosed: isolated
 CC nucleic acid molecules comprising nucleic acid sequence encoding (I); a
 CC construct comprising nucleic acid molecule encoding (I); and host cell
 CC comprising the nucleic acid molecule. (I) Is useful as a therapeutic
 CC agent for controlling lymphocyte homing the mucosal lymphoid tissue thus
 CC reducing inflammatory response, for use in the treatment of diseases
 CC associated with leukocyte infiltration of tissue, e.g. in the treatment
 CC of inflammatory diseases, autoimmune diseases, graft rejection, HIV
 CC infection and monocyte-mediated disorders such as atherosclerosis. (I) Is
 CC useful for detecting and/or measuring the level of CCR2 in a sample (e.g.
 CC tissues or body fluids such as inflammatory exudates, blood, serum, bowel
 CC fluid), and for modulating binding function and/or leukocyte trafficking
 CC modulated by CCR2. This is the amino acid sequence of humanized light
 CC chain 1D9RKB.
 XX
 SQ Sequence 114 AA;
 Query Match 99.0%; Score 584; DB 9; Length 114;
 Best Local Similarity 100.0%; Pred. No. 9e-46;
 Matches 111; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2 VVMTQSPVLSPLVLTGQPASISCKSSQSLSDSGKTFNLNWFQQRPGQSPRLIYLVSRLDS 61
 DB 2 VVMTQSPVLSPLVLTGQPASISCKSSQSLSDSGKTFNLNWFQQRPGQSPRLIYLVSRLDS 61
 QY 62 GVPDRFSGSGGTFTLTLSKRVAEADVGVVYCWQGTHTFPYTFQGTSLRK 112
 DB 62 GVPDRFSGSGGTFTLTLSKRVAEADVGVVYCWQGTHTFPYTFQGTSLRK 112
 RESULT 13
 AAE06950
 ID AAE06950 standard; protein; 112 AA.
 XX

AC AAE06950;
 XX
 DT 11-SEP-2003 (revised)
 DT 16-OCT-2001 (first entry)
 XX
 DE Humanised murine 1D9 antibody kappa light chain variable region, 1D9RKB.
 XX
 XX Murine; humanised antibody; CC-chemokine receptor 2; CCR2; nephrotropic;
 KW neuroprotective; immunosuppressive; human immunodeficiency virus;
 KW HIV infection; cytostatic; vasotropic; leukocyte trafficking; allergy;
 KW inflammatory disorder; autoimmune disorder; rheumatoid arthritis; shock;
 KW multiple sclerosis; atherogenesis; atherosclerosis; restenosis; asthma;
 KW anaphylaxis; malignancy; inflammation; stenosis; allograft rejection;
 KW fibrotic disease; angioplasty; acquired immune deficiency syndrome; AIDS;
 KW inflammatory glomerulopathy; vascular intervention; 1D9 antibody.
 KW neointimal hyperplasia; VK; kappa light chain variable region; 1D9RKB.
 XX
 XX Mus sp.
 OS Homo sapiens.
 OS Chimeric.
 OS
 XX
 XX Key Location/Qualifiers
 FH Region 23..39
 FT /label= CDR1
 FT /note= "Complementarity determining region 1"
 FT Region 55..61
 FT /label= CDR2
 FT /note= "Complementarity determining region 2"
 FT Region 94..102
 FT /label= CDR3
 FT /note= "Complementarity determining region 3"
 XX
 PN WO200157226-A1.
 XX
 XX 09-AUG-2001.
 PD
 XX 02-FEB-2001; 2001WO-US003537.
 PF
 XX 03-FEB-2000; 2000US-00497625.
 PR
 XX (MILL-) MILLENNIUM PHARM INC.
 XX
 XX Larosa GJ, Horvath C, Newman W, Jones ST, O'brien S, O'keefe T;
 XX WPI; 2001-488888/53.
 DR
 XX Humanized immunoglobulin for treating a CC-chemokine receptor 2-mediated
 PT disorder in a patient, comprises a binding specificity for CCR2, and a
 PT non-human antigen binding region and human immunoglobulin.
 XX
 XX Claim 61; Fig 11; 183pp; English.
 PS
 XX The patent discloses a humanised antibody or its antigen-binding
 CC fragment, having binding specificity for CC-chemokine receptor 2 (CCR2),
 CC comprising an antigen binding region of non-human origin and at least a
 CC portion of an immunoglobulin of human origin. The humanised antibodies
 CC are useful for inhibiting the interaction of a cell expressing CCR2. They
 CC are useful for inhibiting or treating HIV infection. The proteins of the
 CC invention are useful for inhibiting leukocyte trafficking, for treating
 CC CCR2-mediated disorders such as inflammatory disorder, autoimmune
 CC disorders such as rheumatoid arthritis and multiple sclerosis.
 CC atherogenesis and atherosclerosis, and for inhibiting restenosis. They
 CC are useful in therapy or diagnosis, and in the manufacture of a
 CC medicament for treating CCR2 mediated disease. They are also useful for
 CC treating allergy, anaphylaxis, malignancy, allergic reaction, shock,
 CC inflammation, histamine and IgE-mediated allergic reaction, restenosis,
 CC stenosis, allograft rejection, fibrotic disease, asthma, inflammatory
 CC glomerulopathies, acquired immune deficiency syndrome (AIDS), restenosis
 CC associated with vascular intervention, including angioplasty and/or stent
 CC placement in a mammal. Humanised antibodies are also useful for
 CC inhibiting narrowing of the lumen of a vessel in a mammal, and inhibiting
 CC neointimal hyperplasia of a vessel in a mammal, preferably associated
 CC with vascular intervention. The present sequence is humanised murine 1D9

CC antibody kappa light chain variable (VK) region, 1D9RKB. (Updated on 11-
 CC SEP-2003 to standardise OS field)
 XX
 SQ Sequence 112 AA;

Query Match 97.8%; Score 577; DB 4; Length 112;
 Best Local Similarity 98.2%; Pred. No. 3.9e-45;
 Matches 110; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 Qy 1 DVVMTQSPVLTGQPASISCKSSQSLDSDGKTFNLNWFQRPQSPRLIYLVSKLD 60
 Db 1 DVVMTQSPVLTGQPASISCKSSQSLDSDGKTFNLNWFQRPQSPRLIYLVSKLD 60
 Qy 61 SGVPDRFSGSGGTFTLKISRVEAEDVGVYVYCWQGHFFPYTFGGTRLEIK 112
 Db 61 SGVPDRFSGSGGTFTLKISRVEAEDVGVYVYCWQGHFFPYTFGGTRLEIK 112

RESULT 14
 AAU09922
 ID AAU09922 standard; protein; 112 AA.
 AC AAU09922;
 XX
 DT 18-JUN-2002 (first entry)
 XX
 DE Humanised 1D9 light chain variable region, 1D9RKB protein sequence.
 KW Human; mouse; 1D9 light chain variable region; vasotropic;
 KW antiinflammatory; collagen disease; immunosuppressive; antiasthmatic;
 KW insulin-dependent diabetes mellitus; inflammatory bowel disease;
 KW ulcerative colitis; HF-21/28; graft rejection; allergic disease;
 KW antiporiatic; 1D9RKB; antiarthritic; nephrotropic; antithyroid;
 KW restenosis; dermatological; anaphylaxis; cell adhesion inhibitor;
 KW vascular injury; autoimmune disease; immunoglobulin; atherosclerosis;
 KW complementarity determining region; CDR; CD18; CCR2; atherosclerosis;
 KW mutant; mutein.
 XX
 OS Homo sapiens.
 OS Mus sp.
 OS Synthetic.
 OS Chimeric.
 XX
 Key Location/Qualifiers
 FH 24. .39
 FT Region
 FT /note= "Complementarity determining region 1 (CDR1),
 FT grafted from mouse mAb 1D9 light chain sequence
 FT (AAU09918)"
 FT Misc-difference 41
 FT /note= "Substitution of Phe residue normally present in
 FT human HF-21/28 sequence (AAU09920) by Leu residue
 FT normally present in mouse mAb 1D9 light chain sequence
 FT (AAU09918)"
 FT Misc-difference 42
 FT /note= "Substitution of Gln residue normally present in
 FT human HF-21/28 sequence (AAU09920) by Leu residue
 FT normally present in mouse mAb 1D9 light chain sequence
 FT (AAU09918)"
 FT Region 55. .61
 FT /note= "Complementarity determining region 2 (CDR2),
 FT grafted from mouse mAb 1D9 light chain sequence
 FT (AAU09918)"
 FT Region 94. .102
 FT /note= "Complementarity determining region 3 (CDR3),
 FT grafted from mouse mAb 1D9 light chain sequence
 FT (AAU09918)"
 FT Misc-difference 112
 FT /note= "Addition of Lys residue normally present in mouse
 FT mAb 1D9 sequence and absent in human antibody HF-21/28
 FT sequence (AAU09920)"
 XX
 PN WO200170266-A2.
 XX

PD 27-SEP-2001.

XX 15-MAR-2001; 2001WO-US008266.

XX 17-MAR-2000; 2000US-00528267.

XX (MILL-) MILLENNIUM PHARM INC.

XX Horvath CJ, Rao PE;

XX WPI; 2001-607511/69.

XX Inhibiting stenosis or restenosis of a blood vessel following vascular
 injury or angioplasty in a subject by administering agent which inhibits
 recruitment or adhesion of neutrophils, mononuclear cells to injury site.

PS Claim 32; Fig 17; 108pp; English.

XX The present invention relates to a new method of inhibiting stenosis or
 CC restenosis of a blood vessel following vascular injury in a subject. The
 CC new method comprises administering to the subject agents which inhibit
 CC the adhesion and/or recruitment of neutrophils and mononuclear cells to a
 CC site of vascular injury by binding CD18 or CCR2. The method of the
 CC invention inhibits stenosis or restenosis of a blood vessel following
 CC vascular injury arising from a vascular intervention procedure such as
 CC for treating a subject having an inflammatory disease or condition
 CC mediated by neutrophil and mononuclear cell activity e.g. asthma and
 CC graft versus host disease. Chronic inflammatory diseases of the lung,
 CC collagen diseases, and insulin-dependent diabetes mellitus can also be
 CC treated. The method is further useful for treating inflammatory bowel
 CC diseases, such as ulcerative colitis. Additional diseases or conditions
 CC include inflammatory or allergic diseases and conditions, including
 CC systemic anaphylaxis of hypersensitivity responses, drug allergies,
 CC psoriasis and inflammatory dermatoses, autoimmune diseases such as
 CC arthritis, graft rejection and other diseases including atherosclerosis.
 CC The present sequence represents the variable region of one of several
 CC humanised 1D9 light chains (AAU09921-AAU09925). These light chains were
 CC used in the invention for the production of anti-CCR2 antibody or antigen
 CC -binding fragment
 XX

SQ Sequence 112 AA;

Query Match 97.8%; Score 577; DB 4; Length 112;
 Best Local Similarity 98.2%; Pred. No. 3.9e-45;
 Matches 110; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 DVVMTQSPVLTGQPASISCKSSQSLDSDGKTFNLNWFQRPQSPRLIYLVSKLD 60

Db 1 DVVMTQSPVLTGQPASISCKSSQSLDSDGKTFNLNWFQRPQSPRLIYLVSKLD 60

Qy 61 SGVPDRFSGSGGTFTLKISRVEAEDVGVYVYCWQGHFFPYTFGGTRLEIK 112

Db 61 SGVPDRFSGSGGTFTLKISRVEAEDVGVYVYCWQGHFFPYTFGGTRLEIK 112

RESULT 15

ABG75531

ID ABG75531 standard; protein; 112 AA.

XX AC ABG75531;

XX 16-APR-2003 (first entry)

DE Humanised mouse mAb 1D9 light chain variable region, 1D9RKBVK.

XX Mouse; stenosis; restenosis; blood vessel; vascular injury; antibody;
 KW antigen binding fragment; cellular adhesion molecule; adhesion;
 KW recruitment; neutrophil; antagonist; CCR2; mononuclear cell; angioplasty;
 KW percutaneous transluminal coronary angioplasty; PTCA; stent;
 KW vascular by-pass surgery; vascular grafting; endarterectomy; atherectomy;
 KW endovascular stenting; prosthetic valve; transplantation;
 KW inflammatory disease; mastitis; vaginitis; cholecystitis;

GenCore version 5.1.9
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: June 10, 2006, 12:05:52 ; Search time 19.3393 Seconds
(without alignments)
506.917 Million cell updates/sec

Title: US-10-733-563-12

Perfect score: 590
Sequence: 1 DVVMTOSPLSLPTLGPAS.....CWOCTHFFYTFGQGTLEIK 112

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 650591 seqs, 87530628 residues

Total number of hits satisfying chosen parameters: 650591

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued Patents_AA:*
1: /EMC Cellerai_SIDS3/ptodata/2/iaa/5 COMB.pep.*
2: /EMC Cellerai_SIDS3/ptodata/2/iaa/6 COMB.pep.*
3: /EMC Cellerai_SIDS3/ptodata/2/iaa/7 COMB.pep.*
4: /EMC Cellerai_SIDS3/ptodata/2/iaa/H COMB.pep.*
5: /EMC Cellerai_SIDS3/ptodata/2/iaa/ECTUS COMB.pep.*
6: /EMC Cellerai_SIDS3/ptodata/2/iaa/RE COMB.pep.*
7: /EMC Cellerai_SIDS3/ptodata/2/iaa/backfiles1.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	590	100.0	112	2	US-09-809-739-14
2	590	100.0	112	2	US-09-840-459-12
3	590	100.0	112	2	US-09-497-625A-12
4	584	99.0	114	2	US-09-840-459-106
5	584	99.0	114	2	US-09-497-625A-106
6	577	97.8	112	2	US-09-809-739-15
7	577	97.8	112	2	US-09-840-459-13
8	577	97.8	112	2	US-09-497-625A-13
9	572	96.9	112	2	US-09-809-739-18
10	572	96.9	112	2	US-09-840-459-107
11	570	96.6	112	2	US-09-809-739-16
12	570	96.6	112	2	US-09-840-459-14
13	570	96.6	112	2	US-09-497-625A-14
14	565	95.8	112	2	US-09-809-739-17
15	565	95.8	112	2	US-09-840-459-15
16	565	95.8	112	2	US-09-497-625A-15
17	536	90.8	112	2	US-09-809-739-11
18	536	90.8	112	2	US-09-840-459-9
19	536	90.8	112	2	US-09-497-625A-9
20	536	90.8	142	2	US-09-840-459-102
21	536	90.8	142	2	US-09-497-625A-102
22	527	89.3	257	2	US-09-419-788-113
23	526	89.2	111	2	US-09-809-739-13
24	526	89.2	111	2	US-09-840-459-59
25	526	89.2	111	2	US-09-497-625A-11
26	526	89.2	111	2	US-09-497-625A-59

27 526 89.2 112 1 US-08-477-877B-89 Sequence 89, Appl
28 526 89.2 112 1 US-08-472-281A-89 Sequence 89, Appl
29 526 89.2 112 1 US-08-477-989B-89 Sequence 89, Appl
30 526 89.2 112 2 US-09-462-140D-97 Sequence 97, Appl
31 524 88.8 113 2 US-09-698-705-7 Sequence 7, Appl
32 524 88.8 218 2 US-09-698-705-12 Sequence 12, Appl
33 521 88.3 112 2 US-09-840-459-54 Sequence 54, Appl
34 521 88.3 112 2 US-09-497-625A-54 Sequence 54, Appl
35 521 88.3 112 2 US-09-254-180C-8 Sequence 8, Appl
36 521 88.3 353 2 US-09-203-958A-4 Sequence 4, Appl
37 520 88.1 111 2 US-09-840-459-11 Sequence 11, Appl
38 520 88.1 112 2 US-09-840-459-58 Sequence 58, Appl
39 520 88.1 112 2 US-09-497-625A-58 Sequence 58, Appl
40 518 87.8 112 2 US-09-647-468-149 Sequence 149, App
41 518 87.8 112 2 US-09-647-468-150 Sequence 150, App
42 518 87.8 131 2 US-09-647-468-163 Sequence 163, App
43 518 87.8 131 2 US-09-647-468-164 Sequence 164, App
44 518 87.8 243 2 US-09-297-181-2 Sequence 2, Appl
45 516 87.5 535 2 US-08-983-035A-38 Sequence 38, Appl

ALIGNMENTS

RESULT 1
US-09-809-739-14 112 1 US-08-477-877B-89 Sequence 89, Appl
; Sequence 14, Application US/09809739 Sequence 89, Appl
; Patent No. 6663863 Sequence 89, Appl
; GENERAL INFORMATION: Sequence 97, Appl
; APPLICANT: Horvath, Christopher J. Sequence 7, Appl
; APPLICANT: Rao, Patricia E. Sequence 12, Appl
; TITLE OF INVENTION: Method of Inhibiting Stenosis and Sequence 54, Appl
; TITLE OF INVENTION: Restenosis Sequence 54, Appl
; FILE REFERENCE: 1855.1069-003 Sequence 8, Appl
; CURRENT APPLICATION NUMBER: US/09/809, 739 Sequence 11, Appl
; CURRENT FILING DATE: 2001-03-15 Sequence 58, Appl
; PRIOR APPLICATION NUMBER: US 09/528, 267 Sequence 58, Appl
; PRIOR FILING DATE: 2000-03-17 Sequence 149, App
; NUMBER OF SEQ ID NOS: 23 Sequence 150, App
; SOFTWARE: FastSeq for Windows Version 4.0 Sequence 163, App
; SEQ ID NO 14 Sequence 164, App
; LENGTH: 112 Sequence 2, Appl
; TYPE: PRT Sequence 38, Appl
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Humanized sequence
US-09-809-739-14

Query Match 100.0%; Score 590; DB 2; Length 112;
Best Local Similarity 100.0%; Pred. No. 3.4e-51;
Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 DVVMTOSPLSLPTLGPASISCKSSQSLSDSGKTFLEWFOORPGOSPRRLIYLSKLD 60
Db 1 DVVMTOSPLSLPTLGPASISCKSSQSLSDSGKTFLEWFOORPGOSPRRLIYLSKLD 60
Qy 61 SGVPDRFSGSGGTDTLKLISRVEADGVVYWCQGTTHFFYTFGQGTLEIK 112
Db 61 SGVPDRFSGSGGTDTLKLISRVEADGVVYWCQGTTHFFYTFGQGTLEIK 112

RESULT 2
US-09-840-459-12
; Sequence 12, Application US/09840459 Sequence 12, Appl
; Patent No. 6696550 Sequence 9, Appl
; GENERAL INFORMATION: Sequence 9, Appl
; APPLICANT: LaRosa, Gregory J. Sequence 102, App
; APPLICANT: Horvath, Christopher Sequence 102, App
; APPLICANT: Newman, Walter Sequence 113, App
; APPLICANT: Jones, S. Tarran Sequence 13, App
; APPLICANT: O'Brien, Siobhan H. Sequence 13, App
; APPLICANT: O'Keefe, Theresa Sequence 11, App
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND Sequence 59, Appl

```
; TITLE OF INVENTION: METHODS OF USE THEREFOR
; FILE REFERENCE: 1855.1052-012
; CURRENT APPLICATION NUMBER: US/09/840,459
; CURRENT FILING DATE: 2001-02-02
; PRIOR FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: 09/497,625
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 107
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 12
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Humanized sequence
US-09-840-459-12

Query Match      100.0%; Score 590; DB 2; Length 112;
Best Local Similarity 100.0%; Pred. No. 3.4e-51;
Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 DVVMTQSPVLSPLPTLGQPASISCKSSQSLDSDGKTFLNWFQORPGQSPRRILIYLSKLD 60
Db 1 DVVMTQSPVLSPLPTLGQPASISCKSSQSLDSDGKTFLNWFQORPGQSPRRILIYLSKLD 60

QY 61 SGVPDRFSGSGGTDFTLKISRVEAEDGVVYCWQGTTHFFYTFGQGTRLLEIK 112
Db 61 SGVPDRFSGSGGTDFTLKISRVEAEDGVVYCWQGTTHFFYTFGQGTRLLEIK 112

RESULT 3
US-09-497-625A-12
; Sequence 12, Application US/09497625A
; Patent No. 6727349
; GENERAL INFORMATION:
; APPLICANT: LaRosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; FILE REFERENCE: 1855.1052-004
; CURRENT APPLICATION NUMBER: US/09/497,625A
; CURRENT FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 106
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 12
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Humanized sequence
US-09-497-625A-12

Query Match      100.0%; Score 590; DB 2; Length 112;
Best Local Similarity 100.0%; Pred. No. 3.4e-51;
Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 DVVMTQSPVLSPLPTLGQPASISCKSSQSLDSDGKTFLNWFQORPGQSPRRILIYLSKLD 60
Db 1 DVVMTQSPVLSPLPTLGQPASISCKSSQSLDSDGKTFLNWFQORPGQSPRRILIYLSKLD 60

QY 61 SGVPDRFSGSGGTDFTLKISRVEAEDGVVYCWQGTTHFFYTFGQGTRLLEIK 112
Db 61 SGVPDRFSGSGGTDFTLKISRVEAEDGVVYCWQGTTHFFYTFGQGTRLLEIK 112
```

```
QY 61 SGVPDRFSGSGGTDFTLKISRVEAEDGVVYCWQGTTHFFYTFGQGTRLLEIK 112
Db 61 SGVPDRFSGSGGTDFTLKISRVEAEDGVVYCWQGTTHFFYTFGQGTRLLEIK 112

RESULT 4
US-09-840-459-106
; Sequence 106, Application US/09840459
; Patent No. 6696550
; GENERAL INFORMATION:
; APPLICANT: LaRosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; FILE REFERENCE: 1855.1052-012
; CURRENT APPLICATION NUMBER: US/09/840,459
; CURRENT FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: PCT/US01/03537
; PRIOR FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: 09/497,625
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 107
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 106
; LENGTH: 114
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Humanized light chain
US-09-840-459-106

Query Match      99.0%; Score 584; DB 2; Length 114;
Best Local Similarity 100.0%; Pred. No. 1.4e-50;
Matches 111; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 VVMTQSPVLSPLPTLGQPASISCKSSQSLDSDGKTFLNWFQORPGQSPRRILIYLSKLD 61
Db 2 VVMTQSPVLSPLPTLGQPASISCKSSQSLDSDGKTFLNWFQORPGQSPRRILIYLSKLD 61

QY 62 GVPDRFSGSGGTDFTLKISRVEAEDGVVYCWQGTTHFFYTFGQGTRLLEIK 112
Db 62 GVPDRFSGSGGTDFTLKISRVEAEDGVVYCWQGTTHFFYTFGQGTRLLEIK 112

RESULT 5
US-09-497-625A-106
; Sequence 106, Application US/09497625A
; Patent No. 6727349
; GENERAL INFORMATION:
; APPLICANT: LaRosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; FILE REFERENCE: 1855.1052-004
; CURRENT APPLICATION NUMBER: US/09/497,625A
; CURRENT FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 106
```

```
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 106
; LENGTH: 114
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Humanized light chain
US-09-497-625A-106

Query Match          99.0%; Score 584; DB 2; Length 114;
Best Local Similarity 100.0%; Pred. No. 1.4e-50;
Matches 111; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 VVMTQSPSLPVTLGQPASISCKSSQSLDSDGKTFLNWFQRPQSPRLIYLVSKLDS 61
Db 2 VVMTQSPSLPVTLGQPASISCKSSQSLDSDGKTFLNWFQRPQSPRLIYLVSKLDS 61

Qy 62 GVPDRFSGSGGTDFTLKISRVEADGVVYCWQGTFFPYTFQGQTRLEIK 112
Db 62 GVPDRFSGSGGTDFTLKISRVEADGVVYCWQGTFFPYTFQGQTRLEIK 112

RESULT 6
US-09-809-739-15
; Sequence 15, Application US/09809739
; Patent No. 6663863
; GENERAL INFORMATION:
; APPLICANT: Horvath, Christopher J.
; APPLICANT: Rao, Patricia E.
; TITLE OF INVENTION: Method of Inhibiting Stenosis and
; TITLE OF INVENTION: Restenosis
; FILE REFERENCE: 1855.1069-003
; CURRENT APPLICATION NUMBER: US/09/809,739
; CURRENT FILING DATE: 2001-03-15
; PRIOR APPLICATION NUMBER: US 09/528,267
; PRIOR FILING DATE: 2000-03-17
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 15
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Humanized sequence
US-09-809-739-15

Query Match          97.8%; Score 577; DB 2; Length 112;
Best Local Similarity 98.2%; Pred. No. 6.6e-50;
Matches 110; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 DVVMTQSPSLPVTLGQPASISCKSSQSLDSDGKTFLNWFQRPQSPRLIYLVSKLD 60
Db 1 DVVMTQSPSLPVTLGQPASISCKSSQSLDSDGKTFLNWLLQRPQSPRLIYLVSKLD 60

Qy 61 SGVPDRFSGSGGTDFTLKISRVEADGVVYCWQGTFFPYTFQGQTRLEIK 112
Db 61 SGVPDRFSGSGGTDFTLKISRVEADGVVYCWQGTFFPYTFQGQTRLEIK 112

RESULT 7
US-09-840-459-13
; Sequence 13, Application US/09840459
; Patent No. 6696550
; GENERAL INFORMATION:
; APPLICANT: LaRosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; TITLE OF INVENTION: METHODS OF USE THEREFOR
; FILE REFERENCE: 1855.1052-012

Query Match          97.8%; Score 577; DB 2; Length 112;
Best Local Similarity 98.2%; Pred. No. 6.6e-50;
Matches 110; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 DVVMTQSPSLPVTLGQPASISCKSSQSLDSDGKTFLNWFQRPQSPRLIYLVSKLD 60
Db 1 DVVMTQSPSLPVTLGQPASISCKSSQSLDSDGKTFLNWLLQRPQSPRLIYLVSKLD 60

Qy 61 SGVPDRFSGSGGTDFTLKISRVEADGVVYCWQGTFFPYTFQGQTRLEIK 112
Db 61 SGVPDRFSGSGGTDFTLKISRVEADGVVYCWQGTFFPYTFQGQTRLEIK 112

RESULT 8
US-09-497-625A-13
; Sequence 13, Application US/09497625A
; Patent No. 6727349
; GENERAL INFORMATION:
; APPLICANT: LaRosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; TITLE OF INVENTION: METHODS OF USE THEREFOR
; FILE REFERENCE: 1855.1052-004
; CURRENT APPLICATION NUMBER: US/09/497,625A
; CURRENT FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 106
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 13
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Humanized sequence
US-09-497-625A-13

Query Match          97.8%; Score 577; DB 2; Length 112;
Best Local Similarity 98.2%; Pred. No. 6.6e-50;
Matches 110; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 DVVMTQSPSLPVTLGQPASISCKSSQSLDSDGKTFLNWFQRPQSPRLIYLVSKLD 60
Db 1 DVVMTQSPSLPVTLGQPASISCKSSQSLDSDGKTFLNWLLQRPQSPRLIYLVSKLD 60

Qy 61 SGVPDRFSGSGGTDFTLKISRVEADGVVYCWQGTFFPYTFQGQTRLEIK 112
Db 61 SGVPDRFSGSGGTDFTLKISRVEADGVVYCWQGTFFPYTFQGQTRLEIK 112
```

Db 61 SGVDFRFGSGGTDFTLKISRVEAEDVGVYVCWQGTFFPYTFGGQTRLEIK 112

RESULT 9

US-09-809-739-18
; Sequence 18, Application US/09809739
; Patent No. 6663863
; GENERAL INFORMATION:
; APPLICANT: Horvath, Christopher J.
; APPLICANT: Rao, Patricia E.
; TITLE OF INVENTION: Method of Inhibiting Stenosis and
; TITLE OF INVENTION: Restenosis
; FILE REFERENCE: 1855.1069-003
; CURRENT APPLICATION NUMBER: US/09/809,739
; CURRENT FILING DATE: 2001-03-15
; PRIOR APPLICATION NUMBER: US 09/528,267
; PRIOR FILING DATE: 2000-03-17
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 18
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Humanized sequence
US-09-809-739-18

Query Match 96.9%; Score 572; DB 2; Length 112;
Best Local Similarity 97.3%; Pred. No. 2.1e-49;
Matches 109; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 DVVMTQSPVLSPLPTLGQPASISCKSSQSLDSDGKTFLNWFQORPGQSPRRLLIYLSKLD 60

Db 1 DVVMTQSPVLSPLPTLGHPASISCKSSQSLDSDGKTFLNWLLQRPQSPRRLLIYLSKLD 60

QY 61 SGVDFRFGSGGTDFTLKISRVEAEDVGVYVCWQGTFFPYTFGGQTRLEIK 112

Db 61 SGVDFRFGSGGTDFTLKISRVEAEDVGVYVCWQGTFFPYTFGGQTRLEIK 112

RESULT 10

US-09-840-459-107
; Sequence 107, Application US/09840459
; Patent No. 6696550
; GENERAL INFORMATION:
; APPLICANT: Larosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; TITLE OF INVENTION: METHODS OF USE THEREFOR
; FILE REFERENCE: 1855.1052-012
; CURRENT APPLICATION NUMBER: US/09/840,459
; CURRENT FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: PCT/US01/03537
; PRIOR FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: 09/497,625
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 107
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 107
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Humanized sequence
US-09-840-459-107

Query Match 96.9%; Score 572; DB 2; Length 112;
Best Local Similarity 97.3%; Pred. No. 2.1e-49;
Matches 109; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 DVVMTQSPVLSPLPTLGQPASISCKSSQSLDSDGKTFLNWFQORPGQSPRRLLIYLSKLD 60

Db 1 DVVMTQSPVLSPLPTLGHPASISCKSSQSLDSDGKTFLNWLLQRPQSPRRLLIYLSKLD 60

QY 61 SGVDFRFGSGGTDFTLKISRVEAEDVGVYVCWQGTFFPYTFGGQTRLEIK 112

Db 61 SGVDFRFGSGGTDFTLKISRVEAEDVGVYVCWQGTFFPYTFGGQTRLEIK 112

RESULT 11

US-09-809-739-16
; Sequence 16, Application US/09809739
; Patent No. 6663863
; GENERAL INFORMATION:
; APPLICANT: Horvath, Christopher J.
; APPLICANT: Rao, Patricia E.
; TITLE OF INVENTION: Method of Inhibiting Stenosis and
; TITLE OF INVENTION: Restenosis
; FILE REFERENCE: 1855.1069-003
; CURRENT APPLICATION NUMBER: US/09/809,739
; CURRENT FILING DATE: 2001-03-15
; PRIOR APPLICATION NUMBER: US 09/528,267
; PRIOR FILING DATE: 2000-03-17
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 16
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Humanized sequence
US-09-809-739-16

Query Match 96.8%; Score 570; DB 2; Length 112;
Best Local Similarity 97.3%; Pred. No. 3.3e-49;
Matches 109; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 DVVMTQSPVLSPLPTLGQPASISCKSSQSLDSDGKTFLNWFQORPGQSPRRLLIYLSKLD 60

Db 1 DVVMTQSPVLSPLPTLGQPASISCKSSQSLDSDGKTFLNWLLQRPQSPRRLLIYLSKLD 60

QY 61 SGVDFRFGSGGTDFTLKISRVEAEDVGVYVCWQGTFFPYTFGGQTRLEIK 112

Db 61 SGVDFRFGSGGTDFTLKISRVEAEDVGVYVCWQGTFFPYTFGGQTRLEIK 112

RESULT 12

US-09-840-459-14
; Sequence 14, Application US/09840459
; Patent No. 6696550
; GENERAL INFORMATION:
; APPLICANT: Larosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; TITLE OF INVENTION: METHODS OF USE THEREFOR
; FILE REFERENCE: 1855.1052-012
; CURRENT APPLICATION NUMBER: US/09/840,459
; CURRENT FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: PCT/US01/03537
; PRIOR FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: 09/497,625
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22

```
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 107
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 14
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Humanized sequence
US-09-840-459-14

Query Match          96.6%; Score 570; DB 2; Length 112;
Best Local Similarity 97.3%; Pred. No. 3.3e-49;
Matches 109; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1 DVVMTQSPVLSPLPVTLGGPASPISCKSSQSLDSDGKTFLNWFQORPGQSPRLIYLVSKLD 60
Db 1 DVVMTQSPVLSPLPVTLGGPASPISCKSSQSLDSDGKTFLNWLLQRPQSPRLIYLVSKLD 60

Qy 61 SGVPDRFSGSGGTDFTLKISRVEAEDGVVYCWQGHFFPYTFGGTRLEIK 112
Db 61 SGVPDRFSGSGGTDFTLKISRVEAEDGVVYCWQGHFFPYTFGGTRLEIK 112

RESULT 13
US-09-497-625A-14
; Sequence 14, Application US/09497625A
; Patent No. 6727349
; GENERAL INFORMATION:
; APPLICANT: LaRosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; FILE OF INVENTION: METHODS OF USE THEREFOR
; FILE REFERENCE: 1855.1052-004
; CURRENT APPLICATION NUMBER: US/09/497,625A
; CURRENT FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 106
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 14
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Humanized sequence
US-09-497-625A-14

Query Match          96.6%; Score 570; DB 2; Length 112;
Best Local Similarity 97.3%; Pred. No. 3.3e-49;
Matches 109; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1 DVVMTQSPVLSPLPVTLGGPASPISCKSSQSLDSDGKTFLNWFQORPGQSPRLIYLVSKLD 60
Db 1 DVVMTQSPVLSPLPVTLGGPASPISCKSSQSLDSDGKTFLNWLLQRPQSPRLIYLVSKLD 60

Qy 61 SGVPDRFSGSGGTDFTLKISRVEAEDGVVYCWQGHFFPYTFGGTRLEIK 112
Db 61 SGVPDRFSGSGGTDFTLKISRVEAEDGVVYCWQGHFFPYTFGGTRLEIK 112

RESULT 14
US-09-809-739-17
; Sequence 17, Application US/09809739
; Patent No. 6663863
; GENERAL INFORMATION:
; APPLICANT: Horvath, Christopher J.
; APPLICANT: Rao, Patricia E.
; TITLE OF INVENTION: Method of Inhibiting Stenosis and
; FILE REFERENCE: 1855.1069-003
; CURRENT APPLICATION NUMBER: US/09/809,739
; CURRENT FILING DATE: 2001-03-15
; PRIOR APPLICATION NUMBER: US 09/528,267
; PRIOR FILING DATE: 2000-03-17
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 17
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Humanized sequence
US-09-809-739-17

Query Match          95.8%; Score 565; DB 2; Length 112;
Best Local Similarity 96.4%; Pred. No. 1e-48;
Matches 108; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1 DVVMTQSPVLSPLPVTLGGPASPISCKSSQSLDSDGKTFLNWFQORPGQSPRLIYLVSKLD 60
Db 1 DVVMTQSPVLSPLPVTLGGPASPISCKSSQSLDSDGKTFLNWLLQRPQSPRLIYLVSKLD 60

Qy 61 SGVPDRFSGSGGTDFTLKISRVEAEDGVVYCWQGHFFPYTFGGTRLEIK 112
Db 61 SGVPDRFSGSGGTDFTLKISRVEAEDGVVYCWQGHFFPYTFGGTRLEIK 112

RESULT 15
US-09-840-459-15
; Sequence 15, Application US/09840459
; Patent No. 6696550
; GENERAL INFORMATION:
; APPLICANT: LaRosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; FILE OF INVENTION: METHODS OF USE THEREFOR
; FILE REFERENCE: 1855.1052-012
; CURRENT APPLICATION NUMBER: US/09/840,459
; CURRENT FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: PCT/US01/03537
; PRIOR FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: 09/497,625
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 107
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 15
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Humanized sequence
US-09-840-459-15

Query Match          95.8%; Score 565; DB 2; Length 112;
Best Local Similarity 96.4%; Pred. No. 1e-48;
Matches 108; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1 DVVMTQSPVLSPLPVTLGGPASPISCKSSQSLDSDGKTFLNWFQORPGQSPRLIYLVSKLD 60
Db 1 DVVMTQSPVLSPLPVTLGGPASPISCKSSQSLDSDGKTFLNWLLQRPQSPRLIYLVSKLD 60
```

Qy 61 SGVDFRFGSGGTDFTLKISRVEAEDVGVYCWQGTHTFPYTFGGTRLEIK 112
Db 61 SGVDFRFGSGGTDFTLKISRVEAEDVGVYCWQGTHTFPYTFGGTRLEIK 112

Search completed: June 10, 2006, 12:08:44
Job time : 20.3393 secs

Result No.	Query			DB	ID	Description
	Score	Match	Length			
1	531	90.0	113	2	F30560	Ig kappa chain V r
2	530	89.8	132	2	C32513	Ig kappa chain V r
3	526	89.2	133	2	S23230	Ig kappa chain pre
4	526	89.2	142	2	S22902	Ig kappa chain V r
5	517	87.6	112	2	A36259	Ig kappa chain V r
6	514	87.1	133	1	K2HURP	Ig kappa chain pre
7	513.5	87.0	114	2	S49572	Ig kappa chain pre
8	512	86.8	111	2	S20709	Ig kappa chain V r
9	512	86.8	112	2	S50491	Ig kappa chain V r
10	506	85.8	133	1	A24452	proteolytic antibo
11	505.5	85.7	140	2	S22658	Ig kappa chain pre
12	505	85.6	133	2	S40324	Ig kappa chain pre
13	503	85.3	131	2	S31577	Ig kappa chain V r
14	501	84.9	112	2	PL0273	Ig kappa chain - m
15	501	84.9	133	2	S42611	Ig kappa chain V r
16	499	84.6	118	2	S40374	HUNVK protein prec
17	499	84.6	122	2	S40338	Ig kappa chain - h
18	496.5	84.2	114	2	B49002	Ig kappa chain - h
19	491	83.2	132	2	S40322	Ig kappa chain - h
20	488	82.7	101	2	A33730	Ig kappa chain V r
21	477	80.8	126	2	S40312	Ig kappa chain - h
22	470	79.7	120	2	S42268	Ig kappa chain V r
23	470	79.7	120	2	S42267	Ig kappa chain V r
24	461.5	78.2	134	2	S40376	Ig kappa chain - h
25	457	77.5	103	2	PH1056	Ig kappa chain - h
26	457	77.5	112	2	A31807	Ig light chain V r
27	456	77.3	103	2	PH1055	Ig kappa chain V r
28	456	77.3	219	2	S16112	Ig kappa chain V r
29	454	76.9	115	2	S38715	Ig kappa chain V r

Query Match 89.8%; Score 530; DB 2; Length 132;

Best Local Similarity 88.4%; Pred. No. 1e-42; Mismatches 8; Indels 5; Gaps 0;
Matches 99; Conservative 8; Mismatches 5; Indels 0; Gaps 0;

Qy 1 DVVMTQSPFLSPVTLGQPASISCKSSQSLDSDGKTFLNWFQQRPGQSPRLIYLVSKLD 60
Db 21 DVVMTQSPFLSVTIGQPASISCKSSQSLDSDGKTYLNWLLQRPQSPKRLIYLVSKLD 80

Qy 61 SGVPDRFSGSGGTDTFTLKISRVEAEDVGVYYCQGTTHFPYTFGQGTRLK 112
Db 81 SGVPDRFTGSGGTDTFTLKISRVEAEDLGVIYCWQGTTHFPRTFGGKTLK 132

RESULT 3
S23230
Ig kappa chain precursor V-J region - human (fragment)
C:Species: Homo sapiens (man)
C>Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 21-Jan-2000
C:Accession: S23230
R:Kennedy, M.A.
J. Exp. Med. 173, 1033-1036, 1991
A:Title: Novel chromosome translocation caused by fusion of immunoglobulin heavy and light chain genes in a human B cell line
A:Reference number: S23230; MUID:91178436; PMID:1840606
A:Accession: S23230
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-133 <KEN>
A:Cross-references: UNIPARC:UPI0000115EA9; EMBL:X55400; PIDN:CAA39072.1; PID:1840606
C:Genetics:
A:Introns: 17/1
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:36-115/Domain: immunoglobulin homology <IMM>

Query Match 89.2%; Score 526; DB 2; Length 133;
Best Local Similarity 90.2%; Pred. No. 2.5e-42;
Matches 101; Conservative 4; Mismatches 7; Indels 0; Gaps 0;

Qy 1 DVVMTQSPFLSPVTLGQPASISCKSSQSLDSDGKTFLNWFQQRPGQSPRLIYLVSKLD 60
Db 21 DVVMTQSPFLSPVTLGQPASISCKSSQSLYSDGNTHLNWFQQRPGQSPRLIYKVSNRD 80

Qy 61 SGVPDRFSGSGGTDTFTLKISRVEAEDVGVYYCQGTTHFPYTFGQGTRLK 112
Db 81 SGVPDRFSGSGGTDTFTLKISRVEAEDVGVYYCQGTTHFPYTFGQGTRLK 132

RESULT 4
S22902
Ig kappa chain V region - human
C:Species: Homo sapiens (man)
C>Date: 19-Feb-1994 #sequence_revision 10-Nov-1995 #text_change 21-Jan-2000
C:Accession: S22902
R:Chastagner, P.; Theze, J.; Zouali, M.
Gene 101, 305-306, 1991
A:Title: Cloning of a gene encoding a lupus-associated human autoantibody V(K) region us
A:Reference number: S22902; MUID:91276289; PMID:1905262
A:Accession: S22902
A:Status: preliminary; translation not shown
A:Molecule type: mRNA
A:Residues: 1-142 <CHA>
A:Cross-references: UNIPARC:UPI0000176CAB; EMBL:X56510
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:47-126/Domain: immunoglobulin homology <IMM>

Query Match 89.2%; Score 526; DB 2; Length 142;
Best Local Similarity 90.1%; Pred. No. 2.7e-42;
Matches 100; Conservative 5; Mismatches 6; Indels 0; Gaps 0;

Qy 1 DVVMTQSPFLSPVTLGQPASISCKSSQSLDSDGKTFLNWFQQRPGQSPRLIYLVSKLD 60
Db 32 DVVMTQSPFLSPVTLGQPASISCKSSQSLVHSDGNTYLNWFLQQRPGQSPRLIYKVSNRD 91

Qy 61 SGVPDRFSGSGGTDTFTLKISRVEAEDVGVYYCQGTTHFPYTFGQGTRLK 111
Db 92 SGVPDRFSGSGGTDTFTLKISRVEAEDVGVYYCQGTTHFPYTFGQGTRLK 142

RESULT 5
A36259
Ig kappa chain V region (TE34) - mouse
C:Species: Mus musculus (house mouse)
C>Date: 18-Jan-1991 #sequence_revision 18-Jan-1991 #text_change 21-Jan-2000
C:Accession: A36259
R:Zilber, B.; Scherf, T.; Levitt, M.; Angliester, J.
Biochemistry 29, 10032-10041, 1990
A:Title: NMR-derived model for a peptide-antibody complex.
A:Reference number: A36259; MUID:91104915; PMID:2271636
A:Accession: A36259
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-112 <ZIL>
A:Cross-references: UNIPARC:UPI0000176AFD; GB:M30458; GB:M30459; GB:M30480; GB:M30481; GB:M30482
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:16-95/Domain: immunoglobulin homology <IMM>

Query Match 87.6%; Score 517; DB 2; Length 112;
Best Local Similarity 86.8%; Pred. No. 1.4e-41;
Matches 97; Conservative 8; Mismatches 7; Indels 0; Gaps 0;

Qy 1 DVVMTQSPFLSPVTLGQPASISCKSSQSLDSDGKTFLNWFQQRPGQSPRLIYLVSKLD 60
Db 1 DVVMTQSPFLSVTIGQPASISCKSSQSLDSDGKTYLNWLLQRPQSPKRLIYLVSKLD 60

Qy 61 SGVPDRFSGSGGTDTFTLKISRVEAEDVGVYYCQGTTHFPYTFGQGTRLK 112
Db 61 SGVPDRFTGSGGTDTFTLKISRVEAEDGVYYCQGTTHFPYTFGQGTRLK 112

RESULT 6
K2HURP
Ig kappa chain precursor V-II region (RPMI) - human
C:Species: Homo sapiens (man)
C>Date: 30-Jun-1987 #sequence_revision 30-Jun-1987 #text_change 09-Jul-2004
C:Accession: A01890
R:Klobeck, H.G.; Meindl, A.; Combratio, G.; Solomon, A.; Zachau, H.G.
Nucleic Acids Res. 13, 6499-6513, 1985
A:Title: Human immunoglobulin kappa light chain genes of subgroups II and III.
A:Reference number: A93588; MUID:86041852; PMID:2997711
A:Accession: A01890
A:Molecule type: DNA
A:Residues: 1-133 <KLO>
A:Cross-references: UNIPROT:P06310; UNIPARC:UPI000012E159
A:Note: the sequence was determined from the differentiated gene
C:Genetics:
A:Gene: GDB:IGKV2
A:Cross-references: GDB:136265
A:Map position: 2p12-2p12
A:Introns: 17/1
C:Complex: An immunoglobulin heterotetramer subunit consists of two identical light (kappa) and two identical heavy (lambda) chain disulfide bonds. In some cases, such as IgA and IgM, the subunits associate into larger oligomers.
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:1-20/Domain: signal sequence #status predicted <SIG>
F:21-133/Product: Ig kappa chain V-II region (RPMI) #status predicted <MAT>
F:21-43/Region: framework 1
F:36-115/Domain: immunoglobulin homology <IMM>
F:44-59/Region: complementarity-determining 1
F:60-74/Region: framework 2
F:75-81/Region: complementarity-determining 2
F:82-113/Region: framework 3
F:114-122/Region: complementarity-determining 3
F:123-133/Region: framework 4
F:43-113/Disulfide bonds: #status predicted

Query Match 87.1%; Score 514; DB 1; Length 133;
 Best Local Similarity 87.5%; Pred. No. 3.3e-41;
 Matches 98; Conservative 7; Mismatches 7; Indels 0; Gaps 0;

Qy 1 DVWMTQSLSPVLTIGQPASISCKSSQSLLSDGKTFLNWFQORPGOSPRRLIYLVSKLD 60
 Db 21 DVWMTQSLSPVLTIGQPASISCKSSQSLLSDGKTFLNWFQORPGOSPRRLIYKVNRD 80

Qy 61 SGVDPDRFSGSGGDTFTLKISRVAEDGVVYCWQGHFFPYTFQGTRLEIK 112
 Db 81 SGVDPDRFSGSGGDTFTLKISRVAEDGVVYCWQGHFFPYTFQGTRLEIK 132

RESULT 7
 S49572
 Ig kappa chain precursor - human (fragment)
 C:Species: Homo sapiens (man)
 C:Date: 06-Mar-1995 #sequence_revision 14-Jul-1995 #text_change 21-Jan-2000
 C:Accession: S49572
 F:Giachino, C.; Padovan, E.; Lanzavecchia, A.
 submitted to the EMBL Data Library, November 1994
 A:Description: k+1 dual receptor B cells are present in the human peripheral repertoire
 A:Reference number: S49571
 A:Accession: S49572
 A>Status: preliminary
 A:Molecule type: mRNA
 A:Residues: 1-114 <GIA>
 A:Cross-references: UNIPARC:UPI0000116709; EMBL:Z46626; NID:g575261; PIDN:CAA86596.1; PT
 C:Superfamily: immunoglobulin V region; immunoglobulin homology
 F:16-95/Domain: immunoglobulin homology <IMM>

Query Match 87.0%; Score 513.5; DB 2; Length 114;
 Best Local Similarity 87.6%; Pred. No. 3.1e-41;
 Matches 99; Conservative 7; Mismatches 6; Indels 1; Gaps 1;

Qy 1 DVWMTQSLSPVLTIGQPASISCKSSQSLLSDGKTFLNWFQORPGOSPRRLIYLVSKLD 60
 Db 1 DVWMTQSLSPVLTIGQPASISCKSSQSLLSDGKTFLNWFQORPGOSPRRLIYKVNRD 60

Qy 61 SGVDPDRFSGSGGDTFTLKISRVAEDGVVYCWQGHFFPYTFQGTRLEIK 112
 Db 61 SGVDPDRFSGSGGDTFTLKISRVAEDGVVYCWQGHFFPYTFQGTRLEIK 113

RESULT 8
 S20709
 Ig kappa chain V region - mouse
 C:Species: Mus musculus (house mouse)
 C:Date: 20-Feb-1995 #sequence_revision 20-Feb-1995 #text_change 21-Jan-2000
 C:Accession: S20709
 R:Brennan, D.M.; Hinds, M.G.; Welsh, J.H.; Tempest, P.R.; Harris, W.J.; Carr, F.J.; Osb
 submitted to the EMBL Data Library, April 1992
 A:Description: Binding specificity and variable region sequences of two monoclonal anti
 A:Reference number: S20706
 A:Accession: S20709
 A>Status: preliminary
 A:Molecule type: DNA
 A:Residues: 1-111 <BRE>
 A:Cross-references: UNIPARC:UPI00001163E; EMBL:Z11917; NID:g52655; PIDN:CAA77975.1; PID
 C:Superfamily: immunoglobulin V region; immunoglobulin homology
 C:Keywords: heterotetramer; immunoglobulin
 F:16-95/Domain: immunoglobulin homology <IMM>

Query Match 86.8%; Score 512; DB 2; Length 111;
 Best Local Similarity 85.6%; Pred. No. 4.2e-41;
 Matches 95; Conservative 9; Mismatches 7; Indels 0; Gaps 0;

Qy 1 DVWMTQSLSPVLTIGQPASISCKSSQSLLSDGKTFLNWFQORPGOSPRRLIYLVSKLD 60
 Db 1 DIQLTQSPVLTIGQPASISCKSSQSLLSDGKTFLNWLLQORPGOSPRRLIYLVSKLD 60

Qy 61 SGVDPDRFSGSGGDTFTLKISRVAEDGVVYCWQGHFFPYTFQGTRLEI 111

Db 81 SGVDRFSGSGGDTFLTKISRVEADVGVYVCQGTHTWSWTFQGTKEIK 132
|||||
RESULT 11
S22658
Ig kappa chain precursor V region (0-81VL) - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 29-Jan-1998 #sequence_revision 06-Feb-1998 #text_change 31-Dec-2004
C;Accession: S22658
R;Hirabayashi, Y.; Munakata, Y.; Sasaki, T.; Sano, H.
Nucleic Acids Res. 20, 2601, 1992
A;Title: Variable regions of a human anti-DNA antibody O-81 possessing lupus nephritis-a
A;Reference number: S22657; MUID:92285150; PMID:1598223
A;Accession: S22658
A;Molecule type: mRNA
A;Residues: 1-140 <HR>
A;Cross-references: UNIPROT:Q8TCD0; UNIPARC:UPI00001769CF; EMBL:X59135
C;Superfamily: immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;1-19/Domain: signal sequence #status predicted <SIG>
F;20-140/Product: Ig kappa chain (fragment) #status predicted <MAT>
F;36-115/Domain: immunoglobulin homology <IMM>
Query Match 85.7%; Score 505.5; DB 2; Length 140;
Best Local Similarity 87.6%; Pred. No. 2.2e-40;
Matches 99; Conservative 5; Mismatches 8; Indels 1; Gaps 1;
Qy 1 DVVMTQSPFLSPVTLGQPASISCKSSQSLSDSGKTFLNWFQORPGQSPRLIYLVSKLD 60
|||
Db 21 DVVMTQSPFLSPVTLGQPASISCKSSQSLSDSGKTFLNWFQORPGQSPRLIYLVSKLD 80
|||
Qy 61 SGVDRFSGSGGDTFLTKISRVEADVGVYVCQGTHTP-PYTFGQGTREIK 112
|||
Db 81 SGVDRFSGSGGDTFLTKISRVEADVGVYVCQGTHTPSPITFGQGTREIK 133
|||
RESULT 12
S40324
Ig kappa chain V region - human
C;Species: Homo sapiens (man)
C;Date: 19-May-1994 #sequence_revision 26-May-1995 #text_change 31-Dec-2004
C;Accession: S40324
R;Klein, R.; Jaenichen, R.; Zachau, H.G.
Eur. J. Immunol. 23, 3248-3271, 1993
A;Title: Expressed human immunoglobulin chi genes and their hypermutation.
A;Reference number: S40312; MUID:94080891; PMID:8258341
A;Accession: S40324
A;Status: preliminary; translation not shown
A;Molecule type: mRNA
A;Residues: 1-133 <KLE>
A;Cross-references: UNIPROT:Q8TCD0; UNIPARC:UPI0000176CAA; EMBL:X72434
C;Superfamily: immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;33-112/Domain: immunoglobulin homology <IMM>
Query Match 85.6%; Score 505; DB 2; Length 133;
Best Local Similarity 84.8%; Pred. No. 2.3e-40;
Matches 95; Conservative 10; Mismatches 7; Indels 0; Gaps 0;
Qy 1 DVVMTQSPFLSPVTLGQPASISCKSSQSLSDSGKTFLNWFQORPGQSPRLIYLVSKLD 60
|||
Db 18 DVVMTQSPFLSPVTLGQPASISCKSSQSLSDSGKTFLNWFQORPGQSPRLIYLVSKLD 77
|||
Qy 61 SGVDRFSGSGGDTFLTKISRVEADVGVYVCQGTHTP-PYTFGQGTREIK 112
|||
Db 78 SGVDRFSGSGGDTFLTKISRVEADVGVYVCQGTHTPFGTQGTKEIK 129
|||
RESULT 13
S31577
Ig kappa chain - mouse (fragment)
C;Species: Mus musculus (house mouse)

C;Date: 20-Feb-1995 #sequence_revision 20-Feb-1995 #text_change 21-Jan-2000
C;Accession: S31577
R;Recinos, A.; Silvey, K.J.; Jensen, R.H.; Stanker, L.H.
submitted to the EMBL Data Library, January 1993
A;Description: Immunoglobulin variable heavy and light chain cDNA sequences for two anti-
A;Reference number: S31577
A;Accession: S31577
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-131 <REC>
A;Cross-references: UNIPARC:UPI000011469C; EMBL:Z19575; NID:G53983; PIDN:CAA79627.1; PID:
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;35-114/Domain: immunoglobulin homology <IMM>
Query Match 85.3%; Score 503; DB 2; Length 131;
Best Local Similarity 84.8%; Pred. No. 3.5e-40;
Matches 95; Conservative 8; Mismatches 9; Indels 0; Gaps 0;
Qy 1 DVVMTQSPFLSPVTLGQPASISCKSSQSLSDSGKTFLNWFQORPGQSPRLIYLVSKLD 60
|||
Db 20 DVVMTQAPLTSLVTGQPASISCKSSHSLSDSGKTYLWLLQRPQSPKRLIYLVSKLD 79
|||
Qy 61 SGVDRFSGSGGDTFLTKISRVEADVGVYVCQGTHTP-PYTFGQGTREIK 112
|||
Db 80 SGVDRFSGSGGDTFLTKISRVEADVGVYVCQGTHTP-PYTFGQGTREIK 131
|||
RESULT 14
PL0273
Ig kappa chain V region (anti-DNA, D23VK) - mouse (fragment)
C;Species: Mus musculus (house mouse)
C;Date: 16-Sep-1992 #sequence_revision 16-Sep-1992 #text_change 09-Jul-2004
C;Accession: PL0273
R;Shlomchik, M.; Mascelli, M.; Shan, H.; Radic, M.Z.; Pisetsky, D.; Marshak-Rothstein, A.
J. Exp. Med. 171, 265-297, 1990
A;Title: Anti-DNA antibodies from autoimmune mice arise by clonal expansion and somatic n
A;Reference number: PL0231; MUID:90111618; PMID:2104919
A;Accession: PL0273
A;Molecule type: mRNA
A;Residues: 1-112 <SHL>
A;Cross-references: UNIPROT:Q8K0F8; UNIPARC:UPI0000115487
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;1-23/Region: framework 1
F;16-95/Domain: immunoglobulin homology <IMM>
F;24-39/Region: complementarity-determining 1
F;40-54/Region: framework 2
F;55-61/Region: complementarity-determining 2
F;62-93/Region: framework 3
F;94-102/Region: complementarity-determining 3
F;103-112/Region: framework 4
Query Match 84.9%; Score 501; DB 2; Length 112;
Best Local Similarity 84.8%; Pred. No. 4.5e-40;
Matches 95; Conservative 10; Mismatches 7; Indels 0; Gaps 0;
Qy 1 DVVMTQSPFLSPVTLGQPASISCKSSQSLSDSGKTFLNWFQORPGQSPRLIYLVSKLD 60
|||
Db 1 DVVMTQTLTSLVTIGQPASISCKSSQSLYRNGKTYLWLLQRPQSPKRLIYLVSKLD 60
|||
Qy 61 SGVDRFSGSGGDTFLTKISRVEADVGVYVCQGTHTP-PYTFGQGTREIK 112
|||
Db 61 SGVDRFSGSGGDTFLTKISRVEADVGVYVCQGTHTP-PYTFGQGTREIK 112
|||
RESULT 15
S42611
HUNK protein precursor - human
C;Species: Homo sapiens (man)
C;Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 21-Jan-2000
C;Accession: S42611
R;Spatz, L.A.; Williams, M.; Brender, B.; Desai, R.; Latov, N.

J. Neuroimmunol. 36, 29-39, 1992
A;Title: DNA sequence analysis and comparison of the variable heavy and light chain regi
A;Reference number: S42610; MUID:92138794; PMID:1370957
A;Accession: S42611
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-133 <SPA>
A;Cross-references: UNIPARC:UPI000011378B; EMBL:X54137; NID:9433989; PIDN:CAA38072.1; PI
C;Superfamily: immunoglobulin V region; immunoglobulin homology
F;36-115/Domain: immunoglobulin homology <IMM>
Query Match 84.9%; Score 501; DB 2; Length 133;
Best Local Similarity 85.6%; Fred. No. 5.4e-40;
Matches 95; Conservative 7; Mismatches 9; Indels 0; Gaps 0;
Qy 1 DVVMTQSPFLSPVTLGQPASISCKSSQSLDSDGKTFLNWFQQRPGQSPRLIYLVSKLD 60
Db 21 DVVMTQSPFLSPVTLGQPASISCKSSQSLVFSFGNTYLNWFQQRPGQSPRLIYKVSNRD 80
Qy 61 SGVPDRFSGSGGTDFTLKISRVEAEDVGVIYCMQGAHWPLTFGGTKVEI 111
Db 81 SGVPDRFSGSGGTDFTLKISRVEAEDVGVIYCMQGAHWPLTFGGTKVEI 131

Search completed: June 10, 2006, 12:06:44
Job time : 12.9399 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.9
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: June 10, 2006, 11:49:06 ; Search time 92.1562 Seconds
(without alignments)
1124.198 Million cell updates/sec

Title: US-10-733-563-12
Perfect score: 590
Sequence: 1 DVNMTQSPSLPVLTPGPAS.....CMQGTHTPPYFGQTRLEIK 112

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2849598 seqs, 925015592 residues

Total number of hits satisfying chosen parameters: 2849598

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : UniProt_7.2.*
1: uniprot_sprot.*
2: uniprot_trembl.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	514	87.1	133	1	KV2F_HUMAN
2	511	86.6	239	2	Q8TCD0_HUMAN
3	496.5	84.2	114	2	Q9UL80_HUMAN
4	491	83.2	239	2	Q58EU8_MOUSE
5	459	77.8	239	2	Q6P491_HUMAN
6	450	76.3	113	1	KV2D_HUMAN
7	449	76.1	113	1	KV2B_HUMAN
8	447	75.8	239	2	Q8NEK0_HUMAN
9	445	75.4	248	2	Q65Z07_9MURI
10	444.5	75.3	115	1	KV2A_HUMAN
11	438	74.2	117	1	KV2E_HUMAN
12	430.5	73.0	115	2	Q5F210_MOUSE
13	430	72.9	113	1	KV2G_MOUSE
14	428	72.5	112	2	Q53VP8_MOUSE
15	418	70.8	219	2	Q65ZC0_MOUSE
16	417.5	70.8	240	2	Q6PIH6_HUMAN
17	411	69.7	234	2	Q5XK24_MOUSE
18	405.5	68.7	112	1	KV2C_HUMAN
19	402	68.1	113	1	KV2E_MOUSE
20	397	67.3	113	1	KV2C_MOUSE
21	396	67.1	112	1	KV2D_MOUSE
22	396	67.1	113	1	KV2F_MOUSE
23	390	66.1	112	1	KV2A_MOUSE
24	390	66.1	112	2	Q6LEH8_MOUSE
25	386.5	65.5	134	1	KV4C_HUMAN
26	385.5	65.3	108	1	KV1_CANFA
27	380.5	64.5	114	1	KV4A_HUMAN
28	378.5	64.2	111	1	KV3L_MOUSE
29	378.5	64.2	111	1	KV3M_MOUSE
30	377.5	64.0	111	1	KV3O_MOUSE
31	372.5	63.1	111	1	KV3Q_MOUSE

32	371.5	63.0	111	1	KV3N_MOUSE
33	371	62.9	110	1	KV3P_MOUSE
34	370	62.7	86	2	Q7Z3Y5_HUMAN
35	369.5	62.6	111	2	Q811U6_MOUSE
36	368.5	62.5	111	1	KV3H_MOUSE
37	365.5	61.9	111	1	KV3J_MOUSE
38	363	61.5	120	1	KV2B_MOUSE
39	361.5	61.3	111	2	Q920E9_MOUSE
40	360.5	61.1	131	1	KV3I_MOUSE
41	360.5	61.1	255	2	Q6KB05_MOUSE
42	359	60.8	133	1	KV4B_HUMAN
43	356.5	60.4	111	1	KV3K_MOUSE
44	356.5	60.4	111	1	KV3U_MOUSE
45	355.5	60.3	240	2	Q52L64_MOUSE

RESULT 1

KV2F_HUMAN	STANDARD;	PRT;	133 AA.
AC P06310;			
DT 01-JAN-1988,	integrated into UniProtKB/Swiss-Prot.		
DT 01-JAN-1988,	sequence version 1.		
DT 07-MAR-2006,	entry version 41.		
DE	Ig kappa chain V-II region RPMI 6410 precursor.		
OS	Homo sapiens (Human)		
OC	Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;		
OC	Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;		
OC	Homo.		
OX	NCBI_TaxID=9606;		
RN	[1]		
RP	NUCLEOTIDE SEQUENCE [GENOMIC DNA].		
RX	MEDLINE=86041852; PubMed=2997711;		
RA	Klobeck H.G., Meindl A., Combratio G., Solomon A., Zachau H.G.;		
RT	"Human immunoglobulin kappa light chain genes of subgroups II and III."		
RL	Nucleic Acids Res. 13:6499-6513(1985).		
CC	Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms		
CC	Distributed under the Creative Commons Attribution-NoDerivs License		
CC	EMBL; Z00020; CAA77315.1; -; Genomic_DNA.		
DR	PIR; A01890; K2HURP.		
DR	HSSP; Q99M37; I191.		
DR	SMR; P06310; 21-133.		
DR	Ensembl; ENSG00000173758; Homo sapiens.		
DR	LinkHub; P06310; -.		
DR	GO; GO:0005576; C:extracellular region; NAS.		
DR	GO; GO:0003823; F:antigen binding; NAS.		
DR	GO; GO:0006955; P:immune response; NAS.		
DR	InterPro; IPR003599; Ig.		
DR	InterPro; IPR007110; Ig-like.		
DR	InterPro; IPR003596; Ig_v.		
DR	InterPro; IPR013106; V-set.		
DR	Pfam; PF07686; V-set; 1.		
DR	SMART; SM00409; IG; 1.		
DR	SMART; SM00406; IGv; 1.		
DR	PROSITE; PS00835; IG_LIKE; 1.		
KW	Immunoglobulin domain; Immunoglobulin V region; Signal.		
FT	SIGNAL 1 20		
FT	CHAIN 21 133		
FT	REGION 21 43		
FT	REGION 44 59		
FT	REGION 60 74		
FT	REGION 75 81		
FT	REGION 82 113		
FT	REGION 114 122		
FT	REGION 123 132		
FT	REGION 133 133		
FT	DISULFID 43 113		
FT	NON_TER 133		

Ig kappa chain V-II region RPMI 6410.
/FTid=PRO_0000015173.
Framework-1.
Complementarity-determining-1.
Framework-2.
Complementarity-determining-2.
Framework-3.
Complementarity-determining-3.
Framework-4.
By similarity.

SQ SEQUENCE 133 AA; 14707 MW; 513CCAF3673009EE CRC64;
 Query Match 87.1%; Score 514; DB 1; Length 133;
 Best Local Similarity 87.5%; Pred. No. 1.6e-45;
 Matches 98; Conservative 7; Mismatches 7; Indels 0; Gaps 0;

QY 1 DVVMTQSPVLTLPVLTQGPASISCKSSQSLDSDGKTFLNWFQORPGQSPRRLLIYVSKLD 60
 DQ 21 DVVMTQSPVLTLPVLTQGPASISCKSSQSLDSDGKTFLNWFQORPGQSPRRLLIYVSKLD 80
 QY 61 SGVDFRFGSGSGTDFTLKISRVEAEDVGYYVCWQGTTHPPTFGQGTTRLEIK 112
 DQ 81 SGVDFRFGSGSGTDFTLKISRVEAEDVGYYVCWQGTTHPPTFGQGTTRLEIK 132

RESULT 2
 ID Q8TCD0_HUMAN PRELIMINARY; PRT; 239 AA.
 AC Q8TCD0;
 DT 01-JUN-2002, integrated into UniProtKB/TrEMBL.
 DT 01-JUN-2002, sequence version 1.
 DT 07-FEB-2006, entry version 24.
 DE Hypothetical protein.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
 OC Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP NUCLEOTIDE SEQUENCE.
 RC TISSUE=Lung;
 RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
 RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
 RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
 RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Heide F.,
 RA Datchenko L., Mardina K., Farmer A.A., Rubin G.M., Hong L.,
 RA Stapleton M., Soares M.B., Bonaldo M.P., Casavant T.L., Scheetz T.E.,
 RA Brownstein M.J., Udén T.B., Toshiyuki S., Carninci P., Prange C.,
 RA Raha S.A., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
 RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
 RA Fahey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
 RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickinson M.C.,
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
 RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalley D.E.,
 RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
 RT "Generation and initial analysis of more than 15,000 full-length human
 Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
 [2]
 RP NUCLEOTIDE SEQUENCE.
 RC TISSUE=Lung;
 RX Strausberg R.;
 RL Submitted (FEB-2002) to the EMBL/GenBank/DBJ databases.
 [3]
 RP NUCLEOTIDE SEQUENCE.
 RX MEDLINE=92285150; PubMed=1598223;
 RA Hirabayashi Y., Munakata Y., Sasaki T., Sano H.;
 RT "Variable regions of a human anti-DNA antibody O-81 possessing lupus
 nephritis-associated idiotype.";
 RL Nucleic Acids Res. 20:2601-0(1992).
 [4]
 RP NUCLEOTIDE SEQUENCE.
 RX MEDLINE=92201291; PubMed=1551402;
 RA Lautner-Rieske A., Huber C., Meindl A., Pargent W., Schable K.F.,
 RA Thiebe R., Zocher I., Zachau H.G.;
 RT "The human immunoglobulin kappa locus. Characterization of the
 duplicated A regions.";
 RL Eur. J. Immunol. 22:1023-1029(1992).
 [5]

RP NUCLEOTIDE SEQUENCE.
 RX MEDLINE=94080891; PubMed=8258341;
 RA Klein R., Jaenichen R., Zachau H.G.;
 RT "Expressed human immunoglobulin kappa genes and their hypermutation.";
 RL Eur. J. Immunol. 23:3248-3262(1993).
 [6]
 RP NUCLEOTIDE SEQUENCE.
 RX MEDLINE=93170387; PubMed=8436174;
 RA Wagner S.D., Luzzatto L.;
 RT "V kappa gene segments rearranged in chronic lymphocytic leukemia are
 distributed over a large portion of the V kappa locus and do not show
 somatic mutation.";
 RL Eur. J. Immunol. 23:391-397(1993).
 CC
 CC Copyrighted by the UniProt Consortium, see <http://www.uniprot.org/terms>
 CC Distributed under the Creative Commons Attribution-NoDerivs License
 CC
 CC EMBL; BC022362; AAH22362.1; -; mRNA.
 DR PIR; S22658; S22658.
 DR PIR; S34095; S34095.
 DR PIR; S40324; S40324.
 DR PIR; S40374; S40374.
 DR PIR; S42267; S42267.
 DR PIR; S42268; S42268.
 DR HSP; P01834; I17Z.
 DR SNR; Q8TCD0; 21-237.
 DR InterPro; IPR003599; Ig.
 DR InterPro; IPR007110; Ig-like.
 DR InterPro; IPR003597; Ig_c1.
 DR InterPro; IPR003006; Ig_MHC.
 DR InterPro; IPR003596; Ig_v.
 DR InterPro; IPR013106; V-set.
 DR Pfam; PF07654; Cl-set; 1.
 DR SMART; SM00409; IG1; 1.
 DR SMART; SM00407; IG1; 1.
 DR SMART; SM00406; IG1; 1.
 DR PROSITE; PS00835; IG LIKE; 2.
 DR PROSITE; PS00290; IG_MHC; UNKNOWN_1.
 KW Hypothetical protein.
 SQ SEQUENCE 239 AA; 26235 MW; FACEDC3A3B03871D CRC64;
 Query Match 86.6%; Score 511; DB 2; Length 239;
 Best Local Similarity 86.6%; Pred. No. 6.3e-45;
 Matches 97; Conservative 8; Mismatches 7; Indels 0; Gaps 0;

QY 1 DVVMTQSPVLTLPVLTQGPASISCKSSQSLDSDGKTFLNWFQORPGQSPRRLLIYVSKLD 60
 DQ 21 DVVMTQSPVLTLPVLTQGPASISCKSSQSLDSDGKTFLNWFQORPGQSPRRLLIYVSKLD 80
 QY 61 SGVDFRFGSGSGTDFTLKISRVEAEDVGYYVCWQGTTHPPTFGQGTTRLEIK 112
 DQ 81 SGVDFRFGSGSGTDFTLKISRVEAEDVGYYVCWQGTTHPPTFGQGTTRLEIK 132

RESULT 3
 ID Q9UL80_HUMAN PRELIMINARY; PRT; 114 AA.
 AC Q9UL80;
 DT 01-MAY-2000, integrated into UniProtKB/TrEMBL.
 DT 01-MAY-2000, sequence version 1.
 DT 07-FEB-2006, entry version 21.
 DE Myosin-reactive immunoglobulin light chain variable region (Fragment).
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
 OC Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP NUCLEOTIDE SEQUENCE.
 RX MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clin.1998.4531;
 RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berny S.M.,
 RA Young D.C.;
 RT "Myosin-reactive autoantibodies in rheumatic carditis and normal

```
RT fetus." ;
RL Clin. Immunol. Immunopathol. 87:184-192 (1998) .
RN [2]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=92352481; PubMed=1322670;
RA Stuber F., Lee S.K., Bridges S.L. Jr, Koopman W.J., Schroeder H.W. Jr,
RA Gaskin F., Fu S.M.;
RT "A rheumatoid factor from a normal individual encoded by VH2 and V
RT kappa II gene segments." ;
RL Arthritis Rheum. 35:900-904 (1992).
RN [3]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=93170387; PubMed=8436174;
RA Wagner S.D., Luzatto L.;
RT "V kappa gene segments rearranged in chronic lymphocytic leukemia are
RT distributed over a large portion of the V kappa locus and do not show
RT somatic mutation." ;
RL Eur. J. Immunol. 23:391-397 (1993).
RN [4]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=92289816; PubMed=1601042;
RA Huber C., Klobeck H.G., Zachau H.G.;
RT "Ongoing V kappa-J kappa recombination after formation of a productive
RT V kappa-J kappa coding joint." ;
RL Eur. J. Immunol. 22:1561-1565 (1992).
CC -----
CC Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution-NoDerivs License
CC -----
DR EMBL; AF035034; AAD56270.1; -; mRNA.
DR PIR; B49002; B49002.
DR PIR; S23638; S23638.
DR PIR; S34094; S34094.
DR PIR; S34095; S34095.
DR HSP; P01625; ILVE.
DR SMR; Q9UL80; 1-114.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig v.
DR InterPro; IPR013106; V-set.
DR SMART; SM00409; IG; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG_LIKE; 1.
DR Immunoglobulin domain.
FT NON_TER 1
FT TER 114
FT NON_TER 114
FT TER 114
SQ SEQUENCE 114 AA; 12775 MW; 070E31E210D1CB01 CRC64;

Query Match 84.2%; Score 496.5; DB 2; Length 114;
Best Local Similarity 85.8%; Pred. No. 9e-44;
Matches 97; Conservative 7; Mismatches 8; Indels 1; Gaps 1;

Qy 1 DVVMTQSPVLSPLPVTLGQPASISCKSSQSLSDSGKTFLNWFQQRPGQSPRLIYLVSCLD 60
Dy 1 DVVMTQSPVLSPLPVTLGQPASISCKSSQSPVSDGNTYLNWFQQRPGQSPRLIYKVSNRD 60

Qy 61 SGVDPDRFSGSGGTDFTLTKISRVEAEDGVVYVCWQGHF-PYTFGGQTRLEIK 112
Dy 61 SGVDPDRFSGSGGTDFTLTKISRVEAEDGVVYVCWQGHFWPTFGQTKVEIK 113

RESULT 4
Q58EUB_MOUSE PRELIMINARY; PRT; 239 AA.
AC Q58EUB_MOUSE
DT 26-APR-2005, integrated into UniProtKB/TrEMBL.
DT 07-FEB-2006, entry version 12.
DE Igk-C protein.
GN Name=Igk-C;
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
```

```
OC Muroidea; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX STRAIN=C2ECH II; TISSUE=Mammary tumor metastasized to lung.
MMTV-LTR/Wnt1 model. Expression driven by an MMTV-LTR enhancer.;
MEDLINE=42338257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausberg R.D., Collins F.S., Wagner L., Shenmen C.F., Schat N.G.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Haieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Udén T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A., Sanchez A.,
RA Fanev J., Helton E., Kettelman M., Madan A., Rodriguez S., Bouffard G.G.,
RA Whitney M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalek U., Smailus D.E.,
RA Scherch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences." ;
Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RX STRAIN=C2ECH II; TISSUE=Mammary tumor metastasized to lung.
MMTV-LTR/Wnt1 model. Expression driven by an MMTV-LTR enhancer.;
NIH MGC Project;
Submitted (MAR-2005) to the EMBL/GenBank/DBJ databases.
CC -----
CC Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution-NoDerivs License
CC -----
DR EMBL; BC091750; AAH91750.1; -; mRNA.
DR SMR; Q58EUB; 21-239.
DR MGI; MGI:96495; Igk-C.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig cl.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig v.
DR InterPro; IPR013106; V-set.
DR Pfam; PF07654; Cl-set; 1.
DR SMART; SM00409; IG; 1.
DR SMART; SM00407; IGcl; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 2.
DR PROSITE; PS00290; IG_MHC; UNKNOWN 1.
SQ SEQUENCE 239 AA; 26302 MW; 98FC4B8EB404215 CRC64;

Query Match 83.2%; Score 491; DB 2; Length 239;
Best Local Similarity 83.9%; Pred. No. 7.8e-43;
Matches 94; Conservative 9; Mismatches 9; Indels 0; Gaps 0;

Qy 1 DVVMTQSPVLSPLPVTLGQPASISCKSSQSLSDSGKTFLNWFQQRPGQSPRLIYLVSCLD 60
Dy 21 DVVMTQSPVLSPLPVTLGQPASISCKSSQSLSDSGKTFLNWFQQRPGQSPRLIYLVSCLD 80

Qy 61 SGVDPDRFSGSGGTDFTLTKISRVEAEDGVVYVCWQGHF-PYTFGGQTRLEIK 112
Dy 81 SGVDPDRFSGSGGTDFTLTKISRVEAEDGVVYVCWQGHFWPTFGGQTKVEIK 132

RESULT 5
Q6P491_HUMAN PRELIMINARY; PRT; 239 AA.
ID Q6P491_HUMAN
AC Q6P491;
DT 05-JUL-2004, integrated into UniProtKB/TrEMBL.
DT 05-JUL-2004, sequence version 1.
```

```

DT 07-FEB-2006, entry version 16.
DE Hypothetical protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Ustin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaby S.J.,
RA Boeak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J.J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smallus D.E.,
RA Schnerch A., Schein J.B., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences."
RN Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
RL [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Skin;
RA Strausberg R.;
RA Submitted (DEC-2003) to the EMBL/GenBank/DBJ databases.
CC -----
CC Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution-NoDerivs License
CC -----
DR EMBL; BC063599; AAH63599.1; -; mRNA.
DR HSPSP; P01837; 1KCU.
DR SMR; O6P491; 21-237.
DR InterPro; IPR003599; Ig-like.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig-cl.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR InterPro; IPR013106; V-set.
DR Pfam; PF07654; C1-set; 1.
DR SMART; SM00409; IG; 1.
DR SMART; SM00407; IGcl; 1.
DR SMART; SM00406; IGv; 1.
DR PROSITE; PS50835; IG_LIKE; 2.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_1.
KW Hypothetical protein_1.
SQ SEQUENCE 239 AA; 26246 MW; CD7313DDFFD358B3 CRC64;

Query Match 77.8%; Score 459; DB 2; Length 239;
Best Local Similarity 77.7%; Pred. No. 1.7e-39;
Matches 87; Conservative 11; Mismatches 14; Indels 0; Gaps 0;

QY 1 DVVMTQSPVLTQPGASISCKSSQSLDSDGKFTFLNWFQRPQGSPRLIYLVSKLD 60
DB 21 DIVMTQTPLSPTVLTQPGASISCKSSQSLDSDGKFTFLNWFQRPQGSPRLIYLVSKLD 80
QY 61 SGVPDRFSGSGSGTDFTLKISRVEAEDVGVYVYCWQGHFPTFGQGRLEIK 112
DB 81 SGVPDRFSGSGAGTDFTLKISRVEAEDVGVYVYCMQVSHFPTFGQGRVLEIK 132

RESULT 6
KV2D_HUMAN
```

```

ID KV2D_HUMAN STANDARD; PRT; 113 AA.
AC P01617;
DT 21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT 21-JUL-1986, sequence version 1.
DT 07-MAR-2006, entry version 45.
DE Ig kappa chain V-II region TEW.
DE Ig kappa chain V-II region TEW.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP PROTEIN SEQUENCE (BENCE-JONES PROTEIN TEW).
RX MEDLINE=74148490; PubMed=4596149;
RA Putnam F.W., Whitley E.J. Jr., Paul C., Davidson J.N.;
RT "Amino acid sequence of a kappa Bence Jones protein from a case of
RT primary amyloidosis."
RL Biochemistry 12:3763-3780 (1973).
RN [2]
RP PROTEIN SEQUENCE OF 1-27 (AMYLOID PROTEIN TEW).
RX MEDLINE=73186638; PubMed=4700495;
RA Terry W.D., Page D.L., Kimura S., Isobe T., Osserman E.F.,
RA Glenner G.G.;
RT "Structural identity of Bence Jones and amyloid fibril proteins in a
RT patient with plasma cell dyscrasia and amyloidosis."
RL J. Clin. Invest. 52:1276-1281 (1973).
CC -!- MISCELLANEOUS: The major amyloid protein appears to be identical
CC with the Bence Jones protein isolated from the same patient.
CC -!- MISCELLANEOUS: This protein was isolated from the urine of a
CC patient with plasma cell dyscrasia and amyloidosis.
CC -!- MISCELLANEOUS: The C region of this chain has the INV (1,2)
CC marker.
CC -----
CC Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution-NoDerivs License
CC -----
DR PIR; A90370; K2HUTW.
DR HSPSP; Q99M37; I191.
DR SMR; P01617; 1-111.
DR LinkHub; P01617; -.
DR GO; GO:0005576; C:extracellular region; NAS.
DR GO; GO:0003823; F:antigen binding; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR InterPro; IPR013106; V-set.
DR Pfam; PF07686; V-set; 1.
DR SMART; SM00409; IG; 1.
DR SMART; SM00406; IGv; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
KW Amyloid; Bence-Jones protein; Direct protein sequencing;
KW Immunoglobulin domain; Immunoglobulin V region.
FT FTid=PRO 0000059761.
FT CHAIN 1 >113
FT REGION 1 23 Complementarity-determining-1.
FT REGION 24 39 Complementarity-determining-1.
FT REGION 40 54 Framework-2.
FT REGION 55 61 Complementarity-determining-2.
FT REGION 62 93 Complementarity-determining-3.
FT REGION 94 102 Complementarity-determining-3.
FT REGION 103 112 Framework-4.
FT DISULFID 23 93 By similarity.
FT NON TER 113 113
SQ SEQUENCE 113 AA; 12316 MW; 0C3C38F81F1843CA CRC64;

Query Match 76.3%; Score 450; DB 1; Length 113;
Best Local Similarity 77.7%; Pred. No. 6.5e-39;
Matches 87; Conservative 8; Mismatches 17; Indels 0; Gaps 0;

QY 1 DVVMTQSPVLTQPGASISCKSSQSLDSDGKFTFLNWFQRPQGSPRLIYLVSKLD 60
DB 1 DIVMTQSPVLTQPGASISCKSSQSLDSDGKFTFLNWFQRPQGSPRLIYLVSKLD 60
```



```
DR PIR; S40357; S40357.
DR HSSP; P01834; 117Z.
DR SMR; Q8NEK0; 21-237.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig cl.
DR InterPro; IPR003006; Ig MHC.
DR InterPro; IPR003596; Ig v.
DR InterPro; IPR013106; V-set.
DR Pfam; PF07654; Cl-set; 1.
DR SMART; SM00409; IG; 1.
DR SMART; SM00407; IGcl; 1.
DR SMART; SM00406; IGv; 1.
DR PROSITE; PS50835; IG LIKE; 2.
DR PROSITE; PS00290; IG_MHC; UNKNOWN 1.
SQ SEQUENCE 239 AA; 26024 MW; F5E20AD3B0552C0A CRC64;

Query Match
Best Local Similarity 75.8%; Score 447; DB 2; Length 239;
Matches 85; Conservative 12; Mismatches 15; Indels 0; Gaps 0;

QY 1 DVVMTQSPFLSPVTLGQPASISCKSSQSLDSDGKTFLNWFQRPQSPRRLLIYLVSKLD 60
Db 21 DIVMTQSPFLSPVTPGEPASISCKSSQSLDSDGNYLDWYLRKPGQSPQLLIYLVGSNRA 80
QY 61 SGVPDRFSGSGGTDFTLKISRVEADGVVYVYCWQTHFPYTFGQGTLEIK 112
Db 81 SGVPDRFSGSGGTDFTLKISRVEADGVVYVYCWQTHFPYTFGQGTLEIK 132

RESULT 9
Q65ZQ7_9MURI PRELIMINARY; PRT; 248 AA.
ID Q65ZQ7_9MURI
AC Q65ZQ7;
DT 11-OCT-2004, integrated into UniProtKB/TrEMBL.
DT 11-OCT-2004, sequence version 1.
DT 07-FEB-2006, entry version 10.
DE B3(Fv)-PE40 (Fragment).
GN Name=B3(Fv)-PE40;
OS Mus sp.
OC Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muroidae; Muridae; Murinae; Mus.
OX NCBI_TaxID=10095;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=92020904; PubMed=1924323;
RA Brinkmann U., Pai L.H., FitzGerald D.J., Willingham M., Pastan I.;
RT "B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete
RT regression of a human carcinoma in mice."
RL Proc. Natl. Acad. Sci. U.S.A. 88:8616-8620(1991).
CC -----
CC Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution-NoDerivs License
CC -----
DR EMBL; S57990; AAB19971.2; -; mRNA.
DR SMR; Q65ZQ7; 4-247.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig v.
DR InterPro; IPR013106; V-set.
DR SMART; SM00409; IG; 2.
DR SMART; SM00406; IGv; 2.
DR PROSITE; PS50835; IG LIKE; 2.
DR KW Immunoglobulin domain.
FT NON TER 248
SQ SEQUENCE 248 AA; 26634 MW; 7A3759B43E570950 CRC64;

Query Match
Best Local Similarity 75.4%; Score 445; DB 2; Length 248;
Matches 83; Conservative 15; Mismatches 14; Indels 0; Gaps 0;

QY 1 DVVMTQSPFLSPVTLGQPASISCKSSQSLDSDGKTFLNWFQRPQSPRRLLIYLVSKLD 60

PIR; B91639; K2HUUC.
DR HSSP; P01751; INQB.
DR SMR; P01614; 2-115.
DR LinkHub; P01614; -.
DR GO; GO:0005576; C:extracellular region; NAS.
DR GO; GO:0003823; F:antigen binding; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig v.
DR InterPro; IPR013106; V-set.
DR Pfam; PF07686; V-set; 1.
DR SMART; SM00409; IG; 1.
DR PROSITE; PS50835; IG LIKE; 1.
DR Bence-Jones protein; Direct protein sequencing; Immunoglobulin domain;
KW Immunoglobulin V region.
FT CHAIN 1 >115
FT DISULFID 24 95
FT NON TER 115 115
FT By similarity.
SQ SEQUENCE 115 AA; 12676 MW; 59E9F90A379569EC CRC64;

Query Match
Best Local Similarity 75.3%; Score 444.5; DB 1; Length 115;
Matches 86; Conservative 12; Mismatches 14; Indels 1; Gaps 1;

QY 1 DVVMTQSPFLSPVTLGQPASISCKSSQSLDSDGKTFLNWFQRPQSPRRLLIYLVSKL 59
Db 2 DIVMTQSPFLSPVTPGEPASISCKSSQSLDSDGNYLDWYLRKPGQSPQLLIYLVSYR 61
QY 60 DSGVPDRFSGSGGTDFTLKISRVEADGVVYVYCWQTHFPYTFGQGTLEIK 112
```

Db 62 ASGVDRFSGSGGTDFTLKISRVAEDVGVYCMQRLIEIPYTFGGQTKLEIR 114

RESULT 11

KV2E HUMAN

ID_KV2E_HUMAN STANDARD; PRT; 117 AA.

AC P06309;

DT 01-JAN-1988, integrated into UniProtKB/Swiss-Prot.

DT 01-JAN-1988, sequence version 1.

DT 07-MAR-2006, entry version 43.

DE Ig kappa chain V-II region GM607 precursor (Fragment).

OS Homo sapiens (Human).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;

OC Homo.

OX NCBI_TaxID=9606;

RN [1]

RP NUCLEOTIDE SEQUENCE (GENOMIC DNA).

RX MEDLINE=84191506; PubMed=6325927;

RA Klobbeck H.G., Solomon A., Zachau H.G.;

RT "Contribution of human V kappa II germ-line genes to light-chain diversity.";

RL Nature 309:73-76(1984).

CC -----

CC Copyrighted by the UniProt Consortium, see <http://www.uniprot.org/terms>

CC Distributed under the Creative Commons Attribution-NoDerivs License

CC -----

DR EMBL: Z00009; -; NOT_ANNOTATED_CDS; Genomic_DNA.

DR PIR: A01889; K2HUGM.

DR HSPF: Q99M37; I191.

DR SMR: P06309; 5-115.

DR LinkHub: P06309; -.

DR GO: GO:0005576; C:extracellular region; NAS.

DR GO: GO:0003823; F:antigen binding; NAS.

DR GO: GO:0006955; P:immune response; NAS.

DR InterPro: IPR003599; Ig.

DR InterPro: IPR007110; Ig-like.

DR InterPro: IPR003596; Ig V.

DR Pfam: PF07686; V-set; 1.

DR SMART: SM00409; IG; 1.

DR PROSITE: PS50835; IG_LIKE; 1.

DR InterPro: IPR003596; Ig V.

DR InterPro: IPR013106; V-set.

DR Pfam: PF07686; V-set; 1.

DR SMART: SM00409; IG; 1.

DR PROSITE: PS50835; IG_LIKE; 1.

DR Immunoglobulin domain; Immunoglobulin V region; Signal.

FT SIGNAL <1 4

FT CHAIN 5 117 Ig kappa chain V-II region GM607.

FT REGION 5 27 Framework-1.

FT REGION 28 43 Framework-2.

FT REGION 44 58 Framework-3.

FT REGION 59 65 Complementarity-determining-1.

FT REGION 66 97 Complementarity-determining-2.

FT REGION 98 106 Complementarity-determining-3.

FT REGION 107 116 Complementarity-determining-4.

FT DISULFID 27 97 By similarity.

FT NON TER 1 1

FT NON TER 117 117

SQ SEQUENCE 117 AA; 12664 MW; 92C57DC719E558B1 CRC64;

Query Match 74.2%; Score 438; DB 1; Length 117;

Best Local Similarity 75.9%; Pred. No. 1.2e-37;

Matches 85; Conservative 11; Mismatches 16; Indels 0; Gaps 0;

Qy 1 DVVMTQSLPLSVTLGQPASISCKSSQSLSDSGKTFLNWFQORPGOSPRRLIYLVSKLD 60

Db 5 DIVMTQSLPLSVTPGSPASISCKSSQSLHSNGYLDWYLPKQPQSPQLLIYLVGNRA 64

Qy 61 SGVDRFSGSGGTDFTLKISRVAEDVGVYCMQRLIEIPYTFGGQTKLEIR 112

Db 65 SGVDRFSGSGGTDFTLKISRVAEDVGVYCMQRLIEIPYTFGGQTKLEIR 116

RESULT 12

QSF210_MOUSE

ID_QSF210_MOUSE PRELIMINARY; PRT; 115 AA.

AC QSF210;

DT 15-MAR-2005, integrated into UniProtKB/TrEMBL.

DT 15-MAR-2005, sequence version 1.

DT 07-FEB-2006, entry version 6.

DE Kappa light chain variable region (Fragment).

GN Name=IgG1 anti-TS1 VL;

OS Mus musculus (Mouse).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;

OC Muridea; Muridae; Murinae; Mus.

OX NCBI_TaxID=10090;

RN [1]

RP NUCLEOTIDE SEQUENCE.

RX MEDLINE=22716456; PubMed=12833571; DOI=10.1002/jmr.617;

RA Erlandsson A., Holm P., Ullen A., Stigbrand T., Sundstrom B.E.;

RT "Studies of the interactions between the anticytokeratin 8 monoclonal antibody TS1, its antigen and its anti-idiotypic antibody alphaTS1.";

RL J. Mol. Recognit. 16:157-163(2003).

RN [2]

RP NUCLEOTIDE SEQUENCE.

RX Erlandsson A.;

RL Submitted (FEB-2005) to the EMBL/GenBank/DBJ databases.

CC -----

CC Copyrighted by the UniProt Consortium, see <http://www.uniprot.org/terms>

CC Distributed under the Creative Commons Attribution-NoDerivs License

CC -----

DR EMBL: AJ884575; CAI56337.1; -; mRNA.

DR InterPro: IPR003599; Ig.

DR InterPro: IPR007110; Ig-like.

DR InterPro: IPR003596; Ig V.

DR InterPro: IPR013106; V-set.

DR SMART: SM00409; IG; 1.

DR SMART: SM00406; IG; 1.

DR PROSITE: PS50835; IG_LIKE; 1.

DR Immunoglobulin domain.

FT NON TER 1 1

FT NON TER 115 115

SQ SEQUENCE 115 AA; 12560 MW; E4D3BF3D63E88007 CRC64;

Query Match 73.0%; Score 430.5; DB 2; Length 115;

Best Local Similarity 74.3%; Pred. No. 7.3e-37;

Matches 84; Conservative 14; Mismatches 14; Indels 1; Gaps 1;

Qy 1 DVVMTQSLPLSVTLGQPASISCKSSQSLSDSGKTFLNWFQORPGOSPRRLIYLVSKLD 60

Db 1 DVVMTQSLPLSVTLGQPASISCKSSQSLVHSNGTYLHWYLPKQPQSPQLLIYKVSNRF 60

Qy 61 SGVDRFSGSGGTDFTLKISRVAEDVGVYCMQRLIEIPYTFGGQTKLEIR 112

Db 61 SGVDRFSGSGGTDFTLKISRVAEDVGVYCMQRLIEIPYTFGGQTKLEIR 113

RESULT 13

KV2G_MOUSE

ID_KV2G_MOUSE STANDARD; PRT; 113 AA.

AC P01631;

DT 21-JUL-1986, integrated into UniProtKB/Swiss-Prot.

DT 21-JUL-1986, sequence version 1.

DT 07-MAR-2006, entry version 39.

DE Ig kappa chain V-II region 26-10.

OS Mus musculus (Mouse).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;

OC Muridea; Muridae; Murinae; Mus.

OX NCBI_TaxID=10090;

RN [1]

RP PROTEIN SEQUENCE.

RX STRAIN=A/J;

RX MEDLINE=83178921; PubMed=6404298;

RA Novotny J., Margolies M.N.;

RT "Amino acid sequence of the light chain variable region from a mouse

```
RT anti-digoxin hybridoma antibody." ;
RL Biochemistry 22:1153-1158(1993).
CC -1- MISCELLANEOUS: This chain was isolated from an IgG2a hybridoma
CC protein that binds digoxin.
-----
CC Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution-NoDerivs License
-----
CC PIR; A01914; KWS26.
DR HSP; Q99M37; I191.
DR Ensembl; ENSMUSG00000055315; Mus musculus.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR InterPro; IPR013106; V-set.
DR Pfam; PF07686; V-set; 1.
DR SMART; SM00409; IG; 1.
DR SMART; SM00406; IGv; 1.
DR PROSITE; PS00835; IG LIKE; 1.
KW Direct protein sequencing; Hybridoma; Immunoglobulin domain;
KW Immunoglobulin V region; Monoclonal antibody.
FT CHAIN 1 >113
FT /Fid=PRO 0000059776.
FT REGION 1 23
FT REGION 24 39
FT REGION 40 54
FT REGION 55 61
FT REGION 62 93
FT REGION 94 102
FT REGION 103 112
FT DISULFID 23 93
FT NON_TER 113 113
FT SEQUENCE 113 AA; 12273 MW; F9F39CE949A84C2A CRC64;

Query Match 72.9%; Score 430; DB 1; Length 113;
Best Local Similarity 74.1%; Pred. No. 8.1e-37;
Matches 83; Conservative 13; Mismatches 16; Indels 0; Gaps 0;

QY 1 DVVMTQSPVLSPLVTLGQPASISCKSSQLSDSGKTFLNWFQQRPGQSPRLIYLVSCLD 60
DB 1 DVVMTQTPVLSPLVSLGDPQASISCRSSQSLVHSNGNTYLNWYLOKAGQSPKLLIYKVS 60
QY 61 SGVPDRFSGSGGTDFTLKISRVEAEDGVVYVYCWQGTTHPTFGQGRLEIK 112
DB 61 SGVPDRFSGSGGTDFTLKISRVEAEDGLIYFCSTHTVPTFGGGRLEIK 112

RESULT 14
Q53VP8_MOUSE PRELIMINARY; PRT; 112 AA.
AC Q53VP8_MOUSE
DT 24-MAY-2005, integrated into UniProtKB/TrEMBL.
DT 24-MAY-2005, sequence version 1.
DT 07-FEB-2006, entry version 4.
DE Kappa chain (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muroidae; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX STRAIN=Balb/c; TISSUE=Spleen;
RX MEDLINE=96319505; PubMed=8768802;
RA Kipp B., Schlaak M., Becker W.M.;
RT "Cloning and expression of a recombinant mouse Fab-fragment
RT recognizing a defined linear epitope of Chironomus thummi major
RT allergen Chi t 1." ;
RL Int. Arch. Allergy Immunol. 110:348-353(1996).
CC Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution-NoDerivs License
-----
Q53VP8_MOUSE PRELIMINARY; PRT; 112 AA.
AC Q53VP8_MOUSE
DT 24-MAY-2005, integrated into UniProtKB/TrEMBL.
DT 24-MAY-2005, sequence version 1.
DT 07-FEB-2006, entry version 4.
DE Kappa chain (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muroidae; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=86136012; PubMed=3937730;
RA Ollier P., Rocca-Serra J., Somme G., Theze J., Fougereau M.;
RT "The idiotypic network and the internal image: possible regulation of
RT a germ-line network by paucigenic encoded Ab2 (anti-idiotypic)
RT antibodies in the GAT system." ;
RL EMBO J. 4:3681-3688(1985).
RN [2]
RP NUCLEOTIDE SEQUENCE OF 108-109.
RA Fougereau M.;
RL Submitted (NOV-1986) to the EMBL/GenBank/DBJ databases.
-----
CC
```

```
CC Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution-NoDerivs License
-----
CC EMBL; X03386; CAA27113.1; -; mRNA.
DR SMR; Q53VP8; 1-112.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00409; IG; 1.
DR SMART; SM00406; IGv; 1.
DR PROSITE; PS00835; IG LIKE; 1.
KW Immunoglobulin domain.
FT NON_TER 1 1
FT NON_TER 112 112
FT SEQUENCE 112 AA; 12270 MW; C844B7881A89C18A CRC64;

Query Match 72.5%; Score 428; DB 2; Length 112;
Best Local Similarity 72.3%; Pred. No. 1.3e-36;
Matches 81; Conservative 14; Mismatches 17; Indels 0; Gaps 0;

QY 1 DVVMTQSPVLSPLVTLGQPASISCKSSQLSDSGKTFLNWFQQRPGQSPRLIYLVSCLD 60
DB 1 DVVMTQTPVLSPLVSLGDPQASISCRSSQSLVHSNGNTYLNWYLOKAGQSPKLLIYKVS 60
QY 61 SGVPDRFSGSGGTDFTLKISRVEAEDGVVYVYCWQGTTHPTFGQGRLEIK 112
DB 61 SGVPDRFSGSGGTDFTLKISRVEAEDGLIYFCSTHTVPTFGGGRLEIK 112

RESULT 15
Q65ZC0_MOUSE PRELIMINARY; PRT; 219 AA.
AC Q65ZC0_MOUSE
DT 11-OCT-2004, integrated into UniProtKB/TrEMBL.
DT 11-OCT-2004, sequence version 1.
DT 07-FEB-2006, entry version 12.
DE Kappa light chain C_region (Fragment).
GN Name=Igk-C;
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muroidae; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX STRAIN=Balb/c; TISSUE=Spleen;
RX MEDLINE=96319505; PubMed=8768802;
RA Kipp B., Schlaak M., Becker W.M.;
RT "Cloning and expression of a recombinant mouse Fab-fragment
RT recognizing a defined linear epitope of Chironomus thummi major
RT allergen Chi t 1." ;
RL Int. Arch. Allergy Immunol. 110:348-353(1996).
CC Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution-NoDerivs License
-----
EMBL; Z37499; CAA85724.1; -; mRNA.
DR MGI; MGI:96495; Igk-C.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig.cl.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_v.
DR InterPro; IPR013106; V-set.
DR Pfam; PF07654; C1-set; 1.
DR SMART; SM00409; IG; 1.
DR SMART; SM00407; IGc1; 1.
DR SMART; SM00406; IGv; 1.
DR PROSITE; PS00835; IG LIKE; 2.
DR PROSITE; PS00290; IG_MHC; 1.
KW Immunoglobulin domain; Repeat.
FT NON_TER 1 1
FT NON_TER 219 219
```


THIS PAGE BLANK (USPTO)

GenCore version 5.1.9
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: June 10, 2006, 12:31:52 ; Search time 63.5676 Seconds
(without alignments)
816.140 Million cell updates/sec

Title: US-10-733-563-12

Perfect score: 590

Sequence: 1 DVVMTQSPSLPVTLGQPAS.....CWQGHFPYTFGGQTRLEIK 112

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2097797 seqs, 463214858 residues

Total number of hits satisfying chosen parameters: 2097797

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications AA Main.*

1: /EMC_Cellerai_SIDS3/ptodata/2/pubpaa/US07_PUBCOMB.pep.*
2: /EMC_Cellerai_SIDS3/ptodata/2/pubpaa/US08_PUBCOMB.pep.*
3: /EMC_Cellerai_SIDS3/ptodata/2/pubpaa/US09_PUBCOMB.pep.*
4: /EMC_Cellerai_SIDS3/ptodata/2/pubpaa/US10A_PUBCOMB.pep.*
5: /EMC_Cellerai_SIDS3/ptodata/2/pubpaa/US10B_PUBCOMB.pep.*
6: /EMC_Cellerai_SIDS3/ptodata/2/pubpaa/US11_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	590	100.0	112	3	US-09-835-087-3 ; Sequence 3, Appli
2	590	100.0	112	3	US-09-809-739-14 ; Sequence 14, Appl
3	590	100.0	112	3	US-09-840-459-14 ; Sequence 12, Appl
4	590	100.0	112	4	US-10-766-773-12 ; Sequence 12, Appl
5	590	100.0	112	4	US-10-766-610-12 ; Sequence 12, Appl
6	590	100.0	112	4	US-10-733-563-12 ; Sequence 12, Appl
7	590	100.0	112	5	US-10-662-061-14 ; Sequence 14, Appl
8	590	100.0	112	6	US-11-075-184A-3 ; Sequence 3, Appli
9	584	99.0	114	4	US-09-840-459-106 ; Sequence 106, App
10	584	99.0	114	4	US-10-766-773-106 ; Sequence 106, App
11	584	99.0	114	4	US-10-766-610-106 ; Sequence 106, App
12	584	99.0	114	4	US-10-733-563-106 ; Sequence 106, App
13	577	97.8	112	3	US-09-835-087-4 ; Sequence 4, Appli
14	577	97.8	112	3	US-09-809-739-15 ; Sequence 15, Appl
15	577	97.8	112	3	US-09-840-459-13 ; Sequence 13, Appl
16	577	97.8	112	4	US-10-766-773-13 ; Sequence 13, Appl
17	577	97.8	112	4	US-10-766-610-13 ; Sequence 13, Appl
18	577	97.8	112	4	US-10-733-563-13 ; Sequence 13, Appl
19	577	97.8	112	5	US-10-662-061-15 ; Sequence 15, Appl
20	577	97.8	112	6	US-11-075-184A-4 ; Sequence 4, Appli
21	572	96.9	112	3	US-09-835-087-7 ; Sequence 7, Appli
22	572	96.9	112	3	US-09-809-739-18 ; Sequence 18, Appl
23	572	96.9	112	3	US-09-840-459-107 ; Sequence 107, App
24	572	96.9	112	4	US-10-766-610-107 ; Sequence 107, App
25	572	96.9	112	4	US-10-733-563-107 ; Sequence 107, App
26	572	96.9	112	5	US-10-662-061-18 ; Sequence 18, Appl
27	572	96.9	112	6	US-11-075-184A-7 ; Sequence 7, Appli

28 570 96.6 112 3 US-09-835-087-5 Sequence 5, Appli
29 570 96.6 112 3 US-09-809-739-16 Sequence 16, Appl
30 570 96.6 112 3 US-09-840-459-14 Sequence 14, Appl
31 570 96.6 112 4 US-10-766-773-14 Sequence 14, Appl
32 570 96.6 112 4 US-10-766-610-14 Sequence 14, Appl
33 570 96.6 112 4 US-10-733-563-14 Sequence 14, Appl
34 570 96.6 112 5 US-10-662-061-16 Sequence 16, Appl
35 570 96.6 112 6 US-11-075-184A-5 Sequence 5, Appli
36 565 95.8 112 3 US-09-835-087-6 Sequence 6, Appli
37 565 95.8 112 3 US-09-809-739-17 Sequence 17, Appl
38 565 95.8 112 3 US-09-840-459-15 Sequence 15, Appl
39 565 95.8 112 4 US-10-766-773-15 Sequence 15, Appl
40 565 95.8 112 4 US-10-766-610-15 Sequence 15, Appl
41 565 95.8 112 4 US-10-733-563-15 Sequence 15, Appl
42 565 95.8 112 5 US-10-662-061-17 Sequence 17, Appl
43 565 95.8 112 6 US-11-075-184A-6 Sequence 6, Appli
44 559 94.7 113 5 US-10-476-265-9 Sequence 9, Appli
45 559 94.7 219 5 US-10-476-265-11 Sequence 11, Appl

ALIGNMENTS

RESULT 1

US-09-835-087-3
; Sequence 3, Application US/09835087
; Patent No. US20020042370A1
; GENERAL INFORMATION:
; APPLICANT: Wayne W. Hancock
; TITLE OF INVENTION: Method of Treating Graft Rejection Using
; TITLE OF INVENTION: Inhibitors of CCR2 Function
; FILE REFERENCE: 1855.2008-003
; CURRENT APPLICATION NUMBER: US/09/835,087
; CURRENT FILING DATE: 2001-09-24
; PRIOR APPLICATION NUMBER: 09/549,448
; PRIOR FILING DATE: 2000-04-14
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Humanized sequence
US-09-835-087-3

Query Match 100.0%; Score 590; DB 3; Length 112;
Best Local Similarity 100.0%; Pred. No. 3.1e-47;
Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 DVVMTQSPSLPVTLGQPASISCKSSQSLDSDGKTFLNWFQORPGQSPRLIYLVSKLD 60
Db 1 DVVMTQSPSLPVTLGQPASISCKSSQSLDSDGKTFLNWFQORPGQSPRLIYLVSKLD 60
Qy 61 SGVDFRFGSGSGTDTFTLKISRVEAEDVGVYVCQGHFPYTFGGQTRLEIK 112
Db 61 SGVDFRFGSGSGTDTFTLKISRVEAEDVGVYVCQGHFPYTFGGQTRLEIK 112

RESULT 2

US-09-809-739-14
; Sequence 14, Application US/09809739
; Patent No. US20020106369A1
; GENERAL INFORMATION:
; APPLICANT: Horvath, Christopher J.
; APPLICANT: Rao, Patricia E.
; TITLE OF INVENTION: Method of Inhibiting Stenosis and
; TITLE OF INVENTION: Restenosis
; FILE REFERENCE: 1855.1069-003
; CURRENT APPLICATION NUMBER: US/09/809,739
; CURRENT FILING DATE: 2001-03-15
; PRIOR APPLICATION NUMBER: US 09/528,267
; PRIOR FILING DATE: 2000-03-17

```
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 14
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Humanized sequence
US-09-809-739-14

Query Match      100.0%; Score 590; DB 3; Length 112;
Best Local Similarity 100.0%; Pred. No. 3.1e-47;
Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 DVVMTOSPLSLPVTLGOPASISCKSSQSLDSDGKTFLNWFQORPGQSPRRLLIYLSKLD 60
Db 1 DVVMTOSPLSLPVTLGOPASISCKSSQSLDSDGKTFLNWFQORPGQSPRRLLIYLSKLD 60

QY 61 SGVPDRFSGSGGTDFTLKISRVEAEDVGYYCQGTTHFFYTFGQGTTRLEIK 112
Db 61 SGVPDRFSGSGGTDFTLKISRVEAEDVGYYCQGTTHFFYTFGQGTTRLEIK 112

RESULT 3
US-09-840-459-12
; Sequence 12, Application US/09840459
; Patent No. US20020150576A1
; GENERAL INFORMATION:
; APPLICANT: Larosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; FILE REFERENCE: 1855.1052-012
; CURRENT APPLICATION NUMBER: US/09/840,459
; PRIOR FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: PCT/US01/03537
; PRIOR FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: 09/497,625
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 107
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 12
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Humanized sequence
US-09-840-459-12

Query Match      100.0%; Score 590; DB 3; Length 112;
Best Local Similarity 100.0%; Pred. No. 3.1e-47;
Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 DVVMTOSPLSLPVTLGOPASISCKSSQSLDSDGKTFLNWFQORPGQSPRRLLIYLSKLD 60
Db 1 DVVMTOSPLSLPVTLGOPASISCKSSQSLDSDGKTFLNWFQORPGQSPRRLLIYLSKLD 60

QY 61 SGVPDRFSGSGGTDFTLKISRVEAEDVGYYCQGTTHFFYTFGQGTTRLEIK 112
Db 61 SGVPDRFSGSGGTDFTLKISRVEAEDVGYYCQGTTHFFYTFGQGTTRLEIK 112

RESULT 4
US-10-766-773-12
; Sequence 12, Application US/10766773
```

```
; Publication No. US20040126851A1
; GENERAL INFORMATION:
; APPLICANT: Larosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; FILE REFERENCE: 1855.1052-028
; CURRENT APPLICATION NUMBER: US/10/766,773
; CURRENT FILING DATE: 2004-01-27
; PRIOR APPLICATION NUMBER: 09/497,625
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 106
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 12
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Humanized sequence
US-10-766-773-12

Query Match      100.0%; Score 590; DB 4; Length 112;
Best Local Similarity 100.0%; Pred. No. 3.1e-47;
Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 DVVMTOSPLSLPVTLGOPASISCKSSQSLDSDGKTFLNWFQORPGQSPRRLLIYLSKLD 60
Db 1 DVVMTOSPLSLPVTLGOPASISCKSSQSLDSDGKTFLNWFQORPGQSPRRLLIYLSKLD 60

QY 61 SGVPDRFSGSGGTDFTLKISRVEAEDVGYYCQGTTHFFYTFGQGTTRLEIK 112
Db 61 SGVPDRFSGSGGTDFTLKISRVEAEDVGYYCQGTTHFFYTFGQGTTRLEIK 112

RESULT 5
US-10-766-610-12
; Sequence 12, Application US/10766610
; Publication No. US20040132980A1
; GENERAL INFORMATION:
; APPLICANT: Larosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; FILE REFERENCE: 1855.1052-029
; CURRENT APPLICATION NUMBER: US/10/766,610
; CURRENT FILING DATE: 2004-01-27
; PRIOR APPLICATION NUMBER: 09/840,459
; PRIOR FILING DATE: 2001-04-23
; PRIOR APPLICATION NUMBER: PCT/US01/03537
; PRIOR FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: 09/497,625
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 107
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 12
; LENGTH: 112
; TYPE: PRT
```

; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Humanized sequence
 US-10-766-610-12

```
Query Match      100.0%; Score 590; DB 4; Length 112;
Best Local Similarity 100.0%; Pred. No. 3.1e-47;
Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

Qy	1	DVVMQTQSPUSLPVTLGQPASISCKSSOSLSDSGKTFLANWFQORQGSPPRLIYLVL
Db	1	DVVMQTQSPUSLPVTLGQPASISCKSSOSLSDSGKTFLANWFQORQGSPPRLIYLVL
Qy	61	SGVPRPFGSGSGTDFTLKISRVAEDVGVYVQWGTHPPTFGGQTRLEIK 112
Db	61	SGVPRPFGSGSGTDFTLKISRVAEDVGVYVQWGTHPPTFGGQTRLEIK 112

Query Match	100.0%	Score 590;	DB 4;	Length 112;
Best Local Similarity	100.0%;	Pred. No. 3.1e-47;		
Matches 112;	Conservative	0;	Mismatches 0;	Indels 0;
Gaps	0;			

Qy 61 SGVDRFSGSGSTDTFTLKISRVEAEDGYYCQGTHFPYTFGGTRLEIK 112
|||
Db 61 SGVDRFSGSGSTDTFTLKISRVEAEDGYYCQGTHFPYTFGGTRLEIK 112

```

; PRIOR APPLICATION NUMBER: US 09/528,267
; PRIOR FILING DATE: 2000-03-17
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 14
; LENGTH: 112

```

```
Query Match      100.0%; Score 590; DB 5; Length 112;
Best Local Similarity 100.0%; Pred. No. 3.1e-47;
Matches 112: Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

Qy 61 SGVPRFSGSGTDFTLKISRVEADVGWYWCQTHFPYTFGQTRLEIK 112

Query Match	100.0%;	Score 590;	DB 6;	Length 112;
Best Local Similarity	100.0%;	pred. No. 3.1e-47;		
Matches 112: Conservative	0;	Mismatches 0;	Indels 0;	Gaps 0;

Qy 61 SGVPDRFGSGSGTDFTLKISRVEADGVVYCWQTHFPYTFGQTRLEIK 112
|||||

Dh 61 SGVPDRFGSGSGTDFTLKISRVEADGVVYCWQTHFPYTFGQTRLEIK 112
|||||

; PRIOR FILING DATE: 2002-06-26
; PRIOR APPLICATION NUMBER: US 60/350,166
; PRIOR FILING DATE: 2001-10-19
; NUMBER OF SEQ ID NOS: 122
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 114
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: humanized light chain
US-10-733-563-106

Query Match 99.0%; Score 584; DB 4; Length 114;
Best Local Similarity 100.0%; Pred. No. 1.le-46;
Matches 111; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 VVMTQSPSLPVTLGQPASISCKSSQLSDSGKTFLNWFQORPGQSPRRLIYLVSKLDS 61
Db 2 VVMTQSPSLPVTLGQPASISCKSSQLSDSGKTFLNWFQORPGQSPRRLIYLVSKLDS 61

Qy 62 GVPDRFSGSGGTDFTLKISRVEAEDGVVYCWQGTFFPYTFGQGTREIK 112
Db 62 GVPDRFSGSGGTDFTLKISRVEAEDGVVYCWQGTFFPYTFGQGTREIK 112

RESULT 13
US-09-835-087-4
; Sequence 4, Application US/09835087
; Patent No. US2002042370A1
; GENERAL INFORMATION:
; APPLICANT: Wayne W. Hancock
; TITLE OF INVENTION: Method of Treating Graft Rejection Using
; TITLE OF INVENTION: Inhibitors of CCR2 Function
; FILE REFERENCE: 1855.2008-003
; CURRENT APPLICATION NUMBER: US/09/835.087
; CURRENT FILING DATE: 2001-09-24
; PRIOR APPLICATION NUMBER: 09/549,448
; PRIOR FILING DATE: 2000-04-14
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Humanized sequence
US-09-835-087-4

Query Match 97.8%; Score 577; DB 3; Length 112;
Best Local Similarity 98.2%; Pred. No. 5e-46;
Matches 110; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 DVVMTQSPSLPVTLGQPASISCKSSQLSDSGKTFLNWFQORPGQSPRRLIYLVSKLD 60
Db 1 DVVMTQSPSLPVTLGQPASISCKSSQLSDSGKTFLNWLLQRPQSPRRLIYLVSKLD 60

Qy 61 SGVPDRFSGSGGTDFTLKISRVEAEDGVVYCWQGTFFPYTFGQGTREIK 112
Db 61 SGVPDRFSGSGGTDFTLKISRVEAEDGVVYCWQGTFFPYTFGQGTREIK 112

RESULT 14
US-09-809-739-15
; Sequence 15, Application US/09809739
; Patent No. US20020106369A1
; GENERAL INFORMATION:
; APPLICANT: Horvath, Christopher J.
; APPLICANT: Rao, Patricia E.
; TITLE OF INVENTION: Method of Inhibiting Stenosis and
; TITLE OF INVENTION: Restenosis
; FILE REFERENCE: 1855.1069-003
; CURRENT APPLICATION NUMBER: US/09/809,739

; CURRENT FILING DATE: 2001-03-15
; PRIOR APPLICATION NUMBER: US 09/528,267
; PRIOR FILING DATE: 2000-03-17
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 15
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Humanized sequence
US-09-809-739-15

Query Match 97.8%; Score 577; DB 3; Length 112;
Best Local Similarity 98.2%; Pred. No. 5e-46;
Matches 110; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 DVVMTQSPSLPVTLGQPASISCKSSQLSDSGKTFLNWFQORPGQSPRRLIYLVSKLD 60
Db 1 DVVMTQSPSLPVTLGQPASISCKSSQLSDSGKTFLNWLLQRPQSPRRLIYLVSKLD 60

Qy 61 SGVPDRFSGSGGTDFTLKISRVEAEDGVVYCWQGTFFPYTFGQGTREIK 112
Db 61 SGVPDRFSGSGGTDFTLKISRVEAEDGVVYCWQGTFFPYTFGQGTREIK 112

RESULT 15
US-09-840-459-13
; Sequence 13, Application US/09840459
; Patent No. US20020150576A1
; GENERAL INFORMATION:
; APPLICANT: LaRosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Sibhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; TITLE OF INVENTION: METHODS OF USE THEREFOR
; FILE REFERENCE: 1855.1052-012
; CURRENT APPLICATION NUMBER: US/09/840,459
; CURRENT FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: PCT/US01/03537
; PRIOR FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: 09/497,625
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 107
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 13
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Humanized sequence
US-09-840-459-13

Query Match 97.8%; Score 577; DB 3; Length 112;
Best Local Similarity 98.2%; Pred. No. 5e-46;
Matches 110; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 DVVMTQSPSLPVTLGQPASISCKSSQLSDSGKTFLNWFQORPGQSPRRLIYLVSKLD 60
Db 1 DVVMTQSPSLPVTLGQPASISCKSSQLSDSGKTFLNWLLQRPQSPRRLIYLVSKLD 60

Qy 61 SGVPDRFSGSGGTDFTLKISRVEAEDGVVYCWQGTFFPYTFGQGTREIK 112
Db 61 SGVPDRFSGSGGTDFTLKISRVEAEDGVVYCWQGTFFPYTFGQGTREIK 112

Search completed: June 10, 2006, 12:38:40
Job time : 64.5676 secs

GenCore version 5.1.9
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: June 10, 2006, 12:32:32 ; Search time 3.86787 Seconds
(without alignments)
366.103 Million cell updates/sec

Title: US-10-733-563-12
Perfect score: 590
Sequence: 1 DVWMTQSLSPVLTLGPAS.....CQWGHFFYPFGQTRLEIK 112

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 64916 seqs, 12643201 residues

Total number of hits satisfying chosen parameters: 64916

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published Applications AA_New:*
1: /EMC_Celerra_SIDS3/ptodata/1/pubpaa/US09_NEW_PUB.pep.*
2: /EMC_Celerra_SIDS3/ptodata/1/pubpaa/US06_NEW_PUB.pep.*
3: /EMC_Celerra_SIDS3/ptodata/1/pubpaa/US07_NEW_PUB.pep.*
4: /EMC_Celerra_SIDS3/ptodata/1/pubpaa/US08_NEW_PUB.pep.*
5: /EMC_Celerra_SIDS3/ptodata/1/pubpaa/PCT_NEW_PUB.pep.*
6: /EMC_Celerra_SIDS3/ptodata/1/pubpaa/US10_NEW_PUB.pep.*
7: /EMC_Celerra_SIDS3/ptodata/1/pubpaa/US11_NEW_PUB.pep.*
8: /EMC_Celerra_SIDS3/ptodata/1/pubpaa/US60_NEW_PUB.pep.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	522	88.5	112	7	US-11-239-308-12
2	511.5	86.7	113	7	US-11-239-308-2
3	511	86.6	113	6	US-10-506-063A-8
4	487	82.5	112	6	US-10-544-050-4
5	470	79.7	100	7	US-11-239-308-45
6	470	79.7	100	7	US-11-239-308-46
7	469	79.5	112	7	US-11-239-308-18
8	463	78.5	112	7	US-11-239-308-6
9	456.5	77.4	113	7	US-11-239-308-4
10	451	76.4	112	7	US-11-211-917-104
11	450	76.3	114	7	US-11-249-296-48
12	444	75.3	112	6	US-10-544-050-3
13	443	75.1	112	7	US-11-239-308-16
14	443	75.1	112	7	US-11-211-917-103
15	443	75.1	112	7	US-11-211-917-111
16	442.5	75.0	113	7	US-11-239-308-14
17	440	74.6	112	7	US-11-211-917-12
18	440	74.6	112	7	US-11-211-917-28
19	440	74.6	112	7	US-11-211-917-94
20	440	74.6	239	7	US-11-211-917-16
21	440	74.6	239	7	US-11-211-917-32
22	439	74.4	112	6	US-10-544-050-1
23	436	73.9	112	7	US-11-211-917-52
24	436	73.9	239	7	US-11-211-917-56
25	435	73.7	112	7	US-11-211-917-60

26	435	73.7	112	7	US-11-211-917-112
27	435	73.7	239	7	US-11-211-917-64
28	434	73.6	112	7	US-11-211-917-4
29	434	73.6	112	7	US-11-211-917-76
30	434	73.6	239	7	US-11-211-917-8
31	434	73.6	239	7	US-11-211-917-80
32	434	73.6	239	7	US-11-211-917-102
33	427	72.4	112	7	US-11-211-917-36
34	427	72.4	239	7	US-11-211-917-40
35	424	71.9	112	7	US-11-216-033-8
36	422	71.5	239	7	US-11-293-697-4028
37	417	70.7	100	7	US-11-239-308-50
38	415	70.3	100	7	US-11-239-308-47
39	415	70.3	148	1	US-09-784-950-36
40	409.5	69.4	113	7	US-11-254-679-54
41	399.5	67.7	101	7	US-11-239-308-44
42	397	67.3	148	1	US-09-784-950-24
43	396	67.1	100	7	US-11-239-308-48
44	391	66.3	100	7	US-11-239-308-49
45	376	63.7	143	1	US-09-784-950-32

ALIGNMENTS

RESULT 1
US-11-239-308-12
; Sequence 12, Application US/11239308
; Publication No. US2006008883A1
; GENERAL INFORMATION:
; APPLICANT: Smider, Vaughn
; APPLICANT: Larrick, James W.
; APPLICANT: Integrigen, Inc.
; TITLE OF INVENTION: Recombinant Catalytic Polypeptides and Their Uses
; FILE REFERENCE: 021216-000310US
; CURRENT APPLICATION NUMBER: US/11/239,308
; PRIOR FILING DATE: 2005-09-28
; PRIOR APPLICATION NUMBER: US/10/683,733
; PRIOR FILING DATE: 2003-10-09
; PRIOR APPLICATION NUMBER: US 60/417,979
; PRIOR FILING DATE: 2002-10-09
; NUMBER OF SEQ ID NOS: 62
; SOFTWARE: Patent In Ver. 2.1
; SEQ ID NO 12
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-239-308-12

Query Match	88.5%	Score 522;	DB 7;	Length 112;
Best Local Similarity	88.4%	Pred. No. 2.2e-43;		
Matches	99;	Conservative	7;	Mismatches 6;
				Indels 0;
				Gaps 0;
QY	1	DVWMTQSLSPVLTLGPASISCKSSQSLSDSGTFLNWFQORPGQSPRLIYLVSKLD	60	
DB	1	DVWMTQSLSPVLTLGPASISCKSSQSLSDSGTFLNWFQORPGQSPRLIYLVSKND	60	
QY	61	SGVPRDFSGSGSGTDTFLTKISRVEADYGVYCMQGTFFPVTFGQGTGLEIK	112	
DB	61	SGVPRDFSGSGSGTDTFLTKISRVEADYGVYCMQGTFFPVTFGQGTKEIK	112	

RESULT 2
US-11-239-308-2
; Sequence 2, Application US/11239308
; Publication No. US2006008883A1
; GENERAL INFORMATION:
; APPLICANT: Smider, Vaughn
; APPLICANT: Larrick, James W.
; APPLICANT: Integrigen, Inc.
; TITLE OF INVENTION: Recombinant Catalytic Polypeptides and Their Uses
; FILE REFERENCE: 021216-000310US
; CURRENT APPLICATION NUMBER: US/11/239,308

```
; CURRENT FILING DATE: 2005-09-28
; PRIOR APPLICATION NUMBER: US/10/683,733
; PRIOR FILING DATE: 2003-10-09
; PRIOR APPLICATION NUMBER: US 60/417,979
; PRIOR FILING DATE: 2002-10-09
; NUMBER OF SEQ ID NOS: 62
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 113
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-239-308-2

Query Match      86.7%; Score 511.5; DB 7; Length 113;
Best Local Similarity 87.6%; Pred. No. 2.2e-42;
Matches 99; Conservative 7; Mismatches 6; Indels 1; Gaps 1;

QY 1 DVVMTQSPVLTGLQPASISCKSSQSLDSDGKTFNLNWFQORPGQSPRLIYLVSCLD 60
DB 1 DVVMTQSPVLTGLQPASISCKSSQSLVSDGNTYLNWFQORPGQSPRLIYKVSNRD 60
QY 61 SGVPRFSGSGGTDFTLKISRVEAEDVGVYYCWMQGTHF-PYTFQGQTRLEIK 112
DB 61 SGVPRFSGSGGTDFTLKISRVEAEDVGVYYCWMQTHWPPWTFQGQTKVEIK 113

RESULT 3
US-10-506-063A-8
; Sequence 8, Application US/10506063A
; Publication No. US20060110771A1
; GENERAL INFORMATION:
; APPLICANT: KATAGIRI, Masanao
; APPLICANT: FUJIMOTO, Shigeru
; APPLICANT: GODA, Yasuhiro
; TITLE OF INVENTION: A protein binding to female hormones and a production thereof
; FILE REFERENCE: 2004-1363A/WMC/00279
; CURRENT APPLICATION NUMBER: US/10/506,063A
; CURRENT FILING DATE: 2004-08-31
; PRIOR APPLICATION NUMBER: JP 2002-055669
; PRIOR FILING DATE: 2002-03-01
; NUMBER OF SEQ ID NOS: 59
; SEQ ID NO 8
; LENGTH: 113
; TYPE: PRT
; ORGANISM: Mouse
US-10-506-063A-8

Query Match      86.6%; Score 511; DB 6; Length 113;
Best Local Similarity 84.8%; Pred. No. 2.5e-42;
Matches 95; Conservative 11; Mismatches 6; Indels 0; Gaps 0;

QY 1 DVVMTQSPVLTGLQPASISCKSSQSLDSDGKTFNLNWFQORPGQSPRLIYLVSCLD 60
DB 1 DVLMQTPLTSLVTGLQPASISCKSSQSLNSDGKTYLHLWLIQRPQSPKRLIYLVSCLD 60
QY 61 SGVPRFSGSGGTDFTLKISRVEAEDVGVYYCWMQGTHF-PYTFQGQTRLEIK 112
DB 61 SGVPRFSGSGGTDFTLKISRVEAEDVGVYYCWMQVTHFPLTFGAGTKLEIK 112

RESULT 4
US-10-544-050-4
; Sequence 4, Application US/10544050
; Publication No. US20060110388A1
; GENERAL INFORMATION:
; APPLICANT: Davies Julian
; TITLE OF INVENTION: Abeta Binding Molecules
; FILE REFERENCE: X-16068
; CURRENT APPLICATION NUMBER: US/10/544,050
; CURRENT FILING DATE: 2005-07-29
; PRIOR APPLICATION NUMBER: 60/446380
; PRIOR FILING DATE: 2003-02-10
; NUMBER OF SEQ ID NOS: 76
```

```
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: humanized heavy chain
US-10-544-050-4

Query Match      82.5%; Score 487; DB 6; Length 112;
Best Local Similarity 83.9%; Pred. No. 4.7e-40;
Matches 94; Conservative 7; Mismatches 11; Indels 0; Gaps 0;

QY 1 DVVMTQSPVLTGLQPASISCKSSQSLDSDGKTFNLNWFQORPGQSPRLIYLVSCLD 60
DB 1 DVVMTQSPVLTGLQPASISCKSSQSLIYSDGNAYLHWFQORPGQSPRLIYKVSNRD 60
QY 61 SGVPRFSGSGGTDFTLKISRVEAEDVGVYYCWMQGTHF-PYTFQGQTRLEIK 112
DB 61 SGVPRFSGSGGTDFTLKISRVEAEDVGVYYCSQSTHVPWTFGGTKVEIK 112

RESULT 5
US-11-239-308-45
; Sequence 45, Application US/11239308
; Publication No. US20060088883A1
; GENERAL INFORMATION:
; APPLICANT: Smider, Vaughn
; APPLICANT: Larrick, James W.
; APPLICANT: Integrigen, Inc.
; TITLE OF INVENTION: Recombinant Catalytic Polypeptides and Their Uses
; FILE REFERENCE: 021216-000310US
; CURRENT APPLICATION NUMBER: US/11/239,308
; CURRENT FILING DATE: 2005-09-28
; PRIOR APPLICATION NUMBER: US/10/683,733
; PRIOR FILING DATE: 2003-10-09
; PRIOR APPLICATION NUMBER: US 60/417,979
; PRIOR FILING DATE: 2002-10-09
; NUMBER OF SEQ ID NOS: 62
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 45
; LENGTH: 100
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-239-308-45

Query Match      79.7%; Score 470; DB 7; Length 100;
Best Local Similarity 90.0%; Pred. No. 1.7e-38;
Matches 90; Conservative 4; Mismatches 6; Indels 0; Gaps 0;

QY 1 DVVMTQSPVLTGLQPASISCKSSQSLDSDGKTFNLNWFQORPGQSPRLIYLVSCLD 60
DB 1 DVVMTQSPVLTGLQPASISCKSSQSLVSDGNTYLNWFQORPGQSPRLIYKVSNRD 60
QY 61 SGVPRFSGSGGTDFTLKISRVEAEDVGVYYCWMQGTHF 100
DB 61 SGVPRFSGSGGTDFTLKISRVEAEDVGVYYCWMQTHWP 100

RESULT 6
US-11-239-308-46
; Sequence 46, Application US/11239308
; Publication No. US20060088883A1
; GENERAL INFORMATION:
; APPLICANT: Smider, Vaughn
; APPLICANT: Larrick, James W.
; APPLICANT: Integrigen, Inc.
; TITLE OF INVENTION: Recombinant Catalytic Polypeptides and Their Uses
; FILE REFERENCE: 021216-000310US
; CURRENT APPLICATION NUMBER: US/11/239,308
; CURRENT FILING DATE: 2005-09-28
; PRIOR APPLICATION NUMBER: US/10/683,733
; PRIOR FILING DATE: 2003-10-09
```



```
; CURRENT APPLICATION NUMBER: US/11/211,917
; CURRENT FILING DATE: 2005-08-25
; PRIOR APPLICATION NUMBER: US/10/292,088
; PRIOR FILING DATE: 2002-11-08
; PRIOR APPLICATION NUMBER: 60/348,980
; PRIOR FILING DATE: 2001-11-09
; NUMBER OF SEQ ID NOS: 147
; SOFTWARE: Patent In Ver. 2.1
; SEQ ID NO 104
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-211-917-104

Query Match 76.4%; Score 451; DB 7; Length 112;
Best Local Similarity 77.7%; Pred. No. 1.2e-36;
Matches 87; Conservative 10; Mismatches 15; Indels 0; Gaps 0;

QY 1 DVVMTQSLPLSVTLTGQPASISCKSSQSLSDSGKTFELNWFQORPGQSPRLIYLVSKLD 60
Db 1 DIVMTQSLPLSVTLTGQPASISCKSSQSLHSNGYNDLWYLQKPGQSPQLLIYLGSNRA 60

QY 61 SGVPRFSGSGGTDFTLKISRVEAEDVGVVYCWGTHFPYTFGGGTRLEIK 112
Db 61 SGVPRFSGSGGTDFTLKISRVEAEDVGVVYCMQALQTPYTFGGGTRLEIK 112

RESULT 11
US-11-249-296-48
; Sequence 48, Application US/11249296
; Publication No. US20060115428A1
; GENERAL INFORMATION:
; APPLICANT: Schering Aktiengesellschaft
; TITLE OF INVENTION: Identification and Characterization of Function-Blocking
; FILE OF INVENTION: Anti-ED-B-Fibronectin Antibodies
; FILE REFERENCE: 33042P DE (WWHC)
; CURRENT APPLICATION NUMBER: US/11/249,296
; CURRENT FILING DATE: 2005-10-14
; NUMBER OF SEQ ID NOS: 90
; SOFTWARE: Patent In Ver. 2.1
; SEQ ID NO 48
; LENGTH: 114
; TYPE: PRT
; ORGANISM: human
US-11-249-296-48

Query Match 76.3%; Score 450; DB 7; Length 114;
Best Local Similarity 77.7%; Pred. No. 1.6e-36;
Matches 87; Conservative 13; Mismatches 12; Indels 0; Gaps 0;

QY 1 DVVMTQSLPLSVTLTGQPASISCKSSQSLSDSGKTFELNWFQORPGQSPRLIYLVSKLD 60
Db 1 DIVMTQSLPLSVTLTGQPASISCKSSQSLHSNGYTDNLWYLQKPGQSPQLLIYLGSYRA 60

QY 61 SGVPRFSGSGGTDFTLKISRVEAEDVGVVYCWGTHFPYTFGGGTRLEIK 112
Db 61 SGVPRFSGSGGTDFTLKISRVEAEDVGVVYCCQYSNPPFTFGGTRLEIK 112

RESULT 12
US-10-544-050-3
; Sequence 3, Application US/10544050
; Publication No. US20060110388A1
; GENERAL INFORMATION:
; APPLICANT: Davies Julian
; TITLE OF INVENTION: Abeta Binding Molecules
; FILE REFERENCE: X-16068
; CURRENT APPLICATION NUMBER: US/10/544,050
; CURRENT FILING DATE: 2005-07-29
; PRIOR APPLICATION NUMBER: 60/446380
; PRIOR FILING DATE: 2003-02-10
; NUMBER OF SEQ ID NOS: 76
; SOFTWARE: Patent In version 3.2
; CURRENT APPLICATION NUMBER: US/11/211,917
; CURRENT FILING DATE: 2005-08-25
; PRIOR APPLICATION NUMBER: 2005-08-25
; PRIOR APPLICATION NUMBER: US/10/292,088
```

```
; SEQ ID NO 3
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: humanized light chain
US-10-544-050-3

Query Match 75.3%; Score 444; DB 6; Length 112;
Best Local Similarity 75.9%; Pred. No. 5.8e-36;
Matches 85; Conservative 12; Mismatches 15; Indels 0; Gaps 0;

QY 1 DVVMTQSLPLSVTLTGQPASISCKSSQSLSDSGKTFELNWFQORPGQSPRLIYLVSKLD 60
Db 1 DIVMTQSLPLSVTLTGQPASISCKSSQSLIYSDGNAYLHWYLQKPGQSPQLLIYKVSNR 60

QY 61 SGVPRFSGSGGTDFTLKISRVEAEDVGVVYCWGTHFPYTFGGGTRLEIK 112
Db 61 SGVPRFSGSGGTDFTLKISRVEAEDVGVVYCSQSTHVPWTFGGGTRLEIK 112

RESULT 13
US-11-239-308-16
; Sequence 16, Application US/11239308
; Publication No. US20060088883A1
; GENERAL INFORMATION:
; APPLICANT: Smider, Vaughn
; APPLICANT: Larrick, James W.
; APPLICANT: IntegriGen, Inc.
; TITLE OF INVENTION: Recombinant Catalytic Polypeptides and Their Uses
; FILE REFERENCE: 021216-000310US
; CURRENT APPLICATION NUMBER: US/11/239,308
; CURRENT FILING DATE: 2005-09-28
; PRIOR APPLICATION NUMBER: US/10/683,733
; PRIOR FILING DATE: 2003-10-09
; PRIOR APPLICATION NUMBER: US 60/417,979
; PRIOR FILING DATE: 2002-10-09
; NUMBER OF SEQ ID NOS: 62
; SOFTWARE: Patent In Ver. 2.1
; SEQ ID NO 16
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-239-308-16

Query Match 75.1%; Score 443; DB 7; Length 112;
Best Local Similarity 75.9%; Pred. No. 7.2e-36;
Matches 85; Conservative 12; Mismatches 15; Indels 0; Gaps 0;

QY 1 DVVMTQSLPLSVTLTGQPASISCKSSQSLSDSGKTFELNWFQORPGQSPRLIYLVSKLD 60
Db 1 DIVMTQSLPLSVTLTGQPASISCKSSQSLHSNGYNDLWYLQKPGQSPQLLIYLGSNRA 60

QY 61 SGVPRFSGSGGTDFTLKISRVEAEDVGVVYCWGTHFPYTFGGGTRLEIK 112
Db 61 SGVPRFSGSGGTDFTLKISRVEAEDVGVVYCMQALQTPWTFGGGTRLEIK 112

RESULT 14
US-11-211-917-103
; Sequence 103, Application US/11211917
; Publication No. US20060093600A1
; GENERAL INFORMATION:
; APPLICANT: BEDIAN, VAHE
; APPLICANT: GLADUE, RONALD P.
; APPLICANT: CORVALAN, JOSE
; APPLICANT: JIA, XIAO-CHI
; APPLICANT: FENG, XIAO
; TITLE OF INVENTION: ANTIBODIES TO CD40
; FILE REFERENCE: ABX-PF/3 US
; CURRENT APPLICATION NUMBER: US/11/211,917
; CURRENT FILING DATE: 2005-08-25
; PRIOR APPLICATION NUMBER: US/10/292,088
```

```

; PRIOR FILING DATE: 2002-11-08
; PRIOR APPLICATION NUMBER: 60/348,980
; PRIOR FILING DATE: 2001-11-09
; NUMBER OF SEQ ID NOS: 147
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 103
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-211-917-103

```

	Query Match	75.1%	Score 443;	DB 7;	Length 112;
	Best Local Similarity	75.9%;	Pred No. 7.2e-36;		
	Matches	85;	Conservative	15;	Mismatches
Qy	1	DVMTGSPSLPYTLGPASISCKSQSLDSDGKTFLLNWFQQRPGQSPRRLLIYLVSKLD	60		
		: : : : : : : : : : : : : : : : : : : : : : : : :			
Db	1	DVMTGSPSLPYTPGEPASISCKRSQSLHNSGNYLDWYLRKPGSQPLLIVLGSNRA	60		
		: : : : : : : : : : : : : : : : : : : : : : : : :			
Qy	61	SGVPDRFSGSGSGTDFTLKISRVAEADGVVYCWQGHFFPYTFQGGTRLEIK	112		
		: : : : : : : : : : : : : : : : : : : : : : : : :			
Db	61	SGVPDRFSGSGSGTDFTLKISRVAEADGVVYCWQALQTPWTFOGTHKVEIK	112		
		: : : : : : : : : : : : : : : : : : : : : : : : :			

RESULT 15

```

US-11-211-917-111
; Sequence 111, Application US/11211917
; Publication No. US20060093600A1
; GENERAL INFORMATION:
; APPLICANT: BEDIAN, VAHE
; APPLICANT: GLADUE, RONALD P.
; APPLICANT: CORVALAN, JOSE
; APPLICANT: JIA, XIAO-CHI
; APPLICANT: FENG, XIAO
; TITLE OF INVENTION: ANTIBODIES TO CD40
; FILE REFERENCE: ABX-PF/3 US
; CURRENT APPLICATION NUMBER: US/11/211,917
; CURRENT FILING DATE: 2005-08-25
; PRIOR APPLICATION NUMBER: US/10/292,088
; PRIOR FILING DATE: 2002-11-08
; PRIOR APPLICATION NUMBER: 60/348,980
; PRIOR FILING DATE: 2001-11-09
; NUMBER OF SEQ ID NOS: 147
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 111
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-211-917-111

```

	Query Match	75.1%	Score 443	DB 7	Length 112
	Best Local Similarity	75.9%	Pred. No. 7.2e-36		
	Matches	85	Conservative	Mismatches 15	Indels 0
	Gaps	0			
QY	1	DVVMOTSLPVTLGOPASISCKSSOSLSDSGKTFINWFOQRPQSGSPRRLLIYLVSKLD	60		
DB	1	DIVMOTSLPVTGPGPASPISCRSSOSLHNSGNYLDMYLKPGSGPQLLIYLGNSRA	60		
QY	61	SGVPDRFSGSGSGTDFTLKISRVEAEDVGVYCWQGHFPYTFQGTTRLRIK	112		
DB	61	SGVPDRFSGSGSGTDFTLKISRVEAEDVGVYCMQALQTPWTFCQGTKVEIK	112		

Search completed: June 10, 2006, 12:39:09
Job time : 3.86787 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.9
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: June 10, 2006, 11:48:47 ; Search time 75.7162 Seconds
(without alignments)
706.511 Million cell updates/sec

Title: US-10-733-563-17
Perfect score: 620
Sequence: 1 EVQLVSGGGLVPGGSLRL.....CTTFYGVNGVGGTLTVSS 117

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2589679 seqs, 457216429 residues

Total number of hits satisfying chosen parameters: 2589679

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_8:*

- 1: Geneseqp1980s:*
- 2: Geneseqp1980s:*
- 3: Geneseqp2000s:*
- 4: Geneseqp2001s:*
- 5: Geneseqp2002s:*
- 6: Geneseqp2003as:*
- 7: Geneseqp2003bs:*
- 8: Geneseqp2004s:*
- 9: Geneseqp2005s:*
- 10: Geneseqp2006s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
1	620	100.0	117	4	Aae06954 Humanised
2	620	100.0	117	4	Aau09927 Humanised
3	620	100.0	117	5	Abg75536 Humanised
4	620	100.0	117	5	Aao14980 Humanised
5	620	100.0	117	5	Adf98240 Humanised
6	620	100.0	117	8	Adq89239 Humanised
7	620	100.0	117	9	Aeb09512 Humanised
8	620	100.0	117	9	Aec92171 Humanised
9	620	100.0	117	9	Aed43689 Humanised
10	620	100.0	119	4	Aae07034 Humanised
11	620	100.0	119	8	Adq89326 Humanised
12	620	100.0	119	9	Aeb09599 Humanised
13	613	98.9	117	4	Aae06955 Humanised
14	613	98.9	117	5	Abg75537 Humanised
15	613	98.9	117	5	Aao14981 Humanised
16	613	98.9	117	5	Adf98241 Humanised
17	613	98.9	117	8	Adq89240 Humanised
18	613	98.9	117	9	Aeb09513 Humanised
19	613	98.9	117	9	Aec92172 Humanised
20	613	98.9	117	9	Aed43690 Humanised
21	604	97.4	117	4	Aae06956 Humanised
22	604	97.4	117	4	Aau09929 Humanised
23	604	97.4	117	4	Aau09928 Humanised

ALIGNMENTS

RESULT 1

AAE06954
ID AAE06954 standard; protein; 117 AA.

XX AAE06954;

XX XX

DT 11-SEP-2003 (revised)

DT 16-OCT-2001 (first entry)

XX XX

DE Humanised murine ID9 antibody heavy chain variable region, 1D9RHA.

XX Murine; humanised antibody; CC-Chemokine receptor 2; CCR2; nephrotropic; neuroprotective; immunosuppressive; human immunodeficiency virus; HIV infection; cytostatic; vasotropic; leukocyte trafficking; allergy; inflammatory disorder; autoimmune disorder; rheumatoid arthritis; shock; multiple sclerosis; atherosclerosis; stenosis; allograft rejection; anaphylaxis; malignancy; inflammation; stenosis; allograft rejection; fibrotic disease; angioplasty; acquired immune deficiency syndrome; AIDS; inflammatory glomerulopathy; vascular intervention; ID9 antibody; neointimal hyperplasia; VH; heavy chain variable region; 1D9RHA.

XX Mus sp.

OS Homo sapiens.

OS Chimeric.

PH Key Location/Qualifiers

FT Region 27..35

FT /label= CDR1

FT /note= "Complementarity determining region 1"

FT Region 50..68

FT /label= CDR2

FT /note= "Complementarity determining region 2"

FT Region 101..106

FT /label= CDR3

FT /note= "Complementarity determining region 3"

PN WO200157226-A1.

PD 09-AUG-2001.

XX 02-FEB-2001; 2001WO-US003537.

PR 03-FEB-2000; 2000US-00497625.

XX (MILL-) MILLENNIUM PHARM INC.

PA

XX

```

PI Larosa GJ, Horvath C, Newman W, Jones ST, O'Brien S, O'Keefe T;
XX WPI; 2001-48888/53.
XX
XX Humanized immunoglobulin for treating a CC-chemokine receptor 2-mediated
PT disorder in a patient, comprises a binding specificity for CCR2, and a
PT non-human antigen binding region and human immunoglobulin.
PT
XX Claim 62; Fig 12; 183pp; English.
PS
XX The patent discloses a humanised antibody or its antigen-binding
XX fragment, having binding specificity for CC-chemokine receptor 2 (CCR2),
XX comprising an antigen binding region of non-human origin and at least a
XX portion of an immunoglobulin of human origin. The humanised antibodies
XX are useful for inhibiting the interaction of a cell expressing CCR2. They
XX are useful for inhibiting or treating HIV infection. The proteins of the
XX CCR2-mediated disorders such as inflammatory disorder, for treating
XX disorders such as rheumatoid arthritis and multiple sclerosis.
XX atherogenesis and atherosclerosis, and for inhibiting restenosis. They
XX are useful in therapy or diagnosis, and in the manufacture of a
XX medicament for treating CCR-2 mediated disease. They are also useful for
XX treating allergy, anaphylaxis, malignancy, chronic and acute
XX inflammation, histamine and IgE-mediated allergic reaction, shock,
XX stomulopathies, acquired immune deficiency syndrome (AIDS), restenosis
XX associated with vascular intervention, including angioplasty and/or stent
XX placement in a mammal. Humanised antibodies are also useful for
XX inhibiting narrowing of the lumen of a vessel in a mammal, and inhibiting
XX neointimal hyperplasia of a vessel in a mammal, preferably associated
XX with vascular intervention. The present sequence is humanised murine 1D9
XX antibody heavy chain variable (VH) region, 1D9RHA. (Updated on 11-SEP-
XX 2003 to standardise OS field)
XX
XX Sequence 117 AA;
XX
XX Query Match 100.0%; Score 620; DB 4; Length 117;
XX Best Local Similarity 100.0%; Pred. No. 8.5e-48;
XX Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIKNNNYAT 60
DB 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIKNNNYAT 60
QY 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGVNGVWGQGLTVTVSS 117
DB 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGVNGVWGQGLTVTVSS 117

RESULT 2
ID AAU09927 standard; protein; 117 AA.
XX
XX AAU09927;
XX
XX 18-JUN-2002 (first entry)
XX
XX Humanised 1D9 heavy chain variable region, 1D9RHA protein sequence.
DE
XX Human; mouse; 4B4'Cl heavy chain variable region; vasotropic;
XX antiinflammatory; collagen disease; immunosuppressive; antiasthmatic;
XX insulin-dependent diabetes mellitus; inflammatory bowel disease;
XX ulcerative colitis; 1D9RHA; graft rejection; allergic disease;
XX antiporiatic; antiarthritic; nephrotropic; antithyroid; restenosis;
XX dermatological; anaphylaxis; cell adhesion inhibitor; vascular injury;
XX autoimmune disease; immunoglobulin; complement inhibitor; determining region;
XX CCR; CD18; CCR2; atherosclerosis; mutant; mutein.
XX
OS Homo sapiens.
OS Mus sp.
OS Synthetic.
OS Chimeric.
XX

```

```

FH Key Location/Qualifiers
FT Region 27..30 /note= "Part of H1 structure loop"
FT Region 31..35 /note= "Complementarity determining region 1 (CDR1),
FT grafted from mouse mAb 1D9 heavy chain sequence
FT (AAU09919)"
FT Region 50..68 /note= "Complementarity determining region 2 (CDR2),
FT grafted from mouse mAb 1D9 heavy chain sequence
FT (AAU09919)"
FT Region 101..108 /note= "Complementarity determining region 3 (CDR3),
FT grafted from mouse mAb 1D9 heavy chain sequence
FT (AAU09919)"
XX WO200170266-A2.
XX
XX 27-SEP-2001.
XX
XX 15-MAR-2001; 2001WO-US008266.
XX
XX 17-MAR-2000; 2000US-00528267.
XX (MILL-) MILLENNIUM PHARM INC.
XX
XX Horvath CJ, Rao PE;
XX WPI; 2001-607511/69.
XX
XX Inhibiting stenosis or restenosis of a blood vessel following vascular
XX injury or angioplasty in a subject by administering agent which inhibits
XX recruitment or adhesion of neutrophils, mononuclear cells to injury site.
XX
XX Claim 32; Fig 18; 108pp; English.
XX
XX The present invention relates to a new method of inhibiting stenosis or
XX restenosis of a blood vessel following vascular injury in a subject. The
XX new method comprises administering to the subject agents which inhibit
XX the adhesion and/or recruitment of neutrophils and mononuclear cells to a
XX site of vascular injury by binding CD18 or CCR2. The method of the
XX invention inhibits stenosis or restenosis of a blood vessel following
XX vascular injury arising from a vascular intervention procedure such as
XX vascular by-pass or transplantation surgery. The method is also useful
XX for treating a subject having an inflammatory disease or condition
XX mediated by neutrophil and mononuclear cell activity e.g. asthma and
XX graft versus host disease. Chronic inflammatory diseases of the lung,
XX collagen diseases, and insulin-dependent diabetes mellitus can also be
XX treated. The method is further useful for treating inflammatory bowel
XX diseases, such as ulcerative colitis. Additional diseases or conditions
XX include inflammatory or allergic diseases and conditions, including
XX systemic anaphylaxis of hypersensitivity responses, drug allergies,
XX psoriasis and inflammatory dermatoses, autoimmune diseases such as
XX arthritis, graft rejection and other diseases including atherosclerosis.
XX This sequence represents the variable region of one of several humanised
XX 1D9 heavy chains (AAU09927-AAU09930). These heavy chains were used in the
XX invention for the production of anti-CCR2 antibody or antigen-binding
XX fragment
XX
XX Sequence 117 AA;
XX
XX Query Match 100.0%; Score 620; DB 4; Length 117;
XX Best Local Similarity 100.0%; Pred. No. 8.5e-48;
XX Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIKNNNYAT 60
DB 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIKNNNYAT 60
QY 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGVNGVWGQGLTVTVSS 117
DB 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGVNGVWGQGLTVTVSS 117

```


RESULT 3
 ABG75536
 ID ABG75536 standard; protein; 117 AA.
 XX
 AC ABG75536;
 XX
 DT 16-APR-2003 (first entry)
 XX
 DE Humanised mouse mAb 1D9 heavy chain variable region, 1D9RHAHVH.
 XX
 KW Mouse; stenosis; restenosis; blood vessel; vascular injury; antibody;
 KW antigen binding fragment; cellular adhesion molecule; adhesion;
 KW recruitment; neutrophil; antagonist; CCR2; mononuclear cell; angioplasty;
 KW percutaneous transluminal coronary angioplasty; PTCA; stent;
 KW vascular by-pass surgery; vascular grafting; endarterectomy; atherectomy;
 KW endovascular stenting; prosthetic valve; transplantation;
 KW inflammatory disease; mastitis; vaginitis; cholecystitis;
 KW chronic bronchitis; asthma; graft-versus-host disease;
 KW chronic inflammatory disease; hypersensitivity pneumonitis;
 KW collagen disease; sarcoidosis; idiopathic; pancreatitis; HF-21/28;
 KW insulin dependent; diabetes mellitus; inflammatory bowel disease;
 KW Crohn's disease; allergic disease; psoriasis; atopic dermatitis; human;
 KW allergic rhinitis; autoimmune disease; arthritis; multiple sclerosis;
 KW graft rejection; atherosclerosis; myositis; therapy; 1D9; 1D9RHAHVH;
 KW heavy chain variable region; VH; complementarity determining region; CDR;
 KW mutant; mutein.
 XX
 OS Mus sp.
 OS Homo sapiens.
 OS Synthetic.
 XX
 XX Key Location/Qualifiers
 XX Region 31..35 /note= "Mouse complementarity determining region 1
 FT (CDR1)"
 FT 50..68 /note= "Mouse complementarity determining region 2
 FT (CDR2)"
 FT 101..106 /note= "Mouse complementarity determining region 3
 FT (CDR3)"
 FT
 XX US2002106369-A1.
 XX
 XX 08-AUG-2002.
 XX
 XX 15-MAR-2001; 2001US-00809739.
 XX
 XX 17-MAR-2000; 2000US-00528267.
 XX (MILL-) MILLENNIUM PHARM INC.
 XX
 XX Horvath CJ, Rao PE;
 XX WPI; 2002-697861/75.
 XX
 XX Inhibiting (re)stenosis of blood vessel following vascular injury, by
 PT administering first and second agents that inhibit adhesion and/or
 PT recruitment of neutrophils and mononuclear cells, respectively to site of
 PT vascular injury.
 XX
 XX Claim 32; Fig 18; 59pp; English.
 XX
 XX The invention discloses a method for inhibiting stenosis or restenosis of
 CC a blood vessel following vascular injury in a subject. The method
 CC involves administering to the subject a first therapeutic agent, which
 CC comprises an antibody or its antigen binding fragment which binds a
 CC cellular adhesion molecule, that inhibits the adhesion and/or recruitment
 CC of neutrophils to a site of vascular injury and a second therapeutic
 CC agent, which comprises an antagonist of CCR2 function, that inhibits
 CC adhesion and/or recruitment of mononuclear cells to a site of vascular
 CC injury. The vascular injury arises from a vascular intervention procedure

CC such as angioplasty (e.g. percutaneous transluminal coronary angioplasty
 CC (PTCA) or angioplasty including placement of a stent), vascular by-pass
 CC surgery, vascular grafting, endarterectomy, atherectomy, endovascular
 CC stenting, insertion of a prosthetic valve and transplantation of organs,
 CC tissues or cells. The method is also useful for treating inflammatory
 CC diseases or conditions mediated by early neutrophil activity and later
 CC mononuclear cell activity. Preferably, the method is useful for treating
 CC a subject having mastitis, vaginitis, cholecystitis, chronic bronchitis,
 CC asthma and graft-versus-host disease, chronic inflammatory disease of
 CC lung, hypersensitivity pneumonitis, collagen diseases, sarcoidosis and
 CC other idiopathic conditions, pancreatitis and insulin dependent diabetes
 CC mellitus. The method is also useful for treating inflammatory bowel
 CC disease, Crohn's disease, inflammatory or allergic rhinitis), autoimmune diseases
 CC (such as arthritis and multiple sclerosis), graft rejection,
 CC atherosclerosis and myositis. The method enables simultaneous inhibition
 CC of neutrophil and mononuclear cell participation in response to vascular
 CC injury or inhibition of neutrophil participation followed by inhibition
 CC of mononuclear cell participation, and thus provides superior therapy for
 CC inhibiting stenosis or restenosis following vascular injury. The sequence
 CC presented is the humanised mouse monoclonal antibody (mAb), 1D9, heavy
 CC chain variable region (VH), 1D9RHAHVH, which is comprised of the mouse 1D9
 CC mAb complementarity determining regions (CDR's) linked by human 4B4'CL
 CC MAB VH regions
 XX
 SQ Sequence 117 AA;
 Query Match 100.0%; Score 620; DB 5; Length 117;
 Best Local Similarity 100.0%; Pred. No. 8.5e-48;
 Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSAYAMNWRQAPGKLEWVGRIKNNYAT 60
 DB 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSAYAMNWRQAPGKLEWVGRIKNNYAT 60
 QY 61 YYADSVKDRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTFYGNVWGQGLTVTVSS 117
 DB 61 YYADSVKDRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTFYGNVWGQGLTVTVSS 117
 RESULT 4
 AAO14980
 ID AAO14980 standard; protein; 117 AA.
 XX
 AC AAO14980;
 XX
 DT 05-SEP-2002 (first entry)
 XX
 DE Humanised murine heavy chain variable region (1D9RHa Vh).
 XX
 KW Mouse; graft rejection; CC chemokine receptor 2 antagonist; mutant;
 KW CCR2 antagonist; anti-CCR2 antibody; kidney transplant; liver transplant;
 KW lung transplant; heart-lung transplant; pancreas transplant; mutein;
 KW bowel transplant; heart transplant; graft versus host disease;
 KW chronic graft rejection; antibody heavy chain variable region; 1D9RHa Vh.
 XX
 OS Mus musculus.
 OS Synthetic.
 XX
 XX US2002042370-A1.
 XX
 XX 11-APR-2002.
 XX
 XX 13-APR-2001; 2001US-00835087.
 XX
 XX 14-APR-2000; 2000US-00549448.
 XX (MILL-) MILLENNIUM PHARM INC.
 XX
 XX Hancock WW;
 XX WPI; 2002-351265/38.
 XX

PT Inhibiting graft rejection, graft versus host disease or chronic
PT rejection of a transplanted graft, involves administering a CCR2
PT antagonist.

XX Claim 26; Fig 2; 16pp; English.

PS The invention comprises a method of inhibiting graft rejection, graft
CC versus host disease or chronic rejection of a transplanted graft. The
CC method involves administering an antagonist of CC chemokine receptor 2
CC (CCR2) and optionally an immunosuppressive agent. The CCR2 antagonist may
CC be an anti-CCR2 antibody (i.e. containing light and heavy chain
CC complementarity determining regions from various non-human origins). CCR2
CC is known to be involved in the rejection of transplanted grafts. The
CC method of the invention is useful for inhibiting graft rejection -
CC particularly allografts such as kidney, liver, lung, heart-lung,
CC pancreas, bowel and heart. The method of the invention is also useful for
CC inhibiting graft versus host disease and for inhibiting chronic rejection
CC of a transplanted graft. The present amino acid sequence represents a
CC humanised murine antibody heavy chain variable region (1D9RHa Vh)

XX Sequence 117 AA;

Qy Query Match 100.0%; Score 620; DB 5; Length 117;
Best Local Similarity 100.0%; Pred. No. 8.5e-48;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIKNNYYAT 60
Db 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIKNNYYAT 60

Qy 61 YYADSVKDRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTFYGVNGVWGQGLTVTVSS 117
Db 61 YYADSVKDRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTFYGVNGVWGQGLTVTVSS 117

RESULT 5

ID ADF98240 standard; protein; 117 AA.

XX ADF98240;

XX 26-FEB-2004 (first entry)

XX Humanised 1D9 heavy chain variable region, 1D9RHA VH, SEQ ID 10.

XX Immunosuppressive; CCR2 function inhibitor; graft rejection;
KW graft versus host disease; CC chemokine receptor 2; CCR2;
KW anti-CCR2 antibody.

OS Synthetic.
OS Mus musculus.
OS Homo sapiens.

XX WO200178653-A2.

XX 25-OCT-2001.

XX 13-APR-2001; 2001WO-US012139.

XX 14-APR-2000; 2000US-00549448.

XX (MILL-) MILLENNIUM PHARM INC.

XX Hancock WW;

XX WPI; 2002-017543/02.

XX Inhibition of rejection of graft e.g. heart or graft versus host disease
PT involves use of CC chemokine receptor 2 inhibitor.

XX Claim 26; Fig 2; 44pp; English.

XX The present invention relates to a method for inhibiting graft rejection

CC or graft versus host diseases. The method comprises administration of a
CC CC chemokine receptor 2 (CCR2) function antagonist to a subject or
CC recipient of a transplanted graft. The CCR2 function antagonist is an
CC anti-CCR2 antibody or its antigen-binding fragment (ADF98233-ADF98237,
CC ADF98240-ADF98249). The method is useful for inhibiting rejection,
CC particularly chronic rejection of a graft, particularly an allograft of
CC kidney, liver, lung, heart-lung, pancreas, bowel and heart, and for
CC inhibiting graft versus host disease for a bone marrow graft.

XX Sequence 117 AA;

Qy Query Match 100.0%; Score 620; DB 5; Length 117;
Best Local Similarity 100.0%; Pred. No. 8.5e-48;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIKNNYYAT 60
Db 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIKNNYYAT 60

Qy 61 YYADSVKDRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTFYGVNGVWGQGLTVTVSS 117
Db 61 YYADSVKDRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTFYGVNGVWGQGLTVTVSS 117

RESULT 6

ID ADF98239 standard; protein; 117 AA.

XX ADF98239;

XX 21-OCT-2004 (first entry)

XX Humanised immunoglobulin protein #5.

XX Immunoglobulin; heavy chain; light chain; CC-chemokine receptor 2; CCR2;
KW inflammatory disease; autoimmune disorder; graft rejection;
KW HIV infection; atherosclerosis; antiinflammatory; immunosuppressive;
KW anti-HIV; virucide; antiarteriosclerotic.

OS Synthetic.

XX US2004151721-A1.

XX 05-AUG-2004.

XX 10-DEC-2003; 2003US-00733563.

XX 19-OCT-2001; 2001US-0350166P.

XX 26-JUN-2002; 2002US-0392364P.

XX 17-OCT-2002; 2002US-00272899.

XX (OKEE/) O'KEEFE T.
PA (PONA/) PONATH P.

XX O'keefe T, Ponath P;

XX WPI; 2004-580175/56.

XX New humanized immunoglobulin CC-chemokine receptor 2 (CCR2) antagonists,
PT useful for diagnosing and/or treating inflammatory or autoimmune
PT diseases, and HIV infection.

XX Claim 1; SEQ ID NO 17; 128pp; English.

XX The invention relates to humanised immunoglobulin heavy and light chains
CC which have specificity for the CC-chemokine receptor 2 (CCR2) and an
CC immunoglobulin or its antigen binding fragment comprising the chains. The
CC humanised immunoglobulin or its antigen binding fragment preferably
CC comprises two heavy chains and two light chains. The humanised
CC immunoglobulin and its heavy and light chains are useful for the
CC diagnosis, prevention and/or treatment of diseases or conditions
CC associated with aberrant expression or activity of the CCR2 polypeptide,
CC such as inflammatory diseases, autoimmune disorders, graft rejection, HIV

CC infection and atherosclerosis. This sequence represents a humanised
 CC immunoglobulin protein of the invention.
 XX
 SQ Sequence 117 AA;

Query Match 100.0%; Score 620; DB 8; Length 117;
 Best Local Similarity 100.0%; Pred. No. 8.5e-48;
 Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIKNNYAT 60
 DB 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIKNNYAT 60

QY 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGVNGVWGQGLTVTVSS 117
 DB 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGVNGVWGQGLTVTVSS 117

RESULT 7
 AEB09512
 ID AEB09512 standard; protein; 117 AA.
 XX
 AC AEB09512;
 XX
 DT 08-SEP-2005 (first entry)
 XX
 DE Humanized 1D9 heavy chain variable region SEQ ID NO 17.
 XX
 KW antiinflammatory; immunosuppressive; anti-HIV; antiarteriosclerotic;
 KW antibody engineering; therapeutic; diagnosis; inflammation;
 KW autoimmune disease; immune disorder; graft rejection; HIV infection;
 KW infection; atherosclerosis; cardiovascular disease; metabolic disorder;
 KW heavy chain variable region.
 XX
 OS Synthetic.
 XX
 FN WO2005060368-A2.
 XX
 PD 07-JUL-2005.
 XX
 PF 10-DEC-2003; 2003WO-US039599.
 XX
 PR 10-DEC-2003; 2003WO-US039599.
 XX
 PA (MILL-) MILLENNIUM PHARM INC.
 XX
 PI Okeefe T, Ponath P;
 XX
 DR WPI; 2005-488561/49.
 XX
 PT New humanized immunoglobulin or its antigen binding portion having
 PT binding specificity for CC-chemokine receptor 2 and having a heavy chain
 PT and light chain, for treating inflammatory diseases, HIV, and autoimmune
 PT diseases.
 XX
 PS Claim 1; SEQ ID NO 17; 192pp; English.
 XX
 CC The invention describes a humanized immunoglobulin (I) or its antigen
 CC binding portion having binding specificity for CC-chemokine receptor 2
 CC (CCR2) and having a heavy chain and a light chain, where the heavy chain
 CC comprises a fully defined 117 and 330 amino acid (SEQ ID NO: 17 and 110)
 CC sequence, given in specification or its portion, and the light chain
 CC comprises a fully defined 112 amino acid (SEQ ID NO: 12) sequence given
 CC in specification. Also described are: a humanized immunoglobulin heavy
 CC chain, or its antigen binding fragment, having binding specificity for
 CC CCR2 and comprising the amino acid sequence of (SEQ ID NO: 17) and the
 CC amino acid of (SEQ ID NO: 110), or its portion; and a humanized
 CC immunoglobulin light chain, or its antigen binding fragment, having
 CC binding specificity for CCR2 and comprising the amino acid sequence of
 CC (SEQ ID NO: 12) and the fully defined 107 amino acid (SEQ ID NO: 112)
 CC sequence, given in specification. The following are disclosed: isolated
 CC nucleic acid molecules comprising nucleic acid sequence encoding (I); a
 CC construct comprising nucleic acid molecule encoding (I); and host cell

CC comprising the nucleic acid molecule. (I) Is useful as a therapeutic
 CC agent for controlling lymphocyte homing the mucosal lymphoid tissue thus
 CC reducing inflammatory response, for use in the treatment of diseases
 CC associated with leukocyte infiltration of tissue, e.g. in the treatment
 CC of inflammatory diseases, autoimmune diseases, graft rejection, HIV
 CC infection and monocyte-mediated disorders such as atherosclerosis. (I) Is
 CC useful for detecting and/or measuring the level of CCR2 in a sample (e.g.
 CC tissues or body fluids such as inflammatory exudates, blood, serum, bowel
 CC fluid), and for modulating binding function and/or leukocyte trafficking
 CC modulated by CCR2. This is the amino acid sequence of a humanized 1D9
 CC heavy chain variable region used in the creation of a humanized anti-CCR2
 CC -antibody.
 XX
 SQ Sequence 117 AA;

Query Match 100.0%; Score 620; DB 9; Length 117;
 Best Local Similarity 100.0%; Pred. No. 8.5e-48;
 Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIKNNYAT 60
 DB 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIKNNYAT 60

QY 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGVNGVWGQGLTVTVSS 117
 DB 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGVNGVWGQGLTVTVSS 117

RESULT 8
 AEC92171
 ID AEC92171 standard; protein; 117 AA.
 XX
 AC AEC92171;
 XX
 DT 01-DEC-2005 (first entry)
 XX
 DE Humanized 1D9 mAb heavy chain variable region protein, 1D9RHA VH.
 XX
 KW Therapeutic; restenosis; vasotropic; cardiovascular disease; stenosis;
 KW pulmonary disease; respiratory-gen.; respiratory disease; stenosis;
 KW inflammatory bowel disease; antiinflammatory; gastrointestinal-gen.;
 KW gastrointestinal disease; inflammation; allergy; antiallergic;
 KW immune disorder; autoimmune disease; immunosuppressive; graft rejection;
 KW inflammation; antiinflammatory; 1D9; monoclonal antibody;
 KW humanized antibody; heavy chain variable region.
 XX
 OS Mus sp.
 OS Homo sapiens.
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT Region 31..35
 FT /note= "Complementarity determining region (CDR) 1"
 FT Region 50..68
 FT /note= "Complementarity determining region (CDR) 2"
 FT Region 101..106
 FT /note= "Complementarity determining region (CDR) 3"
 XX
 FN US2005214299-A1.
 XX
 PD 29-SEP-2005.
 XX
 PF 12-SEP-2003; 2003US-00662061.
 XX
 PR 17-MAR-2000; 2000US-00528267.
 PR 15-MAR-2001; 2001US-00809739.
 XX
 PA (MILL-) MILLENNIUM PHARM INC.
 XX
 PI Horvath CJ, Rao PE;
 XX
 DR WPI; 2005-648726/66.
 XX

PT Inhibiting stenosis in a human blood vessel, by administering an anti-
 PT CD18 antibody, which binds specifically with the CD18 portion of a
 PT mammalian protein which comprises CD18, where stenosis is inhibited in
 PT the vessel.
 XX
 XX Disclosure; SEQ ID NO 20; 56pp; English.
 XX
 XX The invention relates to a method of inhibiting stenosis or restenosis of
 CC a blood vessel following vascular injury, wherein the recruitment and/or
 CC adhesion of neutrophils and the adhesion and/or recruitment of
 CC mononuclear cells to a site of vascular injury is inhibited. The methods
 CC of the invention are useful for inhibiting stenosis or restenosis in a
 CC human blood vessel, inhibiting interaction of a leukocyte having a CD18-
 CC containing cell-surface protein with vascular endothelium in a human,
 CC assessing the presence of leukocytes associated with vascular stenosis in
 CC blood obtained from a human and alleviating a disorder associated with
 CC stenosis in a blood vessel of a human. The invention is useful for
 CC treating mastitis, cholangitis and cholecystitis, chronic inflammatory
 CC diseases of the lungs such as interstitial lung disease and idiopathic
 CC pulmonary disease, hypersensitivity pneumonitis, pancreatitis, insulin-
 CC dependent diabetes mellitus, inflammatory bowel disease such as Crohn's
 CC disease, ulcerative colitis and sprue, inflammatory or allergic diseases
 CC including anaphylaxis, psoriasis, dermatitis, eczema, atopic dermatitis
 CC and allergic rhinitis, autoimmune diseases including arthritis, multiple
 CC sclerosis, myasthenia gravis, juvenile onset diabetes and autoimmune
 CC thyroiditis, graft rejection and other diseases or conditions in which
 CC undesirable inflammatory responses are to be inhibited including
 CC atherosclerosis or myositis. The present sequence is humanized murine 1D9
 CC monoclonal antibody (mAb; also termed as LS132.1D9, ID9-2-121-3-6) heavy
 CC chain variable region (VH) protein.
 XX
 XX Sequence 117 AA;

Query Match 100.0%; Score 620; DB 9; Length 117;
 Best Local Similarity 100.0%; Pred. No. 8.5e-48;
 Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIKNNNYAT 60
 DB 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIKNNNYAT 60
 QY 61 YYADSVKDRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTFYGVNGVWGQGLTVTVSS 117
 DB 61 YYADSVKDRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTFYGVNGVWGQGLTVTVSS 117

RESULT 9
 AED43689
 ID AED43689 standard; protein; 117 AA.
 XX
 AC AED43689;
 XX
 XX 15-DEC-2005 (first entry)
 DT
 DT Humanized murine 1D9 antibody heavy chain variable region 1D9RHA.
 DE
 DE pharmaceutical; anticholinergic; CCR2 receptor; monoclonal antibody;
 KW respiratory-Gen.; antiinflammatory; inflammation; respiratory disease;
 KW antibody 1D9; humanized antibody.
 KW
 OS Mus sp.
 OS Homo sapiens.
 OS Chimeric.
 OS
 OS WO2005094798-A2.
 PN
 PN 13-OCT-2005.
 PD
 XX 22-MAR-2005; 2005WO-EP003005.
 PF
 XX 30-MAR-2004; 2004EP-00007635.
 PR
 XX (BOEH) BOEHRINGER INGELHEIM INT GMBH.
 PA

PA (BOEH) BOEHRINGER INGELHEIM PHARMA GMBH & CO KG.
 XX
 XX Pairret M;
 XX
 XX WPI; 2005-714339/73.
 XX
 XX New pharmaceutical composition containing one or more anticholinergics
 PT and a CCR2 receptor antagonist, and optionally together with an
 PT excipient, useful for treating inflammatory or obstructive diseases of
 PT the respiratory tract.
 XX
 XX Claim 22; SEQ ID NO 8; 39pp; English.
 XX
 XX The invention relates to a pharmaceutical composition containing one or
 CC more anticholinergics and a CCR2 receptor antagonist optionally in the
 CC form of individual optical isomers, their mixtures or racemates, addition
 CC salts, solvates or hydrates, and optionally together with an excipient.
 CC The pharmaceutical composition comprises the anticholinergic that is
 CC selected from tiotropium salts, oxitropium salts or ipratropium salts,
 CC preferably tiotropium salts. The anticholinergic is present in the form
 CC of the chloride, bromide, iodide, methanesulfonate or para-
 CC toluenesulfonate, preferably in the form of the bromide. The CCR2
 CC antagonist is an antibody, which can compete with the CCR2 binding of the
 CC monoclonal antibody 1D9 (ATCC HB-12549). The pharmaceutical composition
 CC is useful for preparing a medicament for treating inflammatory or
 CC obstructive diseases of the respiratory tract. The anticholinergic and
 CC CCR2 antagonist are useful for preparing the pharmaceutical composition.
 CC The present sequence represents the heavy chain variable region of a
 CC humanized murine 1D9 antibody.
 XX
 XX Sequence 117 AA;

Query Match 100.0%; Score 620; DB 9; Length 117;
 Best Local Similarity 100.0%; Pred. No. 8.5e-48;
 Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIKNNNYAT 60
 DB 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIKNNNYAT 60
 QY 61 YYADSVKDRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTFYGVNGVWGQGLTVTVSS 117
 DB 61 YYADSVKDRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTFYGVNGVWGQGLTVTVSS 117

RESULT 10
 AAE07034
 ID AAE07034 standard; protein; 119 AA.
 XX
 AC AAE07034;
 XX
 XX 11-SEP-2003 (revised)
 DT
 DT 16-OCT-2001 (first entry)
 DT
 XX Humanised murine antibody heavy chain 1D9RHA protein.
 DE
 DE Murine; humanised antibody; CC-chemokine receptor 2; CCR2; nephrotropic;
 KW neuroprotective; immunosuppressive; human immunodeficiency virus;
 KW HIV infection; cytostatic; vasotropic; leukocyte trafficking; allergy;
 KW inflammatory disorder; autoimmune disorder; rheumatoid arthritis; shock;
 KW multiple sclerosis; atherogenesis; atherosclerosis; restenosis; asthma;
 KW anaphylaxis; malignancy; inflammation; stenosis; allograft rejection;
 KW fibrotic disease; angioplasty; acquired immune deficiency syndrome; AIDS;
 KW inflammatory glomerulopathy; vascular intervention;
 KW necrotic hyperplasia; antibody 1D9 heavy chain; 1D9RHA.
 XX
 OS Mus sp.
 OS Homo sapiens.
 OS Chimeric.
 OS
 OS WO200157226-A1.
 PN
 XX 09-AUG-2001.
 PD

XX PF 02-FEB-2001; 2001WO-US003537.
XX XX
XX PR 03-FEB-2000; 2000US-00497625.
XX XX
XX XX (MILL-) MILLENNIUM PHARM INC.
XX XX
XX PI Larosa GJ, Horvath C, Newman W, Jones ST, O'brien S, O'keefe T;
XX XX WPI; 2001-488888/53.
XX DR N-PSDB; AAD13179.
XX XX
XX PT Humanized immunoglobulin for treating a CC-chemokine receptor 2-mediated
XX PT disorder in a patient, comprises a binding specificity for CCR2, and a
XX PT non-human antigen binding region and human immunoglobulin.
XX XX
XX PS Disclosure; Fig 23; 183pp; English.
XX XX
XX CC The patent discloses a humanised antibody or its antigen-binding
XX CC fragment, having binding specificity for CC-chemokine receptor 2 (CCR2),
XX CC comprising an antigen binding region of non-human origin and at least a
XX CC portion of an immunoglobulin of human origin. The humanised antibodies
XX CC are useful for inhibiting the interaction of a cell expressing CCR2. They
XX CC are useful for inhibiting or treating HIV infection. The proteins of the
XX CC invention are useful for inhibiting leukocyte trafficking, for treating
XX CC CCR2-mediated disorders such as inflammatory disorder, autoimmune
XX CC disorders such as rheumatoid arthritis and multiple sclerosis,
XX CC atherogenesis and atherosclerosis, and for inhibiting stenosis. They
XX CC are useful in therapy or diagnosis, and in the manufacture of a
XX CC medicament for treating CCR2 mediated disease. They are also useful for
XX CC treating allergy, anaphylaxis, malignancy, chronic and acute
XX CC inflammation, histamine and IgE-mediated allergic reaction, shock,
XX CC stenosis, allograft rejection, fibrotic disease, asthma, inflammatory
XX CC glomerulopathies, acquired immune deficiency syndrome (AIDS), restenosis
XX CC associated with vascular intervention, including angioplasty and/or stent
XX CC placement in a mammal. Humanised antibodies are also useful for
XX CC inhibiting narrowing of the lumen of a vessel in a mammal, and inhibiting
XX CC neointimal hyperplasia of a vessel in a mammal, preferably associated
XX CC with vascular intervention. The present sequence is humanised murine
XX CC antibody heavy chain region, 1D9RHA. 1D9RHA sequence consist of the
XX CC complementarity determining regions (CDRs) of the murine 1D9 antibody
XX CC heavy chain variable (VH) region genetically inserted into the framework
XX CC regions (FRs) of the human 4B4/CL antibody VH region. (Updated on 11-SEP-
XX CC 2003 to standardise OS field)
XX SQ Sequence 119 AA;

Query Match 100.0%; Score 620; DB 4; Length 119;
Best Local Similarity 100.0%; Pred. No. 8.7e-48;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIKNNNYAT 60
Db 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIKNNNYAT 60

QY 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGVNGVGGQGLTVTVSS 117
Db 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGVNGVGGQGLTVTVSS 117

RESULT 11
ADQ89326
ID ADQ89326 standard; protein; 119 AA.
XX
XX AC ADQ89326;
XX XX
XX DT 21-OCT-2004 (first entry)
XX XX
XX DE Humanised immunoglobulin protein #9.
XX XX
XX KW Immunoglobulin; heavy chain; light chain; CC-chemokine receptor 2; CCR2;
XX KW inflammatory disease; autoimmune disorder; graft rejection;
XX KW HIV infection; atherosclerosis; antiinflammatory; immunosuppressive;

KW anti-HIV; virucide; antiarteriosclerotic.
XX Synthetic.
XX PN US2004151721-A1.
XX XX
XX PD 05-AUG-2004.
XX XX
XX PF 10-DEC-2003; 2003US-00733563.
XX XX
XX PR 19-OCT-2001; 2001US-0350166P.
XX PR 26-JUN-2002; 2002US-0392364P.
XX PR 17-OCT-2002; 2002US-00272899.
XX XX
XX PA (OKEE/) O'KEEFE T.
XX PA (PONA/) PONATH P.
XX XX
XX PI O'keefe T, Ponath P;
XX XX WPI; 2004-580175/56.
XX DR N-PSDB; ADQ89319.
XX XX
XX PT New humanized immunoglobulin CC-chemokine receptor 2 (CCR2) antagonists,
XX PT useful for diagnosing and/or treating inflammatory or autoimmune
XX PT diseases, and HIV infection.
XX XX
XX PS Disclosure; SEQ ID NO 104; 128pp; English.
XX XX
XX CC The invention relates to humanised immunoglobulin heavy and light chains
XX CC which have specificity for the CC-chemokine receptor 2 (CCR2) and an
XX CC immunoglobulin or its antigen binding fragment comprising the chains. The
XX CC humanised immunoglobulin or its antigen binding fragment preferably
XX CC comprises two heavy chains and two light chains. The humanised
XX CC immunoglobulin and its heavy and light chains are useful for the
XX CC diagnosis, prevention and/or treatment of diseases or conditions
XX CC associated with aberrant expression or activity of the CCR2 polypeptide,
XX CC such as inflammatory diseases, autoimmune disorders, graft rejection, HIV
XX CC infection and atherosclerosis. This sequence represents a humanised
XX CC immunoglobulin protein of the invention.
XX SQ Sequence 119 AA;

Query Match 100.0%; Score 620; DB 8; Length 119;
Best Local Similarity 100.0%; Pred. No. 8.7e-48;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIKNNNYAT 60
Db 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIKNNNYAT 60

QY 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGVNGVGGQGLTVTVSS 117
Db 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGVNGVGGQGLTVTVSS 117

RESULT 12
AEB09599
ID AEB09599 standard; protein; 119 AA.
XX
XX AC AEB09599;
XX XX
XX DT 08-SEP-2005 (first entry)
XX XX
XX DE Humanized heavy chain 1D9RHA.
XX XX
XX KW antiinflammatory; immunosuppressive; anti-HIV; antiarteriosclerotic;
XX KW antibody engineering; therapeutic; diagnosis; inflammation;
XX KW autoimmune disease; immune disorder; graft rejection; HIV infection;
XX KW infection; atherosclerosis; cardiovascular disease; metabolic disorder;
XX KW heavy chain variable region.
XX XX
XX OS Synthetic.
XX XX

PN WO2005060368-A2.
XX 07-JUL-2005.
XX 10-DEC-2003; 2003WO-US039599.
XX 10-DEC-2003; 2003WO-US039599.
XX (MILL-) MILLENNIUM PHARM INC.
XX O'keefe T, Ponath P;
XX WPI; 2005-488561/49.
XX N-PSDB; AEB09592.
XX New humanized immunoglobulin or its antigen binding portion having
PT binding specificity for CC-chemokine receptor 2 and having a heavy chain
PT and light chain, for treating inflammatory diseases, HIV, and autoimmune
PT diseases.
XX Disclosure; SEQ ID NO 104; 192pp; English.
XX The invention describes a humanized immunoglobulin (I) or its antigen
XX binding portion having binding specificity for CC-chemokine receptor 2
XX (CCR2) and having a heavy chain and a light chain, where the heavy chain
XX comprises a fully defined 117 and 330 amino acid (SEQ ID NO: 17 and 110)
XX sequences, given in specification or its portion, and the light chain
XX comprises a fully defined 112 amino acid (SEQ ID NO: 12) sequence given
XX in specification. Also described are: a humanized immunoglobulin heavy
XX chain, or its antigen binding fragment, having binding specificity for
XX CCR2 and comprising the amino acid sequence of (SEQ ID NO: 17) and the
XX amino acid of (SEQ ID NO: 110), or its portion; and a humanized
XX immunoglobulin light chain, or its antigen binding fragment, having
XX binding specificity for CCR2 and comprising the amino acid sequence of
XX (SEQ ID NO: 12) and the fully defined 107 amino acid (SEQ ID NO: 112)
XX sequence, given in specification. The following are disclosed: isolated
XX nucleic acid molecules comprising nucleic acid sequence encoding (I); a
XX construct comprising nucleic acid molecule encoding (I); and host cell
XX comprising the nucleic acid molecule. (I) Is useful as a therapeutic
XX agent for controlling lymphocyte homing the mucosal lymphoid tissue thus
XX reducing inflammatory response, for use in the treatment of diseases
XX associated with leukocyte infiltration of tissue, e.g. in the treatment
XX of inflammatory diseases, autoimmune diseases, graft rejection, HIV
XX infection and monocyte-mediated disorders such as atherosclerosis. (I) Is
XX useful for detecting and/or measuring the level of CCR2 in a sample (e.g.
XX tissues or body fluids such as inflammatory exudates, blood, serum, bowel
XX fluid), and for modulating binding function and/or leukocyte trafficking
XX modulated by CCR2. This is the amino acid sequence of humanized heavy
XX chain 1D9RHA.
XX Sequence 119 AA;
SQ Query Match 100.0%; Score 620; DB 9; Length 119;
Best Local Similarity 100.0%; Pred. No. 8.7e-48;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 EVQLVESGGGLVPGGSLRLSQAASGFTFSAYANWVRQAPGKLEWVGRIKNNYAT 60
Db 1 EVQLVESGGGLVPGGSLRLSQAASGFTFSAYANWVRQAPGKLEWVGRIKNNYAT 60
Qy 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYCTTFYGNVGWQGTLVTSS 117
Db 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYCTTFYGNVGWQGTLVTSS 117
RESULT 13
AAE06955
ID AAE06955 standard; protein; 117 AA.
XX
AC AAE06955;
XX
DT 11-SEP-2003 (revised)
DT 16-OCT-2001 (first entry)

XX Humanised murine 1D9 antibody heavy chain variable region, 1D9RHB.
DE
XX Murine; humanised antibody; CC-chemokine receptor 2; CCR2; nephrotropic;
XX neuroprotective; immunosuppressive; human immunodeficiency virus;
XX HIV infection; cytostatic; vasotropic; leukocyte trafficking; allergy;
XX inflammatory disorder; autoimmune disorder; rheumatoid arthritis; shock;
XX multiple sclerosis; atherogenesis; atherosclerosis; restenosis; asthma;
XX anaphylaxis; malignancy; inflammation; stenosis; allograft rejection;
XX fibrotic disease; angioplasty; acquired immune deficiency syndrome; AIDS;
XX inflammatory glomerulopathy; vascular intervention; 1D9 antibody;
XX neointimal hyperplasia; VH; heavy chain variable region; 1D9RHB.
OS Mus sp.
OS Homo sapiens.
OS Chimeric.
XX
XX Key Location/Qualifiers
FH Region 27..35
FT /label= CDR1
FT /note= "Complementarity determining region 1"
FT 50..68
FT /label= CDR2
FT /note= "Complementarity determining region 2"
FT 101..106
FT /label= CDR3
FT /note= "Complementarity determining region 3"
XX WO200157226-A1.
PN 09-AUG-2001.
XX 02-FEB-2001; 2001WO-US003537.
XX 03-FEB-2000; 2000US-00497625.
XX (MILL-) MILLENNIUM PHARM INC.
XX Larosa GJ, Horvath C, Newman W, Jones ST, O'brien S, O'keefe T;
XX WPI; 2001-488888/53.
DR Humanized immunoglobulin for treating a CC-chemokine receptor 2-mediated
XX disorder in a patient, comprises a binding specificity for CCR2, and a
XX non-human antigen binding region and human immunoglobulin.
XX Claim 62; Fig 12; 183pp; English.
XX The patent discloses a humanised antibody or its antigen-binding
XX fragment, having binding specificity for CC-chemokine receptor 2 (CCR2),
XX comprising an antigen binding region of non-human origin and at least a
XX portion of an immunoglobulin of human origin. The humanised antibodies
XX are useful for inhibiting the interaction of a cell expressing CCR2. They
XX are useful for inhibiting or treating HIV infection. The proteins of the
XX invention are useful for inhibiting leukocyte trafficking, for treating
XX CCR2-mediated disorders such as inflammatory disorder, autoimmune
XX disorders such as rheumatoid arthritis and multiple sclerosis,
XX atherogenesis and atherosclerosis, and for inhibiting restenosis. They
XX are useful in therapy or diagnosis, and in the manufacture of a
XX medicament for treating CCR-2 mediated disease. They are also useful for
XX treating allergy, anaphylaxis, malignancy, chronic and acute
XX inflammation, histamine and IGE-mediated allergic reaction, shock,
XX stenosis, allograft rejection, fibrotic disease, asthma, inflammatory
XX glomerulopathies, acquired immune deficiency syndrome (AIDS), restenosis
XX associated with vascular intervention, including angioplasty and/or stent
XX placement in a mammal. Humanised antibodies are also useful for
XX inhibiting narrowing of the lumen of a vessel in a mammal, and inhibiting
XX neointimal hyperplasia of a vessel in a mammal, preferably associated
XX with vascular intervention. The present sequence is humanised murine 1D9
XX antibody heavy chain variable (VH) region, 1D9RHB. (Updated on 11-SEP-
XX 2003 to standardise OS field)
XX Sequence 117 AA;

```

Query Match      98.9%; Score 613; DB 4; Length 117;
Best Local Similarity 98.3%; Pred. No. 3.6e-47;
Matches 115; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKGLVWVGRIKNNYAT 60
DB 1 EVQLVESGGGLVPGGSLRLSCAASGFSFNAYAMNVRQAPGKGLVWVGRIKNNYAT 60

QY 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGNVGWGQGLTVTVSS 117
DB 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGNVGWGQGLTVTVSS 117

RESULT 14
ABG75537
ID ABG75537 standard; protein; 117 AA.
XX
AC ABG75537;
XX
DT 16-APR-2003 (first entry)
XX
DE Humanised mouse mAb 1D9 heavy chain variable region, 1D9RHBVH.
XX
KW Mouse; stenosis; restenosis; blood vessel; vascular injury; antibody;
KW antigen binding fragment; cellular adhesion molecule; adhesion;
KW recruitment; neutrophil; antagonist; CCR2; mononuclear cell; angioplasty;
KW percutaneous transluminal coronary angioplasty; PTCA; stent;
KW vascular by-pass surgery; vascular grafting; endarterectomy; atherosclerosis;
KW endovascular stenting; prosthetic valve; transplantation;
KW inflammatory disease; mastitis; vaginitis; cholecystitis;
KW chronic bronchitis; asthma; graft-versus-host disease;
KW collagen inflammatory disease; hypersensitivity pneumonitis;
KW insulin dependent; sarcoidosis; idiopathic; pancreatic; HF-21/28;
KW Crohn's disease; diabetes mellitus; inflammatory bowel disease;
KW allergic rhinitis; autoimmune disease; psoriasis; atopic dermatitis; human;
KW graft rejection; atherosclerosis; myositis; therapy; 1D9; 1D9RHBVH;
KW heavy chain variable region; VH; complementarity determining region; CDR;
KW mutant; mutein.
XX
OS Mus sp.
OS Homo sapiens.
OS Synthetic.
XX
Key Location/Qualifiers
FT Misc-difference 28
FT /note= "Thr derived from the mouse 1D9 mAb sequence"
FT Misc-difference 30
FT /note= "Ser derived from the mouse 1D9 mAb sequence"
FT Region 31..35
FT /note= "Mouse complementarity determining region 1
FT (CDR1)"
FT Region 50..68
FT /note= "Mouse complementarity determining region 2
FT (CDR2)"
FT Region 101..106
FT /note= "Mouse complementarity determining region 3
FT (CDR3)"
XX
US2002106369-A1.
XX
08-AUG-2002.
XX
15-MAR-2001; 2001US-00809739.
XX
17-MAR-2000; 2000US-00528267.
XX (MILL-) MILLENNIUM PHARM INC.
XX
XX Horvath CJ, Rao PE;
XX WPI; 2002-697861/75.
XX

```

```

XX
PT Inhibiting (re)stenosis of blood vessel following vascular injury, by
PT administering first and second agents that inhibit adhesion and/or
PT recruitment of neutrophils and mononuclear cells, respectively to site of
PT vascular injury.
XX
PS Claim 32; Fig 18; 59pp; English.
XX
CC The invention discloses a method for inhibiting stenosis or restenosis of
CC a blood vessel following vascular injury in a subject. The method
CC involves administering to the subject a first therapeutic agent, which
CC comprises an antibody or its antigen binding fragment which binds a
CC cellular adhesion molecule, that inhibits the adhesion and/or recruitment
CC of neutrophils to a site of vascular injury and a second therapeutic
CC agent, which comprises an antagonist of CCR2 function, that inhibits
CC adhesion and/or recruitment of mononuclear cells to a site of vascular
CC injury. The vascular injury arises from a vascular intervention procedure
CC such as angioplasty (e.g. percutaneous transluminal coronary angioplasty
CC (PTCA) or angioplasty including placement of a stent), vascular by-pass
CC surgery, vascular grafting, endarterectomy, atherectomy, endovascular
CC stenting, insertion of a prosthetic valve and transplantation of organs,
CC tissues or cells. The method is also useful for treating inflammatory
CC diseases or conditions mediated by early neutrophil activity and later
CC mononuclear cell activity. Preferably, the method is useful for treating
CC a subject having mastitis, vaginitis, cholecystitis, chronic bronchitis,
CC asthma and graft-versus-host disease, chronic inflammatory disease of
CC lung, hypersensitivity pneumonitis, collagen diseases, sarcoidosis and
CC other idiopathic conditions, pancreatitis and insulin dependent diabetes
CC mellitus. The method is also useful for treating inflammatory bowel
CC disease, Crohn's disease, inflammatory or allergic diseases (such as
CC psoriasis, atopic dermatitis and allergic rhinitis), autoimmune diseases
CC (such as arthritis and multiple sclerosis), graft rejection,
CC atherosclerosis and myositis. The method enables simultaneous inhibition
CC of neutrophil and mononuclear cell participation in response to vascular
CC injury or inhibition of neutrophil participation followed by inhibition
CC of mononuclear cell participation, and thus provides superior therapy for
CC inhibiting stenosis or restenosis following vascular injury. The sequence
CC presented is the humanised mouse monoclonal antibody (mAb), 1D9, heavy
CC chain variable region (VH), 1D9RHBVH, which is comprised of the mouse 1D9
CC mAb complementarity determining regions (CDR's) linked by human 4B4'CL
CC mAb VH regions with a mouse derived Thr at position 28 and Ser at
CC position 30
XX
SQ Sequence 117 AA;

```

```

Query Match      98.9%; Score 613; DB 5; Length 117;
Best Local Similarity 98.3%; Pred. No. 3.6e-47;
Matches 115; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKGLVWVGRIKNNYAT 60
DB 1 EVQLVESGGGLVPGGSLRLSCAASGFSFNAYAMNVRQAPGKGLVWVGRIKNNYAT 60

QY 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGNVGWGQGLTVTVSS 117
DB 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGNVGWGQGLTVTVSS 117

RESULT 15
AAO14981
ID AAO14981 standard; protein; 117 AA.
XX
AC AAO14981;
XX
DT 05-SEP-2002 (first entry)
XX
DE Humanised murine heavy chain variable region (1D9RHB VH).
XX
KW Mouse; graft rejection; CC chemokine receptor 2 antagonist; mutant;
KW CCR2 antagonist; anti-CCR2 antibody; kidney transplant; liver transplant;
KW lung transplant; heart-lung transplant; pancreas transplant; mutein;
KW bowel transplant; heart transplant; graft versus host disease;
KW chronic graft rejection; antibody heavy chain variable region; 1D9RHB VH.

```


XX Mus musculus.
OS Synthetic.
XX US2002042370-A1.
XX 11-APR-2002.
XX
XX 13-APR-2001; 2001US-00835087.
XX
XX 14-APR-2000; 2000US-00549448.
XX (MILL-) MILLENNIUM PHARM INC.
XX
XX Hancock WW;
XX
XX WPI; 2002-351265/38.
XX
XX Inhibiting graft rejection, graft versus host disease or chronic
PT rejection of a transplanted graft, involves administering a CCR2
FT antagonist.
XX
XX Claim 26; Fig 2; 16pp; English.
XX
XX The invention comprises a method of inhibiting graft rejection, graft
CC versus host disease or chronic rejection of a transplanted graft. The
CC method involves administering an antagonist of CC chemokine receptor 2
CC (CCR2) and optionally an immunosuppressive agent. The CCR2 antagonist may
CC be an anti-CCR2 antibody (i.e. containing light and heavy chain
CC complementarity determining regions from various non-human origins). CCR2
CC is known to be involved in the rejection of transplanted grafts. The
CC method of the invention is useful for inhibiting graft rejection -
CC particularly allografts such as kidney, liver, lung, heart-lung,
CC pancreas, bowel and heart. The method of the invention is also useful for
CC inhibiting graft versus host disease and for inhibiting chronic rejection
CC of a transplanted graft. The present amino acid sequence represents a
CC humanised murine antibody heavy chain variable region (ID9RHb Vh)
XX
SQ Sequence 117 AA;

Query Match 98.9%; Score 613; DB 5; Length 117;
Best Local Similarity 98.3%; Pred. No. 3.6e-47;
Matches 115; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIKNNNYAT 60
Db 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIKNNNYAT 60

Qy 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGNVGWGGTFLTVSS 117
Db 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGNVGWGGTFLTVSS 117

Search completed: June 10, 2006, 11:56:18
Job time : 76.7162 secs

GenCore version 5.1.9
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: June 10, 2006, 11:56:42 ; Search time 12.473 Seconds
(without alignments)
902.540 Million cell updates/sec

Title: US-10-733-563-17

Perfect score: 620

Sequence: 1 EVQLVESGGGLVKGGSRL.....CTTFGNGVNGQGLTVTVSS 117

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

PIR_80.*

1: pir1.*

2: pir2.*

3: pir3.*

4: pir4.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	492.5	79.4	137	2 S42467	Ig heavy chain V r
2	490	79.0	121	2 S31106	Ig heavy chain - h
3	485	78.2	127	2 S58213	Ig heavy chain V r
4	483	77.9	121	2 S36005	Ig heavy chain V r
5	482	77.7	117	2 S31109	Ig heavy chain - h
6	480	77.4	121	2 A41940	Ig heavy chain V r
7	479.5	77.3	141	2 I32513	Ig heavy chain pre
8	478	77.1	123	2 A36006	Ig heavy chain V r
9	477	76.9	138	2 A30561	Ig heavy chain pre
10	474	76.5	139	2 S31678	Ig heavy chain V r
11	472.5	76.2	126	2 S44107	Ig heavy chain V-D
12	467	75.3	160	2 S05271	Ig heavy chain pre
13	463.5	74.8	122	2 S30533	Ig heavy chain V r
14	463.5	74.8	147	2 I37780	Ig variable region
15	463	74.7	123	2 S26794	Ig heavy chain V r
16	463	74.7	140	2 S31588	Ig heavy chain V r
17	461	74.4	119	2 C36005	Ig heavy chain V r
18	460	74.2	115	1 AVMS06	Ig heavy chain V-I
19	460	74.2	119	2 S31107	Ig heavy chain - h
20	459.5	74.1	120	2 E49590	Ig heavy chain V r
21	458	73.9	138	2 S31666	Ig heavy chain V r
22	457.5	73.8	120	2 S48798	Ig heavy chain V r
23	456	73.5	119	2 S31108	Ig heavy chain - h
24	456	73.5	143	2 S23624	Ig heavy chain V r
25	454.5	73.3	122	2 E36005	Ig heavy chain V r
26	454.5	73.3	124	2 S20775	Ig heavy chain V r
27	454.5	73.3	124	2 S20782	Ig heavy chain V r
28	454	73.2	119	2 D36005	Ig heavy chain V r
29	454	73.2	123	2 S34009	Ig heavy chain V r

30	454	73.2	140	2 S31686	Ig heavy chain V r
31	453.5	73.1	114	2 S46390	Ig heavy chain V r
32	453	73.1	134	2 S31699	Ig heavy chain V r
33	452	72.9	133	2 S34010	Ig heavy chain V r
34	450	72.6	113	1 AVMSAB	Ig heavy chain V-I
35	450	72.6	113	1 AVMSB7	Ig heavy chain V-I
36	450	72.6	115	1 AVMS82	Ig heavy chain V-I
37	450	72.6	123	2 S31114	Ig heavy chain - h
38	448.5	72.3	140	2 S70442	Ig heavy chain pre
39	448	72.3	125	2 S30531	Ig heavy chain V r
40	448	72.3	135	2 S31598	Ig heavy chain V r
41	447.5	72.2	118	2 S31116	Ig heavy chain - h
42	447	72.1	134	2 S31679	Ig heavy chain V r
43	446.5	72.0	122	2 S20772	Ig heavy chain V r
44	446	71.9	121	2 S31113	Ig heavy chain - h
45	445.5	71.9	114	2 S46391	Ig heavy chain V r

ALIGNMENTS

RESULT 1

S42467

Ig heavy chain V region precursor - mouse

C/Species: Mus musculus (house mouse)

C/Date: 06-Jan-1995 #sequence_revision 06-Jan-1995 #text_change 23-Jul-1999

C/Accession: S42467

R/Shiyanov, P.A.; Beepalov, I.A.; Terletskaya, H.N.; Deyev, S.M.

submitted to the EMBL Data Library, March 1994

A/Reference number: S42466

A/Accession: S42467

A/Status: preliminary

A/Molecule type: mRNA

A/Residues: 1-137 <SH1>

A/Cross-references: UNIPARC:UPI00001161DB; EMBL:X78107; NID:g460798; PIDN:CAAS4997.1; PIR

C/Superfamily: immunoglobulin V region; immunoglobulin homology

C/Keywords: heterotetramer; immunoglobulin

F;34-119/Domain: immunoglobulin homology <IMM>

Query Match 79.4%; Score 492.5; DB 2; Length 137;

Best Local Similarity 79.2%; Pred. No. 3.9e-37;

Matches 95; Conservative 11; Mismatches 9; Indels 5; Gaps 2;

Qy	1	EVQLVESGGGLVKGGSRLSCAASGFTFSAYAMNVRQAPGKLEWVRIRTKNNYAT	60
Db	20	EVQLVESGGGLVQPKSKLSLSCAASGFTFTYAMNVRQAPGKLEWVAIRSKNNYAT	79
Qy	61	YYADSVKDRFTISRDSKNTLYLQMNSLKTEDTAVYYCTTFYGN---GVWGQGLTVTVSS	117
Db	80	YVGNVSKDRFTISRDSQSMLYLQMNLKTEDTAVYYCV--YGNFGFAYWGQGLTVTVSA	137

RESULT 2

S31106

Ig heavy chain - human

C/Species: Homo sapiens (man)

C/Date: 02-Dec-1993 #sequence_revision 26-May-1995 #text_change 17-Mar-1999

C/Accession: S31106

R/Kaaphorst, F.M.; Timmers, E.; Kenter, M.J.H.; van Tol, M.J.D.; Voessen, J.M.; Schuurman,

Eur. J. Immunol. 22, 247-251, 1992

A/Title: Restricted utilization of germ-line V(H)3 genes and short diverse third comple

A/Reference number: S31104; MUID:92111633; PMID:1730252

A/Accession: S31106

A/Status: preliminary; nucleic acid sequence not shown; translation not shown

A/Molecule type: mRNA

A/Residues: 1-121 <RAA>

A/Cross-references: UNIPARC:UPI0000176C8E; EMBL:X62954

A/Note: the nucleotide sequence was submitted to the EMBL Data Library, October 1991

C/Superfamily: immunoglobulin V region; immunoglobulin homology

C/Keywords: heterotetramer; immunoglobulin

F;15-100/Domain: immunoglobulin homology <IMM>

Query Match 79.0%; Score 490; DB 2; Length 121;

```
Best Local Similarity 81.0%; Pred. No. 5.8e-37;
Matches 98; Conservative 5; Mismatches 14; Indels 4; Gaps 1;

Qy 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKGLEWVGRIKTKNNYAT 60
   |||||
Db 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSNAMNVRQAPGKGLEWVGRIKSKTDGGTT 60
   |||||

Qy 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTT-----FYGNGVWGQTLVTSS 116
   |||||
Db 61 DYAAPVKGRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTVIDYIYGMVWGQTTVTSS 120
   |||||

Qy 117 S 117
Db 121 S 121

RESULT 3
S58213
IG heavy chain V region (anti-F(ab')2) - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 13-Jan-1996 #sequence_revision 12-Apr-1996 #text_change 23-Jul-1999
A;Accession: S58213; S58212
R;Welschhof, M.; Terness, P.; Stanescu, D.; Zewe, M.; Hain, C.H.; Doebel, S.; Breitling,
submitted to the EMBL Data Library, July 1995
A;Description: Characterization of heavy and light chain immunoglobulin variable region
A;Reference number: S58206
A;Accession: S58213
A;Molecule type: mRNA
A;Residues: 1-127 <WEL>
A;Cross-references: UNIPARC:UPI000003PEA8; EMBL:X89055; NID:9929638; PIDN:CAA61442.1; PI
A;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-100/Domain: immunoglobulin homology <IMV>

Query Match 78.2%; Score 485; DB 2; Length 127;
Best Local Similarity 75.6%; Pred. No. 1.7e-36;
Matches 96; Conservative 7; Mismatches 14; Indels 10; Gaps 1;

Qy 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKGLEWVGRIKTKNNYAT 60
   |||||
Db 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSGSTMHWVRQASGKRGLEWVGRIKNDNSYAT 60
   |||||

Qy 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTT-----FYGNGVWGQ 110
   |||||
Db 61 AYASVKGRFTISRDDSENTAYLQMSLKIEDTAVYYCTTRGSSWVRGVNGYGMVWGQ 120
   |||||

Qy 111 TLVTSS 117
Db 121 TTVTSS 127

RESULT 4
H36005
IG heavy chain V region (M85) - human
C;Species: Homo sapiens (man)
C;Date: 21-Dec-1990 #sequence_revision 21-Dec-1990 #text_change 16-Dec-1998
C;Accession: H36005
R;Schroeder Jr., H.W.; Wang, J.Y.
Proc. Natl. Acad. Sci. U.S.A. 87, 6146-6150, 1990
A;Title: Preferential utilization of conserved immunoglobulin heavy chain variable gene
A;Reference number: A36005; MUID:90349571; PMID:2117273
A;Accession: H36005
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-121 <SCH>
A;Cross-references: UNIPARC:UPI0000176C28; GB:M34032
C;Genetics:
A;Gene: GDB:IGH@; IGHY1
A;Cross-references: GDB:118731; OMIM:146910
A;Map position: 14q32.33-14q32.33
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-100/Domain: immunoglobulin homology <IMV>
```

```
Query Match 77.9%; Score 483; DB 2; Length 121;
Best Local Similarity 81.0%; Pred. No. 2.4e-36;
Matches 98; Conservative 3; Mismatches 16; Indels 4; Gaps 1;

Qy 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKGLEWVGRIKTKNNYAT 60
   |||||
Db 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSNAMNVRQAPGKGLEWVGRIKSKTDGGTT 60
   |||||

Qy 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFFYNG-----VWGQGLVTSS 116
   |||||
Db 61 DYAAPVKGRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTDRGSSQSGDYWGQGLVTSS 120
   |||||

Qy 117 S 117
Db 121 S 121

RESULT 5
S31109
IG heavy chain - human
C;Species: Homo sapiens (man)
C;Date: 02-Dec-1993 #sequence_revision 26-May-1995 #text_change 17-Mar-1999
A;Accession: S31109
R;Raaphorst, F.M.; Timmers, E.; Kenter, M.J.H.; van Tol, M.J.D.; Vossen, J.M.; Schuurman,
Eur. J. Immunol. 22, 247-251, 1992
A;Title: Restricted utilization of germ-line V(H)3 genes and short diverse third comple
A;Reference number: S31104; MUID:92111633; PMID:1730252
A;Accession: S31109
A;Status: preliminary; nucleic acid sequence not shown; translation not shown
A;Molecule type: mRNA
A;Residues: 1-117 <RAA>
A;Cross-references: UNIPARC:UPI0000176DCA; EMBL:X62960
A;Note: the nucleotide sequence was submitted to the EMBL Data Library, October 1991
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-100/Domain: immunoglobulin homology <IMV>
```

```
Query Match 77.7%; Score 482; DB 2; Length 117;
Best Local Similarity 82.1%; Pred. No. 2.9e-36;
Matches 96; Conservative 4; Mismatches 17; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKGLEWVGRIKTKNNYAT 60
   |||||
Db 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSNAMNVRQAPGKGLEWVGRIKSKTDGGTT 60
   |||||

Qy 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFFYNGVWGQGLVTSS 117
   |||||
Db 61 DYAAPVKGRFTISRDDSKNTLYLQMSLKTEDTAVYYCTATYYFDYWGQGLVTSS 117
   |||||

RESULT 6
A41940
IG heavy chain V region G2b, autoantibody BV04-01 - mouse (fragment)
N;Alternate names: anti-DNA autoantibody BV04-01, heavy chain V region
C;Species: Mus musculus (house mouse)
C;Date: 04-Mar-1993 #sequence_revision 18-Nov-1994 #text_change 07-May-1999
C;Accession: A41940; PLO201
R;Herron, J.N.; He, X.M.; Ballard, D.W.; Blier, P.R.; Pace, P.E.; Bothwell, A.L.; Voss Jr
Proteins 11, 159-175, 1991
A;Title: An autoantibody to single-stranded DNA: comparison of the three-dimensional str
A;Reference number: A41940; MUID:92086633; PMID:1749770
A;Accession: A41940
A;Status: preliminary; not compared with conceptual translation
A;Molecule type: nucleic acid
A;Residues: 1-121 <HER>
A;Cross-references: UNIPARC:UPI0000176D34
A;Note: sequence extracted from NCBI backbone (NCBIP:70715)
R;Smith, R.G.; Voss Jr., E.W.
Mol. Immunol. 27, 463-470, 1990
A;Title: Variable region primary structures of monoclonal anti-DNA autoantibodies from NM
A;Reference number: PLO198; MUID:90309768; PMID:2114528
A;Accession: PLO201
```

A;Molecule type: mRNA
A;Accession: A36006
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-118 <SMI>
A;Cross-references: UNIPARC:UPI0000176D35
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-100/Domain: immunoglobulin homology <IMM>
F;31-35/Region: complementarity-determining 1
F;50-68/Region: complementarity-determining 2
F;101-110/Region: complementarity-determining 3
F;101-106/Region: D region
F;107-115/Region: JH region

Query Match 77.4%; Score 480; DB 2; Length 121;
Best Local Similarity 75.6%; Pred. No. 4.5e-36;
Matches 93; Conservative 13; Mismatches 9; Indels 8; Gaps 2;

Qy 1 EVQLVESGGGLVQPGGSLRLSCLASGFTFSAYAMNVRQAPGKLEWVGRIKNNYAT 60
Db 1 EVQPVETGGGLVQPGGSLRLSCLASGFTFSAYAMNVRQAPGKLEWVGRIKNNYAT 60

Qy 61 YYADSVKDRFTISRDDSKNTLYLQMSLTKEDTAVYYCT-----TTPYGVNGVWGQGLT 114
Db 61 YYADSVKDRFTISRDDSKNTLYLQMSLTKEDTAVYYCTAVYCTGTAWF--AYWGQGLT 118

Qy 115 VSS 117
Db 119 VSA 121

RESULT 7
I32513
Ig heavy chain precursor V region (MRL4) - mouse
C;Species: Mus musculus (house mouse)
C;Date: 21-May-1990 #sequence_revision 31-Dec-1990 #text_change 23-Jul-1999
C;Accession: I32513
R;Kofler, R.; Strohal, R.; Balderas, R.S.; Johnson, M.E.; Noonan, D.J.; Duchosal, M.A.;
J. Clin. Invest. 82, 852-860, 1988
A;Title: Immunoglobulin kappa light chain variable region gene complex organization and
A;Reference number: A94689; MUID:8831394; PMID:3138286
A;Accession: I32513
A;Molecule type: DNA
A;Residues: 1-141 <KOF>
A;Cross-references: UNIPARC:UPI0000114D98; GB:M20829; NID:g196951; PIDN:AAA38849.1; PID:
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;34-119/Domain: immunoglobulin homology <IMM>

Query Match 77.3%; Score 479.5; DB 2; Length 141;
Best Local Similarity 75.4%; Pred. No. 5.8e-36;
Matches 92; Conservative 12; Mismatches 13; Indels 5; Gaps 1;

Qy 1 EVQLVESGGGLVQPGGSLRLSCLASGFTFSAYAMNVRQAPGKLEWVGRIKNNYAT 60
Db 20 EVQLVETGGGLVQPGGSLRLSCLASGFTFSAYAMNVRQAPGKLEWVGRIKNNYAT 79

Qy 61 YYADSVKDRFTISRDDSKNTLYLQMSLTKEDTAVYYCTTFYGN-----GVWGQGLT 115
Db 80 YYADSVKDRFTISRDDSKNTLYLQMSLTKEDTAVYYCVRDAANWSAFAWYWGQGLT 139

Qy 116 SS 117
Db 140 SA 141

RESULT 8
A36006
Ig heavy chain V region (M26) - human
C;Species: Homo sapiens (man)
C;Date: 21-Dec-1990 #sequence_revision 21-Dec-1990 #text_change 16-Dec-1998
C;Accession: A36006
R;Schroeder Jr., H.W.; Wang, J.Y.
Proc. Natl. Acad. Sci. U.S.A. 87, 6146-6150, 1990
A;Title: Preferential utilization of conserved immunoglobulin heavy chain variable gene

A;Reference number: A36005; MUID:90349571; PMID:2117273
A;Accession: A36006
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-123 <SCH>
A;Cross-references: UNIPARC:UPI000003FEBD; GB:M34023
C;Genetic8;
A;Gene: GDB:IGH@; IGHDI1
A;Cross-references: GDB:118731; OMIM:146910
A;Map position: 14q32.33-14q32.33
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-100/Domain: immunoglobulin homology <IMM>

Query Match 77.1%; Score 478; DB 2; Length 123;
Best Local Similarity 78.9%; Pred. No. 6.9e-36;
Matches 97; Conservative 4; Mismatches 16; Indels 6; Gaps 1;

Qy 1 EVQLVESGGGLVQPGGSLRLSCLASGFTFSAYAMNVRQAPGKLEWVGRIKNNYAT 60
Db 1 EVQLVESGGGLVQPGGSLRLSCLASGFTFSAYAMNVRQAPGKLEWVGRIKNNYAT 60

Qy 61 YYADSVKDRFTISRDDSKNTLYLQMSLTKEDTAVYYCTT-----FYGVNGVWGQGLT 114
Db 61 DYAAPVKGRTISRDDSKNTLYLQMSLTKEDTAVYYCTTSGIAVAGTDYWGQGLT 120

Qy 115 VSS 117
Db 121 VSS 123

RESULT 9
A30561
Ig heavy chain precursor V-III region (484) - human (fragment)
N;Alternate names: Ig heavy chain V region (DP-38)
C;Species: Homo sapiens (man)
C;Date: 23-Mar-1989 #sequence_revision 23-Mar-1989 #text_change 23-Jul-1999
C;Accession: A30561; S26931; S34008
R;Sanz, I.; Dang, H.; Takei, M.; Talal, N.; Capra, J.D.
J. Immunol. 142, 883-887, 1989
A;Title: V-H sequence of a human anti-Sm autoantibody. Evidence that autoantibodies can
A;Reference number: A30561; MUID:89110065; PMID:2492331
A;Accession: A30561
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-138 <SAN>
A;Cross-references: UNIPARC:UPI0000176C80
R;Tomlinson, I.M.; Walter, G.; Marks, J.D.; Llewellyn, M.B.; Winter, G.
J. Mol. Biol. 227, 776-798, 1992
A;Title: The repertoire of human germline V(H) sequences reveals about fifty groups of V.
A;Reference number: S26885; MUID:93021117; PMID:1404388
A;Accession: S26931
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 20-119 <TOM>
A;Cross-references: UNIPARC:UPI000011640B; EMBL:Z12338; NID:g32896; PIDN:CAA78208.1; PID:
Eur. J. Immunol. 23, 846-851, 1993
A;Title: Nucleotide sequence analysis of the variable domains of four human monoclonal
A;Reference number: S34001; MUID:93209281; PMID:7681398
A;Accession: S34008
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 20-119 <MAR>
A;Cross-references: UNIPARC:UPI000011640B
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;34-119/Domain: immunoglobulin homology <IMM>

Query Match 76.9%; Score 477; DB 2; Length 138;
Best Local Similarity 81.5%; Pred. No. 9.5e-36;
Matches 97; Conservative 5; Mismatches 15; Indels 2; Gaps 1;

THIS PAGE BLANK (USPTO)


```

DE Anti-lipoteichoic acid heavy chain variable region (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muroidae; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=BALB/c;
RA Stinson J.R., Lopez V., Grinberg L., Mond J.;
RT "The Murine Antibody Response to Lipoteichoic Acid: A Linkage Between
RT Innate and Adaptive Immunity.";
RL Submitted (NOV-2004) to the EMBL/GenBank/DBJ databases.
CC -----
CC Copyrighted by the Uniprot Consortium, see http://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution-NoDerivs License
CC -----
DR EMBL; AY835662; AAX56286.1; -; mRNA.
KW Immunoglobulin domain.
FT NON_TER 1
FT NON_TER 123 123
SQ SEQUENCE 123 AA; 13698 MW; C72457B22E2B8F2 CRC64;

Query Match 78.5%; Score 487; DB 2; Length 123;
Best Local Similarity 75.6%; Pred. No. 2.2e-44;
Matches 93; Conservative 13; Mismatches 11; Indels 6; Gaps 1;

QY 1 EVLVESGGGLVKPGGSLRLSCLASGFTFSAYAMNVRQAPGKLEWVGRIKNNYAT 60
DB 1 EVMLVESGGGLVQPKGSLKSLCASGFTFNAYAMNVRQAPGKLEWVARIRSKNNYAT 60

QY 61 YYADSVKDRFTISRDDSKNTLYLQMNLSKLTEDTAVYVCT- - - - -HWQGTTLV 114
DB 61 FYADSVKDRFTISRDDSQSMLYLQMNLSKLTEDTAMYYCVRRGASGIDYAMDYWGQGTSLT 120

QY 115 VSS 117
DB 121 VSS 123

Query Match 77.7%; Score 482; DB 2; Length 123;
Best Local Similarity 74.8%; Pred. No. 7.7e-44;
Matches 92; Conservative 12; Mismatches 13; Indels 6; Gaps 1;

RESULT 3
Q2VR03_MOUSE PRELIMINARY; PRT; 123 AA.
AC Q2VR03;
DT 10-JAN-2006, integrated into UniProtKB/TrEMBL.
DT 10-JAN-2006, sequence version 1.
DT 07-MAR-2006, entry version 4.
DE Anti-lipoteichoic acid heavy chain variable region (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muroidae; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=BALB/c;
RA Stinson J.R., Lopez V., Grinberg L., Mond J.;
RT "The Murine Antibody Response to Lipoteichoic Acid: A Linkage Between
RT Innate and Adaptive Immunity.";
RL Submitted (DEC-2004) to the EMBL/GenBank/DBJ databases.
CC -----
CC Copyrighted by the Uniprot Consortium, see http://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution-NoDerivs License
CC -----
DR EMBL; AY860430; AAX56292.1; -; mRNA.
KW Immunoglobulin domain.
FT NON_TER 1
FT NON_TER 123 123
SQ SEQUENCE 123 AA; 13727 MW; DB52F1168746BA2E CRC64;

Query Match 77.7%; Score 482; DB 2; Length 123;
Best Local Similarity 74.8%; Pred. No. 7.7e-44;
Matches 92; Conservative 12; Mismatches 13; Indels 6; Gaps 1;

DE Anti-lipoteichoic acid heavy chain variable region (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muroidae; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=BALB/c;
RA Stinson J.R., Lopez V., Grinberg L., Mond J.;
RT "The Murine Antibody Response to Lipoteichoic Acid: A Linkage Between
RT Innate and Adaptive Immunity.";
RL Submitted (NOV-2004) to the EMBL/GenBank/DBJ databases.
CC -----
CC Copyrighted by the Uniprot Consortium, see http://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution-NoDerivs License
CC -----
DR EMBL; AY835666; AAX56290.1; -; mRNA.
KW Immunoglobulin domain.
FT NON_TER 1
FT NON_TER 124 124
SQ SEQUENCE 124 AA; 14085 MW; 4F5000D6AF3AC619 CRC64;

Query Match 77.2%; Score 478.5; DB 2; Length 124;
Best Local Similarity 73.4%; Pred. No. 1.8e-43;
Matches 91; Conservative 13; Mismatches 13; Indels 7; Gaps 1;

QY 1 EVLVESGGGLVKPGGSLRLSCLASGFTFSAYAMNVRQAPGKLEWVGRIKNNYAT 60
DB 1 EVKLHESGGGFVQPKGSLKSLCASGFTFNAYAMNVRQAPGKLEWVARIRSKNNYAT 60

QY 61 YYADSVKDRFTISRDDSKNTLYLQMNLSKLTEDTAVYVCT- - - - -TTFYNGVWGQGTTLV 113
DB 61 YYADSVKDRFTISRDDSQYVYVLYQMNLSKLTEDTAMYYCVRRGSMRSAYAMDYWGQGTSLV 120

QY 114 TVSS 117
DB 121 TVSS 124

RESULT 5
Q66K04_MOUSE PRELIMINARY; PRT; 471 AA.
AC Q66K04;
DT 11-OCT-2004, integrated into UniProtKB/TrEMBL.
DT 11-OCT-2004, sequence version 1.
DT 07-FEB-2006, entry version 17.
DE Igh-1a protein.
GN Name=Igh-1a;
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;

```


Query Match	77.0%;	Score	477.5;	DB 2;	Length	471;
Best Local Similarity	75.4%;	Pred.	No. 1.2e-42;			
Matches 92;	Conservative	12;	Mismatches	13;	Indels	5;
					Gaps	1;

```
DT 21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT 21-JUL-1986, sequence version 1.
DT 07-MAR-2006, entry version 38.
DE Ig heavy chain V-III region J606.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
NCBI_TaxID=10090;
RN [1]
RP PROTEIN SEQUENCE.
RX MEDLINE=8209361; PubMed=6798111;
RA Johnson N., Slankard J., Paul L., Hood L.;
RT "The complete V domain amino acid sequences of two myeloma inulin-
RT binding proteins.";
RL J. Immunol. 128:302-307(1992).
CC -1- MISCELLANEOUS: This chain was isolated from a myeloma protein that
CC binds inulin.
CC -1- SIMILARITY: Contains 1 Ig-like (immunoglobulin-like) domain.
CC -----
CC Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution-NoDerivs License
CC -----
DR PIR; C92811; AVMS06.
DR HSP; P01852; INFD.
DR Ensembl; ENSMUSG00000045097; Mus musculus.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig V.
DR InterPro; IPR013106; V-set.
DR Pfam; PF07686; V-set; 1.
DR SMART; SM00409; IG; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG LIKE; 1.
KW Direct protein sequencing; Immunoglobulin domain;
KW Immunoglobulin V region.
FT CHAIN 1 >115
FT DOMAIN 1 114
FT DISULFID 22 98
FT NON TER 115
SQ SEQUENCE 115 AA; 12810 MW; B67AD6638A121A5F CRC64;

Query Match 74.2%; Score 460; DB 1; Length 115;
Best Local Similarity 73.5%; Pred. No. 1.7e-41;
Matches 86; Conservative 15; Mismatches 14; Indels 2; Gaps 1;

QY 1 EVLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIKNNYAT 60
DB 1 EVKLEESGGGLVPGGSMKLSVCSAGFTFSYNNWVRQSPKGLWVAIRLKSNNYAT 60

QY 61 YYADSVKDRFTISRDDSKNTLYIQMNSLKTEDTAVYYCTTFYNGVWGQGLTVTVSS 117
DB 61 HYAESVKGRTISRDDSKSYLQMNLRADTGIIYCTT--GFAVWGQGLTVTVA 115

RESULT 8
Q9UL90_HUMAN
ID Q9UL90_HUMAN PRELIMINARY; PRT; 113 AA.
AC Q9UL90;
DT 01-MAY-2000, integrated into UniProtKB/TrEMBL.
DT 01-MAY-2000, sequence version 1.
DT 07-FEB-2006, entry version 20.
DE Myosin-reactive immunoglobulin heavy chain variable region (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
NCBI_TaxID=9606;
RN [1]
RP PROTEIN SEQUENCE.
RX MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clin.1998.4531;
RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berney S.M.,
RT "Myosin-reactive autoantibodies in rheumatic carditis and normal
RT placental alkaline phosphatase has a binding site for the human
RT immunoglobulin-G Fc portion.";
```

```
RA Young D.C.;
RT "Myosin-reactive autoantibodies in rheumatic carditis and normal
RT fetus.";
RL Clin. Immunol. Immunopathol. 87:184-192(1998).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=92111633; PubMed=1730252;
RA Raaphorst F.M., Timmers E., Kenter M.J., Van Tol M.J., Vossen J.M.,
RA Schuurman R.K.;
RT "Restricted utilization of germ-line VH3 genes and short diverse third
RT complementarity-determining regions (CDR3) in human fetal B lymphocyte
RT immunoglobulin heavy chain rearrangements.";
RL Eur. J. Immunol. 22:247-251(1992).
CC -----
CC Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution-NoDerivs License
CC -----
DR ENBL; AF035024; AAD56260.1; -; mRNA.
DR PIR; S78486; S78486.
DR HSP; P01772; 2F84.
DR SMR; Q9UL90; 1-113.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig V.
DR InterPro; IPR013106; V-set.
DR SMART; SM00409; IG; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG LIKE; 1.
KW Immunoglobulin domain.
FT NON TER 1
FT NON TER 113
SQ SEQUENCE 113 AA; 12437 MW; ED57FDD19086D07F CRC64;

Query Match 73.1%; Score 453; DB 2; Length 113;
Best Local Similarity 77.8%; Pred. No. 9.4e-41;
Matches 91; Conservative 7; Mismatches 15; Indels 4; Gaps 2;

QY 1 EVLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIKNNYAT 60
DB 1 EVLVESGGGVQPGGSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAFIRVDGNN--K 58

QY 61 YYADSVKDRFTISRDDSKNTLYIQMNSLKTEDTAVYYCTTFYNGVWGQGLTVTVSS 117
DB 59 YYADSVKGRFTISRDNKNTLYIQMNSLRADTAVYYCAK--DLNVWGQGLTVTVSS 113

RESULT 9
Q9UL88_HUMAN
ID Q9UL88_HUMAN PRELIMINARY; PRT; 131 AA.
AC Q9UL88;
DT 01-MAY-2000, integrated into UniProtKB/TrEMBL.
DT 01-MAY-2000, sequence version 1.
DT 07-FEB-2006, entry version 21.
DE Myosin-reactive immunoglobulin heavy chain variable region (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clin.1998.4531;
RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berney S.M.,
RA Young D.C.;
RT "Myosin-reactive autoantibodies in rheumatic carditis and normal
RT fetus.";
RL Clin. Immunol. Immunopathol. 87:184-192(1998).
RN [2]
RP PROTEIN SEQUENCE.
RX MEDLINE=92209522; PubMed=1555592;
RA Makiya R., Stigbrand T.;
RT "Placental alkaline phosphatase has a binding site for the human
RT immunoglobulin-G Fc portion.";
```

```

DR PROSITE; PS50835; IG LIKE; 2.
KW Immunoglobulin_domain.
FT NON TER 1
FT NON TER 240 240
SQ SEQUENCE 240 AA; 25569 MW; FDCPD3645F64B373 CRC64;

Query Match 72.9%; Score 452; DB 2; Length 240;
Best Local Similarity 74.8%; Pred. No. 3e-40;
Matches 89; Conservative 12; Mismatches 14; Indels 4; Gaps 2;

QY 1 EVQLVESGGGLVQPGGSLRLSCAASGFTFSFAYAMNWVRQAPGKGLEWVGRITRTNNNYAT 60
DB 1 QVQLVQSGGGLVQPGGSLRLSCAASGFTFSFSGYGNHWVRQAPGKGLEWVAIVSYGDSN--K 58
QY 61 YYADSVKDRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTFYNGV--WGQGLTLVTYSS 117
DB 59 YYADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCARDWGSDLPWGKGLTLVTYSS 117

RESULT 11
HV27 MOUSE ID HV27 MOUSE STANDARD; PRT; 113 AA.
AC P01756;
DT 21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT 21-JUL-1986, sequence version 1.
DE 07-MAR-2006, entry version 39.
DE Ig heavy chain V-III region A4.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Muridae; Murinae; Mus.
NCBI_TaxID=10090;
[1]
PROTEIN SEQUENCE.
MEDLINE=78158405; PubMed=417344;
Vrana M., Rudikoff S., Potter M.;
"Sequence variation among heavy chains from inulin-binding myeloma
proteins.;"
Proc. Natl. Acad. Sci. U.S.A. 75:1957-1961(1978).
CC -/- MTSCELLANEUS: This chain was isolated from a myeloma protein that
CC binds inulin.
CC -/- SIMILARITY: Contains 1 Ig-like (immunoglobulin-like) domain.
-----
CC Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution-NoDerivs License
-----
PIR; A93818; AUMSAB.
HSP; P01796; IIGC.
SMR; P01796; I-113.
Ensembl; ENSMUSG00000045097; Mus musculus.
InterPro; IPR003599; Ig.
InterPro; IPR007110; Ig-like.
InterPro; IPR003596; Ig_v.
InterPro; IPR013106; V-set.
Pfam; PF07686; V-set; 1.
SMART; SM00409; IG; 1.
SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 1.
KW Direct protein sequencing; Immunoglobulin domain;
KW Immunoglobulin V region.
CHAIN 1 >113
FT FT DOMAIN 1 >113
FT FT DISULFID 22 98
FT FT NON TER 113 113
SQ SEQUENCE 113 AA; 12675 MW; 76658C121C598285 CRC64;

Query Match 72.6%; Score 450; DB 1; Length 113;
Best Local Similarity 73.0%; Pred. No. 2e-40;
Matches 84; Conservative 15; Mismatches 14; Indels 2; Gaps 1;

QY 1 EVQLVESGGGLVQPGGSLRLSCAASGFTFSFAYAMNWVRQAPGKGLEWVGRITRTNNNYAT 60

```

```
Db 1 EVKLESGGGLVPGGSKMLSCVASGFTFSNYMNMWVRQSPKGLWVAIRLKSHNYAT 60
QY 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYCTTFYGNVGWQGLTLVTV 115
Db 61 HYAESVKGRTISRDDSKSYVLQMNLRADTGIYYCTT--GFAYWGQGLTLVTV 113

RESULT 12
HV30_MOUSE STANDARD; PRT; 113 AA.
AC HV30_MOUSE
DT 21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT 21-JUL-1986, sequence version 1.
DT 07-MAR-2006, entry version 38.
DE Ig heavy chain V-III region ABE-47N.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridea; Muridae; Murinae; Mus.
NCBI_TaxID=10090;
[1]
PROTEIN SEQUENCE.
RP MEDLINE=77134726; PubMed=402936;
RA Vrana M., Rudikoff S., Potter M.;
RT "Heavy-chain variable-region sequence from an inulin-binding myeloma
protein.";
RL Biochemistry 16:1170-1175 (1977).
CC -1- MISCELLANEOUS: This chain was isolated from a myeloma protein that
CC binds inulin.
CC -1- SIMILARITY: Contains 1 Ig-like (immunoglobulin-like) domain.
CC Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution-NoDerivs License
-----
DR PIR; A90400; AVMSB7.
DR HSSP; P01810; 2FBJ.
DR SMR; P01799; 1-113.
DR Ensembl; ENSMUSG00000045097; Mus musculus.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_V.
DR InterPro; IPR013106; V-set.
DR Pfam; PF07686; V-set; 1.
DR SMART; SM00409; IG; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
KW Direct protein sequencing; Immunoglobulin domain;
KW Immunoglobulin V region.
FT CHAIN 1 >113
FT DOMAIN 1 >113
FT DISULFID 22 98
FT NON_TER 113
FT SEQUENCE 113 AA; 12675 MW; 76658C16C779845E CRC64;

Query Match 72.6%; Score 450; DB 1; Length 113;
Best Local Similarity 73.0%; Pred. No. 2e-40;
Matches 84; Conservative 16; Mismatches 13; Indels 2; Gaps 1;

QY 1 EVLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIPTKNNYAT 60
Db 1 EVKLESGGGLVPGGSKMLSCVASGFTFSNYMNMWVRQSPKGLWVAIRLKSHNYAT 60

QY 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYCTTFYGNVGWQGLTLVTV 115
Db 61 HYAESVKGRTISRDDSKSYVLQMNLRADTGIYYCTT--GFAYWGQGLTLVTV 113

RESULT 13
HV33_MOUSE STANDARD; PRT; 115 AA.
ID HV33_MOUSE
AC P01802;
DT 21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
```

```
DT 21-JUL-1986, sequence version 1.
DT 07-MAR-2006, entry version 39.
DE Ig heavy chain V-III region W3082.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridea; Muridae; Murinae; Mus.
NCBI_TaxID=10090;
[1]
PROTEIN SEQUENCE.
RP MEDLINE=8209361; PubMed=6798111;
RA Johnson N., Slankard J., Paul L., Hood L.;
RT "The complete V domain amino acid sequences of two myeloma inulin-
binding proteins.";
RL J. Immunol. 128:302-307 (1982).
CC -1- MISCELLANEOUS: This chain was isolated from a myeloma protein that
CC binds inulin.
CC -1- SIMILARITY: Contains 1 Ig-like (immunoglobulin-like) domain.
CC Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution-NoDerivs License
-----
DR PIR; D92811; AVMS82.
DR HSSP; P01852; 1NFD.
DR SMR; P01802; 1-115.
DR Ensembl; ENSMUSG00000045097; Mus musculus.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_V.
DR InterPro; IPR013106; V-set.
DR Pfam; PF07686; V-set; 1.
DR SMART; SM00409; IG; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
KW Direct protein sequencing; Immunoglobulin domain;
KW Immunoglobulin V region.
FT CHAIN 1 >115
FT DOMAIN 1 114
FT DISULFID 22 98
FT NON_TER 115
FT SEQUENCE 115 AA; 12887 MW; 9B4517648C121C5A CRC64;

Query Match 72.6%; Score 450; DB 1; Length 115;
Best Local Similarity 71.8%; Pred. No. 2e-40;
Matches 84; Conservative 17; Mismatches 14; Indels 2; Gaps 1;

QY 1 EVLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIPTKNNYAT 60
Db 1 EVKLESGGGLVPGGSKMLSCVASGFTFSNYMNMWVRQSPKGLWVAIRLKSHNYAT 60

QY 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYCTTFYGNVGWQGLTLVTVSS 117
Db 61 HYAESVKGRTISRDDSKSYVLQMNLRADTGIYYCTT--GFAYWGQGLTLVTVSA 115

RESULT 14
Q96BB9_HUMAN PRELIMINARY; PRT; 597 AA.
ID Q96BB9_HUMAN
AC Q96BB9;
DT 01-DEC-2001, integrated into UniProtKB/TrEMBL.
DT 01-DEC-2001, sequence version 1.
DT 07-FEB-2006, entry version 26.
DE IGHM protein.
GN Name=IGHM;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Hominidae;
OC Homo
OC NCBI_TaxID=9606;
[1]
RP NUCLEOTIDE SEQUENCE.
TI TISSUE=Primary B-Cells;
```


GenCore version 5.1.9
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: June 10, 2006, 12:05:52 ; Search time 20.2027 Seconds
(without alignments)
506.917 Million cell updates/sec

Title: US-10-733-563-17

Perfect score: 620

Sequence: 1 EVQLVESGGGLVPGGSLRL.....CTTFYGNVGWGQGLTVTVSS 117

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 650591 seqs, 87530628 residues

Total number of hits satisfying chosen parameters: 650591

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Issued Patents AA.*

- 1: /EMC_Celerra_SIDS3/ptodata/2/iaa/5_COMB.pep.*
- 2: /EMC_Celerra_SIDS3/ptodata/2/iaa/6_COMB.pep.*
- 3: /EMC_Celerra_SIDS3/ptodata/2/iaa/7_COMB.pep.*
- 4: /EMC_Celerra_SIDS3/ptodata/2/iaa/H_COMB.pep.*
- 5: /EMC_Celerra_SIDS3/ptodata/2/iaa/PTUS_COMB.pep.*
- 6: /EMC_Celerra_SIDS3/ptodata/2/iaa/RE_COMB.pep.*
- 7: /EMC_Celerra_SIDS3/ptodata/2/iaa/backfiles.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	620	100.0	117	2	US-09-809-739-20
2	620	100.0	117	2	US-09-840-459-17
3	620	100.0	117	2	US-09-497-625A-17
4	620	100.0	119	2	US-09-840-459-104
5	620	100.0	119	2	US-09-497-625A-104
6	613	98.9	117	2	US-09-809-739-21
7	613	98.9	117	2	US-09-840-459-18
8	613	98.9	117	2	US-09-497-625A-18
9	604	97.4	117	2	US-09-809-739-22
10	604	97.4	117	2	US-09-840-459-19
11	604	97.4	117	2	US-09-497-625A-19
12	599	96.6	117	2	US-09-809-739-23
13	599	96.6	117	2	US-09-840-459-20
14	599	96.6	117	2	US-09-497-625A-20
15	548	88.4	117	2	US-09-809-739-12
16	548	88.4	117	2	US-09-840-459-10
17	548	88.4	117	2	US-09-497-625A-10
18	548	88.4	148	2	US-09-840-459-100
19	548	88.4	148	2	US-09-497-625A-100
20	488.5	80.4	444	3	US-08-674-716B-53
21	488.5	78.8	116	1	US-08-428-197-10
22	488.5	78.8	116	5	PCT-US93-10555-10
23	487	78.5	123	2	US-09-097-055B-87
24	487	78.5	123	2	US-09-893-615-87
25	485	78.2	125	1	US-08-428-197-9
26	485	78.2	125	5	PCT-US93-10555-9

27 485 78.2 127 2 US-09-840-459-71 Sequence 71, Appl
28 485 78.2 127 2 US-09-497-625A-71 Sequence 71, Appl
29 483.5 78.0 126 2 US-09-840-459-74 Sequence 74, Appl
30 483.5 78.0 126 2 US-09-497-625A-74 Sequence 74, Appl
31 482 77.7 115 2 US-08-767-128-36 Sequence 36, Appl
32 482 77.7 115 2 US-09-840-459-83 Sequence 83, Appl
33 482 77.7 117 2 US-09-497-625A-83 Sequence 83, Appl
34 480.5 77.5 126 2 US-09-840-459-73 Sequence 73, Appl
35 480.5 77.5 126 2 US-09-497-625A-73 Sequence 73, Appl
36 480.5 77.5 130 1 US-08-478-039-70 Sequence 70, Appl
37 480.5 77.5 130 1 US-08-478-039-93 Sequence 93, Appl
38 480.5 77.5 130 1 US-08-476-349A-70 Sequence 70, Appl
39 480.5 77.5 130 1 US-08-476-349A-93 Sequence 93, Appl
40 480 77.4 332 2 US-09-135-121B-7 Sequence 7, Appl
41 478 77.1 123 2 US-09-840-459-94 Sequence 94, Appl
42 478 77.1 123 2 US-09-497-625A-94 Sequence 94, Appl
43 477 76.9 119 1 US-08-428-197-11 Sequence 11, Appl
44 477 76.9 119 2 US-09-809-739-19 Sequence 19, Appl
45 477 76.9 119 2 US-09-840-459-16 Sequence 16, Appl

ALIGNMENTS

RESULT 1
US-09-809-739-20
; Sequence 20, Application US/09809739
; Patent No. 6663863
; GENERAL INFORMATION:
; APPLICANT: Horvath, Christopher J.
; APPLICANT: Rao, Patricia E.
; TITLE OF INVENTION: Method of Inhibiting Stenosis and
; TITLE OF INVENTION: Restenosis
; FILE REFERENCE: 1855.1069-003
; CURRENT APPLICATION NUMBER: US/09/809,739
; PRIOR FILING DATE: 2001-03-15
; PRIOR FILING DATE: 2000-03-17
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 20
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Humanized sequence
US-09-809-739-20

Query Match 100.0%; Score 620; DB 2; Length 117;
Best Local Similarity 100.0%; Pred. No. 1.2e-54;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIKNNYAT 60
Db 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIKNNYAT 60
Qy 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGNVGWGQGLTVTVSS 117
Db 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGNVGWGQGLTVTVSS 117

RESULT 2
US-09-840-459-17
; Sequence 17, Application US/09840459
; Patent No. 6696550
; GENERAL INFORMATION:
; APPLICANT: Larosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND

1 TITLE OF INVENTION: METHODS OF USE THEREFOR
2 FILE REFERENCE: 1855.1052-012
3 CURRENT APPLICATION NUMBER: US/09/840,459
4 CURRENT FILING DATE: 2001-02-02
5 PRIOR APPLICATION NUMBER: PCT/US01/03537
6 PRIOR FILING DATE: 2001-02-02
7 PRIOR APPLICATION NUMBER: 09/497,625
8 PRIOR FILING DATE: 2000-02-03
9 PRIOR APPLICATION NUMBER: 09/359,193
10 PRIOR FILING DATE: 1999-07-22
11 PRIOR APPLICATION NUMBER: 09/121,781
12 PRIOR FILING DATE: 1998-07-23
13 NUMBER OF SEQ ID NOS: 107
14 SOFTWARE: FastSEQ for Windows Version 3.0
15 SEQ ID NO 17
16 LENGTH: 117
17 TYPE: PRT
18 ORGANISM: Artificial Sequence
19 FEATURE:
20 OTHER INFORMATION: Humanized sequence
21 US-09-840-459-17

Query Match 100.0%; Score 620; DB 2; Length 117;
Best Local Similarity 100.0%; Pred. No. 1.2e-54;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSAYANNVVRQAPGKLEWVGRIKNNYAT 60
Db 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSAYANNVVRQAPGKLEWVGRIKNNYAT 60
Qy 61 YYADSVKDRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTFYGNVGWGQGLTVTVSS 117
Db 61 YYADSVKDRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTFYGNVGWGQGLTVTVSS 117

RESULT 3

US-09-497-625A-17
1 Sequence 17, Application US/09497625A
2 Patent No. 6727349
3 GENERAL INFORMATION:
4 APPLICANT: LaRosa, Gregory J.
5 APPLICANT: Horvath, Christopher
6 APPLICANT: Newman, Walter
7 APPLICANT: Jones, S. Tarran H.
8 APPLICANT: O'Brien, Siobhan H.
9 APPLICANT: O'Keefe, Theresa
10 TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
11 FILE REFERENCE: 1855.1052-004
12 CURRENT APPLICATION NUMBER: US/09/497,625A
13 CURRENT FILING DATE: 2000-02-03
14 PRIOR APPLICATION NUMBER: 09/359,193
15 PRIOR FILING DATE: 1999-07-22
16 PRIOR APPLICATION NUMBER: 09/121,781
17 PRIOR FILING DATE: 1998-07-23
18 NUMBER OF SEQ ID NOS: 106
19 SOFTWARE: FastSEQ for Windows Version 3.0
20 SEQ ID NO 17
21 LENGTH: 117
22 TYPE: PRT
23 ORGANISM: Artificial Sequence
24 FEATURE:
25 OTHER INFORMATION: Humanized sequence
26 US-09-497-625A-17

Query Match 100.0%; Score 620; DB 2; Length 117;
Best Local Similarity 100.0%; Pred. No. 1.2e-54;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSAYANNVVRQAPGKLEWVGRIKNNYAT 60
Db 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSAYANNVVRQAPGKLEWVGRIKNNYAT 60

Qy 61 YYADSVKDRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTFYGNVGWGQGLTVTVSS 117
Db 61 YYADSVKDRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTFYGNVGWGQGLTVTVSS 117

RESULT 4

US-09-840-459-104
1 Sequence 104, Application US/09840459
2 Patent No. 6696550
3 GENERAL INFORMATION:
4 APPLICANT: LaRosa, Gregory J.
5 APPLICANT: Horvath, Christopher
6 APPLICANT: Newman, Walter
7 APPLICANT: Jones, S. Tarran
8 APPLICANT: O'Brien, Siobhan H.
9 APPLICANT: O'Keefe, Theresa
10 TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
11 FILE REFERENCE: 1855.1052-012
12 CURRENT APPLICATION NUMBER: US/09/840,459
13 CURRENT FILING DATE: 2001-02-02
14 PRIOR APPLICATION NUMBER: PCT/US01/03537
15 PRIOR FILING DATE: 2001-02-02
16 PRIOR APPLICATION NUMBER: 09/497,625
17 PRIOR FILING DATE: 2000-02-03
18 PRIOR APPLICATION NUMBER: 09/359,193
19 PRIOR FILING DATE: 1999-07-22
20 PRIOR APPLICATION NUMBER: 09/121,781
21 PRIOR FILING DATE: 1998-07-23
22 NUMBER OF SEQ ID NOS: 107
23 SOFTWARE: FastSEQ for Windows Version 3.0
24 SEQ ID NO 104
25 LENGTH: 119
26 TYPE: PRT
27 ORGANISM: Artificial Sequence
28 FEATURE:
29 OTHER INFORMATION: Humanized heavy chain
30 US-09-840-459-104

Query Match 100.0%; Score 620; DB 2; Length 119;
Best Local Similarity 100.0%; Pred. No. 1.2e-54;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSAYANNVVRQAPGKLEWVGRIKNNYAT 60
Db 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSAYANNVVRQAPGKLEWVGRIKNNYAT 60
Qy 61 YYADSVKDRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTFYGNVGWGQGLTVTVSS 117
Db 61 YYADSVKDRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTFYGNVGWGQGLTVTVSS 117

RESULT 5

US-09-497-625A-104
1 Sequence 104, Application US/09497625A
2 Patent No. 6727349
3 GENERAL INFORMATION:
4 APPLICANT: LaRosa, Gregory J.
5 APPLICANT: Horvath, Christopher
6 APPLICANT: Newman, Walter
7 APPLICANT: Jones, S. Tarran
8 APPLICANT: O'Brien, Siobhan H.
9 APPLICANT: O'Keefe, Theresa
10 TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
11 FILE REFERENCE: 1855.1052-004
12 CURRENT APPLICATION NUMBER: US/09/497,625A
13 CURRENT FILING DATE: 2000-02-03
14 PRIOR APPLICATION NUMBER: 09/359,193
15 PRIOR FILING DATE: 1999-07-22
16 PRIOR APPLICATION NUMBER: 09/121,781
17 PRIOR FILING DATE: 1998-07-23
18 NUMBER OF SEQ ID NOS: 106


```
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 104
; LENGTH: 119
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Humanized heavy chain
US-09-497-625A-104

Query Match      100.0%; Score 620; DB 2; Length 119;
Best Local Similarity 100.0%; Pred. No. 1.2e-54;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVQPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIKNNYAT 60
Db 1 EVQLVESGGGLVQPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIKNNYAT 60

Qy 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGVNGVWGQGLTVTVSS 117
Db 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGVNGVWGQGLTVTVSS 117

RESULT 6
US-09-809-739-21
; Sequence 21, Application US/09809739
; Patent No. 6663863
; GENERAL INFORMATION:
; APPLICANT: Horvath, Christopher J.
; APPLICANT: Rao, Patricia E.
; TITLE OF INVENTION: Method of Inhibiting Stenosis and
; TITLE OF INVENTION: Restenosis
; FILE REFERENCE: 1855.1069-003
; CURRENT APPLICATION NUMBER: US/09/809,739
; CURRENT FILING DATE: 2001-03-15
; PRIOR FILING DATE: 2000-03-17
; PRIOR FILING DATE: 2000-03-17
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 21
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Humanized sequence
US-09-809-739-21

Query Match      98.9%; Score 613; DB 2; Length 117;
Best Local Similarity 98.3%; Pred. No. 6.1e-54;
Matches 115; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVQPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIKNNYAT 60
Db 1 EVQLVESGGGLVQPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIKNNYAT 60

Qy 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGVNGVWGQGLTVTVSS 117
Db 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGVNGVWGQGLTVTVSS 117

RESULT 7
US-09-840-459-18
; Sequence 18, Application US/09840459
; Patent No. 6696550
; GENERAL INFORMATION:
; APPLICANT: LaRosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; TITLE OF INVENTION: METHODS OF USE THEREFOR
FILE REFERENCE: 1855.1052-012

Query Match      98.9%; Score 613; DB 2; Length 117;
Best Local Similarity 98.3%; Pred. No. 6.1e-54;
Matches 115; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVQPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIKNNYAT 60
Db 1 EVQLVESGGGLVQPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIKNNYAT 60

Qy 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGVNGVWGQGLTVTVSS 117
Db 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGVNGVWGQGLTVTVSS 117

RESULT 8
US-09-497-625A-18
; Sequence 18, Application US/09497625A
; Patent No. 6727349
; GENERAL INFORMATION:
; APPLICANT: LaRosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; TITLE OF INVENTION: METHODS OF USE THEREFOR
FILE REFERENCE: 1855.1052-004
; CURRENT APPLICATION NUMBER: US/09/497,625A
; CURRENT FILING DATE: 2000-02-03
; PRIOR FILING DATE: 1999-07-22
; PRIOR FILING DATE: 1999-07-22
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 106
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 18
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Humanized sequence
US-09-497-625A-18

Query Match      98.9%; Score 613; DB 2; Length 117;
Best Local Similarity 98.3%; Pred. No. 6.1e-54;
Matches 115; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVQPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIKNNYAT 60
Db 1 EVQLVESGGGLVQPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIKNNYAT 60

Qy 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGVNGVWGQGLTVTVSS 117
Db 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGVNGVWGQGLTVTVSS 117
```

```
Db      61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGNVWGQGLTVTVSS 117

RESULT 9
US-09-809-739-22
; Sequence 22, Application US/09809739
; Patent No. 6663863
; GENERAL INFORMATION:
; APPLICANT: Horvath, Christopher J.
; APPLICANT: Rao, Patricia E.
; TITLE OF INVENTION: Method of Inhibiting Stenosis and
; TITLE OF INVENTION: Restenosis
; FILE REFERENCE: 1855.1069-003
; CURRENT APPLICATION NUMBER: US/09/809,739
; CURRENT FILING DATE: 2001-03-15
; PRIOR APPLICATION NUMBER: US 09/528,267
; PRIOR FILING DATE: 2000-03-17
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Humanized sequence
US-09-809-739-22

Query Match      97.4%; Score 604; DB 2; Length 117;
Best Local Similarity 96.6%; Pred. No. 4.8e-53;
Matches 113; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy      1 EVLVESGGGLVKPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIRTKNNYAT 60
        |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db      1 EVLVESGGGLVKPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIRTKNNYAT 60
        |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

Qy      61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGNVWGQGLTVTVSS 117
        |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db      61 YYADSVKDRYTIISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGNVWGQGLTVTVSS 117
        |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 11
US-09-497-625A-19
; Sequence 19, Application US/09497625A
; Patent No. 6727349
; GENERAL INFORMATION:
; APPLICANT: LaRosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; TITLE OF INVENTION: METHODS OF USE THEREFOR
; FILE REFERENCE: 1855.1052-004
; CURRENT APPLICATION NUMBER: US/09/497,625A
; CURRENT FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 106
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 19
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Humanized sequence
US-09-497-625A-19

Query Match      97.4%; Score 604; DB 2; Length 117;
Best Local Similarity 96.8%; Pred. No. 4.8e-53;
Matches 113; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy      1 EVLVESGGGLVKPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIRTKNNYAT 60
        |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db      1 EVLVESGGGLVKPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIRTKNNYAT 60
        |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

Qy      61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGNVWGQGLTVTVSS 117
        |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db      61 YYADSVKDRYTIISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGNVWGQGLTVTVSS 117
        |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 12
US-09-809-739-23
; Sequence 23, Application US/09809739
; Patent No. 6663863
; GENERAL INFORMATION:
; APPLICANT: Horvath, Christopher J.
; APPLICANT: Rao, Patricia E.
; TITLE OF INVENTION: Method of Inhibiting Stenosis and
; TITLE OF INVENTION: Restenosis
; FILE REFERENCE: 1855.1069-003
; CURRENT APPLICATION NUMBER: US/09/809,739
; CURRENT FILING DATE: 2001-03-15
; PRIOR APPLICATION NUMBER: US 09/528,267
; PRIOR FILING DATE: 2000-03-17
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: FastSeq for Windows Version 4.0
US-09-809-739-23

Query Match      97.4%; Score 604; DB 2; Length 117;
Best Local Similarity 96.8%; Pred. No. 4.8e-53;
Matches 113; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy      1 EVLVESGGGLVKPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIRTKNNYAT 60
        |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db      1 EVLVESGGGLVKPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIRTKNNYAT 60
        |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

Qy      61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGNVWGQGLTVTVSS 117
        |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db      61 YYADSVKDRYTIISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGNVWGQGLTVTVSS 117
        |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 10
US-09-840-459-19
; Sequence 19, Application US/09840459
; Patent No. 6696550
; GENERAL INFORMATION:
; APPLICANT: LaRosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; TITLE OF INVENTION: METHODS OF USE THEREFOR
; FILE REFERENCE: 1855.1052-012
; CURRENT APPLICATION NUMBER: US/09/840,459
; CURRENT FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: PCT/US01/03537
; PRIOR FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: 09/497,625
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 107
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 19
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Humanized sequence
US-09-840-459-19
```

```
; SEQ ID NO 23
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Humanized sequence
US-09-809-739-23

Query Match          96.6%; Score 599; DB 2; Length 117;
Best Local Similarity 95.7%; Pred. No. 1.5e-52;
Matches 112; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKGLEWVGRIKNNYAT 60
Db 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKGLEWVGRIKNNYAT 60

Qy 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGVNGVWGQGLTVTVSS 117
Db 61 YYADSVKDRYTIISRDSDSKNTLYLQMSLKTEDTAVYYCVTFYGVNGVWGQGLTVTVSS 117

RESULT 13
US-09-840-459-20
; Sequence 20, Application US/09840459
; Patent No. 6696550
; GENERAL INFORMATION:
; APPLICANT: LaRosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; FILE REFERENCE: 1855.1052-012
; CURRENT APPLICATION NUMBER: US/09/840,459
; PRIOR FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: PCT/US01/03537
; PRIOR FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: 09/497,625
; PRIOR FILING DATE: 2000-02-03
; PRIOR FILING DATE: 1999-07-22
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 107
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 20
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Humanized sequence
US-09-840-459-20

Query Match          96.6%; Score 599; DB 2; Length 117;
Best Local Similarity 95.7%; Pred. No. 1.5e-52;
Matches 112; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKGLEWVGRIKNNYAT 60
Db 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKGLEWVGRIKNNYAT 60

Qy 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGVNGVWGQGLTVTVSS 117
Db 61 YYADSVKDRYTIISRDSDSKNTLYLQMSLKTEDTAVYYCVTFYGVNGVWGQGLTVTVSS 117

RESULT 14
US-09-497-625A-20
; Sequence 20, Application US/09497625A
; Patent No. 6727349
; GENERAL INFORMATION:
```

```
; APPLICANT: LaRosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; FILE REFERENCE: 1855.1052-004
; CURRENT APPLICATION NUMBER: US/09/497,625A
; CURRENT FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 106
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 20
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Humanized sequence
US-09-497-625A-20

Query Match          96.6%; Score 599; DB 2; Length 117;
Best Local Similarity 95.7%; Pred. No. 1.5e-52;
Matches 112; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKGLEWVGRIKNNYAT 60
Db 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKGLEWVGRIKNNYAT 60

Qy 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGVNGVWGQGLTVTVSS 117
Db 61 YYADSVKDRYTIISRDSDSKNTLYLQMSLKTEDTAVYYCVTFYGVNGVWGQGLTVTVSS 117

RESULT 15
US-09-809-739-12
; Sequence 12, Application US/09809739
; Patent No. 6663863
; GENERAL INFORMATION:
; APPLICANT: Horvath, Christopher J.
; APPLICANT: Rao, Patricia E.
; TITLE OF INVENTION: Method of Inhibiting Stenosis and
; FILE REFERENCE: 1855.1069-003
; CURRENT APPLICATION NUMBER: US/09/809,739
; CURRENT FILING DATE: 2001-03-15
; PRIOR APPLICATION NUMBER: US 09/528,267
; PRIOR FILING DATE: 2000-03-17
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 12
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Unknown
; FEATURE:
; NAME/KEY: SITE
; LOCATION: (1)...(117)
; OTHER INFORMATION: Murine mAb 1D9 heavy chain variable region
; NAME/KEY: SITE
; LOCATION: (31)...(35)
; OTHER INFORMATION: CDR1
; NAME/KEY: SITE
; LOCATION: (50)...(68)
; OTHER INFORMATION: CDR2
; NAME/KEY: SITE
; LOCATION: (101)...(106)
; OTHER INFORMATION: CDR3
; OTHER INFORMATION: Mouse
US-09-809-739-12
```

```
Query Match      88.4%; Score 548; DB 2; Length 117;
Best Local Similarity 86.3%; Pred. No. 1.9e-47;
Matches 101; Conservative 10; Mismatches 6; Indels 0; Gaps 0;

Qy      1 EVQLVESGGGLVQPKGSLKLSCAASGFTFSAYAMNWVRQAPGKGLEWVGRIIRTKNNNYAT 60
        |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db      1 EVQLVESGGGLVQPKGSLKLSCAASGFTFNAYAMNWVRQAPGKGLEWVAIRTKNNNYAT 60
        |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

Qy     61 YYADSVKDRFTISRDDSKNTLYLQMNLSLKTEDTAIVYYCTTFYGNVGWGGTGLVTVSS 117
        |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db     61 YYADSVKDRYTIISRDDSESMFLQMNLSLKTEDTAMYYCVTFYGNVGWGTGTTVTVSS 117
        |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
```

Search completed: June 10, 2006, 12:08:46
Job time : 21.2027 secs

GenCore version 5.1.9
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: June 10, 2006, 12:31:52 ; Search time 66.4054 Seconds
(without alignments)
816.140 Million cell updates/sec

Title: US-10-733-563-17

Perfect score: 620

Sequence: 1 EVQLVESGGGLVPGGSLRL.....CTTFYGNVGWGQGLTVTVSS 117

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2097797 seqs, 463214858 residues

Total number of hits satisfying chosen parameters: 2097797

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications AA Main:*

- 1: /EMC_Celerra_SIDS3/ptodata/2/pubppaa/US07_PUBCOMB.pep:*
- 2: /EMC_Celerra_SIDS3/ptodata/2/pubppaa/US08_PUBCOMB.pep:*
- 3: /EMC_Celerra_SIDS3/ptodata/2/pubppaa/US09_PUBCOMB.pep:*
- 4: /EMC_Celerra_SIDS3/ptodata/2/pubppaa/US10A_PUBCOMB.pep:*
- 5: /EMC_Celerra_SIDS3/ptodata/2/pubppaa/US10B_PUBCOMB.pep:*
- 6: /EMC_Celerra_SIDS3/ptodata/2/pubppaa/US11_PUBCOMB.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	620	100.0	117	3	US-09-835-087-10
2	620	100.0	117	3	US-09-809-739-20
3	620	100.0	117	3	US-09-840-459-17
4	620	100.0	117	4	US-10-766-773-17
5	620	100.0	117	4	US-10-766-610-17
6	620	100.0	117	4	US-10-733-563-17
7	620	100.0	117	5	US-10-662-061-20
8	620	100.0	117	6	US-11-075-184A-8
9	620	100.0	119	3	US-09-840-459-104
10	620	100.0	119	4	US-10-766-773-104
11	620	100.0	119	4	US-10-766-610-104
12	620	100.0	119	4	US-10-733-563-104
13	613	98.9	117	3	US-09-835-087-11
14	613	98.9	117	3	US-09-809-739-21
15	613	98.9	117	3	US-09-840-459-18
16	613	98.9	117	4	US-10-766-773-18
17	613	98.9	117	4	US-10-766-610-18
18	613	98.9	117	4	US-10-733-563-18
19	613	98.9	117	5	US-10-662-061-21
20	613	98.9	117	6	US-11-075-184A-9
21	604	97.4	117	3	US-09-835-087-12
22	604	97.4	117	3	US-09-809-739-22
23	604	97.4	117	3	US-09-840-459-19
24	604	97.4	117	4	US-10-766-773-19
25	604	97.4	117	4	US-10-766-610-19
26	604	97.4	117	4	US-10-733-563-19
27	604	97.4	117	5	US-10-662-061-22

28	604	97.4	117	6	US-11-075-184A-10	Sequence 10, Appl
29	599	96.6	117	3	US-09-835-087-13	Sequence 13, Appl
30	599	96.6	117	3	US-09-809-739-23	Sequence 23, Appl
31	599	96.6	117	3	US-09-840-459-20	Sequence 20, Appl
32	599	96.6	117	4	US-10-766-773-20	Sequence 20, Appl
33	599	96.6	117	4	US-10-766-610-20	Sequence 20, Appl
34	599	96.6	117	5	US-10-733-563-20	Sequence 20, Appl
35	599	96.6	117	5	US-10-662-061-23	Sequence 23, Appl
36	599	96.6	117	6	US-11-075-184A-11	Sequence 11, Appl
37	548	88.4	117	3	US-09-835-087-8	Sequence 8, Appl
38	548	88.4	117	3	US-09-809-739-12	Sequence 12, Appl
39	548	88.4	117	3	US-09-840-459-10	Sequence 10, Appl
40	548	88.4	117	4	US-10-766-773-10	Sequence 10, Appl
41	548	88.4	117	4	US-10-766-610-10	Sequence 10, Appl
42	548	88.4	117	4	US-10-733-563-10	Sequence 10, Appl
43	548	88.4	117	5	US-10-662-061-12	Sequence 12, Appl
44	548	88.4	117	6	US-11-075-184A-2	Sequence 2, Appl
45	548	88.4	125	4	US-10-272-899A-84	Sequence 84, Appl

ALIGNMENTS

RESULT 1
US-09-835-087-10
; Sequence 10, Application US/09835087
; Patent No. US20020042370A1
; GENERAL INFORMATION:
; APPLICANT: Wayne W. Hancock
; TITLE OF INVENTION: Method of Treating Graft Rejection Using
; FILE REFERENCE: 1855.2008-003
; CURRENT APPLICATION NUMBER: US/09/835,087
; CURRENT FILING DATE: 2001-09-24
; PRIOR APPLICATION NUMBER: 09/549,448
; PRIOR FILING DATE: 2000-04-14
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 10
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Humanized sequence
US-09-835-087-10

Query Match	100.0%	Score 620;	DB 3;	Length 117;
Best Local Similarity	100.0%;	Pred. No. 1.9e-49;		
Matches 117;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
Qy	1	EVQLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKGLVWGRIRTKNNYAT	60	
Db	1	EVQLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKGLVWGRIRTKNNYAT	60	
Qy	61	YYADSVKDRFTISRDSDSKNTLYLQMSLTKEDTAVYCTTFFYGNVGWGQGLTVTVSS	117	
Db	61	YYADSVKDRFTISRDSDSKNTLYLQMSLTKEDTAVYCTTFFYGNVGWGQGLTVTVSS	117	

RESULT 2
US-09-809-739-20
; Sequence 20, Application US/09809739
; Patent No. US20020106369A1
; GENERAL INFORMATION:
; APPLICANT: Horvath, Christopher J.
; APPLICANT: Rao, Patricia E.
; TITLE OF INVENTION: Method of Inhibiting Stenosis and
; FILE REFERENCE: 1855.1069-003
; CURRENT APPLICATION NUMBER: US/09/809,739
; CURRENT FILING DATE: 2001-03-15
; PRIOR APPLICATION NUMBER: US 09/528,267
; PRIOR FILING DATE: 2000-03-17

```
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 20
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Humanized sequence
US-09-809-739-20

Query Match      100.0%; Score 620; DB 3; Length 117;
Best Local Similarity 100.0%; Pred. No. 1.9e-49;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIITKNNYAT 60
Db 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIITKNNYAT 60

Qy 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGNVGWGQGLTVTVSS 117
Db 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGNVGWGQGLTVTVSS 117

RESULT 3
US-09-840-459-17
; Sequence 17, Application US/09840459
; Patent No. US20020150576A1
; GENERAL INFORMATION:
; APPLICANT: LaRosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; FILE REFERENCE: 1855.1052-012
; CURRENT APPLICATION NUMBER: US/09/840,459
; PRIOR FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: PCT/US01/03537
; PRIOR FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: 09/497,625
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 107
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 17
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Humanized sequence
US-09-840-459-17

Query Match      100.0%; Score 620; DB 3; Length 117;
Best Local Similarity 100.0%; Pred. No. 1.9e-49;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIITKNNYAT 60
Db 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIITKNNYAT 60

Qy 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGNVGWGQGLTVTVSS 117
Db 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGNVGWGQGLTVTVSS 117

RESULT 4
US-10-766-773-17
; Sequence 17, Application US/10766773
```

```
; Publication No. US20040126851A1
; GENERAL INFORMATION:
; APPLICANT: LaRosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; FILE REFERENCE: 1855.1052-028
; CURRENT APPLICATION NUMBER: US/10/766,773
; CURRENT FILING DATE: 2004-01-27
; PRIOR APPLICATION NUMBER: 09/497,625
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 106
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 17
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Humanized sequence
US-10-766-773-17

Query Match      100.0%; Score 620; DB 4; Length 117;
Best Local Similarity 100.0%; Pred. No. 1.9e-49;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIITKNNYAT 60
Db 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIITKNNYAT 60

Qy 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGNVGWGQGLTVTVSS 117
Db 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGNVGWGQGLTVTVSS 117

RESULT 5
US-10-766-610-17
; Sequence 17, Application US/10766610
; Publication No. US20040132980A1
; GENERAL INFORMATION:
; APPLICANT: LaRosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; FILE REFERENCE: 1855.1052-029
; CURRENT APPLICATION NUMBER: US/10/766,610
; CURRENT FILING DATE: 2004-01-27
; PRIOR APPLICATION NUMBER: 09/840,459
; PRIOR FILING DATE: 2001-04-23
; PRIOR APPLICATION NUMBER: PCT/US01/03537
; PRIOR FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: 09/497,625
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 107
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 17
; LENGTH: 117
; TYPE: PRT
```

```

; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Humanized sequence
US-10-766-610-17

```

Query Match	100.0%	Score 620;	DB 4;	Length 117;
Best Local Similarity	100.0%	Pred. No. 1.9e-49;		
Matches 117; Conservative	0;	Mismatches 0;	Indels 0;	Gaps 0;
Qy	1	EVQLVESGGGLVQPGGSLRLS	CAASGFTFS	YAMNWVRQAPGKGLEWVGRIRTKNNYAT 60
Db	1	EVQLVESGGGLVQPGGSLRLS	CAASGFTFS	YAMNWVRQAPGKGLEWVGRIRTKNNYAT 60
Qy	61	YYADSVKDRFTISRDTSKNTLYLQ	MSLKTEDTAVYICTT	FYGNVGWGGGLTVTVSS 117
Db	61	YYADSVKDRFTISRDTSKNTLYLQ	MSLKTEDTAVYICTT	FYGNVGWGGGLTVTVSS 117

```

RESULT 6
US-10-733-563-17
; Sequence 17, Application US/10733563
; Publication No. US20040151721A1
; GENERAL INFORMATION:
; APPLICANT: O'Keefe, Theresa
; APPLICANT: Ponath, Paul
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; TITLE OF INVENTION: METHODS OF USE THEREOF
; FILE OF INVENTION: METHODS
; FILE REFERENCE: 10448-213001
; CURRENT APPLICATION NUMBER: US/10/733,563
; CURRENT FILING DATE: 2003-12-10
; PRIOR APPLICATION NUMBER: US 10/272,899
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: US 60/392,364
; PRIOR FILING DATE: 2002-06-26
; PRIOR APPLICATION NUMBER: US 60/350,166
; PRIOR FILING DATE: 2001-10-19
; NUMBER OF SEQ ID NOS: 122
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 17
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: humanized sequence
US-10-733-563-17

```

Query Match	100.0%;	Score 620;	DB 4;	Length 117;
Best Local Similarity	100.0%;	Pred. No. 1.9e-49;		
Matches 117;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
QY	1	EVQLVSGGGLVPGGSLRLSCAASGFTFSAYAMNWVRQAPGKGLEWVGRI	TQNNYYAT	60
Db	1	EVQLVSGGGLVPGGSLRLSCAASGFTFSAYAMNWVRQAPGKGLEWVGRI	TQNNYYAT	60
QY	61	YYADSVKDRFTISRDSSKNTLYIQLMNSLTEDTAVYYCTTFYGNVGWGQGL	TLTVVSS	117
Db	61	YYADSVKDRFTISRDSSKNTLYIQLMNSLTEDTAVYYCTTFYGNVGWGQGL	TLTVVSS	117

```

RESULT 7
US-10-662-061-20
; Sequence 20, Application US/10662061
; Publication No. US20050214299A1
; GENERAL INFORMATION:
; APPLICANT: Horvath, Christopher J.
; APPLICANT: Rao, Patricia E.
; TITLE OF INVENTION: Method of Inhibiting Stenosis and
; TITLE OF INVENTION: Restenosis
; FILE REFERENCE: 1855.1069-003
; CURRENT APPLICATION NUMBER: US/10/662,061
; CURRENT FILING DATE: 2003-09-12
; PRIOR APPLICATION NUMBER: US/09/809,739
; PRIOR FILING DATE: 2001-03-15

```

```

; PRIOR APPLICATION NUMBER: US 09/528,267
; PRIOR FILING DATE: 2000-03-17
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 20
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Humanized sequence
US-10-662-061-20

```

Query Match	100.0%;	Score 620;	DB 5;	Length 117;
Best Local Similarity	100.0%;	Pred. No. 1.9e-49;		
Matches 117;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
Qy	1	EVQLVDSGGGLVPGGSLRLSCAASGFTFSAYAMNWVRQAPGKGLEWVGRI	TNNYAT	60
Db	1	EVQLVDSGGGLVPGGSLRLSCAASGFTFSAYAMNWVRQAPGKGLEWVGRI	TNNYAT	60
Qy	61	YYADSVKDRFTISRDSDSKNTLYIQMNSLTEDTAVYYCTTFYGNVGWGQGL	LTIVSS	117
Db	61	YYADSVKDRFTISRDSDSKNTLYIQMNSLTEDTAVYYCTTFYGNVGWGQGL	LTIVSS	117

```

RESULT 8
US-11-075-184A-8
; Sequence 8, Application US/11075184A
; Publication No. US20050260139A1
; GENERAL INFORMATION:
; APPLICANT: Boehringer Ingelheim International GmbH
; APPLICANT: PAIRET, Michel
; TITLE OF INVENTION: Pharmaceutical Compositions based on Anticholinergics and CCR2
; TITLE OF INVENTION: Receptor Antagonists
; FILE REFERENCE: 1/1669
; CURRENT APPLICATION NUMBER: US/11/075,184A
; PRIOR APPLICATION DATE: 2005-03-08
; PRIOR APPLICATION NUMBER: EP 04 007 635.8
; PRIOR FILING DATE: 2004-03-30
; NUMBER OF SEQ ID NOS: 11
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 8
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Humanized Murine 1D9 antibody kappa light chain variable region,
; OTHER INFORMATION: 1D9RKE
US-11-075-184A-8

```

	Query Match	100.0%;	Score 620;	DB 6;	Length 117;
	Best Local Similarity	100.0%;	Pred. No. 1.9e-49;		
	Matches 117; Conservative	0;	Mismatches 0;	Indels 0;	Gaps 0;
Qy	1	EVLVESGGGLVKPGSLRLSCAASGFTTSAYAMNNVWROAPGKLEWVGIRTKNNNYAT	60		
Db	1	EVLVESGGGLVKPGSLRLSCAASGFTTSAYAMNNVWROAPGKLEWVGIRTKNNNYAT	60		
Qy	61	YIADSVKDRAFTSRDSSKNLYLQNMSLKTEDPAVIYCCTTFYNGVWGQGTLVTVSS	117		
Db	61	YIADSVKDRAFTSRDSSKNLYLQNMSLKTEDPAVIYCCTTFYNGVWGQGTLVTVSS	117		

```

RESULT 9
US-09-840-459-104
; Sequence 104, Application US/09840459
; Patent No. US20020150576A1
; GENERAL INFORMATION:
; APPLICANT: Lakosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.

```

; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; METHODS OF USE THEREFOR
; FILE REFERENCE: 1855.1052-012
; CURRENT APPLICATION NUMBER: US/09/840,459
; CURRENT FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: PCT/US01/03537
; PRIOR FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: 09/497,625
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 107
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 104
; LENGTH: 119
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Humanized heavy chain
; US-09-840-459-104

Query Match 100.0%; Score 620; DB 3; Length 119;
Best Local Similarity 100.0%; Pred. No. 1.9e-49;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVOLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIKNNYAT 60
|
Db 1 EVOLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIKNNYAT 60
|
Qy 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGNVGWGQGLTVTVSS 117
|
Db 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGNVGWGQGLTVTVSS 117
|

RESULT 10

US-10-766-773-104
; Sequence 104, Application US/10766773
; Publication No. US20040126851A1
; GENERAL INFORMATION:
; APPLICANT: LaRosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; METHODS OF USE THEREFOR
; FILE REFERENCE: 1855.1052-028
; CURRENT APPLICATION NUMBER: US/10/766,773
; CURRENT FILING DATE: 2004-01-27
; PRIOR APPLICATION NUMBER: 09/497,625
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 106
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 104
; LENGTH: 119
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Humanized heavy chain
; US-10-766-773-104

Query Match 100.0%; Score 620; DB 4; Length 119;
Best Local Similarity 100.0%; Pred. No. 1.9e-49;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVOLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIKNNYAT 60
|
Db 1 EVOLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIKNNYAT 60
|
Qy 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGNVGWGQGLTVTVSS 117
|
Db 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGNVGWGQGLTVTVSS 117
|

RESULT 11

US-10-766-610-104
; Sequence 104, Application US/10766610
; Publication No. US20040132980A1
; GENERAL INFORMATION:
; APPLICANT: LaRosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; METHODS OF USE THEREFOR
; FILE REFERENCE: 1855.1052-029
; CURRENT APPLICATION NUMBER: US/10/766,610
; CURRENT FILING DATE: 2004-01-27
; PRIOR APPLICATION NUMBER: 09/840,459
; PRIOR FILING DATE: 2001-04-23
; PRIOR APPLICATION NUMBER: PCT/US01/03537
; PRIOR FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: 09/497,625
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 107
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 104
; LENGTH: 119
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Humanized heavy chain
; US-10-766-610-104

Query Match 100.0%; Score 620; DB 4; Length 119;
Best Local Similarity 100.0%; Pred. No. 1.9e-49;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVOLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIKNNYAT 60
|
Db 1 EVOLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIKNNYAT 60
|
Qy 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGNVGWGQGLTVTVSS 117
|
Db 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGNVGWGQGLTVTVSS 117
|

RESULT 12

US-10-733-563-104
; Sequence 104, Application US/10733563
; Publication No. US20040151721A1
; GENERAL INFORMATION:
; APPLICANT: O'Keefe, Theresa
; APPLICANT: Ponath, Paul
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; METHODS OF USE THEREOF
; FILE REFERENCE: 10448-213001
; CURRENT APPLICATION NUMBER: US/10/733,563
; CURRENT FILING DATE: 2003-12-10
; PRIOR APPLICATION NUMBER: US 10/272,899
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: US 60/392,364

; PRIOR FILING DATE: 2002-06-26
; PRIOR APPLICATION NUMBER: US 60/350,166
; PRIOR FILING DATE: 2001-10-19
; NUMBER OF SEQ ID NOS: 122
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 104
; LENGTH: 119
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: humanized heavy chain
US-10-733-563-104

Query Match 100.0%; Score 620; DB 4; Length 119;
Best Local Similarity 100.0%; Pred. No. 1.9e-49;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 EVOLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIKNNYAT 60
Db 1 EVOLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIKNNYAT 60
Qy 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGNVGWQGTTLTVSS 117
Db 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGNVGWQGTTLTVSS 117

RESULT 13

US-09-835-087-11
; Sequence 11, Application US/09835087
; Patent No. US20020042370A1
; GENERAL INFORMATION:
; APPLICANT: Wayne W. Hancock
; TITLE OF INVENTION: Method of Treating Graft Rejection Using
; TITLE OF INVENTION: Inhibitors of CCR2 Function
; FILE REFERENCE: 1855.2008-003
; CURRENT APPLICATION NUMBER: US/09/835,087
; CURRENT FILING DATE: 2001-09-24
; PRIOR APPLICATION NUMBER: 09/549,448
; PRIOR FILING DATE: 2000-04-14
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 11
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Humanized sequence
US-09-835-087-11

Query Match 98.9%; Score 613; DB 3; Length 117;
Best Local Similarity 98.3%; Pred. No. 8.2e-49;
Matches 115; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
Qy 1 EVOLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIKNNYAT 60
Db 1 EVOLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIKNNYAT 60
Qy 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGNVGWQGTTLTVSS 117
Db 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGNVGWQGTTLTVSS 117

RESULT 14

US-09-809-739-21
; Sequence 21, Application US/09809739
; Patent No. US20020106369A1
; GENERAL INFORMATION:
; APPLICANT: Horvath, Christopher J.
; APPLICANT: Rao, Patricia E.
; TITLE OF INVENTION: Method of Inhibiting Stenosis and
; TITLE OF INVENTION: Restenosis
; FILE REFERENCE: 1855.1089-003
; CURRENT APPLICATION NUMBER: US/09/809,739

; CURRENT FILING DATE: 2001-03-15
; PRIOR APPLICATION NUMBER: US 09/528,267
; PRIOR FILING DATE: 2000-03-17
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 21
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Humanized sequence
US-09-809-739-21

Query Match 98.9%; Score 613; DB 3; Length 117;
Best Local Similarity 98.3%; Pred. No. 8.2e-49;
Matches 115; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
Qy 1 EVOLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIKNNYAT 60
Db 1 EVOLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIKNNYAT 60
Qy 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGNVGWQGTTLTVSS 117
Db 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGNVGWQGTTLTVSS 117

RESULT 15

US-09-840-459-18
; Sequence 18, Application US/09840459
; Patent No. US20020150576A1
; GENERAL INFORMATION:
; APPLICANT: LaRosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; TITLE OF INVENTION: METHODS OF USE THEREFOR
; FILE REFERENCE: 1855.1052-012
; CURRENT APPLICATION NUMBER: US/09/840,459
; CURRENT FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: PCT/US01/03537
; PRIOR FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: 09/497,625
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 107
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 18
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Humanized sequence
US-09-840-459-18

Query Match 98.9%; Score 613; DB 3; Length 117;
Best Local Similarity 98.3%; Pred. No. 8.2e-49;
Matches 115; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
Qy 1 EVOLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIKNNYAT 60
Db 1 EVOLVESGGGLVPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIKNNYAT 60
Qy 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGNVGWQGTTLTVSS 117
Db 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGNVGWQGTTLTVSS 117

Search completed: June 10, 2006, 12:38:41
Job time : 66.4054 secs

GenCore version 5.1.9
Copyright (c) 1993 - 2006 Bioceleration Ltd.
OM protein - protein search, using sw model
Run on: June 10, 2006, 12:32:32 ; Search time 4.04054 Seconds
(without alignments)
366.103 Million cell updates/sec
Title: US-10-733-563-17
Perfect score: 620
Sequence: 1 EVQLVESGGGLVPGGSLRL.....CTTFYGNVGWGQGLTVTVSS 117
Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5
Searched: 64916 seqs, 12643201 residues
Total number of hits satisfying chosen parameters: 64916

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries
Database : Published_Applications_AA_New.*
1: /EMC_Celerra_SIDS3/ptodata/1/pubpaa/US09_NEW_PUB.pep.*
2: /EMC_Celerra_SIDS3/ptodata/1/pubpaa/US06_NEW_PUB.pep.*
3: /EMC_Celerra_SIDS3/ptodata/1/pubpaa/US07_NEW_PUB.pep.*
4: /EMC_Celerra_SIDS3/ptodata/1/pubpaa/US08_NEW_PUB.pep.*
5: /EMC_Celerra_SIDS3/ptodata/1/pubpaa/PCT_NEW_PUB.pep.*
6: /EMC_Celerra_SIDS3/ptodata/1/pubpaa/US10_NEW_PUB.pep.*
7: /EMC_Celerra_SIDS3/ptodata/1/pubpaa/US11_NEW_PUB.pep.*
8: /EMC_Celerra_SIDS3/ptodata/1/pubpaa/US60_NEW_PUB.pep.*
Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	490.5	79.1	112	6	US-10-544-050-5
2	479.5	77.3	120	7	US-11-075-891-33
3	479.5	77.3	254	7	US-11-075-891-6
4	479.5	77.3	254	7	US-11-075-891-12
5	479.5	77.3	254	7	US-11-075-891-18
6	474.5	76.5	120	7	US-11-075-891-34
7	474.5	76.5	254	7	US-11-075-891-8
8	474.5	76.5	254	7	US-11-075-891-14
9	474.5	76.5	254	7	US-11-075-891-20
10	470.5	75.9	120	7	US-11-075-891-35
11	470.5	75.9	254	7	US-11-075-891-10
12	470.5	75.9	254	7	US-11-075-891-16
13	470.5	75.9	254	7	US-11-075-891-22
14	464.5	74.9	116	7	US-11-249-296-76
15	464	74.8	291	7	US-11-154-103-1
16	464	74.8	291	7	US-11-154-103-2
17	462	74.5	113	7	US-11-219-121-24
18	461.5	74.4	448	7	US-11-219-121-28
19	461	74.4	288	6	US-10-539-403-2
20	459.5	74.1	126	6	US-10-994-679-64
21	458.5	74.0	116	7	US-11-249-296-82
22	458	73.9	113	7	US-11-249-296-46
23	457.5	73.8	116	7	US-11-249-296-30
24	457.5	73.8	116	7	US-11-249-296-80
25	457.5	73.8	116	7	US-11-249-296-86

26	457.5	73.8	116	7	US-11-249-296-88
27	456.5	73.6	122	7	US-11-254-679-36
28	455.5	73.5	116	7	US-11-249-296-84
29	455	73.4	119	7	US-11-254-182-6
30	455	73.4	119	7	US-11-254-182-30
31	455	73.4	119	7	US-11-300-563-11
32	455	73.4	119	7	US-11-106-762-13
33	455	73.4	570	1	US-09-784-950-18
34	454.5	73.3	112	6	US-10-544-050-6
35	454	73.2	123	7	US-11-211-917-117
36	453	73.1	123	7	US-11-219-563-69
37	452.5	73.0	116	7	US-11-249-296-10
38	452.5	73.0	116	7	US-11-249-296-34
39	451	72.7	123	7	US-11-211-917-115
40	450.5	72.7	116	7	US-11-249-296-22
41	450.5	72.7	122	7	US-11-254-679-72
42	450.5	72.7	124	7	US-11-211-917-50
43	450.5	72.7	124	7	US-11-211-917-96
44	450.5	72.7	469	7	US-11-211-917-54
45	450	72.6	123	7	US-11-211-917-116

ALIGNMENTS

RESULT 1
US-10-544-050-5
; Sequence 5, Application US/10544050
; Publication No. US20060110388A1
; GENERAL INFORMATION:
; APPLICANT: Davies Julian
; TITLE OF INVENTION: Abeta Binding Molecules
; FILE REFERENCE: X-16068
; CURRENT APPLICATION NUMBER: US/10/544,050
; CURRENT FILING DATE: 2005-07-29
; PRIOR APPLICATION NUMBER: 60/446380
; PRIOR FILING DATE: 2003-02-10
; NUMBER OF SEQ ID NOS: 76
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5
; LENGTH: 112
; TYPE: PRT
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: humanized light chain
US-10-544-050-5

Query Match 79.1%; Score 490.5; DB 6; Length 112;
Best Local Similarity 82.9%; Pred. No. 2.6e-40;
Matches 97; Conservative 6; Mismatches 9; Indels 5; Gaps 2;
QY 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYAVAMNVRQAPGKLEWVGRIKKNVAT 60
Db 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYRSMVSRQAPGKLEWVGQINSVGN--ST 58
QY 61 YYADSVKDRFTISRDDSKNTLYLQMSLKTEDTAVYYCTTFYGNVGWGQGLTVTVSS 117
Db 59 YYPDVKGRFTISRDDSKNTLYLQMSLKTEDTAVYYCTT---GDYWGQGLTVTVSS 112

RESULT 2
US-11-075-891-33
; Sequence 33, Application US/11075891
; Publication No. US20060088521A1
; GENERAL INFORMATION:
; APPLICANT: MAHADEVAN, DARUKA
; TITLE OF INVENTION: COMPOSITION AND METHOD FOR CANCER TREATMENT
; FILE REFERENCE: 263922US96
; CURRENT APPLICATION NUMBER: US/11/075,891
; CURRENT FILING DATE: 2005-03-10
; PRIOR APPLICATION NUMBER: US 60/557,258
; PRIOR FILING DATE: 2004-03-27
; NUMBER OF SEQ ID NOS: 36

```
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 33
; LENGTH: 120
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Peptide
US-11-075-891-33

Query Match          77.3%; Score 479.5; DB 7; Length 120;
Best Local Similarity 78.3%; Pred. No. 3.1e-39;
Matches 94; Conservative 7; Mismatches 16; Indels 3; Gaps 1;

QY 1 EVQLVESGGGLVQPGGSLRLSCAASGFTFSAYAMNVRQAPGKGLVGVGRIRTKNNYAT 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 EVQLVESGGGLVQPGGSLRLSCAASGFTFSAYAMNVRQAPGKGLVGVGRIRTKSDNYGA 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

QY 61 YYADSVKDRFTISRDDSKNTLYLQNSLKTEDTAVYYCTT---FYGNGVWGOGTLVTYSS 117
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 61 KYAESVGRGFTISRDDSKNSLYLQNSLKTEDTAVYYCARTPWVYAMDCWGGGTLVTYSS 120

RESULT 3
US-11-075-891-6
; Sequence 6, Application US/11075891
; Publication No. US20060088521A1
; GENERAL INFORMATION:
; APPLICANT: MAHADEVAN, DARUKA
; TITLE OF INVENTION: COMPOSITION AND METHOD FOR CANCER TREATMENT
; FILE REFERENCE: 263922US96
; CURRENT APPLICATION NUMBER: US/11/075,891
; CURRENT FILING DATE: 2005-03-10
; PRIOR APPLICATION NUMBER: US 60/557,258
; PRIOR FILING DATE: 2004-03-27
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 6
; LENGTH: 254
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-11-075-891-6

Query Match          77.3%; Score 479.5; DB 7; Length 254;
Best Local Similarity 78.3%; Pred. No. 6.7e-39;
Matches 94; Conservative 7; Mismatches 16; Indels 3; Gaps 1;

QY 1 EVQLVESGGGLVQPGGSLRLSCAASGFTFSAYAMNVRQAPGKGLVGVGRIRTKNNYAT 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 2 EVQLVESGGGLVQPGGSLRLSCAASGFTFSAYAMNVRQAPGKGLVGVGRITVKSDNYGA 61
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

QY 61 YYADSVKDRFTISRDDSKNTLYLQNSLKTEDTAVYYCTT---FYGNGVWGOGTLVTYSS 117
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 62 KYAESVGRGFTISRDDSKNSLYLQNSLKTEDTAVYYCARTPWVYAMDCWGGGTLVTYSS 121

RESULT 4
US-11-075-891-12
; Sequence 12, Application US/11075891
; Publication No. US20060088521A1
; GENERAL INFORMATION:
; APPLICANT: MAHADEVAN, DARUKA
; TITLE OF INVENTION: COMPOSITION AND METHOD FOR CANCER TREATMENT
; FILE REFERENCE: 263922US96
; CURRENT APPLICATION NUMBER: US/11/075,891
; CURRENT FILING DATE: 2005-03-10
; PRIOR APPLICATION NUMBER: US 60/557,258
; PRIOR FILING DATE: 2004-03-27
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 12
; LENGTH: 254
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-11-075-891-12

Query Match          77.3%; Score 479.5; DB 7; Length 254;
Best Local Similarity 78.3%; Pred. No. 6.7e-39;
Matches 94; Conservative 7; Mismatches 16; Indels 3; Gaps 1;

QY 1 EVQLVESGGGLVQPGGSLRLSCAASGFTFSAYAMNVRQAPGKGLVGVGRIRTKNNYAT 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 2 EVQLVESGGGLVQPGGSLRLSCAASGFTFSAYAMNVRQAPGKGLVGVGRITVKSDNYGA 61
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

QY 61 YYADSVKDRFTISRDDSKNTLYLQNSLKTEDTAVYYCTT---FYGNGVWGOGTLVTYSS 117
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 62 KYAESVGRGFTISRDDSKNSLYLQNSLKTEDTAVYYCARTPWVYAMDCWGGGTLVTYSS 121

RESULT 5
US-11-075-891-18
; Sequence 18, Application US/11075891
; Publication No. US20060088521A1
; GENERAL INFORMATION:
; APPLICANT: MAHADEVAN, DARUKA
; TITLE OF INVENTION: COMPOSITION AND METHOD FOR CANCER TREATMENT
; FILE REFERENCE: 263922US96
; CURRENT APPLICATION NUMBER: US/11/075,891
; CURRENT FILING DATE: 2005-03-10
; PRIOR APPLICATION NUMBER: US 60/557,258
; PRIOR FILING DATE: 2004-03-27
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 18
; LENGTH: 254
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-11-075-891-18

Query Match          77.3%; Score 479.5; DB 7; Length 254;
Best Local Similarity 78.3%; Pred. No. 6.7e-39;
Matches 94; Conservative 7; Mismatches 16; Indels 3; Gaps 1;

QY 1 EVQLVESGGGLVQPGGSLRLSCAASGFTFSAYAMNVRQAPGKGLVGVGRIRTKNNYAT 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 2 EVQLVESGGGLVQPGGSLRLSCAASGFTFSAYAMNVRQAPGKGLVGVGRITVKSDNYGA 61
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

QY 61 YYADSVKDRFTISRDDSKNTLYLQNSLKTEDTAVYYCTT---FYGNGVWGOGTLVTYSS 117
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 62 KYAESVGRGFTISRDDSKNSLYLQNSLKTEDTAVYYCARTPWVYAMDCWGGGTLVTYSS 121

RESULT 6
US-11-075-891-34
; Sequence 34, Application US/11075891
; Publication No. US20060088521A1
; GENERAL INFORMATION:
; APPLICANT: MAHADEVAN, DARUKA
; TITLE OF INVENTION: COMPOSITION AND METHOD FOR CANCER TREATMENT
; FILE REFERENCE: 263922US96
; CURRENT APPLICATION NUMBER: US/11/075,891
; CURRENT FILING DATE: 2005-03-10
; PRIOR APPLICATION NUMBER: US 60/557,258
; PRIOR FILING DATE: 2004-03-27
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 34
; LENGTH: 120
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-11-075-891-34
```

; OTHER INFORMATION: Synthetic Peptide
US-11-075-891-34

Query Match 76.5%; Score 474.5; DB 7; Length 120;
Best Local Similarity 76.7%; Pred. No. 9.2e-39;
Matches 92; Conservative 8; Mismatches 17; Indels 3; Gaps 1;

QY 1 EVLVESGGGLVKPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIKNNYAT 60
DB 1 EVLVESGGGLVKPGGSLRLSCATSGFTFSNRYRMHWVRQAPGKLEWIGVITKSDNYGA 60

QY 61 YYADSVKDRFTISRDDSKNTLYLQNSLKTEDTAVYYCTT---FYGNGVWGOGTLVTYSS 117
DB 61 KYAESVGRGFTISRDDSKNSLYLQNSLKTEDTAVYYCARTPWVYAMDCWGGGTLVTYSS 120

RESULT 7
US-11-075-891-8
; Sequence 8, Application US/11075891
; Publication No. US20060088521A1
; GENERAL INFORMATION:
; APPLICANT: MAHADEVAN, DARUKA
; TITLE OF INVENTION: COMPOSITION AND METHOD FOR CANCER TREATMENT
; CURRENT APPLICATION NUMBER: US/11/075,891
; CURRENT FILING DATE: 2005-03-10
; PRIOR APPLICATION NUMBER: US 60/557,258
; PRIOR FILING DATE: 2004-03-27
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 8
; LENGTH: 254
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-11-075-891-8

Query Match 76.5%; Score 474.5; DB 7; Length 254;
Best Local Similarity 76.7%; Pred. No. 2e-38;
Matches 92; Conservative 8; Mismatches 17; Indels 3; Gaps 1;

QY 1 EVLVESGGGLVKPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIKNNYAT 60
DB 2 EVLVESGGGLVKPGGSLRLSCATSGFTFSNRYRMHWVRQAPGKLEWIGVITKSDNYGA 61

QY 61 YYADSVKDRFTISRDDSKNTLYLQNSLKTEDTAVYYCTT---FYGNGVWGOGTLVTYSS 117
DB 62 KYAESVGRGFTISRDDSKNSLYLQNSLKTEDTAVYYCARTPWVYAMDCWGGGTLVTYSS 121

RESULT 8
US-11-075-891-14
; Sequence 14, Application US/11075891
; Publication No. US20060088521A1
; GENERAL INFORMATION:
; APPLICANT: MAHADEVAN, DARUKA
; TITLE OF INVENTION: COMPOSITION AND METHOD FOR CANCER TREATMENT
; CURRENT APPLICATION NUMBER: US/11/075,891
; CURRENT FILING DATE: 2005-03-10
; PRIOR APPLICATION NUMBER: US 60/557,258
; PRIOR FILING DATE: 2004-03-27
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 14
; LENGTH: 254
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-11-075-891-14

Query Match 76.5%; Score 474.5; DB 7; Length 254;
Best Local Similarity 76.7%; Pred. No. 2e-38;
Matches 92; Conservative 8; Mismatches 17; Indels 3; Gaps 1;

QY 1 EVLVESGGGLVKPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIKNNYAT 60
DB 2 EVLVESGGGLVKPGGSLRLSCATSGFTFSNRYRMHWVRQAPGKLEWIGVITKSDNYGA 61

QY 61 YYADSVKDRFTISRDDSKNTLYLQNSLKTEDTAVYYCTT---FYGNGVWGOGTLVTYSS 117
DB 62 KYAESVGRGFTISRDDSKNSLYLQNSLKTEDTAVYYCARTPWVYAMDCWGGGTLVTYSS 121

RESULT 9
US-11-075-891-20
; Sequence 20, Application US/11075891
; Publication No. US20060088521A1
; GENERAL INFORMATION:
; APPLICANT: MAHADEVAN, DARUKA
; TITLE OF INVENTION: COMPOSITION AND METHOD FOR CANCER TREATMENT
; FILE REFERENCE: 263922US96
; CURRENT APPLICATION NUMBER: US/11/075,891
; CURRENT FILING DATE: 2005-03-10
; PRIOR APPLICATION NUMBER: US 60/557,258
; PRIOR FILING DATE: 2004-03-27
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 20
; LENGTH: 254
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-11-075-891-20

Query Match 76.5%; Score 474.5; DB 7; Length 254;
Best Local Similarity 76.7%; Pred. No. 2e-38;
Matches 92; Conservative 8; Mismatches 17; Indels 3; Gaps 1;

QY 1 EVLVESGGGLVKPGGSLRLSCAASGFTFSAYAMNVRQAPGKLEWVGRIKNNYAT 60
DB 2 EVLVESGGGLVKPGGSLRLSCATSGFTFSNRYRMHWVRQAPGKLEWIGVITKSDNYGA 61

QY 61 YYADSVKDRFTISRDDSKNTLYLQNSLKTEDTAVYYCTT---FYGNGVWGOGTLVTYSS 117
DB 62 KYAESVGRGFTISRDDSKNSLYLQNSLKTEDTAVYYCARTPWVYAMDCWGGGTLVTYSS 121

RESULT 10
US-11-075-891-35
; Sequence 35, Application US/11075891
; Publication No. US20060088521A1
; GENERAL INFORMATION:
; APPLICANT: MAHADEVAN, DARUKA
; TITLE OF INVENTION: COMPOSITION AND METHOD FOR CANCER TREATMENT
; FILE REFERENCE: 263922US96
; CURRENT APPLICATION NUMBER: US/11/075,891
; CURRENT FILING DATE: 2005-03-10
; PRIOR APPLICATION NUMBER: US 60/557,258
; PRIOR FILING DATE: 2004-03-27
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 35
; LENGTH: 120
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Peptide
US-11-075-891-35

Query Match 75.9%; Score 470.5; DB 7; Length 120;
Best Local Similarity 75.8%; Pred. No. 2.2e-38;
Matches 91; Conservative 9; Mismatches 17; Indels 3; Gaps 1;


```

RESULT 15
US-11-154-103-1
; Sequence 1, Application US/11154103
; Publication No. US20060099205A1
; GENERAL INFORMATION:
; APPLICANT: ADAMS, GREGORY P.
; APPLICANT: HORAK, EVA M.
; APPLICANT: WEINER, MARKS D.
; APPLICANT: JAMES, MARKS D.
; TITLE OF INVENTION: BISPECIFIC SINGLE CHAIN Fv ANTIBODY MOLECULES AND METHODS OF USE
; TITLE OF INVENTION: THEREOF
; FILE REFERENCE: 407T-000420US
; CURRENT APPLICATION NUMBER: US/11/154,103
; CURRENT FILING DATE: 2005-06-15
; PRIOR APPLICATION NUMBER: US 60/370,276
; PRIOR FILING DATE: 2002-04-02
; PRIOR APPLICATION NUMBER: US10/406,830
; PRIOR FILING DATE: 2003-04-04
; NUMBER OF SEQ ID NOS: 57
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1
; LENGTH: 291
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic antibody.
US-11-154-103-1

```

[illegible]

Search completed: June 10, 2006, 12:39:10
Job time : 4.04054 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.9
 Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: June 12, 2006, 17:04:30 ; Search time 213.707 Seconds
 (without alignments)
 706.020 Million cell updates/sec

Title: US-10-733-563-110
 Perfect score: 1765
 Sequence: 1 ASTKGPSVFLPAPSKSTSG.....MHEALHNYTKSLSLSPGK 330

Scoring table: BLOSUM62
 Gapop 10.0 , Gapext 0.5

Searched: 2589679 seqs, 457216429 residues
 Total number of hits satisfying chosen parameters: 2589679

Minimum DB seq length: 0
 Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
 Maximum Match 100%
 Listing first 1000 summaries

Database : A_Geneseq_8.*
 1: Geneseqp1980s.*
 2: Geneseqp1990s.*
 3: Geneseqp2000s.*
 4: Geneseqp2001s.*
 5: Geneseqp2002s.*
 6: Geneseqp2003as.*
 7: Geneseqp2003bs.*
 8: Geneseqp2004s.*
 9: Geneseqp2005s.*
 10: Geneseqp2006s.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1765	100.0	330	8	ADQ89332 Human imm
2	1765	100.0	330	9	AEB09605 Human Igg
3	1765	100.0	333	8	ADJ95914 Human Igg
4	1765	100.0	333	8	ADQ89336 Human imm
5	1765	100.0	333	9	AEB09609 Human Igg
6	1765	100.0	356	8	ADJ95974 Human Igg
7	1765	100.0	444	3	AAY32263 Humanised
8	1765	100.0	448	8	ADP88447 Antibody
9	1765	100.0	448	8	ADP88431 Antibody
10	1765	100.0	448	10	AEF27216 Anti-CD4
11	1765	100.0	448	10	AEF27200 Anti-CD4
12	1765	100.0	450	9	AEF27200 Humanized
13	1765	100.0	462	9	AEB08800 Anti-NOGO
14	1765	100.0	467	6	ADA47334 TRX1 heav
15	1765	100.0	467	6	ADA47336 TRX1 heav
16	1765	100.0	467	8	ADP88446 Antibody
17	1765	100.0	467	8	ADP88430 Antibody
18	1765	100.0	467	8	ADQ87966 Heavy cha
19	1765	100.0	467	8	ADQ87974 Heavy cha
20	1765	100.0	467	10	AEF27213 Anti-CD4
21	1765	100.0	467	10	AEF27197 Anti-CD4
22	1765	100.0	467	10	AEF27215 Anti-CD4
23	1765	100.0	467	10	AEF27199 Anti-CD4

24	1765	100.0	473	5	ABC70743	Abg70743 Mouse/hum
25	1765	100.0	475	8	ADL23051	Adl23051 Mouse/hum
26	1765	100.0	475	8	ADL23054	Adl23054 Humanised
27	1765	100.0	475	8	ADS88803	Ads88803 Humanised
28	1765	100.0	475	8	ADS88792	Ads88792 A mouse/h
29	1758	99.6	469	7	ADL23199	Adl23199 Human ant
30	1756	99.5	330	4	AAB04071	Aab04071 Zcytor 10
31	1756	99.5	330	5	AAM47856	Aam47856 Human Ig-
32	1756	99.5	330	5	AAE21960	Aae21960 Human dea
33	1756	99.5	330	5	ABB81641	Abb81641 Human Igg
34	1756	99.5	330	5	ABB05736	Abb05736 Human imm
35	1756	99.5	330	6	ABP71856	Abp71856 Human Igg
36	1756	99.5	330	6	AAE32915	Aae32915 Human imm
37	1756	99.5	330	6	AAE32627	Aae32627 Human DR6
38	1756	99.5	330	6	ABR82103	Abr82103 Human A2-
39	1756	99.5	330	6	AAO31102	Aao31102 Human A2-
40	1756	99.5	330	6	ABR55836	AbR55836 Anti-Ang-
41	1756	99.5	330	6	AAO30893	Aao30893 Human imm
42	1756	99.5	330	7	ADF11389	Adf11389 Anti-OpGL
43	1756	99.5	330	7	ADF97351	Adf97351 Human Igg
44	1756	99.5	330	7	ADF83605	Adf83605 Cytokine
45	1756	99.5	330	7	ADF75001	Adf75001 Human Ig
46	1756	99.5	330	8	ADM41537	Adm41537 Anti-inte
47	1756	99.5	330	8	ADM68311	Adm68311 Human Igg
48	1756	99.5	330	8	ADR43460	Adr43460 Heavy cha
49	1756	99.5	330	8	ADR31605	Adr31605 Human Igg
50	1756	99.5	330	8	ADS87909	Ads87909 Anti-IFN-
51	1756	99.5	330	8	ADN33230	Adn33230 IqG1-CH h
52	1756	99.5	330	8	ADS94906	Ad94906 Anti-IFN-
53	1756	99.5	330	8	ADS333009	Ads333009 Human Igg
54	1756	99.5	330	8	ADT88869	Adt88869 Human Igg
55	1756	99.5	330	8	ADT51577	Adt51577 Heavy cha
56	1756	99.5	330	8	ADT51581	Adt51581 Heavy cha
57	1756	99.5	330	8	ADT51724	Adt51724 Human Hui
58	1756	99.5	330	8	ADU68015	Adu68015 Mouse ant
59	1756	99.5	330	9	ADW08868	Adw08868 IGF-IR an
60	1756	99.5	330	9	ADM86657	Adm86657 Human imm
61	1756	99.5	330	9	ADX97894	Adx97894 Human Ig
62	1756	99.5	330	9	ADX98273	Adx98273 Human ant
63	1756	99.5	330	9	ADY51253	Ady51253 Human Igg
64	1756	99.5	330	9	ADY58147	Ady58147 Human Igg
65	1756	99.5	330	9	ADY26687	Ady26687 Human ant
66	1756	99.5	330	9	AEA12531	Aea12531 Human Igg
67	1756	99.5	330	9	AEA25942	Aea25942 Human imm
68	1756	99.5	330	9	AEA48148	Aea48148 Human Igg
69	1756	99.5	330	9	ABE86186	Aeb86186 Amino aci
70	1756	99.5	330	9	ASEC08181	Aec08181 Heavy cha
71	1756	99.5	330	9	AEC81727	Aec81727 Human imm
72	1756	99.5	330	9	AED12326	Aed12326 Human Igg
73	1756	99.5	330	9	AED08855	Aed08855 Human imm
74	1756	99.5	330	9	AED41916	Aed41916 Deimmuniz
75	1756	99.5	330	9	AED28069	Aed28069 Human Gam
76	1756	99.5	330	9	AED28067	Aed28067 Human Igg
77	1756	99.5	330	10	AEF11770	Aef11770 Human Scf
78	1756	99.5	330	10	AEF16289	Aef16289 Humanized
79	1756	99.5	330	10	AEF16285	Aef16285 Human OST
80	1756	99.5	330	10	AEF51200	Aef51200 Human imm
81	1756	99.5	330	10	AEF82207	Aef82207 Human imm
82	1756	99.5	330	10	AEF11432	Aeg11432 Immunoglo
83	1756	99.5	332	8	ADL35095	Adl35095 Human Igg
84	1756	99.5	332	9	ADM07455	Adm07455 Human Igg
85	1756	99.5	333	8	ADJ95912	Adj95912 Human Igg
86	1756	99.5	333	8	ADL22761	Adl22761 Human ant
87	1756	99.5	335	9	AEC22665	Aec22665 Secreted
88	1756	99.5	351	2	AAR43685	Aar43685 Human kap
89	1756	99.5	356	8	ADJ95976	Adj95976 Immunoglo
90	1756	99.5	371	1	AAP91918	Aap91918 Sequence
91	1756	99.5	442	6	ABR39465	Abr39465 Humanised
92	1756	99.5	442	6	ABR39474	Abr39474 Humanised
93	1756	99.5	442	6	ABU08311	Abu08311 Humanised
94	1756	99.5	442	6	ABU08320	Abu08320 Humanised
95	1756	99.5	442	6	ABR39793	Abr39793 Humanised
96	1756	99.5	442	6	ABB80113	Abb80113 Deglycosy

97	1756	99.5	442	6	ABB80109	Abb80109 Heavy cha	170	1756	99.5	461	4	AAU07745	Aau07745 Humanised
98	1756	99.5	442	7	AD894066	Ad894066 Humanised	171	1756	99.5	461	6	ABR39844	AbR39844 Hu266 N56
99	1756	99.5	442	7	AD894075	Ad894075 Humanised	172	1756	99.5	461	6	ABR39847	AbR39847 Hu266 N56
100	1756	99.5	442	8	ADN61714	Adn61714 Humanised	173	1756	99.5	461	6	ABR39843	AbR39843 Hu266 N56
101	1756	99.5	444	6	AAE35327	Aae35327 Humanised	174	1756	99.5	461	6	ABR39848	AbR39848 Hu266 N56
102	1756	99.5	444	6	AAE34876	Aae34876 BIWA4/8 a	175	1756	99.5	462	9	ABO08804	Aeb08804 Reference
103	1756	99.5	444	8	ADL15443	Adl15443 Humanised	176	1756	99.5	463	9	ADM72025	Adm72025 Chimeric
104	1756	99.5	444	8	ADL15443	Adl15443 Humanised	177	1756	99.5	463	10	AEF50991	Aef50991 Variable
105	1756	99.5	444	8	AD000851	Ado00851 Humanised	178	1756	99.5	464	8	ADU68011	Adu68011 Mouse ant
106	1756	99.5	444	9	ABE29789	Aeb29789 Humanised	179	1756	99.5	464	9	AEA41072	Aea41072 Human ant
107	1756	99.5	445	6	AAO31101	Aao31101 Human A2-	180	1756	99.5	464	9	AED41918	Aed41918 Deimmuniz
108	1756	99.5	445	7	ADFL11421	Adfl11421 2E11 anti	181	1756	99.5	464	9	AED41912	Aed41912 Deimmuniz
109	1756	99.5	445	7	ADFL11429	Adfl11429 18B2 anti	182	1756	99.5	464	9	AED41920	Aed41920 Deimmuniz
110	1756	99.5	445	9	ADY74778	Ady74778 Rat anti-	183	1756	99.5	464	9	AED41924	Aed41924 Deimmuniz
111	1756	99.5	445	10	AEF11768	Aef11768 Human SCF	184	1756	99.5	465	4	ABD41922	Abd41922 Deimmuniz
112	1756	99.5	446	7	ADFL11425	Adfl11425 2D8 anti-	185	1756	99.5	465	4	ABD41922	Abd41922 Deimmuniz
113	1756	99.5	446	7	ADFL11437	Adfl11437 9H7 anti-	186	1756	99.5	465	9	ADX83744	Adx83744 Human Igg
114	1756	99.5	446	7	ADFL11433	Adfl11433 16E1 anti	187	1756	99.5	465	9	ADX83744	Adx83744 Human Igg
115	1756	99.5	446	7	ADFL11417	Adfl11417 22B3 anti	188	1756	99.5	467	2	AAE22759	Aae22759 Reshaped
116	1756	99.5	447	2	ADY311669	Ady311669 Human Igg	189	1756	99.5	467	2	AAE22758	Aae22758 Reshaped
117	1756	99.5	447	8	ADQ311274	Adq311274 Humanised	190	1756	99.5	467	7	ADM05608	Adm05608 Human pro
118	1756	99.5	447	8	ADQ311271	Adq311271 Murine 11	191	1756	99.5	467	8	ADM41567	Adm41567 Anti-inte
119	1756	99.5	447	8	ADQ311276	Adq311276 Humanised	192	1756	99.5	467	9	ADY30112	Ady30112 Human Igg
120	1756	99.5	447	8	AD887928	Ad887928 Anti-IFN-	193	1756	99.5	468	5	AEAC88538	Aec88538 Human CDN
121	1756	99.5	447	8	AD887924	Ad887924 Anti-IFN-	194	1756	99.5	468	6	ABE27928	Abe27928 Human CSE
122	1756	99.5	447	8	AD887926	Ad887926 Anti-IFN-	195	1756	99.5	468	6	ABP58275	Abp58275 Humanised
123	1756	99.5	447	8	AD887939	Ad887939 Anti-IFN-	196	1756	99.5	468	8	ADY46819	Ady46819 Human ant
124	1756	99.5	447	8	AD894936	Ad894936 Anti-IFN-	197	1756	99.5	468	9	ADY91369	Ady91369 Anti-KID3
125	1756	99.5	447	8	AD894923	Ad894923 Anti-IFN-	198	1756	99.5	468	10	AEAE99093	Aee99093 RSV antib
126	1756	99.5	447	8	AD894921	Ad894921 Anti-IFN-	199	1756	99.5	469	8	ADMA1555	Adma1555 Anti-inte
127	1756	99.5	447	8	AD894925	Ad894925 Anti-IFN-	200	1756	99.5	469	8	ADMA1561	Adma1561 Anti-inte
128	1756	99.5	447	9	AEBl2291	Aeb12291 Human Igg	201	1756	99.5	469	10	AEAE99092	Aee99092 RSV antib
129	1756	99.5	448	9	AAW49203	Aam49203 Humanised	202	1756	99.5	470	2	AAE22757	Aae22757 Reshaped
130	1756	99.5	448	9	ADZ99442	Adz99442 Humanised	203	1756	99.5	470	3	AAU77289	Aau77289 Protein #
131	1756	99.5	448	10	AEAG01544	Aeg01544 Kallikrei	204	1756	99.5	470	3	AAU77289	Aau77289 Protein #
132	1756	99.5	449	2	AAW49816	Aaw49816 Amino aci	205	1756	99.5	470	7	ADBE5576	Adbe5576 Human pro
133	1756	99.5	449	2	AAW49816	Aaw49816 Amino aci	206	1756	99.5	470	8	ADM72027	Adm72027 Chimeric
134	1756	99.5	449	6	ABP58273	Abp58273 Humanised	207	1756	99.5	470	8	ADM72031	Adm72031 Chimeric
135	1756	99.5	449	9	ADL35159	Adl35159 Humanised	208	1756	99.5	470	9	ADX83715	Adx83715 Human bet
136	1756	99.5	449	9	ADZ80769	Adz80769 Amino aci	209	1756	99.5	470	10	AEF50998	Aef50998 Variable
137	1756	99.5	449	9	ADZ99434	Adz99434 Humanised	210	1756	99.5	470	10	AEF50993	Aef50993 Variable
138	1756	99.5	450	6	ABG74713	Abg74713 Murine hu	211	1756	99.5	471	7	ADM05609	Adm05609 Human pro
139	1756	99.5	450	7	ABR83153	AbR83153 Hu007 ant	212	1756	99.5	471	8	ADM72029	Adm72029 Chimeric
140	1756	99.5	450	8	AD818704	Ad818704 Protein s	213	1756	99.5	471	8	ADR09218	Adr09218 Human pro
141	1756	99.5	450	8	AD818706	Ad818706 Protein s	214	1756	99.5	471	9	AEAC88539	Aec88539 Human CDN
142	1756	99.5	450	8	AD818710	Ad818710 Protein s	215	1756	99.5	471	10	AEF50996	Aef50996 Variable
143	1756	99.5	450	8	AD818702	Ad818702 Protein s	216	1756	99.5	472	6	ADP58289	Adp58289 Humanised
144	1756	99.5	450	8	AD818708	Ad818708 Protein s	217	1756	99.5	472	7	ADM05388	Adm05388 Human pro
145	1756	99.5	450	9	AED19128	Aed19128 Humanized	218	1756	99.5	472	8	ADQ66377	Adq66377 Novel hum
146	1756	99.5	450	10	AEF80308	Aef80308 Antibody	219	1756	99.5	472	8	ADQ66377	Adq66377 Novel hum
147	1756	99.5	450	10	AEF80304	Aef80304 Antibody	220	1756	99.5	472	8	ADQ66377	Adq66377 Novel hum
148	1756	99.5	451	10	AEF80304	Aef80304 Tie recep	221	1756	99.5	473	4	AEAC88318	Aec88318 Sequence
149	1756	99.5	451	4	AAE12715	Aae12715 Human rec	222	1756	99.5	473	4	AEAC88318	Aec88318 Human CDN
150	1756	99.5	451	6	ABU58807	Abu58807 Mucin 1 (223	1756	99.5	473	4	AEAC88318	Aec88318 Human typ
151	1756	99.5	451	8	ADL92469	Adl92469 Antibody	224	1756	99.5	473	4	AEAC88318	Aec88318 Human typ
152	1756	99.5	451	8	ADL92469	Adl92469 Antibody	225	1756	99.5	473	7	ADM05599	Adm05599 Human pro
153	1756	99.5	451	8	ADU68151	Adu68151 Novel var	226	1756	99.5	473	8	ADM97513	Adm97513 CD1d-IgG-
154	1756	99.5	451	8	ADU68151	Adu68151 Novel var	227	1756	99.5	473	9	AEAC88529	Aec88529 Human CDN
155	1756	99.5	451	9	AED19166	Aed19166 Humanized	228	1756	99.5	474	7	ADM05597	Adm05597 Human pro
156	1756	99.5	451	10	AEAF27225	Aef27225 Humanized	229	1756	99.5	474	9	AEAC88527	Aec88527 Human CDN
157	1756	99.5	452	2	AAV30201	Aav30201 Heavy cha	230	1756	99.5	475	2	AAE20057	Aae20057 Heavy cha
158	1756	99.5	452	9	AEAD34780	Aead34780 Chimeric	231	1756	99.5	475	2	AAE20057	Aae20057 Heavy cha
159	1756	99.5	453	6	ABP58287	Abp58287 Humanised	232	1756	99.5	475	4	AAE20057	Aae20057 Heavy cha
160	1756	99.5	453	6	ABP58287	Abp58287 Humanised	233	1756	99.5	475	4	AAE20057	Aae20057 Heavy cha
161	1756	99.5	453	8	ADT55443	Adt55443 Anti IGE	234	1756	99.5	475	8	ADL23053	Adl23053 Mouse aci
162	1756	99.5	453	8	ADT55443	Adt55443 Anti IGE	235	1756	99.5	475	8	ADL23056	Adl23056 Humanised
163	1756	99.5	453	9	ADY26726	Ady26726 Anti-NGF-	236	1756	99.5	475	8	ADL23056	Adl23056 Humanised
164	1756	99.5	453	9	ABE56309	Aeb56309 Anti-IGE	237	1756	99.5	475	8	ADL23056	Adl23056 Humanised
165	1756	99.5	455	10	AEF19882	Aef19882 Humanized	238	1756	99.5	475	8	ADL23056	Adl23056 Humanised
166	1756	99.5	455	10	AEF19881	Aef19881 Humanized	239	1756	99.5	476	2	AAE20057	Aae20057 Heavy cha
167	1756	99.5	455	10	AEF19884	Aef19884 Humanized	240	1756	99.5	476	2	AAE20057	Aae20057 Heavy cha
168	1756	99.5	457	9	AEF19883	Aef19883 Humanized	241	1756	99.5	476	2	AAE20057	Aae20057 Heavy cha
169	1756	99.5	461	2	AAE20057	Aae20057 Heavy cha	242	1756	99.5	476	9	AEAC88533	Aec88533 Human CDN

243	1756	99.5	477	7	ADM05604	Adm05604 Human pro	316	1753	99.3	470	9	ADZ51043	Adz51043 Amino aci
244	1756	99.5	477	8	ADQ65990	Novel hum	317	1753	99.3	476	9	AED19758	Aed19758 Chimeric
245	1756	99.5	477	8	ADL10018	Human pro	318	1753	99.3	480	9	AED19756	Aed19756 Chimeric
246	1756	99.5	477	9	AEC88534	Human CDN	319	1753	99.3	713	8	ADN97491	Adn97491 Artificia
247	1756	99.5	478	8	ADG67023	Novel hum	320	1753	99.3	715	8	ADN97489	Adn97489 Artificia
248	1756	99.5	481	2	AAR24442	Sequence	321	1752	99.3	329	2	AAR91806	Aar91806 Human imm
249	1756	99.5	485	9	ADX83727	Human IGG	322	1752	99.3	329	2	ADP56389	Adp56389 Human PRO
250	1756	99.5	502	8	ADN97493	CD1d-IGG-	323	1752	99.3	329	10	AEPF72978	Aepf72978 Human IGG
251	1756	99.5	534	2	AAR26531	Sequence	324	1752	99.3	330	9	ADZ69645	Adz69645 Human IGG
252	1756	99.5	541	5	AAR29077	Human IL-	325	1752	99.3	330	9	ADZ69654	Adz69654 Human IGG
253	1756	99.5	541	8	ADS31713	Soluble I	326	1752	99.3	330	9	ADZ69615	Adz69615 Human IGG
254	1756	99.5	541	8	ADS92715	IL-22RA s	327	1752	99.3	330	9	ADZ69623	Adz69623 Human IGG
255	1756	99.5	547	4	AAB85279	Human IL-	328	1752	99.3	330	9	ADZ69623	Adz69623 Human IGG
256	1756	99.5	547	5	ABG67210	Interleuk	329	1752	99.3	446	8	ADP19328	Adp19328 Chimeric
257	1756	99.5	547	5	AAR23362	Human IL-	330	1752	99.3	448	8	ADP84969	Adp84969 Chimeric
258	1756	99.5	547	8	ADJ83334	Human IL-	331	1752	99.3	451	8	ADL92472	Adl92472 Antibody
259	1756	99.5	547	9	ADM64569	IL-20RA a	332	1752	99.3	451	8	ADU68154	Adu68154 Novel var
260	1756	99.5	551	9	AEC05756	Homo-cont	333	1752	99.3	451	10	AEPF51206	Aepf51206 Human ant
261	1756	99.5	551	9	AEC05755	Homo-cont	334	1752	99.3	451	10	AEPF51206	Aepf51206 Human ant
262	1756	99.5	557	9	AEC05753	Homo-cont	335	1752	99.3	462	3	AAB29408	Aab29408 Human mon
263	1756	99.5	557	9	AEC05752	Homo-cont	336	1752	99.3	468	9	AEA18640	Aea18640 Amino aci
264	1756	99.5	557	9	AEC05754	Homo-cont	337	1752	99.3	470	3	AAV44721	Aav44721 Human imm
265	1756	99.5	558	5	AAR29076	Human IL-	338	1752	99.3	470	5	AAE27923	Aae27923 Human C2B
266	1756	99.5	567	5	AAE13733	Human Zai	339	1752	99.3	470	6	ABB28232	Abb28232 Antibody
267	1756	99.5	571	4	AAB85278	Human IL-	340	1752	99.3	471	10	AEE86008	Aee86008 Anthrax t
268	1756	99.5	571	5	AAU04065	Human IL-	341	1752	99.3	471	9	AEC88530	Aec88530 Human CDN
269	1756	99.5	571	5	ABG67209	Interleuk	342	1752	99.3	475	2	AAW11641	Aaw11641 Human ant
270	1756	99.5	571	8	AAE23359	Human IL-	343	1752	99.3	475	2	AAW11639	Aaw11639 Human ant
271	1756	99.5	571	8	ADJ83333	Human IL-	344	1752	99.3	475	2	AAQ65032	Aaq65032 Novel hum
272	1756	99.5	581	9	ADM64568	IL-20RA a	345	1752	99.3	476	2	AAW01818	Aaw01818 Primatise
273	1756	99.5	581	4	AAB81972	Angliosi	346	1752	99.3	476	2	AAW01822	Aaw01822 Primatise
274	1756	99.5	582	4	AAB81987	Angliosi	347	1752	99.3	476	2	AAW63761	Aaw63761 Macaque p
275	1756	99.5	582	4	AAB81991	Angliosi	348	1752	99.3	476	2	AAW63765	Aaw63765 Macaque p
276	1756	99.5	583	4	AAE83156	Angliosi	349	1752	99.3	476	5	AAU11539	Aau11539 Protein s
277	1756	99.5	595	2	AAW86003	Anti-5T4	350	1752	99.3	476	5	AAU11646	Aau11646 Protein s
278	1756	99.5	613	8	ADR46827	Human bet	351	1752	99.3	476	6	AAE37360	Aae37360 Monkey 7C
279	1756	99.5	649	8	ADM97531	CD1d-IGG	352	1752	99.3	477	2	AAAR47453	Aaar47453 Chit184.12
280	1756	99.5	652	2	AAW48650	Heavy cha	353	1752	99.3	478	2	AAW63763	Aaw63763 Macaque p
281	1756	99.5	659	8	ADS75345	Chimeric	354	1752	99.3	478	5	AAU11644	Aau11644 Protein s
282	1756	99.5	690	3	AAV92195	Human IL-	355	1751	99.2	329	8	ADP51717	Adp51717 Human OST
283	1756	99.5	729	1	AAE93008	Genetic C	356	1751	99.2	330	8	ADP51717	Adp51717 Human OST
284	1756	99.5	729	3	AAV59168	CD4-Ig fu	357	1751	99.2	330	9	ADY74806	Ady74806 Human IGG
285	1756	99.5	731	4	AAW52156	Humanised	358	1751	99.2	330	9	ADZ69637	Adz69637 Human IGG
286	1756	99.5	741	4	AAW52159	Humanised	359	1751	99.2	330	9	ADZ69616	Adz69616 Human IGG
287	1756	99.5	951	2	AAW70798	Human gp1	360	1751	99.2	330	9	ADZ69650	Adz69650 Human IGG
288	1756	99.5	951	3	AAV92186	Human gp1	361	1751	99.2	330	9	ADZ69642	Adz69642 Human IGG
289	1756	99.5	951	7	ABW02166	Human gp1	362	1751	99.2	330	9	ADZ69620	Adz69620 Human IGG
290	1756	99.5	961	3	AAV92187	Human gp1	363	1751	99.2	330	9	ADZ69600	Adz69600 Human IGG
291	1756	99.5	972	7	ADG87101	Glucosamyl	364	1751	99.2	330	9	ADZ69611	Adz69611 Human IGG
292	1756	99.5	975	7	ADG87102	Glucosamyl	365	1751	99.2	330	9	ADZ69619	Adz69619 Human IGG
293	1754	99.4	330	9	ADZ69626	Human IGG	366	1751	99.2	330	9	ADZ69634	Adz69634 Human IGG
294	1754	99.4	330	9	ADZ69628	Human IGG	367	1751	99.2	330	10	AEPF16352	Aepf16352 Human IGG
295	1754	99.4	592	4	AAE83838	Amino aci	368	1751	99.2	445	8	ADJ11308	Adj11308 BHA10 VH#
296	1753	99.3	330	8	ADN97485	Artificia	369	1751	99.2	447	6	AAE33524	Aae33524 Human AOC
297	1753	99.3	330	8	ADT51725	Human Hul	370	1751	99.2	447	6	AAE33522	Aae33522 Human AOC
298	1753	99.3	330	8	ADT51718	Human OST	371	1751	99.2	447	9	AEF13531	Aef13531 Mature ch
299	1753	99.3	330	9	ADZ69635	Human IGG	372	1751	99.2	448	6	ABR55871	AbR55871 Human imm
300	1753	99.3	330	9	ADZ69647	Human IGG	373	1751	99.2	448	8	ADN49728	Adn49728 Human imm
301	1753	99.3	330	10	AEPF16353	Human IGG	374	1751	99.2	448	8	ADU74404	Adu74404 Human imm
302	1753	99.3	446	8	ADT51688	Dacilizuma	375	1751	99.2	448	9	AED12731	Aed12731 Heavy cha
303	1753	99.3	446	10	AEPF16403	Humanized	376	1751	99.2	449	5	AAO18400	Aao18400 Mature hu
304	1753	99.3	447	8	ADT51699	Fontolizu	377	1751	99.2	449	9	AEC36337	Aec36337 Human CBE
305	1753	99.3	447	10	AEPF16414	Humanized	378	1751	99.2	449	9	AEC92138	Aec92138 Anti-t-huPR
306	1753	99.3	448	8	ADT19760	Chimeric	379	1751	99.2	459	2	AAAR42066	Aaar42066 Human ant
307	1753	99.3	464	9	AED19760	Chimeric	380	1751	99.2	464	4	AAE72232	Aae72232 Humanised
308	1753	99.3	465	7	ADL23152	Mouse/hum	381	1751	99.2	464	8	ADU11354	Adj11354 BHA10 VH#
309	1753	99.3	465	7	ADL23135	Mouse/hum	382	1751	99.2	470	3	AAAB08026	Aaab08026 A dimeric
310	1753	99.3	465	7	ADL23150	Mouse/hum	383	1751	99.2	470	7	ADMO5607	Adm05607 Human pro
311	1753	99.3	465	9	ADW48323	Anti-epit	384	1751	99.2	470	9	AEC88537	Aec88537 Human CDN
312	1753	99.3	465	9	ADW48340	Anti-epit	385	1751	99.2	476	8	ADP09212	Adp09212 Human pro
313	1753	99.3	465	9	ADW48338	Anti-epit	386	1751	99.2	697	8	AQO07403	Aqo07403 hCBE11/hb
314	1753	99.3	469	8	ADU17617	Human ant	387	1751	99.2	697	8	AQD12180	Aqd12180 Heavy cha
315	1753	99.3	469	8	ADU17474	Human ant	388	1751	99.2	701	8	ADQ07409	Adq07409 hCBE11 mo

389	1751	99.2	701	8	AD012186	Adn12186 Heavy cha	462	1750	99.2	451	8	ADN07039	Adn07039 Anti-IGE
390	1751	99.2	709	9	AE922142	Aec922142 Mature He	463	1750	99.2	451	8	ADN07035	Adn07035 Anti-IGE
391	1751	99.2	729	4	AAW522158	Aam522158 Humanized	464	1750	99.2	451	8	ADT55442	Adt55442 Anti-IGE
392	1751	99.2	739	4	AAW522161	Aam522161 Humanized	465	1750	99.2	451	8	ADT55441	Adt55441 Anti-IGE
393	1750	99.2	739	4	AAW522161	Aam522161 Humanized	466	1750	99.2	451	9	ADW00659	Adw00659 Human ant
394	1750	99.2	330	6	AB987556	Abb987556 Human hea	467	1750	99.2	451	9	ADW00661	Adw00661 Human ant
395	1750	99.2	330	6	AB987556	Abb987556 Human hea	468	1750	99.2	451	9	ADW00657	Adw00657 Human ant
396	1750	99.2	330	8	AD091427	Adg91427 Amino aci	469	1750	99.2	451	9	ADW00657	Adw00657 Human ant
397	1750	99.2	330	8	AD592917	Adg92917 Human IGG	470	1750	99.2	451	9	ADW79894	Adw79894 Anti-IGE
398	1750	99.2	330	8	AD751176	Adt51176 Human OST	471	1750	99.2	451	9	ABE56308	Abt56308 Anti-IGE
399	1750	99.2	330	8	AD751175	Adt51175 Human OST	472	1750	99.2	451	9	ABE56307	Abt56307 Anti-IGE
400	1750	99.2	330	8	AD751174	Adt51174 Human OST	473	1750	99.2	451	9	ABE56307	Abt56307 Anti-IGE
401	1750	99.2	330	9	ADW86658	Adw86658 Human Imm	474	1750	99.2	451	9	AED89918	Aed89918 Anti-IGE
402	1750	99.2	330	9	AD269610	Adt269610 Human IGG	475	1750	99.2	451	9	AED89920	Aed89920 Anti-IGE
403	1750	99.2	330	9	AD269612	Adt269612 Human IGG	476	1750	99.2	451	9	AED89916	Aed89916 Anti-IGE
404	1750	99.2	330	9	AD269646	Adt269646 Human IGG	477	1750	99.2	451	10	AE905002	Aeg05002 Anti-CD20
405	1750	99.2	330	9	AD269603	Adt269603 Human IGG	478	1750	99.2	452	2	AY29458	Aay29458 Recombina
406	1750	99.2	330	9	AD269639	Adt269639 Human IGG	479	1750	99.2	452	3	AY77766	Aay77766 Humanized
407	1750	99.2	330	9	AD269655	Adt269655 Human IGG	480	1750	99.2	452	3	AAAB30322	Aab30322 Humanized
408	1750	99.2	330	9	AD269651	Adt269651 Human IGG	481	1750	99.2	452	6	ABU13799	Abu13799 Humanized
409	1750	99.2	330	9	AD269601	Adt269601 Human IGG	482	1750	99.2	452	6	ABU13799	Abu13799 Humanized
410	1750	99.2	330	9	AD269602	Adt269602 Human IGG	483	1750	99.2	452	6	ABU13799	Abu13799 Humanized
411	1750	99.2	330	9	AD269632	Adt269632 Human IGG	484	1750	99.2	452	6	ABU13799	Abu13799 Humanized
412	1750	99.2	330	9	AD269613	Adt269613 Human IGG	485	1750	99.2	452	6	ABU13799	Abu13799 Humanized
413	1750	99.2	330	9	AD269656	Adt269656 Human IGG	486	1750	99.2	452	6	ABU13799	Abu13799 Humanized
414	1750	99.2	330	9	AD269607	Adt269607 Human IGG	487	1750	99.2	452	6	ABU13799	Abu13799 Humanized
415	1750	99.2	330	9	AD269614	Adt269614 Human IGG	488	1750	99.2	452	6	ABU13799	Abu13799 Humanized
416	1750	99.2	330	9	AD269636	Adt269636 Human IGG	489	1750	99.2	452	6	ABU13799	Abu13799 Humanized
417	1750	99.2	330	9	AD269609	Adt269609 Human IGG	490	1750	99.2	452	6	ABU13799	Abu13799 Humanized
418	1750	99.2	330	9	AD269631	Adt269631 Human IGG	491	1750	99.2	452	6	ABU13799	Abu13799 Humanized
419	1750	99.2	330	9	AD269633	Adt269633 Human IGG	492	1750	99.2	452	6	ABU13799	Abu13799 Humanized
420	1750	99.2	330	9	AD269638	Adt269638 Human IGG	493	1750	99.2	452	6	ABU13799	Abu13799 Humanized
421	1750	99.2	330	9	AD269627	Adt269627 Human IGG	494	1750	99.2	452	6	ABU13799	Abu13799 Humanized
422	1750	99.2	330	9	AD269652	Adt269652 Human IGG	495	1750	99.2	452	6	ABU13799	Abu13799 Humanized
423	1750	99.2	330	9	AD269653	Adt269653 Human IGG	496	1750	99.2	452	6	ABU13799	Abu13799 Humanized
424	1750	99.2	330	9	AD270836	Adt70836 Human IGG	497	1750	99.2	452	6	ABU13799	Abu13799 Humanized
425	1750	99.2	330	9	AD270837	Adt70837 Human IGG	498	1750	99.2	452	6	ABU13799	Abu13799 Humanized
426	1750	99.2	330	9	AE28909	Aeb28909 Human Imm	499	1750	99.2	452	6	ABU13799	Abu13799 Humanized
427	1750	99.2	330	9	AE28908	Aeb28908 Human Imm	500	1750	99.2	452	6	ABU13799	Abu13799 Humanized
428	1750	99.2	330	9	AE28908	Aeb28908 Human Imm	501	1750	99.2	452	6	ABU13799	Abu13799 Humanized
429	1750	99.2	330	9	AE28908	Aeb28908 Human Imm	502	1750	99.2	452	6	ABU13799	Abu13799 Humanized
430	1750	99.2	330	10	AEF16349	Aef16349 Human IGG	503	1750	99.2	452	6	ABU13799	Abu13799 Humanized
431	1750	99.2	330	10	AEF16351	Aef16351 Human IGG	504	1750	99.2	452	6	ABU13799	Abu13799 Humanized
432	1750	99.2	330	10	AEF16350	Aef16350 Human IGG	505	1750	99.2	452	6	ABU13799	Abu13799 Humanized
433	1750	99.2	330	10	AEF16350	Aef16350 Human IGG	506	1750	99.2	452	6	ABU13799	Abu13799 Humanized
434	1750	99.2	371	1	AP93558	App93558 Linkered	507	1750	99.2	452	6	ABU13799	Abu13799 Humanized
435	1750	99.2	446	8	AD751687	Adt51687 Dacilizuma	508	1750	99.2	452	6	ABU13799	Abu13799 Humanized
436	1750	99.2	446	8	AD751686	Adt51686 Dacilizuma	509	1750	99.2	452	6	ABU13799	Abu13799 Humanized
437	1750	99.2	446	10	AEF16401	Aef16401 Humanized	510	1750	99.2	452	6	ABU13799	Abu13799 Humanized
438	1750	99.2	446	10	AEF16402	Aef16402 Humanized	511	1750	99.2	452	6	ABU13799	Abu13799 Humanized
439	1750	99.2	447	8	AD751697	Adt51697 Fontolizu	512	1750	99.2	452	6	ABU13799	Abu13799 Humanized
440	1750	99.2	447	8	AD751698	Adt51698 Fontolizu	513	1750	99.2	452	6	ABU13799	Abu13799 Humanized
441	1750	99.2	447	10	AEF16412	Aef16412 Humanized	514	1750	99.2	452	6	ABU13799	Abu13799 Humanized
442	1750	99.2	447	10	AEF16413	Aef16413 Humanized	515	1750	99.2	452	6	ABU13799	Abu13799 Humanized
443	1750	99.2	449	10	AEF03142	Aef03142 Pertuzuma	516	1750	99.2	452	6	ABU13799	Abu13799 Humanized
444	1750	99.2	449	10	AEF27312	Aef27312 Humanized	517	1750	99.2	452	6	ABU13799	Abu13799 Humanized
445	1750	99.2	450	3	AEAl1269	Aeal1269 Lys450-mo	518	1750	99.2	452	6	ABU13799	Abu13799 Humanized
446	1750	99.2	450	3	AEAl1270	Aeal1270 Asp1021so	519	1750	99.2	452	6	ABU13799	Abu13799 Humanized
447	1750	99.2	451	2	AAW95659	Aaw95659 Mus muscu	520	1750	99.2	452	6	ABU13799	Abu13799 Humanized
448	1750	99.2	451	2	AAW95663	Aaw95663 Mus muscu	521	1750	99.2	452	6	ABU13799	Abu13799 Humanized
449	1750	99.2	451	2	AAW95661	Aaw95661 Mus muscu	522	1750	99.2	452	6	ABU13799	Abu13799 Humanized
450	1750	99.2	451	2	AAW50031	Aay50031 Human E27	523	1750	99.2	452	6	ABU13799	Abu13799 Humanized
451	1750	99.2	451	3	AAW85201	Aay85201 Light cha	524	1750	99.2	452	6	ABU13799	Abu13799 Humanized
452	1750	99.2	451	3	AAW807473	Aab07473 Amino aci	525	1750	99.2	452	6	ABU13799	Abu13799 Humanized
453	1750	99.2	451	4	AAW47088	Aab47088 Anti-IGE	526	1750	99.2	452	6	ABU13799	Abu13799 Humanized
454	1750	99.2	451	4	AAW76952	Aab76952 Full leng	527	1750	99.2	452	6	ABU13799	Abu13799 Humanized
455	1750	99.2	451	4	AAW76948	Aab76948 Full leng	528	1750	99.2	452	6	ABU13799	Abu13799 Humanized
456	1750	99.2	451	4	AAW76950	Aab76950 Full leng	529	1750	99.2	452	6	ABU13799	Abu13799 Humanized
457	1750	99.2	451	4	AAW74212	Aab74212 E27 anti-	530	1750	99.2	452	6	ABU13799	Abu13799 Humanized
458	1750	99.2	451	6	ABU62798	Abu62798 E27 anti-	531	1750	99.2	452	6	ABU13799	Abu13799 Humanized
459	1750	99.2	451	7	ADF29039	Adf29039 Human ant	532	1750	99.2	452	6	ABU13799	Abu13799 Humanized
460	1750	99.2	451	8	AD751670	Adt751670 anti-CD11	533	1750	99.2	452	6	ABU13799	Abu13799 Humanized
461	1750	99.2	451	8	ADN07037	Adn07037 Anti-IGE	534	1749	99.1	330	8	ADN36570	Adn36570 Chemokine

535	1749	99.1	330	9	ADZ69625	Adz69625 Human Igg	608	1747	99.0	449	7	ABR82262	Abt82262 Chimeric
536	1749	99.1	330	9	ADZ69630	Adz69630 Human Igg	609	1747	99.0	449	8	ADH34585	Adh34585 0011 heav
537	1749	99.1	330	9	ADZ69648	Adz69648 Human Igg	610	1747	99.0	449	8	ADP84137	Adp84137 Anti-mono
538	1749	99.1	330	9	ADZ69605	Adz69605 Human Igg	611	1747	99.0	449	8	ADP84131	Adp84131 Anti-mono
539	1749	99.1	330	9	ADZ69629	Adz69629 Human Igg	612	1747	99.0	449	8	ADZ23346	Adz23346 Human CD7
540	1749	99.1	330	9	ADZ69606	Adz69606 Human Igg	613	1747	99.0	449	8	ADZ31793	Adz31793 Chimeric
541	1749	99.1	330	9	ADZ69604	Adz69604 Human Igg	614	1747	99.0	449	10	AEE73324	Aee73324 Human ant
542	1749	99.1	330	9	ADZ69617	Adz69617 Human Igg	615	1747	99.0	450	4	AAE10521	AAe10521 Humanised
543	1749	99.1	330	9	ADZ69622	Adz69622 Human Igg	616	1747	99.0	450	4	AAE10525	AAe10525 Humanised
544	1749	99.1	330	9	ADZ69618	Adz69618 Human Igg	617	1747	99.0	450	4	AAE10513	AAe10513 Humanised
545	1749	99.1	330	9	ADZ69641	Adz69641 Human Igg	618	1747	99.0	450	4	AAE10515	AAe10515 Humanised
546	1749	99.1	330	9	ADZ69649	Adz69649 Human Igg	619	1747	99.0	450	4	AAE10517	AAe10517 Humanised
547	1749	99.1	330	9	ADZ69644	Adz69644 Human Igg	620	1747	99.0	450	4	AAE10523	AAe10523 Humanised
548	1749	99.1	330	10	AEF51211	Aef51211 Human imm	621	1747	99.0	450	4	AAE10519	AAe10519 Humanised
549	1749	99.1	400	7	ADD13790	Add13790 Plasmid p	622	1747	99.0	450	4	AAE10509	AAe10509 Humanised
550	1749	99.1	447	8	ABG11479	Abg11479 Chimeric	623	1747	99.0	450	4	AAE10511	AAe10511 Humanised
551	1748	99.0	330	5	ABG31479	Abg31479 Aglycosyl	624	1747	99.0	450	5	ABP66572	Abp66572 Human RSV
552	1748	99.0	330	9	ADZ69643	Adz69643 Human Igg	625	1747	99.0	450	5	ABP66578	Abp66578 Human RSV
553	1748	99.0	330	9	ADZ69621	Adz69621 Human Igg	626	1747	99.0	450	5	ABP66576	Abp66576 Human RSV
554	1748	99.0	330	9	ADZ69640	Adz69640 Human Igg	627	1747	99.0	450	5	ABP66582	Abp66582 Human RSV
555	1748	99.0	330	9	ADZ69624	Adz69624 Human Igg	628	1747	99.0	450	5	ABP66608	Abp66608 Human RSV
556	1748	99.0	330	10	AEF95114	Aef95114 Human Igg	629	1747	99.0	450	5	ABP66590	Abp66590 Human RSV
557	1748	99.0	448	8	ADP88439	Adp88439 Antibody	630	1747	99.0	450	5	ABP66610	Abp66610 Human RSV
558	1748	99.0	448	8	ADP88455	Adp88455 Antibody	631	1747	99.0	450	5	ABP66588	Abp66588 Human RSV
559	1748	99.0	448	10	AEF27208	Aef27208 Anti-CD4	632	1747	99.0	450	5	ABP66596	Abp66596 Human RSV
560	1748	99.0	448	10	AEF27224	Aef27224 Anti-CD4	633	1747	99.0	450	5	ABP66602	Abp66602 Human RSV
561	1748	99.0	449	3	AAV68810	Aav68810 A rat hea	634	1747	99.0	450	5	ABP66606	Abp66606 Human RSV
562	1748	99.0	451	9	ADW79892	Adw79892 Anti-IgE	635	1747	99.0	450	5	ABP66604	Abp66604 Human RSV
563	1748	99.0	467	6	ADA47341	Ada47341 TRX1 agly	636	1747	99.0	450	5	ABP66586	Abp66586 Human RSV
564	1748	99.0	467	6	ADA47342	Ada47342 TRX1 agly	637	1747	99.0	450	5	ABP66594	Abp66594 Human RSV
565	1748	99.0	467	8	ADP88454	Adp88454 Antibody	638	1747	99.0	450	5	ABP66598	Abp66598 Human RSV
566	1748	99.0	467	8	ADP88438	Adp88438 Antibody	639	1747	99.0	450	5	ABP66564	Abp66564 Human RSV
567	1748	99.0	467	8	ADQ87970	Adq87970 Heavy cha	640	1747	99.0	450	5	ABP66566	Abp66566 Human RSV
568	1748	99.0	467	10	AEF27207	Aef27207 Anti-CD4	641	1747	99.0	450	5	ABP66580	Abp66580 Human RSV
569	1748	99.0	467	10	AEF27264	Aef27264 Anti-CD4	642	1747	99.0	450	5	ABP66592	Abp66592 Human RSV
570	1748	99.0	467	10	AEF27205	Aef27205 Anti-CD4	643	1747	99.0	450	5	ABP66600	Abp66600 Human RSV
571	1748	99.0	467	10	AEF27223	Aef27223 Anti-CD4	644	1747	99.0	450	5	ABP66574	Abp66574 Human RSV
572	1748	99.0	467	10	AEF27221	Aef27221 Anti-CD4	645	1747	99.0	450	5	ABP66562	Abp66562 Human RSV
573	1748	99.0	468	8	ADQ07413	Adq07413 Mature CB	646	1747	99.0	450	5	ABP66568	Abp66568 Human RSV
574	1748	99.0	468	8	ADQ12196	Adq12196 CBE11 pen	647	1747	99.0	450	5	ABP66570	Abp66570 Human RSV
575	1748	99.0	468	7	ADM05602	Adm05602 Human pro	648	1747	99.0	450	5	ABU69427	Abu69427 Respirato
576	1748	99.0	469	9	AEC88532	Aec88532 Human cDN	649	1747	99.0	450	6	ABU69443	Abu69443 Respirato
577	1748	99.0	472	7	ADM05610	Adm05610 Human pro	650	1747	99.0	450	6	ABU69437	Abu69437 Respirato
578	1748	99.0	472	9	AEC88540	Aec88540 Human cDN	651	1747	99.0	450	6	ABU69467	Abu69467 Respirato
579	1748	99.0	477	8	ADL10091	Adl10091 Human pro	652	1747	99.0	450	6	ABU69471	Abu69471 Respirato
580	1747	99.0	330	8	ADT51720	Adt51720 Human OSt	653	1747	99.0	450	6	ABU69435	Abu69435 Respirato
581	1747	99.0	330	9	AE886185	Aeb86185 Amino aci	654	1747	99.0	450	6	ABU69451	Abu69451 Respirato
582	1747	99.0	330	10	AEF16358	Aef16358 Human Igg	655	1747	99.0	450	6	ABU69455	Abu69455 Respirato
583	1747	99.0	330	10	AEF09132	Aeg09132 Tie recep	656	1747	99.0	450	6	ABU69459	Abu69459 Respirato
584	1747	99.0	434	7	ADZ35960	Adz35960 SYNAGIS a	657	1747	99.0	450	6	ABU69429	Abu69429 Respirato
585	1747	99.0	445	9	ADX02218	Adx02218 SARS coro	658	1747	99.0	450	6	ABU69439	Abu69439 Respirato
586	1747	99.0	446	8	ADT51689	Adt51689 Daclizuma	659	1747	99.0	450	6	ABU69433	Abu69433 Respirato
587	1747	99.0	446	9	ADX01861	Adx01861 SARS coro	660	1747	99.0	450	6	ABU69453	Abu69453 Respirato
588	1747	99.0	446	10	AEF16404	Aef16404 Humanized	661	1747	99.0	450	6	ABU69463	Abu69463 Respirato
589	1747	99.0	447	8	AEF51700	Aef51700 Fontolizu	662	1747	99.0	450	6	ABU69473	Abu69473 Respirato
590	1747	99.0	447	9	AEBA46954	Aeb46954 CD1a spec	663	1747	99.0	450	6	ABU69425	Abu69425 Respirato
591	1747	99.0	447	9	AEBA46964	Aeb46964 CD1a spec	664	1747	99.0	450	6	ABU69441	Abu69441 Respirato
592	1747	99.0	447	9	AEBA46962	Aeb46962 CD1a spec	665	1747	99.0	450	6	ABU69445	Abu69445 Respirato
593	1747	99.0	447	10	AEF16415	Aef16415 Humanized	666	1747	99.0	450	6	ABU69433	Abu69433 Respirato
594	1747	99.0	448	5	ABE999224	Abe999224 Chimeric	667	1747	99.0	450	6	ABU69465	Abu69465 Respirato
595	1747	99.0	448	8	ADF71916	Adf71916 Hu3G8VH-2	668	1747	99.0	450	6	ABU69431	Abu69431 Respirato
596	1747	99.0	448	8	ADF71912	Adf71912 Hu3G8VH-5	669	1747	99.0	450	6	ABU69461	Abu69461 Respirato
597	1747	99.0	448	8	ADR23352	Adr23352 Human CD7	670	1747	99.0	450	6	ABU69449	Abu69449 Respirato
598	1747	99.0	448	8	ADR23354	Adr23354 Human CD7	671	1747	99.0	450	6	ABU69469	Abu69469 Respirato
599	1747	99.0	448	9	ADW11298	Adw11298 Human C-t	672	1747	99.0	450	6	ABG75662	Abg75662 Synagis h
600	1747	99.0	448	9	ADW11296	Adw11296 Human C-t	673	1747	99.0	450	7	ADE35928	Ades35928 SYNAGIS a
601	1747	99.0	448	9	ADW11294	Adw11294 Human C-t	674	1747	99.0	450	7	ADE35948	Ades35948 SYNAGIS a
602	1747	99.0	448	9	ADW90319	Adw90319 Phage scF	675	1747	99.0	450	7	ADE35920	Ades35920 SYNAGIS a
603	1747	99.0	448	9	ADX01871	Adx01871 SARS coro	676	1747	99.0	450	7	ADE35926	Ades35926 SYNAGIS a
604	1747	99.0	448	9	ADY80252	Ady80252 Amino aci	677	1747	99.0	450	7	ADE35934	Ades35934 SYNAGIS a
605	1747	99.0	448	9	AEBA46960	Aeb46960 CD1a spec	678	1747	99.0	450	7	ADE35932	Ades35932 SYNAGIS a
606	1747	99.0	448	9	AEBA46958	Aeb46958 CD1a spec	679	1747	99.0	450	7	ADE35936	Ades35936 SYNAGIS a
607	1747	99.0	448	9	AEBA46956	Aeb46956 CD1a spec	680	1747	99.0	450	7	ADE35940	Ades35940 SYNAGIS a

681	1747	99.0	450	7	AD335952	Ad335952	SYNAGIS a	754	1747	99.0	450	9	ABC76855	Aec76855	SYNAGIS-d
682	1747	99.0	450	7	AD335938	Ad335938	SYNAGIS a	755	1747	99.0	450	9	ABC76843	Aec76843	SYNAGIS-d
683	1747	99.0	450	7	AD335956	Ad335956	SYNAGIS a	756	1747	99.0	450	9	ABC76871	Aec76871	SYNAGIS-d
684	1747	99.0	450	7	AD335968	Ad335968	SYNAGIS a	757	1747	99.0	450	9	ABC76877	Aec76877	SYNAGIS-d
685	1747	99.0	450	7	AD335946	Ad335946	SYNAGIS a	758	1747	99.0	450	9	ABC76839	Aec76839	SYNAGIS a
686	1747	99.0	450	7	AD335966	Ad335966	SYNAGIS a	759	1747	99.0	450	9	ABC76859	Aec76859	SYNAGIS-d
687	1747	99.0	450	7	AD335964	Ad335964	SYNAGIS a	760	1747	99.0	450	9	ABC76885	Aec76885	SYNAGIS-d
688	1747	99.0	450	7	AD335930	Ad335930	SYNAGIS a	761	1747	99.0	450	9	ABC76845	Aec76845	SYNAGIS-d
689	1747	99.0	450	7	AD335962	Ad335962	SYNAGIS a	762	1747	99.0	450	9	ABC76847	Aec76847	SYNAGIS-d
690	1747	99.0	450	7	AD335958	Ad335958	SYNAGIS a	763	1747	99.0	450	9	ABC76865	Aec76865	SYNAGIS-d
691	1747	99.0	450	7	AD335954	Ad335954	SYNAGIS a	764	1747	99.0	450	9	ABC76875	Aec76875	SYNAGIS-d
692	1747	99.0	450	7	AD335932	Ad335932	SYNAGIS a	765	1747	99.0	450	9	ABC76887	Aec76887	SYNAGIS-d
693	1747	99.0	450	7	AD335924	Ad335924	SYNAGIS a	766	1747	99.0	450	9	ABC76879	Aec76879	SYNAGIS-d
694	1747	99.0	450	7	AD335944	Ad335944	SYNAGIS a	767	1747	99.0	450	9	ABC76883	Aec76883	SYNAGIS-d
695	1747	99.0	450	7	AD335950	Ad335950	SYNAGIS a	768	1747	99.0	450	9	ABC76857	Aec76857	SYNAGIS-d
696	1747	99.0	450	8	AD334587	Adh34587	023 heavy	769	1747	99.0	450	9	ABC76869	Aec76869	SYNAGIS-d
697	1747	99.0	450	9	ADW20110	Adw20110	RSV antiG	770	1747	99.0	450	9	ABC76851	Aec76851	SYNAGIS-d
698	1747	99.0	450	9	ADW20082	Adw20082	RSV antiG	771	1747	99.0	450	9	ABC76881	Aec76881	SYNAGIS-d
699	1747	99.0	450	9	ADW20072	Adw20072	RSV antiG	772	1747	99.0	451	5	ABP66584	Human RSV	
700	1747	99.0	450	9	ADW20096	Adw20096	RSV antiG	773	1747	99.0	451	6	ABU69447	Respirato	
701	1747	99.0	450	9	ADW20100	Adw20100	RSV antiG	774	1747	99.0	451	7	ABU69447	Respirato	
702	1747	99.0	450	9	ADW20104	Adw20104	RSV antiG	775	1747	99.0	451	8	ADH34584	008 heavy	
703	1747	99.0	450	9	ADW20064	Adw20064	RSV antiG	776	1747	99.0	451	8	ADH34586	021 heavy	
704	1747	99.0	450	9	ADW20068	Adw20068	RSV antiG	777	1747	99.0	451	8	ADR23348	Human CD7	
705	1747	99.0	450	9	ADW20080	Adw20080	RSV antiG	778	1747	99.0	451	8	ADR23350	Human CD7	
706	1747	99.0	450	9	ADW20090	Adw20090	RSV antiG	779	1747	99.0	451	8	ADR23344	Human CD7	
707	1747	99.0	450	9	ADW20094	Adw20094	RSV antiG	780	1747	99.0	451	9	ADW20084	RSV antiG	
708	1747	99.0	450	9	ADW20062	Adw20062	RSV antiG	781	1747	99.0	451	9	ADX01865	SARS coro	
709	1747	99.0	450	9	ADW20102	Adw20102	RSV antiG	782	1747	99.0	451	9	ABE07066	RSV-speci	
710	1747	99.0	450	9	ADW20070	Adw20070	RSV antiG	783	1747	99.0	451	9	ABC76861	SYNAGIS-d	
711	1747	99.0	450	9	ADW20098	Adw20098	RSV antiG	784	1747	99.0	452	9	ADX01863	SARS coro	
712	1747	99.0	450	9	ADW20106	Adw20106	RSV antiG	785	1747	99.0	452	9	ADY70962	Human mon	
713	1747	99.0	450	9	ADW20108	Adw20108	RSV antiG	786	1747	99.0	452	10	ABE73716	Human ant	
714	1747	99.0	450	9	ADW20076	Adw20076	RSV antiG	787	1747	99.0	455	9	ADY70958	Human mon	
715	1747	99.0	450	9	ADW20092	Adw20092	RSV antiG	788	1747	99.0	457	9	ADY70954	Human mon	
716	1747	99.0	450	9	ADW20074	Adw20074	RSV antiG	789	1747	99.0	457	10	ABE73712	Human ant	
717	1747	99.0	450	9	ADW20078	Adw20078	RSV antiG	790	1747	99.0	466	10	ABE17836	Heavy cha	
718	1747	99.0	450	9	ADW20086	Adw20086	RSV antiG	791	1747	99.0	467	9	ABC20875	Low risk	
719	1747	99.0	450	9	ADW20066	Adw20066	RSV antiG	792	1747	99.0	467	9	ABC20877	Low + mod	
720	1747	99.0	450	9	ADW20088	Adw20088	RSV antiG	793	1747	99.0	468	7	AD664201	MN14HCF p	
721	1747	99.0	450	9	ADX02216	Adx02216	SARS coro	794	1747	99.0	468	7	ADF60815	HMN-14 he	
722	1747	99.0	450	9	ADX01867	Adx01867	SARS coro	795	1747	99.0	468	8	ADS14299	EGFR anti	
723	1747	99.0	450	9	ADX01869	Adx01869	SARS coro	796	1747	99.0	468	10	ABE86004	Anthrax t	
724	1747	99.0	450	9	AE807080	Aeb07080	RSV-speci	797	1747	99.0	469	7	ABR61529	Humanised	
725	1747	99.0	450	9	AE807050	Aeb07050	RSV-speci	798	1747	99.0	469	7	ABR61527	Humanised	
726	1747	99.0	450	9	AE807072	Aeb07072	RSV-speci	799	1747	99.0	469	9	ADY86264	Anti-huma	
727	1747	99.0	450	9	AE807058	Aeb07058	RSV-speci	800	1747	99.0	469	9	AEA12650	Variant h	
728	1747	99.0	450	9	AE807048	Aeb07048	RSV-speci	801	1747	99.0	469	9	AEA18906	Variant h	
729	1747	99.0	450	9	AE807056	Aeb07056	RSV-speci	802	1747	99.0	469	9	AEA18546	Variant h	
730	1747	99.0	450	9	AE807062	Aeb07062	RSV-speci	803	1747	99.0	469	9	AEA10639	Human ant	
731	1747	99.0	450	9	AE807064	Aeb07064	RSV-speci	804	1747	99.0	469	9	AD225712	Monoclonal	
732	1747	99.0	450	9	AE807082	Aeb07082	RSV-speci	805	1747	99.0	469	9	AD224413	Human CHI	
733	1747	99.0	450	9	AE807084	Aeb07084	RSV-speci	806	1747	99.0	469	9	AD25978	Ant-CD40	
734	1747	99.0	450	9	AE807086	Aeb07086	RSV-speci	807	1747	99.0	470	2	AAW83036	Anti-Fas	
735	1747	99.0	450	9	AE807078	Aeb07078	RSV-speci	808	1747	99.0	470	2	AAW83037	Anti-Fas	
736	1747	99.0	450	9	AE807060	Aeb07060	RSV-speci	809	1747	99.0	470	3	AAW814779	Humanised	
737	1747	99.0	450	9	AE807068	Aeb07068	RSV-speci	810	1747	99.0	470	3	AAW814776	Humanised	
738	1747	99.0	450	9	AE807076	Aeb07076	RSV-speci	811	1747	99.0	470	3	AAW90926	Humanised	
739	1747	99.0	450	9	AE807070	Aeb07070	RSV-speci	812	1747	99.0	470	3	AAW90934	Humanised	
740	1747	99.0	450	9	AE807046	Aeb07046	RSV-speci	813	1747	99.0	470	3	AAW90935	Humanised	
741	1747	99.0	450	9	AE807044	Aeb07044	RSV-speci	814	1747	99.0	470	3	AAW90933	Humanised	
742	1747	99.0	450	9	AE807054	Aeb07054	RSV-speci	815	1747	99.0	470	3	AAW90936	Humanised	
743	1747	99.0	450	9	AE807090	Aeb07090	RSV-speci	816	1747	99.0	470	3	AAW90929	Humanised	
744	1747	99.0	450	9	AE807092	Aeb07092	RSV-speci	817	1747	99.0	470	5	ABB74941	Humanised	
745	1747	99.0	450	9	AE807052	Aeb07052	RSV-speci	818	1747	99.0	470	5	ABB74944	Humanised	
746	1747	99.0	450	9	AE807074	Aeb07074	RSV-speci	819	1747	99.0	470	5	ABB74945	Humanised	
747	1747	99.0	450	9	AE807088	Aeb07088	RSV-speci	820	1747	99.0	470	5	ABB74898	Humanised	
748	1747	99.0	450	9	AE8076849	Aec76849	SYNAGIS-d	821	1747	99.0	470	5	ABB74904	Mouse hum	
749	1747	99.0	450	9	AE8076863	Aec76863	SYNAGIS-d	822	1747	99.0	470	5	ABB74902	Humanised	
750	1747	99.0	450	9	AE8076841	Aec76841	SYNAGIS-d	823	1747	99.0	470	5	ABB74903	Mouse hum	
751	1747	99.0	450	9	AE8076867	Aec76867	SYNAGIS-d	824	1747	99.0	470	5	ABB74895	Humanised	
752	1747	99.0	450	9	AE8076873	Aec76873	SYNAGIS-d	825	1747	99.0	470	9	ABE48573	Human Igg	
753	1747	99.0	450	9	AE8076853	Aec76853	SYNAGIS-d	826	1747	99.0	472	2	AAW50157	Chimeric	

827	1747	99.0	473	4	AAB36206	Aab36206 Human imm	900	1745	98.9	544	8	ADR66914	Adr66914 Human pro
828	1747	99.0	473	7	ADM05996	Adm05996 Human pro	901	1745	98.9	544	8	ADR66016	Adr66016 Human pro
829	1747	99.0	473	7	AEC88926	Aec88926 Human cDN	902	1745	98.9	545	8	ADU06496	Adu06496 Novel bro
830	1747	99.0	474	4	AAU14177	Aau14177 Human nov	903	1745	98.9	730	4	AAU52157	Aau52157 Humanised
831	1747	99.0	474	5	AAO14065	Aao14065 Heavy cha	904	1745	98.9	740	4	AAW52160	Aaw52160 Humanised
832	1747	99.0	474	6	ABU08017	Abu08017 Human mon	905	1744	98.8	329	8	ADH75410	Adh75410 Human Igg
833	1747	99.0	474	7	ADF65775	Adf65775 Human mon	906	1744	98.8	332	7	ABR63190	Abr63190 Mutated a
834	1747	99.0	474	7	ADM05955	Adm05955 Human pro	907	1744	98.8	469	9	AEA12649	Aea12649 Heavy cha
835	1747	99.0	474	8	ADJ92515	Adj92515 Human SQJ	908	1744	98.8	469	9	AEA18905	Aea18905 Heavy cha
836	1747	99.0	474	9	AEA12653	Aea12653 Heavy cha	909	1744	98.8	469	9	AEA18545	Aea18545 Heavy cha
837	1747	99.0	474	9	AEA18909	Aea18909 Variant h	910	1744	98.8	469	9	AEA10838	Aea10838 Human ant
838	1747	99.0	474	9	AEA18549	Aea18549 Variant o	911	1744	98.8	469	9	AEA10638	Aea10638 Human ant
839	1747	99.0	474	9	AEA10842	Aea10842 Human ant	912	1744	98.8	469	9	AED25711	Aed25711 Monoclonal
840	1747	99.0	474	9	AEA10842	Aea10842 Human ant	912	1744	98.8	469	9	AED25711	Aed25711 Monoclonal
841	1747	99.0	474	9	AED25715	Aed25715 Monoclonal	913	1744	98.8	469	9	AED25977	Aed25977 Ant-CD40
842	1747	99.0	474	9	AEC88885	Aec88885 Human cDN	914	1744	98.8	469	8	ADR72764	Adr72764 Human mon
843	1747	99.0	474	9	AED24416	Aed24416 Human CHI	915	1744	98.8	474	8	ADU98007	Adu98007 Protein f
844	1747	99.0	474	9	AED25981	Aed25981 Ant-CD40	916	1744	98.8	474	9	AEA12652	Aea12652 Heavy cha
845	1747	99.0	475	10	AEE23615	Aee23615 Novel hum	917	1744	98.8	474	9	AEA18908	Aea18908 Heavy cha
846	1747	99.0	475	9	ABE48567	Abe48567 Human Igg	918	1744	98.8	474	9	AEA18548	Aea18548 Heavy cha
847	1747	99.0	476	6	ABU08022	Abu08022 Monoclonal	919	1744	98.8	474	9	AEA10641	Aea10641 Human ant
848	1747	99.0	476	7	ADF65788	Adf65788 Human ant	920	1744	98.8	474	9	AED25714	Aed25714 Monoclonal
849	1747	99.0	476	8	ADJ92523	Adj92523 Human SQ5	921	1744	98.8	474	9	AED24415	Aed24415 Human CHI
850	1747	99.0	476	9	ADV99723	Adv99723 Human rab	922	1744	98.8	474	9	AED25980	Aed25980 Ant-CD40
851	1747	99.0	477	4	AAU14288	Aau14288 Human nov	923	1744	98.8	556	5	AAE29073	Aae29073 Human IL-
852	1747	99.0	477	10	AEE23726	Aee23726 Novel hum	924	1744	98.8	559	4	ABE85286	Abe85286 IL-20RA e
853	1747	99.0	478	7	ADB65658	Adb65658 Human pro	925	1744	98.8	559	5	ABG67217	Abg67217 IL-20RA e
854	1747	99.0	489	7	ADB65175	Adb65175 Human pro	926	1744	98.8	559	5	AAE23361	Aae23361 Human IL-
855	1747	99.0	526	9	ABE48561	Abe48561 Human Igg	927	1744	98.8	559	8	ADJ83342	Adj83342 Human IL-
856	1747	99.0	579	6	ADG87073	Adg87073 KS antibo	928	1744	98.8	559	9	ADW64577	Adw64577 IL-20RA a
857	1746	98.9	472	2	AAW01820	Aaw01820 Anti-rhes	930	1744	98.8	559	9	AEA28863	Aea28863 Human IL-
858	1746	98.9	478	2	AAW01820	Aaw01820 Primate	931	1744	98.8	573	5	AAE29072	Aae29072 Human IL-
859	1746	98.9	667	9	AEA38767	Aea38767 Humanized	932	1744	98.8	594	4	AAU04062	Aau04062 Human IL-
860	1746	98.9	667	9	AEA38769	Aea38769 Humanized	933	1744	98.8	594	4	AAU04062	Aau04062 Human IL-
861	1746	98.9	667	9	AED53761	Aed53761 Amino aci	934	1744	98.8	594	5	ABG67205	Abg67205 IL-20RA e
862	1746	98.9	667	9	AED53763	Aed53763 Amino aci	935	1744	98.8	594	5	AAE23358	Aae23358 Human IL-
863	1746	98.9	729	3	AAU51078	Aau51078 Human fus	936	1744	98.8	594	8	ADJ83303	Adj83303 Human IL-
864	1745.5	98.9	333	6	ABR42733	AbR42733 Anti-ties	937	1744	98.8	594	9	ADW64540	Adw64540 IL-20RA a
865	1745.5	98.9	339	9	ADW24785	Adw24785 Human var	938	1744	98.8	594	9	AEA50124	Aea50124 Human IL-
866	1745.5	98.9	339	9	ADW24743	Adw24743 Human var	939	1744	98.8	594	9	AEA28862	Aea28862 Human IL-
867	1745.5	98.9	339	9	ADW08941	Adw08941 Mammalian	940	1743	98.8	329	8	ADH75387	Adh75387 Human Igg
868	1745.5	98.9	339	9	ADZ08810	Adz08810 Mammalian	941	1743	98.8	329	8	ADT99194	Adt99194 Human rec
869	1745.5	98.9	339	9	ADZ44467	Adz44467 Human MCP	942	1743	98.8	359	9	AED85880	Aed85880 Igg1 expr
870	1745.5	98.9	339	9	AEA16542	Aea16542 Human Igg	943	1743	98.8	467	10	AEF38712	Aef38712 Monoclonal
871	1745.5	98.9	339	9	AEF72777	Aef72777 Anti-Ltal	944	1743	98.8	472	7	ADM05606	Adm05606 Human cDN
872	1745.5	98.9	339	9	AEC94905	Aec94905 Anti-IL-1	945	1743	98.8	472	7	ADM05606	Adm05606 Human cDN
873	1745.5	98.9	339	9	AED21951	Aed21951 GLP-1 CHI	946	1743	98.8	474	10	AEF17112	Aef17112 B. brevis
874	1745.5	98.9	339	9	AED49127	Aed49127 Heavy cha	947	1743	98.8	474	10	AEF17109	Aef17109 B. brevis
875	1745	98.9	329	10	AEF57797	Aef57797 Anti-IL-1	948	1743	98.8	474	10	AEF18357	Aef18357 Outer wal
876	1745	98.9	330	8	ADT51719	Adt51719 Human OST	949	1743	98.8	474	10	AEF18354	Aef18354 Anti-VEGF
877	1745	98.9	330	10	AEF16357	Aef16357 Human Igg	950	1743	98.8	476	8	ADQ90730	Adq90730 CD4-IgG1
878	1745	98.9	402	9	AEC22661	Aec22661 Membrane	951	1743	98.8	729	3	ABU19507	Abu19507 Human Igg
879	1745	98.9	446	8	ADT51690	Adt51690 Daclizuma	952	1742	98.7	330	7	ADJ94620	Adj94620 Human Igg
880	1745	98.9	446	10	AEF16405	Aef16405 Humanized	953	1742	98.7	465	7	ADW64199	Adw64199 IL2HCF pr
881	1745	98.9	447	6	AEF33523	Aef33523 Human AQC	954	1742	98.7	470	7	ADM05506	Adm05506 Human cDN
882	1745	98.9	447	6	ADT51701	Adt51701 Fontolizu	955	1742	98.7	470	9	AEC88436	Aec88436 Human cDN
883	1745	98.9	447	10	AEF16416	Aef16416 Humanized	956	1742	98.7	575	8	ADP42961	Adp42961 Humanised
884	1745	98.9	448	10	AEF27304	Aef27304 Humanized	957	1742	98.7	669	9	ADY97271	Ady97271 Exemplary
885	1745	98.9	449	3	AEA11268	Aea11268 Aspi02iso	958	1741	98.6	443	9	ABE43843	Abe43843 Human Hul
886	1745	98.9	449	3	AEA11271	Aea11271 Aspi02suc	959	1741	98.6	446	2	AAW05829	Aaw05829 Humanised
887	1745	98.9	449	3	AEA11266	Aea11266 Humanized	960	1741	98.6	451	10	AEG04998	Aeg04998 Anti-CD20
888	1745	98.9	449	7	ADH85320	Adh85320 Heavy cha	961	1741	98.6	452	2	AAW69316	Aaw69316 Anti-IL-8
889	1745	98.9	449	8	ADP11668	Adp11668 anti-HBR2	962	1741	98.6	452	9	ABE17638	Abe17638 Heavy cha
890	1745	98.9	449	8	ADH34511	Adh34511 Heavy cha	963	1741	98.6	454	2	AAU30774	Aau30774 H52H4-160
891	1745	98.9	449	8	ADM31929	Adm31929 Humanized	964	1741	98.6	466	2	AAU24812	Aau24812 Sequence
892	1745	98.9	449	9	ADX80642	Adx80642 Traetuzum	965	1741	98.6	473	7	ADM05593	Adm05593 Human pro
893	1745	98.9	449	9	AED20674	Aed20674 Traetuzum	966	1741	98.6	473	9	AEC88523	Aec88523 Human cDN
894	1745	98.9	449	10	AEF03140	Aef03140 Traetuzum	967	1741	98.6	476	6	AAE37364	Aae37364 Monkey 16
895	1745	98.9	449	10	AEF27302	Aef27302 Humanized	968	1741	98.6	479	6	AAE37362	Aae37362 Monkey 7B
896	1745	98.9	451	10	AEF64965	Aef64965 Mature 2H	969	1741	98.6	979	7	ADG87079	Adg87079 Fusion pr
897	1745	98.9	451	10	ABE10486	Abe10486 Humanized	970	1740.5	98.6	451	5	ABE47726	Abe47726 Heavy cha
898	1745	98.9	467	10	AEF27306	Aef27306 Humanized	971	1740	98.6	330	9	AED07841	Aed07841 Human Igg
899	1745	98.9	468	8	ADQ66840	Adq66840 Novel hum	972	1740	98.6	330	10	AEG04978	Aeg04978 Human Igg

973 1740 98.6 451 10 AEG05000 Anti-CD20
 974 1740 98.6 466 4 AEG03755 Chimeric
 975 1740 98.6 472 2 AAY50166 Human res
 976 1740 98.6 476 4 AAB49243 Chimeric
 977 1740 98.6 667 9 AAB38768 Humanized
 978 1740 98.6 667 9 AED53762 Amino aci
 979 1739.5 98.6 329 10 AEG04979 Human IgG
 980 1739 98.5 453 2 AAR33311 Humanised
 981 1739 98.5 453 3 AAY85199 Heavy cha
 982 1739 98.5 468 2 AAW85689 D9D10 hea
 983 1739 98.5 711 2 AAW85692 MoTAbII f
 984 1738 98.5 330 9 AEA48173 Variant I
 985 1738 98.5 342 3 AAB53463 Human col
 986 1738 98.5 467 8 ADQ87978 Heavy cha
 987 1737 98.4 329 10 AEF51651 Anti-VEGF
 988 1735.5 98.4 329 8 ADS82579 Human IgG
 989 1736 98.4 447 9 AEB13695 Human ant
 990 1736 98.4 449 9 AEA48168 Mouse ant
 991 1736 98.4 539 8 ADE10009 Human pro
 992 1735 98.3 443 9 AEB43847 Human Bul
 993 1735 98.3 452 9 ADW03411 Humanized
 994 1735 98.3 452 9 AEE18948 Humanized
 995 1735 98.3 452 10 AEE26248 2H7.v31 a
 996 1735 98.3 452 10 AEE64958 Mature 2H
 997 1735 98.3 452 10 AEE10479 Humanized
 998 1735 98.3 452 10 AEE70765 Humanized
 999 1735 98.3 452 10 AEE70765 Humanized
 1000 1735 98.3 452 10 AEE70777 Humanized

ALIGNMENTS

RESULT 1
 ADQ89332
 ID ADQ89332 standard; protein; 330 AA.
 AC ADQ89332;
 XX
 XX 21-OCT-2004 (first entry)
 XX
 XX Human immunoglobulin protein #44.
 DE
 XX Human; immunoglobulin; heavy chain; light chain; CC-chemokine receptor 2;
 KW CCR2; inflammatory disease; autoimmune disorder; graft rejection;
 KW HIV infection; atherosclerosis; antiinflammatory; immunosuppressive;
 KW anti-HIV; virucide; antiarteriosclerotic.
 XX
 OS Homo sapiens.
 XX
 XX US2004151721-A1.
 XX
 XX 05-AUG-2004.
 XX
 XX 10-DEC-2003; 2003US-00733563.
 XX
 XX 19-OCT-2001; 2001US-0350166P.
 PR 26-JUN-2002; 2002US-0392364P.
 PR 17-OCT-2002; 2002US-00272899.
 XX
 XX (OKEE/) O'KEEFE T.
 PA (PONA/) PONAATH P.
 XX
 XX O'keefe T, Ponath P;
 PI
 XX WPI; 2004-580175/56.
 DR
 XX
 XX New humanized immunoglobulin CC-chemokine receptor 2 (CCR2) antagonists,
 PT useful for diagnosing and/or treating inflammatory or autoimmune
 PT diseases, and HIV infection.
 XX
 PS Claim 1; SEQ ID NO 110; 128pp; English.
 XX

CC The invention relates to humanised immunoglobulin heavy and light chains
 CC which have specificity for the CC-chemokine receptor 2 (CCR2) and an
 CC immunoglobulin or its antigen binding fragment comprising the chains. The
 CC humanised immunoglobulin or its antigen binding fragment preferably
 CC comprises two heavy chains and two light chains. The humanised
 CC immunoglobulin and its heavy and light chains are useful for the
 CC diagnosis, prevention and/or treatment of diseases or conditions
 CC associated with aberrant expression or activity of the CCR2 polypeptide,
 CC such as inflammatory diseases, autoimmune disorders, graft rejection, HIV
 CC infection and atherosclerosis. This sequence represents a human
 CC immunoglobulin protein of the invention.
 XX
 XX Sequence 330 AA;

Query Match 100.0%; Score 1765; DB 8; Length 330;
 Best Local Similarity 100.0%; Pred. No. 5.1e-124;
 Matches 330; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 ASTKGPSVFPPLAPSSKSTSGGTAAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSS 60
 DB 1 ASTKGPSVFPPLAPSSKSTSGGTAAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSS 60
 QY 61 GLYSLSVVTVFPSSSLGTQTYICNVNHPKSNKTKVDKKVEPKSCDKTHTCPCPAPELAGA 120
 DB 61 GLYSLSVVTVFPSSSLGTQTYICNVNHPKSNKTKVDKKVEPKSCDKTHTCPCPAPELAGA 120
 QY 121 PSVFLPPPKKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNATKPREEOYN 180
 DB 121 PSVFLPPPKKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNATKPREEOYN 180
 QY 181 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
 DB 181 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
 QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFPLYSKLTVDKSRW 300
 DB 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFPLYSKLTVDKSRW 300
 QY 301 QQGNVFSCSVNHEALHNHYTQKSLSLSPGK 330
 DB 301 QQGNVFSCSVNHEALHNHYTQKSLSLSPGK 330

RESULT 2
 AEB09605
 ID AEB09605 standard; protein; 330 AA.
 XX
 XX AEB09605;
 XX
 XX 08-SEP-2005 (first entry)
 XX
 XX Human IgG1 constant region FcRmut SEQ ID NO 110.
 DE
 XX
 XX antinflammatory; immunosuppressive; anti-HIV; antiarteriosclerotic;
 KW antibody engineering; therapeutic; diagnosis; inflammation;
 KW autoimmune disease; immune disorder; graft rejection; HIV infection;
 KW infection; atherosclerosis; cardiovascular disease; metabolic disorder;
 KW heavy chain constant region.
 XX
 OS Homo sapiens.
 XX
 XX WO2005060368-A2.
 XX
 XX 07-JUL-2005.
 XX
 XX 10-DEC-2003; 2003WO-US039599.
 PR 10-DEC-2003; 2003WO-US039599.
 XX
 XX (MILL-) MILLENNIUM PHARM INC.
 XX
 XX Okeefe T, Ponath P;
 PI
 XX

DR WPI; 2005-488561/49.
XX N-PSDB; AEB09606.
XX New humanized immunoglobulin or its antigen binding portion having
PT binding specificity for CC-chemokine receptor 2 and having a heavy chain
PT and light chain, for treating inflammatory diseases, HIV, and autoimmune
PT diseases.
XX
XX Claim 1; SEQ ID NO 110; 192pp; English.
XX
XX The invention describes a humanized immunoglobulin (I) or its antigen
CC binding portion having binding specificity for CC-chemokine receptor 2
CC (CCR2) and having a heavy chain and a light chain, where the heavy chain
CC comprises a fully defined 117 and 330 amino acid (SEQ ID NO: 17 and 110)
CC sequence, given in specification or its portion, and the light chain
CC comprises a fully defined 112 amino acid (SEQ ID NO: 12) sequence given
CC in specification. Also described are: a humanized immunoglobulin heavy
CC chain, or its antigen binding fragment, having binding specificity for
CC CCR2 and comprising the amino acid sequence of (SEQ ID NO: 17) and the
CC amino acid of (SEQ ID NO: 110), or its portion; and a humanized
CC immunoglobulin light chain, or its antigen binding fragment, having
CC binding specificity for CCR2 and comprising the amino acid sequence of
CC (SEQ ID NO: 12) and the fully defined 107 amino acid (SEQ ID NO: 112)
CC sequence, given in specification. The following are disclosed: isolated
CC nucleic acid molecules comprising nucleic acid sequence encoding (I); a
CC construct comprising nucleic acid molecule encoding (I); and host cell
CC comprising the nucleic acid molecule. (I) is useful as a therapeutic
CC agent for controlling lymphocyte homing the mucosal lymphoid tissue thus
CC reducing inflammatory response, for use in the treatment of diseases
CC associated with leukocyte infiltration of tissue, e.g. in the treatment
CC of inflammatory diseases, autoimmune diseases, graft rejection, HIV
CC infection and monocyte-mediated disorders such as atherosclerosis. (I) is
CC useful for detecting and/or measuring the level of CCR2 in a sample (e.g.
CC tissues or body fluids such as inflammatory exudates, blood, serum, bowel
CC fluid), and for modulating binding function and/or leukocyte trafficking
CC modulated by CCR2. This is the amino acid sequence of human IgG1 constant
CC region FcRmut used in the creation of a humanized anti-CCR2-antibody.
XX
XX Sequence 330 AA;
SQ
Query Match 100.0%; Score 1765; DB 9; Length 330;
Best Local Similarity 100.0%; Pred. No. 5.1e-124;
Matches 330; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 ASTKGPSVFPFLAPSSKSTSGGTAALGCLVKDYFPPPTVSNWNSGALTSGVHTFPAVLQSS 60
DB 1 ASTKGPSVFPFLAPSSKSTSGGTAALGCLVKDYFPPPTVSNWNSGALTSGVHTFPAVLQSS 60
QY 61 GLYSLSSVVTVPPSSSLGTQTYICNVNHPKSNKVDKVEPKSCDKTHTCPPCPAPELAGA 120
DB 61 GLYSLSSVVTVPPSSSLGTQTYICNVNHPKSNKVDKVEPKSCDKTHTCPPCPAPELAGA 120
QY 121 PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 180
DB 121 PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 180
QY 181 STYRVSVLTVLHQDLNKGKEYCKVSNKALPAPIEKTISKAKGQPREPOVYTLPPSRDE 240
DB 181 STYRVSVLTVLHQDLNKGKEYCKVSNKALPAPIEKTISKAKGQPREPOVYTLPPSRDE 240
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
DB 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
QY 301 OQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330
DB 301 OQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330
RESULT 3
ADJ95914
ID ADJ95914 standard; protein; 333 AA.
XX

AC ADJ95914;
XX
XX 06-MAY-2004 (first entry)
XX Human IgG heavy chain constant region FCRmut.
DE cytostatic; antibody therapy; immunoglobulin cassette construct;
KW immunoglobulin leader molecule; immunoglobulin domain;
KW immunoglobulin therapeutic molecule; monoclonal; cancer; immunoglobulin G;
KW IgG; heavy chain constant region; FCRmut; human.
XX
XX Homo sapiens.
OS Synthetic.
XX US2004033561-A1.
XX
XX 19-FEB-2004.
XX
XX 17-OCT-2002; 2002US-00272899.
XX
XX 19-OCT-2001; 2001US-0350166P.
PR 26-JUN-2002; 2002US-0392364P.
XX
XX (MILL-) MILLENNIUM PHARM INC.
XX
XX O'keefe TL, Healey JJ, Newman W, Ponath PD, Keyt BA;
PI
XX WPI: 2004-180050/17.
DR N-PSDB; ADJ95913.
XX
XX New isolated nucleic acid molecules having an immunoglobulin cassette
PT construct, useful for producing immunoglobulin therapeutic molecules
PT termed monoclonal, used as a therapeutic group in cancer disorders.
XX
XX Example 2; SEQ ID NO 10; 84pp; English.
XX
XX The invention describes an isolated nucleic acid molecule comprising an
CC immunoglobulin cassette construct, wherein the immunoglobulin cassette
CC comprises an immunoglobulin leader molecule operably linked to a stable
CC immunoglobulin domain region. The methods and compositions of the present
CC invention are useful for producing immunoglobulins, in particular
CC immunoglobulin therapeutic molecules termed monoclonal, used as a
CC therapeutic group in cancer disorders. This is the amino acid sequence of
CC the human immunoglobulin G (IgG) heavy chain constant region mutant
CC FCRmut used in the creation of immunoglobulin DNA cassette constructs.
XX
XX Sequence 333 AA;
SQ
Query Match 100.0%; Score 1765; DB 8; Length 333;
Best Local Similarity 100.0%; Pred. No. 5.1e-124;
Matches 330; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 ASTKGPSVFPFLAPSSKSTSGGTAALGCLVKDYFPPPTVSNWNSGALTSGVHTFPAVLQSS 60
DB 4 ASTKGPSVFPFLAPSSKSTSGGTAALGCLVKDYFPPPTVSNWNSGALTSGVHTFPAVLQSS 63
QY 61 GLYSLSSVVTVPPSSSLGTQTYICNVNHPKSNKVDKVEPKSCDKTHTCPPCPAPELAGA 120
DB 64 GLYSLSSVVTVPPSSSLGTQTYICNVNHPKSNKVDKVEPKSCDKTHTCPPCPAPELAGA 123
QY 121 PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 180
DB 124 PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 183
QY 181 STYRVSVLTVLHQDLNKGKEYCKVSNKALPAPIEKTISKAKGQPREPOVYTLPPSRDE 240
DB 184 STYRVSVLTVLHQDLNKGKEYCKVSNKALPAPIEKTISKAKGQPREPOVYTLPPSRDE 243
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
DB 244 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 303
QY 301 OQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330

```
Db 304 QQGNVFCSCVMHEALHNHYTKLSLSPGK 333
|||||
RESULT 4
ADQ89336
ID ADQ89336 standard; protein; 333 AA.
XX
AC ADQ89336;
XX
DT 21-OCT-2004 (first entry)
XX
DE Human immunoglobulin protein #46.
XX
KW Human; immunoglobulin; heavy chain; light chain; CC-chemokine receptor 2;
KW CCR2; inflammatory disease; autoimmune disorder; graft rejection;
KW HIV infection; atherosclerosis; anti-inflammatory; immunosuppressive;
KW anti-HIV; virucide; antiarteriosclerotic.
XX
OS Homo sapiens.
XX
PN US2004151721-A1.
XX
PD 05-AUG-2004.
XX
PF 10-DEC-2003; 2003US-00733563.
XX
PR 19-OCT-2001; 2001US-0350166P.
PR 26-JUN-2002; 2002US-0392364P.
PR 17-OCT-2002; 2002US-00272899.
XX
PA (OKEE/) O'KEEFE T.
PA (PONA/) PONATH P.
XX
PI O'keefe T, Ponath P;
XX
WPI; 2004-580175/56.
XX
New humanized immunoglobulin CC-chemokine receptor 2 (CCR2) antagonists,
PT useful for diagnosing and/or treating inflammatory or autoimmune
PT diseases, and HIV infection.
XX
PS Disclosure; SEQ ID NO 114; 128pp; English.
XX
The invention relates to humanised immunoglobulin heavy and light chains
CC which have specificity for the CC-chemokine receptor 2 (CCR2) and an
CC immunoglobulin or its antigen binding fragment comprising the chains. The
CC humanised immunoglobulin or its antigen binding fragment preferably
CC comprises two heavy chains and two light chains. The humanised
CC immunoglobulin and its heavy and light chains are useful for the
CC diagnosis, prevention and/or treatment of diseases or conditions
CC associated with aberrant expression or activity of the CCR2 polypeptide,
CC such as inflammatory diseases, autoimmune disorders, graft rejection, HIV
CC infection and atherosclerosis. This sequence represents a human
CC immunoglobulin protein of the invention.
XX
SQ Sequence 333 AA;
Query Match 100.0%; Score 1765; DB 8; Length 333;
Best Local Similarity 100.0%; Pred. No. 5.1e-124;
Matches 330; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 ASTKGPSVFPPLAPSSKSTSGGTAALGLCKVDFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
|||||
Db 4 ASTKGPSVFPPLAPSSKSTSGGTAALGLCKVDFPEPVTVSWNSGALTSGVHTFPAVLQSS 63
|||||
QY 61 GLYSLSVVTVPSLSIGTQYICNVNHPKSNITKVKVEPKSCDKTHCTCPCPAPELAGA 120
|||||
Db 64 GLYSLSVVTVPSLSIGTQYICNVNHPKSNITKVKVEPKSCDKTHCTCPCPAPELAGA 123
|||||
QY 121 PSVFLFPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
|||||
Db 124 PSVFLFPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 183
|||||
QY 181 STYRVSVLTIVLHQDWLNGKEYKCKVSNKALPAPIEKTIISKAKGQPREPQVYTLPPSRDE 240
|||||
Db 184 STYRVSVLTIVLHQDWLNGKEYKCKVSNKALPAPIEKTIISKAKGQPREPQVYTLPPSRDE 243
|||||
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRW 300
|||||
Db 244 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRW 303
|||||
QY 301 QQGNVFCSCVMHEALHNHYTKLSLSPGK 330
|||||
Db 304 QQGNVFCSCVMHEALHNHYTKLSLSPGK 333
|||||
RESULT 5
AEB09609
ID AEB09609 standard; protein; 333 AA.
XX
AC AEB09609;
XX
DT 08-SEP-2005 (first entry)
XX
DE Human IgG1 constant region FcRmut SEQ ID NO 114.
XX
KW antiinflammatory; immunosuppressive; anti-HIV; antiarteriosclerotic;
KW antibody engineering; therapeutic; diagnosis; inflammation;
KW autoimmune disease; immune disorder; graft rejection; HIV infection;
KW infection; atherosclerosis; cardiovascular disease; metabolic disorder;
KW light chain constant region.
XX
OS Homo sapiens.
XX
PN WO2005060368-A2.
XX
PD 07-JUL-2005.
XX
PF 10-DEC-2003; 2003WO-US039599.
XX
PR 10-DEC-2003; 2003WO-US039599.
XX
PA (MILL-) MILLENNIUM PHARM INC.
XX
PI Okeefe T, Ponath P;
XX
WPI; 2005-488561/49.
DR N-PSDB; AEB09610.
XX
New humanized immunoglobulin or its antigen binding portion having
PT binding specificity for CC-chemokine receptor 2 and having a heavy chain
PT and light chain, for treating inflammatory diseases, HIV, and autoimmune
PT diseases.
XX
PS Disclosure; SEQ ID NO 114; 192pp; English.
XX
The invention describes a humanized immunoglobulin (I) or its antigen
CC binding portion having binding specificity for CC-chemokine receptor 2
CC (CCR2) and having a heavy chain and a light chain, where the heavy chain
CC comprises a fully defined 117 and 330 amino acid (SEQ ID NO: 17 and 110)
CC sequence, given in specification or its portion, and the light chain
CC comprises a fully defined 112 amino acid (SEQ ID NO: 12) sequence given
CC in specification. Also described are: a humanized immunoglobulin heavy
CC chain, or its antigen binding fragment, having binding specificity for
CC CCR2 and comprising the amino acid sequence of (SEQ ID NO: 17) and the
CC amino acid of (SEQ ID NO: 110), or its portion; and a humanized
CC immunoglobulin light chain, or its antigen binding fragment, having
CC binding specificity for CCR2 and comprising the amino acid sequence of
CC (SEQ ID NO: 12) and the fully defined 107 amino acid (SEQ ID NO: 112)
CC sequence, given in specification. The following are disclosed: isolated
CC nucleic acid molecules comprising nucleic acid sequence encoding (I); a
CC construct comprising nucleic acid molecule encoding (I); and host cell
CC comprising the nucleic acid molecule. (I) is useful as a therapeutic
CC agent for controlling lymphocyte homing the mucosal lymphoid tissue thus
CC reducing inflammatory response, for use in the treatment of diseases
```

CC associated with leukocyte infiltration of tissue, e.g. in the treatment
CC of inflammatory diseases, autoimmune diseases, graft rejection, HIV
CC infection and monocytic-mediated disorders such as atherosclerosis. (I) Is
CC useful for detecting and/or measuring the level of CCR2 in a sample (e.g.
CC tissues or body fluids such as inflammatory exudates, blood, serum, bowel
CC fluid), and for modulating binding function and/or leukocyte trafficking
CC modulated by CCR2. This is the amino acid sequence of human IgG1 constant
CC region FcRmut used in the creation of a humanized anti-CCR2-antibody.
XX
SQ Sequence 333 AA;

Query Match 100.0%; Score 1765; DB 9; Length 333;
Best Local Similarity 100.0%; Pred. No. 5.1e-124; Mismatches 0; Gaps 0;
Matches 330; Conservative 0; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSMNSGALTSGVHTFPAVLQSS 60
DB 4 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSMNSGALTSGVHTFPAVLQSS 63
QY 61 GLYSLSVVTVPSSSLIGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELAGA 120
DB 64 GLYSLSVVTVPSSSLIGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELAGA 123
QY 121 PSVFLPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
DB 124 PSVFLPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 183
QY 181 STYRVSVLVTLVHQLDNLNGKEYCKVSNKALPAPIEKTISKAKGQPREPOVYTLPPSRDE 240
DB 184 STYRVSVLVTLVHQLDNLNGKEYCKVSNKALPAPIEKTISKAKGQPREPOVYTLPPSRDE 243
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVPLDSDGSFFLYSKLTVDKSRW 300
DB 244 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVPLDSDGSFFLYSKLTVDKSRW 303
QY 301 QGQNVFSCVMHEALHNHYTQKSLSLSPGK 330
DB 304 QGQNVFSCVMHEALHNHYTQKSLSLSPGK 333

RESULT 6
ADJ95974
ID ADJ95974 standard; protein; 356 AA.

XX ADJ95974;
AC
DT 06-MAY-2004 (first entry)
XX
DE Immunoglobulin DNA cassette polypeptide seqid 70.

XX cytostatic; antibody therapy; immunoglobulin cassette construct;
KW immunoglobulin leader molecule; immunoglobulin domain;
KW immunoglobulin therapeutic molecule; monobody; cancer.
XX
OS Synthetic.

XX US2004033561-A1.
XX
XX 19-FEB-2004.
XX
XX 17-OCT-2002; 2002US-00272899.
XX
XX 19-OCT-2001; 2001US-0350166P.
XX
XX 26-JUN-2002; 2002US-0392364P.
XX
XX (MILL-) MILLENNIUM PHARM INC.

XX O'keefe TL, Healey JJ, Newman W, Ponath PD, Keyt BA;
PI
XX WPI; 2004-180050/17.
XX
XX N-PSDB; ADJ95973.
XX

PT New isolated nucleic acid molecules having an immunoglobulin cassette

PT construct, useful for producing immunoglobulin therapeutic molecules
PT termed monobodies, used as a therapeutic group in cancer disorders.
XX
XX Disclosure; SEQ ID NO 70; 84pp; English.
XX
CC The invention describes an isolated nucleic acid molecule comprising an
CC immunoglobulin cassette construct, wherein the immunoglobulin cassette
CC comprises an immunoglobulin leader molecule operably linked to a stable
CC immunoglobulin domain region. The methods and compositions of the present
CC invention are useful for producing immunoglobulins, in particular
CC immunoglobulin therapeutic molecules termed monobodies, used as a
CC therapeutic group in cancer disorders. This is the amino acid sequence of
CC an immunoglobulin DNA cassette construct.
XX
SQ Sequence 356 AA;

Query Match 100.0%; Score 1765; DB 8; Length 356;
Best Local Similarity 100.0%; Pred. No. 5.6e-124; Mismatches 0; Gaps 0;
Matches 330; Conservative 0; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSMNSGALTSGVHTFPAVLQSS 60
DB 27 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSMNSGALTSGVHTFPAVLQSS 86
QY 61 GLYSLSVVTVPSSSLIGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELAGA 120
DB 87 GLYSLSVVTVPSSSLIGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELAGA 146
QY 121 PSVFLPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
DB 147 PSVFLPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 206
QY 181 STYRVSVLVTLVHQLDNLNGKEYCKVSNKALPAPIEKTISKAKGQPREPOVYTLPPSRDE 240
DB 207 STYRVSVLVTLVHQLDNLNGKEYCKVSNKALPAPIEKTISKAKGQPREPOVYTLPPSRDE 266
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVPLDSDGSFFLYSKLTVDKSRW 300
DB 267 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVPLDSDGSFFLYSKLTVDKSRW 326
QY 301 QGQNVFSCVMHEALHNHYTQKSLSLSPGK 330
DB 327 QGQNVFSCVMHEALHNHYTQKSLSLSPGK 356

RESULT 7
AAJ32263
ID AAJ32263 standard; protein; 444 AA.

XX AAJ32263;
AC
DT 15-FEB-2000 (first entry)
XX
DE Humanised anti-CD23 Mab C11 heavy chain.

XX CD23; FCERII; IgE receptor; monoclonal antibody; C11; mouse; human;
KW monoclonal antibody; chimeric antibody; humanised antibody;
KW complementarity determining region; CDR; autoimmune disease;
KW inflammation; arthritis; lupus erythematosus; multiple sclerosis;
KW Hashimoto's thyroiditis; diabetes; uveitis; dermatitis; psoriasis;
KW urticaria; nephrotic syndrome; glomerulonephritis;
KW inflammatory bowel disease; ulcerative colitis; Crohn's disease;
KW Sjogren's syndrome; allergy; asthma; rhinitis; eczema; insulinitis;
KW graft-versus-host disease; COPD; bronchitis; diabetes; B-cell malignancy;
KW therapy.

OS Homo sapiens.
OS Synthetic.
XX
XX Key Location/Qualifiers
XX Region 1..30
XX /note= "framework region 1"
XX Region 31..35

Db 239 PSVFLPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVVHNAKTKPREEQYN 298
QY 181 STYRVSVLTIVLHQLDNLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Db 299 STYRVSVLTIVLHQLDNLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 358
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSLKLTVDKSRW 300
Db 359 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSLKLTVDKSRW 418
QY 301 QGQNVFSCSVMEALHNNHYTQKLSLSPGK 330
Db 419 QGQNVFSCSVMEALHNNHYTQKLSLSPGK 448
RESULT 9
ADP88431 standard, protein; 448 AA.
XX AC ADP88431;
XX AC
XX DT 09-SEP-2004 (first entry)
XX DE Antibody TRX1 heavy chain SEQ ID NO: 8.
XX DE immunosuppressive; transplant rejection; antigen tolerance; antibody;
XX KW TRX1.
XX OS Unidentified.
XX XX WO2004052398-A1.
XX PN 24-JUN-2004.
XX PD
XX PF 09-DEC-2003; 2003WO-US039165.
XX PR 09-DEC-2002; 2002US-0431839P.
XX PA (TOLE-) TOLERRX INC.
XX PI Windsor-Hines D, Rao P, Ringler DJ;
XX PS WPI; 2004-468712/44.
XX DR
XX PT Treating a primate to induce tolerance to at least one antigen comprises
XX PT administering at least one anti-CD4 antibody or its fragment in an
XX PT initial dose of at least 40 mg/kg and at least one compound that inhibits
XX PT CD8+ T cells.
XX PS Disclosure; SEQ ID NO 8; 113pp; English.
XX CC The present invention relates to a process of treating a primate to
XX CC induce tolerance to at least one antigen, which comprises administering
XX CC to the primate at least one anti-CD4 antibody or its fragment in an
XX CC initial dose of at least 40 mg/kg and at least one compound that inhibits
XX CC CD8+ T cells, where the anti-CD4 antibody or its fragment is present in
XX CC the primate when the antigen is present in the primate. The method is
XX CC useful in treating a primate to induce tolerance to at least one foreign
XX CC antigen to prevent transplant rejection. The present sequence is an
XX CC antibody fragment used in the exemplification of the invention.
XX SQ Sequence 448 AA;
Query Match 100.0%; Score 1765; DB 8; Length 448;
Best Local Similarity 100.0%; Pred. NO. 7.4e-124;
Matches 330; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 ASTKGPSVFPLAPPSSKSTSGGTAALGCLVKDYFPPPTVSMNSGALTSGVHTFPAVLQSS 60
Db 119 ASTKGPSVFPLAPPSSKSTSGGTAALGCLVKDYFPPPTVSMNSGALTSGVHTFPAVLQSS 178
QY 61 GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHHTCPPCPAPELAGA 120

Db 179 GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHHTCPPCPAPELAGA 238
QY 121 PSVFLPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVVHNAKTKPREEQYN 180
Db 239 PSVFLPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVVHNAKTKPREEQYN 298
QY 181 STYRVSVLTIVLHQLDNLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Db 299 STYRVSVLTIVLHQLDNLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 358
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSLKLTVDKSRW 300
Db 359 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSLKLTVDKSRW 418
QY 301 QGQNVFSCSVMEALHNNHYTQKLSLSPGK 330
Db 419 QGQNVFSCSVMEALHNNHYTQKLSLSPGK 448
RESULT 10
AEF27216
ID AEF27216 standard; protein; 448 AA.
XX AC AEF27216;
XX DT 09-MAR-2006 (first entry)
XX DE Anti-CD4 antibody TRX1 heavy chain without leader sequence SEQ ID NO:24.
XX KW antibody engineering; immunotherapy; immunosuppressive; cd4.
XX OS Synthetic.
XX XX
XX FH Key
XX FT Region 1..30 Location/Qualifiers
XX FT /note= "Framework region"
XX FT Region 31..35
XX FT /note= "CDR1"
XX FT Region 36..49
XX FT /note= "Framework region"
XX FT Region 50..66
XX FT /note= "CDR2"
XX FT Region 67..98
XX FT /note= "Framework region"
XX FT Region 99..107
XX FT /note= "CDR3"
XX FT Region 108..118
XX FT /note= "Framework region"
XX FT Region 119..448
XX FT /note= "Modified constant region"
XX FT Modified-site 298..300
XX FT /note= "Glycosylated"
XX XX US2006002921-A1.
XX PN 05-JAN-2006.
XX PD
XX XX 21-JUN-2005; 2005US-00158505.
XX PR 22-JUN-2004; 2004US-0582181P.
XX XX (TOLE-) TOLERRX INC.
XX XX Windsor-Hines D, Rao P, Ringler DJ, Ponath P;
XX XX WPI; 2006-066198/07.
XX XX Treating a primate to induce tolerance to a foreign antigen, e.g. an
XX PT allogeneic or xenogeneic transplanted antigen, comprises administering an
XX PT anti-CD4 antibody or its CD4 binding fragment.
XX PS Disclosure; SEQ ID NO 24; 116pp; English.

XX The invention relates to a novel method for treating a primate, to induce
CC tolerance to at least one foreign antigen, comprises administering to the
CC primate at least one anti-CD4 antibody or its CD4 binding fragment. The
CC method of the invention has immunosuppressive activity. The method is
CC useful in immunotherapy. The methods are useful for treating a primate to
CC induce tolerance to at least one foreign antigen, e.g., an allogeneic or
CC xenogeneic transplanted antigen. The present sequence represents an anti-
CC CD4 antibody heavy chain of the invention without leader sequence.
SQ Sequence 448 AA;

Query Match 100.0%; Score 1765; DB 10; Length 448;
Best Local Similarity 100.0%; Pred. No. 7.4e-124;
Matches 330; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTWNSGALTSVHTFPAVLQSS 60
DB 119 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTWNSGALTSVHTFPAVLQSS 178

QY 61 GLYSLSSVTVTPSSSLGTQTYICNVNHPKSNTKVDKVEPKSCDKTHTCPCPAPELAGA 120
DB 179 GLYSLSSVTVTPSSSLGTQTYICNVNHPKSNTKVDKVEPKSCDKTHTCPCPAPELAGA 238

QY 121 PSVFLFPPPKDPTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREEOYN 180
DB 239 PSVFLFPPPKDPTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREEOYN 298

QY 181 STYRVSVTLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVTLPPSRDE 240
DB 299 STYRVSVTLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVTLPPSRDE 358

QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300
DB 359 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 418

QY 301 QQGNVFSCVMHEALHNHYTOKSLSPGK 330
DB 419 QQGNVFSCVMHEALHNHYTOKSLSPGK 448

RESULT 11
AEF27200
ID AEF27200 standard; protein; 448 AA.
XX
AC AEF27200;
XX
DT 09-MAR-2006 (first entry)
XX
DE Anti-CD4 antibody TRX1 heavy chain without leader sequence SEQ ID NO:8.
XX
KW antibody engineering; immunotherapy; immunosuppressive; cd4.
XX
OS Synthetic.
XX
FH Key
FT Region 1..30 Location/Qualifiers
FT /note= "Framework region"
FT 31..35
FT /note= "CDR1"
FT 36..49
FT /note= "Framework region"
FT 50..66
FT /note= "CDR2"
FT 67..98
FT /note= "Framework region"
FT 99..107
FT /note= "CDR3"
FT 108..118
FT /note= "Framework region"
FT 119..448
FT /note= "Modified constant region"
FT Modified-site 298..300

FT /note= "Glycosylated"
XX US2006002921-A1.
PN 05-JAN-2006.
XX 21-JUN-2005; 2005US-00158505.
PF 22-JUN-2004; 2004US-0582181P.
PR (TOLE-) TOLERRX INC.
XX Winsor-Hines D, Rao P, Ringler DJ, Ponath P;
PI WPI; 2006-066198/07.
DR
XX Treating a primate to induce tolerance to a foreign antigen, e.g. an
PT allogeneic or xenogeneic transplanted antigen, comprises administering an
PT anti-CD4 antibody or its CD4 binding fragment.
XX
PS Disclosure; SEQ ID NO 8; 116pp; English.
XX
CC The invention relates to a novel method for treating a primate, to induce
CC tolerance to at least one foreign antigen, comprises administering to the
CC primate at least one anti-CD4 antibody or its CD4 binding fragment. The
CC method of the invention has immunosuppressive activity. The method is
CC useful in immunotherapy. The methods are useful for treating a primate to
CC induce tolerance to at least one foreign antigen, e.g., an allogeneic or
CC xenogeneic transplanted antigen. The present sequence represents an anti-
CC CD4 antibody heavy chain of the invention without leader sequence.
SQ Sequence 448 AA;

Query Match 100.0%; Score 1765; DB 10; Length 448;
Best Local Similarity 100.0%; Pred. No. 7.4e-124;
Matches 330; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTWNSGALTSVHTFPAVLQSS 60
DB 119 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTWNSGALTSVHTFPAVLQSS 178

QY 61 GLYSLSSVTVTPSSSLGTQTYICNVNHPKSNTKVDKVEPKSCDKTHTCPCPAPELAGA 120
DB 179 GLYSLSSVTVTPSSSLGTQTYICNVNHPKSNTKVDKVEPKSCDKTHTCPCPAPELAGA 238

QY 121 PSVFLFPPPKDPTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREEOYN 180
DB 239 PSVFLFPPPKDPTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREEOYN 298

QY 181 STYRVSVTLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVTLPPSRDE 240
DB 299 STYRVSVTLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVTLPPSRDE 358

QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300
DB 359 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 418

QY 301 QQGNVFSCVMHEALHNHYTOKSLSPGK 330
DB 419 QQGNVFSCVMHEALHNHYTOKSLSPGK 448

RESULT 12
AED19177
ID AED19177 standard; protein; 450 AA.
XX
AC AED19177;
XX
DT 15-DEC-2005 (first entry)
XX
DE Humanized oncostatin M antibody 15E10 heavy chain, Fc mutated.
XX heavy chain; oncostatin M; therapeutic; antibody production;
KW

KW rheumatoid arthritis; osteoarthritis; psoriasis; asthma;
 KW chronic obstructive pulmonary disease; pulmonary disease; dementia; pain;
 KW immune disorder; inflammation; musculoskeletal disease;
 KW dermatological disease; respiratory disease; neurological disease;
 KW cardiovascular disease; metabolic disorder; neoplasm; atherosclerosis;
 KW cancer; Antiarthritic; Antirheumatic; Antipsoriatic; Antiinflammatory;
 KW Respiratory-Gen.; Antiaschmatic; Neuroprotective; Nootropic; Analgesic;
 KW Antiarteriosclerotic; Cytostatic.
 XX
 OS Mus musculus.
 OS Homo sapiens.
 OS Chimeric.
 XX
 PN WO2005095457-A2.
 FN
 PD 13-OCT-2005.
 XX
 XX 29-MAR-2005; 2005WO-GB001147.
 XX
 XX 30-MAR-2004; 2004GB-00007193.
 PR 30-MAR-2004; 2004GB-00007197.
 XX
 XX (GLAX) GLAXO GROUP LTD.
 PA
 XX Ellis JH, Eon-Duval A, Germaschewski V, Plumpton C, Rapson NT;
 PI West MR;
 XX
 XX WPI; 2005-725491/74.
 XX
 XX New therapeutic antibody that specifically binds human Oncostatin M
 PT (hOSM) and modulates the interaction between OSM and gp130, useful for
 PT treating, e.g. rheumatoid arthritis, psoriasis, severe asthma, or
 PT multiple sclerosis.
 XX
 PS Disclosure; SEQ ID NO 61; 197pp; English.
 XX
 XX The invention relates to a therapeutic antibody that specifically binds
 CC Oncostatin M (OSM), preferably human OSM (hOSM), and modulates the
 CC interaction between OSM and gp130. The therapeutic antibody or antigen
 CC binding fragment is useful in the manufacture of a medicament for the
 CC treatment of a disease responsive to modulation of the interaction
 CC between hOSM and gp130 such as rheumatoid arthritis, osteoarthritis,
 CC psoriasis, asthma, or COPD. The therapeutic antibody, which specifically
 CC binds the protein backbone of glycosylated hOSM is also useful in the
 CC manufacture of a medicament for the treatment of a disease or disorder
 CC selected from an arthritic disease such as rheumatoid arthritis, juvenile
 CC onset arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis
 CC such as chronic plaque disease, inflammatory lung disease such as COPD or
 CC severe asthma, multiple sclerosis, dementia such as Alzheimer's disease,
 CC pain such as neuropathic or inflammatory pain, atherosclerosis, diseases
 CC of cell cycle regulation such as cancer (e.g. prostate), or myeloma. The
 CC therapeutic antibody or antigen-binding fragment is useful in the
 CC treatment of the above diseases. The present sequence represents the
 CC amino acid sequence of the humanized oncostatin M binding antibody 15E10
 CC heavy chain.
 XX
 SQ Sequence 450 AA;
 Query Match 100.0%; Score 1765; DB 9; Length 450;
 Best Local Similarity 100.0%; Pred. No. 7.4e-124; Mismatches 0; Gaps 0;
 Matches 330; Conservative 0; Indels 0;

QY 1 ASTKGSPVFPFLAPSSKSTGGTAALGCLVKDYFPEPTVSMNSGALTSGVHTFPAVLQSS 60
 DB 121 ASTKGSPVFPFLAPSSKSTGGTAALGCLVKDYFPEPTVSMNSGALTSGVHTFPAVLQSS 180
 QY 61 GLYSLSVVTPSSSLGTQTYICNVNHPKSNTPKDKVPEKSCDKTHTCPPCPAPELAGA 120
 DB 181 GLYSLSVVTPSSSLGTQTYICNVNHPKSNTPKDKVPEKSCDKTHTCPPCPAPELAGA 240
 QY 121 PSVFLFPKPKDKTLMISRTPEVTCVVVDSHEDPEVKFNWYDGVGVHNAKTKPREQYN 180
 DB 241 PSVFLFPKPKDKTLMISRTPEVTCVVVDSHEDPEVKFNWYDGVGVHNAKTKPREQYN 300

QY 181 STYRVSVLTVLHQDLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
 DB 301 STYRVSVLTVLHQDLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 360
 QY 241 LTKNQVSLTCLVKGYGPPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW 300
 DB 361 LTKNQVSLTCLVKGYGPPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW 420
 QY 301 QOGNVFSCSVMEALHNHYTOKLSLSLSPGK 330
 DB 421 QOGNVFSCSVMEALHNHYTOKLSLSLSPGK 450

RESULT 13

AEB08800

ID AEB08800 standard; protein; 462 AA.

XX AEB08800;

XX 08-SEP-2005 (first entry)

XX Anti-NOGO-antibody heavy chain SEQ ID NO 88.

XX cerebroprotective; vasotropic; neuroprotective; vulnerary; nootropic;
 KW antiparkinsonian; anticonvulsant; neuroleptic; antibody engineering;
 KW pharmaceutical; cerebrovascular ischemia; cardiovascular disease;
 KW neurological disease; brain injury; injury; spinal cord injury;
 KW Alzheimers disease; degeneration; dementia; neuropathy;
 KW parkinsons disease; Huntingtons chorea; Genetic disorder;
 KW multiple sclerosis; immune disorder; Creutzfeldt Jakob disease;
 KW infection; schizophrenia; psychiatric disorder; motor neurone disease;
 KW cns-gen.; muscular-gen.

XX Synthetic.

XX WO2005061544-A2.

XX 07-JUL-2005.

XX 20-DEC-2004; 2004WO-GB0053325.

XX 22-DEC-2003; 2003GB-00029684.

XX 22-DEC-2003; 2003GB-00029711.

XX (GLAX) GLAXO GROUP LTD.

XX Ellis JH, Eon-Duval A, Grundy RI, Hussain F, Mcadam R;
 PI Plumpton C, Prinjha RK, Wilson PA;

XX WPI; 2005-479448/48.
 XX N-PSDB; AEB08802.

XX New antibody or its functional fragment that binds with and neutralizes
 PT human neurite outgrowth useful for treating or prophylaxis of stroke and
 PT other neurological disease e.g. traumatic brain injury, spinal cord
 PT injury, Alzheimer's disease.

XX Example 8; SEQ ID NO 88; 143pp; English.

XX The invention describes an antibody (A1) or its functional fragment, that
 CC binds with and neutralizes human neurite outgrowth (NOGO). Also described
 CC are: providing a first vector encoding a heavy chain of the antibody;
 CC providing a second vector encoding a light chain of the antibody; co-
 CC transfecting a mammalian host cell with the first and second vectors;
 CC culturing the host cell in culture media (preferably serum free) under
 CC conditions permissive to the secretion of the antibody from the host cell
 CC into the culture media; recovering (and optionally purifying) the
 CC secreted antibody; and promoting axonal sprouting involving contacting a
 CC human axon with an anti-NOGO antibody. The antibody is useful in the
 CC preparation of a medicament for treating or prophylaxis of stroke and
 CC other neurological disease/disorders (e.g. traumatic brain injury, spinal
 CC cord injury, Alzheimer's disease, frontotemporal dementias (taupopathies),

CC peripheral neuropathy, Parkinson's disease, Huntington's disease and
CC multiple sclerosis); Creutzfeldt-jakob disease (CJD), Schizophrenia,
CC amyotrophic lateral sclerosis (ALS), inclusion body myositis. The
CC antibody inhibits neurodegeneration and/or promotes functional recovery
CC in a human patient suffering, or at risk of developing, stroke or other
CC neurological diseases/disorder. This is the amino acid sequence of an
CC anti-NOGO-antibody heavy chain created in the invention.
XX
SQ Sequence 462 AA;

Query Match 100.0%; Score 1765; DB 9; Length 462;
Best Local Similarity 100.0%; Pred. No. 7.7e-124;
Matches 330; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSMNSGALTSGVHTFPAVLQSS 60
DB 133 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSMNSGALTSGVHTFPAVLQSS 192

QY 61 GLYSLSVVTVPPSSSLGTQTYICNVNHPKSNKVDKVEPKSCDKTHTCPPCPAPELAGA 120
DB 193 GLYSLSVVTVPPSSSLGTQTYICNVNHPKSNKVDKVEPKSCDKTHTCPPCPAPELAGA 252

QY 121 PSVFLFPPKPKDGLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 180
DB 253 PSVFLFPPKPKDGLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 312

QY 181 STYRVVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
DB 313 STYRVVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 372

QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300
DB 373 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 432

QY 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330
DB 433 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 462

RESULT 14
ADA47334
ID ADA47334 standard; protein; 467 AA.
XX
AC ADA47334;
XX
DT 20-NOV-2003 (first entry)
XX
DE TRX1 heavy chain encoding DNA #SEQ ID 7.
XX
KW Antibody; TRX1; immunosuppressive; immunomodulator; vaccine; antigen;
KW graft rejection; autoimmune disease; humanised.
XX
OS Homo sapiens.
XX
PN WO2002102853-A2.
XX
PD 27-DEC-2002.
XX
PF 14-JUN-2002; 2002WO-GB002796.
XX
PR 14-JUN-2001; 2001GB-00014517.
PR 20-SEP-2001; 2001GB-00022724.
PR 19-OCT-2001; 2001US-0345194P.
PR 18-APR-2002; 2002US-0373470P.
PR 18-APR-2002; 2002US-0373471P.
XX
(ISIS-) ISIS INNOVATION LTD.
PA (UYCA-) UNIV CAMBRIDGE TECH SERVICES LTD.
PA (TOLE-) TOLERRX INC.
XX
Frewin M, Waldmann H, Gorman S, Hale G, Rao P, Kornaga T;
PI Ringler D, Cobbold S, Winsor-Hines D;
XX

DR WPI: 2003-1755228/17.
DR N-PSDB; ADA47333.
XX
PT Treating a primate to induce tolerance to at least one antigen, useful
PT for inhibiting graft rejection or treating an autoimmune disease,
PT comprises administering a TRX1 antibody to reduce the amount of CD4+
PT CD25+ cells produced.
XX
XX Claim 26; Fig 1D; 13lpp; English.
XX
CC The invention relates to a method for treating a primate to induce
CC tolerance to at least one antigen. The method of the invention comprises
CC administering at least one compound which when in a primary mixed
CC lymphocyte reaction in vitro reduces the amount of CD4+ CD25+ cells
CC produced. The preferred compound is a humanised antibody or its fragment,
CC that does not bind to the Fc receptor, and includes CDRs that are free of
CC a glycosylation site. The method of the invention is useful for inducing
CC tolerance to at least one antigen, specifically for inhibiting,
CC ameliorating or reducing an immune response to an antigen. The antibody
CC is useful for manufacturing a medicament for inducing tolerance to an
CC antigen (possibly in the form of a vaccine), for inhibiting an immune
CC response, for inhibiting the rejection of a graft (such as an organ) in a
CC human patient, and for treating an autoimmune disease. The current
CC sequence represents the TRX1 heavy chain.
XX
SQ Sequence 467 AA;

Query Match 100.0%; Score 1765; DB 6; Length 467;
Best Local Similarity 100.0%; Pred. No. 7.8e-124;
Matches 330; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSMNSGALTSGVHTFPAVLQSS 60
DB 138 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSMNSGALTSGVHTFPAVLQSS 197

QY 61 GLYSLSVVTVPPSSSLGTQTYICNVNHPKSNKVDKVEPKSCDKTHTCPPCPAPELAGA 120
DB 198 GLYSLSVVTVPPSSSLGTQTYICNVNHPKSNKVDKVEPKSCDKTHTCPPCPAPELAGA 257

QY 121 PSVFLFPPKPKDGLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 180
DB 258 PSVFLFPPKPKDGLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 317

QY 181 STYRVVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
DB 318 STYRVVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 377

QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300
DB 378 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 437

QY 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330
DB 438 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 467

RESULT 15
ADA47336
ID ADA47336 standard; protein; 467 AA.
XX
AC ADA47336;
XX
DT 20-NOV-2003 (first entry)
XX
DE TRX1 heavy chain #SEQ ID 9.
XX
KW Antibody; TRX1; immunosuppressive; immunomodulator; vaccine; antigen;
KW graft rejection; autoimmune disease; humanised.
XX
OS Homo sapiens.
XX
FH Key
FT Peptide 1..19
Location/Qualifiers

FT	Region	/label= leader peptide	
FT	50..54		
FT	/label= CDR		
FT	69..85		
FT	/label= CDR		
FT	118..126		
FT	/label= CDR		
XX			
PN	WO2002102853-A2.		
XX			
PD	27-DEC-2002.		
XX			
PF	14-JUN-2002; 2002WO-GB002796.		
XX			
PR	14-JUN-2001; 2001GB-00014517.		
PR	20-SEP-2001; 2001GB-00022724.		
PR	19-OCT-2001; 2001US-0345194P.		
PR	18-APR-2002; 2002US-0373470P.		
PR	18-APR-2002; 2002US-0373471P.		
XX			
PA	(ISIS-) ISIS INNOVATION LTD.		
PA	(UYCA-) UNIV CAMBRIDGE TECH SERVICES LTD.		
PA	(TOLE-) TOLEREX INC.		
XX			
PI	Frewin M, Waldmann H, Gorman S, Hale G, Rao P, Kornaga T;		
PI	Ringler D, Cobbold S, Winsor-Hines D;		
XX			
DR	WPI; 2003-175228/17.		
XX			
PT	Treating a primate to induce tolerance to at least one antigen, useful		
PT	for inhibiting graft rejection or treating an autoimmune disease,		
PT	comprises administering a TRX1 antibody to reduce the amount of CD4+		
PT	CD25+ cells produced.		
XX			
PS	Claim 27; Fig 1F; 131pp; English.		
XX			
CC	The invention relates to a method for treating a primate to induce		
CC	tolerance to at least one antigen. The method of the invention comprises		
CC	administering at least one compound which when in a primary mixed		
CC	lymphocyte reaction in vitro reduces the amount of CD4+ CD25+ cells		
CC	produced. The preferred compound is a humanised antibody or its fragment,		
CC	that does not bind to the Fc receptor, and includes CDRs that are free of		
CC	a glycosylation site. The method of the invention is useful for inducing		
CC	tolerance to at least one antigen, specifically for inhibiting,		
CC	ameliorating or reducing an immune response to an antigen. The antibody		
CC	is useful for manufacturing a medicament for inducing tolerance to an		
CC	antigen (possibly in the form of a vaccine), for inhibiting an immune		
CC	response, for inhibiting the rejection of a graft (such as an organ) in a		
CC	human patient, and for treating an autoimmune disease. The current		
CC	sequence represents the TRX1 heavy chain amino acid sequence.		
XX			
SQ	Sequence 467 AA;		
	Query Match	100.0%; Score 1765; DB 6; Length 467;	
	Best Local Similarity	100.0%; Pred. No. 7.8e-124;	
	Matches 330; Conservative	0; Mismatches 0; Indels 0; Gaps 0;	
QY	1	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSMNSGALTSGVHTFPAVLQSS	60
DB	138	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSMNSGALTSGVHTFPAVLQSS	197
QY	61	GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPPCPAPELAGA	120
DB	198	GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPPCPAPELAGA	257
QY	121	PSVFLFPPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPRREQYN	180
DB	258	PSVFLFPPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPRREQYN	317
QY	181	STYRVVSVLTVTHQDNLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE	240
DB	318	STYRVVSVLTVTHQDNLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE	377

QY	241	LTKNOVSLTCLVKGYFSPDSIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW	300
DB	378	LTKNOVSLTCLVKGYFSPDSIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW	437
QY	301	QOQNVFSCVMHEALHNHYTOKLSLSLSPGK	330
DB	438	QOQNVFSCVMHEALHNHYTOKLSLSLSPGK	467
	RESULT 16		
	ADP88446		
ID	ADP88446	standard; protein; 467 AA.	
XX			
AC	ADP88446;		
XX			
DT	09-SEP-2004	(first entry)	
XX			
DE	Antibody TRX1 heavy chain with leader sequence SEQ ID NO: 23.		
XX			
KW	immunosuppressive; transplant rejection; antigen tolerance; antibody;		
KW	TRX1.		
XX			
OS	Unidentified.		
XX			
PN	WO2004052398-Al.		
XX			
PD	24-JUN-2004.		
XX			
PF	09-DEC-2003; 2003WO-US039165.		
XX			
PR	09-DEC-2002; 2002US-0431839P.		
XX			
PA	(TOLE-) TOLEREX INC.		
XX			
PI	Windsor-Hines D, Rao P, Ringler DJ;		
XX			
DR	WPI; 2004-468712/44.		
DR	N-PSDB; ADP88444, ADP88445.		
XX			
PT	Treating a primate to induce tolerance to at least one antigen comprises		
PT	administering at least one anti-CD4 antibody or its fragment in an		
PT	initial dose of at least 40 mg/kg and at least one compound that inhibits		
PT	CD8+ T cells.		
XX			
PS	Disclosure; SEQ ID NO 23; 113pp; English.		
XX			
CC	The present invention relates to a process of treating a primate to		
CC	induce tolerance to at least one antigen, which comprises administering		
CC	to the primate at least one anti-CD4 antibody or its fragment in an		
CC	initial dose of at least 40 mg/kg and at least one compound that inhibits		
CC	CD8+ T cells, where the anti-CD4 antibody or its fragment is present in		
CC	the primate when the antigen is present in the primate. The method is		
CC	useful in treating a primate to induce tolerance to at least one foreign		
CC	antigen to prevent transplant rejection. The present sequence is an		
CC	antibody fragment used in the exemplification of the invention.		
XX			
SQ	Sequence 467 AA;		
	Query Match	100.0%; Score 1765; DB 8; Length 467;	
	Best Local Similarity	100.0%; Pred. No. 7.8e-124;	
	Matches 330; Conservative	0; Mismatches 0; Indels 0; Gaps 0;	
QY	1	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSMNSGALTSGVHTFPAVLQSS	60
DB	138	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSMNSGALTSGVHTFPAVLQSS	197
QY	61	GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPPCPAPELAGA	120
DB	198	GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPPCPAPELAGA	257
QY	121	PSVFLFPPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPRREQYN	180
DB	258	PSVFLFPPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPRREQYN	317
QY	181	STYRVVSVLTVTHQDNLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE	240
DB	318	STYRVVSVLTVTHQDNLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE	377

```

QY 161 STYRVSVLTVLHODWLNKGYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
DB 318 STYRVSVLTVLHODWLNKGYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 377
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRW 300
DB 378 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRW 437
QY 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330
DB 438 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 467

RESULT 17
ADP88430
ID ADP88430 standard; protein; 467 AA.
AC ADP88430;
DT 09-SEP-2004 (first entry)
XX Antibody TRX1 heavy chain with leader sequence SEQ ID NO: 7.
DE immunosuppressive; transplant rejection; antigen tolerance; antibody;
KW TRX1.
XX Unidentified.
OS WO2004052398-A1.
XX PN 24-JUN-2004.
XX PD 09-DEC-2003; 2003WO-US039165.
XX PF 09-DEC-2002; 2002US-04318399.
XX PR (TOLE-) TOLERRX INC.
XX PA Windsor-Hines D, Rao P, Ringler DJ;
XX PI WPI; 2004-468712/44.
XX DR N-PSDB; ADP88429, ADP88428.
XX XX Treating a primate to induce tolerance to at least one antigen comprises
PT administering at least one anti-CD4 antibody or its fragment in an
PT initial dose of at least 40 mg/kg and at least one compound that inhibits
PT CD8+ T cells.
XX PS Disclosure; SEQ ID NO 7; 113pp; English.
XX CC The present invention relates to a process of treating a primate to
CC induce tolerance to at least one antigen, which comprises administering
CC to the primate at least one anti-CD4 antibody or its fragment in an
CC initial dose of at least 40 mg/kg and at least one compound that inhibits
CC CD8+ T cells, where the anti-CD4 antibody or its fragment is present in
CC the primate when the antigen is present in the primate. The method is
CC useful in treating a primate to induce tolerance to at least one foreign
CC antigen to prevent transplant rejection. The present sequence is an
CC antibody fragment used in the exemplification of the invention.
XX SQ Sequence 467 AA;

Query Match 100.0%; Score 1765; DB 8; Length 467;
Best Local Similarity 100.0%; Pred. No. 7.8e-124;
Matches 330; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
DB 138 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 197
QY 61 GLYSLSSVVTVFPPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPPCPAPELAGA 120

```

```

DB 198 GLYSLSSVVTVFPPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPPCPAPELAGA 257
QY 121 PSVFLFPPPKPQDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
DB 258 PSVFLFPPPKPQDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 317
QY 181 STYRVSVLTVLHODWLNKGYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
DB 318 STYRVSVLTVLHODWLNKGYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 377
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRW 300
DB 378 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRW 437
QY 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330
DB 438 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 467

RESULT 18
ADQ87966
ID ADQ87966 standard; protein; 467 AA.
XX AC ADQ87966;
XX DT 04-NOV-2004 (first entry)
XX DE Heavy chain of a humanised TRX1 antibody #1.
XX KW Primate; tolerance; antigen; mixed lymphocyte reaction; MLR; CD4+; CD25+;
KW IL-2; IL-4; IL-12; immune response; graft rejection; immunosuppressive;
KW antirheumatic; antiarthritic; antidiabetic; neuroprotective;
KW antiinflammatory; antiallergic; antiasthmatic; cytostatic; antimicrobial;
KW transplant; graft-versus-host disease; autoimmune disease; inflammation;
KW allergy; asthma; cancer; infection; humanised; TRX1; heavy.
XX OS Unidentified.
XX FH Key
FT Peptide 1..19 Location/Qualifiers
FT Region 20..49 /label= Leader peptide
FT Region 50..54 /label= Framework region 1
FT Region 55..68 /label= Complementarity determining region 1
FT Region 69..85 /label= Framework region 2
FT Region 86..117 /label= Complementarity determining region 2
FT Region 118..126 /label= Framework region 3
FT Region 127..137 /label= Complementarity determining region 3
FT Region 138..467 /label= Framework region 4
FT Region /label= Constant region
XX WO2004067554-A2.
XX 12-AUG-2004.
XX 28-JAN-2004; 2004WO-US002643.
XX 29-JAN-2003; 2003US-00353708.
XX (TOLE-) TOLERRX INC.
XX PA (ISIS-) ISIS INNOVATION LTD.
XX PA (UYCA-) UNIV CAMBRIDGE TECH SERVICES LTD.
XX Frewin M, Waldmann H, Gorman S, Hale G, Rao P, Kornaga T;
XX Ringler D, Cobbold S, Winsor-Hines D;

```


CC mixed lymphocyte reaction. The compound or the combination being
CC administered in an amount and for a time so as to induce tolerance
CC against the antigen, the compound or the combination being present in the
CC primate when the antigen is present in the primate. The invention further
CC comprises: an antibody that binds to the same epitope as the humanised
CC antibody given in the specification; a composition comprising the
CC antibody and a pharmaceutical carrier; inducing tolerance to an antigen
CC in a patient; inhibiting an immune response in a patient or for
CC inhibiting the rejection of a graft in a human patient; and screening for
CC a compound, or a combination of at least two compounds for use in
CC inducing tolerance. The compositions of the invention have the following
CC activities: immunosuppressive, antirheumatic, antiarthritic,
CC antidiabetic, neuroprotective, antiinflammatory, antiallergic,
CC antiasthmatic, cycostatic, and antimicrobial. The composition and methods
CC are useful for inhibiting, preventing or ameliorating an immune response
CC against an antigen, such as in the inhibition or treatment of transplant
CC rejection, graft-versus-host disease, autoimmune diseases (e.g.
CC rheumatoid arthritis, diabetes or multiple sclerosis), inflammation,
CC allergy, asthma, cancer or infections. These may also be used for
CC identifying compounds or agents useful for inducing tolerance against
CC antigens. This sequence represents the protein of a humanised TRX1
XX antibody region of the invention.
SQ Sequence 467 AA;

Query Match 100.0%; Score 1765; DB 8; Length 467;
Best Local Similarity 100.0%; Pred. No. 7.8e-124; Indels 0; Gaps 0;
Matches 330; Conservative 0; Mismatches 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSMNSGALTSGVHTFPAVLQSS 60
Db 138 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSMNSGALTSGVHTFPAVLQSS 197

QY 61 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPCPAPELAGA 120
Db 198 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPCPAPELAGA 257

QY 121 PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 180
Db 258 PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 317

QY 181 STYRVSVLTVLHQDLNKGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Db 318 STYRVSVLTVLHQDLNKGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 377

QY 241 LTKNQVSLTCLVKGYFSPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRW 300
Db 378 LTKNQVSLTCLVKGYFSPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRW 437

QY 301 QQGNVFCVSMVHEALHNHYTQKSLSLSPGK 330
Db 438 QQGNVFCVSMVHEALHNHYTQKSLSLSPGK 467

RESULT 20
AEF27213
ID AEF27213 standard; protein; 467 AA.
XX AC AEF27213;
XX DT 09-MAR-2006 (first entry)
XX DE Anti-CD4 antibody TRX1 heavy chain SEQ ID NO:21.
XX KW antibody engineering; immunotherapy; immunosuppressive; cd4.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT Peptide 1..19
XX FT 20..49 /label= Leader sequence
XX FT Region /note= "Framework region"

FT Region 50..54 /note= "CDR1"
FT Region 55..68 /note= "Framework region"
FT Region 69..85 /note= "CDR2"
FT Region 86..117 /note= "Framework region"
FT Region 118..126 /note= "CDR3"
FT Region 127..137 /note= "Framework region"
FT Region 138..147 /note= "Modified constant region"
FT Modified-site 317..319 /note= "Glycosylated"
PN US2006002921-A1.
PD 05-JAN-2006.
PF 21-JUN-2005; 2005US-00158505.
PR 22-JUN-2004; 2004US-0582181P.
XX (TOLE-) TOLERX INC.
XX Winsor-Hines D, Rao P, Ringler DJ, Ponath P;
DR WPI; 2006-066198/07.
XX N-PSDB; AEF27214.
PT Treating a primate to induce tolerance to a foreign antigen, e.g. an
FT allogeneic or xenogeneic transplanted antigen, comprises administering an
XX anti-CD4 antibody or its CD4 binding fragment.
PS Example 1; SEQ ID NO 21; 116pp; English.
XX The invention relates to a novel method for treating a primate, to induce
CC tolerance to at least one foreign antigen, comprises administering to the
CC primate at least one anti-CD4 antibody or its CD4 binding fragment. The
CC method of the invention has immunosuppressive activity. The method is
CC useful in immunotherapy. The methods are useful for treating a primate to
CC induce tolerance to at least one foreign antigen, e.g., an allogeneic or
CC xenogeneic transplanted antigen. The present sequence represents an anti-
XX CD4 antibody heavy chain of the invention.
SQ Sequence 467 AA;

Query Match 100.0%; Score 1765; DB 10; Length 467;
Best Local Similarity 100.0%; Pred. No. 7.8e-124; Indels 0; Gaps 0;
Matches 330; Conservative 0; Mismatches 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSMNSGALTSGVHTFPAVLQSS 60
Db 138 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSMNSGALTSGVHTFPAVLQSS 197

QY 61 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPCPAPELAGA 120
Db 198 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPCPAPELAGA 257

QY 121 PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 180
Db 258 PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 317

QY 181 STYRVSVLTVLHQDLNKGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Db 318 STYRVSVLTVLHQDLNKGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 377

QY 241 LTKNQVSLTCLVKGYFSPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRW 300
Db 378 LTKNQVSLTCLVKGYFSPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRW 437

QY 301 QQGNVFCSCVMHEALHNHYTKSLSPGK 330
 DB 438 QQGNVFCSCVMHEALHNHYTKSLSPGK 467

RESULT 21

AEF27197
 ID AEF27197 standard; protein; 467 AA.

XX AEF27197;

XX 09-MAR-2006 (first entry)

XX Anti-CD4 antibody TRX1 heavy chain SEQ ID NO:5.

XX antibody engineering; immunotherapy; immunosuppressive; cd4.

XX Synthetic.

XX Key Location/Qualifiers
 FT Peptide 1..19
 FT /label= Leader sequence
 FT Region 20..49
 FT /note= "Framework region"
 FT Region 50..54
 FT /note= "CDR1"
 FT Region 55..68
 FT /note= "Framework region"
 FT Region 69..85
 FT /note= "CDR2"
 FT Region 86..117
 FT /note= "Framework region"
 FT Region 118..126
 FT /note= "CDR3"
 FT Region 127..137
 FT /note= "Framework region"
 FT Region 138..467
 FT /note= "Modified constant region"
 FT Modified-site 317..319
 FT /note= "Glycosylated"

XX US2006002921-A1.

XX 05-JAN-2006.

XX 21-JUN-2005; 2005US-00158505.

XX 22-JUN-2004; 2004US-0582181P.

XX (TOLE-) TOLEREX INC.

XX Winsor-Hines D, Rao P, Ringle DJ, Ponath P;

XX WPI; 2006-066198/07.

XX N-PSDB; AEF27198.

XX Treating a primate to induce tolerance to a foreign antigen, e.g. an allogeneic or xenogeneic transplanted antigen, comprises administering an anti-CD4 antibody or its CD4 binding fragment.

XX Example 1; SEQ ID NO 5; 116pp; English.

XX The invention relates to a novel method for treating a primate, to induce tolerance to at least one foreign antigen, comprises administering to the primate at least one anti-CD4 antibody or its CD4 binding fragment. The method of the invention has immunosuppressive activity. The method is useful in immunotherapy. The methods are useful for treating a primate to induce tolerance to at least one foreign antigen, e.g., an allogeneic or xenogeneic transplanted antigen. The present sequence represents an anti-CD4 antibody heavy chain of the invention.

XX Sequence 467 AA;

Query Match 100.0%; Score 1765; DB 10; Length 467;
 Best Local Similarity 100.0%; Pred. No. 7.8e-124;
 Matches 330; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ASTKGPSVPLAPSSKSTSGGTAALGCLVKDYFPPETVTVSNWNGALTSVHTTTPAVLQSS 60
 DB 138 ASTKGPSVPLAPSSKSTSGGTAALGCLVKDYFPPETVTVSNWNGALTSVHTTTPAVLQSS 197

QY 61 GLYSLSVVTVPSLSLGTOTYICNVNHKPSNTKVDKKVPEPKSCDKTKHTCCPCPAPELAGA 120
 DB 198 GLYSLSVVTVPSLSLGTOTYICNVNHKPSNTKVDKKVPEPKSCDKTKHTCCPCPAPELAGA 257

QY 121 PSVFLFPPPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
 DB 258 PSVFLFPPPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 317

QY 181 STYRVSVLTIVLHODWLNQKEYKCKVSNKALPAPIEKTISKAKGQPREPOVYTLPPSRDE 240
 DB 318 STYRVSVLTIVLHODWLNQKEYKCKVSNKALPAPIEKTISKAKGQPREPOVYTLPPSRDE 377

QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSSFFLYSKLTVDKSRW 300
 DB 378 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSSFFLYSKLTVDKSRW 437

QY 301 QQGNVFCSCVMHEALHNHYTKSLSPGK 330
 DB 438 QQGNVFCSCVMHEALHNHYTKSLSPGK 467

RESULT 22

AEF27215

ID AEF27215 standard; protein; 467 AA.

XX AEF27215;

XX 09-MAR-2006 (first entry)

XX Anti-CD4 antibody TRX1 heavy chain with leader sequence SEQ ID NO:23.

XX antibody engineering; immunotherapy; immunosuppressive; cd4.

XX Synthetic.

XX Key Location/Qualifiers
 FH Peptide 1..19
 FT /label= Leader sequence
 FT Region 20..49
 FT /note= "Framework region"
 FT Region 50..54
 FT /note= "CDR1"
 FT Region 55..68
 FT /note= "Framework region"
 FT Region 69..85
 FT /note= "CDR2"
 FT Region 86..117
 FT /note= "Framework region"
 FT Region 118..126
 FT /note= "CDR3"
 FT Region 127..137
 FT /note= "Framework region"
 FT Region 138..467
 FT /note= "Modified constant region"
 FT Modified-site 317..319
 FT /note= "Glycosylated"

XX US2006002921-A1.

XX 05-JAN-2006.

XX 21-JUN-2005; 2005US-00158505.

XX 22-JUN-2004; 2004US-0582181P.

```
PA (TOLE-) TOLERRX INC.
XX Winsor-Hines D, Rao P, Ringler DJ, Ponath P;
XX WPI; 2006-066198/07.
DR N-PSDB; AEF27214.
XX
PT Treating a primate to induce tolerance to a foreign antigen, e.g. an
FT allogeneic or xenogeneic transplanted antigen, comprises administering an
FT anti-CD4 antibody or its CD4 binding fragment.
XX
PS Disclosure; SEQ ID NO 23; 116pp; English.
XX
CC The invention relates to a novel method for treating a primate, to induce
CC tolerance to at least one foreign antigen, comprises administering to the
CC primate at least one anti-CD4 antibody or its CD4 binding fragment. The
CC method of the invention has immunosuppressive activity. The method is
CC useful in immunotherapy. The methods are useful for treating a primate to
CC induce tolerance to at least one foreign antigen, e.g., an allogeneic or
CC xenogeneic transplanted antigen. The present sequence represents an anti-
CC CD4 antibody heavy chain of the invention with leader sequence.
XX
SQ Sequence 467 AA;

Query Match 100.0%; Score 1765; DB 10; Length 467;
Best Local Similarity 100.0%; Pred. No. 7.8e-124;
Matches 330; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
DB 138 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 197

QY 61 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPCPAPELAGA 120
DB 198 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPCPAPELAGA 257

QY 121 PSVLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
DB 258 PSVLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 317

QY 181 STYRVSVSLTVLHQDLWLGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVTLPPSRDE 240
DB 318 STYRVSVSLTVLHQDLWLGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVTLPPSRDE 377

QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
DB 378 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 437

QY 301 QQGNVFCSVMHEALHNHYTQKSLSLSPGK 330
DB 438 QQGNVFCSVMHEALHNHYTQKSLSLSPGK 467

RESULT 23
ID AEF27199
XX AEF27199 standard; protein; 467 AA.
XX AC AEF27199;
XX DT 09-MAR-2006 (first entry)
XX DE Anti-CD4 antibody TRX1 heavy chain with leader sequence SEQ ID NO:7.
XX antibody engineering; immunotherapy; immunosuppressive; cd4.
XX OS Synthetic.
XX FH Key Location/Qualifiers
FT Peptide 1..19
FT Region 20..49
FT /note= "Framework region"
FT 50..54
```

```
FT Region /note= "CDR1"
FT 55..68
FT /note= "Framework region"
FT Region 69..85
FT /note= "CDR2"
FT Region 86..117
FT /note= "Framework region"
FT Region 118..126
FT /note= "CDR3"
FT Region 127..137
FT /note= "Framework region"
FT Region 138..146
FT /note= "Modified constant region"
FT Modified-site 317..319
FT /note= "Glycosylated"
XX US2006002921-A1.
XX 05-JAN-2006.
XX 21-JUN-2005; 2005US-00158505.
XX 22-JUN-2004; 2004US-0582181P.
XX (TOLE-) TOLERRX INC.
XX Winsor-Hines D, Rao P, Ringler DJ, Ponath P;
XX N-PSDB; AEF27198.
XX WPI; 2006-066198/07.
XX DR N-PSDB; AEF27198.
XX
PT Treating a primate to induce tolerance to a foreign antigen, e.g. an
FT allogeneic or xenogeneic transplanted antigen, comprises administering an
FT anti-CD4 antibody or its CD4 binding fragment.
XX
PS Disclosure; SEQ ID NO 7; 116pp; English.
XX
CC The invention relates to a novel method for treating a primate, to induce
CC tolerance to at least one foreign antigen, comprises administering to the
CC primate at least one anti-CD4 antibody or its CD4 binding fragment. The
CC method of the invention has immunosuppressive activity. The method is
CC useful in immunotherapy. The methods are useful for treating a primate to
CC induce tolerance to at least one foreign antigen, e.g., an allogeneic or
CC xenogeneic transplanted antigen. The present sequence represents an anti-
CC CD4 antibody heavy chain of the invention with leader sequence.
XX
SQ Sequence 467 AA;

Query Match 100.0%; Score 1765; DB 10; Length 467;
Best Local Similarity 100.0%; Pred. No. 7.8e-124;
Matches 330; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
DB 138 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 197

QY 61 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPCPAPELAGA 120
DB 198 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPCPAPELAGA 257

QY 121 PSVLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
DB 258 PSVLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 317

QY 181 STYRVSVSLTVLHQDLWLGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVTLPPSRDE 240
DB 318 STYRVSVSLTVLHQDLWLGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVTLPPSRDE 377

QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
DB 378 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 437

QY 301 QQGNVFCSVMHEALHNHYTQKSLSLSPGK 330
```



```
Query Match      100.0%; Score 1765; DB 8; Length 475;
Best Local Similarity 100.0%; Pred. No. 8e-124;
Matches 330; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
    |||||
Db 146 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 205

QY 61 GLYSLSSVTVTPSSSLGTQTYICNVNHPKSNKTKVDKVEPKSCDKTHTCPPCPAPELAGA 120
    |||||
Db 206 GLYSLSSVTVTPSSSLGTQTYICNVNHPKSNKTKVDKVEPKSCDKTHTCPPCPAPELAGA 265

QY 121 PSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 180
    |||||
Db 266 PSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 325

QY 181 STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPPQVYTLPPSRDE 240
    |||||
Db 326 STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPPQVYTLPPSRDE 385

QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW 300
    |||||
Db 386 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW 445

QY 301 QQGNVFSCSVMHAEALHNHYTQKSLSLSPGK 330
    |||||
Db 446 QQGNVFSCSVMHAEALHNHYTQKSLSLSPGK 475

RESULT 26
ADL23054
ID ADL23054 standard; protein; 475 AA.
XX
AC ADL23054;
XX
DT 20-MAY-2004 (first entry)
XX
DE Humanised anti-MAG antibody #1.
XX
KW antibody; MAG; myelin associated glycoprotein; stroke;
KW neurodegenerative disorder; gene therapy; vaccine; human.
XX
OS Homo sapiens.
OS Chimeric.
OS Unidentified.
XX
FN WO2004014953-A2.
XX
PD 19-FEB-2004.
XX
PF 05-AUG-2002; 2003WO-EP008749.
XX
PR 06-AUG-2002; 2002GB-00018229.
XX
PR 06-AUG-2002; 2002GB-00018230.
XX
PR 06-AUG-2002; 2002GB-00018232.
XX
PR 06-AUG-2002; 2002GB-00018234.
XX
PA (GLAX ) GLAXO GROUP LTD.
XX
PI Ellis JH, Germaschewski V;
XX
WPI; 2004-180641/17.
XX
DR
XX
PT New altered antibody that binds to and neutralizes myelin associated
PT glycoprotein (MAG), useful for preparing a composition for treating or
PT preventing stroke or other neurodegenerative disorders e.g., Alzheimer's
PT disease.
XX
PS Example 4; Fig 5; 67pp; English.
XX
CC The present invention relates to a new altered antibody or its functional
CC fragment, which binds to and neutralizes myelin associated glycoprotein
```

```
CC (MAG) and comprises a light chain variable domain (VL) comprising
CC complementary determining region light 1 (CDRL1), CDRL2 or CDRL3 and/or a
CC heavy chain variable domain (VH) comprising CDRH1, CDRH2 or CDRH3. The
CC antibody is useful for preparing a composition for treating or preventing
CC stroke or other neurodegenerative disorders in a human, e.g., traumatic
CC brain injury, Alzheimer's disease, dementias, peripheral neuropathy,
CC Parkinson's disease, Huntington's disease and multiple sclerosis. The
CC present sequence is a humanised anti-MAG antibody.
XX
SQ Sequence 475 AA;
    Query Match      100.0%; Score 1765; DB 8; Length 475;
    Best Local Similarity 100.0%; Pred. No. 8e-124;
    Matches 330; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
    |||||
Db 146 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 205

QY 61 GLYSLSSVTVTPSSSLGTQTYICNVNHPKSNKTKVDKVEPKSCDKTHTCPPCPAPELAGA 120
    |||||
Db 206 GLYSLSSVTVTPSSSLGTQTYICNVNHPKSNKTKVDKVEPKSCDKTHTCPPCPAPELAGA 265

QY 121 PSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 180
    |||||
Db 266 PSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 325

QY 181 STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPPQVYTLPPSRDE 240
    |||||
Db 326 STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPPQVYTLPPSRDE 385

QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW 300
    |||||
Db 386 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW 445

QY 301 QQGNVFSCSVMHAEALHNHYTQKSLSLSPGK 330
    |||||
Db 446 QQGNVFSCSVMHAEALHNHYTQKSLSLSPGK 475

RESULT 27
ADS88803
ID ADS88803 standard; protein; 475 AA.
XX
AC ADS88803;
XX
DT 16-DEC-2004 (first entry)
XX
DE Humanised anti-MAG antibody heavy chain.
XX
KW oligodendrocyte; stroke; neurological disease;
KW myelin-associated glycoprotein; MAG; anti-MAG antibody;
KW Alzheimer's disease; multiple sclerosis.
XX
OS Homo sapiens.
OS Synthetic.
XX
FN WO2004083363-A2.
XX
PD 30-SEP-2004.
XX
PF 02-FEB-2004; 2004WO-EP001016.
XX
PR 19-MAR-2003; 2003GB-00006309.
XX
PA (GLAX ) GLAXO GROUP LTD.
XX
PI Vinson M, Irving EA;
XX
WPI; 2004-691029/67.
XX
PT Promoting oligodendrocyte survival in humans with neurological diseases,
PT such as Alzheimer's disease, multiple sclerosis and/or stroke, using an
```


PT anti-myelin-associated glycoprotein (MAG) antibody.
XX Claim 17; SEQ ID NO 18; 45pp; English.
XX
XX The specification describes a method for promoting oligodendrocyte
CC survival in a human suffering or at risk of developing stroke or another
CC neurological diseases. The method comprises administering to the human an
CC anti-myelin-associated glycoprotein (MAG) antibody or its functional
CC fragment. The anti-MAG antibody or its functional fragment is useful in
CC the manufacture of a medicament for the promotion of oligodendrocyte
CC survival in a human suffering from or at risk of developing stroke or
CC another neurological disease. They can also be used in treating
CC neurological diseases, such as Alzheimer's disease, multiple sclerosis
CC and/or stroke, by promoting oligodendrocyte survival. The present
CC sequence represents a humanised immunoglobulin heavy chain in which the
CC humanised anti-MAG heavy chain variable region is associated with a
CC functional immunoglobulin secretion signal sequence, and with an altered
CC form of the human IgG1 constant region in which Kabat residues 248 and
CC 250 have been mutated to alanine in order to disable the effector
CC functions of binding to FcγmARI and complement protein Clq. Antibodies
CC used in the method of the invention may comprise the present heavy chain.
XX
SQ Sequence 475 AA;

Query Match 100.0%; Score 1765; DB 8; Length 475;
Best Local Similarity 100.0%; Pred. No. 8e-124;
Matches 330; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTWNSGALTSGLVHTFPAVLQSS 60
Db 146 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTWNSGALTSGLVHTFPAVLQSS 205

Qy 61 GLYSLSVVTVPPSSSLGTQTYICNVNHPKSNKTKVDKVEPKSCDKTHTCPPCPAPELAGA 120
Db 206 GLYSLSVVTVPPSSSLGTQTYICNVNHPKSNKTKVDKVEPKSCDKTHTCPPCPAPELAGA 265

Qy 121 PSVFLFPKPKDITLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREQYN 180
Db 266 PSVFLFPKPKDITLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREQYN 325

Qy 181 STYRVSVVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Db 326 STYRVSVVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 385

Qy 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
Db 386 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 445

Qy 301 QQGNVFSCSVNHEALHNHYTQKSLSLSPGK 330
Db 446 QQGNVFSCSVNHEALHNHYTQKSLSLSPGK 475

RESULT 28
AD888792
ID AD888792 standard; protein; 475 AA.
XX
XX AD888792;
XX
XX 16-DEC-2004 (first entry)
XX
XX A mouse/human chimeric anti-MAG antibody heavy chain.
XX
XX oligodendrocyte; stroke; neurological disease;
KW myelin-associated glycoprotein; MAG; anti-MAG antibody;
KW Alzheimer's disease; multiple sclerosis;
KW chain complementarity determining region; CDR; chimera.
XX
XX Mus sp.
OS Homo sapiens.
OS Chimeric.
OS
FN WO2004083363-A2.

XX 30-SEP-2004.
XX
XX 02-FEB-2004; 2004WO-EP001016.
XX
XX 19-MAR-2003; 2003GB-00006309.
XX
XX (GLAX) GLAXO GROUP LTD.
XX
XX Vinson M, Irving EA;
XX
XX WPI; 2004-691029/67.
XX
XX Promoting oligodendrocyte survival in humans with neurological diseases,
PT such as Alzheimer's disease, multiple sclerosis and/or stroke, using an
PT anti-myelin-associated glycoprotein (MAG) antibody.
XX
XX Claim 9; SEQ ID NO 7; 45pp; English.
XX
XX The specification describes a method for promoting oligodendrocyte
CC survival in a human suffering or at risk of developing stroke or another
CC neurological diseases. The method comprises administering to the human an
CC anti-myelin-associated glycoprotein (MAG) antibody or its functional
CC fragment. The anti-MAG antibody or its functional fragment is useful in
CC the manufacture of a medicament for the promotion of oligodendrocyte
CC survival in a human suffering from or at risk of developing stroke or
CC another neurological disease. They can also be used in treating
CC neurological diseases, such as Alzheimer's disease, multiple sclerosis
CC and/or stroke, by promoting oligodendrocyte survival. The present
CC sequence represents a mouse/human chimeric anti-MAG antibody heavy chain
CC in which the murine anti-MAG heavy chain variable region is associated
CC with a functional immunoglobulin secretion signal sequence, and with an
CC altered form of the human IgG1 constant region, and in which Kabat
CC residues 248 and 250 have been mutated to alanine in order to disable the
CC effector functions of binding to FcγmARI and complement protein Clq.
CC Antibodies used in the method of the invention may comprise the present
CC heavy chain.
XX
SQ Sequence 475 AA;

Query Match 100.0%; Score 1765; DB 8; Length 475;
Best Local Similarity 100.0%; Pred. No. 8e-124;
Matches 330; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTWNSGALTSGLVHTFPAVLQSS 60
Db 146 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTWNSGALTSGLVHTFPAVLQSS 205

Qy 61 GLYSLSVVTVPPSSSLGTQTYICNVNHPKSNKTKVDKVEPKSCDKTHTCPPCPAPELAGA 120
Db 206 GLYSLSVVTVPPSSSLGTQTYICNVNHPKSNKTKVDKVEPKSCDKTHTCPPCPAPELAGA 265

Qy 121 PSVFLFPKPKDITLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREQYN 180
Db 266 PSVFLFPKPKDITLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREQYN 325

Qy 181 STYRVSVVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Db 326 STYRVSVVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 385

Qy 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
Db 386 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 445

Qy 301 QQGNVFSCSVNHEALHNHYTQKSLSLSPGK 330
Db 446 QQGNVFSCSVNHEALHNHYTQKSLSLSPGK 475

RESULT 29
ADL23199
ID ADL23199 standard; protein; 469 AA.
XX

ADL23199;
 20-MAY-2004 (first entry)
 Human anti-CD18 antibody heavy chain.
 Human; bactericidal/permeability-increasing protein; BPI; Ep-CAM; CAB2.1;
 recombinant polypeptide production; ING-1; antibody; anti-CD18 antibody;
 cosmetic product.
 Homo sapiens.
 US2003203447-A1.
 30-OCT-2003.
 31-MAR-2003; 2003US-00404724.
 29-MAR-2002; 2002US-0368530P.
 (HORWITZ) HORWITZ A H.
 Horwitz AH;
 WPI; 2003-875646/81.
 N-PSDB; ADL23198.
 Producing recombinant polypeptide, useful for treating or diagnosing
 comprises culturing cells transformed or transfected with a vector
 comprising multiple copies of a transcription unit separated by a
 selective marker gene.
 Example 13; SEQ ID NO 72; 133pp; English.
 The invention relates to producing a recombinant polypeptide comprising
 culturing cells, which have been transformed or transfected with a
 vector, or its segment comprising multiple copies of a transcription unit
 separated by at least one selective marker gene, where the transcription unit
 encodes a polypeptide under selective conditions. Also included are
 a vector or segment comprising multiple copies of a transcription unit
 separated by at least one selective marker gene where the transcription
 unit encodes a polypeptide, a host cell comprising an expression vector
 or segment and a stable cell line comprising an expression vector or
 segment. Each transcription unit is under the control of its own promoter
 and 3' untranslated region, where the promoter is an SV40, HSV, bovine
 growth hormone, thymidine kinase, MPSV, mouse beta globin, human BFI, MSV
 -LTR, RSV, MMTV-LTR, CMV, MLV, Chinese hamster elongation factor or mouse
 Abelson LTR promoter. The expression vector further comprises multiple
 enhancers. The transcription unit also encodes two different subunits of
 a multimeric protein, an immunoglobulin light and heavy chain
 polypeptides or at least the variable regions of the immunoglobulin light
 and heavy chain polypeptides. It further encodes a BPI protein
 (bactericidal/permeability-increasing protein) product. The protein
 product BPI protein fragment, BPI analogue, BPI variant or BPI-derived
 peptide. The transcription unit encodes an rBPI21 and is under the
 control of an hCMV promoter and mouse light chain 3' untranslated region,
 where the vector further comprises 0, 1 or 2 copies of a human heavy
 chain enhancer and either a gpt or neo gene. Other genes suitable for
 expression using the method of the invention are Ep-CAM and CAB2.1 (both
 not defined). The immunoglobulin may be the ING-1 chimaeric mouse/human
 antibody (or humanised versions or proline substitution mutants) or an
 anti-CD18 antibody. The method is useful for producing recombinant
 polypeptide. Recombinant polypeptide compositions are useful in
 therapies, in diagnostic procedures or as tools in preventive medicine.
 Recombinant polypeptides are also found in a wide array of both health
 and cosmetic products, used to increase the quality of life. Complex
 polypeptide products are also routinely used in research laboratories
 both as end products of analyses and as agents in assays for the study or
 preparation of other molecules. Advantages of the present invention
 includes increased recombinant polypeptide production, increased
 production efficiency, greater control and/or regulation over the
 qualities of the polypeptide expressed, increased stability of cell
 lines, and/or decreased costs for materials, reagents and/or other

CC resources. The present sequence represents a light or heavy chain from a
 CC antibody gene suitable for inclusion in the transcription unit of the
 CC invention.
 XX
 SQ Sequence 469 AA;
 Query Match 99.6%; Score 1758; DB 7; Length 469;
 Best Local Similarity 99.7%; Pred. No. 2.6e-123;
 Matches 329; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 ASTKGPSVFPLAPSSKSTSGGTAAALGCLVKDYFPEPTVTSWNSGALTSGVHTFPAVLQSS 60
 DB 140 ASTKGPSVFPLAPSSKSTSGGTAAALGCLVKDYFPEPTVTSWNSGALTSGVHTFPAVLQSS 199
 QY 61 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKYTHTCPCPAPELAGA 120
 DB 200 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKYTHTCPCPAPELAGA 259
 QY 121 PSVFLFPPPKDITLMISRTPEVTCVVDVSHEDPEVKENWYVDGVEVHNATKPREQYN 180
 DB 260 PSVFLFPPPKDITLMISRTPEVTCVVDVSHEDPEVKENWYVDGVEVHNATKPREQYN 319
 QY 181 STYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIISKAKGQPREPQVYTLPPSRDE 240
 DB 320 STYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIISKAKGQPREPQVYTLPPSRDE 379
 QY 241 LTKQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFPLYSKLTVDKSRW 300
 DB 380 LTKQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFPLYSKLTVDKSRW 439
 QY 301 QGQNVFSCSVNMEALHNHYTOKSLSLSPGK 330
 DB 440 QGQNVFSCSVNMEALHNHYTOKSLSLSPGK 469
 RESULT 30
 AAB04071
 ID AAB04071 standard; protein; 330 AA.
 XX
 AC AAB04071;
 XX
 DT 11-APR-2001 (first entry)
 XX
 DE Zcytor 10::IGG gamma fusion peptide.
 XX
 KW zcytor 10 cytokine receptor; cytokine; receptor; antibody; ligand;
 KW binding; detection; modulation; recombinant cell; haematopoietic cell;
 KW lymphoid cell; myeloid cell; lymph; immune system; blood; bone;
 KW inflammatory response; inflammation; spleen; human.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO2000068381-A1.
 XX
 PD 16-NOV-2000.
 XX
 PF 11-MAY-2000; 2000WO-US012924.
 XX
 PR 11-MAY-1999; 99US-00309861.
 XX
 PA (ZYMO) ZYMOGENETICS INC.
 XX
 PI Presnell SR, Foster DC, Hammond AK, Lok S;
 XX
 DR WPI; 2001-016096/02.
 DR N-PSDB; AAA54473.
 XX
 PT New cytokine receptor mouse zcytor 10, useful for detecting ligands that
 PT stimulate proliferation or development of hematopoietic, lymphoid and
 PT myeloid cells.
 XX
 PS Example 17; Page 120-121; 134pp; English.

AAE21960
ID AAE21960 standard; protein; 330 AA.
XX
AC AAE21960;
XX
DT 25-JUL-2002 (first entry)
XX
DE Human death domain containing receptor (DR6) protein-related protein.
XX
KW Human; therapy; death domain containing receptor; DR6; receptor; anaemia;
KW apoptosis; rheumatoid arthritis; eczema; asthma; psoriasis; pancreatitis;
KW diabetes; cancer; multiple sclerosis; Graves disease; glomerulonephritis;
KW transplant rejection; systemic lupus erythematosus; hepatitis; cirrhosis;
KW autoimmune; gastritis; dermatosis; cardiopathy; infertility; haemostatic;
KW H. pylori-associated ulceration; antiinflammatory; vasodilator; virucide;
KW acquired immunodeficiency syndrome; AIDS; human immunodeficiency virus;
KW HIV; haemolytic uraemic syndrome; HUS; immunodeficiency; neuroprotective;
KW adult respiratory distress syndrome; ARDS; cytostatic; thyromimetic;
KW dermatological; hepatotropic; antibacterial.
XX
OS Homo sapiens.
XX
FN WO200185209-A2.
XX
PD 15-NOV-2001.
XX
PF 30-APR-2001; 2001WO-US011735.
XX
PR 10-MAY-2000; 2000US-0203015P.
XX
PA (ELIT) LILLY & CO ELI.
XX
PI Heuer JG, Liu J, Na S, Song HY, Yang D;
XX
DR WPI; 2002-351283/38.
XX
PT Treating or preventing T cell or Th2 cell mediated condition e.g., asthma
PT or multiple sclerosis in mammal, comprises administering composition
PT comprising death domain containing receptor, DR6 agonist or antagonist.
XX
PS Disclosure; Page 132-133; 133pp; English.
XX
CC The invention relates to a method for treating or preventing a T cell
CC mediated condition or a Th2 cell mediated condition in a mammal. The
CC method comprising administering to the mammal a pharmaceutical
CC composition comprising a death domain containing receptor (DR6) agonist
CC or antagonist. The method is useful for treating or preventing a T cell
CC mediated condition or a Th2 cell mediated condition in a mammal. A DR6
CC agonist is useful in the manufacture of a medicament for treating or
CC preventing at least one symptom associated with aberrant apoptosis, graft
CC -versus-host disease (GVHD), rheumatoid arthritis, eczema, asthma, atopy,
CC inflammatory bowel disease, vasculitis, psoriasis, pancreatitis, insulin-
CC dependent diabetes mellitus, cancer, multiple sclerosis, Hashimoto's
CC thyroiditis, Graves disease, transplant rejection, systemic lupus
CC erythematosus, autoimmune dermatosis, autoimmune cardiopathy, autoimmune
CC infertility, Behcet's disease, autoimmune gastritis, fibrosing lung
CC disease, organ rejection after transplantation, thrombotic
CC thrombocytopenic purpura (TTP), chronic glomerulonephritis, haemolytic
CC uraemic syndrome (HUS), aplastic anaemia, myelodysplasia, multiple organ
CC dysfunction syndrome (MODS), adult respiratory distress syndrome (ARDS)
CC or a condition or symptom related to the above mentioned diseases in a
CC mammal. An DR6 antagonist is useful in the manufacture of a medicament
CC for treating or preventing at least one symptom associated with
CC immunodeficiency, aberrant apoptosis, bacterial, viral or microbial
CC infection, complications of infection, human immunodeficiency virus
CC (HIV), HIV-induced lymphoma, HIV-induced acquired immunodeficiency
CC syndrome (AIDS), fulminant viral hepatitis B, fulminant viral hepatitis
CC C, autoimmune hepatitis, chronic hepatitis, chronic cirrhosis, H. pylori
CC associated ulceration, cytoprotection during cancer treatment,
CC recuperation from chemotherapy, recuperation from irradiation therapy, or
CC a condition or symptom related to the above mentioned diseases in a
CC mammal. The present sequence is human DR6 protein-related protein

SQ Sequence 330 AA;
Query Match 99.5%; Score 1756; DB 5; Length 330;
Best Local Similarity 99.4%; Pred. No. 2.4e-123;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1 ASTKGPSVFPPLAPSSKSTSGCTAALGCLIVKDYPPEPVTVSNNGALTSVHTFFAVLQSS 60
DB 1 ASTKGPSVFPPLAPSSKSTSGCTAALGCLIVKDYPPEPVTVSNNGALTSVHTFFAVLQSS 60
QY 61 GLYSLSVVTVPPSSSLGTQTYICNVNHPKSNKYVDKVKVEPKSCDKTHTCPCPAPELAGA 120
DB 61 GLYSLSVVTVPPSSSLGTQTYICNVNHPKSNKYVDKVKVEPKSCDKTHTCPCPAPELAGG 120
QY 121 PSVFLFPPKPDKDTLMISRTPEVTCVVDVSHEDDEVKFNWYVDGVEVHNATKPREEOYN 180
DB 121 PSVFLFPPKPDKDTLMISRTPEVTCVVDVSHEDDEVKFNWYVDGVEVHNATKPREEOYN 180
QY 181 STYRVSVLVTLVHODWLNKGEYKCKVSNKALPAPIEKTISKAKGPQPEPVYTLPPSRDE 240
DB 181 STYRVSVLVTLVHODWLNKGEYKCKVSNKALPAPIEKTISKAKGPQPEPVYTLPPSRDE 240
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFPLYKLTVDKSRW 300
DB 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFPLYKLTVDKSRW 300
QY 301 QQGNVFSCSVMHEALHNHYTOKSLSLSPGK 330
DB 301 QQGNVFSCSVMHEALHNHYTOKSLSLSPGK 330
RESULT 33
ABB81641
ID ABB81641 standard; protein; 330 AA.
XX
AC ABB81641;
XX
DT 25-SEP-2002 (first entry)
XX
DE Human IgG gamma 1 heavy chain SEQ ID NO:15.
XX
KW Human; zcytor19; cytokine receptor; immunosuppressive; cytostatic;
KW antiarthritic; neuroprotective; antiinflammatory;
KW antidabetic; nephrotropic; dermatological; anti-HIV; haemostatic;
KW vaccine; immune system; T-cell specific leukaemia; lymphoma; lupus;
KW autoimmune disease; rheumatoid arthritis; multiple sclerosis; HIV;
KW diabetes mellitus; inflammatory bowel disease; Crohn's disease; asthma;
KW immunologic renal disease; glomerulonephritis; vasculitis; polyarteritis;
KW mesangioproliferative disease; chronic lymphocytic leukaemia; bronchitis;
KW secondary glomerulonephritis; scleroderma; amyloidosis; multiple myeloma;
KW haemolytic uraemic syndrome; renal neoplasm; urological neoplasm;
KW emphysema; chronic airway disease.
XX
OS Homo sapiens.
FN WO200244209-A2.
XX
PD 06-JUN-2002.
XX
PF 28-NOV-2001; 2001WO-US044808.
XX
PR 28-NOV-2000; 2000US-0253561P.
XX 07-FEB-2001; 2001US-0267211P.
XX (ZYMO) ZYMOGENETICS INC.
XX Presnell SR, Xu W, Novak JE, Whitmore TE, Grant FJ;
XX WPI; 2002-527700/56.
XX N-PSDB; ABQ73076.
XX Novel Zycitor19 polypeptides and polynucleotides useful for stimulating
XX immune responses in animals for producing antibodies, and for treating

PT autoimmune diseases, leukemia and asthma.
XX Example 7; Page 171-172; 200pp; English.
XX
XX The present invention describes an isolated human zcytor19 protein (I),
CC and truncated zcytor19 proteins. (I) has immunosuppressive, cytostatic,
CC antirheumatic, antiarthritic, neuroprotective, antiinflammatory,
CC antidiabetic, nephrotropic, dermatological, anti-HIV and haemostatic
CC activities, and can be used in vaccines. (I) or an antibody binding (I)
CC can be used for suppressing the immune system for reducing rejection of
CC tissue or organ transplants and grafts and for treating T-cell specific
CC leukaemias or lymphomas and autoimmune diseases including rheumatoid
CC arthritis, multiple sclerosis, diabetes mellitus, inflammatory bowel
CC disease and Crohn's disease. The antibodies can also be used for treating
CC immunologic renal diseases, glomerulonephritis, mesangiolonephritis or
CC disease, chronic lymphocytic leukaemia, secondary glomerulonephritis or
CC vasculitis associated with lupus, polyarteritis, scleroderma, HIV-related
CC diseases, amyloidosis and haemolytic uraemic syndrome. (I) and the
CC antibodies can also be used for renal or urological neoplasms and
CC multiple myelomas, asthma, bronchitis, emphysema and other chronic airway
CC diseases. Human zcytor19 is located to chromosome 1, more specifically to
CC chromosome lp36.11. The present sequence represents a human IgG gamma 1
CC heavy chain protein, which is used in an example from the present
CC invention
XX
SQ Sequence 330 AA;

Query Match 99.5%; Score 1756; DB 5; Length 330;
Best Local Similarity 99.4%; Pred. No. 2.4e-123;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
Db 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60

QY 61 GLYSLSVVTVFPSSSLGTQTYICNVNHPKSNTKVDKVPKSCDKTHTCPPCPAPELAGA 120
Db 61 GLYSLSVVTVFPSSSLGTQTYICNVNHPKSNTKVDKVPKSCDKTHTCPPCPAPELGG 120

QY 121 PSVELFPPKPKDGLMISRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNAKTKPREEQYN 180
Db 121 PSVELFPPKPKDGLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180

QY 181 STYRVSVSLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Db 181 STYRVSVSLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240

QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKGRW 300
Db 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKGRW 300

QY 301 QOQNVFSCSVMEALHNHYTQKSLSLSPGK 330
Db 301 QOQNVFSCSVMEALHNHYTQKSLSLSPGK 330

RESULT 34
ABB05736
ID ABB05736 standard; protein; 330 AA.
XX
XX ABB05736;
XX
XX 01-MAY-2002 (first entry)
XX
XX Human immunoglobulin G gamma 1 protein sequence SEQ ID NO:38.
DE
XX Zcytor17; chromosome 5; 5q11; cytokine receptor; immunomodulatory;
KW antiinflammatory; antiviral; antirheumatic; antiarthritic; cytostatic;
KW muscular; lymphoid; immune; inflammatory; splenic; blood; bone;
KW infection; immunosuppression; cytotoxicity; leukopenia; Crohn's disease;
KW autoimmune disease; rheumatoid arthritis; multiple sclerosis; cancer;
XX inflammatory disease; pancreatitis; inflammatory bowel disease.

OS Homo sapiens.
XX WO200200721-A2.
XX
XX 03-JAN-2002.
PD
XX 26-JUN-2001; 2001WO-US020484.
FF
XX 26-JUN-2000; 2000US-0214282P.
XX
PR 29-JUN-2000; 2000US-0214955P.
PR
PR 08-FEB-2001; 2001US-0267963P.
PR
XX (ZYMO) ZYMOGENETICS INC.
PA
XX Sprecher CA, Presnell SR, Gao Z, Whitmore TE, Kuijper JL;
PI Maurer MF;
PI
XX WPI; 2002-090519/12.
DR N-PSDB; ABA93797.
DR
XX Isolated polynucleotide encoding a cytokine receptor zcytor17 which is
XX useful for treating and diagnosing lymphoid, immune, inflammatory,
PT splenic, blood or bone disorders.
PT
XX
PS Example 17; Page 187-188; 235pp; English.
XX
CC The present invention describes a cytokine receptor designated zcytor17.
CC Zcytor17 has immunomodulatory, antiinflammatory, antiviral, cytostatic,
CC antirheumatic, antiarthritic and muscular activities. The zcytor17
CC proteins are useful for treating and diagnosing lymphoid, immune,
CC inflammatory, splenic, blood or bone disorders. Agonists or anti-
CC zcytor17 antibodies are useful in stimulating cell-mediated immunity and
CC for stimulating lymphocyte proliferation, such as in the treatment of
CC infections involving immunosuppression, including certain viral
CC infections. They are also useful for inducing cytotoxicity and for
CC treating leukopenias. Antagonist of zcytor17 polypeptides are useful for
CC treating autoimmune diseases (e.g. rheumatoid arthritis and multiple
CC sclerosis), inflammatory diseases (e.g. Crohn's disease), cancer,
CC pancreatitis, and inflammatory bowel disease. Zcytor17 was mapped to
CC chromosome 5, specifically to the 5q11 chromosomal region. ABA93767 to
CC ABA93843 and ABB05730 to ABB05745 represent sequences used in the
CC exemplification of the present invention
XX
SQ Sequence 330 AA;

Query Match 99.5%; Score 1756; DB 5; Length 330;
Best Local Similarity 99.4%; Pred. No. 2.4e-123;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
Db 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60

QY 61 GLYSLSVVTVFPSSSLGTQTYICNVNHPKSNTKVDKVPKSCDKTHTCPPCPAPELAGA 120
Db 61 GLYSLSVVTVFPSSSLGTQTYICNVNHPKSNTKVDKVPKSCDKTHTCPPCPAPELGG 120

QY 121 PSVELFPPKPKDGLMISRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNAKTKPREEQYN 180
Db 121 PSVELFPPKPKDGLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180

QY 181 STYRVSVSLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Db 181 STYRVSVSLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240

QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKGRW 300
Db 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKGRW 300

QY 301 QOQNVFSCSVMEALHNHYTQKSLSLSPGK 330
Db 301 QOQNVFSCSVMEALHNHYTQKSLSLSPGK 330

[illegible]

CC rheumatoid arthritis, asthma, eczema, inflammatory bowel disease, cancer,
CC vasculitis, psoriasis, insulin-dependent diabetes mellitus, pancreatitis,
CC psoriasis, multiple sclerosis, Hashimoto's thyroiditis, Graves' disease,
CC transplant rejection, systemic lupus erythematosus, Behcet's disease,
CC autoimmune nephropathy, autoimmune haematopathy, idiopathic interstitial
CC pneumonia, hypersensitivity pneumonitis, autoimmune dermatosis,
CC autoimmune cardiopathy, autoimmune infertility, autoimmune gastritis,
CC fibrosing lung disease, fulminant viral hepatitis B, fulminant viral
CC hepatitis C, autoimmune hepatitis, chronic hepatitis, chronic cirrhosis,
CC Helicobacter pylori-associated ulceration, organ rejection after
CC transplantation, chronic glomerulonephritis, thrombotic thrombocytopenic
CC purpura (TTP) and haemolytic uraemic syndrome (HUS), aplastic anaemia,
CC myelodysplasia, multiple organ dysfunction syndrome (MDS), adult
CC respiratory distress syndrome (ARDS), and at least one condition or
CC symptom related to the conditions, in a mammal; and (3) use of DR6
CC antagonist in the manufacture of a medicament for treating or preventing
CC at least one symptom associated with conditions (C2) such as aberrant
CC apoptosis, immunodeficiency, bacterial infection, viral infection,
CC microbial infection, complications of infection, HIV, HIV-induced
CC lymphoma, HIV-induced AIDS, fulminant viral hepatitis B, fulminant viral
CC hepatitis C, autoimmune hepatitis, chronic hepatitis, chronic cirrhosis,
CC H. pylori-associated ulceration, cytoprotection during cancer treatment,
CC recuperation from chemotherapy, recuperation from irradiation therapy,
CC and at least one condition or symptom related to the conditions, in a
CC mammal. DR6 has immunosuppressive, antirheumatic, antiarthritic,
CC antiasthmatic, dermatological, antiinflammatory, antipsoriatic,
CC antidibetic, cytostatic, neuroprotective, thyromimetic, antithyroid,
CC nephrotropic, antiinfertility, vasotropic, virucide, hepatotropic,
CC antibacterial, antitumor, haemostatic, antianemic, antimicrobial and
CC anti-HIV activities. (M1) is useful for treating or preventing at least
CC one symptom associated with (C1) in a mammal, preferably human, by
CC administering DR6 agonist, and for treating or preventing at least one
CC symptom associated with (C2) by administering DR6 antagonist. The present
CC sequence represents a human DR6 related amino acid sequence, which is
CC given in the exemplification of the present invention

XX
SQ Sequence 330 AA;

Query Match 99.5%; Score 1756; DB 6; Length 330;
Best Local Similarity 99.4%; Pred. No. 2.4e-123;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSS 60
DB 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSS 60

QY 61 GLYSLSVVTVFPSSSLGTQTYICNVNHPKSNPKVDKVEPKSCDKTHTCPPCPAPPELLAG 120
DB 61 GLYSLSVVTVFPSSSLGTQTYICNVNHPKSNPKVDKVEPKSCDKTHTCPPCPAPPELLAG 120

QY 121 PSVFLFPPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNATKPREEQYN 180
DB 121 PSVFLFPPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNATKPREEQYN 180

QY 181 STYRVSVLTVLHQDLNKGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVTLPPSRDE 240
DB 181 STYRVSVLTVLHQDLNKGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVTLPPSRDE 240

QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
DB 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300

QY 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330
DB 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330

RESULT 39
AAO31102
ID AAO31102 standard; protein; 330 AA.
XX
AC AAO31102;
XX

DT 06-OCT-2003 (first entry)
XX Human A2-G8 SCF antibody heavy chain constant region.
DE
XX Human; antibody; stem cell factor; mast cell growth factor; asthma; SCF;
KW steel factor; c-kit ligand; gene therapy; heavy chain.
XX
OS Homo sapiens.
XX
PN WO2003051311-A2.
XX
PD 26-JUN-2003.
XX
PF 16-DEC-2002; 2002WO-US040227.
XX
PR 17-DEC-2001; 2001US-0342174P.
XX
PA (FARB) BAYER CORP.
XX
PI Takeuchi T, Tomkinson A, Neben S;
XX
XX WPI; 2003-523500/49.
DR N-PSDB; AAL62618.
XX
PT New purified human antibody that binds to stem cell factor protein,
PT useful for preparing a composition for treating asthma.
XX
XX Example 10; Page 47-48; 94pp; English.
XX
XX The invention provides human antibodies that bind to stem cell factor
XX (SCF) protein. SCF is also known as mast cell growth factor, steel factor
XX or c-kit ligand. Antibodies of the invention are useful for preparing
XX compositions for treating asthma. They are also used in gene therapy. The
XX present sequence is human SCF antibody heavy chain constant region
XX
SQ Sequence 330 AA;

Query Match 99.5%; Score 1756; DB 6; Length 330;
Best Local Similarity 99.4%; Pred. No. 2.4e-123;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSS 60
DB 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSS 60

QY 61 GLYSLSVVTVFPSSSLGTQTYICNVNHPKSNPKVDKVEPKSCDKTHTCPPCPAPPELLAG 120
DB 61 GLYSLSVVTVFPSSSLGTQTYICNVNHPKSNPKVDKVEPKSCDKTHTCPPCPAPPELLAG 120

QY 121 PSVFLFPPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNATKPREEQYN 180
DB 121 PSVFLFPPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNATKPREEQYN 180

QY 181 STYRVSVLTVLHQDLNKGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVTLPPSRDE 240
DB 181 STYRVSVLTVLHQDLNKGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVTLPPSRDE 240

QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
DB 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300

QY 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330
DB 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330

RESULT 40
ABR55836
ID ABR55836 standard; protein; 330 AA.
XX
AC ABR55836;
XX
DT 02-SEP-2003 (first entry)

XX DE Anti-Ang-2 antibody IgG1 constant region.
XX KW Ang-2; angiotensin-2; anorectic; cytostatic; antiarteriosclerotic;
KW gynaecological; antiinflammatory; osteopathic; antipsoriatic; cancer;
XX angiogenesis; antibody; human.
XX OS Homo sapiens.
XX PN WO2003030833-A2.
XX PD 17-APR-2003.
XX XX 11-OCT-2002; 2002WO-US032613.
XX PF 11-OCT-2001; 2001US-0328604P.
XX PR 10-OCT-2002; 2002US-00269805.
XX XX (AMGE-) AMGEN INC.
XX PA Olinar JD;
XX PI WPI; 2003-504963/47.
XX DR New specific binding agents (i.e. anti-Angiotensin-2 antibodies), useful
XX PT for inhibiting undesired angiogenesis, or treating e.g. cancers, obesity,
XX PT hemangioma, arteriosclerosis, atherosclerosis or endometriosis.
XX XX Example 4; Page 96; 161pp; English.
XX PS The invention relates to a specific binding agent, which comprises at
XX CC least one peptide selected from any of 62 peptides (ABR55769-830) or its
XX CC fragment. The binding agents are antibodies that recognize and bind to
XX CC angiotensin-2 (Ang-2). The specific binding agent, particularly the
XX CC antibody, is useful for inhibiting undesired angiogenesis, treating
XX CC cancers, inhibiting undesired angiogenesis, modulating or inhibiting Ang-
XX CC 2 activity, modulating vascular permeability or plasma leakage, or
XX CC treating a disease (e.g. ocular neovascular disease, obesity,
XX CC haemangioma, arteriosclerosis, inflammatory disease,
XX CC inflammatory disorders, atherosclerosis, endometriosis, neoplastic
XX CC disease, bone-related disease, or psoriasis) in a mammal. The present
XX CC sequence represents a human IgG1 constant region of an anti-Ang-2
XX CC antibody
XX SQ Sequence 330 AA;
Query Match 99.5%; Score 1756; DB 6; Length 330;
Best Local Similarity 99.4%; Pred. No. 2.4e-123;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1 ASTKGPSVFPPLAPSSKSTSGGTAALGCLVKDYFPEPTVSNWNSGALTSGVHTFPAVLQSS 60
Db 1 ASTKGPSVFPPLAPSSKSTSGGTAALGCLVKDYFPEPTVSNWNSGALTSGVHTFPAVLQSS 60
QY 61 GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHHTCCPPAPPELAGA 120
Db 61 GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHHTCCPPAPPELAGG 120
QY 121 PSVFLFPKPKDPTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 180
Db 121 PSVFLFPKPKDPTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 180
QY 181 STYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Db 181 STYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRW 300
Db 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRW 300
QY 301 QGQVFCSWMEALHNHYTQKSLSLSPGK 330
Db 301 QGQVFCSWMEALHNHYTQKSLSLSPGK 330

RESULT 41

AAO30893
XX ID AAO30893 standard; protein; 330 AA.
XX AC AAO30893;
XX XX 22-SEP-2003 (first entry)
XX DT Human immunoglobulin gamma (IgG) 1 constant region.
XX DE Cytokine; interleukin-2; IL-2; cancer; viral infection; immune disorder;
XX KW gene therapy; immunoglobulin; Ig; human.
XX XX Homo sapiens.
XX OS WO2003048334-A2.
XX PN 12-JUN-2003.
XX PD 04-DEC-2002; 2002WO-US038780.
XX PF 04-DEC-2001; 2001US-0337113P.
XX PR 12-APR-2002; 2002US-0371966P.
XX XX (EMDL-) EMD LEXIGEN RES CENT CORP.
XX PA Gillies SD;
XX PI WPI; 2003-513757/48.
XX DR New fusion protein comprising a non-IL-2 moiety fused to a mutant IL-2
XX PT moiety, useful for preparing a composition for treating cancer, viral
XX CC infections or immune disorders.
XX PS Example 1; Page 51-53; 71pp; English.
XX CC The invention relates to cytokine fusion proteins with increased
XX CC therapeutic index and methods for increasing the therapeutic index of
XX CC such fusion proteins. The fusion protein comprises a non-interleukin-2
XX CC (IL-2) moiety fused to a mutant IL-2 moiety. It is useful for preparing a
XX CC composition for treating cancer, viral infections or immune disorders.
XX CC The fusion protein is also used in gene therapy. The present sequence is
XX CC human immunoglobulin gamma (IgG) constant region. This sequence is used
XX CC to illustrate the method of the invention
XX SQ Sequence 330 AA;
Query Match 99.5%; Score 1756; DB 6; Length 330;
Best Local Similarity 99.4%; Pred. No. 2.4e-123;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1 ASTKGPSVFPPLAPSSKSTSGGTAALGCLVKDYFPEPTVSNWNSGALTSGVHTFPAVLQSS 60
Db 1 ASTKGPSVFPPLAPSSKSTSGGTAALGCLVKDYFPEPTVSNWNSGALTSGVHTFPAVLQSS 60
QY 61 GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHHTCCPPAPPELAGA 120
Db 61 GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHHTCCPPAPPELAGG 120
QY 121 PSVFLFPKPKDPTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 180
Db 121 PSVFLFPKPKDPTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 180
QY 181 STYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Db 181 STYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRW 300
Db 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRW 300

```

QY 301 OQGNVFCSCVMHEALHNHYTKSLSPGK 330
DB 301 OQGNVFCSCVMHEALHNHYTKSLSPGK 330

RESULT 42
ADFL1389
ID ADFL1389 standard; protein; 330 AA.
AC ADFL1389;
XX
XX 12-FEB-2004 (first entry)
DE Anti-OPGL antibody heavy chain constant region SEQ ID NO:2.
KW human; antibody; osteoprotegerin ligand; OPGL; osteopenic disorder;
KW osteopathic; antiarthritic; cytostatic; gene therapy; bone disorder;
KW osteoporosis; bone loss; arthritis; Paget's disease; osteopenia.
XX
OS Homo sapiens.
XX
XX WO2003086289-A2.
XX
XX PD
XX
XX 23-OCT-2003.
XX
XX 07-APR-2003; 2003WO-US010749.
XX
XX 05-APR-2002; 2002US-0370407P.
XX
XX (AMGE-) AMGEN INC.
XX
XX Boyle WJ, Medlock E, Sullivan JK, Elliott RL, Martin F, Huang H;
XX WPI; 2003-845253/78.
XX N-PSDB; ADFL1388.
XX
XX New isolated antibody that specifically binds osteoprotegerin ligand,
XX useful for diagnosing or treating bone disorders, such as osteoporosis,
XX bone loss from arthritis, Paget's disease or osteopenia.
XX
XX Example 3; SEQ ID NO 2; 156pp; English.
XX
XX The present invention describes an isolated human antibody (I) that
XX specifically binds osteoprotegerin ligand (OPGL). Also described: (1) a
XX pharmaceutical composition comprising a pharmaceutical carrier and a
XX therapeutic amount of (I); (2) methods of treating an osteopenic disorder
XX in a patient, comprising administering to a patient the pharmaceutical
XX composition of (I) or a pharmaceutical amount of (I); and (3) a method
XX for detecting OPGL in a biological sample, comprising contacting the
XX sample with (I) under conditions that allow for binding of the antibody
XX to OPGL, and measuring the level of bound antibody in the sample. (I) has
XX osteopathic, antiarthritic and cytostatic activities, and can be used in
XX gene therapy. The composition and methods are useful in diagnosing or
XX treating bone disorders, such as osteoporosis, bone loss from arthritis,
XX Paget's disease or osteopenia. The antibody (I) may also be used for
XX detecting OPGL in biological samples and in identifying cells or tissues
XX that produce the protein. The present sequence represents a sequence
XX which is used in the exemplification of the present invention.
XX
XX Sequence 330 AA;

Query Match 99.5%; Score 1756; DB 7; Length 330;
Best Local Similarity 99.4%; Pred. No. 2.4e-123;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
DB 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
QY 61 GLYSLSSVTVTPSSSLGTQTYICNVNHPKPSNTKVDKVPKSCDKTHTCPCPAPPELLAG 120
DB 61 GLYSLSSVTVTPSSSLGTQTYICNVNHPKPSNTKVDKVPKSCDKTHTCPCPAPPELLAG 120

QY 121 PSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREEQYN 180
DB 121 PSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREEQYN 180
QY 181 STYRVSVLTVLHODWLNKKEYCKVSNKALPAPIEKTISKAKGQPREPQVYVTLPPSRDE 240
DB 181 STYRVSVLTVLHODWLNKKEYCKVSNKALPAPIEKTISKAKGQPREPQVYVTLPPSRDE 240
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRW 300
DB 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRW 300
QY 301 OQGNVFCSCVMHEALHNHYTKSLSPGK 330
DB 301 OQGNVFCSCVMHEALHNHYTKSLSPGK 330

RESULT 43
ADE97351
ID ADE97351 standard; protein; 330 AA.
XX
XX AC ADE97351;
XX
XX DT 12-FEB-2004 (first entry)
XX
XX DE Human IgG1 heavy chain constant region protein - SEQ ID 20.
XX
XX immunoadhesin; immunoglobulin heavy chain; J chain; joining; toxin;
XX virucide; antibacterial; anthrax; rhinovirus infection; common cold;
XX intercellular adhesion molecule; ICAM-1; human; constant region; IgG.
XX
XX Homo sapiens.
XX
XX WO2003064992-A2.
XX
XX 07-AUG-2003.
XX
XX 25-OCT-2002; 2002WO-US034197.
XX
XX 26-OCT-2001; 2001US-00047542.
XX
XX (PLAN-) PLANET BIOTECHNOLOGY INC.
XX (LARR/) LARRICK J W.
XX (WYCO/) WYCOFF K L.
XX Larrick JW, Wycoff KL;
XX WPI; 2003-636816/60.
XX N-PSDB; ADE97350, ADE97376.
XX
XX New immunoadhesin, useful for treating anthrax and rhinovirus, comprises
XX chimeric toxin receptor protein linked to immunoglobulin heavy chain, and
XX J chain and secretory component associated with the chimeric toxin
XX receptor protein.
XX
XX Disclosure; SEQ ID NO 20; 288pp; English.
XX
XX The invention relates to a novel immunoadhesin comprising a chimeric
XX toxin receptor protein consisting of a toxin receptor protein linked to
XX at least a portion of an immunoglobulin heavy chain with a J (joining)
XX chain and secretory component (SC) associated with the chimeric toxin
XX receptor protein. The immunoadhesin comprises a chimeric bacterial or
XX viral toxin receptor protein and the immunoadhesin has plant-specific
XX glycosylation. The immunoadhesin of the invention demonstrates virucide
XX and antibacterial activities and may be useful for reducing the binding
XX of a viral or bacterial antigen to a host cell and thus for treating or
XX preventing anthrax, as well as human rhinovirus infection which results
XX in the common cold. The current sequence is that of the human
XX immunoadhesin-related protein of the invention.
XX
XX Sequence 330 AA;

Query Match 99.5%; Score 1756; DB 7; Length 330;

```

Best Local Similarity 99.4%; Pred. No. 2.4e-123; Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
QY 1	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
DB 1	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
QY 61	GLYSLSVVTVPSSSLGTQTYICNVNHPKSNKVDKVEPKSCDKTHTCPCPAPELAGA 120
DB 61	GLYSLSVVTVPSSSLGTQTYICNVNHPKSNKVDKVEPKSCDKTHTCPCPAPELAGG 120
QY 121	PSVFLFPPKPKDITLMISRTPEVTCVVVDVSHEDPEVKENWYDGVVEVNAKTKPREEQYN 180
DB 121	PSVFLFPPKPKDITLMISRTPEVTCVVVDVSHEDPEVKENWYDGVVEVNAKTKPREEQYN 180
QY 181	STYRVVSVLTVQLHODWLNKGEYKCKVSNKALPAPIEKTIISKAKGQPRPQVYVTLPPSRDE 240
DB 181	STYRVVSVLTVQLHODWLNKGEYKCKVSNKALPAPIEKTIISKAKGQPRPQVYVTLPPSRDE 240
QY 241	LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300
DB 241	LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300
QY 301	QCGNVFSCVMHEALHNHYTQKSLSLSPGK 330
DB 301	QCGNVFSCVMHEALHNHYTQKSLSLSPGK 330
RESULT 44 ADF83605 ID ADF83605 standard; protein; 330 AA.	
AC	ADF83605;
DT	26-FEB-2004 (first entry)
DE	Cytokine receptor related human Zcytor19 protein, SEQ ID No 15.
KW	soluble cytokine receptor; virucide; cytostatic; immunosuppressive;
KW	anti-rheumatic; antiarthritic; neuroprotective; antidiabetic;
KW	nephrotropic; antiinflammatory; viral infection; cancer;
KW	autoimmune disease; ligand blocking; human.
OS	Homo sapiens.
PN	WO2003089603-A2.
XX	
XX	30-OCT-2003.
XX	
PF	18-APR-2003; 2003WO-US012030.
XX	
PR	19-APR-2002; 2002US-0373813P.
XX	
PA	(ZYMO) ZYMOGENETICS INC.
XX	
PI	Presnell SR, Xu W, Novak JE, Whitmore TE, Grant FJ;
PI	Kindsvogel WR, Klucher KM;
XX	
DR	WPI; 2003-854110/79.
DR	N-PSDB; ADF83604.
XX	
PT	New Zcytor19 receptor polypeptides and polynucleotides, useful for
PT	detecting and treating viral infections, cancer or autoimmune diseases
PT	(e.g. rheumatoid arthritis, multiple sclerosis, diabetes or
PT	glomerulonephritis).
XX	
PS	Example 7; SEQ ID NO 15; 186pp; English.
XX	
CC	The invention relates to a novel isolated polynucleotide that encodes a
CC	soluble cytokine receptor polypeptide. The encoded polypeptide comprises:
CC	a sequence of 211 amino acids fully defined in the specification, or a
CC	region from amino acid residues 21-163, 1-163, 21-211 or 1-211; or a
CC	sequence at least 90% identical to the 211 amino acids. The cytokine

CC	polynucleotides and polypeptides have the following activities: virucide,
CC	cytostatic, immunosuppressive, antirheumatic, antiarthritic,
CC	neuroprotective, antidiabetic, nephrotropic, and antiinflammatory. The
CC	composition and methods are useful in detecting and treating viral
CC	infections, cancer or autoimmune diseases (e.g. rheumatoid arthritis,
CC	multiple sclerosis, diabetes, glomerulonephritis or inflammatory bowel
CC	diseases) in vitro and in vivo. The ligand-binding receptor polypeptides
CC	may also be used in blocking ligand activity in vitro and in vivo. This
CC	sequence represents a cytokine receptor related human protein of the
XX	invention.
SQ	Sequence 330 AA;
Query Match 99.5%; Score 1756; DB 7; Length 330; Best Local Similarity 99.4%; Pred. No. 2.4e-123; Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
QY 1	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
DB 1	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
QY 61	GLYSLSVVTVPSSSLGTQTYICNVNHPKSNKVDKVEPKSCDKTHTCPCPAPELAGA 120
DB 61	GLYSLSVVTVPSSSLGTQTYICNVNHPKSNKVDKVEPKSCDKTHTCPCPAPELAGG 120
QY 121	PSVFLFPPKPKDITLMISRTPEVTCVVVDVSHEDPEVKENWYDGVVEVNAKTKPREEQYN 180
DB 121	PSVFLFPPKPKDITLMISRTPEVTCVVVDVSHEDPEVKENWYDGVVEVNAKTKPREEQYN 180
QY 181	STYRVVSVLTVQLHODWLNKGEYKCKVSNKALPAPIEKTIISKAKGQPRPQVYVTLPPSRDE 240
DB 181	STYRVVSVLTVQLHODWLNKGEYKCKVSNKALPAPIEKTIISKAKGQPRPQVYVTLPPSRDE 240
QY 241	LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300
DB 241	LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300
QY 301	QCGNVFSCVMHEALHNHYTQKSLSLSPGK 330
DB 301	QCGNVFSCVMHEALHNHYTQKSLSLSPGK 330
RESULT 45 ADF75001 ID ADF75001 standard; protein; 330 AA.	
AC	ADF75001;
DT	26-FEB-2004 (first entry)
DE	Human Ig gamma-1 heavy chain constant region.
KW	Human; fusion protein; epitope; major histocompatibility complex;
KW	MHC type II; T-cell receptor; immunogenicity; glycosylation; cytokine;
KW	hormone.
OS	Homo sapiens.
XX	
PN	US2003166877-A1.
XX	
PD	04-SEP-2003.
XX	
PF	29-MAR-2002; 2002US-00112582.
XX	
PR	30-MAR-2001; 2001US-0280625P.
XX	
PA	(LEXI-) LEXIGEN PHARM CORP.
XX	
PI	Gillies SD, Way J, Hamilton AA;
PI	WPI; 2003-898110/82.
DR	
XX	
PT	Reducing the immunogenecity of a fusion protein by identifying a

PT candidate T-cell epitope within a junction region spanning a fusion
PT protein and changing an amino acid within the junction region.
XX
PS Disclosure; SEQ ID NO 1; 34pp; English.
XX
XX The invention relates to reducing the immunogenicity of a fusion protein
CC comprising: identifying a candidate T-cell epitope (binding to MHC class
CC II (major histocompatibility complex)) within a junction region spanning
CC a fusion protein and changing an amino acid within the junction region to
CC reduce the ability of the candidate T-cell epitope to interact with a T-
CC cell receptor. Also included are a method for reducing the immunogenicity
CC of a fusion protein, a fusion protein with reduced immunogenicity and a
CC nucleic acid encoding the fusion protein with reduced immunogenicity. The
CC method also comprises introducing a glycosylation site within 5 or 2
CC amino acids of the fusion junction. The first protein of the fusion
CC protein comprises IgG1 or IgG2, having a C-terminal that is linked to the
CC N-terminus of the second protein. The second protein comprises cytokine
CC or hormone activity. The junction region comprises a spacer or linker. It
CC comprises an Asn-X-Ser/Thr-Gly-amino acid sequence, where X is any amino
CC acid. It comprises an IgG sequence having an ARAI amino acid sequence
CC instead of an LSS amino acid sequence. The method is useful for reducing
CC the immunogenicity of a fusion protein. The present sequence is a human
CC IgG protein suitable for inclusion in a fusion protein.
XX
SQ Sequence 330 AA;

Query Match 99.5%; Score 1756; DB 7; Length 330;
Best Local Similarity 99.4%; Pred. No. 2.4e-123;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSS 60
DB 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSS 60
QY 61 GLYSLSVVTVFPSSSLGTQTVICNVNHNKPSNTKVDKVEPKSCDKTHTCPCPAPELAGA 120
DB 61 GLYSLSVVTVFPSSSLGTQTVICNVNHNKPSNTKVDKVEPKSCDKTHTCPCPAPELAGG 120
QY 121 PSVLFPPPKDXTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNATKPREQYN 180
DB 121 PSVLFPPPKDXTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNATKPREQYN 180
QY 181 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
DB 181 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSLKLTVDKSRW 300
DB 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSLKLTVDKSRW 300
QY 301 QGQNVFSCSVNHEALHNHYTQKSLSLSPGK 330
DB 301 QGQNVFSCSVNHEALHNHYTQKSLSLSPGK 330

RESULT 46
ADM41537
ID ADM41537 standard; protein; 330 AA.
XX
AC ADM41537;
XX
DT 03-JUN-2004 (first entry)
XX
DE Anti-interleukin-1 receptor type 1 antibody heavy chain constant region.
XX Human; monoclonal antibody; antibody; interleukin-1; receptor;
KW antiasthmatic; antiinflammatory; dermatological; antiallergic;
KW protozoacide; antirheumatic; antiarthritic; osteopathic; vasotropic;
KW analgesic; antidiabetic; nephrotropic; antianaemic; nootropic;
KW anticonvulsant; dermatological; antigitout; antiparkinsonian; antidiabetic;
KW cytostatic.
XX
OS Homo sapiens.

XX WO2004022718-A2.
XX 18-MAR-2004.
XX
XX 05-SEP-2003; 2003WO-US027978.
XX
XX 06-SEP-2002; 2002US-0408719P.
XX (AMGE-) AMGEN INC.
XX
XX Varnum B, Vezina C, Witte A, Qian X, Martin F, Huang H;
PI Elliott G;
XX
XX WPI; 2004-248462/23.
XX N-PSDB; ADM41536.
XX
XX Isolated human antibody that specifically binds interleukin-1 receptor
XX type 1 (IL-1R1) useful for treating IL-1 mediated diseases such as
XX rheumatoid arthritis, osteoarthritis and inflammatory conditions.
XX
XX Disclosure; SEQ ID NO 2; 179pp; English.
XX
XX The present sequence is that of a human anti-interleukin-1 receptor type
XX 1 (IL-1R1) monoclonal antibody (Mab) heavy chain IgG1 constant region.
XX Human Mabs to IL-1R1 were prepared using the HCo7 strain of transgenic
XX mice, which expresses human antibody genes. These mice were immunised
XX with purified recombinant IL-1R1, and splenocytes from immunised mice
XX were fused to a mouse myeloma cell line to generate hybridomas.
XX Hybridomas which secreted a Mab that bound with high avidity to IL-1R1
XX were selected. The Mabs inhibit IL-1 signalling by competing with IL-
XX lbeta and IL-1alpha binding to IL-1R. These Mabs, as well as single chain
XX antibodies single chain Fv antibodies, Fab antibodies, Fab' antibodies
XX and (Fab')2 antibodies derived from them, are used in methods of treating
XX IL-1 mediated diseases or for detecting the amount of IL-1R1 in a sample.
XX IL-1 mediated diseases include acute pancreatitis, amyotrophic lateral
XX sclerosis, Alzheimer's disease, cachexia, anorexia, asthma, scleroderma,
XX atherosclerosis, autoimmune vasculitis, chronic fatigue syndrome,
XX Clostridium associated illnesses, coronary conditions, cancer including
XX leukaemia and tumour metastasis, diabetes, endometriosis, fever,
XX fibromyalgia, glomerulonephritis, graft versus host disease,
XX osteoarthritis, rheumatoid arthritis, inflammatory eye disease,
XX ischaemia, Kawasaki's disease, learning impairment, lung disease,
XX multiple sclerosis, myopathy, osteoporosis, pain, Parkinson's disease,
XX periodontal disease, pre-term labour, psoriasis, reperfusion injury,
XX septic shock, side effects of radiation therapy, temporal mandibular
XX joint disease, sleep disturbance, uveitis, or an inflammatory condition
XX resulting from strain, sprain, cartilage damage, trauma, orthopaedic
XX surgery, infection or other disease processes.
XX
SQ Sequence 330 AA;
Query Match 99.5%; Score 1756; DB 8; Length 330;
Best Local Similarity 99.4%; Pred. No. 2.4e-123;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSS 60
DB 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSS 60
QY 61 GLYSLSVVTVFPSSSLGTQTVICNVNHNKPSNTKVDKVEPKSCDKTHTCPCPAPELAGA 120
DB 61 GLYSLSVVTVFPSSSLGTQTVICNVNHNKPSNTKVDKVEPKSCDKTHTCPCPAPELAGG 120
QY 121 PSVLFPPPKDXTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNATKPREQYN 180
DB 121 PSVLFPPPKDXTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNATKPREQYN 180
QY 181 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
DB 181 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSLKLTVDKSRW 300

Db 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRW 300
QY 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330
Db 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330

RESULT 47
ADM68911
ID ADM68911 standard; protein; 330 AA.
XX
AC ADM68911;
XX
DT 03-JUN-2004 (first entry)
XX
DE Human IgG1 heavy chain.
XX
KW Human; batch reformatting vector; ligand screening; phagemid;
KW phage display vector; pBRV; pRRV; internal ribosome entry site; IRBS;
KW rapid reformatting vector; IgG1; immunoglobulin; heavy chain.
XX
OS Homo sapiens.
XX
PN US2003224408-A1.
XX
PD 04-DEC-2003.
XX
PF 07-MAR-2003; 2003US-00383902.
XX
PR 07-MAR-2002; 2002US-0362403P.
XX
PA (DYAX-) DYAX CORP.
XX
PI Hoogenboom HRJM, Mullberg J, Ladner RC;
XX
WPI: 2004-119700/12.
DR N-PSDB; ADM68909.
XX

Screening ligands, by providing initial nucleic acid cassettes, modifying
cassette in single reaction mixture, introducing modified cassette into
mammalian cell, expressing modified cassette in transfected cells.

Disclosure; SEQ ID NO 6; 63pp; English.

The invention relates to screening ligands, by providing several initial
nucleic acid cassettes, modifying each nucleic acid cassette in single
reaction mixture so that it is functional in a second expression system,
introducing each modified nucleic acid cassette into a mammalian cell to
produce a mixture of transfected cells, and expressing each modified
nucleic acid cassette in transfected cells. Also included are screening
nucleic acids (involving providing a number of first different nucleic
acids, each encoding a hetero oligomeric candidate ligand, selecting a
subset of a number of first different nucleic acids by contacting
candidate ligands encoded by the members of a number of first different
nucleic acids to a target, reformatting each nucleic acid of the subset
for mammalian cell expression, such that each nucleic acid encodes a
hetero-oligomeric protein that includes a first functional domain of one
subunit of the candidate ligand, a second functional domain of another
subunit of the candidate ligand and an effector domain not encoded by the
nucleic acids of a number of first different nucleic acids, introducing
members of the subset into a mammalian cell to form several expression
cells that can produce the protein that includes the functional domain
and the effector domain, and screening the expression cells to identify
cells that produce at least a threshold amount of a ligand-effector
domain fusion protein) and evaluating display library members (involving
providing several display library members, determining an assessment for
each library member with respect to a property, storing information about
the assessments of the library members in a computer database, filtering
the information to identify a subset of the library members, and
reformatting each member of the subset for expression in a mammalian cell
by a method that comprises disposing nucleic acid for each member of the
selected subset into a single container). The method is useful for

CC screening ligands. Bacterial and mammalian expression vectors
CC (reformatting vectors) were prepared that support the transfer
CC individually or en masse of Fab heavy and light chain genes from a
CC bacterial expression vector to a mammalian expression vector. Typically,
CC the display vector was a phagemid or phage display vector, which mediate
CC the expression of the Fab on the surface of the bacteriophage M13 or fd.
CC The Fab-encoding segment was transferred from the bacterial display
CC vector to the eukaryotic vector, e.g., pBRV or pRRV by restricting the
CC sites of pBRV (batch reformatting vector) or pRRV (rapid reformatting
CC vector). This vector contained a CMV eukaryotic promoter in place of the
CC first bacterial leader sequence. The VH-CH1 sequence was no longer fused
CC to gene III but was fused in-frame to a sequence encoding an
CC immunoglobulin Fc region, e.g., including Hinge-CH2-CH3. Two intervening
CC segments which were inserted between heavy and light chain coding
CC sequences were I-ES between the EcoRI and XbaI site for internal ribosome
CC entry and translation of the second coding region. The present sequence
CC represents the human IgG1 heavy chain for use in the constructs of the
CC method of the invention.
XX
SQ Sequence 330 AA;
Query Match 99.5%; Score 1756; DB 8; Length 330;
Best Local Similarity 99.4%; Pred. No. 2.4e-123;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
Db 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
QY 61 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHCTCPCPAPELAGA 120
Db 61 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHCTCPCPAPELGG 120
QY 121 PSVFLFPPPKPXTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNNAKTKPREEQYN 180
Db 121 PSVFLFPPPKPXTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNNAKTKPREEQYN 180
QY 181 STYRVSVLTVLHQDLNGKEYKCKVSNKALPAPIEKTIISKAKGQPREPQVYTLPPSRDE 240
Db 181 STYRVSVLTVLHQDLNGKEYKCKVSNKALPAPIEKTIISKAKGQPREPQVYTLPPSRDE 240
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRW 300
Db 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRW 300
QY 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330
Db 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330

RESULT 48
ADR43460
ID ADR43460 standard; protein; 330 AA.
XX
AC ADR43460;
XX
DT 04-NOV-2004 (first entry)
XX
DE Heavy chain constant region of clone Mab 136.
XX
KW antibody; variable light chain; variable heavy chain; Antiallergic;
KW Dermatological; Immunosuppressive; IGE; asthma; allergic rhinitis;
KW eczema; urticaria; atopic dermatitis; food allergy; CDR.
XX
OS Unidentified.
XX
PN WO2004070011-A2.
XX
PD 19-AUG-2004.
XX
PF 02-FEB-2004; 2004WO-US002894.
XX

```
PR 01-FEB-2003; 2003US-0444229P.
XX (TANO-) TANOX INC.
XX Singh S, Foster C, Wu H;
XX WPI; 2004-604433/58.
XX New high affinity human monoclonal antibodies, particularly those
PT directed against isotypic determinants of immunoglobulin E, useful for
PT asthma, allergic rhinitis, eczema, urticaria, atopic dermatitis, or a
PT food allergy.
XX
XX Claim 15; SEQ ID NO 60; 101pp; English.
XX
CC The present invention relates to an antibody comprising a variable light
CC chain region or a variable heavy chain region. The antibody and methods
CC are useful for treating a disorder associated with an abnormally high IgE
CC level, e.g. asthma, allergic rhinitis, eczema, urticaria, atopic
CC dermatitis, or a food allergy. The present sequence represents an
CC antibody region of clone Mab 136.
XX
SQ Sequence 330 AA;
Query Match 99.5%; Score 1756; DB 8; Length 330;
Best Local Similarity 99.4%; Pred. No. 2.4e-123;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
DB 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
QY 61 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPPCPAPELAGA 120
DB 61 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPPCPAPELAGG 120
QY 121 PSVFLFPPKPKDITLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREEQYN 180
DB 121 PSVFLFPPKPKDITLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREEQYN 180
QY 181 STYRVSVSLTVLHQDLNGLNGKEYKCKVSNKALPAPIEKTIISKAGQPREPQVYVTLPPSRDE 240
DB 181 STYRVSVSLTVLHQDLNGLNGKEYKCKVSNKALPAPIEKTIISKAGQPREPQVYVTLPPSRDE 240
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSPFLYSKLTVDKSRW 300
DB 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSPFLYSKLTVDKSRW 300
QY 301 QQGNVFSCVMHEALHNHYTOKSLSPGK 330
DB 301 QQGNVFSCVMHEALHNHYTOKSLSPGK 330
RESULT 49
ADR31605
ID ADR31605 standard; protein; 330 AA.
XX
XX ADR31605;
XX
XX 04-NOV-2004 (first entry)
XX Human IgG1 CH1-3 protein.
XX
XX Antibody; diagnostic; prophylaxis; therapy; heavy chain constant region;
XX CH; human; IgG1.
XX
XX Homo sapiens.
XX
XX WO2004070010-A2.
XX
XX 19-AUG-2004.
XX
XX 02-FEB-2004; 2004WO-US002892.
```

```
XX 01-FEB-2003; 2003US-0444229P.
XX (TANO-) TANOX INC.
XX Singh S, Foster C, Wu H;
XX WPI; 2004-604432/58.
XX
XX Generating a humanized, high affinity antibody from an antibody of
PT interest comprises selecting a suitable human template as the framework
PT for the H and L chain variable domains of the high affinity antibody to
PT be made.
XX
XX Example 11; SEQ ID NO 60; 100pp; English.
XX
CC The invention relates to a method for generating a humanised high
CC affinity antibody from an antibody of interest. The method involves
CC selecting a suitable human template as the framework for the H (heavy)
CC and L (light) chain variable (V) domains of the high affinity antibody to
CC be made. The method is useful for generating high affinity antibodies
CC useful in diagnostics, prophylaxis and treatment of diseases. The present
CC sequence is human IgG1 CH (heavy chain constant region) protein.
XX
XX Sequence 330 AA;
Query Match 99.5%; Score 1756; DB 8; Length 330;
Best Local Similarity 99.4%; Pred. No. 2.4e-123;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
DB 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
QY 61 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPPCPAPELAGA 120
DB 61 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPPCPAPELAGG 120
QY 121 PSVFLFPPKPKDITLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREEQYN 180
DB 121 PSVFLFPPKPKDITLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREEQYN 180
QY 181 STYRVSVSLTVLHQDLNGLNGKEYKCKVSNKALPAPIEKTIISKAGQPREPQVYVTLPPSRDE 240
DB 181 STYRVSVSLTVLHQDLNGLNGKEYKCKVSNKALPAPIEKTIISKAGQPREPQVYVTLPPSRDE 240
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSPFLYSKLTVDKSRW 300
DB 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSPFLYSKLTVDKSRW 300
QY 301 QQGNVFSCVMHEALHNHYTOKSLSPGK 330
DB 301 QQGNVFSCVMHEALHNHYTOKSLSPGK 330
RESULT 50
ADS87909
ID ADS87909 standard; protein; 330 AA.
XX
XX ADS87909;
XX
XX 18-NOV-2004 (first entry)
XX
XX Anti-IFN-gamma antibody heavy chain constant region SEQ ID NO:2.
DE
XX antibody; interferon gamma; IFN-gamma; IFN-gamma mediated disease;
XX anti-inflammatory; antiarthritic; anti-HIV; antianaemic;
XX anti-arteriosclerotic; hepatotropic; antipsoriatic; antidiabetic;
XX gene therapy; AIDS; rheumatoid arthritis; inflammatory bowel disease;
XX multiple sclerosis; Addison's disease; type I diabetes; psoriasis;
XX myasthenia gravis; cirrhosis; lupus nephritis; atherosclerosis;
XX systemic lupus erythematosus; sarcoidosis; Sjogren's syndrome;
XX vasculitis; Grave's disease; Guillain-Barre syndrome; haemolytic anaemia;
```

KW immunoglobulin G1; IgG1; anti-IFN-gamma antibody; human.
XX Homo sapiens.
XX WO2004034988-A2.
XX PD 29-APR-2004.
XX PF 14-OCT-2003; 2003WO-US032678.
XX PR 16-OCT-2002; 2002US-0419057P.
XX PR 17-JUN-2003; 2003US-0479241P.
XX PA (AMGE-) AMGEN INC.
XX PI Welcher A, Chute H, Li L, Huang H;
XX WPI; 2004-348323/32.
XX DR N-PSDB; ADS87908.
XX New antibody that binds specifically to IFN-gamma and comprising a heavy
PT chain CDR3, useful in preparing a composition for treating IFN-gamma
PT mediated diseases e.g., AIDS, psoriasis, myasthenia gravis, cirrhosis or
PT atherosclerosis.
XX Example 4; SEQ ID NO 2; 115pp; English.
PS The present invention describes an isolated antibody which binds
CC specifically to interferon (IFN)-gamma and comprises a heavy chain
CC complementarity determining region (CDR) 3 having a sequence comprising
CC at least 7 amino acids of the 8-amino acid sequence of SEQ ID NO:36
CC (ADS87943) in the same order and spacing, or an amino acid sequence of
CC (ADS87943) in the same order and spacing, or an isolated polynucleotide
CC SEQ ID NO:37 (ADS87944). Also described: (1) an isolated polynucleotide
CC encoding the antibody; (2) a method of treating an IFN-gamma mediated
CC disease; and (3) a composition comprising a carrier and the antibody. The
CC IFN-gamma binding antibody has anti-inflammatory, antiarthritic, anti-
CC HIV, antianemic, antiarteriosclerotic, hepatotropic, antipsoriatic and
CC antidiabetic activities, and can be used in gene therapy. The antibody is
CC useful in treating IFN-gamma mediated disease, e.g., AIDS, rheumatoid
CC arthritis, inflammatory bowel disease, multiple sclerosis, Addison's
CC disease, type I diabetes, psoriasis, myasthenia gravis, cirrhosis, lupus
CC nephritis, atherosclerosis, systemic lupus erythematosus, sarcoidosis,
CC Sjogren's syndrome, vasculitis, Grave's disease, Guillain-Barre syndrome
CC or haemolytic anaemia. The present sequence represents an immunoglobulin
CC G1 (IgG1) anti-IFN-gamma heavy chain constant region, which is used in
CC the exemplification of the present invention.
XX SQ Sequence 330 AA;
Query Match 99.5%; Score 1756; DB 8; Length 330;
Best Local Similarity 99.4%; Pred. No. 2.4e-123;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1 ASTKGPSVFPFLAPSSTSGGTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSS 60
DB 1 ASTKGPSVFPFLAPSSTSGGTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSS 60
QY 61 GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPCPAPELAGA 120
DB 61 GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPCPAPELAGG 120
QY 121 PSVFLFPKPKDGLMIKSTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREEQYN 180
DB 121 PSVFLFPKPKDGLMIKSTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREEQYN 180
QY 181 STYRVSVLTVLHQLDNLNGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
DB 181 STYRVSVLTVLHQLDNLNGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300
DB 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300

QY 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330
DB 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330
RESULT 51
ID ADN33230 standard; protein; 330 AA.
XX AC ADN33230;
XX DT 18-NOV-2004 (first entry)
XX DE IgG1-CH heavy chain constant region.
XX KW IgG1-CH; antibody; IgG; heavy chain constant region;
KW FcRn binding affinity; asthma; autoimmune disease; cancer;
KW viral infection; antiasthmatic; immunosuppressive; cytostatic; virucide.
XX OS Unidentified.
XX PN WO2004035752-A2.
XX PD 29-APR-2004.
XX PF 15-OCT-2003; 2003WO-US033037.
XX PR 15-OCT-2002; 2002US-0418972P.
XX PR 10-APR-2003; 2003US-0462014P.
XX PR 03-JUN-2003; 2003US-0475762P.
XX PR 29-AUG-2003; 2003US-0499048P.
XX PA (PROT-) PROTEIN DESIGN LABS INC.
XX PI Hinton PR, Tsurushita N, Tso YJ, Vasquez M;
XX WPI; 2004-348446/32.
XX New modified antibody of class IgG having an altered FcRn binding
PT affinity and/or serum half-life, useful in immunology and protein
PT engineering, and for diagnosing or treating asthma, autoimmune diseases,
PT cancer and viral infections.
XX Disclosure; SEQ ID NO 3; 140pp; English.
XX The invention relates to a modified antibody of class IgG where at least
CC one amino acid residue from the heavy chain constant region is different
CC from that present in an unmodified class IgG antibody, and where the FcRn
CC binding affinity and/or serum half-life of the modified antibody is
CC altered relative to that of the unmodified antibody. The methods and
CC compositions of the present invention are useful in the fields of
CC immunology and protein engineering, in particular for using modified
CC class IgG antibodies for diagnosing and treating asthma, autoimmune
CC diseases, cancer and viral infections. This sequence represents the
CC antibody IgG1-CH heavy chain constant region of the invention.
XX SQ Sequence 330 AA;
Query Match 99.5%; Score 1756; DB 8; Length 330;
Best Local Similarity 99.4%; Pred. No. 2.4e-123;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1 ASTKGPSVFPFLAPSSTSGGTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSS 60
DB 1 ASTKGPSVFPFLAPSSTSGGTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSS 60
QY 61 GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPCPAPELAGA 120
DB 61 GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPCPAPELAGG 120
QY 121 PSVFLFPKPKDGLMIKSTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREEQYN 180
DB 121 PSVFLFPKPKDGLMIKSTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREEQYN 180

QY 181 STYRVSVLTVLHODWLNKKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Db 181 STYRVSVLTVLHODWLNKKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSLKLTVDKSRW 300
Db 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSLKLTVDKSRW 300
QY 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330
Db 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330
RESULT 52
ADS94906
ID ADS94906 standard; protein; 330 AA.
AC ADS94906;
XX
XX 02-DEC-2004 (first entry)
DT
DE Anti-IFN-gamma antibody heavy chain constant region SEQ ID NO:2.
KW antibody; interferon gamma; IFN-gamma; IFN-gamma mediated disease;
KW anti-inflammatory; antiarthritic; anti-HIV; antianaemic;
KW antiarteriosclerotic; hepatotropic; antipsoriatic; antidiabetic;
KW gene therapy; AIDS; rheumatoid arthritis; inflammatory bowel disease;
KW multiple sclerosis; Addison's disease; type I diabetes; psoriasis;
KW myasthenia gravis; cirrhosis; lupus nephritis; atherosclerosis;
KW systemic lupus erythematosus; sarcoidosis; Sjogren's syndrome;
KW vasculitis; Grave's disease; Guillain-Barre syndrome; haemolytic anaemia;
KW immunoglobulin G1; IgG1; anti-IFN-gamma antibody; human.
XX
OS Homo sapiens.
XX
XX WO2004035747-A2.
XX
XX 29-APR-2004.
XX
XX 16-OCT-2003; 2003WO-US032871.
XX
XX 16-OCT-2002; 2002US-0419057P.
PR 17-JUN-2003; 2003US-0479241P.
XX
XX (AMGE-) AMGEN INC.
PA (MEDA-) MEDAREX INC.
XX
XX Welcher AA, Chute HT, Li Y, Huang H;
PI
XX WPI; 2004-348443/32.
DR N-PSDB; ADS94905.
XX
XX New human anti-interferon-gamma neutralizing antibodies for treating
PT interferon-gamma-mediated diseases, such as AIDS, rheumatoid arthritis,
PT diabetes, Grave's disease, psoriasis, atherosclerosis or transplant
PT rejection.
XX
XX Example 4; SEQ ID NO 2; 115pp; English.
PS
XX The present invention describes an isolated antibody which binds
CC specifically to interferon (IFN)-gamma and comprises a heavy chain
CC complementarity determining region (CDR) 3 having a sequence comprising
CC at least 7 amino acids of the 8-amino acid sequence of SEQ ID NO:36
CC (ADS94940) in the same order and spacing, or an amino acid sequence of
CC SEQ ID NO:37 (ADS94941). Also described: (1) an isolated polynucleotide
CC encoding the antibody; (2) a method of treating an IFN-gamma mediated
CC disease; and (3) a composition comprising a carrier and the antibody. The
CC IFN-gamma binding antibody has anti-inflammatory, antiarthritic, anti-
CC HIV, antianaemic, antiarteriosclerotic, hepatotropic, antipsoriatic and
CC antidiabetic activities, and can be used in gene therapy. The antibody is
CC useful in treating IFN-gamma mediated disease, e.g., AIDS, rheumatoid
CC arthritis, inflammatory bowel disease, multiple sclerosis, Addison's

CC disease, type I diabetes, psoriasis, myasthenia gravis, cirrhosis, lupus
CC nephritis, atherosclerosis, systemic lupus erythematosus, sarcoidosis,
CC Sjogren's syndrome, vasculitis, Grave's disease, Guillain-Barre syndrome
CC or haemolytic anaemia. The present sequence represents an immunoglobulin
CC G1 (IgG1) anti-IFN-gamma heavy chain constant region, which is used in
CC the exemplification of the present invention.
XX
XX Sequence 330 AA;
Query Match 99.5%; Score 1756; DB 8; Length 330;
Best Local Similarity 99.4%; Pred. No. 2.4e-123;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
Db 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
QY 61 GLYSLSSVTVTPSSSLGTQTVICNVNHKPSNTKVDKKVEPKSCDKTHTCTCPCPAPELAGA 120
Db 61 GLYSLSSVTVTPSSSLGTQTVICNVNHKPSNTKVDKKVEPKSCDKTHTCTCPCPAPELGG 120
QY 121 PSVELFPPPKDPTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
Db 121 PSVELFPPPKDPTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
QY 181 STYRVSVLTVLHODWLNKKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Db 181 STYRVSVLTVLHODWLNKKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSLKLTVDKSRW 300
Db 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSLKLTVDKSRW 300
QY 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330
Db 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330
RESULT 53
ADS33009
ID ADS33009 standard; protein; 330 AA.
XX
XX AC ADS33009;
XX
XX DT 30-DEC-2004 (first entry)
XX
XX DE Human IgG1 chain C polypeptide.
XX
XX Human; IgG1 chain C; constant heavy immunoglobulin domain;
KW membrane-anchored receptor; growth factor; cytokine; TRAIL; TNF; VEGF;
KW IL-15; apoptosis; autoimmune disorder; AIDS; heart disorder;
KW myocardial infarction; graft-versus-host-disorder; transplant rejection;
KW spinal cord injury; paraplegia; sepsis; hepatitis; inflammation;
KW ischaemic reperfusion injury; renal disorder.
XX
XX OS Homo sapiens.
XX
XX WO2004085478-A2.
XX
XX PD 07-OCT-2004.
XX
XX PF 26-MAR-2004; 2004WO-EP003239.
XX
XX PR 26-MAR-2003; 2003EP-00006949.
XX
XX PA (APOG-) APOGENIX BIOTECHNOLOGY AG.
XX
XX PI Walczak H;
XX
XX DR WPI; 2004-700134/68.
XX
XX PT New fusion protein comprising at least one first domain comprising a
PT biologically active polypeptide fused to a heterologous second domain,

PT useful for the prophylaxis and/or treatment of disorders associated with
PT apoptosis.

XX Disclosure; Fig 2; 44pp; English.

XX The invention relates to a fusion protein comprising at least one first
XX domain comprising a biologically active polypeptide fused to a
XX heterologous second domain comprising at least a portion of a constant
XX immunoglobulin domain where there is at least one amino acid overlap
XX between the first domain and the second domain in the fusion region. The
XX invention also relates to a nucleic acid molecule encoding the fusion
XX protein or its precursor, a cell transformed or transfected with the
XX nucleic acid molecule, a non-human organism transformed or transfected
XX with the nucleic acid molecule, a pharmaceutical composition comprising
XX as an active agent the fusion protein or the nucleic acid molecule, and
XX manufacturing a fusion protein comprising at least one first domain
XX comprising a biologically active polypeptide fused to a second domain
XX comprising at least a portion of a constant immunoglobulin domain with
XX reduced immunogenic potential, where the first domain is fused to the
XX second domain with at least one amino acid overlap. The fusion protein
XX comprises a first domain selected from a ligand-binding domain of a
XX receptor and a receptor-binding domain of a ligand. The first domain is a
XX ligand-binding receptor domain comprising an extracellular domain of a
XX membrane-anchored receptor or its ligand-binding fragment. The receptor
XX is selected from death receptors, growth factor receptors and cytokine
XX receptors. The receptor is selected from CD95, a TRAIL receptor, a TNF
XX receptor and a VEGF receptor. The first domain is a receptor-binding
XX ligand domain. The ligand is selected from death ligands, growth factors
XX and cytokines. The ligand is selected from CD95 ligand, TRAIL, TNF, VEGF
XX and IL-15. The first domain is derived from a human protein. The second
XX domain comprises at least a portion of a constant heavy immunoglobulin
XX domain. The second domain is an Fc fragment of a constant heavy
XX immunoglobulin domain comprising the CH2 and CH3 domain and optionally at
XX least a part of the hinge region. The second domain comprises at least a
XX portion of a constant IgG1, IgG2, IgG3 or IgG4 immunoglobulin domain or
XX its variant. The second domain is derived from a human immunoglobulin.
XX The fusion proteins are useful for the prophylaxis and/or treatment of
XX disorders associated with apoptosis such as autoimmune disorders, AIDS,
XX heart disorders such as myocardial infarction, graft-versus-host-
XX disorders such as transplant rejection, spinal cord injuries such as
XX paraplegia, sepsis, hepatitis, disorders associated with inflammation,
XX ischaemic reperfusion injury and renal disorders. This sequence
XX represents a human IgG1 chain C polypeptide used in the scope of the
XX invention.

XX Sequence 330 AA;

Query Match 99.5%; Score 1756; DB 8; Length 330;
Best Local Similarity 99.4%; Pred. No. 2.4e-123;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1 ASTKGPSVFPPLAPSSKSTSGGTAALGCLVKDYFPEPTVSNVNSGALTSGVHTFPAVLQSS 60
DB 1 ASTKGPSVFPPLAPSSKSTSGGTAALGCLVKDYFPEPTVSNVNSGALTSGVHTFPAVLQSS 60
QY 61 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPCPAPELAGA 120
DB 61 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPCPAPELGG 120
QY 121 PSVFLFPPPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVFNATKTPREEQYN 180
DB 121 PSVFLFPPPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVFNATKTPREEQYN 180
QY 181 STYRVSVLTVLHQDLNKEVKCKVSNKALPAPIEKTISAKAGQPREPQVYITLPPSRDE 240
DB 181 STYRVSVLTVLHQDLNKEVKCKVSNKALPAPIEKTISAKAGQPREPQVYITLPPSRDE 240
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
DB 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
QY 301 QGQNVFSCSVMEALHNNHYTKLSLSPGK 330
|||||

DB 301 QGQNVFSCSVMEALHNNHYTKLSLSPGK 330

RESULT 54

ADT88869
XX ID ADT88869 standard; protein; 330 AA.
XX AC ADT88869;
XX DT 30-DEC-2004 (first entry)
XX DE Human IgG1 antibody constant domain SEQ ID NO:8.
XX antibody; IGF-IR; Insulin-like growth factor I receptor; cytostatic;
XX antibody therapy; tumor; cancer; IgG1.

XX Homo sapiens.

XX WO2004087756-A2.
XX PD 14-OCT-2004.

XX PF 01-APR-2004; 2004WO-EP003442.

XX PR 02-APR-2003; 2003US-0459837P.

XX PR 15-APR-2003; 2003US-0463003P.

XX (HOFF) HOFFMANN LA ROCHE & CO AG F.

XX PI Graus Y, Kopetzki E, Kuenkele K, Mundigl O, Parren P, Rebers F;
PI Schumacher R, Van De Winkel J, Van Vugt M;
XX WPI: 2004-737667/72.
XX N-PSDB; ADT88868.

XX DR New antibody binding to insulin-like growth factor I receptor (IGF-IR)
XX and inhibiting the binding of IGF-I and IGF-II to IGF-IR, useful for
XX treating cancers of the colon, breast, prostate and lung.
XX PS Disclosure; SEQ ID NO 8; 81pp; English.

XX The invention relates to a novel antibody binding to insulin-like growth
XX factor I receptor (IGF-IR) and inhibiting the binding of IGF-I and IGF-II
XX to IGF-IR. An antibody binding to insulin-like growth factor I receptor
XX (IGF-IR) and inhibiting the binding of IGF-I and IGF-II to IGF-IR, where
XX the antibody is of IgG1 isotype and shows a ratio of inhibition of the
XX binding of IGF-I to IGF-IR to the inhibition of binding of IGF-II to IGF-
XX IR of 1.3 to 3.1 and induces cell death of 20% or more cells of a
XX preparation of IGF-IR expressing cells after 24 hours at a concentration
XX of the antibody of 100 nM by ADCC, is new. An antibody of the invention
XX has cytostatic activity, and may have a use in antibody therapy. The
XX methods and compositions of the present invention are useful for the
XX treatment of tumors and cancers of the colon, breast, prostate and lung
XX using antibodies against human insulin-like growth factor I receptor (IGF
XX -IR). The present sequence represents the constant domain of a human IgG1
XX type antibody.

XX Sequence 330 AA;

Query Match 99.5%; Score 1756; DB 8; Length 330;
Best Local Similarity 99.4%; Pred. No. 2.4e-123;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1 ASTKGPSVFPPLAPSSKSTSGGTAALGCLVKDYFPEPTVSNVNSGALTSGVHTFPAVLQSS 60
DB 1 ASTKGPSVFPPLAPSSKSTSGGTAALGCLVKDYFPEPTVSNVNSGALTSGVHTFPAVLQSS 60
QY 61 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPCPAPELAGA 120
DB 61 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPCPAPELGG 120
QY 121 PSVFLFPPPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVFNATKTPREEQYN 180
|||||

Db 121 PSVFLFPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
Qy 181 STYRVSVLTVLHODWLNKEYCKVSNKALPAPIEKTISKAKGQPRQPQVYTLPPSRDE 240
Db 181 STYRVSVLTVLHODWLNKEYCKVSNKALPAPIEKTISKAKGQPRQPQVYTLPPSRDE 240
Qy 241 LTKNOVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW 300
Db 241 LTKNOVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW 300
Qy 301 QQGNVFCSCVMHEALHNHYTOKSLSLSPGK 330
Db 301 QQGNVFCSCVMHEALHNHYTOKSLSLSPGK 330

RESULT 55

ADT51577

ID ADT51577 standard; protein; 330 AA.

XX

XX

XX

DT 13-JAN-2005 (first entry)

XX

DE Heavy chain constant region of human OST577-IgG1.

XX

KW Human; antibody; immunoglobulin G; IgG; heavy chain constant region; CH;

KW FcRn binding affinity; serum half-life; dactilizumab; fontolizumab;

KW visilizumab; M200; cancer; inflammatory disorder; asthma;

KW autoimmune disease; viral infection; cytostatic; antiinflammatory;

KW antiasthmatic; immunosuppressive; virucide.

XX

OS Homo sapiens.

XX

XX

PN WO2004092219-A2.

XX

XX

XX

XX 09-APR-2004; 2004WO-US011213.

XX

PR 10-APR-2003; 2003US-0462014P.

PR

PR 03-JUN-2003; 2003US-0475762P.

PR

PR 29-AUG-2003; 2003US-0499048P.

PR

PR 15-OCT-2003; 2003US-00687118.

XX

XX (PROT-) PROTEIN DESIGN LABS INC.

XX

XX

PI Hinton PR, Tsurushita N, Tso JY, Vasquez M;

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

CC heavy chain constant region is phenylalanine, or the amino acid residue
CC 250 from the heavy chain constant region is glutamine and the amino acid
CC residue 428 from the heavy chain constant region is phenylalanine, or the
CC amino acid residue 250 from the heavy chain constant region is glutamine
CC and the amino acid residue 428 from the heavy chain constant region is
CC leucine. The modified therapeutic antibody of class IgG has an in vivo
CC elimination half-life of at least 1.3-fold longer than that of the
CC corresponding unmodified class IgG antibody. The composition and methods
CC of the invention are useful for various diagnostic and therapeutic
CC purposes, especially in the treatment of cancer, inflammatory disorders
CC (e.g. asthma), autoimmune diseases or viral infections. The present
CC sequence represents a CH region of a human IgG antibody.

SQ Sequence 330 AA;

Query Match

Best Local Similarity 99.5%; Score 1756; DB 8; Length 330;

Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

XX

XX

XX

Qy 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLOSS 60

Db 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLOSS 60

Qy 61 GLYSLSSVTVTPSSSLGTQTYICNVNHPKSNKTKVDKVEPKSCDKTHTCPCPAPDELAGA 120

Db 61 GLYSLSSVTVTPSSSLGTQTYICNVNHPKSNKTKVDKVEPKSCDKTHTCPCPAPDELGG 120

Qy 121 PSVFLFPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180

Db 121 PSVFLFPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180

Qy 181 STYRVSVLTVLHODWLNKEYCKVSNKALPAPIEKTISKAKGQPRQPQVYTLPPSRDE 240

Db 181 STYRVSVLTVLHODWLNKEYCKVSNKALPAPIEKTISKAKGQPRQPQVYTLPPSRDE 240

Qy 241 LTKNOVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW 300

Db 241 LTKNOVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW 300

Qy 301 QQGNVFCSCVMHEALHNHYTOKSLSLSPGK 330

Db 301 QQGNVFCSCVMHEALHNHYTOKSLSLSPGK 330

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

RESULT 56

ADT51581

ID ADT51581 standard; protein; 330 AA.

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

Heavy chain constant region of human Hvd10-IgG1.

Human; antibody; immunoglobulin G; IgG; heavy chain constant region; CH;
FcRn binding affinity; serum half-life; dactilizumab; fontolizumab;
visilizumab; M200; cancer; inflammatory disorder; asthma;
autoimmune disease; viral infection; cytostatic; antiinflammatory;
antiasthmatic; immunosuppressive; virucide.

Homo sapiens.

WO2004092219-A2.

28-OCT-2004.

09-APR-2004; 2004WO-US011213.

10-APR-2003; 2003US-0462014P.

03-JUN-2003; 2003US-0475762P.

29-AUG-2003; 2003US-0499048P.

15-OCT-2003; 2003US-00687118.

XX

XX

XX

XX

XX

XX

XX

Query Match 99.5%; Score 1756; DB 8; Length 330;
Best Local Similarity 99.4%; Pred. No. 2.4e-123;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTWNSGALTSVHTFPAVLQSS 60
Db 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTWNSGALTSVHTFPAVLQSS 60

Qy 61 GLYSLSVVTVPPSSSLGTQTYICNVNHPKSNKVDKKVEPKSCDKTHTCPPCPAPELAGA 120
Db 61 GLYSLSVVTVPPSSSLGTQTYICNVNHPKSNKVDKKVEPKSCDKTHTCPPCPAPELAGG 120

Qy 121 PSVFLFPKPXDITLMISRTPEVTCVVVDVSHEDPEVKFNWYDGVVEHNATKPREEQYN 180
Db 121 PSVFLFPKPXDITLMISRTPEVTCVVVDVSHEDPEVKFNWYDGVVEHNATKPREEQYN 180

Qy 181 STYRVSVLTVLHQDLNKGKEYKCKVSNKALPAPIEKTISKAKGQPREPPQVYTLPPSRDE 240
Db 181 STYRVSVLTVLHQDLNKGKEYKCKVSNKALPAPIEKTISKAKGQPREPPQVYTLPPSRDE 240

Qy 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPVLDSDGSFPLYSKLTVDKSRW 300
Db 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPVLDSDGSFPLYSKLTVDKSRW 300

Qy 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330
Db 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330

RESULT 58
ADU68015
ID ADU68015 standard; protein; 330 AA.
AC ADU68015;
XX
XX
DT 10-FEB-2005 (first entry)
XX
DE Mouse anti-PSMA antibody deJ591heavy chain constant region.
XX
XX antibody; antibody engineering; antibody therapy; prostate tumor;
KW cytostatic; prostate specific membrane antigen; PSMA;
KW heavy chain constant region; mutein; heavy chain variable region.
XX
OS Mus musculus.
OS Synthetic.
XX
XX WO2004098535-A2.
XX
XX 18-NOV-2004.
XX
XX 03-MAR-2004; 2004WO-US006586.
XX
XX 03-MAR-2003; 2003US-00379838.
XX
XX 30-MAY-2003; 2003US-00449379.
XX
XX (MILL-) MILLENNIUM PHARM INC.
XX
XX
XX Horvath CJ, Webb IJ;
XX
XX WPI; 2004-805058/79.
XX
XX N-PSDB; ADU68014.
XX
XX Use of an anti-prostate specific membrane antigen (anti-PSMA) antibody or
XX antigen-binding fragment for treating prostate cancer or monitoring a
XX patient receiving an anti-PSMA antibody to treat prostate cancer.
XX
XX Disclosure; SEQ ID NO 136; 284pp; English.
XX
XX The invention relates to the use of an anti-prostate specific membrane
XX antigen (anti-PSMA) antibody or antigen-binding fragment for treating
XX prostate cancer, monitoring a patient receiving an anti-PSMA antibody to
XX treat prostate cancer, or selecting a patient for treatment with an anti-

CC PSMA antibody. Also included are a method of treating prostate cancer in
CC a subject, a method of monitoring a patient receiving an anti-PSMA
CC antibody to treat prostate cancer and a method of selecting a patient for
CC treatment with an anti-PSMA antibody. Also disclosed are anti-PSMA
CC antibodies. The antibody or antigen-binding fragment is a human antibody
CC (or antigen-binding fragment) a modified antibody (or an antigen-binding
CC fragment). The modified antibody is selected from CDR-grafted antibodies,
CC humanized antibody, delaminized antibody, or antigen binding fragments.
CC The modified antibody or antigen-binding fragment has one or more CDRs
CC (complementarity determining region) from a mouse monoclonal antibody
CC selected from J591, J415, J533, or E99. The anti-PSMA antibody or antigen
CC -binding fragment is useful for treating prostate cancer, monitoring a
CC patient receiving an anti-PSMA antibody to treat prostate cancer, or
CC selecting a patient for treatment with an anti-PSMA antibody. The present
CC sequence is a functional region from a delaminized heavy chain variable
CC and constant region from one of the mouse monoclonal antibodies listed
CC above.
XX
XX Sequence 330 AA;
SQ

Query Match 99.5%; Score 1756; DB 8; Length 330;
Best Local Similarity 99.4%; Pred. No. 2.4e-123;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTWNSGALTSVHTFPAVLQSS 60
Db 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTWNSGALTSVHTFPAVLQSS 60

Qy 61 GLYSLSVVTVPPSSSLGTQTYICNVNHPKSNKVDKKVEPKSCDKTHTCPPCPAPELAGA 120
Db 61 GLYSLSVVTVPPSSSLGTQTYICNVNHPKSNKVDKKVEPKSCDKTHTCPPCPAPELAGG 120

Qy 121 PSVFLFPKPXDITLMISRTPEVTCVVVDVSHEDPEVKFNWYDGVVEHNATKPREEQYN 180
Db 121 PSVFLFPKPXDITLMISRTPEVTCVVVDVSHEDPEVKFNWYDGVVEHNATKPREEQYN 180

Qy 181 STYRVSVLTVLHQDLNKGKEYKCKVSNKALPAPIEKTISKAKGQPREPPQVYTLPPSRDE 240
Db 181 STYRVSVLTVLHQDLNKGKEYKCKVSNKALPAPIEKTISKAKGQPREPPQVYTLPPSRDE 240

Qy 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPVLDSDGSFPLYSKLTVDKSRW 300
Db 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPVLDSDGSFPLYSKLTVDKSRW 300

Qy 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330
Db 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330

RESULT 59
ADW08868
ID ADW08868 standard; protein; 330 AA.
XX
XX ADW08868;
XX
XX 07-APR-2005 (first entry)
XX
XX IGF-IR antibody 18 constant region domain, SEQ ID 6.
DE
XX Cytostatic; Antibody; antibody therapy; antibody production;
KW insulin-like growth factor I receptor; IGF-IR; constant region.
XX
XX Homo sapiens.
OS
XX US2005008642-A1.
XX
XX 13-JAN-2005.
XX
XX 08-JUL-2004; 2004US-00886838.
XX
XX 10-JUL-2003; 2003EP-00015526.
XX
XX (GRAU/) GRAUS Y.
PA

PA (KOE/) KOPETZKI E.
PA (KUN/) KUNKELE K.
PA (MUN/) MUNDIGL O.
PA (PARR/) PARRIN P.
PA (REBE/) REBERS F.
PA (SCHU/) SCHUMACHER R.
PA (WIN/) VAN DE WINKEL J.
PA (VUGT/) VUGT M V.
XX
PI Graus Y, Kopetzki E, Kuenkele K, Mundigl O, Parren P, Rebers F;
PI Schumacher R, Van De Winkel J, Vugt MV;
XX WPI; 2005-099927/11.
DR N-PSDB; ADW08667.
XX
PT Novel antibody capable of inhibiting binding of insulin like growth
PT factor I (IGF-I) and IGF-II to IGF-I receptor, useful for treating
PT cancer.
XX
XX
PS Disclosure; SEQ ID NO 6; 38pp; English.
XX
CC The present invention relates to antibodies 18 and 22, (A1) which bind to
CC insulin like growth factor I receptor (IGF-IR). The antibody is capable
CC of inhibiting the binding of IGF-I and IGF-II to IGF-IR, and is of the
CC IGF1 isotype. The antibodies induce cell death of 20% or more cells of a
CC preparation of IGF-IR expressing cells by antibody dependent cellular
CC toxicity (ADCC). (A1) are useful for making a pharmaceutical composition
CC which inhibits the binding of IGF-I and IGF-II to IGF-IR, which involves
CC combining (A1) with a carrier. (A1) is also useful for treating a patient
CC in need of an antitumor therapy, which involves administering (A1) alone
CC or in combination with a cytotoxic agent, its prodrug or cytotoxic
CC radiotherapy to the patient. The present sequence is the constant region
CC of antibody 18.
XX
SQ Sequence 330 AA;

Query Match 99.5%; Score 1756; DB 9; Length 330;
Best Local Similarity 99.4%; Pred. No. 2.4e-123;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVTSWNSGALTSGVHTFPAVLQSS 60
Db 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVTSWNSGALTSGVHTFPAVLQSS 60

Qy 61 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPPCPAPELAGA 120
Db 61 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPPCPAPELAGG 120

Qy 121 PSVFLFPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKATKPREQYN 180
Db 121 PSVFLFPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKATKPREQYN 180

Qy 181 STYRVSVLTVLHODWLNKGVKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Db 181 STYRVSVLTVLHODWLNKGVKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240

Qy 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSGCSFYLKSLTVDKSRW 300
Db 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSGCSFYLKSLTVDKSRW 300

Qy 301 QGQNVFSCSVMEALHNHYTQKSLSLSPGK 330
Db 301 QGQNVFSCSVMEALHNHYTQKSLSLSPGK 330

RESULT 60
ADW86657
ID ADW86657 standard; protein; 330 AA.
XX
XX AC ADW86657;
XX
XX DT 21-APR-2005 (first entry)
XX

DE Human immunoglobulin gamma-1 chain constant region IgG1 protein.
XX
XX crystallography; tumor necrosis factor receptor 2; antirheumatic;
KW antiarthritic; antipsoriatic; cardiovascular-Gen.; antibacterial;
KW virucide; protozoacide; antileptic; neuroprotective; analgesic;
KW antipyretic; cytostatic; antianemic; respiratory-Gen.; dermatological;
KW endocrine-Gen.; uropathic; auditory; osteopathic; anorectic;
KW gynecological; immunosuppressive; nootropic; etanercept; TNF-alpha;
KW tumor necrosis factor alpha; rheumatoid arthritis; psoriatic arthritis;
KW psoriasis; ankylosing spondylitis; cardiovascular disease;
KW bacterial infection; viral infection; protozoal infection;
KW hyperlipidemia; neurological disease; pain; fever; anemia; tumor;
KW pulmonary disease; obesity.
XX
OS Homo sapiens.
XX
XX WO2005012353-A1.
XX
XX 10-FEB-2005.
XX
XX 29-JUL-2004; 2004WO-US024738.
XX
XX 01-AUG-2003; 2003US-0491827P.
XX
XX (AMGE-) AMGEN INC.
XX
XX Osslund TD, Clogston CL, Crampton SL, Bass RB;
XX WPI; 2005-142876/15.
XX
XX Crystal of therapeutic etanercept polypeptide (tumor necrosis factor
XX receptor 2 polypeptide) useful for treating conditions such as rheumatoid
XX arthritis, psoriatic arthritis, psoriasis and ankylosing spondylitis.
XX
XX Disclosure; SEQ ID NO 2; 76pp; English.
XX
XX This invention relates to a novel crystal of etanercept (tumor necrosis
XX factor receptor 2 polypeptide). The invention may be useful for the
XX development of compounds with an antirheumatic, antiarthritic,
XX antipsoriatic, cardiovascular-Gen., antibacterial, virucide,
XX protozoacide, antileptic, neuroprotective, analgesic, antipyretic,
XX cytostatic, antianemic, respiratory-Gen., dermatological,
XX uropathic, auditory, osteopathic, anorectic, gynecological,
XX immunosuppressive or nootropic activity. A composition developed by
XX reconstituting crystalline etanercept is useful for preparing a
XX medicament for treating a condition characterized by excessive TNF-alpha
XX (tumor necrosis factor alpha) levels. The medicament reduces levels of
XX TNF-alpha in the serum or tissues of the subject. The condition is
XX rheumatoid arthritis, psoriatic arthritis, psoriasis, or ankylosing
XX spondylitis. The compound may be useful for treating a disease chosen
XX from cardiovascular disorders, bacterial, viral or protozoal infections,
XX familial combined hyperlipidemia (FCH), neurological disorders, pain,
XX fever, oncologic and hematologic disorders, anemia, solid tumors,
XX pulmonary disorders, rheumatic and skin disorders, disorders of endocrine
XX system, disorders of genitourinary system, disorders that involves
XX hearing loss, non-arthritis medical conditions of the bones and joints,
XX obesity, disorders that affect female reproductive system, autoimmune
XX disorders, autism spectrum disorder and other pervasive developmental
XX disorders. The present sequence is that of the human immunoglobulin gamma
XX -1 chain constant region IgG1 protein which is related to the invention.
SQ Sequence 330 AA;

Query Match 99.5%; Score 1756; DB 9; Length 330;
Best Local Similarity 99.4%; Pred. No. 2.4e-123;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVTSWNSGALTSGVHTFPAVLQSS 60
Db 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVTSWNSGALTSGVHTFPAVLQSS 60

Qy 61 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPPCPAPELAGA 120
Db 61 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPPCPAPELAGA 120

Db 61 GLYSLSSVVTVPSSSLGTTQYICNVNHNKPSNTKVDKVKVEPKSCDKTHTCTPCPAPPELLGG 120
Qy 121 PSVFLFPPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNATKPRREEQYN 180
Db 121 PSVFLFPPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNATKPRREEQYN 180
Qy 181 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVTLPPSRDE 240
Db 181 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVTLPPSRDE 240
Qy 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFPLYSKLTVDKSRW 300
Db 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFPLYSKLTVDKSRW 300
Qy 301 QQGNVFCVSMVHEALHNHYTQKSLSLSPGK 330
Db 301 QQGNVFCVSMVHEALHNHYTQKSLSLSPGK 330

RESULT 61

ADX97894
ID ADX97894 standard; protein; 330 AA.

XX AC ADX97894;

XX DT 05-MAY-2005 (first entry)

XX DE Human Ig gamma-1 chain.

XX KW immunoglobulin gamma-1 chain; Ig gamma-1 chain; cytokine; pharmaceutical;
XX KW allergy; asthma; fibrosis; immune deficiency; cancer; antiallergic;
XX KW antiasthmatic; antiinflammatory; immunostimulant; cytostatic.

XX OS Homo sapiens.

XX PN WO2005014646-A1.

XX PD 17-FEB-2005.

XX PF 14-JUN-2004; 2004WO-US018753.

XX PR 11-JUN-2003; 2003US-0477548P.

XX PA (AMHP) WYETH.

XX PI Wood CR, Murtha-Riel P, Lee GW, Leonard M;

XX DR WPI; 2005-152547/16.

XX DR N-PSDB; ADX97893.

XX PT Producing an interleukin (IL)-13 antagonist polypeptide to treat
XX PT disorders associated with IL-13 activity (e.g. allergy), comprises co-
XX PT expressing an IL-13 antagonist polypeptide with a nucleic acid encoding a
XX PT complexing polypeptide.

XX PS Disclosure; SEQ ID NO 8; 77pp; English.

XX The invention relates to a method of producing an interleukin-13 (IL-13)
XX antagonist polypeptide. The method comprises co-expressing an IL-13
XX antagonist polypeptide with a nucleic acid encoding a complexing
XX polypeptide for the IL-13 antagonist polypeptide. Also described are
XX methods of reducing the level of IL-13 or a cytokine in a patient, a
XX pharmaceutical composition comprising the IL-13 antagonist polypeptide
XX produced by the above method or the IL-13 Ralph2Fc polypeptide, and a
XX pharmaceutical carrier, and a purified preparation of a soluble IL-13
XX antagonist polypeptide, where at least 40% of the soluble IL-13
XX antagonist polypeptide is present in monomer or dimer form following
XX incubation for at least one week at 4 degrees centigrade. The complexing
XX polypeptide comprises the amino acid sequence of human IL-13 polypeptide
XX as fully defined in the specification (SEQ ID NO: 17) or comprises a
XX variant amino acid sequence of SEQ ID NO: 17, where the arginine at amino
XX acid 126 is replaced with aspartic acid, glutamic acid or proline. The
XX composition and methods of the invention are useful for treating

CC conditions associated with aberrant IL-13 activity or expression, such as
CC allergies, asthma, fibrosis, immune deficiencies, or cancer. This
CC sequence represents human immunoglobulin gamma-1 (Ig gamma-1) chain.
XX
SQ Sequence 330 AA;

Query Match 99.5%; Score 1756; DB 9; Length 330;
Best Local Similarity 99.4%; Pred. No. 2.4e-123;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 ASTKGPSVFPLAPSSKSTSGTAAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60

Db 1 ASTKGPSVFPLAPSSKSTSGTAAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60

Qy 61 GLYSLSSVVTVPSSSLGTTQYICNVNHNKPSNTKVDKVKVEPKSCDKTHTCTPCPAPELAGA 120

Db 61 GLYSLSSVVTVPSSSLGTTQYICNVNHNKPSNTKVDKVKVEPKSCDKTHTCTPCPAPELGG 120

Qy 121 PSVFLFPPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNATKPRREEQYN 180

Db 121 PSVFLFPPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNATKPRREEQYN 180

Qy 181 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVTLPPSRDE 240

Db 181 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVTLPPSRDE 240

Qy 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFPLYSKLTVDKSRW 300

Db 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFPLYSKLTVDKSRW 300

Qy 301 QQGNVFCVSMVHEALHNHYTQKSLSLSPGK 330

Db 301 QQGNVFCVSMVHEALHNHYTQKSLSLSPGK 330

RESULT 62

ADX98273
ID ADX98273 standard; protein; 330 AA.

XX AC ADX98273;

XX DT 05-MAY-2005 (first entry)

XX DE Human anti-HGF antibody IgG1 heavy chain constant region protein -SEQ 45.

XX KW antibody; cytostatic; cancer; neoplasm; solid tumor;
XX KW hepatocyte growth factor; HGF; heavy chain constant region;
XX KW immunoglobulin G1.

XX OS Homo sapiens.

XX PN WO2005017107-A2.

XX PD 24-FEB-2005.

XX PF 16-JUL-2004; 2004WO-US018936.

XX PR 18-JUL-2003; 2003US-0488681P.

XX PA (AMGE-) AMGEN INC.

XX PA (ABGE-) ABGENIX INC.

XX PI Burgess TL, Coxon A, Green LL, Zhang K;

XX DR WPI; 2005-182350/19.

XX DR N-PSDB; ADX98250.

XX New polypeptide comprising a complementarity determining region (CDR)
XX consisting of CDR1a, CDR2a, CDR3a, CDR1b, CDR2b or CDR3b and capable of
XX binding hepatocyte growth factor, useful in preparing a composition for
XX treating cancer.

XX Example 3; SEQ ID NO 45; 301pp; English.

XX The invention relates to a novel isolated polypeptide comprising at least
 CC one complementarity-determining region (CDR) consisting of CDR1a, CDR2a
 CC or CDR3a, or CDR1b, CDR2b or CDR3b. The polypeptide, in association with
 CC an antibody heavy or light chain, is capable of binding hepatocyte growth
 CC factor (HGF). HGF, also known as scatter factor (SF), has been identified
 CC as a potent mitogen for hepatocytes and also as a secretory protein of
 CC fibroblasts and smooth muscles that acts to induce motility of epithelial
 CC cells. The polypeptide demonstrates cytostatic activity and may be useful
 CC in preparing a composition for treating cancer or a solid tumor. The
 CC current sequence is that of the human anti-HGF antibody IgG1 heavy chain
 CC constant region protein -SEQ 45 of the invention.

XX Sequence 330 AA;

Query Match 99.5%; Score 1756; DB 9; Length 330;
 Best Local Similarity 99.4%; Pred. No. 2.4e-123;
 Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSMNSGALTSGVHFTFPAVLQSS 60
 DB 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSMNSGALTSGVHFTFPAVLQSS 60

QY 61 GLYSLSSVTVPPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHITCPCPAPELAGA 120
 DB 61 GLYSLSSVTVPPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHITCPCPAPELGG 120

QY 121 PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
 DB 121 PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180

QY 181 STYRVSVLTVLHQDLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
 DB 181 STYRVSVLTVLHQDLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240

QY 241 LTKNQVSLTCLVKGYFSPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW 300
 DB 241 LTKNQVSLTCLVKGYFSPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW 300

QY 301 QGQNVFSCVMHEALHNHYTQKSLSLSPGK 330
 DB 301 QGQNVFSCVMHEALHNHYTQKSLSLSPGK 330

RESULT 63

ADY51253
 ID ADY51253 standard; protein; 330 AA.

XX AC ADY51253;

XX DT 19-MAY-2005 (first entry)

XX DE Human IgG1 SEQ ID NO:22.

XX Immunoglobulin G1; hematopoiesis; hyperproliferation; cytostatic;
 KW antianemic; antiinflammatory; antipsoriatic; gastrointestinal-gen.;
 KW dermatological; coagulant; immunostimulant; cerebroprotective;
 KW vasotropic; antiulcer.

OS Homo sapiens.

XX Key Location/Qualifiers

FT Misc-difference 97 /note= "Optionally replaced by R"

FT FT Misc-difference 239 /note= "Optionally replaced by E"

FT FT Misc-difference 241 /note= "Optionally replaced by M"

XX US2005049194-A1.

XX PD 03-MAR-2005.

XX cytostatic; virucide; immunomodulator; cancer; viral infection;

PF 31-OCT-2003; 2003US-00698907.

XX 09-NOV-2001; 2001US-0345206P.

PR 02-JUL-2002; 2002US-0393272P.

PR 08-NOV-2002; 2003US-00291290.

PR 03-APR-2003; 2003US-0460488P.

XX (FRIS/) FRISEN J.

PA (HOLM/) HOLMBERG J.

XX Frisen J, Holmberg J;

XX WPI; 2005-195317/20.

XX Use of ephrin and its molecules for alleviating a symptom or a disorder

PT with reduced levels of hematopoiesis, increased levels of cellular

PT proliferation in an intestinal tract, or abnormal level of cellular

PT proliferation in a tissue.

XX Disclosure; SEQ ID NO 22; 68pp; English.

XX The invention relates to a novel use of ephrin, ephrin inhibitors, and

CC ephrin receptors for alleviating a symptom of a disorder having reduced

CC levels of hematopoiesis, having increased levels of cellular

CC proliferation in an intestinal tract, or having an abnormal level of

CC cellular proliferation in a tissue. A composition of the invention has

CC cytostatic, antianemic, antiinflammatory, antipsoriatic, gastrointestinal

CC -gen., dermatological, coagulant, immunostimulant, cerebroprotective,

CC vasotropic, and antiulcer activity. The present sequence represents human

CC Immunoglobulin G1 (IgG1).

XX Sequence 330 AA;

Query Match 99.5%; Score 1756; DB 9; Length 330;

Best Local Similarity 99.4%; Pred. No. 2.4e-123;

Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSMNSGALTSGVHFTFPAVLQSS 60

DB 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSMNSGALTSGVHFTFPAVLQSS 60

QY 61 GLYSLSSVTVPPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHITCPCPAPELAGA 120

DB 61 GLYSLSSVTVPPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHITCPCPAPELGG 120

QY 121 PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180

DB 121 PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180

QY 181 STYRVSVLTVLHQDLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240

DB 181 STYRVSVLTVLHQDLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240

QY 241 LTKNQVSLTCLVKGYFSPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW 300

DB 241 LTKNQVSLTCLVKGYFSPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW 300

QY 301 QGQNVFSCVMHEALHNHYTQKSLSLSPGK 330

DB 301 QGQNVFSCVMHEALHNHYTQKSLSLSPGK 330

RESULT 64

ADY58147

ID ADY58147 standard; protein; 330 AA.

XX AC ADY58147;

XX DT 19-MAY-2005 (first entry)

XX DE Human IgG gamma 1 constant region.

XX cytostatic; virucide; immunomodulator; cancer; viral infection;

XX KW

KW	immune disorder; IgG; immunoglobulin; neoplasm; infection.	KW	neurological disease; NGF; nerve growth factor; heavy chain.
XX		XX	
OS	Homo sapiens.	OS	Homo sapiens.
XX		XX	
PN	WO2005021592-A2.	PN	WO2005019266-A2.
XX		XX	
PD	10-MAR-2005.	PD	03-MAR-2005.
XX		XX	
PF	30-AUG-2004; 2004WO-EP009642.	PF	15-JUL-2004; 2004WO-US022876.
XX		XX	
PR	28-AUG-2003; 2003US-0498618P.	PR	15-JUL-2003; 2003US-0487431P.
XX		XX	
PA	(MERE) MERCK PATENT GMBH.	PA	(AMGE-) AMGEN INC.
XX		XX	
PI	Gillies S, lauder S, Way J;	PI	Wiid KD, Treanor JUS, Huang H, Inoue H, Zhang TJ, Martin F;
XX		XX	
DR	WPI; 2005-214544/22.	DR	WPI; 2005-202606/21.
XX		XX	N-PSDB; ADY26686.
PT	New protein comprising an interleukin-2 protein, where Lys8 and Lys9 of the interleukin-2 protein are replaced with non-lysine amino acids, useful for treating cancer, viral infection, and an immune disorder.	PT	New human anti-nerve growth factor (NGF) neutralizing antibodies useful for manufacturing a medicament for treating painful disorders (e.g. acute pain) or conditions associated with increased expression or sensitivity to NGF.
XX		PT	
PS	Disclosure; SEQ ID NO 7; 39pp; English.	PT	
XX		XX	
CC	The invention relates to a protein comprising an interleukin-2 protein, where Lys 8 and Lys 9 of the interleukin-2 protein are replaced with non-lysine amino acids. The protein, nucleic acid, and pharmaceutical composition are useful for the manufacture of a medicament for treating cancer, viral infection, and an immune disorder. The present sequence represents the amino acid sequence of human IgG gamma 4 constant region.	PS	Disclosure; SEQ ID NO 2; 190pp; English.
XX		XX	
CC		CC	The invention describes an isolated human antibody that interacts with or binds specifically to human nerve growth factor (NGF) and neutralize the function of NGF. Also described are: methods of treating a condition caused by increased expression of NGF or increased sensitivity to NGF in a patient; methods for detecting NGF in a biological sample; an NGF specific binding agent comprising any of the 59 amino acid sequences comprising, for e.g. 123, 107 or 14 amino acids, as mentioned in the specification, and where the binding agent can bind to NGF; a pharmaceutical composition comprising a pharmaceutical carrier and a therapeutic amount of the antibody or binding agent cited above; or a medicament for treating a painful disorder or condition associated with increased expression of NGF or increased sensitivity to NGF; the medicament comprising a pharmaceutical amount of a monoclonal antibody or its immunologically functional immunoglobulin fragment, or pharmaceutical salts of the monoclonal antibody or the fragment, where the monoclonal antibody is at least one of the monoclonal antibody cited above, and a pharmaceutical carrier, diluent or excipient; a nucleic acid molecule or polynucleotide that encodes the above antibody or binding agent; an isolated cell line that produces the above antibody or binding agent; an expression vector comprising the above polynucleotide; and a host cell comprising the nucleic acid or expression vector. The composition (including the antibody) and methods are useful for manufacturing a medicament for treating a painful disorder (e.g. acute pain, dental pain, or pain from trauma or cancer), or a condition associated with increased expression of NGF or increased sensitivity to NGF. This is the amino acid sequence of a human NGF antibody heavy chain.
XX		CC	
XX		XX	
Query Match	99.5%; Score 1756; DB 9; Length 330;	Query Match	99.5%; Score 1756; DB 9; Length 330;
Best Local Similarity	99.4%; Pred. No. 2.4e-123;	Best Local Similarity	99.4%; Pred. No. 2.4e-123;
Matches 328; Conservative	0; Mismatches 2; Indels 0; Gaps 0;	Matches 328; Conservative	0; Mismatches 2; Indels 0; Gaps 0;
QY	1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSWNSGALTSVHTFPAVLQSS 60	QY	1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSWNSGALTSVHTFPAVLQSS 60
Db	1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSWNSGALTSVHTFPAVLQSS 60	Db	1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSWNSGALTSVHTFPAVLQSS 60
QY	61 GLYSLSSVVTVPPSSSLGTQTYICNVNHPKSNTKVDKKVEPKSCDKTHTCPPCPAPELAGA 120	QY	61 GLYSLSSVVTVPPSSSLGTQTYICNVNHPKSNTKVDKKVEPKSCDKTHTCPPCPAPELAGA 120
Db	61 GLYSLSSVVTVPPSSSLGTQTYICNVNHPKSNTKVDKKVEPKSCDKTHTCPPCPAPELAGG 120	Db	61 GLYSLSSVVTVPPSSSLGTQTYICNVNHPKSNTKVDKKVEPKSCDKTHTCPPCPAPELGG 120
QY	121 PSVFLFPPKPKDGLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNATKPREEQYN 180	QY	121 PSVFLFPPKPKDGLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNATKPREEQYN 180
Db	121 PSVFLFPPKPKDGLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNATKPREEQYN 180	Db	121 PSVFLFPPKPKDGLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNATKPREEQYN 180
QY	181 STYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240	QY	181 STYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Db	181 STYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240	Db	181 STYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
QY	241 LTKQVSLTCLVKGFYPDI AVEVESNGQPENNYKTTTPVLDSGSGFFLYSKLTVDKSRW 300	QY	241 LTKQVSLTCLVKGFYPDI AVEVESNGQPENNYKTTTPVLDSGSGFFLYSKLTVDKSRW 300
Db	241 LTKQVSLTCLVKGFYPDI AVEVESNGQPENNYKTTTPVLDSGSGFFLYSKLTVDKSRW 300	Db	241 LTKQVSLTCLVKGFYPDI AVEVESNGQPENNYKTTTPVLDSGSGFFLYSKLTVDKSRW 300
QY	301 QGQNVFSCSVNHEALHNHYTQKSLSLSPGK 330	QY	301 QGQNVFSCSVNHEALHNHYTQKSLSLSPGK 330
Db	301 QGQNVFSCSVNHEALHNHYTQKSLSLSPGK 330	Db	301 QGQNVFSCSVNHEALHNHYTQKSLSLSPGK 330
RESULT 65		RESULT 65	
ADY26687		ADY26687	
ID	ADY26687 standard; protein; 330 AA.	ID	ADY26687 standard; protein; 330 AA.
XX		XX	
AC	ADY26687;	AC	ADY26687;
XX		XX	
DI	19-MAY-2005 (first entry)	DI	19-MAY-2005 (first entry)
XX		XX	
DE	Human anti-NGF-antibody heavy chain SEQ ID NO 2.	DE	Human anti-NGF-antibody heavy chain SEQ ID NO 2.
XX		XX	
KW	analgesic; gene therapy; antibody engineering; pharmaceutical; pain;	KW	analgesic; gene therapy; antibody engineering; pharmaceutical; pain;

Db 181 STYRVSVLTVLHQDLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRW 300
Db 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRW 300
QY 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330
Db 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330

RESULT 66
AEA12531
ID AEA12531 standard; protein; 330 AA.
AC AEA12531;
XX
DT 14-JUL-2005 (first entry)
XX
DE Human IgG1 constant region.
XX
KW CD52; antibody; cytostatic; antiinflammatory; antirheumatic;
KW antiarthritic; neuroprotective; immunosuppressive; gastrointestinal-Gen.;
KW dermatological; vasotropic; lymphoid leukemia; lymphoma;
KW autoimmune disease; multiple sclerosis; rheumatoid arthritis; vasculitis;
KW uveitis; inflammatory bowel disease; scleroderma; transplantation.
XX
OS Homo sapiens.
XX
PN WO2005042581-A2.
XX
PD 12-MAY-2005.
XX
PF 29-OCT-2004; 2004WO-IB003879.
XX
PR 01-NOV-2003; 2003US-0516210P.
XX
PA (BIOV-) BIOVATION LTD.
XX
PI Carr FU, Hamilton AA;
XX
PI WPI; 2005-346857/35.
XX
DR N-PSDB; AEA12644.

Anti-CD52 antibody, useful for treating lymphoid malignancies or
PT autoimmune conditions, is modified to reduce the number of potential T-
PT cell epitopes to reduce undesirable immune responses to the antibody.
XX
PS Example 2; SEQ ID NO 139; 171pp; English.
XX
CC The invention relates to a novel anti-CD52 antibody. The novel antibody
CC consists of a heavy chain comprising a V-region heavy chain with a
CC substituted variant of SEQ ID NO. 1 (AEA12393) and a light chain
CC comprising a V-region light chain with a substituted variant of SEQ ID
CC NO. 2 (AEA12394). The invention further comprises a pharmaceutical
CC composition comprising the antibody and a carrier; a method for treating
CC a lymphoid malignancy or autoimmune condition in a patient;
CC immunosuppressing a patient prior to or subsequent to transplantation of
CC an organ; an expression vector comprising a nucleic acid sequence coding
CC for a V-region heavy chain comprising a substituted variant of the 121-
CC amino acid sequence (SEQ ID NO. 1) or light chain comprising a
CC substituted variant of the 107-amino acid sequence (SEQ ID NO. 2),
CC operably linked to an expression control sequence; and a cultured cell
CC comprising or transfected with the vector. The novel anti-CD52 antibody
CC and the composition it used in have the following activities: cytostatic,
CC antiinflammatory, antirheumatic, antiarthritic, neuroprotective,
CC immunosuppressive, gastrointestinal-Gen., dermatological and vasotropic.
CC The anti-CD52 antibody is useful in preparing a composition for treating
CC lymphoid malignancies, e.g., leukemia or lymphoma, or autoimmune
CC conditions, e.g., multiple sclerosis, rheumatoid arthritis, systemic
CC vasculitis, uveitis, inflammatory bowel disease or scleroderma. The
CC antibody is also useful for immunosuppressing a patient prior or
CC subsequent to transplantation of an organ. This sequence represents a

CC human IgG1 constant region of the invention.
XX
SQ Sequence 330 AA;
Query Match 99.5%; Score 1756; DB 9; Length 330;
Best Local Similarity 99.4%; Pred. No. 2.4e-123;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1 ASTKGPSVFPLAPSSKSTSGGTAAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
Db 1 ASTKGPSVFPLAPSSKSTSGGTAAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
QY 61 GLYSLSSVTVTPSSSLGTQTYICNVNHPKSNVTKDKKVEPKSCDKTHCTCPCPAPDELAGA 120
Db 61 GLYSLSSVTVTPSSSLGTQTYICNVNHPKSNVTKDKKVEPKSCDKTHCTCPCPAPDELGG 120
QY 121 PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
Db 121 PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
QY 181 STYRVSVLTVLHQDLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Db 181 STYRVSVLTVLHQDLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRW 300
Db 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRW 300
QY 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330
Db 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330

RESULT 67
AEA25942
ID AEA25942 standard; protein; 330 AA.
XX
AC AEA25942;
XX
DT 28-JUL-2005 (first entry)
XX
DE Human immunoglobulin constant region, SEQ ID No:25.
XX
KW antibody; antibody production; immunoglobulin; transformation;
KW expression; heavy chain constant region; light chain constant region.
XX
OS Homo sapiens.
XX
PN WO2005047335-A1.
XX
PD 26-MAY-2005.
XX
PF 13-NOV-2004; 2004WO-KR002943.
XX
PR 13-NOV-2003; 2003KR-00080299.
XX
PA (HANM-) HANMI PHARM CO LTD.
XX
PI Jung SY, Kim JS, Park YJ, Choi K, Kwon SC, Lee GS;
XX WPI; 2005-372351/38.
XX
PT Producing an immunoglobulin constant region by transforming a prokaryotic
PT cell with a vector encoding an E. coli-derived signal sequence and an
PT immunoglobulin constant region.
XX
PS Claim 9; SEQ ID NO 25; 92pp; English.
XX
CC The invention relates to a method of producing an immunoglobulin constant
CC region on a large scale. The method comprises transforming a prokaryotic
CC cell with a recombinant expression vector including a nucleotide sequence
CC encoding an E. coli-derived signal sequence and a nucleotide sequence
CC encoding an immunoglobulin constant region, culturing a resulting

CC transformant, and isolating and purifying the immunoglobulin constant
 CC region expressed by the transformant. Also described is an immunoglobulin
 CC constant region prepared by the method above. The immunoglobulin constant
 CC region is a constant region from IgG, IgA, IgM, IgE, IgD, or their
 CC combinations and hybrids. The IgG is a constant region from IgG1, IgG2,
 CC IgG3, IgG4, or their combinations and hybrids, preferably an IgG4
 CC constant region, i.e. a human aglycosylated IgG4 constant region. The
 CC immunoglobulin constant region is composed of one to four domains, e.g.
 CC CH1, CH2, CH3, and CH4 domains, where the immunoglobulin constant region
 CC further comprises a hinge region. The recombinant expression vector
 CC comprises a nucleotide sequence encoding a heavy chain constant region
 CC and a nucleotide sequence encoding a light chain constant region. The
 CC immunoglobulin constant region has a sequence of 109-330 amino acids (SEQ
 CC ID NOS: 21-25, 27, 29, 30, 34 or 35). The E. coli-derived signal sequence
 CC is a signal sequence, e.g. alkaline phosphatase, penicillinase, lpp, heat
 CC -stable enterotoxin II, Lamb, PhoB, PhoE, OmpA, or maltose binding
 CC protein, where the heat-stable enterotoxin II signal peptide comprises
 CC any of the 11 sequences of given in the specification (SEQ ID NOS: 36-
 CC 46). The method of the invention is useful for the mass production of an
 CC immunoglobulin constant region. This sequence represents a human
 CC immunoglobulin constant region that can be produced by the method of the
 CC invention.

XX Sequence 330 AA;

Query Match 99.5%; Score 1756; DB 9; Length 330;

Best Local Similarity 99.4%; Pred. No. 2.4e-123; Mismatches 2; Indels 0; Gaps 0;

Matches 328; Conservative 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSNVNSGALTSGVHTFPAVLQSS 60

DB 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSNVNSGALTSGVHTFPAVLQSS 60

QY 61 GLYSSSVVTVPPSSSLGQTQYICNVNHPKSTNTKVDKVEPKSCDKTHTCPPCPAPELAGA 120

DB 61 GLYSSSVVTVPPSSSLGQTQYICNVNHPKSTNTKVDKVEPKSCDKTHTCPPCPAPELAGG 120

QY 121 PSVFLFPKPKDGLMISRTPEVTCVVDVSHEDPEVKENWYVDGVEVHNATKPREEQYN 180

DB 121 PSVFLFPKPKDGLMISRTPEVTCVVDVSHEDPEVKENWYVDGVEVHNATKPREEQYN 180

QY 181 STYRVSVVLTVLHQLDNLNGKEYCKVSNKALPAPIEKTISKAGQPREPQVYVTLPPSRDE 240

DB 181 STYRVSVVLTVLHQLDNLNGKEYCKVSNKALPAPIEKTISKAGQPREPQVYVTLPPSRDE 240

QY 241 LTKQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300

DB 241 LTKQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300

QY 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330

DB 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330

RESULT 68

AEA48148

ID AEA48148 standard; protein; 330 AA.

XX AEA48148;

DT 25-AUG-2005 (first entry)

XX Human IgG1 constant region.

XX Antibody engineering; immunoglobulin; epidermal growth factor receptor;
 KW diagnosis; Cytostatic; Immunosuppressive; Antiinflammatory;
 KW Immunomodulator; Antimicrobial; cancer; autoimmune disease;
 KW immune disorder; inflammation; infection; antibody therapy.

XX Homo sapiens.

XX WO2005056606-A2.

XX

PD 23-JUN-2005.

XX 03-DEC-2004; 2004WO-US040479.

XX 03-DEC-2003; 2003US-0526799P.

XX (XENC-) XENCOR INC.

XX Lazar GA, Dang W, Desjarlais JR, Hammond PW, Vielmetter J;

XX WPI; 2005-445151/45.

XX Novel anti-human epidermal growth factor receptor (EGFR) comprising
 PT variant human immunoglobulin G constant region, useful for treating or
 PT diagnosing cancer, autoimmune diseases, infections, inflammatory
 PT disorders or immune disorders.

XX Example 1; Fig 1; 120pp; English.

XX The invention relates to an anti-human EGFR antibody (I) comprising a
 CC variant human immunoglobulin G constant region, according to the
 CC formula/consensus sequence appearing as AEA48172. The antibody comprises
 CC an a variant human IgG1 and a light chain variable region variant or
 CC heavy chain variable region variant form the mouse anti-EGFR antibody
 CC C225. The antibody is useful for diagnosing or treating cancer.
 CC autoimmune diseases, inflammatory disorders, infectious diseases or
 CC immune disorders (chosen from a long list given in the specification).
 CC The present sequence is the wild-type human IgG1 constant region.

XX Sequence 330 AA;

Query Match 99.5%; Score 1756; DB 9; Length 330;

Best Local Similarity 99.4%; Pred. No. 2.4e-123;

Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSNVNSGALTSGVHTFPAVLQSS 60

DB 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSNVNSGALTSGVHTFPAVLQSS 60

QY 61 GLYSSSVVTVPPSSSLGQTQYICNVNHPKSTNTKVDKVEPKSCDKTHTCPPCPAPELAGA 120

DB 61 GLYSSSVVTVPPSSSLGQTQYICNVNHPKSTNTKVDKVEPKSCDKTHTCPPCPAPELAGG 120

QY 121 PSVFLFPKPKDGLMISRTPEVTCVVDVSHEDPEVKENWYVDGVEVHNATKPREEQYN 180

DB 121 PSVFLFPKPKDGLMISRTPEVTCVVDVSHEDPEVKENWYVDGVEVHNATKPREEQYN 180

QY 181 STYRVSVVLTVLHQLDNLNGKEYCKVSNKALPAPIEKTISKAGQPREPQVYVTLPPSRDE 240

DB 181 STYRVSVVLTVLHQLDNLNGKEYCKVSNKALPAPIEKTISKAGQPREPQVYVTLPPSRDE 240

QY 241 LTKQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300

DB 241 LTKQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300

QY 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330

DB 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330

RESULT 69

AEA86186

ID AEA86186 standard; protein; 330 AA.

XX AEA86186;

XX 06-OCT-2005 (first entry)

XX Amino acid sequence of z allotype of human IgG1.

XX antibody; CD20; Fc region; antibody-dependent cell-mediated cytotoxicity;
 KW complement-dependent cytotoxicity; cytostatic; hematological disease;
 KW immune disorder; neoplasm; immunotherapy; lymphoma; infection;

KW antimicrobial; infection; antiinflammatory; gastrointestinal; gen.;
 KW gastrointestinal disease; immune disorder; inflammation; antiarthritic;
 KW antirheumatic; musculoskeletal disease; kidney transplant;
 KW Crohn's disease; rheumatoid arthritis; breast tumor; endocrine disease;
 KW gynecology and obstetrics; colon tumor; gastrointestinal disease; IgG1;
 KW z allototype.
 XX
 OS Homo sapiens.
 XX
 PN WO2005070963-A1.
 XX
 XX 04-AUG-2005.
 XX
 XX 10-JAN-2005; 2005WO-US000013.
 XX
 XX 12-JAN-2004; 2004US-0535764P.
 XX
 XX (MOLE-) APPLIED MOLECULAR EVOLUTION INC.
 XX
 PI Allan BW, Marquis DM, Tang Y, Watkins JD;
 XX
 XX WPI; 2005-542271/55.
 DR
 XX Novel anti-CD20 antibody comprising variant of parent human Fc region,
 PT useful in immunotherapy of diseases such as lymphoma, infectious disease,
 PT Crohn's disease, rheumatoid arthritis, breast and colon cancer.
 XX
 XX Disclosure; SEQ ID NO 12; 160pp; English.
 PS
 XX The specification describes an antibody which specifically binds human
 CC CD20, comprising a variant of a parent human Fc region which has at least
 CC one amino acid substitution compared to the parent Fc region, and the
 CC amino acid substitution is at a position corresponding to a position of
 CC the human Fc sequence chosen from 247, 251, 256, 268, 280, 330, 332, 339,
 CC 378 and 440. Antibodies of the invention mediate antibody-dependent cell-
 CC mediated cytotoxicity (ADCC) in the presence of effector cells or
 CC mediate complement-dependent cytotoxicity (CDC) more effectively than
 CC the antibody comprising the parent Fc region. Antibodies of the invention
 CC are useful in the immunotherapy of lymphoma, infectious disease, kidney
 CC transplant, Crohn's disease, rheumatoid arthritis, breast and colon
 CC cancer. They are useful as an affinity purification reagent, and in
 CC diagnostic assays for detecting expression of an antigen of interest in
 CC specific cells, tissues, or serum, and also useful in vivo diagnostic
 CC assays. The present sequence represents a z allotype of human IgG1,
 CC including the CH1, hinge, CH2 and CH3 regions.
 XX
 SQ Sequence 330 AA;
 Query Match 99.5%; Score 1756; DB 9; Length 330;
 Best Local Similarity 99.4%; Pred. No. 2.4e-123;
 Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1 ASTKGPSVFPPLAPSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
 DB 1 ASTKGPSVFPPLAPSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
 QY 61 GLYSLSVVTVPSLSLGTQTYICNVNHPKSNTKVDKVPKSCDKTHTCPPCPAPELAGA 120
 DB 61 GLYSLSVVTVPSLSLGTQTYICNVNHPKSNTKVDKVPKSCDKTHTCPPCPAPELGG 120
 QY 121 PSVFLFPKPKDITLMISRTPEVTVVVDVSHEDPEVKFNWYVDGEVHNNAKTKPREQYN 180
 DB 121 PSVFLFPKPKDITLMISRTPEVTVVVDVSHEDPEVKFNWYVDGEVHNNAKTKPREQYN 180
 QY 181 STYRVVSVLTVLHQLWLNCKEYCKVSNKALPAIEKTIISKAKGQPREPQVYTLPPSRDE 240
 DB 181 STYRVVSVLTVLHQLWLNCKEYCKVSNKALPAIEKTIISKAKGQPREPQVYTLPPSRDE 240
 QY 241 LFNKQVSLTCLVKGFPPSDIAVEVESNGQPENNYKTTTPVLDSDGFFLYSKLTVDKGRW 300
 DB 241 LFNKQVSLTCLVKGFPPSDIAVEVESNGQPENNYKTTTPVLDSDGFFLYSKLTVDKGRW 300
 QY 301 QQGNVFCSCVMHEALHNHYTKQSLSPGK 330

Db 301 QQGNVFCSCVMHEALHNHYTKQSLSPGK 330

RESULT 70

AEC08181
 ID AEC08181 standard; protein; 330 AA.

AC AEC08181;

XX 20-OCT-2005 (first entry)

DE Heavy chain constant region used to create anti-IgE monoclonal antibody.

KW epitope mapping; immunoglobulin; antibody; antibody production;

KW monoclonal antibody; heavy chain constant region; IgG1;

KW immune stimulation; allergy; asthma; atopic dermatitis; urticaria;

KW eczema; antiallergic; antiasthmatic; dermatological; antiinflammatory;

XX vaccine.

OS Homo sapiens.

PN WO2005075504-A1.

XX 18-AUG-2005.

XX 29-JUL-2004; 2004WO-US024360.

XX 02-FEB-2004; 2004WO-US002892.

XX 02-FEB-2004; 2004WO-US002894.

XX (TANO-) TANOX INC.

XX Singh S, Huang D, Fung SCM;

XX WPI; 2005-564560/57.

PT New isolated peptides useful for inducing an immunological response in mammals or for treating or preventing allergic conditions, such as asthma, atopic dermatitis, urticaria or eczema.

PS Example 11; SEQ ID NO 60; 110pp; English.

XX The invention relates to the isolation of novel peptide epitopes derived from the CH3 domain of immunoglobulin E (IgE) which are recognized by high affinity antibodies that bind specifically to IgE. The novel IgE epitopes are useful for active or passive immunization of a mammal. The isolated IgE peptide epitope preferably comprises an amino acid sequence selected from a fully defined sequence given as SEQ ID Nos 72-77 in the specification. Also described are: (1) methods for preparing or making a polyclonal or monoclonal antibodies; (2) a polyclonal or monoclonal antibody (mAb) produced by the above method; (3) an isolated antibody that specifically binds to the above peptide; (4) a composition comprising the above peptide or (polyclonal or monoclonal) antibody, and a physiological carrier, diluent, stabilizer or excipient; (5) a kit comprising the antibody cited above; (6) a method of inducing an immunological response to IgE in a mammal; (7) an isolated nucleic acid encoding the above peptide; and (8) vectors and host cells comprising the nucleic acid cited above. The composition and methods of the invention are useful for inducing an immunological response in mammals, or for treating or preventing allergic conditions (e.g. asthma, atopic dermatitis, urticaria or eczema). This sequence represents a heavy chain constant region from human IgG1 that is used to create an anti-IgE monoclonal antibody in the examples of the present invention.

XX Sequence 330 AA;

Query Match 99.5%; Score 1756; DB 9; Length 330;
 Best Local Similarity 99.4%; Pred. No. 2.4e-123;
 Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPPLAPSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60

Db 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSS 60
QY 61 GLYSLSVVTVPSSSLGTQTYICNVNHPKSNTKVDKVEPKSCDKTHTCPPCPAPBLAGA 120
Db 61 GLYSLSVVTVPSSSLGTQTYICNVNHPKSNTKVDKVEPKSCDKTHTCPPCPAPBLGG 120
QY 121 PSVELFPKPKDKTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREQVN 180
Db 121 PSVELFPKPKDKTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREQVN 180
QY 181 STYRVSVLTVLHQDLNKGKEYCKVSKNKPAPAEIKTISKAKGPRPQVVTLPSPRDE 240
Db 181 STYRVSVLTVLHQDLNKGKEYCKVSKNKPAPAEIKTISKAKGPRPQVVTLPSPRDE 240
QY 241 LTKNQVSLTCLVKGYFSPDSIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKGRW 300
Db 241 LTKNQVSLTCLVKGYFSPDSIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKGRW 300
QY 301 QQGNVFCSVMHEALHNHYTQKSLSLSPCK 330
Db 301 QQGNVFCSVMHEALHNHYTQKSLSLSPCK 330

RESULT 71
AEC81727
ID AEC81727 standard; protein; 330 AA.
XX AC AEC81727;
XX DT 01-DEC-2005 (first entry)
XX DE Human immunoglobulin gamma 1 heavy chain.
XX KW Fusion protein; protein production; immunoglobulin; IgG; antibody;
XX KW heavy chain.
XX OS Homo sapiens.
XX FH Key Location/Qualifiers
FT Domain 1..98 /label = CH1
FT Region 99..113 /label = Hinge
FT Misc-difference 103 /note= "Cys residue involved in disulfide bonding to the light chain constant region"
FT Misc-difference 109 /note= "Cys residue involved in disulfide bonding to the heavy chain constant region"
FT Misc-difference 112 /note= "Cys residue involved in disulfide bonding to the heavy chain constant region"
FT Domain 114..223 /label = CH2
FT Domain 224..330 /label = CH3
XX WO2005087810-A2.
XX 22-SEP-2005.
XX 08-MAR-2005; 2005WO-US007590.
XX 08-MAR-2004; 2004US-0551174P.
XX (ZYMO) ZYMOGENETICS INC.
XX Moore MD, Fox BA;
XX WPI; 2005-630945/64.
XX New dimeric protein comprising a first polypeptide fusion disulfide bonded to a second polypeptide fusion, useful as cytokine antagonist for

PT treating cancers, or as growth factor agonist for promoting tissue growth.
XX Example 1; SEQ ID NO 1; 85pp; English.
CC The present invention relates to dimeric fusion proteins and methods of making them. A claimed dimeric protein comprises a first polypeptide fusion disulfide bonded to a second polypeptide fusion. The first polypeptide fusion has the formula P1-L1-D1-(P2)n, where: P1 is a first non-immunoglobulin polypeptide; L1 is a first polypeptide linker of 18-32 amino acid residues where x of these residues are Cys residues; D1 is a first dimerizing domain selected from an immunoglobulin CH1 domain, a T-cell receptor C alpha domain, a T-cell receptor C beta domain, a major histocompatibility complex (MHC) class I alpha 3 domain, beta2-microglobulin, a MHC class II alpha 2 domain, and a MHC class II beta 2 domain; P2 is a linking polypeptide of 1-29 amino acid residues where at least one residue is Cys; and n is 0 or 1. The second polypeptide fusion has the formula P3-L2-D2, where: P3 is a second non-immunoglobulin polypeptide; L2 is a second polypeptide linker of 18-32 amino acid residues, where y of these residues are Cys residues; and D2 is a second dimerizing domain selected from an immunoglobulin light chain constant domain, a T-cell receptor C alpha domain, a T-cell receptor C beta domain, a MHC class I alpha 3 domain, beta2-microglobulin, a MHC class II alpha 2 domain and a MHC class II beta 2 domain. In the dimeric protein, each of x and y is an integer of 1-8, and x=y. Also claimed are dimeric proteins in which: P1 and P3 are different; n=1; x=2 and y=2; each of P1 and P3 is an extracellular domain of a cell surface receptor, including a human cell surface receptor; each of P1 and P3 is not a member of the immunoglobulin superfamily; and each of P1 and P3 is individually selected from interleukin-17 receptor, interleukin-20 receptor A or B, interleukin-21 receptor, interleukin-28 receptor A, interleukin-31 receptor A, CRF2-4 or gammaC. In a further claimed polypeptide fusion, D1 is an immunoglobulin CH1 domain, and D2 is an immunoglobulin kappa light chain constant domain or immunoglobulin lambda light chain constant domain. In a further claimed dimeric protein: (a) one of P1 and P3 is a zcytor7 extracellular domain and the other of P1 and P3 is a DIRS1 extracellular domain; (b) one of P1 and P3 is a zcytor11 extracellular domain and the other of P1 and P3 is a DIRS1 extracellular domain; (c) one of P1 and P3 is a zalphall extracellular domain and the other of P1 and P3 is an interleukin-2 receptor gamma common extracellular domain; or (d) one P1 and P3 is a PDGF alpha receptor extracellular domain and the other of P1 and P3 is a PDGF beta receptor extracellular domain. Also claimed are polypeptide fusions of formula P1-L-D1-(P2)n and P3-L-D2, polynucleotides encoding each polypeptide fusion, expression vectors, cultured cells, and a method of making the dimeric proteins of the invention by culturing cells comprising first and second expression units such that the encoded polypeptide fusions are produced as a dimeric protein. A dimeric protein consisting of 2 polypeptide chains joined via at least one disulfide bond, where each polypeptide chain is a polypeptide fusion of formula P3-L-D2, and a method of making this dimeric protein, are also claimed. The dimeric proteins of the invention can be used for diagnosis, therapy, or research to provide one or more activities associated with the first and second non-immunoglobulin polypeptides. Such activities include receptor binding, receptor activation and ligand binding. Therapeutic uses include use as cytokine antagonists for treatment of cancers or immunological disorders, growth factor agonists to promote tissue growth or healing or to promote development of vasculature or other tissue. Diagnostic uses include use as targeting agents for radioisotopes or other labels. The present sequence is that of the human immunoglobulin gamma 1 heavy chain, which includes a CH1 domain and hinge region that can be used in polypeptide fusions of the invention.

SQ Sequence 330 AA;
Query Match 99.5%; Score 1756; DB 9; Length 330;
Best Local Similarity 99.4%; Pred. No. 2.4e-123;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSS 60
DB 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSS 60

Qy	61	GLYSLSSVVTVPSSSLGQTQYICNVNHKPSNTKVDKVKVPKSCDKTHTCPCPAPELAGA	120
Db	61	GLYSLSSVVTVPSSSLGQTQYICNVNHKPSNTKVDKVKVPKSCDKTHTCPCPAPELGG	120
Qy	121	PSVFLFPPPKPKDTLMISRTPEVTCVVDVSHEDPEVAFNMYVDGVEVHNAKTKPREEQYN	180
Db	121	PSVFLFPPPKPKDTLMISRTPEVTCVVDVSHEDPEVAFNMYVDGVEVHNAKTKPREEQYN	180
Qy	181	STYRVVSVLTVLHQDLWNGKEYKCKVSNKALPAPIEKTISKAKGQPREPOVYTLPPSRDE	240
Db	181	STYRVVSVLTVLHQDLWNGKEYKCKVSNKALPAPIEKTISKAKGQPREPOVYTLPPSRDE	240
Qy	241	LFKNQVSLTCLVKGFYPSDIAVEVNESGQPENNYKTTTPVLDSGSEFELYSLTVDKSRW	300
Db	241	LFKNQVSLTCLVKGFYPSDIAVEVNESGQPENNYKTTTPVLDSGSEFELYSLTVDKSRW	300
Qy	301	QQGNVFSCSVMHEALHNHYTQKSLSLSPGK	330
Db	301	QQGNVFSCSVMHEALHNHYTQKSLSLSPGK	330
RESULT	72		
ID	AED12326		
ID	AED12326	standard; protein; 330 AA.	
AC	AED12326;		
XX	XX		
XX	XX	01-DEC-2005 (first entry)	
XX	XX		
DE	XX	Human Igg1 heavy chain constant domain, SEQ ID 44.	
XX	XX		
KW	XX	Neuroprotective; Vulnerary; Vasotropic; Cerebroprotective;	
KW	XX	spinal cord injury; brain injury; paralysis; neurodegenerative disease;	
KW	XX	cerebrovascular ischemia; heavy chain constant region.	
OS	XX	Homo sapiens.	
PN	XX		
PN	XX	US2005215770-A1.	
PD	XX		
PD	XX	29-SEP-2005.	
XX	XX		
XX	XX	25-MAR-2005; 2005US-00090847.	
PR	XX		
XX	XX	26-MAR-2004; 2004US-0556386P.	
XX	XX		
PA	XX	(HUMA-) HUMAN GENOME SCI INC.	
XX	XX		
PI	XX	Bell A, Rosen CA;	
XX	XX		
XX	XX	WPI; 2005-648835/66.	
XX	XX		
PT	XX	New antibody or its fragment that specifically binds Nogo receptor	
PT	XX	(Nogor), useful in preparing a composition for treating or ameliorating	
PT	XX	spinal cord injury, brain trauma, paralysis, neurodegenerative disorders	
XX	XX	or stroke.	
XX	XX		
XX	XX	Disclosure; SEQ ID NO 44; 81pp; English.	
XX	XX		
CC	XX	The present invention relates to a novel antibody or its fragment (e.g.	
CC	XX	an scFv) that binds to the Nogo receptor (Nogor; AED12284). The antibody	
CC	XX	comprises a Variable Heavy Complementarity Determining Region (VHCDR)1,	
CC	XX	VHCDR2 or VHCDR3 and a Variable Light Complementarity Determining Region	
CC	XX	(VLCDR)1, VLCDR2 or VLCDR3. The antibody prevents binding or inhibits	
CC	XX	interaction of Nogor with: p75(NTR) (AED12288); LINGO-1 (AED12289); Nogo	
CC	XX	(AED12285); Omgp (AED12286); or WAG (AED12287), and promotes neurite	
CC	XX	outgrowth or axonal regeneration. The antibody is useful in preparing a	
CC	XX	composition for treating or ameliorating spinal cord injury, brain	
CC	XX	trauma, paralysis, neurodegenerative disorders or stroke. The present	
CC	XX	sequence can be used with anti-Nogor VH and/ or VL domain sequences to	
XX	XX	produce the antibodies of the invention.	
XX	XX		
SQ	XX	Sequence 330 AA;	

CC antibody is administered in combination with a second agent consisting of
CC a neuroprotective, neuroreparative, neurotrophic, neurorestorative,
CC neurogenerative or neuroconstructive agent. the present sequence,
CC represents a human immunoglobulin G1 heavy chain constant domain amino
CC acid sequence, which is used in the exemplification of the present
CC invention.

XX SQ Sequence 330 AA;
Query Match 99.5%; Score 1756; DB 9; Length 330;
Best Local Similarity 99.4%; Pred. No. 2.4e-123;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
Db 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
Qy 61 GLYSLSVVTVPPSSSLGTQTYICNVNHPKSNTKVDKVEPKSCDKTHTCPPCPAPELAGA 120
Db 61 GLYSLSVVTVPPSSSLGTQTYICNVNHPKSNTKVDKVEPKSCDKTHTCPPCPAPELGG 120
Qy 121 PSVFLFPPKPKDITLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREQYN 180
Db 121 PSVFLFPPKPKDITLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREQYN 180
Qy 181 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPOVYITLPPSRDE 240
Db 181 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPOVYITLPPSRDE 240
Qy 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFPLYSKLTVDKSRW 300
Db 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFPLYSKLTVDKSRW 300
Qy 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330
Db 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330

RESULT 74
AED41916
ID AED41916 standard; protein; 330 AA.
XX AED41916;
AC AED41916;
DT 15-DEC-2005 (first entry)
DE Deimmunized PSMA J591 heavy chain constant region.
XX prostate tumor; cytostatic; andrology; genitourinary disease; neoplasm;
KW antibody; prostate specific membrane antigen; PSMA;
KW heavy chain constant region.

XX Mus musculus.
OS
PN WO2005094882-A1.
XX
PD 13-OCT-2005.
XX
PF 03-MAR-2004; 2004WO-US006543.
XX
PR 03-MAR-2004; 2004WO-US006543.
XX
PA (MILL-) MILLENNIUM PHARM INC.
XX
PI Horvath CJ, Webb IJ;
XX
DR WPI; 2005-703269/72.
XX
DR N-PSDB; AED41915.
XX

XX Treating prostate cancer in a subject by administering to the subject 2-
PT 24 doses of an antibody or its antigen binding fragment that binds to the
PT extracellular domain of prostate specific membrane antigen (PSMA), and is
PT coupled to DM1.

XX Disclosure; SEQ ID NO 136; 291pp; English.
XX
CC The invention relates to a method of treating prostate cancer, in a
CC subject which comprises administering to the subject two to twenty-four
CC doses of an antibody or its antigen binding fragment, which binds to the
CC extracellular domain of prostate specific membrane antigen (PSMA) and
CC which is coupled to DM1, where each dose comprises 175-500 mg/m2 of the
CC antibody or its antigen binding fragment, to thus treat the subject. The
CC method is useful for treating prostate cancer. The present sequence
CC represents the amino acid sequence of a mouse prostate specific membrane
CC antigen (PSMA) antibody heavy chain.

XX SQ Sequence 330 AA;
Query Match 99.5%; Score 1756; DB 9; Length 330;
Best Local Similarity 99.4%; Pred. No. 2.4e-123;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
Db 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
Qy 61 GLYSLSVVTVPPSSSLGTQTYICNVNHPKSNTKVDKVEPKSCDKTHTCPPCPAPELAGA 120
Db 61 GLYSLSVVTVPPSSSLGTQTYICNVNHPKSNTKVDKVEPKSCDKTHTCPPCPAPELGG 120
Qy 121 PSVFLFPPKPKDITLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREQYN 180
Db 121 PSVFLFPPKPKDITLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREQYN 180
Qy 181 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPOVYITLPPSRDE 240
Db 181 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPOVYITLPPSRDE 240
Qy 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFPLYSKLTVDKSRW 300
Db 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFPLYSKLTVDKSRW 300
Qy 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330
Db 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330

RESULT 75
AED28069
ID AED28069 standard; protein; 330 AA.
XX AED28069;
AC AED28069;
DT 15-DEC-2005 (first entry)
DE Human gamma1 heavy chain constant region (CH) L234A/L235A (IgG1v2).
XX
XX Gene therapy; antibody therapy; inflammation; antiinflammatory;
KW thrombosis; anticoagulant; thrombolytic; cardiovascular disease;
KW hematological disease; peripheral arterial occlusive disease; vasotropic;
KW ischemia; antibody; heavy chain constant region; IgG; immunoglobulin;
KW mutein.
XX
OS Homo sapiens.
XX
PN US2005226876-A1.
XX
PD 13-OCT-2005.
XX
PF 08-APR-2005; 2005US-00102403.
XX
PR 13-APR-2004; 2004EP-00008722.
XX
PA (GRAU/) GRAUS Y.
PA (HIMB/) HIMBER J.
PA (JANS/) JANSEN-MOLENAAR M.

PA (KLIN/) KLING D.
PA (KOPE/) KOPETZKI E.
PA (PARR/) PARRIN P.
PA (REBE/) REBERS F.
PA (STEL/) STEINER B.
PA (STER/) STERN A.
PA (STRE/) STREIN P.
PA (STUB/) STUBENRAUCH K.
PA (WIN/) VAN DE WINKEL J.
PA (VUG/) VAN VUGT M.
XX
XX
PI Graus Y, Himber J, Jansen-Molenaar M, Kling D, Kopetzki E;
PI Parren P, Rebers F, Steiner B, Stern A, Strein P, Stubenrauch K;
PI Van De Winkel J, Van Vugt M;
XX
XX WPI; 2005-723886/74.
XX
XX New antibody containing a Fc part from human origin, binding to P-
PT selectin and non-binding to complement factor C1q, for preparing a
PT medicament for treating e.g., peripheral arterial occlusive disease.
XX
XX Example; SEQ ID NO 26; 50pp; English.
XX
XX The invention relates to an antibody containing a Fc part from human
CC origin, binding to P-selectin (CD62P, GMP-140, PADGEM or LECAM-3) and non
CC -binding to complement factor C1q. The anti-P-selectin antibody is useful
CC in preparing a medicament for treating inflammatory or thrombotic
CC disorders, preferably peripheral arterial occlusive disease (PAOD) or
CC critical limb ischemia (CLI). It is also useful in gene therapy and in
CC antibody therapy. The present sequence is the human Ig gammal heavy chain
CC constant region L234A/L235A (IgG1v1). This sequence is used in the
CC construction of expression plasmids for an anti-P-selectin IgG1 HuMab.
XX
XX Sequence 330 AA;

Query Match 99.5%; Score 1756; DB 9; Length 330;
Best Local Similarity 99.4%; Pred. No. 2.4e-123;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1 ASTKGPSVFPFLAPSSKSTSGGTAALGCLVKDYFPEPTVMSWNSGALTSGVHTFPAVLQSS 60
DB 1 ASTKGPSVFPFLAPSSKSTSGGTAALGCLVKDYFPEPTVMSWNSGALTSGVHTFPAVLQSS 60
QY 61 GLYSLSVVTVFPSSSLGTQTYICNVNHPKPSNTKVDKVEPKSCDKHTHTCPPCPAPELAGA 120
DB 61 GLYSLSVVTVFPSSSLGTQTYICNVNHPKPSNTKVDKVEPKSCDKHTHTCPPCPAPEAAGG 120
QY 121 PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 180
DB 121 PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 180
QY 181 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
DB 181 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPTPVLDSDGSFFLYSKLTVDKSRW 300
DB 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPTPVLDSDGSFFLYSKLTVDKSRW 300
QY 301 QGQNVFSCSVMEALHNHYTQKSLSLSPCK 330
DB 301 QGQNVFSCSVMEALHNHYTQKSLSLSPCK 330

RESULT 76
AED28067
ID AED28067 standard; protein; 330 AA.
XX
XX AED28067;
AC
DT 15-DEC-2005 (first entry)
XX
DE Human Igammal heavy chain constant region (CH).

XX
KW Gene therapy; antibody therapy; inflammation; antiinflammatory;
KW thrombosis; anticoagulant; thrombolytic; cardiovascular disease;
KW hematological disease; peripheral arterial occlusive disease; vasotropic;
KW ischemia; antibody; heavy chain constant region; IgG; immunoglobulin.
XX
OS Homo sapiens.
XX
XX US2005226876-A1.
XX
XX 13-OCT-2005.
XX
XX 08-APR-2005; 2005US-00102403.
XX
XX 13-APR-2004; 2004EP-00008722.
XX
XX (GRAU/) GRAUS Y.
XX (HIMB/) HIMBER J.
XX (JANS/) JANSSEN-MOLENAAR M.
XX (KLIN/) KLING D.
XX (KOPE/) KOPETZKI E.
XX (PARR/) PARRIN P.
XX (REBE/) REBERS F.
XX (STEL/) STEINER B.
XX (STER/) STERN A.
XX (STRE/) STREIN P.
XX (STUB/) STUBENRAUCH K.
XX (WIN/) VAN DE WINKEL J.
XX (VUG/) VAN VUGT M.
XX
XX Graus Y, Himber J, Jansen-Molenaar M, Kling D, Kopetzki E;
XX Parren P, Rebers F, Steiner B, Stern A, Strein P, Stubenrauch K;
XX Van De Winkel J, Van Vugt M;
XX
XX WPI; 2005-723886/74.
XX
XX New antibody containing a Fc part from human origin, binding to P-
PT selectin and non-binding to complement factor C1q, for preparing a
PT medicament for treating e.g., peripheral arterial occlusive disease.
XX
XX Disclosure; SEQ ID NO 24; 50pp; English.
XX
XX The invention relates to an antibody containing a Fc part from human
CC origin, binding to P-selectin (CD62P, GMP-140, PADGEM or LECAM-3) and non
CC -binding to complement factor C1q. The anti-P-selectin antibody is useful
CC in preparing a medicament for treating inflammatory or thrombotic
CC disorders, preferably peripheral arterial occlusive disease (PAOD) or
CC critical limb ischemia (CLI). It is also useful in gene therapy and in
CC antibody therapy. The present sequence is the human Ig gammal heavy chain
CC constant region. This sequence is used in the construction of expression
CC plasmids for an anti-P-selectin IgG1 HuMab.
XX
XX Sequence 330 AA;

Query Match 99.5%; Score 1756; DB 9; Length 330;
Best Local Similarity 99.4%; Pred. No. 2.4e-123;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1 ASTKGPSVFPFLAPSSKSTSGGTAALGCLVKDYFPEPTVMSWNSGALTSGVHTFPAVLQSS 60
DB 1 ASTKGPSVFPFLAPSSKSTSGGTAALGCLVKDYFPEPTVMSWNSGALTSGVHTFPAVLQSS 60
QY 61 GLYSLSVVTVFPSSSLGTQTYICNVNHPKPSNTKVDKVEPKSCDKHTHTCPPCPAPELAGA 120
DB 61 GLYSLSVVTVFPSSSLGTQTYICNVNHPKPSNTKVDKVEPKSCDKHTHTCPPCPAPELGG 120
QY 121 PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 180
DB 121 PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 180
QY 181 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
DB 181 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240


```
QY      241 LTKQVSLTCLVKGFPSPDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300
Db      |||||
Db      241 LTKQVSLTCLVKGFPSPDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300
QY      301 QQGNVFCSCVMHEALHNHYTKSLSPGK 330
Db      |||||
Db      301 QQGNVFCSCVMHEALHNHYTKSLSPGK 330

RESULT 77
AEFI1770
ID AEFI1770 standard; protein; 330 AA.
XX
AC AEFI1770;
XX
DT 09-MAR-2006 (first entry)
XX
DE Human SCF-binding Ab A2-G8 heavy chain constant region.
XX
KW antibody therapy; antibody engineering; asthma; inflammation;
KW antiasthmatic; stem cell factor; SCF; heavy chain constant region.
XX
OS Homo sapiens.
OS Synthetic.
XX
FN WO200602064-A2.
XX
PD 05-JAN-2006.
XX
PF 14-JUN-2005; 2005WO-US021043.
XX
PR 14-JUN-2004; 2004US-00867506.
PR 14-JUN-2004; 2004US-0579462P.
XX
PA (ABRO-) AEROVANCE INC.
XX
PI Neben S, Takeuchi T, Tomkinson A, Delaria K, Yan X, Wong T;
PI Longphre M;
XX
DR WPI; 2006-079812/08.
DR N-PSDB; AEFI1769.
XX
PT New purified human antibody, which binds to stem cell factor protein,
PT useful for treating asthma or a human disorder in which stem cell factor
PT protein is expressed in certain cells.
XX
XX Example 10; SEQ ID NO 81; 108pp; English.
XX
PS The invention relates to: a purified human antibody (IgG) or fragment
PS thereof which binds to stem cell factor protein; a preparation comprising
PS the antibody, and/or a carrier; isolated polynucleotide(s) encoding the
PS antibody; an expression vector comprising the polynucleotide(s); a host
PS cell comprising the expression vector; a method of producing a human
PS antibody; a method of treating asthma or a human disorder in which stem
PS cell factor protein is expressed in certain cells; and a method for
PS identifying a disorder in which stem cell factor protein level is
PS elevated. The purified human antibody comprises the heavy chain variable
PS region human VH3 consensus framework residues, the light chain variable
PS region human V-kappa-1 or V-lambda-1 consensus framework residues, and
PS may be optionally bound to a cytotoxic molecule or detectable label. The
PS antibody, compositions and methods are useful for treating asthma or a
PS human disorder in which stem cell factor protein is expressed in certain
PS cells. This sequence is a human stem cell factor-binding antibody A2-G8
PS heavy chain constant region.
XX
SQ Sequence 330 AA;

Query Match 99.5%; Score 1756; DB 10; Length 330;
Best Local Similarity 99.4%; Pred. No. 2.4e-123;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSS 60
|||
1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSS 60
61 GLYSLSVVTVFPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELAGA 120
|||
61 GLYSLSVVTVFPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELGG 120
121 PSVELFPPPKKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVFNATKPREEQYN 180
|||
121 PSVELFPPPKKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVFNATKPREEQYN 180
181 STYRVSVLTVLHODWLNKKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
|||
181 STYRVSVLTVLHODWLNKKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
241 LTKQVSLTCLVKGFPSPDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300
|||
241 LTKQVSLTCLVKGFPSPDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300
301 QQGNVFCSCVMHEALHNHYTKSLSPGK 330
|||
301 QQGNVFCSCVMHEALHNHYTKSLSPGK 330

RESULT 78
AEFI6289
ID AEFI6289 standard; protein; 330 AA.
XX
AC AEFI6289;
XX
DT 09-MAR-2006 (first entry)
XX
DE Humanized antibody, Hu1D10, heavy chain constant region.
XX
KW monoclonal antibody; humanized antibody; immunoglobulin; Hu1D10; IgG;
KW heavy chain constant region; antibody engineering; therapeutic; vaccine;
KW cancer; neoplasm; inflammation; asthma; autoimmune disease;
KW viral infection; cytostatic; antiinflammatory; antiasthmatic;
KW immunosuppressive; virucide.
XX
OS Homo sapiens.
OS Synthetic.
XX
FN WO2005123780-A2.
XX
PD 29-DEC-2005.
XX
PF 08-APR-2005; 2005WO-US011996.
XX
PR 09-APR-2004; 2004US-00822300.
PR 09-APR-2004; 2004WO-US011213.
XX
PA (PROT-) PROTEIN DESIGN LABS INC.
XX
PI Hinton PR, Tsurushita N, Tso YJ, Vasquez M;
XX
DR WPI; 2006-067459/07.
XX
PT New modified monoclonal antibody of class IgG with altered FcRn binding
PT affinity, useful for treating a condition, e.g. cancer, inflammatory
PT conditions such as asthma, autoimmune diseases, or viral infections.
XX
PS Disclosure; SEQ ID NO 7; 310pp; English.
XX
CC The invention relates to modified monoclonal antibodies of class IgG with
CC FcRn binding affinity altered relative to that of an unmodified
CC monoclonal antibody of class IgG. The modified monoclonal antibody of
CC class IgG comprises a heavy chain constant region where at least amino
CC acid residues 250 and 428 are different from the residues present in the
CC unmodified monoclonal antibody and where the unmodified monoclonal
CC antibody is selected from the group consisting of an anti-CD25, an anti-
CC CD3, an anti-IFNgamma, or an anti-alphasbeta1 integrin. Also disclosed
CC are: (1) a method of modifying an antibody of class IgG; (2) a method of
```


CC producing a modified antibody of class IgG with an altered binding
CC affinity for FcRn and/or an altered serum half life as compared with an
CC unmodified antibody; (3) a vector comprising a polynucleotide encoding
CC one or more heavy or light chain sequences; (4) a host cell comprising
CC the vector; and (5) polynucleotide sequences encoding the modified
CC antibodies. The unmodified monoclonal antibody is an anti-CD25 of IgG1 or
CC IgG2M3 isotype. The modified antibodies of the invention can be used in
CC prophylactic and therapeutic compositions, such as vaccines, for treating
CC a condition, e.g. cancer, inflammatory conditions such as asthma,
CC autoimmune diseases, or viral infections. The antibodies can also be used
CC in diagnostic applications. This sequence represents a region of a
CC humanized antibody.
XX

Sequence 330 AA;
Query Match 99.5%; Score 1756; DB 10; Length 330;
Best Local Similarity 99.4%; Pred. No. 2.4e-123;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSMNSGALTSGVHTFPAVLQSS 60
DB 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSMNSGALTSGVHTFPAVLQSS 60
QY 61 GLYSLSVVTVPPSSSLGTQTYICNVNHPKPSNTKVDKVEPKSCDKTHHTCPPCPAPELAGA 120
DB 61 GLYSLSVVTVPPSSSLGTQTYICNVNHPKPSNTKVDKVEPKSCDKTHHTCPPCPAPELGG 120
QY 121 PSVFLFPPKPKDITLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNNAKTKPREEQYN 180
DB 121 PSVFLFPPKPKDITLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNNAKTKPREEQYN 180
QY 181 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
DB 181 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
DB 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
QY 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330
DB 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330

RESULT 79
AEF16285
ID AEF16285 standard; protein; 330 AA.
XX
AC AEF16285;
XX
DT 09-MAR-2006 (first entry)
XX
DE Human OST577-IgG1 antibody, heavy chain constant region.
XX
KW monoclonal antibody; immunoglobulin; OST577; IgG1;
KW heavy chain constant region; antibody engineering; therapeutic; vaccine;
KW cancer; neoplasm; inflammation; asthma; autoimmune disease;
KW viral infection; cytostatic; antiinflammatory; antiasthmatic;
KW immunosuppressive; virucide.
XX
OS Homo sapiens.
XX
PN WO2005123780-A2.
XX
PD 29-DEC-2005.
XX
PF 08-APR-2005; 2005WO-US011996.
XX
PR 09-APR-2004; 2004US-00822300.
PR 09-APR-2004; 2004WO-US011213.
XX
PA (PROT-) PROTEIN DESIGN LABS INC.
XX

PI Hinton PR, Tsurushita N, Tso YJ, Vasquez M;
DR WPI; 2006-067459/07.
XX
PT New modified monoclonal antibody of class IgG with altered FcRn binding
PT affinity, useful for treating a condition, e.g. cancer, inflammatory
PT conditions such as asthma, autoimmune diseases, or viral infections.
XX
PS Disclosure; SEQ ID NO 3; 310pp; English.
XX
CC The invention relates to modified monoclonal antibodies of class IgG with
CC FcRn binding affinity altered relative to that of an unmodified
CC monoclonal antibody of class IgG. The modified monoclonal antibody of
CC class IgG comprises a heavy chain constant region where at least amino
CC acid residues 250 and 428 are different from the residues present in the
CC unmodified monoclonal antibody and where the unmodified monoclonal
CC antibody is selected from the group consisting of an anti-CD25, an anti-
CC CD3, an anti-IFNgamma, or an anti-alpha5beta1 integrin. Also disclosed
CC are: (1) a method of modifying an antibody of class IgG; (2) a method of
CC producing a modified antibody of class IgG with an altered binding
CC affinity for FcRn and/or an altered serum half life as compared with an
CC unmodified antibody; (3) a vector comprising a polynucleotide encoding
CC one or more heavy or light chain sequences; (4) a host cell comprising
CC the vector; and (5) polynucleotide sequences encoding the modified
CC antibodies. The unmodified monoclonal antibody is an anti-CD25 of IgG1 or
CC IgG2M3 isotype. The modified antibodies of the invention can be used in
CC prophylactic and therapeutic compositions, such as vaccines, for treating
CC a condition, e.g. cancer, inflammatory conditions such as asthma,
CC autoimmune diseases, or viral infections. The antibodies can also be used
CC in diagnostic applications. This sequence represents a region of the
CC human anti-hepatitis B virus antibody OST577-IgG1.
XX

Sequence 330 AA;

Query Match 99.5%; Score 1756; DB 10; Length 330;
Best Local Similarity 99.4%; Pred. No. 2.4e-123;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSMNSGALTSGVHTFPAVLQSS 60
DB 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSMNSGALTSGVHTFPAVLQSS 60
QY 61 GLYSLSVVTVPPSSSLGTQTYICNVNHPKPSNTKVDKVEPKSCDKTHHTCPPCPAPELAGA 120
DB 61 GLYSLSVVTVPPSSSLGTQTYICNVNHPKPSNTKVDKVEPKSCDKTHHTCPPCPAPELGG 120
QY 121 PSVFLFPPKPKDITLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNNAKTKPREEQYN 180
DB 121 PSVFLFPPKPKDITLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNNAKTKPREEQYN 180
QY 181 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
DB 181 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
DB 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
QY 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330
DB 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330

RESULT 80
AEF51200
ID AEF51200 standard; protein; 330 AA.
XX
AC AEF51200;
XX
DT 23-MAR-2006 (first entry)
XX
DE Human immunoglobulin G1 Fc amino acid sequence SEQ ID NO:1.
XX

KW immunoglobulin; antibody; immunoglobulin G1; IgG1; immunosuppressive;
KW antinflammatory; antibacterial; virucide; fungicide; protozoacide;
KW antiparasitic; cytostatic; antibody therapy; autoimmune disease;
KW inflammation; infectious disease; cancer.
XX Homo sapiens.
XX US2006024298-A1.
XX PD 02-FEB-2006.
XX PF 05-MAY-2005; 2005US-00124620.
XX PR 03-MAR-2003; 2003US-00379392.
XX PR 26-SEP-2003; 2003US-00672280.
XX PR 26-MAR-2004; 2004US-00822231.
XX PA (XENC-) XENCOR INC.
XX PI Lazar GA, Dang W, Desjarlais JJ, Karki SB, Vafa O, Hayes R;
XX WPI; 2006-117602/12.
XX DR New protein comprising an Fc variant of a human Fc polypeptide, where the
XX PT variant exhibits altered binding to an Fc ligand as compared to human Fc
XX PT polypeptide, useful for treating or preventing autoimmune or inflammatory
XX PT diseases.
XX PS Claim 1; SEQ ID NO 1; 138pp; English.
XX PX The invention relates to a protein comprising an Fc variant of a human Fc
XX CC polypeptide comprising the 330 amino acid sequence of AEF51200, where the
XX CC variant exhibits altered binding to an Fc ligand as compared to human Fc
XX CC polypeptide, where the variant comprises Formula (I), and where the
XX CC variant comprises 1-4 amino acid substitutions as compared to AEF51200.
XX CC Also described: (1) a method for engineering optimized Fc variants; (2)
XX CC an isolated nucleic acid encoding the Fc variants; (3) vectors containing
XX CC the nucleic acids; (4) host cells containing the vectors; (5) a method
XX CC for producing the Fc variants; and (6) a composition comprising the Fc
XX CC polypeptides. The protein is useful for diagnosing, treating, and
XX CC preventing autoimmune and inflammatory diseases, infectious diseases, and
XX CC cancers. It can also be used for preventing or treating congestive heart
XX CC failure, myocarditis, acne, osteoporosis, periodontal disease,
XX CC osteomalacia, bone metastasis, bone pain management, humoral malignant
XX CC hypercalcemia, periodontal reconstruction, spinal cord injury, and bone
XX CC fractures; metabolic conditions such as Gaucher's disease; endocrine
XX CC conditions such as Cushing's syndrome; and neurological conditions. The
XX CC present sequence represents a human immunoglobulin G1 (IgG1) Fc amino
XX CC acid sequence, which is used in the exemplification of the present
XX CC invention.
XX SQ Sequence 330 AA;

Query Match 99.5%; Score 1756; DB 10; Length 330;
Best Local Similarity 99.4%; Pred. No. 2.4e-123;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0,

Qy 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSNVNSGALTSGVHTFPAVLQSS 60
Db 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSNVNSGALTSGVHTFPAVLQSS 60

Qy 61 GLYSLSVVTVPPSSSLGTQTYICNVNHRPSNTKVDKVEPKSCDKTHRCPCPAPELAGA 120
Db 61 GLYSLSVVTVPPSSSLGTQTYICNVNHRPSNTKVDKVEPKSCDKTHRCPCPAPELGG 120

Qy 121 PSVFLFPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNATKPREEQYN 180
Db 121 PSVFLFPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNATKPREEQYN 180

Qy 181 STYRVSVSLTVLHQDLNGKEYCKVSNKALPAPIEKTISKAKGQPRFPQVYTLPPSRDE 240
Db 181 STYRVSVSLTVLHQDLNGKEYCKVSNKALPAPIEKTISKAKGQPRFPQVYTLPPSRDE 240

Qy 241 LTKQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFYLSTLVDSKRW 300
Db 241 LTKQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFYLSTLVDSKRW 300

Qy 301 QQGNVFSVCSVMHEALHNHYTQKSLSLSPGK 330
Db 301 QQGNVFSVCSVMHEALHNHYTQKSLSLSPGK 330

RESULT 81
AEF82207
ID AEF82207 standard; protein; 330 AA.
XX AC AEF82207;
XX DT 06-APR-2006 (first entry)
XX DE Human immunoglobulin G1 heavy chain constant region protein.
XX KW immunogenicity; fusion protein; immunoglobulin;
XX KW heavy chain constant region.
XX OS Homo sapiens.
XX PN US2006025573-A1.
XX PD 02-FEB-2006.
XX PF 23-SEP-2005; 2005US-00233683.
XX PR 30-MAR-2001; 2001US-0280625P.
XX PR 29-MAR-2002; 2002US-00112582.
XX PA (MERE) MERCK PATENT GMBH.
XX PI Gillies SD, Way J, Hamilton AA;
XX DR WPI; 2006-201465/21.
XX PT Reducing immunogenicity of fusion protein, by identifying T-cell epitope
XX PT within a junction region, and making amino acid substitutions or
XX PT deletions to reduce the ability of T-cell epitope to interact with T cell
XX PT receptor.
XX PS Disclosure; SEQ ID NO 1; 34pp; English.
XX CC The invention relates to a method for reducing the immunogenicity of a
XX CC fusion protein. The method comprises: (a) identifying a candidate T-cell
XX CC epitope within a junction region spanning a fusion junction of a fusion
XX CC protein, where the fusion protein comprises an immunoglobulin moiety
XX CC fused to a non-immunoglobulin moiety; and (b) making one or more amino
XX CC acid substitutions or deletions within the junction region to reduce the
XX CC ability of the candidate T-cell epitope to interact with a T cell
XX CC receptor. Also described: (1) a fusion protein produced by the method
XX CC above; (2) a fusion protein with reduced immunogenicity comprising a non-
XX CC immunoglobulin protein and an immunoglobulin protein fused to the non-
XX CC immunoglobulin protein via a fusion junction, where the amino acid
XX CC sequence of a junction region surrounding the fusion junction is modified
XX CC by substitution or deletion of one or more amino acids to remove a non-
XX CC self T-cell epitope; and (3) a nucleic acid encoding a fusion protein
XX CC with reduced immunogenicity, the fusion protein comprising an
XX CC immunoglobulin protein, and a non-immunoglobulin protein fused to the
XX CC immunoglobulin protein via a fusion junction, where the amino acid
XX CC sequence of a junction region spanning the fusion junction is modified to
XX CC remove a non-self T-cell epitope. The compositions and methods are useful
XX CC for producing fusion proteins, e.g. immunocytokines, immunofusins,
XX CC immunoligands, other antibody and Fc fusion proteins, cytokine-cytokine
XX CC fusion proteins, and albumin fusion proteins, with reduced
XX CC immunogenicity, which are useful in therapy. The present sequence
XX CC represents a human immunoglobulin gamma 1 (IgG1) heavy chain constant
XX CC (Fc) region amino acid sequence, which is used in the exemplification of
XX CC the present invention.

SQL	Sequence 330 AA;	
XX	Query Match	99.5%; Score 1756; DB 10; Length 330;
XX	Best Local Similarity	99.4%; Pred. No. 2.4e-123;
CC	Matches 328; Conservative	0; Mismatches 2; Indels 0; Gaps 0;
QY	1	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
DB	1	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
QY	61	GLYSLSSVTVTPSSSLGTQTYICNVNHPKSNTKVDKVEPKSCDKTHTCPPCPAPELAGA 120
DB	61	GLYSLSSVTVTPSSSLGTQTYICNVNHPKSNTKVDKVEPKSCDKTHTCPPCPAPELGG 120
QY	121	PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYDGVGVHNNAKTKPREEQYN 180
DB	121	PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYDGVGVHNNAKTKPREEQYN 180
QY	181	STYRVSVTLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
DB	181	STYRVSVTLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
QY	241	LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSLKLTVDKSRW 300
DB	241	LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSLKLTVDKSRW 300
QY	301	QOQNVFSCSVMHREALHNHYTQKSLSLSPGK 330
DB	301	QOQNVFSCSVMHREALHNHYTQKSLSLSPGK 330
RESULT 82		
ADG11432		
ID	AEG11432 standard; protein; 330 AA.	
XX	AC	AEG11432;
XX	20-APR-2006	(first entry)
DT	Immunoglobulin G1 (IgG1) kappa constant domain SEQ ID NO 81.	
DE		
XX	cytostatic; neuroprotective; virucide; immunosuppressive; antiarthritic;	
KW	anti-HIV; procoagulant; antiinflammatory; gastrointestinal-gen.;	
KW	antiallergic; vasotropic; diagnosis; prognosis; therapeutic; screening;	
KW	antibody; cancer; neoplasm; hyperproliferation; inflammation;	
KW	autoimmune disease; immune disorder; rheumatoid arthritis; antirheumatic;	
KW	musculoskeletal disease; graft versus host disease; Crohns disease;	
KW	gastrointestinal disease; Wegener granulomatosis;	
KW	neurodegenerative disease; neuroprotective; neurological disease;	
KW	viral infection; infection; HIV infection; cytomegalovirus infection;	
KW	Pneumocystitis carinii infection; Kaposi's sarcoma; dermatological disease;	
KW	light chain constant region.	
XX	Homo sapiens.	
OS		
XX	WO2005105841-A2.	
PW		
XX	10-NOV-2005.	
PD		
XX	11-MAR-2005; 2005WO-US008377.	
PF		
XX	12-MAR-2004; 2004US-0552184P.	
PR		
XX	(HUMA-) HUMAN GENOME SCI INC.	
PA		
XX	Roschke V, Rosen CA, Ruben SM;	
PI		
XX	WPI; 2006-231015/24.	
DR		
XX	New antibody that immunospecifically binds G-protein Chemokine Receptor	
PT	(CCR5) polypeptide, useful in preparing a composition for treating or	
PT	preventing e.g., rheumatoid arthritis, neurodegenerative disease or viral	
PT	infection.	
XX		
XX	Disclosure; SEQ ID NO 81; 523pp; English.	
PS	The invention describes a new isolated antibody that immunospecifically	
CC	binds G-protein Chemokine Receptor (CCR5) polypeptide comprising a first	
CC	or second amino acid sequence that is at least 85, 90, 95, 96, 97, 98, 99	
CC	or 100% identical to an amino acid sequence of the VH or VL domain,	
CC	respectively, of the antibody expressed by the hybridoma cell line	
CC	deposited under ATCC Deposit No. PTA-5861. Also described are: a	
CC	polynucleotide encoding at least the VH or VL domain of the isolated	
CC	antibody; a vector comprising the polynucleotide; a host cell comprising	
CC	the vector or polynucleotide; a cell line engineered to express the	
CC	antibody; a method of making an antibody; a method of detecting	
CC	expression of a CCR5 polypeptide; a method of detecting, diagnosing,	
CC	prognosing or monitoring cancer or other hyperproliferative disorders;	
CC	and a kit comprising the antibody. The isolated antibody is useful in	
CC	preparing a composition for treating or preventing a disease or disorder,	
CC	e.g., a disease or disorder associated with inflammation, defective or	
CC	aberrant chemotaxis of immune cells or T-cell antigen presenting cell	
CC	interaction, a disease or disorder associated with lack of CCR5 function	
CC	or of aberrant CCR5 ligand expression, autoimmune disease, rheumatoid	
CC	arthritis, graft-versus-host disease, Crohn's disease, Wegner's	
CC	granulomatosis, neurodegenerative disease, or viral, HIV,	
CC	cytomegalovirus, poxvirus, Pneumocystitis carinii infection or Kaposi's	
CC	sarcoma. This is the amino acid sequence of human IgG1 kappa constant	
CC	domain.	
XX		
SQL	Sequence 330 AA;	
XX	Query Match	99.5%; Score 1756; DB 10; Length 330;
XX	Best Local Similarity	99.4%; Pred. No. 2.4e-123;
CC	Matches 328; Conservative	0; Mismatches 2; Indels 0; Gaps 0;
QY	1	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
DB	1	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
QY	61	GLYSLSSVTVTPSSSLGTQTYICNVNHPKSNTKVDKVEPKSCDKTHTCPPCPAPELAGA 120
DB	61	GLYSLSSVTVTPSSSLGTQTYICNVNHPKSNTKVDKVEPKSCDKTHTCPPCPAPELGG 120
QY	121	PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYDGVGVHNNAKTKPREEQYN 180
DB	121	PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYDGVGVHNNAKTKPREEQYN 180
QY	181	STYRVSVTLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
DB	181	STYRVSVTLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
QY	241	LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSLKLTVDKSRW 300
DB	241	LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSLKLTVDKSRW 300
QY	301	QOQNVFSCSVMHREALHNHYTQKSLSLSPGK 330
DB	301	QOQNVFSCSVMHREALHNHYTQKSLSLSPGK 330
RESULT 83		
ADL35095		
ID	ADL35095 standard; protein; 332 AA.	
XX	AC	ADL35095;
XX	03-JUN-2004	(first entry)
DT	Human IgG1 (hOAT) kappa heavy chain constant domain protein SeqID 98.	
DE		
XX	antibody; variable domain; framework region; FR; huFR;	
KW	immune system molecule; kappa; anti-tissue factor; hOAT; human.	
XX	Homo sapiens.	
OS		
XX		

PN WO2004020579-A2.
XX
PD 11-MAR-2004.
XX
PF 06-AUG-2003; 2003WO-US024637.
XX
PR 29-AUG-2002; 2002US-00230880.
XX
PA (SUNO-) SUNOL MOLECULAR CORP.
XX
XX Wong HC, Stinson JR, Mosquera LA;
XX WPI; 2004-239169/22.
XX
PT Producing humanized antibodies for diagnostic and therapeutic purposes
PT comprises optimizing similarity between individual antibody framework
PT regions to help identify human framework regions suitable for making the
PT antibodies.
XX
XX Disclosure; SEQ ID NO 98; 137pp; English.
XX
XX This invention relates to a novel method for producing a humanised
CC antibody variable (V) domain or its fragment by optimising sequence
CC similarity between individual antibody framework regions (FRs) in order
CC to identify suitable human FRs (huFRs). Specifically, it refers to novel
CC immune system molecules i.e. humanised monoclonal antibodies that exhibit
CC suitable binding affinity with reduced immunogenicity in humans. The
CC present invention describes a method of mutagenising DNA of non-human FRs
CC to encode humanised FRs having an amino acid sequence that is
CC substantially identical to the selected human FR previously identified
CC through sequence similarity searching. As such, this method provides
CC a humanised light or heavy chain V domains of the sequence huFR1-huFR2
CC -CDR2-huFR3-CDR3-huFR4, which can be used as therapeutic or diagnostic
CC products to treat and/or diagnose diseases in humans and animals.
CC Furthermore, the method expands the number of best fit possibilities that
CC can be generated and provides a rational basis for assembling nearly all
CC humanised immune system molecules of interest. This polypeptide sequence
CC is the human IgG1 kappa heavy chain constant domain protein of the
CC invention.
XX
SQ Sequence 332 AA;
Query Match 99.5%; Score 1756; DB 8; Length 332;
Best Local Similarity 99.4%; Pred. No. 2.4e-123; Mismatches 2; Indels 0; Gaps 0;
Matches 328; Conservative 0;
QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSMNSGALTSGVHTFPAVLQSS 60
DB 3 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSMNSGALTSGVHTFPAVLQSS 62
QY 61 GLYSLSSVTVTPSSSLGTQTYICNVNHRKPSNTKVDKVEPKSCDKTHTCPCPAPELAGA 120
DB 63 GLYSLSSVTVTPSSSLGTQTYICNVNHRKPSNTKVDKVEPKSCDKTHTCPCPAPELGG 122
QY 121 PSVFLFPKPKDLMISRTPEVTCVVDSHEDPEVKFNWYVDGVEVHNATKPREQYN 180
DB 123 PSVFLFPKPKDLMISRTPEVTCVVDSHEDPEVKFNWYVDGVEVHNATKPREQYN 182
QY 181 STYRVSVSLTVLHODWLNGKEYCKVSNKALPAPIEKTISKAKGQPREPPQVYVTPPSRDE 240
DB 183 STYRVSVSLTVLHODWLNGKEYCKVSNKALPAPIEKTISKAKGQPREPPQVYVTPPSRDE 242
QY 241 LTKNQVSLTCLVKGPYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFPLYSKLTVDKSRW 300
DB 243 LTKNQVSLTCLVKGPYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFPLYSKLTVDKSRW 302
QY 301 QQGNVFSCVMEALHNHYTQKSLSLSPGK 330
DB 303 QQGNVFSCVMEALHNHYTQKSLSLSPGK 332
RESULT 84
ADM07455

ID ADM07455 standard; protein; 332 AA.
XX
AC ADM07455;
XX
DT 07-APR-2005 (first entry)
XX
DE Human IgG1 heavy chain constant domain.
XX
KW Blood-clotting; heavy chain constant region; inflammation;
KW antiinflammatory; antibody; tissue factor; sepsis;
KW disseminated intravascular coagulation; anticoagulant;
KW hematological disease; thrombosis; lung injury; respiratory-gen.;
KW respiratory distress syndrome; Immunosuppressive; Antibacterial;
KW Antiarthritic; Antianemic; anemia; rheumatoid arthritis;
KW glomerulonephritis; multiple sclerosis; psoriasis; Sjogren's syndrome;
KW inflammatory bowel disease.
XX
OS Homo sapiens.
XX
PN WO2005004793-A2.
XX
PD 20-JAN-2005.
XX
PF 04-JUN-2004; 2004WO-US017900.
XX
PR 19-JUN-2003; 2003US-0480254P.
PR 22-JAN-2004; 2004US-0538892P.
XX
PA (SUNO-) SUNOL MOLECULAR CORP.
XX
PI Jiao J, Wong HC, Egan JO;
XX WPI; 2005-091964/10.
DR
XX Preventing or treating sepsis or inflammation in mammals comprises
PT administering a humanized or chimeric antibody that binds to a human
PT tissue factor to form a complex in which factor X or IX binding to the
PT complex is inhibited.
XX
PS Example 1; Fig 5; 109pp; English.
XX
CC The invention relates to preventing or treating a sepsis or inflammatory
CC disease in a mammal comprising administering to the mammal a therapeutic
CC amount of at least one humanized antibody, chimeric antibody, or their
CC fragment that binds specifically to tissue factor (TF) to form a complex,
CC where factor X or IX binding to the complex is inhibited and the
CC administration prevents or treats the sepsis in the mammal. Also included
CC are a kit for performing the above method and reducing an inflammatory
CC cytokine production in a mammal. The inflammatory disease is associated
CC with arthritis (preferably rheumatoid arthritis), glomerulonephritis,
CC multiple sclerosis, psoriasis, Sjogren's syndrome, or inflammatory bowel
CC disease. The method also treats or prevents a sepsis-induced anemia or a
CC sepsis-related condition in a mammal, where the sepsis-related condition
CC is DIC, fibrin deposition, thrombosis, lung injury, or sepsis-associated
CC renal disorder. The lung injury is acute lung injury (ALI) or acute
CC respiratory distress syndrome (ARDS). The sepsis-associated renal
CC disorder is acute tubular necrosis. The methods and kit are useful for
CC preventing or treating sepsis or sepsis-related conditions (e.g. DIC or
CC anemia) or inflammatory diseases (e.g. arthritis). The humanized
CC antibodies are based on the chimeric antibody ch36 which comprises the
CC light and heavy chain variable regions (VL or VH) of an anti-TF antibody
CC fused to the human IgG4 heavy and kappa light constant regions. The CDRs
CC (complementarity determining region) and FRs (framework regions) are then
CC humanized. The present sequence represents a human heavy chain constant
CC region used to make the chimeric antibody.
XX
SQ Sequence 332 AA;
Query Match 99.5%; Score 1756; DB 9; Length 332;
Best Local Similarity 99.4%; Pred. No. 2.4e-123; Mismatches 2; Indels 0; Gaps 0;
Matches 328; Conservative 0;
QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSMNSGALTSGVHTFPAVLQSS 60

Db 3 ASTKGPSVFPLAPSSKSTGGTAALGCLVKDYFPEPVTVMNSGALTSGVHTFPAVLQSS 62
Qy 61 GLYSLSSVTVTPSSSLGTQTYICNVNHPKSNKVDKKVEPKSCDKTHHTCPPCPAPAPELAGA 120
Db 63 GLYSLSSVTVTPSSSLGTQTYICNVNHPKSNKVDKKVEPKSCDKTHHTCPPCPAPAPELGG 122
Qy 121 PSVFLFPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNNAKTKPREEQYN 180
Db 123 PSVFLFPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNNAKTKPREEQYN 182
Qy 181 STYRVSVLTVLHQDLNKGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Db 183 STYRVSVLTVLHQDLNKGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 242
Qy 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSLKLTVDKSRW 300
Db 243 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSLKLTVDKSRW 302
Qy 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330
Db 303 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 332

RESULT 85
ADJ95912
ID ADJ95912 standard; protein; 333 AA.
XX AC ADJ95912;
XX DT 06-MAY-2004 (first entry)
XX DE Human IgG heavy chain constant region.
XX KW cytostatic; antibody therapy; immunoglobulin cassette construct;
KW immunoglobulin leader molecule; immunoglobulin domain;
KW immunoglobulin therapeutic molecule; monobody; cancer; immunoglobulin G;
KW IgG; heavy chain constant region; human.
XX OS Homo sapiens.
XX PN US2004033561-A1.
XX PD 19-FEB-2004.
XX PF 17-OCT-2002; 2002US-00272899.
XX PR 19-OCT-2001; 2001US-0350166P.
XX PR 26-JUN-2002; 2002US-0392364P.
XX PA (MILL-) MILLENNIUM PHARM INC.
XX PI O'keefe TL, Healey JJ, Newman W, Ponath PD, Keyt BA;
XX WPI; 2004-180050/17.
XX DR N-PSDB; ADJ95911.
XX PT New isolated nucleic acid molecules having an immunoglobulin cassette
PT construct, useful for producing immunoglobulin therapeutic molecules
PT termed monobodies, used as a therapeutic group in cancer disorders.
XX Example 2; SEQ ID NO 8; 84pp; English.
XX The invention describes an isolated nucleic acid molecule comprising an
CC immunoglobulin cassette construct, wherein the immunoglobulin cassette
CC comprises an immunoglobulin leader molecule operably linked to a stable
CC immunoglobulin domain region. The methods and compositions of the present
CC invention are useful for producing immunoglobulins, in particular
CC immunoglobulin therapeutic molecules termed monobodies, used as a
CC therapeutic group in cancer disorders. This is the amino acid sequence of
CC the human immunoglobulin G (IgG) heavy chain constant region used in the
CC creation of immunoglobulin DNA cassette constructs.

SQ Sequence 333 AA;
Query Match 99.5%; Score 1756; DB 8; Length 333;
Best Local Similarity 99.4%; Pred. No. 2.4e-123;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1 ASTKGPSVFPLAPSSKSTGGTAALGCLVKDYFPEPVTVMNSGALTSGVHTFPAVLQSS 60
Db 4 ASTKGPSVFPLAPSSKSTGGTAALGCLVKDYFPEPVTVMNSGALTSGVHTFPAVLQSS 63
Qy 61 GLYSLSSVTVTPSSSLGTQTYICNVNHPKSNKVDKKVEPKSCDKTHHTCPPCPAPAPELAGA 120
Db 64 GLYSLSSVTVTPSSSLGTQTYICNVNHPKSNKVDKKVEPKSCDKTHHTCPPCPAPAPELGG 123
Qy 121 PSVFLFPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNNAKTKPREEQYN 180
Db 124 PSVFLFPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNNAKTKPREEQYN 183
Qy 181 STYRVSVLTVLHQDLNKGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Db 184 STYRVSVLTVLHQDLNKGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 243
Qy 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSLKLTVDKSRW 300
Db 244 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSLKLTVDKSRW 303
Qy 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330
Db 304 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 333
RESULT 86
ADL22761
ID ADL22761 standard; protein; 333 AA.
XX AC ADL22761;
XX DT 20-MAY-2004 (first entry)
XX DE Human antibody heavy chain variable region.
XX KW antibody; human; heavy chain variable region; therapeutic.
XX OS Homo sapiens.
XX PN WO2004013278-A2.
XX PD 12-FEB-2004.
XX PF 01-AUG-2003; 2003WO-KR001555.
XX PR 02-AUG-2002; 2002KR-00045765.
XX PR 02-AUG-2002; 2002KR-00045767.
XX PR 02-AUG-2002; 2002KR-00045768.
XX PA (YUHA-) YUHAN CORP.
XX PI Lee J, Ko I, Song M, Kim C, Lee J, Yoo T, Kim J, Park S;
XX WPI; 2004-157108/15.
XX DR N-PSDB; ADL22760.
XX PT New expression vectors for an antibody heavy chain variable region,
PT lambda light chain variable region or kappa light chain variable region,
PT useful in developing therapeutic antibodies, e.g. humanized or chimeric
XX antibodies.
XX Example 3; Page 34-35; 39pp; English.
XX The present invention relates to an expression vector for an antibody
CC heavy chain variable region, a lambda light chain variable region or a
CC kappa light chain variable region. The expression vectors are useful in
CC the development of therapeutic antibodies, e.g. humanized or chimeric

CC antibodies. The present sequence is a human heavy chain variable region
CC of the invention.
XX
SQ Sequence 333 AA;
Query Match 99.5%; Score 1756; DB 8; Length 333;
Best Local Similarity 99.4%; Pred. No. 2.4e-123;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1 ASTKGPSVFPLAPSSKSTSGGTAAAGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSS 60
Db 4 ASTKGPSVFPLAPSSKSTSGGTAAAGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSS 63
Qy 61 GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELAGA 120
Db 64 GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG 123
Qy 121 PSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
Db 124 PSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 183
Qy 181 STYRVSVLTVLHQDLNKGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVTLPPSRDE 240
Db 184 STYRVSVLTVLHQDLNKGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVTLPPSRDE 243
Qy 241 LTKQVSLTCLVKGFPYSDIAVEWESNGQPENNYKTTTPVLDSDGSPFLYSLKLTVDKSRW 300
Db 244 LTKQVSLTCLVKGFPYSDIAVEWESNGQPENNYKTTTPVLDSDGSPFLYSLKLTVDKSRW 303
Qy 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330
Db 304 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 333
RESULT 87
AEC22665
ID AEC22665 standard; protein; 335 AA.
XX
AC AEC22665;
XX
DT 20-OCT-2005 (first entry)
XX
DE Secreted IgG constant domain.
XX
KW multispecific antibody; promoter; bispecific antibody; immunoglobulin.
XX
OS Homo sapiens.
XX
PN WO2005072112-A2.
XX
PD 11-AUG-2005.
XX
PF 30-DEC-2004; 2004WO-US043806.
XX
PR 31-DEC-2003; 2003US-0533241P.
XX
PA (VACC-) VACCINEX INC.
XX
FI Zauderer M, Paris M;
XX
DR WPI; 2005-648912/66.
DR N-PSDB; AEC22664.
XX
PT Identifying polynucleotides encoding a bispecific antibody by introducing
PT a first library of polynucleotides encoding immunoglobulin subunit
PT polypeptides into eukaryotic host cells capable of expressing the
PT bispecific antibody.
XX
PS Example 1; SEQ ID NO 35; 254pp; English.
XX
CC The invention relates to a method of identifying polynucleotides which
CC encode a bispecific antibody which comprises introducing a library of
CC polynucleotides encoding first and second heavy chain and light chain

CC immunoglobulin subunit polypeptides into eukaryotic host cells,
CC expression and recovery of the antibodies or their antigen-binding
CC fragments. The method is useful in identifying polynucleotides which
CC encode a bispecific antibody or its bispecific antigen-binding fragment.
CC The present sequence represents an immunoglobulin constant domain.
XX
SQ Sequence 335 AA;
Query Match 99.5%; Score 1756; DB 9; Length 335;
Best Local Similarity 99.4%; Pred. No. 2.4e-123;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1 ASTKGPSVFPLAPSSKSTSGGTAAAGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSS 60
Db 6 ASTKGPSVFPLAPSSKSTSGGTAAAGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSS 65
Qy 61 GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELAGA 120
Db 66 GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG 125
Qy 121 PSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
Db 126 PSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 185
Qy 181 STYRVSVLTVLHQDLNKGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVTLPPSRDE 240
Db 186 STYRVSVLTVLHQDLNKGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVTLPPSRDE 245
Qy 241 LTKQVSLTCLVKGFPYSDIAVEWESNGQPENNYKTTTPVLDSDGSPFLYSLKLTVDKSRW 300
Db 246 LTKQVSLTCLVKGFPYSDIAVEWESNGQPENNYKTTTPVLDSDGSPFLYSLKLTVDKSRW 305
Qy 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330
Db 306 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 335
RESULT 88
AAR43685
ID AAR43685 standard; protein; 351 AA.
XX
AC AAR43685;
XX
DT 25-MAR-2003 (revised)
DT 25-MAY-1994 (first entry)
XX
DE Human kappa immunoglobulin light chain constant domain.
XX
KW Human; immunoglobulin; constant; region; humanised; P-selectin; light;
KW blocking; antibody; heavy; chain; variable; murine; thrombotic disease;
KW monoclonal; PBL.3; CDR; complementarity determining region; leukocyte;
KW expression vector; coexpression; pHCNV-1748HA-gammaCi-dhfr; epitope;
KW pHCNV-1748RLA-KR-neo; PBL.3/Humanised version A; vascular endothelium;
KW pHCNV-1747CH-gammaCi-neo; pHCNV-1747-CL-KR-neo; PBL.3 chimera;
KW acute lung injury; ischaemia reperfusion injury; inflammation.
XX
OS Homo sapiens.
XX
FI Key Location/Qualifiers
XX Domain 22..119
FT /note= "CH1 domain"
FT Region 120..134
FT /note= "Hinge region"
FT Domain 135..244
FT /note= "CH2 domain"
FT Domain 245..352
FT /note= "CH3 domain"
XX
PN WO9321956-A1.
XX
PD 11-NOV-1993.
XX
PF 04-MAY-1993; 93WO-US004274.

XX 05-MAY-1992; 92US-00880196.
XX (CYTE-) CYTEL CORP.
XX Chestnut RW, Polley MJ, Paulson JC;
XX WPI; 1993-368423/46.
XX N-PSDB; AAQ51547.
XX Anti-P-selectin antibody for ischaemia acute lung injury treatment -
XX useful to treat inflammation and pathological conditions of intercellular
XX adhesion by competitive inhibition assay.
XX Example 10; Fig 9; 82pp; English.
XX The sequences given in AAR43685-86 represent human immunoglobulin
XX constant regions which were used in the production of the humanised P-
XX selectin blocking antibody, along with the heavy and light chain variable
XX region coding sequences of the murine monoclonal antibody PBI.3, given in
XX AAR43687-88. The CDRs from PBI.3 heavy and light chains were substituted
XX for the CDRs of human heavy and light chains. The humanised variable
XX regions were inserted into expression vectors. By coexpression of
XX appropriate combinations of heavy and light chains, several humanised
XX antibodies can be expressed. Coexpression of pHCMV-1748RHA-gammaCI-dhfr
XX and pHCMV-1748RLA-KR-neo gives rise to the PBI.3/Humanised version A.
XX Coexpression of pHCMV-1747CH- gammaCI-neo and pHCMV-1747-CL-KR-neo gives
XX rise to the PBI.3 chimera. These humanised antibodies selectively bind
XX epitopes on P-selectin and block adhesion of leukocytes to the vascular
XX endothelium. They may be used to treat inflammatory and thrombotic
XX diseases and other pathological conditions involving P-selectin and
XX antibodies to it, esp. acute lung injury and ischaemia reperfusion
XX injury. (Updated on 25-MAR-2003 to correct PN field.)
XX SQ Sequence 351 AA;
Query Match 99.5%; Score 1756; DB 2; Length 351;
Best Local Similarity 99.4%; Pred. No. 2.6e-123;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1 ASTKGPSVFPPLAPSSKSTSGGTAALGCLVKDYFPEPTVWSNNGALTSGVHTFPAVLQSS 60
DB 22 ASTKGPSVFPPLAPSSKSTSGGTAALGCLVKDYFPEPTVWSNNGALTSGVHTFPAVLQSS 81
QY 61 GLYSLSVVTVFPSSSLGTQTYICNVNHPKSNKTKVDKVEPKSCDKTHTCPCPAPPELAGA 120
DB 82 GLYSLSVVTVFPSSSLGTQTYICNVNHPKSNKTKVDKVEPKSCDKTHTCPCPAPPELAGG 141
QY 121 PSVFLPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 180
DB 142 PSVFLPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 201
QY 181 STYRVSVVLTVLHODWLNKKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
DB 202 STYRVSVVLTVLHODWLNKKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 261
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW 300
DB 262 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW 321
QY 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330
DB 322 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 351
RESULT 89
ADJ95976
ID ADJ95976 standard; protein; 356 AA.
XX AC ADJ95976;
XX DT 06-MAY-2004 (first entry)
XX

DE Immunoglobulin DNA cassette polypeptide seqid 72.
XX cytostatic; antibody therapy; immunoglobulin cassette construct;
KW immunoglobulin leader molecule; immunoglobulin domain;
KW immunoglobulin therapeutic molecule; monobody; cancer.
XX Synthetic.
XX US2004033561-A1.
XX 19-FEB-2004.
XX 17-OCT-2002; 2002US-00272899.
XX 19-OCT-2001; 2001US-0350166P.
XX 26-JUN-2002; 2002US-0392364P.
XX (MILL-) MILLENNIUM PHARM INC.
XX O'keefe TL, Healey JJ, Newman W, Ponath PD, Keyt BA;
XX WPI; 2004-180050/17.
XX N-PSDB; ADJ95975.
XX New isolated nucleic acid molecules having an immunoglobulin cassette
XX construct, useful for producing immunoglobulin therapeutic molecules
XX termed monobodies, used as a therapeutic group in cancer disorders.
XX Disclosure; SEQ ID NO 72; 84pp; English.
XX The invention describes an isolated nucleic acid molecule comprising an
XX immunoglobulin cassette construct, wherein the immunoglobulin cassette
XX comprises an immunoglobulin leader molecule operably linked to a stable
XX immunoglobulin domain region. The methods and compositions of the present
XX invention are useful for producing immunoglobulins, in particular
XX immunoglobulin therapeutic molecules termed monobodies, used as a
XX therapeutic group in cancer disorders. This is the amino acid sequence of
XX an immunoglobulin DNA cassette construct.
XX SQ Sequence 356 AA;
Query Match 99.5%; Score 1756; DB 8; Length 356;
Best Local Similarity 99.4%; Pred. No. 2.6e-123;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1 ASTKGPSVFPPLAPSSKSTSGGTAALGCLVKDYFPEPTVWSNNGALTSGVHTFPAVLQSS 60
DB 27 ASTKGPSVFPPLAPSSKSTSGGTAALGCLVKDYFPEPTVWSNNGALTSGVHTFPAVLQSS 86
QY 61 GLYSLSVVTVFPSSSLGTQTYICNVNHPKSNKTKVDKVEPKSCDKTHTCPCPAPPELAGA 120
DB 87 GLYSLSVVTVFPSSSLGTQTYICNVNHPKSNKTKVDKVEPKSCDKTHTCPCPAPPELAGG 146
QY 121 PSVFLPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 180
DB 147 PSVFLPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 206
QY 181 STYRVSVVLTVLHODWLNKKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
DB 207 STYRVSVVLTVLHODWLNKKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 266
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW 300
DB 267 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW 326
QY 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330
DB 327 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 356
RESULT 90
AAP91918
ID AAP91918 standard; protein; 371 AA.


```

XX AAP91918;
AC
XX
XX
DT 25-MAR-2003 (revised)
DT 31-OCT-2002 (revised)
DT 14-MAY-1990 (first entry)
DE
XX Sequence of the linked immunoglobulin gamma chain fragment.
XX Immunoglobulin gamma chain; IgG1 heavy chain constant region.
KW
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
FH Misc-difference 42..43
FT /note= "Insert site"
FT Misc-difference 144..145
FT /note= "Insert site"
XX
XX EP314317-A.
XX
XX 03-MAY-1989.
XX
XX 03-OCT-1988; 88EP-00309194.
XX
XX 02-OCT-1987; 87US-00104329.
XX
XX 28-SEP-1988; 88US-00250785.
XX
XX (GETH ) GENENTECH INC.
XX
XX Capon DJ, Gregory TJ;
PI
XX
XX WPI; 1989-131855/18.
XX
XX N-PSDB; AAN90779.
XX
XX Compens. contg. adhesion variants - useful in therapy and diagnostics,
XX e.g. CD4 variants which are therapeutically useful for treating human
XX immuno-deficiency virus.
XX
XX Disclosure; Fig 4a-4b; 36pp; English.
XX
XX It may be fused to the first 180 N-terminal residues of CD4 at the C-
XX terminus. The fusion protein may be used for antiviral of
XX immunomodulatory therapy particularly in treatment of HIV infection.
XX (Updated on 31-OCT-2002 to add missing OS field.) (Updated on 25-MAR-2003
XX to correct PR field.) (Updated on 25-MAR-2003 to correct PI field.)
XX
XX Sequence 371 AA;
XX
XX Query Match 99.5%; Score 1756; DB 1; Length 371;
XX Best Local Similarity 99.4%; Pred. No. 2.8e-123;
XX Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSMNSGALTSGVHTFPAVLQSS 60
XX
XX 42 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSMNSGALTSGVHTFPAVLQSS 101
XX
XX 61 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELAGA 120
XX
XX 102 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELAGG 161
XX
XX 121 PSVFLFPPKPKDPTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREEOYN 180
XX
XX 162 PSVFLFPPKPKDPTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREEOYN 221
XX
XX 181 STYRVSVLTVLHQDLNKGKEYKCKVSNKALPAPIEKTISAKAGQPREPQVYITLPPSRDE 240
XX
XX 222 STYRVSVLTVLHQDLNKGKEYKCKVSNKALPAPIEKTISAKAGQPREPQVYITLPPSRDE 281
XX
XX 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300
XX
XX 282 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 341

```

```

QY 301 QQGVFSCSVNHEALHNHYTKSLSPCK 330
DB 342 QQGVFSCSVNHEALHNHYTKSLSPCK 371

RESULT 91
ABR39465
ID ABR39465 standard; protein; 442 AA.
XX
AC ABR39465;
XX
DT 12-JUN-2003 (first entry)
XX
DE Humanised anti-Abeta antibody 266 heavy chain.
XX
KW Amyloid-beta; Abeta; antibody 266; nootropic; neuroprotective; CDR;
KW immunostimulant.
XX
OS Homo sapiens.
XX
XX WO2003016467-A2.
XX
XX PD
XX
XX 27-FEB-2003.
XX
XX 14-AUG-2002; 2002WO-US021324.
XX
XX 17-AUG-2001; 2001US-0313576P.
XX
XX 28-MAY-2002; 2002US-0383851P.
XX
XX (ELIL ) LILLY & CO ELI.
XX
XX Bales KR, Paul SM;
XX
XX WPI; 2003-289975/28.
XX
XX Treating or reducing the progression of diseases associated with amyloid-
XX beta peptide, e.g. Alzheimer's disease, vascular dementia or mild
XX cognitive impairment, comprises administering an anti-amyloid-beta
XX peptide antibody.
XX
XX Disclosure; Page 20-22; 84pp; English.
XX
XX The invention relates to treating cognitive symptoms or reducing disease
XX progression in a subject having a condition or disease associated with
XX amyloid-beta peptide (Abeta). The method involves administering an amount
XX of an anti-Abeta antibody that has greater affinity for soluble Abeta
XX than 10-9 M, that has affinity (KD) for soluble Abeta1-40 or Abeta1-42
XX higher than 10-9 M, or that has greater affinity for soluble Abeta than
XX antibody 266 has. The method or the anti-Abeta antibody is useful in
XX preparing a medicament for treating cognitive symptoms or reducing
XX disease progression in a subject having a condition or disease associated
XX with Abeta. The condition or disease is Alzheimer's disease, Down's
XX syndrome, cerebral amyloid angiopathy, vascular dementia, or mild
XX cognitive impairment. The present sequence represents a humanised anti-
XX Abeta antibody 266 heavy chain
XX
XX Sequence 442 AA;
XX
XX Query Match 99.5%; Score 1756; DB 6; Length 442;
XX Best Local Similarity 99.4%; Pred. No. 3.4e-123;
XX Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSMNSGALTSGVHTFPAVLQSS 60
XX
XX 113 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSMNSGALTSGVHTFPAVLQSS 172
XX
XX 61 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELAGA 120
XX
XX 173 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELAGG 232
XX
XX 121 PSVFLFPPKPKDPTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREEOYN 180
XX
XX 233 PSVFLFPPKPKDPTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREEOYN 292

```



```

ABR39793
ID ABR39793 standard; peptide; 442 AA.
XX
AC ABR39793;
XX
DT 18-AUG-2003 (first entry)
XX
DE Humanised anti-Abeta antibody 266 heavy chain.
XX
KW Amyloid-beta; Abeta; antibody 266; neurotropic; neuroprotective; CDR;
KW immunostimulant.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Misc-difference 56
FT /note= "Xaa is any amino acid, provided that if Xaa at
FT position 57 is neither Asp nor Pro and Xaa at position 59
FT is Ser or Thr, then Xaa at position 56 is not Asn"
FT
FT Misc-difference 57
FT /note= "Xaa is any amino acid, provided that if Xaa at
FT position 56 is Asn and Xaa at position 58 is Ser or Thr,
FT then Xaa at position 57 is Asp or Pro"
FT
FT Misc-difference 58
FT /note= "Xaa is any amino acid, provided that if Xaa at
FT position 56 is Asn and Xaa at position 57 is neither Asp
FT nor Pro, then Xaa at position 58 is neither Ser nor Thr"
XX
PN WO2003016466-A2.
XX
PD 27-FEB-2003.
XX
PF 14-AUG-2002; 2002WO-US021322.
XX
PR 17-AUG-2001; 2001US-0313224P.
XX
PA (ELIL ) LILLY & CO ELI.
XX
PI Jia AY, Taurushita N, Vasquez MJ;
XX
WPI; 2003-278557/27.
XX
New antibodies comprising a heavy chain and a light chain complementarity
determining regions from antibody 266, for treating and preventing
conditions associated with the A beta peptide, e.g. Alzheimer's disease
or Down syndrome.
XX
PS Disclosure; Page 21-23; 82pp; English.
XX
The invention relates to an anti-Abeta (amyloid-beta peptide) antibody
266. The antibodies are useful for treating and preventing conditions
associated with the Abeta peptide, such as Alzheimer's disease, Down
syndrome, and cerebral amyloid angiopathy; for diagnosing diseases in
humans; for determining whether a human subject will respond to treatment
using humanized antibodies against Abeta; for treating, preventing and
reversing cognitive decline in clinical or pre-clinical Alzheimer's
disease, Down's syndrome or cerebral amyloid angiopathy; for inhibiting
formation of amyloid plaques of the effects of toxic soluble Abeta
species in humans. Treatment of the patients with antibody will inhibit
or prevent cognitive decline typically associated with disease
progression and reverses it. The present sequence represents a preferred
heavy chain of the humanised anti-Abeta antibody 266
XX
SQ Sequence 442 AA;
Query Match 99.5%; Score 1756; DB 6; Length 442;
Best Local Similarity 99.4%; Pred. No. 3.4e-123;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
1 ASTKGPSVFPFLAPSRSKSTGGTAALGCLVKDIPPEPVTVWNSGALTSGVHTFPAVLQSS 60
113 ASTKGPSVFPFLAPSRSKSTGGTAALGCLVKDIPPEPVTVWNSGALTSGVHTFPAVLQSS 172

```

```

QY 61 GLYSLSSVVTVPSSSLGTQTYICNVNHRKPSNTKVDKKVEPKSCDKTHTCTPPCPAPELAGA 120
DB 173 GLYSLSSVVTVPSSSLGTQTYICNVNHRKPSNTKVDKKVEPKSCDKTHTCTPPCPAPELGG 232
QY 121 PSVFLFPKPKDXTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
DB 233 PSVFLFPKPKDXTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 292
QY 181 STYRVSVVLTVLHQDLNKGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVTLPPSRDE 240
DB 293 STYRVSVVLTVLHQDLNKGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVTLPPSRDE 352
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
DB 353 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 412
QY 301 QGQNVFSCVMHEALHNNHYTKSLSLSPGK 330
DB 413 QGQNVFSCVMHEALHNNHYTKSLSLSPGK 442
RESULT 96
ABB80113
ID ABB80113 standard; protein; 442 AA.
XX
AC ABB80113;
XX
DT 13-JUN-2003 (first entry)
XX
DE Deglycosylated heavy chain.
XX
KW Complementarity determining region; CDR; humanised; mouse; 266; light;
KW heavy; variable; domain; antibody; preclinical; clinical;
KW Alzheimer's disease; epitope; amyloid beta peptide; Abeta;
KW central nervous system; plasma.
XX
OS Homo sapiens.
OS Mus musculus.
XX
FH Key Location/Qualifiers
FT Misc-difference 56
FT /label= Any amino acid
FT /note= "Provided that if Xaa57 is neither Asp nor Pro and
FT Xaa58 is Ser or Thr, then Xaa56 is not Asn"
FT
FT Misc-difference 57
FT /label= Any amino acid
FT /note= "Provided that if Xaa56 is Asn and Xaa58 is Ser or
FT Thr, then Xaa57 is Asp or Pro"
FT
FT Misc-difference 58
FT /label= Any amino acid
FT /note= "Provided that if Xaa56 is Asn and Xaa57 is
FT neither Asp nor Pro, then Xaa58 is neither Ser nor Thr"
XX
WO2003015617-A2.
XX
27-FEB-2003.
XX
16-AUG-2002; 2002WO-US026321.
XX
17-AUG-2001; 2001US-0313221P.
XX
17-AUG-2001; 2001US-0313224P.
XX
23-OCT-2001; 2001US-0334987P.
XX
(PN ) UNIV WASHINGTON.
XX
(ELIL ) LILLY & CO ELI.
XX
Holtzman DM, Demattos R, Bales KR, Cummins DJ, Paul SM;
XX
WPI; 2003-278505/27.
XX
Diagnosing preclinical or clinical Alzheimer's disease in a subject by
administering an antibody which specifically binds an epitope.
XX

```

PS Claim 8; Page 20-22; 64pp; English.

XX This sequence represents the preferred heavy chain from a deglycosylated

CC version of the humanised mouse antibody 266 heavy chain of the invention.

CC The antibody of the invention specifically binds an epitope, preferably

CC the amyloid beta peptide (Abeta). The antibodies sequester Abeta from its

CC bound, circulating form in blood and alter clearance of soluble and bound

CC forms of Abeta in central nervous system and plasma. The antibodies

CC specifically bind an epitope representing amino acids 13-28 of the Abeta

CC molecule. Deglycosylation of the heavy chain CDR2, as in this sequence,

CC causes higher affinity for Abeta. The antibody of the invention may be

CC used for diagnosing preclinical or clinical Alzheimer's disease

XX

SQ Sequence 442 AA;

Query Match 99.5%; Score 1756; DB 6; Length 442;

Best Local Similarity 99.4%; Pred. No. 3.4e-123;

Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTWNSGALTSVHTFPAVLQSS 60

DB 113 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTWNSGALTSVHTFPAVLQSS 172

QY 61 GLYSLSVVTVPPSSSLGTQTYICNVNHPKSNKVDKVEPKSCDKTHTCPCPAPELAGA 120

DB 173 GLYSLSVVTVPPSSSLGTQTYICNVNHPKSNKVDKVEPKSCDKTHTCPCPAPELAGG 232

QY 121 PSVFLFPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180

DB 233 PSVFLFPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 292

QY 181 STYRVVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240

DB 293 STYRVVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 352

QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300

DB 353 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 412

QY 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330

DB 413 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 442

RESULT 97

ID ABB80109 standard; protein; 442 AA.

AC ABB80109;

XX

DT 13-JUN-2003 (first entry)

XX

DE Heavy chain.

XX

XX Complementarity determining region; CDR; humanised; mouse; 266; light;

KW heavy; variable; domain; antibody; preclinical; clinical;

KW Alzheimer's disease; epitope; amyloid beta peptide; Abeta;

KW central nervous system; plasma.

XX

OS Homo sapiens.

OS Mus musculus.

PN WO2003015617-A2.

XX

XX 27-FEB-2003.

XX

XX 16-AUG-2002; 2002WO-US026321.

XX

PR 17-AUG-2001; 2001US-0313221P.

PR 17-AUG-2001; 2001US-0313224P.

PR 23-OCT-2001; 2001US-0334987P.

XX

PA (UNIW) UNIV WASHINGTON.

PA (ELIL) LILLY & CO ELI.

PI Holtzman DM, Denattos R, Bales KR, Cummins DJ, Paul SM;

XX WPI; 2003-278505/27.

DR

XX Diagnosing preclinical or clinical Alzheimer's disease in a subject by

PT administering an antibody which specifically binds an epitope.

XX

PS Disclosure; Page 15-16; 64pp; English.

XX

CC The sequences given in AAG80104-09 represent preferred antibodies of the

CC invention. This sequence represents the preferred heavy chain. The

CC humanised antibody of the invention may be used for diagnosing

CC preclinical or clinical Alzheimer's disease. The antibody specifically

CC binds an epitope, preferably the amyloid beta peptide (Abeta). The

CC antibodies sequester Abeta from its bound, circulating form in blood and

CC alter clearance of soluble and bound forms of Abeta in central nervous

CC system and plasma. The antibodies specifically bind an epitope

CC representing amino acids 13-28 of the Abeta molecule

XX

SQ Sequence 442 AA;

Query Match 99.5%; Score 1756; DB 6; Length 442;

Best Local Similarity 99.4%; Pred. No. 3.4e-123;

Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTWNSGALTSVHTFPAVLQSS 60

DB 113 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTWNSGALTSVHTFPAVLQSS 172

QY 61 GLYSLSVVTVPPSSSLGTQTYICNVNHPKSNKVDKVEPKSCDKTHTCPCPAPELAGA 120

DB 173 GLYSLSVVTVPPSSSLGTQTYICNVNHPKSNKVDKVEPKSCDKTHTCPCPAPELAGG 232

QY 121 PSVFLFPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180

DB 233 PSVFLFPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 292

QY 181 STYRVVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240

DB 293 STYRVVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 352

QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300

DB 353 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 412

QY 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330

DB 413 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 442

RESULT 98

ID ADE94066 standard; protein; 442 AA.

XX

AC ADE94066;

XX

DT 12-FEB-2004 (first entry)

XX

DE Humanised anti-Abeta antibody 266 heavy chain SEQ ID NO:12.

XX

XX anxiety disorder; mood disorder; anti-Abeta antibody; Abeta; nootropic;

KW neuroprotective; antidepressant; neuroleptic; tranquilliser;

KW gene therapy; Alzheimer's disease; chronic amyloid angiopathy;

KW depression; major depressive episode; unipolar major depression;

KW schizophrenia; simple phobia; social phobia; agoraphobia; panic disorder;

KW obsessive-compulsive disorder; post-traumatic stress disorder.

XX

OS Synthetic.

OS Mus sp.

OS Homo sapiens.

XX

PN WO2003090772-A1.
XX 06-NOV-2003.
XX 17-APR-2003; 2003WO-US010473.
XX 25-APR-2002; 2002US-0375462P.
XX (ELIL) LILLY & CO ELI.
XX Gerlai RT;
XX WPI; 2003-865528/80.
XX Treating, preventing and/or diagnosing a condition related to Abeta
XX expression, such as anxiety or mood disorders, including Alzheimer's
XX disease, depression, and schizophrenia, by administering an anti-Abeta
XX antibody to the subject.
XX Claim 24; SEQ ID NO 12; 64pp; English.
XX The present invention describes a method for treating an anxiety disorder
XX or a mood disorder in an elderly subject. The method comprises
XX administering an anti-Abeta antibody to the subject. Also described are
XX Abeta nucleic acids, polypeptides, antibodies and pharmaceutical
XX compositions used in the methods of the invention. Abeta has nootropic,
XX neuroprotective, antidepressant, neuroleptic and tranquilliser
XX activities, and can be used in gene therapy. The methods and compositions
XX of the present invention are useful for treating, preventing and/or
XX diagnosing a condition related to Abeta expression, such as anxiety or
XX mood disorders, including Alzheimer's disease, chronic amyloid
XX angiopathy, depression, major or minor depression, a major depressive
XX episode, a unipolar major depression, schizophrenia, simple phobia,
XX social phobia, agoraphobia, panic disorder, obsessive-compulsive disorder
XX or post-traumatic stress disorder. The present sequence is used in the
XX exemplification of the present invention.
XX Sequence 442 AA;
Query Match 99.5%; Score 1756; DB 7; Length 442;
Best Local Similarity 99.4%; Pred. No. 3.4e-123;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVMSWGALTSVHTFPVAVLQSS 60
Db |||||
113 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVMSWGALTSVHTFPVAVLQSS 172
QY 61 GLYSLSVVTVPPSSSLGTQTYICNVNHPKPSNTKVDKVEPKSCDKTHTCPPCPAPELAGA 120
Db |||||
173 GLYSLSVVTVPPSSSLGTQTYICNVNHPKPSNTKVDKVEPKSCDKTHTCPPCPAPELAGG 232
QY 121 PSVFLFPKPKDGLMISRTPEVTVVVDVSHEDPEVKENWYVDGVENNAKTKPREQVN 180
Db |||||
233 PSVFLFPKPKDGLMISRTPEVTVVVDVSHEDPEVKENWYVDGVENNAKTKPREQVN 292
QY 181 STYRVSVLTVLHQDLNGLKEYCKVKNKALPAPIEKTIISKAKGQPREPPQVYTLPPSRDE 240
Db |||||
293 STYRVSVLTVLHQDLNGLKEYCKVKNKALPAPIEKTIISKAKGQPREPPQVYTLPPSRDE 352
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSGDSFLLYSKLTVDKGRW 300
Db |||||
353 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSGDSFLLYSKLTVDKGRW 412
QY 301 OQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330
Db |||||
413 OQGNVFCSCVMHEALHNHYTQKSLSLSPGK 442
RESULT 99
ADE94075
ID ADE94075 standard; protein; 442 AA.
XX
AC ADE94075;

XX 12-FEB-2004 (first entry)
XX Humanised anti-Abeta antibody heavy chain SEQ ID NO:21.
XX anxiety disorder; mood disorder; anti-Abeta antibody; Abeta; nootropic;
XX neuroprotective; antidepressant; neuroleptic; tranquilliser;
XX gene therapy; Alzheimer's disease; chronic amyloid angiopathy;
XX depression; major depressive episode; unipolar major depression;
XX schizophrenia; simple phobia; social phobia; agoraphobia; panic disorder;
XX obsessive-compulsive disorder; post-traumatic stress disorder.
XX Synthetic.
XX Mus sp.
XX Homo sapiens.
XX Key Location/Qualifiers
XX Misc-difference 56
XX /note= "X at position 56 is any amino acid, provided that
XX if X at position 57 is neither Asp nor Pro and X at
XX position 59 is Ser or Thr, then X at position 56 is not
XX Asn"
XX Misc-difference 57
XX /note= "X at position 57 is any amino acid, provided that
XX if X at position 56 is Asn and X at position 58 is Ser or
XX Thr, then X at position 57 is Asp or Pro"
XX Misc-difference 58
XX /note= "X at position 58 is any amino acid, provided that
XX if X at position 56 is Asn and X at position 57 is
XX neither Asp nor Pro, then X at position 58 is neither Ser
XX nor Thr"
XX WO2003090772-A1.
XX 06-NOV-2003.
XX 17-APR-2003; 2003WO-US010473.
XX 25-APR-2002; 2002US-0375462P.
XX (ELIL) LILLY & CO ELI.
XX Gerlai RT;
XX WPI; 2003-865528/80.
XX Treating, preventing and/or diagnosing a condition related to Abeta
XX expression, such as anxiety or mood disorders, including Alzheimer's
XX disease, depression, and schizophrenia, by administering an anti-Abeta
XX antibody to the subject.
XX Claim 24; SEQ ID NO 21; 64pp; English.
XX The present invention describes a method for treating an anxiety disorder
XX or a mood disorder in an elderly subject. The method comprises
XX administering an anti-Abeta antibody to the subject. Also described are
XX Abeta nucleic acids, polypeptides, antibodies and pharmaceutical
XX compositions used in the methods of the invention. Abeta has nootropic,
XX neuroprotective, antidepressant, neuroleptic and tranquilliser
XX activities, and can be used in gene therapy. The methods and compositions
XX of the present invention are useful for treating, preventing and/or
XX diagnosing a condition related to Abeta expression, such as anxiety or
XX mood disorders, including Alzheimer's disease, chronic amyloid
XX angiopathy, depression, major or minor depression, a major depressive
XX episode, a unipolar major depression, schizophrenia, simple phobia,
XX social phobia, agoraphobia, panic disorder, obsessive-compulsive disorder
XX or post-traumatic stress disorder. The present sequence is used in the
XX exemplification of the present invention.
XX Sequence 442 AA;
Query Match 99.5%; Score 1756; DB 7; Length 442;
Best Local Similarity 99.4%; Pred. No. 3.4e-123;

GenCore version 5.1.9
Copyright (c) 1993 - 2006 Bioacceleration Ltd.
OM protein - protein search, using sw model
Run on: June 10, 2006, 11:56:42 ; Search time 35.1802 Seconds
(without alignments)
902.540 Million cell updates/sec
Title: US-10-733-563-110
Perfect score: 1765
Sequence: 1 ASTKGPSVFPLAPSSKSTG.....MHEALHNHYTQKSLSLSPGK 330
Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283416 segs, 96216763 residues
Total number of hits satisfying chosen parameters: 283416
Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries
Database : PIR 80: *
1: pir1: *
2: pir2: *
3: pir3: *
4: pir4: *

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES			
Result No.	Score	Query Match	Description
1	1756	99.5	IG gamma-1 chain C
2	1619.5	91.8	IG gamma-3 chain C
3	1617.5	91.6	IG gamma-3 chain C
4	1608	91.1	IG gamma-2 chain C
5	1579.5	89.5	IG gamma-4 chain C
6	1259	71.3	IG gamma 2a chain
7	1253	71.0	IG gamma 2b chain
8	1252.5	71.0	IG heavy chain V r
9	1249	70.8	IG gamma-1 chain C
10	1243	70.4	IG gamma chain C r
11	1235	70.0	IG gamma 1 chain c
12	1231	69.7	IG gamma chain C r
13	1219.5	68.1	IG gamma-2 chain C
14	1201.5	68.1	IG gamma-1 chain -
15	1195.5	67.7	IG heavy chain pre
16	1176.5	66.7	IG heavy chain C r
17	1157.5	65.6	monoclonal antibod
18	1156	65.5	IG gamma-1 chain C
19	1154	65.4	IG gamma-1 chain C
20	1144	64.8	IG gamma-1 chain C
21	1140	64.6	IG gamma-3 heavy c
22	1139	64.5	IG gamma-1 chain C
23	1135.5	64.3	IG gamma-2b chain
24	1130	64.0	IG gamma-3 chain C
25	1119	63.4	IG gamma-3 chain C
26	1115	63.2	IG gamma-2a chain
27	1115	63.2	IG gamma-2a chain
28	1114.5	63.1	IG gamma-2c chain
29	1114	63.1	IG gamma-2a chain

30 1112.5 63.0 335 1 G2MSAB
31 1110 62.9 399 1 G2MSAM
32 1100 62.3 446 2 S40295
33 1092.5 61.9 327 2 S06611
34 1078 61.1 405 1 G2MSEM
35 1063 60.2 475 2 S01321
36 1061 60.1 277 2 I47162
37 1060.5 60.1 474 1 G2MS11
38 707 40.1 180 2 I46732
39 672.5 38.1 548 2 S38864
40 577.5 32.7 249 2 S69340
41 574.5 32.5 218 2 A36040
42 571 32.4 152 2 S14236
43 560 31.7 549 2 S04845
44 536 30.4 241 2 S69131
45 534 30.3 220 2 A49444

ALIGNMENTS

IG gamma-1 chain C region - human
C:Species: Homo sapiens (man)
C:Date: 31-Jan-1981 #sequence revision 18-Aug-1982 #text change 09-Jul-2004
C:Accession: A93433; S36861; S33887; B90563; A90564; B91668; A91723; A02146
R:Ellison, J.W.; Berson, B.J.; Hood, L.E.
Nucleic Acids Res. 10, 4071-4079, 1982
A:Title: The nucleotide sequence of a human immunoglobulin C-gamma1 gene.
A:Reference number: A93433; MUID:82274238; PMID:6287432
A:Accession: A93433
A:Molecule type: DNA
A:Residues: 1-330 <ELL>
A:Cross-references: UNIPROT:P01857; UNIPARC:UPI0000034COE; EMBL:Z17370
A>Note: this sequence has the G1m(17) allotypic marker, 97-Lys, and the G1m(1) markers, R:
R:Harris, L.J.
submitted to the EMBL Data Library, October 1992
A:Reference number: S33904
A:Accession: S36861
A:Molecule type: DNA
A:Residues: 2-330 <HAR>
A:Cross-references: UNIPARC:UPI000013CGFE; EMBL:Z17370
R:Takahashi, N.; Ueda, S.; Obata, M.; Nikaido, T.; Nakai, S.; Honjo, T.
Cell 29, 671-679, 1982
A:Title: Structure of human immunoglobulin gamma genes: implications for evolution of a
A:Reference number: S33887; MUID:83001943; PMID:6811139
A:Accession: S33887
A:Molecule type: DNA
A:Residues: 88-113/235-330 <TAK>
A:Cross-references: UNIPARC:UPI000017378B; UNIPARC:UPI000017378C; EMBL:Z17370
R:Cunningham, B.A.; Rutishauser, U.; Gall, W.E.; Gottlieb, P.D.; Waxdal, M.J.; Edelman, C.
Biochemistry 9, 3161-3170, 1970
A:Title: The covalent structure of a human gammaG-immunoglobulin. VII. Amino acid sequen
A:Reference number: A90563; MUID:71064024; PMID:5489771
A:Contents: myeloma protein Eu
A:Accession: B90563
A:Molecule type: protein
A:Residues: 1-96, R', 98-135 <CUN>
A:Cross-references: UNIPARC:UPI000017378D
A>Note: this sequence has the G1m(3) marker, 97-Arg
R:Rutishauser, U.; Cunningham, B.A.; Bennett, C.; Konigsberg, W.H.; Edelman, G.M.
Biochemistry 9, 3171-3181, 1970
A:Title: The covalent structure of a human gammaG-immunoglobulin. VIII. Amino acid sequen
A:Reference number: A90564; MUID:71064025; PMID:5530842
A:Contents: Eu
A:Accession: A90564
A:Molecule type: protein
A:Residues: 136-154, 'Q', 156-165, 'Q', 167-176, 'Q', 178-194, 'N', 196-197, 'D', 199-238, 'E', 240, '
A:Cross-references: UNIPARC:UPI000017378E
A>Note: this sequence has the G1m(non-1) markers, 239-Glu and 241-Met
R:Ponstingl, H.; Hilschmann, N.

Hoppe-Seyler's Z. Physiol. Chem. 357, 1571-1604, 1976
A:Title: Die Primaerstruktur eines monoklonalen IgG1-Immunglobulins (Myelomprotein Nie),
igen Primaerstruktur.
A:Reference number: A91668; MUID:77070269; PMID:826475
A:Contents: myeloma protein Nie
A:Accession: B91668
A:Molecule type: protein
A:Residues: 1-34, 'Q', 36-96, 'K', 98-115, 'Q', 117-197, 'D', 199-238, 'D', 240, 'L', 242-268, 'E', 27
A:Cross-references: UNIPARC:UPI000017379F
A:Note: this sequence has the G1m(17) and G1m(1) markers
R:Schmidt, W.E.; Jung, H.D.; Palm, W.; Hilschmann, N.
Hoppe-Seyler's Z. Physiol. Chem. 364, 713-747, 1983
A:Title: Die Primaerstruktur des kristallisierten monoklonalen Immunglobulins IgG1 KOI
A:Reference number: A91723; MUID:83289131; PMID:6884994
A:Contents: myeloma protein KOI; disulfide bonds
A:Accession: A91723
A:Molecule type: protein
A:Residues: 1-96, 'R', 98-197, 'D', 199-238, 'E', 240, 'M', 242-266, 'D', 268-271, 'D', 273-330 <SCH
A:Cross-references: UNIPARC:UPI0000173790
A:Note: this sequence has the G1m(3) and G1m(non-1) markers
R:Call, W.E.; Edelman, G.W.
Biochemistry 9, 3188-3196, 1970
A:Title: The covalent structure of a human gammaG-immunoglobulin. X. Intrachain disulfid
A:Reference number: A90565; MUID:71064027; PMID:4923144
A:Contents: annotation; disulfide bonds
R:Dreker, L.; Schwarz, J.; Reichel, W.; Hilschmann, N.
Hoppe-Seyler's Z. Physiol. Chem. 357, 1515-1540, 1976
A:Title: Rule of antibody structure. The primary structure of monoclonal IgG1 immunoglob
enbromide cleavage products, and the disulfide bridges.
A:Reference number: A91667; MUID:77070267; PMID:1002129
A:Contents: annotation; disulfide bonds
C:Genetics:
A:Gene: GDB:IGHG1
A:Cross-references: GDB:120085; OMIM:147100
A:Map position: 14q32.33-14q32.33
A:Introns: 99/1; 114/1; 224/1
C:Complex: An immunoglobulin heterotetramer subunit consists of two identical light (kap
hain disulfide bonds. In some cases, such as IgA and IgM, the subunits associate into la
C:Superfamily: immunoglobulin C region; immunoglobulin homology
C:Keywords: duplication; glycoprotein; heterotetramer; immunoglobulin
F:137-206/Domain: immunoglobulin homology <IM1>
F:243-310/Domain: immunoglobulin homology <IM2>
F:27-83, 144-204, 250-308/Disulfide bonds: #status experimental
F:103/Disulfide bonds: interchain (to light chain) #status experimental
F:109,112/Disulfide bonds: interchain (to heavy chain) #status experimental
F:180/Binding site: carbohydrate (Asn) (covalent) #status experimental
Query Match 99.5%; Score 1756; DB 1; Length 330;
Best Local Similarity 99.4%; Pred. No. 9.8e-114; Mismatches 0; Indels 0; Gaps 0;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVWNSGALTSGVHTFPAVLQSS 60
DB 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVWNSGALTSGVHTFPAVLQSS 60
QY 61 GLYSLSVVTVPSSSLGTQTYICNVNHPKSNTKVDKVPKSCDTHTCPCPAPPELLGG 120
DB 61 GLYSLSVVTVPSSSLGTQTYICNVNHPKSNTKVDKVPKSCDTHTCPCPAPPELLGG 120
QY 121 PSVFLPPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYDGVFNHNAKTKPREEQYN 180
DB 121 PSVFLPPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYDGVFNHNAKTKPREEQYN 180
QY 181 STYRVSVSLTVLHQLDNLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
DB 181 STYRVSVSLTVLHQLDNLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPPVLDSDGSFFLYSKLTVDKSRW 300
DB 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPPVLDSDGSFFLYSKLTVDKSRW 300
QY 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330

||||| 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330
RESULT 2
A23511
Ig gamma-3 chain C region (allotype G3m(b)) - human
C:Species: Homo sapiens (man)
C>Date: 28-Dec-1987 #sequence_revision 28-Dec-1987 #text_change 23-Jul-1999
C:Accession: A23511
R:Huck, S.; Fort, P.; Crawford, D.H.; Lefranc, M.P.; Lefranc, G.
Nucleic Acids Res. 14, 1779-1789, 1986
A:Title: Sequence of a human immunoglobulin gamma 3 heavy chain constant region gene: con
A:Reference number: A23511; MUID:86148507; PMID:3081877
A:Accession: A23511
A:Molecule type: DNA
A:Residues: 1-377 <HUC>
A:Cross-references: UNIPARC:UPI000004718F; GB:X03604; GB:M12958; NID:g33070; PIDN:CAA2724
C:Genetics:
A:Gene: GDB:IGHG3
A:Cross-references: GDB:119339; OMIM:147120
A:Map position: 14q32.33-14q32.33
A:Introns: 98/3; 115/3; 130/3; 145/3; 160/3; 270/3
C:Superfamily: immunoglobulin C region; immunoglobulin homology
C:Keywords: immunoglobulin
F:20-85/Domain: immunoglobulin homology <IMM>
Query Match 91.8%; Score 1619.5; DB 2; Length 377;
Best Local Similarity 81.4%; Pred. No. 2.9e-104;
Matches 307; Conservative 10; Mismatches 13; Indels 47; Gaps 1;
QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVWNSGALTSGVHTFPAVLQSS 60
DB 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVWNSGALTSGVHTFPAVLQSS 60
QY 61 GLYSLSVVTVPSSSLGTQTYICNVNHPKSNTKVDKVV-----EPKCDKTHTCPPCPAPELAGAPSVLFPKP 133
DB 61 GLYSLSVVTVPSSSLGTQTYICNVNHPKSNTKVDKVELTKPLGDTTHTCPRCEPKSC 120
QY 99 -----EPKCDKTHTCPPCPAPELAGAPSVLFPKP 133
DB 121 DTPPPCPCEPKSCDTPPPCPCEPKSCDTPPPCPCEPKSCDTPPPCPCEPKSCDTPPPCPCEPKSCDTPPPCP 180
QY 134 LMISRTPEVTCVVDVSHEDPEVKFNWYDGVFNHNAKTKPREEQYNSTYRVSVSLTVLH 193
DB 181 LMISRTPEVTCVVDVSHEDPEVKFNWYDGVFNHNAKTKPREEQYNSTYRVSVSLTVLH 240
QY 194 QDWLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVK 253
DB 241 QDWLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVK 300
QY 254 GFYPDSIAVEWESNGQPENNYKTPPPVLDSDGSFFLYSKLTVDKSRWQQGNVFCSCVMHE 313
DB 301 GFYPDSIAVEWESNGQPENNYKTPPPVLDSDGSFFLYSKLTVDKSRWQQGNVFCSCVMHE 360
QY 314 ALHNHYTQKSLSLSPGK 330
DB 361 ALHNRYTQKSLSLSPGK 377
RESULT 3
A60764
Ig gamma-3 chain C region, form LAT - human
C:Species: Homo sapiens (man)
C>Date: 14-May-1993 #sequence_revision 14-May-1993 #text_change 31-Dec-2004
C:Accession: A60764
R:Huck, S.; Lefranc, G.; Lefranc, M.P.
Immunogenetics 30, 250-257, 1989
A:Title: A human immunoglobulin IGHG3 allele (Gmb0, b1, c3, c5, u) with an IGHG4 convert
A:Reference number: A60764; MUID:90007613; PMID:2571587
A:Accession: A60764
A:Status: preliminary
A:Molecule type: DNA

A;Residues: 1-377 <HUC>
A;Cross-references: UNIPROT:Q8N4Y9; UNIPARC:UPI0000176F0B
C;Superfamily: immunoglobulin homology
C;Keywords: immunoglobulin
F;20-85/Domain: immunoglobulin homology <IMM>

Query Match 91.6%; Score 1617.5; DB 2; Length 377;
Best Local Similarity 81.4%; Pred. No. 4e-104;
Matches 307; Conservative 10; Mismatches 13; Indels 47; Gaps 1;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVWNSGALTSGVHTFPAVLQSS 60
DB 1 ASTKGPSVFPLAPCSRSTGSGAAAGCLVKDYFPEPTVWNSGALTSGVHTFPAVLQSS 60

QY 61 GLYSLSVVTVFPSSSLGTQTYICNVNHKPSNTKVDKKV----- 98
DB 61 GLYSLSVVTVFPSSSLGTQTYICNVNHKPSNTKVDKKVPLGDTHTCPRCPKSC 120

QY 99 -----EPKSCDTHCTCPAPAPELAGAPSVFLPPPKPKDT 133
DB 121 DTPPPCPRCPEPKSCDTPPPCPRCPEPKSCDTPPPCPAPAPELLAGPSVFLPPPKPKDT 180

QY 134 LMISTPEVTCVVDVSHEDPEVKENWYVDGVEVHNNAKTKPREQVNSTYRVVSVLTVLH 193
DB 181 LMISTPEVTCVVDVSHEDPEVQPKWYVDGVEVHNNAKTKPREQVNSTYRVVSVLTVLH 240

QY 194 QDWLNGKEYKCKVSNKALPAPIEKTIISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVK 253
DB 241 QDWLNGKEYKCKVSNKALPAPIEKTIISKAKGQPREPQVYTLPPSRDEMTKNQVSLTCLVK 300

QY 254 GYPSDIAVEWESNGQPENNYKTPPVLDSDGSFYLKSLYVDKSRWQGNVFPSCSVHME 313
DB 301 GYPSDIAVEWESNGQPENNYKTPPVLDSDGSFYLKSLYVDKSRWQGNVFPSCSVHME 360

QY 314 ALHNHYTQKSLSLSPGK 330
DB 361 ALHNRYTQKSLSLSPGK 377

RESULT 4
G2HU
Ig gamma-2 chain C region - human
C;Species: Homo sapiens (man)
C;Date: 30-Apr-1981 #sequence revision 13-Jun-1983 #text_change 09-Jul-2004
C;Accession: A93906; A92809; A90752; A93132; A02148
R;Ellison, J.; Hood, L.
Proc. Natl. Acad. Sci. U.S.A. 79, 1984-1988, 1982
A;Title: Linkage and sequence homology of two human immunoglobulin gamma heavy chain con
A;Reference number: A93906; MUID:82197621; PMID:6804948
A;Accession: A93906
A;Molecule type: DNA
A;Residues: 1-326 <ELL>
A;Cross-references: UNIPROT:P01859; UNIPARC:UPI000003BFCC; GB:V00554; GB:J00230; NID:g32
A;Note: Lys-326 is probably removed posttranslationally
R;Wang, A.C.; Tung, E.; Fudenberg, H.H.
J. Immunol. 125, 1048-1054, 1980
A;Title: The primary structure of a human IgG2 heavy chain: genetic, evolutionary, and f
A;Reference number: A92809; MUID:81007873; PMID:6774012
A;Contents: myeloma protein Til
A;Accession: A92809
A;Molecule type: protein
A;Residues: 1-19,'Q',21-57,'Z',59,'A',61-193,'D',195-325 <WAN>
A;Cross-references: UNIPARC:UPI0000173791
A;Note: Trp-156 is at or near the complement-binding site
R;Connell, G.E.; Parr, D.M.; Hofmann, T.
Can. J. Biochem. 57, 758-767, 1979
A;Title: The amino acid sequences of the three heavy chain constant region domains of a
A;Reference number: A90752; MUID:80001357; PMID:113060
A;Contents: myeloma protein Zie
A;Accession: A90752
A;Molecule type: protein
A;Residues: 1-24,'E',26-57,'EV',60-85;132-171,'ZZZ',175,'B',177-193,'D',195-196,'Q',198-
A;Cross-references: UNIPARC:UPI0000173792; UNIPARC:UPI0000173793

A;Note: this sequence has since been revised
R;Hofmann, T.; Parr, D.M.
Mol. Immunol. 16, 923-925, 1979
A;Title: A note on the amino acid sequence of residues 381-391 of human immunoglobulin g
A;Reference number: A93132; MUID:80114419; PMID:118920
A;Contents: Zie
A;Accession: A93132
A;Molecule type: protein
A;Residues: 238-275 <HOF>
A;Cross-references: UNIPARC:UPI0000173794
R;Hofmann, T.; Parr, D.M.
submitted to the Aclab, March 1980
A;Reference number: A94591
A;Contents: annotation; Zie, revisions to residues 25, 59, 60, and 264-268
A;Note: the revised sequence differs from that shown in having 60-Ala and in the amidatic
ned
R;Milstein, C.; Frangione, B.
Biochem. J. 121, 217-225, 1971
A;Title: Disulphide bridges of the heavy chain of human immunoglobulin G2.
A;Reference number: A90253; MUID:72033500; PMID:4940472
A;Contents: annotation; myeloma protein Sa, disulfide bonds
R;Frangione, B.; Milstein, C.; Pink, J.R.L.
Nature 221, 145-148, 1969
A;Title: Structural studies of immunoglobulin G.
A;Reference number: A93157; MUID:69064124; PMID:5782707
A;Contents: annotation; Sa, disulfide bonds
C;Genetics:
A;Gene: GDB:IGHG2
A;Cross-references: GDB:119338; OMIM:147110
A;Map position: 14q32.33-14q32.33
C;Complex: An immunoglobulin heterotetramer subunit consists of two identical light (kap
hain disulfide bonds. In some cases, such as IgA and IgM, the subunits associate into la
C;Superfamily: immunoglobulin C region; immunoglobulin homology
C;Keywords: duplication; glycoprotein; heterotetramer; immunoglobulin
F;20-85/Domain: immunoglobulin homology <IM1>
F;133-202/Domain: immunoglobulin homology <IM2>
F;239-306/Domain: immunoglobulin homology <IM3>
F;14/Disulfide bonds: interchain (to light chain) #status experimental
F;27-83,140-200,246-304/Disulfide bonds: #status experimental
F;102,103,106,109/Disulfide bonds: interchain (to heavy chain) #status experimental
F;176/Binding site: carbohydrate (Asn) (covalent) #status predicted

Query Match 91.1%; Score 1608; DB 1; Length 326;
Best Local Similarity 91.5%; Pred. No. 1.5e-103;
Matches 302; Conservative 12; Mismatches 12; Indels 4; Gaps 2;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVWNSGALTSGVHTFPAVLQSS 60
DB 1 ASTKGPSVFPLAPCSRSTGSGAAAGCLVKDYFPEPTVWNSGALTSGVHTFPAVLQSS 60

QY 61 GLYSLSVVTVFPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDTHCTCPAPAPELAGA 120
DB 61 GLYSLSVVTVFPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDTHCTCPAPAPVAG- 116

QY 121 PSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNNAKTKPREQVN 180
DB 117 PSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVQFNWYVDGVEVHNNAKTKPREQFN 176

QY 181 STYRVSVLTVLHODWLNQKEYKCKVSNKALPAPIEKTIISKAKGQPREPQVYTLPPSRDE 240
DB 177 STYRVSVLTVLHODWLNQKEYKCKVSNKALPAPIEKTIISKAKGQPREPQVYTLPPSRDE 236

QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFYLKSLYVDKSRW 300
DB 237 MTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFYLKSLYVDKSRW 296

QY 301 QGQNVFSCSVNHEALHNHYTQKSLSLSPGK 330
DB 297 QGQNVFSCSVNHEALHNHYTQKSLSLSPGK 326

RESULT 5
G4HU

Ig gamma-4 chain C region - human
C:Species: Homo sapiens (man)
C>Date: 02-Apr-1982 #sequence_revision 02-Apr-1982 #text_change 09-Jul-2004
C:Accession: A09333; A90249; A02150
R:Ellison, J.; Buxbaum, J.; Hood, L.
DNA 1, 11-18, 1981
A:Title: Nucleotide sequence of a human immunoglobulin C-gamma4 gene.
A:Reference number: A90333; MUID:83157104; PMID:6299662
A:Accession: A90333
A:Molecule type: DNA
A:Residues: 1-327 <ELL>
A:Cross-references: UNIPROT:P01861; UNIPARC:UPI0000047190
A:Note: the sequence was determined from the germline gene
R:Pink, J.R.L.; Buttery, S.H.; De Vries, G.M.; Milstein, C.
Biochem. J. 117, 33-47, 1970
A:Title: Human immunoglobulin subclasses. Partial amino acid sequence of the constant x
A:Reference number: A90249; MUID:70207560; PMID:4192699
A:Accession: A90249
A:Molecule type: protein
A:Residues: 1-30; 81-326 <PIN>
A:Cross-references: UNIPARC:UPI0000173795; UNIPARC:UPI0000173796
C:Genetics:
A:Gene: GDB:IGHG4
A:Cross-references: GDB:119340; OMIM:147130
A:Map position: 14q32.33-14q32.33
A:Introns: 99/1; 111/1; 221/1
C:Complex: An immunoglobulin heterotetramer subunit consists of two identical light (kap
hain disulfide bonds. In some cases, such as IgA and IgM, the subunits associate into la
C:Superfamily: immunoglobulin C region; immunoglobulin homology
C:Keywords: duplication; glycoprotein; heterotetramer; immunoglobulin
F:20-85/Domain: immunoglobulin homology <IM1>
F:99-110/Region: hinge
F:134-203/Domain: immunoglobulin homology <IM2>
F:240-307/Domain: immunoglobulin homology <IM3>
F:147/Disulfide bonds: interchain (to light chain) #status experimental
F:27-83,141-201,247-305/Disulfide bonds: #status predicted
F:106,109/Disulfide bonds: interchain (to heavy chain) #status experimental
F:177/Binding site: carbohydrate (Asn) (covalent) #status predicted

Query Match 89.5%; Score 1579.5; DB 1; Length 327;
Best Local Similarity 90.3%; Pred. No. 1.4e-101;
Matches 298; Conservative 12; Mismatches 17; Indels 3; Gaps 1;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVTSWNSGALTSGVHTFPAVLQSS 60
DB 1 ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPTVTSWNSGALTSGVHTFPAVLQSS 60

QY 61 GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPCPAPPELAGA 120
DB 61 GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPCPAPPELAGA 120

QY 121 PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
DB 118 PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQFN 177

QY 181 STYRVSVLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW 240
DB 178 STYRVSVLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW 237

QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW 300
DB 238 MTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW 297

QY 301 QGQNVFSCSVMHAEALHNHYTQKSLSLSPGK 330
DB 298 QGQNVFSCSVMHAEALHNHYTQKSLSLSPGK 327

RESULT 6
147159
Ig gamma 2a chain constant region - pig (fragment)
C:Species: Sus scrofa domestica (domestic pig)
C>Date: 21-Feb-1997 #sequence_revision 21-Feb-1997 #text_change 21-Jan-2000

C:Accession: I47159
R:Kaczkovics, I.; Sun, J.; Butler, J.E.
J. Immunol. 153, 3565-3573, 1994
A:Title: Five putative subclasses of swine Igg identified from the cDNA sequences of a
A:Reference number: I47158; MUID:95015845; PMID:7930579
A:Accession: I47159
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: mRNA
A:Residues: 1-328 <KAC>
A:Cross-references: UNIPARC:UPI0000115524; EMBL:U03779; NID:G433123; PIDN:AAAS2217.1; PII
C:Genetics:
A:Gene: IGG2a
C:Superfamily: immunoglobulin C region; immunoglobulin homology
F:133-202/Domain: immunoglobulin homology <IMM>

Query Match 71.3%; Score 1259; DB 2; Length 328;
Best Local Similarity 70.2%; Pred. No. 1.6e-79;
Matches 233; Conservative 42; Mismatches 51; Indels 6; Gaps 3;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVTSWNSGALTSGVHTFPAVLQSS 60
DB 1 APKTAPLVYPLAPCSRDTSGPNVALGCLASSYFPEPTVTTWNSGALSSGVHTFFSVLPQS 60

QY 61 GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPCPAPPELAGA 120
DB 61 GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPCPAPPELAGA 120

QY 121 PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
DB 117 PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQFN 176

QY 181 STYRVSVLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR 240
DB 177 STYRVSVLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR 236

QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR 298
DB 237 LSRKVSITCLVIGFYPPDIDVEQWRNGQPEEGNYRTTPPQQVDVGTYFLYSKFSVDKA 296

QY 299 RWQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330
DB 297 SWQGGIFQCAVMHEALHNHYTQKSLSLSPGK 328

RESULT 7
147160
Ig gamma 2b chain constant region - pig (fragment)
C:Species: Sus scrofa domestica (domestic pig)
C>Date: 21-Feb-1997 #sequence_revision 21-Feb-1997 #text_change 21-Jan-2000

C:Accession: I47160
R:Kaczkovics, I.; Sun, J.; Butler, J.E.
J. Immunol. 153, 3565-3573, 1994
A:Title: Five putative subclasses of swine Igg identified from the cDNA sequences of a
A:Reference number: I47158; MUID:95015845; PMID:7930579
A:Accession: I47160
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: mRNA
A:Residues: 1-328 <KAC>
A:Cross-references: UNIPARC:UPI0000115525; EMBL:U03780; NID:G433125; PIDN:AAAS2218.1; PII
C:Genetics:
A:Gene: IGG2b
C:Superfamily: immunoglobulin C region; immunoglobulin homology
F:133-202/Domain: immunoglobulin homology <IMM>

Query Match 71.0%; Score 1253; DB 2; Length 328;
Best Local Similarity 69.9%; Pred. No. 4.2e-79;
Matches 232; Conservative 41; Mismatches 53; Indels 6; Gaps 3;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVTSWNSGALTSGVHTFPAVLQSS 60
DB 1 APKTAPLVYPLAPCSRDTSGPNVALGCLASSYFPEPTVTTWNSGALSSGVHTFFSVLPQS 60

QY 61 GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPCPAPPELAGA 120

Db 61 GLYSLSSMVTVPASSLSKSYTCNNVHPATTTKVDKRVGKT---KPPCPICPACESPG- 116
Qy 121 PSVFLPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
Db 117 PSVFIIPPFPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 176
Qy 181 STYRVSVSLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Db 177 STYRVSVSLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPHASE 236
Qy 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQ--PENNYKTTTPPVLDSDGSPFLYSKLTVDKS 298
Db 237 LRSKSVISCTLVIGFYPPDIDVEWQNGQPEPEEGNRYTTPQQDVGDTYFLYSKFSVDKA 296
Qy 299 RWQOGNVFSCSVMEALHNNHYTKLSLSLSPGK 330
Db 297 SWGGGIFQCAVNVMEALHNNHYTKLSKTPGK 328

RESULT 8

S69339

Ig heavy chain v region precursor - human

C:Species: Homo sapiens (man)
C:Date: 19-Mar-1997 #sequence_revision 19-Mar-1997 #text_change 01-Dec-2000
C:Accession: S69339; S72664
R:Khamlichi, A.A.; Aucouturier, P.; Preud'homme, J.L.; Cogne, M.
Eur. J. Biochem. 229, 54-60, 1995
A:Title: Structure of abnormal heavy chains in human heavy-chain-deposition disease.
A:Reference number: S69339; PMID:95262687; PMID:7744049
A:Accession: S69339
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-374 <KHA>
A:Cross-references: UNIPARC:UPI0000176P24; EMBL:X81695

R:Khamlichi, A.A.

submitted to the EMBL Data Library, September 1994

A:Accession: S72664

A:Status: preliminary

A:Molecule type: mRNA

A:Residues: 1-140, 'C', 142-374 <KH2>

A:Cross-references: UNIPARC:UPI0000176P25; EMBL:X81695

C:Superfamily: immunoglobulin C region; immunoglobulin homology

Query Match 71.0%; Score 1252.5; DB 2; Length 374;
Best Local Similarity 89.0%; Pred. No. 5.4e-79;
Matches 235; Conservative 3; Mismatches 15; Indels 11; Gaps 2;
Qy 78 TOTYICNVN-----HK-PSNTKVDKVKPKSCDKTHTCPPCPAPELAGAPSVFLF 126
Db 111 TATYCGYSVEGYGQGRFHSWQGLTVTVSSEPKSCDKTHTCPPCPAPELLGPSVFLF 170
Qy 127 PKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRV 186
Db 171 PKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRV 230
Qy 187 SVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQV 246
Db 231 SVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDEMTKNQV 290
Qy 247 SLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPVLDSDGSPFLYSKLTVDKSRWQGNVY 306
Db 291 SLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPVLDSDGSPFLYSKLTVDKSRWQGNVY 350

Qy 78 TOTYICNVN-----HK-PSNTKVDKVKPKSCDKTHTCPPCPAPELAGAPSVFLF 126
Db 111 TATYCGYSVEGYGQGRFHSWQGLTVTVSSEPKSCDKTHTCPPCPAPELLGPSVFLF 170
Qy 127 PKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRV 186
Db 171 PKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRV 230
Qy 187 SVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQV 246
Db 231 SVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDEMTKNQV 290
Qy 247 SLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPVLDSDGSPFLYSKLTVDKSRWQGNVY 306
Db 291 SLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPVLDSDGSPFLYSKLTVDKSRWQGNVY 350

RESULT 9

S31866

Ig gamma-1 chain C region - synthetic

C:Species: synthetic
A:Note: Homo sapiens (man) gene engineered and expressed in Escherichia coli
C:Date: 06-Jan-1995 #sequence_revision 17-Mar-1997 #text_change 19-May-2000
C:Accession: S31866
R:Filpula, D.
submitted to the EMBL Data Library, February 1993
A:Description: Screening method for protein-protein interactions of cloned gene products.
A:Reference number: S31866
A:Accession: S31866
A:Molecule type: mRNA
A:Residues: 1-255 <PIL>
A:Cross-references: UNIPARC:UPI000011F41F; EMBL:X70421; NID:G33068; PIDN:CAA49866.1; PID:
C:Keywords: immunoglobulin
F:1-22/Region: Escherichia coli outer membrane protein A precursor
F:23-255/Region: human Ig gamma-1 chain C region

Query Match 70.8%; Score 1249; DB 4; Length 255;
Best Local Similarity 96.7%; Pred. No. 5.9e-79;
Matches 231; Conservative 0; Mismatches 8; Indels 0; Gaps 0;
Qy 92 TKVDKVKVPKSCDKTHTCPPCPAPELAGAPSVFLFPKPKDTLMISRTPEVTCVVVDVSH 151
Db 17 TVAQADVESKSCDKTHTCPPCPAPELLGPSVFLFPKPKDTLMISRTPEVTCVVVDVSH 76
Qy 152 EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVTLHQDWLNGKEYKCKVSNKAL 211
Db 77 EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVTLHQDWLNGKEYKCKVSNKAL 136
Qy 212 PAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPE 271
Db 137 PAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPE 196
Qy 272 NNYKTTTPPVLDSDGSPFLYSKLTVDKSRWQGNVFCSCVMHEALHNNHYTKLSLSLSPGK 330
Db 197 NNYKTTTPPVLDSDGSPFLYSKLTVDKSRWQGNVFCSCVMHEALHNNHYTKLSLSLSPGK 255

RESULT 10

PT0207

Ig gamma chain C region - chimpanzee

C:Species: Pan troglodytes (chimpanzee)
C:Date: 23-Nov-1991 #sequence_revision 23-Nov-1991 #text_change 16-Jul-1999
C:Accession: PT0207
R:Ehrlich, P.H.; Moustafa, Z.A.; Oestberg, L.
Mol. Immunol. 28, 319-322, 1991
A:Title: Nucleotide sequence of chimpanzee Fc and hinge regions.
A:Reference number: PT0207; PMID:91287716; PMID:2062315
A:Accession: PT0207
A:Molecule type: mRNA
A:Residues: 1-234 <EHR>
A:Cross-references: UNIPARC:UPI0000176F05
C:Superfamily: immunoglobulin C region; immunoglobulin homology
C:Keywords: immunoglobulin
F:48-117/Domain: immunoglobulin homology <IMM>

Query Match 70.4%; Score 1243; DB 2; Length 234;
Best Local Similarity 97.9%; Pred. No. 1.4e-78;
Matches 229; Conservative 1; Mismatches 4; Indels 0; Gaps 0;
Qy 90 SNTKVDKVKPKSCDKTHTCPPCPAPELAGAPSVFLFPKPKDTLMISRTPEVTCVVVDV 149
Db 1 SNTKVDKVKPKSCDKTHTCPPCPAPELLGPSVFLFPKPKDTLMISRTPEVTCVVVDV 60
Qy 150 SHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVTLHQDWLNGKEYKCKVSNK 209
Db 61 SHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVTLHQDWLNGKEYKCKVSNK 120
Qy 210 ALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ 269
Db 121 ALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ 180
Qy 270 PENNYKTTTPPVLDSDGSPFLYSKLTVDKSRWQGNVFCSCVMHEALHNNHYTKLS 323

Db 181 PENNYKTTTPPVLDSDGSFFLYSKLTVDKSRWQGNVFSVMSVHEALHNNHYTQKS 234

RESULT 11

I47158

IG gamma 1 chain constant region - pig (fragment)

C;Species: Sus scrofa domestica (domestic pig)

C;Date: 21-Feb-1997 #sequence_revision 21-Feb-1997 #text_change 21-Jan-2000

C;Accession: I47158

R;Kacskovics, I.; Sun, J.; Butler, J.E.

J. Immunol. 153, 3565-3573, 1994

A;Title: Five putative subclasses of swine IgG identified from the cDNA sequences of a

A;Reference number: I47158; MUID:95015845; PMID:7930579

A;Accession: I47158

A;Status: preliminary; translated from GB/EMBL/DBJ

A;Molecule type: mRNA

A;Residues: 1-328 <KAC>

A;Cross-references: UNIPARC:UPI0000115523; EMBL:U03778; NID:G433121; PIDN:AAA52216.1; PI

C;Genetics:

A;Gene: IgG1

C;Superfamily: immunoglobulin C region; immunoglobulin homology

F;I33-202/Domain: immunoglobulin homology <IMM>

Query Match 70.0%; Score 1235; DB 2; Length 328;

Best Local Similarity 69.6%; Pred. No. 7.4e-78;

Matches 231; Conservative 39; Mismatches 56; Indels 6; Gaps 3;

QY 1 ASTKGPSVPLAPSSKSTGGTAALGCLVKDYFPEPTVWNSGALTSGVHTFPAVLQSS 60

Db 1 APKTAPSVVPLAPCGRDVSGPNVALGLASSYFPEPTVTWNSGALTSGVHTFPAVLQSS 60

QY 61 GLYSLSVVTVPSSSIGTQYICNVNHPKSNKTKVDKVEPKSCDKTHTHTCPCPAPELAGA 120

Db 61 GLYSLSVVTVPSASSSKSYTCNVNHPATTKVDKRV--GIHQPTCPICPGCEVAG- 116

QY 121 PSVFLFPPPKDLMISRTPEVTCVVVDVSHEDPEVKFNWYDGVGVHNAKTKPREEQYN 180

Db 117 PSVFIFFPPPKDLMISQTPETVTCVVVDVSKHAEQFSWYDGVGVHNAKTRPKEEQFN 176

QY 181 STYRVSVLTVLHQDLNMGKEYCKVSNKALPAPIETKISKAKGQRPQVYTLPPSRDE 240

Db 117 STYRVSVLPIQHODLKGKFEKCKVNNVDLPAPITRTISKAIGQSRPQVYTLPPPAE 236

QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGO--PENNYKTTTPPVLDSDGSFFLYSKLTVDKS 298

Db 237 LRSKVTLLCLVIGFPDPIHVEWKSNGQPEPEGNRTPTTPQDDVDGTFFLYSKLAVDKA 296

QY 299 RWOQGNVFSVMSVHEALHNNHYTQKSLSPGK 330

Db 297 RWDHDKFECAVMHEALHNNHYTQKSIKTQK 328

RESULT 12

I47161

IG gamma 3 chain constant region - pig (fragment)

C;Species: Sus scrofa domestica (domestic pig)

C;Date: 21-Feb-1997 #sequence_revision 21-Feb-1997 #text_change 21-Jan-2000

C;Accession: I47161

R;Kacskovics, I.; Sun, J.; Butler, J.E.

J. Immunol. 153, 3565-3573, 1994

A;Title: Five putative subclasses of swine IgG identified from the cDNA sequences of a

A;Reference number: I47158; MUID:95015845; PMID:7930579

A;Accession: I47161

A;Status: preliminary; translated from GB/EMBL/DBJ

A;Molecule type: mRNA

A;Residues: 1-328 <KAC>

A;Cross-references: UNIPARC:UPI0000115526; EMBL:U03781; NID:G433127; PIDN:AAA52219.1; PI

C;Genetics:

A;Gene: IgG3

C;Superfamily: immunoglobulin C region; immunoglobulin homology

F;I33-202/Domain: immunoglobulin homology <IMM>

Query Match 69.7%; Score 1231; DB 2; Length 328;

Best Local Similarity 69.3%; Pred. No. 1.4e-77;

Matches 230; Conservative 40; Mismatches 56; Indels 6; Gaps 3;

QY 1 ASTKGPSVPLAPSSKSTGGTAALGCLVKDYFPEPTVWNSGALTSGVHTFPAVLQSS 60

Db 1 APKTAPSVVPLAPCGRDVSGPNVALGLASSYFPEPTVTWNSGALTSGVHTFPAVLQSS 60

QY 61 GLYSLSVVTVPSSSIGTQYICNVNHPKSNKTKVDKVEPKSCDKTHTHTCPCPAPELAGA 120

Db 61 GLYSLSVVTVPSASSSKSYTCNVNHPATTKVDKRVGKT--KPPCPICPGCEVAG- 116

QY 121 PSVFLFPPPKDLMISRTPEVTCVVVDVSHEDPEVKFNWYDGVGVHNAKTKPREEQYN 180

Db 117 PSVFIFFPPPKDLMISQTPETVTCVVVDVSKHAEQFSWYDGVGVHNAKTRPKEEQFN 176

QY 181 STYRVSVLTVLHQDLNMGKEYCKVSNKALPAPIETKISKAKGQRPQVYTLPPSRDE 240

Db 177 STYRVSVLPIQHODLKGKFEKCKVNNVDLPAPITRTISKAIGQSRPQVYTLPPPAE 236

QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGO--PENNYKTTTPPVLDSDGSFFLYSKLTVDKS 298

Db 237 LRSKVTLLCLVIGFPDPIHVEWKSNGQPEPEGNRTPTTPQDDVDGTFFLYSKLAVDKA 296

QY 299 RWOQGNVFSVMSVHEALHNNHYTQKSLSPGK 330

Db 297 RWDHGETECVAMHEALHNNHYTQKSIKTQK 328

RESULT 13

GHRB

IG gamma chain C region - rabbit

C;Species: Oryctolagus cuniculus (domestic rabbit)

C;Date: 24-Apr-1984 #sequence_revision 15-Nov-1984 #text_change 09-Jul-2004

C;Accession: A91749; A90290; A93928; A90245; A94416; A02161

R;Bernstein, K.E.; Alexander, C.B.; Mage, R.G.

Immunogenetics 18, 387-397, 1983

A;Title: Nucleotide sequence of a rabbit IgG heavy chain from the recombinant F-I haplotype

A;Reference number: A91749; MUID:84030930; PMID:6313520

A;Accession: A91749

A;Molecule type: mRNA

A;Residues: 1-323 <BER>

A;Cross-references: UNIPROT:P01870; UNIPARC:UPI000012B37D

A;Note: this sequence has the d12 allotypic marker, 104-Thr, and the e14 marker, 185-Thr

R;Pratt, D.M.; Mole, L.E.

Biochem. J. 151, 337-349, 1975

A;Title: Sequence studies on the constant region of the Fd sections of rabbit immunoglob

A;Reference number: A90290; MUID:76135469; PMID:1243651

A;Accession: A90290

A;Molecule type: protein

A;Residues: 1-47, 'E', 49-71, 'PV', 72-128 <PRA>

A;Cross-references: UNIPARC:UPI00001737AB

R;Martens, C.L.; Moore, K.W.; Steinmetz, M.; Hood, L.; Knight, K.L.

Proc. Natl. Acad. Sci. U.S.A. 79, 6018-6022, 1982

A;Title: Heavy chain genes of rabbit IgG; isolation of a cDNA encoding gamma heavy chain

A;Reference number: A93928; MUID:83299917; PMID:6193512

A;Accession: A93928

A;Molecule type: mRNA

A;Residues: 88-103, 'M', 105-143, 'E', 145-184, 'A', 186, 'E', 188-266 <WAR>

A;Cross-references: UNIPARC:UPI000016C5ED; GB:M16426; NID:g165111; PIDN:AAA31289.1; PID:9

A;Note: this sequence has the d11 allotypic marker, 104-Met, and the e15 allotypic marker

R;Fruchter, R.G.; Jackson, S.A.; Mole, L.E.; Porter, R.R.

Biochem. J. 116, 249-259, 1970

A;Title: Sequence studies of the Fd section of the heavy chain of rabbit immunoglobulin C

A;Reference number: A90245; MUID:70110015; PMID:5461106

A;Accession: A90245

A;Molecule type: protein

A;Residues: 132-143, 'E', 145-161 <FRU>

A;Cross-references: UNIPARC:UPI00001737AC

R;Hilli, R.L.; Lebowitz, H.E.; Fellows Jr., R.E.; Delaney, R.

in Gamma Globulins, Nobel Symp. 3, Killander, J., ed., pp.109-127, Almqvist and Wiksell,

A;Reference number: A94416

A;Accession: A94416

A;Molecule type: protein

A;Residues: 129-131,155-172,'D',174-184,'A',186,'E',188-200,'D',202-217,'E',219-232,'Q',
A;Cross-references: UNIPARC:UPI00001737AD; UNIPARC:UPI00001737AE
A;Note: this has the e15 allotypic marker, 185-Ala
C;Complex: An immunoglobulin heterotetramer subunit consists of two identical light (kap
hain disulfide bonds. In some cases, such as IGA and IGM, the subunits associate into la
C;Superfamily: immunoglobulin C region; immunoglobulin homology
C;Keywords: duplication; glycoprotein; heterotetramer; immunoglobulin
F;20-82/Domain: immunoglobulin homology <IMI>
F;130-199/Domain: immunoglobulin homology <IM2>
F;236-303/Domain: immunoglobulin homology <IM3>
F;173/Binding site: carbohydrate (Asn) (covalent) #status predicted

Query Match 69.1%; Score 1219.5; DB 1; Length 323;
Best Local Similarity 69.4%; Pred. No. 8.4e-77;
Matches 227; Conservative 34; Mismatches 59; Indels 7; Gaps 2;

QY 4 KGPSVFLPAPSSKSTSGTAAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY 63
DB 4 KARSVFPLAPCCGDTSSITVLGCLVKGYLPEPVTVWNSGTLUNGRTFPPSRQSSGLY 63

QY 64 SLSSVVTVFSSSLGTQTYICNVNHPKPSNTKVKDKVPEPKSCDKTHTCPPCPAPELAGAPSV 123
DB 64 SLSSVVTVFSSSS---QPVTNCVAHPATNTKVDKTVAPSTCSK----PTCPPPELLGSPSV 116

QY 124 FLPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY 183
DB 117 FIPPPKPKDTLMISRTPEVTCVVVDVSDQDPEVQFTWYINNEQVRTARPLREQQNSTI 176

QY 184 RVSVLTVLHODWLNKGKEYKCKVSNKALPAPIEKTISKAKGQPREPOVYTLPPSRDELTK 243
DB 177 RVVSTLPIITHQDWRGKEFKCKVHNAKALPAPIEKTISKAKGQPLEPKVYTMGPREEELS 236

QY 244 NOVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPTPPVLDSGDSFFLYSKLTVDKSRWQQG 303
DB 237 RSVSLTCMNGFYPSDISVEWENKGAEDNYKTTTPAVLDSGDSGYFLYKLSVPTSEWQRG 296

QY 304 NVFSCSVMEALHNHYTQKSLSLSPGK 330
DB 297 DVFTCSVMHEALHNHYTQKSISRSPGK 323

RESULT 14
G2GP
Ig gamma-2 chain C region - guinea pig
C;Species: Cavia porcellus (Guinea pig)
C;Date: 07-May-1981 #sequence revision 07-May-1981 #text change 09-Jul-2004
C;Accession: A94553; A90352; A90359; A90384; A90385; A02151
R;Trischmann, T.M.
submitted to the Atlas, April 1975
A;Reference number: A94553
A;Accession: A94553
A;Molecule type: protein
A;Residues: 1-3 <TRI>
A;Cross-references: UNIPROT:P01862; UNIPARC:UPI000017379E
R;Birstein, B.K.; Hussain, Q.Z.; Cebra, J.J.
Biochemistry 10, 18-25, 1971
A;Title: Structure of heavy chain from strain 13 guinea pig immunoglobulin-G(2). III. Am
A;Reference number: A90352; MUID:71058471; PMID:5538606
A;Accession: A90352
A;Molecule type: protein
A;Residues: 4-68 <BIR>
A;Cross-references: UNIPARC:UPI000017379F
R;Turner, K.J.; Cebra, J.J.
Biochemistry 10, 9-17, 1971
A;Title: Structure of heavy chain from strain 13 guinea pig immunoglobulin-G(2). II. Am
A;Reference number: A90359; MUID:71058486; PMID:5538616
A;Accession: A90359
A;Molecule type: protein
A;Residues: 69-133;312-329 <TUR>
A;Cross-references: UNIPARC:UPI00001737A0; UNIPARC:UPI00001737A1
R;Tracey, D.E.; Cebra, J.J.
Biochemistry 13, 4796-4803, 1974
A;Title: Primary structure of the C-H2 homology region from guinea pig IgG2 antibodies.

A;Reference number: A90384; MUID:75036072; PMID:4429665
A;Accession: A90384
A;Molecule type: protein
A;Residues: 134-226 <TRA>
A;Cross-references: UNIPARC:UPI00001737A2
R;Trischmann, T.M.; Cebra, J.J.
Biochemistry 13, 4804-4811, 1974
A;Title: Primary structure of the C-H3 homology region from guinea pig IgG2 antibodies.
A;Reference number: A90385; MUID:75036073; PMID:4609467
A;Accession: A90385
A;Molecule type: protein
A;Residues: 227-311 <TR2>
A;Cross-references: UNIPARC:UPI00001737A3
R;Oliveira, B.; Lamm, M.E.
Biochemistry 10, 26-31, 1971
A;Title: Interchain disulfide bridges of guinea pig gamma-2- immunoglobulin.
A;Reference number: A90354; MUID:71058474; PMID:4922544
A;Contents: annotation; disulfide bonds
A;Note: Cys-16 is involved in a heavy-light chain bond
A;Title: Cys-107, and Cys-110 form inter-heavy chain bonds
C;Comment: This chain was isolated from pooled serum of strain 13 inbred guinea pigs.
C;Complex: An immunoglobulin heterotetramer subunit consists of two identical light (kap
hain disulfide bonds. In some cases, such as IGA and IGM, the subunits associate into la
C;Superfamily: immunoglobulin C region; immunoglobulin homology
C;Keywords: duplication; glycoprotein; heterotetramer; immunoglobulin
F;21-81/Domain: immunoglobulin homology <IM1>
F;135-204/Domain: immunoglobulin homology <IM2>
F;241-310/Domain: immunoglobulin homology <IM3>
F;28-79/Disulfide bonds: #status experimental
F;142-202/Disulfide bonds: #status experimental
F;178/Binding site: carbohydrate (Asn) (covalent) #status experimental
F;248-308/Disulfide bonds: #status experimental

Query Match 68.1%; Score 1201.5; DB 1; Length 329;
Best Local Similarity 69.7%; Pred. No. 1.5e-75;
Matches 232; Conservative 28; Mismatches 64; Indels 9; Gaps 4;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
DB 2 ARTTAPSVFPLAASCVDTSGMTLCLVKGYFPEPVTVKWSGALTSGVHTFPAVLQ-S 60

QY 61 GLYSLSVVTVFSSSLGTQTYICNVNHPKPSNTKVKDKVPEPKSCDKTH--TCPPCPAPELA 118
DB 61 GLYSLSVMVTVFSSSQKAT-----CNVAHPASSTKVDKTVPEIRTP2PBPCTCKPCPPPEML 116

QY 119 GAPSVFLPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRERQ 178
DB 117 GGPSVFIFFPKPKDTLMISLTPTVTCVVVDVSDQDPEVQFTWFDVNKPKVGNATKPRVEQ 176

QY 179 YNSTYRVSVLTVLHODWLNKGKEYKCKVSNKALPAPIEKTISKAKGQPREPOVYTLPPSR 238
DB 177 YNTTFRVESVLP1QHQDWLRGKEFKCKVYNAKALPAPIEKTISKKGAPRMPDVTLPFSR 236

QY 239 DELTKNOVSLTCLVKGFYPSDIAVEWESNGQP--ENNVKTTTPVLDSGDSFFLYSKLTVD 296
DB 237 DELSKSKSVTCLTIINFFPADIHVWASNRVPSVSKYNTPEPIDADGSGFLYSLKLTVD 296

QY 297 KSRWQQGQNVFSCSVMEALHNHYTQKSLSLSPG 329
DB 297 KSAWDQGVTVYTCVMEALHNHYTOKAISRSPG 329

RESULT 15
S31459
Ig gamma-1 chain - sheep (fragment)
C;Species: Ovis orientalis aries, Ovis ammon aries (domestic sheep)
C;Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 16-Jul-1999
C;Accession: S31459
R;Patzi, S.; Nau, F.
submitted to the EMBL Data Library, December 1992
A;Reference number: S31459
A;Accession: S31459
A;Status: preliminary

GenCore version 5.1.9
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: June 10, 2006, 11:49:06 ; Search time 271.532 Seconds
(without alignments)
1124.198 Million cell updates/sec

Title: US-10-733-563-110
Perfect score: 1765
Sequence: 1 ASTKGPSVPLPSPSKSTSG.....MHEALNHYTKSLSLSPCK 330

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2849598 seqs, 925015592 residues

Total number of hits satisfying chosen parameters: 2849598

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Uniprot 7.2.2*

1: uniprot_sprot.*

2: uniprot_trembl.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1756	99.5	330	1 IGHG1_HUMAN	P01857 homo sapien
2	1756	99.5	465	2 Q6GMX6_HUMAN	Q6gmxx6 homo sapien
3	1756	99.5	469	2 Q569F4_HUMAN	Q569f4 homo sapien
4	1756	99.5	469	2 Q727P5_HUMAN	Q727p5 homo sapien
5	1756	99.5	470	2 Q6PJ44_HUMAN	Q6pj44 homo sapien
6	1756	99.5	470	2 Q725W1_HUMAN	Q725w1 homo sapien
7	1756	99.5	475	2 Q5EFES_HUMAN	Q5efe5 homo sapien
8	1756	99.5	475	2 Q6GMW7_HUMAN	Q6gmw7 homo sapien
9	1756	99.5	476	2 Q6GNX1_HUMAN	Q6gnx1 homo sapien
10	1753	99.3	466	2 Q6IN78_HUMAN	Q6in78 homo sapien
11	1753	99.3	472	2 Q6N089_HUMAN	Q6n089 homo sapien
12	1752	99.3	473	2 Q6P055_HUMAN	Q6p055 homo sapien
13	1752	99.3	475	2 Q6MZQ6_HUMAN	Q6mzq6 homo sapien
14	1752	99.3	480	2 Q6N094_HUMAN	Q6n094 homo sapien
15	1752	99.3	481	2 Q6N097_HUMAN	Q6n097 homo sapien
16	1752	99.3	482	2 Q72351_HUMAN	Q72351 homo sapien
17	1749	99.1	466	2 Q6N096_HUMAN	Q6n096 homo sapien
18	1747	99.0	348	2 Q6PPX1_HUMAN	Q6ppy1 homo sapien
19	1747	99.0	478	2 Q6P181_HUMAN	Q6p181 homo sapien
20	1747	99.0	480	2 Q6P0F1_HUMAN	Q6pf01 homo sapien
21	1745	98.9	475	2 Q6N095_HUMAN	Q6n095 homo sapien
22	1745	98.9	544	2 Q6PJ95_HUMAN	Q6pj95 homo sapien
23	1737	98.4	473	2 Q6MZV7_HUMAN	Q6mzv7 homo sapien
24	1687	95.6	475	2 Q5RE17_PONPY	Q5re17 pongo pygma
25	1619.5	91.8	518	2 Q6N030_HUMAN	Q6n030 homo sapien
26	1619.5	91.8	519	2 Q5EM2_HUMAN	Q5emb2 homo sapien
27	1615.5	91.5	521	2 Q8N4Y9_HUMAN	Q8n4y9 homo sapien
28	1608	91.1	326	1 IGHG2_HUMAN	P01859 homo sapien
29	1608	91.1	417	2 Q6N093_HUMAN	Q6n093 homo sapien
30	1604.5	90.9	509	2 Q8NF17_HUMAN	Q8nf17 homo sapien
31	1603	90.8	465	2 Q6PE64_HUMAN	Q6pe64 homo sapien

RESULT 1

ID	IGHG1_HUMAN	STANDARD;	PRT;	330 AA.
AC	P01857;			
DT	21-JUL-1986,	integrated into UniProtKB/Swiss-Prot.		
DT	21-JUL-1986,	sequence version 1.		
DT	07-FEB-2006,	entry version 62.		
DE	Ig gamma-1	chain C region.		
GN	Name=IGHG1;			
OS	Homo sapiens (Human).			
OC	Eukaryota; Metazoa;	Chordata; Craniata; Vertebrata; Euteleostomi;		
OC	Mammalia; Eutheria;	Euarchontoglires; Primates; Catarrhini; Hominidae;		
OC	Homo.			
OX	NCBI_TaxID=9606;			
RN	[1]			
RP	NUCLEOTIDE SEQUENCE (GENOMIC DNA).			
RP	MEDLINE=82274238;	PubMed=6287432;		
RA	Ellison J.W., Berson B.J., Hood L.E.;			
RT	"The nucleotide sequence of a human immunoglobulin C gamma1 gene."			
RL	Nucleic Acids Res. 10:4071-4079(1982).			
RN	[2]			
RP	PROTEIN SEQUENCE OF 1-135 (MYELOMA PROTEIN EU).			
RP	MEDLINE=71064024;	PubMed=5489771;		
RA	Cunningham B.A., Rutishauser U., Gall W.E., Gottlieb P.D.,			
RA	Waxdal M.J., Edelman G.M.;			
RT	"The covalent structure of a human gamma G-immunoglobulin. VII. Amino acid sequence of heavy-chain cyanogen bromide fragments H1-H4."			
RL	Biochemistry 9:3161-3170(1970).			
RN	[3]			
RP	PROTEIN SEQUENCE OF 136-329 (EU).			
RP	MEDLINE=71064025;	PubMed=5530842;		
RA	Rutishauser U., Cunningham B.A., Bennett C., Konigsberg W.H.,			
RA	Edelman G.M.;			
RT	"The covalent structure of a human gamma G-immunoglobulin. 8. Amino acid sequence of heavy-chain cyanogen bromide fragments H5-H7."			
RL	Biochemistry 9:3171-3181(1970).			
RN	[4]			
RP	PROTEIN SEQUENCE (MYELOMA PROTEIN NIE).			
RP	MEDLINE=77070269;	PubMed=826475;		
RA	Ponstingl H., Hilschmann N.;			
RT	"The rule of antibody structure. The primary structure of a monoclonal IgG1 immunoglobulin (myeloma protein Nie). III. The chymotryptic peptides of the H-chain, alignment of the tryptic peptides and discussion of the complete structure."			
RL	Hoppe-Seyler's Z. Physiol. Chem. 357:1571-1604(1976).			
RN	[5]			
RP	PROTEIN SEQUENCE (MYELOMA PROTEIN KOL), AND DISULFIDE BONDS.			
RP	MEDLINE=83289131;	PubMed=6884994;		
RA	Schmidt W.E., Jung H.-D., Palm W., Hilschmann N.;			
RT	"Three-dimensional structure determination of antibodies. Primary structure of crystallized monoclonal immunoglobulin IgG1 KOL, I."			
RL	Hoppe-Seyler's Z. Physiol. Chem. 364:713-747(1993).			
RN	[6]			
RP	DISULFIDE BONDS.			

Q68cn4 homo sapien
Q6mzu6 homo sapien
P01861 homo sapien
Q8tc63 homo sapien
Q6mxx7 homo sapien
Q86tt2 homo sapien
Q95m34 equus caball
Q96pq8 homo sapien
Q65z12 mus sp. fv/
P01870 oryctolagus
P01862 cavia porce
Q99lc4 mus musculu
Q65zq1 homo sapien
P20759 rattus norv

ALIGNMENTS


```

RX MEDLINE=71064027; PubMed=4923144;
RA Gall W.E., Edelman G.M.;
RT "The covalent structure of a human gamma G-immunoglobulin. X.
RT Intrachain disulfide bonds.";
RL Biochemistry 9:3188-3196(1970).
RN [7]
RP DISULFIDE BONDS.
RX MEDLINE=7070267; PubMed=1002129;
RA Dreker L., Schwarz J., Reichel W., Hilschmann N.;
RT "Rule of antibody structure. The primary structure of a monoclonal
RT IgG1 immunoglobulin (myeloma protein Nie), I: purification and
RT characterization of the protein, the L- and H-chains, the cyanogen
RT bromide cleavage products, and the disulfide bridges.";
RL Hoppe-Seyler's Z. Physiol. Chem. 357:1515-1540(1976).
RN [8]
RP X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS).
RX MEDLINE=81208100; PubMed=7236608;
RA Deisenhofer J.;
RT "Crystallographic refinement and atomic models of a human Fc fragment
RT and its complex with fragment B of protein A from Staphylococcus
RT aureus at 2.9- and 2.8-A resolution.";
RL Biochemistry 20:2361-2370(1981).
CC -I- MISCELLANEOUS: Nie has the G1M(17) allotypic marker, 97-K, and the
CC G1M(1) markers, 239-D and 241-L. KOL and EU sequences have the
CC G1M(3) marker and the G1M (non-1) markers.
CC -I- MISCELLANEOUS: Nie also differs in the amidation states of 35,
CC 116, 198, 269 and 272.
CC -I- MISCELLANEOUS: EU also differs in the amidation states of residues
CC 155, 166, 177, 195, 198, 269, and 272 and in the order of residues
CC 268-272.
CC -I- MISCELLANEOUS: KOL also differs in the amidation states of
CC residues 198, 267 and 272.
CC -----
CC Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution-NoDerivs License
CC -----
DR EMBL; J00228; AAC82527.1; ALT_INIT; Genomic_DNA.
DR PIR; A93433; GHHU.
DR PDB; 1AJ7; X-ray; H=1-103.
DR PDB; 1AQK; X-ray; H=1-103.
DR PDB; 1DSB; X-ray; B/H=1-101.
DR PDB; 1DS1; X-ray; H=1-101.
DR PDB; 1D6V; X-ray; H=1-101.
DR PDB; 1DN2; X-ray; A/B=120-326.
DR PDB; 1E4K; X-ray; A/B=106-330.
DR PDB; 1FC1; X-ray; A/B=106-329.
DR PDB; 1FC2; X-ray; D=106-329.
DR PDB; 1FCC; X-ray; A=121-326.
DR PDB; 1H2H; X-ray; H/K=1-330.
DR PDB; 1I7Z; X-ray; B/D=1-103.
DR PDB; 1I1S; X-ray; A/B=107-330.
DR PDB; 1I1X; X-ray; A/B=107-330.
DR PDB; 1L6X; X-ray; A=120-326.
DR PDB; 1LQX; X-ray; A/B=119-330.
DR PDB; 1T83; X-ray; A/B=107-330.
DR PDB; 2RC5; X-ray; H=1-103.
DR HGNC; HGNC:5525; IGHG1.
DR MIM; 147100; gene.
DR LinkHub; P01857; -.
DR GO; GO:0005624; C:membrane fraction; NAS.
DR GO; GO:0003823; F:antigen binding; TAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig cl.
DR InterPro; IPR003006; Ig_MHC.
DR Pfam; PF07654; C1-set; 3.
DR SMART; SM00407; IGC1; 2.
DR PROSITE; PS00835; IG_LIKE; 3.
DR PROSITE; PS00290; IG_MHC; 2.
KW 3D-structure; Direct protein sequencing; Glycoprotein;
KW Immunoglobulin C region; Immunoglobulin domain.
FT CHAIN <1 330
FT Ig gamma-1 chain C region.
FT /FTID=PRO_0000153578.

```

```

CH1.
Hinge.
CH2.
CH3.
N-linked (GlcNAc...).
Interchain (with light chain).
Interchain (with heavy chain).
Interchain (with heavy chain).
K -> R (in G1M(3) marker).
/FTID=VAR_003886.
D -> E (in G1M(non-1) marker).
/FTID=VAR_003887.
L -> M (in G1M(non-1) marker).
/FTID=VAR_003888.

```

```

FT REGION 1 98
FT REGION 99 110
FT REGION 111 223
FT REGION 224 330
FT CARBOHYD 180 180
FT DISULFID 27 83
FT DISULFID 103 103
FT DISULFID 109 109
FT DISULFID 112 112
FT DISULFID 144 204
FT DISULFID 250 308
FT VARIANT 97 97
FT VARIANT 239 239
FT VARIANT 241 241
FT NON TER 1 1
FT STRAND 4 4
FT STRAND 7 11
FT STRAND 13 13
FT STRAND 15 16
FT STRAND 18 18
FT STRAND 20 35
FT STRAND 38 41
FT HELIX 42 44
FT TURN 45 45
FT TURN 48 49
FT STRAND 50 52
FT STRAND 56 57
FT TURN 59 60
FT STRAND 61 61
FT STRAND 63 75
FT TURN 76 78
FT STRAND 82 87
FT HELIX 88 90
FT TURN 91 91
FT STRAND 92 97
FT STRAND 105 106
FT STRAND 108 108
FT STRAND 111 111
FT STRAND 118 120
FT STRAND 122 126
FT HELIX 130 134
FT TURN 136 137
FT STRAND 138 138
FT STRAND 141 149
FT STRAND 151 153
FT STRAND 157 162
FT TURN 163 164
FT STRAND 165 167
FT STRAND 171 172
FT STRAND 176 177
FT TURN 179 180
FT STRAND 181 181
FT STRAND 183 190
FT HELIX 193 197
FT TURN 198 199
FT STRAND 202 207
FT TURN 209 210
FT STRAND 211 213
FT STRAND 215 219
FT STRAND 224 224
FT STRAND 227 227
FT STRAND 230 234
FT HELIX 238 242
FT STRAND 243 258
FT STRAND 261 266
FT TURN 267 268
FT STRAND 269 271
FT STRAND 274 276
FT STRAND 280 281
FT TURN 283 284

```


FT STRAND 285 285
FT STRAND 287 296

Query Match 99.5%; Score 1756; DB 1; Length 330;
Best Local Similarity 99.4%; Pred. No. 3.3e-125;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASTKGPSVPLAPSSKSTGGTAAALGCLVKDYFPEPTVTVSNWNGALTSQVHTFPAVLQSS 60
DB 1 ASTKGPSVPLAPSSKSTGGTAAALGCLVKDYFPEPTVTVSNWNGALTSQVHTFPAVLQSS 60

QY 61 GLYSLSSVTVTPSSSLGTQYICNVNHRKPSNTKVDKKVPEKSCDKTHTCPPCPAPAPLAGA 120
DB 61 GLYSLSSVTVTPSSSLGTQYICNVNHRKPSNTKVDKKVPEKSCDKTHTCPPCPAPAPLAGG 120

QY 121 PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVVHNHNAKTPREEQYN 180
DB 121 PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVVHNHNAKTPREEQYN 180

QY 181 STYRVVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
DB 181 STYRVVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240

QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW 300
DB 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW 300

QY 301 QCGNVFSCVMHEALHNHYTQKSLSLSPGK 330
DB 301 QCGNVFSCVMHEALHNHYTQKSLSLSPGK 330

RESULT 2

Q6GMX6 HUMAN
ID Q6GMX6 HUMAN PRELIMINARY; PRT; 465 AA.
AC Q6GMX6
DT 19-JUL-2004, integrated into UniProtKB/TrEMBL.
DT 19-JUL-2004, sequence version 1.
DT 07-FEB-2006, entry version 16.
DE Hypothetical protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Primary B-Cells;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahy J., Helton E., Kettaman M., Madan A., Rodrigues S., Sanchez A.,
RA Whitling M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA Scherch A., Schein J.B., Jones S.D.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Primary B-Cells;
RA Strausberg R.;

RL Submitted (JUN-2004) to the EMBL/GenBank/DBJ databases.
CC -----
CC Copyrighted by the UniProt Consortium, see <http://www.uniprot.org/terms>
CC Distributed under the Creative Commons Attribution-NonDerive License
CC -----
DR EMBL; BC073766; AAH73766.1; -, mRNA.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig_c1.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR InterPro; IPR013106; V-set.
DR Pfam; PF07654; C1-set; 3.
DR SMART; SM00409; IG1; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
KW Hypothetical protein.
SQ SEQUENCE 465 AA; 51083 MW; B3A9B7D0FDB1386E CRC64;

Query Match 99.5%; Score 1756; DB 2; Length 465;
Best Local Similarity 99.4%; Pred. No. 5.1e-125;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASTKGPSVPLAPSSKSTGGTAAALGCLVKDYFPEPTVTVSNWNGALTSQVHTFPAVLQSS 60
DB 136 ASTKGPSVPLAPSSKSTGGTAAALGCLVKDYFPEPTVTVSNWNGALTSQVHTFPAVLQSS 195

QY 61 GLYSLSSVTVTPSSSLGTQYICNVNHRKPSNTKVDKKVPEKSCDKTHTCPPCPAPLAGA 120
DB 196 GLYSLSSVTVTPSSSLGTQYICNVNHRKPSNTKVDKKVPEKSCDKTHTCPPCPAPLAGG 255

QY 121 PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVVHNHNAKTPREEQYN 180
DB 256 PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVVHNHNAKTPREEQYN 315

QY 181 STYRVVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
DB 316 STYRVVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 375

QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW 300
DB 376 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW 435

QY 301 QCGNVFSCVMHEALHNHYTQKSLSLSPGK 330
DB 436 QCGNVFSCVMHEALHNHYTQKSLSLSPGK 465

RESULT 3

Q569F4 HUMAN
ID Q569F4 HUMAN PRELIMINARY; PRT; 469 AA.
AC Q569F4
DT 10-MAY-2005, integrated into UniProtKB/TrEMBL.
DT 10-MAY-2005, sequence version 1.
DT 07-FEB-2006, entry version 8.
DE IGHG1 protein.
GN Name=IGHG1;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Lymph;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahy J., Helton E., Kettaman M., Madan A., Rodrigues S., Sanchez A.,
RA Whitling M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA Scherch A., Schein J.B., Jones S.D.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Primary B-Cells;
RA Strausberg R.;

RA Stapleton M., Soares M.B., Ronaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahy J., Helton E., Kettelman M., Madan A., Rodrigues S., Sanchez A.,
RA Whitling M., Touchman J.W., Green E.D., Dickson M.C.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.,
RT "Generation and initial analysis of more than 15,000 full-length human
RL and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
RN [2]
RN NUCLEOTIDE SEQUENCE.
RC TISSUE=Lymph;
RG NIH MGC Project;
RL Submitted (APR-2005) to the EMBL/GenBank/DBJ databases.
CC -----
CC Copyrighted by the UniProt Consortium, see <http://www.uniprot.org/terms>
CC Distributed under the Creative Commons Attribution-NoDerivs License
CC -----
DR EMBL; BC092518; AAH92518.1; -; mRNA.
DR SMR; Q569F4; 20-469.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig_c1.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR InterPro; IPR013106; V-set.
DR Pfam; PF07654; C1-set; 3.
DR SMART; SM00409; IG; 1.
DR SMART; SM00406; IGV; 2.
DR PROSITE; PS50835; IG LIKE; 4.
DR PROSITE; PS00230; IG_MHC; UNKNOWN 2.
DR SEQUENCE 469 AA; 51254 MW; AC13448E3047784F CRC64;
Query Match 99.5%; Score 1756; DB 2; Length 469;
Best Local Similarity 99.4%; Pred. No. 5.2e-125;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSS 60
DB 140 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSS 199
QY 61 GLYSLSSVTVTPSSSLGTQTYICNVNHPKPSNTKVDKKVPEKPSCKDKTHTCPPCPAPELLAG 120
DB 200 GLYSLSSVTVTPSSSLGTQTYICNVNHPKPSNTKVDKKVPEKPSCKDKTHTCPPCPAPELLGG 259
QY 121 PSVFLPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
DB 260 PSVFLPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 319
QY 181 STYRVSVLTIVLHODWLNQKEKCKVSNKALPAPIETKISKAKGQPREPQVTLPPSRDE 240
DB 320 STYRVSVLTIVLHODWLNQKEKCKVSNKALPAPIETKISKAKGQPREPQVTLPPSRDE 379
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPTPVLDSDGSFFLYSKLTVDKSRW 300
DB 380 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPTPVLDSDGSFFLYSKLTVDKSRW 439
QY 301 QGQNVFSCSMHEALHNHYTQKSLSLSPGK 330
DB 440 QGQNVFSCSMHEALHNHYTQKSLSLSPGK 469
RESULT 4
Q727P5 HUMAN PRELIMINARY; PRT; 469 AA.
ID Q727P5 HUMAN
AC Q727P5;

DT 01-OCT-2003, integrated into UniProtKB/TrEMBL.
DT 01-OCT-2003, sequence version 1.
DE 07-FEB-2006, entry version 20.
DE IGHG1 protein.
GN Name=IGHG1;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RN NUCLEOTIDE SEQUENCE.
RC TISSUE=Spleen;
RG NIH MGC Project;
RL Submitted (APR-2003) to the EMBL/GenBank/DBJ databases.
CC -----
CC Copyrighted by the UniProt Consortium, see <http://www.uniprot.org/terms>
CC Distributed under the Creative Commons Attribution-NoDerivs License
CC -----
DR EMBL; BC051328; AAHS1328.1; -; mRNA.
DR HSP; P01857; IGHZ.
DR SMR; Q727P5; 20-469.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig_c1.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR InterPro; IPR013106; V-set.
DR Pfam; PF07654; C1-set; 3.
DR SMART; SM00409; IG; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN 2.
DR SEQUENCE 469 AA; 51395 MW; C8D5BE12BAAF795C CRC64;
Query Match 99.5%; Score 1756; DB 2; Length 469;
Best Local Similarity 99.4%; Pred. No. 5.2e-125;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSS 60
DB 140 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSS 199
QY 61 GLYSLSSVTVTPSSSLGTQTYICNVNHPKPSNTKVDKKVPEKPSCKDKTHTCPPCPAPELLAG 120
DB 200 GLYSLSSVTVTPSSSLGTQTYICNVNHPKPSNTKVDKKVPEKPSCKDKTHTCPPCPAPELLGG 259
QY 121 PSVFLPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180

```
Db 260 PSVFLFPKPKDGLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 319
QY 181 STYRVSVLTCLVQDVLNGKEYCKVSKNKPAPLPIEKTISKAKGQPREPOVYTLPPSRDE 240
Db 320 STYRVSVLTCLVQDVLNGKEYCKVSKNKPAPLPIEKTISKAKGQPREPOVYTLPPSRDE 379
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPTPPVLDSGDSFFLYSKLTVDKSRW 300
Db 380 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPTPPVLDSGDSFFLYSKLTVDKSRW 439
QY 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330
Db 440 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 469

RESULT 5
Q6PJA4 HUMAN
ID Q6PJA4_HUMAN PRELIMINARY; PRT; 470 AA.
AC Q6PJA4;
DT 05-JUL-2004, integrated into UniProtKB/TrEMBL.
DT 05-JUL-2004, sequence version 1.
DT 07-FEB-2006, entry version 16.
DE IGHG1 protein.
GN Name=IGHG1;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Primary B-Cells;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G., Schuler G.D.,
RA Klausner R.D., Collins F.S., Wagner K.H., Shenmen C.M., Bhat N.K.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Hsieh F.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullany S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
RA Whitling M., Touchman J.W., Green E.D., Dickson M.C.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalhus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RL and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Primary B-Cells;
RG NIH MGC Project;
RL Submitted (DEC-2001) to the EMBL/GenBank/DBJ databases.
CC -----
CC Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution-NoDerivs License
CC -----
CC EMBL; BC018747; AAH18747.1; -; mRNA.
DR HSSP; P01861; 1ADQ.
DR SMR; Q6PJA4; 20-470.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig_c1.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR InterPro; IPR013106; V-set.
DR Pfam; PF07654; C1-set; 3.
```

```
DR SMART; SM00409; IG; 1.
DR SMART; SM00407; IGC1; 2.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG LIKE; 4.
DR PROSITE; PS00390; IG_MHC; UNKNOWN 2.
SQ SEQUENCE 470 AA; 51716 MW; 7B49556A11FD7D99 CRC64;

Query Match 99.5%; Score 1756; DB 2; Length 470;
Best Local Similarity 99.4%; Pred. No. 5.2e-125;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASTKGPSVEPLAPSKSTSGGTAALGCLVKDYFPPPTVSWNSGALTSGVHTFPAVLQSS 60
Db 141 ASTKGPSVEPLAPSKSTSGGTAALGCLVKDYFPPPTVSWNSGALTSGVHTFPAVLQSS 200
QY 61 GLYSLSVVTVFSSSLGTQTYICNVNHKPSNTKVKVKEPKSCDKTHTCTCPPAPELAGA 120
Db 201 GLYSLSVVTVFSSSLGTQTYICNVNHKPSNTKVKVKEPKSCDKTHTCTCPPAPELAGG 260
QY 121 PSVFLFPKPKDGLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
Db 261 PSVFLFPKPKDGLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 320
QY 181 STYRVSVLTCLVQDVLNGKEYCKVSKNKPAPLPIEKTISKAKGQPREPOVYTLPPSRDE 240
Db 321 STYRVSVLTCLVQDVLNGKEYCKVSKNKPAPLPIEKTISKAKGQPREPOVYTLPPSRDE 380
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPTPPVLDSGDSFFLYSKLTVDKSRW 300
Db 381 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPTPPVLDSGDSFFLYSKLTVDKSRW 440
QY 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330
Db 441 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 470

RESULT 6
Q7Z5W1 HUMAN
ID Q7Z5W1_HUMAN PRELIMINARY; PRT; 470 AA.
AC Q7Z5W1;
DT 01-OCT-2003, integrated into UniProtKB/TrEMBL.
DT 01-OCT-2003, sequence version 1.
DT 07-FEB-2006, entry version 20.
DE Hypothetical protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Spleen;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G., Schuler G.D.,
RA Klausner R.D., Collins F.S., Wagner K.H., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Ussdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullany S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
RA Whitling M., Touchman J.W., Green E.D., Dickson M.C.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalhus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RL and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
```

```

RN NUCLEOTIDE SEQUENCE.
RC TISSUE=Spleen;
RA Strausberg R.;
RL Submitted (JUN-2003) to the EMBL/GenBank/DBJ databases.
CC Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution-NoDerivs License
CC -----
DR EMBL; BC053984; AH53984.1; -, mRNA.
DR HSSP; P01857; 1HZH.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig_c1.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR InterPro; IPR013106; V-set.
DR Pfam; PF07654; C1-set; 3.
DR SMART; SM00409; IG1; 1.
DR SMART; SM00406; IG1; 2.
DR PROSITE; PS00835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
KW Hypothetical protein.
SQ SEQUENCE 470 AA; 51204 MW; 778CF34521483E1A CRC64;

Query Match 99.5%; Score 1756; DB 2; Length 470;
Best Local Similarity 99.4%; Pred. No. 5.2e-125;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASTKGPSVFLAPSSKSTGGTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSS 60
DB 141 ASTKGPSVFLAPSSKSTGGTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSS 200
QY 61 GLYSLSSVTVTPSSSLGTQYICNVNHPKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLAG 120
DB 201 GLYSLSSVTVTPSSSLGTQYICNVNHPKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG 260
QY 121 PSVFLPPPKPDLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
DB 261 PSVFLPPPKPDLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 320
QY 181 STYRVSVLTVLHQDLNKGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
DB 321 STYRVSVLTVLHQDLNKGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 380
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSLKLTVDKSRW 300
DB 381 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSLKLTVDKSRW 440
QY 301 QQGNVFCSCVMHEALHNNHYTKSLSLSPGK 330
DB 441 QQGNVFCSCVMHEALHNNHYTKSLSLSPGK 470

RESULT 7
QSEFE5 HUMAN PRELIMINARY; PRT; 475 AA.
AC QSEFE5;
DT 15-MAR-2005, integrated into UniProtKB/TrEMBL.
DT 15-MAR-2005, sequence version 1.
DT 07-FEB-2006, entry version 8.
DE Anti-Rhd monoclonal T125 gammal heavy chain precursor.
OS Homo sapiens (human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RA Gaucher C., Klein P., Beliard R.;
RT "Sequence determination of the recombinant human anti-Rhd monoclonal
RT antibody T125.";
```

```

RL Submitted (JAN-2005) to the EMBL/GenBank/DBJ databases.
CC Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution-NoDerivs License
CC -----
DR EMBL; AY894992; AA82028.1; -, mRNA.
DR SMR; QSEFE5; 20-475.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig_c1.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR InterPro; IPR013106; V-set.
DR Pfam; PF07654; C1-set; 3.
DR SMART; SM00409; IG1; 1.
DR SMART; SM00406; IG1; 2.
DR PROSITE; PS00835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
KW Signal.
FT SIGNAL 1 19 Potential.
FT CHAIN 20 475 anti-Rhd monoclonal T125 gammal heavy
FT chain.
SQ SEQUENCE 475 AA; 52362 MW; 1367D400DC7D2859 CRC64;

Query Match 99.5%; Score 1756; DB 2; Length 475;
Best Local Similarity 99.4%; Pred. No. 5.3e-125;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASTKGPSVFLAPSSKSTGGTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSS 60
DB 146 ASTKGPSVFLAPSSKSTGGTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSS 205
QY 61 GLYSLSSVTVTPSSSLGTQYICNVNHPKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLAG 120
DB 206 GLYSLSSVTVTPSSSLGTQYICNVNHPKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG 265
QY 121 PSVFLPPPKPDLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
DB 266 PSVFLPPPKPDLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 325
QY 181 STYRVSVLTVLHQDLNKGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
DB 326 STYRVSVLTVLHQDLNKGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 385
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSLKLTVDKSRW 300
DB 386 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSLKLTVDKSRW 445
QY 301 QQGNVFCSCVMHEALHNNHYTKSLSLSPGK 330
DB 446 QQGNVFCSCVMHEALHNNHYTKSLSLSPGK 475

RESULT 8
Q6GMW7 HUMAN PRELIMINARY; PRT; 475 AA.
AC Q6GMW7;
DT 19-JUL-2004, integrated into UniProtKB/TrEMBL.
DT 19-JUL-2004, sequence version 1.
DT 07-FEB-2006, entry version 16.
DE Hypothetical protein.
OS Homo sapiens (human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Spleen;
RX MEDLINE=23388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
```

RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettelman M., Madan A., Rodrigues S., Sanchez A.,
RA Whitling M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RL and mouse cDNA sequences";
RN Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Spleen;
RA Strausberg R.;
RL Submitted (JUN-2004) to the EMBL/GenBank/DBJ databases.
CC -----
CC Copyrighted by the UniProt Consortium, see <http://www.uniprot.org/terms>
CC Distributed under the Creative Commons Attribution-NoDerivs License
CC -----
CC EMBL; BC073782; AAH73782.1; -; mRNA.
DR InterPro; IPR003599; Ig-like.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig-cl.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; C1-set; 3.
DR SMART; SM00409; IG1; 1.
DR SMART; SM00407; IGcl; 2.
DR SMART; SM00406; IGv; 1.
DR PROSITE; PS00835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
KW Hypothetical protein_2.
SQ SEQUENCE 475 AA; 51987 MW; 2A1FE5D736860F8 CRC64;

Query Match 99.5%; Score 1756; DB 2; Length 475;
Best Local Similarity 99.4%; Pred. No. 5.3e-125;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPPLAPSSKSTSGGTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSS 60
DB 146 ASTKGPSVFPPLAPSSKSTSGGTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSS 205
QY 61 GLYSLSSVTVTPSSSLGTQTYICNVNHPKSNTKVDKVPKSCDKTKHTCPPCPAPELAGA 120
DB 206 GLYSLSSVTVTPSSSLGTQTYICNVNHPKSNTKVDKVPKSCDKTKHTCPPCPAPELGG 265
QY 121 PSVFLFPPPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYDGVGVHNAKTKPREEQYN 180
DB 266 PSVFLFPPPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYDGVGVHNAKTKPREEQYN 325
QY 181 STYRVVSVLTVLDHQLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
DB 326 STYRVVSVLTVLDHQLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 385
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFELYSLKLTVDKSRW 300
DB 386 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFELYSLKLTVDKSRW 445
QY 301 QQGNVFCSVMHEALHNHYTQKSLSLSPGK 330
DB 446 QQGNVFCSVMHEALHNHYTQKSLSLSPGK 475

Q6GMX1 HUMAN
ID O6GMX1 PRELIMINARY; PRT; 476 AA.
AC O6GMX1;
DT 19-JUL-2004, integrated into UniProtKB/TrEMBL.
DT 07-FEB-2006, entry version 16.
DE Hypothetical protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Spleen;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettelman M., Madan A., Rodrigues S., Sanchez A.,
RA Whitling M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RL and mouse cDNA sequences";
RN Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Spleen;
RA Strausberg R.;
RL Submitted (JUN-2004) to the EMBL/GenBank/DBJ databases.
CC -----
CC Copyrighted by the UniProt Consortium, see <http://www.uniprot.org/terms>
CC Distributed under the Creative Commons Attribution-NoDerivs License
CC -----
CC EMBL; BC073773; AAH73773.1; -; mRNA.
DR InterPro; IPR003599; Ig-like.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig-cl.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; C1-set; 3.
DR SMART; SM00409; IG1; 1.
DR SMART; SM00407; IGcl; 2.
DR SMART; SM00406; IGv; 1.
DR PROSITE; PS00835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
KW Hypothetical protein_2.
SQ SEQUENCE 476 AA; 52286 MW; 622AABA5C62DDE9D CRC64;

Query Match 99.5%; Score 1756; DB 2; Length 476;
Best Local Similarity 99.4%; Pred. No. 5.3e-125;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPPLAPSSKSTSGGTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSS 60
DB 147 ASTKGPSVFPPLAPSSKSTSGGTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSS 206
QY 61 GLYSLSSVTVTPSSSLGTQTYICNVNHPKSNTKVDKVPKSCDKTKHTCPPCPAPELAGA 120
DB 207 GLYSLSSVTVTPSSSLGTQTYICNVNHPKSNTKVDKVPKSCDKTKHTCPPCPAPELGG 266

```
QY 121 PSVFLPPPKDQTLMSRTPEVTCVVVDVSHEDPEVKENWYVDGVVHNAKTKPREEQYN 180
Db 267 PSVFLPPPKDQTLMSRTPEVTCVVVDVSHEDPEVKFNWYVDGVVHNAKTKPREEQYN 326
QY 181 STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Db 327 STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 386
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRW 300
Db 387 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRW 446
QY 301 QCGNVFSCSVMEALHNNHYTKSLSLSPGK 330
Db 447 QCGNVFSCSVMEALHNNHYTKSLSLSPGK 476

RESULT 10
Q6IN78 HUMAN
ID Q6IN78_HUMAN PRELIMINARY; PRT; 466 AA.
AC Q6IN78;
DT 05-JUL-2004, integrated into UniProtKB/TrEMBL.
DT 05-JUL-2004, sequence version 1.
DE 07-FEB-2006, entry version 16.
DE IGHG1 protein.
GN Name=IGHG1;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]_TaxID=9606;
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Peripheral Nervous System;
RX MEDLINE=2238257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Klausner R.D., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shemmen C.M., Schuler G.D.,
RA Altschul S.F., Zebberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M.J., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalish D.E.,
RA Scherch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2];
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Peripheral Nervous System;
RG NIH MGC Project;
RL Submitted (JUN-2004) to the EMBL/GenBank/DBJ databases.
CC -----
CC Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution-NoDerivs License
CC -----
CC EMBL; BC072419; AAH72419.1; -; mRNA.
DR HSSP; P01861; 1A0Q.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig.cl.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_V.
DR Pfam; PF07654; C1-set; 3.
DR SMART; SM00409; IG; 1.
DR SMART; SM00406; IGv; 1.

Q6N089 HUMAN
ID Q6N089_HUMAN PRELIMINARY; PRT; 472 AA.
AC Q6N089;
DT 05-JUL-2004, integrated into UniProtKB/TrEMBL.
DT 05-JUL-2004, sequence version 1.
DT 07-FEB-2006, entry version 14.
DE Hypothetical protein DKFP686P15220.
GN Name=DKFP686P15220;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]_TaxID=9606;
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Rectum tumor;
RG The German cDNA Consortium;
RA Wambutt R., Heubner D., Mewes H.W., Weil B., Amid C., Osanger A.,
RA Fobo G., Han M., Wiemann S.;
RL Submitted (JAN-2005) to the EMBL/GenBank/DBJ databases.
CC -----
CC Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution-NoDerivs License
CC -----
CC EMBL; BX640627; CAE45781.1; -; mRNA.
DR HSSP; P01861; 1A0Q.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig.cl.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_V.
DR InterPro; IPR013106; V-set.
DR Pfam; PF07654; C1-set; 3.
DR SMART; SM00409; IG; 1.
DR SMART; SM00407; IGcl; 2.
DR SMART; SM00406; IGv; 1.
```

```
DR SMART; SM00409; IG; 1.
DR SMART; SM00407; IGcl; 2.
DR SMART; SM00406; IGv; 1.
DR PROSITE; PS0835; IG LIKE; 4.
DR PROSITE; PS00290; IG MHC; UNKNOWN 2.
SQ SEQUENCE 466 AA; 50854 MW; 53EB0BCED81076E CRC64;

Query Match 99.3%; Score 1753; DB 2; Length 466;
Best Local Similarity 99.1%; Pred. No. 8.7e-125;
Matches 327; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGLCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
Db 137 ASTKGPSVFPLAPSSKSTSGGTAALGLCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 196
QY 61 GLYSLSSVTVTPSSSLGTQTYICNVNHPKSNKTVDKKPEPKSCDKTHTCPPCPAPELLAG 120
Db 197 GLYSLSSVTVTPSSSLGTQTYICNVNHPKSNKTVDKRVERPKSCDKTHTCPPCPAPELLGG 256
QY 121 PSVFLPPPKDQTLMSRTPEVTCVVVDVSHEDPEVKENWYVDGVVHNAKTKPREEQYN 180
Db 257 PSVFLPPPKDQTLMSRTPEVTCVVVDVSHEDPEVKFNWYVDGVVHNAKTKPREEQYN 316
QY 181 STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Db 317 STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 376
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRW 300
Db 377 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRW 436
QY 301 QCGNVFSCSVMEALHNNHYTKSLSLSPGK 330
Db 437 QCGNVFSCSVMEALHNNHYTKSLSLSPGK 466

RESULT 11
Q6N089 HUMAN
ID Q6N089_HUMAN PRELIMINARY; PRT; 472 AA.
AC Q6N089;
DT 05-JUL-2004, integrated into UniProtKB/TrEMBL.
DT 05-JUL-2004, sequence version 1.
DT 07-FEB-2006, entry version 14.
DE Hypothetical protein DKFP686P15220.
GN Name=DKFP686P15220;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]_TaxID=9606;
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Rectum tumor;
RG The German cDNA Consortium;
RA Wambutt R., Heubner D., Mewes H.W., Weil B., Amid C., Osanger A.,
RA Fobo G., Han M., Wiemann S.;
RL Submitted (JAN-2005) to the EMBL/GenBank/DBJ databases.
CC -----
CC Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution-NoDerivs License
CC -----
CC EMBL; BX640627; CAE45781.1; -; mRNA.
DR HSSP; P01861; 1A0Q.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig.cl.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_V.
DR InterPro; IPR013106; V-set.
DR Pfam; PF07654; C1-set; 3.
DR SMART; SM00409; IG; 1.
DR SMART; SM00407; IGcl; 2.
DR SMART; SM00406; IGv; 1.
```


DR PROSITE; PS00835; IG LIKE; 4.
DR PROSITE; PS00290; IG MHC; UNKNOWN 2.
KW Hypothetical protein.
SQ SEQUENCE 472 AA; 51725 MW; 26CB340D0046D279 CRC64;

Query Match 99.3%; Score 1753; DB 2; Length 472;
Best Local Similarity 99.1%; Pred. No. 8.8e-125;
Matches 327; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASTKGPSVFLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
DB 143 ASTKGPSVFLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 202
QY 61 GLYSLSSVTVTPSSSLGTQTYICNVNHPKSNKTKVDKVEPKSCDKTHTCPPCPAPELAGA 120
DB 203 GLYSLSSVTVTPSSSLGTQTYICNVNHPKSNKTKVDKVEPKSCDKTHTCPPCPAPELGG 262
QY 121 PSVFLPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
DB 263 PSVFLPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 322
QY 181 STYRVSVLTVLHODWLNKKEYCKVSNKALPAPIEKTISKAKGQPREPOVYTLPPSRDE 240
DB 323 STYRVSVLTVLHODWLNKKEYCKVSNKALPAPIEKTISKAKGQPREPOVYTLPPSRDE 382
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSLKLTVDKSRW 300
DB 383 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSLKLTVDKSRW 442
QY 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330
DB 443 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 472

RESULT 12
Q6P055 HUMAN
ID Q6P055 HUMAN PRELIMINARY; PRT; 473 AA.
AC Q6P055;
DT 05-JUL-2004, integrated into UniProtKB/TrEMBL.
DT 05-JUL-2004, sequence version 1.
DT 07-FEB-2006, entry version 15.
DE Hypothetical protein.
OS Homo sapiens (human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Peripheral Nervous System;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Klausner R.D., Feingold E.A., Grouse L.H., Deige J.G.,
RA Strausberg R.L., Collins F.S., Wagner L., Sherman C.M., Schuler G.D.,
RA Altschul S.F., Zebner B., Buettow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McSwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettaman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.

RC TISSUE=Peripheral Nervous System;
RA Strausberg R.;
RL Submitted (JAN-2004) to the EMBL/GenBank/DBJ databases.
CC
CC Copyrighted by the UniProt Consortium, see <http://www.uniprot.org/terms>
CC Distributed under the Creative Commons Attribution-NoDerivs License
CC
CC
DR EMBL; BC065820; AAH65820.1; -; mRNA.
DR HSSP; P01861; IADO.
DR InterPro; IPR003599; IG.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003597; IG-cl.
DR InterPro; IPR003006; IG.MHC.
DR InterPro; IPR003596; IG.v.
DR InterPro; IPR013106; V-set.
DR Pfam; PF07654; Cl-set; 3.
DR SMART; SM00409; IG.1.
DR SMART; SM00407; IGcl; 2.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG LIKE; 4.
DR PROSITE; PS00290; IG MHC; UNKNOWN 2.
KW Hypothetical protein.
SQ SEQUENCE 473 AA; 51344 MW; 9816D56A77129B57 CRC64;

Query Match 99.3%; Score 1752; DB 2; Length 473;
Best Local Similarity 99.1%; Pred. No. 1.1e-124;
Matches 327; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 ASTKGPSVFLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
DB 144 ASTKGPSVFLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 203
QY 61 GLYSLSSVTVTPSSSLGTQTYICNVNHPKSNKTKVDKVEPKSCDKTHTCPPCPAPELAGA 120
DB 204 GLYSLSSVTVTPSSSLGTQTYICNVNHPKSNKTKVDKVEPKSCDKTHTCPPCPAPELGG 263
QY 121 PSVFLPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
DB 264 PSVFLPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 323
QY 181 STYRVSVLTVLHODWLNKKEYCKVSNKALPAPIEKTISKAKGQPREPOVYTLPPSRDE 240
DB 324 STYRVSVLTVLHODWLNKKEYCKVSNKALPAPIEKTISKAKGQPREPOVYTLPPSRDE 383
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSLKLTVDKSRW 300
DB 384 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSLKLTVDKSRW 443
QY 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330
DB 444 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 473

RESULT 13
Q6MZQ6 HUMAN
ID Q6MZQ6 HUMAN PRELIMINARY; PRT; 475 AA.
AC Q6MZQ6;
DT 05-JUL-2004, integrated into UniProtKB/TrEMBL.
DT 05-JUL-2004, sequence version 1.
DT 07-FEB-2006, entry version 13.
DE Hypothetical protein DKFP686G11190.
GN Name=DKFP686G11190;
OS Homo sapiens (human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Esophagus tumor;
RG The German cDNA Consortium;
RA Bahr A., Lauber J., Mewes H.W., Weil B., Amid C., Osanger A., Fobo G.,
RA Han M., Wiemann S.;

```

RL Submitted (JAN-2005) to the EMBL/GenBank/DBJ databases.
CC -----
CC Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution-NoDerivs License
CC -----
DR EMBL; BX640947; CAE45972.1; -, mRNA.
DR HSSP; P01861; IADQ.
DR SMR; O6MZQ6; 20-475.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig.cl.
DR InterPro; IPR003006; Ig.MHC.
DR InterPro; IPR003596; Ig.v.
DR InterPro; IPR013106; V-set.
DR Pfam; PF07654; C1-set; 3.
DR SMART; SM00409; IG; 1.
DR SMART; SM00407; IG; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG LIKE; 4.
DR PROSITE; PS00290; IG.MHC; UNKNOWN_2.
KW Hypothetical protein.
SQ SEQUENCE 475 AA; 52043 MW; B7EAE255A26F4B8E CRC64;

Query Match          99.3%; Score 1752; DB 2; Length 475;
Best Local Similarity 99.1%; Pred. No. 1.1e-124;
Matches 327; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVWNSGALTSGVHTFPAVLQSS 60
DB 146 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVWNSGALTSGVHTFPAVLQSS 205
QY 61 GLYSLSVVTPSSSLGTQTYICNVNHPKSNKTVKDKVPEKSCDKTHTCPPCPAPAPLAGA 120
DB 206 GLYSLSVVTPSSSLGTQTYICNVNHPKSNKTVKDKVPEKSCDKTHTCPPCPAPAPLAGG 265
QY 121 PSVFLPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
DB 266 PSVFLPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 325
QY 181 STYRVVSVLTVLDHQMNLGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
DB 326 STYRVVSVLTVLDHQMNLGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 385
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300
DB 386 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 445
QY 301 QQGNVFSCSVMHEALHNHYTQKSLSLSPGK 330
DB 446 QQGNVFSCSVMHEALHNHYTQKSLSLSPGK 475

RESULT 14
Q6N094 HUMAN PRELIMINARY; PRT; 480 AA.
AC Q6N094;
DT 05-JUL-2004, integrated into UniProtKB/TrEMBL.
DT 05-JUL-2004, sequence version 1.
DT 07-FEB-2006, entry version 14.
DE Hypothetical protein DKFZp686O01196.
GN Name=DKFZp686O01196;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Esophagus tumor;
RG The German cDNA Consortium;
RA Wambutt R., Heubner D., Mewes H.W., Weil B., Amid C., Osanger A.,
RA Fobo G., Han M., Wiemann S.;
RA Submitted (JAN-2005) to the EMBL/GenBank/DBJ databases.
RL

```

```

CC -----
CC Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution-NoDerivs License
CC -----
DR EMBL; BX640622; CAE45776.1; -, mRNA.
DR HSSP; P01861; IADQ.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig.cl.
DR InterPro; IPR003006; Ig.MHC.
DR InterPro; IPR003596; Ig.v.
DR InterPro; IPR013106; V-set.
DR Pfam; PF07654; C1-set; 3.
DR SMART; SM00409; IG; 1.
DR SMART; SM00407; IG; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG LIKE; 4.
DR PROSITE; PS00290; IG.MHC; UNKNOWN_2.
KW Hypothetical protein.
SQ SEQUENCE 480 AA; 52613 MW; 225247F3D35ABC18 CRC64;

Query Match          99.3%; Score 1752; DB 2; Length 480;
Best Local Similarity 99.1%; Pred. No. 1.1e-124;
Matches 327; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVWNSGALTSGVHTFPAVLQSS 60
DB 151 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVWNSGALTSGVHTFPAVLQSS 210
QY 61 GLYSLSVVTPSSSLGTQTYICNVNHPKSNKTVKDKVPEKSCDKTHTCPPCPAPAPLAGA 120
DB 211 GLYSLSVVTPSSSLGTQTYICNVNHPKSNKTVKDKVPEKSCDKTHTCPPCPAPAPLAGG 270
QY 121 PSVFLPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
DB 271 PSVFLPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 330
QY 181 STYRVVSVLTVLDHQMNLGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
DB 331 STYRVVSVLTVLDHQMNLGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 390
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300
DB 391 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 450
QY 301 QQGNVFSCSVMHEALHNHYTQKSLSLSPGK 330
DB 451 QQGNVFSCSVMHEALHNHYTQKSLSLSPGK 480

RESULT 15
Q6N097 HUMAN PRELIMINARY; PRT; 481 AA.
AC Q6N097;
DT 05-JUL-2004, integrated into UniProtKB/TrEMBL.
DT 05-JUL-2004, sequence version 1.
DT 07-FEB-2006, entry version 13.
DE Hypothetical protein DKFZp686H20196.
GN Name=DKFZp686H20196;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Esophagus tumor;
RG The German cDNA Consortium;
RA Wambutt R., Heubner D., Mewes H.W., Weil B., Amid C., Osanger A.,
RA Fobo G., Han M., Wiemann S.;
RA Submitted (JAN-2005) to the EMBL/GenBank/DBJ databases.
CC

```


CC Distributed under the Creative Commons Attribution-NoDerivs License
CC -----
DR EMBL; BX640619; CAB45773.1; -; mRNA.
DR HSSP; P01861; IADQ.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig_c1.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR InterPro; IPR013106; V-set.
DR Pfam; PF07654; C1-set; 3.
DR SMART; SM00409; IG; 1.
DR SMART; SM00407; IGC1; 2.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
KW Hypothetical protein.
SQ SEQUENCE 481 AA; 52759 MW; 47220D9E64BDF98B CRC64;

Query Match 99.3%; Score 1752; DB 2; Length 481;
Best Local Similarity 99.1%; Pred. No. 1.le-124;
Matches 327; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 ASTKGPSVFLAPSSKSTSGTAAALGCLVKDYPPETVTVSWNSGALTSGVHTFPVAVLQSS 60
Db |||||
152 ASTKGPSVFLAPSSKSTSGTAAALGCLVKDYPPETVTVSWNSGALTSGVHTFPVAVLQSS 211

QY 61 GLYSLSVVTVPSSSLGTQTYICNVNHPKSNTKVDKKVPKSCDKTHTCPCPAPELAGA 120
Db |||||
212 GLYSLSVVTVPSSSLGTQTYICNVNHPKSNTKVDKKVPKSCDKTHTCPCPAPELLGG 271

QY 121 PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
Db |||||
272 PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 331

QY 181 STYRVVSVLTVTLHODMNLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Db |||||
332 STYRVVSVLTVTLHODMNLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 391

QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFELYSLTVDKSRW 300
Db |||||
392 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFELYSLTVDKSRW 451

QY 301 QQGNVFSCSVMHEALHNHYTQKSLSLSPGK 330
Db |||||
452 QQGNVFSCSVMHEALHNHYTQKSLSLSPGK 481

Search completed: June 10, 2006, 12:05:28
Job time : 272.532 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.9
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: June 10, 2006, 12:05:52 ; Search time 56.982 Seconds
(without alignments)
506.917 Million cell updates/sec

Title: US-10-733-563-110

Perfect score: 1765
Sequence: 1 ASTKGSPVFLAPSSKSTSG.....MHEALHNHYTKSLSPGK 330

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 650591 seqs, 87530628 residues

Total number of hits satisfying chosen parameters: 650591

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

- Database : Issued Patents AA:*
- 1: /EMC Celerra_SIDS3/ptodata/2/iaa/5 COMB.pcp.*
 - 2: /EMC Celerra_SIDS3/ptodata/2/iaa/6 COMB.pcp.*
 - 3: /EMC Celerra_SIDS3/ptodata/2/iaa/7 COMB.pcp.*
 - 4: /EMC Celerra_SIDS3/ptodata/2/iaa/H COMB.pcp.*
 - 5: /EMC Celerra_SIDS3/ptodata/2/iaa/PCTUS COMB.pcp.*
 - 6: /EMC Celerra_SIDS3/ptodata/2/iaa/RE COMB.pcp.*
 - 7: /EMC Celerra_SIDS3/ptodata/2/iaa/backfiles1.pcp.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1765	100.0	444	3	US-09-674-716B-53
2	1756	99.5	330	2	US-10-112-582A-1
3	1756	99.5	371	1	US-08-236-311-7
4	1756	99.5	371	2	US-08-457-918-7
5	1756	99.5	371	2	US-10-157-408-7
6	1756	99.5	444	2	US-10-147-849-7
7	1756	99.5	446	2	US-08-397-411-7
8	1756	99.5	449	1	US-08-458-516-13
9	1756	99.5	467	2	US-08-030-175-41
10	1756	99.5	467	2	US-08-030-175-42
11	1756	99.5	470	2	US-10-104-047-3730
12	1756	99.5	476	1	US-08-378-939-10
13	1756	99.5	547	2	US-09-746-359A-54
14	1756	99.5	567	2	US-09-825-561A-16
15	1756	99.5	571	2	US-09-746-359A-53
16	1756	99.5	951	2	US-09-313-942-9
17	1756	99.5	951	2	US-10-282-162-9
18	1752	99.3	462	2	US-09-289-942A-7
19	1752	99.3	475	2	US-09-740-002-27
20	1752	99.3	476	2	US-08-487-550-4
21	1752	99.3	476	2	US-08-487-550-12
22	1752	99.3	476	2	US-09-526-098-4
23	1752	99.3	476	2	US-09-526-098-12
24	1752	99.3	476	2	US-09-383-916-4
25	1752	99.3	476	2	US-09-383-916-12
26	1752	99.3	476	2	US-09-758-173-4

ALIGNMENTS

RESULT 1

US-09-674-716B-53
; Sequence 53, Application US/09674716B
; Patent No. 7008623
; GENERAL INFORMATION:
; APPLICANT: BONNEFOY, Jean-Yves M.P.
; APPLICANT: CROWE, James S.
; APPLICANT: ELLIS, Jonathan H.
; APPLICANT: RAPSON, Nicholas T.
; APPLICANT: SHEARIN, Jean
; TITLE OF INVENTION: Antibodies to CD23, derivatives thereof, and their therapeutic u
; FILE REFERENCE: 1430-256 / PG3433USw0
; CURRENT APPLICATION NUMBER: US/09/674,716B
; CURRENT FILING DATE: 2001-01-22
; PRIOR APPLICATION NUMBER: CA 2,328,606
; PRIOR FILING DATE: 1999-05-07
; PRIOR APPLICATION NUMBER: PCT/GB99/01434
; PRIOR FILING DATE: 1999-05-07
; PRIOR APPLICATION NUMBER: GB 9809839.5
; PRIOR FILING DATE: 1998-05-09
; NUMBER OF SEQ ID NOS: 54
; SOFTWARE: MS Word
; SEQ ID NO 53
; LENGTH: 444
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Humanised anti-CD23 antibody

US-09-674-716B-53

Query Match 100.0%; Score 1765; DB 3; Length 444;
Best Local Similarity 100.0%; Pred. No. 1.2e-157;
Matches 330; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	ASTKGSPVFLAPSSKSTSGGTAALCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSS	60
Db	115	ASTKGSPVFLAPSSKSTSGGTAALCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSS	174
QY	61	GLYSSSVTVTPSSSLGTQTYICNVNHPKSNTKVDKKVEPKSKCDKTHTCPPCPAPELAGA	120
Db	175	GLYSSSVTVTPSSSLGTQTYICNVNHPKSNTKVDKKVEPKSKCDKTHTCPPCPAPELAGA	234
QY	121	PSVFLPPPKKDTLMISRPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKRREQYN	180
Db	235	PSVFLPPPKKDTLMISRPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKRREQYN	294
QY	181	STYRVSVLTIVLHODWLNKGKCYKSNKALPAPIEKTISKAKGQPREPOVYTLPPSRDE	240
Db	295	STYRVSVLTIVLHODWLNKGKCYKSNKALPAPIEKTISKAKGQPREPOVYTLPPSRDE	354

QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
DB 355 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 414
QY 301 QQGNVFSCSVMHEALHNHYTQKSLSLSPGK 330
DB 415 QQGNVFSCSVMHEALHNHYTQKSLSLSPGK 444

RESULT 2

US-10-112-582A-1
; Sequence 1, Application US/10112582A
; Patent No. 6992174
; GENERAL INFORMATION:
; APPLICANT: Gillies, Stephen
; TITLE OF INVENTION: Reducing the Immunogenicity of Fusion Proteins
; FILE REFERENCE: LEX-017
; CURRENT APPLICATION NUMBER: US/10/112,582A
; CURRENT FILING DATE: 2002-03-29
; PRIOR APPLICATION NUMBER: US 60/280,625
; PRIOR FILING DATE: 2001-03-30
; NUMBER OF SEQ ID NOS: 59
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
; LENGTH: 330
; TYPE: PRT
; ORGANISM: Homo sapiens
; NAME/KEY: misc feature
; FEATURE:
; OTHER INFORMATION: human Ig gamma heavy chain C region
US-10-112-582A-1

Query Match 99.5%; Score 1756; DB 2; Length 330;
Best Local Similarity 99.4%; Pred. No. 5.5e-157;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASTKGPSVPLAPSSKSTSGGTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSS 60
DB 1 ASTKGPSVPLAPSSKSTSGGTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSS 60
QY 61 GLYSLSVVTVPSSSISGTQYICNVNHPKSNKTKVDKKEPKSCDKTHTCPPCPAPLAGA 120
DB 61 GLYSLSVVTVPSSSISGTQYICNVNHPKSNKTKVDKKEPKSCDKTHTCPPCPAPLAGG 120
QY 121 PSVFLPPPKKPTLMIKSRTEPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
DB 121 PSVFLPPPKKPTLMIKSRTEPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
QY 181 STYRVVSVLTVLDHQLWNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
DB 181 STYRVVSVLTVLDHQLWNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
DB 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
QY 301 QQGNVFSCSVMHEALHNHYTQKSLSLSPGK 330
DB 301 QQGNVFSCSVMHEALHNHYTQKSLSLSPGK 330

RESULT 3

US-08-236-311-7
; Sequence 7, Application US/08236311
; Patent No. 5565335
; GENERAL INFORMATION:
; APPLICANT: Capon, Daniel J.
; APPLICANT: Gregory, Timothy J.
; TITLE OF INVENTION: Adhesion Variants
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.

; STREET: 460 Point San Bruno Blvd
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: patin (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/236,311
; FILING DATE: 02-MAY-1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/936190
; FILING DATE: 26-AUG-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/842777
; FILING DATE: 18-FEB-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/250785
; FILING DATE: 28-SEP-1988
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/104329
; FILING DATE: 02-OCT-1987
; ATTORNEY/AGENT INFORMATION:
; NAME: Hasak, Janet E.
; REGISTRATION NUMBER: 28,616
; REFERENCE/DOCKET NUMBER: 444P1C2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415/225-1896
; TELEFAX: 415/952-9881
; TELEX: 910/371-7168
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 371 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; US-08-236-311-7

Query Match 99.5%; Score 1756; DB 1; Length 371;
Best Local Similarity 99.4%; Pred. No. 6.6e-157;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASTKGPSVPLAPSSKSTSGGTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSS 60
DB 42 ASTKGPSVPLAPSSKSTSGGTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSS 101
QY 61 GLYSLSVVTVPSSSISGTQYICNVNHPKSNKTKVDKKEPKSCDKTHTCPPCPAPLAGA 120
DB 102 GLYSLSVVTVPSSSISGTQYICNVNHPKSNKTKVDKKEPKSCDKTHTCPPCPAPLAGG 161
QY 121 PSVFLPPPKKPTLMIKSRTEPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
DB 162 PSVFLPPPKKPTLMIKSRTEPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 221
QY 181 STYRVVSVLTVLDHQLWNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
DB 222 STYRVVSVLTVLDHQLWNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 281
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
DB 282 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 341
QY 301 QQGNVFSCSVMHEALHNHYTQKSLSLSPGK 330
DB 342 QQGNVFSCSVMHEALHNHYTQKSLSLSPGK 371

RESULT 4
US-08-457-918-7
; Sequence 7, Application US/08457918

```

; Patent No. 6117655
; GENERAL INFORMATION:
; APPLICANT: Capon, Daniel J.
; APPLICANT: Gregory, Timothy J.
; TITLE OF INVENTION: Adhesion Variants
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.
; STREET: 460 Point San Bruno Blvd
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patin (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/457,918
; FILING DATE: 1-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/236311
; FILING DATE: 02-MAY-1994
; APPLICATION DATA:
; APPLICATION NUMBER: 07/936190
; FILING DATE: 26-AUG-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/842777
; FILING DATE: 18-FEB-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/250785
; FILING DATE: 28-SEP-1988
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/104329
; FILING DATE: 02-OCT-1987
; ATTORNEY/AGENT INFORMATION:
; NAME: Kubinec, Jeffrey S.
; REGISTRATION NUMBER: 36,575
; REFERENCE/DOCKET NUMBER: P0444PIC3
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415/225-8228
; TELEFAX: 415/952-9881
; TELEX: 910/371-7168
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 371 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; US-08-457-918-7

Query Match          99.5%; Score 1756; DB 2; Length 371;
Best Local Similarity 99.4%; Pred. No. 6.6e-157;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASTKGPSVFLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTTFAVLQSS 60
DB 42 ASTKGPSVFLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTTFAVLQSS 101
QY 61 GLYSLSVVTVFSSSLGTQTYICNVNHPKSNVTVDGVEVHNKTPKPREEQYN 180
DB 102 GLYSLSVVTVFSSSLGTQTYICNVNHPKSNVTVDGVEVHNKTPKPREEQYN 161
QY 121 PSVFLFPKPKDTLMISRPETVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTPKPREEQYN 221
DB 162 PSVFLFPKPKDTLMISRPETVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTPKPREEQYN 240
QY 181 STYRVVSVLTVLDHQMNGEKYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 280
DB 222 STYRVVSVLTVLDHQMNGEKYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 281
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSLKLTVDKSRW 300

; Patent No. 6117655
; GENERAL INFORMATION:
; APPLICANT: Capon, Daniel J.
; APPLICANT: Gregory, Timothy J.
; TITLE OF INVENTION: Adhesion Variants
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.
; STREET: 460 Point San Bruno Blvd
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patin (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/457,918
; FILING DATE: 1-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/236311
; FILING DATE: 02-MAY-1994
; APPLICATION DATA:
; APPLICATION NUMBER: 07/936190
; FILING DATE: 26-AUG-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/842777
; FILING DATE: 18-FEB-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/250785
; FILING DATE: 28-SEP-1988
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/104329
; FILING DATE: 02-OCT-1987
; ATTORNEY/AGENT INFORMATION:
; NAME: Kubinec, Jeffrey S.
; REGISTRATION NUMBER: 36,575
; REFERENCE/DOCKET NUMBER: P0444PIC3
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415/225-8228
; TELEFAX: 415/952-9881
; TELEX: 910/371-7168
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 371 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; US-10-733-563-110-7

Query Match          99.5%; Score 1756; DB 2; Length 371;
Best Local Similarity 99.4%; Pred. No. 6.6e-157;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASTKGPSVFLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTTFAVLQSS 60
DB 42 ASTKGPSVFLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTTFAVLQSS 101
QY 61 GLYSLSVVTVFSSSLGTQTYICNVNHPKSNVTVDGVEVHNKTPKPREEQYN 180
DB 102 GLYSLSVVTVFSSSLGTQTYICNVNHPKSNVTVDGVEVHNKTPKPREEQYN 161
QY 121 PSVFLFPKPKDTLMISRPETVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTPKPREEQYN 221
DB 162 PSVFLFPKPKDTLMISRPETVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTPKPREEQYN 240
QY 181 STYRVVSVLTVLDHQMNGEKYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 280
DB 222 STYRVVSVLTVLDHQMNGEKYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 281
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSLKLTVDKSRW 341
```

QY 121 PSVFLPPPKDGLMIKSRTEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
DB 162 PSVFLPPPKDGLMIKSRTEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 221
QY 181 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPOVYTLPPSRDE 240
DB 222 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPOVYTLPPSRDE 281
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW 300
DB 282 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW 341
QY 301 QQGNVFSCSVMHEALHNHYTQKSLSLSPGK 330
DB 342 QQGNVFSCSVMHEALHNHYTQKSLSLSPGK 371

RESULT 6
US-10-147-849-7
; Sequence 7, Application US/10147849
; Patent No. 6972324
; GENERAL INFORMATION:
; APPLICANT: Adolf, Gather
; APPLICANT: Ostermann, Elinborg
; APPLICANT: Patzelt, Erik
; APPLICANT: Sproll, Marlies
; APPLICANT: Heider, Karl-Heinz
; APPLICANT: Miglietta, John
; APPLICANT: van Dongen, Augustinus Antonius Maria Silvester
; TITLE OF INVENTION: Antibodies specific for CD44v6
; FILE REFERENCE: 1011.2210002
; CURRENT APPLICATION NUMBER: US/10/147,849
; CURRENT FILING DATE: 2002-05-20
; PRIOR APPLICATION NUMBER: US 60/325147
; PRIOR FILING DATE: 2001-09-26
; PRIOR APPLICATION NUMBER: US 60/323075
; PRIOR FILING DATE: 2001-09-19
; PRIOR APPLICATION NUMBER: EP 01112237.1
; PRIOR FILING DATE: 2001-05-18
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 7
; LENGTH: 444
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:humanized
; OTHER INFORMATION: antibody sequence
US-10-147-849-7

Query Match 99.5%; Score 1756; DB 2; Length 444;
Best Local Similarity 99.4%; Pred. No. 8.6e-157;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASKGPSVFPLAPSSKSTSGGTAALGLCLVKDYFPEPVTVSWNSGALTSGVHTTTPAVLQSS 60
DB 115 ASKGPSVFPLAPSSKSTSGGTAALGLCLVKDYFPEPVTVSWNSGALTSGVHTTTPAVLQSS 174
QY 61 GLYSLSVTVTPSSSLGTQYIICNVNHNKPSNTKVDKKVEPKSCDKTKHTCPCPAPELAGA 120
DB 175 GLYSLSVTVTPSSSLGTQYIICNVNHNKPSNTKVDKKVEPKSCDKTKHTCPCPAPELAGG 234
QY 121 PSVFLPPPKDGLMIKSRTEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
DB 235 PSVFLPPPKDGLMIKSRTEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 294
QY 181 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPOVYTLPPSRDE 240
DB 295 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPOVYTLPPSRDE 354
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW 300

DB 355 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW 414
QY 301 QQGNVFSCSVMHEALHNHYTQKSLSLSPGK 330
DB 415 QQGNVFSCSVMHEALHNHYTQKSLSLSPGK 444

RESULT 7
US-08-397-411-7
; Sequence 7, Application US/08397411
; Patent No. 6129914
; GENERAL INFORMATION:
; APPLICANT: Weiner, George
; APPLICANT: Gingrich, Roger
; APPLICANT: Link, Brian
; APPLICANT: Tso, J. Yun
; TITLE OF INVENTION: Bispecific Antibody Effective to Treat
; TITLE OF INVENTION: B-Cell Lymphoma and Cell Line
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew
; STREET: One Market Plaza, Steuart Tower, Suite 2000
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM: disk
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/397,411
; FILING DATE: 01-MAR-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/859,583
; FILING DATE: 27-MAR-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Smith, William M.
; REGISTRATION NUMBER: 30,223
; REFERENCE/DOCKET NUMBER: 011823-004901
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-326-2400
; TELEFAX: 415-326-2422
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 446 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-397-411-7

Query Match 99.5%; Score 1756; DB 2; Length 446;
Best Local Similarity 99.4%; Pred. No. 8.6e-157;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASKGPSVFPLAPSSKSTSGGTAALGLCLVKDYFPEPVTVSWNSGALTSGVHTTTPAVLQSS 60
DB 117 ASKGPSVFPLAPSSKSTSGGTAALGLCLVKDYFPEPVTVSWNSGALTSGVHTTTPAVLQSS 176
QY 61 GLYSLSVTVTPSSSLGTQYIICNVNHNKPSNTKVDKKVEPKSCDKTKHTCPCPAPELAGA 120
DB 177 GLYSLSVTVTPSSSLGTQYIICNVNHNKPSNTKVDKKVEPKSCDKTKHTCPCPAPELAGG 236
QY 121 PSVFLPPPKDGLMIKSRTEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
DB 237 PSVFLPPPKDGLMIKSRTEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 296
QY 181 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPOVYTLPPSRDE 240
DB 297 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPOVYTLPPSRDE 356

Qy	241	LTKQVSLTCLVKGPYSDIAVEWESNGQPNENYKTTPEVLDSGDSFFLYSKLTVDKSRW	300
Db	357	LTKQVSLTCLVKGPYSDIAVEWESNGQPNENYKTTPEVLDSGDSFFLYSKLTVDKSRW	416
Qy	301	QQGNVFCSCVMHEALHNHYTKQSLSLSPCK	330
Db	417	QQGNVFCSCVMHEALHNHYTKQSLSLSPCK	446

```

RESULT 8
US-08-458-516-13.
; Sequence 13, Application US/08458516
; Patent No. 5777085
; GENERAL INFORMATION:
; APPLICANT: Co, Man Sung
; APPLICANT: Tso, J. Yun
; TITLE OF INVENTION: Humanized Antibodies Reactive with
; TITLE OF INVENTION: GPIIb/IIIa
; NUMBER OF SEQUENCES: 23
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: William M. Smith
; STREET: One Market Plaza, Steuart Tower, Suite 2000
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/458,516
; FILING DATE:
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/059,159
; FILING DATE: 03-MAY-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Smith, William M.
; REGISTRATION NUMBER: 30,223
; REFERENCE/DOCKET NUMBER: 11823-37-3
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-326-2400
; TELEFAX: 415-326-2422
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 449 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-458-516-13

```

Query Match	99.5%;	Score 1756;	DB 1;	Length 449;
Best Local Similarity	99.4%;	Pred. No. 8.7e-157;		
Matches 328;	Conservative 0;	Mismatches 2;	Indels 0;	Gaps 0;
QY 1	ASTKGPVVFPLAPSSKSTSGTGAALGCLVKDYFPEPTVTSWNSGALTSGVHTFPAVLQSS 60			
Db 120	ASTKGPVVFPLAPSSKSTSGTGAALGCLVKDYFPEPTVTSWNSGALTSGVHTFPAVLQSS 179			
QY 61	GLTSLSSVWTVPSSSLGTQTQYICNVNHPKSNTKVDKVKPKSCDKTHTCPCPAPELAGA 120			
Db 180	GLTSLSSVWTVPSSSLGTQIYICNVNHPKSNTKVDKVKPKSCDKTHTCPCPAPELLGG 239			
QY 121	PSVFLPPPKPKDTLIMISRTPEVTCVVDVSHEDPEVFNKTVYDGVFVHNNAKTKPREQYN 180			
Db 240	PSVFLPPPKPKDTLIMISRTPEVTCVVDVSHEDPEVFNKTVYDGVFVHNNAKTKPREQYN 299			
QY 181	STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIKAKGQPREPQVYITLPPSRDE 240			

300	STYRVUSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAQGPREFQVYTLPPSRDE	359
241	LTKNQVSLTCLVKGFYPSDIAVEGESNQGPENNYKTTTPVLDSGDSFFLYSKLTVDKSRM	300
360	LTKNQVSLTCLVKGFYPSDIAVEGESNQGPENNYKTTTPVLDSGDSFFLYSKLTVDKSRM	419
301	QQGNVFSCSVMHEALHNHYTQKSLSLSPGK	330
420	QQGNVFSCSVMHEALHNHYTQKSLSLSPGK	449

RESULT 9
 US-08-030-175-41
 ; Sequence 41, Application US/08030175
 ; Patent No. 6767996
 ; GENERAL INFORMATION:
 ; APPLICANT: Gorman, Scott D.
 ; APPLICANT: Clark, Michael R.
 ; APPLICANT: Cobbold, Stephen P.
 ; APPLICANT: Waldmann, Herman
 ; TITLE OF INVENTION: ALTERED ANTIBODIES AND THEIR PREPARATION
 ; NUMBER OF SEQUENCES: 43
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Rothwell, Figg, Ernst & Kurz, P. C.
 ; STREET: 555 13TH ST., NW Suite 701 East
 ; CITY: Washington
 ; STATE: D. C.
 ; COUNTRY: U.S.
 ; ZIP: 20004
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Floppy disk, 5.25 inch, 360 kb storage
 ; COMPUTER: IBM AT compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS V 3.2
 ; SOFTWARE: Wordperfect 5.0 (Dos Text)
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/030,175
 ; FILING DATE: 17-MAY-1993
 ; CLASSIFICATION: 424
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: PCT/GB91/01578
 ; FILING DATE: 13-SEP-1991
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Ernst, Barbara G.
 ; REGISTRATION NUMBER: 30,377
 ; REFERENCE/DOCKET NUMBER: 1768-113
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (202) 783-6040
 ; TELEFAX: (202) 783-6031
 ; INFORMATION FOR SEQ ID NO. 41:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 467 amino acids
 ; TYPE: amino acid
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: protein
 ; US-08-030-175-41

	Query Match	99.5%	Score 1756;	DB 2;	Length 467;
	Best Local Similarity	99.4%;	Pred. No. 9.2e-157;		
	Matches 328; Conservative	0;	Mismatches 2;	Indels 0;	Gaps 0
Qy	1	ASTKGPVFPPLAPSSKSTSGTGAALGCLVKDYPPEPVTVSNWSGALTSGVHTFPAVL	SS 60		
Db	138	ASTKGPVFPPLAPSSKSTSGTGAALGCLVKDYPPEPVTVSNWSGALTSGVHTFPAVL	SS 197		
Qy	61	GLYSLSVWTVPSSSLGTQTYICNVNHKPSNTKVDKVPKSCDKTHTCPCPAPELAGA	SS 120		
Db	198	GLYSLSVWTVPSSSLGTQTYICNVNHKPSNTKVDKVPKSCDKTHTCPCPAPELGG	SS 257		
Qy	121	PSVFLPPKPKDITLMISRTPEVTCVVDVSHDEPVENKVMYVDGVENVNAKTKPREEQYN	SS 180		
Db	258	PSVFLPPKPKDITLMISRTPEVTCVVDVSHDEPVENKVMYVDGVENVNAKTKPREEQYN	SS 317		
Qy	181	STVRVSVLTVLHODLNGKEYKCKVSNKALPAPIEKTISAKAGQEPFPQVYVTLPPSRDE	SS 240		

Db 318 STYRVSVLTVLHODWLNKGYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 377
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
Db 378 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 437
QY 301 QQGNVFCSVMHEALHNHYTQKSLSLSPGK 330
Db 438 QQGNVFCSVMHEALHNHYTQKSLSLSPGK 467

RESULT 10
US-08-030-175-42
; Sequence 42, Application US/08030175
; Patent No. 6767996
; GENERAL INFORMATION:
; APPLICANT: Gorman, Scott D.
; APPLICANT: Clark, Michael R.
; APPLICANT: Cobboid, Stephen P.
; APPLICANT: Waldmann, Herman
; TITLE OF INVENTION: ALTERED ANTIBODIES AND THEIR PREPARATION
; NUMBER OF SEQUENCES: 43
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Rothwell, Figg, Ernst & Kurz, P. C.
; STREET: 555 13TH St., NW, Suite 701 East
; CITY: Washington
; STATE: D. C.
; COUNTRY: U.S.
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk, 5.25 inch, 360 Kb storage
; COMPUTER: IBM AT compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS V 3.2
; SOFTWARE: WordPerfect 5.0 (Dos Text)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/030,175
; FILING DATE: 17-MAY-1993
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/GE91/01578
; FILING DATE: 13-SEP-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Ernst, Barbara G.
; REGISTRATION NUMBER: 30,377
; REFERENCE/DOCKET NUMBER: 1768-113
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202)783-6040
; TELEFAX: (202)783-6031
; INFORMATION FOR SEQ ID NO: 42:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 467 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-030-175-42

Query Match 99.5%; Score 1756; DB 2; Length 467;
Best Local Similarity 99.4%; Pred. No. 9.2e-157;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVWSNMGALTSGLTSVHTFPVAVLQSS 60
Db 138 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVWSNMGALTSGLTSVHTFPVAVLQSS 197
QY 61 GLYSLSSVTVTPSSSLGTQYICNVNHNKPSNTKVDKKVEPKSCDKTHHTCCPPCPAPELAGA 120
Db 198 GLYSLSSVTVTPSSSLGTQYICNVNHNKPSNTKVDKKVEPKSCDKTHHTCCPPCPAPELAGG 257
QY 121 PSVFLPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAAKTKPREEQYN 180
Db 258 PSVFLPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAAKTKPREEQYN 317

QY 181 STYRVSVLTVLHODWLNKGYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Db 318 STYRVSVLTVLHODWLNKGYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 377
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
Db 378 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 437
QY 301 QQGNVFCSVMHEALHNHYTQKSLSLSPGK 330
Db 438 QQGNVFCSVMHEALHNHYTQKSLSLSPGK 467

RESULT 11
US-10-104-047-3730
; Sequence 3730, Application US/10104047
; Patent No. 6943241
; GENERAL INFORMATION:
; APPLICANT: HELIX RESEARCH INSTITUTE
; TITLE OF INVENTION: No. 6943241el full length cdna
; FILE REFERENCE: H1-A0105
; CURRENT APPLICATION NUMBER: US/10/104,047
; CURRENT FILING DATE: 2002-03-25
; PRIOR APPLICATION NUMBER:
; PRIOR FILING DATE:
; NUMBER OF SEQ ID NOS: 4096
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 3730
; LENGTH: 470
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-104-047-3730

Query Match 99.5%; Score 1756; DB 2; Length 470;
Best Local Similarity 99.4%; Pred. No. 9.3e-157;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVWSNMGALTSGLTSVHTFPVAVLQSS 60
Db 141 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVWSNMGALTSGLTSVHTFPVAVLQSS 200
QY 61 GLYSLSSVTVTPSSSLGTQYICNVNHNKPSNTKVDKKVEPKSCDKTHHTCCPPCPAPELAGA 120
Db 201 GLYSLSSVTVTPSSSLGTQYICNVNHNKPSNTKVDKKVEPKSCDKTHHTCCPPCPAPELAGG 260
QY 121 PSVFLPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAAKTKPREEQYN 180
Db 261 PSVFLPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAAKTKPREEQYN 320
QY 181 STYRVSVLTVLHODWLNKGYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Db 321 STYRVSVLTVLHODWLNKGYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 380
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
Db 381 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 440
QY 301 QQGNVFCSVMHEALHNHYTQKSLSLSPGK 330
Db 441 QQGNVFCSVMHEALHNHYTQKSLSLSPGK 470

RESULT 12
US-08-378-939-10
; Sequence 10, Application US/08378939
; Patent No. 5876961
; GENERAL INFORMATION:
; APPLICANT: CROWE, JAMES SCOTT
; APPLICANT: LEWIS, ALAN PETER
; TITLE OF INVENTION: PRODUCTION OF ANTIBODIES
; NUMBER OF SEQUENCES: 46
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ROTHWELL, FIGG, ERNST & KURZ


```
/ STREET: 555 THIRTEENTH ST. N.W.
/ CITY: WASHINGTON
/ STATE: D. C.
/ COUNTRY: U.S.
/ ZIP: 20004
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: PatentIn Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/378,939
/ FILING DATE:
/ CLASSIFICATION: 435
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 07/952640
/ FILING DATE: 01-DEC-1992
/ ATTORNEY/AGENT INFORMATION:
/ NAME: ERNST, BARBARA G
/ REGISTRATION NUMBER: 30,377
/ REFERENCE/DOCKET NUMBER: 1808-118
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (202) 783-6040
/ TELEFAX: (202) 783-6031
/ INFORMATION FOR SEQ ID NO: 10:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 476 amino acids
/ TYPE: amino acid
/ TOPOLOGY: linear
/ MOLECULE TYPE: protein
US-08-378-939-10

Query Match 99.5%; Score 1756; DB 1; Length 476;
Best Local Similarity 99.4%; Pred. No. 9.5e-157;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASTKGSPVPLAPSSKSTSGGTAALGCLVKDYPPPTVSVNSGALTSGVHTTTPAVLQSS 60
Db 147 ASTKGSPVPLAPSSKSTSGGTAALGCLVKDYPPPTVSVNSGALTSGVHTTTPAVLQSS 206
QY 61 GLYSLSVVTVPSSSISGTTQYICNVNHPKSNKVDKKVPEKSCDKHTHTCCPCPAPELAGA 120
Db 207 GLYSLSVVTVPSSSISGTTQYICNVNHPKSNKVDKKVPEKSCDKHTHTCCPCPAPELAGG 266
QY 121 PSVFLPPPKPDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
Db 267 PSVFLPPPKPDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 326
QY 181 STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPOVYTLPPSRDE 240
Db 327 STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPOVYTLPPSRDE 386
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
Db 387 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 446
QY 301 QQGNVFSCSVMHEALHNHYTQKSLSLSPGK 330
Db 447 QQGNVFSCSVMHEALHNHYTQKSLSLSPGK 476

RESULT 13
US-09-746-359A-54
; Sequence 54, Application US/09746359A
; Patent No. 6610286
; GENERAL INFORMATION:
; APPLICANT: Thompson, Penny
; APPLICANT: Foster, Donald C.
; APPLICANT: Xu, Wenfeng
; APPLICANT: Madden, Karen L.
; APPLICANT: Kelly, James D.
; APPLICANT: Sprecher, Cindy A.
; APPLICANT: Blumberg, Hal

STREET: 555 THIRTEENTH ST. N.W.
CITY: WASHINGTON
STATE: D. C.
COUNTRY: U.S.
ZIP: 20004
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/378,939
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/952640
FILING DATE: 01-DEC-1992
ATTORNEY/AGENT INFORMATION:
NAME: ERNST, BARBARA G
REGISTRATION NUMBER: 30,377
REFERENCE/DOCKET NUMBER: 1808-118
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 783-6040
TELEFAX: (202) 783-6031
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 476 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-378-939-10

Query Match 99.5%; Score 1756; DB 1; Length 476;
Best Local Similarity 99.4%; Pred. No. 9.5e-157;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASTKGSPVPLAPSSKSTSGGTAALGCLVKDYPPPTVSVNSGALTSGVHTTTPAVLQSS 60
Db 147 ASTKGSPVPLAPSSKSTSGGTAALGCLVKDYPPPTVSVNSGALTSGVHTTTPAVLQSS 206
QY 61 GLYSLSVVTVPSSSISGTTQYICNVNHPKSNKVDKKVPEKSCDKHTHTCCPCPAPELAGA 120
Db 207 GLYSLSVVTVPSSSISGTTQYICNVNHPKSNKVDKKVPEKSCDKHTHTCCPCPAPELAGG 266
QY 121 PSVFLPPPKPDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
Db 267 PSVFLPPPKPDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 326
QY 181 STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPOVYTLPPSRDE 240
Db 327 STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPOVYTLPPSRDE 386
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
Db 387 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 446
QY 301 QQGNVFSCSVMHEALHNHYTQKSLSLSPGK 330
Db 447 QQGNVFSCSVMHEALHNHYTQKSLSLSPGK 476

RESULT 14
US-09-825-561A-16
; Sequence 16, Application US/09825561A
; Patent No. 6777539
; GENERAL INFORMATION:
; APPLICANT: Sprecher, Cindy A.
; APPLICANT: No. 6777539ak, Julia E.
; APPLICANT: West, James W.
; APPLICANT: Presnell, Scott R.
; APPLICANT: Holly, Richard D.
; APPLICANT: Nelson, Andrew J.
; TITLE OF INVENTION: SOLUBLE ZALPHA11 CYTOKINE RECEPTORS
; FILE REFERENCE: 00-22
; CURRENT APPLICATION NUMBER: US/09/825,561A
; CURRENT FILING DATE: 2000-04-05
; PRIOR APPLICATION NUMBER: US 60/194,731
; PRIOR FILING DATE: 2000-04-05
; PRIOR APPLICATION NUMBER: US 60/222,121
; PRIOR FILING DATE: 2000-07-28
; NUMBER OF SEQ ID NOS: 86
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 16
; LENGTH: 567
; TYPE: PRT

APPLICANT: Eagan, Maribeth A.
APPLICANT: Jaspers, Stephen R.
APPLICANT: Chandrasekhar, Yasmin A.
APPLICANT: No. 6610286ak, Julia E.
TITLE OF INVENTION: Method for Treating Inflammation
FILE REFERENCE: 99-108
CURRENT APPLICATION NUMBER: US/09/746,359A
CURRENT FILING DATE: 2001-05-21
PRIOR APPLICATION NUMBER: 60/171,969
PRIOR FILING DATE: 1999-12-23
PRIOR APPLICATION NUMBER: 60/213,341
PRIOR FILING DATE: 2000-06-22
NUMBER OF SEQ ID NOS: 72
SOFTWARE: FastSEQ for Windows Version 3.0
SEQ ID NO 54
LENGTH: 547
TYPE: PRT
ORGANISM: Homo sapiens
US-09-746-359A-54

Query Match 99.5%; Score 1756; DB 2; Length 547;
Best Local Similarity 99.4%; Pred. No. 1.2e-156;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASTKGSPVPLAPSSKSTSGGTAALGCLVKDYPPPTVSVNSGALTSGVHTTTPAVLQSS 60
Db 218 ASTKGSPVPLAPSSKSTSGGTAALGCLVKDYPPPTVSVNSGALTSGVHTTTPAVLQSS 277
QY 61 GLYSLSVVTVPSSSISGTTQYICNVNHPKSNKVDKKVPEKSCDKHTHTCCPCPAPELAGA 120
Db 278 GLYSLSVVTVPSSSISGTTQYICNVNHPKSNKVDKKVPEKSCDKHTHTCCPCPAPELAGG 337
QY 121 PSVFLPPPKPDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
Db 338 PSVFLPPPKPDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 397
QY 181 STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPOVYTLPPSRDE 240
Db 398 STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPOVYTLPPSRDE 457
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
Db 458 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 517
QY 301 QQGNVFSCSVMHEALHNHYTQKSLSLSPGK 330
Db 518 QQGNVFSCSVMHEALHNHYTQKSLSLSPGK 547
```

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: soluble zalphallin/IgGgamma1 polypeptide
US-09-825-561A-16

Query Match          99.5%; Score 1756; DB 2; Length 567;
Best Local Similarity 99.4%; Pred. No. 1.2e-156;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
DB 238 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 297

QY 61 GLYSLSVVTVPSSSSLGTQTYICNVNHPKSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
DB 298 GLYSLSVVTVPSSSSLGTQTYICNVNHPKSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 357

QY 121 PSVFLFPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
DB 358 PSVFLFPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 417

QY 181 STYRVSVSLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
DB 418 STYRVSVSLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 477

QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPVLDSDGSGFFLYSKLTVDKSRW 300
DB 478 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPVLDSDGSGFFLYSKLTVDKSRW 537

QY 301 QQGNVFSCSVMHEALHNHYTQKSLSLSPGK 330
DB 538 QQGNVFSCSVMHEALHNHYTQKSLSLSPGK 567
```

```
RESULT 15
US-09-746-359A-53
; Sequence 53, Application US/09746359A
; Patent No. 6610286
; GENERAL INFORMATION:
; APPLICANT: Thompson, Penny
; APPLICANT: Foster, Donald C.
; APPLICANT: Xu, Wenfeng
; APPLICANT: Madden, Karen L.
; APPLICANT: Kelly, James D.
; APPLICANT: Sprecher, Cindy A.
; APPLICANT: Blumberg, Hal
; APPLICANT: Eagan, Maribeth A.
; APPLICANT: Jaspers, Stephen R.
; APPLICANT: Chandrasekhar, Yasmin A.
; APPLICANT: No. 6610286ak, Julia E.
; TITLE OF INVENTION: Method for Treating Inflammation
; FILE REFERENCE: 99-108
; CURRENT APPLICATION NUMBER: US/09/746,359A
; CURRENT FILING DATE: 2001-05-21
; PRIOR APPLICATION NUMBER: 60/171,969
; PRIOR FILING DATE: 1999-12-23
; PRIOR APPLICATION NUMBER: 60/213,341
; PRIOR FILING DATE: 2000-06-22
; NUMBER OF SEQ ID NOS: 72
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 53
; LENGTH: 571
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-746-359A-53

Query Match          99.5%; Score 1756; DB 2; Length 571;
Best Local Similarity 99.4%; Pred. No. 1.2e-156;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
DB 242 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 301
```

Search completed: June 10, 2006, 12:08:45
Job time : 57.982 secs

GenCore version 5.1.9
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: June 12, 2006, 17:10:25 ; Search time 307.346 Seconds

(without alignments)
497.358 Million cell updates/sec

Title: US-10-733-563-110

Perfect score: 1765

Sequence: 1 ASTKGPSVFPLAPSSKSTSG.....MHEALHNNHYTKQSLSPGK 330

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2097797 seqs, 463214858 residues

Total number of hits satisfying chosen parameters: 2097797

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Listing first 1000 summaries

Database : Published Applications_AA_Main:*

- 1: /EMC_Celerra_SIDS3/ptodata/2/pubpaa/US07_PUBCOMB.pep:*
- 2: /EMC_Celerra_SIDS3/ptodata/2/pubpaa/US08_PUBCOMB.pep:*
- 3: /EMC_Celerra_SIDS3/ptodata/2/pubpaa/US09_PUBCOMB.pep:*
- 4: /EMC_Celerra_SIDS3/ptodata/2/pubpaa/US10A_PUBCOMB.pep:*
- 5: /EMC_Celerra_SIDS3/ptodata/2/pubpaa/US10B_PUBCOMB.pep:*
- 6: /EMC_Celerra_SIDS3/ptodata/2/pubpaa/US11_PUBCOMB.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1765	100.0	330	4	US-10-733-563-110
2	1765	100.0	333	4	US-10-272-899A-10
3	1765	100.0	333	4	US-10-733-563-114
4	1765	100.0	356	4	US-10-272-899A-70
5	1765	100.0	448	4	US-10-171-452A-42
6	1765	100.0	448	4	US-10-171-452A-54
7	1765	100.0	448	4	US-10-353-708-42
8	1765	100.0	448	4	US-10-353-708-54
9	1765	100.0	448	4	US-10-731-984-8
10	1765	100.0	448	4	US-10-731-984-24
11	1765	100.0	448	6	US-11-158-505-8
12	1765	100.0	448	6	US-11-158-505-24
13	1765	100.0	462	6	US-11-177-648-9
14	1765	100.0	462	6	US-11-177-648-26
15	1765	100.0	462	6	US-11-177-648-27
16	1765	100.0	462	6	US-11-177-648-28
17	1765	100.0	462	6	US-11-177-648-29
18	1765	100.0	462	6	US-11-177-648-30
19	1765	100.0	462	6	US-11-177-648-31
20	1765	100.0	462	6	US-11-177-648-32
21	1765	100.0	462	6	US-11-177-648-33
22	1765	100.0	462	6	US-11-177-648-79
23	1765	100.0	462	6	US-11-177-648-92
24	1765	100.0	462	6	US-11-177-648-93
25	1765	100.0	462	6	US-11-177-648-94
26	1765	100.0	462	6	US-11-177-648-95
27	1765	100.0	462	6	US-11-177-648-96

28	1765	100.0	462	6	US-11-177-648-97	Sequence 97, Appl
29	1765	100.0	462	6	US-11-177-648-98	Sequence 98, Appl
30	1765	100.0	467	4	US-10-171-452A-53	Sequence 53, Appl
31	1765	100.0	467	4	US-10-353-708-53	Sequence 53, Appl
32	1765	100.0	467	4	US-10-731-984-7	Sequence 7, Appl
33	1765	100.0	467	4	US-10-731-984-23	Sequence 23, Appl
34	1765	100.0	467	6	US-11-158-505-5	Sequence 5, Appl
35	1765	100.0	467	6	US-11-158-505-7	Sequence 7, Appl
36	1765	100.0	467	6	US-11-158-505-21	Sequence 21, Appl
37	1765	100.0	467	6	US-11-158-505-23	Sequence 23, Appl
38	1759	98.7	473	4	US-10-467-253-13	Sequence 13, Appl
39	1758	99.6	469	4	US-10-404-724-72	Sequence 72, Appl
40	1756	99.5	330	3	US-09-995-898A-15	Sequence 15, Appl
41	1756	99.5	330	3	US-09-892-949-38	Sequence 38, Appl
42	1756	99.5	330	4	US-10-047-542-20	Sequence 20, Appl
43	1756	99.5	330	4	US-10-269-805-68	Sequence 68, Appl
44	1756	99.5	330	4	US-10-310-719-8	Sequence 8, Appl
45	1756	99.5	330	4	US-10-112-582-1	Sequence 1, Appl
46	1756	99.5	330	4	US-10-320-231A-81	Sequence 81, Appl
47	1756	99.5	330	4	US-10-383-902A-6	Sequence 6, Appl
48	1756	99.5	330	4	US-10-408-901-2	Sequence 2, Appl
49	1756	99.5	330	4	US-10-420-034A-15	Sequence 15, Appl
50	1756	99.5	330	4	US-10-257-907-5	Sequence 5, Appl
51	1756	99.5	330	4	US-10-656-769-2	Sequence 2, Appl
52	1756	99.5	330	4	US-10-772-331-38	Sequence 38, Appl
53	1756	99.5	330	5	US-10-475-326-1	Sequence 1, Appl
54	1756	99.5	330	5	US-10-815-449-8	Sequence 8, Appl
55	1756	99.5	330	5	US-10-684-957-2	Sequence 2, Appl
56	1756	99.5	330	5	US-10-886-838-6	Sequence 6, Appl
57	1756	99.5	330	5	US-10-822-300-3	Sequence 3, Appl
58	1756	99.5	330	5	US-10-822-300-7	Sequence 7, Appl
59	1756	99.5	330	5	US-10-687-118-3	Sequence 3, Appl
60	1756	99.5	330	5	US-10-687-118-7	Sequence 7, Appl
61	1756	99.5	330	5	US-10-901-735-2	Sequence 2, Appl
62	1756	99.5	330	5	US-10-698-907-22	Sequence 22, Appl
63	1756	99.5	330	5	US-10-928-305-7	Sequence 7, Appl
64	1756	99.5	330	5	US-10-480-109-5	Sequence 5, Appl
65	1756	99.5	330	5	US-10-891-658-2	Sequence 2, Appl
66	1756	99.5	330	5	US-10-867-506-81	Sequence 81, Appl
67	1756	99.5	330	5	US-10-937-596-31	Sequence 31, Appl
68	1756	99.5	330	5	US-10-893-576-45	Sequence 45, Appl
69	1756	99.5	330	5	US-10-868-373-8	Sequence 8, Appl
70	1756	99.5	330	5	US-10-901-736-60	Sequence 60, Appl
71	1756	99.5	330	5	US-10-982-555-38	Sequence 38, Appl
72	1756	99.5	330	5	US-10-493-909-20	Sequence 20, Appl
73	1756	99.5	330	5	US-10-982-440-68	Sequence 68, Appl
74	1756	99.5	330	6	US-11-004-054-1	Sequence 1, Appl
75	1756	99.5	330	6	US-11-026-998-22	Sequence 22, Appl
76	1756	99.5	330	6	US-11-027-309A-22	Sequence 22, Appl
77	1756	99.5	330	6	US-11-090-836-44	Sequence 44, Appl
78	1756	99.5	330	6	US-11-090-846-44	Sequence 44, Appl
79	1756	99.5	330	6	US-11-090-847-44	Sequence 44, Appl
80	1756	99.5	330	6	US-11-102-403-24	Sequence 24, Appl
81	1756	99.5	330	6	US-11-102-403-26	Sequence 26, Appl
82	1756	99.5	330	6	US-11-022-289-11	Sequence 11, Appl
83	1756	99.5	330	6	US-11-075-351-1	Sequence 1, Appl
84	1756	99.5	330	6	US-11-165-141-15	Sequence 15, Appl
85	1756	99.5	330	6	US-11-102-621-3	Sequence 3, Appl
86	1756	99.5	330	6	US-11-102-621-7	Sequence 7, Appl
87	1756	99.5	330	6	US-11-005-726-164	Sequence 164, App
88	1756	99.5	330	6	US-11-124-620-1	Sequence 1, Appl
89	1756	99.5	330	6	US-11-233-683-1	Sequence 1, Appl
90	1756	99.5	330	6	US-11-218-813-136	Sequence 136, App
91	1756	99.5	330	3	US-09-990-586-98	Sequence 98, Appl
92	1756	99.5	332	4	US-10-310-113-167	Sequence 167, App
93	1756	99.5	332	4	US-10-230-880-98	Sequence 98, Appl
94	1756	99.5	332	6	US-11-122-622-98	Sequence 98, Appl
95	1756	99.5	332	6	US-10-272-899A-8	Sequence 8, Appl
96	1756	99.5	333	4	US-11-024-251-35	Sequence 35, Appl
97	1756	99.5	335	6	US-10-272-899A-72	Sequence 72, Appl
98	1756	99.5	356	4	US-10-157-408-7	Sequence 7, Appl
99	1756	99.5	371	4	US-10-097-044A-7	Sequence 7, Appl
100	1756	99.5	371	4		

101	1756	99.5	371	4	US-10-769-247-7	Sequence 7, Appli	174	1756	99.5	470	5	US-10-887-230-14	Sequence 14, Appli
102	1756	99.5	442	4	US-10-228-435A-12	Sequence 12, Appli	175	1756	99.5	470	5	US-10-938-353-98	Sequence 98, Appli
103	1756	99.5	442	4	US-10-487-322-12	Sequence 12, Appli	176	1756	99.5	470	6	US-11-072-512-3730	Sequence 3730, Ap
104	1756	99.5	442	5	US-10-487-326-12	Sequence 12, Appli	177	1756	99.5	471	4	US-10-108-260A-4294	Sequence 4294, Ap
105	1756	99.5	442	5	US-10-487-326-21	Sequence 21, Appli	178	1756	99.5	472	4	US-10-108-260A-4073	Sequence 4073, Ap
106	1756	99.5	442	5	US-10-486-908-12	Sequence 12, Appli	179	1756	99.5	472	5	US-10-497-475-20	Sequence 20, Appli
107	1756	99.5	442	5	US-10-486-908-16	Sequence 16, Appli	180	1756	99.5	473	4	US-10-108-260A-4284	Sequence 4284, Ap
108	1756	99.5	442	5	US-10-512-527-12	Sequence 12, Appli	181	1756	99.5	474	4	US-10-108-260A-4282	Sequence 4282, Ap
109	1756	99.5	442	5	US-10-512-527-21	Sequence 21, Appli	182	1756	99.5	476	3	US-09-747-669-3	Sequence 3, Appli
110	1756	99.5	442	5	US-10-487-324A-12	Sequence 12, Appli	183	1756	99.5	476	4	US-10-290-703-3	Sequence 3, Appli
111	1756	99.5	442	5	US-10-487-324A-21	Sequence 21, Appli	184	1756	99.5	476	4	US-10-409-938-15	Sequence 15, Appli
112	1756	99.5	442	6	US-11-224-623-12	Sequence 12, Appli	185	1756	99.5	476	4	US-10-108-260A-4288	Sequence 4288, Ap
113	1756	99.5	444	4	US-10-150-475A-6	Sequence 6, Appli	186	1756	99.5	477	4	US-10-108-260A-4289	Sequence 4289, Ap
114	1756	99.5	444	4	US-10-704-522-6	Sequence 6, Appli	187	1756	99.5	485	5	US-10-887-230-26	Sequence 26, Appli
115	1756	99.5	444	4	US-10-645-215-6	Sequence 6, Appli	188	1756	99.5	541	4	US-10-471-151-32	Sequence 32, Appli
116	1756	99.5	444	6	US-11-136-538-7	Sequence 7, Appli	189	1756	99.5	541	4	US-10-807-837-4	Sequence 4, Appli
117	1756	99.5	444	6	US-11-173-320-6	Sequence 6, Appli	190	1756	99.5	547	3	US-09-746-359A-54	Sequence 54, Appli
118	1756	99.5	444	6	US-11-173-320-6	Sequence 6, Appli	191	1756	99.5	547	3	US-09-951-268-40	Sequence 40, Appli
119	1756	99.5	445	4	US-10-320-231A-79	Sequence 79, Appli	192	1756	99.5	547	3	US-09-745-732A-54	Sequence 54, Appli
120	1756	99.5	445	4	US-10-408-901-34	Sequence 34, Appli	193	1756	99.5	547	4	US-10-424-658-54	Sequence 54, Appli
121	1756	99.5	445	4	US-10-408-901-42	Sequence 42, Appli	194	1756	99.5	551	6	US-11-022-289-7	Sequence 7, Appli
122	1756	99.5	445	5	US-10-867-506-79	Sequence 79, Appli	195	1756	99.5	551	6	US-11-022-289-8	Sequence 8, Appli
123	1756	99.5	445	5	US-10-937-596-3	Sequence 3, Appli	196	1756	99.5	557	6	US-11-022-289-4	Sequence 4, Appli
124	1756	99.5	446	4	US-10-408-901-30	Sequence 30, Appli	197	1756	99.5	557	6	US-11-022-289-5	Sequence 5, Appli
125	1756	99.5	446	4	US-10-408-901-38	Sequence 38, Appli	198	1756	99.5	557	6	US-11-022-289-6	Sequence 6, Appli
126	1756	99.5	446	4	US-10-408-901-46	Sequence 46, Appli	199	1756	99.5	558	4	US-10-471-151-31	Sequence 31, Appli
127	1756	99.5	446	4	US-10-408-901-50	Sequence 50, Appli	200	1756	99.5	567	3	US-09-825-561A-16	Sequence 16, Appli
128	1756	99.5	446	4	US-10-435-299-7	Sequence 7, Appli	201	1756	99.5	567	5	US-10-872-087-16	Sequence 16, Appli
129	1756	99.5	446	5	US-10-947-432-2	Sequence 2, Appli	202	1756	99.5	571	3	US-09-746-359A-53	Sequence 53, Appli
130	1756	99.5	447	3	US-09-256-156-1	Sequence 1, Appli	203	1756	99.5	571	3	US-09-951-268-30	Sequence 30, Appli
131	1756	99.5	447	5	US-10-684-937-17	Sequence 17, Appli	204	1756	99.5	571	3	US-09-745-732A-53	Sequence 53, Appli
132	1756	99.5	447	5	US-10-684-957-19	Sequence 19, Appli	205	1756	99.5	571	4	US-10-424-658-53	Sequence 53, Appli
133	1756	99.5	447	5	US-10-684-957-21	Sequence 21, Appli	206	1756	99.5	600	4	US-10-334-235-38	Sequence 38, Appli
134	1756	99.5	447	6	US-10-684-957-32	Sequence 32, Appli	207	1756	99.5	613	5	US-10-769-141-10	Sequence 10, Appli
135	1756	99.5	447	6	US-11-010-797-2	Sequence 2, Appli	208	1756	99.5	613	5	US-10-903-191-10	Sequence 10, Appli
136	1756	99.5	448	4	US-10-378-567-2	Sequence 2, Appli	209	1756	99.5	659	4	US-10-809-790-4	Sequence 4, Appli
137	1756	99.5	448	5	US-10-985-584-18	Sequence 18, Appli	210	1756	99.5	731	3	US-09-825-012-46	Sequence 46, Appli
138	1756	99.5	449	5	US-10-635-908-16	Sequence 16, Appli	211	1756	99.5	741	3	US-09-825-012-55	Sequence 55, Appli
139	1756	99.5	449	5	US-10-635-908-18	Sequence 18, Appli	212	1756	99.5	951	3	US-09-313-942-9	Sequence 9, Appli
140	1756	99.5	449	5	US-10-476-265-12	Sequence 12, Appli	213	1756	99.5	951	3	US-09-935-868-9	Sequence 9, Appli
141	1756	99.5	449	5	US-10-985-584-10	Sequence 10, Appli	214	1756	99.5	951	4	US-10-287-035-9	Sequence 9, Appli
142	1756	99.5	449	6	US-11-056-776-5	Sequence 5, Appli	215	1756	99.5	951	4	US-10-282-162-9	Sequence 9, Appli
143	1756	99.5	450	5	US-10-503-504-11	Sequence 11, Appli	216	1756	99.5	951	6	US-11-134-114-9	Sequence 9, Appli
144	1756	99.5	450	5	US-10-484-280-18	Sequence 18, Appli	217	1756	99.5	972	4	US-10-418-836-38	Sequence 38, Appli
145	1756	99.5	450	6	US-11-158-505-33	Sequence 33, Appli	218	1756	99.5	972	6	US-11-007-886-38	Sequence 38, Appli
146	1756	99.5	450	6	US-11-049-536-701	Sequence 701, App	219	1756	99.5	975	6	US-10-418-836-39	Sequence 39, Appli
147	1756	99.5	450	6	US-11-199-739-701	Sequence 701, App	220	1756	99.5	975	6	US-11-007-886-39	Sequence 39, Appli
148	1756	99.5	451	3	US-09-822-698A-26	Sequence 26, Appli	221	1754	99.4	330	5	US-10-966-673-27	Sequence 27, Appli
149	1756	99.5	451	5	US-10-849-615-69	Sequence 69, Appli	222	1754	99.4	330	5	US-10-966-673-29	Sequence 29, Appli
150	1756	99.5	451	5	US-10-822-231-1	Sequence 1, Appli	223	1754	99.4	592	5	US-10-016-686-4	Sequence 4, Appli
151	1756	99.5	451	6	US-11-158-505-33	Sequence 33, Appli	224	1753	99.3	330	4	US-10-679-620-58	Sequence 58, Appli
152	1756	99.5	453	4	US-10-813-483-6	Sequence 6, Appli	225	1753	99.3	330	5	US-10-822-300-71	Sequence 71, Appli
153	1756	99.5	453	5	US-10-484-790A-18	Sequence 18, Appli	226	1753	99.3	330	5	US-10-687-118-71	Sequence 71, Appli
154	1756	99.5	453	5	US-10-891-658-41	Sequence 41, Appli	227	1753	99.3	330	5	US-10-966-673-36	Sequence 36, Appli
155	1756	99.5	453	5	US-10-497-475-12	Sequence 12, Appli	228	1753	99.3	330	5	US-10-966-673-48	Sequence 48, Appli
156	1756	99.5	453	6	US-11-013-966-6	Sequence 6, Appli	229	1753	99.3	330	6	US-11-132-143-58	Sequence 58, Appli
157	1756	99.5	453	6	US-11-208-422-23	Sequence 23, Appli	230	1753	99.3	330	6	US-11-102-621-71	Sequence 71, Appli
158	1756	99.5	457	5	US-10-778-915-1	Sequence 1, Appli	231	1753	99.3	446	5	US-10-822-300-121	Sequence 121, App
159	1756	99.5	464	5	US-10-938-353-102	Sequence 102, App	232	1753	99.3	446	6	US-11-102-621-121	Sequence 121, App
160	1756	99.5	464	6	US-11-218-813-132	Sequence 132, App	233	1753	99.3	447	5	US-10-822-300-132	Sequence 132, App
161	1756	99.5	465	5	US-10-887-230-43	Sequence 43, Appli	234	1753	99.3	447	6	US-11-102-621-132	Sequence 132, App
162	1756	99.5	465	6	US-11-034-655-5	Sequence 5, Appli	235	1753	99.3	448	4	US-10-449-566-107	Sequence 107, App
163	1756	99.5	465	6	US-11-034-655-12	Sequence 12, Appli	236	1753	99.3	465	4	US-10-404-724-8	Sequence 8, Appli
164	1756	99.5	467	4	US-10-108-260A-4293	Sequence 4293, Ap	237	1753	99.3	465	4	US-10-404-724-23	Sequence 23, Appli
165	1756	99.5	467	4	US-10-656-769-32	Sequence 32, Appli	238	1753	99.3	465	5	US-10-404-724-25	Sequence 25, Appli
166	1756	99.5	468	5	US-10-769-144-2	Sequence 2, Appli	239	1753	99.3	465	5	US-10-816-276-4	Sequence 4, Appli
167	1756	99.5	468	5	US-10-476-265-20	Sequence 20, Appli	240	1753	99.3	465	5	US-10-816-276-19	Sequence 19, Appli
168	1756	99.5	468	5	US-10-943-640-4	Sequence 4, Appli	241	1753	99.3	465	5	US-10-816-276-21	Sequence 21, Appli
169	1756	99.5	468	5	US-10-903-191-2	Sequence 2, Appli	242	1753	99.3	469	5	US-10-429-660-10	Sequence 10, Appli
170	1756	99.5	468	6	US-11-056-776-6	Sequence 6, Appli	243	1753	99.3	469	5	US-10-429-662-10	Sequence 10, Appli
171	1756	99.5	469	4	US-10-656-769-20	Sequence 20, Appli	244	1753	99.3	470	5	US-10-961-567A-9	Sequence 9, Appli
172	1756	99.5	469	4	US-10-656-769-26	Sequence 26, Appli	245	1753	99.3	713	4	US-10-679-620-64	Sequence 64, Appli
173	1756	99.5	470	4	US-10-104-047-3730	Sequence 3730, Ap	246	1753	99.3	713	6	US-11-132-143-64	Sequence 64, Appli

247	1753	99.3	715	4	US-10-679-620-62	Sequence 62, Appl	320	1750	99.2	330	5	US-10-822-300-67	Sequence 67, Appl
248	1753	99.3	715	6	US-11-132-143-62	Sequence 62, Appl	321	1750	99.2	330	5	US-10-822-300-68	Sequence 68, Appl
249	1752	99.3	329	6	US-11-186-423-4	Sequence 4, Appl	322	1750	99.2	330	5	US-10-822-300-69	Sequence 69, Appl
250	1752	99.3	330	5	US-10-966-673-16	Sequence 16, Appl	323	1750	99.2	330	5	US-10-687-118-67	Sequence 67, Appl
251	1752	99.3	330	5	US-10-966-673-24	Sequence 24, Appl	324	1750	99.2	330	5	US-10-687-118-68	Sequence 68, Appl
252	1752	99.3	330	5	US-10-966-673-46	Sequence 46, Appl	325	1750	99.2	330	5	US-10-687-118-69	Sequence 69, Appl
253	1752	99.3	330	5	US-10-966-673-55	Sequence 55, Appl	326	1750	99.2	330	5	US-10-901-735-3	Sequence 3, Appl
254	1752	99.3	451	6	US-10-822-231-4	Sequence 4, Appl	327	1750	99.2	330	5	US-10-706-689-2	Sequence 2, Appl
255	1752	99.3	451	6	US-11-124-620-7	Sequence 7, Appl	328	1750	99.2	330	5	US-10-706-689-3	Sequence 3, Appl
256	1752	99.3	451	6	US-11-208-422-25	Sequence 25, Appl	329	1750	99.2	330	5	US-10-988-360-2	Sequence 2, Appl
257	1752	99.3	468	5	US-10-981-738-13	Sequence 13, Appl	330	1750	99.2	330	5	US-10-988-360-3	Sequence 3, Appl
258	1752	99.3	471	4	US-10-108-260A-4285	Sequence 4285, Ap	331	1750	99.2	330	5	US-10-966-673-2	Sequence 2, Appl
259	1752	99.3	475	3	US-09-740-002-27	Sequence 27, Appl	332	1750	99.2	330	5	US-10-966-673-3	Sequence 3, Appl
260	1752	99.3	475	4	US-10-325-698-27	Sequence 27, Appl	333	1750	99.2	330	5	US-10-966-673-4	Sequence 4, Appl
261	1752	99.3	476	3	US-09-758-173-4	Sequence 4, Appl	334	1750	99.2	330	5	US-10-966-673-8	Sequence 8, Appl
262	1752	99.3	476	3	US-09-758-173-12	Sequence 12, Appl	335	1750	99.2	330	5	US-10-966-673-9	Sequence 9, Appl
263	1752	99.3	476	3	US-09-948-4298-4	Sequence 4, Appl	336	1750	99.2	330	5	US-10-966-673-10	Sequence 10, Appl
264	1752	99.3	476	3	US-09-948-4298-12	Sequence 12, Appl	337	1750	99.2	330	5	US-10-966-673-11	Sequence 11, Appl
265	1752	99.3	476	4	US-10-124-905-4	Sequence 4, Appl	338	1750	99.2	330	5	US-10-966-673-13	Sequence 13, Appl
266	1752	99.3	476	4	US-10-124-905-12	Sequence 12, Appl	339	1750	99.2	330	5	US-10-966-673-14	Sequence 14, Appl
267	1752	99.3	476	4	US-10-124-807-4	Sequence 4, Appl	340	1750	99.2	330	5	US-10-966-673-15	Sequence 15, Appl
268	1752	99.3	476	4	US-10-124-807-12	Sequence 12, Appl	341	1750	99.2	330	5	US-10-966-673-28	Sequence 28, Appl
269	1752	99.3	476	4	US-10-291-532-4	Sequence 4, Appl	342	1750	99.2	330	5	US-10-966-673-32	Sequence 32, Appl
270	1752	99.3	476	4	US-10-291-532-12	Sequence 12, Appl	343	1750	99.2	330	5	US-10-966-673-33	Sequence 33, Appl
271	1752	99.3	476	5	US-10-986-780-4	Sequence 4, Appl	344	1750	99.2	330	5	US-10-966-673-34	Sequence 34, Appl
272	1752	99.3	476	6	US-10-986-780-12	Sequence 12, Appl	345	1750	99.2	330	5	US-10-966-673-37	Sequence 37, Appl
273	1752	99.3	476	6	US-11-139-499-4	Sequence 4, Appl	346	1750	99.2	330	5	US-10-966-673-39	Sequence 39, Appl
274	1752	99.3	476	6	US-11-139-499-12	Sequence 12, Appl	347	1750	99.2	330	5	US-10-966-673-40	Sequence 40, Appl
275	1752	99.3	478	3	US-09-758-173-8	Sequence 8, Appl	348	1750	99.2	330	5	US-10-966-673-47	Sequence 47, Appl
276	1752	99.3	478	3	US-09-948-4298-8	Sequence 8, Appl	349	1750	99.2	330	5	US-10-966-673-52	Sequence 52, Appl
277	1752	99.3	478	4	US-10-124-905-8	Sequence 8, Appl	350	1750	99.2	330	5	US-10-966-673-53	Sequence 53, Appl
278	1752	99.3	478	4	US-10-124-807-8	Sequence 8, Appl	351	1750	99.2	330	5	US-10-966-673-54	Sequence 54, Appl
279	1752	99.3	478	5	US-10-291-532-8	Sequence 8, Appl	352	1750	99.2	330	5	US-10-966-673-56	Sequence 56, Appl
280	1752	99.3	478	5	US-10-986-780-8	Sequence 8, Appl	353	1750	99.2	330	5	US-10-966-673-57	Sequence 57, Appl
281	1752	99.3	478	6	US-11-139-499-8	Sequence 8, Appl	354	1750	99.2	330	6	US-11-022-289-1	Sequence 1, Appl
282	1751	99.2	330	5	US-10-822-300-70	Sequence 70, Appl	355	1750	99.2	330	6	US-11-102-621-67	Sequence 67, Appl
283	1751	99.2	330	5	US-10-687-118-70	Sequence 70, Appl	356	1750	99.2	330	6	US-11-102-621-68	Sequence 68, Appl
284	1751	99.2	330	5	US-10-966-673-1	Sequence 1, Appl	357	1750	99.2	330	6	US-11-102-621-69	Sequence 69, Appl
285	1751	99.2	330	5	US-10-966-673-12	Sequence 12, Appl	358	1750	99.2	330	6	US-11-201-825-55	Sequence 55, Appl
286	1751	99.2	330	5	US-10-966-673-17	Sequence 17, Appl	359	1750	99.2	446	5	US-10-822-300-119	Sequence 119, App
287	1751	99.2	330	5	US-10-966-673-20	Sequence 20, Appl	360	1750	99.2	446	5	US-10-822-300-120	Sequence 120, App
288	1751	99.2	330	5	US-10-966-673-21	Sequence 21, Appl	361	1750	99.2	446	6	US-11-102-621-119	Sequence 119, App
289	1751	99.2	330	5	US-10-966-673-35	Sequence 35, Appl	362	1750	99.2	446	6	US-11-102-621-120	Sequence 120, App
290	1751	99.2	330	5	US-10-966-673-38	Sequence 38, Appl	363	1750	99.2	447	5	US-10-822-300-130	Sequence 130, App
291	1751	99.2	330	5	US-10-966-673-43	Sequence 43, Appl	364	1750	99.2	447	6	US-10-822-300-131	Sequence 131, App
292	1751	99.2	330	5	US-10-966-673-51	Sequence 51, Appl	365	1750	99.2	447	6	US-11-102-621-130	Sequence 130, App
293	1751	99.2	330	6	US-11-102-621-70	Sequence 70, Appl	366	1750	99.2	447	6	US-11-102-621-131	Sequence 131, App
294	1751	99.2	447	4	US-10-474-832-4	Sequence 4, Appl	367	1750	99.2	449	6	US-11-154-337-17	Sequence 17, Appl
295	1751	99.2	447	4	US-10-474-832-6	Sequence 6, Appl	368	1750	99.2	449	6	US-11-182-908-24	Sequence 24, Appl
296	1751	99.2	448	4	US-10-411-037-56	Sequence 56, Appl	369	1750	99.2	451	3	US-09-920-171-14	Sequence 14, Appl
297	1751	99.2	448	4	US-10-411-026-56	Sequence 56, Appl	370	1750	99.2	451	3	US-09-920-171-16	Sequence 16, Appl
298	1751	99.2	448	4	US-10-410-962-56	Sequence 56, Appl	371	1750	99.2	451	3	US-09-920-171-18	Sequence 18, Appl
299	1751	99.2	448	4	US-10-411-049-56	Sequence 56, Appl	372	1750	99.2	451	3	US-09-925-179-65	Sequence 65, Appl
300	1751	99.2	448	4	US-10-410-930-56	Sequence 56, Appl	373	1750	99.2	451	3	US-09-925-179-66	Sequence 66, Appl
301	1751	99.2	448	4	US-10-410-997-56	Sequence 56, Appl	374	1750	99.2	451	3	US-09-925-179-68	Sequence 68, Appl
302	1751	99.2	448	4	US-10-411-012-56	Sequence 56, Appl	375	1750	99.2	451	3	US-09-792-938-2	Sequence 2, Appl
303	1751	99.2	448	4	US-10-287-994-56	Sequence 56, Appl	376	1750	99.2	451	4	US-10-113-996-14	Sequence 14, Appl
304	1751	99.2	448	4	US-10-410-913-56	Sequence 56, Appl	377	1750	99.2	451	4	US-10-113-996-16	Sequence 16, Appl
305	1751	99.2	448	5	US-10-410-980-56	Sequence 56, Appl	378	1750	99.2	451	4	US-10-113-996-18	Sequence 18, Appl
306	1751	99.2	448	5	US-10-410-890-56	Sequence 56, Appl	379	1750	99.2	451	4	US-10-292-869-2	Sequence 2, Appl
307	1751	99.2	448	5	US-10-492-261-56	Sequence 56, Appl	380	1750	99.2	451	4	US-10-423-299-4	Sequence 4, Appl
308	1751	99.2	448	6	US-11-183-205-56	Sequence 56, Appl	381	1750	99.2	451	4	US-10-835-642-2	Sequence 2, Appl
309	1751	99.2	470	4	US-10-108-260A-4292	Sequence 4292, Ap	382	1750	99.2	451	4	US-10-813-483-4	Sequence 4, Appl
310	1751	99.2	470	6	US-11-019-180-4	Sequence 4, Appl	383	1750	99.2	451	4	US-10-813-483-5	Sequence 5, Appl
311	1751	99.2	663	4	US-10-412-406-32	Sequence 32, Appl	384	1750	99.2	451	5	US-10-757-863-2	Sequence 2, Appl
312	1751	99.2	729	3	US-09-825-012-52	Sequence 52, Appl	385	1750	99.2	451	5	US-10-791-619-14	Sequence 14, Appl
313	1751	99.2	729	3	US-09-825-012-61	Sequence 61, Appl	386	1750	99.2	451	5	US-10-791-619-16	Sequence 16, Appl
314	1751	99.2	4852	4	US-10-412-406-33	Sequence 33, Appl	387	1750	99.2	451	5	US-10-791-619-18	Sequence 18, Appl
315	1750	99.2	330	3	US-09-301-593-22	Sequence 22, Appl	388	1750	99.2	451	5	US-10-714-000-2	Sequence 2, Appl
316	1750	99.2	330	4	US-10-121-464-20	Sequence 20, Appl	389	1750	99.2	451	5	US-10-698-073-9	Sequence 9, Appl
317	1750	99.2	330	4	US-10-159-006-22	Sequence 22, Appl	390	1750	99.2	451	5	US-10-968-237-65	Sequence 65, Appl
318	1750	99.2	331	4	US-10-688-925-53	Sequence 53, Appl	391	1750	99.2	451	5	US-10-968-237-66	Sequence 66, Appl
319	1750	99.2	330	4	US-10-741-481-45	Sequence 45, Appl	392	1750	99.2	451	5	US-10-968-237-68	Sequence 68, Appl

393	1750	99.2	451	5	US-10-982-470-2	Sequence 2, Appli	466	1749	99.1	330	5	US-10-966-673-30	Sequence 30, Appl
394	1750	99.2	451	5	US-10-923-327-7	Sequence 7, Appli	467	1749	99.1	330	5	US-10-966-673-31	Sequence 31, Appl
395	1750	99.2	451	5	US-10-923-327-9	Sequence 9, Appli	468	1749	99.1	330	5	US-10-966-673-42	Sequence 42, Appl
396	1750	99.2	451	5	US-10-923-327-11	Sequence 11, Appli	469	1749	99.1	330	5	US-10-966-673-45	Sequence 45, Appl
397	1750	99.2	451	6	US-11-013-966-4	Sequence 4, Appli	470	1749	99.1	330	5	US-10-966-673-49	Sequence 49, Appl
398	1750	99.2	451	6	US-11-013-966-5	Sequence 5, Appli	471	1749	99.1	330	5	US-10-966-673-50	Sequence 50, Appl
399	1750	99.2	451	6	US-11-158-839-2	Sequence 2, Appli	472	1749	99.1	449	6	US-11-080-587-6	Sequence 6, Appli
400	1750	99.2	451	6	US-11-208-422-20	Sequence 20, Appli	473	1749	99.1	450	6	US-11-155-843-176	Sequence 176, App
401	1750	99.2	451	6	US-11-208-422-21	Sequence 21, Appli	474	1748	99.0	330	5	US-10-966-673-22	Sequence 22, Appl
402	1750	99.2	451	6	US-11-208-422-22	Sequence 22, Appli	475	1748	99.0	330	5	US-10-966-673-25	Sequence 25, Appl
403	1750	99.2	452	3	US-09-726-258-71	Sequence 71, Appli	476	1748	99.0	330	5	US-10-966-673-41	Sequence 41, Appl
404	1750	99.2	452	4	US-10-818-765-4	Sequence 4, Appli	477	1748	99.0	330	5	US-10-966-673-44	Sequence 44, Appl
405	1750	99.2	452	5	US-10-861-049-16	Sequence 16, Appli	478	1748	99.0	448	4	US-10-171-452A-48	Sequence 48, Appl
406	1750	99.2	452	5	US-10-861-049-46	Sequence 46, Appli	479	1748	99.0	448	4	US-10-171-452A-60	Sequence 60, Appl
407	1750	99.2	452	6	US-11-021-874-16	Sequence 16, Appli	480	1748	99.0	448	4	US-10-353-708-48	Sequence 48, Appl
408	1750	99.2	452	6	US-11-021-874-46	Sequence 46, Appli	481	1748	99.0	448	4	US-10-353-708-60	Sequence 60, Appl
409	1750	99.2	452	6	US-11-005-677-4	Sequence 4, Appli	482	1748	99.0	448	4	US-10-731-984-16	Sequence 16, Appl
410	1750	99.2	452	6	US-11-006-136-4	Sequence 4, Appli	483	1748	99.0	448	4	US-10-731-984-32	Sequence 32, Appl
411	1750	99.2	452	6	US-11-120-338-14	Sequence 14, Appli	484	1748	99.0	448	6	US-11-158-505-16	Sequence 16, Appl
412	1750	99.2	452	6	US-11-107-028-32	Sequence 32, Appli	485	1748	99.0	448	6	US-11-158-505-32	Sequence 32, Appl
413	1750	99.2	452	6	US-11-108-820-26	Sequence 26, Appli	486	1748	99.0	449	3	US-03-736-371B-21	Sequence 21, Appl
414	1750	99.2	452	6	US-11-143-077-14	Sequence 14, Appli	487	1748	99.0	449	4	US-10-463-442-21	Sequence 21, Appli
415	1750	99.2	452	6	US-11-143-386-14	Sequence 14, Appli	488	1748	99.0	451	5	US-10-698-073-7	Sequence 7, Appli
416	1750	99.2	452	6	US-11-187-364-14	Sequence 14, Appli	489	1748	99.0	467	4	US-10-171-452A-41	Sequence 41, Appl
417	1750	99.2	452	6	US-11-208-422-27	Sequence 27, Appli	490	1748	99.0	467	4	US-10-171-452A-47	Sequence 47, Appl
418	1750	99.2	452	6	US-11-259-232-71	Sequence 71, Appli	491	1748	99.0	467	4	US-10-171-452A-59	Sequence 59, Appl
419	1750	99.2	453	3	US-09-301-593-18	Sequence 18, Appli	492	1748	99.0	467	4	US-10-353-708-41	Sequence 41, Appl
420	1750	99.2	453	4	US-10-159-006-18	Sequence 18, Appli	493	1748	99.0	467	4	US-10-353-708-47	Sequence 47, Appl
421	1750	99.2	454	5	US-10-835-641-22	Sequence 22, Appli	494	1748	99.0	467	4	US-10-353-708-59	Sequence 59, Appl
422	1750	99.2	470	4	US-10-020-786-9	Sequence 9, Appli	495	1748	99.0	467	4	US-10-731-984-15	Sequence 15, Appl
423	1750	99.2	470	4	US-10-227-694-5	Sequence 5, Appli	496	1748	99.0	467	4	US-10-731-984-31	Sequence 31, Appl
424	1750	99.2	470	5	US-10-754-212-6	Sequence 6, Appli	497	1748	99.0	467	6	US-11-158-505-13	Sequence 13, Appl
425	1750	99.2	470	5	US-10-697-995-3	Sequence 3, Appli	498	1748	99.0	467	6	US-11-158-505-15	Sequence 15, Appl
426	1750	99.2	470	5	US-10-697-995-6	Sequence 6, Appli	499	1748	99.0	467	6	US-11-158-505-29	Sequence 29, Appl
427	1750	99.2	470	5	US-10-697-995-18	Sequence 18, Appli	500	1748	99.0	467	6	US-11-158-505-31	Sequence 31, Appl
428	1750	99.2	470	6	US-11-071-261-9	Sequence 9, Appli	501	1748	99.0	467	6	US-11-158-505-72	Sequence 72, Appl
429	1750	99.2	471	5	US-10-877-363-4	Sequence 4, Appli	502	1748	99.0	469	4	US-10-108-260A-4287	Sequence 4287, Ap
430	1750	99.2	471	5	US-10-922-651-4	Sequence 4, Appli	503	1748	99.0	472	4	US-10-108-260A-4295	Sequence 4295, Ap
431	1750	99.2	471	5	US-10-861-049-4	Sequence 4, Appli	504	1748	99.0	475	3	US-03-740-002-25	Sequence 25, Appl
432	1750	99.2	471	6	US-11-021-874-4	Sequence 4, Appli	505	1748	99.0	475	4	US-10-325-698-35	Sequence 35, Appl
433	1750	99.2	471	6	US-11-106-820-25	Sequence 25, Appli	506	1747	99.0	330	4	US-10-366-709-52	Sequence 52, Appl
434	1750	99.2	471	6	US-11-190-364-22	Sequence 22, Appli	507	1747	99.0	330	5	US-10-822-300-76	Sequence 76, Appl
435	1750	99.2	471	6	US-11-147-780-22	Sequence 22, Appli	508	1747	99.0	330	5	US-10-687-118-76	Sequence 76, Appl
436	1750	99.2	476	4	US-10-020-786-11	Sequence 11, Appli	509	1747	99.0	330	5	US-11-102-621-76	Sequence 76, Appl
437	1750	99.2	476	5	US-10-697-995-9	Sequence 9, Appli	510	1747	99.0	446	5	US-10-822-300-122	Sequence 122, App
438	1750	99.2	476	6	US-11-071-291-11	Sequence 11, Appli	511	1747	99.0	446	6	US-11-102-621-122	Sequence 122, App
439	1750	99.2	479	5	US-10-697-995-12	Sequence 12, Appli	512	1747	99.0	447	4	US-10-379-392-116	Sequence 116, App
440	1750	99.2	548	6	US-11-022-289-3	Sequence 3, Appli	513	1747	99.0	447	5	US-10-822-300-133	Sequence 133, App
441	1750	99.2	557	6	US-11-022-289-2	Sequence 2, Appli	514	1747	99.0	447	6	US-11-102-621-133	Sequence 133, App
442	1750	99.2	564	6	US-11-022-289-10	Sequence 10, Appli	515	1747	99.0	448	4	US-10-449-566-111	Sequence 111, App
443	1750	99.2	666	5	US-10-981-356A-25	Sequence 25, Appli	516	1747	99.0	448	4	US-10-449-566-115	Sequence 115, App
444	1750	99.2	666	5	US-10-981-356A-27	Sequence 27, Appli	517	1747	99.0	448	4	US-10-467-546-4	Sequence 4, Appli
445	1750	99.2	666	6	US-11-096-046-27	Sequence 27, Appli	518	1747	99.0	448	5	US-10-666-332-4	Sequence 4, Appli
446	1750	99.2	667	5	US-10-764-428-7	Sequence 7, Appli	519	1747	99.0	449	4	US-10-318-397-22	Sequence 22, Appl
447	1750	99.2	667	5	US-10-764-428-13	Sequence 13, Appli	520	1747	99.0	449	4	US-10-317-747-22	Sequence 22, Appl
448	1750	99.2	667	5	US-10-764-428-25	Sequence 25, Appli	521	1747	99.0	450	3	US-09-796-848A-37	Sequence 37, Appl
449	1750	99.2	667	6	US-11-096-046-25	Sequence 25, Appli	522	1747	99.0	450	3	US-09-796-848A-39	Sequence 39, Appl
450	1750	99.2	669	5	US-10-764-428-21	Sequence 21, Appli	523	1747	99.0	450	3	US-09-796-848A-41	Sequence 41, Appl
451	1750	99.2	669	5	US-10-764-428-23	Sequence 23, Appli	524	1747	99.0	450	3	US-09-796-848A-43	Sequence 43, Appl
452	1750	99.2	670	5	US-10-764-428-5	Sequence 5, Appli	525	1747	99.0	450	3	US-09-796-848A-45	Sequence 45, Appl
453	1750	99.2	670	5	US-10-764-428-9	Sequence 9, Appli	526	1747	99.0	450	3	US-09-796-848A-47	Sequence 47, Appl
454	1750	99.2	670	5	US-10-764-428-11	Sequence 11, Appli	527	1747	99.0	450	3	US-09-796-848A-49	Sequence 49, Appl
455	1750	99.2	670	5	US-10-764-428-27	Sequence 27, Appli	528	1747	99.0	450	3	US-09-796-848A-51	Sequence 51, Appl
456	1750	99.2	692	5	US-10-981-356A-46	Sequence 26, Appli	529	1747	99.0	450	3	US-09-796-848A-53	Sequence 53, Appl
457	1750	99.2	695	6	US-11-096-046-26	Sequence 26, Appli	530	1747	99.0	450	3	US-09-996-288-208	Sequence 208, App
458	1749	99.1	329	4	US-10-370-749-48	Sequence 48, Appli	531	1747	99.0	450	3	US-09-996-288-210	Sequence 210, App
459	1749	99.1	330	5	US-10-966-673-5	Sequence 5, Appli	532	1747	99.0	450	3	US-09-996-288-212	Sequence 212, App
460	1749	99.1	330	5	US-10-966-673-6	Sequence 6, Appli	533	1747	99.0	450	3	US-09-996-288-214	Sequence 214, App
461	1749	99.1	330	5	US-10-966-673-7	Sequence 7, Appli	534	1747	99.0	450	3	US-09-996-288-216	Sequence 216, App
462	1749	99.1	330	5	US-10-966-673-18	Sequence 18, Appli	535	1747	99.0	450	3	US-09-996-288-218	Sequence 218, App
463	1749	99.1	330	5	US-10-966-673-19	Sequence 19, Appli	536	1747	99.0	450	3	US-09-996-288-220	Sequence 220, App
464	1749	99.1	330	5	US-10-966-673-23	Sequence 23, Appli	537	1747	99.0	450	3	US-09-996-288-222	Sequence 222, App
465	1749	99.1	330	5	US-10-966-673-26	Sequence 26, Appli	538	1747	99.0	450	3	US-09-996-288-224	Sequence 224, App

539	1747	99.0	450	3	US-09-996-288-226	Sequence 226, App	612	1747	99.0	450	5	US-10-962-285-226	Sequence 226, App
540	1747	99.0	450	3	US-09-996-288-228	Sequence 228, App	613	1747	99.0	450	5	US-10-962-285-228	Sequence 228, App
541	1747	99.0	450	3	US-09-996-288-232	Sequence 232, App	614	1747	99.0	450	5	US-10-962-285-232	Sequence 232, App
542	1747	99.0	450	3	US-09-996-288-234	Sequence 234, App	615	1747	99.0	450	5	US-10-962-285-234	Sequence 234, App
543	1747	99.0	450	3	US-09-996-288-236	Sequence 236, App	616	1747	99.0	450	5	US-10-962-285-236	Sequence 236, App
544	1747	99.0	450	3	US-09-996-288-238	Sequence 238, App	617	1747	99.0	450	5	US-10-962-285-238	Sequence 238, App
545	1747	99.0	450	3	US-09-996-288-240	Sequence 240, App	618	1747	99.0	450	5	US-10-962-285-240	Sequence 240, App
546	1747	99.0	450	3	US-09-996-288-242	Sequence 242, App	619	1747	99.0	450	5	US-10-962-285-242	Sequence 242, App
547	1747	99.0	450	3	US-09-996-288-244	Sequence 244, App	620	1747	99.0	450	5	US-10-962-285-244	Sequence 244, App
548	1747	99.0	450	3	US-09-996-288-246	Sequence 246, App	621	1747	99.0	450	5	US-10-962-285-246	Sequence 246, App
549	1747	99.0	450	3	US-09-996-288-248	Sequence 248, App	622	1747	99.0	450	5	US-10-962-285-248	Sequence 248, App
550	1747	99.0	450	3	US-09-996-288-250	Sequence 250, App	623	1747	99.0	450	5	US-10-962-285-250	Sequence 250, App
551	1747	99.0	450	3	US-09-996-288-252	Sequence 252, App	624	1747	99.0	450	5	US-10-962-285-252	Sequence 252, App
552	1747	99.0	450	3	US-09-996-288-254	Sequence 254, App	625	1747	99.0	450	5	US-10-962-285-254	Sequence 254, App
553	1747	99.0	450	3	US-09-996-288-256	Sequence 256, App	626	1747	99.0	450	5	US-10-962-285-256	Sequence 256, App
554	1747	99.0	450	3	US-09-996-265-208	Sequence 208, App	627	1747	99.0	450	5	US-10-403-180-208	Sequence 208, App
555	1747	99.0	450	3	US-09-996-265-210	Sequence 210, App	628	1747	99.0	450	5	US-10-403-180-210	Sequence 210, App
556	1747	99.0	450	3	US-09-996-265-212	Sequence 212, App	629	1747	99.0	450	5	US-10-403-180-212	Sequence 212, App
557	1747	99.0	450	3	US-09-996-265-214	Sequence 214, App	630	1747	99.0	450	5	US-10-403-180-214	Sequence 214, App
558	1747	99.0	450	3	US-09-996-265-216	Sequence 216, App	631	1747	99.0	450	5	US-10-403-180-216	Sequence 216, App
559	1747	99.0	450	3	US-09-996-265-218	Sequence 218, App	632	1747	99.0	450	5	US-10-403-180-218	Sequence 218, App
560	1747	99.0	450	3	US-09-996-265-220	Sequence 220, App	633	1747	99.0	450	5	US-10-403-180-220	Sequence 220, App
561	1747	99.0	450	3	US-09-996-265-222	Sequence 222, App	634	1747	99.0	450	5	US-10-403-180-222	Sequence 222, App
562	1747	99.0	450	3	US-09-996-265-224	Sequence 224, App	635	1747	99.0	450	5	US-10-403-180-224	Sequence 224, App
563	1747	99.0	450	3	US-09-996-265-226	Sequence 226, App	636	1747	99.0	450	5	US-10-403-180-226	Sequence 226, App
564	1747	99.0	450	3	US-09-996-265-228	Sequence 228, App	637	1747	99.0	450	5	US-10-403-180-228	Sequence 228, App
565	1747	99.0	450	3	US-09-996-265-232	Sequence 232, App	638	1747	99.0	450	5	US-10-403-180-232	Sequence 232, App
566	1747	99.0	450	3	US-09-996-265-234	Sequence 234, App	639	1747	99.0	450	5	US-10-403-180-234	Sequence 234, App
567	1747	99.0	450	3	US-09-996-265-236	Sequence 236, App	640	1747	99.0	450	5	US-10-403-180-236	Sequence 236, App
568	1747	99.0	450	3	US-09-996-265-238	Sequence 238, App	641	1747	99.0	450	5	US-10-403-180-238	Sequence 238, App
569	1747	99.0	450	3	US-09-996-265-240	Sequence 240, App	642	1747	99.0	450	5	US-10-403-180-240	Sequence 240, App
570	1747	99.0	450	3	US-09-996-265-242	Sequence 242, App	643	1747	99.0	450	5	US-10-403-180-242	Sequence 242, App
571	1747	99.0	450	3	US-09-996-265-244	Sequence 244, App	644	1747	99.0	450	5	US-10-403-180-244	Sequence 244, App
572	1747	99.0	450	3	US-09-996-265-246	Sequence 246, App	645	1747	99.0	450	5	US-10-403-180-246	Sequence 246, App
573	1747	99.0	450	3	US-09-996-265-248	Sequence 248, App	646	1747	99.0	450	5	US-10-403-180-248	Sequence 248, App
574	1747	99.0	450	3	US-09-996-265-250	Sequence 250, App	647	1747	99.0	450	5	US-10-403-180-250	Sequence 250, App
575	1747	99.0	450	3	US-09-996-265-252	Sequence 252, App	648	1747	99.0	450	5	US-10-403-180-252	Sequence 252, App
576	1747	99.0	450	3	US-09-996-265-254	Sequence 254, App	649	1747	99.0	450	5	US-10-403-180-254	Sequence 254, App
577	1747	99.0	450	3	US-09-996-265-256	Sequence 256, App	650	1747	99.0	450	5	US-10-403-180-256	Sequence 256, App
578	1747	99.0	450	4	US-10-135-636-1	Sequence 1, Appli	651	1747	99.0	450	6	US-11-199-739-723	Sequence 723, App
579	1747	99.0	450	5	US-10-900-230-208	Sequence 208, App	652	1747	99.0	451	3	US-09-996-288-230	Sequence 230, App
580	1747	99.0	450	5	US-10-900-230-210	Sequence 210, App	653	1747	99.0	451	3	US-09-996-288-230	Sequence 230, App
581	1747	99.0	450	5	US-10-900-230-212	Sequence 212, App	654	1747	99.0	451	5	US-10-900-230-230	Sequence 230, App
582	1747	99.0	450	5	US-10-900-230-214	Sequence 214, App	655	1747	99.0	451	5	US-10-962-285-230	Sequence 230, App
583	1747	99.0	450	5	US-10-900-230-216	Sequence 216, App	656	1747	99.0	451	5	US-10-403-180-230	Sequence 230, App
584	1747	99.0	450	5	US-10-900-230-218	Sequence 218, App	657	1747	99.0	468	4	US-10-377-109-2	Sequence 2, Appli
585	1747	99.0	450	5	US-10-900-230-220	Sequence 220, App	658	1747	99.0	469	4	US-10-377-121-18	Sequence 18, Appl
586	1747	99.0	450	5	US-10-900-230-222	Sequence 222, App	659	1747	99.0	469	4	US-10-377-121-22	Sequence 22, Appl
587	1747	99.0	450	5	US-10-900-230-224	Sequence 224, App	660	1747	99.0	469	5	US-10-858-186-14	Sequence 14, Appl
588	1747	99.0	450	5	US-10-900-230-226	Sequence 226, App	661	1747	99.0	470	4	US-10-216-484-89	Sequence 89, Appl
589	1747	99.0	450	5	US-10-900-230-228	Sequence 228, App	662	1747	99.0	470	4	US-10-216-484-117	Sequence 117, App
590	1747	99.0	450	5	US-10-900-230-232	Sequence 232, App	663	1747	99.0	470	4	US-10-216-484-143	Sequence 143, App
591	1747	99.0	450	5	US-10-900-230-234	Sequence 234, App	664	1747	99.0	470	4	US-10-216-484-145	Sequence 145, App
592	1747	99.0	450	5	US-10-900-230-236	Sequence 236, App	665	1747	99.0	470	4	US-10-216-484-147	Sequence 147, App
593	1747	99.0	450	5	US-10-900-230-238	Sequence 238, App	666	1747	99.0	470	4	US-10-216-484-157	Sequence 157, App
594	1747	99.0	450	5	US-10-900-230-240	Sequence 240, App	667	1747	99.0	470	4	US-10-384-933-89	Sequence 89, Appl
595	1747	99.0	450	5	US-10-900-230-242	Sequence 242, App	668	1747	99.0	470	4	US-10-384-933-117	Sequence 117, App
596	1747	99.0	450	5	US-10-900-230-244	Sequence 244, App	669	1747	99.0	470	4	US-10-384-933-143	Sequence 143, App
597	1747	99.0	450	5	US-10-900-230-246	Sequence 246, App	670	1747	99.0	470	4	US-10-384-933-145	Sequence 145, App
598	1747	99.0	450	5	US-10-900-230-248	Sequence 248, App	671	1747	99.0	470	4	US-10-384-933-147	Sequence 147, App
599	1747	99.0	450	5	US-10-900-230-250	Sequence 250, App	672	1747	99.0	470	4	US-10-384-933-157	Sequence 157, App
600	1747	99.0	450	5	US-10-900-230-252	Sequence 252, App	673	1747	99.0	470	6	US-11-041-095-22	Sequence 22, Appl
601	1747	99.0	450	5	US-10-900-230-254	Sequence 254, App	674	1747	99.0	472	3	US-09-301-593-30	Sequence 30, Appl
602	1747	99.0	450	5	US-10-900-230-256	Sequence 256, App	675	1747	99.0	472	3	US-09-301-593-43	Sequence 43, Appl
603	1747	99.0	450	5	US-10-962-285-208	Sequence 208, App	676	1747	99.0	472	4	US-10-159-006-30	Sequence 30, Appl
604	1747	99.0	450	5	US-10-962-285-210	Sequence 210, App	677	1747	99.0	472	4	US-10-159-006-43	Sequence 43, Appl
605	1747	99.0	450	5	US-10-962-285-212	Sequence 212, App	678	1747	99.0	473	4	US-10-108-260A-4681	Sequence 4681, Ap
606	1747	99.0	450	5	US-10-962-285-214	Sequence 214, App	679	1747	99.0	474	3	US-09-848-832-3	Sequence 3, Appli
607	1747	99.0	450	5	US-10-962-285-216	Sequence 216, App	680	1747	99.0	474	4	US-10-225-108A-3	Sequence 3, Appli
608	1747	99.0	450	5	US-10-962-285-218	Sequence 218, App	681	1747	99.0	474	4	US-10-291-265-284	Sequence 284, App
609	1747	99.0	450	5	US-10-962-285-220	Sequence 220, App	682	1747	99.0	474	4	US-10-108-260A-4640	Sequence 4640, Ap
610	1747	99.0	450	5	US-10-962-285-222	Sequence 222, App	683	1747	99.0	474	4	US-10-461-148-1	Sequence 1, Appli
611	1747	99.0	450	5	US-10-962-285-224	Sequence 224, App	684	1747	99.0	474	6	US-11-000-463-284	Sequence 284, App

685	1747	99.0	475	6	US-11-041-095-16	Sequence 16, Appl	758	1742	98.7	575	4	US-10-737-208A-6	Sequence 6, Appl
686	1747	99.0	476	4	US-10-225-108A-16	Sequence 16, Appl	759	1742	98.7	669	5	US-10-900-928-3	Sequence 3, Appl
687	1747	99.0	476	4	US-10-461-148-9	Sequence 9, Appl	760	1741	98.6	443	6	US-11-040-071-1	Sequence 1, Appl
688	1747	99.0	477	4	US-10-291-265-395	Sequence 395, Appl	761	1741	98.6	452	5	US-10-861-049-22	Sequence 22, Appl
689	1747	99.0	477	6	US-11-000-463-395	Sequence 395, Appl	762	1741	98.6	452	6	US-11-021-874-22	Sequence 22, Appl
690	1747	99.0	478	4	US-10-104-047-3812	Sequence 3812, Ap	763	1741	98.6	473	4	US-10-108-260A-4278	Sequence 4278, Ap
691	1747	99.0	478	6	US-11-072-512-3812	Sequence 3812, Ap	764	1741	98.6	979	4	US-10-418-836-16	Sequence 16, Appl
692	1747	99.0	489	4	US-10-104-047-3329	Sequence 3329, Ap	765	1741	98.6	979	6	US-11-007-886-16	Sequence 16, Appl
693	1747	99.0	489	6	US-11-072-512-3329	Sequence 3329, Ap	766	1740	98.6	466	5	US-10-937-046-11	Sequence 11, Appl
694	1747	99.0	526	6	US-11-041-095-10	Sequence 10, Appl	767	1740	98.6	476	4	US-10-660-128-12	Sequence 12, Appl
695	1747	99.0	579	4	US-10-138-727A-41	Sequence 41, Appl	768	1740	98.6	666	5	US-10-981-356A-29	Sequence 29, Appl
696	1747	99.0	579	6	US-11-174-186-41	Sequence 41, Appl	769	1740	98.6	667	6	US-11-096-046-29	Sequence 29, Appl
697	1747	99.0	979	4	US-10-418-836-10	Sequence 10, Appl	770	1739	98.5	453	3	US-09-802-077-8	Sequence 8, Appl
698	1747	99.0	979	6	US-11-007-886-10	Sequence 10, Appl	771	1739	98.5	453	3	US-09-802-077-8	Sequence 8, Appl
699	1746	98.9	447	4	US-10-379-392-117	Sequence 117, App	772	1739	98.5	453	3	US-09-925-299-1003	Sequence 1003, Ap
700	1746	98.9	666	5	US-10-981-356A-28	Sequence 28, Appl	773	1739	98.5	453	3	US-09-925-299-1003	Sequence 1003, Ap
701	1746	98.9	666	5	US-10-981-356A-30	Sequence 30, Appl	774	1739	98.5	468	4	US-10-071-485-67	Sequence 67, Appl
702	1746	98.9	667	6	US-11-096-046-28	Sequence 28, Appl	775	1739	98.5	468	5	US-10-985-581-67	Sequence 67, Appl
703	1746	98.9	667	6	US-11-096-046-30	Sequence 30, Appl	776	1739	98.5	711	4	US-10-071-485-90	Sequence 90, Appl
704	1745.5	98.9	339	5	US-10-872-932A-36	Sequence 36, Appl	777	1739	98.5	711	5	US-10-985-581-90	Sequence 90, Appl
705	1745.5	98.9	339	5	US-10-810-881A-35	Sequence 35, Appl	778	1738	98.5	342	3	US-09-925-299-1003	Sequence 1003, Ap
706	1745.5	98.9	339	5	US-10-981-936-35	Sequence 35, Appl	779	1738	98.5	342	3	US-09-925-299-1003	Sequence 1003, Ap
707	1745.5	98.9	339	5	US-10-999-866-35	Sequence 35, Appl	780	1738	98.5	447	4	US-10-379-392-141	Sequence 141, Appl
708	1745.5	98.9	339	5	US-10-935-005B-66	Sequence 66, Appl	781	1736.5	98.4	329	5	US-10-798-380-37	Sequence 37, Appl
709	1745	98.9	339	6	US-11-061-821-35	Sequence 35, Appl	782	1736	98.4	447	6	US-11-004-590-231	Sequence 231, Appl
710	1745	98.9	329	6	US-11-149-309-17	Sequence 17, Appl	783	1736	98.4	449	6	US-11-004-590-231	Sequence 231, Appl
711	1745	98.9	329	6	US-11-155-843-128	Sequence 128, App	784	1735	98.3	443	6	US-11-040-071-5	Sequence 5, Appl
712	1745	98.9	329	6	US-11-155-843-141	Sequence 141, App	785	1735	98.3	452	5	US-10-861-049-17	Sequence 17, Appl
713	1745	98.9	330	5	US-10-822-300-75	Sequence 75, Appl	786	1735	98.3	452	5	US-10-861-049-17	Sequence 20, Appl
714	1745	98.9	330	5	US-10-687-118-75	Sequence 75, Appl	787	1735	98.3	452	6	US-11-021-874-17	Sequence 17, Appl
715	1745	98.9	330	6	US-11-102-621-75	Sequence 75, Appl	788	1735	98.3	452	6	US-11-021-874-20	Sequence 20, Appl
716	1745	98.9	402	6	US-11-024-251-31	Sequence 31, Appl	789	1735	98.3	452	6	US-11-120-338-15	Sequence 15, Appl
717	1745	98.9	446	5	US-10-822-300-123	Sequence 123, App	790	1735	98.3	452	6	US-11-120-338-15	Sequence 15, Appl
718	1745	98.9	446	6	US-11-102-621-123	Sequence 123, App	791	1735	98.3	452	6	US-11-107-028-33	Sequence 33, Appl
719	1745	98.9	446	6	US-11-102-621-123	Sequence 123, App	792	1735	98.3	452	6	US-11-107-028-45	Sequence 45, Appl
720	1745	98.9	447	5	US-10-474-832-5	Sequence 5, Appl	793	1735	98.3	452	6	US-11-106-820-28	Sequence 28, Appl
721	1745	98.9	447	5	US-10-822-300-134	Sequence 134, App	794	1735	98.3	452	6	US-11-143-077-15	Sequence 15, Appl
722	1745	98.9	448	6	US-11-102-621-134	Sequence 134, App	795	1735	98.3	452	6	US-11-143-386-15	Sequence 15, Appl
723	1745	98.9	448	6	US-11-182-908-16	Sequence 16, Appl	796	1735	98.3	452	6	US-11-187-364-15	Sequence 15, Appl
724	1745	98.9	449	4	US-10-253-366-2	Sequence 2, Appl	797	1735	98.3	452	6	US-11-208-422-28	Sequence 28, Appl
725	1745	98.9	449	4	US-10-316-694-2	Sequence 2, Appl	798	1735	98.3	452	6	US-11-208-422-44	Sequence 44, Appl
726	1745	98.9	449	4	US-10-325-974-2	Sequence 2, Appl	799	1735	98.3	471	5	US-11-208-422-44	Sequence 44, Appl
727	1745	98.9	449	4	US-10-428-239-2	Sequence 2, Appl	800	1735	98.3	471	6	US-10-861-049-11	Sequence 11, Appl
728	1745	98.9	449	4	US-10-653-843-2	Sequence 2, Appl	801	1735	98.3	471	6	US-11-021-874-11	Sequence 11, Appl
729	1745	98.9	449	5	US-10-877-532-2	Sequence 2, Appl	802	1735	98.3	471	6	US-11-106-820-27	Sequence 27, Appl
730	1745	98.9	449	5	US-10-949-683-2	Sequence 2, Appl	803	1735	98.3	471	6	US-11-190-364-23	Sequence 23, Appl
731	1745	98.9	449	6	US-11-084-729-2	Sequence 2, Appl	804	1734.5	98.3	450	5	US-11-147-780-23	Sequence 23, Appl
732	1745	98.9	449	6	US-11-154-337-15	Sequence 15, Appl	805	1734	98.2	449	6	US-10-698-073-11	Sequence 11, Appl
733	1745	98.9	451	6	US-11-182-908-14	Sequence 14, Appl	806	1730	98.0	449	6	US-11-004-590-230	Sequence 230, App
734	1745	98.9	451	6	US-11-120-338-22	Sequence 22, Appl	807	1730	98.0	470	5	US-11-004-590-230	Sequence 20, Appl
735	1745	98.9	451	6	US-11-143-386-22	Sequence 22, Appl	808	1729	98.0	447	4	US-10-697-995-21	Sequence 21, Appl
736	1745	98.9	467	6	US-11-182-908-18	Sequence 18, Appl	809	1729	98.0	451	6	US-10-379-392-143	Sequence 143, App
737	1745	98.9	730	3	US-09-825-012-49	Sequence 49, Appl	810	1729	98.0	452	6	US-11-187-364-29	Sequence 29, Appl
738	1744	98.8	332	4	US-10-323-904-1	Sequence 1, Appl	811	1729	98.0	452	6	US-11-120-338-17	Sequence 17, Appl
739	1744	98.8	556	4	US-10-471-151-26	Sequence 26, Appl	812	1729	98.0	452	6	US-11-107-028-47	Sequence 47, Appl
740	1744	98.8	559	3	US-09-746-359A-62	Sequence 62, Appl	813	1729	98.0	452	6	US-11-107-028-47	Sequence 47, Appl
741	1744	98.8	559	3	US-09-951-268-39	Sequence 39, Appl	814	1729	98.0	452	6	US-11-106-820-30	Sequence 30, Appl
742	1744	98.8	559	3	US-09-745-792A-62	Sequence 62, Appl	815	1729	98.0	452	6	US-11-106-820-45	Sequence 45, Appl
743	1744	98.8	559	4	US-10-424-658-62	Sequence 62, Appl	816	1729	98.0	452	6	US-11-143-386-17	Sequence 17, Appl
744	1744	98.8	559	4	US-10-994-116-78	Sequence 78, Appl	817	1729	98.0	452	6	US-11-208-422-40	Sequence 40, Appl
745	1744	98.8	559	5	US-10-994-151-78	Sequence 78, Appl	818	1729	98.0	464	4	US-11-208-422-46	Sequence 46, Appl
746	1744	98.8	573	4	US-10-471-151-25	Sequence 25, Appl	819	1729	98.0	464	4	US-11-032-037B-26	Sequence 26, Appl
747	1744	98.8	594	3	US-09-746-359A-23	Sequence 23, Appl	820	1729	98.0	464	4	US-10-029-988B-26	Sequence 26, Appl
748	1744	98.8	594	3	US-09-951-268-24	Sequence 24, Appl	821	1729	98.0	464	4	US-10-032-423A-26	Sequence 26, Appl
749	1744	98.8	594	3	US-09-745-792A-23	Sequence 23, Appl	822	1729	98.0	464	4	US-10-029-926B-26	Sequence 26, Appl
750	1744	98.8	594	4	US-10-424-658-23	Sequence 23, Appl	823	1729	98.0	468	5	US-10-723-003-12	Sequence 12, Appl
751	1744	98.8	594	5	US-10-994-116-77	Sequence 77, Appl	824	1729	98.0	468	5	US-10-723-003-20	Sequence 20, Appl
752	1744	98.8	594	5	US-10-994-151-77	Sequence 77, Appl	825	1729	98.0	468	6	US-11-004-639-12	Sequence 12, Appl
753	1743	98.8	329	4	US-10-370-749-25	Sequence 25, Appl	826	1729	98.0	470	5	US-11-004-639-20	Sequence 20, Appl
754	1743	98.8	329	5	US-10-426-334-1	Sequence 1, Appl	827	1729	98.0	470	6	US-10-723-003-40	Sequence 40, Appl
755	1743	98.8	447	4	US-10-379-392-119	Sequence 11, Appl	828	1729	98.0	472	5	US-11-004-639-40	Sequence 40, Appl
756	1743	98.8	472	4	US-10-108-260A-4291	Sequence 4291, Ap	829	1729	98.0	472	5	US-10-723-003-54	Sequence 54, Appl
757	1743	98.8	470	4	US-10-108-260A-4191	Sequence 4191, Ap	830	1729	98.0	624	5	US-11-024-639-54	Sequence 54, Appl
758	1742	98.7	470	4	US-10-108-260A-4291	Sequence 4291, Ap	831	1729	98.0	624	5	US-10-723-003-22	Sequence 22, Appl

831	1729	98.0	624	5	US-10-723-003-30	Sequence 30, Appl	904	1608	91.1	326	5	US-10-872-932A-37	Sequence 37, Appl
832	1729	98.0	624	6	US-11-004-639-24	Sequence 24, Appl	905	1608	91.1	326	5	US-10-928-305-8	Sequence 8, Appl
833	1729	98.0	624	6	US-11-004-639-30	Sequence 30, Appl	906	1608	91.1	326	5	US-10-891-658-4	Sequence 4, Appl
834	1729	98.0	626	5	US-10-723-003-44	Sequence 44, Appl	907	1608	91.1	326	5	US-10-893-576-46	Sequence 46, Appl
835	1729	98.0	626	5	US-11-004-639-44	Sequence 44, Appl	908	1608	91.1	326	5	US-10-810-881A-36	Sequence 36, Appl
836	1729	98.0	628	5	US-10-723-003-58	Sequence 58, Appl	909	1608	91.1	326	5	US-10-981-936-36	Sequence 36, Appl
837	1729	98.0	628	5	US-11-004-639-58	Sequence 58, Appl	910	1608	91.1	326	5	US-10-999-866-36	Sequence 36, Appl
838	1729	98.0	639	5	US-10-723-003-26	Sequence 26, Appl	911	1608	91.1	326	5	US-10-493-909-22	Sequence 22, Appl
839	1729	98.0	639	5	US-10-723-003-32	Sequence 32, Appl	912	1608	91.1	326	5	US-10-935-005B-67	Sequence 67, Appl
840	1729	98.0	639	6	US-11-004-639-26	Sequence 26, Appl	913	1608	91.1	326	6	US-11-001-980-2	Sequence 2, Appl
841	1729	98.0	639	6	US-11-004-639-32	Sequence 32, Appl	914	1608	91.1	326	6	US-11-001-980-6	Sequence 6, Appl
842	1729	98.0	641	5	US-10-723-003-46	Sequence 46, Appl	915	1608	91.1	326	6	US-11-004-054-4	Sequence 4, Appl
843	1729	98.0	641	6	US-11-004-639-46	Sequence 46, Appl	916	1608	91.1	326	6	US-11-026-998-23	Sequence 23, Appl
844	1729	98.0	643	5	US-10-723-003-60	Sequence 60, Appl	917	1608	91.1	326	6	US-11-027-309A-23	Sequence 23, Appl
845	1729	98.0	643	6	US-11-004-639-60	Sequence 60, Appl	918	1608	91.1	326	6	US-11-144-248-28	Sequence 28, Appl
846	1726	97.8	329	6	US-11-102-403-25	Sequence 25, Appl	919	1608	91.1	326	6	US-11-061-821-36	Sequence 36, Appl
847	1726	97.8	579	4	US-10-310-719-32	Sequence 32, Appl	920	1608	91.1	326	6	US-11-144-222-28	Sequence 28, Appl
848	1724	97.7	447	4	US-10-379-392-142	Sequence 142, Appl	921	1608	91.1	326	6	US-11-182-343-28	Sequence 28, Appl
849	1724	97.7	451	6	US-11-120-338-25	Sequence 25, Appl	922	1608	91.1	326	6	US-11-124-620-2	Sequence 2, Appl
850	1724	97.7	451	6	US-11-143-077-22	Sequence 22, Appl	923	1608	91.1	326	6	US-11-233-683-2	Sequence 2, Appl
851	1724	97.7	451	6	US-11-143-386-25	Sequence 25, Appl	924	1608	91.1	443	3	US-09-256-156-2	Sequence 2, Appl
852	1724	97.7	451	6	US-11-187-364-34	Sequence 34, Appl	925	1608	91.1	444	6	US-11-085-368-89	Sequence 89, Appl
853	1722	97.6	447	4	US-10-379-392-118	Sequence 118, Appl	926	1608	91.1	445	5	US-10-644-277-2	Sequence 2, Appl
854	1719	97.4	447	4	US-10-379-392-120	Sequence 120, Appl	927	1608	91.1	445	5	US-10-644-277-18	Sequence 18, Appl
855	1719	97.4	452	6	US-11-107-028-46	Sequence 46, Appl	928	1608	91.1	445	5	US-10-644-277-38	Sequence 38, Appl
856	1718	97.3	330	3	US-11-208-422-43	Sequence 43, Appl	929	1608	91.1	445	5	US-10-644-277-90	Sequence 90, Appl
857	1718	97.3	330	3	US-09-847-208-2	Sequence 2, Appl	930	1608	91.1	449	5	US-10-891-658-40	Sequence 40, Appl
858	1718	97.3	330	4	US-10-000-439-2	Sequence 2, Appl	931	1608	91.1	451	4	US-10-153-382-17	Sequence 17, Appl
859	1716	97.2	481	4	US-10-409-938-23	Sequence 23, Appl	932	1608	91.1	451	5	US-10-612-497-70	Sequence 70, Appl
860	1700	96.3	451	5	US-10-822-231-5	Sequence 5, Appl	933	1608	91.1	451	5	US-10-776-649-70	Sequence 70, Appl
861	1691	95.8	451	6	US-11-124-620-5	Sequence 5, Appl	934	1608	91.1	451	6	US-11-085-368-17	Sequence 17, Appl
862	1681	95.2	447	4	US-11-124-620-5	Sequence 5, Appl	935	1608	91.1	451	6	US-11-128-900-70	Sequence 70, Appl
863	1678	95.1	380	4	US-10-379-392-151	Sequence 151, Appl	936	1608	91.1	460	5	US-10-938-353-14	Sequence 14, Appl
864	1639	92.9	580	4	US-10-272-899A-106	Sequence 106, Appl	937	1608	91.1	460	5	US-10-938-353-26	Sequence 26, Appl
865	1636	92.7	362	4	US-10-112-582-3	Sequence 3, Appl	938	1608	91.1	460	5	US-10-938-353-74	Sequence 74, Appl
866	1636	92.7	362	6	US-11-233-683-3	Sequence 3, Appl	939	1608	91.1	461	5	US-10-938-353-2	Sequence 2, Appl
867	1632	92.5	580	4	US-10-310-719-35	Sequence 35, Appl	940	1608	91.1	461	5	US-10-938-353-34	Sequence 34, Appl
868	1622	91.9	377	6	US-10-822-300-113	Sequence 113, Appl	941	1608	91.1	461	5	US-10-938-353-66	Sequence 66, Appl
869	1622	91.9	377	6	US-11-102-621-113	Sequence 113, Appl	942	1608	91.1	462	5	US-10-828-782A-18	Sequence 18, Appl
870	1622	91.9	519	4	US-10-312-354-19	Sequence 19, Appl	943	1608	91.1	462	5	US-10-910-901-2	Sequence 2, Appl
871	1619	91.8	377	3	US-09-925-664-45	Sequence 45, Appl	944	1608	91.1	462	5	US-10-910-901-14	Sequence 14, Appl
872	1619	91.8	377	3	US-09-925-192-45	Sequence 45, Appl	945	1608	91.1	462	6	US-11-238-983-2	Sequence 2, Appl
873	1619	91.8	377	5	US-10-047-542-24	Sequence 24, Appl	946	1608	91.1	463	4	US-10-153-382-13	Sequence 13, Appl
874	1619	91.8	377	5	US-10-822-300-115	Sequence 115, Appl	947	1608	91.1	463	4	US-10-656-769-34	Sequence 34, Appl
875	1619	91.8	377	5	US-10-872-932A-38	Sequence 38, Appl	948	1608	91.1	463	5	US-10-612-497-1	Sequence 1, Appl
876	1619	91.8	377	5	US-10-810-881A-37	Sequence 37, Appl	949	1608	91.1	463	5	US-10-612-497-4	Sequence 4, Appl
877	1619	91.8	377	5	US-10-981-936-37	Sequence 37, Appl	950	1608	91.1	463	5	US-10-612-497-63	Sequence 63, Appl
878	1619	91.8	377	5	US-10-999-866-37	Sequence 37, Appl	951	1608	91.1	463	5	US-10-612-497-68	Sequence 68, Appl
879	1619	91.8	377	5	US-10-493-909-24	Sequence 24, Appl	952	1608	91.1	463	5	US-10-612-497-68	Sequence 68, Appl
880	1619	91.8	377	5	US-10-935-005B-68	Sequence 68, Appl	953	1608	91.1	463	5	US-10-776-649-4	Sequence 4, Appl
881	1619	91.8	377	6	US-11-061-821-37	Sequence 37, Appl	954	1608	91.1	463	5	US-10-776-649-63	Sequence 63, Appl
882	1619	91.8	377	6	US-11-102-621-115	Sequence 115, Appl	955	1608	91.1	463	5	US-10-776-649-68	Sequence 68, Appl
883	1619	91.8	377	6	US-11-124-620-3	Sequence 3, Appl	956	1608	91.1	463	5	US-10-910-901-10	Sequence 10, Appl
884	1619	91.8	494	3	US-09-256-156-3	Sequence 3, Appl	957	1608	91.1	463	5	US-10-938-353-6	Sequence 6, Appl
885	1618	91.7	516	4	US-10-108-260A-4283	Sequence 4283, Appl	958	1608	91.1	463	6	US-11-085-368-3	Sequence 3, Appl
886	1617	91.6	339	4	US-10-272-899A-18	Sequence 18, Appl	959	1608	91.1	463	6	US-11-085-368-13	Sequence 13, Appl
887	1617	91.6	359	4	US-10-272-899A-76	Sequence 76, Appl	960	1608	91.1	463	6	US-11-085-368-41	Sequence 41, Appl
888	1615	91.5	516	4	US-10-108-260A-4452	Sequence 4452, Appl	961	1608	91.1	463	6	US-11-085-368-53	Sequence 53, Appl
889	1615	91.5	518	4	US-10-225-108A-10	Sequence 10, Appl	962	1608	91.1	463	6	US-11-085-368-53	Sequence 53, Appl
890	1615	91.5	518	4	US-10-461-148-4	Sequence 4, Appl	963	1608	91.1	463	6	US-11-031-485-2	Sequence 2, Appl
891	1615	91.5	520	4	US-10-108-260A-4767	Sequence 4767, Appl	964	1608	91.1	463	6	US-11-031-485-6	Sequence 6, Appl
892	1615	91.5	535	4	US-10-108-260A-4247	Sequence 4247, Appl	965	1608	91.1	463	6	US-11-128-900-1	Sequence 1, Appl
893	1615	91.5	310	4	US-10-060-714-25	Sequence 25, Appl	966	1608	91.1	463	6	US-11-128-900-4	Sequence 4, Appl
894	1610	91.2	376	5	US-10-891-658-26	Sequence 26, Appl	967	1608	91.1	463	6	US-11-128-900-63	Sequence 63, Appl
895	1610	91.2	499	5	US-10-891-658-43	Sequence 43, Appl	968	1608	91.1	463	6	US-11-128-900-68	Sequence 68, Appl
896	1608	91.1	339	4	US-10-272-899A-16	Sequence 16, Appl	969	1608	91.1	464	4	US-10-153-382-9	Sequence 9, Appl
897	1608	91.1	326	4	US-10-047-542-22	Sequence 22, Appl	970	1608	91.1	464	4	US-10-292-088-22	Sequence 22, Appl
898	1608	91.1	326	4	US-10-310-719-9	Sequence 9, Appl	971	1608	91.1	464	5	US-10-612-497-2	Sequence 2, Appl
899	1608	91.1	326	4	US-10-113-582-2	Sequence 2, Appl	972	1608	91.1	464	5	US-10-612-497-66	Sequence 66, Appl
900	1608	91.1	326	4	US-10-038-591-28	Sequence 28, Appl	973	1608	91.1	464	5	US-10-776-649-2	Sequence 2, Appl
901	1608	91.1	326	4	US-10-656-769-6	Sequence 6, Appl	974	1608	91.1	464	5	US-10-776-649-66	Sequence 66, Appl
902	1608	91.1	326	4	US-10-773-444A-28	Sequence 28, Appl	975	1608	91.1	464	5	US-10-938-353-22	Sequence 22, Appl
903	1608	91.1	326	5	US-10-756-153-32	Sequence 32, Appl	976	1608	91.1	464	6	US-11-085-368-9	Sequence 9, Appl

977 1608 91.1 464 6 US-11-085-368-45
978 1608 91.1 464 6 US-11-031-485-52
979 1608 91.1 464 6 US-11-128-900-2
980 1608 91.1 464 6 US-11-128-900-66
981 1608 91.1 465 4 US-10-292-088-38
982 1608 91.1 465 4 US-10-656-769-22
983 1608 91.1 465 4 US-10-656-769-28
984 1608 91.1 466 4 US-10-292-088-30
985 1608 91.1 466 4 US-10-292-088-70
986 1608 91.1 466 4 US-10-292-088-86
987 1608 91.1 466 5 US-10-938-353-10
988 1608 91.1 466 5 US-10-938-353-30
989 1608 91.1 466 5 US-10-938-353-62
990 1608 91.1 467 4 US-10-180-648-2
991 1608 91.1 468 6 US-11-031-485-56
992 1608 91.1 468 6 US-11-086-289-14
993 1608 91.1 468 6 US-11-086-289-22
994 1608 91.1 469 4 US-10-292-088-54
995 1608 91.1 469 6 US-11-031-485-34
996 1608 91.1 469 6 US-11-031-485-42
997 1608 91.1 469 6 US-11-031-485-60
998 1608 91.1 470 3 US-09-859-053-28
999 1608 91.1 470 3 US-09-859-053-32
1000 1608 91.1 470 3 US-09-859-053-36

ALIGNMENTS

RESULT 1
US-10-733-563-110
; Sequence 110, Application US/10733563
; Publication No. US20040151721A1
; GENERAL INFORMATION:
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; TITLE OF INVENTION: METHODS OF USE THEREOF
; FILE REFERENCE: 10448-213001
; CURRENT APPLICATION NUMBER: US/10/733,563
; PRIOR FILING DATE: 2003-12-10
; PRIOR APPLICATION NUMBER: US 10/272,899
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: US 60/392,364
; PRIOR FILING DATE: 2002-06-26
; PRIOR APPLICATION NUMBER: US 60/350,166
; NUMBER OF SEQ ID NOS: 122
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 110
; LENGTH: 330
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: human IgG1-FcRmut protein
US-10-733-563-110

Query Match 100.0%; Score 1765; DB 4; Length 330;
Best Local Similarity 100.0%; Pred. No. 1.4e-128;
Matches 330; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSNVNSGALTSGVHTFPAVLQSS 60
Db 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSNVNSGALTSGVHTFPAVLQSS 60
Qy 61 GLYSLSSVVTVPSSSLGTQYICNVNHPKSTNTKVDKVEPKSCDKTHTCPCPAPELAGA 120
Db 61 GLYSLSSVVTVPSSSLGTQYICNVNHPKSTNTKVDKVEPKSCDKTHTCPCPAPELAGA 120
Qy 121 PSVFLFPPKPKDITLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKTPREEQYN 180
Db 121 PSVFLFPPKPKDITLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKTPREEQYN 180

Qy 181 STYRVSVLYTLVHODWLNKGEYKCKVSNKALPAPIEKTISKAKGPREPQVYTLPPSRDE 240
Db 181 STYRVSVLYTLVHODWLNKGEYKCKVSNKALPAPIEKTISKAKGPREPQVYTLPPSRDE 240
Qy 241 LTKQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSPFLYSKLTVDKSRW 300
Db 241 LTKQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSPFLYSKLTVDKSRW 300
Qy 301 QOQNVFSCVMHEALHNHYTOKSLSPGK 330
Db 301 QOQNVFSCVMHEALHNHYTOKSLSPGK 330
RESULT 2
US-10-272-899A-10
; Sequence 10, Application US/10272899A
; Publication No. US20040033561A1
; GENERAL INFORMATION:
; APPLICANT: O'Keefe, Theresa L.
; APPLICANT: Healy, Judith Jacques
; APPLICANT: Newman, Walter
; APPLICANT: Ponath, Paul
; APPLICANT: Bruce Keyt
; TITLE OF INVENTION: MONOBODY CONSTRUCTS, METHODS OF PRODUCTION, AND METHODS OF
; TITLE OF INVENTION: USE THEREFOR
; FILE REFERENCE: MP101-244P2RM
; CURRENT APPLICATION NUMBER: US/10/272,899A
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/350,166
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: 60/392,364
; PRIOR FILING DATE: 2002-06-26
; NUMBER OF SEQ ID NOS: 110
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 10
; LENGTH: 333
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: human IgG1-FcRmut protein
US-10-272-899A-10
Query Match 100.0%; Score 1765; DB 4; Length 333;
Best Local Similarity 100.0%; Pred. No. 1.4e-128; Indels 0; Gaps 0;
Matches 330; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSNVNSGALTSGVHTFPAVLQSS 60
Db 4 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSNVNSGALTSGVHTFPAVLQSS 63
Qy 61 GLYSLSSVVTVPSSSLGTQYICNVNHPKSTNTKVDKVEPKSCDKTHTCPCPAPELAGA 120
Db 64 GLYSLSSVVTVPSSSLGTQYICNVNHPKSTNTKVDKVEPKSCDKTHTCPCPAPELAGA 123
Qy 121 PSVFLFPPKPKDITLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKTPREEQYN 180
Db 124 PSVFLFPPKPKDITLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKTPREEQYN 183
Qy 181 STYRVSVLYTLVHODWLNKGEYKCKVSNKALPAPIEKTISKAKGPREPQVYTLPPSRDE 240
Db 184 STYRVSVLYTLVHODWLNKGEYKCKVSNKALPAPIEKTISKAKGPREPQVYTLPPSRDE 243
Qy 241 LTKQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSPFLYSKLTVDKSRW 300
Db 244 LTKQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSPFLYSKLTVDKSRW 303
Qy 301 QOQNVFSCVMHEALHNHYTOKSLSPGK 330
Db 304 QOQNVFSCVMHEALHNHYTOKSLSPGK 333
RESULT 3

```
US-10-733-563-114
; Sequence 114, Application US/10733563
; Publication No. US20040151721A1
; GENERAL INFORMATION:
; APPLICANT: O'Keefe, Theresa
; APPLICANT: Ponath, Paul
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; TITLE OF INVENTION: METHODS OF USE THEREOF
; FILE REFERENCE: 10448-213001
; CURRENT APPLICATION NUMBER: US/10/733,563
; CURRENT FILING DATE: 2003-12-10
; PRIOR APPLICATION NUMBER: US 10/272,899
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: US 60/392,364
; PRIOR FILING DATE: 2002-06-26
; PRIOR APPLICATION NUMBER: US 60/350,166
; PRIOR FILING DATE: 2001-10-19
; NUMBER OF SEQ ID NOS: 122
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 114
; LENGTH: 333
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: human IgG1-FcRmut protein
US-10-733-563-114

Query Match      100.0%; Score 1765; DB 4; Length 333;
Best Local Similarity 100.0%; Pred. No. 1.4e-128;
Matches 330; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVMSWGALTSVHTFPAVLQSS 60
DB 4 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVMSWGALTSVHTFPAVLQSS 63
QY 61 GLYSLSVVTPSSSLGQTQYICNVNHRKPSNTKVDKVEPKSCDKTHTCPPCPAPELAGA 120
DB 64 GLYSLSVVTPSSSLGQTQYICNVNHRKPSNTKVDKVEPKSCDKTHTCPPCPAPELAGA 123
QY 121 PSVFLFPKPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 180
DB 124 PSVFLFPKPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 183
QY 181 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVTLPPSRDE 240
DB 184 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVTLPPSRDE 243
QY 241 LTKNQVSLTCLVKGYFPSDIAVEWESNGQPENNYKTTTPVLDSGGSFFLYSKLTVDKSRW 300
DB 244 LTKNQVSLTCLVKGYFPSDIAVEWESNGQPENNYKTTTPVLDSGGSFFLYSKLTVDKSRW 303
QY 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330
DB 304 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 333

RESULT 4
US-10-733-899A-70
; Sequence 70, Application US/10272899A
; Publication No. US20040033561A1
; GENERAL INFORMATION:
; APPLICANT: O'Keefe, Theresa L.
; APPLICANT: Healy, Judith Jacques
; APPLICANT: Newman, Walter
; APPLICANT: Ponath, Paul
; APPLICANT: Bruce Keyt
; TITLE OF INVENTION: IMMUNOGLOBULIN DNA CASSETTE MOLECULES,
; TITLE OF INVENTION: MONOCLONAL CONSTRUCTS, METHODS OF PRODUCTION, AND METHODS OF
; TITLE OF INVENTION: USE THEREOF
; FILE REFERENCE: MP101-244P2RM
; CURRENT APPLICATION NUMBER: US/10/272,899A
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/350,166
```

```
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: 60/392,364
; PRIOR FILING DATE: 2002-06-26
; NUMBER OF SEQ ID NOS: 110
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 70
; LENGTH: 356
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: immunoglobulin cassette protein sequence
; OTHER INFORMATION: Leader-HuFCRm_56
US-10-272-899A-70

Query Match      100.0%; Score 1765; DB 4; Length 356;
Best Local Similarity 100.0%; Pred. No. 1.6e-128;
Matches 330; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVMSWGALTSVHTFPAVLQSS 60
DB 27 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVMSWGALTSVHTFPAVLQSS 86
QY 61 GLYSLSVVTPSSSLGQTQYICNVNHRKPSNTKVDKVEPKSCDKTHTCPPCPAPELAGA 120
DB 87 GLYSLSVVTPSSSLGQTQYICNVNHRKPSNTKVDKVEPKSCDKTHTCPPCPAPELAGA 146
QY 121 PSVFLFPKPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 180
DB 147 PSVFLFPKPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 206
QY 181 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVTLPPSRDE 240
DB 207 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVTLPPSRDE 266
QY 241 LTKNQVSLTCLVKGYFPSDIAVEWESNGQPENNYKTTTPVLDSGGSFFLYSKLTVDKSRW 300
DB 267 LTKNQVSLTCLVKGYFPSDIAVEWESNGQPENNYKTTTPVLDSGGSFFLYSKLTVDKSRW 326
QY 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330
DB 327 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 356

RESULT 5
US-10-171-452A-42
; Sequence 42, Application US/10171452A
; Publication No. US20030108518A1
; GENERAL INFORMATION:
; APPLICANT: Frewin, Mark
; APPLICANT: Waldmann, Herman
; APPLICANT: Gorman, Scott
; APPLICANT: Hale, Geoff
; APPLICANT: Rao, Patricia
; APPLICANT: Kornaga, Tadeusz
; APPLICANT: Ringler, Douglas
; APPLICANT: Cobboid, Stephen
; APPLICANT: Winsor-Hines, Dawn
; TITLE OF INVENTION: TRX1 Antibody and Uses Therefor
; FILE REFERENCE: 695458-59
; CURRENT APPLICATION NUMBER: US/10/171,452A
; CURRENT FILING DATE: 2003-02-10
; PRIOR APPLICATION NUMBER: US60/373,471
; PRIOR FILING DATE: 2002-04-18
; PRIOR APPLICATION NUMBER: US60/373,470
; PRIOR FILING DATE: 2002-04-18
; PRIOR APPLICATION NUMBER: US60/345,194
; PRIOR FILING DATE: 2002-10-19
; PRIOR APPLICATION NUMBER: GB0122724.8
; PRIOR FILING DATE: 2001-09-20
; PRIOR APPLICATION NUMBER: GB0114517.6
; PRIOR FILING DATE: 2001-06-14
; NUMBER OF SEQ ID NOS: 60
; SEQ ID NO 42
```

```
; LENGTH: 448
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Heavy chain of humanized antibody
US-10-171-452A-42

Query Match      100.0%; Score 1765; DB 4; Length 448;
Best Local Similarity 100.0%; Pred. No. 2.1e-128;
Matches 330; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
DB 119 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 178

QY 61 GLYSSVVTVPPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPPCPAPELLAGA 120
DB 179 GLYSSVVTVPPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPPCPAPELLAGA 238

QY 121 PSVFLFPPKPKDITLMISRTPEVTCVVDVSHEDPEVKENWYVDGVEVHNAKTKPREEQYN 180
DB 239 PSVFLFPPKPKDITLMISRTPEVTCVVDVSHEDPEVKENWYVDGVEVHNAKTKPREEQYN 298

QY 181 STYRVSVSLTVLHODWLNAGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
DB 299 STYRVSVSLTVLHODWLNAGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 358

QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFPLYSKLTVDKSRW 300
DB 359 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFPLYSKLTVDKSRW 418

QY 301 QQGNVFSCSVMEALHNHYTOKSLSLSPGK 330
DB 419 QQGNVFSCSVMEALHNHYTOKSLSLSPGK 448
```

```
RESULT 6
US-10-171-452A-54
; Sequence 54, Application US/10171452A
; Publication No. US20030108518A1
; GENERAL INFORMATION:
; APPLICANT: Frewin, Mark
; APPLICANT: Waldmann, Herman
; APPLICANT: Gorman, Scott
; APPLICANT: Hale, Geoff
; APPLICANT: Rao, Patricia
; APPLICANT: Kornaga, Tadeusz
; APPLICANT: Ringler, Douglas
; APPLICANT: Cobbold, Stephen
; APPLICANT: Winsor-Hines, Dawn
; TITLE OF INVENTION: Trx1 Antibody and Uses Therefor
; FILE REFERENCE: 695458-59
; CURRENT APPLICATION NUMBER: US/10/171,452A
; CURRENT FILING DATE: 2003-02-10
; PRIOR APPLICATION NUMBER: US60/373,471
; PRIOR FILING DATE: 2002-04-18
; PRIOR APPLICATION NUMBER: US60/373,470
; PRIOR FILING DATE: 2002-04-18
; PRIOR APPLICATION NUMBER: US60/345,194
; PRIOR FILING DATE: 2002-10-19
; PRIOR APPLICATION NUMBER: GB0122724.8
; PRIOR FILING DATE: 2001-09-20
; PRIOR APPLICATION NUMBER: GB0114517.6
; PRIOR FILING DATE: 2001-06-14
; NUMBER OF SEQ ID NOS: 60
; SEQ ID NO 54
; LENGTH: 448
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Heavy chain of humanized antibody
US-10-171-452A-54
```

```
Query Match      100.0%; Score 1765; DB 4; Length 448;
Best Local Similarity 100.0%; Pred. No. 2.1e-128;
Matches 330; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
DB 119 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 178

QY 61 GLYSSVVTVPPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPPCPAPELLAGA 120
DB 179 GLYSSVVTVPPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPPCPAPELLAGA 238

QY 121 PSVFLFPPKPKDITLMISRTPEVTCVVDVSHEDPEVKENWYVDGVEVHNAKTKPREEQYN 180
DB 239 PSVFLFPPKPKDITLMISRTPEVTCVVDVSHEDPEVKENWYVDGVEVHNAKTKPREEQYN 298

QY 181 STYRVSVSLTVLHODWLNAGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
DB 299 STYRVSVSLTVLHODWLNAGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 358

QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFPLYSKLTVDKSRW 300
DB 359 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFPLYSKLTVDKSRW 418

QY 301 QQGNVFSCSVMEALHNHYTOKSLSLSPGK 330
DB 419 QQGNVFSCSVMEALHNHYTOKSLSLSPGK 448

RESULT 7
US-10-353-708-42
; Sequence 42, Application US/10353708
; Publication No. US20030219403A1
; GENERAL INFORMATION:
; APPLICANT: Frewin, Mark
; APPLICANT: Waldmann, Herman
; APPLICANT: Gorman, Scott
; APPLICANT: Hale, Geoff
; APPLICANT: Rao, Patricia
; APPLICANT: Kornaga, Tadeusz
; APPLICANT: Ringler, Douglas
; APPLICANT: Cobbold, Stephen
; APPLICANT: Winsor-Hines, Dawn
; TITLE OF INVENTION: Compositions and Methods of Tolerizing a Primate to an Antigen
; FILE REFERENCE: 695458-73
; CURRENT APPLICATION NUMBER: US/10/353,708
; CURRENT FILING DATE: 2003-01-29
; PRIOR APPLICATION NUMBER: US10/171,452
; PRIOR FILING DATE: 2002-06-13
; PRIOR APPLICATION NUMBER: US60/373,471
; PRIOR FILING DATE: 2002-04-18
; PRIOR APPLICATION NUMBER: US60/373,470
; PRIOR FILING DATE: 2002-04-18
; PRIOR APPLICATION NUMBER: US60/345,194
; PRIOR FILING DATE: 2002-10-19
; PRIOR APPLICATION NUMBER: GB0122724.8
; PRIOR FILING DATE: 2001-09-20
; PRIOR APPLICATION NUMBER: GB0114517.6
; PRIOR FILING DATE: 2001-06-14
; NUMBER OF SEQ ID NOS: 60
; SEQ ID NO 42
; LENGTH: 448
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Heavy chain of humanized antibody
US-10-353-708-42

Query Match      100.0%; Score 1765; DB 4; Length 448;
Best Local Similarity 100.0%; Pred. No. 2.1e-128;
Matches 330; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
DB 119 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 178

QY 61 GLYSSVVTVPPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPPCPAPELLAGA 120
DB 179 GLYSSVVTVPPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPPCPAPELLAGA 238

QY 121 PSVFLFPPKPKDITLMISRTPEVTCVVDVSHEDPEVKENWYVDGVEVHNAKTKPREEQYN 180
DB 239 PSVFLFPPKPKDITLMISRTPEVTCVVDVSHEDPEVKENWYVDGVEVHNAKTKPREEQYN 298

QY 181 STYRVSVSLTVLHODWLNAGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
DB 299 STYRVSVSLTVLHODWLNAGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 358

QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFPLYSKLTVDKSRW 300
DB 359 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFPLYSKLTVDKSRW 418

QY 301 QQGNVFSCSVMEALHNHYTOKSLSLSPGK 330
DB 419 QQGNVFSCSVMEALHNHYTOKSLSLSPGK 448
```

Db 119 ASTKGPSVFPLAPSSKSTGGTAAALGCLVKDYFPEPTVSMNSGALTSGVHTFPAVLQSS 178
Qy 61 GLYSLSVVTVPPSSSLGTQTYICNVNHPKSNTKVDKVEPKSCDKTHTCPPCPAPELAGA 120
Db 179 GLYSLSVVTVPPSSSLGTQTYICNVNHPKSNTKVDKVEPKSCDKTHTCPPCPAPELAGA 238
Qy 121 PSVFLFPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
Db 239 PSVFLFPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 298
Qy 181 STYRVSVLTVLHODWLNKGYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Db 299 STYRVSVLTVLHODWLNKGYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 358
Qy 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW 300
Db 359 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW 418
Qy 301 QQGNVFCVSMHEALHNHYTQKSLSLSPGK 330
Db 419 QQGNVFCVSMHEALHNHYTQKSLSLSPGK 448

RESULT 8

US-10-353-708-54
; Sequence 54, Application US/10353708
; Publication No. US20030219403A1
; GENERAL INFORMATION:
; APPLICANT: Frewin, Mark
; APPLICANT: Waldmann, Herman
; APPLICANT: Gorman, Scott
; APPLICANT: Hale, Geoff
; APPLICANT: Rao, Patricia
; APPLICANT: Kornaga, Tadeusz
; APPLICANT: Ringler, Douglas
; APPLICANT: Cobbold, Stephen
; APPLICANT: Winsor-Hines, Dawn
; TITLE OF INVENTION: Compositions and Methods of Tolerizing a Primate to an Antigen
; FILE REFERENCE: 695458-73
; CURRENT APPLICATION NUMBER: US/10/353,708
; CURRENT FILING DATE: 2003-01-29
; PRIOR APPLICATION NUMBER: US10/171,452
; PRIOR FILING DATE: 2002-06-13
; PRIOR APPLICATION NUMBER: US60/373,471
; PRIOR FILING DATE: 2002-04-18
; PRIOR APPLICATION NUMBER: US60/373,470
; PRIOR FILING DATE: 2002-04-18
; PRIOR APPLICATION NUMBER: US60/345,194
; PRIOR FILING DATE: 2002-10-19
; PRIOR APPLICATION NUMBER: GB0122724.8
; PRIOR FILING DATE: 2001-09-20
; PRIOR APPLICATION NUMBER: GB0114517.6
; PRIOR FILING DATE: 2001-06-14
; NUMBER OF SEQ ID NOS: 60
; SEQ ID NO 54
; LENGTH: 448
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Heavy chain of humanized antibody
US-10-353-708-54

Query Match 100.0%; Score 1765; DB 4; Length 448;
Best Local Similarity 100.0%; Pred. No. 2.1e-128;
Matches 330; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 ASTKGPSVFPLAPSSKSTGGTAAALGCLVKDYFPEPTVSMNSGALTSGVHTFPAVLQSS 60
Db 119 ASTKGPSVFPLAPSSKSTGGTAAALGCLVKDYFPEPTVSMNSGALTSGVHTFPAVLQSS 178
Qy 61 GLYSLSVVTVPPSSSLGTQTYICNVNHPKSNTKVDKVEPKSCDKTHTCPPCPAPELAGA 120

Db 179 GLYSLSVVTVPPSSSLGTQTYICNVNHPKSNTKVDKVEPKSCDKTHTCPPCPAPELAGA 238
Qy 121 PSVFLFPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
Db 239 PSVFLFPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 298
Qy 181 STYRVSVLTVLHODWLNKGYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Db 299 STYRVSVLTVLHODWLNKGYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 358
Qy 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW 300
Db 359 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW 418
Qy 301 QQGNVFCVSMHEALHNHYTQKSLSLSPGK 330
Db 419 QQGNVFCVSMHEALHNHYTQKSLSLSPGK 448

RESULT 9

US-10-731-984-8
; Sequence 8, Application US/10731984
; Publication No. US20040175381A1
; GENERAL INFORMATION:
; APPLICANT: WINDSOR-HINES, Dawn
; APPLICANT: RAO, Patricia
; APPLICANT: RINGLER, Douglas J.
; TITLE OF INVENTION: INDUCING TOLERANCE IN PRIMATES
; FILE REFERENCE: TLN-022
; CURRENT APPLICATION NUMBER: US/10/731,984
; CURRENT FILING DATE: 2003-12-09
; PRIOR APPLICATION NUMBER: 60/431839
; PRIOR FILING DATE: 2002-12-09
; NUMBER OF SEQ ID NOS: 70
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 448
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Chimeric Sequence
US-10-731-984-8

Query Match 100.0%; Score 1765; DB 4; Length 448;
Best Local Similarity 100.0%; Pred. No. 2.1e-128;
Matches 330; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 ASTKGPSVFPLAPSSKSTGGTAAALGCLVKDYFPEPTVSMNSGALTSGVHTFPAVLQSS 60
Db 119 ASTKGPSVFPLAPSSKSTGGTAAALGCLVKDYFPEPTVSMNSGALTSGVHTFPAVLQSS 178
Qy 61 GLYSLSVVTVPPSSSLGTQTYICNVNHPKSNTKVDKVEPKSCDKTHTCPPCPAPELAGA 120
Db 179 GLYSLSVVTVPPSSSLGTQTYICNVNHPKSNTKVDKVEPKSCDKTHTCPPCPAPELAGA 238
Qy 121 PSVFLFPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
Db 239 PSVFLFPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 298
Qy 181 STYRVSVLTVLHODWLNKGYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Db 299 STYRVSVLTVLHODWLNKGYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 358
Qy 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW 300
Db 359 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW 418
Qy 301 QQGNVFCVSMHEALHNHYTQKSLSLSPGK 330
Db 419 QQGNVFCVSMHEALHNHYTQKSLSLSPGK 448

RESULT 10

```
US-10-731-984-24
; Sequence 24, Application US/10731984
; Publication No. US20040175381A1
; GENERAL INFORMATION:
; APPLICANT: WINSOR-HINES, Dawn
; APPLICANT: RAO, Patricia
; APPLICANT: RINGLER, Douglas J.
; TITLE OF INVENTION: INDUCING TOLERANCE IN PRIMATES
; FILE REFERENCE: TLN-022
; CURRENT APPLICATION NUMBER: US/10/731,984
; CURRENT FILING DATE: 2003-12-09
; PRIOR APPLICATION NUMBER: 60/431839
; PRIOR FILING DATE: 2002-12-09
; NUMBER OF SEQ ID NOS: 70
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 24
; LENGTH: 448
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Chimeric Sequence
US-10-731-984-24

Query Match      100.0%; Score 1765; DB 4; Length 448;
Best Local Similarity 100.0%; Pred. No. 2.1e-128;
Matches 330; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSMNSGALTSGVHTFPAVLQSS 60
DB 119 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSMNSGALTSGVHTFPAVLQSS 178
QY 61 GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHHTCPCPAPELAGA 120
DB 179 GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHHTCPCPAPELAGA 238
QY 121 PSVFLFPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNATKPREEQYN 180
DB 239 PSVFLFPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNATKPREEQYN 298
QY 181 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVTLPPSRDE 240
DB 299 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVTLPPSRDE 358
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSPFLYSLKLTVDKSRW 300
DB 359 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSPFLYSLKLTVDKSRW 418
QY 301 OQGNVFCSCVMHEALHNNHYTKLSLSPGK 330
DB 419 OQGNVFCSCVMHEALHNNHYTKLSLSPGK 448

RESULT 11
US-11-158-505-8
; Sequence 8, Application US/11158505
; Publication No. US20060002921A1
; GENERAL INFORMATION:
; APPLICANT: WINSOR-HINES, Dawn
; APPLICANT: RAO, Patricia
; APPLICANT: RINGLER, Douglas J.
; APPLICANT: PONATH, PAUL
; TITLE OF INVENTION: OPTIMIZED DOSING OF ANTI-CD4 ANTIBODIES FOR TOLERANCE
; FILE REFERENCE: TLN-031
; CURRENT APPLICATION NUMBER: US/11/158,505
; CURRENT FILING DATE: 2005-06-21
; PRIOR APPLICATION NUMBER: 60/582,181
; PRIOR FILING DATE: 2004-06-22
; NUMBER OF SEQ ID NOS: 76
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 8
; LENGTH: 448
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: heavy chain construct
US-11-158-505-8

Query Match      100.0%; Score 1765; DB 6; Length 448;
Best Local Similarity 100.0%; Pred. No. 2.1e-128;
Matches 330; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSMNSGALTSGVHTFPAVLQSS 60
DB 119 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSMNSGALTSGVHTFPAVLQSS 178
QY 61 GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHHTCPCPAPELAGA 120
DB 179 GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHHTCPCPAPELAGA 238
```

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic TRX1
; OTHER INFORMATION: antibody heavy chain construct
US-11-158-505-8

Query Match      100.0%; Score 1765; DB 6; Length 448;
Best Local Similarity 100.0%; Pred. No. 2.1e-128;
Matches 330; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSMNSGALTSGVHTFPAVLQSS 60
DB 119 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSMNSGALTSGVHTFPAVLQSS 178
QY 61 GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHHTCPCPAPELAGA 120
DB 179 GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHHTCPCPAPELAGA 238
QY 121 PSVFLFPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNATKPREEQYN 180
DB 239 PSVFLFPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNATKPREEQYN 298
QY 181 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVTLPPSRDE 240
DB 299 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVTLPPSRDE 358
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSPFLYSLKLTVDKSRW 300
DB 359 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSPFLYSLKLTVDKSRW 418
QY 301 OQGNVFCSCVMHEALHNNHYTKLSLSPGK 330
DB 419 OQGNVFCSCVMHEALHNNHYTKLSLSPGK 448

RESULT 12
US-11-158-505-24
; Sequence 24, Application US/11158505
; Publication No. US20060002921A1
; GENERAL INFORMATION:
; APPLICANT: WINSOR-HINES, Dawn
; APPLICANT: RAO, Patricia
; APPLICANT: RINGLER, Douglas J.
; APPLICANT: PONATH, PAUL
; TITLE OF INVENTION: OPTIMIZED DOSING OF ANTI-CD4 ANTIBODIES FOR TOLERANCE
; FILE REFERENCE: TLN-031
; CURRENT APPLICATION NUMBER: US/11/158,505
; CURRENT FILING DATE: 2005-06-21
; PRIOR APPLICATION NUMBER: 60/582,181
; PRIOR FILING DATE: 2004-06-22
; NUMBER OF SEQ ID NOS: 76
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 24
; LENGTH: 448
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic TRX1
; OTHER INFORMATION: heavy chain construct
US-11-158-505-24

Query Match      100.0%; Score 1765; DB 6; Length 448;
Best Local Similarity 100.0%; Pred. No. 2.1e-128;
Matches 330; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSMNSGALTSGVHTFPAVLQSS 60
DB 119 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSMNSGALTSGVHTFPAVLQSS 178
QY 61 GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHHTCPCPAPELAGA 120
DB 179 GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHHTCPCPAPELAGA 238
```



```
; PRIOR FILING DATE: 2004-12-20
; PRIOR APPLICATION NUMBER: GB0329711.6
; PRIOR FILING DATE: 2003-12-22
; PRIOR APPLICATION NUMBER: GB0329684.5
; PRIOR FILING DATE: 2003-12-22
; NUMBER OF SEQ ID NOS: 113
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 27
; LENGTH: 462
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: 2A10 heavy chain humanised construct H6
US-11-177-648-27

Query Match      100.0%; Score 1765; DB 6; Length 462;
Best Local Similarity 100.0%; Pred. No. 2.2e-128;
Matches 330; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
Db 133 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 192
Qy 61 GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPCPAPELAGA 120
Db 193 GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPCPAPELAGA 252
Qy 121 PSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREEQYN 180
Db 253 PSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREEQYN 312
Qy 181 STYRVSVLTVLHQQDLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Db 313 STYRVSVLTVLHQQDLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 372
Qy 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
Db 373 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 432
Qy 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330
Db 433 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 462
```

```
RESULT 16
US-11-177-648-28
; Sequence 28, Application US/11177648
; Publication No. US20060029603A1
; GENERAL INFORMATION:
; APPLICANT: Jonathon Henry ELLIS
; APPLICANT: Paul Andrew HAMBLIN
; APPLICANT: Paul Alexander WILSON
; APPLICANT: Alan Peter LEWIS
; TITLE OF INVENTION: IMMUNOGLOBULINS
; FILE REFERENCE: PB60608-2
; CURRENT APPLICATION NUMBER: US/11/177,648
; PRIOR FILING DATE: 2005-07-06
; PRIOR APPLICATION NUMBER: PCT/GB2004/005325
; PRIOR FILING DATE: 2004-12-20
; PRIOR APPLICATION NUMBER: GB0329711.6
; PRIOR FILING DATE: 2003-12-22
; PRIOR APPLICATION NUMBER: GB0329684.5
; PRIOR FILING DATE: 2003-12-22
; NUMBER OF SEQ ID NOS: 113
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 28
; LENGTH: 462
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: 2A10 heavy chain humanised construct H700
US-11-177-648-28
```

```
Query Match      100.0%; Score 1765; DB 6; Length 462;
Best Local Similarity 100.0%; Pred. No. 2.2e-128;
Matches 330; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
Db 133 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 192
Qy 61 GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPCPAPELAGA 120
Db 193 GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPCPAPELAGA 252
Qy 121 PSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREEQYN 180
Db 253 PSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREEQYN 312
Qy 181 STYRVSVLTVLHQQDLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Db 313 STYRVSVLTVLHQQDLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 372
Qy 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
Db 373 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 432
Qy 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330
Db 433 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 462
```

```
RESULT 17
US-11-177-648-29
; Sequence 29, Application US/11177648
; Publication No. US20060029603A1
; GENERAL INFORMATION:
; APPLICANT: Jonathon Henry ELLIS
; APPLICANT: Paul Andrew HAMBLIN
; APPLICANT: Paul Alexander WILSON
; APPLICANT: Alan Peter LEWIS
; TITLE OF INVENTION: IMMUNOGLOBULINS
; FILE REFERENCE: PB60608-2
; CURRENT APPLICATION NUMBER: US/11/177,648
; CURRENT FILING DATE: 2005-07-06
; PRIOR APPLICATION NUMBER: PCT/GB2004/005325
; PRIOR FILING DATE: 2004-12-20
; PRIOR APPLICATION NUMBER: GB0329711.6
; PRIOR FILING DATE: 2003-12-22
; PRIOR APPLICATION NUMBER: GB0329684.5
; PRIOR FILING DATE: 2003-12-22
; NUMBER OF SEQ ID NOS: 113
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 29
; LENGTH: 462
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: 2A10 heavy chain humanised construct H14
US-11-177-648-29
```

```
Query Match      100.0%; Score 1765; DB 6; Length 462;
Best Local Similarity 100.0%; Pred. No. 2.2e-128;
Matches 330; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
Db 133 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 192
Qy 61 GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPCPAPELAGA 120
Db 193 GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPCPAPELAGA 252
Qy 121 PSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREEQYN 180
Db 253 PSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREEQYN 312
```



```
; PRIOR FILING DATE: 2003-12-22
; PRIOR APPLICATION NUMBER: GB0329684.5
; PRIOR FILING DATE: 2003-12-22
; NUMBER OF SEQ ID NOS: 113
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 32
; LENGTH: 462
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: 2A10 heavy chain humanised construct H17
US-11-177-648-32

Query Match          100.0%; Score 1765; DB 6; Length 462;
Best Local Similarity 100.0%; Pred. No. 2.2e-128;
Matches 330; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
DB 133 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 192
QY 61 GLYSLSVVTVPPSSSLGTQTYICNVNHPKSNKTKVDKKVEPKSCDKTHTCPPCPAPELAGA 120
DB 193 GLYSLSVVTVPPSSSLGTQTYICNVNHPKSNKTKVDKKVEPKSCDKTHTCPPCPAPELAGA 252
QY 121 PSVFLFPPKPKDITLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVVEHNAKTKPREEQYN 180
DB 253 PSVFLFPPKPKDITLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVVEHNAKTKPREEQYN 312
QY 181 STYRVSVSLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIISKAKGQPREPQVYITLPPSRDE 240
DB 313 STYRVSVSLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIISKAKGQPREPQVYITLPPSRDE 372
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSEFELYSLKLTVDKSRW 300
DB 373 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSEFELYSLKLTVDKSRW 432
QY 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330
DB 433 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 462

RESULT 21
US-11-177-648-33
; Sequence 33, Application US/11177648
; Publication No. US20060029603A1
; GENERAL INFORMATION:
; APPLICANT: Jonathon Henry ELLIS
; APPLICANT: Paul Andrew HAMBLIN
; APPLICANT: Alan Peter LEWIS
; TITLE OF INVENTION: IMMUNOGLOBULINS
; FILE REFERENCE: PB60608-2
; CURRENT APPLICATION NUMBER: US/11/177,648
; PRIOR FILING DATE: 2005-07-06
; PRIOR APPLICATION NUMBER: PCT/GB2004/005325
; PRIOR FILING DATE: 2004-12-20
; PRIOR APPLICATION NUMBER: GB0329711.6
; PRIOR FILING DATE: 2003-12-22
; PRIOR APPLICATION NUMBER: GB0329684.5
; PRIOR FILING DATE: 2003-12-22
; NUMBER OF SEQ ID NOS: 113
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 33
; LENGTH: 462
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: 2A10 heavy chain humanised construct H18
US-11-177-648-33

Query Match          100.0%; Score 1765; DB 6; Length 462;
Best Local Similarity 100.0%; Pred. No. 2.2e-128;
Matches 330; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
DB 133 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 192
QY 61 GLYSLSVVTVPPSSSLGTQTYICNVNHPKSNKTKVDKKVEPKSCDKTHTCPPCPAPELAGA 120
DB 193 GLYSLSVVTVPPSSSLGTQTYICNVNHPKSNKTKVDKKVEPKSCDKTHTCPPCPAPELAGA 252
QY 121 PSVFLFPPKPKDITLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVVEHNAKTKPREEQYN 180
DB 253 PSVFLFPPKPKDITLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVVEHNAKTKPREEQYN 312
QY 181 STYRVSVSLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIISKAKGQPREPQVYITLPPSRDE 240
DB 313 STYRVSVSLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIISKAKGQPREPQVYITLPPSRDE 372
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSEFELYSLKLTVDKSRW 300
DB 373 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSEFELYSLKLTVDKSRW 432
QY 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330
DB 433 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 462
```

```
Matches 330; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
DB 133 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 192
QY 61 GLYSLSVVTVPPSSSLGTQTYICNVNHPKSNKTKVDKKVEPKSCDKTHTCPPCPAPELAGA 120
DB 193 GLYSLSVVTVPPSSSLGTQTYICNVNHPKSNKTKVDKKVEPKSCDKTHTCPPCPAPELAGA 252
QY 121 PSVFLFPPKPKDITLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVVEHNAKTKPREEQYN 180
DB 253 PSVFLFPPKPKDITLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVVEHNAKTKPREEQYN 312
QY 181 STYRVSVSLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIISKAKGQPREPQVYITLPPSRDE 240
DB 313 STYRVSVSLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIISKAKGQPREPQVYITLPPSRDE 372
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSEFELYSLKLTVDKSRW 300
DB 373 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSEFELYSLKLTVDKSRW 432
QY 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330
DB 433 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 462

RESULT 22
US-11-177-648-79
; Sequence 79, Application US/11177648
; Publication No. US20060029603A1
; GENERAL INFORMATION:
; APPLICANT: Jonathon Henry ELLIS
; APPLICANT: Paul Andrew HAMBLIN
; APPLICANT: Alan Peter LEWIS
; TITLE OF INVENTION: IMMUNOGLOBULINS
; FILE REFERENCE: PB60608-2
; CURRENT APPLICATION NUMBER: US/11/177,648
; PRIOR FILING DATE: 2005-07-06
; PRIOR APPLICATION NUMBER: PCT/GB2004/005325
; PRIOR FILING DATE: 2004-12-20
; PRIOR APPLICATION NUMBER: GB0329711.6
; PRIOR FILING DATE: 2003-12-22
; PRIOR APPLICATION NUMBER: GB0329684.5
; PRIOR FILING DATE: 2003-12-22
; NUMBER OF SEQ ID NOS: 113
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 79
; LENGTH: 462
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: 2A10 heavy chain humanised construct H1
US-11-177-648-79

Query Match          100.0%; Score 1765; DB 6; Length 462;
Best Local Similarity 100.0%; Pred. No. 2.2e-128;
Matches 330; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
DB 133 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 192
QY 61 GLYSLSVVTVPPSSSLGTQTYICNVNHPKSNKTKVDKKVEPKSCDKTHTCPPCPAPELAGA 120
DB 193 GLYSLSVVTVPPSSSLGTQTYICNVNHPKSNKTKVDKKVEPKSCDKTHTCPPCPAPELAGA 252
QY 121 PSVFLFPPKPKDITLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVVEHNAKTKPREEQYN 180
DB 253 PSVFLFPPKPKDITLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVVEHNAKTKPREEQYN 312
QY 181 STYRVSVSLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIISKAKGQPREPQVYITLPPSRDE 240
```

```
Db 313 STYRVSVLTVLHQDLNGKCKVSNKALPAPIEKTISKAGOPREPQVYTLPPSRDE 372
QY 241 LTKNOVSLTCLVKGFYPSDIAVEWESNGOPENNYKTPPVLDSDGSFFLYSKLTVDKSRW 300
Db 373 LTKNQVSLTCLVKGFYPSDIAVEWESNGOPENNYKTPPVLDSDGSFFLYSKLTVDKSRW 432
QY 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330
Db 433 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 462

RESULT 23
US-11-177-648-92
; Sequence 92, Application US/11177648
; Publication No. US20060029603A1
; GENERAL INFORMATION:
; APPLICANT: Jonathon Henry ELLIS
; APPLICANT: Paul Andrew HAMBLIN
; APPLICANT: Paul Alexander WILSON
; APPLICANT: Alan Peter LEWIS
; TITLE OF INVENTION: IMMUNOGLOBULINS
; FILE REFERENCE: PB60608-2
; CURRENT FILING DATE: 2005-07-06
; PRIOR APPLICATION NUMBER: PCT/GB2004/005325
; PRIOR FILING DATE: 2004-12-20
; PRIOR APPLICATION NUMBER: GB0329711.6
; PRIOR FILING DATE: 2003-12-22
; PRIOR APPLICATION NUMBER: GB0329684.5
; PRIOR FILING DATE: 2003-12-22
; NUMBER OF SEQ ID NOS: 113
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 92
; LENGTH: 462
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: 2A10 heavy chain humanised construct H19
US-11-177-648-92

Query Match 100.0%; Score 1765; DB 6; Length 462;
Best Local Similarity 100.0%; Pred. No. 2.2e-128;
Matches 330; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSMNSGALTSGVHTFPAVLQSS 60
Db 133 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSMNSGALTSGVHTFPAVLQSS 192
QY 61 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELAGA 120
Db 193 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELAGA 252
QY 121 PSVFLPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 180
Db 253 PSVFLPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 312
QY 181 STYRVSVLTVLHQDLNGKCKVSNKALPAPIEKTISKAGOPREPQVYTLPPSRDE 240
Db 313 STYRVSVLTVLHQDLNGKCKVSNKALPAPIEKTISKAGOPREPQVYTLPPSRDE 372
QY 241 LTKNOVSLTCLVKGFYPSDIAVEWESNGOPENNYKTPPVLDSDGSFFLYSKLTVDKSRW 300
Db 373 LTKNQVSLTCLVKGFYPSDIAVEWESNGOPENNYKTPPVLDSDGSFFLYSKLTVDKSRW 432
QY 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330
Db 433 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 462

RESULT 24
US-11-177-648-93
; Sequence 93, Application US/11177648
```

```
; Publication No. US20060029603A1
; GENERAL INFORMATION:
; APPLICANT: Jonathon Henry ELLIS
; APPLICANT: Paul Andrew HAMBLIN
; APPLICANT: Paul Alexander WILSON
; APPLICANT: Alan Peter LEWIS
; TITLE OF INVENTION: IMMUNOGLOBULINS
; FILE REFERENCE: PB60608-2
; CURRENT FILING DATE: 2005-07-06
; PRIOR APPLICATION NUMBER: PCT/GB2004/005325
; PRIOR FILING DATE: 2004-12-20
; PRIOR APPLICATION NUMBER: GB0329711.6
; PRIOR FILING DATE: 2003-12-22
; PRIOR APPLICATION NUMBER: GB0329684.5
; PRIOR FILING DATE: 2003-12-22
; NUMBER OF SEQ ID NOS: 113
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 93
; LENGTH: 462
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: 2A10 heavy chain humanised construct H20
US-11-177-648-93

Query Match 100.0%; Score 1765; DB 6; Length 462;
Best Local Similarity 100.0%; Pred. No. 2.2e-128;
Matches 330; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSMNSGALTSGVHTFPAVLQSS 60
Db 133 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSMNSGALTSGVHTFPAVLQSS 192
QY 61 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELAGA 120
Db 193 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELAGA 252
QY 121 PSVFLPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 180
Db 253 PSVFLPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 312
QY 181 STYRVSVLTVLHQDLNGKCKVSNKALPAPIEKTISKAGOPREPQVYTLPPSRDE 240
Db 313 STYRVSVLTVLHQDLNGKCKVSNKALPAPIEKTISKAGOPREPQVYTLPPSRDE 372
QY 241 LTKNOVSLTCLVKGFYPSDIAVEWESNGOPENNYKTPPVLDSDGSFFLYSKLTVDKSRW 300
Db 373 LTKNQVSLTCLVKGFYPSDIAVEWESNGOPENNYKTPPVLDSDGSFFLYSKLTVDKSRW 432
QY 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330
Db 433 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 462

RESULT 25
US-11-177-648-94
; Sequence 94, Application US/11177648
; Publication No. US20060029603A1
; GENERAL INFORMATION:
; APPLICANT: Jonathon Henry ELLIS
; APPLICANT: Paul Andrew HAMBLIN
; APPLICANT: Paul Alexander WILSON
; APPLICANT: Alan Peter LEWIS
; TITLE OF INVENTION: IMMUNOGLOBULINS
; FILE REFERENCE: PB60608-2
; CURRENT FILING DATE: 2005-07-06
; PRIOR APPLICATION NUMBER: PCT/GB2004/005325
; PRIOR FILING DATE: 2004-12-20
; PRIOR APPLICATION NUMBER: GB0329711.6
; PRIOR FILING DATE: 2003-12-22
; PRIOR APPLICATION NUMBER: GB0329684.5
```

```
; PRIOR FILING DATE: 2003-12-22
; NUMBER OF SEQ ID NOS: 113
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 94
; LENGTH: 462
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: 2A10 heavy chain humanised construct H21
US-11-177-648-94

Query Match          100.0%; Score 1765; DB 6; Length 462;
Best Local Similarity 100.0%; Pred. No. 2.2e-128;
Matches 330; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVTSWNSGALTSGVHTFPAVLQSS 60
Db 133 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVTSWNSGALTSGVHTFPAVLQSS 192
QY 61 GLYSLSVVTVPPSSSLGTQTYICNVNHHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELAGA 120
Db 193 GLYSLSVVTVPPSSSLGTQTYICNVNHHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELAGA 252
QY 121 PSVFLFPPKPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPRREQYN 180
Db 253 PSVFLFPPKPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPRREQYN 312
QY 181 STYRVSVSLTVLHQDLNGKEYKCKVSNKALPAPIEKTISAKAGQPREPQVYITLPPSRDE 240
Db 313 STYRVSVSLTVLHQDLNGKEYKCKVSNKALPAPIEKTISAKAGQPREPQVYITLPPSRDE 372
QY 241 LTKQVSLTCLVKGFPYPSDIAVEWESNGQPENNYKTTPVLDSDGSFFLYSKLTVDKSRW 300
Db 373 LTKQVSLTCLVKGFPYPSDIAVEWESNGQPENNYKTTPVLDSDGSFFLYSKLTVDKSRW 432
QY 301 QQGNVFSCVMHEALHNNHYTKQSLSPGK 330
Db 433 QQGNVFSCVMHEALHNNHYTKQSLSPGK 462

RESULT 27
US-11-177-648-96
; Sequence 96, Application US/11177648
; Publication No. US20060029603A1
; GENERAL INFORMATION:
; APPLICANT: Jonathon Henry ELLIS
; APPLICANT: Paul Andrew HAMBLIN
; APPLICANT: Paul Alexander WILSON
; APPLICANT: Alan Peter LEWIS
; TITLE OF INVENTION: IMMUNOGLOBULINS
; FILE REFERENCE: PB60608-2
; CURRENT APPLICATION NUMBER: US/11/177,648
; CURRENT FILING DATE: 2005-07-06
; PRIOR APPLICATION NUMBER: PCT/GB2004/005325
; PRIOR FILING DATE: 2004-12-20
; PRIOR APPLICATION NUMBER: GB0329711.6
; PRIOR FILING DATE: 2003-12-22
; PRIOR APPLICATION NUMBER: GB0329684.5
; PRIOR FILING DATE: 2003-12-22
; NUMBER OF SEQ ID NOS: 113
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 96
; LENGTH: 462
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: 2A10 heavy chain humanised construct H23
US-11-177-648-96

Query Match          100.0%; Score 1765; DB 6; Length 462;
Best Local Similarity 100.0%; Pred. No. 2.2e-128;
Matches 330; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVTSWNSGALTSGVHTFPAVLQSS 60
Db 133 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVTSWNSGALTSGVHTFPAVLQSS 192
QY 61 GLYSLSVVTVPPSSSLGTQTYICNVNHHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELAGA 120
Db 193 GLYSLSVVTVPPSSSLGTQTYICNVNHHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELAGA 252
QY 121 PSVFLFPPKPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPRREQYN 180
Db 253 PSVFLFPPKPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPRREQYN 312
QY 181 STYRVSVSLTVLHQDLNGKEYKCKVSNKALPAPIEKTISAKAGQPREPQVYITLPPSRDE 240
Db 313 STYRVSVSLTVLHQDLNGKEYKCKVSNKALPAPIEKTISAKAGQPREPQVYITLPPSRDE 372
QY 241 LTKQVSLTCLVKGFPYPSDIAVEWESNGQPENNYKTTPVLDSDGSFFLYSKLTVDKSRW 300
Db 373 LTKQVSLTCLVKGFPYPSDIAVEWESNGQPENNYKTTPVLDSDGSFFLYSKLTVDKSRW 432
QY 301 QQGNVFSCVMHEALHNNHYTKQSLSPGK 330
Db 433 QQGNVFSCVMHEALHNNHYTKQSLSPGK 462

RESULT 26
US-11-177-648-95
; Sequence 95, Application US/11177648
; Publication No. US20060029603A1
; GENERAL INFORMATION:
; APPLICANT: Jonathon Henry ELLIS
; APPLICANT: Paul Andrew HAMBLIN
; APPLICANT: Paul Alexander WILSON
; APPLICANT: Alan Peter LEWIS
; TITLE OF INVENTION: IMMUNOGLOBULINS
; FILE REFERENCE: PB60608-2
; CURRENT APPLICATION NUMBER: US/11/177,648
; CURRENT FILING DATE: 2005-07-06
; PRIOR APPLICATION NUMBER: PCT/GB2004/005325
; PRIOR FILING DATE: 2004-12-20
; PRIOR APPLICATION NUMBER: GB0329711.6
; PRIOR FILING DATE: 2003-12-22
; PRIOR APPLICATION NUMBER: GB0329684.5
; PRIOR FILING DATE: 2003-12-22
; NUMBER OF SEQ ID NOS: 113
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 95
; LENGTH: 462
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: 2A10 heavy chain humanised construct H22
US-11-177-648-95

Query Match          100.0%; Score 1765; DB 6; Length 462;
Best Local Similarity 100.0%; Pred. No. 2.2e-128;
Matches 330; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW 300
Db 373 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW 432
QY 301 OQGNVFCSCVMHEALHNNHYTKSLSPGK 330
Db 433 OQGNVFCSCVMHEALHNNHYTKSLSPGK 462

RESULT 28
US-11-177-648-97
; Sequence 97, Application US/11177648
; Publication No. US20060029603A1
; GENERAL INFORMATION:
; APPLICANT: Jonathon Henry ELLIS
; APPLICANT: Paul Andrew HAMBLIN
; APPLICANT: Alan Peter LEWIS
; TITLE OF INVENTION: IMMUNOGLOBULINS
; FILE REFERENCE: PB60608-2
; CURRENT APPLICATION NUMBER: US/11/177,648
; CURRENT FILING DATE: 2005-07-06
; PRIOR APPLICATION NUMBER: PCT/GB2004/005325
; PRIOR FILING DATE: 2004-12-20
; PRIOR APPLICATION NUMBER: GB0329711.6
; PRIOR FILING DATE: 2003-12-22
; PRIOR APPLICATION NUMBER: GB0329684.5
; PRIOR FILING DATE: 2003-12-22
; NUMBER OF SEQ ID NOS: 113
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 97
; LENGTH: 462
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: 2A10 heavy chain humanised construct H24
US-11-177-648-97

Query Match 100.0%; Score 1765; DB 6; Length 462;
Best Local Similarity 100.0%; Pred. No. 2.2e-128;
Matches 330; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
Db 133 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 192
QY 61 GLYSLSSVTVFPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPCPAPELAGA 120
Db 193 GLYSLSSVTVFPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPCPAPELAGA 252
QY 121 PSVFLFPPPKPDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
Db 253 PSVFLFPPPKPDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 312
QY 181 STYRVSVSLTVLHQDLNKGKEYKCKVSKNKAALPAIEKTIISKAKGQPREPQVYTLPPSRDE 240
Db 313 STYRVSVSLTVLHQDLNKGKEYKCKVSKNKAALPAIEKTIISKAKGQPREPQVYTLPPSRDE 372
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW 300
Db 373 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW 432
QY 301 OQGNVFCSCVMHEALHNNHYTKSLSPGK 330
Db 433 OQGNVFCSCVMHEALHNNHYTKSLSPGK 462

RESULT 29
US-11-177-648-98
; Sequence 98, Application US/11177648
; Publication No. US20060029603A1
; GENERAL INFORMATION:
; APPLICANT: Jonathon Henry ELLIS
; APPLICANT: Paul Andrew HAMBLIN
; APPLICANT: Alan Peter LEWIS
; TITLE OF INVENTION: IMMUNOGLOBULINS
; FILE REFERENCE: PB60608-2
; CURRENT APPLICATION NUMBER: US/11/177,648
; CURRENT FILING DATE: 2005-07-06
; PRIOR APPLICATION NUMBER: PCT/GB2004/005325
; PRIOR FILING DATE: 2004-12-20
; PRIOR APPLICATION NUMBER: GB0329711.6
; PRIOR FILING DATE: 2003-12-22
; PRIOR APPLICATION NUMBER: GB0329684.5
; PRIOR FILING DATE: 2003-12-22
; NUMBER OF SEQ ID NOS: 113
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 98
; LENGTH: 462
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: 2A10 heavy chain humanised construct H25
US-11-177-648-98

Query Match 100.0%; Score 1765; DB 6; Length 462;
Best Local Similarity 100.0%; Pred. No. 2.2e-128;
Matches 330; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
Db 133 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 192
QY 61 GLYSLSSVTVFPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPCPAPELAGA 120
Db 193 GLYSLSSVTVFPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPCPAPELAGA 252
QY 121 PSVFLFPPPKPDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
Db 253 PSVFLFPPPKPDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 312
QY 181 STYRVSVSLTVLHQDLNKGKEYKCKVSKNKAALPAIEKTIISKAKGQPREPQVYTLPPSRDE 240
Db 313 STYRVSVSLTVLHQDLNKGKEYKCKVSKNKAALPAIEKTIISKAKGQPREPQVYTLPPSRDE 372
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW 300
Db 373 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW 432
QY 301 OQGNVFCSCVMHEALHNNHYTKSLSPGK 330
Db 433 OQGNVFCSCVMHEALHNNHYTKSLSPGK 462

RESULT 30
US-10-171-452A-53
; Sequence 53, Application US/10171452A
; Publication No. US20030108518A1
; GENERAL INFORMATION:
; APPLICANT: Frewin, Mark
; APPLICANT: Waldmann, Herman
; APPLICANT: Gorman, Scott
; APPLICANT: Hale, Geoff
; APPLICANT: Rao, Patricia
; APPLICANT: Kornaga, Tadeusz
; APPLICANT: Ringler, Douglas
; APPLICANT: Cobbold, Stephen
; APPLICANT: Winsor-Hines, Dawn
; TITLE OF INVENTION: TRX1 Antibody and Uses Therefor
; FILE REFERENCE: 695458-59
; CURRENT APPLICATION NUMBER: US/10/171,452A
; CURRENT FILING DATE: 2003-02-10
; PRIOR APPLICATION NUMBER: US60/373,471
; PRIOR FILING DATE: 2002-04-18
```

```
; PRIOR APPLICATION NUMBER: US60/373,470
; PRIOR FILING DATE: 2002-04-18
; PRIOR APPLICATION NUMBER: US60/345,194
; PRIOR FILING DATE: 2002-10-19
; PRIOR APPLICATION NUMBER: GB0122724.8
; PRIOR FILING DATE: 2001-09-20
; PRIOR APPLICATION NUMBER: GB0114517.6
; PRIOR FILING DATE: 2001-06-14
; NUMBER OF SEQ ID NOS: 60
; LENGTH: 467
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Heavy chain of humanized antibody
US-10-171-452A-53

Query Match      100.0%; Score 1765; DB 4; Length 467;
Best Local Similarity 100.0%; Pred. No. 2.2e-128;
Matches 330; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSS 60
Db 138 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSS 197

Qy 61 GLYSLSSVTVVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHCTCPCPAPELAGA 120
Db 198 GLYSLSSVTVVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHCTCPCPAPELAGA 257

Qy 121 PSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREEOYN 180
Db 258 PSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREEOYN 317

Qy 181 STYRVSVSLTVLHQDLNKGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Db 318 STYRVSVSLTVLHQDLNKGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 377

Qy 241 LTKQVSLTCLVKGFYPSDIAVEHESNGQPENNYKTTTPVLDSDGSFPLYSKLTVDKSRW 300
Db 378 LTKQVSLTCLVKGFYPSDIAVEHESNGQPENNYKTTTPVLDSDGSFPLYSKLTVDKSRW 437

Qy 301 QQGNVFCSVMHEALHNHYTOKSLSLSPGK 330
Db 438 QQGNVFCSVMHEALHNHYTOKSLSLSPGK 467

RESULT 31
US-10-353-708-53
; Sequence 53, Application US/10353708
; Publication No. US20030219403A1
; GENERAL INFORMATION:
; APPLICANT: Frewin, Mark
; APPLICANT: Waldmann, Herman
; APPLICANT: Gorman, Scott
; APPLICANT: Hale, Geoff
; APPLICANT: Rao, Patricia
; APPLICANT: Kornaga, Jadeusz
; APPLICANT: Ringler, Douglas
; APPLICANT: Cobbold, Stephen
; APPLICANT: Winsor-Hines, Dawn
; TITLE OF INVENTION: Compositions and Methods of Tolerizing a Primate to an Antigen
; FILE REFERENCE: 695458-73
; CURRENT APPLICATION NUMBER: US/10/353,708
; PRIOR FILING DATE: 2003-01-29
; PRIOR APPLICATION NUMBER: US10/171,452
; PRIOR FILING DATE: 2002-06-13
; PRIOR APPLICATION NUMBER: US60/373,471
; PRIOR FILING DATE: 2002-04-18
; PRIOR APPLICATION NUMBER: US60/373,470
; PRIOR FILING DATE: 2002-04-18
; PRIOR APPLICATION NUMBER: US60/345,194
; PRIOR FILING DATE: 2002-10-19
; PRIOR APPLICATION NUMBER: GB0122724.8
```

```
; PRIOR FILING DATE: 2001-09-20
; PRIOR APPLICATION NUMBER: GB0114517.6
; PRIOR FILING DATE: 2001-06-14
; NUMBER OF SEQ ID NOS: 60
; SEQ ID NO 53
; LENGTH: 467
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Heavy chain of humanized antibody
US-10-353-708-53

Query Match      100.0%; Score 1765; DB 4; Length 467;
Best Local Similarity 100.0%; Pred. No. 2.2e-128;
Matches 330; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSS 60
Db 138 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSS 197

Qy 61 GLYSLSSVTVVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHCTCPCPAPELAGA 120
Db 198 GLYSLSSVTVVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHCTCPCPAPELAGA 257

Qy 121 PSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREEOYN 180
Db 258 PSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREEOYN 317

Qy 181 STYRVSVSLTVLHQDLNKGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Db 318 STYRVSVSLTVLHQDLNKGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 377

Qy 241 LTKQVSLTCLVKGFYPSDIAVEHESNGQPENNYKTTTPVLDSDGSFPLYSKLTVDKSRW 300
Db 378 LTKQVSLTCLVKGFYPSDIAVEHESNGQPENNYKTTTPVLDSDGSFPLYSKLTVDKSRW 437

Qy 301 QQGNVFCSVMHEALHNHYTOKSLSLSPGK 330
Db 438 QQGNVFCSVMHEALHNHYTOKSLSLSPGK 467

RESULT 32
US-10-731-984-7
; Sequence 7, Application US/10731984
; Publication No. US20040175381A1
; GENERAL INFORMATION:
; APPLICANT: WINDSOR-HINES, Dawn
; APPLICANT: RAO, Patricia
; APPLICANT: RINGLER, Douglas J.
; TITLE OF INVENTION: INDUCING TOLERANCE IN PRIMATES
; FILE REFERENCE: TLN-022
; CURRENT APPLICATION NUMBER: US/10/731,984
; CURRENT FILING DATE: 2003-12-09
; PRIOR APPLICATION NUMBER: 60/431839
; PRIOR FILING DATE: 2002-12-09
; NUMBER OF SEQ ID NOS: 70
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 7
; LENGTH: 467
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Chimeric Sequence
US-10-731-984-7

Query Match      100.0%; Score 1765; DB 4; Length 467;
Best Local Similarity 100.0%; Pred. No. 2.2e-128;
Matches 330; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSS 60
Db 138 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSS 197
```

```
QY 61 GLYSLSVVTVFPSSSLGTQTYICNVNHPKSNKVDKVEPKSCDKTHHTCPPCPAPELAGA 120
Db 198 GLYSLSVVTVFPSSSLGTQTYICNVNHPKSNKVDKVEPKSCDKTHHTCPPCPAPELAGA 257
QY 121 PSVFLFPKPKDQTLMSRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
Db 258 PSVFLFPKPKDQTLMSRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 317
QY 181 STYRVSVVLTVLHQDLNKGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Db 318 STYRVSVVLTVLHQDLNKGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 377
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300
Db 378 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 437
QY 301 QQGNVFCSCVMHEALHNNHYTKQSLSPGK 330
Db 438 QQGNVFCSCVMHEALHNNHYTKQSLSPGK 467

RESULT 33
US-10-731-984-23
; Sequence 23, Application US/107311984
; Publication No. US20040175381A1
; GENERAL INFORMATION:
; APPLICANT: WINDSOR-HINES, Dawn
; APPLICANT: RAO, Patricia
; APPLICANT: RINGLER, Douglas J.
; TITLE OF INVENTION: INDUCING TOLERANCE IN PRIMATES
; FILE REFERENCE: TLN-022
; CURRENT APPLICATION NUMBER: US/10/731,984
; CURRENT FILING DATE: 2003-12-09
; PRIOR APPLICATION NUMBER: 60/431839
; PRIOR FILING DATE: 2002-12-09
; NUMBER OF SEQ ID NOS: 70
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 467
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Chimeric Sequence
US-10-731-984-23

Query Match 100.0%; Score 1765; DB 4; Length 467;
Best Local Similarity 100.0%; Pred. No. 2.2e-128; Mismatches 0; Indels 0; Gaps 0;
Matches 330; Conservative 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVMNSGALTSGVHTFPAVLQSS 60
Db 138 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVMNSGALTSGVHTFPAVLQSS 197
QY 61 GLYSLSVVTVFPSSSLGTQTYICNVNHPKSNKVDKVEPKSCDKTHHTCPPCPAPELAGA 120
Db 198 GLYSLSVVTVFPSSSLGTQTYICNVNHPKSNKVDKVEPKSCDKTHHTCPPCPAPELAGA 257
QY 121 PSVFLFPKPKDQTLMSRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
Db 258 PSVFLFPKPKDQTLMSRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 317
QY 181 STYRVSVVLTVLHQDLNKGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Db 318 STYRVSVVLTVLHQDLNKGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 377
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300
Db 378 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 437
QY 301 QQGNVFCSCVMHEALHNNHYTKQSLSPGK 330
Db 438 QQGNVFCSCVMHEALHNNHYTKQSLSPGK 467
```

```
RESULT 34
US-11-158-505-5
; Sequence 5, Application US/11158505
; Publication No. US20060002921A1
; GENERAL INFORMATION:
; APPLICANT: WINSOR-HINES, DAWN
; APPLICANT: RAO, PATRICIA
; APPLICANT: RINGLER, DOUGLAS J
; APPLICANT: PONATH, PAUL
; TITLE OF INVENTION: OPTIMIZED DOSING OF ANTI-CD4 ANTIBODIES FOR TOLERANCE
; TITLE OF INVENTION: INDUCTION IN PRIMATES
; FILE REFERENCE: TLN-031
; CURRENT APPLICATION NUMBER: US/11/158,505
; CURRENT FILING DATE: 2005-06-21
; PRIOR APPLICATION NUMBER: 60/582,181
; PRIOR FILING DATE: 2004-06-22
; NUMBER OF SEQ ID NOS: 76
; SOFTWARE: Patent in Ver. 3.3
; SEQ ID NO 5
; LENGTH: 467
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic TRX1
; OTHER INFORMATION: antibody heavy chain construct
US-11-158-505-5

Query Match 100.0%; Score 1765; DB 6; Length 467;
Best Local Similarity 100.0%; Pred. No. 2.2e-128; Mismatches 0; Indels 0; Gaps 0;
Matches 330; Conservative 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVMNSGALTSGVHTFPAVLQSS 60
Db 138 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVMNSGALTSGVHTFPAVLQSS 197
QY 61 GLYSLSVVTVFPSSSLGTQTYICNVNHPKSNKVDKVEPKSCDKTHHTCPPCPAPELAGA 120
Db 198 GLYSLSVVTVFPSSSLGTQTYICNVNHPKSNKVDKVEPKSCDKTHHTCPPCPAPELAGA 257
QY 121 PSVFLFPKPKDQTLMSRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
Db 258 PSVFLFPKPKDQTLMSRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 317
QY 181 STYRVSVVLTVLHQDLNKGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Db 318 STYRVSVVLTVLHQDLNKGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 377
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300
Db 378 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 437
QY 301 QQGNVFCSCVMHEALHNNHYTKQSLSPGK 330
Db 438 QQGNVFCSCVMHEALHNNHYTKQSLSPGK 467

RESULT 35
US-11-158-505-7
; Sequence 7, Application US/11158505
; Publication No. US20060002921A1
; GENERAL INFORMATION:
; APPLICANT: WINSOR-HINES, DAWN
; APPLICANT: RAO, PATRICIA
; APPLICANT: RINGLER, DOUGLAS J
; APPLICANT: PONATH, PAUL
; TITLE OF INVENTION: OPTIMIZED DOSING OF ANTI-CD4 ANTIBODIES FOR TOLERANCE
; TITLE OF INVENTION: INDUCTION IN PRIMATES
; FILE REFERENCE: TLN-031
; CURRENT APPLICATION NUMBER: US/11/158,505
; CURRENT FILING DATE: 2005-06-21
; PRIOR APPLICATION NUMBER: 60/582,181
; PRIOR FILING DATE: 2004-06-22
```



```

; NUMBER OF SEQ ID NOS: 76
; SOFTWARE: PatentIn ver. 3.3
; SEQ ID NO 7
; LENGTH: 467
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic TRX1
; OTHER INFORMATION: antibody heavy chain construct
US-11-158-505-7

Query Match          100.0%; Score 1765; DB 6; Length 467;
Best Local Similarity 100.0%; Pred. No. 2.2e-128;
Matches 330; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ASTKGPVFFPLAPSKSTSGTAAALGCLVKDYFPEPVTVSNWNSGALTSGVHTFPAVLQSS 60
    |||||
Db 138 ASTKGPVFFPLAPSKSTSGTAAALGCLVKDYFPEPVTVSNWNSGALTSGVHTFPAVLQSS 197
    |||||

Qy 61 GLYSLSVVTVSPSSSLGTQTVICNVNHKPSNTKVDKVEPKSCDKHTHTCPPCPAPELAGA 120
    |||||
Db 198 GLYSLSVVTVSPSSSLGTQTVICNVNHKPSNTKVDKVEPKSCDKHTHTCPPCPAPELAGA 257
    |||||

Qy 121 PSVFLFPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREPQYN 180
    |||||
Db 258 PSVFLFPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREPQYN 317
    |||||

Qy 181 STYRWVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYITLPPSRDE 240
    |||||
Db 318 STYRWVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYITLPPSRDE 377
    |||||

Qy 241 LTKNOVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW 300
    |||||
Db 378 LTKNOVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW 437
    |||||

Qy 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330
    |||||
Db 438 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 467
    |||||

RESULT 36
US-11-158-505-21
; Sequence 21, Application US/11158505
; Publication No. US20060002921A1
; GENERAL INFORMATION:
; APPLICANT: WINSOR-HINES, DAWN
; APPLICANT: RAO, PATRICIA
; APPLICANT: RINGLER, DOUGLAS J
; APPLICANT: PONATH, PAUL
; TITLE OF INVENTION: OPTIMIZED DOSING OF ANTI-CD4 ANTIBODIES FOR TOLERANCE
; TITLE OF INVENTION: INDUCTION IN PRIMATES
; FILE REFERENCE: TLN-031
; CURRENT APPLICATION NUMBER: US/11/158,505
; CURRENT FILING DATE: 2005-06-21
; PRIOR APPLICATION NUMBER: 60/582,181
; PRIOR FILING DATE: 2004-06-22
; NUMBER OF SEQ ID NOS: 76
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 21
; LENGTH: 467
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic TRX1
; OTHER INFORMATION: heavy chain construct
US-11-158-505-21

Query Match          100.0%; Score 1765; DB 6; Length 467;
Best Local Similarity 100.0%; Pred. No. 2.2e-128;
Matches 330; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ASTKGPVFFPLAPSKSTSGTAAALGCLVKDYFPEPVTVSNWNSGALTSGVHTFPAVLQSS 60
    |||||

```



```
Db 61 GLYSLSSVVTVFPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCCPCPAPPELLGG 120
Qy 121 PSVFLFPPKPKDTLMSRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
Db 121 PSVFLFPPKPKDTLMSRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
Qy 181 STYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPPQVYITLPPSRDE 240
Db 181 STYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPPQVYITLPPSRDE 240
Qy 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300
Db 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300
Qy 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330
Db 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330

RESULT 41
US-09-892-949-38
; Sequence 38, Application US/09892949
; Publication No. US20030096339A1
; GENERAL INFORMATION:
; APPLICANT: Sprecher, Cindy A.
; APPLICANT: Presnell, Scott R.
; APPLICANT: Gao, Zeren
; APPLICANT: Whitmore, Theodore E.
; APPLICANT: Kuijper, Joseph L.
; APPLICANT: Maurer, Mark F.
; TITLE OF INVENTION: CYTOKINE RECEPTOR ZCYTOR17
; FILE REFERENCE: 00-42
; CURRENT APPLICATION NUMBER: US/09/892,949
; CURRENT FILING DATE: 2001-06-26
; PRIOR APPLICATION NUMBER: US 60/214,282
; PRIOR FILING DATE: 2000-06-26
; PRIOR APPLICATION NUMBER: US 60/214,955
; PRIOR FILING DATE: 2000-06-29
; PRIOR APPLICATION NUMBER: US 60/267,963
; PRIOR FILING DATE: 2001-08-02
; NUMBER OF SEQ ID NOS: 93
; SOFTWARE: FaastSeq for Windows Version 3.0
; SEQ ID NO 38
; LENGTH: 330
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-892-949-38

Query Match 99.5%; Score 1756; DB 3; Length 330;
Best Local Similarity 99.4%; Pred. No. 7.1e-128;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
Db 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
Qy 61 GLYSLSSVVTVFPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCCPCPAPELAGA 120
Db 61 GLYSLSSVVTVFPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCCPCPAPELGG 120
Qy 121 PSVFLFPPKPKDTLMSRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
Db 121 PSVFLFPPKPKDTLMSRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
Qy 181 STYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPPQVYITLPPSRDE 240
Db 181 STYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPPQVYITLPPSRDE 240
Qy 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300
Db 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300
Qy 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330
Db 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330

RESULT 42
US-10-047-542-20
; Sequence 20, Application US/10047542
; Publication No. US20020168367A1
; GENERAL INFORMATION:
; APPLICANT: LARRICK, JAMES W.
; APPLICANT: WYCOFF, KEITH L.
; TITLE OF INVENTION: NOVEL IMMUNOADHESINS FOR TREATING AND PREVENTING VIRAL
; TITLE OF INVENTION: AND BACTERIAL DISEASES
; FILE REFERENCE: 030905.0004.C1P1
; CURRENT APPLICATION NUMBER: US/10/047,542
; CURRENT FILING DATE: 2001-10-26
; PRIOR APPLICATION NUMBER: PCT/US01/13932
; PRIOR FILING DATE: 2001-04-28
; PRIOR APPLICATION NUMBER: 60/200,298
; PRIOR FILING DATE: 2000-04-28
; NUMBER OF SEQ ID NOS: 101
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 20
; LENGTH: 330
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-047-542-20

Query Match 99.5%; Score 1756; DB 4; Length 330;
Best Local Similarity 99.4%; Pred. No. 7.1e-128;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
Db 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
Qy 61 GLYSLSSVVTVFPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCCPCPAPELAGA 120
Db 61 GLYSLSSVVTVFPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCCPCPAPELGG 120
Qy 121 PSVFLFPPKPKDTLMSRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
Db 121 PSVFLFPPKPKDTLMSRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
Qy 181 STYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPPQVYITLPPSRDE 240
Db 181 STYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPPQVYITLPPSRDE 240
Qy 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300
Db 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300
Qy 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330
Db 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330

RESULT 43
US-10-269-805-68
; Sequence 68, Application US/10269805
; Publication No. US20030124129A1
; GENERAL INFORMATION:
; APPLICANT: OLINER, JONATHAN D.
; TITLE OF INVENTION: ANGIOPOETIN-2 SPECIFIC BINDING AGENTS
; FILE REFERENCE: A-722
; CURRENT APPLICATION NUMBER: US/10/269,805
; CURRENT FILING DATE: 2002-10-10
; PRIOR APPLICATION NUMBER: US 60/328,604
; PRIOR FILING DATE: 2001-10-11
; NUMBER OF SEQ ID NOS: 76
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 68
; LENGTH: 330
```

```
Db 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330
Qy 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330

RESULT 42
US-10-047-542-20
; Sequence 20, Application US/10047542
; Publication No. US20020168367A1
; GENERAL INFORMATION:
; APPLICANT: LARRICK, JAMES W.
; APPLICANT: WYCOFF, KEITH L.
; TITLE OF INVENTION: NOVEL IMMUNOADHESINS FOR TREATING AND PREVENTING VIRAL
; TITLE OF INVENTION: AND BACTERIAL DISEASES
; FILE REFERENCE: 030905.0004.C1P1
; CURRENT APPLICATION NUMBER: US/10/047,542
; CURRENT FILING DATE: 2001-10-26
; PRIOR APPLICATION NUMBER: PCT/US01/13932
; PRIOR FILING DATE: 2001-04-28
; PRIOR APPLICATION NUMBER: 60/200,298
; PRIOR FILING DATE: 2000-04-28
; NUMBER OF SEQ ID NOS: 101
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 20
; LENGTH: 330
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-047-542-20

Query Match 99.5%; Score 1756; DB 4; Length 330;
Best Local Similarity 99.4%; Pred. No. 7.1e-128;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
Db 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
Qy 61 GLYSLSSVVTVFPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCCPCPAPELAGA 120
Db 61 GLYSLSSVVTVFPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCCPCPAPELGG 120
Qy 121 PSVFLFPPKPKDTLMSRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
Db 121 PSVFLFPPKPKDTLMSRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
Qy 181 STYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPPQVYITLPPSRDE 240
Db 181 STYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPPQVYITLPPSRDE 240
Qy 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300
Db 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300
Qy 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330
Db 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330

RESULT 43
US-10-269-805-68
; Sequence 68, Application US/10269805
; Publication No. US20030124129A1
; GENERAL INFORMATION:
; APPLICANT: OLINER, JONATHAN D.
; TITLE OF INVENTION: ANGIOPOETIN-2 SPECIFIC BINDING AGENTS
; FILE REFERENCE: A-722
; CURRENT APPLICATION NUMBER: US/10/269,805
; CURRENT FILING DATE: 2002-10-10
; PRIOR APPLICATION NUMBER: US 60/328,604
; PRIOR FILING DATE: 2001-10-11
; NUMBER OF SEQ ID NOS: 76
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 68
; LENGTH: 330
```

```
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-269-805-68

Query Match          99.5%; Score 1756; DB 4; Length 330;
Best Local Similarity 99.4%; Pred. No. 7,1e-128;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
DB 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
QY 61 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPPCPAPELAGA 120
DB 61 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPPCPAPELAGG 120
QY 121 PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
DB 121 PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
QY 181 STYRVSVSLTVLHQDLNKGKEYKCKVSNKALPAPIEKTIISKAKGQPREPQVYVTLPPSRDE 240
DB 181 STYRVSVSLTVLHQDLNKGKEYKCKVSNKALPAPIEKTIISKAKGQPREPQVYVTLPPSRDE 240
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
DB 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
QY 301 OQGNVFCSCVMHEALHNYHTOKSLSLSPGK 330
DB 301 OQGNVFCSCVMHEALHNYHTOKSLSLSPGK 330

RESULT 44
US-10-310-719-8
; Sequence 8, Application US/10310719
; Publication No. US20030166163A1
; GENERAL INFORMATION:
; APPLICANT: Gillies, Stephen
; TITLE OF INVENTION: Immunocytokines With Modulated Selectivity
; FILE REFERENCE: LEX-020
; CURRENT APPLICATION NUMBER: US/10/310,719
; PRIOR FILING DATE: 2002-12-04
; PRIOR APPLICATION NUMBER: 60/337,113
; PRIOR FILING DATE: 2001-12-04
; PRIOR APPLICATION NUMBER: 60/371,966
; PRIOR FILING DATE: 2002-04-12
; NUMBER OF SEQ ID NOS: 37
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 8
; LENGTH: 330
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc
; LOCATION: (1)..(330)
; OTHER INFORMATION: Igg1 constant region
US-10-310-719-8

Query Match          99.5%; Score 1756; DB 4; Length 330;
Best Local Similarity 99.4%; Pred. No. 7,1e-128;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
DB 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
QY 61 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPPCPAPELAGA 120
DB 61 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPPCPAPELAGG 120
QY 121 PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
DB 121 PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180

; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-269-805-68

Query Match          99.5%; Score 1756; DB 4; Length 330;
Best Local Similarity 99.4%; Pred. No. 7,1e-128;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 121 PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
DB 121 PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
QY 181 STYRVSVSLTVLHQDLNKGKEYKCKVSNKALPAPIEKTIISKAKGQPREPQVYVTLPPSRDE 240
DB 181 STYRVSVSLTVLHQDLNKGKEYKCKVSNKALPAPIEKTIISKAKGQPREPQVYVTLPPSRDE 240
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
DB 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
QY 301 OQGNVFCSCVMHEALHNYHTOKSLSLSPGK 330
DB 301 OQGNVFCSCVMHEALHNYHTOKSLSLSPGK 330

RESULT 45
US-10-112-582-1
; Sequence 1, Application US/10112582
; Publication No. US20030166877A1
; GENERAL INFORMATION:
; APPLICANT: Gillies, Stephen
; TITLE OF INVENTION: Reducing the Immunogenicity of Fusion Proteins
; FILE REFERENCE: LEX-017
; CURRENT APPLICATION NUMBER: US/10/112,582
; PRIOR FILING DATE: 2002-03-29
; PRIOR APPLICATION NUMBER: US 60/280,625
; PRIOR FILING DATE: 2001-03-30
; NUMBER OF SEQ ID NOS: 59
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1
; LENGTH: 330
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc feature
; OTHER INFORMATION: human Ig gamma heavy chain C region
US-10-112-582-1

Query Match          99.5%; Score 1756; DB 4; Length 330;
Best Local Similarity 99.4%; Pred. No. 7,1e-128;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
DB 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
QY 61 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPPCPAPELAGA 120
DB 61 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPPCPAPELAGG 120
QY 121 PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
DB 121 PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
QY 181 STYRVSVSLTVLHQDLNKGKEYKCKVSNKALPAPIEKTIISKAKGQPREPQVYVTLPPSRDE 240
DB 181 STYRVSVSLTVLHQDLNKGKEYKCKVSNKALPAPIEKTIISKAKGQPREPQVYVTLPPSRDE 240
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
DB 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
QY 301 OQGNVFCSCVMHEALHNYHTOKSLSLSPGK 330
DB 301 OQGNVFCSCVMHEALHNYHTOKSLSLSPGK 330

RESULT 46
US-10-320-231A-81
; Sequence 81, Application US/10320231A
; Publication No. US20030194405A1
; GENERAL INFORMATION:
; APPLICANT: Neben, Steven
```

```
; APPLICANT: Takeuchi, Toshihiko
; APPLICANT: Tomkinson, Adrian
; TITLE OF INVENTION: Antibody Inhibiting Stem Cell Factor Activity And Use For
; FILE REFERENCE: 7430*163
; CURRENT APPLICATION NUMBER: US/10/320,231A
; CURRENT FILING DATE: 2002-12-19
; PRIOR APPLICATION NUMBER: US 60/342,174
; PRIOR FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 85
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 81
; LENGTH: 330
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-320-231A-81

Query Match      99.5%; Score 1756; DB 4; Length 330;
Best Local Similarity 99.4%; Pred. No. 7,1e-128;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTWNSGALTSVHTFPAVLQSS 60
Db |||||
Qy 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTWNSGALTSVHTFPAVLQSS 60
Db |||||
Qy 61 GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPCPAPELAGA 120
Db |||||
Qy 61 GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPCPAPELGG 120
Db |||||
Qy 121 PSVFLFPPKPKDPTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREEQYN 180
Db |||||
Qy 121 PSVFLFPPKPKDPTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREEQYN 180
Db |||||
Qy 181 STYRVSVSLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Db |||||
Qy 181 STYRVSVSLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Db |||||
Qy 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFPLYSKLTVDKSRW 300
Db |||||
Qy 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFPLYSKLTVDKSRW 300
Db |||||
Qy 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330
Db |||||
Qy 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330
Db |||||

RESULT 47
US-10-383-902A-6
; Sequence 6, Application US/10383902A
; Publication No. US20030224408A1
; GENERAL INFORMATION:
; APPLICANT: Hoogenboom, Henricus Renerus Jacobus Mattheus
; APPLICANT: Mullberg, Jurgen
; APPLICANT: Ladner, Robert C.
; TITLE OF INVENTION: LIGAND SCREENING AND DISCOVERY
; FILE REFERENCE: 10280-042001
; CURRENT APPLICATION NUMBER: US/10/383,902A
; CURRENT FILING DATE: 2003-03-07
; PRIOR APPLICATION NUMBER: US 60/362,403
; PRIOR FILING DATE: 2002-03-07
; NUMBER OF SEQ ID NOS: 58
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 330
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetically generated plasmid sequence
US-10-383-902A-6

Query Match      99.5%; Score 1756; DB 4; Length 330;
Best Local Similarity 99.4%; Pred. No. 7,1e-128;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTWNSGALTSVHTFPAVLQSS 60
Db |||||
Qy 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTWNSGALTSVHTFPAVLQSS 60
Db |||||
Qy 61 GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPCPAPELAGA 120
Db |||||
Qy 61 GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPCPAPELGG 120
Db |||||
Qy 121 PSVFLFPPKPKDPTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREEQYN 180
Db |||||
Qy 121 PSVFLFPPKPKDPTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREEQYN 180
Db |||||
Qy 181 STYRVSVSLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Db |||||
Qy 181 STYRVSVSLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Db |||||
Qy 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFPLYSKLTVDKSRW 300
Db |||||
Qy 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFPLYSKLTVDKSRW 300
Db |||||
Qy 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330
Db |||||
Qy 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330
Db |||||

RESULT 48
US-10-408-901-2
; Sequence 2, Application US/10408901
; Publication No. US20040023313A1
; GENERAL INFORMATION:
; APPLICANT: Boyle, William
; APPLICANT: Huang, Haichun
; APPLICANT: Elliot, Robin
; APPLICANT: Sullivan, John
; APPLICANT: Medlock, Eugene
; APPLICANT: Martin, Francis
; TITLE OF INVENTION: Human Anti-OPGL Neutralizing Antibodies As Selective OPGL Pathway
; TITLE OF INVENTION: Inhibitors
; FILE REFERENCE: MBHB 01-1145-A
; CURRENT APPLICATION NUMBER: US/10/408,901
; CURRENT FILING DATE: 2003-04-07
; NUMBER OF SEQ ID NOS: 76
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2
; LENGTH: 330
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-408-901-2

Query Match      99.5%; Score 1756; DB 4; Length 330;
Best Local Similarity 99.4%; Pred. No. 7,1e-128;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTWNSGALTSVHTFPAVLQSS 60
Db |||||
Qy 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTWNSGALTSVHTFPAVLQSS 60
Db |||||
Qy 61 GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPCPAPELAGA 120
Db |||||
Qy 61 GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPCPAPELGG 120
Db |||||
Qy 121 PSVFLFPPKPKDPTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREEQYN 180
Db |||||
Qy 121 PSVFLFPPKPKDPTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREEQYN 180
Db |||||
Qy 181 STYRVSVSLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Db |||||
Qy 181 STYRVSVSLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Db |||||
Qy 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFPLYSKLTVDKSRW 300
Db |||||
Qy 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFPLYSKLTVDKSRW 300
Db |||||
```



```
QY 121 PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
Db 121 PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180

QY 181 STYRVSVSLTVLHQDLNKGKEYKCKVSNKALPAPIEKTISKAKGQPREPPQVYVTLPPSRDE 240
Db 181 STYRVSVSLTVLHQDLNKGKEYKCKVSNKALPAPIEKTISKAKGQPREPPQVYVTLPPSRDE 240

QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300
Db 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300

QY 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330
Db 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330

RESULT 52
US-10-772-531-38
; Sequence 38, Application US/10772531
; Publication No. US20040142422A1
; GENERAL INFORMATION:
; APPLICANT: Sprecher, Cindy A.
; APPLICANT: Presnell, Scott R.
; APPLICANT: Gao, Zeren
; APPLICANT: Whitmore, Theodore E.
; APPLICANT: Kuljper, Joseph L.
; APPLICANT: Maurer, Mark F.
; TITLE OF INVENTION: CYTOKINE RECEPTOR 2CYTOR17
; FILE REFERENCE: 00-42
; CURRENT APPLICATION NUMBER: US/10/772,531
; CURRENT FILING DATE: 2004-02-05
; PRIOR APPLICATION NUMBER: US/09/892,949
; PRIOR FILING DATE: 2001-06-26
; PRIOR APPLICATION NUMBER: US 60/214,282
; PRIOR FILING DATE: 2000-06-26
; PRIOR APPLICATION NUMBER: US 60/214,955
; PRIOR FILING DATE: 2000-06-29
; PRIOR APPLICATION NUMBER: US 60/267,963
; PRIOR FILING DATE: 2001-08-02
; NUMBER OF SEQ ID NOS: 93
; SOFTWARE: FaastSeq for Windows Version 3.0
; SEQ ID NO 38
; LENGTH: 330
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-772-531-38

Query Match 99.5%; Score 1756; DB 4; Length 330;
Best Local Similarity 99.4%; Pred. No. 7.1e-128;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
Db 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60

QY 61 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHHTCPCPAPELAGA 120
Db 61 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHHTCPCPAPELAGG 120

QY 121 PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
Db 121 PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180

QY 181 STYRVSVSLTVLHQDLNKGKEYKCKVSNKALPAPIEKTISKAKGQPREPPQVYVTLPPSRDE 240
Db 181 STYRVSVSLTVLHQDLNKGKEYKCKVSNKALPAPIEKTISKAKGQPREPPQVYVTLPPSRDE 240

QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300
Db 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300

QY 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330
Db 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330
```

```
Db 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330

RESULT 53
US-10-479-326-1
; Sequence 1, Application US/10479326
; Publication No. US20040198961A1
; GENERAL INFORMATION:
; APPLICANT: Tanox, INC.
; APPLICANT: AN, Ling-Ling
; APPLICANT: WU, Herren
; APPLICANT: FUNG, Michael
; TITLE OF INVENTION: Fce FUSION PROTEINS FOR TREATMENT OF ALLERGY AND ASTHMA
; FILE REFERENCE: TNX01-02PCT
; CURRENT APPLICATION NUMBER: US/10/479,326
; CURRENT FILING DATE: 2003-12-02
; PRIOR APPLICATION NUMBER: US60/298,710
; PRIOR FILING DATE: 2001-06-15
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1
; LENGTH: 330
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: PEPTIDE
; LOCATION: (1)..(330)
US-10-479-326-1

Query Match 99.5%; Score 1756; DB 4; Length 330;
Best Local Similarity 99.4%; Pred. No. 7.1e-128;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
Db 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60

QY 61 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHHTCPCPAPELAGA 120
Db 61 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHHTCPCPAPELAGG 120

QY 121 PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
Db 121 PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180

QY 181 STYRVSVSLTVLHQDLNKGKEYKCKVSNKALPAPIEKTISKAKGQPREPPQVYVTLPPSRDE 240
Db 181 STYRVSVSLTVLHQDLNKGKEYKCKVSNKALPAPIEKTISKAKGQPREPPQVYVTLPPSRDE 240

QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300
Db 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300

QY 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330
Db 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330

RESULT 54
US-10-815-449-8
; Sequence 8, Application US/10815449
; Publication No. US20040228859A1
; GENERAL INFORMATION:
; APPLICANT: GRAUS, Yvo
; APPLICANT: KOPETZKI, Erhard
; APPLICANT: KUENKELE, Klaus-Peter
; APPLICANT: MUNDIGL, Olaf
; APPLICANT: PARREN, Paul
; APPLICANT: REERS, Frank
; APPLICANT: SCHUMACHER, Ralf
; APPLICANT: Van de WINKEL, Jan
; APPLICANT: Van VUGT, Martine
```

```
; TITLE OF INVENTION: Antibodies against insulin-like growth factor I receptor and uses
; FILE OF INVENTION: thereof
; FILE REFERENCE: 21655 US2
; CURRENT APPLICATION NUMBER: US/10/815,449
; CURRENT FILING DATE: 2004-04-01
; PRIOR APPLICATION NUMBER: US 60/459,837
; PRIOR FILING DATE: 2003-04-02
; PRIOR APPLICATION NUMBER: US 60/463,003
; PRIOR FILING DATE: 2003-04-15
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8
; LENGTH: 330
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-815-449-8

Query Match      99.5%; Score 1756; DB 5; Length 330;
Best Local Similarity 99.4%; Pred. No. 7,1e-128;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
DB 1 ASTKGPSVFPPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
QY 61 GLYSLSSVVTVFSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPPCPAPELAGA 120
DB 61 GLYSLSSVVTVFSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPPCPAPELAGG 120
QY 121 PSVFLFPPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 180
DB 121 PSVFLFPPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 180
QY 181 STYRVSVSLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPOVYITLPSSRDE 240
DB 181 STYRVSVSLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPOVYITLPSSRDE 240
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
DB 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
QY 301 QCGNVFSCVMHEALHNNHYTKSLSPGK 330
DB 301 QCGNVFSCVMHEALHNNHYTKSLSPGK 330

RESULT 55
US-10-684-957-2
; Sequence 2, Application US/10684957
; Publication No. US20050004353A1
; GENERAL INFORMATION:
; APPLICANT: Amgen, Inc.
; APPLICANT: Welcher, Andrew
; APPLICANT: Chute, Hilary
; APPLICANT: Li, Luke
; APPLICANT: Huang, Haichun
; TITLE OF INVENTION: Human anti-IFN-gamma Neutralizing Antibodies as Selective IFN-gam
; FILE REFERENCE: 01-1635-B
; CURRENT APPLICATION NUMBER: US/10/684,957
; PRIOR FILING DATE: 2003-10-14
; PRIOR APPLICATION NUMBER: US 60/419,057
; PRIOR FILING DATE: 2002-10-16
; PRIOR APPLICATION NUMBER: US 60/479,241
; PRIOR FILING DATE: 2003-06-17
; NUMBER OF SEQ ID NOS: 57
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2
; LENGTH: 330
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-684-957-2
```

```
Query Match      99.5%; Score 1756; DB 5; Length 330;
Best Local Similarity 99.4%; Pred. No. 7,1e-128;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
DB 1 ASTKGPSVFPPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
QY 61 GLYSLSSVVTVFSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPPCPAPELAGA 120
DB 61 GLYSLSSVVTVFSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPPCPAPELAGG 120
QY 121 PSVFLFPPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 180
DB 121 PSVFLFPPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 180
QY 181 STYRVSVSLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPOVYITLPSSRDE 240
DB 181 STYRVSVSLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPOVYITLPSSRDE 240
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
DB 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300

RESULT 56
US-10-886-838-6
; Sequence 6, Application US/10886838
; Publication No. US20050008642A1
; GENERAL INFORMATION:
; APPLICANT: Hoffmann-La Roche Inc.
; TITLE OF INVENTION: Antibodies against insulin-like growth factor I receptor and uses
; FILE REFERENCE: 21695
; CURRENT APPLICATION NUMBER: US/10/886,838
; CURRENT FILING DATE: 2004-07-08
; PRIOR APPLICATION NUMBER: EP 03015526
; PRIOR FILING DATE: 2003-07-10
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 6
; LENGTH: 330
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-886-838-6

Query Match      99.5%; Score 1756; DB 5; Length 330;
Best Local Similarity 99.4%; Pred. No. 7,1e-128;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
DB 1 ASTKGPSVFPPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
QY 61 GLYSLSSVVTVFSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPPCPAPELAGA 120
DB 61 GLYSLSSVVTVFSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPPCPAPELAGG 120
QY 121 PSVFLFPPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 180
DB 121 PSVFLFPPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 180
QY 181 STYRVSVSLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPOVYITLPSSRDE 240
DB 181 STYRVSVSLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPOVYITLPSSRDE 240
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
DB 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
```



```
QY 301 OQGNVFCSCVMHEALHNNHYTKSLSPGK 330
Db 301 OQGNVFCSCVMHEALHNNHYTKSLSPGK 330

RESULT 57
US-10-822-300-3
; Sequence 3, Application US/10822300
; Publication No. US20050014934A1
; GENERAL INFORMATION:
; APPLICANT: Hinton, et al.
; TITLE OF INVENTION: ALTERATION OF FcRn BINDING AFFINITIES OR SERUM HALF-LIVES OF
; FILE REFERENCE: 05882.0039.CPUS01
; CURRENT APPLICATION NUMBER: US/10/822,300
; CURRENT FILING DATE: 2004-04-09
; NUMBER OF SEQ ID NOS: 146
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3
; LENGTH: 330
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-822-300-3

Query Match 99.5%; Score 1756; DB 5; Length 330;
Best Local Similarity 99.4%; Pred. No. 7.1e-128;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
Db 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
QY 61 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHKTCPPCPAPELAGA 120
Db 61 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHKTCPPCPAPELAGG 120
QY 121 PSVFLFPPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
Db 121 PSVFLFPPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
QY 181 STYRVSVLTIVLHODWLNAGEYKCKVSNKALPAPIEKTIISKAGQPREPQVYVTLPPSRDE 240
Db 181 STYRVSVLTIVLHODWLNAGEYKCKVSNKALPAPIEKTIISKAGQPREPQVYVTLPPSRDE 240
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
Db 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300

RESULT 58
US-10-822-300-7
; Sequence 7, Application US/10822300
; Publication No. US20050014934A1
; GENERAL INFORMATION:
; APPLICANT: Hinton, et al.
; TITLE OF INVENTION: ALTERATION OF FcRn BINDING AFFINITIES OR SERUM HALF-LIVES OF
; FILE REFERENCE: 05882.0039.CPUS01
; CURRENT APPLICATION NUMBER: US/10/822,300
; CURRENT FILING DATE: 2004-04-09
; NUMBER OF SEQ ID NOS: 146
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 330
; TYPE: PRT
; ORGANISM: Humanized antibody
; FEATURE:
; OTHER INFORMATION: Humanized antibody
```

```
US-10-822-300-7

Query Match 99.5%; Score 1756; DB 5; Length 330;
Best Local Similarity 99.4%; Pred. No. 7.1e-128;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
Db 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
QY 61 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHKTCPPCPAPELAGA 120
Db 61 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHKTCPPCPAPELAGG 120
QY 121 PSVFLFPPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
Db 121 PSVFLFPPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
QY 181 STYRVSVLTIVLHODWLNAGEYKCKVSNKALPAPIEKTIISKAGQPREPQVYVTLPPSRDE 240
Db 181 STYRVSVLTIVLHODWLNAGEYKCKVSNKALPAPIEKTIISKAGQPREPQVYVTLPPSRDE 240
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
Db 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300

RESULT 59
US-10-687-118-3
; Sequence 3, Application US/10687118
; Publication No. US20050032114A1
; GENERAL INFORMATION:
; APPLICANT: Hinton, et al.
; TITLE OF INVENTION: ALTERATION OF FcRn BINDING AFFINITIES OR SERUM HALF-LIVES OF
; FILE REFERENCE: 05882.0039.NPUS04
; CURRENT APPLICATION NUMBER: US/10/687,118
; CURRENT FILING DATE: 2003-10-15
; NUMBER OF SEQ ID NOS: 112
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3
; LENGTH: 330
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-687-118-3

Query Match 99.5%; Score 1756; DB 5; Length 330;
Best Local Similarity 99.4%; Pred. No. 7.1e-128;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
Db 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
QY 61 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHKTCPPCPAPELAGA 120
Db 61 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHKTCPPCPAPELAGG 120
QY 121 PSVFLFPPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
Db 121 PSVFLFPPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
QY 181 STYRVSVLTIVLHODWLNAGEYKCKVSNKALPAPIEKTIISKAGQPREPQVYVTLPPSRDE 240
Db 181 STYRVSVLTIVLHODWLNAGEYKCKVSNKALPAPIEKTIISKAGQPREPQVYVTLPPSRDE 240
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
Db 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
```



```

; GENERAL INFORMATION:
; APPLICANT: Liu, Jinqi
; APPLICANT: Na, Songqing
; APPLICANT: Song, Ho
; APPLICANT: Yang, Derek
; TITLE OF INVENTION: TREATING B-CELL MEDIATED DISEASES BY MODULATING DR6 ACTIVITY
; FILE REFERENCE: X-15237
; CURRENT APPLICATION NUMBER: US/10/480,109
; CURRENT FILING DATE: 2004-06-08
; PRIOR APPLICATION NUMBER: 60/342,632
; FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5
; LENGTH: 330
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-480-109-5

Query Match      99.5%; Score 1756; DB 5; Length 330;
Best Local Similarity 99.4%; Pred. No. 7,1e-128;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
Db      1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60

Qy      61 GLYSLSSVTVFPSSSLGTQTYICNVNHPKSNTKVDKKVEPKSCDKTHTCPPCPAPELAGA 120
Db      61 GLYSLSSVTVFPSSSLGTQTYICNVNHPKSNTKVDKKVEPKSCDKTHTCPPCPAPELAGG 120

Qy      121 PSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREEQYN 180
Db      121 PSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREEQYN 180

Qy      181 STYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIISKAKGQPREPQVYTLPPSRDE 240
Db      181 STYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIISKAKGQPREPQVYTLPPSRDE 240

Qy      241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300
Db      241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300

Qy      301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330
Db      301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330

RESULT 63
US-10-928-305-7
; Sequence 7, Application US/10928305
; Publication No. US20050069521A1
; GENERAL INFORMATION:
; APPLICANT: Gillies, Stephen D.
; APPLICANT: Lauder, Scott
; APPLICANT: Way, Jeffrey
; TITLE OF INVENTION: ENHANCING THE CIRCULATING HALF-LIFE OF INTERLEUKIN-2 PROTEINS
; FILE REFERENCE: LEX-024
; CURRENT APPLICATION NUMBER: US/10/928,305
; CURRENT FILING DATE: 2004-08-27
; PRIOR APPLICATION NUMBER: US 60/498,618
; PRIOR FILING DATE: 2003-08-28
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 7
; LENGTH: 330
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-928-305-7

Query Match      99.5%; Score 1756; DB 5; Length 330;
Best Local Similarity 99.4%; Pred. No. 7,1e-128;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
Db      1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60

Qy      61 GLYSLSSVTVFPSSSLGTQTYICNVNHPKSNTKVDKKVEPKSCDKTHTCPPCPAPELAGA 120
Db      61 GLYSLSSVTVFPSSSLGTQTYICNVNHPKSNTKVDKKVEPKSCDKTHTCPPCPAPELAGG 120

Qy      121 PSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREEQYN 180
Db      121 PSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREEQYN 180

Qy      181 STYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIISKAKGQPREPQVYTLPPSRDE 240
Db      181 STYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIISKAKGQPREPQVYTLPPSRDE 240

Qy      241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300
Db      241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300

Qy      301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330
Db      301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330

RESULT 64
US-10-480-109-5
; Sequence 5, Application US/10480109
; Publication No. US20050069540A1
```

```

; GENERAL INFORMATION:
; APPLICANT: Liu, Jinqi
; APPLICANT: Na, Songqing
; APPLICANT: Song, Ho
; APPLICANT: Yang, Derek
; TITLE OF INVENTION: TREATING B-CELL MEDIATED DISEASES BY MODULATING DR6 ACTIVITY
; FILE REFERENCE: X-15237
; CURRENT APPLICATION NUMBER: US/10/480,109
; CURRENT FILING DATE: 2004-06-08
; PRIOR APPLICATION NUMBER: 60/342,632
; FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5
; LENGTH: 330
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-480-109-5

Query Match      99.5%; Score 1756; DB 5; Length 330;
Best Local Similarity 99.4%; Pred. No. 7,1e-128;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
Db      1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60

Qy      61 GLYSLSSVTVFPSSSLGTQTYICNVNHPKSNTKVDKKVEPKSCDKTHTCPPCPAPELAGA 120
Db      61 GLYSLSSVTVFPSSSLGTQTYICNVNHPKSNTKVDKKVEPKSCDKTHTCPPCPAPELAGG 120

Qy      121 PSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREEQYN 180
Db      121 PSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREEQYN 180

Qy      181 STYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIISKAKGQPREPQVYTLPPSRDE 240
Db      181 STYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIISKAKGQPREPQVYTLPPSRDE 240

Qy      241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300
Db      241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300

Qy      301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330
Db      301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330

RESULT 65
US-10-891-658-2
; Sequence 2, Application US/10891658
; Publication No. US20050074821A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth, Wild
; APPLICANT: Treanor, James
; APPLICANT: Huang, Haichun
; APPLICANT: Inoue, Heather
; APPLICANT: Zhang, Tie J.
; APPLICANT: Martin, Frank
; TITLE OF INVENTION: Human anti-NGF Neutralizing Antibodies as Selective NGF Pathway
; FILE REFERENCE: 02-1240
; CURRENT APPLICATION NUMBER: US/10/891,658
; CURRENT FILING DATE: 2004-07-15
; PRIOR APPLICATION NUMBER: US 60/487,431
; PRIOR FILING DATE: 2003-07-15
; NUMBER OF SEQ ID NOS: 138
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2
; LENGTH: 330
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-891-658-2
```

```
Query Match          99.5%; Score 1756; DB 5; Length 330;
Best Local Similarity 99.4%; Pred. No. 7.1e-128;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 ASTKGPSVFPPLAPSSKSTGGTAALGCLVKDYFPEPVTVMNSGALTSGVHTFPAVLQSS 60
Db 1 ASTKGPSVFPPLAPSSKSTGGTAALGCLVKDYFPEPVTVMNSGALTSGVHTFPAVLQSS 60

Qy 61 GLYSLSSVVTVFSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPPCPAPELAGA 120
Db 61 GLYSLSSVVTVFSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPPCPAPELGG 120

Qy 121 PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 180
Db 121 PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 180

Qy 181 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Db 181 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240

Qy 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRW 300
Db 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRW 300

Qy 301 QOQNVFSCVMHEALHNNHYTKSLSLSPGK 330
Db 301 QOQNVFSCVMHEALHNNHYTKSLSLSPGK 330

RESULT 66
US-10-867-506-81
; Sequence 81, Application US/10867506
; Publication No. US20050112698A1
; GENERAL INFORMATION:
; APPLICANT: Neben, Steven
; APPLICANT: Takeuchi, Toshihiko
; APPLICANT: Tomkinson, Adrian
; APPLICANT: Delaria, Kathy
; APPLICANT: Van, Kelly
; APPLICANT: Wong, Teresa
; APPLICANT: Longphre, Malinda
; TITLE OF INVENTION: Antibody Inhibiting Stem Cell Factor Activity And Use For
; FILE REFERENCE: 11334*10
; CURRENT APPLICATION NUMBER: US/10/867,506
; PRIOR FILING DATE: 2004-06-14
; PRIOR APPLICATION NUMBER: US 10/320,231
; PRIOR FILING DATE: 2002-12-16
; PRIOR APPLICATION NUMBER: US 60/342,174
; NUMBER OF SEQ ID NOS: 101
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 81
; LENGTH: 330
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-867-506-81

Query Match          99.5%; Score 1756; DB 5; Length 330;
Best Local Similarity 99.4%; Pred. No. 7.1e-128;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 ASTKGPSVFPPLAPSSKSTGGTAALGCLVKDYFPEPVTVMNSGALTSGVHTFPAVLQSS 60
Db 1 ASTKGPSVFPPLAPSSKSTGGTAALGCLVKDYFPEPVTVMNSGALTSGVHTFPAVLQSS 60

Qy 61 GLYSLSSVVTVFSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPPCPAPELAGA 120
Db 61 GLYSLSSVVTVFSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPPCPAPELGG 120

Qy 121 PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 180
Db 121 PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 180
```

```
Db 121 PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 180
Qy 181 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Db 181 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Qy 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRW 300
Db 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRW 300

Qy 301 QOQNVFSCVMHEALHNNHYTKSLSLSPGK 330
Db 301 QOQNVFSCVMHEALHNNHYTKSLSLSPGK 330

RESULT 67
US-10-937-596-31
; Sequence 31, Application US/10937596
; Publication No. US20050118169A1
; GENERAL INFORMATION:
; APPLICANT: BARTKE, ILSE
; APPLICANT: CARR, FRANCIS
; APPLICANT: CHIZZONITE, RICHARD ANTHONY
; APPLICANT: EUGUI, ELSIE M.
; APPLICANT: FERTIG, GEORG
; APPLICANT: HAMILTON, ANITA
; APPLICANT: LANZENDOERFER, MARTIN
; APPLICANT: RUEGER, PETRA
; APPLICANT: SCHUMACHER, RALF
; APPLICANT: TRUITT, THERESA PATRICIA
; TITLE OF INVENTION: ANTIBODIES AGAINST INTERLEUKIN-1 RECEPTOR AND USBS THEREOF
; FILE REFERENCE: CD21842-US1
; CURRENT APPLICATION NUMBER: US/10/937,596
; CURRENT FILING DATE: 2004-09-09
; PRIOR APPLICATION NUMBER: 60/501,681
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: EP 03029659.4
; PRIOR FILING DATE: 2003-12-23
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 31
; LENGTH: 330
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-937-596-31
```

```
Query Match          99.5%; Score 1756; DB 5; Length 330;
Best Local Similarity 99.4%; Pred. No. 7.1e-128;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 ASTKGPSVFPPLAPSSKSTGGTAALGCLVKDYFPEPVTVMNSGALTSGVHTFPAVLQSS 60
Db 1 ASTKGPSVFPPLAPSSKSTGGTAALGCLVKDYFPEPVTVMNSGALTSGVHTFPAVLQSS 60

Qy 61 GLYSLSSVVTVFSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPPCPAPELAGA 120
Db 61 GLYSLSSVVTVFSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPPCPAPELGG 120

Qy 121 PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 180
Db 121 PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 180

Qy 181 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Db 181 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Qy 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRW 300
Db 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRW 300

Qy 301 QOQNVFSCVMHEALHNNHYTKSLSLSPGK 330
Db 301 QOQNVFSCVMHEALHNNHYTKSLSLSPGK 330
```

```
RESULT 68
US-10-893-576-45
; Sequence 45, Application US/108933576
; Publication No. US20050118643A1
; GENERAL INFORMATION:
; APPLICANT: BURGESS, TERESA L.
; APPLICANT: COXON, ANGELA
; APPLICANT: GREEN, LARRY L.
; APPLICANT: ZHANG, KE
; TITLE OF INVENTION: SPECIFIC BINDING AGENTS TO HEPATOCYTE GROWTH FACTOR
; FILE REFERENCE: 06843.0051-00000
; CURRENT APPLICATION NUMBER: US/10/893,576
; CURRENT FILING DATE: 2004-07-16
; PRIOR FILING DATE: 2003-07-18
; NUMBER OF SEQ ID NOS: 194
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 45
; LENGTH: 330
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic Human IgG1
; OTHER INFORMATION: Constant Region
US-10-893-576-45

Query Match          99.5%; Score 1756; DB 5; Length 330;
Best Local Similarity 99.4%; Pred. No. 7,1e-128;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
DB 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
QY 61 GLYSLSSVVTVPPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPCPAPELAGA 120
DB 61 GLYSLSSVVTVPPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPCPAPELGG 120
QY 121 PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
DB 121 PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
QY 181 STYRVSVSLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
DB 181 STYRVSVSLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300
DB 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300
QY 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330
DB 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330

RESULT 69
US-10-868-373-8
; Sequence 8, Application US/10868373
; Publication No. US20050118683A1
; GENERAL INFORMATION:
; APPLICANT: Wood, C. et al.
; TITLE OF INVENTION: METHOD FOR PRODUCING A POLYPEPTIDE
; FILE REFERENCE: 22058-547
; CURRENT APPLICATION NUMBER: US/10/868,373
; CURRENT FILING DATE: 2004-06-14
; PRIOR FILING DATE: 2003-06-11
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: PatentIn Ver. 2.1.1
; SEQ ID NO 8
; LENGTH: 330

Query Match          99.5%; Score 1756; DB 5; Length 330;
Best Local Similarity 99.4%; Pred. No. 7,1e-128;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
DB 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
QY 61 GLYSLSSVVTVPPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPCPAPELAGA 120
DB 61 GLYSLSSVVTVPPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPCPAPELGG 120
QY 121 PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
DB 121 PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
QY 181 STYRVSVSLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
DB 181 STYRVSVSLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300
DB 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300
QY 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330
DB 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330

RESULT 70
US-10-977-369-139
; Sequence 139, Application US/10977369
; Publication No. US20050152898A1
; GENERAL INFORMATION:
; APPLICANT: Carr, Francis J.
; APPLICANT: Hamilton, Anita A.
; TITLE OF INVENTION: MODIFIED ANTI-CD52 ANTIBODY
; FILE REFERENCE: ILEX:095US
; CURRENT APPLICATION NUMBER: US/10/977,369
; CURRENT FILING DATE: 2004-10-29
; PRIOR APPLICATION NUMBER: 60/516,210
; PRIOR FILING DATE: 2003-11-01
; NUMBER OF SEQ ID NOS: 231
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 139
; LENGTH: 330
; TYPE: PRT
; ORGANISM: Homo Sapiens
US-10-977-369-139

Query Match          99.5%; Score 1756; DB 5; Length 330;
Best Local Similarity 99.4%; Pred. No. 7,1e-128;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
DB 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
QY 61 GLYSLSSVVTVPPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPCPAPELAGA 120
DB 61 GLYSLSSVVTVPPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPCPAPELGG 120
QY 121 PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
DB 121 PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
QY 181 STYRVSVSLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
DB 181 STYRVSVSLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
```

QY 241 LTKNOVSLTCLVKGFYPSDIAVEWESNGOPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
Db 241 LTKNOVSLTCLVKGFYPSDIAVEWESNGOPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
QY 301 QQGNVFCSCVMHEALHNHYTKSLSPGK 330
Db 301 QQGNVFCSCVMHEALHNHYTKSLSPGK 330

RESULT 71
US-10-901-736-60
; Sequence 60, Application US/10901736
; Publication No. US2005016990A1
; GENERAL INFORMATION:
; APPLICANT: TANOX, INC.
; APPLICANT: SINGH, Sanjaya
; APPLICANT: HUANG, Danyang
; APPLICANT: FUNG, Sek Chung
; TITLE OF INVENTION: Identification of Unique, High Affinity Ige Epitopes
; FILE REFERENCE: TNX-1030
; CURRENT APPLICATION NUMBER: US/10/901,736
; CURRENT FILING DATE: 2004-07-29
; PRIOR APPLICATION NUMBER: 60/444,229
; PRIOR FILING DATE: 2003-02-01
; PRIOR APPLICATION NUMBER: PCT/US04/02892
; PRIOR FILING DATE: 2004-02-02
; PRIOR APPLICATION NUMBER: PCT/US04/02894
; PRIOR FILING DATE: 2004-02-02
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 60
; LENGTH: 330
; TYPE: PRT
; ORGANISM: ARTIFICIAL
; FEATURE:
; OTHER INFORMATION: CONSTANT REGION OF HUMAN IgG1

US-10-901-736-60
Query Match 99.5%; Score 1756; DB 5; Length 330;
Best Local Similarity 99.4%; Pred. No. 7, 1e-128;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSMNSGALTSGVHTFPAVLQSS 60
Db 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSMNSGALTSGVHTFPAVLQSS 60
QY 61 GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPPCPAPELAGA 120
Db 61 GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPPCPAPELGG 120
QY 121 PSVFLFPPPKDPTLMISRTPEVTCVVDVSHEDPEVKENWYVDGVEVHNATKPREEQYN 180
Db 121 PSVFLFPPPKDPTLMISRTPEVTCVVDVSHEDPEVKENWYVDGVEVHNATKPREEQYN 180
QY 181 STYRVSVLTVLHQDLNKGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Db 181 STYRVSVLTVLHQDLNKGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
QY 241 LTKNOVSLTCLVKGFYPSDIAVEWESNGOPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
Db 241 LTKNOVSLTCLVKGFYPSDIAVEWESNGOPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
QY 301 QQGNVFCSCVMHEALHNHYTKSLSPGK 330
Db 301 QQGNVFCSCVMHEALHNHYTKSLSPGK 330

RESULT 72
US-10-982-555-38
; Sequence 38, Application US/10982555
; Publication No. US20050214801A1
; GENERAL INFORMATION:
; APPLICANT: LARRICK, JAMES W.
; APPLICANT: WYCOFF, KEITH L.
; TITLE OF INVENTION: NOVEL IMMUNOADHESINS FOR TREATING AND PREVENTING TOXICITY
; FILE REFERENCE: 41514-20004.01
; CURRENT APPLICATION NUMBER: US/10/493,909
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: PCT/US01/13932
; PRIOR FILING DATE: 2001-04-28
; PRIOR APPLICATION NUMBER: 60/200,298
; PRIOR FILING DATE: 2000-04-28
; NUMBER OF SEQ ID NOS: 101
; SOFTWARE: Patentin Ver. 2.1
US-10-901-736-60
Query Match 99.5%; Score 1756; DB 5; Length 330;
Best Local Similarity 99.4%; Pred. No. 7, 1e-128;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSMNSGALTSGVHTFPAVLQSS 60
Db 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSMNSGALTSGVHTFPAVLQSS 60
QY 61 GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPPCPAPELAGA 120
Db 61 GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPPCPAPELGG 120
QY 121 PSVFLFPPPKDPTLMISRTPEVTCVVDVSHEDPEVKENWYVDGVEVHNATKPREEQYN 180
Db 121 PSVFLFPPPKDPTLMISRTPEVTCVVDVSHEDPEVKENWYVDGVEVHNATKPREEQYN 180
QY 181 STYRVSVLTVLHQDLNKGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Db 181 STYRVSVLTVLHQDLNKGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
QY 241 LTKNOVSLTCLVKGFYPSDIAVEWESNGOPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
Db 241 LTKNOVSLTCLVKGFYPSDIAVEWESNGOPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
QY 301 QQGNVFCSCVMHEALHNHYTKSLSPGK 330
Db 301 QQGNVFCSCVMHEALHNHYTKSLSPGK 330

; APPLICANT: Sprecher, Cindy A.
; APPLICANT: Presnell, Scott R.
; APPLICANT: Gao, Zeren
; APPLICANT: Whitmore, Theodore E.
; APPLICANT: Kuiper, Joseph L.
; APPLICANT: Maurer, Mark F.
; TITLE OF INVENTION: CYTOKINE RECEPTOR ZCYTOR17
; FILE REFERENCE: 00-42
; CURRENT APPLICATION NUMBER: US/10/982,555
; CURRENT FILING DATE: 2004-11-05
; PRIOR APPLICATION NUMBER: US/09/892,949
; PRIOR FILING DATE: 2001-06-26
; PRIOR APPLICATION NUMBER: US 60/214,282
; PRIOR FILING DATE: 2000-06-26
; PRIOR APPLICATION NUMBER: US 60/214,955
; PRIOR FILING DATE: 2000-06-29
; PRIOR APPLICATION NUMBER: US 60/267,963
; PRIOR FILING DATE: 2001-08-02
; NUMBER OF SEQ ID NOS: 93
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 38
; LENGTH: 330
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-982-555-38

Query Match 99.5%; Score 1756; DB 5; Length 330;
Best Local Similarity 99.4%; Pred. No. 7, 1e-128;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSMNSGALTSGVHTFPAVLQSS 60
Db 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSMNSGALTSGVHTFPAVLQSS 60
QY 61 GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPPCPAPELAGA 120
Db 61 GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPPCPAPELGG 120
QY 121 PSVFLFPPPKDPTLMISRTPEVTCVVDVSHEDPEVKENWYVDGVEVHNATKPREEQYN 180
Db 121 PSVFLFPPPKDPTLMISRTPEVTCVVDVSHEDPEVKENWYVDGVEVHNATKPREEQYN 180
QY 181 STYRVSVLTVLHQDLNKGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Db 181 STYRVSVLTVLHQDLNKGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
QY 241 LTKNOVSLTCLVKGFYPSDIAVEWESNGOPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
Db 241 LTKNOVSLTCLVKGFYPSDIAVEWESNGOPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
QY 301 QQGNVFCSCVMHEALHNHYTKSLSPGK 330
Db 301 QQGNVFCSCVMHEALHNHYTKSLSPGK 330

RESULT 73
US-10-493-909-20
; Sequence 20, Application US/10493909
; Publication No. US20060015969A1
; GENERAL INFORMATION:
; APPLICANT: LARRICK, JAMES W.
; APPLICANT: WYCOFF, KEITH L.
; TITLE OF INVENTION: NOVEL IMMUNOADHESINS FOR TREATING AND PREVENTING TOXICITY
; FILE REFERENCE: 41514-20004.01
; CURRENT APPLICATION NUMBER: US/10/493,909
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: PCT/US01/13932
; PRIOR FILING DATE: 2001-04-28
; PRIOR APPLICATION NUMBER: 60/200,298
; PRIOR FILING DATE: 2000-04-28
; NUMBER OF SEQ ID NOS: 101
; SOFTWARE: Patentin Ver. 2.1

```
; SEQ ID NO 20
; LENGTH: 330
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-493-909-20

Query Match      99.5%; Score 1756; DB 5; Length 330;
Best Local Similarity 99.4%; Pred. No. 7.1e-128;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
Db 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
Qy 61 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPCPAPELAGA 120
Db 61 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPCPAPELGG 120
Qy 121 PSVFLFPPKPKDGLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREEOYN 180
Db 121 PSVFLFPPKPKDGLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREEOYN 180
Qy 181 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVTLPPSRDE 240
Db 181 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVTLPPSRDE 240
Qy 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW 300
Db 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW 300
Qy 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330
Db 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330

RESULT 74
US-10-982-440-68
; Sequence 88, Application US/10982440
; Publication No. US20060018909A1
; GENERAL INFORMATION:
; APPLICANT: Oliner, John
; TITLE OF INVENTION: Angiopoietin-2 Specific Binding Agents
; FILE REFERENCE: 04-881-A
; CURRENT APPLICATION NUMBER: US/10/982,440
; CURRENT FILING DATE: 2004-11-04
; PRIOR APPLICATION NUMBER: 60/620,161
; PRIOR FILING DATE: 2004-10-19
; NUMBER OF SEQ ID NOS: 215
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 68
; LENGTH: 330
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-982-440-68

Query Match      99.5%; Score 1756; DB 5; Length 330;
Best Local Similarity 99.4%; Pred. No. 7.1e-128;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
Db 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
Qy 61 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPCPAPELAGA 120
Db 61 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPCPAPELGG 120
Qy 121 PSVFLFPPKPKDGLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREEOYN 180
Db 121 PSVFLFPPKPKDGLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREEOYN 180
Qy 181 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVTLPPSRDE 240
Db 181 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVTLPPSRDE 240
Qy 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW 300
Db 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW 300
Qy 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330
Db 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330

RESULT 75
US-11-004-054-1
; Sequence 1, Application US/11004054
; Publication No. US2005014213A1
; GENERAL INFORMATION:
; APPLICANT: Lazar, Gregory Alan
; APPLICANT: Dang, Wei
; APPLICANT: Desjarlais, John R.
; APPLICANT: Hammond, Philip W.
; APPLICANT: Vielmetter, Jost
; TITLE OF INVENTION: OPTIMIZED PROTEINS THAT TARGET THE EPIDERMAL GROWTH FACTOR
; FILE REFERENCE: 185834/US/2
; CURRENT APPLICATION NUMBER: US/11/004,054
; CURRENT FILING DATE: 2004-12-03
; PRIOR APPLICATION NUMBER: US 60/526,799
; PRIOR FILING DATE: 2003-12-03
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1
; LENGTH: 330
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-004-054-1

Query Match      99.5%; Score 1756; DB 6; Length 330;
Best Local Similarity 99.4%; Pred. No. 7.1e-128;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
Db 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
Qy 61 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPCPAPELAGA 120
Db 61 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPCPAPELGG 120
Qy 121 PSVFLFPPKPKDGLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREEOYN 180
Db 121 PSVFLFPPKPKDGLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREEOYN 180
Qy 181 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVTLPPSRDE 240
Db 181 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVTLPPSRDE 240
Qy 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW 300
Db 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW 300
Qy 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330
Db 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330

RESULT 76
US-11-026-998-22
; Sequence 22, Application US/11026998
; Publication No. US2005019221A1
; GENERAL INFORMATION:
; APPLICANT: Gillies, Stephen D.
; APPLICANT: Lauder, Scott
```

Query Match 99.5%; Score 1756; DB 6; Length 330;
Best Local Similarity 99.4%; Pred. No. 7.1e-128;
Matches 328; Conservative 0; Mismatches 2; Indels


```
RESULT 79
US-11-090-846-44
; Sequence 44, Application US/11090846
; Publication No. US20050214289A1
; GENERAL INFORMATION:
; APPLICANT: Bell, et al.
; TITLE OF INVENTION: Antibodies Against Nogo Receptor
; FILE REFERENCE: PF611
; CURRENT APPLICATION NUMBER: US/11/090,846
; CURRENT FILING DATE: 2005-03-25
; PRIOR APPLICATION NUMBER: US 60/556,442
; PRIOR FILING DATE: 2004-03-26
; NUMBER OF SEQ ID NOS: 49
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 44
; LENGTH: 330
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-090-846-44

Query Match      99.5%; Score 1756; DB 6; Length 330;
Best Local Similarity 99.4%; Pred. No. 7.1e-128;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 ASTKGPSVFPLAPSSKSTSGGTAAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
Db 1 ASTKGPSVFPLAPSSKSTSGGTAAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
Qy 61 GLYSLSSVVTVFPPSSSLGQTQYICNVNHPKSTNTKVDKVEPKSCDKTHTCPPCPAPELAGA 120
Db 61 GLYSLSSVVTVFPPSSSLGQTQYICNVNHPKSTNTKVDKVEPKSCDKTHTCPPCPAPELAGG 120
Qy 121 PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKATPKPREQYN 180
Db 121 PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKATPKPREQYN 180
Qy 181 STYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVTLPPSRDE 240
Db 181 STYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVTLPPSRDE 240
Qy 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSEFFLYSKLTVDKSRW 300
Db 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSEFFLYSKLTVDKSRW 300
Qy 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330
Db 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330

RESULT 81
US-11-102-403-24
; Sequence 24, Application US/11102403
; Publication No. US20050226876A1
; GENERAL INFORMATION:
; APPLICANT: GRAUS, YVO
; APPLICANT: HIMBER, JACQUES
; APPLICANT: JANSEN-MOLENAAR, MIRANDA
; APPLICANT: KLING, DOROTHEE
; APPLICANT: KOPETZKI, ERHARD
; APPLICANT: PABEN, PAUL
; APPLICANT: REBERS, FRANK
; APPLICANT: STEINER, BEAT
; APPLICANT: STERN, ANNE
; APPLICANT: STREIN, PAMELA
; APPLICANT: STUBENRAUCH, KAY-GUNNAR
; APPLICANT: VAN DE WINKEL, JAN
; APPLICANT: VAN VUUT, MARTINE
; TITLE OF INVENTION: ANTI-P SELECTIN ANTIBODIES
; FILE REFERENCE: 22354
; CURRENT APPLICATION NUMBER: US/11/102,403
; CURRENT FILING DATE: 2005-04-08
; PRIOR APPLICATION NUMBER: EP 04008722.3
; PRIOR FILING DATE: 2004-04-13
; NUMBER OF SEQ ID NOS: 55
; SOFTWARE: Patent in ver. 3.3
; SEQ ID NO 24
; LENGTH: 330
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-102-403-24

Query Match      99.5%; Score 1756; DB 6; Length 330;
Best Local Similarity 99.4%; Pred. No. 7.1e-128;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 ASTKGPSVFPLAPSSKSTSGGTAAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
Db 1 ASTKGPSVFPLAPSSKSTSGGTAAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
Qy 61 GLYSLSSVVTVFPPSSSLGQTQYICNVNHPKSTNTKVDKVEPKSCDKTHTCPPCPAPELAGA 120
Db 61 GLYSLSSVVTVFPPSSSLGQTQYICNVNHPKSTNTKVDKVEPKSCDKTHTCPPCPAPELAGG 120
Qy 121 PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKATPKPREQYN 180
Db 121 PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKATPKPREQYN 180
Qy 181 STYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVTLPPSRDE 240
Db 181 STYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVTLPPSRDE 240
Qy 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSEFFLYSKLTVDKSRW 300
Db 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSEFFLYSKLTVDKSRW 300
Qy 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330
Db 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330

RESULT 80
US-11-090-847-44
; Sequence 44, Application US/11090847
; Publication No. US20050215770A1
; GENERAL INFORMATION:
; APPLICANT: Bell, et al.
; TITLE OF INVENTION: Antibodies Against Nogo Receptor
; FILE REFERENCE: PF609
; CURRENT APPLICATION NUMBER: US/11/090,847
; CURRENT FILING DATE: 2005-03-25
; PRIOR APPLICATION NUMBER: US 60/556,386
; PRIOR FILING DATE: 2004-03-26
; NUMBER OF SEQ ID NOS: 249
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 44
; LENGTH: 330
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-090-847-44

Query Match      99.5%; Score 1756; DB 6; Length 330;
Best Local Similarity 99.4%; Pred. No. 7.1e-128;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 ASTKGPSVFPLAPSSKSTSGGTAAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
Db 1 ASTKGPSVFPLAPSSKSTSGGTAAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
Qy 61 GLYSLSSVVTVFPPSSSLGQTQYICNVNHPKSTNTKVDKVEPKSCDKTHTCPPCPAPELAGA 120
Db 61 GLYSLSSVVTVFPPSSSLGQTQYICNVNHPKSTNTKVDKVEPKSCDKTHTCPPCPAPELAGG 120
Qy 121 PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKATPKPREQYN 180
Db 121 PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKATPKPREQYN 180
Qy 181 STYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVTLPPSRDE 240
Db 181 STYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVTLPPSRDE 240
Qy 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSEFFLYSKLTVDKSRW 300
Db 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSEFFLYSKLTVDKSRW 300
Qy 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330
Db 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330
```


QY 181 STYRVSVLTVLHQDLNGKEYCKVSNKALPAPIEKTISKAKGPPEPVYTLPPSRDE 240
Db 181 STYRVSVLTVLHQDLNGKEYCKVSNKALPAPIEKTISKAKGPPEPVYTLPPSRDE 240
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300
Db 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300
QY 301 QQGNVFSCSVMEALHNHYTQKSLSLSPGK 330
Db 301 QQGNVFSCSVMEALHNHYTQKSLSLSPGK 330

RESULT 82

US-11-102-403-26
; Sequence 26, Application US/11102403
; Publication No. US20050226876A1
; GENERAL INFORMATION:
; APPLICANT: GRAUS, YVO
; APPLICANT: HIMBER, JACQUES
; APPLICANT: JANSEN-MOLENAAR, MIRANDA
; APPLICANT: KLING, DOROTHEE
; APPLICANT: KOPETZKI, ERHARD
; APPLICANT: PAREN, PAUL
; APPLICANT: REBERS, FRANK
; APPLICANT: STEINER, BEAT
; APPLICANT: STERN, ANNE
; APPLICANT: STREIN, PAMELA
; APPLICANT: STUBENRAUCH, KAY-GUNNAR
; APPLICANT: VAN DE WINKEL, JAN
; APPLICANT: VAN VUGT, MARTINE
; TITLE OF INVENTION: ANTI-P SELECTIN ANTIBODIES
; FILE REFERENCE: 22354
; CURRENT APPLICATION NUMBER: US/11/102,403
; CURRENT FILING DATE: 2005-04-08
; PRIOR APPLICATION NUMBER: EP 04008722.3
; PRIOR FILING DATE: 2004-04-13
; NUMBER OF SEQ ID NOS: 55
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 26
; LENGTH: 330
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-102-403-26

Query Match 99.5%; Score 1756; DB 6; Length 330;
Best Local Similarity 99.4%; Pred. No. 7.1e-128;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSS 60
Db 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSS 60
QY 61 GLYSLSSVTVTPSSSLGTQTYICNVNHRKPSNTKVDKVEPKSCDKHTHTCPCPAPELAGA 120
Db 61 GLYSLSSVTVTPSSSLGTQTYICNVNHRKPSNTKVDKVEPKSCDKHTHTCPCPAPEAAGG 120
QY 121 PSVFLFPPPKDPTLMISRTPEVTCVVDVSHEDPEVKENWYVDGVEVHNATKPREQYN 180
Db 121 PSVFLFPPPKDPTLMISRTPEVTCVVDVSHEDPEVKENWYVDGVEVHNATKPREQYN 180
QY 181 STYRVSVLTVLHQDLNGKEYCKVSNKALPAPIEKTISKAKGPPEPVYTLPPSRDE 240
Db 181 STYRVSVLTVLHQDLNGKEYCKVSNKALPAPIEKTISKAKGPPEPVYTLPPSRDE 240
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300
Db 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300
QY 301 QQGNVFSCSVMEALHNHYTQKSLSLSPGK 330
Db 301 QQGNVFSCSVMEALHNHYTQKSLSLSPGK 330

RESULT 83

US-11-022-289-11
; Sequence 11, Application US/11022289
; Publication No. US20050249723A1
; GENERAL INFORMATION:
; APPLICANT: LAZAR, Gregory Alan
; TITLE OF INVENTION: FC POLYPEPTIDES WITH NOVEL FC LIGAND BINDING SITES
; FILE REFERENCE: 185831/US/2
; CURRENT APPLICATION NUMBER: US/11/022,289
; CURRENT FILING DATE: 2004-12-21
; PRIOR APPLICATION NUMBER: US 60/531,752
; PRIOR FILING DATE: 2003-12-22
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 11
; LENGTH: 330
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-022-289-11

Query Match 99.5%; Score 1756; DB 6; Length 330;
Best Local Similarity 99.4%; Pred. No. 7.1e-128;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSS 60
Db 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSS 60
QY 61 GLYSLSSVTVTPSSSLGTQTYICNVNHRKPSNTKVDKVEPKSCDKHTHTCPCPAPELAGA 120
Db 61 GLYSLSSVTVTPSSSLGTQTYICNVNHRKPSNTKVDKVEPKSCDKHTHTCPCPAPELGG 120
QY 121 PSVFLFPPPKDPTLMISRTPEVTCVVDVSHEDPEVKENWYVDGVEVHNATKPREQYN 180
Db 121 PSVFLFPPPKDPTLMISRTPEVTCVVDVSHEDPEVKENWYVDGVEVHNATKPREQYN 180
QY 181 STYRVSVLTVLHQDLNGKEYCKVSNKALPAPIEKTISKAKGPPEPVYTLPPSRDE 240
Db 181 STYRVSVLTVLHQDLNGKEYCKVSNKALPAPIEKTISKAKGPPEPVYTLPPSRDE 240
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300
Db 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300
QY 301 QQGNVFSCSVMEALHNHYTQKSLSLSPGK 330
Db 301 QQGNVFSCSVMEALHNHYTQKSLSLSPGK 330

RESULT 84

US-11-075-351-1
; Sequence 1, Application US/11075351
; Publication No. US20050260716A1
; GENERAL INFORMATION:
; APPLICANT: MOORE, Margaret D.
; APPLICANT: FOX, Brian A.
; TITLE OF INVENTION: DIMERIC FUSION PROTEINS AND MATERIALS
; FILE REFERENCE: 02-16
; CURRENT APPLICATION NUMBER: US/11/075,351
; CURRENT FILING DATE: 2005-03-08
; NUMBER OF SEQ ID NOS: 63
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 330
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-075-351-1
Query Match 99.5%; Score 1756; DB 6; Length 330;
Best Local Similarity 99.4%; Pred. No. 7.1e-128;

```
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1 ASTKGPSVFPPLAPSSKSTSGGTAALGCLVKDYFPEPVTWNSNGALTSKVHTFPFAVLQSS 60
DB 1 ASTKGPSVFPPLAPSSKSTSGGTAALGCLVKDYFPEPVTWNSNGALTSKVHTFPFAVLQSS 60
QY 61 GLYSLSVVTVFPSSSLGTQTYICNVNHPKSNTKVDKKVEPKSCDKTHTCCPCPAPELAGA 120
DB 61 GLYSLSVVTVFPSSSLGTQTYICNVNHPKSNTKVDKKVEPKSCDKTHTCCPCPAPELAGG 120
QY 121 PSVFLFPPKPDTLMIKRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
DB 121 PSVFLFPPKPDTLMIKRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
QY 181 STYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYITLPPSRDE 240
DB 181 STYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYITLPPSRDE 240
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFPLYSKLTVDKSRW 300
DB 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFPLYSKLTVDKSRW 300
QY 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330
DB 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330

RESULT 85
US-11-165-141-15
; Sequence 15, Application US/11165141
; Publication No. US20050266485A1
; GENERAL INFORMATION:
; APPLICANT: Fresnell, Scott R.
; APPLICANT: Xu, Wenfeng
; APPLICANT: Novak, Julia E.
; APPLICANT: Whitmore, Theodore E.
; APPLICANT: Grant, Francis J.
; TITLE OF INVENTION: CYTOKINE RECEPTOR ZCYTOR19
; FILE REFERENCE: 00-108
; CURRENT APPLICATION NUMBER: US/11/165,141
; CURRENT FILING DATE: 2005-06-23
; PRIOR APPLICATION NUMBER: US/09/995,898
; PRIOR FILING DATE: 2001-11-28
; PRIOR APPLICATION NUMBER: US 60/253,561
; PRIOR FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US 60/267,211
; PRIOR FILING DATE: 2001-02-07
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 15
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-165-141-15

Query Match 99.5%; Score 1756; DB 6; Length 330;
Best Local Similarity 99.4%; Pred. No. 7.1e-128;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1 ASTKGPSVFPPLAPSSKSTSGGTAALGCLVKDYFPEPVTWNSNGALTSKVHTFPFAVLQSS 60
DB 1 ASTKGPSVFPPLAPSSKSTSGGTAALGCLVKDYFPEPVTWNSNGALTSKVHTFPFAVLQSS 60
QY 61 GLYSLSVVTVFPSSSLGTQTYICNVNHPKSNTKVDKKVEPKSCDKTHTCCPCPAPELAGA 120
DB 61 GLYSLSVVTVFPSSSLGTQTYICNVNHPKSNTKVDKKVEPKSCDKTHTCCPCPAPELAGG 120
QY 121 PSVFLFPPKPDTLMIKRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
DB 121 PSVFLFPPKPDTLMIKRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
QY 181 STYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYITLPPSRDE 240
DB 181 STYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYITLPPSRDE 240
```

```
DB 181 STYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYITLPPSRDE 240
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFPLYSKLTVDKSRW 300
DB 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFPLYSKLTVDKSRW 300
QY 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330
DB 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330

RESULT 86
US-11-102-621-3
; Sequence 3, Application US/11102621
; Publication No. US20050276799A1
; GENERAL INFORMATION:
; APPLICANT: ProteIn Design Labs, Inc.
; APPLICANT: Hinton, Paul R.
; APPLICANT: Tsurushita, Naoya
; APPLICANT: Tso, J. Yun
; APPLICANT: Vasquez, Maximiliano
; TITLE OF INVENTION: ANTIBODIES OF FcRN BINDING AFFINITIES OR SERUM HALF-LIVES OF
; FILE REFERENCE: 05882.0039.00PC03
; CURRENT APPLICATION NUMBER: US/11/102,621
; CURRENT FILING DATE: 2005-04-08
; PRIOR APPLICATION NUMBER: US 10/822,300
; PRIOR FILING DATE: 2004-04-09
; NUMBER OF SEQ ID NOS: 146
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3
; LENGTH: 330
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-102-621-3

Query Match 99.5%; Score 1756; DB 6; Length 330;
Best Local Similarity 99.4%; Pred. No. 7.1e-128;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1 ASTKGPSVFPPLAPSSKSTSGGTAALGCLVKDYFPEPVTWNSNGALTSKVHTFPFAVLQSS 60
DB 1 ASTKGPSVFPPLAPSSKSTSGGTAALGCLVKDYFPEPVTWNSNGALTSKVHTFPFAVLQSS 60
QY 61 GLYSLSVVTVFPSSSLGTQTYICNVNHPKSNTKVDKKVEPKSCDKTHTCCPCPAPELAGA 120
DB 61 GLYSLSVVTVFPSSSLGTQTYICNVNHPKSNTKVDKKVEPKSCDKTHTCCPCPAPELAGG 120
QY 121 PSVFLFPPKPDTLMIKRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
DB 121 PSVFLFPPKPDTLMIKRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
QY 181 STYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYITLPPSRDE 240
DB 181 STYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYITLPPSRDE 240
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFPLYSKLTVDKSRW 300
DB 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFPLYSKLTVDKSRW 300
QY 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330
DB 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330

RESULT 87
US-11-102-621-7
; Sequence 7, Application US/11102621
; Publication No. US20050276799A1
; GENERAL INFORMATION:
; APPLICANT: ProteIn Design Labs, Inc.
; APPLICANT: Hinton, Paul R.
; APPLICANT: Tsurushita, Naoya
```

APPLICANT: Tso, J. Yun
APPLICANT: Vasquez, Maximiliano
TITLE OF INVENTION: ALTERATION OF FcRn BINDING AFFINITIES OR SERUM HALF-LIVES OF
FILE REFERENCE: ANTIBODIES BY MUTAGENESIS
FILE REFERENCE: 05882.0039.00PC03
CURRENT APPLICATION NUMBER: US/11/102,621
CURRENT FILING DATE: 2005-04-08
PRIOR APPLICATION NUMBER: US 10/822,300
PRIOR FILING DATE: 2004-04-09
NUMBER OF SEQ ID NOS: 146
SOFTWARE: Patentin version 3.2
SEQ ID NO 7
LENGTH: 330
TYPE: PRT
ORGANISM: artificial
FEATURE:
OTHER INFORMATION: Humanized antibody
US-11-102-621-7

Query Match 99.5%; Score 1756; DB 6; Length 330;
Best Local Similarity 99.4%; Pred. No. 7.1e-128;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1 ASTKGPSVFPPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
Db 1 ASTKGPSVFPPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
QY 61 GLYSLSVVTVPSSSISLGTQTYICNVNHPKSNKVDKVKVEPKSCDKTHTCPPCPAPELAGA 120
Db 61 GLYSLSVVTVPSSSISLGTQTYICNVNHPKSNKVDKVKVEPKSCDKTHTCPPCPAPELAGG 120
QY 121 PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNNAKTKPREEQYN 180
Db 121 PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNNAKTKPREEQYN 180
QY 181 STYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIISKAKGQPREPOVYTLPPSRDE 240
Db 181 STYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIISKAKGQPREPOVYTLPPSRDE 240
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSEFFLYSKLTVDKSRW 300
Db 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSEFFLYSKLTVDKSRW 300
QY 301 QQGNVFSCSVMEALHNHYTQKSLSLSPGK 330
Db 301 QQGNVFSCSVMEALHNHYTQKSLSLSPGK 330

RESULT 88
US-11-005-726-164
Sequence 164, Application US/11005726
Publication No. US20060018903A1
GENERAL INFORMATION:
APPLICANT: HELLENDORN, Koen
APPLICANT: BAKER, Matthew
APPLICANT: CARR, Francis J.
TITLE OF INVENTION: TNF ALPHA-BINDING POLYPEPTIDE
FILE REFERENCE: MER-131
CURRENT APPLICATION NUMBER: US/11/005,726
CURRENT FILING DATE: 2004-12-07
PRIOR APPLICATION NUMBER: 10/495,146
PRIOR FILING DATE: 2004-05-10
PRIOR APPLICATION NUMBER: PCT/EP02/12566
PRIOR FILING DATE: 2002-11-11
PRIOR APPLICATION NUMBER: EP 01126859.8
PRIOR FILING DATE: 2001-11-12
NUMBER OF SEQ ID NOS: 165
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 164
LENGTH: 330
TYPE: PRT
ORGANISM: Artificial Sequence

FEATURE:
OTHER INFORMATION: anti-TNF alpha chimeric antibody heavy chain
OTHER INFORMATION: constant region
US-11-005-726-164
Query Match 99.5%; Score 1756; DB 6; Length 330;
Best Local Similarity 99.4%; Pred. No. 7.1e-128;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1 ASTKGPSVFPPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
Db 1 ASTKGPSVFPPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
QY 61 GLYSLSVVTVPSSSISLGTQTYICNVNHPKSNKVDKVKVEPKSCDKTHTCPPCPAPELAGA 120
Db 61 GLYSLSVVTVPSSSISLGTQTYICNVNHPKSNKVDKVKVEPKSCDKTHTCPPCPAPELAGG 120
QY 121 PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNNAKTKPREEQYN 180
Db 121 PSVFLFPPPKDPTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNNAKTKPREEQYN 180
QY 181 STYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIISKAKGQPREPOVYTLPPSRDE 240
Db 181 STYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIISKAKGQPREPOVYTLPPSRDE 240
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSEFFLYSKLTVDKSRW 300
Db 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSEFFLYSKLTVDKSRW 300
QY 301 QQGNVFSCSVMEALHNHYTQKSLSLSPGK 330
Db 301 QQGNVFSCSVMEALHNHYTQKSLSLSPGK 330

RESULT 89
US-11-124-620-1
Sequence 1, Application US/11124620
Publication No. US20060024298A1
GENERAL INFORMATION:
APPLICANT: Lazar, Gregory Alan
APPLICANT: Dang, Wei
APPLICANT: Desjarlais, John R.
APPLICANT: Karki, Sher Bahadur
APPLICANT: Vafa, Omid
APPLICANT: Hayes, Robert
TITLE OF INVENTION: OPTIMIZED FC VARIANTS
FILE REFERENCE: A-71386-9
CURRENT APPLICATION NUMBER: US/11/124,620
CURRENT FILING DATE: 2005-05-05
PRIOR APPLICATION NUMBER: US 60/568,440
PRIOR FILING DATE: 2004-07-15
PRIOR APPLICATION NUMBER: US 60/589,906
PRIOR FILING DATE: 2004-07-20
PRIOR APPLICATION NUMBER: US 60/627,026
PRIOR FILING DATE: 2004-11-09
PRIOR APPLICATION NUMBER: US 60/626,991
PRIOR FILING DATE: 2004-11-10
PRIOR APPLICATION NUMBER: US 60/627,774
PRIOR FILING DATE: 2004-11-12
PRIOR APPLICATION NUMBER: US 10/822,231
PRIOR FILING DATE: 2004-03-26
PRIOR APPLICATION NUMBER: US 10/672,280
PRIOR FILING DATE: 2003-09-26
PRIOR APPLICATION NUMBER: US 10/379,392
PRIOR FILING DATE: 2003-03-03
NUMBER OF SEQ ID NOS: 11
SOFTWARE: Patentin version 3.3
SEQ ID NO 1
LENGTH: 330
TYPE: PRT
ORGANISM: Homo sapiens
US-11-124-620-1


```
; PRIOR APPLICATION NUMBER: 09/293,854
; PRIOR FILING DATE: 1999-04-16
; NUMBER OF SEQ ID NOS: 102
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 98
; LENGTH: 332
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-990-586-98

Query Match          99.5%; Score 1756; DB 3; Length 332;
Best Local Similarity 99.4%; Pred. No. 7.1e-128;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSMNSGALTSGVHTFPAVLQSS 60
Db 3 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSMNSGALTSGVHTFPAVLQSS 62

QY 61 GLYSLSVVTVPPSSSLGTQTYICNVNHPKSN TKVDKKVEPKSCDKTHTCPCPAPELAGA 120
Db 63 GLYSLSVVTVPPSSSLGTQTYICNVNHPKSN TKVDKKVEPKSCDKTHTCPCPAPELGG 122

QY 121 PSVFLFPPPKD TLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
Db 123 PSVFLFPPPKD TLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 182

QY 181 STYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Db 183 STYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 242

QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
Db 243 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 302

QY 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330
Db 303 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 332
```

```
RESULT 93
US-10-310-113-167
; Sequence 167, Application US/10310113
; Publication No. US20030176664A1
; GENERAL INFORMATION:
; APPLICANT: JIAO, JIN-AN
; APPLICANT: WONG, HING C.
; APPLICANT: NIEVES, ESPERANZA LILIANA
; TITLE OF INVENTION: USE OF ANTI-TISSUE FACTOR ANTIBODIES FOR TREATING
; FILE REFERENCE: 58122(71758)
; CURRENT APPLICATION NUMBER: US/10/310,113
; PRIOR FILING DATE: 2002-12-04
; PRIOR APPLICATION NUMBER: 09/990,586
; PRIOR FILING DATE: 2001-11-21
; PRIOR APPLICATION NUMBER: 60/343,306
; PRIOR FILING DATE: 2001-10-29
; PRIOR APPLICATION NUMBER: 09/293,854
; PRIOR FILING DATE: 1999-04-16
; PRIOR APPLICATION NUMBER: 08/814,806
; PRIOR FILING DATE: 1997-03-10
; NUMBER OF SEQ ID NOS: 169
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 167
; LENGTH: 332
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-310-113-167

Query Match          99.5%; Score 1756; DB 4; Length 332;
Best Local Similarity 99.4%; Pred. No. 7.1e-128;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSMNSGALTSGVHTFPAVLQSS 60
Db 3 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSMNSGALTSGVHTFPAVLQSS 62

QY 61 GLYSLSVVTVPPSSSLGTQTYICNVNHPKSN TKVDKKVEPKSCDKTHTCPCPAPELAGA 120
Db 63 GLYSLSVVTVPPSSSLGTQTYICNVNHPKSN TKVDKKVEPKSCDKTHTCPCPAPELGG 122

QY 121 PSVFLFPPPKD TLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
Db 123 PSVFLFPPPKD TLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 182

QY 181 STYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Db 183 STYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 242

QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
Db 243 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 302

QY 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330
Db 303 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 332

RESULT 94
US-10-230-880-98
; Sequence 98, Application US/10230880
; Publication No. US20030190705A1
; GENERAL INFORMATION:
; APPLICANT: WONG, HING C.
; APPLICANT: STINSON, JEFFREY L.
; APPLICANT: MOSQUERA, LUIS A.
; TITLE OF INVENTION: METHOD OF HUMANIZING IMMUNE SYSTEM MOLECULES
; FILE REFERENCE: 71758/58066
; CURRENT APPLICATION NUMBER: US/10/230,880
; CURRENT FILING DATE: 2002-12-23
; PRIOR APPLICATION NUMBER: 09/990,586
; PRIOR FILING DATE: 2001-11-21
; PRIOR APPLICATION NUMBER: 60/343,306
; PRIOR FILING DATE: 2001-10-29
; PRIOR APPLICATION NUMBER: 09/293,854
; PRIOR FILING DATE: 1999-04-16
; NUMBER OF SEQ ID NOS: 174
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 98
; LENGTH: 332
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-230-880-98

Query Match          99.5%; Score 1756; DB 4; Length 332;
Best Local Similarity 99.4%; Pred. No. 7.1e-128;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSMNSGALTSGVHTFPAVLQSS 60
Db 3 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSMNSGALTSGVHTFPAVLQSS 62

QY 61 GLYSLSVVTVPPSSSLGTQTYICNVNHPKSN TKVDKKVEPKSCDKTHTCPCPAPELAGA 120
Db 63 GLYSLSVVTVPPSSSLGTQTYICNVNHPKSN TKVDKKVEPKSCDKTHTCPCPAPELGG 122

QY 121 PSVFLFPPPKD TLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
Db 123 PSVFLFPPPKD TLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 182

QY 181 STYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Db 183 STYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 242

QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
```

```
Db 243 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSLKLTVDKSRW 302
QY 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330
Db 303 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 332

RESULT 95
US-11-122-622-98
; Sequence 98, Application US/11122622
; Publication No. US2006003901A1
; GENERAL INFORMATION:
; APPLICANT: JIAO, JIN-AN
; APPLICANT: WONG, HING C.
; TITLE OF INVENTION: ANTIBODIES FOR INHIBITING BLOOD COAGULATION AND METHODS
; FILE REFERENCE: 71758/46943-CIP2
; CURRENT APPLICATION NUMBER: US/11/122,622
; CURRENT FILING DATE: 2005-05-05
; PRIOR APPLICATION NUMBER: US/09/990,586
; PRIOR FILING DATE: 2001-11-21
; PRIOR APPLICATION NUMBER: 09/293,854
; PRIOR FILING DATE: 1999-04-16
; NUMBER OF SEQ ID NOS: 102
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 98
; LENGTH: 332
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-122-622-98

Query Match 99.5%; Score 1756; DB 6; Length 332;
Best Local Similarity 99.4%; Pred. No. 7.1e-128;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
Db 3 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 62
QY 61 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELAGA 120
Db 63 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG 122
QY 121 PSVFLFPPPKDPTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREEQYN 180
Db 123 PSVFLFPPPKDPTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREEQYN 182
QY 181 STYRVSVVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Db 183 STYRVSVVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 242
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSLKLTVDKSRW 300
Db 243 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSLKLTVDKSRW 302
QY 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330
Db 303 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 332

RESULT 96
US-10-272-899A-8
; Sequence 8, Application US/10272899A
; Publication No. US20040033561A1
; GENERAL INFORMATION:
; APPLICANT: O'Keefe, Theresa L.
; APPLICANT: Healy, Judith Jacques
; APPLICANT: Newman, Walter
; APPLICANT: Ponath, Paul
; APPLICANT: Bruce Keyt
; TITLE OF INVENTION: IMMUNOGLOBULIN DNA CASSETTE MOLECULES,
; FILE REFERENCE: MONOBODY CONSTRUCTS, METHODS OF PRODUCTION, AND METHODS OF
; TITLE OF INVENTION: USE THEREFOR
```

```
; FILE REFERENCE: MP101-244P2RM
; CURRENT APPLICATION NUMBER: US/10/272,899A
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/350,166
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: 60/392,364
; PRIOR FILING DATE: 2002-06-26
; NUMBER OF SEQ ID NOS: 110
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 333
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: human IgG1-WT protein
US-10-272-899A-8

Query Match 99.5%; Score 1756; DB 4; Length 333;
Best Local Similarity 99.4%; Pred. No. 7.2e-128;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
Db 4 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 63
QY 61 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELAGA 120
Db 64 GLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG 123
QY 121 PSVFLFPPPKDPTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREEQYN 180
Db 124 PSVFLFPPPKDPTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREEQYN 183
QY 181 STYRVSVVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Db 184 STYRVSVVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 243
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSLKLTVDKSRW 300
Db 244 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSLKLTVDKSRW 303
QY 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330
Db 304 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 333

RESULT 97
US-11-024-251-35
; Sequence 35, Application US/11024251
; Publication No. US20050266425A1
; GENERAL INFORMATION:
; APPLICANT: Zauderer, Maurice
; APPLICANT: Paris, Mark
; TITLE OF INVENTION: Methods for Producing and Identifying Multispecific Antibodies
; FILE REFERENCE: 1843.0230001
; CURRENT APPLICATION NUMBER: US/11/024,251
; CURRENT FILING DATE: 2004-12-29
; PRIOR APPLICATION NUMBER: 60/533,241
; PRIOR FILING DATE: 2003-12-31
; NUMBER OF SEQ ID NOS: 129
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 35
; LENGTH: 335
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: IgG Secretd Constant Domain
US-11-024-251-35

Query Match 99.5%; Score 1756; DB 6; Length 335;
Best Local Similarity 99.4%; Pred. No. 7.2e-128;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

QY 1 ASTKGPSVFLAPSSKSTGGTAALGCLVKDYFPEPVTVMNSGALTSGVHTFPAVLQSS 60
Db 6 ASTKGPSVFLAPSSKSTGGTAALGCLVKDYFPEPVTVMNSGALTSGVHTFPAVLQSS 65
QY 61 GLYSLSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHHTCCPPAPPELLAGA 120
Db 66 GLYSLSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHHTCCPPAPPELLGG 125
QY 121 PSVFLFPPPKPDKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 180
Db 126 PSVFLFPPPKPDKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 185
QY 181 STYRVSVLTVLHODWLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Db 186 STYRVSVLTVLHODWLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 245
QY 241 LTKNQVSLTCLVKGFVPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRW 300
Db 246 LTKNQVSLTCLVKGFVPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRW 305
QY 301 QQGNVFSCVMEALHNHYTQKSLSLSPGK 330
Db 306 QQGNVFSCVMEALHNHYTQKSLSLSPGK 335
RESULT 98
US-10-272-899A-72
; Sequence 72, Application US/10272899A
; Publication No. US20040033561A1
; GENERAL INFORMATION:
; APPLICANT: O'Keefe, Theresa L.
; APPLICANT: Healy, Judith Jacques
; APPLICANT: Newman, Walter
; APPLICANT: Ponath, Paul
; APPLICANT: Bruce Keyt
; TITLE OF INVENTION: IMMUNOGLOBULIN DNA CASSETTE MOLECULES,
; TITLE OF INVENTION: MONOBODY CONSTRUCTS, METHODS OF PRODUCTION, AND METHODS OF
; FILE OF INVENTION: USE THEREFOR
; FILE REFERENCE: MPI01-244P2RM
; CURRENT APPLICATION NUMBER: US/10/272,899A
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/350,166
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: 60/392,364
; PRIOR FILING DATE: 2002-06-26
; NUMBER OF SEQ ID NOS: 110
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 72
; LENGTH: 356
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: immunoglobulin cassette protein sequence
; OTHER INFORMATION: Leader-HuWT_55
US-10-272-899A-72
Query Match 99.5%; Score 1756; DB 4; Length 356;
Best Local Similarity 99.4%; Pred. No. 7.8e-128;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1 ASTKGPSVFLAPSSKSTGGTAALGCLVKDYFPEPVTVMNSGALTSGVHTFPAVLQSS 60
Db 27 ASTKGPSVFLAPSSKSTGGTAALGCLVKDYFPEPVTVMNSGALTSGVHTFPAVLQSS 86
QY 61 GLYSLSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHHTCCPPAPPELLAGA 120
Db 87 GLYSLSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHHTCCPPAPPELLGG 146
QY 121 PSVFLFPPPKPDKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 180
Db 147 PSVFLFPPPKPDKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 206
QY 181 STYRVSVLTVLHODWLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240

Db 207 STYRVSVLTVLHODWLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 266
QY 241 LTKNQVSLTCLVKGFVPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRW 300
Db 267 LTKNQVSLTCLVKGFVPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRW 326
QY 301 QQGNVFSCVMEALHNHYTQKSLSLSPGK 330
Db 327 QQGNVFSCVMEALHNHYTQKSLSLSPGK 356
RESULT 99
US-10-157-408-7
; Sequence 7, Application US/10157408
; Publication No. US20030104535A1
; GENERAL INFORMATION:
; APPLICANT: Capon, Daniel J.
; Gregory, Timothy J.
; TITLE OF INVENTION: Adhesion Variants
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.
; STREET: 460 Point San Bruno Blvd
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: patin (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/157,408
; FILING DATE: 28-May-2002
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/457,918
; FILING DATE: 1-JUN-1995
; APPLICATION NUMBER: 08/236311
; FILING DATE: 02-MAY-1994
; APPLICATION NUMBER: 07/936190
; FILING DATE: 26-AUG-1992
; APPLICATION NUMBER: 07/842777
; FILING DATE: 18-FEB-1992
; APPLICATION NUMBER: 07/250785
; FILING DATE: 28-SEP-1988
; APPLICATION NUMBER: 07/104329
; FILING DATE: 02-OCT-1987
; ATTORNEY/AGENT INFORMATION:
; NAME: Kubinec, Jeffrey S.
; REGISTRATION NUMBER: 36,575
; REFERENCE/DOCKET NUMBER: P0444PIC3
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415/225-8228
; TELEFAX: 415/952-9881
; TELEX: 910/371-7168
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 371 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 7:
US-10-157-408-7
Query Match 99.5%; Score 1756; DB 4; Length 371;
Best Local Similarity 99.4%; Pred. No. 8.2e-128;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1 ASTKGPSVFLAPSSKSTGGTAALGCLVKDYFPEPVTVMNSGALTSGVHTFPAVLQSS 60
Db 42 ASTKGPSVFLAPSSKSTGGTAALGCLVKDYFPEPVTVMNSGALTSGVHTFPAVLQSS 101

QY 61 GLYSLSSVVTVPPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPPCPAPELAGA 120
Db 102 GLYSLSSVVTVPPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPPCPAPELGG 161
QY 121 PSVFLFPPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
Db 162 PSVFLFPPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 221
QY 181 STYRVSVSLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGPREPQVYVTLPPSRDE 240
Db 222 STYRVSVSLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGPREPQVYVTLPPSRDE 281
QY 241 LTKNQVSLTCLVKGFYPSDIAVEHESNGPENNYKTTTPVLDSDGSFELYSKLTVDKSRW 300
Db 282 LTKNQVSLTCLVKGFYPSDIAVEHESNGPENNYKTTTPVLDSDGSFELYSKLTVDKSRW 341
QY 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330
Db 342 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 371

RESULT 100

US-10-097-044A-7
; Sequence 7, Application US/10097044A
; Publication No. US20030143220A1

GENERAL INFORMATION:

; APPLICANT: Capon, Daniel J.
; Gregory, Timothy J.
; TITLE OF INVENTION: Adhesion Variants
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Genentech, Inc.
; STREET: 460 Point San Bruno Blvd
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080

COMPUTER READABLE FORM:

; MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: datin (Genentech)

; CURRENT APPLICATION DATA: US/10/097, 044A
; FILING DATE: 28-May-2002
; CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US/08/457,918
; FILING DATE: 1-JUN-1995
; APPLICATION NUMBER: 08/236311
; FILING DATE: 02-MAY-1994
; APPLICATION NUMBER: 07/936190
; FILING DATE: 26-AUG-1992
; APPLICATION NUMBER: 07/842777
; FILING DATE: 18-FEB-1992
; APPLICATION NUMBER: 07/250785
; FILING DATE: 28-SEP-1988
; APPLICATION NUMBER: 07/104329
; FILING DATE: 02-OCT-1987

ATTORNEY/AGENT INFORMATION:

; NAME: Kubinec, Jeffrey S.
; REGISTRATION NUMBER: 36,575
; REFERENCE/DOCKET NUMBER: P0444PIC3
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415/225-8228
; TELEFAX: 415/952-9881
; TELEX: 910/371-7168

INFORMATION FOR SEQ ID NO: 7:

; SEQUENCE CHARACTERISTICS:
; LENGTH: 371 amino acids
; TYPE: amino acid
; TOPOLOGY: linear

; SEQUENCE DESCRIPTION: SEQ ID NO: 7:
US-10-097-044A-7

Query Match 99.5%; Score 1756; DB 4; Length 371;
Best Local Similarity 99.4%; Pred. No. 8.2e-128;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
Db 42 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 101
QY 61 GLYSLSSVVTVPPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPPCPAPELAGA 120
Db 102 GLYSLSSVVTVPPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHTCPPCPAPELGG 161
QY 121 PSVFLFPPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 180
Db 162 PSVFLFPPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN 221
QY 181 STYRVSVSLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGPREPQVYVTLPPSRDE 240
Db 222 STYRVSVSLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGPREPQVYVTLPPSRDE 281
QY 241 LTKNQVSLTCLVKGFYPSDIAVEHESNGPENNYKTTTPVLDSDGSFELYSKLTVDKSRW 300
Db 282 LTKNQVSLTCLVKGFYPSDIAVEHESNGPENNYKTTTPVLDSDGSFELYSKLTVDKSRW 341
QY 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330
Db 342 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 371

Search completed: June 12, 2006, 17:30:55
Job time : 314.346 secs

GenCore version 5.1.9
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: June 10, 2006, 12:32:32 ; Search time 11.3964 Seconds
(without alignments)
366.103 Million cell updates/sec

Title: US-10-733-563-110
Perfect score: 1765
Sequence: 1 ASTKGPSVFPLAPSSKSTSG.....MHEALHNHYTQKSLSLSPGK 330

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 64916 seqs, 12643201 residues

Total number of hits satisfying chosen parameters: 64916

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications AA New.*

- 1: /EMC_Celerra_SIDS3/ptodata/1/pubpaa/US09_NEW_PUB.pep.*
- 2: /EMC_Celerra_SIDS3/ptodata/1/pubpaa/US06_NEW_PUB.pep.*
- 3: /EMC_Celerra_SIDS3/ptodata/1/pubpaa/US07_NEW_PUB.pep.*
- 4: /EMC_Celerra_SIDS3/ptodata/1/pubpaa/US08_NEW_PUB.pep.*
- 5: /EMC_Celerra_SIDS3/ptodata/1/pubpaa/PCT_NEW_PUB.pep.*
- 6: /EMC_Celerra_SIDS3/ptodata/1/pubpaa/US10_NEW_PUB.pep.*
- 7: /EMC_Celerra_SIDS3/ptodata/1/pubpaa/US11_NEW_PUB.pep.*
- 8: /EMC_Celerra_SIDS3/ptodata/1/pubpaa/US60_NEW_PUB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1759	99.7	330	7	US-11-221-902-87
2	1756	99.5	330	7	US-11-219-563-136
3	1756	99.5	453	7	US-11-254-182-44
4	1756	99.5	464	7	US-11-219-563-132
5	1756	99.5	467	7	US-11-293-697-4293
6	1756	99.5	471	7	US-11-293-697-4294
7	1756	99.5	472	7	US-11-293-697-4073
8	1756	99.5	473	7	US-11-293-697-4284
9	1756	99.5	474	7	US-11-293-697-4282
10	1756	99.5	476	7	US-11-293-697-4288
11	1756	99.5	477	7	US-11-293-697-4289
12	1754	99.4	330	7	US-11-221-902-88
13	1752	99.3	471	7	US-11-293-697-4285
14	1751	99.2	448	7	US-11-183-218-56
15	1751	99.2	470	7	US-11-293-697-4292
16	1751	99.2	472	6	US-10-546-594-130
17	1751	99.2	697	7	US-11-155-444-2
18	1751	99.2	701	7	US-11-155-444-8
19	1750	99.2	330	7	US-11-221-902-25
20	1750	99.2	330	7	US-11-221-902-86
21	1750	99.2	447	7	US-11-219-121-30
22	1750	99.2	447	7	US-11-219-121-32
23	1750	99.2	448	7	US-11-219-121-28
24	1750	99.2	449	7	US-11-254-182-24
25	1750	99.2	450	7	US-11-221-902-2

ALIGNMENTS

RESULT 1

US-11-221-902-87
; Sequence 87, Application US/11221902
; Publication No. US20060088522A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: HUMANIZED ANTI-5T4 ANTIBODIES AND ANTI-5T4/CALICHEAMICIN CONJUGATE
; FILE REFERENCE: 040000-0317285
; CURRENT APPLICATION NUMBER: US/11/221,902
; CURRENT FILING DATE: 2005-09-09
; NUMBER OF SEQ ID NOS: 89
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 87
; LENGTH: 330
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-221-902-87

Query Match 99.7%; Score 1759; DB 7; Length 330;
Best Local Similarity 99.4%; Pred. No. 8.4e-133;
Matches 328; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY	1	ASTKGPSVFPLAPSSKSTSGGTAAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS	60
Db	1	ASTKGPSVFPLAPSSKSTSGGTAAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS	60
QY	61	GLYSLSSVTVFPSSSLGTQTVICNVNHPKSNTKVDKVPKSCDKTHTCPCPAPELAGA	120
Db	61	GLYSLSSVTVFPSSSLGTQTVICNVNHPKSNTKVDKVPKSCDKTHTCPCPAPELAGA	120
QY	121	PSVFLFPPKPKDLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVFNAKTKPREQYN	180
Db	121	PSVFLFPPKPKDLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVFNAKTKPREQYN	180
QY	181	STYRVSVSLTVLHQDLNGKCYKCKVSNKALPAPIEKTISKAKGQRPQVYTLPPSRDE	240
Db	181	STYRVSVSLTVLHQDLNGKCYKCKVSNKALPAPIEKTISKAKGQRPQVYTLPPSRDE	240
QY	241	LTKQVSLTCLVKGFYPSDIAVEWESNGQPNNYKTTTPVLDSDGSFFLYSKLTVDKSRW	300
Db	241	LTKQVSLTCLVKGFYPSDIAVEWESNGQPNNYKTTTPVLDSDGSFFLYSKLTVDKSRW	300
QY	301	QQGNVFCSVMHEALHNHYTQKSLSLSPGK	330
Db	301	QQGNVFCSVMHEALHNHYTQKSLSLSPGK	330

RESULT 2

```
US-11-219-563-136
; Sequence 136, Application US/11219563
; Publication No. US20060088539A1
; GENERAL INFORMATION:
; APPLICANT: Bander, Neil
; TITLE OF INVENTION: MODIFIED ANTIBODIES TO PROSTATE-SPECIFIC
; FILE OF INVENTION: MEMBRANE ANTIGEN AND USES THEREOF
; FILE REFERENCE: 13651.001 (BZL-001)
; CURRENT APPLICATION NUMBER: US/11/219,563
; CURRENT FILING DATE: 2005-09-02
; PRIOR APPLICATION NUMBER: PCT/US04/06586
; PRIOR FILING DATE: 2004-03-03
; PRIOR APPLICATION NUMBER: US 10/379,838
; PRIOR FILING DATE: 2003-03-03
; PRIOR APPLICATION NUMBER: 10/449,379
; PRIOR FILING DATE: 2003-05-30
; NUMBER OF SEQ ID NOS: 144
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 136
; LENGTH: 330
; TYPE: PRT
; ORGANISM: Artificial Sequence
; OTHER INFORMATION: Heavy chain constant region of deJ591 spans
US-11-219-563-136

Query Match          99.5%; Score 1756; DB 7; Length 330;
Best Local Similarity 99.4%; Pred. No. 1.5e-132;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
DB 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
QY 61 GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHHTCPCPAPELAGA 120
DB 61 GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHHTCPCPAPELAGA 120
QY 121 PSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNKTKPRREQYN 180
DB 121 PSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNKTKPRREQYN 180
QY 181 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
DB 181 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
DB 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSGFFLYSKLTVDKSRW 300
QY 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330
DB 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330

RESULT 3
US-11-254-182-44
; Sequence 44, Application US/11254182
; Publication No. US20060088523A1
; GENERAL INFORMATION:
; APPLICANT: ANDYA, JAMES
; APPLICANT: GWEE, SHIANG C.
; APPLICANT: LIU, JUN
; APPLICANT: SHEN, YE
; TITLE OF INVENTION: ANTIBODY FORMULATIONS
; FILE REFERENCE: P2104R1
; CURRENT APPLICATION NUMBER: US/11/254,182
; CURRENT FILING DATE: 2005-10-19
; PRIOR APPLICATION NUMBER: US 60/620,413
; PRIOR FILING DATE: 2004-10-20
; NUMBER OF SEQ ID NOS: 74
; SEQ ID NO 44
; LENGTH: 453

US-11-219-563-132
; Sequence 132, Application US/11219563
; Publication No. US20060088539A1
; GENERAL INFORMATION:
; APPLICANT: Bander, Neil
; TITLE OF INVENTION: MODIFIED ANTIBODIES TO PROSTATE-SPECIFIC
; FILE OF INVENTION: MEMBRANE ANTIGEN AND USES THEREOF
; FILE REFERENCE: 13651.001 (BZL-001)
; CURRENT APPLICATION NUMBER: US/11/219,563
; CURRENT FILING DATE: 2005-09-02
; PRIOR APPLICATION NUMBER: PCT/US04/06586
; PRIOR FILING DATE: 2004-03-03
; PRIOR APPLICATION NUMBER: US 10/379,838
; PRIOR FILING DATE: 2003-03-03
; PRIOR APPLICATION NUMBER: 10/449,379
; PRIOR FILING DATE: 2003-05-30
; NUMBER OF SEQ ID NOS: 144
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 132
; LENGTH: 464
; TYPE: PRT
; ORGANISM: Artificial Sequence
; OTHER INFORMATION: Heavy chain variable and constant region of deJ591
US-11-219-563-132

Query Match          99.5%; Score 1756; DB 7; Length 464;
Best Local Similarity 99.4%; Pred. No. 2.2e-132;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
DB 135 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 194
QY 61 GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHHTCPCPAPELAGA 120
DB 195 GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHHTCPCPAPELAGG 254

US-11-219-563-132
; Sequence 132, Application US/11219563
; Publication No. US20060088539A1
; GENERAL INFORMATION:
; APPLICANT: Bander, Neil
; TITLE OF INVENTION: MODIFIED ANTIBODIES TO PROSTATE-SPECIFIC
; FILE OF INVENTION: MEMBRANE ANTIGEN AND USES THEREOF
; FILE REFERENCE: 13651.001 (BZL-001)
; CURRENT APPLICATION NUMBER: US/11/219,563
; CURRENT FILING DATE: 2005-09-02
; PRIOR APPLICATION NUMBER: PCT/US04/06586
; PRIOR FILING DATE: 2004-03-03
; PRIOR APPLICATION NUMBER: US 10/379,838
; PRIOR FILING DATE: 2003-03-03
; PRIOR APPLICATION NUMBER: 10/449,379
; PRIOR FILING DATE: 2003-05-30
; NUMBER OF SEQ ID NOS: 144
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 132
; LENGTH: 464
; TYPE: PRT
; ORGANISM: Artificial Sequence
; OTHER INFORMATION: Heavy chain variable and constant region of deJ591
US-11-219-563-132

Query Match          99.5%; Score 1756; DB 7; Length 464;
Best Local Similarity 99.4%; Pred. No. 2.2e-132;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
DB 135 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 194
QY 61 GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHHTCPCPAPELAGA 120
DB 195 GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKVEPKSCDKTHHTCPCPAPELAGG 254
```


Db 203 GLYSLSVVVTPSSSLGTQTYICNVNHNKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG 262
Qy 121 PSVFLFPPPKDXTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 180
Db 263 PSVFLFPPPKDXTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 322
Qy 181 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPOVYITLPPSRDE 240
Db 323 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPOVYITLPPSRDE 382
Qy 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFELYSKLTVDKSRW 300
Db 383 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFELYSKLTVDKSRW 442
Qy 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330
Db 443 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 472

RESULT 8
US-11-293-697-4284
; Sequence 4284, Application US/11293697
; Publication No. US20060105376A1
; GENERAL INFORMATION:
; APPLICANT: HELIX RESEARCH INSTITUTE
; TITLE OF INVENTION: Novel full length cDNA
; FILE REFERENCE: H1-A0106
; CURRENT APPLICATION NUMBER: US/11/293,697
; CURRENT FILING DATE: 2005-12-05
; PRIOR APPLICATION NUMBER: US/10/108,260
; PRIOR FILING DATE: 2002-03-28
; NUMBER OF SEQ ID NOS: 5458
; SOFTWARE: Patent in Ver. 2.1
; SEQ ID NO 4284
; LENGTH: 473
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-293-697-4284

Query Match 99.5%; Score 1756; DB 7; Length 473;
Best Local Similarity 99.4%; Pred. No. 2.3e-132;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
Db 144 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 203
Qy 61 GLYSLSVVVTPSSSLGTQTYICNVNHNKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLAGA 120
Db 204 GLYSLSVVVTPSSSLGTQTYICNVNHNKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG 263
Qy 121 PSVFLFPPPKDXTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 180
Db 264 PSVFLFPPPKDXTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 323
Qy 181 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPOVYITLPPSRDE 240
Db 324 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPOVYITLPPSRDE 383
Qy 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFELYSKLTVDKSRW 300
Db 384 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFELYSKLTVDKSRW 443
Qy 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330
Db 444 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 473

RESULT 9
US-11-293-697-4282
; Sequence 4282, Application US/11293697
; Publication No. US20060105376A1
; GENERAL INFORMATION:

; APPLICANT: HELIX RESEARCH INSTITUTE
; TITLE OF INVENTION: Novel full length cDNA
; FILE REFERENCE: H1-A0106
; CURRENT APPLICATION NUMBER: US/11/293,697
; CURRENT FILING DATE: 2005-12-05
; PRIOR APPLICATION NUMBER: US/10/108,260
; PRIOR FILING DATE: 2002-03-28
; NUMBER OF SEQ ID NOS: 5458
; SOFTWARE: Patent in Ver. 2.1
; SEQ ID NO 4282
; LENGTH: 474
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-293-697-4282

Query Match 99.5%; Score 1756; DB 7; Length 474;
Best Local Similarity 99.4%; Pred. No. 2.3e-132;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
Db 145 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 204
Qy 61 GLYSLSVVVTPSSSLGTQTYICNVNHNKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLAGA 120
Db 205 GLYSLSVVVTPSSSLGTQTYICNVNHNKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG 264
Qy 121 PSVFLFPPPKDXTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 180
Db 265 PSVFLFPPPKDXTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKTKPREEQYN 324
Qy 181 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPOVYITLPPSRDE 240
Db 325 STYRVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPOVYITLPPSRDE 384
Qy 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFELYSKLTVDKSRW 300
Db 385 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFELYSKLTVDKSRW 444
Qy 301 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 330
Db 445 QQGNVFSCVMHEALHNHYTQKSLSLSPGK 474

RESULT 10
US-11-293-697-4288
; Sequence 4288, Application US/11293697
; Publication No. US20060105376A1
; GENERAL INFORMATION:
; APPLICANT: HELIX RESEARCH INSTITUTE
; TITLE OF INVENTION: Novel full length cDNA
; FILE REFERENCE: H1-A0106
; CURRENT APPLICATION NUMBER: US/11/293,697
; CURRENT FILING DATE: 2005-12-05
; PRIOR APPLICATION NUMBER: US/10/108,260
; PRIOR FILING DATE: 2002-03-28
; NUMBER OF SEQ ID NOS: 5458
; SOFTWARE: Patent in Ver. 2.1
; SEQ ID NO 4288
; LENGTH: 476
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-293-697-4288

Query Match 99.5%; Score 1756; DB 7; Length 476;
Best Local Similarity 99.4%; Pred. No. 2.3e-132;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 60
Db 147 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS 206
Qy 61 GLYSLSVVVTPSSSLGTQTYICNVNHNKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLAGA 120

```
Db 207 GYLSLSSVVTPSSSLGTQYICNVNHPKSNTKVDKKVEPKSCDKTHTCCPCPAPELLGG 266
QY 121 PSVFLPPPKPDKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKATKPREEQYN 180
Db 267 PSVFLPPPKPDKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKATKPREEQYN 326
QY 181 STYRVVSVLTVLHQDLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Db 327 STYRVVSVLTVLHQDLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 386
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300
Db 387 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 446
QY 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330
Db 447 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 476

RESULT 11
US-11-293-697-4289
; Sequence 4289, Application US/11293697
; Publication No. US20060105376A1
; GENERAL INFORMATION:
; APPLICANT: HELIX RESEARCH INSTITUTE
; TITLE OF INVENTION: Novel full length cDNA
; FILE REFERENCE: H1-A0106
; CURRENT APPLICATION NUMBER: US/11/293,697
; CURRENT FILING DATE: 2005-12-05
; PRIOR APPLICATION NUMBER: US/10/108,260
; NUMBER OF SEQ ID NOS: 5458
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4289
; LENGTH: 477
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-293-697-4289

Query Match 99.5%; Score 1756; DB 7; Length 477;
Best Local Similarity 99.4%; Pred. No. 2.3e-132;
Matches 328; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVMNSGALTSGVHTFPAVLQSS 60
Db 148 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVMNSGALTSGVHTFPAVLQSS 207
QY 61 GYLSLSSVVTPSSSLGTQYICNVNHPKSNTKVDKKVEPKSCDKTHTCCPCPAPELLAGA 120
Db 208 GYLSLSSVVTPSSSLGTQYICNVNHPKSNTKVDKKVEPKSCDKTHTCCPCPAPELLGG 267
QY 121 PSVFLPPPKPDKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKATKPREEQYN 180
Db 268 PSVFLPPPKPDKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKATKPREEQYN 327
QY 181 STYRVVSVLTVLHQDLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Db 328 STYRVVSVLTVLHQDLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 387
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300
Db 388 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 447
QY 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330
Db 448 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 477

RESULT 12
US-11-221-902-88
; Sequence 88, Application US/11221902
; Publication No. US20060088522A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: HUMANIZED ANTI-5T4 ANTIBODIES AND ANTI-5T4/CALICHEAMICIN CONJUGA
; FILE REFERENCE: 040000-0317285
; CURRENT APPLICATION NUMBER: US/11/221,902
; CURRENT FILING DATE: 2005-09-09
; NUMBER OF SEQ ID NOS: 89
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 88
; LENGTH: 330
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-221-902-88

Query Match 99.4%; Score 1754; DB 7; Length 330;
Best Local Similarity 99.1%; Pred. No. 2.1e-132;
Matches 327; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVMNSGALTSGVHTFPAVLQSS 60
Db 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVMNSGALTSGVHTFPAVLQSS 60
QY 61 GYLSLSSVVTPSSSLGTQYICNVNHPKSNTKVDKKVEPKSCDKTHTCCPCPAPELLAGA 120
Db 61 GYLSLSSVVTPSSSLGTQYICNVNHPKSNTKVDKKVEPKSCDKTHTCCPCPAPELLAGA 120
QY 121 PSVFLPPPKPDKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKATKPREEQYN 180
Db 121 PSVFLPPPKPDKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNKATKPREEQYN 180
QY 181 STYRVVSVLTVLHQDLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
Db 181 STYRVVSVLTVLHQDLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE 240
QY 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300
Db 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300
QY 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330
Db 301 QQGNVFCSCVMHEALHNHYTQKSLSLSPGK 330

RESULT 13
US-11-293-697-4285
; Sequence 4285, Application US/11293697
; Publication No. US20060105376A1
; GENERAL INFORMATION:
; APPLICANT: HELIX RESEARCH INSTITUTE
; TITLE OF INVENTION: Novel full length cDNA
; FILE REFERENCE: H1-A0106
; CURRENT APPLICATION NUMBER: US/11/293,697
; CURRENT FILING DATE: 2005-12-05
; PRIOR APPLICATION NUMBER: US/10/108,260
; PRIOR FILING DATE: 2002-03-28
; NUMBER OF SEQ ID NOS: 5458
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4285
; LENGTH: 471
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-293-697-4285

Query Match 99.3%; Score 1752; DB 7; Length 471;
Best Local Similarity 99.1%; Pred. No. 4.7e-132;
Matches 327; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVMNSGALTSGVHTFPAVLQSS 60
Db 142 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVMNSGALTSGVHTFPAVLQSS 201
QY 61 GYLSLSSVVTPSSSLGTQYICNVNHPKSNTKVDKKVEPKSCDKTHTCCPCPAPELLAGA 120
```

Db 202 GLYSLSSVVTVPSSSLGTQTYICNVNHPKSNTKVDKVEPKSCDKTHTCPPCPAPPELLGG 261
Qy 121 PSVFLFPPKPKDXTLMISRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNATKPREQYN 180
Db 262 PSVFLFPPKPKDXTLMISRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNATKPREQYN 321
Qy 181 STYRVSVLTVLHQDLNKGKEYCKVSNKALPAPIEKTISKAKGQPREPPQVYVTLPPSRDE 240
Db 322 STYRVSVLTVLHQDLNKGKEYCKVSNKALPAPIEKTISKAKGQPREPPQVYVTLPPSRDE 381
Qy 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300
Db 382 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 441
Qy 301 QGQNVFSCVMHEALHNHYTQKSLSLSPG 330
Db 442 QGQNVFSCVMHEALHNHYTQKSLSLSPG 471

RESULT 14
US-11-183-218-56
; Sequence 56, Application US/11183218
; Publication No. US2006008906A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryne
; TITLE OF INVENTION: ERYTHROPOIETIN: REMODELING AND
; TITLE OF INVENTION: GLYCOCONJUGATION OF ERYTHROPOIETIN
; FILE REFERENCE: 040853-01-5083-US02
; CURRENT APPLICATION NUMBER: US/11/183,218
; CURRENT FILING DATE: 2005-07-15
; PRIOR APPLICATION NUMBER: US 10/410,945
; PRIOR FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: PCT/US02/32263
; PRIOR FILING DATE: 2002-10-09
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-11-19
; PRIOR APPLICATION NUMBER: US 60/334,301
; PRIOR FILING DATE: 2001-11-28
; PRIOR APPLICATION NUMBER: US 60/334,233
; PRIOR FILING DATE: 2001-11-28
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 56
; LENGTH: 448
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-183-218-56

Query Match 99.2%; Score 1751; DB 7; Length 448;
Best Local Similarity 99.4%; Pred. No. 5.3e-132;
Matches 327; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSWNSGALTSQVHTEPFAVLQSS 60
Db 120 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSWNSGALTSQVHTEPFAVLQSS 179

Qy 61 GLYSLSSVVTVPSSSLGTQTYICNVNHPKSNTKVDKVEPKSCDKTHTCPPCPAPELAGA 120
Db 180 GLYSLSSVVTVPSSSLGTQTYICNVNHPKSNTKVDKVEPKSCDKTHTCPPCPAPELGG 239
Qy 121 PSVFLFPPKPKDXTLMISRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNATKPREQYN 180
Db 240 PSVFLFPPKPKDXTLMISRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNATKPREQYN 299
Qy 181 STYRVSVLTVLHQDLNKGKEYCKVSNKALPAPIEKTISKAKGQPREPPQVYVTLPPSRDE 240
Db 300 STYRVSVLTVLHQDLNKGKEYCKVSNKALPAPIEKTISKAKGQPREPPQVYVTLPPSRDE 359
Qy 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300
Db 360 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 419
Qy 301 QGQNVFSCVMHEALHNHYTQKSLSLSPG 329
Db 420 QGQNVFSCVMHEALHNHYTQKSLSLSPG 448

RESULT 15
US-11-293-697-4292
; Sequence 4292, Application US/11293697
; Publication No. US20060105376A1
; GENERAL INFORMATION:
; APPLICANT: HELIX RESEARCH INSTITUTE
; TITLE OF INVENTION: Novel full length cDNA
; FILE REFERENCE: H1-A0106
; CURRENT APPLICATION NUMBER: US/11/293,697
; CURRENT FILING DATE: 2005-12-05
; PRIOR APPLICATION NUMBER: US/10/108,260
; PRIOR FILING DATE: 2002-03-28
; NUMBER OF SEQ ID NOS: 5458
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4292
; LENGTH: 470
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-293-697-4292

Query Match 99.2%; Score 1751; DB 7; Length 470;
Best Local Similarity 99.1%; Pred. No. 5.7e-132;
Matches 327; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSWNSGALTSQVHTEPFAVLQSS 60
Db 141 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSWNSGALTSQVHTEPFAVLQSS 200
Qy 61 GLYSLSSVVTVPSSSLGTQTYICNVNHPKSNTKVDKVEPKSCDKTHTCPPCPAPELAGA 120
Db 201 GLYSLSSVVTVPSSSLGTQTYICNVNHPKSNTKVDKVEPKSCDKTHTCPPCPAPELGG 260
Qy 121 PSVFLFPPKPKDXTLMISRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNATKPREQYN 180
Db 261 PSVFLFPPKPKDXTLMISRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNATKPREQYN 320
Qy 181 STYRVSVLTVLHQDLNKGKEYCKVSNKALPAPIEKTISKAKGQPREPPQVYVTLPPSRDE 240
Db 321 STYRVSVLTVLHQDLNKGKEYCKVSNKALPAPIEKTISKAKGQPREPPQVYVTLPPSRDE 380
Qy 241 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 300
Db 381 LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW 440
Qy 301 QGQNVFSCVMHEALHNHYTQKSLSLSPG 330
Db 441 QGQNVFSCVMHEALHNHYTQKSLSLSPG 470

Search completed: June 10, 2006, 12:39:10
Job time : 12.3964 secs

GenCore version 5.1.9
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: June 12, 2006, 17:04:30 ; Search time 69.2929 seconds

(without alignments)
706.020 Million cell updates/sec

Title: US-10-733-563-112

Perfect score: 553

Sequence: 1 RTVAAPSVIFPPSDEQLKSLKLA.....EVTHQGLSSPVTKSFNRGEC 107

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2589679 seqs, 457216429 residues

Total number of hits satisfying chosen parameters: 2589679

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 1000 summaries

Database : A_Geneseq_8.*

1: Geneseqp1980s.*

2: Geneseqp1990s.*

3: Geneseqp2000s.*

4: Geneseqp2001s.*

5: Geneseqp2002s.*

6: Geneseqp2003as.*

7: Geneseqp2003bs.*

8: Geneseqp2004s.*

9: Geneseqp2005s.*

10: Geneseqp2006s.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	553	100.0	107	2	AAW40578 Human kap
2	553	100.0	107	2	AAW50152 Human kap
3	553	100.0	107	2	AAW92425 Human kap
4	553	100.0	107	2	AAW08745 Human kap
5	553	100.0	107	3	AAW27000 Human kap
6	553	100.0	107	5	ABG31883 Human kap
7	553	100.0	107	6	ABG98755 Human kap
8	553	100.0	107	6	ABR42732 Anti-tiss
9	553	100.0	107	6	ABR42734 Anti-tiss
10	553	100.0	107	6	ABR55835 Anti-Ang
11	553	100.0	107	7	ADJ94622 Human kap
12	553	100.0	107	8	ADJ77161 Anti-VAP-
13	553	100.0	107	8	ADL35096 Human Igg
14	553	100.0	107	8	ADL35094 Human Igg
15	553	100.0	107	8	ADM41539 Anti-inte
16	553	100.0	107	8	ADK18336 Amino aci
17	553	100.0	107	8	ADN97487 Artificia
18	553	100.0	107	8	ADQ89334 Human imm
19	553	100.0	107	8	ADS87911 Anti-IFN-
20	553	100.0	107	8	ADS94908 Anti-IFN-
21	553	100.0	107	8	ADT88871 Human Igg
22	553	100.0	107	8	ADT51583 Light cha
23	553	100.0	107	8	ADU68013 Mouse ant

24	553	100.0	107	9	ADW08870 IGF-IR an
25	553	100.0	107	9	ADW07454 Human kap
26	553	100.0	107	9	ADW24748 Variable
27	553	100.0	107	9	ADW24790 Variable
28	553	100.0	107	9	ADX98272 Human ant
29	553	100.0	107	9	ADY26693 Human ant
30	553	100.0	107	9	ADY74804 Human Igg
31	553	100.0	107	9	ADZ08815 Mammalian
32	553	100.0	107	9	ADZ08946 Amyloid a
33	553	100.0	107	9	ADZ44472 Human imm
34	553	100.0	107	9	AEA25951 Human imm
35	553	100.0	107	9	AEA16547 Human MCP
36	553	100.0	107	9	AEA45321 Apolipopr
37	553	100.0	107	9	AEA45323 Apolipopr
38	553	100.0	107	9	AEA37411 Anti-huma
39	553	100.0	107	9	AEA37415 Anti-huma
40	553	100.0	107	9	AEB09607 Human C k
41	553	100.0	107	9	AEB09607 Human C k
42	553	100.0	107	9	AEB72782 Anti-LfAl
43	553	100.0	107	9	AEC81787 Human imm
44	553	100.0	107	9	AED01341 Light cha
45	553	100.0	107	9	AED01379 Immunoglob
46	553	100.0	107	9	AEC94910 Anti-IL-1
47	553	100.0	107	9	AED41914 Deimmuniz
48	553	100.0	107	9	AED49132 Light cha
49	553	100.0	107	9	AED28066 Human kap
50	553	100.0	107	9	AED66964 Human kap
51	553	100.0	107	10	AEF16291 Humanized
52	553	100.0	107	10	AEF38694 Anti-body
53	553	100.0	107	10	AEF57798 Anti-IL-1
54	553	100.0	107	10	AEF63498 Human imm
55	553	100.0	107	10	AEF09130 Tie recep
56	553	100.0	108	8	ADL22765 Human ant
57	553	100.0	108	9	ADW15047 Human Fab
58	553	100.0	108	9	AEA52525 Human ant
59	553	100.0	109	8	ADJ95916 Human kap
60	553	100.0	109	8	AQD89338 Human imm
61	553	100.0	109	9	AEB09611 Human C k
62	553	100.0	117	7	ADD13779 Ig lambda
63	553	100.0	121	8	ADN98370 Human Igg
64	553	100.0	133	9	AED85881 Ig kappa
65	553	100.0	134	8	ADJ95970 Immunoglo
66	553	100.0	143	1	AAW93559 Sequence
67	553	100.0	155	9	AEB27727 Humanized
68	553	100.0	193	4	AAW52145 Humanised
69	553	100.0	201	2	AAW29770 P-selecti
70	553	100.0	212	5	ABP51955 Humanised
71	553	100.0	212	6	AAW031100 Human A2-
72	553	100.0	212	10	AEF11766 Human SCF
73	553	100.0	212	10	AEF11804 SCF-blindi
74	553	100.0	212	10	AEF11801 SCF-blindi
75	553	100.0	212	10	AEF11803 SCF-blindi
76	553	100.0	212	10	AEF11805 SCF-blindi
77	553	100.0	212	10	AEF11806 SCF-blindi
78	553	100.0	212	10	AEF11800 SCF-blindi
79	553	100.0	212	10	AEF11802 SCF-blindi
80	553	100.0	213	2	AAW04301 Antibody
81	553	100.0	213	4	AAE10516 Humanised
82	553	100.0	213	4	AAE10526 Humanised
83	553	100.0	213	4	AAE10512 Humanised
84	553	100.0	213	4	AAE10514 Humanised
85	553	100.0	213	4	AAE10524 Humanised
86	553	100.0	213	4	AAE10518 Humanised
87	553	100.0	213	4	AAE10522 Humanised
88	553	100.0	213	4	AAE10510 Humanised
89	553	100.0	213	4	AAE10520 Humanised
90	553	100.0	213	4	AAE83157 Ganglios
91	553	100.0	213	5	ABP66573 Human RSV
92	553	100.0	213	5	ABP66591 Human RSV
93	553	100.0	213	5	ABP66607 Human RSV
94	553	100.0	213	5	ABP66605 Human RSV
95	553	100.0	213	5	ABP66569 Human RSV
96	553	100.0	213	5	ABP66585 Human RSV

97	553	100.0	213	5	ABP66597	Abp66597 Human RSV	170	553	100.0	213	7	ADE35969	SYNAGIS a
98	553	100.0	213	5	ABP66581	Abp66581 Human RSV	171	553	100.0	213	7	ADE35937	SYNAGIS a
99	553	100.0	213	5	ABP66589	Abp66589 Human RSV	172	553	100.0	213	7	ADE35945	SYNAGIS a
100	553	100.0	213	5	ABP66563	Abp66563 Human RSV	173	553	100.0	213	7	ADE35957	SYNAGIS a
101	553	100.0	213	5	ABP66575	Abp66575 Human RSV	174	553	100.0	213	7	ADE35943	SYNAGIS a
102	553	100.0	213	5	ABP66601	Abp66601 Human RSV	175	553	100.0	213	7	ADE35953	SYNAGIS a
103	553	100.0	213	5	ABP66571	Abp66571 Human RSV	176	553	100.0	213	7	ADE35955	SYNAGIS a
104	553	100.0	213	5	ABP66579	Abp66579 Human RSV	177	553	100.0	213	7	ADE35938	LM4-type
105	553	100.0	213	5	ABP66593	Abp66593 Human RSV	178	553	100.0	213	7	ADJ79837	LM3-type
106	553	100.0	213	5	ABP66611	Abp66611 Human RSV	179	553	100.0	213	7	ADJ79810	Humanized
107	553	100.0	213	5	ABP66595	Abp66595 Human RSV	180	553	100.0	213	7	ADJ79839	LM5-type
108	553	100.0	213	5	ABP66565	Abp66565 Human RSV	181	553	100.0	213	8	ADL15441	Humanised
109	553	100.0	213	5	ABP66567	Abp66567 Human RSV	182	553	100.0	213	8	ADL15445	Humanised
110	553	100.0	213	5	ABP66609	Abp66609 Human RSV	183	553	100.0	213	8	ADL92471	Antibody
111	553	100.0	213	5	ABP66583	Abp66583 Human RSV	184	553	100.0	213	8	ADO00849	Humanised
112	553	100.0	213	5	ABP66587	Abp66587 Human RSV	185	553	100.0	213	8	ADO00853	Humanised
113	553	100.0	213	5	ABP66599	Abp66599 Human RSV	186	553	100.0	213	8	ADP44641	Human ant
114	553	100.0	213	5	ABP66577	Abp66577 Human RSV	187	553	100.0	213	8	ADP88495	Humanised
115	553	100.0	213	5	AU72810	Au72810 TRA-8 lig	188	553	100.0	213	8	ADS18711	Protein s
116	553	100.0	213	5	AAU72818	AAU72818 DNA encod	189	553	100.0	213	8	ADS33303	Anti-CD20
117	553	100.0	213	5	AAU72817	AAU72817 DNA encod	190	553	100.0	213	8	ADTS1702	Visilizum
118	553	100.0	213	6	AAU72816	AAU72816 DNA encod	191	553	100.0	213	8	ADTS1685	Dacilizuma
119	553	100.0	213	6	ABU69426	Abu69426 Respirato	192	553	100.0	213	8	ADU68153	Novel var
120	553	100.0	213	6	ABU69472	Abu69472 Respirato	193	553	100.0	213	8	ADU80277	CD20 bind
121	553	100.0	213	6	ABU69442	Abu69442 Respirato	194	553	100.0	213	8	ADW20067	RSV antig
122	553	100.0	213	6	ABU69462	Abu69462 Respirato	195	553	100.0	213	9	ADW20069	RSV antig
123	553	100.0	213	6	ABU69432	Abu69432 Respirato	196	553	100.0	213	9	ADW20079	RSV antig
124	553	100.0	213	6	ABU69434	Abu69434 Respirato	197	553	100.0	213	9	ADW20099	RSV antig
125	553	100.0	213	6	ABU69436	Abu69436 Respirato	198	553	100.0	213	9	ADW20073	RSV antig
126	553	100.0	213	6	ABU69450	Abu69450 Respirato	199	553	100.0	213	9	ADW20081	RSV antig
127	553	100.0	213	6	ABU69460	Abu69460 Respirato	200	553	100.0	213	9	ADW20085	RSV antig
128	553	100.0	213	6	ABU69468	Abu69468 Respirato	201	553	100.0	213	9	ADW20075	RSV antig
129	553	100.0	213	6	ABU69474	Abu69474 Respirato	202	553	100.0	213	9	ADW20089	RSV antig
130	553	100.0	213	6	ABU69458	Abu69458 Respirato	203	553	100.0	213	9	ADW20095	RSV antig
131	553	100.0	213	6	ABU69464	Abu69464 Respirato	204	553	100.0	213	9	ADW20107	RSV antig
132	553	100.0	213	6	ABU69446	Abu69446 Respirato	205	553	100.0	213	9	ADW20109	RSV antig
133	553	100.0	213	6	ABU69470	Abu69470 Respirato	206	553	100.0	213	9	ADW20065	RSV antig
134	553	100.0	213	6	ABU69430	Abu69430 Respirato	207	553	100.0	213	9	ADW20087	RSV antig
135	553	100.0	213	6	ABU69438	Abu69438 Respirato	208	553	100.0	213	9	ADW20091	RSV antig
136	553	100.0	213	6	ABU69454	Abu69454 Respirato	209	553	100.0	213	9	ADW20063	RSV antig
137	553	100.0	213	6	ABU69456	Abu69456 Respirato	210	553	100.0	213	9	ADW20105	RSV antig
138	553	100.0	213	6	ABU69440	Abu69440 Respirato	211	553	100.0	213	9	ADW20077	RSV antig
139	553	100.0	213	6	ABU69444	Abu69444 Respirato	212	553	100.0	213	9	ADW20083	RSV antig
140	553	100.0	213	6	ABU69448	Abu69448 Respirato	213	553	100.0	213	9	ADW20093	RSV antig
141	553	100.0	213	6	ABU69428	Abu69428 Respirato	214	553	100.0	213	9	ADW20101	RSV antig
142	553	100.0	213	6	ABU69452	Abu69452 Respirato	215	553	100.0	213	9	ADW20097	RSV antig
143	553	100.0	213	6	AAO29886	Aao29886 LM5 fusio	216	553	100.0	213	9	ADW20071	RSV antig
144	553	100.0	213	6	AAO29878	Aao29878 LM2 fusio	217	553	100.0	213	9	ADW20111	RSV antig
145	553	100.0	213	6	AAO29884	Aao29884 LM3 fusio	218	553	100.0	213	9	ADW03409	Humanized
146	553	100.0	213	6	AAO29885	Aao29885 LM4 fusio	219	553	100.0	213	9	ADW77076	Light cha
147	553	100.0	213	6	AAE35326	Aae35326 Humanised	220	553	100.0	213	9	ADX18542	VEGF-spec
148	553	100.0	213	6	AAE34878	Aae34878 B1W4/8 a	221	553	100.0	213	9	ADY50070	Endotheli
149	553	100.0	213	6	AAE34877	Aae34877 B1W4/4 ant	222	553	100.0	213	9	ADZ99429	Humanized
150	553	100.0	213	6	ABG75668	Abg75668 Synagis l	223	553	100.0	213	9	AEA60641	Human but
151	553	100.0	213	6	AAE33521	Aae33521 Human AQC	224	553	100.0	213	9	AEBO7087	RSV-speci
152	553	100.0	213	6	AAE33445	Aae33445 KS antibo	225	553	100.0	213	9	AEBO7071	RSV-speci
153	553	100.0	213	7	ABE35929	Abe35929 SYNAGIS a	226	553	100.0	213	9	ABEBO7065	RSV-speci
154	553	100.0	213	7	ABE35921	Abe35921 SYNAGIS a	227	553	100.0	213	9	ABEBO7069	RSV-speci
155	553	100.0	213	7	ABE35939	Abe35939 SYNAGIS a	228	553	100.0	213	9	ABEBO7093	RSV-speci
156	553	100.0	213	7	ABE35959	Abe35959 SYNAGIS a	229	553	100.0	213	9	ABEBO7045	RSV-speci
157	553	100.0	213	7	ABE35935	Abe35935 SYNAGIS a	230	553	100.0	213	9	ABEBO7053	RSV-speci
158	553	100.0	213	7	ABE35941	Abe35941 SYNAGIS a	231	553	100.0	213	9	ABEBO7079	RSV-speci
159	553	100.0	213	7	ABE35927	Abe35927 SYNAGIS a	232	553	100.0	213	9	ABEBO7083	RSV-speci
160	553	100.0	213	7	ABE35947	Abe35947 SYNAGIS a	233	553	100.0	213	9	ABEBO7049	RSV-speci
161	553	100.0	213	7	ABE35949	Abe35949 SYNAGIS a	234	553	100.0	213	9	ABEBO7075	RSV-speci
162	553	100.0	213	7	ADE35963	Ade35963 SYNAGIS a	235	553	100.0	213	9	ABEBO7091	RSV-speci
163	553	100.0	213	7	ADE35931	Ade35931 SYNAGIS a	236	553	100.0	213	9	ABEBO7055	RSV-speci
164	553	100.0	213	7	ADE35933	Ade35933 SYNAGIS a	237	553	100.0	213	9	ABEBO7073	RSV-speci
165	553	100.0	213	7	ADE35923	Ade35923 SYNAGIS a	238	553	100.0	213	9	ABEBO7047	RSV-speci
166	553	100.0	213	7	ADE35965	Ade35965 SYNAGIS a	239	553	100.0	213	9	ABEBO7057	RSV-speci
167	553	100.0	213	7	ADE35951	Ade35951 SYNAGIS a	240	553	100.0	213	9	ABEBO7061	RSV-speci
168	553	100.0	213	7	ADE35925	Ade35925 SYNAGIS a	241	553	100.0	213	9	ABEBO7067	RSV-speci
169	553	100.0	213	7	ADE35967	Ade35967 SYNAGIS a	242	553	100.0	213	9	ABEBO7051	RSV-speci

243	553	100.0	213	9	AEB07063	Aeb07063 RSV-speci	316	553	100.0	214	2	AAW34506	Aaw34506 Light cha
244	553	100.0	213	9	AEB07077	Aeb07077 RSV-speci	317	553	100.0	214	2	ADE51519	Ades51519 p-ANCA re
245	553	100.0	213	9	AEB07081	Aeb07081 RSV-speci	318	553	100.0	214	2	AAW49815	Aaw49815 Amino aci
246	553	100.0	213	9	AEB07089	Aeb07089 RSV-speci	319	553	100.0	214	2	AAW64671	Aaw64671 Human UC
247	553	100.0	213	9	AEB07059	Aeb07059 RSV-speci	320	553	100.0	214	2	AAW06842	Aay06842 Seq ID No
248	553	100.0	213	9	AEB17637	Aeb17637 Light cha	321	553	100.0	214	2	AAW08600	Aay08600 JP1112785
249	553	100.0	213	9	AEB29787	Aeb29787 Humanized	322	553	100.0	214	2	AAW08599	Aay08599 Anti-huma
250	553	100.0	213	9	AEB29791	Aeb29791 Humanized	323	553	100.0	214	2	AAW95615	Aaw95615 Humanized
251	553	100.0	213	9	AEB29782	Aeb29782 Humanized	324	553	100.0	214	2	AAW34039	AAW34039 NANUC-2 a
252	553	100.0	213	9	AEB29778	Aeb29778 Humanized	325	553	100.0	214	2	AAW30632	AAW30632 Recombina
253	553	100.0	213	9	AEB13533	Aeb13533 Mature ch	326	553	100.0	214	2	AAW08754	Aay08754 Human ant
254	553	100.0	213	9	AEC40038	Aec40038 Light cha	327	553	100.0	214	2	AAW30202	Aay30202 Light cha
255	553	100.0	213	9	AEC76842	Aec76842 SYNAGIS-d	328	553	100.0	214	2	AAW57337	AAW57337 UC PANCA
256	553	100.0	213	9	AEC76846	Aec76846 SYNAGIS-d	329	553	100.0	214	3	AAW93735	AAW93735 The kappa
257	553	100.0	213	9	AEC76884	Aec76884 SYNAGIS-d	330	553	100.0	214	3	AAW29407	AAW29407 Human mon
258	553	100.0	213	9	AEC76848	Aec76848 SYNAGIS-d	331	553	100.0	214	3	AEA11265	AEA11265 Humanized
259	553	100.0	213	9	AEC76852	Aec76852 SYNAGIS-d	332	553	100.0	214	3	AEA11267	AEA11267 Deamidate
260	553	100.0	213	9	AEC76886	Aec76886 SYNAGIS-d	333	553	100.0	214	4	AAW66777	AAW66777 rhuWAB CD
261	553	100.0	213	9	AEC76854	Aec76854 SYNAGIS-d	334	553	100.0	214	5	ABP66603	ABP66603 Human RSV
262	553	100.0	213	9	AEC76874	Aec76874 SYNAGIS-d	335	553	100.0	214	5	AAE19696	AAE19696 Antibody
263	553	100.0	213	9	AEC76850	Aec76850 SYNAGIS-d	336	553	100.0	214	5	AAO18399	AAO18399 Mature hu
264	553	100.0	213	9	AEC76856	Aec76856 SYNAGIS-d	337	553	100.0	214	5	ABG31889	ABG31889 Humanised
265	553	100.0	213	9	AEC76872	Aec76872 SYNAGIS-d	338	553	100.0	214	5	ABA47727	ABA47727 Light cha
266	553	100.0	213	9	AEC76860	Aec76860 SYNAGIS-d	339	553	100.0	214	5	ABW99223	ABW99223 Chimeric
267	553	100.0	213	9	AEC76862	Aec76862 SYNAGIS-d	340	553	100.0	214	6	AAE35890	AAE35890 Human 11.
268	553	100.0	213	9	AEC76878	Aec76878 SYNAGIS-d	341	553	100.0	214	6	ABU69466	ABU69466 Respirato
269	553	100.0	213	9	AEC76858	Aec76858 SYNAGIS-d	342	553	100.0	214	6	ABR55870	ABR55870 Human imm
270	553	100.0	213	9	AEC76870	Aec76870 SYNAGIS-d	343	553	100.0	214	6	ABG74711	ABG74711 Murine hu
271	553	100.0	213	9	AEC76888	Aec76888 SYNAGIS-d	344	553	100.0	214	7	ADB85319	ADB85319 Light cha
272	553	100.0	213	9	AEC76868	Aec76868 SYNAGIS-d	345	553	100.0	214	7	ADC26157	ADC26157 Anti-VEGF
273	553	100.0	213	9	AEC76876	Aec76876 SYNAGIS-d	346	553	100.0	214	7	ADC26154	ADC26154 Parent an
274	553	100.0	213	9	AEC76844	Aec76844 SYNAGIS-d	347	553	100.0	214	7	ADC26164	ADC26164 Humanised
275	553	100.0	213	9	AEC76864	Aec76864 SYNAGIS-d	348	553	100.0	214	7	ADC26166	ADC26166 Humanised
276	553	100.0	213	9	AEC76882	Aec76882 SYNAGIS-d	349	553	100.0	214	7	ADC26156	ADC26156 Anti-VEGF
277	553	100.0	213	9	AEC76840	Aec76840 SYNAGIS a	350	553	100.0	214	7	ADC73235	ADC73235 Protein s
278	553	100.0	213	9	AEC76866	Aec76866 SYNAGIS-d	351	553	100.0	214	7	ABR83150	ABR83150 Hu007 ant
279	553	100.0	213	9	AED19129	Aed19129 Humanized	352	553	100.0	214	7	ADE35961	ADE35961 SYNAGIS a
280	553	100.0	213	9	AED19167	Aed19167 Humanized	353	553	100.0	214	7	ADE01486	ADE01486 CDP870 li
281	553	100.0	213	9	AED01052	Aed01052 Anti-NGF	354	553	100.0	214	7	ADF11431	ADF11431 18B2 anti
282	553	100.0	213	9	AEB18959	Aeb18959 Humanized	355	553	100.0	214	7	ADF11423	ADF11423 2E11 anti
283	553	100.0	213	9	AEB18926	Aeb18926 Humanized	356	553	100.0	214	8	ADF11667	ADF11667 anti-HER2
284	553	100.0	213	9	AEB18956	Aeb18956 Humanized	357	553	100.0	214	8	ADF11669	ADF11669 anti-CD11
285	553	100.0	213	9	AEB18962	Aeb18962 Humanized	358	553	100.0	214	8	ADF73140	ADF73140 Humanized
286	553	100.0	213	9	AEB18944	Aeb18944 Humanized	359	553	100.0	214	8	ADF69630	ADF69630 Humanized
287	553	100.0	213	9	AEB18958	Aeb18958 Humanized	360	553	100.0	214	8	ADH34232	ADH34232 Anti-huma
288	553	100.0	213	9	AEB18953	Aeb18953 Humanized	361	553	100.0	214	8	ADH34591	ADH34591 023 light
289	553	100.0	213	9	AEB18963	Aeb18963 Humanized	362	553	100.0	214	8	ADH34510	ADH34510 Light cha
290	553	100.0	213	10	AEE26264	Aee26264 Humanized	363	553	100.0	214	8	ADJ11307	ADJ11307 BHA10 VU#
291	553	100.0	213	10	AEE26249	Aee26249 Humanized	364	553	100.0	214	8	ADK52358	ADK52358 Human ant
292	553	100.0	213	10	AEE26244	Aee26244 Humanized	365	553	100.0	214	8	ADK52358	ADK52358 Anti-TNFA
293	553	100.0	213	10	AEE64956	Aee64956 Mature 2H	366	553	100.0	214	8	ADL70799	ADL70799 Anti-TNFA
294	553	100.0	213	10	AEE64959	Aee64959 Mature 2H	367	553	100.0	214	8	ADK18342	ADK18342 Amino aci
295	553	100.0	213	10	AEE10477	Aee10477 Humanized	368	553	100.0	214	8	ADM31928	ADM31928 Humanised
296	553	100.0	213	10	AEE10480	Aee10480 Humanized	369	553	100.0	214	8	ADN49727	ADN49727 Human imm
297	553	100.0	213	10	AEE70763	Aee70763 Humanized	370	553	100.0	214	8	ADN98361	ADN98361 Human IGG
298	553	100.0	213	10	AEE70776	Aee70776 Humanized	371	553	100.0	214	8	ADQ31280	ADQ31280 Humanised
299	553	100.0	213	10	AEP05019	Aef05019 Humanized	372	553	100.0	214	8	ADQ31272	ADQ31272 Murine 11
300	553	100.0	213	10	AEP05022	Aef05022 Humanized	373	553	100.0	214	8	ADQ31278	ADQ31278 Humanised
301	553	100.0	213	10	AEP27226	Aef27226 Humanized	374	553	100.0	214	8	AQO07672	AQO07672 Amino aci
302	553	100.0	213	10	AEF16417	Aef16417 Humanized	375	553	100.0	214	8	AQO07415	AQO07415 Mature CB
303	553	100.0	213	10	AEF16400	Aef16400 Humanized	376	553	100.0	214	8	ADQ12198	ADQ12198 CBE11 pen
304	553	100.0	213	10	AEF51205	Aef51205 Human ant	377	553	100.0	214	8	ADR23360	ADR23360 Human CD7
305	553	100.0	213	10	AEP64240	Aef64240 Humanized	378	553	100.0	214	8	ADR23358	ADR23358 Human CD7
306	553	100.0	213	10	AEP65387	Aef65387 Anti-RhD	379	553	100.0	214	8	ADR23366	ADR23366 Human CD7
307	553	100.0	213	10	AEP65406	Aef65406 Anti-RhD	380	553	100.0	214	8	ADR23364	ADR23364 Human CD7
308	553	100.0	213	10	AEG04996	Aeg04996 Anti-CD20	381	553	100.0	214	8	ADS18705	ADS18705 Protein s
309	553	100.0	213	10	AEF95120	Aef95120 Anti-CD20	382	553	100.0	214	8	ADS18703	ADS18703 Protein s
310	553	100.0	214	2	AAR30776	Aar30776 H5216-158	383	553	100.0	214	8	ADT55440	ADT55440 Anti Ige
311	553	100.0	214	2	AAR43338	Aar43338 Complelet	384	553	100.0	214	8	ADT51696	ADT51696 Fontolizu
312	553	100.0	214	2	AAW05828	Aaw05828 Humanised	385	553	100.0	214	8	ADU74403	ADU74403 Human imm
313	553	100.0	214	2	AAW45517	Aaw45517 NANUC-2 1	386	553	100.0	214	8	ADU86568	ADU86568 Immunoglo
314	553	100.0	214	2	AAW07615	Aaw07615 Ulcerativ	387	553	100.0	214	8	ADU86567	ADU86567 Immunoglo
315	553	100.0	214	2	AAW34504	Aaw34504 Light cha	388	553	100.0	214	8	ADU86523	ADU86523 Immunoglo

389	553	100.0	214	9	ADW20103	Adw20103	RSV antiag	462	553	100.0	214	10	AEF65375	Aef65375	Anti-Rhd
390	553	100.0	214	9	ADW77068	Adw77068	Light cha	463	553	100.0	214	10	AEF65419	Aef65419	Anti-Rhd
391	553	100.0	214	9	ADW44597	Adw44597	PRIMATEIZE	464	553	100.0	214	10	AEF65392	Aef65392	Anti-Rhd
392	553	100.0	214	9	ADW11300	Adw11300	Human C-t	465	553	100.0	214	10	AEF65379	Aef65379	Anti-Rhd
393	553	100.0	214	9	ADW90321	Adw90321	Phage scF	466	553	100.0	214	10	AEF65377	Aef65377	Anti-Rhd
394	553	100.0	214	9	ADX18554	Adx18554	VEGF-spec	467	553	100.0	214	10	AEF65402	Aef65402	Anti-Rhd
395	553	100.0	214	9	ADX18564	Adx18564	VEGF-spec	468	553	100.0	214	10	AEF65400	Aef65400	Anti-Rhd
396	553	100.0	214	9	ADX18569	Adx18569	VEGF-spec	469	553	100.0	214	10	AEF65402	Aef65402	Anti-Rhd
397	553	100.0	214	9	ADX18559	Adx18559	VEGF-spec	470	553	100.0	215	2	AEF65402	Aef65402	Anti-Rhd
398	553	100.0	214	9	ADX18555	Adx18555	VEGF-spec	471	553	100.0	215	2	AEF65402	Aef65402	Anti-Rhd
399	553	100.0	214	9	ADX18555	Adx18555	VEGF-spec	472	553	100.0	215	2	AEF65402	Aef65402	Anti-Rhd
400	553	100.0	214	9	ADX18562	Adx18562	VEGF-spec	473	553	100.0	215	7	ADF11419	Adf11419	22B3 anti
401	553	100.0	214	9	ADX18546	Adx18546	VEGF-spec	474	553	100.0	215	7	ADF11419	Adf11419	22B3 anti
402	553	100.0	214	9	ADX18568	Adx18568	VEGF-spec	475	553	100.0	215	7	ADF11419	Adf11419	9H7 anti-
403	553	100.0	214	9	ADX18544	Adx18544	VEGF-spec	476	553	100.0	215	7	ADF11427	Adf11427	2D8 anti-
404	553	100.0	214	9	ADX18553	Adx18553	VEGF-spec	477	553	100.0	215	7	ADJ32146	Adj32146	Human int
405	553	100.0	214	9	ADX18557	Adx18557	VEGF-spec	478	553	100.0	215	8	ADQ31885	Adq31885	Antibody
406	553	100.0	214	9	ADX20220	Adx20220	SARS coro	479	553	100.0	215	8	ADQ31891	Adq31891	Antibody
407	553	100.0	214	9	ADX01873	Adx01873	SARS coro	480	553	100.0	215	8	ADR23356	Adr23356	Human CD7
408	553	100.0	214	9	ADX27044	Adx27044	Murine ht	481	553	100.0	215	8	ARM83746	Arm83746	Human dia
409	553	100.0	214	9	ADX80641	Adx80641	Trastuzum	482	553	100.0	215	8	ADS87927	Ads87927	Anti-IFN-
410	553	100.0	214	9	ADY50072	Ady50072	Endotheli	483	553	100.0	215	8	ADS87929	Ads87929	Anti-IFN-
411	553	100.0	214	9	ADY26729	Ady26729	Anti-NGF-	484	553	100.0	215	8	ADS87925	Ads87925	Anti-IFN-
412	553	100.0	214	9	ADY80251	Ady80251	Amino aci	485	553	100.0	215	8	ADS94926	Ads94926	Anti-IFN-
413	553	100.0	214	9	ADY70960	Ady70960	Human mon	486	553	100.0	215	8	ADS94922	Ads94922	Anti-IFN-
414	553	100.0	214	9	AEA36339	Aea36339	Human CBE	487	553	100.0	215	8	ADS94924	Ads94924	Anti-IFN-
415	553	100.0	214	9	AEA3853	Aea3853	VEGF rela	488	553	100.0	215	8	ADT51708	Adt51708	M200 anti
416	553	100.0	214	9	AEA13907	Aea13907	VEGF rela	489	553	100.0	215	8	ADT77644	Adt77644	Antibody
417	553	100.0	214	9	AEA13911	Aea13911	VEGF rela	490	553	100.0	215	8	ADU86570	Adu86570	Immunoglo
418	553	100.0	214	9	AEA13860	Aea13860	VEGF rela	491	553	100.0	215	9	ADY50068	Ady50068	Endotheli
419	553	100.0	214	9	AEA13947	Aea13947	VEGF rela	492	553	100.0	215	9	ADY50064	Ady50064	Endotheli
420	553	100.0	214	9	AEA13849	Aea13849	VEGF rela	493	553	100.0	215	9	AEBA48819	Aeb48819	Anti-onco
421	553	100.0	214	9	AEA13849	Aea13849	VEGF rela	494	553	100.0	215	9	AEBS1163	Aeb51163	Chimeric
422	553	100.0	214	9	AEA13915	Aea13915	VEGF rela	495	553	100.0	215	9	AEBS1169	Aeb51169	Chimeric
423	553	100.0	214	9	AEA14679	Aea14679	VEGF rela	496	553	100.0	215	9	AEBS18932	Aeb18932	Humanized
424	553	100.0	214	9	AEA13913	Aea13913	VEGF rela	497	553	100.0	215	10	AEF12091	Aef12091	Anti-alpha
425	553	100.0	214	9	AEA13951	Aea13951	VEGF rela	498	553	100.0	215	10	AEF16423	Aef16423	Chimeric
426	553	100.0	214	9	AEA13909	Aea13909	VEGF rela	499	553	100.0	215	10	AEF65404	Aef65404	Anti-Rhd
427	553	100.0	214	9	AEA14262	Aea14262	VEGF rela	500	553	100.0	215	10	AEF65398	Aef65398	Anti-Rhd
428	553	100.0	214	9	AEA13861	Aea13861	VEGF rela	501	553	100.0	215	10	AEF65401	Aef65401	Anti-Rhd
429	553	100.0	214	9	AEA13912	Aea13912	VEGF rela	502	553	100.0	215	10	AEF65391	Aef65391	Anti-Rhd
430	553	100.0	214	9	AEA14264	Aea14264	VEGF rela	503	553	100.0	215	10	AEF65428	Aef65428	Anti-Rhd
431	553	100.0	214	9	AEA13917	Aea13917	VEGF rela	504	553	100.0	215	10	AEF65429	Aef65429	Anti-Rhd
432	553	100.0	214	9	AEA48169	Aea48169	Mouse ant	505	553	100.0	215	10	AEF65420	Aef65420	Anti-Rhd
433	553	100.0	214	9	AEA48166	Aea48166	Mouse ant	506	553	100.0	215	10	AEF65386	Aef65386	Anti-Rhd
434	553	100.0	214	9	AEBS07085	Aeb07085	RSV-speci	507	553	100.0	215	10	AEF65414	Aef65414	Anti-Rhd
435	553	100.0	214	9	AEBS6306	Aeb56306	Anti-IGF	508	553	100.0	215	10	AEF65378	Aef65378	Anti-Rhd
436	553	100.0	214	9	AEBA6966	Aeb46966	CD1a spec	509	553	100.0	215	10	AEF65394	Aef65394	Anti-Rhd
437	553	100.0	214	9	AEBA27968	Aeb27968	Humanized	510	553	100.0	215	10	AEF65415	Aef65415	Anti-Rhd
438	553	100.0	214	9	AEC16144	Aec16144	Human ant	511	553	100.0	215	10	AEF65425	Aef65425	Anti-Rhd
439	553	100.0	214	9	AEC76880	Aec76880	SYNAGIS-d	512	553	100.0	215	10	AEF65413	Aef65413	Anti-Rhd
440	553	100.0	214	9	AED20673	Aed20673	Trastuzum	513	553	100.0	215	10	AEF65385	Aef65385	Anti-Rhd
441	553	100.0	214	9	AED04291	Aed04291	Human ant	514	553	100.0	215	10	AEF65422	Aef65422	Anti-Rhd
442	553	100.0	214	9	AED04363	Aed04363	Human ant	515	553	100.0	215	10	AEF65388	Aef65388	Anti-Rhd
443	553	100.0	214	9	AED12732	Aed12732	Light cha	516	553	100.0	215	10	AEF65390	Aef65390	Anti-Rhd
444	553	100.0	214	9	AED66970	Aed66970	Humanized	517	553	100.0	215	10	AEF65397	Aef65397	Anti-Rhd
445	553	100.0	214	9	AED76655	Aed76655	Human Her	518	553	100.0	215	10	AEF65409	Aef65409	Anti-Rhd
446	553	100.0	214	10	AEF24412	Aef24412	Human 1-7	519	553	100.0	216	8	ADS87940	Ads87940	Anti-IFN-
447	553	100.0	214	10	AEF16411	Aef16411	Humanized	520	553	100.0	216	8	ADS94937	Ads94937	Anti-IFN-
448	553	100.0	214	10	AEF03139	Aef03139	Trastuzum	521	553	100.0	216	10	AEF65403	Aef65403	Anti-Rhd
449	553	100.0	214	10	AEF03141	Aef03141	Pertuzuma	522	553	100.0	216	10	AEF65412	Aef65412	Anti-Rhd
450	553	100.0	214	10	AEF27301	Aef27301	Humanized	523	553	100.0	216	10	AEF65376	Aef65376	Anti-Rhd
451	553	100.0	214	10	AEF27303	Aef27303	Humanized	524	553	100.0	216	10	AEF65381	Aef65381	Anti-Rhd
452	553	100.0	214	10	AEF41639	Aef41639	Humanized	525	553	100.0	216	10	AEF65374	Aef65374	Anti-Rhd
453	553	100.0	214	10	AEF80296	Aef80296	Antibody	526	553	100.0	216	10	AEF65380	Aef65380	Anti-Rhd
454	553	100.0	214	10	AEF80300	Aef80300	Antibody	527	553	100.0	216	10	AEF65393	Aef65393	Anti-Rhd
455	553	100.0	214	10	AEF65405	Aef65405	Anti-Rhd	528	553	100.0	216	10	AEF65423	Aef65423	Anti-Rhd
456	553	100.0	214	10	AEF65424	Aef65424	Anti-Rhd	529	553	100.0	216	10	AEF01545	Aeg01545	Kallikrei
457	553	100.0	214	10	AEF65382	Aef65382	Anti-Rhd	530	553	100.0	217	9	ADY74780	Ady74780	Rat anti-
458	553	100.0	214	10	AEF65384	Aef65384	Anti-Rhd	531	553	100.0	217	10	AEF27311	Aef27311	Humanized
459	553	100.0	214	10	AEF65407	Aef65407	Anti-Rhd	532	553	100.0	217	10	AEF65411	Aef65411	Anti-Rhd
460	553	100.0	214	10	AEF65410	Aef65410	Anti-Rhd	533	553	100.0	217	10	AEF65383	Aef65383	Anti-Rhd
461	553	100.0	214	10	AEF65421	Aef65421	Anti-Rhd	534	553	100.0	218	2	AAR33312	Aar33312	Humanised

535	553	100.0	218	2	AAW13563	Aaw13563 Humanised	608	553	100.0	219	7	AAE39095	Aae39095 Protein #
536	553	100.0	218	2	AAW95660	Aaw95660 Mus muscu	609	553	100.0	219	7	ADJ94065	Ades94065 Humanised
537	553	100.0	218	2	AAW95664	Aaw95664 Mus muscu	610	553	100.0	219	7	ADJ32152	Adj32152 Human int
538	553	100.0	218	2	AAW95662	Aaw95662 Mus muscu	611	553	100.0	219	7	ADJ32150	Adj32150 Human int
539	553	100.0	218	2	AAW95669	Aaw95669 Mus muscu	612	553	100.0	219	7	ADJ32140	Adj32140 Human int
540	553	100.0	218	2	AAW95658	Aaw95658 Mus muscu	613	553	100.0	219	7	ADJ32138	Adj32138 Human int
541	553	100.0	218	2	AAW50030	Aay50030 Human E27	614	553	100.0	219	8	ADH34589	Adh34589 011 light
542	553	100.0	218	3	AAW85020	Aay85020 Light cha	615	553	100.0	219	8	ADH34590	Adh34590 021 light
543	553	100.0	218	3	AAW807472	Aab07472 Amino aci	616	553	100.0	219	8	ADH34588	Adh34588 008 light
544	553	100.0	218	4	AAW47087	Aab47087 Anti-IGE	617	553	100.0	219	8	ADI35160	Adi35160 Humanised
545	553	100.0	218	4	AAW76947	Aab76947 Full vari	618	553	100.0	219	8	ADN07066	Adn07066 F(ab)-pha
546	553	100.0	218	4	AAW76949	Aab76949 Full leng	619	553	100.0	219	8	ADN61713	Adn61713 Humanised
547	553	100.0	218	4	AAW76951	Aab76951 Full leng	620	553	100.0	219	8	ADP84971	Adp84971 Chimeric
548	553	100.0	218	4	AAW76953	Aab76953 Variable	621	553	100.0	219	8	ADR19332	Adr19332 Chimeric
549	553	100.0	218	4	AAW76958	Aab76958 Variable	622	553	100.0	219	8	ADR19331	Adr19331 Chimeric
550	553	100.0	218	4	AAW74211	Aab74211 E27 anti-	623	553	100.0	219	9	ADW00688	Adw00688 Expressio
551	553	100.0	218	5	AAW49204	Aam49204 Humanised	624	553	100.0	219	9	ADW77072	Adw77072 Light cha
552	553	100.0	218	6	ABU62797	Abu62797 E27 anti-	625	553	100.0	219	10	ABE99308	Aee99308 Kappa lig
553	553	100.0	218	7	ABR82261	AbR82261 Chimeric	626	553	100.0	219	10	ABF18985	Aef18985 Humanized
554	553	100.0	218	7	ABR69597	Adf69597 Human ant	627	553	100.0	219	10	ABF18986	Aef18986 Humanized
555	553	100.0	218	7	ADP29038	Adf29038 Anti-IGE	628	553	100.0	219	10	AEF34625	Aef34625 Fab-4D5 C
556	553	100.0	218	8	ADF71899	Adf71899 Hu3G8VL-1	629	553	100.0	219	10	AEF65418	Aef65418 Anti-RBD
557	553	100.0	218	8	ADF71903	Adf71903 Hu3G8VL-4	630	553	100.0	220	2	AAW07528	Aaw07528 Anti-HGF
558	553	100.0	218	8	ADF71920	Adf71920 Hu3G8VL-2	631	553	100.0	220	2	AAW50172	Aay50172 Antibody
559	553	100.0	218	8	ADN07034	Adn07034 Anti-IGE	632	553	100.0	220	2	ADK52298	Adk52298 Human ant
560	553	100.0	218	8	ADN07045	Adn07045 Anti-IGE	633	553	100.0	220	8	ADK52386	Adk52386 Human ant
561	553	100.0	218	8	ADN07036	Adn07036 Anti-IGE	634	553	100.0	220	8	ADK52314	Adk52314 Human ant
562	553	100.0	218	8	ADN07038	Adn07038 Anti-IGE	635	553	100.0	220	8	ADK52362	Adk52362 Human ant
563	553	100.0	218	8	ADN07040	Adn07040 Anti-IGE	636	553	100.0	220	8	ADK52334	Adk52334 Human ant
564	553	100.0	218	8	ADP84136	Adp84136 Anti-mono	637	553	100.0	220	8	ADO06858	Ado06858 Virucidal
565	553	100.0	218	8	ADP84130	Adp84130 Anti-body	638	553	100.0	220	8	ADO06856	Ado06856 Virucidal
566	553	100.0	218	8	ADP88427	Adp88427 Antibody	639	553	100.0	220	8	ADP42960	Adp42960 Humanised
567	553	100.0	218	8	ADP88451	Adp88451 Antibody	640	553	100.0	220	9	ADW77054	Adw77054 Light cha
568	553	100.0	218	8	ADS31792	AdS31792 Chimeric	641	553	100.0	220	9	ADW77046	Adw77046 Light cha
569	553	100.0	218	8	ADP55439	Adt55439 Anti IGE	642	553	100.0	220	9	ADW44589	Adw44589 Antibody
570	553	100.0	218	8	ADP55438	Adt55438 Anti IGE	643	553	100.0	220	9	ABE43844	Aeb43844 Human Hui
571	553	100.0	218	8	ADW00660	Adw00660 Human ant	644	553	100.0	220	10	ABE99275	Aee99275 Light cha
572	553	100.0	218	9	ADW00667	Adw00667 Human ant	645	553	100.0	222	9	AEC92140	Aec92140 Chimeric
573	553	100.0	218	9	ADW00656	Adw00656 Human ant	646	553	100.0	222	9	AEC92144	Aec92144 DNA encod
574	553	100.0	218	9	ADW00662	Adw00662 Human ant	647	553	100.0	222	10	ABE99293	Aee99293 Anti-RON
575	553	100.0	218	9	ADW00691	Adw00691 Human ant	648	553	100.0	232	2	AAW80616	Aaw80616 Anti-huma
576	553	100.0	218	9	ADW00692	Adw00692 Human ant	649	553	100.0	232	6	ABG76490	Abg76490 Light cha
577	553	100.0	218	9	ADW00658	Adw00658 Human ant	650	553	100.0	232	7	ADP64204	Adp64204 MN14LC pr
578	553	100.0	218	9	ADW79895	Adw79895 Anti-IGE	651	553	100.0	232	7	ADP60817	Adp60817 HMN-14 11
579	553	100.0	218	9	ADW79893	Adw79893 Anti-IGE	652	553	100.0	232	8	ADP79583	Adp79583 2H7.v16 L
580	553	100.0	218	9	ADW79897	Adw79897 Anti-IGE	653	553	100.0	232	8	ADW03398	Adw03398 Human ant
581	553	100.0	218	9	ADW79902	Adw79902 Anti-IGE	654	553	100.0	232	9	ADW21318	Adw21318 Mouse ant
582	553	100.0	218	9	ADW79891	Adw79891 Anti-IGE	655	553	100.0	232	9	ADW00804	Adw00804 Humanized
583	553	100.0	218	9	ADY74808	Ady74808 Rat anti-	656	553	100.0	232	9	ADY62624	Ady62624 Humanized
584	553	100.0	218	9	ADZ99438	Adz99438 Humanized	657	553	100.0	232	9	ADZ99447	Adz99447 12G8 anti
585	553	100.0	218	9	ABE13693	Aeb13693 Human ant	658	553	100.0	232	9	ABE18943	Aee18943 Humanized
586	553	100.0	218	9	ABE56304	Aeb56304 Anti-IGE	659	553	100.0	232	10	ABE26243	Aee26243 Humanized
587	553	100.0	218	9	ABE56305	Aeb56305 Anti-IGE	660	553	100.0	232	2	AAW22755	Aar22755 Reshaped
588	553	100.0	218	9	AED06841	Aed06841 Light cha	661	553	100.0	233	2	AAW22754	Aar22754 Reshaped
589	553	100.0	218	9	AED89915	Aed89915 Anti-IGE	662	553	100.0	233	2	AAW30777	Aar30777 PH52-9.0
590	553	100.0	218	9	AED89926	Aed89926 Anti-IGE	663	553	100.0	233	2	AAW85690	Aaw85690 D9D10 11g
591	553	100.0	218	9	AED89917	Aed89917 Anti-IGE	664	553	100.0	233	3	AAW93704	Aay93704 The kappa
592	553	100.0	218	9	AED89921	Aed89921 Anti-IGE	665	553	100.0	233	3	AAW93731	Aay93731 The kappa
593	553	100.0	218	9	AED89919	Aed89919 Anti-IGE	666	553	100.0	233	4	ABW49242	Abw49242 Chimeric
594	553	100.0	218	10	ABF27196	Aef27196 Anti-CD4	667	553	100.0	233	6	ABW35886	Aab35886 Human 4.8
595	553	100.0	218	10	ABF27220	Aef27220 Anti-CD4	668	553	100.0	233	7	ABR61526	AbR61526 Humanised
596	553	100.0	218	10	ABF18405	Aef18405 HANA prot	669	553	100.0	233	7	ABR61528	AbR61528 Human ant
597	553	100.0	219	2	AAW29459	Aay29459 Recombina	670	553	100.0	233	7	ADL23195	AdL23195 Human ant
598	553	100.0	219	3	AAW77767	Aay77767 Humanised	671	553	100.0	233	8	ADP77160	AdP77160 Anti-VAP-
599	553	100.0	219	3	ABW30323	Abw30323 Humanised	672	553	100.0	233	8	ADM41575	Adm41575 Anti-inte
600	553	100.0	219	6	ABP58286	Abp58286 Humanised	673	553	100.0	233	8	ADL93656	AdL93656 Human CD4
601	553	100.0	219	6	ABR39464	AbR39464 Humanised	674	553	100.0	233	8	ADL93655	AdL93655 Human CD4
602	553	100.0	219	6	ABU08310	Abu08310 Humanised	675	553	100.0	233	8	ADR46823	Adr46823 Human ant
603	553	100.0	219	6	ABU13800	Abu13800 Humanised	676	553	100.0	233	8	ADU23620	AdU23620 Human IGG
604	553	100.0	219	6	ABU59513	Abu59513 Humanised	677	553	100.0	233	8	ADU68009	AdU68009 Mouse ant
605	553	100.0	219	6	ABR37992	AbR37992 Humanised	678	553	100.0	233	9	ABW45889	Abw45889 Human mon
606	553	100.0	219	6	ABR80108	AbR80108 Light cha	679	553	100.0	233	9	ABW45851	Abw45851 Human mon
607	553	100.0	219	6	ABP58272	Abp58272 Humanised	680	553	100.0	233	9	ABD04283	Aeb04283 Human ant

827	553	100.0	236	10	AAE94840	Aee94840 Antibody	900	553	100.0	238	3	AAW90922	Humanised
828	553	100.0	236	10	AAE94869	Aee94869 Antibody	901	553	100.0	238	3	AAW90930	Humanised
829	553	100.0	236	10	AEF54367	Aef54367 Human lig	902	553	100.0	238	4	AAW72235	Humanised
830	553	100.0	236	10	AEF54345	Aef54345 Human ant	903	553	100.0	238	4	AAW72231	Humanised
831	553	100.0	236	10	AEF54346	Aef54346 Human lig	904	553	100.0	238	4	AAW72227	Humanised
832	553	100.0	236	10	AEF54349	Aef54349 Human ant	905	553	100.0	238	4	AAW72233	Humanised
833	553	100.0	236	10	AEF54350	Aef54350 Human lig	906	553	100.0	238	4	AAU07744	Humanised
834	553	100.0	236	10	AEF34921	Aef34921 Human ant	907	553	100.0	238	4	AAE03754	Chimeric
835	553	100.0	236	10	AEF34917	Aef34917 Human ant	908	553	100.0	238	5	ABB74937	Humanised
836	553	100.0	236	10	AEF34918	Aef34918 Human ger	909	553	100.0	238	5	ABB74938	Humanised
837	553	100.0	236	10	AEF34922	Aef34922 Human ger	910	553	100.0	238	5	ABB74939	Humanised
838	553	100.0	236	10	AEF73710	Aef73710 Human IL-	911	553	100.0	238	5	ABB74942	Humanised
839	553	100.0	237	2	AAE24047	Aar24047 Light cha	912	553	100.0	238	5	ABB74943	Humanised
840	553	100.0	237	2	AAW70703	Aaw70703 Protein e	913	553	100.0	238	5	ABE74943	Humanised
841	553	100.0	237	2	AAW95622	Aaw95622 pS1130 ex	914	553	100.0	238	5	ABE70744	Mouse/hum
842	553	100.0	237	2	AAW30634	Aaw30634 Recombina	915	553	100.0	238	5	AAE27930	Human CSE
843	553	100.0	237	2	AAW73873	Aaw73873 Human ant	916	553	100.0	238	5	ABB74897	Humanised
844	553	100.0	237	3	AAW96289	Aay96289 Human IGF	917	553	100.0	238	5	ABB74899	Humanised
845	553	100.0	237	3	AAW96298	Aay96298 Human IGF	918	553	100.0	238	5	ABB74892	Humanised
846	553	100.0	237	3	AAW96301	Aay96301 Human IGF	919	553	100.0	238	5	ABB74893	Humanised
847	553	100.0	237	4	AAW66784	Aab66784 Protein e	920	553	100.0	238	5	ABB74891	Humanised
848	553	100.0	237	5	ABB81107	Abb81107 Anti-VEGF	921	553	100.0	238	5	ABB74896	Humanised
849	553	100.0	237	5	ABB81106	Abb81106 Anti-tiss	922	553	100.0	238	5	ABB74901	Humanised
850	553	100.0	237	5	ABP51952	Abp51952 Plasmid p	923	553	100.0	238	6	ABP58288	Humanised
851	553	100.0	237	6	ABP72745	Abp72745 Anti-CD18	924	553	100.0	238	6	ABR41582	Human DIT
852	553	100.0	237	6	ABP72747	Abp72747 Anti-tiss	925	553	100.0	238	6	ABR39842	Humanised
853	553	100.0	237	7	ABR61570	Abt-61570 HIV-1 neu	926	553	100.0	238	6	ABR82839	Antibody
854	553	100.0	237	7	ADK69943	Adk69943 Immunoglo	927	553	100.0	238	6	ADA47330	TRX1 ligh
855	553	100.0	237	8	ADL93658	Adl93658 Human CD4	928	553	100.0	238	6	ADA47332	TRX1 ligh
856	553	100.0	237	8	ADL93657	Adl93657 Human CD4	929	553	100.0	238	7	ADL93652	Human CD4
857	553	100.0	237	8	ADL93651	Adl93651 Human CD4	930	553	100.0	238	8	ADL93653	Human CD4
858	553	100.0	237	8	ADL93651	Adl93651 Human CD4	931	553	100.0	238	8	ADL93649	Human CD4
859	553	100.0	237	8	ADL93651	Adl93651 Human CD4	932	553	100.0	238	8	ADL93650	Human CD4
860	553	100.0	237	8	ADL93651	Adl93651 Human CD4	933	553	100.0	238	8	ADL93654	Human CD4
861	553	100.0	237	8	ADL93651	Adl93651 Human CD4	934	553	100.0	238	8	ADL93654	Human CD4
862	553	100.0	237	8	ADL93651	Adl93651 Human CD4	935	553	100.0	238	8	ADL93652	Human CD4
863	553	100.0	237	8	ADL93651	Adl93651 Human CD4	936	553	100.0	238	8	ADL93653	Human CD4
864	553	100.0	237	8	ADL93651	Adl93651 Human CD4	937	553	100.0	238	8	ADL93649	Human CD4
865	553	100.0	237	8	ADL93651	Adl93651 Human CD4	938	553	100.0	238	8	ADL93650	Human CD4
866	553	100.0	237	8	ADL93651	Adl93651 Human CD4	939	553	100.0	238	8	ADL93654	Human CD4
867	553	100.0	237	8	ADL93651	Adl93651 Human CD4	940	553	100.0	238	8	ADL93654	Human CD4
868	553	100.0	237	8	ADL93651	Adl93651 Human CD4	941	553	100.0	238	8	ADL93654	Human CD4
869	553	100.0	237	8	ADL93651	Adl93651 Human CD4	942	553	100.0	238	8	ADL93654	Human CD4
870	553	100.0	237	8	ADL93651	Adl93651 Human CD4	943	553	100.0	238	8	ADL93654	Human CD4
871	553	100.0	237	8	ADL93651	Adl93651 Human CD4	944	553	100.0	238	8	ADL93654	Human CD4
872	553	100.0	237	9	ABE27976	Abm27976 Human dia	945	553	100.0	238	8	ADS88804	Humanised
873	553	100.0	237	10	AAE47632	Aee47632 Humanized	946	553	100.0	238	8	ADS88785	Sequence
874	553	100.0	237	10	AEF17108	Aef17108 B. brevis	947	553	100.0	238	9	ADY30114	Human IGG
875	553	100.0	237	10	AEF17111	Aef17111 B. brevis	948	553	100.0	238	9	ADY91367	Anti-KID3
876	553	100.0	237	10	AEF18356	Aef18356 Middle wa	949	553	100.0	238	9	AEBO8041	Murine/hu
877	553	100.0	237	10	AEF18353	Aef18353 Middle wa	950	553	100.0	238	9	AEBO8041	Anti-NOGO
878	553	100.0	237	10	AEF18353	Aef18353 Middle wa	951	553	100.0	238	9	AEBO8041	Anti-NOGO
879	553	100.0	238	2	AAE93554	Aar93554 Monoclonal	952	553	100.0	238	9	AEBO8041	Anti-NOGO
880	553	100.0	238	2	AAW14937	Aaw14937 Murine an	953	553	100.0	238	9	AEBO8041	Anti-NOGO
881	553	100.0	238	2	AAW14936	Aaw14936 2A2 Human	954	553	100.0	238	9	AEBO8041	Anti-NOGO
882	553	100.0	238	2	AAW14942	Aaw14942 3F4 Human	955	553	100.0	238	9	AEBO8041	Anti-NOGO
883	553	100.0	238	2	AAW14931	Aaw14931 Murine an	956	553	100.0	238	9	AEBO8041	Anti-NOGO
884	553	100.0	238	2	AAW83035	Aaw83035 Anti-Fas	957	553	100.0	238	9	AEBO8041	Anti-NOGO
885	553	100.0	238	2	AAW83034	Aaw83034 Anti-Fas	958	553	100.0	238	9	AEBO8041	Anti-NOGO
886	553	100.0	238	2	AAW83033	Aaw83033 Anti-Fas	959	553	100.0	238	9	AEBO8041	Anti-NOGO
887	553	100.0	238	2	AAW83032	Aaw83032 Anti-Fas	960	553	100.0	238	9	AEBO8041	Anti-NOGO
888	553	100.0	238	2	AAW83031	Aaw83031 Anti-Fas	961	553	100.0	238	9	AEBO8041	Anti-NOGO
889	553	100.0	238	3	AAW14774	Aab14774 Humanised	962	553	100.0	238	10	AEF27195	Anti-CD4
890	553	100.0	238	3	AAW14773	Aab14773 Humanised	963	553	100.0	238	10	AEF27195	Anti-CD4
891	553	100.0	238	3	AAW14772	Aab14772 Humanised	964	553	100.0	238	10	AEF27195	Anti-CD4
892	553	100.0	238	3	AAW14771	Aab14771 Humanised	965	553	100.0	238	10	AEF27195	Anti-CD4
893	553	100.0	238	3	AAW14770	Aab14770 Humanised	966	553	100.0	238	10	AEF27195	Anti-CD4
894	553	100.0	238	3	AAW90931	Aaw90931 Humanised	967	553	100.0	238	10	AEF27195	Anti-CD4
895	553	100.0	238	3	AAW90932	Aaw90932 Humanised	968	553	100.0	238	10	AEF27195	Anti-CD4
896	553	100.0	238	3	AAW90933	Aaw90933 Humanised	969	553	100.0	238	10	AEF27195	Anti-CD4
897	553	100.0	238	3	AAW90934	Aaw90934 Humanised	970	553	100.0	238	10	AEF27195	Anti-CD4
898	553	100.0	238	3	AAW90928	Aaw90928 Humanised	971	553	100.0	238	10	AEF27195	Anti-CD4
899	553	100.0	238	3	AAW90923	Aaw90923 Humanised	972	553	100.0	238	10	AEF27195	Anti-CD4

973 553 100.0 239 3 AAY82612 Human PTH
 974 553 100.0 239 3 AAY82613 Human PTH
 975 553 100.0 239 3 AAU77288 Protein #
 976 553 100.0 239 3 AAB12914 Anti-huma
 977 553 100.0 239 3 AAB12916 Anti-huma
 978 553 100.0 239 3 AAB12913 Anti-huma
 979 553 100.0 239 3 AAB12915 Anti-huma
 980 553 100.0 239 5 AAU11540 Protein s
 981 553 100.0 239 6 AAE37361 Monkey 7B
 982 553 100.0 239 6 ABR48456 Human Cal
 983 553 100.0 239 6 ABP58274 Humanised
 984 553 100.0 239 7 ADE28405 Human ant
 985 553 100.0 239 7 ADE28421 Human ant
 986 553 100.0 239 7 ADE28465 Human ant
 987 553 100.0 239 7 ADE28461 Human ant
 988 553 100.0 239 7 ADE28521 Human ant
 989 553 100.0 239 7 ADE28397 Human ant
 990 553 100.0 239 7 ABG75316 Anti-CD22
 991 553 100.0 239 7 ADM05343 Human pro
 992 553 100.0 239 7 ADL23137 Mouse/hum
 993 553 100.0 239 7 ADL23170 Mouse/hum
 994 553 100.0 239 7 ADL23168 Mouse/hum
 995 553 100.0 239 7 ADL23176 Mouse/hum
 996 553 100.0 239 7 ADL23133 Mouse/hum
 997 553 100.0 239 7 ADL23166 Mouse/hum
 998 553 100.0 239 7 ADL23174 Mouse/hum
 999 553 100.0 239 7 ADL23172 Mouse/hum
 1000 553 100.0 239 7 ADL23139 Mouse/hum

ALIGNMENTS

RESULT 1
 AAW40578
 ID AAW40578 standard; protein; 107 AA.
 AC AAW40578;
 XX
 XX 21-JUL-1998 (first entry)
 DE Human kappa CL domain protein fragment.
 XX
 KW Immunoglobulin G; IGG molecule; human; Fc region; LFA-1 receptor;
 KW disorder; salvage receptor binding epitope; cell adherence interaction;
 KW lymphocyte; T cell inflammatory response.
 XX
 OS Homo sapiens.
 XX
 XX US5739277-A.
 PN
 XX 14-APR-1998.
 PD
 XX 14-APR-1995; 95US-00422101.
 PF
 XX 14-APR-1995; 95US-00422101.
 PR
 XX (GETH) GENENTECH INC.
 PA
 XX Snedecor BR, Presta LG;
 PI
 XX WPI; 1998-250490/22.
 DR
 XX Polypeptide(s) that are not Fc fragments and have an increased half-life
 PT - are useful for the treatment of LFA-1 mediated disorders.
 XX
 PS Disclosure; Fig 2; 38pp; English.

XX This protein fragment is derived from a human immunoglobulin kappa CL
 CC domain and is used to describe a novel method to produce polypeptides
 CC which contain an epitope from the Fc region of an IGG molecule and a
 CC mutated salvage receptor binding epitope. They are useful for the
 CC treatment of LFA-1 mediated disorders. These are conditions caused by

CC cell adherence interactions involving the LFA-1 receptor on lymphocytes,
 CC e.g. T cell inflammatory responses. The mutated salvage receptor sequence
 CC in the polypeptides means that they have increased in vivo circulatory
 CC half-lives when compared to normal Fc regions of IGG molecules
 XX
 SQ Sequence 107 AA;

Query Match 100.0%; Score 553; DB 2; Length 107;
 Best Local Similarity 100.0%; Pred. No. 4.3e-48;
 Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQKVDNALQSGNSQESVTEQD 60

Db 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQKVDNALQSGNSQESVTEQD 60

QY 61 SKDSTYSLSSTLTLSKADYERKHVYACVETHTQGLSSPVTKSFNRGEC 107

Db 61 SKDSTYSLSSTLTLSKADYERKHVYACVETHTQGLSSPVTKSFNRGEC 107

RESULT 2

AAV50152
 ID AAV50152 standard; protein; 107 AA.

XX AAV50152;

XX 31-JAN-2000 (first entry)

XX Human kappa light chain constant region.

XX Antibody; monoclonal; F19; fibrinogen activation protein alpha; FAP;
 KW humanisation; complementarity determining region; CDR; CDR grafting;
 KW reshaped; reactive stroma; fibroblast; epithelial cancer; diagnosis;
 KW immune response; framework sequence; constant region; variable region;
 KW producibility; treatment; cancer; colorectal; lung; breast; head; neck;
 KW ovarian; lung; bladder; pancreatic; metastasis; detection; wound healing;
 KW skin inflammation; tumour; immunogenicity; light chain.

XX Homo sapiens.

XX EP953639-A1.

XX 03-NOV-1999.

XX 30-APR-1998; 98EP-00107925.

XX 30-APR-1998; 98EP-00107925.

XX (BOEH) BOEHRINGER INGELHEIM INT GMBH.

XX Park JE, Garin-Chesa P, Bamberger U, Leger O, Saldanha J;
 PI Rettig WJ;

XX WPI; 1999-621833/54.

XX N-PSDB; AAZ32777.

XX New antibody protein, useful for treating cancer and for imaging presence
 PT of activated stromal fibroblasts in healing wound or inflamed skin.

XX Disclosure; Fig 20; 143pp; English.

XX This sequence represents a human kappa light chain, the cDNA of which was
 CC used in the construction of a nucleotide encoding the light chain of a
 CC human reshaped monoclonal antibody F19. F19 (AFCC Accession number HB
 CC 8269) is a murine monoclonal antibody against fibroblast activation
 CC protein alpha (FAP). FAP is a cell surface molecule of reactive stromal
 CC fibroblasts, and its induction is a highly consistent molecular trait of
 CC the reactive stroma of many types of epithelial cancer. Although F19 may
 CC be useful in vitro, e.g., for diagnosis, its applications for in vivo use
 CC in humans are problematic as it elicits a human anti-mouse response which
 CC reduces the efficacy of the antibody in patients and impairs continued
 CC administration. The novel human reshaped F19 was humanised by grafting
 CC the murine complementarity determining regions (CDRs) of F19 onto human

CC variable region framework sequences, and then joining these "reshaped
CC human" variable regions to human constant regions. These modifications
CC also result in the improved producibility in eukaryotic cell culture
CC systems as compared to a chimeric antibody having the entire variable
CC regions of F19 joined to human constant regions. The human reshaped F19
CC antibody has low immunogenicity for humans and is useful for treating
CC cancers e.g., colorectal cancers, non-small cell lung cancers, breast
CC cancers, head and neck cancers, ovarian cancers, lung cancers, bladder
CC cancers, pancreatic cancers and metastatic cancers. It is also useful for
CC the detection of activated stromal fibroblasts in a healing wound,
CC inflamed skin or a tumour in a human patient
XX
SQ Sequence 107 AA;

Query Match 100.0%; Score 553; DB 2; Length 107;
Best Local Similarity 100.0%; Pred. No. 4.3e-48;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
QY 61 SKDSTYSLSSSTLTLSKADYERKHVYACEVTHOGLSSPVTKSFNRGEC 107
Db 61 SKDSTYSLSSSTLTLSKADYERKHVYACEVTHOGLSSPVTKSFNRGEC 107

RESULT 3
AAW92425
ID AAW92425 standard; peptide; 107 AA.
XX
AC AAW92425;
XX
DT 23-APR-1999 (first entry)
XX
DE Human Kappa protein CL domain.
XX
KW Antibody; salvage receptor binding epitope; Fab; F(ab')2; immunoglobulin;
KW CH region; CL region; kidney; Fc region; CH1 domain; CH2 domain; IgG;
KW kappa protein; renal clearance rate; circulatory half-life.
XX
OS Homo sapiens.
XX
PN US5869046-A.
XX
PD 09-FEB-1999.
XX
PF 14-APR-1995; 95US-00422092.
XX
PR 14-APR-1995; 95US-00422092.
XX
PA (GETH) GENENTECH INC.
XX
PI Presta LG, Snedecor BR;
XX
DR WPI; 1999-152694/13.
XX
PT Production of antibody fragments with reduced renal clearance - by
PT introducing salvage receptor binding epitope into CH1 or CL region.
XX
PS Disclosure; Col 55-58; 38pp; English.
XX

XX This invention describes a method for preparing a variant Fab or F(ab')2
XX polypeptide having increased half-life in vivo, where the polypeptide
XX contains an Ig or Ig-like domain comprising a CH1 and/or CL region, is
XX cleared from the kidneys and does not contain an IgG Fc region. The
XX method involves altering the polypeptide within the CH1 or CL region to
XX incorporate a salvage receptor binding epitope taken from two loops of a
XX CH2 domain of an IgG Fc region. The polypeptides have a reduced renal
XX clearance rate and an increased circulatory half-life. This sequence
XX represents a human kappa protein CL domain used in the method of the
XX invention

SQ Sequence 107 AA;
Query Match 100.0%; Score 553; DB 2; Length 107;
Best Local Similarity 100.0%; Pred. No. 4.3e-48;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
QY 61 SKDSTYSLSSSTLTLSKADYERKHVYACEVTHOGLSSPVTKSFNRGEC 107
Db 61 SKDSTYSLSSSTLTLSKADYERKHVYACEVTHOGLSSPVTKSFNRGEC 107

RESULT 4
AAW08745
ID AAY08745 standard; protein; 107 AA.
XX
AC AAY08745;
XX
DT 10-AUG-1999 (first entry)
XX
DE Human Kappa-CL domain.
XX
KW IgG; immunoglobulin G; CH1 domain; human; anti-CD18; IgG1; IgG2; IgG3;
KW IgG4; Kappa-CL domain; lambda-CL domain; focal ischaemic stroke;
KW cerebroprotective; cerebral artery obstruction; blood flow; infarct;
KW CD18 extracellular domain; endothelium; CD11b/CD18 complex dissociation;
KW antibody.
XX
OS Homo sapiens.
XX
PN US5914112-A.
XX
PD 22-JUN-1999.
XX
PF 22-JAN-1997; 97US-00788800.
XX
PR 23-JAN-1996; 96US-0093038P.
XX
PA (GETH) GENENTECH INC.
PA (UYVE-) UNIV VERMONT & STATE AGRIC COLLEGE.
XX
PI Thomas GR, Bednar MM, Gross CE;
XX
DR WPI; 1999-370483/31.
XX
PT Anti-CD18 antibodies in stroke.
XX
PS Disclosure; Fig 4A-B; 25pp; English.

XX This invention describes a method for improving the clinical outcome in
XX focal ischaemic stroke by administering novel anti-CD18 antibody which
XX has cerebroprotective properties. The invention particularly describes a
XX method of treating focal ischaemic stroke caused by the obstruction of a
XX main cerebral artery which comprises administering an anti-CD18 antibody
XX to increase the blood flow or reduce the infarct size, where: (1) the
XX antibody binds to an extracellular domain of CD18 and inhibits or reduces
XX the ability of the cell expressing CD18 to bind to endothelium, (2) the
XX antibody binds CD18 with an affinity of less than 4 nm, or (3) the
XX antibody dissociates CD11b/CD18 complex. This sequence represents the
XX human Kappa-CL domain which is used to illustrate the method of the
XX invention

SQ Sequence 107 AA;
Query Match 100.0%; Score 553; DB 2; Length 107;
Best Local Similarity 100.0%; Pred. No. 4.3e-48;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60

DT 23-JAN-2003 (first entry)
 XX Human kappa light constant chain.
 DE
 XX
 KW Human; cytostatic; antitumor; immunosuppressive; antiallergic;
 KW humanised; antibody; fibroblast activation protein alpha; FAPalpha;
 KW cancer; monoclonal antibody F19; colorectal cancer;
 KW non-small cell lung carcinoma; breast cancer; pancreatic cancer; tumour;
 KW systemic autoimmune disease; allergy; light chain; constant region.
 XX
 OS Homo sapiens.
 XX
 XX WO200283171-A2.
 PN
 XX
 XX 24-OCT-2002.
 PD
 XX
 XX 11-APR-2002; 2002WO-EP004041.
 PF
 XX
 XX 12-APR-2001; 2001US-0283868P.
 PR
 XX (BOEH) BOEHRINGER INGELHEIM INT GMBH.
 PA (BOEH) BOEHRINGER INGELHEIM PHARM INC.
 PA
 XX Amelsberg A, Scott A, Tanswell P;
 PI
 XX WPI; 2003-058609/05.
 DR N-PSDB; ABV74601.
 DR
 XX
 XX Use of a humanized antibody which specifically binds to fibroblast
 PT activation protein alpha for manufacturing a medicament for treating
 PT cancer.
 PT
 XX
 XX Claim 7; Page 55; 57pp; English.
 PS
 XX The present invention relates to the use of a humanised antibody (I),
 CC which specifically binds to fibroblast activation protein alpha
 CC (FAPalpha), for manufacturing a medicament for treating cancer. (I) has
 CC the complementary determining region (CDR) of the monoclonal antibody
 CC F19, but has framework modifications resulting in improved producibility
 CC in host cells as compared to a chimeric antibody having the variable
 CC regions of F19 and foreign constant regions. To generate (I), a chimeric
 CC antibody was constructed having variable regions of the light and heavy
 CC chains of F19 and human light and heavy constant regions. (I) is useful
 CC for treating a patient suffering from a pathological condition
 CC characterised by expression of FAPalpha, such as colorectal cancer, non-
 CC small cell lung carcinoma, breast cancer, pancreatic cancer, tumours,
 CC systemic autoimmune diseases and allergies. The present sequence is human
 CC kappa light constant chain which was used to produce (I)
 XX
 SQ Sequence 107 AA;
 Query Match 100.0%; Score 553; DB 6; Length 107;
 Best Local Similarity 100.0%; Pred. No. 4.3e-48;
 Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
 Db 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
 QY 61 SKDSTYLSLSSTLTLSKADYKHKYKVCVTHQGLSSPVTKSFNRGEC 107
 Db 61 SKDSTYLSLSSTLTLSKADYKHKYKVCVTHQGLSSPVTKSFNRGEC 107
 RESULT 8
 ABR42732
 ID ABR42732 standard; protein; 107 AA.
 XX
 XX ABR42732;
 AC
 XX 26-AUG-2003 (first entry)
 DT
 XX Anti-tissue factor humanized antibody light chain constant region.

XX Tissue factor; humanization; antibody; anticoagulant; cytostatic;
 KW antiinflammatory; mouse; human; hOAT.
 XX
 OS Mus sp.
 OS Homo sapiens.
 OS Chimeric.
 XX WO2003037911-A2.
 PN
 XX 08-MAY-2003.
 PD
 XX 29-OCT-2002; 2002WO-US034727.
 PF
 XX 29-OCT-2001; 2001US-0343306P.
 PR 21-NOV-2001; 2001US-00990586.
 XX
 XX (SUNO-) SUNOL MOLECULAR CORP.
 PA
 XX Jiao J, Wong HC, Nieves EL, Mosquera LA;
 PI WPI; 2003-468399/44.
 DR
 XX New humanized antibody that binds specifically to human tissue factor,
 PT useful for in vivo diagnostic methods, or for inhibiting blood
 PT coagulation or blood clot formation, angiogenesis, tumor metastases or
 PT inflammation in a mammal.
 PT
 XX Example 10; Fig 14A; 110pp; English.
 PS
 XX The present sequence is the protein sequence of the light chain constant
 CC region of anti-human tissue factor (TF) humanized antibody hOAT
 CC (humanised ch36-IgG1). Humanized antibodies of the invention provide
 CC superior anticoagulant activity by binding native human TF with high
 CC affinity and specificity. The antibodies bind human TF, either alone or
 CC present in a TF:Factor VIIa complex, effectively preventing Factor X (or
 CC Factor IX) binding to TF or the complex, and thereby reducing blood
 CC coagulation. The humanized antibodies are useful for inhibiting blood
 CC coagulation or blood clot formation, angiogenesis, tumour metastases or
 CC inflammation in a mammal. They are also useful as drug carriers, as
 CC cytotoxic agents, for reducing TF levels in mammals, and for in vivo
 CC diagnosis
 CC
 SQ Sequence 107 AA;
 Query Match 100.0%; Score 553; DB 6; Length 107;
 Best Local Similarity 100.0%; Pred. No. 4.3e-48;
 Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
 Db 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
 QY 61 SKDSTYLSLSSTLTLSKADYKHKYKVCVTHQGLSSPVTKSFNRGEC 107
 Db 61 SKDSTYLSLSSTLTLSKADYKHKYKVCVTHQGLSSPVTKSFNRGEC 107
 RESULT 9
 ABR42734
 ID ABR42734 standard; protein; 107 AA.
 XX
 XX ABR42734;
 AC
 XX 26-AUG-2003 (first entry)
 DT
 XX Anti-tissue factor humanized antibody light chain constant region.
 DE
 XX Tissue factor; humanization; antibody; anticoagulant; cytostatic;
 KW antiinflammatory; mouse; human; hOAT.
 XX
 OS Mus sp.
 OS Homo sapiens.

```
OS Chimeric.
XX WO2003037911-A2.
PN
XX
PD
XX
PF 08-MAY-2003.
XX
XX 29-OCT-2002; 2002WO-US034727.
XX
XX 29-OCT-2001; 2001US-0343306P.
PR
XX 21-NOV-2001; 2001US-00990586.
XX
XX (SUNO-) SUNOL MOLECULAR CORP.
XX
XX Jiao J, Wong HC, Nieves EL, Mosquera LA;
PI WPI; 2003-468399/44.
XX
XX New humanized antibody that binds specifically to human tissue factor,
PT useful for in vivo diagnostic methods, or for inhibiting blood
PT coagulation or blood clot formation, angiogenesis, tumor metastases or
PT inflammation in a mammal.
XX
XX Example 10; Fig 15A; 110pp; English.
XX
XX The present sequence is the protein sequence of the light chain constant
CC region of anti-human tissue factor (TF) humanized antibody hPAT
CC (humanised ch36-IgG4). Humanized antibodies of the invention provide
CC superior anticoagulant activity by binding native human TF with high
CC affinity and specificity. The antibodies bind human TF, either alone or
CC present in a TF:Factor VIIa complex, effectively preventing Factor X (or
CC Factor IX) binding to TF or the complex, and thereby reducing blood
CC coagulation. The humanized antibodies are useful for inhibiting blood
CC coagulation or blood clot formation, angiogenesis, tumour metastases or
CC inflammation in a mammal. They are also useful as drug carriers, as
CC cytotoxic agents, for reducing TF levels in mammals, and for in vivo
CC diagnosis
XX
XX Sequence 107 AA;
SQ
Query Match 100.0%; Score 553; DB 6; Length 107;
Best Local Similarity 100.0%; Pred. No. 4.3e-48;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
DB 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
QY 61 SKDSTYSLSTLTLSKADYERKHVKYVACEVTHQGLSSPVTKSFNRGEC 107
DB 61 SKDSTYSLSTLTLSKADYERKHVKYVACEVTHQGLSSPVTKSFNRGEC 107
RESULT 10
ABR55835
ID ABR55835 standard; protein; 107 AA.
XX
XX ABR55835;
AC
XX
XX 02-SEP-2003 (first entry)
DT
XX
XX Anti-Ang-2 antibody kappa constant region.
DE
XX
XX Ang-2; angiopoietin-2; anorectic; cytostatic; antiarteriosclerotic;
KW gynaecological; antiinflammatory; osteopathic; antipsoriatic; cancer;
KW angiogenesis; antibody.
XX
XX Homo sapiens.
OS
XX WO2003030833-A2.
PN
XX
XX 17-APR-2003.
PD
XX
XX 11-OCT-2002; 2002WO-US032613.
PF
XX
XX 11-OCT-2001; 2001US-0328604P.
PR
XX 10-OCT-2002; 2002US-00269805.
XX
XX (AMGE-) AMGEN INC.
XX
XX Oliner JD;
PI
XX
XX WPI; 2003-504963/47.
XX
XX New specific binding agents (i.e. anti-Angiopoietin-2 antibodies), useful
PT for inhibiting undesired angiogenesis, or treating e.g. cancers, obesity,
PT hemangioma, arteriosclerosis, atherosclerosis or endometriosis.
XX
XX Example 4; Page 96; 161pp; English.
XX
XX The invention relates to a specific binding agent, which comprises at
CC least one peptide selected from any of 62 peptides (ABR55769-830) or its
CC fragment. The binding agents are antibodies that recognize and bind to
CC angiopoietin-2 (Ang-2). The specific binding agent, particularly the
CC antibody, is useful for inhibiting undesired angiogenesis, treating
CC cancers, inhibiting undesired angiogenesis, modulating or inhibiting Ang-
CC 2 activity, modulating vascular permeability or plasma leakage, or
CC treating a disease (e.g. ocular neovascular disease, obesity,
CC haemangioblastoma, haemangioma, arteriosclerosis, inflammatory disease,
CC inflammatory disorders, atherosclerosis, endometriosis, neoplastic
CC disease, bone-related disease, or psoriasis) in a mammal. The present
CC sequence represents a human kappa constant region of an anti-Ang-2
CC antibody
XX
XX Sequence 107 AA;
SQ
Query Match 100.0%; Score 553; DB 6; Length 107;
Best Local Similarity 100.0%; Pred. No. 4.3e-48;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
DB 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
QY 61 SKDSTYSLSTLTLSKADYERKHVKYVACEVTHQGLSSPVTKSFNRGEC 107
DB 61 SKDSTYSLSTLTLSKADYERKHVKYVACEVTHQGLSSPVTKSFNRGEC 107
RESULT 11
ADJ94622
ID ADJ94622 standard; protein; 107 AA.
XX
XX ADJ94622;
AC
XX
XX 06-MAY-2004 (first entry)
DT
XX
XX Human kappa chain (CK) constant region.
DE
XX
XX humanised anti-CD20 monoclonal antibody; hCD20 monoclonal antibody; Mab;
KW IVIAB variable region; B-cell lymphoma; leukaemia; autoimmune disease;
KW thrombocytopenia; lupus; rheumatoid arthritis; kappa chain; human; CK;
KW constant region.
XX
XX Homo sapiens.
OS
XX WO2003068821-A2.
PN
XX
XX 21-AUG-2003.
PD
XX
XX 14-FEB-2003; 2003WO-GB000665.
PF
XX
XX 14-FEB-2002; 2002US-0356132P.
PR
XX 07-OCT-2002; 2002US-0416232P.
XX
XX (IMMU-) IMMUNOMEDICS INC.
XX (MCCA/) MCCALL J D.
PA
```

XX PI Hansen H, Qu Z, Goldenberg DM;
XX WPI; 2003-697522/66.
DR N-PSDB; ADJ94621.
XX New humanized anti-CD20 monoclonal antibody (MAB) that retains
PT substantially the B-cell and B-cell lymphoma and leukemia cell targeting
PT of the murine anti-CD20 MAB, useful for treating B-cell lymphoma,
PT leukemia or an autoimmune diseases.
XX Example 1; Fig 7B; 106pp; English.
XX The invention comprises a humanised anti-CD20 (hCD20) monoclonal antibody
CC (MAB) or its antigen-binding fragment containing the complementarity
CC determining regions (CDRe) of at least one murine anti-CD20 Mab variable
CC region and the framework regions (FRs) of at least one human IIVIAB
CC variable region. The antibodies of the invention are useful for
CC diagnosing or preventing B-cell lymphoma, leukaemia or an autoimmune
CC disease (e.g. thrombocytopenia, lupus or rheumatoid arthritis). The
CC present amino acid sequence represents a human kappa chain (CK) constant
CC region.
XX Sequence 107 AA;
SQ
Query Match 100.0%; Score 553; DB 7; Length 107;
Best Local Similarity 100.0%; Pred. No. 4.3e-48;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
DB 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
QY 61 SKDSTYSLSTLTLSKADYEHKHKVYACEVTHQGLSSPVTKSFNRGEC 107
DB 61 SKDSTYSLSTLTLSKADYEHKHKVYACEVTHQGLSSPVTKSFNRGEC 107
RESULT 12
ADF77161
ID ADF77161 standard; protein; 107 AA.
XX ADF77161;
AC ADF77161;
XX 26-FEB-2004 (first entry)
DT Anti-VAP-1 monoclonal antibody L chain constant region.
XX complementarity determining region; CDR; mouse;
KW Vascular Adhesion Protein-1; VAP-1; antibody; heavy; light; chain;
KW chimeric; inflammatory disorder; rheumatoid arthritis;
KW inflammatory bowel disease; autoimmune disease; psoriasis;
KW immunoscintigraphic imaging.
XX Homo sapiens.
OS Homo sapiens.
XX WO2003093319-A1.
FN 13-NOV-2003.
PD 28-APR-2003; 2003WO-FI000330.
PF 29-APR-2002; 2002FI-00000807.
PR (BIOT-) BIOTIE THERAPIES CORP.
PA Jalkanen S, Salmi M, Laukkanen M, Clark MR;
XX WPI; 2004-022642/02.
XX New chimeric anti-Vascular Adhesion Protein-1 monoclonal antibodies and
PT encoding nucleic acid molecules, useful for diagnosing and treating
PT chronic inflammatory disorders, e.g. rheumatoid arthritis or psoriasis.

XX Claim 18; SEQ ID NO 22; 56pp; English.
XX This sequence represents the constant region of a human anti-Vascular
CC Adhesion Protein-1 (VAP-1) antibody light chain. This sequence may be
CC used in the production of a chimeric mouse-human anti-VAP-1 antibody. The
CC nucleic acid molecules, polypeptides or antibodies are useful in treating
CC VAP-1 mediated inflammatory disorders, such as rheumatoid arthritis,
CC inflammatory bowel disease, autoimmune diseases or psoriasis. The
CC chimeric VAP-1 antibody is further used for in vitro and in vivo
CC diagnostic applications, including in vivo immunoscintigraphic imaging of
CC inflammation sites. The chimeric MAB's of the invention have improved
CC kinetic properties compared to the corresponding murine antibodies.
XX Sequence 107 AA;
SQ
Query Match 100.0%; Score 553; DB 8; Length 107;
Best Local Similarity 100.0%; Pred. No. 4.3e-48;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
DB 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
QY 61 SKDSTYSLSTLTLSKADYEHKHKVYACEVTHQGLSSPVTKSFNRGEC 107
DB 61 SKDSTYSLSTLTLSKADYEHKHKVYACEVTHQGLSSPVTKSFNRGEC 107
RESULT 13
ADL35096
ID ADL35096 standard; protein; 107 AA.
XX ADL35096;
AC ADL35096;
XX 03-JUN-2004 (first entry)
DT Human IgG4 (hFAT) kappa light chain constant domain protein SeqID 99.
XX antibody; variable domain; framework region; FR; huFR;
KW immune system molecule; kappa; anti-tissue factor; hFAT; human.
XX Homo sapiens.
OS WO2004020579-A2.
FN 11-MAR-2004.
PD 06-AUG-2003; 2003WO-US024637.
PF 29-AUG-2002; 2002US-00230880.
PR (SUNO-) SUNOL MOLECULAR CORP.
PA Wong HC, Stinson JR, Mosquera LA;
XX WPI; 2004-239169/22.
FN Producing humanized antibodies for diagnostic and therapeutic purposes
PT comprises optimizing similarity between individual antibody framework
PT regions to help identify human framework regions suitable for making the
PT antibodies.
XX Disclosure; SEQ ID NO 99; 137pp; English.
XX This invention relates to a novel method for producing a humanised
CC antibody variable (V) domain or its fragment by optimising sequence
CC similarity between individual antibody framework regions (FRs) in order
CC to identify suitable human FRs (huFRs). Specifically, it refers to novel
CC immune system molecules i.e. humanised monoclonal antibodies that exhibit
CC suitable binding affinity with reduced immunogenicity in humans. The
CC present invention describes a method of mutagenising DNA of non-human FRs
CC to encode humanised FRs having an amino acid sequence that is

CC substantially identical to the selected human FR previously identified
 CC through sequence similarity searching. As such, this method provides
 CC humanised light or heavy chain V domains of the sequence huFR1-CDR1-huFR2
 CC -CDR2-huFR3-CDR3-huFR4, which can be used as therapeutic or diagnostic
 CC products to treat and/ or diagnose diseases in humans and animals.
 CC Furthermore, the method expands the number of best fit possibilities that
 CC can be generated and provides a rational basis for assembling nearly all
 CC humanised immune system molecules of interest. This polypeptide sequence
 CC is the human IgG4 kappa light chain constant domain protein of the
 CC invention.

SQ Sequence 107 AA;
 Query Match 100.0%; Score 553; DB 8; Length 107;
 Best Local Similarity 100.0%; Pred. No. 4.3e-48;
 Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
 Db 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
 QY 61 SKDSTYLSSTLTLSKADYERKHVKYACEVTHQGLSSPVTKSFNRGEC 107
 Db 61 SKDSTYLSSTLTLSKADYERKHVKYACEVTHQGLSSPVTKSFNRGEC 107

RESULT 14

ADL35094
 ID ADL35094 standard; protein; 107 AA.

AC ADL35094;

DT 03-JUN-2004 (first entry)

DE Human IgG1 (hOAT) kappa light chain constant domain protein SeqID 97.

KW antibody; variable domain; framework region; FR; huFR;
 KW immune system molecule; kappa; anti-tissue factor; hOAT; human.

OS Homo sapiens.

XX WO2004020579-A2.

XX 11-MAR-2004.

XX 06-AUG-2003; 2003WO-US024637.

XX 29-AUG-2002; 2002US-00230880.

XX (SUNO-) SUNOL MOLECULAR CORP.

XX Wong HC, Stinson JR, Mosquera LA;

XX WPI; 2004-239169/22.

XX Producing humanized antibodies for diagnostic and therapeutic purposes
 PT comprises optimizing similarity between individual antibody framework
 PT regions to help identify human framework regions suitable for making the
 PT antibodies.

XX Disclosure; SEQ ID NO 97; 137pp; English.

XX This invention relates to a novel method for producing a humanised
 CC antibody variable (V) domain or its fragment by optimising sequence
 CC similarity between individual antibody framework regions (FRs) in order
 CC to identify suitable human FRs (huFRs). Specifically, it refers to novel
 CC immune system molecules i.e. humanised monoclonal antibodies that exhibit
 CC suitable binding affinity with reduced immunogenicity in humans. The
 CC present invention describes a method of mutagenising DNA of non-human FRs
 CC to encode humanised FRs having an amino acid sequence that is
 CC substantially identical to the selected human FR previously identified
 CC through sequence similarity searching. As such, this method provides
 CC humanised light or heavy chain V domains of the sequence huFR1-CDR1-huFR2

CC -CDR2-huFR3-CDR3-huFR4, which can be used as therapeutic or diagnostic
 CC products to treat and/ or diagnose diseases in humans and animals.
 CC Furthermore, the method expands the number of best fit possibilities that
 CC can be generated and provides a rational basis for assembling nearly all
 CC humanised immune system molecules of interest. This polypeptide sequence
 CC is the human IgG1 kappa light chain constant domain protein of the
 CC invention.

SQ Sequence 107 AA;

Query Match 100.0%; Score 553; DB 8; Length 107;
 Best Local Similarity 100.0%; Pred. No. 4.3e-48;
 Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60

Db 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60

QY 61 SKDSTYLSSTLTLSKADYERKHVKYACEVTHQGLSSPVTKSFNRGEC 107

Db 61 SKDSTYLSSTLTLSKADYERKHVKYACEVTHQGLSSPVTKSFNRGEC 107

RESULT 15

ADM41539
 ID ADM41539 standard; protein; 107 AA.

XX ADM41539;

XX 03-JUN-2004 (first entry)

XX Anti-interleukin-1 receptor type 1 antibody kappa chain constant region.

KW Human; monoclonal antibody; antibody; interleukin-1; receptor;
 KW antiasthmatic; antiinflammatory; dermatological; antiallergic;
 KW protozoacide; anti rheumatic; antiarthritic; osteopathic; vasotropic;
 KW analgesic; antidiabetic; nephrotropic; antianaemic; nootropic;
 KW anticonvulsant; dermatological; antigen; antiparkinsonian; antidiabetic;
 KW cyostatic.

XX Homo sapiens.

XX WO2004022718-A2.

XX 18-MAR-2004.

XX 05-SEP-2003; 2003WO-US027978.

XX 06-SEP-2002; 2002US-0408719P.

XX (AMGE-) AMGEN INC.

XX Varnum B, Vezina C, Witte A, Qian X, Martin F, Huang H;
 XX Elliott G;

XX WPI; 2004-248462/23.

XX N-PSDB; ADM41538.

XX Isolated human antibody that specifically binds interleukin-1 receptor
 PT type 1 (IL-1R1) useful for treating IL-1 mediated diseases such as
 PT rheumatoid arthritis, osteoarthritis and inflammatory conditions.

XX Disclosure; SEQ ID NO 4; 179pp; English.

XX The present sequence is that of a human anti-interleukin-1 receptor type
 CC 1 (IL-1R1) monoclonal antibody (MAB) kappa chain constant region. Human
 CC MABs to IL-1R1 were prepared using the HCo7 strain of transgenic mice,
 CC which expresses human antibody genes. These mice were immunised with
 CC purified recombinant IL-1R1, and splenocytes from immunised mice were
 CC fused to a mouse myeloma cell line to generate hybridomas. Hybridomas
 CC which secreted a MAB that bound with high avidity to IL-1R1 were
 CC selected. The MABs inhibit IL-1 signalling by competing with IL-1beta and
 CC IL-1alpha binding to IL-1R. These MABs, as well as single chain

CC antibodies single chain Fv antibodies, Fab antibodies, Fab' antibodies
 CC and (Fab')2 antibodies derived from them, are used in methods of treating
 CC IL-1 mediated diseases or for detecting the amount of IL-1 α in a sample.
 CC IL-1 mediated diseases include acute pancreatitis, amyotrophic lateral
 CC sclerosis, Alzheimer's disease, cachexia, anorexia, asthma,
 CC atherosclerosis, autoimmune vasculitis, chronic fatigue syndrome,
 CC Clostridium associated illnesses, coronary endometrios, fever,
 CC leukaemia and tumour metastasis, diabetes, endometrios, fever,
 CC fibromyalgia, glomerulonephritis, graft versus host disease,
 CC osteoarthritis, rheumatoid arthritis, inflammatory eye disease,
 CC ischaemia, Kawasaki's disease, learning impairment, lung disease,
 CC multiple sclerosis, myopathy, osteoporosis, pain, Parkinson's disease,
 CC periodontal disease, pre-term labour, psoriasis, reperfusion injury,
 CC septic shock, side effects of radiation therapy, temporal mandibular
 CC joint disease, sleep disturbance, uveitis, or an inflammatory condition
 CC resulting from strain, sprain, cartilage damage, trauma, orthopaedic
 CC surgery, infection or other disease processes.
 XX
 SQ Sequence 107 AA;

Query Match 100.0%; Score 553; DB 8; Length 107;
 Best Local Similarity 100.0%; Pred. No. 4.3e-48;
 Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIIPPSPDEQLKSGTASVCLNNFYPREAKVQKVDNALQSGNSQESVTEQD 60
 Db |||||
 QY 61 SKDSTYSLSSTLTLSKADYEHKHKVYACVTHQGLSSPVTKSNRGE 107
 Db |||||

RESULT 16
 ADK18336
 ID ADK18336 standard; protein; 107 AA.
 XX
 AC ADK18336;
 XX
 DT 17-JUN-2004 (first entry)
 XX
 DE Amino acid sequence of human kappa CL domain.
 XX
 KW Cerebral blood flow; infarct size; focal ischaemic stroke;
 KW Cerebral artery; tissue plasminogen activator; tPA; anti-CD18 antibody;
 KW humanised H52 antibody; huH52 Fab; stroke; cerebroprotective; vasotropic;
 KW human; kappa; CL domain.
 XX
 OS Homo sapiens.
 XX
 PN US2004057951-A1.
 XX
 PD 25-MAR-2004.
 XX
 PF 31-MAR-2003; 2003US-00404286.
 XX
 PR 23-JAN-1996; 96US-0093038P.
 PR 22-JAN-1997; 97US-00788800.
 PR 17-FEB-1999; 99US-00251652.
 PR 20-DEC-2000; 2000US-00811384.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Bednar MM, Gross CE, Thomas GR, Gross L;
 PI WPI; 2004-257111/24.
 DR
 XX

Increasing cerebral blood flow and/or reducing infarct size in focal
 ischemic stroke caused by obstruction of a main cerebral artery in a
 human comprises co-administering tissue plasminogen activator and anti-
 CD18 antibody.
 XX
 PS Disclosure; SEQ ID NO 5; 26pp; English.

XX The present invention relates to a method for increasing cerebral blood
 CC flow and/or reducing infarct size in focal ischaemic stroke caused by
 CC obstruction of a main cerebral artery in a mammal, particularly humans.
 CC The method comprises co-administering tissue plasminogen activator (tPA)
 CC and anti-CD18 antibody to the mammal, where neither the tPA nor the anti-
 CC CD18 antibody is administered to the mammal until about 3-5 hours after
 CC the onset of focal ischaemic stroke. The anti-CD18 antibody is a
 CC humanised H52 antibody (huH52 Fab). The anti-CD18 antibody binds to an
 CC extracellular domain of CD18 and inhibits or reduces the ability of a
 CC cell expressing CD18 to bind to endothelium. The anti-CD18 antibody binds
 CC CD18 with an affinity of 1-4 nm or less. The anti-CD18 antibody
 CC dissociates the CD11b/CD18 complex. The anti-CD18 antibody binds to the
 CC epitope bound by H52 antibody. The anti-CD18 antibody and the tPA are
 CC simultaneously administered to the mammal, or the anti-CD18 antibody is
 CC administered before the tPA is administered to the mammal. The method is
 CC useful in increasing cerebral blood flow and/or reducing infarct size in
 CC focal ischaemic stroke caused by obstruction of a main cerebral artery in
 CC a human. The antibodies are particularly useful for treating stroke.
 CC Unlike previous methods, the new method of treatment does not require
 CC prior administration of a thrombolytic agent to the mammal in order to
 CC remove an embolus/thrombus, and therefore increases cerebral blood flow
 CC and/or reduces infarct size. The present sequence represents a human
 CC kappa CL domain.
 XX
 SQ Sequence 107 AA;

Query Match 100.0%; Score 553; DB 8; Length 107;
 Best Local Similarity 100.0%; Pred. No. 4.3e-48;
 Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIIPPSPDEQLKSGTASVCLNNFYPREAKVQKVDNALQSGNSQESVTEQD 60
 Db |||||
 QY 61 SKDSTYSLSSTLTLSKADYEHKHKVYACVTHQGLSSPVTKSNRGE 107
 Db |||||

RESULT 17
 ADN97487
 ID ADN97487 standard; protein; 107 AA.
 XX
 AC ADN97487;
 XX
 DT 01-JUL-2004 (first entry)
 XX
 DE Artificial protein construction protein #2.
 XX
 KW artificial proprotein; propeptide; protein engineering; antibody.
 XX
 OS Unidentified.
 XX
 PN WO2004031362-A2.
 XX
 PD 15-APR-2004.
 XX
 PF 03-OCT-2003; 2003WO-US031420.
 XX
 PR 03-OCT-2002; 2002US-0415940P.
 XX
 PA (LARG-) LARGE SCALE BIOLOGY CORP.
 XX
 PI Reini SJ, Edwards P;
 PI WPI; 2004-330170/30.
 DR N-PSDB; ADN97486.
 XX
 PT New artificial proprotein comprises three peptide sequences, useful for
 PT artificial multimeric protein engineering in eukaryotes.
 XX
 PS Example 15; SEQ ID NO 60; 244pp; English.

XX The invention relates to an artificial proprotein comprising three
 CC peptide sequences: a first peptide sequence of interest, a propeptide
 CC sequence attached to the C-terminus of the first peptide sequence of
 CC interest, and a second peptide of interest attached to the C-terminus of
 CC the propeptide sequence. The artificial proprotein and polynucleotides
 CC are useful for artificial multimeric protein engineering, e.g. antibodies
 CC and antibody fragments in eukaryotes. This sequence corresponds to a
 CC protein used in the generation of the protein of the invention.

XX Sequence 107 AA;

Query Match 100.0%; Score 553; DB 8; Length 107;
 Best Local Similarity 100.0%; Pred. No. 4.3e-48;
 Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTRQD 60
 Db 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTRQD 60
 QY 61 SKDSTYSLSSTLTLSKADYKHKYACVETHQGLSSPVTKSPNRRGEC 107
 Db 61 SKDSTYSLSSTLTLSKADYKHKYACVETHQGLSSPVTKSPNRRGEC 107

RESULT 18

ADQ89334
 ID ADQ89334 standard; protein; 107 AA.

AC ADQ89334;
 DT 21-OCT-2004 (first entry)
 XX Human immunoglobulin protein #45.
 DE Human; immunoglobulin; heavy chain; light chain; CC-chemokine receptor 2;
 KW CCR2; inflammatory disease; autoimmune disorder; graft rejection;
 KW HIV infection; atherosclerosis; antiinflammatory; immunosuppressive;
 KW anti-HIV; virucide; antiarteriosclerotic.

XX Homo sapiens.

OS US2004151721-A1.

XX 05-AUG-2004.

XX 10-DEC-2003; 2003US-00733563.

XX 19-OCT-2001; 2001US-0350166P.

XX 26-JUN-2002; 2002US-0392364P.

XX 17-OCT-2002; 2002US-00272899.

XX (ORKEE/) O'KEEFE T.

XX (PONA/) PONATH P.

XX O'keefe T, Ponath P;

XX WPI; 2004-580175/56.

XX New humanized immunoglobulin CC-chemokine receptor 2 (CCR2) antagonists,
 PT useful for diagnosing and/or treating inflammatory or autoimmune
 PT diseases, and HIV infection.

XX Claim 5; SEQ ID NO 112; 128pp; English.

XX The invention relates to humanised immunoglobulin heavy and light chains
 CC which have specificity for the CC-chemokine receptor 2 (CCR2) and an
 CC immunoglobulin or its antigen binding fragment comprising the chains. The
 CC humanised immunoglobulin or its antigen binding fragment preferably
 CC comprises two heavy chains and two light chains. The humanised
 CC immunoglobulin and its heavy and light chains are useful for the
 CC diagnosis, prevention and/or treatment of diseases or conditions
 CC associated with aberrant expression or activity of the CCR2 polypeptide,

CC such as inflammatory diseases, autoimmune disorders, graft rejection, HIV
 CC infection and atherosclerosis. This sequence represents a human
 CC immunoglobulin protein of the invention.

XX Sequence 107 AA;

Query Match 100.0%; Score 553; DB 8; Length 107;
 Best Local Similarity 100.0%; Pred. No. 4.3e-48;
 Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTRQD 60
 Db 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTRQD 60
 QY 61 SKDSTYSLSSTLTLSKADYKHKYACVETHQGLSSPVTKSPNRRGEC 107
 Db 61 SKDSTYSLSSTLTLSKADYKHKYACVETHQGLSSPVTKSPNRRGEC 107

RESULT 19

ADS87911
 ID ADS87911 standard; protein; 107 AA.

XX ADS87911;

DT 18-NOV-2004 (first entry)

XX Anti-IFN-gamma antibody light chain constant region SEQ ID NO:4.

XX antibody; interferon gamma; IFN-gamma; IFN-gamma mediated disease;
 KW anti-inflammatory; antiarthritic; anti-HIV; antianaemic;
 KW antiarteriosclerotic; hepatotropic; antipsoriatic; antidiabetic;
 KW gene therapy; AIDS; rheumatoid arthritis; inflammatory bowel disease;
 KW multiple sclerosis; Addison's disease; type I diabetes; psoriasis;
 KW myasthenia gravis; cirrhosis; lupus nephritis; atherosclerosis;
 KW systemic lupus erythematosus; sarcoidosis; Sjogren's syndrome;
 KW vasculitis; Grave's disease; Guillain-Barre syndrome; haemolytic anaemia;
 KW immunoglobulin G1; IgG1; anti-IFN-gamma antibody; human.

XX Homo sapiens.

XX WO2004034988-A2.

XX 29-APR-2004.

XX 14-OCT-2003; 2003WO-US032678.

XX 16-OCT-2002; 2002US-0419057P.

XX 17-JUN-2003; 2003US-0479241P.

XX (AMGE-) AMGEN INC.

XX Welcher A, Chute H, Li L, Huang H;

XX WPI; 2004-348323/32.

XX N-PSDB; ADS87910.

XX New antibody that binds specifically to IFN-gamma and comprising a heavy
 PT chain CDR3, useful in preparing a composition for treating IFN-gamma
 PT mediated diseases e.g., AIDS, psoriasis, myasthenia gravis, cirrhosis or
 PT atherosclerosis.

XX Example 4; SEQ ID NO 4; 115pp; English.

XX The present invention describes an isolated antibody which binds
 CC specifically to interferon (IFN)-gamma and comprises a heavy chain
 CC complementarity determining region (CDR) 3 having a sequence comprising
 CC at least 7 amino acids of the 8-amino acid sequence of SEQ ID NO:36
 CC (ADS87943) in the same order and spacing, or an amino acid sequence of
 CC SEQ ID NO:37 (ADS87944). Also described: (1) an isolated polynucleotide
 CC encoding the antibody; (2) a method of treating an IFN-gamma mediated
 CC disease; and (3) a composition comprising a carrier and the antibody. The
 CC IFN-gamma binding antibody has anti-inflammatory, antiarthritic, anti-

CC HIV, antianaemic, antiarteriosclerotic, hepatotropic, antipsoriatic and
CC antidiabetic activities, and can be used in gene therapy. The antibody is
CC useful in treating IFN-gamma mediated disease, e.g., AIDS, rheumatoid
CC arthritis, inflammatory bowel disease, multiple sclerosis, Addison's
CC disease, type I diabetes, psoriasis, myaethenia gravis, cirrhosis, lupus
CC nephritis, atherosclerosis, systemic lupus erythematosus, sarcoidosis,
CC Sjogren's syndrome, vasculitis, Grave's disease, Guillain-Barre syndrome
CC or haemolytic anaemia. The present sequence represents an immunoglobulin
CC G1 (IgG1) anti-IFN-gamma light chain constant region, which is used in
CC the exemplification of the present invention.
XX
SQ Sequence 107 AA;

Query Match 100.0%; Score 553; DB 8; Length 107;
Best Local Similarity 100.0%; Pred. No. 4.3e-48;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYFPKAVQWKVDNALQSGNSQESVTEQD 60
DB 1 RTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYFPKAVQWKVDNALQSGNSQESVTEQD 60

QY 61 SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 107
DB 61 SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 107

RESULT 20
ADS94908
ID ADS94908 standard; protein; 107 AA.
XX
AC ADS94908;
XX
DT 02-DEC-2004 (first entry)
XX
DE Anti-IFN-gamma antibody light chain constant region SEQ ID NO:4.
XX
KW antibody; interferon gamma; IFN-gamma; IFN-gamma mediated disease;
KW anti-inflammatory; antiarthritic; anti-HIV; antianaemic;
KW antiarteriosclerotic; hepatotropic; antipsoriatic; antidiabetic;
KW gene therapy; AIDS; rheumatoid arthritis; inflammatory bowel disease;
KW multiple sclerosis; Addison's disease; type I diabetes; psoriasis;
KW myaethenia gravis; cirrhosis; lupus nephritis; atherosclerosis;
KW systemic lupus erythematosus; sarcoidosis; Sjogren's syndrome;
KW vasculitis; Grave's disease; Guillain-Barre syndrome; haemolytic anaemia;
KW immunoglobulin G1; IgG1; anti-IFN-gamma antibody; human.
XX
OS Homo sapiens.
XX
PN WO2004035747-A2.
XX
PD 29-APR-2004.
XX
PF 16-OCT-2003; 2003WO-US032871.
XX
PR 16-OCT-2002; 2002US-0419057P.
PR 17-JUN-2003; 2003US-0479241P.
XX
PA (AMGE-) AMGEN INC.
PA (MEDA-) MEDAREX INC.
XX
XX Welcher AA, Chute HT, Li Y, Huang H;
XX
XX WPI; 2004-348443/32.
DR N-PSDB; ADS94907.
XX
XX New human anti-interferon-gamma neutralizing antibodies for treating
PT interferon-gamma-mediated diseases, such as AIDS, rheumatoid arthritis,
PT diabetes, Grave's disease, psoriasis, atherosclerosis or transplant
PT rejection.
XX
XX Example 4; SEQ ID NO 4; 115pp; English.
PS
XX The present invention describes an isolated antibody which binds

CC specifically to interferon (IFN)-gamma and comprises a heavy chain
CC complementarity determining region (CDR) 3 having a sequence comprising
CC at least 7 amino acids of the 8-amino acid sequence of SEQ ID NO:36
CC (ADS94940) in the same order and spacing, or an amino acid sequence of
CC SEQ ID NO:37 (ADS94941). Also described: (1) an isolated polynucleotide
CC encoding the antibody; (2) a method of treating an IFN-gamma mediated
CC disease; and (3) a composition comprising a carrier and the antibody. The
CC IFN-gamma binding antibody has anti-inflammatory, antiarthritic, anti-
CC HIV, antianaemic, antiarteriosclerotic, hepatotropic, antipsoriatic and
CC antidiabetic activities, and can be used in gene therapy. The antibody is
CC useful in treating IFN-gamma mediated disease, e.g., AIDS, rheumatoid
CC arthritis, inflammatory bowel disease, multiple sclerosis, Addison's
CC disease, type I diabetes, psoriasis, myaethenia gravis, cirrhosis, lupus
CC nephritis, atherosclerosis, systemic lupus erythematosus, sarcoidosis,
CC Sjogren's syndrome, vasculitis, Grave's disease, Guillain-Barre syndrome
CC or haemolytic anaemia. The present sequence represents an immunoglobulin
CC G1 (IgG1) anti-IFN-gamma light chain constant region, which is used in
CC the exemplification of the present invention.
XX
SQ Sequence 107 AA;

Query Match 100.0%; Score 553; DB 8; Length 107;
Best Local Similarity 100.0%; Pred. No. 4.3e-48;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYFPKAVQWKVDNALQSGNSQESVTEQD 60
DB 1 RTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYFPKAVQWKVDNALQSGNSQESVTEQD 60

QY 61 SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 107
DB 61 SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 107

RESULT 21
ADT88871
ID ADT88871 standard; protein; 107 AA.
XX
AC ADT88871;
XX
DT 30-DEC-2004 (first entry)
XX
DE Human IgG1 antibody constant domain SEQ ID NO:10.
XX
KW antibody; IGF-IR; Insulin-like growth factor I receptor; cytostatic;
KW antibody therapy; tumor; cancer; IgG1.
XX
OS Homo sapiens.
XX
PN WO2004087756-A2.
XX
PD 14-OCT-2004.
XX
PF 01-APR-2004; 2004WO-EP003442.
XX
PR 02-APR-2003; 2003US-0459837P.
PR 15-APR-2003; 2003US-0463003P.
XX
PA (HOFF) HOFFMANN LA ROCHE & CO AG F.
XX
XX Graus Y, Kopetzki E, Kuenkele K, Mundigl O, Parren P, Rebers F;
PI Schumacher R, Van De Winkel J, Van Vugt M;
XX
XX WPI; 2004-737667/72.
DR N-PSDB; ADT88870.
XX
XX New antibody binding to insulin-like growth factor I receptor (IGF-IR)
PT and inhibiting the binding of IGF-I and IGF-II to IGF-IR, useful for
PT treating cancers of the colon, breast, prostate and lung.
XX
XX Disclosure; SEQ ID NO 10; 81pp; English.
PS
XX The invention relates to a novel antibody binding to insulin-like growth

CC factor I receptor (IGF-IR) and inhibiting the binding of IGF-I and IGF-II
 CC to IGF-IR. An antibody binding to insulin-like growth factor I receptor
 CC (IGF-IR) and inhibiting the binding of IGF-I and IGF-II to IGF-IR, where
 CC the antibody is of IgG1 isotype and shows a ratio of inhibition of the
 CC binding of IGF-I to IGF-IR to the inhibition of binding of IGF-II to IGF-
 CC IR of 1:3 to 3:1 and induces cell death of 20% or more cells of a
 CC preparation of IGF-IR expressing cells after 24 hours at a concentration
 CC of the antibody of 100 nM by ADCC, is new. An antibody of the invention
 CC has cytostatic activity, and may have a use in antibody therapy. The
 CC methods and compositions of the present invention are useful for the
 CC treatment of tumors and cancers of the colon, breast, prostate and lung
 CC using antibodies against human insulin-like growth factor I receptor (IGF
 CC -IR). The present sequence represents the constant domain of a human IgG1
 CC type antibody.

XX Sequence 107 AA;

Query Match 100.0%; Score 553; DB 8; Length 107;
 Best Local Similarity 100.0%; Pred. No. 4.3e-48;
 Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
 Db 1 RTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
 QY 61 SKDSTYSLSTLTLSKADYKHKYVACEVTHQGLSSPVTKSFNRGEC 107
 Db 61 SKDSTYSLSTLTLSKADYKHKYVACEVTHQGLSSPVTKSFNRGEC 107

RESULT 22

ADTS1583
 ID ADTS1583 standard; protein; 107 AA.

AC ADTS1583;

XX 13-JAN-2005 (first entry)

XX Light chain constant region of human Hu1D10-IgG2M3.

XX Human; antibody; immunoglobulin G; IgG; light chain constant region; CL;
 KW FcRn binding affinity; serum half-life; dactilizumab; fontolizumab;
 KW visilizumab; M200; cancer; inflammatory disorder; asthma;
 KW autoimmune disease; viral infection; cytostatic; antiinflammatory;
 KW antiasthmatic; immunosuppressive; virucide.

XX Homo sapiens.

XX WO2004092219-A2.

XX 28-OCT-2004.

XX 09-APR-2004; 2004WO-US011213.

XX 10-APR-2003; 2003US-0462014P.

PR 03-JUN-2003; 2003US-0475762P.

PR 29-AUG-2003; 2003US-0499048P.

PR 15-OCT-2003; 2003US-00687118.

XX (PROT-) PROTEIN DESIGN LABS INC.

XX Hinton PR, Taurushita N, Tso JY, Vasquez M;

XX WPI; 2004-758341/74.

XX New modified antibodies of class IgG that have altered binding affinities
 PT for FcRn or altered serum half-lives, useful for diagnosing or treating
 PT for e.g. cancer, inflammation, autoimmune diseases or viral infections.

PS Disclosure; SEQ ID NO 9; 157pp; English.

XX The present invention relates to a modified human antibody of class

CC immunoglobulin G (IgG) where at least one amino acid residue from the

CC heavy chain constant (CH) region selected from amino acid residues 250,
 CC 314 and 428 is different from that present in an unmodified class IgG
 CC antibody, and where the FcRn binding affinity and/or serum half-life of
 CC the modified antibody is altered relative to that of the unmodified
 CC antibody. The numbering of the residues in the heavy chain is that of the
 CC EU index. Also disclosed are methods of modifying an antibody of class
 CC IgG and producing the modified antibody cited, and a pharmaceutical
 CC composition comprising the above modified immunoglobulins, proteins and
 CC other bioactive molecules having altered half-lives. The unmodified or
 CC naturally occurring class IgG antibody is selected from dactilizumab,
 CC fontolizumab, visilizumab and M200. The amino acid residue 250 from the
 CC heavy chain constant region is glutamic acid or glutamine, or the amino
 CC acid residue 428 from the heavy chain constant region is phenylalanine or
 CC leucine. Alternatively, the amino acid residue 250 from the heavy chain
 CC constant region is glutamic acid and the amino acid residue 428 from the
 CC heavy chain constant region is phenylalanine, or the amino acid residue
 CC 250 from the heavy chain constant region is glutamine and the amino acid
 CC residue 428 from the heavy chain constant region is phenylalanine, or the
 CC amino acid residue 250 from the heavy chain constant region is glutamine
 CC and the amino acid residue 428 from the heavy chain constant region is
 CC leucine. The modified therapeutic antibody of class IgG has an in vivo
 CC elimination half-life of at least 1.3-fold longer than that of the
 CC corresponding unmodified class IgG antibody. The composition and methods
 CC of the invention are useful for various diagnostic and therapeutic
 CC purposes, especially in the treatment of cancer, inflammatory disorders
 CC (e.g. asthma), autoimmune diseases or viral infections. The present
 CC sequence represents a light chain constant (CL) region of a human IgG
 XX antibody.

XX Sequence 107 AA;

Query Match 100.0%; Score 553; DB 8; Length 107;

Best Local Similarity 100.0%; Pred. No. 4.3e-48;

Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60

Db 1 RTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60

QY 61 SKDSTYSLSTLTLSKADYKHKYVACEVTHQGLSSPVTKSFNRGEC 107

Db 61 SKDSTYSLSTLTLSKADYKHKYVACEVTHQGLSSPVTKSFNRGEC 107

RESULT 23

ADU68013

ID ADU68013 standard; protein; 107 AA.

XX AC ADU68013;

XX 10-FEB-2005 (first entry)

XX Mouse anti-PSMA antibody deJ591 light chain constant region.

XX antibody; antibody engineering; antibody therapy; prostate tumor;
 KW cytostatic; prostate specific membrane antigen; PSMA;
 KW light chain constant region; mutein.

OS Mus musculus.

OS Synthetic.

XX WO2004098535-A2.

XX 18-NOV-2004.

XX 03-MAR-2004; 2004WO-US006586.

XX 03-MAR-2003; 2003US-00379838.

XX 30-MAY-2003; 2003US-00449379.

XX (MILL-) MILLENNIUM PHARM INC.

XX Horvath CJ, Webb IJ;

XX WPI; 2004-805058/79.
 DR N-PSDB; ADU68012.
 XX
 PT Use of an anti-prostate specific membrane antigen (anti-PSMA) antibody or
 PT antigen-binding fragment for treating prostate cancer or monitoring a
 PT patient receiving an anti-PSMA antibody to treat prostate cancer.
 XX
 PS Disclosure; SEQ ID NO 134; 284pp; English.
 XX
 CC The invention relates to the use of an anti-prostate specific membrane
 CC antigen (anti-PSMA) antibody or antigen-binding fragment for treating
 CC prostate cancer, monitoring a patient receiving an anti-PSMA antibody to
 CC treat prostate cancer, or selecting a patient for treatment with an anti-
 CC PSMA antibody. Also included are a method of treating prostate cancer in
 CC a subject, a method of monitoring a patient receiving an anti-PSMA
 CC antibody to treat prostate cancer and a method of selecting a patient for
 CC treatment with an anti-PSMA antibody. Also disclosed are anti-PSMA
 CC antibodies. The antibody or antigen-binding fragment is a human antibody
 CC (or antigen-binding fragment), a modified antibody (or an antigen-binding
 CC fragment). The modified antibody is selected from CDR-grafted antibody,
 CC humanized antibody, deimmunized antibody, or antigen binding fragments.
 CC The modified antibody or antigen-binding fragment has one or more CDRs
 CC (complementarity determining region) from a mouse monoclonal antibody
 CC selected from J591, J415, J533, or E99. The anti-PSMA antibody or antigen
 CC binding fragment is useful for treating prostate cancer, monitoring a
 CC patient receiving an anti-PSMA antibody to treat prostate cancer, or
 CC selecting a patient for treatment with an anti-PSMA antibody. The present
 CC sequence is a deimmunized light chain constant region from one of the
 CC mouse monoclonal antibodies listed above.

XX Sequence 107 AA;
 SQ

Query Match 100.0%; Score 553; DB 8; Length 107;
 Best Local Similarity 100.0%; Pred. No. 4.3e-48;
 Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
 DB 1 RTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
 QY 61 SKDSTYSLSSLTLSKADYERKHVKYACEVTHQGLSSPVTKSFNRGEC 107
 DB 61 SKDSTYSLSSLTLSKADYERKHVKYACEVTHQGLSSPVTKSFNRGEC 107

RESULT 24
 ADW08870
 ID ADW08870 standard; protein; 107 AA.
 XX
 AC ADW08870;
 XX
 XX 07-APR-2005 (first entry)
 DT
 DE IGF-IR antibody 22 constant region domain, SEQ ID 8.

XX Cytostatic; Antibody; antibody therapy; antibody production;
 KW insulin-like growth factor I receptor; IGF-IR; constant region.
 XX Homo sapiens.

OS US2005008642-A1.
 XX 13-JAN-2005.
 PD
 XX 08-JUL-2004; 2004US-00986838.
 PF
 XX 10-JUL-2003; 2003EP-00015526.

XX (GRAU/) GRAUS Y.
 PA (KOPE/) KOPETZKI E.
 PA (KUEN/) KUENKELE K.
 PA (MUND/) MUNDIGL O.

PA (PARR/) PARREN P.
 PA (REBE/) REBERS F.
 PA (SCHU/) SCHUMACHER R.
 PA (VWIN/) VAN DE WINKEL J.
 PA (VUGT/) VUGT M V.
 XX
 PI Graus Y, Kopetzki E, Kuenkele K, Mundigl O, Parren P, Rebers F;
 PI Schumacher R, Van De Winkel J, Vugt MW;
 DR WPI; 2005-099927/11.
 DR N-PSDB; ADW08869.

XX Novel antibody capable of inhibiting binding of insulin like growth
 PT factor I (IGF-I) and IGF-II to IGF-I receptor, useful for treating
 PT cancer.

XX Disclosure; SEQ ID NO 8; 38pp; English.

XX The present invention relates to antibodies 18 and 22, (A1) which bind to
 CC insulin like growth factor I receptor (IGF-IR). The antibody is capable
 CC of inhibiting the binding of IGF-I and IGF-II to IGF-IR, and is of the
 CC IGI1 isotype. The antibodies induce cell death of 20% or more cells of a
 CC preparation of IGF-IR expressing cells by antibody dependent cellular
 CC toxicity (ADCC). (A1) are useful for making a pharmaceutical composition
 CC which inhibits the binding of IGF-I and IGF-II to IGF-IR, which involves
 CC combining (A1) with a carrier. (A1) is also useful for treating a patient
 CC in need of an antitumor therapy, which involves administering (A1) alone
 CC or in combination with a cytotoxic agent, its prodrug or cytotoxic
 CC radiotherapy to the patient. The present sequence is the constant region
 CC of antibody 22.

XX Sequence 107 AA;
 SQ

Query Match 100.0%; Score 553; DB 9; Length 107;
 Best Local Similarity 100.0%; Pred. No. 4.3e-48;
 Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
 DB 1 RTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
 QY 61 SKDSTYSLSSLTLSKADYERKHVKYACEVTHQGLSSPVTKSFNRGEC 107
 DB 61 SKDSTYSLSSLTLSKADYERKHVKYACEVTHQGLSSPVTKSFNRGEC 107

RESULT 25
 ADW07454
 ID ADW07454 standard; protein; 107 AA.
 XX
 AC ADW07454;
 XX
 XX 07-APR-2005 (first entry)
 DT
 DE Human kappa light chain constant domain.

XX Blood-clotting; light chain constant region; inflammation;
 KW antiinflammatory; antibody; tissue factor; sepsis;
 KW disseminated intravascular coagulation; anticoagulant;
 KW hematological disease; thrombosis; lung injury; respiratory-gen.;
 KW respiratory distress syndrome; immunosuppressive; Antibacterial;
 KW Antiarthritic; Antianemic; anemia; rheumatoid arthritis;
 KW glomerulonephritis; multiple sclerosis; psoriasis; sjogren's syndrome;
 KW inflammatory bowel disease.

XX Homo sapiens.
 OS
 XX WO2005004793-A2.
 PF
 XX 20-JAN-2005.

XX 04-JUN-2004; 2004WO-US017900.
 PF
 XX

PR 19-JUN-2003; 2003US-0480254P.
PR 22-JAN-2004; 2004US-0538892P.
PA (SUNO-) SUNOL MOLECULAR CORP.
XX Jiao J, Wong HC, Egan JO;
XX WPI; 2005-091964/10.
DR
XX
PT Preventing or treating sepsis or inflammation in mammals comprises
PT administering a humanized or chimeric antibody that binds to a human
PT tissue factor to form a complex in which factor X or IX binding to the
PT complex is inhibited.
XX
PS Example 1; Fig 5; 109pp; English.
XX
CC The invention relates to preventing or treating a sepsis or inflammatory
CC disease in a mammal comprising administering to the mammal a therapeutic
CC amount of at least one humanized antibody, chimeric antibody, or their
CC fragment that binds specifically to tissue factor (TF) to form a complex,
CC where factor X or IX binding to the complex is inhibited and the
CC administration prevents or treats the sepsis in the mammal. Also included
CC are a kit for performing the above method and reducing an inflammatory
CC cytokine production in a mammal. The inflammatory disease is associated
CC with arthritis (preferably rheumatoid arthritis), glomerulonephritis,
CC multiple sclerosis, psoriasis, Sjogren's syndrome, or inflammatory bowel
CC disease. The method also treats or prevents a sepsis-induced anemia or a
CC sepsis-related condition in a mammal, where the sepsis-related condition
CC is DIC, fibrin deposition, thrombosis, lung injury, or sepsis-associated
CC renal disorder. The lung injury is acute lung injury (ALI) or acute
CC respiratory distress syndrome (ARDS). The sepsis-associated renal
CC disorder is acute tubular necrosis. The methods and kit are useful for
CC preventing or treating sepsis or sepsis-related conditions (e.g. DIC or
CC anemia) or inflammatory diseases (e.g. arthritis). The humanized
CC antibodies are based on the chimeric antibody ch36 which comprises the
CC light and heavy chain variable regions (VL or VH) of an anti-TF antibody
CC fused to the human IgG4 heavy and kappa light constant regions. The CDRs
CC (complementarity determining region) and FRs (framework regions) are then
CC humanized. The present sequence represents the human light chain constant
CC region used to make the chimeric antibody.
XX
SQ Sequence 107 AA;
Query Match 100.0%; Score 553; DB 9; Length 107;
Best Local Similarity 100.0%; Pred. No. 4.3e-48; Mismatches 0; Indels 0; Gaps 0;
Matches 107; Conservative 0;
QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 1 RTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
QY 61 SKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 107
Db 61 SKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 107
RESULT 26
ADW24748
ID ADW24748 standard; protein; 107 AA.
XX
AC ADW24748;
XX
DT 07-APR-2005 (first entry)
XX
DE Variable kappa light chain constant region version 1.
XX
KW cytostatic; gene therapy; antibody; light chain variable region;
KW diagnosis; pharmaceutical; tumor; cytostatic; neoplasm.
XX
OS Homo sapiens.
XX
FN WO2005005604-A2.
XX

PD 20-JAN-2005.
XX
PF 21-JUN-2004; 2004WO-US019783.
XX
PR 30-JUN-2003; 2003US-0483654P.
XX
PA (CENZ) CENTOCOR INC.
XX
PI Lu J;
XX
WPI; 2005-092074/10.
DR
PT New target Ig derived protein comprising a target binding sequence and a
PT portion of a heavy or light chain variable or constant region, useful in
PT preparing a composition for diagnosing or treating a target related
PT condition, e.g. tumor.
XX
PS Claim 4; SEQ ID NO 41; 321pp; English.
XX
CC The invention describes an isolated target immunoglobulin (Ig) derived
CC protein comprising a target binding sequence and a portion of a heavy or
CC light chain variable region or a portion of a heavy or light chain
CC constant region and optionally a substitution, insertion or deletion as
CC given in the specification. An isolated target Ig derived protein
CC comprises a target binding sequence and a portion of a heavy or light
CC chain variable region comprising 10-125 or 10-75 contiguous amino acids
CC of the sequence comprising 91-132 or 77-107 amino acids, respectively, or
CC its FR1, FR2, FR3 or FR4 fragment, or a portion of a heavy or light chain
CC constant region comprising 10-384 or 10-107 contiguous amino acids of the
CC sequence comprising 326-497 or 107 amino acids, respectively, or its FR1,
CC FR2, FR3, FR4, CH1, CH2, CH3, hinge1, hinge2, hinge3 or hinge4 fragment
CC and optionally a substitution, insertion or deletion as given in the
CC specification. Also described are: an isolated nucleic acid encoding an
CC isolated target Ig derived protein; a vector comprising the isolated
CC nucleic acid; a prokaryotic or eukaryotic host cell comprising the
CC isolated nucleic acid; a method for producing an isolated target Ig
CC derived protein; a composition comprising the isolated target Ig derived
CC protein and a carrier or diluent; an anti-idiotype Ig derived protein
CC that specifically binds target Ig derived protein; a method for
CC diagnosing or treating a target related condition in a cell, tissue,
CC organ or animal; a medical device comprising target Ig derived protein
CC that is suitable for contacting or administering the target Ig derived
CC protein; an article of manufacture for human pharmaceutical or diagnostic
CC use, comprising packaging material and a container comprising a solution
CC or lyophilized form of target Ig derived protein; and a method for
CC producing an isolated mammalian target Ig derived protein. The target Ig
CC derived protein is useful in preparing a composition for diagnosing or
CC treating a target related condition in a cell, tissue, organ or animal,
CC e.g. tumor. This is the amino acid sequence of variable kappa light chain
CC constant region. Note: This sequence differs from the version given in
CC figure 41 in which the X residues have been expanded to represent the
CC whole CDR regions.
XX
SQ Sequence 107 AA;
Query Match 100.0%; Score 553; DB 9; Length 107;
Best Local Similarity 100.0%; Pred. No. 4.3e-48; Mismatches 0; Indels 0; Gaps 0;
Matches 107; Conservative 0;
QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 1 RTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
QY 61 SKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 107
Db 61 SKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 107
RESULT 27
ADW24790
ID ADW24790 standard; protein; 107 AA.
XX
AC ADW24790;
XX

[illegible]

	isolated nucleic acid vector comprising an isolated nucleic acid encoding	
	an amyloid antibody, (v) a prokaryotic or eukaryotic host cell comprising	
	an isolated nucleic acid encoding an amyloid antibody, (vi) a method of	
	producing at least one amyloid antibody, (vii) a composition comprising	
	at least one of any of the isolated mammalian amyloid antibodies	
	mentioned, and at least one pharmaceutical carrier or diluent, (viii) an	
	anti-idiotypic antibody or fragment that specifically binds at least one	
	of the amyloid antibodies mentioned, (ix) a method of diagnosing or	
	treating an amyloid related condition in a cell, tissue, organ or animal,	
	comprising contacting or administering a composition comprising at least	
	one of the antibodies mentioned, with, or to, the cell, tissue, organ or	
	animal, (x) a medical device comprising at least one amyloid antibody	
	mentioned, where the device is suitable for contacting or administering	
	at least one amyloid antibody, (xi) an article of manufacture for human	
	pharmaceutical or diagnostic use, comprising packaging material and a	
	container comprising a solution or a lyophilized form of at least one of	
	the amyloid antibodies mentioned, and (xii) a method of producing at	
	least one of the isolated mammalian amyloid antibodies, comprising	
	providing a host cell or transgenic animal or transgenic plant or plant	
	cell capable of expressing the antibody in recoverable amounts. The	
	methods and compositions of the present invention are useful for	
	producing therapeutic compositions and devices for treating amyloid-	
	associated disorders, such as Alzheimer's disease, cancer, allergies,	
	autoimmune disease, Parkinson's disease, AIDS, multiple sclerosis,	
	migraine, dementia and infections. This sequence represents a light chain	
	constant region useful in the antibody of the invention.	
	Sequence 107 AA;	
	Query Match 100.0%; Score 553; DB 9; Length 107;	
	Best Local Similarity 100.0%; Pred. No. 4.3e-48;	
	Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
Qy	1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60	
Dd	1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60	
Qy	61 SKDSTYSLSSLTLSKADYEKKHKVYACEVTHQGLSPVTKSFNRGEC 107	
Dd	61 SKDSTYSLSSLTLSKADYEKKHKVYACEVTHQGLSPVTKSFNRGEC 107	
RESULT 32		
ADZ08946		
ID	ADZ08946 standard; protein; 107 AA.	
AC	ADZ08946;	
XX		
DT	16-JUN-2005 (first entry)	
DE	Amyloid antibody, light chain constant region prototype, Igkappa.	
XX		
KW	amyloid; antibody engineering; antibody production;	
KW	amyloid-associated disorder; Alzheimers disease; cancer; allergy;	
KW	autoimmune disease; Parkinsons disease;	
KW	acquired immune deficiency syndrome; multiple sclerosis; migraine;	
KW	dementia; infection; nootropic; neuroprotective; cyostatic;	
KW	antiallergic; immunosuppressive; antiparkinsonian; antimigraine;	
KW	antimicrobial; anti-HIV; light chain constant region.	
OS	Mammalia.	
OS	Synthetic.	
XX		
PN	WO2005028511-A2.	
XX		
PD	31-MAR-2005.	
PF		
XX	26-MAR-2004; 2004WO-US0009522.	
XX		
PR	28-MAR-2003; 2003US-0458469P.	
PR	28-MAR-2003; 2003US-0458474P.	
PR	28-MAR-2003; 2003US-0458509P.	
PR	28-MAR-2003; 2003US-0458510P.	

XX antibody; antibody production; immunoglobulin; transformation;
KW expression; heavy chain constant region; light chain constant region.
XX Homo sapiens.
XX WO2005047335-A1.
XX 26-MAY-2005.
XX 13-NOV-2004; 2004WO-KR002943.
XX 13-NOV-2003; 2003KR-00080299.
XX (HANN-) HANMI PHARM CO LTD.
XX Jung SY, Kim JS, Park YJ, Choi K, Kwon SC, Lee GS;
XX WPI; 2005-372351/38.
XX Producing an immunoglobulin constant region by transforming a prokaryotic
PT cell with a vector encoding an E. coli-derived signal sequence and an
PT immunoglobulin constant region.
XX Claim 9; SEQ ID NO 34; 92pp; English.
XX The invention relates to a method of producing an immunoglobulin constant
CC region on a large scale. The method comprises transforming a prokaryotic
CC cell with a recombinant expression vector including a nucleotide sequence
CC encoding an E. coli-derived signal sequence and a nucleotide sequence
CC encoding an immunoglobulin constant region, culturing a resulting
CC transformant, and isolating and purifying the immunoglobulin constant
CC region expressed by the transformant. Also described is an immunoglobulin
CC constant region prepared by the method above. The immunoglobulin constant
CC region is a constant region from IgG, IgA, IgM, IgE, IgD, or their
CC combinations and hybrids. The IgG is a constant region from IgG1, IgG2,
CC IgG3, IgG4, or their combinations and hybrids, preferably an IgG4
CC constant region, i.e. a human aglycosylated IgG4 constant region. The
CC immunoglobulin constant region is composed of one to four domains, e.g.
CC CH1, CH2, CH3, and CH4 domains, where the immunoglobulin constant region
CC further comprises a hinge region. The recombinant expression vector
CC comprises a nucleotide sequence encoding a heavy chain constant region
CC and a nucleotide sequence encoding a light chain constant region. The
CC immunoglobulin constant region has a sequence of 109-330 amino acids (SEQ
CC ID NOS: 21-25, 27, 29, 30, 34 or 35). The E. coli-derived signal sequence
CC is a signal sequence, e.g. alkaline phosphatase, penicillinase, Ipp, heat
CC -stable enterotoxin II, LamB, PhoE, PelB, OmpA or maltose binding
CC protein, where the heat-stable enterotoxin II signal peptide comprises
CC any of the 11 sequences of given in the specification (SEQ ID NOS: 36-
CC 46). The method of the invention is useful for the mass production of an
CC immunoglobulin constant region. This sequence represents a human
CC immunoglobulin constant region that can be produced by the method of the
XX invention.
XX Sequence 107 AA;
Query Match 100.0%; Score 553; DB 9; Length 107;
Best Local Similarity 100.0%; Pred. No. 4.3e-48;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
DB 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
QY 61 SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 107
DB 61 SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 107
RESULT 35
ID AEA16547 standard; protein; 107 AA.
XX

AC AEA16547;
XX 28-JUL-2005 (first entry)
XX Human MCP-1 immunoglobulin heavy chain constant region, Ig-kappa-c.
XX monocyte chemoattractant protein-1; MCP-1; immunoglobulin;
KW immunosuppressive; immunostimulant; cardiovascular-Gen.; antimicrobial;
KW cytostatic; neuroprotective; vulnery; antirheumatic; Muscle relaxant;
KW analgesic; anesthetic; antipsoriatic; antithyroid; antidiarrheic;
KW antitussive; antiemetic; antiulcer; laxative; anticoagulant; metabolic;
KW cytostatic; antidepressant; antimanic; neuroleptic; tranquilizer;
KW hypnotic; CNS-Gen.; antiasthmatic; auditory; immune disorder;
KW cardiovascular disease; infectious disease; malignant disease;
KW neurological disease; wound healing; trauma.
XX Homo sapiens.
XX WO2005044200-A2.
XX 19-MAY-2005.
XX 05-NOV-2004; 2004WO-US037024.
XX 05-NOV-2003; 2003US-0517370P.
XX (CENZ) CENTOCOR INC.
XX Yan L, Nakada MT, Das A;
XX WPI; 2005-356202/36.
XX Treating at least one human monocyte chemoattractant protein-1 (MCP-1)
PT related pathology, e.g. immune, neurologic, or cardiovascular diseases,
PT comprises administering at least one MCP-1 immunoglobulin-derived protein
PT to the animal.
XX Disclosure; SEQ ID NO 40; 96pp; English.
XX The invention relates to a novel method for treating at least one human
CC monocyte chemoattractant protein-1 (MCP-1) related pathology. The method
CC comprises contacting or administering a therapeutically effective amount
CC of at least one MCP-1 immunoglobulin (Ig) derived protein to the cells,
CC tissue or animal, where the MCP-1 Ig derived protein inhibits a
CC biological activity of MCP-1, in vivo, in vitro or in situ. The method
CC and MCP-1 composition have the following activities: immunosuppressive,
CC immunostimulant, cardiovascular-Gen., antimicrobial, cytostatic,
CC neuroprotective, vulnery, antirheumatic, muscle-relaxant, analgesic,
CC anesthetic, sedative, antipsoriatic, antithyroid, antidiarrheic,
CC antitussive, antiemetic, antiulcer, laxative, anticoagulant, metabolic,
CC cytostatic, antidepressant, antimanic, neuroleptic, tranquilizer,
CC hypnotic, CNS-Gen., antiasthmatic, and auditory. The method and
CC composition are useful for treating at least one human MCP-1 related
CC pathology, such as an immune related disease, a cardiovascular disease,
CC an infectious disease, a malignant disease, a neurological disease, or
CC any wound or trauma. This sequence represents a human monocyte
CC chemoattractant protein-1 immunoglobulin derived protein of the
CC invention.
XX Sequence 107 AA;
Query Match 100.0%; Score 553; DB 9; Length 107;
Best Local Similarity 100.0%; Pred. No. 4.3e-48;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
DB 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
QY 61 SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 107
DB 61 SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 107

```
RESULT 36
AEA45321
ID AEA45321 standard; protein; 107 AA.
XX
AC AEA45321;
XX
DT 11-AUG-2005 (first entry)
XX
DE Apolipoprotein E C-terminal domain related sequence, SEQ ID 519.
XX
KW Neuroprotective; Nootropic; Antidiabetic; Endocrine-Gen.; Nephrotropic;
KW Antiparkinsonian; Anticonvulsant; Respiratory-Gen; Apolipoprotein E;
KW Alzheimers disease; amyloidosis; Parkinsons disease; Huntingtons chorea;
KW Kuru; Dementia; non-insulin dependent diabetes; Down syndrome;
KW Spongiform encephalopathy; Creutzfeldt Jakob disease;
KW motor neurone disease; chronic obstructive pulmonary disease.
XX
OS Homo sapiens.
XX
PN GB2408508-A.
XX
PD 01-JUN-2005.
XX
PF 26-NOV-2004; 2004GB-00026043.
XX
PR 28-NOV-2003; 2003US-0525174P.
XX
PA (ASTR ) ASTRAZENCA AB.
XX
PI (DYAX-) DYAX CORP.
XX
PI Nordstedt C, Goldschmidt T, Henderikx M, Hoet R, Hoogenboom H;
PI Hufton S, Andersson CV, Lindquist J, Sunnemark D, Leonov S;
XX
DR WPI; 2005-408785/42.
XX
New human antibody or antibody fragment which binds to a sequence of the
PT C-terminal domain of Apolipoprotein E (ApoE-CTD), useful for
PT manufacturing a medicament for treating or preventing an amyloid disorder
PT e.g. Alzheimers disease.
XX
PS Claim 36; SEQ ID NO 519; 392pp; English.
XX
The present invention relates to a human antibody or antibody fragment,
CC which binds to the C-terminal domain of Apolipoprotein E (ApoE-CTD;
CC AEA44803) and also to human plaques. The antibody or its fragment is
CC useful for manufacturing a medicament for treating or preventing an
CC amyloid disorder such as Alzheimers disease, senile systemic
CC amyloidosis, secondary systemic amyloidosis, familial amyloid polynuropathy III,
CC familial non-neuropathic amyloidosis, hereditary cerebral amyloid
CC angioathy, Familial British Dementia, Hemodialysis-related amyloidosis,
CC familial amyloid polynuropathy I, familial amyloid polynuropathy III,
CC familial non-neuropathic amyloidosis, hereditary cerebral amyloid
CC angioathy, Familial British Dementia, hemodialysis-related amyloidosis,
CC amyloidosis, secondary systemic amyloidosis, senile systemic amyloidosis,
CC familial amyloid polynuropathy I, familial amyloid polynuropathy III,
CC amyloidosis, type II diabetes, Hereditary renal amyloidosis, Pituitary-gland
CC amyloidosis, injection localized amyloidosis, Medullary carcinoma of the
CC thyroid, Atrial amyloidosis, Familial Danish dementia (PDD), Downs
CC syndrome, Spongiform encephalopathies, Sporadic Creutzfeldt-Jakob
CC disease, Gerstmann-Straussler-Scheinker Disease (GSS), Kuru, Parkinsons
CC disease, Huntingtons disease, Familial amyotrophic lateral sclerosis, and
CC chronic obstructive pulmonary disease. The present sequence was used to
CC illustrate the invention.
XX
SQ Sequence 107 AA;
Query Match 100.0%; Score 553; DB 9; Length 107;
Best Local Similarity 100.0%; Pred. No. 4.3e-48;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTRQD 60
DB 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTRQD 60
QY 61 SKDSTYSLSSTLTLSKADYERKHYACEVTHQGLSSPVTKSFNRGEC 107
DB 61 SKDSTYSLSSTLTLSKADYERKHYACEVTHQGLSSPVTKSFNRGEC 107
RESULT 37
AEA45323
ID AEA45323 standard; protein; 107 AA.
XX
AC AEA45323;
XX
DT 11-AUG-2005 (first entry)
XX
DE Apolipoprotein E C-terminal domain related sequence, SEQ ID 521.
XX
KW Neuroprotective; Nootropic; Antidiabetic; Endocrine-Gen.; Nephrotropic;
KW Antiparkinsonian; Anticonvulsant; Respiratory-Gen; Apolipoprotein E;
KW Alzheimers disease; amyloidosis; Parkinsons disease; Huntingtons chorea;
KW Kuru; Dementia; non-insulin dependent diabetes; Down syndrome;
KW Spongiform encephalopathy; Creutzfeldt Jakob disease;
KW motor neurone disease; chronic obstructive pulmonary disease.
XX
OS Homo sapiens.
XX
PN GB2408508-A.
XX
PD 01-JUN-2005.
XX
PF 26-NOV-2004; 2004GB-00026043.
XX
PR 28-NOV-2003; 2003US-0525174P.
XX
PA (ASTR ) ASTRAZENCA AB.
XX
PI (DYAX-) DYAX CORP.
XX
PI Nordstedt C, Goldschmidt T, Henderikx M, Hoet R, Hoogenboom H;
PI Hufton S, Andersson CV, Lindquist J, Sunnemark D, Leonov S;
XX
DR WPI; 2005-408785/42.
XX
New human antibody or antibody fragment which binds to a sequence of the
PT C-terminal domain of Apolipoprotein E (ApoE-CTD), useful for
PT manufacturing a medicament for treating or preventing an amyloid disorder
PT e.g. Alzheimers disease.
XX
PS Claim 33; SEQ ID NO 521; 392pp; English.
XX
The present invention relates to a human antibody or antibody fragment,
CC which binds to the C-terminal domain of Apolipoprotein E (ApoE-CTD;
CC AEA44803) and also to human plaques. The antibody or its fragment is
CC useful for manufacturing a medicament for treating or preventing an
CC amyloid disorder such as Alzheimers disease, primary systemic
CC amyloidosis, secondary systemic amyloidosis, familial amyloid polynuropathy III,
CC familial non-neuropathic amyloidosis, hereditary cerebral amyloid
CC angioathy, Familial British Dementia, Hemodialysis-related amyloidosis,
CC familial amyloid polynuropathy I, familial amyloid polynuropathy III,
CC amyloidosis, type II diabetes, Hereditary renal amyloidosis, Pituitary-gland
CC amyloidosis, injection localized amyloidosis, Medullary carcinoma of the
CC thyroid, Atrial amyloidosis, Familial Danish dementia (PDD), Downs
CC syndrome, Spongiform encephalopathies, Sporadic Creutzfeldt-Jakob
CC disease, Gerstmann-Straussler-Scheinker Disease (GSS), Kuru, Parkinsons
CC disease, Huntingtons disease, Familial amyotrophic lateral sclerosis, and
CC chronic obstructive pulmonary disease. The present sequence was used to
CC illustrate the invention.
XX
SQ Sequence 107 AA;
Query Match 100.0%; Score 553; DB 9; Length 107;
Best Local Similarity 100.0%; Pred. No. 4.3e-48;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTRQD 60
DB 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTRQD 60
QY 61 SKDSTYSLSSTLTLSKADYERKHYACEVTHQGLSSPVTKSFNRGEC 107
```

Db 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Qy 61 SKDSTYSLSTLTLSKADYERKHVYACEVTHOGLSSPVTKSFNRGEC 107
Db 61 SKDSTYSLSTLTLSKADYERKHVYACEVTHOGLSSPVTKSFNRGEC 107
RESULT 38
AEA37411
ID AEA37411 standard; protein; 107 AA.
XX AEA37411;
AC AEA37411;
DT 25-AUG-2005 (first entry)
XX Anti-human CD40 antibody 3.1.1 light chain constant region.
DE antibody engineering; cytostatic; vaccine; cancer; CD40; antibody;
KW light chain constant region.
XX Homo sapiens.
OS US2005136055-A1.
PN 23-JUN-2005.
PD 02-DEC-2004; 2004US-00001980.
PF 22-DEC-2003; 2003US-0531639P.
PR (PFIZ) PFIZER INC.
PA Gladue RP, Cusmano JD, Bedian V;
PI WPI; 2005-444081/45.
PN Treating cancer in a patient by administering a CD40 agonist antibody or
PT its fragment according to an intermittent dosing regimen of at least two
PT cycles, each cycle comprising a dosing period during and a resting
PT period.
XX Disclosure; SEQ ID NO 4; 18pp; English.
PS The invention relates to a method of treating cancer in a patient by
XX administering a CD40 agonist antibody or its fragment according to an
XX intermittent dosing regimen of at least two cycles, each cycle
XX comprising: (a) a dosing period during which a therapeutically effective
XX amount of the CD40 agonist antibody is administered to the patient and,
XX thereafter; (b) a resting period. The CD40 agonist antibody or its
XX fragment is useful in the manufacture of a medicament for treating cancer
XX in a patient. This sequence corresponds to the constant region of the
XX light chain from the antibody 3.1.1 used in the method of the invention.
XX Sequence 107 AA;
Qy Query Match 100.0%; Score 553; DB 9; Length 107;
Best Local Similarity 100.0%; Pred. No. 4.3e-48;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Qy 61 SKDSTYSLSTLTLSKADYERKHVYACEVTHOGLSSPVTKSFNRGEC 107
Db 61 SKDSTYSLSTLTLSKADYERKHVYACEVTHOGLSSPVTKSFNRGEC 107
RESULT 39
AEA37415
ID AEA37415 standard; protein; 107 AA.
XX AEA37415;
AC AEA37415;

XX 25-AUG-2005 (first entry)
DT Anti-human CD40 antibody 21.4.1 light chain constant region.
XX antibody engineering; cytostatic; vaccine; cancer; CD40; antibody;
KW light chain constant region.
XX Homo sapiens.
OS US2005136055-A1.
PN 23-JUN-2005.
PD 02-DEC-2004; 2004US-00001980.
PF 22-DEC-2003; 2003US-0531639P.
PR (PFIZ) PFIZER INC.
PA Gladue RP, Cusmano JD, Bedian V;
PI WPI; 2005-444081/45.
PN Treating cancer in a patient by administering a CD40 agonist antibody or
PT its fragment according to an intermittent dosing regimen of at least two
PT cycles, each cycle comprising a dosing period during and a resting
PT period.
XX Disclosure; SEQ ID NO 8; 18pp; English.
PS The invention relates to a method of treating cancer in a patient by
XX administering a CD40 agonist antibody or its fragment according to an
XX intermittent dosing regimen of at least two cycles, each cycle
XX comprising: (a) a dosing period during which a therapeutically effective
XX amount of the CD40 agonist antibody is administered to the patient and,
XX thereafter; (b) a resting period. The CD40 agonist antibody or its
XX fragment is useful in the manufacture of a medicament for treating cancer
XX in a patient. This sequence corresponds to the constant region of the
XX light chain from the antibody 21.4.1 used in the method of the invention.
XX Sequence 107 AA;
Qy Query Match 100.0%; Score 553; DB 9; Length 107;
Best Local Similarity 100.0%; Pred. No. 4.3e-48;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Qy 61 SKDSTYSLSTLTLSKADYERKHVYACEVTHOGLSSPVTKSFNRGEC 107
Db 61 SKDSTYSLSTLTLSKADYERKHVYACEVTHOGLSSPVTKSFNRGEC 107
RESULT 40
AEB09607
ID AEB09607 standard; protein; 107 AA.
XX AEB09607;
AC AEB09607;
DT 08-SEP-2005 (first entry)
XX Human C kappa constant region SEQ ID NO 112.
DE antiinflammatory; immunosuppressive; anti-HIV; antiarteriosclerotic;
KW antibody engineering; therapeutic; diagnosis; inflammation;
KW autoimmune disease; immune disorder; graft rejection; HIV infection;
KW infection; atherosclerosis; cardiovascular disease; metabolic disorder;
KW heavy chain constant region.
XX Homo sapiens.

```
XX WO2005060368-A2.
XX
XX 07-JUL-2005.
XX
XX 10-DEC-2003; 2003WO-US039599.
XX
XX 10-DEC-2003; 2003WO-US039599.
XX
XX (MILL-) MILLENNIUM PHARM INC.
XX
XX Okeefe T, Ponath P;
XX
XX WPI; 2005-488561/49.
XX
XX N-PSDB; AEB09608.
XX
XX New humanized immunoglobulin or its antigen binding portion having
XX binding specificity for CC-chemokine receptor 2 and having a heavy chain
XX and light chain, for treating inflammatory diseases, HIV, and autoimmune
XX diseases.
XX
XX Claim 1; SEQ ID NO 112; 192pp; English.
XX
XX The invention describes a humanized immunoglobulin (I) or its antigen
XX binding portion having binding specificity for CC-chemokine receptor 2
XX (CCR2) and having a heavy chain and a light chain, where the heavy chain
XX comprises a fully defined 117 and 330 amino acid (SEQ ID NO: 17 and 110)
XX sequence, given in specification or its portion, and the light chain
XX comprises a fully defined 112 amino acid (SEQ ID NO: 12) sequence given
XX in specification. Also described are: a humanized immunoglobulin heavy
XX chain, or its antigen binding fragment, having binding specificity for
XX CCR2 and comprising the amino acid sequence of (SEQ ID NO: 17) and the
XX amino acid of (SEQ ID NO: 110), or its portion; and a humanized
XX immunoglobulin light chain, or its antigen binding fragment, having
XX binding specificity for CCR2 and comprising the amino acid sequence of
XX (SEQ ID NO: 12) and the fully defined 107 amino acid (SEQ ID NO: 112)
XX sequence, given in specification. The following are disclosed: isolated
XX nucleic acid molecules comprising nucleic acid sequence encoding (1); a
XX construct comprising nucleic acid molecule encoding (1); and host cell
XX comprising the nucleic acid molecule. (1) is useful as a therapeutic
XX agent for controlling lymphocyte homing the mucosal lymphoid tissue thus
XX reducing inflammatory response, for use in the treatment of diseases
XX associated with leukocyte infiltration of tissue, e.g. in the treatment
XX of inflammatory diseases, autoimmune diseases, graft rejection, HIV
XX infection and monocyte-mediated disorders such as atherosclerosis. (1) is
XX useful for detecting and/or measuring the level of CCR2 in a sample (e.g.
XX tissues or body fluids such as inflammatory exudates, blood, serum, bowel
XX fluid), and for modulating binding function and/or leukocyte trafficking
XX modulated by CCR2. This is the amino acid sequence of human C kappa
XX constant region used in the creation of a humanized anti-CCR2-antibody.
XX
XX Sequence 107 AA;
XX
XX Query Match 100.0%; Score 553; DB 9; Length 107;
XX Best Local Similarity 100.0%; Pred. No. 4.3e-48;
XX Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTRQD 60
XX
XX 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTRQD 60
XX
XX 61 SKDSTYSLSSTLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 107
XX
XX 61 SKDSTYSLSSTLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 107
XX
XX RESULT 41
XX AEB72782
XX ID AEB72782 standard; protein; 107 AA.
XX
XX AC AEB72782;
XX
XX 06-OCT-2005 (first entry)
XX
XX
```

```
XX Anti-LtAlpha antibody light chain constant region Igkappac.
XX
XX antibody; Anorectic; Immunosuppressive; Cardiovascular-Gen; Cytostatic;
XX Neuroprotective; Vaccine; lymphotoxin alpha; obesity; immune disorder;
XX cardiovascular disease; infection; neurological disease.
XX
XX Synthetic.
XX
XX WO2005067477-A2.
XX
XX 28-JUL-2005.
XX
XX 30-NOV-2004; 2004WO-US040018.
XX
XX 08-DEC-2003; 2003US-0527794P.
XX
XX (CENZ ) CENTOCOR INC.
XX
XX Giles-Komar J, Scallon BJ, Cai A;
XX
XX WPI; 2005-522703/53.
XX
XX New anti-human lymphotoxin alpha antibody, useful for diagnosing or
XX treating immune, cardiovascular, infectious disease, malignant, or
XX neurological disease, or obesity.
XX
XX Disclosure; SEQ ID NO 40; 114pp; English.
XX
XX This sequence represents a mammalian anti-lymphotoxin alpha (LtAlfa)
XX antibody light chain constant region. The antibody preferably comprises
XX at least one variable region AEB72785AEB72787 at least one light chain
XX complementarity determining region (CDR) AEB72797AEB72798AEB72799 and at
XX least one heavy chain CDR AEB72800AEB72801AEB72802. The antibody binds
XX LtAlfa with an affinity of 10-9 to 10-2 M. The antibody substantially
XX neutralizes at least one activity of at least one LtAlfa protein. The
XX antibody and compositions, medical devices, and methods for its
XX production, are useful for diagnosing or treating a LtAlfa related
XX condition, e.g. obesity, an immune related disease, a cardiovascular
XX disease, an infectious disease, a malignant disease, or a neurological
XX disease.
XX
XX Sequence 107 AA;
XX
XX Query Match 100.0%; Score 553; DB 9; Length 107;
XX Best Local Similarity 100.0%; Pred. No. 4.3e-48;
XX Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTRQD 60
XX
XX 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTRQD 60
XX
XX 61 SKDSTYSLSSTLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 107
XX
XX 61 SKDSTYSLSSTLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 107
XX
XX RESULT 42
XX AEC81787
XX ID AEC81787 standard; protein; 107 AA.
XX
XX AC AEC81787;
XX
XX 01-DEC-2005 (first entry)
XX
XX Human immunoglobulin light chain constant region kappa.
XX
XX Fusion protein; protein production; immunoglobulin; antibody;
XX light chain constant region.
XX
XX Homo sapiens.
XX
XX WO2005087810-A2.
XX
XX
```

XX PD 22-SEP-2005.
XX PF 08-MAR-2005; 2005WO-US007590.
XX PR 08-MAR-2004; 2004US-0551174P.
XX PA (ZYMO) ZYMOGENETICS INC.
XX PI Moore MD, Fox BA;
XX WPI; 2005-630945/64.
XX DR New dimeric protein comprising a first polypeptide fusion disulfide
XX PT bonded to a second polypeptide fusion, useful as cytokine antagonist for
XX PT treating cancers, or as growth factor agonist for promoting tissue
XX PT growth.
XX PS Disclosure; SEQ ID NO 61; 85pp; English.
XX PS
XX CC The present invention relates to dimeric fusion proteins and methods of
XX CC making them. A claimed dimeric protein comprises a first polypeptide
XX CC fusion disulfide bonded to a second polypeptide fusion. The first
XX CC polypeptide fusion has the formula P1-L1-D1-(P2)n, where: P1 is a first
XX CC non-immunoglobulin polypeptide; L1 is a first polypeptide linker of 18-32
XX CC amino acid residues where x of these residues are Cys residues; D1 is a
XX CC first dimerizing domain selected from an immunoglobulin CH1 domain, a T-
XX CC cell receptor C alpha domain, a T-cell receptor C beta domain, a major
XX CC histocompatibility complex (MHC) class I alpha 3 domain, beta2-
XX CC microglobulin, a MHC class II alpha 2 domain, and a MHC class II beta 2
XX CC domain; P2 is a linking polypeptide of 1-29 amino acid residues where at
XX CC least one residue is Cys; and n is 0 or 1. The second polypeptide fusion
XX CC has the formula P3-L2-D2, where: P3 is a second non-immunoglobulin
XX CC polypeptide; L2 is a second polypeptide linker of 18-32 amino acid
XX CC residues, where y of these residues are Cys residues; and D2 is a second
XX CC dimerizing domain selected from an immunoglobulin light chain constant
XX CC domain, a T-cell receptor C alpha domain, a T-cell receptor C beta
XX CC domain, a MHC class I alpha 3 domain, beta2-microglobulin, a MHC class II
XX CC alpha 2 domain and a MHC class II beta 2 domain. In the dimeric protein,
XX CC each of x and y is an integer of 1-8, and x=y. Also claimed are dimeric
XX CC proteins in which: P1 and P3 are different; n=1; x=2 and y=2; each of P1
XX CC and P3 is an extracellular domain of a cell surface receptor, including a
XX CC human cell surface receptor; each of P1 and P3 is not a member of the
XX CC immunoglobulin superfamily; and each of P1 and P3 is individually
XX CC selected from interleukin-17 receptor, interleukin-20 receptor A or B,
XX CC interleukin-21 receptor, interleukin-28 receptor A, interleukin-31
XX CC receptor A, CCR2-4 or gammaC. In a further claimed polypeptide fusion, D1
XX CC is an immunoglobulin CH1 domain, and D2 is an immunoglobulin kappa light
XX CC chain constant domain or immunoglobulin lambda light chain constant
XX CC domain. In a further claimed dimeric protein: (a) one of P1 and P3 is a
XX CC zcytor7 extracellular domain and the other of P1 and P3 is a DIRS1
XX CC extracellular domain; (b) one of P1 and P3 is a zcytor11 extracellular
XX CC domain and the other of P1 and P3 is a DIRS1 extracellular domain; (c)
XX CC one of P1 and P3 is a zalphall extracellular domain and the other of P1
XX CC and P3 is an interleukin-2 receptor gamma common extracellular domain; or
XX CC (d) one of P1 and P3 is a PDGFR alpha receptor extracellular domain and the
XX CC other of P1 and P3 is a PDGFR beta receptor extracellular domain. Also
XX CC claimed are polypeptide fusions of formula P1-L1-D1-(P2)n and P3-L-D2,
XX CC polynucleotides encoding each polypeptide fusion, expression vectors,
XX CC cultured cells, and a method of making the dimeric proteins of the
XX CC invention by culturing cells comprising first and second expression units
XX CC such that the encoded polypeptide fusions are produced as a dimeric
XX CC protein. A dimeric protein consisting of 2 polypeptide chains joined via
XX CC at least one disulfide bond, where each polypeptide chain is a
XX CC polypeptide fusion of formula P3-L-D2, and a method of making this
XX CC dimeric protein, are also claimed. The dimeric proteins of the invention
XX CC can be used for diagnosis, therapy, or research to provide one or more
XX CC activities associated with the first and second non-immunoglobulin
XX CC polypeptides. Such activities include receptor binding, receptor
XX CC activation and ligand binding. Therapeutic uses include use as cytokine
XX CC antagonists for treatment of cancers or immunological disorders, growth
XX CC factor agonists to promote tissue growth or healing or to promote
XX CC development of vasculature or other tissue. Diagnostic uses include use

CC as targeting agents for radioisotopes or other labels. The present
CC sequence is that of a human immunoglobulin light chain kappa constant
CC region, which can be used in fusion proteins of the invention.
XX Sequence 107 AA;
SQ Query Match 100.0%; Score 553; DB 9; Length 107;
Best Local Similarity 100.0%; Pred. No. 4.3e-48;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEOD 60
DB 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEOD 60
QY 61 SKDSTYSLSSTLTLSKADYEHKVKYACEVTHQGLSSPVTKSFNRGEC 107
DB 61 SKDSTYSLSSTLTLSKADYEHKVKYACEVTHQGLSSPVTKSFNRGEC 107
RESULT 43
AED01341
ID AED01341 standard; protein; 107 AA.
XX AC AED01341;
XX DT 01-DEC-2005 (first entry)
XX DE Light chain constant region C kappa.
XX KW immunomodulatory; antimicrobial; antiinflammatory; neuroprotective;
XX KW cytostatic; immunogenicity; antibody therapy; antibody engineering;
XX KW diagnostic; therapeutic; autoimmune disease; immunosuppressive;
XX KW immune disorder; infection; inflammation; neurological disease; neoplasia;
XX KW cancer; light chain constant region.
XX OS Homo sapiens.
XX PN WO2005092325-A2.
XX PD 06-OCT-2005.
XX PF 24-MAR-2005; 2005WO-US010199.
XX PR 24-MAR-2004; 2004US-0556353P.
XX PR 21-MAY-2004; 2004US-0573302P.
XX PR 01-JUL-2004; 2004US-0585328P.
XX PR 09-JUL-2004; 2004US-0586837P.
XX PR 06-AUG-2004; 2004US-0599741P.
XX PR 02-SEP-2004; 2004US-0607398P.
XX PR 29-SEP-2004; 2004US-0614944P.
XX PR 14-OCT-2004; 2004US-0619409P.
XX PA (XENC-) XENCOR INC.
XX PI Lazar GA, Karki SB;
XX WPI; 2005-684098/70.
XX PT New antibody variant comprising an amino acid modification outside the Fc
XX PT region, for treating antibody-related disorders e.g. autoimmune,
XX PT immunological, infectious, and neurological diseases.
XX PS Example; Fig 3c; 92pp; English.
XX CC The invention describes an antibody variant (I) comprising an amino acid
XX CC modification outside the Fc region, where the modification improves
XX CC affinity of (I) for one or more effector ligands relative to the parent
XX CC antibody. Also disclosed are: a method for engineering optimizing (I);
XX CC isolated nucleic acids encoding (I); vectors comprising the nucleic
XX CC acids, optionally operably linked to control sequences; host cells
XX CC comprising the vector; methods for producing and optionally recovering
XX CC (I); and composition comprising (I) and carrier or diluent. (I) is useful
XX CC as a therapeutic, diagnostic or research reagent. (I) is useful for

CC treating an antibody-related disorder chosen from autoimmune diseases,
 CC immunological diseases, infectious diseases, inflammatory diseases,
 CC neurological diseases, and oncological and neoplastic diseases including
 CC cancer (e.g. carcinoma, lymphoma, blastoma, sarcoma, leukemia,
 CC neuroendocrine tumors and melanoma). (I) Has improved affinity for
 CC effector ligands relative to parent antibody. (I) Has enhanced stability,
 CC solubility, function and clinical use, and reduced immunogenicity in
 CC humans. This is the amino acid sequence of an immunoglobulin light chain
 CC constant region.

XX Sequence 107 AA;

Query Match 100.0%; Score 553; DB 9; Length 107;
 Best Local Similarity 100.0%; Pred. No. 4.3e-48;
 Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTRQD 60
 Db 1 RTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTRQD 60
 QY 61 SKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 107
 Db 61 SKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 107

RESULT 44

AED01379
 ID AED01379 standard; protein; 107 AA.

AC AED01379;

XX 01-DEC-2005 (first entry)

XX Immunoglobulin kappa light chain constant region.

XX immunomodulatory; antimicrobial; antiinflammatory; neuroprotective;
 KW cystostatic; immunogenicity; antibody therapy; antibody engineering;
 KW diagnostic; therapeutic; autoimmune disease; immunosuppressive;
 KW immune disorder; infection; inflammation; neurological disease; neoplasm;
 KW cancer; light chain constant region; immunoglobulin.

XX Homo sapiens.

PN WO2005092925-A2.

XX 06-OCT-2005.

XX 24-MAR-2005; 2005WO-US010199.

XX 24-MAR-2004; 2004US-0556353P.

PR 21-MAY-2004; 2004US-0573302P.

PR 01-JUL-2004; 2004US-0585328P.

PR 09-JUL-2004; 2004US-0586837P.

PR 06-AUG-2004; 2004US-0599741P.

PR 02-SEP-2004; 2004US-0607398P.

PR 29-SEP-2004; 2004US-061494P.

PR 14-OCT-2004; 2004US-0619403P.

XX (XENC-) XENCOR INC.

XX Lazar GA, Karki SB;

XX WPI; 2005-684098/70.

XX New antibody variant comprising an amino acid modification outside the Fc
 PT region, for treating antibody-related disorders e.g. autoimmune,
 PT immunological, infectious, and neurological diseases.
 XX Example 3; Fig 15b-c; 92pp; English.

XX The invention describes an antibody variant (I) comprising an amino acid
 CC modification outside the Fc region, where the modification improves
 CC affinity of (I) for one or more effector ligands relative to the parent

CC antibody. Also disclosed are: a method for engineering optimizing (I);
 CC isolated nucleic acids encoding (I); vectors comprising the nucleic
 CC acids, optionally, operably linked to control sequences; host cells
 CC comprising the vector; methods for producing and optionally recovering
 CC (I); and composition comprising (I) and carrier or diluent. (I) is useful
 CC as a therapeutic, diagnostic or research reagent. (I) is useful for
 CC treating an antibody-related disorder chosen from autoimmune diseases,
 CC immunological diseases, infectious diseases, inflammatory diseases,
 CC neurological diseases, and oncological and neoplastic diseases including
 CC cancer (e.g. carcinoma, lymphoma, blastoma, sarcoma, leukemia,
 CC neuroendocrine tumors and melanoma). (I) Has improved affinity for
 CC effector ligands relative to parent antibody. (I) Has enhanced stability,
 CC solubility, function and clinical use, and reduced immunogenicity in
 CC humans. This is the amino acid sequence of an immunoglobulin light chain
 CC constant region.

XX Sequence 107 AA;

Query Match 100.0%; Score 553; DB 9; Length 107;
 Best Local Similarity 100.0%; Pred. No. 4.3e-48;
 Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTRQD 60
 Db 1 RTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTRQD 60
 QY 61 SKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 107
 Db 61 SKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 107

RESULT 45

AEC94910
 ID AEC94910 standard; protein; 107 AA.

XX AEC94910;

XX 01-DEC-2005 (first entry)

XX Anti-IL-13-antibody light chain constant region Ig kappa c.

XX immunomodulator; cardiovascular-gen.; antimicrobial; cytostatic;
 KW neuroprotective; vulnery; therapeutic; immune modulation;
 KW immune disorder; cardiovascular disease; infection; neoplasm;
 KW neurological disease; trauma; light chain constant region.

OS Homo sapiens.

OS Synthetic.

XX WO2005091853-A2.

XX 06-OCT-2005.

XX 18-FEB-2005; 2005WO-US005249.

XX 27-FEB-2004; 2004US-0548658P.

XX (CENZ) CENTOCOR INC.

XX Heavner GA, Li L, Oneil K;

XX WPI; 2005-664875/68.

XX Treating human IL-13 related pathology comprises use of least one IL-13
 PT immunoglobulin derived protein comprising 3 or more of 7 defined
 PT characteristics such as apparent Kd for human IL-13 wt or specific mutant
 PT less than or equal to 0.5 nM.

PS Disclosure; SEQ ID NO 40; 98pp; English.

XX The invention describes a method of treating a human IL-13 related

CC pathology comprising contacting or administering at least one IL-13
 CC immunoglobulin (Ig) derived protein to the cells, tissue or animal, where

CC the IL-13 Ig derived protein inhibits at least one biological activity of
 CC the IL-13, in vivo, in vitro or in situ and comprises at least 3 of 7
 CC specific characteristics such as an apparent Kd for human IL-13 wt or
 CC specific mutant less than or equal to 0.5 nM (as determined by BIA core).
 CC Also described is an anti-IL-13 composition, comprising a therapeutically
 CC effective amount of the at least one IL-13 Ig derived protein. The method
 CC and composition are useful for treating at least one human IL-13 related
 CC pathology, e.g. immune-related disease, a cardiovascular disease, an
 CC infectious disease, a malignant disease, a neurologic disease, or any
 CC wound or trauma. This is the amino acid sequence of an anti-IL-13-
 CC antibody light chain constant region.

XX Sequence 107 AA;

Query Match 100.0%; Score 553; DB 9; Length 107;

Best Local Similarity 100.0%; Pred. No. 4.3e-48;

Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60

Db 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60

QY 61 SKDSTYLSSTLTLSKADYERKHVYACEVTHOGLSPVTKSFNRGEC 107

Db 61 SKDSTYLSSTLTLSKADYERKHVYACEVTHOGLSPVTKSFNRGEC 107

RESULT 46

AED41914

ID AED41914 standard; protein; 107 AA.

XX AC AED41914;

XX DT 15-DEC-2005. (first entry)

XX DE Deimmunized PSMA J591 light chain constant region.

XX KW prostate tumor; cytostatic; andrology; genitourinary disease; neoplasm;

XX KW antibody; prostate specific membrane antigen; PSMA;

XX KW light chain constant region.

XX OS Mus musculus.

XX PN WO2005094882-A1.

XX PD 13-OCT-2005.

XX PF 03-MAR-2004; 2004WO-US006543.

XX PR 03-MAR-2004; 2004WO-US006543.

XX PA (MILL-) MILLENNIUM PHARM INC.

XX PI Horvath CJ, Webb IJ;

XX DR WPI; 2005-703269/72.

XX DR N-PSDB; AED41913.

XX PT Treating prostate cancer in a subject by administering to the subject 2-
 PT 24 doses of an antibody or its antigen binding fragment that binds to the
 PT extracellular domain of prostate specific membrane antigen (PSMA), and is
 PT coupled to DM1.

XX PS Disclosure; SEQ ID NO 134; 291pp; English.

XX CC The invention relates to a method of treating prostate cancer, in a
 CC subject which comprises administering to the subject two to twenty-four
 CC doses of an antibody or its antigen binding fragment, which binds to the
 CC extracellular domain of prostate specific membrane antigen (PSMA) and
 CC which is coupled to DM1, where each dose comprises 175-500 mg/m² of the
 CC antibody or its antigen binding fragment, to thus treat the subject. The
 CC method is useful for treating prostate cancer. The present sequence
 CC represents the amino acid sequence of a mouse prostate specific membrane

CC antigen (PSMA) antibody heavy chain.

XX Sequence 107 AA;

Query Match 100.0%; Score 553; DB 9; Length 107;

Best Local Similarity 100.0%; Pred. No. 4.3e-48;

Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60

Db 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60

QY 61 SKDSTYLSSTLTLSKADYERKHVYACEVTHOGLSPVTKSFNRGEC 107

Db 61 SKDSTYLSSTLTLSKADYERKHVYACEVTHOGLSPVTKSFNRGEC 107

RESULT 47

AED49132

ID AED49132 standard; protein; 107 AA.

XX AC AED49132;

XX DT 15-DEC-2005 (first entry)

XX DE Light chain constant region - Igkc.

XX KW antibody engineering; heavy chain; light chain; variable region;

XX KW constant region.

XX OS Homo sapiens.

XX OS Synthetic.

XX PN WO2005098039-A2.

XX PD 20-OCT-2005.

XX PF 28-MAR-2005; 2005WO-US010086.

XX PR 31-MAR-2004; 2004US-0558090P.

XX PA (CENZ) CENTOCOR INC.

XX PI Lu J;

XX DR WPI; 2005-725786/74.

XX PT Selecting, generating, comparing or analyzing human antibody amino acid
 PT or nucleic acid sequences comprises accessing antibody sequence databases
 PT and classifying sequences into groups, superfamilies, and/or subfamilies.

XX PS Disclosure; SEQ ID NO 40; 51pp; English.

XX CC This sequence represents the light chain constant region from a consensus
 CC antibody sequence which was used in the method of the invention for
 CC selecting, generating, comparing or analyzing human or human derived
 CC antibody or antibody fusion protein amino acid or nucleic acid sequences.
 CC The method comprises: (a) accessing antibody sequence databases and
 CC collecting constant, complementarity determining regions (CDR), and/or
 CC variable region sequences; (b) subjecting the data collected in step (a)
 CC to Algorithm 1, where the sequences are classified into groups,
 CC superfamilies, and/or subfamilies; (c) performing sequence alignment
 CC on all sequences assigned to a given subfamily in step (b); (d) displaying
 CC subfamily multiple sequence alignment result of step (c); (e) accessing
 CC antibody sequence databases and collecting variable region sequences; (f)
 CC subjecting the data collected in step (e) to Algorithm 2, where the
 CC variable region sequences are classified into superfamilies and
 CC subfamilies; (g) performing multiple sequence alignment on all sequences
 CC assigned to a given subfamily in step (f); (h) displaying subfamily
 CC multiple sequence alignment results of step (g); (i) subjecting the
 CC multiple sequence alignment data generated in step (g) or (h) to
 CC Algorithm 3, where each amino acid substitution is examined and the
 CC substitution's frequency of occurrence at a given position is calculated;

CC (j) determining the constant region subfamily prototype sequence and
CC substitutions; (k) displaying the constant region subfamily prototype
CC sequence and substitutions generated by step (j); (l) determining the
CC variable region subfamily prototype sequence and substitutions; (m)
CC displaying the variable region subfamily prototype sequence and
CC substitutions generated by step (l); and (n) exporting the displayed
CC results from step (d), (h), (k) or (m) to a web interface, where the
CC displays can be viewed and BLAST searching can be performed. The method,
CC computer programs, data and databases, computer readable media, computer
CC systems, and apparatus are useful for selecting, generating, comparing or
CC analyzing human or human derived antibody or antibody fusion protein
CC amino acid or nucleic acid sequences and are used for research,
CC diagnostic and/or therapeutic products.

XX Sequence 107 AA;

Query Match 100.0%; Score 553; DB 9; Length 107;
Best Local Similarity 100.0%; Pred. No. 4.3e-48;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RTVAAPSVFIPTSPDEQLKSGTASVVCLLNNFYPREAKVQKVDNALQSGNSQESVTEQD 60

Db 1 RTVAAPSVFIPTSPDEQLKSGTASVVCLLNNFYPREAKVQKVDNALQSGNSQESVTEQD 60

Qy 61 SKDSTYSLSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 107

Db 61 SKDSTYSLSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 107

RESULT 48

AED28066

ID AED28066 standard; protein; 107 AA.

AC AED28066;

DT 15-DEC-2005 (first entry)

DE Human kappa light chain constant region (CL).

KW Gene therapy; antibody therapy; inflammation; antiinflammatory;

KW thrombosis; anticoagulant; thrombolytic; cardiovascular disease;

KW hematological disease; peripheral arterial occlusive disease; vasotropic;

KW ischemia; monoclonal antibody; light chain constant region.

XX Homo sapiens.

OS US2005226876-A1.

PN 13-OCT-2005.

PD 08-APR-2005; 2005US-00102403.

PF 13-APR-2004; 2004EP-00008722.

PR (GRAU/) GRAUS Y.

PA (HIMB/) HIMBER J.

PA (JANS/) JANSSEN-MOLENAAR M.

PA (KLIN/) KLING D.

PA (KOPE/) KOPETZKI E.

PA (PARR/) PARRIN P.

PA (REBE/) REBERS F.

PA (STEL/) STEINER B.

PA (STER/) STERN A.

PA (STRE/) STREIN P.

PA (STUB/) STUBENRAUCH K.

PA (VWIN/) VAN DE WINKEL J.

PA (VUG/) VAN VUGT M.

XX Graus Y, Himber J, Jansen-Molenaar M, Kling D, Kopetzki E;

PI Parren P, Rebers F, Steiner B, Stern A, Strein P, Stubenrauch K;

PI Van De Winkel J, Van Vugt M;

XX WPI; 2005-723886/74.

XX New antibody containing a Fc part from human origin, binding to P-
PT selectin and non-binding to complement factor C1q, for preparing a
PT medicament for treating e.g., peripheral arterial occlusive disease.

XX Disclosure; SEQ ID NO 23; 50pp; English.

XX The invention relates to an antibody containing a Fc part from human
CC origin, binding to P-selectin (CD62P, GMP-140, PADGEM or LECAM-3) and non
CC binding to complement factor C1q. The anti-P-selectin antibody is useful
CC in preparing a medicament for treating inflammatory or thrombotic
CC disorders, preferably peripheral arterial occlusive disease (PAOD) or
CC critical limb ischemia (CLI). It is also useful in gene therapy and in
CC antibody therapy. The present sequence is the human kappa light chain
CC constant region. This sequence is used in the construction of expression
CC plasmids for an anti-P-selectin IgG1 HuMab.

XX Sequence 107 AA;

Query Match 100.0%; Score 553; DB 9; Length 107;

Best Local Similarity 100.0%; Pred. No. 4.3e-48;

Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RTVAAPSVFIPTSPDEQLKSGTASVVCLLNNFYPREAKVQKVDNALQSGNSQESVTEQD 60

Db 1 RTVAAPSVFIPTSPDEQLKSGTASVVCLLNNFYPREAKVQKVDNALQSGNSQESVTEQD 60

Qy 61 SKDSTYSLSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 107

Db 61 SKDSTYSLSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 107

RESULT 49

AED66964

ID AED66964 standard; protein; 107 AA.

AC AED66964;

DT 12-JAN-2006 (first entry)

DE Human kappa chain constant region (CL) domain consensus sequence.

KW Antibody therapy; cerebrovascular ischemia; cerebroprotective;

KW vasotropic; cardiovascular disease; neurological disease;

KW light chain constant region.

XX Homo sapiens.

OS US2005255108-A1.

PN 17-NOV-2005.

PD 28-DEC-2004; 2004US-00025712.

PF 23-JAN-1996; 96US-0093038P.

PR 22-JAN-1997; 97US-00788800.

PR 17-FEB-1999; 99US-00251852.

PR 20-DEC-2000; 2000US-00811384.

PR 31-MAR-2003; 2003US-00404286.

XX (BEDN/) BEDNAR M M.

PA (GROS/) GROSS C E.

PA (GROS/) GROSS L J.

PA (THOM/) THOMAS G R.

XX Bednar MM, Gross CE, Gross LJ, Thomas GR;

PI WPI; 2005-768272/78.

XX Increasing cerebral blood flow and/or reducing infarct size in focal

PT ischemic stroke caused by obstruction of a main cerebral artery in a

PT human mammal by co-administering tissue plasminogen activator (t-PA) and

PT anti-CD18 antibody.

XX Disclosure; SEQ ID NO 5; 26pp; English.

XX The present invention relates to a method of increasing cerebral blood flow and/or reducing infarct size in focal ischemic stroke caused by obstruction of a main cerebral artery in a human mammal. The method involves the step of co-administering therapeutically effective amounts of tissue plasminogen activator (tPA) and anti-CD18 antibody (e.g. H52) to the mammal, where neither the tPA nor the anti-CD18 antibody is administered to the mammal until about 3-5 hours after the onset of focal ischemic stroke. The present sequence is a human kappa chain constant region (CL) domain consensus sequence. This sequence is used in alignment with the Fabvib variant derived from an anti-CD18 antibody.

XX Sequence 107 AA;

Query Match 100.0%; Score 553; DB 9; Length 107;
Best Local Similarity 100.0%; Pred. No. 4.3e-48;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db |||||
1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60

QY 61 SKDSTYSLSSTLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 107
Db |||||
61 SKDSTYSLSSTLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 107

RESULT 50
AEF16291
ID AEF16291 standard; protein; 107 AA.

AC AEF16291;
XX
XX 09-MAR-2006 (first entry)
XX Humanized antibody, HuD10, light chain constant region.
XX monoclonal antibody; humanized antibody; immunoglobulin; HuD10; IgG;
XX light chain constant region; antibody engineering; therapeutic; vaccine;
XX cancer; neoplasm; inflammation; asthma; autoimmune disease;
XX viral infection; cytostatic; antiinflammatory; antiasthmatic;
XX immunosuppressive; virucide.
XX Homo sapiens.
XX Synthetic.
XX WO2005123780-A2.
XX 29-DEC-2005.
XX 08-APR-2005; 2005WO-US011996.
XX 09-APR-2004; 2004US-00822300.
XX 09-APR-2004; 2004WO-US011213.
XX (PROT-) PROTEIN DESIGN LABS INC.
XX Hinton PR, Tsurushita N, Tso YJ, Vasquez M;
XX WPI; 2006-067459/07.
XX New modified monoclonal antibody of class IGG with altered FcRn binding
XX affinity, useful for treating a condition, e.g. cancer, inflammatory
XX conditions such as asthma, autoimmune diseases, or viral infections.
XX Disclosure; SEQ ID NO 9; 310pp; English.

XX The invention relates to modified monoclonal antibodies of class IgG with FcRn binding affinity altered relative to that of an unmodified monoclonal antibody of class IgG. The modified monoclonal antibody of class IgG comprises a heavy chain constant region where at least amino

CC acid residues 250 and 428 are different from the residues present in the unmodified monoclonal antibody and where the unmodified monoclonal antibody is selected from the group consisting of an anti-CD25, an anti-CD3, an anti-IFNGamma, or an anti-alphabeta integrin. Also disclosed are: (1) a method of modifying an antibody of class IgG; (2) a method of producing a modified antibody of class IgG with an altered binding affinity for FcRn and/or an altered serum half life as compared with an unmodified antibody; (3) a vector comprising a polynucleotide encoding one or more heavy or light chain sequences; (4) a host cell comprising the vector; and (5) polynucleotide sequences encoding the modified antibodies. The unmodified monoclonal antibody is an anti-CD25 of IgG1 or IgG2M3 isotype. The modified antibodies of the invention can be used in prophylactic and therapeutic compositions, such as vaccines, for treating a condition, e.g. cancer, inflammatory conditions such as asthma, autoimmune diseases, or viral infections. The antibodies can also be used in diagnostic applications. This sequence represents a region of a humanized antibody.

XX Sequence 107 AA;

Query Match 100.0%; Score 553; DB 10; Length 107;
Best Local Similarity 100.0%; Pred. No. 4.3e-48;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db |||||
1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60

QY 61 SKDSTYSLSSTLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 107
Db |||||
61 SKDSTYSLSSTLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 107

RESULT 51
AEF38694
ID AEF38694 standard; protein; 107 AA.

AC AEF38694;
XX
XX 23-MAR-2006 (first entry)
XX Antibody sHlgM12 light chain constant region SEQ ID NO 7.
XX antiallergic; antiasthmatic; gastrointestinal-gen.; neuroprotective;
XX antiinflammatory; immunomodulator; immunostimulant; immunotherapy;
XX immune stimulation; monoclonal antibody; asthma; antiasthmatic;
XX inflammation; respiratory disease; multiple sclerosis; neuroprotective;
XX immune disorder; neurological disease; irritable bowel syndrome;
XX gastrointestinal-gen.; gastrointestinal disease; sHlgM12;
XX light chain constant region.
XX Homo sapiens.
XX WO2006004988-A2.
XX 12-JAN-2006.
XX 30-JUN-2005; 2005WO-US023440.
XX 30-JUN-2004; 2004US-00881661.
XX 05-NOV-2004; 2004US-00983104.
XX (MAYO-) MAYO FOUND MEDICAL EDUCATION & RES.
XX Pease LR, Radhakrishnan S, Van Keulen V, Ciric B, Iijima K;
XX Kita H;
XX WPI; 2006-100770/10.
XX New purified sHlgM12 polypeptides, useful for enhancing immune responses,
XX modifying an existing state of immune responsiveness, immunizing
XX individuals, or treating or inhibiting the development of allergic
XX asthma.

XX Claim 5; SEQ ID NO 7; 102pp; English.

PS The invention describes a purified polypeptide comprising an amino acid

XX sequence that is 80.0-99.9% identical to 2 fully defined 106 or 118 amino

CC acid sequences (SEQ ID NO. 6 or 8) given in the specification. Also

CC described are: an isolated nucleic acid encoding a polypeptide that

CC comprises an amino acid sequence that is 80.0-99.9% identical to SEQ ID

CC NO. 6 or 8; a composition comprising: a polypeptide and a carrier, where

CC the polypeptide comprises an amino acid sequence that is 80.0-99.9%

CC identical to SEQ ID NO. 6 or 8; or a nucleic acid molecule and a carrier,

CC where the nucleic acid encodes a polypeptide comprising an amino acid

CC sequence that is 80.0-99.9% identical to SEQ ID NO. 6 or 8; an isolated

CC nucleic acid molecule comprising a nucleotide sequence that is 80.0-99.9%

CC identical to SEQ ID NO. 13 or 14; treating allergic asthma in a mammal in

CC need; inhibiting development of allergic asthma in a mammal; inhibiting a

CC Th 2 response in a mammal; modulating a state of immune responsiveness in

CC a mammal; modifying dendritic cell function in a mammal; and a

CC recombinantly produced polypeptide that binds specifically to B7-DC

CC molecules on a cell, where the binding results in cross-linking of the B7

CC -DC molecules. The polypeptides and nucleic acids are useful for

CC enhancing immune responses, enhancing DC function, modifying an existing

CC state of immune responsiveness, immunizing individuals, or treating or

CC inhibiting the development of allergic asthma. They can also be used for

CC treating or reducing the development of other conditions involving a

CC pathological immune response (e.g. irritable bowel disease or multiple

CC sclerosis). This is the amino acid sequence of antibody shlgM12 light

CC chain constant region.

XX Sequence 107 AA;

SQ

Query Match 100.0%; Score 553; DB 10; Length 107;

Best Local Similarity 100.0%; Pred. No. 4.3e-48;

Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFPYPREAKVQKVDNALQSGNSQESVTEQD 60

DB 1 RTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFPYPREAKVQKVDNALQSGNSQESVTEQD 60

QY 61 SKDSTYSLSSTLTLSKADYERKHVKYACEVTHQGLSSPVTKSFNRGEC 107

DB 61 SKDSTYSLSSTLTLSKADYERKHVKYACEVTHQGLSSPVTKSFNRGEC 107

RESULT 52

AEF57798

ID AEF57798 standard; protein; 107 AA.

AC AEF57798;

XX

DT 23-MAR-2006 (first entry)

XX

DE Anti-IL-13-antibody constant light chain SEQ ID NO 18.

XX

KW antiasthmatic; dermatological; respiratory-gen.; immunosuppressive;

KW antiinflammatory; cytostatic; virucide; anti-allergic;

KW gastrointestinal-gen.; vaccine; antibody; diagnosis; therapeutic; asthma;

KW antiasthmatic; chronic obstructive pulmonary disease; respiratory-gen.;

KW infection; viral infection; virucide; autoimmune disorder;

KW immunosuppressive; immune disorder; inflammatory bowel disease;

KW antiinflammatory; gastrointestinal-gen.; gastrointestinal disease;

KW inflammation; allergic rhinitis; anti-allergic; ear, nose, throat disease;

KW immune disorder; respiratory disease; light chain constant region.

XX

OS Homo sapiens.

XX

PN WO2005123126-A2.

XX

PD 29-DEC-2005.

XX

PF 09-JUN-2005; 2005WO-US020160.

XX

PR 09-JUN-2004; 2004US-0578473P.

PR 09-JUN-2004; 2004US-0578736P.

PR 22-JUN-2004; 2004US-0581375P.

XX (AMHP) WYETH.

XX Kasaian MT, Tchistiakova L, Veldman GM, Marquette KA, Tan X;

PI Donaldson DD, Lin LL, Shane T, Tam AS, Feyfant E, Wood NL, Fitz LJ;

PI Widom AM, Parris KD, Goldman SJ;

XX WPI; 2006-172770/18.

XX New antibody against human interleukin-13, useful for diagnosing,

PT preventing, and/or treating a disorder, e.g. asthma, tumors, allergic

PT rhinitis, or inflammatory bowel disease.

XX

PS Claim 22; SEQ ID NO 18; 169pp; English.

XX The invention describes an antibody, or its antigen-binding, that binds

CC to interleukin (IL)-13. Also described are: a pharmaceutical composition

CC comprising the antibody, or its antigen-binding fragment above and a

CC pharmaceutical carrier; a nucleic acid that comprises a sequence that

CC encodes a polypeptide that comprises a heavy chain immunoglobulin

CC variable region or a light chain immunoglobulin variable region described

CC above; a host cell comprising a nucleic acid sequence that encodes the

CC antibody, or its antigen-binding fragment, above; providing a recombinant

CC antibody; treating an IL-13-associated disorder; and detecting the

CC presence of IL-13 in a sample. The antibody, composition, and method are

CC useful for diagnosing, preventing, and/or treating IL-13 associated

CC disorder, e.g. asthmatic disorders, atopic disorders, chronic obstructive

CC pulmonary disease (COPD), conditions involving airway inflammation,

CC eosinophilia, fibrosis and excess mucus production, inflammatory

CC conditions, autoimmune conditions, tumors or cancers, viral infection,

CC suppression of expression of protective type 1 immune responses, allergic

CC rhinitis, or inflammatory bowel disease. This is the amino acid sequence

CC of the light chain constant region of anti-IL-13-antibodies of the

XX invention.

XX Sequence 107 AA;

SQ

Query Match 100.0%; Score 553; DB 10; Length 107;

Best Local Similarity 100.0%; Pred. No. 4.3e-48;

Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFPYPREAKVQKVDNALQSGNSQESVTEQD 60

DB 1 RTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFPYPREAKVQKVDNALQSGNSQESVTEQD 60

QY 61 SKDSTYSLSSTLTLSKADYERKHVKYACEVTHQGLSSPVTKSFNRGEC 107

DB 61 SKDSTYSLSSTLTLSKADYERKHVKYACEVTHQGLSSPVTKSFNRGEC 107

RESULT 53

AEF63498

ID AEF63498 standard; protein; 107 AA.

XX

AC AEF63498;

XX

DT 20-APR-2006 (first entry)

XX

DE Human immunoglobulin light chain kappa CL domain.

XX

KW Therapeutic; psoriasis; antipsoriatic; inflammatory bowel disease;

KW antiinflammatory; gastrointestinal-gen.; Crohns disease;

KW ulcerative colitis; anti-ulcer; respiratory distress syndrome;

KW respiratory-gen.; dermatitis; dermatological; meningitis;

KW neuroprotective; encephalitis; uveitis; ophthalmological; allergy;

KW anti-allergic; eczema; asthma; antiasthmatic; hypersensitivity;

KW immunosuppressive; poison ivy; poison oak; atherosclerosis;

KW antiarteriosclerotic; leukocyte adhesion deficiency; autoimmune disease;

KW rheumatoid arthritis; antiarthritic; antirheumatic;

KW systemic lupus erythematosus; diabetes mellitus; antidiabetic;

KW multiple sclerosis; hashimoto's disease; antithyroid; sjogrens syndrome;

KW juvenile onset diabetes; delayed hypersensitivity;
KW mycobacterium tuberculosis infection; antibacterial; sarcoidosis;
KW polymyositis; muscular-gen.; granulomatosis; vasculitis; vasotropic;
KW pernicious anemia; antianemic; inflammation; sepsis; trauma; vulnery;
KW autoimmune hemolytic anemia; myasthenia gravis;
KW graft versus host disease; hemorrhagic shock; pulmonary fibrosis;
KW B-cell lymphoma; cytostatic; antibody; immunoglobulin;
KW light chain constant region.
XX
XX
OS Homo sapiens.
XX
XX
PN US6998253-B1.
XX
PD 14-FEB-2006.
XX
XX 31-JUL-2000; 2000US-00628568.
XX
PR 14-APR-1995; 95US-00422112.
XX
XX (GETH) GENENTECH INC.
XX
XX Presta LG, Snedecor BR;
PI
XX
XX WPI; 2006-151963/16.
XX
XX New nucleic acid encoding modified polypeptide with improved in vivo half
PT -life, comprises Ig constant domain or Ig-like constant domain and a
PT salvage receptor binding epitope, useful for treating, e.g. psoriasis or
PT dermatitis.
XX
XX Disclosure; SEQ ID NO 8; 38pp; English.
PS
XX The present invention provides a nucleic acid encoding a modified
CC polypeptide with an improved in vivo half-life. The modified polypeptide
CC comprises an immunoglobulin (Ig) constant domain or Ig-like constant
CC domain and a salvage receptor binding epitope within the Ig constant
CC domain or Ig-like constant domain. The invention is useful for treating
CC LFA-1-mediated disorders such as inflammatory skin diseases including
CC psoriasis, responses associated with inflammatory bowel disease (such as
CC Crohn's disease and ulcerative colitis), adult respiratory distress
CC syndrome, dermatitis, meningitis, encephalitis, uveitis, allergic
CC conditions such as eczema and asthma, skin hypersensitivity reactions
CC (including poison ivy and poison oak), atherosclerosis, leukocyte
CC adhesion deficiency, autoimmune diseases such as rheumatoid arthritis,
CC systemic lupus erythematosus, diabetes mellitus, multiple sclerosis,
CC Reynaud's syndrome, autoimmune thyroiditis, Sjogren's syndrome, juvenile
CC onset diabetes and immune responses associated with delayed
CC hypersensitivity mediated by cytokines and T-lymphocytes typically found
CC in tuberculosis, sarcoidosis, polymyositis, granulomatosis and
CC vasculitis, pernicious anemia, diseases involving leukocyte diapedesis,
CC CNS inflammatory disorder, multiple organ injury syndrome secondary to
CC septicemia or trauma, autoimmune hemolytic anemia, myasthenia gravis,
CC antigen-antibody complex mediated diseases, all types of
CC transplantations, including graft versus host or host versus graft
CC disease, hemorrhagic shock, pulmonary oxygen toxicity, pulmonary
CC fibrosis, wound repair and B-cell lymphomas. The invention is also useful
CC for detecting CD11a or CD18 in vitro or in vivo. The present sequence is
CC a human immunoglobulin (Ig) light chain kappa CL domain. This sequence is
CC used in alignment with Fab vlb variant protein derived from anti-CD18
CC antibody.
XX
XX Sequence 107 AA;
SQ
Query Match 100.0%; Score 553; DB 10; Length 107;
Best Local Similarity 100.0%; Pred. No. 4.3e-48;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYPPEAKVKQMDNALQSGNSQESVTEQD 60
DB 1 RTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYPPEAKVKQMDNALQSGNSQESVTEQD 60
QY 61 SKDSTYSLSSTLTLSKADYERKHVYACEVTHQGLSSPVTKSPNRGEC 107
|||||

Db 61 SKDSTYSLSSTLTLSKADYERKHVYACEVTHQGLSSPVTKSPNRGEC 107
RESULT 54
AEG09130
ID AEG09130 standard; protein; 107 AA.
XX
AC AEG09130;
XX
DT 20-APR-2006 (first entry)
XX
DE Tie receptor-specific antibody E3, light constant region, SEQ ID:732.
XX
KW Tie; receptor tyrosine kinase; pharmaceutical; angiogenesis inhibition;
KW cancer; cytostatic; neoplasm; diagnosis; angiogenesis disorder;
KW antiangiogenic; wound healing; vulnery; inflammation; antiinflammatory;
KW psoriasis; antipsoriatic; rheumatoid arthritis; antiarthritis;
KW antirheumatic; retinopathy; ophthalmological; diabetic retinopathy;
KW antidiabetic; retinal neovascularization; Tie 1 receptor; antibody.
XX
OS Homo sapiens.
XX
XX WO2006020706-A2.
XX
PD 23-FEB-2006.
XX
XX 09-AUG-2005; 2005WO-US028413.
XX
PR 12-AUG-2004; 2004US-00916840.
PR 12-AUG-2004; 2004WO-US026116.
PR 02-FEB-2005; 2005US-00049536.
XX
XX (DYAX-) DYAX CORP.
XX
XX Wood CR, Dransfield DT, Pieters H, Hoet R, Hufton SE;
PI
XX WPI; 2006-174134/18.
XX
XX New isolated protein comprises heavy chain and light chain immunoglobulin
PT variable domain sequences, which binds to Tie1 ectodomain, useful for
PT treating, preventing, or diagnosing inflammatory diseases, cancers, or
PT retinal disorders.
XX
XX Example 33; SEQ ID NO 732; 310pp; English.
PS
XX The new invention relates to modulating Tie complex formation or
CC interactions between Tie complex components. Tie1 and Tie2 are receptor
CC tyrosine kinases. Specifically described is a protein comprising a heavy
CC chain immunoglobulin variable domain sequence and a light chain
CC immunoglobulin variable domain sequence, where the protein binds to Tie1
CC ectodomain. The protein can bind to an extracellular domain such as a Ig-
CC like C2-type domain, an EGF-like domain, and a fibonectin type III
CC repeats region. Also described are a pharmaceutical comprising the
CC protein; a method of inhibiting vascular development; a method of
CC providing a post-operative adjuvant therapy; a protein comprising SEQ ID
CC NO. 723 and 724; and a nucleic acid encoding the heavy chain (HC) or
CC light chain (LC) immunoglobulin variable domain sequence of the protein
CC above. The amino acid sequences of the HC variable domain sequence
CC comprises CDR1, CDR2, and CDR3 sequences from the E3 clone, and the LC
CC variable domain sequence comprises CDR1, CDR2, and CDR3 sequences from
CC the E3 clone. The protein also comprises the HC and/or LC immunoglobulin
CC variable domains of the E3 antibody. Preferably, the protein inhibits
CC tube formation by HUVEC cells in vitro. The protein is a Fab or an IgG.
CC The protein also has two antigen-binding sites, each of which binds to
CC Tie1. Preferably, the subject has vasculature-dependent cancer or tumor.
CC The isolated protein is useful for treating or diagnosing endothelial
CC cell disorders, blood vessel development disorders, wound healing,
CC inflammatory diseases (e.g. psoriasis and rheumatoid arthritis), cancers,
CC and retinal disorders (e.g. diabetic retinopathy, corneal
CC neovascularization, or ischemic retinopathy). This sequence is a human
CC Tie1 receptor-specific germlined F allotype E3 antibody, light constant
CC region.
XX

```
SQ Sequence 107 AA;
Query Match 100.0%; Score 553; DB 10; Length 107;
Best Local Similarity 100.0%; Pred. No. 4.3e-48;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIPPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
DB 1 RTVAAPSVFIPPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60

QY 61 SKDSTYLSSTLTLSKADYERKHVKVACEVTHQGLSSPVTKSFNRGEC 107
DB 61 SKDSTYLSSTLTLSKADYERKHVKVACEVTHQGLSSPVTKSFNRGEC 107

RESULT 55
ID ADL22765
XX ADL22765 standard; protein; 108 AA.
AC ADL22765;
XX
XX 20-MAY-2004 (first entry)
XX Human antibody kappa light chain variable region.
XX antibody; human; light chain variable region; therapeutic; kappa.
XX Homo sapiens.
XX WO2004013278-A2.
XX
XX PD 12-FEB-2004.
XX
XX PF 01-AUG-2003; 2003WO-KR001555.
XX
XX PR 02-AUG-2002; 2002KR-00045765.
XX
XX PR 02-AUG-2002; 2002KR-00045767.
XX
XX PR 02-AUG-2002; 2002KR-00045768.
XX
XX (YUHA-) YUHAN CORP.
XX
XX PI Lee J, Ko I, Song M, Kim C, Lee J, Yoo T, Kim J, Park S;
XX
XX WPI; 2004-157108/15.
XX
XX DR N-PSDB; ADL22764.
XX
XX New expression vectors for an antibody heavy chain variable region,
XX lambda light chain variable region or kappa light chain variable region,
XX useful in developing therapeutic antibodies, e.g. humanized or chimeric
XX antibodies.
XX
XX PS Example 13; Page 37; 39pp; English.
XX
XX The present invention relates to an expression vector for an antibody
XX heavy chain variable region, a lambda light chain variable region or a
XX kappa light chain variable region. The expression vectors are useful in
XX the development of therapeutic antibodies, e.g. humanized or chimeric
XX antibodies. The present sequence is a human antibody kappa light chain
XX variable region of the invention.
XX
XX SQ Sequence 108 AA;
Query Match 100.0%; Score 553; DB 8; Length 108;
Best Local Similarity 100.0%; Pred. No. 4.4e-48;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIPPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
DB 2 RTVAAPSVFIPPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 61

QY 61 SKDSTYLSSTLTLSKADYERKHVKVACEVTHQGLSSPVTKSFNRGEC 107
DB 62 SKDSTYLSSTLTLSKADYERKHVKVACEVTHQGLSSPVTKSFNRGEC 108

RESULT 56
ADM15047
XX ADM15047 standard; protein; 108 AA.
ID
XX
XX AC ADM15047;
XX
XX DT 07-APR-2005 (first entry)
XX
XX Human Fab light chain constant region gammal.
XX
XX Antibody production; light chain constant region; antimicrobial;
XX antibacterial; fungicide; antiinflammatory; antiarthritic; antirheumatic;
XX antiparasitic; osteopathic; gastrointestinal-gen.; cytosstatic;
XX antiallergic; dermatological; neuroprotective; immunosuppressive;
XX antidiabetic; antiasthmatic; CNS-gen.; respiratory-gen.; antianemic;
XX antistickling; immunotherapy; infection; inflammation; cancer;
XX immune disorder; genetic disorder; metabolic disorder;
XX neurological disease.
XX
XX OS Homo sapiens.
XX
XX Key Location/Qualifiers
XX Modified-site 108
XX /note= "Interchain Cys to which effector molecules may be
XX attached"
XX
XX WO2005003169-A2.
XX
XX PD 13-JAN-2005.
XX
XX PF 01-JUL-2004; 2004WO-GB002810.
XX
XX PR 01-JUL-2003; 2003GB-00015457.
XX
XX PR 20-AUG-2003; 2003GB-00019588.
XX
XX (CLLT ) CELLTech R & D LTD.
XX
XX Humphreys DP, Heywood SP;
XX
XX WPI; 2005-081945/09.
XX
XX N-PSDB; ADM15051.
XX
XX Antibody Fab fragment useful in detection or treatment of diseases such
XX as infectious disease, rheumatoid arthritis, cancer, asthma and diabetes,
XX comprises heavy chain constant region terminating at interchain cysteine
XX of CH1.
XX
XX Claim 9; SEQ ID NO 2; 30pp; English.
XX
XX A claimed antibody Fab fragment comprises a heavy chain constant region
XX that terminates at the interchain Cys of the heavy chain constant region
XX (CH1). The interchain Cys of CH1 is covalently linked to the interchain
XX Cys of the light chain constant region (CL). One or more effector
XX molecules, such as polyethylene glycol, may be attached to the Fab
XX fragment. The effector molecule is attached to a Cys residue in the CH1
XX and CL which would otherwise be linked to each other via a disulfide
XX bond. Also claimed is a mixture containing 2 or more Fab fragments, where
XX the mixture is enriched for Fab fragments in which the CH1 domain
XX terminates at the interchain Cys, the heavy chains in the fragments are
XX not covalently bonded to the light chains, and the fragments have an
XX effector molecule attached to a Cys in the CL or CH1. Vectors comprising
XX DNA sequences encoding the CL and/or CH1 regions of an antibody Fab
XX fragment are also claimed, as well as host cells, a process for producing
XX an antibody Fab fragment, and a pharmaceutical composition comprising an
XX antibody Fab fragment. The method avoids the need to engineer modified
XX hinge regions and/or surface amino acid substitutions, which are required
XX for site-specific effector molecule attachment. The Fab fragments are
XX useful in the detection or treatment of a number of diseases or disorders
XX such as infectious disease e.g., bacterial infection, fungal infection;
XX inflammatory disease/autoimmunity e.g., rheumatoid arthritis,
```


CC osteoarthritis, inflammatory bowel disease; cancer; allergic/atopic
CC disease e.g., asthma, eczema; congenital disease e.g., cystic fibrosis,
CC sickle cell anemia; dermatological disease e.g., psoriasis; neurological
CC disease e.g., multiple sclerosis; transplants e.g., organ transplant
CC rejection, graft-versus-host disease; and metabolic/idiopathic disease
CC e.g., diabetes. The present sequence is the protein sequence of human
CC gamma 1 Fab CL. This was used in an example from the invention for the
CC creation of novel 'truncated' Fab fragments. An antibody Fab fragment
CC comprising this sequence is claimed.

SQ Sequence 108 AA;
Query Match 100.0%; Score 553; DB 9; Length 108;
Best Local Similarity 100.0%; Pred. No. 4.4e-48;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 2 RTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 61

Qy 61 SKDSTYSLSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 107
Db 62 SKDSTYSLSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 108

RESULT 57
AEA52525
ID AEA52525 standard; protein; 108 AA.
AC AEA52525;
XX
DT 11-AUG-2005 (first entry)
XX
DE Human antibody light chain constant region - SEQ ID 2.
XX
KW multiple sclerosis; neuroprotective; light chain constant region.
XX
OS Homo sapiens.
XX
PN WO2005051422-A1.
XX
PD 09-JUN-2005.
XX
PF 16-NOV-2004; 2004WO-GB004850.
XX
PR 21-NOV-2003; 2003GB-00027181.
XX
PR 30-JUL-2004; 2004GB-00017115.
XX
PA (CLLT) CELLTECH R & D LTD.
XX
PI Christie MI, Mead RJ, Robinson MK, Rapecki SE;
XX
DR WPI; 2005-405309/41.
XX
PT Use of an inhibitor of interleukin-17 activity (e.g. an antibody) for the
PT manufacture of a medicament for the treatment and/or prophylaxis of
PT multiple sclerosis.
XX
PS Disclosure; SEQ ID NO 2; 55pp; English.
XX
CC The invention comprises an inhibitor of interleukin 17 (IL-17). The
CC inhibitor of the invention is useful for the treatment and/or prophylaxis
CC of multiple sclerosis, or for manufacturing a medicament for the
CC treatment and/or prophylaxis of multiple sclerosis. The present amino
CC acid sequence represents a human antibody light chain constant region.

SQ Sequence 108 AA;
Query Match 100.0%; Score 553; DB 9; Length 108;
Best Local Similarity 100.0%; Pred. No. 4.4e-48;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60

Db 2 RTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 61

Qy 61 SKDSTYSLSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 107

Db 62 SKDSTYSLSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 108

RESULT 58
ADJ95916
ID ADJ95916 standard; protein; 109 AA.
XX
AC ADJ95916;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human kappa constant region.
XX
DE cytostatic; antibody therapy; immunoglobulin cassette construct;
KW immunoglobulin leader molecule; immunoglobulin domain;
KW immunoglobulin therapeutic molecule; monobody; cancer; human;
KW kappa constant region.
XX
OS Homo sapiens.
XX
PN US2004033561-A1.
XX
PD 19-FEB-2004.
XX
PF 17-OCT-2002; 2002US-00272899.
XX
PR 19-OCT-2001; 2001US-0350166P.
PR 26-JUN-2002; 2002US-0392364P.
XX
PA (MILL-) MILLENNIUM PHARM INC.
XX
PI O'Keefe TL, Healey JJ, Newman W, Ponath PD, Keyt BA;
XX
DR WPI; 2004-180050/17.
XX
DR N-PSDB; ADJ95915.
XX
PT New isolated nucleic acid molecules having an immunoglobulin cassette
PT construct, useful for producing immunoglobulin therapeutic molecules
PT termed monobodies, used as a therapeutic group in cancer disorders.
XX
PS Example 2; SEQ ID NO 12; 84pp; English.
XX
CC The invention describes an isolated nucleic acid molecule comprising an
CC immunoglobulin cassette construct, wherein the immunoglobulin cassette
CC comprises an immunoglobulin leader molecule operably linked to a stable
CC immunoglobulin domain region. The methods and compositions of the present
CC invention are useful for producing immunoglobulins, in particular
CC immunoglobulin therapeutic molecules termed monobodies, used as a
CC therapeutic group in cancer disorders. This is the amino acid sequence of
CC the human kappa constant region that can be used in the creation of
CC immunoglobulin DNA cassette constructs.

SQ Sequence 109 AA;
Query Match 100.0%; Score 553; DB 8; Length 109;
Best Local Similarity 100.0%; Pred. No. 4.4e-48;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60

Db 3 RTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 62

Qy 61 SKDSTYSLSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 107

Db 63 SKDSTYSLSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 109

RESULT 59

```
ADQ89338
ID ADQ89338 standard; protein; 109 AA.
XX
AC ADQ89338;
XX
XX 21-OCT-2004 (first entry)
XX
DE Human immunoglobulin protein #47.
XX
XX Human; immunoglobulin; heavy chain; light chain; CC-chemokine receptor 2;
KW CCR2; inflammatory disease; autoimmune disorder; graft rejection;
KW HIV infection; atherosclerosis; antiinflammatory; immunosuppressive;
KW anti-HIV; virucide; antiarteriosclerotic.
XX
XX Homo sapiens.
XX
XX US2004151721-A1.
XX
XX 05-AUG-2004.
XX
XX 10-DEC-2003; 2003US-00733563.
XX
XX 19-OCT-2001; 2001US-0350166P.
XX
XX 26-JUN-2002; 2002US-0392364P.
XX
XX 17-OCT-2002; 2002US-00272899.
XX
XX (OKEE/) O'KEEFE T.
XX
XX (PONA/) PONATH P.
XX
XX O'keefe T, Ponath P;
XX
XX WPI; 2004-580175/56.
XX
XX New humanized immunoglobulin CC-chemokine receptor 2 (CCR2) antagonists,
PT useful for diagnosing and/or treating inflammatory or autoimmune
PT diseases, and HIV infection.
XX
XX Disclosure; SEQ ID NO 116; 128pp; English.
XX
XX The invention relates to humanised immunoglobulin heavy and light chains
CC which have specificity for the CC-chemokine receptor 2 (CCR2) and an
CC immunoglobulin or its antigen binding fragment comprising the chains. The
CC humanised immunoglobulin or its antigen binding fragment preferably
CC comprises two heavy chains and two light chains. The humanised
CC immunoglobulin and its heavy and light chains are useful for the
CC diagnosis, prevention and/or treatment of diseases or conditions
CC associated with aberrant expression or activity of the CCR2 polypeptide,
CC such as inflammatory diseases, autoimmune disorders, graft rejection, HIV
CC infection and atherosclerosis. This sequence represents a human
CC immunoglobulin protein of the invention.
XX
XX Sequence 109 AA;
XX
XX Query Match 100.0%; Score 553; DB 8; Length 109;
XX Best Local Similarity 100.0%; Pred. No. 4.4e-48;
XX Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
XX
XX 3 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 62
XX
XX 61 SKDSTYSLSSTLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 107
XX
XX 63 SKDSTYSLSSTLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 109
XX
XX RESULT 60
XX AEB09611
XX ID AEB09611 standard; protein; 109 AA.
XX
XX AC AEB09611;
XX
XX 08-SEP-2005 (first entry)
XX
XX Human C kappa constant region SEQ ID NO 116.
XX
XX antiinflammatory; immunosuppressive; anti-HIV; antiarteriosclerotic;
XX antibody engineering; therapeutic; diagnosis; inflammation;
XX autoimmune disease; immune disorder; graft rejection; HIV infection;
XX infection; atherosclerosis; cardiovascular disease; metabolic disorder;
XX light chain constant region.
XX
XX Homo sapiens.
XX
XX WO2005060368-A2.
XX
XX 07-JUL-2005.
XX
XX 10-DEC-2003; 2003WO-US039599.
XX
XX 10-DEC-2003; 2003WO-US039599.
XX
XX (MILL-) MILLENNIUM PHARM INC.
XX
XX Okeefe T, Ponath P;
XX
XX WPI; 2005-488561/49.
XX
XX N-PSDB; AEB09612.
XX
XX New humanized immunoglobulin or its antigen binding portion having
PT binding specificity for CC-chemokine receptor 2 and having a heavy chain
PT and light chain, for treating inflammatory diseases, HIV, and autoimmune
PT diseases.
XX
XX Disclosure; SEQ ID NO 116; 192pp; English.
XX
XX The invention describes a humanized immunoglobulin (I) or its antigen
CC binding portion having binding specificity for CC-chemokine receptor 2
CC (CCR2) and having a heavy chain and a light chain, where the heavy chain
CC comprises a fully defined 117 and 330 amino acid (SEQ ID NO: 17 and 110)
CC sequence, given in specification or its portion, and the light chain
CC comprises a fully defined 112 amino acid (SEQ ID NO: 12) sequence given
CC in specification. Also described are: a humanized immunoglobulin heavy
CC chain, or its antigen binding fragment, having binding specificity for
CC CCR2 and comprising the amino acid sequence of (SEQ ID NO: 17) and the
CC amino acid of (SEQ ID NO: 110), or its portion; and a humanized
CC immunoglobulin light chain, or its antigen binding fragment, having
CC binding specificity for CCR2 and comprising the amino acid sequence of
CC (SEQ ID NO: 12) and the fully defined 107 amino acid (SEQ ID NO: 112)
CC sequence, given in specification. The following are disclosed: isolated
CC nucleic acid molecules comprising nucleic acid sequence encoding (I); a
CC construct comprising nucleic acid molecule encoding (I); and host cell
CC comprising the nucleic acid molecule. (I) is useful as a therapeutic
CC agent for controlling lymphocyte homing the mucosal lymphoid tissue thus
CC reducing inflammatory response, for use in the treatment of diseases
CC associated with leukocyte infiltration of tissue, e.g. in the treatment
CC of inflammatory diseases, autoimmune diseases, graft rejection, HIV
CC infection and monocytic-mediated disorders such as atherosclerosis. (I) is
CC useful for detecting and/or measuring the level of CCR2 in a sample (e.g.
CC tissues or body fluids such as inflammatory exudates, blood, serum, bowel
CC fluid), and for modulating binding function and/or leukocyte trafficking
CC modulated by CCR2. This is the amino acid sequence of human C kappa
CC constant region used in the creation of a humanized anti-CCR2-antibody.
XX
XX Sequence 109 AA;
XX
XX Query Match 100.0%; Score 553; DB 9; Length 109;
XX Best Local Similarity 100.0%; Pred. No. 4.4e-48;
XX Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
XX
XX 3 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 62
XX
XX 61 SKDSTYSLSSTLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 107
XX
XX 63 SKDSTYSLSSTLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 109
XX
XX RESULT 60
XX AEB09611
XX ID AEB09611 standard; protein; 109 AA.
XX
XX AC AEB09611;
XX
XX 08-SEP-2005 (first entry)
```

```
Db 63 SKDSTYSLSTLTLSKADYKHKVYACEVTHQGLSPVTKSFNRGEC 109
RESULT 61
AEC22657
ID AEC22657 standard; protein; 110 AA.
XX
AC AEC22657;
XX
DT 20-OCT-2005 (first entry)
XX
DE Ig lambda constant region.
XX
KW multispecific antibody; promoter; bispecific antibody; immunoglobulin.
XX
OS Homo sapiens.
XX
FN WO2005072112-A2.
XX
PD 11-AUG-2005.
XX
PF 30-DEC-2004; 2004WO-US043806.
XX
PR 31-DEC-2003; 2003US-0533241P.
XX
PA (VACC-) VACCINEX INC.
XX
PI Zauderer M, Paris M;
XX
WI WI; 2005-648912/66.
DR N-PSDB; AEC22656.
XX
PT Identifying polynucleotides encoding a bispecific antibody by introducing
PT a first library of polynucleotides encoding immunoglobulin subunit
PT polypeptides into eukaryotic host cells capable of expressing the
PT bispecific antibody.
XX
PS Example 1; SEQ ID NO 27; 254pp; English.
XX
CC The invention relates to a method of identifying polynucleotides which
CC encode a bispecific antibody which comprises introducing a library of
CC polynucleotides encoding first and second heavy chain and light chain
CC immunoglobulin subunit polypeptides into eukaryotic host cells,
CC expression and recovery of the antibodies or their antigen-binding
CC fragments. The method is useful in identifying polynucleotides which
CC encode a bispecific antibody or its bispecific antigen-binding fragment.
CC The present sequence represents an immunoglobulin constant region.
XX
SQ Sequence 110 AA;
Query Match 100.0%; Score 553; DB 9; Length 110;
Best Local Similarity 100.0%; Pred. No. 4.5e-48;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 4 RTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 63
QY 61 SKDSTYSLSTLTLSKADYKHKVYACEVTHQGLSPVTKSFNRGEC 107
Db 64 SKDSTYSLSTLTLSKADYKHKVYACEVTHQGLSPVTKSFNRGEC 110
RESULT 62
ADD13779
ID ADD13779 standard; protein; 117 AA.
XX
AC ADD13779;
XX
DT 01-JAN-2004 (first entry)
XX
DE Plasmid pBS MhKappaM protein.
XX
KW library; transfection; humanized monoclonal antibody; antigen;
KW T cell receptor; circular.
XX
OS Synthetic.
OS Homo sapiens.
OS Mus sp.
XX
FN EP1298207-A1.
XX
PD 02-APR-2003.
XX
PF 01-OCT-2001; 2001EP-00123596.
XX
PR 01-OCT-2001; 2001EP-00123596.
XX
PA (DEKR-) DEUT KREBSFORSCHUNGSZENTRUM.
XX
PI Breitling F, Moldenhauer G, Poustka A, Kuehlwein T;
XX
WI WI; 2003-383833/37.
XX
PT Preparing library of protein-producing eukaryotic cells, useful for
PT producing humanized high-affinity antibodies, comprises introducing
PT specific recombination signals into chromosomal gene loci and integrating
PT a variety of DNA sequences.
XX
PS Example 1; Fig 12A; 75pp; German.
XX
CC This invention describes a novel method of preparing a library of protein
CC -producing eukaryotic cells comprising (a) introducing specific
CC recombination signals into one or two chromosomal gene loci, (b)
CC Expanding at least one of the modified cells, (c) Transfecting many
CC different DNA sequences, each flanked by recombination signals, into the
CC expanded cells and (d) Integrating the DNA sequences into the gene loci
CC on the basis of the recombination signals and the appropriate
CC recombinase. The resulting cells express different proteins, each from an
CC integrated DNA sequence and the proteins are bound to the cell surface.
CC The method is particularly used to produce libraries of humanized
CC monoclonal antibodies, for selection of those with affinity for
CC particular antigens and useful for diagnostic or therapeutic use.
CC Libraries of T cell receptors may also be prepared. The method produces
CC libraries of high diversity; provides easy, quick and automatable
CC selection from a large number of proteins, allows relatively simple
CC alteration of the expressed gene (e.g. fusion to other protein-coding
CC sequences), is suitable for large scale protein production and allows
CC simple verification and characterization of selected cell lines. The
CC method does not require incorporation of a resistance marker. This
CC sequence represents the construct pBS MhKappaM described in the
CC disclosure of the invention.
XX
SQ Sequence 117 AA;
Query Match 100.0%; Score 553; DB 7; Length 117;
Best Local Similarity 100.0%; Pred. No. 4.8e-48;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 11 RTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 70
QY 61 SKDSTYSLSTLTLSKADYKHKVYACEVTHQGLSPVTKSFNRGEC 107
Db 71 SKDSTYSLSTLTLSKADYKHKVYACEVTHQGLSPVTKSFNRGEC 117
RESULT 63
ADN98370
ID ADN98370 standard; protein; 121 AA.
XX
AC ADN98370;
XX
DT 29-JUL-2004 (first entry)
XX
```

DE Human IgG kappa light chain protein homologue #8.
XX cytotoxic molecule; radionuclide; toxin; chemotherapeutic agent;
KW drug discovery; antibody; protein co-ordinate data.
XX Unidentified.
OS WO2004039843-A1.
PN 13-MAY-2004.
XX 12-SEP-2003; 2003WO-SE001435.
XX 31-OCT-2002; 2002SE-00003226.
XX (AMSH) AMERSHAM BIOSCIENCES AB.
PA Axen A, Baumann H, Carredano E;
XX WPI; 2004-400141/37.
XX Novel human IgG kappa light chain and IgG heavy chain binding pocket
PT polypeptides, useful for binding cytotoxic molecules, radionuclides,
PT toxins and chemotherapeutic agents, and for drug discovery.
XX Disclosure; Fig 2; 63pp; English.
XX The invention relates to an isolated and purified polypeptide (I) having
CC portion of human IgG kappa light chain starting at 93-110 and ending at
CC 187-214 amino acids of human IgG kappa light chain of sequence of 214
CC amino acids (S1) fully defined in specification, or portion of human IgG
CC heavy chain starting at 106-128 and ending at 215-225 amino acids of 225
CC amino acids sequence (S2) fully defined in specification. (I) is useful
CC for identifying a potential ligand to a human kappa-Fab constant part-
CC comprising composition which involves generating a three-dimensional
CC structure of the binding pocket of (I), employing the three-dimensional
CC structure to design a candidate ligand, providing the candidate ligand,
CC contacting the candidate ligand with a human kappa-Fab constant part-
CC comprising composition comprising the binding pocket to verify any
CC binding, and optionally, repeating the above steps of employing,
CC providing and contacting. (I) is useful for evaluating the potential or
CC ability of a chemical entity to associate with a human kappa-Fab constant
CC part-comprising composition which involves providing a virtual library of
CC chemical entities, docking the chemical entities to the binding pocket of
CC (I), defining at least one query based on the results of the docking
CC operation, screening all entities docked, while in the docked
CC conformation with the query, for evaluating the potential or ability of
CC the chemical entity to bind to the compound or the binding pocket,
CC inspection and, optionally, removal of redundancy, and providing one or
CC more of the chemical entities that bound the binding pocket and
CC experimentally testing their binding to a human kappa-Fab constant part-
CC comprising composition, and, if more than one chemical entity was tested,
CC rating the affinities of the chemical entity to human kappa-Fab constant
CC part-comprising composition. The method further involves filtering and
CC removing redundancy among the entities of the library provided. The
CC results of the docking operation are evaluated by visual inspection of
CC the contact between the interacting surface of the binding pocket and the
CC molecular surface(s). (I) is useful for identifying or isolating a ligand
CC capable of selective binding of a human kappa-Fab constant part-
CC comprising composition, in site-specific modification of a human kappa-
CC Fab constant part-comprising composition. The modification is a
CC stabilization of Fab-folding by binding a ligand selectively to the
CC compound or binding pocket. (I) is also useful in an immunological assay
CC for detecting human kappa-Fab constant part-comprising composition. (I)
CC is useful for binding cytotoxic molecules, radionuclides, toxins and
CC chemotherapeutic agents, and for drug discovery. This sequence
XX corresponds to a homologue of the human IgG kappa light chain

Sequence 121 AA;
Query Match 100.0%; Score 553; DB 8; Length 121;
Best Local Similarity 100.0%; Pred. No. 5.1e-48;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTTQD 60
DB 15 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTTQD 74
QY 61 SKDSTYSLSSSTLTLSKADYEHKVKYACEVTHQGLSSPVTKSFNRGEC 107
DB 75 SKDSTYSLSSSTLTLSKADYEHKVKYACEVTHQGLSSPVTKSFNRGEC 121

RESULT 64
AED85881
ID AED85881 standard; protein; 133 AA.
XX AED85881;
XX 12-JAN-2006 (first entry)
XX Ig kappa expression vector pMORPH_h_Igkappa_1 protein.
XX immunosuppressive; hematological; cytostatic; antiinflammatory;
KW antirheumatic; antiarthritic; antibody; CD38; hematological disease;
KW inflammation; light chain.
XX Homo sapiens.
OS Synthetic.
XX WO2005103083-A2.
XX 03-NOV-2005.
XX 07-FEB-2005; 2005WO-IB002476.
XX 06-FEB-2004; 2004US-0541911P.
PR 26-FEB-2004; 2004US-0547584P.
PR 18-MAR-2004; 2004US-0553948P.
PR 06-AUG-2004; 2004US-0599014P.
XX (MORP-) MORPHOSYS AG.
XX Tesar M, Jager U;
XX WPI; 2005-734713/75.
DR N-PSDB; AED85872.
XX New isolated human or humanized antibody or its functional fragment
PT comprising an antigen-binding region that is specific for an epitope of
PT CD38, useful for treating hematological or inflammatory disorders.
XX Disclosure; Fig 9; 98pp; English.
XX The invention relates to an isolated human or humanized antibody or its
CC functional fragment comprising an antigen-binding region that is specific
CC for an epitope of CD38. The antibody or its functional fragment is useful
CC for treating a disorder or condition associated with the undesired
CC presence of CD38+ cells, e.g. hematological disease, such as multiple
CC myeloma, chronic lymphocytic leukemia, chronic myelogenous leukemia,
CC acute myelogenous leukemia, and acute lymphocytic leukemia; or an
CC inflammatory disease such as rheumatoid arthritis and systemic lupus
CC erythematosus. The present sequence represents the amino acid sequence of
CC the Ig kappa expression vector pMORPH_h_Igkappa_1 protein.
XX Sequence 133 AA;
Query Match 100.0%; Score 553; DB 9; Length 133;
Best Local Similarity 100.0%; Pred. No. 5.7e-48;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTTQD 60
DB 27 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTTQD 86
QY 61 SKDSTYSLSSSTLTLSKADYEHKVKYACEVTHQGLSSPVTKSFNRGEC 107

Db 87 SKDSTYSLSTLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 133

RESULT 65
ADJ95970
ID ADJ95970 standard; protein; 134 AA.
AC ADJ95970;
DT 06-MAY-2004 (first entry)
DE Immunoglobulin DNA cassette polypeptide seqid 66.
KW cytostatic; antibody therapy; immunoglobulin cassette construct;
KW immunoglobulin leader molecule; immunoglobulin domain;
KW immunoglobulin therapeutic molecule; monobody; cancer.
XX Synthetic.

OS US2004033561-A1.
PN 19-FEB-2004.
PD 17-OCT-2002; 2002US-00272899.
PF 19-OCT-2001; 2001US-0350166P.
PR 26-JUN-2002; 2002US-0392364P.
XX (MILL-) MILLENNIUM PHARM INC.
PI O'keefe TL, Healey JJ, Newman W, Ponath PD, Keyt BA;
DR WPI; 2004-180050/17.
DR N-PSDB; ADJ95969.
XX New isolated nucleic acid molecules having an immunoglobulin cassette
PT construct, useful for producing immunoglobulin therapeutic molecules
PT termed monobodies, used as a therapeutic group in cancer disorders.
XX Disclosure; SEQ ID NO 66; 84pp; English.
XX The invention describes an isolated nucleic acid molecule comprising an
CC immunoglobulin cassette construct, wherein the immunoglobulin cassette
CC comprises an immunoglobulin leader molecule operably linked to a stable
CC immunoglobulin domain region. The methods and compositions of the present
CC invention are useful for producing immunoglobulins, in particular
CC immunoglobulin therapeutic molecules termed monobodies, used as a
CC therapeutic group in cancer disorders. This is the amino acid sequence of
CC an immunoglobulin DNA cassette construct.

XX Sequence 134 AA;
Query Match 100.0%; Score 553; DB 8; Length 134;
Best Local Similarity 100.0%; Pred. No. 5.7e-48;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 RTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTRQD 60
Db 28 RTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTRQD 87
Qy 61 SKDSTYSLSTLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 107
Db 88 SKDSTYSLSTLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 134

RESULT 66
AAP93559
ID AAP93559 standard; protein; 143 AA.
XX AAP93559;
AC AAP93559;
XX 25-MAR-2003 (revised)

DT 28-JAN-1991 (first entry)
XX Sequence of human kappa light chain fragment.
XX HIV; antiviral; therapy; diagnosis.
XX Homo sapiens.
XX Key Location/Qualifiers
XX Region 1..37
XX /label
XX /note= "light variable and joining"
XX Region 37..38
XX /note= "insert site"
XX Region 38..38
XX /note= "light constant"
XX WO8902922-A.
XX 06-APR-1989.
XX 03-OCT-1988; 88WO-US003414.
XX 02-OCT-1987; 87US-00104329.
XX 28-SEP-1988; 88US-00250785.
XX (GETH) GENENTECH INC.
XX Capon DJ, Gregory TJ;
XX WPI; 1989-114397/15.
XX P-PSDB; AAP93559.
XX New nucleic acid sequences encoding adhesion, esp. CD 4, variants -
PT partic. with trans-membrane domain inactivated or fused to other peptide,
PT useful esp. for treating HIV infections.
XX Example; Fig 5; 78pp; English.
XX It is employed in the prepn. of CD4 fusions. The insert site is given in
CC the Features Table. CD4 fusion proteins can have antiviral and
CC immunomodulatory activity are esp. useful for treating HIV infections,
CC regardless of genetic variation within the virus. They and antibodies
CC raised against them can also be used diagnostically for assaying adhesions
CC and their ligands. (Updated on 25-MAR-2003 to correct PR field.) (Updated
CC on 25-MAR-2003 to correct PA field.)
XX Sequence 143 AA;
Query Match 100.0%; Score 553; DB 1; Length 143;
Best Local Similarity 100.0%; Pred. No. 6.2e-48;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 RTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTRQD 60
Db 37 RTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTRQD 96
Qy 61 SKDSTYSLSTLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 107
Db 97 SKDSTYSLSTLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 143
RESULT 67
AEB27727
ID AEB27727 standard; protein; 155 AA.
XX AEB27727;
XX 08-SEP-2005 (first entry)
XX Humanized 2H7 antibody light chain sequence.
XX Antibody therapy; immunotherapy; autoimmune disease;

KW B-lymphocyte-restricted differentiation antigen; Bp35; arthritis;
 KW immunosuppressive; antirheumatic; antiarthritic; antiinflammatory;
 KW dermatological; gastrointestinal; anticancer; antitumorigenic;
 KW antiarteriosclerotic; vasotropic; thyromimetic; antidiabetic;
 KW nephrotropic; nootropic; neuroprotective; cardiant; CD20-antagonist.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX WO2005060999-A2.
 PN
 XX
 PD 07-JUL-2005.
 XX
 XX 07-DEC-2004; 2004WO-US040949.
 PF
 XX 19-DEC-2003; 2003US-0531363P.
 PR
 XX (GETH) GENENTECH INC.
 PA
 XX Brunetta PG;
 PI
 XX WPI; 2005-488599/49.
 DR
 XX Treating autoimmune diseases, such as rheumatoid arthritis, psoriasis,
 PT inflammatory bowel disease, Crohn's disease, ulcerative colitis, eczema,
 PT asthma, lupus, atherosclerosis and diabetes, using CD20 antagonists or
 PT antibodies.
 XX
 XX Disclosure; SEQ ID NO 3; Sipp; English.
 PS
 XX The invention relates to treating autoimmune disease in a patient. The
 CC method involves detecting CD20 antigen (also called human B-lymphocyte-
 CC restricted differentiation antigen, Bp35) or CD20-positive B cells in a
 CC sample from the patient. When CD20 or CD20-positive B cells is detected
 CC in the sample, a CD20 antagonist or antibody is administered to the
 CC patient to treat the autoimmune disease. Also disclosed are CD20
 CC proteins, nucleic acids and antibodies used in the methods of the
 CC invention. The CD20 antagonist in treating autoimmune disease comprises
 CC an antibody that is not conjugated with a cytotoxic agent and comprises
 CC rituximab or humanized 2H7. The antibody is also conjugated with a
 CC cytotoxic agent. The methods and compositions of the present invention
 CC are useful for diagnosing or treating autoimmune diseases, such as
 CC rheumatoid arthritis, psoriasis, inflammatory bowel disease, Crohn's
 CC disease, ulcerative colitis, eczema, asthma, lupus, atherosclerosis,
 CC aplastic anemia, Sjogren's syndrome, autoimmune thyroiditis, diabetes,
 CC Guillain-Barre syndrome, glomerulonephritis and coronary artery disease.
 CC The method consists essentially of administering the antagonist to the
 CC mammal. The CD20 protein or nucleic acid is detected in the initial step.
 CC The present sequence represents the light chain sequence of a humanized
 CC 2H7 antibody.
 XX
 XX Sequence 155 AA;
 SQ
 Query Match 100.0%; Score 553; DB 9; Length 155;
 Best Local Similarity 100.0%; Pred. No. 6.9e-48;
 Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
 DB 49 RTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 108
 QY 61 SKDSTYLSSTLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 107
 DB 109 SKDSTYLSSTLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 155
 RESULT 68
 AAM52145
 ID AAM52145 standard; protein; 193 AA.
 XX
 AC AAM52145;
 XX
 DT 05-FEB-2002 (first entry)

XX Humanised HMFG1 light chain.
 DE
 XX Humanised monoclonal antibody; polymorphic epithelial mucin; PEM1;
 KW cytotoxic; endonuclease; DNase I; human; cytostatic; cancer; apoptosis.
 KW
 OS Synthetic.
 OS WO200174905-A1.
 PN
 XX 11-OCT-2001.
 PD
 XX 26-MAR-2001; 2001WO-GB001324.
 PF
 XX 03-APR-2000; 2000GB-00080849.
 PR
 PR 02-OCT-2000; 2000US-0237159P.
 XX
 XX (ANTI-) ANTISOMA RES LTD.
 PA
 XX Young RJ;
 PI
 XX WPI; 2001-662969/76.
 DR
 XX Novel compound used to treat cancer has target cell-specific portion
 PT comprising humanized monoclonal antibody having specificity for
 PT polymorphic epithelial mucin, and cytotoxic portion having
 PT endonucleolytic activity.
 XX
 XX Claim 20; Fig 3; 176pp; English.
 PS
 XX The invention relates to a compound which comprises a target cell-
 CC specific portion, comprising an humanised monoclonal antibody, having
 CC specificity for polymorphic epithelial mucin (PEM) or its antigen binding
 CC fragment and a cytotoxic portion having endonucleolytic activity,
 CC exemplified by AAM52154-AAM52168 and encoded by ABA02682-ABA02728. The
 CC compound has cytostatic activity useful for treating cancer and acting as
 CC a potential inducer of apoptosis
 XX
 XX Sequence 193 AA;
 SQ
 Query Match 100.0%; Score 553; DB 4; Length 193;
 Best Local Similarity 100.0%; Pred. No. 9.1e-48;
 Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
 DB 87 RTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 146
 QY 61 SKDSTYLSSTLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 107
 DB 147 SKDSTYLSSTLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 193
 RESULT 69
 AAY29770
 ID AAY29770 standard; protein; 201 AA.
 XX
 AC AAY29770;
 XX
 XX 04-NOV-1999 (first entry)
 DT
 XX P-selectin ligand and kappa chain constant region fusion protein.
 DE
 XX Human; P-selectin ligand; glycoprotein; fusion protein; infection;
 KW inflammation; intercellular adhesion; ulcerative colitis; asthma;
 KW diabetes; transplant rejection; myocardial infarction; thermal injury;
 KW metastatic condition; autoimmune thyroiditis; multiple sclerosis;
 KW Reynaud's syndrome; neutrophilic dermatitis; Sweet's syndrome;
 KW Grave's disease; glomerulonephritis; gingivitis; periodontitis;
 KW Crohn's disease; necrotising enterocolitis.
 XX
 OS Homo sapiens.
 OS Synthetic.

XX WO9943834-A2.
 XX 02-SEP-1999.
 XX 25-FEB-1999; 99WO-US004302.
 XX 27-FEB-1998; 98US-00032080.
 XX (GEMY) GENETICS INST INC.
 XX Larsen GR, Sako DS, Chang X, Veldman GM, Cumming D, Kumar R;
 PI Shaw G, Camphausen R, Davis M;
 XX WPI; 1999-527628/44.
 DR N-PSDB; AA208843.
 XX New P-selectin ligand fusion proteins, used for treating e.g.
 PT inflammation, infections, asthma, diabetes, ulcerative colitis or
 PT transplant rejection.
 XX Claim 66; Page 128-129; 145pp; English.
 XX The present invention describes P-selectin ligand fusion proteins
 CC comprising amino acids 42-60, 42-310, 42-88, 42-118 or 42-189 of
 CC the P-selectin ligand protein. The fusion proteins comprising a P-
 CC selectin ligand act as ligands for P-selectin on human endothelial cells
 CC and platelets. The isolated P-selectin ligand proteins may be useful in
 CC treating conditions characterized by P-, E- or L-selectin mediated
 CC intercellular adhesion e.g. myocardial infarction, bacterial or viral
 CC infection, metastatic conditions, inflammatory disorders, thermal injury
 CC such as burns or frostbite, autoimmune thyroiditis, experimental allergic
 CC encephalomyelitis, multiple sclerosis, multiple organ injury syndrome
 CC secondary to trauma, diabetes, Reynaud's syndrome, neutrophilic
 CC dermatosis (Sweet's syndrome), inflammatory bowel disease, Grave's
 CC disease, glomerulonephritis, gingivitis, periodontitis, haemolytic
 CC uraemic syndrome, ulcerative colitis, Crohn's disease, necrotising
 CC enterocolitis, granulocyte transfusion associated syndrome, or cytokine-
 CC induced toxicity. Isolated P-selectin ligand proteins may also be useful
 CC in organ transplantation, both to prepare organs for transplantation and
 CC to quell organ transplant rejection. P-selectin ligand proteins may be
 CC used to treat haemodialysis and leukophoresis patients or used as an
 CC antineoplastic agent. The fusion proteins can also be used to treat a
 CC condition which is affected by the protein to which the P-selectin ligand
 CC protein is fused. The fusion proteins can be used for the production of
 CC antibodies for use in therapy, detection, diagnosis and drug screening.
 CC AA208839 to AA208850 encode specifically claimed fusion proteins from the
 CC present invention, which are given in AA29766 to AA29777
 XX Sequence 201 AA;
 XX Query Match 100.0%; Score 553; DB 2; Length 201;
 XX Best Local Similarity 100.0%; Pred. No. 9.6e-48; Indels 0; Gaps 0;
 XX Matches 107; Conservative 0; Mismatches 0;
 QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
 Db 95 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 154
 QY 61 SKDSTYSLSSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 107
 Db 155 SKDSTYSLSSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 201
 XX RESULT 70
 XX ABP51955
 ID ABP51955 standard; protein; 212 AA.
 XX ABP51955;
 AC
 DT 09-OCT-2002 (first entry)
 XX Humanised anti-CD18 kappa LC sequence SEQ ID NO:5.

XX Bacterial host; protease; degp; prc; spr; anti-VEGF antibody; antibody;
 KW humanised; Apo2 ligand; anti-CD18; anti-tissue factor; 2C4; anti-CD20;
 KW anti-vascular endothelial growth factor; anti-Her-2; anti-CD40; Fab;
 KW anti-CD11a; Fab'; Fab'2; Fab'2-leucine zipper fusion; anti-VEGF Fab.
 XX Homo sapiens.
 OS Synthetic.
 XX WO200248376-A2.
 XX 20-JUN-2002.
 XX 07-DEC-2001; 2001WO-US047581.
 XX 14-DEC-2000; 2000US-0256162P.
 XX (GETH) GENENTECH INC.
 PA Chen CY;
 PI WPI; 2002-583522/62.
 DR Novel Escherichia coli strain useful for producing polypeptide, deficient
 PT in degp and prc encoding protease, and harboring mutant spr gene, product
 PT of gene suppresses growth phenotypes of strains harbouring prc mutants.
 XX Example 1; Fig 10; 63pp; English.
 XX The present invention describes an Escherichia coli strain (I) deficient
 CC in chromosomal degp and prc encoding protease degp and prc, respectively,
 CC and harbouring a mutant spr gene, the product of mutant spr gene
 CC suppresses growth phenotypes exhibited by strains harbouring prc mutants.
 CC (I) is useful for producing a polypeptide, by culturing (I) comprising
 CC nucleic acid encoding the polypeptide, which is heterologous to the
 CC strain, such that the nucleic acid is expressed, and recovering the
 CC heterologous polypeptide from the strain. The heterologous polypeptide is
 CC proteolytically sensitive. Culturing of (I) is performed in a fermentor
 CC under conditions of high- or low-cell density fermentation. The
 CC polypeptide is recovered from the periplasm or culture medium of the
 CC strain. The polypeptide is an antibody (humanised or full-length
 CC antibody) or Apo2 ligand. The antibody is an anti-CD18, anti-vascular
 CC endothelial growth factor (VEGF), anti-tissue factor, 2C4, anti-Her-2,
 CC anti-CD20, anti-CD40, or anti-CD11a antibody. The antibody is also an
 CC antibody fragment having a light chain (kappa light chain). The antibody
 CC fragment is a Fab, Fab', Fab'2 or Fab'2-leucine zipper fusion, anti-CD18
 CC Fab'2-leucine zipper fusion, anti-tissue factor Fab'2-leucine zipper
 CC fusion or anti-VEGF Fab, with or without a histidine or lysine tag, anti-
 CC tissue factor Fab'2-leucine zipper fusion with a 6-histidine tag, or anti-
 CC -CD18 Fab'2-leucine zipper fusion with a 6-histidine tag, and anti-CD18
 CC Fab'2-leucine zipper fusion with a 6-lysine tag. The present sequence
 CC represents a humanised anti-CD18 kappa LC sequence from the present
 CC invention
 XX Sequence 212 AA;
 XX Query Match 100.0%; Score 553; DB 5; Length 212;
 XX Best Local Similarity 100.0%; Pred. No. 1e-47;
 XX Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
 Db 106 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 165
 QY 61 SKDSTYSLSSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 107
 Db 166 SKDSTYSLSSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 212
 XX RESULT 71
 XX AAO31100
 ID AAO31100 standard; protein; 212 AA.
 XX


```

AC AAO31100;
XX
DT 06-OCT-2003 (first entry)
XX
DE Human A2-G8 SCF antibody light chain variable and constant region.
XX
DE Human; antibody; stem cell factor; mast cell growth factor; asthma; SCF;
KW steel factor; c-kit ligand; gene therapy.
XX
OS Homo sapiens.
XX
XX WO2003051311-A2.
XX
XX PN 26-JUN-2003.
XX
XX PD 16-DEC-2002; 2002WO-US040227.
XX
XX PF 17-DEC-2001; 2001US-0342174P.
XX
XX PR (FARB ) BAYER CORP.
XX
XX PA Takeuchi T, Tomkinson A, Neben S;
XX
XX PI WPI; 2003-523500/49.
XX
XX DR New purified human antibody that binds to stem cell factor protein,
XX useful for preparing a composition for treating asthma.
XX
XX PT Claim 9; Page 46; 94pp; English.
XX
XX PS The invention provides human antibodies that bind to stem cell factor
XX (SCF) protein. SCF is also known as mast cell growth factor, steel factor
XX or c-kit ligand. Antibodies of the invention are useful for preparing
XX compositions for treating asthma. They are also used in gene therapy. The
XX present sequence is human SCF antibody light chain variable and constant
XX region
XX
XX SQ Sequence 212 AA;
XX
XX Query Match 100.0%; Score 553; DB 6; Length 212;
XX Best Local Similarity 100.0%; Pred. No. 1e-47;
XX Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
XX 106 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 165
XX
XX QY 61 SKDSTYSLSSTLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 107
XX 166 SKDSTYSLSSTLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 212
XX
XX Db
XX
XX RESULT 72
XX AEF11766
XX ID AEF11766 standard; protein; 212 AA.
XX
XX AC AEF11766;
XX
XX DT 09-MAR-2006 (first entry)
XX
XX DE Human SCF-binding Ab A2-G8 light chain variable + constant regions.
XX
XX KW antibody therapy; antibody engineering; asthma; inflammation;
XX antiasthmatic; stem cell factor; SCF; light chain variable region;
XX light chain constant region.
XX
XX OS Homo sapiens.
XX
XX OS Synthetic.
XX
XX FH Key Location/Qualifiers
XX FT 22..32
XX FT /label= CDR 1
XX FT /note= "Complementarity determining region 1"
XX

```

```

FT Region 48..54
FT /label= CDR_2
FT /note= "Complementarity determining region 2"
FT Region 87..94
FT /label= CDR 3
FT /note= "Complementarity determining region 3"
XX
XX WO2006002064-A2.
XX
XX PD 05-JAN-2006.
XX
XX PF 14-JUN-2005; 2005WO-US021043.
XX
XX PR 14-JUN-2004; 2004US-00867506.
XX
XX PR 14-JUN-2004; 2004US-0579462P.
XX
XX PA (AERO-) AEROVANCE INC.
XX
XX PI Neben S, Takeuchi T, Tomkinson A, Delaria K, Yan K, Wong T;
XX Longphre M;
XX
XX DR WPI; 2006-079812/08.
XX
XX PS New purified human antibody, which binds to stem cell factor protein,
XX useful for treating asthma or a human disorder in which stem cell factor
XX protein is expressed in certain cells.
XX
XX PS Claim 30; SEQ ID NO 77; 108pp; English.
XX
XX CC The invention relates to: a purified human antibody (IgG) or fragment
XX thereof which binds to stem cell factor protein; a preparation comprising
XX the antibody, and/or a carrier; isolated polynucleotide(s) encoding the
XX antibody; an expression vector comprising the polynucleotide(s); a host
XX cell comprising the expression vector; a method of producing a human
XX antibody; a method of treating asthma or a human disorder in which stem
XX cell factor protein is expressed in certain cells; and a method for
XX identifying a disorder in which stem cell factor protein level is
XX elevated. The purified human antibody comprises the heavy chain variable
XX region human VH3 consensus framework residues, the light chain variable
XX region human V-kappa-1 or V-lambda-1 consensus framework residues, and
XX may be optionally bound to a cytotoxic molecule or detectable label. The
XX antibody, compositions and methods are useful for treating asthma or a
XX human disorder in which stem cell factor protein is expressed in certain
XX cells. This sequence is human stem cell factor-binding antibody A2-G8
XX light chain variable and constant regions. Note: claim 9 refers to SEQ ID
XX NO:77 as heavy chain variable and constant regions, but all other
XX mentions of SEQ ID NO:77 in the specification, including claim 30, refer
XX to it as light chain variable and constant regions.
XX
XX SQ Sequence 212 AA;
XX
XX Query Match 100.0%; Score 553; DB 10; Length 212;
XX Best Local Similarity 100.0%; Pred. No. 1e-47;
XX Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
XX 106 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 165
XX
XX QY 61 SKDSTYSLSSTLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 107
XX 166 SKDSTYSLSSTLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 212
XX
XX Db
XX
XX RESULT 73
XX AEF11804
XX ID AEF11804 standard; protein; 212 AA.
XX
XX AC AEF11804;
XX
XX DT 09-MAR-2006 (first entry)
XX
XX DE SCF-binding Ab A2-G8 light chain variable + constant regions variant 5.
XX

```

XX antibody therapy; antibody engineering; asthma; inflammation;
 KW antiasthmatic; stem cell factor; SCF; light chain variable region;
 KW light chain constant region.
 XX Homo sapiens.
 OS Synthetic.
 XX WO2006002064-A2.
 XX 05-JAN-2006.
 XX 14-JUN-2005; 2005WO-US021043.
 XX 14-JUN-2004; 2004US-00867506.
 PR 14-JUN-2004; 2004US-0579462P.
 XX (AERO-) AEROVANCE INC.
 XX Neben S, Takeuchi T, Tomkinson A, Delaria K, Yan K, Wong T;
 PI Longphre M;
 XX WPI; 2006-079812/08.
 XX New purified human antibody, which binds to stem cell factor protein,
 PT useful for treating asthma or a human disorder in which stem cell factor
 PT protein is expressed in certain cells.
 XX Claim 30; Page; 108pp; English.
 XX The invention relates to: a purified human antibody (IgG) or fragment
 CC thereof which binds to stem cell factor protein; a preparation comprising
 CC the antibody, and/or a carrier; isolated polynucleotide(s) encoding the
 CC antibody; an expression vector comprising the polynucleotide(s); a host
 CC cell comprising the expression vector; a method of producing a human
 CC cell factor protein is expressed in certain cells; and a method for
 CC identifying a disorder in which stem cell factor protein level is
 CC elevated. The purified human antibody comprises the heavy chain variable
 CC region human V-kappa-1 or V-lambda-1 consensus framework residues, and
 CC may be optionally bound to a cytotoxic molecule or detectable label. The
 CC antibody, compositions and methods are useful for treating asthma or a
 CC human disorder in which stem cell factor protein is expressed in certain
 CC cells. This sequence is a variant of human stem cell factor-binding
 CC antibody A2-G8 light chain variable and constant regions. Note: this
 CC sequence is not shown in the specification but is derived from the human
 CC stem cell factor-binding antibody A2-G8 light chain variable and constant
 CC regions (AEF11766) and SCF-binding antibody clone B9 kappa-1 light chain
 CC variable region CDR3 (AEF11779).
 XX Sequence 212 AA;
 SQ Query Match 100.0%; Score 553; DB 10; Length 212;
 Best Local Similarity 100.0%; Pred. No. 1e-47;
 Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTRQD 60
 DB 106 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTRQD 165
 QY 61 SKDSTYSLSSSTLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 107
 DB 166 SKDSTYSLSSSTLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 212
 RESULT 74
 AEF11801
 ID AEF11801 standard; protein; 212 AA.
 XX AEF11801;
 AC AEF11801;
 XX 09-MAR-2006 (first entry)

XX SCF-binding Ab A2-G8 light chain variable + constant regions variant 2.
 DE antibody therapy; antibody engineering; asthma; inflammation;
 KW antiasthmatic; stem cell factor; SCF; light chain variable region;
 KW light chain constant region.
 XX Homo sapiens.
 OS Synthetic.
 XX WO2006002064-A2.
 XX 05-JAN-2006.
 XX 14-JUN-2005; 2005WO-US021043.
 XX 14-JUN-2004; 2004US-00867506.
 PR 14-JUN-2004; 2004US-0579462P.
 XX (AERO-) AEROVANCE INC.
 XX Neben S, Takeuchi T, Tomkinson A, Delaria K, Yan K, Wong T;
 PI Longphre M;
 XX WPI; 2006-079812/08.
 XX New purified human antibody, which binds to stem cell factor protein,
 PT useful for treating asthma or a human disorder in which stem cell factor
 PT protein is expressed in certain cells.
 XX Claim 30; Page; 108pp; English.
 XX The invention relates to: a purified human antibody (IgG) or fragment
 CC thereof which binds to stem cell factor protein; a preparation comprising
 CC the antibody, and/or a carrier; isolated polynucleotide(s) encoding the
 CC antibody; an expression vector comprising the polynucleotide(s); a host
 CC cell comprising the expression vector; a method of producing a human
 CC cell factor protein is expressed in certain cells; and a method for
 CC identifying a disorder in which stem cell factor protein level is
 CC elevated. The purified human antibody comprises the heavy chain variable
 CC region human V-kappa-1 or V-lambda-1 consensus framework residues, and
 CC may be optionally bound to a cytotoxic molecule or detectable label. The
 CC antibody, compositions and methods are useful for treating asthma or a
 CC human disorder in which stem cell factor protein is expressed in certain
 CC cells. This sequence is a variant of human stem cell factor-binding
 CC antibody A2-G8 light chain variable and constant regions. Note: this
 CC sequence is not shown in the specification but is derived from the human
 CC stem cell factor-binding antibody A2-G8 light chain variable and constant
 CC regions (AEF11766) and SCF-binding antibody clone A12 kappa-1 light chain
 CC variable region CDR3 (AEF11776).
 XX Sequence 212 AA;
 SQ Query Match 100.0%; Score 553; DB 10; Length 212;
 Best Local Similarity 100.0%; Pred. No. 1e-47;
 Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTRQD 60
 DB 106 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTRQD 165
 QY 61 SKDSTYSLSSSTLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 107
 DB 166 SKDSTYSLSSSTLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 212
 RESULT 75
 AEF11803
 ID AEF11803 standard; protein; 212 AA.
 XX AEF11803;
 AC AEF11803;

```
XX 09-MAR-2006 (first entry)
DT
DE SCF-binding Ab A2-G8 light chain variable + constant regions variant 4.
DE
XX antibody therapy; antibody engineering; asthma; inflammation;
XX antiasthmatic; stem cell factor; SCF; light chain variable region;
KW light chain constant region.
XX
OS Homo sapiens.
OS Synthetic.
XX
XX WO2006002064-A2.
XX
XX 05-JAN-2006.
XX
XX 14-JUN-2005; 2005WO-US021043.
XX
XX 14-JUN-2004; 2004US-00867506.
XX
XX 14-JUN-2004; 2004US-0579462P.
XX
XX (AERO-) AEROVANCE INC.
XX
XX Neben S, Takeuchi T, Tomkinson A, Delaria K, Yan K, Wong T;
XX Longphre M;
XX
XX WPI; 2006-079812/08.
XX
XX New purified human antibody, which binds to stem cell factor protein,
XX useful for treating asthma or a human disorder in which stem cell factor
XX protein is expressed in certain cells.
XX
XX Claim 30; Page; 108pp; English.
XX
XX The invention relates to: a purified human antibody (IgG) or fragment
XX thereof which binds to stem cell factor protein; a preparation comprising
XX the antibody, and/or a carrier; isolated polynucleotide(s) encoding the
XX antibody; an expression vector comprising the polynucleotide(s); a host
XX cell comprising the expression vector; a method of producing a human
XX antibody; a method of treating asthma or a human disorder in which stem
XX cell factor protein is expressed in certain cells; and a method for
XX identifying a disorder in which stem cell factor protein level is
XX elevated. The purified human antibody comprises the heavy chain variable
XX region human V-kappa-1 or V-lambda-1 consensus framework residues, and
XX may be optionally bound to a cytotoxic molecule or detectable label. The
XX antibody, compositions and methods are useful for treating asthma or a
XX human disorder in which stem cell factor protein is expressed in certain
XX cells. This sequence is a variant of human stem cell factor-binding
XX antibody A2-G8 light chain variable and constant regions. Note: this
XX sequence is not shown in the specification but is derived from the human
XX stem cell factor-binding antibody A2-G8 light chain variable and constant
XX regions (AEF11766) and SCF-binding antibody clone A8 kappa-1 light chain
XX variable region CDR3 (AEF11778).
XX
XX Sequence 212 AA;
XX
XX Query Match 100.0%; Score 553; DB 10; Length 212;
XX Best Local Similarity 100.0%; Pred. No. 1e-47;
XX Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
XX Db 106 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 165
XX
XX 61 SKDSTYSLSSTLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 107
XX Qy
XX 166 SKDSTYSLSSTLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 212
XX Db
XX
XX RESULT 76
XX AEF11805
XX ID AEF11805 standard; protein; 212 AA.
```

```
XX AEF11805;
AC
XX 09-MAR-2006 (first entry)
DT
DE SCF-binding Ab A2-G8 light chain variable + constant regions variant 6.
DE
XX antibody therapy; antibody engineering; asthma; inflammation;
XX antiasthmatic; stem cell factor; SCF; light chain variable region;
KW light chain constant region.
XX
OS Homo sapiens.
OS Synthetic.
XX
XX WO2006002064-A2.
XX
XX 05-JAN-2006.
XX
XX 14-JUN-2005; 2005WO-US021043.
XX
XX 14-JUN-2004; 2004US-00867506.
XX
XX 14-JUN-2004; 2004US-0579462P.
XX
XX (AERO-) AEROVANCE INC.
XX
XX Neben S, Takeuchi T, Tomkinson A, Delaria K, Yan K, Wong T;
XX Longphre M;
XX
XX WPI; 2006-079812/08.
XX
XX New purified human antibody, which binds to stem cell factor protein,
XX useful for treating asthma or a human disorder in which stem cell factor
XX protein is expressed in certain cells.
XX
XX Claim 30; Page; 108pp; English.
XX
XX The invention relates to: a purified human antibody (IgG) or fragment
XX thereof which binds to stem cell factor protein; a preparation comprising
XX the antibody, and/or a carrier; isolated polynucleotide(s) encoding the
XX antibody; an expression vector comprising the polynucleotide(s); a host
XX cell comprising the expression vector; a method of producing a human
XX antibody; a method of treating asthma or a human disorder in which stem
XX cell factor protein is expressed in certain cells; and a method for
XX identifying a disorder in which stem cell factor protein level is
XX elevated. The purified human antibody comprises the heavy chain variable
XX region human V-kappa-1 or V-lambda-1 consensus framework residues, and
XX may be optionally bound to a cytotoxic molecule or detectable label. The
XX antibody, compositions and methods are useful for treating asthma or a
XX human disorder in which stem cell factor protein is expressed in certain
XX cells. This sequence is a variant of human stem cell factor-binding
XX antibody A2-G8 light chain variable and constant regions. Note: this
XX sequence is not shown in the specification but is derived from the human
XX stem cell factor-binding antibody A2-G8 light chain variable and constant
XX regions (AEF11766) and SCF-binding antibody clone F5L kappa-1 light chain
XX variable region CDR3 (AEF11780).
XX
XX Sequence 212 AA;
XX
XX Query Match 100.0%; Score 553; DB 10; Length 212;
XX Best Local Similarity 100.0%; Pred. No. 1e-47;
XX Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
XX Qy 106 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 165
XX
XX 61 SKDSTYSLSSTLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 107
XX Qy
XX 166 SKDSTYSLSSTLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 212
XX Db
XX
XX RESULT 77
```

```
AEF11806
ID AEF11806 standard; protein; 212 AA.
AC AEF11806;
XX
XX
DT 09-MAR-2006 (first entry)
DE SCF-binding Ab A2-G8 light chain variable + constant regions variant 7.
KW antibody therapy; antibody engineering; asthma; inflammation;
KW antiasthmatic; stem cell factor; SCF; light chain variable region;
XX light chain constant region.
OS Homo sapiens.
OS Synthetic.
XX
XX WO2006002064-A2.
XX
XX 05-JAN-2006.
XX
XX 14-JUN-2005; 2005WO-US021043.
XX
XX 14-JUN-2004; 2004US-00867506.
XX
XX 14-JUN-2004; 2004US-0579462P.
XX
XX (AERO-) AEROVANCE INC.
XX
XX Neben S, Takeuchi T, Tomkinson A, Delaria K, Yan K, Wong T;
XX Longphre M;
XX
XX WPI; 2006-079812/08.
XX
XX New purified human antibody, which binds to stem cell factor protein,
XX useful for treating asthma or a human disorder in which stem cell factor
XX protein is expressed in certain cells.
XX
XX Claim 30; Page; 108pp; English.
XX
XX The invention relates to: a purified human antibody (IgG) or fragment
XX thereof which binds to stem cell factor protein; a preparation comprising
XX the antibody, and/or a carrier; isolated polynucleotide(s) encoding the
XX antibody; an expression vector comprising the polynucleotide(s); a host
XX cell comprising the expression vector; a method of producing a human
XX cell factor protein is expressed in certain cells; and a method for
XX identifying a disorder in which stem cell factor protein level is
XX elevated. The purified human antibody comprises the heavy chain variable
XX region human V-kappa-1 or V-lambda-1 consensus framework residues, and
XX may be optionally bound to a cytotoxic molecule or detectable label. The
XX antibody, compositions and methods are useful for treating asthma or a
XX human disorder in which stem cell factor protein is expressed in certain
XX cells. This sequence is a variant of human stem cell factor-binding
XX antibody A2-G8 light chain variable and constant regions. Note: this
XX sequence is not shown in the specification but is derived from the human
XX stem cell factor-binding antibody A2-G8 light chain variable and constant
XX regions (AEF11766) and SCF-binding antibody clone D5 kappa-1 light chain
XX variable region CDR3 (AEF11781).
```

```
AEF11806
ID AEF11806 standard; protein; 212 AA.
AC AEF11806;
XX
XX
DT 09-MAR-2006 (first entry)
DE SCF-binding Ab A2-G8 light chain variable + constant regions variant 7.
KW antibody therapy; antibody engineering; asthma; inflammation;
KW antiasthmatic; stem cell factor; SCF; light chain variable region;
XX light chain constant region.
OS Homo sapiens.
OS Synthetic.
XX
XX WO2006002064-A2.
XX
XX 05-JAN-2006.
XX
XX 14-JUN-2005; 2005WO-US021043.
XX
XX 14-JUN-2004; 2004US-00867506.
XX
XX 14-JUN-2004; 2004US-0579462P.
XX
XX (AERO-) AEROVANCE INC.
XX
XX Neben S, Takeuchi T, Tomkinson A, Delaria K, Yan K, Wong T;
XX Longphre M;
XX
XX WPI; 2006-079812/08.
XX
XX New purified human antibody, which binds to stem cell factor protein,
XX useful for treating asthma or a human disorder in which stem cell factor
XX protein is expressed in certain cells.
XX
XX Claim 30; Page; 108pp; English.
XX
XX The invention relates to: a purified human antibody (IgG) or fragment
XX thereof which binds to stem cell factor protein; a preparation comprising
XX the antibody, and/or a carrier; isolated polynucleotide(s) encoding the
XX antibody; an expression vector comprising the polynucleotide(s); a host
XX cell comprising the expression vector; a method of producing a human
XX cell factor protein is expressed in certain cells; and a method for
XX identifying a disorder in which stem cell factor protein level is
XX elevated. The purified human antibody comprises the heavy chain variable
XX region human V-kappa-1 or V-lambda-1 consensus framework residues, and
XX may be optionally bound to a cytotoxic molecule or detectable label. The
XX antibody, compositions and methods are useful for treating asthma or a
XX human disorder in which stem cell factor protein is expressed in certain
XX cells. This sequence is a variant of human stem cell factor-binding
XX antibody A2-G8 light chain variable and constant regions. Note: this
XX sequence is not shown in the specification but is derived from the human
XX stem cell factor-binding antibody A2-G8 light chain variable and constant
XX regions (AEF11766) and SCF-binding antibody clone D5 kappa-1 light chain
XX variable region CDR3 (AEF11781).
```

```
Sequence 212 AA;
Query Match 100.0%; Score 553; DB 10; Length 212;
Best Local Similarity 100.0%; Pred. No. 1e-47;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
DB 106 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 165
QY 61 SKDSTYSLSSTLTLSKADYERHKVYACEVTHQGLSSPVTKSFNRGEC 107
DB 166 SKDSTYSLSSTLTLSKADYERHKVYACEVTHQGLSSPVTKSFNRGEC 212
```

```
Sequence 212 AA;
Query Match 100.0%; Score 553; DB 10; Length 212;
Best Local Similarity 100.0%; Pred. No. 1e-47;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
DB 106 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 165
QY 61 SKDSTYSLSSTLTLSKADYERHKVYACEVTHQGLSSPVTKSFNRGEC 107
DB 166 SKDSTYSLSSTLTLSKADYERHKVYACEVTHQGLSSPVTKSFNRGEC 212
```

```
Db      166 SKDSTYSLSTLTLSKADYKHKYVACEVTHQGLSSPVTKSFNRGEC 212
RESULT 79
ID      AEF11802 standard; protein; 212 AA.
XX
AC      AEF11802;
XX
XX      09-MAR-2006 (first entry)
XX
XX      SCF-binding Ab A2-G8 light chain variable + constant regions variant 3.
XX
XX      antibody therapy; antibody engineering; asthma; inflammation;
KW      antiasthmatic; stem cell factor; SCF; light chain variable region;
KW      light chain constant region.
XX
XX      Homo sapiens.
OS      Synthetic.
OS
FN      WO2006002064-A2.
XX
XX
XX      05-JAN-2006.
XX
XX      14-JUN-2005; 2005WO-US021043.
XX
XX      14-JUN-2004; 2004US-00867506.
PR      14-JUN-2004; 2004US-0579462P.
XX
XX      (AERO-) AEROVANCE INC.
XX
XX      Neben S, Takeuchi T, Tomkinson A, Delaria K, Yan K, Wong T;
PI      Longphre M;
XX
XX      WPI; 2006-079812/08.
DR
XX
XX      New purified human antibody, which binds to stem cell factor protein,
PT      useful for treating asthma or a human disorder in which stem cell factor
PT      protein is expressed in certain cells.
XX
XX      Claim 30; Page; 108pp; English.
PS
XX
XX      The invention relates to: a purified human antibody (IgG) or fragment
CC      thereof which binds to stem cell factor protein; a preparation comprising
CC      the antibody, and/or a carrier; isolated polynucleotide(s) encoding the
CC      antibody; an expression vector comprising the polynucleotide(s); a host
CC      cell comprising the expression vector; a method of producing a human
CC      antibody; a method of treating asthma or a human disorder in which stem
CC      cell factor protein is expressed in certain cells; and a method for
CC      identifying a disorder in which stem cell factor protein level is
CC      elevated. The purified human antibody comprises the heavy chain variable
CC      region human VH3 consensus framework residues, the light chain variable
CC      region human V-kappa-1 or V-lambda-1 consensus framework residues, and
CC      may be optionally bound to a cytotoxic molecule or detectable label. The
CC      antibody, compositions and methods are useful for treating asthma or a
CC      human disorder in which stem cell factor protein is expressed in certain
CC      cells. This sequence is a variant of human stem cell factor-binding
CC      antibody A2-G8 light chain variable and constant regions. Note: this
CC      sequence is not shown in the specification but is derived from the human
CC      stem cell factor-binding antibody A2-G8 light chain variable and constant
CC      regions (AEF11766) and SCF-binding antibody clone D6L kappa-1 light chain
CC      variable region CDR3 (AEF11777).
XX
XX      Sequence 212 AA;
SQ
Query Match      100.0%; Score 553; DB 10; Length 212;
Best Local Similarity 100.0%; Pred. No. 1e-47;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 RTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYPREAKVQKVDNALQSGNSQESVTEQD 60
Db      106 RTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYPREAKVQKVDNALQSGNSQESVTEQD 165

RESULT 81
ID      AAE10516 standard; protein; 213 AA.
XX
XX      61 SKDSTYSLSTLTLSKADYKHKYVACEVTHQGLSSPVTKSFNRGEC 107
XX
XX      167 SKDSTYSLSTLTLSKADYKHKYVACEVTHQGLSSPVTKSFNRGEC 213
XX
```

AC AAE10516;
 XX 10-DEC-2001 (first entry)
 XX Humanised high potency antibody clone 24 full length light chain.
 DE
 XX
 DE
 XX
 KW Human; light chain; respiratory syncytial virus infection; virucide;
 KW parainfluenza virus; therapy; high potency antibody; drug; cocaine;
 KW cancer cell; toxic substance.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX WO200164751-A2.
 PN
 XX
 PD 07-SEP-2001.
 XX
 XX 01-MAR-2001; 2001WO-US006815.
 PF
 XX 01-MAR-2000; 2000US-0186252P.
 PR
 XX (MEDI-) MEDIMMUNE INC.
 PA
 XX Young JF, Koenig S, Johnson LS, Huse WD, Wu H, Watkins JD;
 PI WPI; 2001-582150/65.
 XX
 DR High potency recombinant antibody, useful for preventing and treating
 XX diseases induced or caused by viruses, especially respiratory syncytial
 XX virus and parainfluenza virus, has high kinetic association rate
 XX constant.
 XX
 PS Claim 23; Page 83-84; 98pp; English.
 XX
 CC The invention relates to a high potency antibody including its
 CC immunologically active portions, fragments and segments other than
 CC vitaxin. The antibody has increased potency, high rate constant for
 CC antibody-antigen complex formation and high affinity for any desired
 CC antigen. The high potency antibody is also useful for nullifying or
 CC ameliorating the effects of addictive drugs, such as cocaine. The high
 CC potency has specificity for antigenic determinants found on microbes such
 CC as viruses, bacteria or fungi, antigens found on cancer cells and toxic
 CC substances or product of toxic substances. The high potency antibody is
 CC useful for preventing or treating a disease caused by a virus such as
 CC respiratory syncytial virus (RSV) and parainfluenza virus (PIV). The
 CC present sequence is humanised high potency antibody full length light
 CC chain variable region
 XX
 SQ Sequence 213 AA;
 Query Match 100.0%; Score 553; DB 4; Length 213;
 Best Local Similarity 100.0%; Pred. No. 1e-47;
 Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RTVAAPSVFIPPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
 DB 107 RTVAAPSVFIPPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166
 QY 61 SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 107
 DB 167 SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 213
 RESULT 82
 AAE10526
 ID AAE10526 standard; protein; 213 AA.
 XX
 AC AAE10526;
 XX
 XX 10-DEC-2001 (first entry)
 DT Humanised high potency antibody clone 22 full length light chain.
 XX

KW Human; light chain; respiratory syncytial virus infection; virucide;
 KW parainfluenza virus; therapy; high potency antibody; drug; cocaine;
 KW cancer cell; toxic substance.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX WO200164751-A2.
 PN
 XX
 PD 07-SEP-2001.
 XX
 XX 01-MAR-2001; 2001WO-US006815.
 PF
 XX 01-MAR-2000; 2000US-0186252P.
 PR
 XX (MEDI-) MEDIMMUNE INC.
 PA
 XX Young JF, Koenig S, Johnson LS, Huse WD, Wu H, Watkins JD;
 PI WPI; 2001-582150/65.
 XX
 DR High potency recombinant antibody, useful for preventing and treating
 XX diseases induced or caused by viruses, especially respiratory syncytial
 XX virus and parainfluenza virus, has high kinetic association rate
 XX constant.
 XX
 PS Claim 23; Page 96; 98pp; English.
 XX
 CC The invention relates to a high potency antibody including its
 CC immunologically active portions, fragments and segments other than
 CC vitaxin. The antibody has increased potency, high rate constant for
 CC antibody-antigen complex formation and high affinity for any desired
 CC antigen. The high potency antibody is also useful for nullifying or
 CC ameliorating the effects of addictive drugs, such as cocaine. The high
 CC potency has specificity for antigenic determinants found on microbes such
 CC as viruses, bacteria or fungi, antigens found on cancer cells and toxic
 CC substances or product of toxic substances. The high potency antibody is
 CC useful for preventing or treating a disease caused by a virus such as
 CC respiratory syncytial virus (RSV) and parainfluenza virus (PIV). The
 CC present sequence is humanised high potency antibody full length light
 CC chain variable region
 XX
 SQ Sequence 213 AA;
 Query Match 100.0%; Score 553; DB 4; Length 213;
 Best Local Similarity 100.0%; Pred. No. 1e-47;
 Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RTVAAPSVFIPPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
 DB 107 RTVAAPSVFIPPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166
 QY 61 SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 107
 DB 167 SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 213
 RESULT 83
 AAE10512
 ID AAE10512 standard; protein; 213 AA.
 XX
 AC AAE10512;
 XX
 XX 10-DEC-2001 (first entry)
 DT Humanised high potency antibody clone 26 full length light chain.
 DE
 XX
 KW Human; light chain; respiratory syncytial virus infection; virucide;
 KW parainfluenza virus; therapy; high potency antibody; drug; cocaine;
 KW cancer cell; toxic substance.
 XX
 OS Homo sapiens.
 OS Synthetic.

```
XX WO200164751-A2.
XX 07-SEP-2001.
XX 01-MAR-2001; 2001WO-US006815.
XX 01-MAR-2000; 2000US-0186252P.
XX (MEDI-) MEDIMMUNE INC.
XX Young JF, Koenig S, Johnson LS, Huse WD, Wu H, Watkins JD;
XX WPI; 2001-582150/65.
XX High potency recombinant antibody, useful for preventing and treating
XX diseases induced or caused by viruses, especially respiratory syncytial
XX virus and parainfluenza virus, has high kinetic association rate
XX constant.
XX Claim 23; Page 78-79; 98pp; English.
XX The invention relates to a high potency antibody including its
XX immunologically active portions, fragments and segments other than
XX vitaxin. The antibody has increased potency, high rate constant for
XX antibody-antigen complex formation and high affinity for any desired
XX antigen. The high potency antibody is also useful for nullifying or
XX ameliorating the effects of addictive drugs, such as cocaine. The high
XX potency has specificity for antigenic determinants found on microbes such
XX as viruses, bacteria or fungi, antigens found on cancer cells and toxic
XX substances or product of toxic substances. The high potency antibody is
XX useful for preventing or treating a disease caused by a virus such as
XX respiratory syncytial virus (RSV) and parainfluenza virus (PIV). The
XX present sequence is humanised high potency antibody full length light
XX chain variable region
XX Sequence 213 AA;
XX Query Match 100.0%; Score 553; DB 4; Length 213;
XX Best Local Similarity 100.0%; Pred. No. 1e-47;
XX Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
XX 107 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166
XX
XX 61 SKDSTYSLSSSTLTLSKADYKHKYVACEVTHQGLSSPVTGKSFNRGEC 107
XX 167 SKDSTYSLSSSTLTLSKADYKHKYVACEVTHQGLSSPVTGKSFNRGEC 213
XX
XX RESULT 84
XX AAE10514
XX ID AAE10514 standard; protein; 213 AA.
XX AC AAE10514;
XX XX Humanised high potency antibody clone 18 full length light chain.
XX DT 10-DEC-2001 (first entry)
XX DE Human; light chain; respiratory syncytial virus infection; virucide;
XX KW parainfluenza virus; therapy; high potency antibody; drug; cocaine;
XX KW cancer cell; toxic substance.
XX XX Homo sapiens.
XX OS Synthetic.
XX XX WO200164751-A2.
XX PN 07-SEP-2001.
XX PD 01-MAR-2001; 2001WO-US006815.
XX PF 01-MAR-2000; 2000US-0186252P.
XX PI (MEDI-) MEDIMMUNE INC.
XX Young JF, Koenig S, Johnson LS, Huse WD, Wu H, Watkins JD;
XX WPI; 2001-582150/65.
XX High potency recombinant antibody, useful for preventing and treating
XX diseases induced or caused by viruses, especially respiratory syncytial
XX virus and parainfluenza virus, has high kinetic association rate
XX constant.
XX Claim 23; Page 78-79; 98pp; English.
XX The invention relates to a high potency antibody including its
XX immunologically active portions, fragments and segments other than
XX vitaxin. The antibody has increased potency, high rate constant for
XX antibody-antigen complex formation and high affinity for any desired
XX antigen. The high potency antibody is also useful for nullifying or
XX ameliorating the effects of addictive drugs, such as cocaine. The high
XX potency has specificity for antigenic determinants found on microbes such
XX as viruses, bacteria or fungi, antigens found on cancer cells and toxic
XX substances or product of toxic substances. The high potency antibody is
XX useful for preventing or treating a disease caused by a virus such as
XX respiratory syncytial virus (RSV) and parainfluenza virus (PIV). The
XX present sequence is humanised high potency antibody full length light
XX chain variable region
XX Sequence 213 AA;
XX Query Match 100.0%; Score 553; DB 4; Length 213;
XX Best Local Similarity 100.0%; Pred. No. 1e-47;
XX Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
XX 107 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166
XX
XX 61 SKDSTYSLSSSTLTLSKADYKHKYVACEVTHQGLSSPVTGKSFNRGEC 107
XX 167 SKDSTYSLSSSTLTLSKADYKHKYVACEVTHQGLSSPVTGKSFNRGEC 213
XX
XX RESULT 84
XX AAE10514
XX ID AAE10514 standard; protein; 213 AA.
XX AC AAE10514;
XX XX Humanised high potency antibody clone 18 full length light chain.
XX DT 10-DEC-2001 (first entry)
XX DE Human; light chain; respiratory syncytial virus infection; virucide;
XX KW parainfluenza virus; therapy; high potency antibody; drug; cocaine;
XX KW cancer cell; toxic substance.
XX XX Homo sapiens.
XX OS Synthetic.
XX XX WO200164751-A2.
XX PN 07-SEP-2001.
XX PD 01-MAR-2001; 2001WO-US006815.
XX PF 01-MAR-2000; 2000US-0186252P.
XX PI (MEDI-) MEDIMMUNE INC.
XX Young JF, Koenig S, Johnson LS, Huse WD, Wu H, Watkins JD;
```

```
XX 01-MAR-2000; 2000US-0186252P.
XX (MEDI-) MEDIMMUNE INC.
XX Young JF, Koenig S, Johnson LS, Huse WD, Wu H, Watkins JD;
XX WPI; 2001-582150/65.
XX High potency recombinant antibody, useful for preventing and treating
XX diseases induced or caused by viruses, especially respiratory syncytial
XX virus and parainfluenza virus, has high kinetic association rate
XX constant.
XX Claim 23; Page 80-81; 98pp; English.
XX The invention relates to a high potency antibody including its
XX immunologically active portions, fragments and segments other than
XX vitaxin. The antibody has increased potency, high rate constant for
XX antibody-antigen complex formation and high affinity for any desired
XX antigen. The high potency antibody is also useful for nullifying or
XX ameliorating the effects of addictive drugs, such as cocaine. The high
XX potency has specificity for antigenic determinants found on microbes such
XX as viruses, bacteria or fungi, antigens found on cancer cells and toxic
XX substances or product of toxic substances. The high potency antibody is
XX useful for preventing or treating a disease caused by a virus such as
XX respiratory syncytial virus (RSV) and parainfluenza virus (PIV). The
XX present sequence is humanised high potency antibody full length light
XX chain variable region
XX Sequence 213 AA;
XX Query Match 100.0%; Score 553; DB 4; Length 213;
XX Best Local Similarity 100.0%; Pred. No. 1e-47;
XX Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
XX 107 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166
XX
XX 61 SKDSTYSLSSSTLTLSKADYKHKYVACEVTHQGLSSPVTGKSFNRGEC 107
XX 167 SKDSTYSLSSSTLTLSKADYKHKYVACEVTHQGLSSPVTGKSFNRGEC 213
XX
XX RESULT 85
XX AAE10524
XX ID AAE10524 standard; protein; 213 AA.
XX AC AAE10524;
XX XX Humanised high potency antibody clone 21 full length light chain.
XX DT 10-DEC-2001 (first entry)
XX DE Human; light chain; respiratory syncytial virus infection; virucide;
XX KW parainfluenza virus; therapy; high potency antibody; drug; cocaine;
XX KW cancer cell; toxic substance.
XX XX Homo sapiens.
XX OS Synthetic.
XX XX WO200164751-A2.
XX PN 07-SEP-2001.
XX PD 01-MAR-2001; 2001WO-US006815.
XX PF 01-MAR-2000; 2000US-0186252P.
XX PR 01-MAR-2000; 2000US-0186252P.
XX PA (MEDI-) MEDIMMUNE INC.
XX Young JF, Koenig S, Johnson LS, Huse WD, Wu H, Watkins JD;
```


XX WPI; 2001-582150/65.
XX High potency recombinant antibody, useful for preventing and treating
PT diseases induced or caused by viruses, especially respiratory syncytial
PT virus and parainfluenza virus, has high kinetic association rate
PT constant.
XX Claim 23; Page 93-94; 98pp; English.
PS The invention relates to a high potency antibody including its
CC immunologically active portions, fragments and segments other than
CC vitaxin. The antibody has increased potency, high rate constant for
CC antibody-antigen complex formation and high affinity for any desired
CC antigen. The high potency antibody is also useful for nullifying or
CC ameliorating the effects of addictive drugs, such as cocaine. The high
CC potency has specificity for antigenic determinants found on microbes such
CC as viruses, bacteria or fungi, antigens found on cancer cells and toxic
CC substances or product of toxic substances. The high potency antibody is
CC useful for preventing or treating a disease caused by a virus such as
CC respiratory syncytial virus (RSV) and parainfluenza virus (PIV). The
CC present sequence is humanised high potency antibody full length light
CC chain variable region
XX
SQ Sequence 213 AA;
Query Match 100.0%; Score 553; DB 4; Length 213;
Best Local Similarity 100.0%; Pred. No. 1e-47;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 107 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166
QY 61 SKDSTYSLSSTLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 107
Db 167 SKDSTYSLSSTLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 213
RESULT 86
AAE10518
ID AAE10518 standard; protein; 213 AA.
AC AAE10518;
XX 10-DEC-2001 (first entry)
XX Humanised high potency antibody clone 19 full length light chain.
DE Human; light chain; respiratory syncytial virus infection; virucide;
KW parainfluenza virus; therapy; high potency antibody; drug; cocaine;
KW cancer cell; toxic substance.
XX Homo sapiens.
OS Synthetic.
XX WO200164751-A2.
PN 01-MAR-2001; 2001WO-US006815.
XX 07-SEP-2001.
PD 01-MAR-2001; 2001WO-US006815.
PF 01-MAR-2001; 2001WO-US006815.
PP 01-MAR-2000; 2000US-0186252P.
XX (MEDI-) MEDIMUNE INC.
PA Young JF, Koenig S, Johnson LS, Huse WD, Wu H, Watkins JD;
PI WPI; 2001-582150/65.
XX High potency recombinant antibody, useful for preventing and treating
PT diseases induced or caused by viruses, especially respiratory syncytial
PT virus and parainfluenza virus, has high kinetic association rate

PT constant.
XX Claim 23; Page 86; 98pp; English.
XX The invention relates to a high potency antibody including its
CC immunologically active portions, fragments and segments other than
CC vitaxin. The antibody has increased potency, high rate constant for
CC antibody-antigen complex formation and high affinity for any desired
CC antigen. The high potency antibody is also useful for nullifying or
CC ameliorating the effects of addictive drugs, such as cocaine. The high
CC potency has specificity for antigenic determinants found on microbes such
CC as viruses, bacteria or fungi, antigens found on cancer cells and toxic
CC substances or product of toxic substances. The high potency antibody is
CC useful for preventing or treating a disease caused by a virus such as
CC respiratory syncytial virus (RSV) and parainfluenza virus (PIV). The
CC present sequence is humanised high potency antibody full length light
CC chain variable region
XX
SQ Sequence 213 AA;
Query Match 100.0%; Score 553; DB 4; Length 213;
Best Local Similarity 100.0%; Pred. No. 1e-47;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 107 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166
QY 61 SKDSTYSLSSTLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 107
Db 167 SKDSTYSLSSTLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 213
RESULT 87
AAE10522
ID AAE10522 standard; protein; 213 AA.
AC AAE10522;
XX 10-DEC-2001 (first entry)
XX Humanised high potency antibody clone 23 full length light chain.
DE Human; light chain; respiratory syncytial virus infection; virucide;
KW parainfluenza virus; therapy; high potency antibody; drug; cocaine;
KW cancer cell; toxic substance.
XX Homo sapiens.
OS Synthetic.
XX WO200164751-A2.
PN 01-MAR-2001; 2001WO-US006815.
XX 07-SEP-2001.
PD 01-MAR-2001; 2001WO-US006815.
PF 01-MAR-2000; 2000US-0186252P.
XX (MEDI-) MEDIMUNE INC.
PA Young JF, Koenig S, Johnson LS, Huse WD, Wu H, Watkins JD;
PI WPI; 2001-582150/65.
XX High potency recombinant antibody, useful for preventing and treating
PT diseases induced or caused by viruses, especially respiratory syncytial
PT virus and parainfluenza virus, has high kinetic association rate
PT constant.
XX Claim 23; Page 91; 98pp; English.
XX The invention relates to a high potency antibody including its
CC immunologically active portions, fragments and segments other than

CC vitaxin. The antibody has increased potency, high rate constant for
CC antibody-antigen complex formation and high affinity for any desired
CC antigen. The high potency antibody is also useful for nullifying or
CC ameliorating the effects of addictive drugs, such as cocaine. The high
CC potency has specificity for antigenic determinants found on microbes such
CC as viruses, bacteria or fungi, antigens found on cancer cells and toxic
CC substances or product of toxic substances. The high potency antibody is
CC useful for preventing or treating a disease caused by a virus such as
CC respiratory syncytial virus (RSV) and parainfluenza virus (PIV). The
CC present sequence is humanised high potency antibody full length light
CC chain variable region
XX
SQ Sequence 213 AA;

Query Match 100.0%; Score 553; DB 4; Length 213;
Best Local Similarity 100.0%; Pred. No. 1e-47;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTRQD 60
107 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTRQD 166

DB 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTRQD 60
107 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTRQD 166

QY 61 SKDSTYSLSSTLTLSKADYERKHVYACEVTHQGLSSPVTGKSFNRGEC 107
167 SKDSTYSLSSTLTLSKADYERKHVYACEVTHQGLSSPVTGKSFNRGEC 213

DB 167 SKDSTYSLSSTLTLSKADYERKHVYACEVTHQGLSSPVTGKSFNRGEC 213

RESULT 88
AAE10510
ID AAE10510 standard; protein; 213 AA.
XX
AC AAE10510;
XX
DT 10-DEC-2001 (first entry)
XX
DE Humanised high potency antibody clone 25 full length light chain.
XX
DE Human; light chain; respiratory syncytial virus infection; virucide;
KW parainfluenza virus; therapy; high potency antibody; drug; cocaine;
KW cancer cell; toxic substance.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200164751-A2.
XX
PD 07-SEP-2001.
XX
PF 01-MAR-2001; 2001WO-US006815.
XX
PR 01-MAR-2000; 2000US-0186252P.
XX
PA (MEDI-) MEDIMUNE INC.
XX
PI Young JF, Koenig S, Johnson LS, Huse WD, Wu H, Watkins JD;
XX
DR WPI; 2001-582150/65.
XX
XX High potency recombinant antibody, useful for preventing and treating
PT diseases induced or caused by viruses, especially respiratory syncytial
PT virus and parainfluenza virus, has high kinetic association rate
PT constant.
XX
PS Claim 23; Page 75-76; 98pp; English.
XX
XX The invention relates to a high potency antibody including its
CC immunologically active portions, fragments and segments other than
CC vitaxin. The antibody has increased potency, high rate constant for
CC antibody-antigen complex formation and high affinity for any desired
CC antigen. The high potency antibody is also useful for nullifying or
CC ameliorating the effects of addictive drugs, such as cocaine. The high
CC potency has specificity for antigenic determinants found on microbes such
CC as viruses, bacteria or fungi, antigens found on cancer cells and toxic

CC substances or product of toxic substances. The high potency antibody is
CC useful for preventing or treating a disease caused by a virus such as
CC respiratory syncytial virus (RSV) and parainfluenza virus (PIV). The
CC present sequence is humanised high potency antibody full length light
CC chain variable region
XX
SQ Sequence 213 AA;

Query Match 100.0%; Score 553; DB 4; Length 213;
Best Local Similarity 100.0%; Pred. No. 1e-47;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTRQD 60
107 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTRQD 166

DB 107 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTRQD 166

QY 61 SKDSTYSLSSTLTLSKADYERKHVYACEVTHQGLSSPVTGKSFNRGEC 107
167 SKDSTYSLSSTLTLSKADYERKHVYACEVTHQGLSSPVTGKSFNRGEC 213

DB 167 SKDSTYSLSSTLTLSKADYERKHVYACEVTHQGLSSPVTGKSFNRGEC 213

RESULT 89
AAE10520
ID AAE10520 standard; protein; 213 AA.
XX
AC AAE10520;
XX
DT 10-DEC-2001 (first entry)
XX
DE Humanised high potency antibody clone 20 full length light chain.
XX
DE Human; light chain; respiratory syncytial virus infection; virucide;
KW parainfluenza virus; therapy; high potency antibody; drug; cocaine;
KW cancer cell; toxic substance.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200164751-A2.
XX
PD 07-SEP-2001.
XX
PF 01-MAR-2001; 2001WO-US006815.
XX
PR 01-MAR-2000; 2000US-0186252P.
XX
PA (MEDI-) MEDIMUNE INC.
XX
PI Young JF, Koenig S, Johnson LS, Huse WD, Wu H, Watkins JD;
XX
DR WPI; 2001-582150/65.
XX
XX High potency recombinant antibody, useful for preventing and treating
PT diseases induced or caused by viruses, especially respiratory syncytial
PT virus and parainfluenza virus, has high kinetic association rate
PT constant.
XX
PS Claim 23; Page 88-89; 98pp; English.
XX
XX The invention relates to a high potency antibody including its
CC immunologically active portions, fragments and segments other than
CC vitaxin. The antibody has increased potency, high rate constant for
CC antibody-antigen complex formation and high affinity for any desired
CC antigen. The high potency antibody is also useful for nullifying or
CC ameliorating the effects of addictive drugs, such as cocaine. The high
CC potency has specificity for antigenic determinants found on microbes such
CC as viruses, bacteria or fungi, antigens found on cancer cells and toxic
CC substances or product of toxic substances. The high potency antibody is
CC useful for preventing or treating a disease caused by a virus such as
CC respiratory syncytial virus (RSV) and parainfluenza virus (PIV). The
CC present sequence is humanised high potency antibody full length light
CC chain variable region
XX

SQ	Sequence 213 AA;		
Query Match	100.0%; Score 553; DB 4; Length 213;		
Best Local Similarity	100.0%; Pred. No. 1e-47;		
Matches 107; Conservative	0; Mismatches 0; Indels 0; Gaps 0;		
QY	1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60		
DB	107 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166		
QY	61 SKDSTYLSLSTLTLSKADYEHKHKVYACEVTHQGLSSPVTKSFNRGEC 107		
DB	167 SKDSTYLSLSTLTLSKADYEHKHKVYACEVTHQGLSSPVTKSFNRGEC 213		
RESULT 90			
AAB83157			
ID	AAB83157 standard; protein; 213 AA.		
AC	AAB83157;		
DT	02-JUL-2001 (first entry)		
DE	Ganglioside GM2 antibody-related protein #2.		
XX	Ganglioside; GM2; antibody; cytostatic; cytotoxic; cancer.		
OS	Unidentified.		
PN	WO200123431-A1.		
PD	05-APR-2001.		
PF	29-SEP-2000; 2000WO-JP006775.		
PR	30-SEP-1999; 99JP-00278292.		
PA	(KYOW) KYOWA HAKKO KOGYO KK.		
PI	Hanai N, Nakamura K, Niwa R;		
DR	WPI; 2001-266142/27.		
PT	Monoclonal antibodies against ganglioside GM2 combined with drugs, radioisotopes or proteins for treatment and diagnosis of cancer.		
PS	Claim 43; Page 65-67; 80pp; Japanese.		
CC	The present invention relates to derivatives of an antibody against ganglioside GM2. The antibody may be a monoclonal antibody or its fragments. The antibody is combined with a radioactive isotope, protein or small drug in the treatment and diagnosis of cancer		
XX	SQ Sequence 213 AA;		
Query Match	100.0%; Score 553; DB 4; Length 213;		
Best Local Similarity	100.0%; Pred. No. 1e-47;		
Matches 107; Conservative	0; Mismatches 0; Indels 0; Gaps 0;		
QY	1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60		
DB	107 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166		
QY	61 SKDSTYLSLSTLTLSKADYEHKHKVYACEVTHQGLSSPVTKSFNRGEC 107		
DB	167 SKDSTYLSLSTLTLSKADYEHKHKVYACEVTHQGLSSPVTKSFNRGEC 213		
RESULT 91			
ABP66573			
ID	ABP66573 standard; protein; 213 AA.		
XX	ABP66573;		
AC			

XX	04-DEC-2002 (first entry)		
XX	Human RSV antibody variable light chain.		
XX	Human; variable heavy domain; variable light domain; CDR; VH; VL; RSV; complementarity determining region; respiratory syncytial virus; virucide; pulmonary; antiinflammatory; cardiant; anti-Hiv; vaccine; immunostimulant; gene therapy; cystic fibrosis; bone marrow transplant; bronchopulmonary dysplasia; congenital heart disease; congenital immunodeficiency; acquired immunodeficiency.		
OS	Homo sapiens.		
XX	WO200243660-A2.		
XX	06-JUN-2002.		
XX	28-NOV-2001; 2001WO-US044807.		
PR	28-NOV-2000; 2000US-00724396.		
XX	28-NOV-2000; 2000US-00724531.		
PA	(MEDI-) MEDIUMMUNE INC.		
XX	Young JF, Koenig S, Johnson LS;		
PI	WPI; 2002-706803/76.		
XX	Antibody for treating respiratory syncytial virus (RSV) infection, comprises a variable heavy/light domain or complementarity determining regions 1 - 3 of variable light/heavy chains, that immunospecifically binds to RSV antigen.		
PT	Disclosure; Page 254; 298pp; English.		
PS	The invention relates to a novel antibody comprising a variable heavy (VH) domain, variable light (VL) domain, VH complementarity determining region (CDR)-1, VH CDR2, VH CDR3, VL CDR1, VL CDR2 or VL CDR3, where the antibody immunospecifically binds to a respiratory syncytial virus (RSV) antigen, and where the antibody is not SYNAGIS (RTM). The antibody of the invention has virucide, pulmonary, antiinflammatory, cardiant, anti-Hiv, and immunostimulant activity. The polynucleotides of the invention may have a use in a vaccine, and in gene therapy. The antibody is useful for treating or ameliorating a RSV infection in a human. The antibody is also useful for preventing, treating or ameliorating one or more symptoms associated with RSV infection in a mammal, e.g. cystic fibrosis, bronchopulmonary dysplasia, congenital heart disease, congenital immunodeficiency or acquired immunodeficiency, or after a bone marrow transplant. The sequence represents a variable domain of a human RSV antibody of the invention		
XX	SQ Sequence 213 AA;		
Query Match	100.0%; Score 553; DB 5; Length 213;		
Best Local Similarity	100.0%; Pred. No. 1e-47;		
Matches 107; Conservative	0; Mismatches 0; Indels 0; Gaps 0;		
QY	1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60		
DB	107 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166		
QY	61 SKDSTYLSLSTLTLSKADYEHKHKVYACEVTHQGLSSPVTKSFNRGEC 107		
DB	167 SKDSTYLSLSTLTLSKADYEHKHKVYACEVTHQGLSSPVTKSFNRGEC 213		
RESULT 92			
ABP66591			
ID	ABP66591 standard; protein; 213 AA.		
XX	ABP66591;		
AC			

DT	04-DEC-2002	(first entry)	
XX	Human RSV antibody variable light chain.		
XX	Human; variable heavy domain; variable light domain; CDR; VH; VL; RSV;		
XX	complementarity determining region; respiratory syncytial virus;		
XX	virucide; pulmonary; antiinflammatory; cardiant; anti-HIV; vaccine;		
XX	immunostimulant; gene therapy; cystic fibrosis; bone marrow transplant;		
XX	bronchopulmonary dysplasia; congenital heart disease;		
XX	congenital immunodeficiency; acquired immunodeficiency.		
XX	Homo sapiens.		
OS	WO200243660-A2.		
XX	06-JUN-2002.		
XX	28-NOV-2001; 2001WO-US044807.		
XX	28-NOV-2000; 2000US-00724396.		
XX	28-NOV-2000; 2000US-00724531.		
XX	(MEDI-) MEDIUMMUNE INC.		
XX	Young JF, Koenig S, Johnson LS;		
XX	WPI; 2002-706803/76.		
XX	Antibody for treating respiratory syncytial virus (RSV) infection,		
XX	comprises a variable heavy/light domain or complementarity determining		
XX	regions 1 - 3 of variable light/heavy chains, that immunospecifically		
XX	binds to RSV antigen.		
XX	Disclosure; Page 274-275; 298pp; English.		
XX	The invention relates to a novel antibody comprising a variable heavy		
XX	(VH) domain, variable light (VL) domain, VH complementarity determining		
XX	region (CDR)-1, VH CDR2, VH CDR3, VL CDR1, VL CDR2 or VL CDR3, where the		
XX	antibody immunospecifically binds to a respiratory syncytial virus (RSV)		
XX	antigen, and where the antibody is not SYNAGIS (RTM). The antibody of the		
XX	invention has virucide, pulmonary, antiinflammatory, cardiant, anti-HIV,		
XX	and immunostimulant activity. The polynucleotides of the invention may		
XX	have a use in a vaccine, and in gene therapy. The antibody is useful for		
XX	treating or ameliorating a RSV infection in a human. The antibody is also		
XX	useful for preventing, treating or ameliorating one or more symptoms		
XX	associated with RSV infection in a mammal, e.g. cystic fibrosis,		
XX	bronchopulmonary dysplasia, congenital heart disease, congenital		
XX	immunodeficiency or acquired immunodeficiency, or after a bone marrow		
XX	transplant. The sequence represents a variable domain of a human RSV		
XX	antibody of the invention		
XX	Sequence 213 AA;		
XX	Query Match 100.0%; Score 553; DB 5; Length 213;		
XX	Best Local Similarity 100.0%; Pred. No. 1e-47;		
XX	Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;		
XX	1 RTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60		
XX	107 RTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166		
XX	61 SKDSTVLSLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 107		
XX	167 SKDSTVLSLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 213		
XX	RESULT 93		
XX	ABP66607		
XX	ID ABP66607 standard; protein; 213 AA.		
XX	AC ABP66607;		
XX	04-DEC-2002 (first entry)		

```

DE Human RSV antibody variable light chain.
XX
XX Human; variable heavy domain; variable light domain; CDR; VH; VL; RSV;
KW complementarity determining region; respiratory syncytial virus;
KW virucide; pulmonary; antiinflammatory; cardiant; anti-HIV; vaccine;
KW immunostimulant; gene therapy; cystic fibrosis; bone marrow transplant;
KW bronchopulmonary dysplasia; congenital heart disease;
KW congenital immunodeficiency; acquired immunodeficiency.
XX
OS Homo sapiens.
XX
XX WO200243660-A2.
XX
XX 06-JUN-2002.
XX
XX 28-NOV-2001; 2001WO-US044807.
XX
XX 28-NOV-2000; 2000US-00724396.
XX
XX 28-NOV-2000; 2000US-00724531.
XX
XX (MEDI-) MEDIUMMUNE INC.
XX
XX Young JF, Koenig S, Johnson LS;
XX
XX WPI; 2002-706803/76.
XX
XX Antibody for treating respiratory syncytial virus (RSV) infection,
PT comprises a variable heavy/light domain or complementarity determining
PT regions 1 - 3 of variable light/heavy chains, that immunospecifically
PT binds to RSV antigen.
XX
XX Disclosure; Page 290; 298pp; English.
XX
XX The invention relates to a novel antibody comprising a variable heavy
CC (VH) domain, variable light (VL) domain, VH complementarity determining
CC region (CDR)-1, VH CDR2, VH CDR3, VL CDR1, VL CDR2 or VL CDR3, where the
CC antibody immunospecifically binds to a respiratory syncytial virus (RSV)
CC antigen, and where the antibody is not SYNAGIS (RTM). The antibody of the
CC invention has virucide, pulmonary, antiinflammatory, cardiant, anti-HIV,
CC and immunostimulant activity. The polynucleotides of the invention may
CC have a use in a vaccine, and in gene therapy. The antibody is useful for
CC treating or ameliorating a RSV infection in a human. The antibody is also
CC useful for preventing, treating or ameliorating one or more symptoms
CC associated with RSV infection in a mammal, e.g. cystic fibrosis,
CC bronchopulmonary dysplasia, congenital heart disease, congenital
CC immunodeficiency or acquired immunodeficiency, or after a bone marrow
CC transplant. The sequence represents a variable domain of a human RSV
CC antibody of the invention
XX
XX Sequence 213 AA;
XX
XX Query Match 100.0%; Score 553; DB 5; Length 213;
XX Best Local Similarity 100.0%; Pred. No. 1e-47;
XX Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
XX DB 107 RTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166
XX
XX QY 61 SKDSTYISLSTLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 107
XX DB 167 SKDSTYISLSTLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 213
XX
XX RESULT 95
XX ABP66569
XX ID ABP66569 standard; protein; 213 AA.
XX
XX AC ABP66569;
XX
XX 04-DEC-2002 (first entry)
XX
XX Human RSV antibody variable light chain.
XX

```

```

XX
XX Human RSV antibody variable light chain.
XX
XX Human; variable heavy domain; variable light domain; CDR; VH; VL; RSV;
KW complementarity determining region; respiratory syncytial virus;
KW virucide; pulmonary; antiinflammatory; cardiant; anti-HIV; vaccine;
KW immunostimulant; gene therapy; cystic fibrosis; bone marrow transplant;
KW bronchopulmonary dysplasia; congenital heart disease;
KW congenital immunodeficiency; acquired immunodeficiency.
XX
OS Homo sapiens.
XX
XX WO200243660-A2.
XX
XX 06-JUN-2002.
XX
XX 28-NOV-2001; 2001WO-US044807.
XX
XX 28-NOV-2000; 2000US-00724396.
XX
XX 28-NOV-2000; 2000US-00724531.
XX
XX (MEDI-) MEDIUMMUNE INC.
XX
XX Young JF, Koenig S, Johnson LS;
XX
XX WPI; 2002-706803/76.
XX
XX Antibody for treating respiratory syncytial virus (RSV) infection,
PT comprises a variable heavy/light domain or complementarity determining
PT regions 1 - 3 of variable light/heavy chains, that immunospecifically
PT binds to RSV antigen.
XX
XX Disclosure; Page 290; 298pp; English.
XX
XX The invention relates to a novel antibody comprising a variable heavy
CC (VH) domain, variable light (VL) domain, VH complementarity determining
CC region (CDR)-1, VH CDR2, VH CDR3, VL CDR1, VL CDR2 or VL CDR3, where the
CC antibody immunospecifically binds to a respiratory syncytial virus (RSV)
CC antigen, and where the antibody is not SYNAGIS (RTM). The antibody of the
CC invention has virucide, pulmonary, antiinflammatory, cardiant, anti-HIV,
CC and immunostimulant activity. The polynucleotides of the invention may
CC have a use in a vaccine, and in gene therapy. The antibody is useful for
CC treating or ameliorating a RSV infection in a human. The antibody is also
CC useful for preventing, treating or ameliorating one or more symptoms
CC associated with RSV infection in a mammal, e.g. cystic fibrosis,
CC bronchopulmonary dysplasia, congenital heart disease, congenital
CC immunodeficiency or acquired immunodeficiency, or after a bone marrow
CC transplant. The sequence represents a variable domain of a human RSV
CC antibody of the invention
XX
XX Sequence 213 AA;
XX
XX Query Match 100.0%; Score 553; DB 5; Length 213;
XX Best Local Similarity 100.0%; Pred. No. 1e-47;
XX Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
XX DB 107 RTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166
XX
XX QY 61 SKDSTYISLSTLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 107
XX DB 167 SKDSTYISLSTLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 213
XX
XX RESULT 95
XX ABP66569
XX ID ABP66569 standard; protein; 213 AA.
XX
XX AC ABP66569;
XX
XX 04-DEC-2002 (first entry)
XX
XX Human RSV antibody variable light chain.
XX

```

KW Human; variable heavy domain; variable light domain; CDR; VH; VL; RSV;
KW complementarity determining region; respiratory syncytial virus;
KW virucide; pulmonary; antiinflammatory; cardiant; anti-HIV; vaccine;
KW immunostimulant; gene therapy; cystic fibrosis; bone marrow transplant;
KW bronchopulmonary dysplasia; congenital heart disease;
KW congenital immunodeficiency; acquired immunodeficiency.
XX
OS Homo sapiens.
XX
XX WO200243660-A2.
XX
XX PD 06-JUN-2002.
XX
XX PF 28-NOV-2001; 2001WO-US044807.
XX
XX PR 28-NOV-2000; 2000US-00724396.
XX
XX PR 28-NOV-2000; 2000US-00724531.
XX
XX PA (MEDI-) MEDIUMMUNE INC.
XX
XX PI Young JF, Koenig S, Johnson LS;
XX
XX DR WPI; 2002-706803/76.
XX
XX PT Antibody for treating respiratory syncytial virus (RSV) infection,
PT comprises a variable heavy/light domain or complementarity determining
PT regions 1 - 3 of variable light/heavy chains, that immunospecifically
PT binds to RSV antigen.
XX
XX PS Disclosure; Page 267-268; 298pp; English.
XX
XX CC The invention relates to a novel antibody comprising a variable heavy
XX (VH) domain, variable light (VL) domain, VH complementarity determining
XX region (CDR)-1, VH CDR2, VL CDR1, VL CDR2 or VL CDR3, where the
XX antibody immunospecifically binds to a respiratory syncytial virus (RSV)
XX antigen, and where the antibody is not SYNAGIS (RTM). The antibody of the
XX invention has virucide, pulmonary, antiinflammatory, cardiant, anti-HIV,
XX and immunostimulant activity. The polynucleotides of the invention may
XX have a use in a vaccine, and in gene therapy. The antibody is useful for
XX treating or ameliorating a RSV infection in a human. The antibody is also
XX useful for preventing, treating or ameliorating one or more symptoms
XX associated with RSV infection in a mammal, e.g. cystic fibrosis,
XX bronchopulmonary dysplasia, congenital heart disease, congenital
XX immunodeficiency or acquired immunodeficiency, or after a bone marrow
XX transplant. The sequence represents a variable domain of a human RSV
XX antibody of the invention
SQ Sequence 213 AA;

Query Match 100.0%; Score 553; DB 5; Length 213;
Best Local Similarity 100.0%; Pred. No. 1e-47;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
DB 107 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166

QY 61 SKDSTYSLSSLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 107
DB 167 SKDSTYSLSSLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 213

RESULT 97
ABP66597
ID ABP66597 standard; protein; 213 AA.
XX
XX AC ABP66597;
XX
XX DT 04-DEC-2002 (first entry)
XX
XX DE Human RSV antibody variable light chain.
XX
XX KW Human; variable heavy domain; variable light domain; CDR; VH; VL; RSV;

KW complementarity determining region; respiratory syncytial virus;
KW virucide; pulmonary; antiinflammatory; cardiant; anti-HIV; vaccine;
KW immunostimulant; gene therapy; cystic fibrosis; bone marrow transplant;
KW bronchopulmonary dysplasia; congenital heart disease;
KW congenital immunodeficiency; acquired immunodeficiency.
XX
OS Homo sapiens.
XX
XX PN WO200243660-A2.
XX
XX PD 06-JUN-2002.
XX
XX PF 28-NOV-2001; 2001WO-US044807.
XX
XX PR 28-NOV-2000; 2000US-00724396.
XX
XX PR 28-NOV-2000; 2000US-00724531.
XX
XX PA (MEDI-) MEDIUMMUNE INC.
XX
XX PI Young JF, Koenig S, Johnson LS;
XX
XX DR WPI; 2002-706803/76.
XX
XX PT Antibody for treating respiratory syncytial virus (RSV) infection,
PT comprises a variable heavy/light domain or complementarity determining
PT regions 1 - 3 of variable light/heavy chains, that immunospecifically
PT binds to RSV antigen.
XX
XX PS Disclosure; Page 281; 298pp; English.
XX
XX CC The invention relates to a novel antibody comprising a variable heavy
XX (VH) domain, variable light (VL) domain, VH complementarity determining
XX region (CDR)-1, VH CDR2, VL CDR1, VL CDR2 or VL CDR3, where the
XX antibody immunospecifically binds to a respiratory syncytial virus (RSV)
XX antigen, and where the antibody is not SYNAGIS (RTM). The antibody of the
XX invention has virucide, pulmonary, antiinflammatory, cardiant, anti-HIV,
XX and immunostimulant activity. The polynucleotides of the invention may
XX have a use in a vaccine, and in gene therapy. The antibody is useful for
XX treating or ameliorating a RSV infection in a human. The antibody is also
XX useful for preventing, treating or ameliorating one or more symptoms
XX associated with RSV infection in a mammal, e.g. cystic fibrosis,
XX bronchopulmonary dysplasia, congenital heart disease, congenital
XX immunodeficiency or acquired immunodeficiency, or after a bone marrow
XX transplant. The sequence represents a variable domain of a human RSV
XX antibody of the invention
SQ Sequence 213 AA;

Query Match 100.0%; Score 553; DB 5; Length 213;
Best Local Similarity 100.0%; Pred. No. 1e-47;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
DB 107 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166

QY 61 SKDSTYSLSSLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 107
DB 167 SKDSTYSLSSLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 213

RESULT 98
ABP66581
ID ABP66581 standard; protein; 213 AA.
XX
XX AC ABP66581;
XX
XX DT 04-DEC-2002 (first entry)
XX
XX DE Human RSV antibody variable light chain.
XX
XX KW Human; variable heavy domain; variable light domain; CDR; VH; VL; RSV;
KW complementarity determining region; respiratory syncytial virus;

KW virucide; pulmonary; antiinflammatory; cardiant; anti-HIV; vaccine;
KW immunostimulant; gene therapy; cystic fibrosis; bone marrow transplant;
KW bronchopulmonary dysplasia; congenital heart disease;
KW congenital immunodeficiency; acquired immunodeficiency.
XX
OS Homo sapiens.
XX
XX WO200243660-A2.
XX
XX 06-JUN-2002.
XX
XX 28-NOV-2001; 2001WO-US044807.
XX
XX 28-NOV-2000; 2000US-00724396.
XX
XX 28-NOV-2000; 2000US-00724531.
XX
XX (MEDI-) MEDIUMMUNE INC.
XX
XX Young JF, Koenig S, Johnson LS;
XX
XX WPI; 2002-706803/76.
XX
XX Antibody for treating respiratory syncytial virus (RSV) infection,
XX comprises a variable heavy/light domain or complementarity determining
XX regions 1 - 3 of variable light/heavy chains, that immunospecifically
XX binds to RSV antigen.
XX
XX Disclosure; Page 263; 298pp; English.
XX
XX The invention relates to a novel antibody comprising a variable heavy
XX (VH) domain, variable light (VL) domain, VH complementarity determining
XX region (CDR)-1, VH CDR2, VL CDR3, VL CDR1 or VL CDR3, where the
XX antibody immunospecifically binds to a respiratory syncytial virus (RSV)
XX antigen, and where the antibody is not SYNAGIS (RTM). The antibody of the
XX invention has virucide, pulmonary, antiinflammatory, cardiant, anti-HIV,
XX and immunostimulant activity. The polynucleotides of the invention may
XX have a use in a vaccine, and in gene therapy. The antibody is useful for
XX treating or ameliorating a RSV infection in a human. The antibody is also
XX useful for preventing, treating or ameliorating one or more symptoms
XX associated with RSV infection in a mammal, e.g. cystic fibrosis,
XX bronchopulmonary dysplasia, congenital heart disease, congenital
XX immunodeficiency or acquired immunodeficiency, or after a bone marrow
XX transplant. The sequence represents a variable domain of a human RSV
XX antibody of the invention
XX
SQ Sequence 213 AA;

Query Match 100.0%; Score 553; DB 5; Length 213;
Best Local Similarity 100.0%; Pred. No. 1e-47;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
DB 107 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166
OY 61 SKDSTYLSLSTLTLSKADYEHKVKVACEVTHQGLSSPVTKSFNRGEC 107
DB 167 SKDSTYLSLSTLTLSKADYEHKVKVACEVTHQGLSSPVTKSFNRGEC 213

RESULT 99
ABP66589
ID ABP66589 standard; protein; 213 AA.
XX
XX AC ABP66589;
XX
XX 04-DEC-2002 (first entry)
XX
XX Human RSV antibody variable light chain.
XX
XX Human; variable heavy domain; variable light domain; CDR; VH; VL; RSV;
KW complementarity determining region; respiratory syncytial virus;
KW virucide; pulmonary; antiinflammatory; cardiant; anti-HIV; vaccine;

KW immunostimulant; gene therapy; cystic fibrosis; bone marrow transplant;
KW bronchopulmonary dysplasia; congenital heart disease;
KW congenital immunodeficiency; acquired immunodeficiency.
XX
OS Homo sapiens.
XX
XX WO200243660-A2.
XX
XX 06-JUN-2002.
XX
XX 28-NOV-2001; 2001WO-US044807.
XX
XX 28-NOV-2000; 2000US-00724396.
XX
XX 28-NOV-2000; 2000US-00724531.
XX
XX (MEDI-) MEDIUMMUNE INC.
XX
XX Young JF, Koenig S, Johnson LS;
XX
XX WPI; 2002-706803/76.
XX
XX Antibody for treating respiratory syncytial virus (RSV) infection,
XX comprises a variable heavy/light domain or complementarity determining
XX regions 1 - 3 of variable light/heavy chains, that immunospecifically
XX binds to RSV antigen.
XX
XX Disclosure; Page 272; 298pp; English.
XX
XX The invention relates to a novel antibody comprising a variable heavy
XX (VH) domain, variable light (VL) domain, VH complementarity determining
XX region (CDR)-1, VH CDR2, VL CDR3, VL CDR1 or VL CDR3, where the
XX antibody immunospecifically binds to a respiratory syncytial virus (RSV)
XX antigen, and where the antibody is not SYNAGIS (RTM). The antibody of the
XX invention has virucide, pulmonary, antiinflammatory, cardiant, anti-HIV,
XX and immunostimulant activity. The polynucleotides of the invention may
XX have a use in a vaccine, and in gene therapy. The antibody is useful for
XX treating or ameliorating a RSV infection in a human. The antibody is also
XX useful for preventing, treating or ameliorating one or more symptoms
XX associated with RSV infection in a mammal, e.g. cystic fibrosis,
XX bronchopulmonary dysplasia, congenital heart disease, congenital
XX immunodeficiency or acquired immunodeficiency, or after a bone marrow
XX transplant. The sequence represents a variable domain of a human RSV
XX antibody of the invention
XX
SQ Sequence 213 AA;

Query Match 100.0%; Score 553; DB 5; Length 213;
Best Local Similarity 100.0%; Pred. No. 1e-47;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
DB 107 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166
OY 61 SKDSTYLSLSTLTLSKADYEHKVKVACEVTHQGLSSPVTKSFNRGEC 107
DB 167 SKDSTYLSLSTLTLSKADYEHKVKVACEVTHQGLSSPVTKSFNRGEC 213

RESULT 100
ABP66563
ID ABP66563 standard; protein; 213 AA.
XX
XX AC ABP66563;
XX
XX 04-DEC-2002 (first entry)
XX
XX Human RSV antibody variable light chain.
XX
XX Human; variable heavy domain; variable light domain; CDR; VH; VL; RSV;
KW complementarity determining region; respiratory syncytial virus;
KW virucide; pulmonary; antiinflammatory; cardiant; anti-HIV; vaccine;
KW immunostimulant; gene therapy; cystic fibrosis; bone marrow transplant;

KW bronchopulmonary dysplasia; congenital heart disease;
KW congenital immunodeficiency; acquired immunodeficiency.

OS Homo sapiens.

PN WO200243660-A2.

XX 06-JUN-2002.

PD 28-NOV-2001; 2001WO-US044807.

XX 28-NOV-2000; 2000US-00724396.

PR 28-NOV-2000; 2000US-00724531.

XX (MEDI-) MEDIUMMUNE INC.

PA Young JF, Koenig S, Johnson LS;

XX WPI; 2002-706803/76.

DR Antibody for treating respiratory syncytial virus (RSV) infection,
XX comprises a variable heavy/light domain or complementarity determining
PT regions 1 - 3 of variable light/heavy chains, that immunospecifically
PT binds to RSV antigen.

XX Disclosure; Page 243; 298pp; English.

CC The invention relates to a novel antibody comprising a variable heavy
CC (VH) domain, variable light (VL) domain, VH complementarity determining
CC region (CDR)-1, VH CDR3, VL CDR1, VL CDR2 or VL CDR3, where the
CC antibody immunospecifically binds to a respiratory syncytial virus (RSV)
CC antigen, and where the antibody is not SYNAGIS (RTM). The antibody of the
CC invention has virucide, pulmonary, antiinflammatory, cardiant, anti-HIV,
CC and immunostimulant activity. The polynucleotides of the invention may
CC have a use in a vaccine, and in gene therapy. The antibody is useful for
CC treating or ameliorating a RSV infection in a human. The antibody is also
CC useful for preventing, treating or ameliorating one or more symptoms
CC associated with RSV infection in a mammal, e.g. cystic fibrosis,
CC bronchopulmonary dysplasia, congenital heart disease, congenital
CC immunodeficiency or acquired immunodeficiency, or after a bone marrow
CC transplant. The sequence represents a variable domain of a human RSV
CC antibody of the invention

XX SQ Sequence 213 AA;

Query Match 100.0%; Score 553; DB 5; Length 213;
Best Local Similarity 100.0%; Pred. No. 1e-47;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	RTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db	107	RTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166
Qy	61	SKDSTYLSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 107
Db	167	SKDSTYLSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 213

Search completed: June 12, 2006, 17:09:46
Job time : 96.2929 secs

GenCore version 5.1.9
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: June 10, 2006, 11:56:42 ; Search time 11.4069 Seconds
(without alignments)
902.540 Million cell updates/sec

Title: US-10-733-563-112

Perfect score: 553

Sequence: 1 RTVAAPSVFIFFPSPDBQLKS.....EVTHQGLSSPVTKSFNRGEC 107

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : PIR 80:*

1: piri:*

2: piri:*

3: piri:*

4: piri:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	553	100.0	215	2 JE0243	Ig kappa chain NIG
2	553	100.0	215	2 JE0244	Ig kappa chain NIG
3	553	100.0	215	2 JE0242	Ig kappa chain NIG
4	550	99.5	135	2 S52059	JC-kappa protein -
5	548	99.1	106	1 K3HU	Ig kappa chain C r
6	537	97.1	216	2 JE0241	Ig kappa chain Am3
7	520	94.0	215	2 A23746	Ig kappa chain V-I
8	513	92.8	99	2 A37927	Ig kappa chain C r
9	507	91.7	99	2 S26653	Ig kappa chain C r
10	372	67.3	240	2 S06084	Ig kappa chain pre
11	367	66.4	106	1 K1RTB	Ig kappa chain C r
12	366	66.2	178	2 PT0219	Ig kappa chain V-C
13	359	64.9	106	1 K1RTA	Ig kappa chain C r
14	358	64.7	217	2 S42772	Ig kappa chain - m
15	358	64.7	218	2 S68241	Ig kappa chain V r
16	358	64.7	219	2 S38865	Ig kappa chain - m
17	352	63.7	218	2 JC5810	monoclonal antibod
18	352	63.7	219	2 S52028	Ig kappa chain - m
19	352	63.7	219	2 PC4203	Ig kappa chain (mo
20	352	63.7	219	2 S16112	Ig kappa chain V r
21	352	63.7	220	2 A31790	Ig kappa chain V r
22	352	63.7	225	2 S37484	Ig kappa chain - m
23	352	63.7	234	2 S14337	Ig kappa chain pre
24	352	63.7	234	2 S01320	Ig kappa chain pre
25	352	63.7	235	2 S25058	Ig kappa chain - m
26	350	63.3	106	1 K1MS	Ig kappa chain C r
27	350	63.3	126	2 I54782	gene Pvt-1a/Ig-Ck
28	348	62.9	225	2 JL0029	Ig kappa chain pre
29	345	62.4	230	2 S33161	Ig kappa chain - s

ALIGNMENTS

RESULT 1

JE0243

Ig kappa chain NIG93 precursor - human

C;Species: Homo sapiens (man)

C;Date: 05-Dec-1998 #sequence_revision 05-Dec-1998 #text_change 21-Jan-2000

C;Accession: JE0243

R;Alim, M.A.; Hara, Y.; Hossain, M.S.; Takeda, K.; Yamagata, F.; Yamaki, S.; Kazi, H.; T

submitted to JIPID, November 1998

A;Description: A new subgroup of k type light chains (VKV) identified in cases of AL amy

A;Reference number: JE0243

A;Accession: JE0243

A;Molecule type: protein

A;Residues: 1-215 <ALI>

A;Cross-references: UNIPARC:UPI0000176984

A;Superfamily: immunoglobulin V region; immunoglobulin homology

F;16-90/Domain: immunoglobulin homology <INM>

Query Match 100.0%; Score 553; DB 2; Length 215;

Best Local Similarity 100.0%; Pred. No. 1.6e-46;

Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIFFPSPDBQLKSGTASVVCLLNFPYPRKQVQKVDNALQSGNSQESVTEQD 60

DB 109 RTVAAPSVFIFFPSPDBQLKSGTASVVCLLNFPYPRKQVQKVDNALQSGNSQESVTEQD 168

QY 61 SKDSTVLSSTLTLSKADYEHKHYACEVTHQGLSSPVTKSFNRGEC 107

DB 169 SKDSTVLSSTLTLSKADYEHKHYACEVTHQGLSSPVTKSFNRGEC 215

RESULT 2

JE0244

Ig kappa chain NIG2 precursor - human

C;Species: Homo sapiens (man)

C;Date: 05-Dec-1998 #sequence_revision 05-Dec-1998 #text_change 21-Jan-2000

C;Accession: JE0244

R;Alim, M.A.; Hara, Y.; Hossain, M.S.; Takeda, K.; Yamagata, F.; Yamaki, S.; Kazi, H.; T

submitted to JIPID, November 1998

A;Description: A new subgroup of k type light chains (VKV) identified in cases of AL amy

A;Reference number: JE0243

A;Accession: JE0244

A;Molecule type: protein

A;Residues: 1-215 <ALI>

A;Cross-references: UNIPARC:UPI0000176982

C;Superfamily: immunoglobulin V region; immunoglobulin homology

F;16-90/Domain: immunoglobulin homology <INM>

Query Match 100.0%; Score 553; DB 2; Length 215;

Best Local Similarity 100.0%; Pred. No. 1.6e-46;

Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIFFPSPDBQLKSGTASVVCLLNFPYPRKQVQKVDNALQSGNSQESVTEQD 60

```
|||||
109 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 168
QY 61 SKDSTYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 107
Db 169 SKDSTYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 215

RESULT 3
JE0242
Ig kappa chain NIG26 precursor - human
C/Species: Homo sapiens (man)
C/Date: 05-Dec-1998 #sequence_revision 05-Dec-1998 #text_change 21-Jan-2000
C/Accession: JE0242
R/Alim, M.A.; Yamaki, S.; Hossain, M.S.; Takeda, K.; Kojima, M.; Takashi, I.; Shinoda, T.
submitted to JIPID, November 1998
A/Description: Structure relationship of kappatype light chains with AL amyloidosis: Mul
A/Reference number: JE0241
A/Accession: JE0242
A/Molecule type: protein
A/Residues: 1-215 <ALI>
A/Cross-references: UNIPARC:UPI0000176983
C/Superfamily: immunoglobulin V region; immunoglobulin homology
F;16-91/Domain: immunoglobulin homology <IMM>

Query Match 100.0%; Score 553; DB 2; Length 215;
Best Local Similarity 100.0%; Pred. No. 1.6e-46;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 109 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 168
QY 61 SKDSTYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 107
Db 169 SKDSTYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 215

RESULT 4
S52059
JC-kappa protein - human
C/Species: Homo sapiens (man)
C/Date: 14-Jul-1995 #sequence_revision 21-Jul-1995 #text_change 08-Sep-2000
C/Accession: S52059
R/Frances, V.; Pandrau-Garcia, D.; Guret, C.; Ho, S.; Wang, Z.; Duvert, V.; Saeland, S.;
EMBO J. 13, 5937-5943, 1994
A/Title: A surrogate 15 kDa JC-kappa protein is expressed in combination with mu heavy c
A/Reference number: S52059; MUID:95112804; PMID:781342
A/Accession: S52059
A/Status: preliminary
A/Molecule type: mRNA
A/Residues: 1-135 <FRA>
A/Cross-references: UNIPARC:UPI00001184D0
C/Superfamily: pre-B cell omega light chain; immunoglobulin homology

Query Match 99.5%; Score 550; DB 2; Length 135;
Best Local Similarity 99.1%; Pred. No. 1.8e-46;
Matches 106; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 29 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 88
QY 61 SKDSTYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 107
Db 89 SKDSTYSLSTLTLSKADYEKHKLYACEVTHQGLSSPVTKSFNRGEC 135

RESULT 5
K3HU
Ig kappa chain C region - human
C/Species: Homo sapiens (man)
C/Date: 31-Dec-1980 #sequence_revision 02-Jul-1998 #text_change 09-Jul-2004
```

```
C/Accession: B90562; A91651; A90806; A94417; A91639; A92047; A94242; B37927; A02116; S021
R/Gottlieb, P.D.; Cunningham, B.A.; Rutishauser, U.; Edelman, G.M.
Biochemistry 9, 3155-3161, 1970
A/Title: The covalent structure of a human gammaG-immunoglobulin. VI. Amino acid sequence
A/Reference number: A90562; MUID:71064023; PMID:5489770
A/Contents: myeloma protein Eu
A/Accession: B90562
A/Molecule type: protein
A/Residues: 1-106 <GOT>
A/Cross-references: UNIPROT:P01834; UNIPARC:UPI000002F106
A/Note: this sequence has the Inv (3) allotypic marker, 45-Ala and 83-Val
R/Galli, W.E.; Edelman, G.M.
Biochemistry 9, 3188-3196, 1970
A/Title: The covalent structure of a human gammaG-immunoglobulin. X. Intrachain disulfide
A/Reference number: A90563; MUID:71064027; PMID:4923144
A/Contents: annotation; Eu, disulfide bonds
R/Suter, L.; Barnikol, H.U.; Watanabe, S.; Hilschmann, N.
Hoppe-Seyler's Z. Physiol. Chem. 353, 189-208, 1972
A/Title: Die Primaerstruktur einer monoklonalen Immunglobulin-L-Kette vom kappa-Typ, Subg
A/Reference number: A91651; MUID:72188439; PMID:5027703
A/Contents: Bence Jones protein Ti
A/Accession: A91651
A/Molecule type: protein
A/Residues: 1-106 <SUT>
A/Cross-references: UNIPARC:UPI000002F106
R/Hietter, P.A.; Max, E.E.; Seidman, J.G.; Maizel Jr., J.V.; Leder, P.
Cell 22, 197-207, 1980
A/Title: Cloned human and mouse kappa immunoglobulin constant and J region genes conserve
A/Reference number: A90806; MUID:81042304; PMID:6775818
A/Accession: A90806
A/Molecule type: DNA
A/Residues: 1-106 <HIE>
A/Cross-references: UNIPARC:UPI000002F106; GB:J00241; NID:933140; PIDN:CAA23823.1; PID:91
R/Hilschmann, N.; Barnikol, H.U.; Hess, M.; Langer, B.; Ponstingl, H.; Steinmetz-Kayne, N.
in Gamma Globulins: Structure and Function, Franek, F., and Shugar, D., eds., pp.57-74, f
A/Reference number: A94417
A/Contents: Bence Jones protein Roy
A/Accession: A94417
A/Molecule type: protein
A/Residues: 1-44, 'A', 46-56, 'Q', 58-82, 'L', 84-106 <HIL>
A/Cross-references: UNIPARC:UPI000017376D
A/Note: this sequence has the Inv (1,2) allotypic marker, 45-Ala and 83-Leu
R/Hilschmann, N.
Hoppe-Seyler's Z. Physiol. Chem. 348, 1718-1722, 1967
A/Title: Die vollständige Aminosäuresequenz des Bence-Jones-Proteins Cum. (kappa-Typ) .
A/Reference number: A91639; MUID:68242259; PMID:5586923
A/Contents: Bence Jones protein Cum
A/Accession: A91639
A/Molecule type: protein
A/Residues: 1-56, 'Q', 58-106 <HI2>
A/Cross-references: UNIPARC:UPI000017376E
R/Titani, K.; Shinoda, T.; Putnam, F.W.
J. Biol. Chem. 244, 3550-3560, 1969
A/Title: The amino acid sequence of a kappa type Bence-Jones protein. III. The complete e
A/Reference number: A92047; MUID:69234734; PMID:4893682
A/Contents: Bence Jones protein Ag
A/Accession: A92047
A/Molecule type: protein
A/Residues: 1-13, 'N', 15-106 <TIT>
A/Cross-references: UNIPARC:UPI000017376F
R/Kohler, H.; Shimizu, A.; Paul, C.; Putnam, F.W.
Science 169, 56-59, 1970
A/Title: Macroglobulin structure: variable sequence of light and heavy chains.
A/Reference number: A94242; MUID:70201507; PMID:5447531
A/Contents: Waldenström's macroglobulin Ou
A/Accession: A94242
A/Molecule type: protein
A/Residues: 1-13, 'N', 15-106 <KOH>
A/Cross-references: UNIPARC:UPI000017376F
R/Kurth, J.H.; Bowcock, A.M.; Erlich, H.A.; Nevo, S.; Cavalli-Sforza, L.L.
Am. J. Hum. Genet. 48, 613-620, 1991
A/Title: Km typing with PCR: application to population screening.
```

A;Reference number: A37927; MUID:91150772; PMID:19000145
A;Accession: B37927
A;Status: not compared with conceptual translation
A;Molecule type: DNA
A;Residues: 8-106 <KUR>
A;Cross-references: UNIPARC:UPI0000173770
A;Note: allotype Inv(3)
R;Steiner, V.; Chang, J.Y.
FEBS Lett. 222, 6-10, 1987
A;Title: Chemical modification of the carboxyl groups of protein substrates enhances the
A;Reference number: S02572; MUID:88005152; PMID:3115831
A;Contents: annotation
C;Genetics:

A;Gene: GDB:IGKC
A;Cross-references: GDB:120088; OMIM:147200
A;Map position: 2p12-2p12
C;Complex: an immunoglobulin heterotetramer subunit consists of two identical light (kappa) chain disulfide bonds; in some cases, such as IgA and IgM, the subunits associate into 16
C;Superfamily: immunoglobulin C region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;19-88/Domain: immunoglobulin homology <IMM>
F;26-86/Disulfide bonds: #status experimental
F;106/Disulfide bonds: interchain (to heavy chain) #status experimental

Query Match 99.1%; Score 548; DB 1; Length 106;
Best Local Similarity 100.0%; Pred. No. 2.1e-46;
Matches 106; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 TVAAPSVFIPPPDEQLKSGTASVCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 61
DB 1 TVAAPSVFIPPPDEQLKSGTASVCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
QY 62 KDSYSLSSLTSLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 107
DB 61 KDSYSLSSLTSLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 106

RESULT 6
JE0241
Ig kappa chain Am37 precursor - human
C;Species: Homo sapiens (man)
C;Date: 05-Dec-1998 #sequence_revision 05-Dec-1998 #text_change 21-Jan-2000
C;Accession: JE0241
R;Allim, M.A.; Yanaki, S.; Hossain, M.S.; Takeda, K.; Kojima, M.; Takashi, I.; Shinoda, T.
submitted to JIPID, November 1998
A;Description: Structure relationship of kappa type light chains with AL amyloidosis: Mul
A;Reference number: JE0241
A;Accession: JE0241
A;Molecule type: protein
A;Residues: 1-216 <ALI>
A;Cross-references: UNIPARC:UPI0000176981
C;Superfamily: immunoglobulin V region; immunoglobulin homology
F;16-92/Domain: immunoglobulin homology <IMM>

Query Match 97.1%; Score 537; DB 2; Length 216;
Best Local Similarity 97.2%; Pred. No. 5.7e-45;
Matches 104; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIPPPDEQLKSGTASVCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
DB 110 RTVAAPSVFIPPPDEQLKSGTASVCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 169
QY 61 KDSYSLSSLTSLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 107
DB 170 KDSYSLSSLTSLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 216

RESULT 7
A23746
Ig kappa chain V-III (KAU cold agglutinin) - human
C;Species: Homo sapiens (man)
C;Date: 30-Dec-1991 #sequence_revision 30-Dec-1991 #text_change 21-Jan-2000
C;Accession: A23746

R;Leoni, J.; Ghiso, J.; Goni, F.; Frangione, B.
J. Biol. Chem. 266, 2836-2842, 1991
A;Title: The primary structure of the Fab fragment of protein KAU, a monoclonal immunoglobulin
A;Reference number: A23746; MUID:91151575; PMID:1993660
A;Accession: A23746
A;Status: preliminary
A;Molecule type: protein
A;Residues: 1-215 <LEO>
A;Cross-references: UNIPARC:UPI0000176985
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;16-91/Domain: immunoglobulin homology <IMM>

Query Match 94.0%; Score 520; DB 2; Length 215;
Best Local Similarity 98.1%; Pred. No. 2.6e-43;
Matches 104; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIPPPDEQLKSGTASVCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
DB 109 RTVAAPSVFIPPPDEQLKSGTASVCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 168
QY 61 KDSYSLSSLTSLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 106
DB 169 KDSYSLSSLTSLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 214

RESULT 8
A37927
Ig kappa chain C region (allotype Inv(1,2)) - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 28-Feb-1992 #sequence_revision 28-Feb-1992 #text_change 21-Jan-2000
C;Accession: A37927
R;Kurth, J.H.; Bowcock, A.M.; Erlich, H.A.; Nevo, S.; Cavalli-Sforza, L.L.
Am. J. Hum. Genet. 48, 613-620, 1991

A;Title: Km typing with PCR: application to population screening.
A;Reference number: A37927; MUID:91150772; PMID:1900145
A;Accession: A37927
A;Status: preliminary; not compared with conceptual translation
A;Molecule type: DNA
A;Residues: 1-99 <KUR>

A;Cross-references: UNIPARC:UPI0000176ED6
C;Superfamily: immunoglobulin C region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;12-81/Domain: immunoglobulin homology <IMM>

Query Match 92.8%; Score 513; DB 2; Length 99;
Best Local Similarity 99.0%; Pred. No. 5e-43;
Matches 98; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 9 FIPPPDEQLKSGTASVCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 68
DB 1 FIPPPDEQLKSGTASVCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
QY 69 SSTLTSLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 107
DB 61 SSTLTSLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 99

RESULT 9
S26653
Ig kappa chain C region - chimpanzee (fragment)
C;Species: Pan troglodytes (chimpanzee)
C;Date: 19-Mar-1997 #sequence_revision 18-Jul-1997 #text_change 21-Jan-2000
C;Accession: S26653
R;Ehrlich, P.H.; Moustafa, Z.A.; Harfeldt, K.E.; Isaacson, C.; Oestberg, L.
Hum. Antibodies Hybridomas 1, 23-26, 1990
A;Title: Potential of primate monoclonal antibodies to substitute for human antibodies:
A;Reference number: S26652; MUID:91355693; PMID:2129418
A;Accession: S26653
A;Status: translation not shown
A;Molecule type: mRNA
A;Residues: 1-99 <EHR>
A;Cross-references: UNIPARC:UPI0000176ED5; EMBL:X65287

C;Superfamily: immunoglobulin C region; immunoglobulin homology
C;Keywords: immunoglobulin
F;19-88/Domain: immunoglobulin homology <IMM>

Query Match 91.7%; Score 507; DB 2; Length 99;
Best Local Similarity 100.0%; Pred. No. 1.9e-42;
Matches 99; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 TVAAPSVFIFFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS 61
Db 1 TVAAPSVFIFFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS 60

QY 62 KDSTYSLSTLTLSKADYKHKVYACVTHOGLSSPVTK 100
Db 61 KDSTYSLSTLTLSKADYKHKVYACVTHOGLSSPVTK 99

RESULT 10
S06084
Ig kappa chain precursor - rat
C;Species: Rattus norvegicus (Norway rat)
C;Date: 28-Feb-1990 #sequence_revision 28-Feb-1990 #text_change 21-Jan-2000
C;Accession: S06084
R;Crowe, J.S.; Smith, M.A.; Cooper, H.J.
Nucleic Acids Res. 17, 7992, 1989
A;Title: Nucleotide sequence of Y3-Ag 1.2.3. rat myeloma immunoglobulin kappa chain cDNA
A;Reference number: S06084; MUID:90016888; PMID:2508067
A;Accession: S06084
A;Molecule type: mRNA
A;Residues: 1-240 <CRO>
A;Cross-references: UNIPARC:UPI0000113764; EMBL:X16129; NID:G56457; PIDN:CAA34256.1; PID
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;1-20/Domain: signal sequence #status predicted <SIG>
F;21-240/Product: Ig kappa chain #status predicted <MAT>
F;153-222/Domain: immunoglobulin homology <IMM>

Query Match 67.3%; Score 372; DB 2; Length 240;
Best Local Similarity 65.4%; Pred. No. 7.4e-29;
Matches 70; Conservative 13; Mismatches 24; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIFFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 134 RADAAPVSVFIFFPSTEQLATGGASVVCLLNNFYPRDISVKWKIDGTERDGLDSDVTDQD 193

QY 61 SKDSTYSLSTLTLSKADYKHKVYACVTHOGLSSPVTKSFNRGEC 107
Db 194 SKDSTYMSSTLSLKADYKESHNLTYCEVVHKTSSSPVVKSFNRNEC 240

RESULT 11
K1RTB
Ig kappa chain C region (allele b) - rat
C;Species: Rattus norvegicus (Norway rat)
C;Date: 18-Aug-1982 #sequence_revision 18-Aug-1982 #text_change 09-Jul-2004
C;Accession: A93901; A92807; A02117
R;Sheppard, H.W.; Gutman, G.A.
Proc. Natl. Acad. Sci. U.S.A. 78, 7064-7068, 1981
A;Title: Allelic forms of rat kappa chain genes: evidence for strong selection at the le
A;Reference number: A93901; MUID:82082587; PMID:6273908
A;Accession: A93901
A;Molecule type: DNA
A;Residues: 1-106 <SHE>
A;Cross-references: UNIPROT:P01835; UNIPARC:UPI000012DB83; GB:V01241; GB:J00745; GB:J025
A;Experimental source: strain LOU
R;Starace, V.; Querinjean, P.
J. Immunol. 115, 59-62, 1975
A;Title: The primary structure of a rat kappa Bence Jones protein: phylogenetic relation
A;Reference number: A92807; MUID:75212238; PMID:807630
A;Contents: Bence Jones protein S211
A;Accession: A92807
A;Molecule type: protein
A;Residues: 1,'N',3-29,'K',31-47,49-78,'Q',80-86,'Q',88-98,'W',99,'N',101-106 <STA>

A;Cross-references: UNIPARC:UPI0000173771
C;Complex: An immunoglobulin heterotetramer subunit consists of two identical light (kapi
hain disulfide bonds. In some cases, such as IgA and IgM, the subunits associate into lai
C;Superfamily: immunoglobulin C region; immunoglobulin homology
C;Keywords: heterotetramer
F;19-88/Domain: immunoglobulin homology <IMM>
F;26-86/Disulfide bonds: #status predicted
F;106/Disulfide bonds: interchain (to heavy chain) #status predicted

Query Match 66.4%; Score 367; DB 1; Length 106;
Best Local Similarity 65.4%; Pred. No. 8.7e-29;
Matches 68; Conservative 14; Mismatches 22; Indels 0; Gaps 0;

QY 4 AAPSVFIFFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKD 63
Db 3 AAPTVSIFPPSTEQLATGGASVVCLLMNNFYPRDISVKWKIDGTERDGLDSDVTDQDSKD 62

QY 64 STYSLSTLTLSKADYKHKVYACVTHOGLSSPVTKSFNRGEC 107
Db 63 STYMSSTLSLKADYKESHNLTYCEVVHKTSSSPVVKSFNRNEC 106

RESULT 12
PT0219
Ig kappa chain V-C region (PLC18) - pig (fragment)
C;Species: Sus scrofa domestica (domestic pig)
C;Date: 31-Dec-1991 #sequence_revision 31-Dec-1991 #text_change 11-Jan-2000
C;Accession: PT0219
R;Lammers, B.M.; Beaman, K.D.; Kim, Y.B.
Mol. Immunol. 28, 877-880, 1991
A;Title: Sequence analysis of porcine immunoglobulin light chain cDNAs.
A;Reference number: PT0219; MUID:91342694; PMID:1715030
A;Accession: PT0219
A;Molecule type: mRNA
A;Residues: 1-178 <LAM>
A;Cross-references: UNIPARC:UPI00001151A1; GB:M59321; NID:g164508; PIDN:AAA03520.1; PID:
A;Experimental source: spleen, strain Minnesota Miniature
A;Note: the authors translated the codon CTC for residue 141 as Ser
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;12-18/Domain: V region (fragment) <VRG>
F;19-51/Region: complementarity-determining 1
F;52-60/Region: complementarity-determining 2
F;61-70/Region: framework 2
F;71-178/Domain: C region <CRG>
F;96-156/Disulfide bonds: #status predicted
F;176/Disulfide bonds: interchain #status predicted

Query Match 66.2%; Score 366; DB 2; Length 178;
Best Local Similarity 64.5%; Pred. No. 2e-28;
Matches 69; Conservative 13; Mismatches 25; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIFFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 70 RADAKPSVFIFFPSKEQLATPTVSVCLINNFFPREISVKWKVDGVVQSSGHGSDSVTEQD 129

QY 61 SKDSTYSLSTLTLSKADYKHKVYACVTHOGLSSPVTKSFNRGEC 107
Db 130 SKDSTYSLSTLSLPTSOYLSHNLXSCEVTHKTLASPLVTSFNRNEC 176

RESULT 13
K1RTA
Ig kappa chain C region (allele a) - rat
C;Species: Rattus norvegicus (Norway rat)
C;Date: 18-Aug-1982 #sequence_revision 10-Sep-1982 #text_change 09-Jul-2004
C;Accession: A02118
R;Sheppard, H.W.; Gutman, G.A.
Proc. Natl. Acad. Sci. U.S.A. 78, 7064-7068, 1981
A;Title: Allelic forms of rat kappa chain genes: evidence for strong selection at the le
A;Reference number: A93901; MUID:82082587; PMID:6273908
A;Accession: A02118

Query Match	64.7%	Score 358	DB 2	Length 218
Best Local Similarity	61.7%	Pred. No. 1.5e-27		
Matches	66	Conservative 15	Mismatches 26	Indels 0
Gaps	0			
Qy	1	RTVAAPSVFIFPPSDDEQLSGTASVCLLNFPYPRKAKVQWKVDNALQSGNSQESVTEQD	60	
Db	112	RADAAPTVISFPPSSSEQLTSGGASVVCFLNFPYPKDINVKWKIDGSRQGVLSNWTQD	171	
Qy	61	SKDSTVSLSTLTLSKADIYKHKVYACEVTHQGLSPVTKSFNRGEC	107	
Db	172	SKDSTVMSLTLLTKDEYERHNSYTCETHTKTSTPIVKSFNRGEC	218	

Search completed: June 10, 2006, 12:06:43
Job time : 12.4069 secs

RESULT 14
S42772
Ig kappa chain - mouse
C:Species: Mus musculus (house mouse)
C:Date: 06-Jan-1995 #sequence_revision 06-Jan-1995 #text_change 21-Jan-2000
C:Accession: S42772
R:Schellekens, G.A.
submitted to the EMBL Data Library, November 1993
A:Reference number: S42771
A:Accession: S42772
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-217 <SCH>
A:Cross-references: UNIPARC:UPI00001161CD; EMBL:X75536; NID:G414143; PIDN:CAA53226.1; PI
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:14-93/Domain: immunoglobulin homology <IMM>

```

Query Match      64.7%; Score 358; DB 2; Length 217;
Best Local Similarity 61.7%; Pred. No. 1.5e-27;
Matches 66; Conservative 15; Mismatches 26; Indels 0; Gaps 0;

Qy 1 RTVAAPSVFIFPPSDEQLKSGTASVCLLNNFYPREAKVQKVDNALQSGNSQESVTEQD 60
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 111 RADAAPTVSIFPPSDEQLTSGASVCFNNFYPKDINVKWIDGSRQGVNLNSWTDQD 170
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

Qy 61 SKSTYSLSSTLTLSKADYKHKYVACEVTHQGLSSPVTKSFNRGEC 107
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 171 SKDSTYSMSSTLTLTQDEYRHNSYTCETHKSTSPVKSFNRGEC 217
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

```

RESULT 15
S68241
IG kappa chain V region (Mab13-1) - mouse (fragment)
N;Alternate names: immunoglobulin light chain
C;Species: Mus musculus (house mouse)
C;Date: 24-Aug-1996 #sequence_revision 13-Mar-1997 #text_change 20-Jun-2000
C;Accession: S68241; S68214
R;Takagi, M.; Kohda, K.; Hamuro, T.; Harada, A.; Yamaguchi, H.; Kamachi, M.; Imanaka, T.
submitted to the EMBL Data Library, March 1994
A;Description: Specific peroxidase activity by formation of an antibody L-chain-porphyrin
A;Reference number: S68241
A;Accession: S68241
A;Molecule type: mRNA
A;Residues: 1-218 <UNK>
A;Cross-references: UNIPARC:UPI000011B263; EMBL:D29670; NID:g473962; PIDN:BAA06141.1; PIR:R;Takagi, M.; Kohda, K.; Hamuro, T.; Harada, A.; Yamaguchi, H.; Kamachi, M.; Imanaka, T.
FEBS Lett. 375, 273-276. 1995

THIS PAGE BLANK (USPTO)

GenCore version 5.1.9
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: June 10, 2006, 11:49:06 ; Search time 88.042 Seconds
(without alignments)
1124.198 Million cell updates/sec

Title: US-10-733-563-112

Perfect score: 553

Sequence: 1 RTVAAPSVFIPPSDQLKS.....EVTHQGLSPVTKSFNRGEC 107

Scoring table:

BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2849598 seqs, 925015592 residues

Total number of hits satisfying chosen parameters: 2849598

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Uniprot 7.2.2*

1: uniprot_sprot:*

2: uniprot_trembl:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query %	Match	Length	DB	ID	Description
1	553	100.0	120	2	Q6P5R5	HUMAN	Q6P5R5 homo sapien
2	553	100.0	234	2	Q5EFE6	HUMAN	Q5EFE6 homo sapien
3	553	100.0	234	2	Q7Z473	HUMAN	Q7Z473 homo sapien
4	553	100.0	235	2	Q6GMV9	HUMAN	Q6GMV9 homo sapien
5	553	100.0	235	2	Q6GMW0	HUMAN	Q6GMW0 homo sapien
6	553	100.0	235	2	Q6PJP2	HUMAN	Q6PJP2 homo sapien
7	553	100.0	236	2	Q502W4	HUMAN	Q502W4 homo sapien
8	553	100.0	236	2	Q6GMW1	HUMAN	Q6GMW1 homo sapien
9	553	100.0	236	2	Q6GMX0	HUMAN	Q6GMX0 homo sapien
10	553	100.0	236	2	Q6GMX8	HUMAN	Q6GMX8 homo sapien
11	553	100.0	236	2	Q6GMX9	HUMAN	Q6GMX9 homo sapien
12	553	100.0	236	2	Q6P5S8	HUMAN	Q6P5S8 homo sapien
13	553	100.0	236	2	Q6PIH4	HUMAN	Q6PIH4 homo sapien
14	553	100.0	236	2	Q6PIH7	HUMAN	Q6PIH7 homo sapien
15	553	100.0	236	2	Q6PIL8	HUMAN	Q6PIL8 homo sapien
16	553	100.0	236	2	Q6PIT5	HUMAN	Q6PIT5 homo sapien
17	553	100.0	236	2	Q7Z3V4	HUMAN	Q7Z3V4 homo sapien
18	553	100.0	239	2	Q6P491	HUMAN	Q6P491 homo sapien
19	553	100.0	239	2	Q8TCD0	HUMAN	Q8TCD0 homo sapien
20	553	100.0	240	2	Q6PIH6	HUMAN	Q6PIH6 homo sapien
21	549	99.3	239	2	Q8NEK0	HUMAN	Q8NEK0 homo sapien
22	548	99.1	106	1	KAC	HUMAN	Q01834 homo sapien
23	548	99.1	234	2	Q569T9	HUMAN	Q569T9 homo sapien
24	369	66.7	234	2	Q4KM66	RAT	Q4KM66 rattus norv
25	369	66.7	234	2	Q5M838	RAT	Q5M838 rattus norv
26	367	66.4	106	1	KACB	RAT	P01835 rattus norv
27	359	64.9	106	1	KACA	RAT	P01836 rattus norv
28	358	64.7	219	2	Q65ZC0	MOUSE	Q65ZC0 mus musculus
29	352	63.7	234	2	Q5XKG4	MOUSE	Q5XKG4 mus musculus
30	352	63.7	235	2	Q58EV6	MOUSE	Q58EV6 mus musculus
31	352	63.7	235	2	Q5XFY8	MOUSE	Q5XFY8 mus musculus

32	352	63.7	236	2	Q52L95	MOUSE	Q52L95 mus musculus
33	352	63.7	236	2	Q7TS98	MOUSE	Q7TS98 mus musculus
34	352	63.7	237	2	Q3KQK1	MOUSE	Q3KQK1 mus musculus
35	352	63.7	237	2	Q569Y8	MOUSE	Q569Y8 mus musculus
36	352	63.7	238	2	Q58EU4	MOUSE	Q58EU4 mus musculus
37	352	63.7	238	2	Q66J57	MOUSE	Q66J57 mus musculus
38	352	63.7	239	2	Q58EU8	MOUSE	Q58EU8 mus musculus
39	352	63.7	240	2	Q52L64	MOUSE	Q52L64 mus musculus
40	352	63.7	241	2	Q63ZX4	MOUSE	Q63ZX4 mus musculus
41	350	63.3	106	1	KAC	MOUSE	P01837 mus musculus
42	306.5	55.4	106	1	KACB	RABIT	P01839 oryctolagus
43	292	52.8	189	2	Q569I7	HUMAN	Q569I7 homo sapien
44	259.5	46.9	116	2	Q6LEJ1	RABIT	Q6LEJ1 oryctolagus
45	259.5	46.9	116	2	Q6LEJ2	RABIT	Q6LEJ2 oryctolagus

ALIGNMENTS

RESULT 1
Q6P5R5 HUMAN PRELIMINARY; PRT; 120 AA.
AC Q6P5R5;
DT 05-JUL-2004, integrated into UniProtKB/TREMBL.
DT 05-JUL-2004, sequence version 1.
DT 21-FEB-2006, entry version 19.
DE IGKC protein.
GN IGKC;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Glandular pool- thyroid;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A., Sanchez A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodriguez Y., Bouffard G.G.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinaki M.I., Skalak U., Smailus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences.";
Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
[2]
NUCLEOTIDE SEQUENCE.
RC TISSUE=Glandular pool- thyroid;
RG NIH MGC Project;
RL Submitted (NOV-2003) to the EMBL/GenBank/DBJ databases.
CC -!- FUNCTION: Beta-2-microglobulin is the beta-chain of major
histocompatibility complex class I molecules (By similarity).
CC
CC Copyrighted by the UniProt Consortium, see <http://www.uniprot.org/terms>
Distributed under the Creative Commons Attribution-NoDerivs License

CC EMBL; BC062732; AAH62732.1; -; mRNA.
CC HSSP; P01837; 1KU.
CC SNR; Q6P5R5; 3-120.
CC Ensembl; ENSG00000163245; Homo sapiens.
CC GO; GO:0030106; F:MHC class I receptor activity; IEA.

DR GO; GO:0019883; P:antigen presentation, endogenous antigen; IEA.
 DR GO; GO:0019885; P:antigen processing, endogenous antigen via . . .; IEA.
 DR GO; GO:0006955; P:immune response; IEA.
 DR InterPro; IPR007110; Ig-like.
 DR InterPro; IPR003597; Ig.cl.
 DR InterPro; IPR003006; Ig.MHC.
 DR Pfam; PF07654; Cl-set; 1.
 DR SMART; SM00407; IGcl; 1.
 DR PROSITE; PS50835; IG LIKE; 1.
 DR PROSITE; PS00290; IG_MHC; UNKNOWN_1.
 KW Immune response; Immunoglobulin domain; MHC I.
 SQ SEQUENCE 120 AA; 13153 MW; B42FA2928C5C8F1F CRC64;

Query Match 100.0%; Score 553; DB 2; Length 120;
 Best Local Similarity 100.0%; Pred. No. 4.5e-47;
 Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
 Db 14 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 73
 Qy 61 SKDSTYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 107
 Db 74 SKDSTYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 120

RESULT 2
 QSEFE6_HUMAN
 ID QSEFE6_HUMAN PRELIMINARY; PRT; 234 AA.
 AC QSEFE6;
 DT 15-MAR-2005, integrated into UniProtKB/TrEMBL.
 DT 07-FEB-2006, entry version 1.
 DE Anti-Rhd monoclonal T125 kappa light chain precursor.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
 OC Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP NUCLEOTIDE SEQUENCE.
 RA Gaucher C., Klein P., Beliard R.;
 RT "Sequence determination of the recombinant human anti-Rhd monoclonal antibody T125";
 RL Submitted (JAN-2005) to the EMBL/GenBank/DBJ databases.
 CC -----
 CC Copyrighted by the UniProt Consortium, see <http://www.uniprot.org/terms>
 CC Distributed under the Creative Commons Attribution-NoDerivs License
 CC -----
 DR EMBL; AY894991; AAW82027.1; -; mRNA.
 DR SMR; OSEFE6; 22-234.
 DR InterPro; IPR003599; Ig.
 DR InterPro; IPR007110; Ig-like.
 DR InterPro; IPR003597; Ig.cl.
 DR InterPro; IPR003006; Ig.MHC.
 DR InterPro; IPR003596; Ig_v.
 DR InterPro; IPR013106; V-set.
 DR Pfam; PF07654; Cl-set; 1.
 DR SMART; SM00409; IG; 1.
 DR SMART; SM00407; IGcl; 1.
 DR SMART; SM00406; IGv; 1.
 DR PROSITE; PS50835; IG LIKE; 2.
 DR PROSITE; PS00290; IG_MHC; UNKNOWN_1.
 KW Signal.
 FT SIGNAL 1 20 Potential.
 FT CHAIN 21 234 anti-Rhd monoclonal T125 kappa light chain.
 FT CHAIN 21 234
 SQ SEQUENCE 234 AA; 25698 MW; 866DCD1E4FD7D5EA CRC64;

Query Match 100.0%; Score 553; DB 2; Length 234;
 Best Local Similarity 100.0%; Pred. No. 9.9e-47;
 Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
 Db 128 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 187
 Qy 61 SKDSTYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 107
 Db 188 SKDSTYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 234

RESULT 3
 Q72473_HUMAN
 ID Q72473_HUMAN PRELIMINARY; PRT; 234 AA.
 AC Q72473;
 DT 01-OCT-2003, integrated into UniProtKB/TrEMBL.
 DT 01-OCT-2003, sequence version 1.
 DT 07-FEB-2006, entry version 21.
 DE IGKC protein.
 DE IGKC protein.
 GN Name=IGKC;
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
 OC Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP NUCLEOTIDE SEQUENCE.
 RC TISSUE=Lung;
 RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
 RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
 RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
 RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
 RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
 RA Stapleton M., Soares M.B., Donald M.F., Casavant T.L., Scheetz T.E.,
 RA Brownstein M.J., Udwin T.B., Toshiyuki S., Carninci P., Prange C.,
 RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
 RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
 RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
 RA Fahey J., Helton E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,
 RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
 RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
 RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
 RT "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.";
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
 RN [2]
 RP NUCLEOTIDE SEQUENCE.
 RC TISSUE=Lung;
 RG NIH MGC Project;
 RL Submitted (AUG-2003) to the EMBL/GenBank/DBJ databases.
 CC -----
 CC Copyrighted by the UniProt Consortium, see <http://www.uniprot.org/terms>
 CC Distributed under the Creative Commons Attribution-NoDerivs License
 CC -----
 DR EMBL; BC056256; AAH56256.1; -; mRNA.
 DR HSSP; P01834; lHEZ.
 DR SMR; Q72473; 22-234.
 DR Ensembl; ENSG00000163245; Homo sapiens.
 DR InterPro; IPR003599; Ig.
 DR InterPro; IPR007110; Ig-like.
 DR InterPro; IPR003597; Ig.cl.
 DR InterPro; IPR003006; Ig.MHC.
 DR InterPro; IPR003596; Ig_v.
 DR InterPro; IPR013106; V-set.
 DR Pfam; PF07654; Cl-set; 1.
 DR SMART; SM00409; IG; 1.
 DR SMART; SM00407; IGcl; 1.
 DR SMART; SM00406; IGv; 1.
 DR PROSITE; PS50835; IG LIKE; 2.
 DR PROSITE; PS00290; IG_MHC; UNKNOWN_1.
 SQ SEQUENCE 234 AA; 25674 MW; 1A2C259BAB51BC0F CRC64;

Query Match 100.0%; Score 553, DB 2; Length 234;
 Best Local Similarity 100.0%; Pred. No. 9,9e-47;
 Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIFPPSDEQKSGTASVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
 |||||
 DB 128 RTVAAPSVFIFPPSDEQKSGTASVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 187
 |||||

QY 61 SKDSTYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 107
 |||||
 DB 188 SKDSTYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 234
 |||||

RESULT 4
 Q6GMV9_HUMAN
 ID Q6GMV9_HUMAN PRELIMINARY; PRT; 235 AA.
 AC Q6GMV9;
 DT 19-JUL-2004, integrated into UniProtKB/TrEMBL.
 DT 19-JUL-2004, sequence version 1.
 DT 07-FEB-2006, entry version 16.
 DE Hypothetical protein.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
 OC Homo.
 OX NCBI_TaxID=9606;
 [1]
 RN NUCLEOTIDE SEQUENCE.
 RP TISSUE=Spleen;
 RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
 RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
 RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
 RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
 RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
 RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
 RA Brownstein M.J., Udwin T.B., Toshiyuki S., Carninci P., Prange C.,
 RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullany S.J.,
 RA Raha S.S., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
 RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
 RA Fahey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
 RA Whiting J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
 RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
 RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
 RT "Generation and initial analysis of more than 15,000 full-length human
 and mouse cDNA sequences.";
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
 [2]
 RN NUCLEOTIDE SEQUENCE.
 RP TISSUE=Spleen;
 RA Strausberg R.;
 RL Submitted (JUN-2004) to the EMBL/GenBank/DBJ databases.
 CC Copyrighted by the UniProt Consortium, see <http://www.uniprot.org/terms>
 CC Distributed under the Creative Commons Attribution-NoDerivs License
 CC -----
 CC EMBL; BC073793; AAH73793.1; -; mRNA.
 DR SNR; Q6GMV9; 21-235.
 DR InterPro; IPR003599; Ig.
 DR InterPro; IPR007110; Ig-like.
 DR InterPro; IPR003597; Ig_c1.
 DR InterPro; IPR003006; Ig_MHC.
 DR InterPro; IPR003596; Ig_v.
 DR InterPro; IPR013106; V-set.
 DR SMART; SM00409; IG; 1.
 DR SMART; SM00407; IGC1; 1.
 DR SMART; SM00406; IGv; 1.
 DR PROSITE; PS50835; IG_LIKE; 2.

DR PROSITE; PS00290; IG_MHC; UNKNOWN_1.
 KW Hypothetical protein.
 SQ SEQUENCE 235 AA; 25646 MW; DF32B580BAD19E4B CRC64;

Query Match 100.0%; Score 553; DB 2; Length 235;
 Best Local Similarity 100.0%; Pred. No. 1e-46;
 Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIFPPSDEQKSGTASVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
 |||||
 DB 129 RTVAAPSVFIFPPSDEQKSGTASVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 188
 |||||

QY 61 SKDSTYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 107
 |||||
 DB 189 SKDSTYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 235
 |||||

RESULT 5
 Q6GMW0_HUMAN
 ID Q6GMW0_HUMAN PRELIMINARY; PRT; 235 AA.
 AC Q6GMW0;
 DT 19-JUL-2004, integrated into UniProtKB/TrEMBL.
 DT 19-JUL-2004, sequence version 1.
 DT 07-FEB-2006, entry version 17.
 DE IGKV1-5 protein.
 GN Name=IGKV1-5;
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
 OC Homo.
 OX NCBI_TaxID=9606;
 [1]
 RN NUCLEOTIDE SEQUENCE.
 RP TISSUE=Spleen;
 RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
 RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
 RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
 RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
 RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
 RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
 RA Brownstein M.J., Udwin T.B., Toshiyuki S., Carninci P., Prange C.,
 RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullany S.J.,
 RA Raha S.S., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
 RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
 RA Fahey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
 RA Whiting J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
 RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
 RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
 RT "Generation and initial analysis of more than 15,000 full-length human
 and mouse cDNA sequences.";
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
 [2]
 RN NUCLEOTIDE SEQUENCE.
 RP TISSUE=Spleen;
 RA Director MSC Project;
 RL Submitted (JUN-2004) to the EMBL/GenBank/DBJ databases.
 CC Copyrighted by the UniProt Consortium, see <http://www.uniprot.org/terms>
 CC Distributed under the Creative Commons Attribution-NoDerivs License
 CC -----
 CC EMBL; BC073792; AAH73792.1; -; mRNA.
 DR SNR; Q6GMW0; 21-233.
 DR InterPro; IPR003599; Ig.
 DR InterPro; IPR007110; Ig-like.
 DR InterPro; IPR003597; Ig_c1.
 DR InterPro; IPR003006; Ig_MHC.
 DR InterPro; IPR003596; Ig_v.
 DR InterPro; IPR013106; V-set.
 DR Pfam; PF07654; C1-set; 1.

```
DR SMART; SM00409; IG; 1.
DR SMART; SM00407; IGC1; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG_LIKE; 2.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_1.
SQ SEQUENCE 235 AA; 25765 MW; 4360C36B6D4133P5 CRC64;

Query Match 100.0%; Score 553; DB 2; Length 235;
Best Local Similarity 100.0%; Pred. No. 1e-46;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 129 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 188

QY 61 SKDSTYSLSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 107
Db 189 SKDSTYSLSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 235

RESULT 6
Q6PJF2 HUMAN PRELIMINARY; PRT; 235 AA.
AC Q6PJF2;
DT 05-JUL-2004, integrated into UniProtKB/TrEMBL.
DT 05-JUL-2004, sequence version 1.
DE Hypothetical protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=22398257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.P., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Ustin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
RA Whitling M., Touchman J.W., Green E.D., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickinson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalilus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RL [2]
RN NUCLEOTIDE SEQUENCE.
RP TISSUE=Glandular pool- thyroid;
RC NIH MGC Project;
RG Submitted (MAY-2005) to the EMBL/GenBank/DBJ databases.
CC
CC Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution-NoDerivs license
CC -----
DR HSP; P01837; 1KCU.
DR SNR; Q6PJF2; 21-235.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig_c1.
DR InterPro; IPR003006; Ig_MHC.
```

```
DR InterPro; IPR003596; Ig_v.
DR InterPro; IPR013106; V-set.
DR Pfam; PF07654; CI-set; 1.
DR SMART; SM00409; IG; 1.
DR SMART; SM00407; IGC1; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG_LIKE; 2.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_1.
KW Hypothetical protein.
SQ SEQUENCE 235 AA; 25521 MW; F33A145A396BA285 CRC64;

Query Match 100.0%; Score 553; DB 2; Length 235;
Best Local Similarity 100.0%; Pred. No. 1e-46;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 129 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 188

QY 61 SKDSTYSLSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 107
Db 189 SKDSTYSLSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 235

RESULT 7
Q502W4 HUMAN PRELIMINARY; PRT; 236 AA.
AC Q502W4;
DT 07-JUN-2005, integrated into UniProtKB/TrEMBL.
DT 07-JUN-2005, sequence version 1.
DT 07-FEB-2006, entry version 7.
DE IGKC protein.
GN Name=IGKC;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX TISSUE=Glandular pool- thyroid;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.P., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Ustin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
RA Whitling M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickinson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalilus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RL [2]
RN NUCLEOTIDE SEQUENCE.
RP TISSUE=Glandular pool- thyroid;
RG NIH MGC Project;
RG Submitted (MAY-2005) to the EMBL/GenBank/DBJ databases.
CC
CC Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution-NoDerivs license
CC -----
DR HSP; P01837; 1KCU.
DR SNR; Q6PJF2; 21-235.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig_c1.
DR InterPro; IPR003006; Ig_MHC.
```

```
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig cl.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; Cl-set; 1.
DR SMART; SM00409; IGV; 1.
DR SMART; SM00407; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 2.
DR PROSITE; PS00290; IG_MHC; UNKNOWN 1.
SQ SEQUENCE 236 AA; 25936 MW; E2DF79AC18756AA9 CRC64;

Query Match 100.0%; Score 553; DB 2; Length 236;
Best Local Similarity 100.0%; Pred. No. 1e-46;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 130 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 189

QY 61 SKDSTYSLSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 107
Db 190 SKDSTYSLSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 236

RESULT 8
Q6GMW1 HUMAN
ID Q6GMW1_HUMAN PRELIMINARY; PRT; 236 AA.
AC Q6GMW1.
DT 19-JUL-2004, integrated into UniProtKB/TrEMBL.
DT 19-JUL-2004, sequence version 1.
DT 07-FEB-2006, entry version 17.
DE IGKC protein.
GN Name=IGKC;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Spleen;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner K.H., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M.J., Ustin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Casavant T.L., Scheetz T.E.,
RA Brownstein M., Soares M.B., Bonaldo M.F., Abramson R.D., Mullany S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs S.W.,
RA Fahey J., Helton E., Kettaman M., Madan A., Rodrigues S., Sanchez A.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalka U., Smailus D.E.,
RA Schnurch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RL proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Spleen;
RG NIH MGC Project;
RL Submitted (JUN-2004) to the EMBL/GenBank/DBJ databases.
CC Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution-NoDerivs License
CC
```

```
DR EMBL; BC073791; AAH73791.1; -, mRNA.
DR SMR; Q6GMW1; 24-236.
DR Ensemble; ENSG00000163245; Homo sapiens.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig-cl.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; Cl-set; 1.
DR SMART; SM00409; IGV; 1.
DR SMART; SM00407; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 2.
DR PROSITE; PS00290; IG_MHC; UNKNOWN 1.
SQ SEQUENCE 236 AA; 25751 MW; 5BF6A087AFAC437 CRC64;

Query Match 100.0%; Score 553; DB 2; Length 236;
Best Local Similarity 100.0%; Pred. No. 1e-46;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 130 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 189

QY 61 SKDSTYSLSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 107
Db 190 SKDSTYSLSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 236

RESULT 9
Q6GMW0 HUMAN
ID Q6GMW0_HUMAN PRELIMINARY; PRT; 236 AA.
AC Q6GMW0.
DT 19-JUL-2004, integrated into UniProtKB/TrEMBL.
DT 19-JUL-2004, sequence version 1.
DT 07-FEB-2006, entry version 16.
DE Hypothetical protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Spleen;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner K.H., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M.J., Ustin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Casavant T.L., Scheetz T.E.,
RA Brownstein M., Soares M.B., Bonaldo M.F., Abramson R.D., Mullany S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs S.W.,
RA Fahey J., Helton E., Kettaman M., Madan A., Rodrigues S., Sanchez A.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalka U., Smailus D.E.,
RA Schnurch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "generation and initial analysis of more than 15,000 full-length human
RL proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Spleen;
RG NIH MGC Project;
RL Submitted (JUN-2004) to the EMBL/GenBank/DBJ databases.
CC Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution-NoDerivs License
CC
```

CC Copyrighted by the UniProt Consortium, see <http://www.uniprot.org/terms>
CC Distributed under the Creative Commons Attribution-NoDerivs License
CC -----
DR ENBL; BC073775; AAH73775.1; -; mRNA.
DR SMR; Q6GMX0; 23-236.
DR Ensembl; ENSG00000163245; Homo sapiens.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig-cl.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; C1-set; 1.
DR SMART; SM00409; IG; 1.
DR SMART; SM00407; IGcl; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG_LIKE; 2.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_1.
KW Hypothetical protein.
SQ SEQUENCE 236 AA; 25807 MW; 864EA08C7E92BF8F CRC64;

Query Match 100.0%; Score 553; DB 2; Length 236;
Best Local Similarity 100.0%; Pred. No. 1e-46;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db |||||
QY 130 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 189
Db |||||

QY 61 SKDSTYSLSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 107
Db |||||
QY 190 SKDSTYSLSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 236
Db |||||

RESULT 10
Q6GMX8 HUMAN
ID Q6GMX8 HUMAN PRELIMINARY; PRT; 236 AA.
AC Q6GMX8;
DT 19-JUL-2004, integrated into UniProtKB/TrEMBL.
DT 19-JUL-2004, sequence version 1.
DT 07-FEB-2006, entry version 17.
DE IGKC protein.
GN Name=IGKC;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Primary B-Cells;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettaman M., Madan A., Rodrigues S., Sanchez A.,
RA Whitling M., Madan A.C., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalilus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]

RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Primary B-Cells;
RG NIH MGC Project;
RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
CC -----
CC Copyrighted by the UniProt Consortium, see <http://www.uniprot.org/terms>
CC Distributed under the Creative Commons Attribution-NoDerivs License
CC -----
DR ENBL; BC073764; AAH73764.1; -; mRNA.
DR SMR; Q6GMX8; 24-235.
DR Ensembl; ENSG00000163245; Homo sapiens.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig-cl.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; C1-set; 1.
DR SMART; SM00409; IG; 1.
DR SMART; SM00407; IGcl; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG_LIKE; 2.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_1.
SQ SEQUENCE 236 AA; 25707 MW; 4FC6E14B6559EFC9 CRC64;

Query Match 100.0%; Score 553; DB 2; Length 236;
Best Local Similarity 100.0%; Pred. No. 1e-46;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db |||||
QY 130 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 189
Db |||||

QY 61 SKDSTYSLSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 107
Db |||||
QY 190 SKDSTYSLSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 236
Db |||||

RESULT 11
Q6GMX9 HUMAN
ID Q6GMX9 HUMAN PRELIMINARY; PRT; 236 AA.
AC Q6GMX9;
DT 19-JUL-2004, integrated into UniProtKB/TrEMBL.
DT 19-JUL-2004, sequence version 1.
DT 07-FEB-2006, entry version 17.
DE IGKC protein.
GN Name=IGKC;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Primary B-Cells;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Udell T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettaman M., Madan A., Rodrigues S., Sanchez A.,
RA Whitling M., Madan A.C., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalilus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;

RT "Generation and initial analysis of more than 15,000 full-length human
 RL and mouse cDNA sequences.";
 RN Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).

RP [2]
 RC NUCLEOTIDE SEQUENCE
 RG NIH MGC Project;
 RL Submitted (JUN-2004) to the EMBL/GenBank/DBJ databases.

CC Copyrighted by the Uniprot Consortium, see <http://www.uniprot.org/terms>
 CC Distributed under the Creative Commons Attribution-NoDerivs License

CC -----
 CC EMBL; BC073763; AAH73763.1; -; mRNA.
 DR SMR; Q6GMX9; 23-236.

DR Ensembl; ENSG0000163245; Homo sapiens.
 DR InterPro; IPR003599; Ig.

DR InterPro; IPR007110; Ig-like.

DR InterPro; IPR003597; Ig-cl.

DR InterPro; IPR003006; Ig_MHC.

DR InterPro; IPR013106; V-set.

DR Pfam; PF07654; Cl-set; 1.

DR SMART; SM00409; IG; 1.

DR SMART; SM00407; IGcl; 1.

DR SMART; SM00406; IGV; 1.

DR PROSITE; PSS0835; IG LIKE; 2.

DR PROSITE; PS00290; IG_MHC; UNKNOWN 1.

DR PROSITE; PS00290; IG_MHC; UNKNOWN 1.

SQ SEQUENCE 236 AA; 25924 MW; FDE2093DC560CF77 CRC64;

Query Match 100.0%; Score 553; DB 2; Length 236;

Best Local Similarity 100.0%; Pred. No. 1e-46;

Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 RTVAAPSVFIFPPSDEQKSGTASVCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60

130 RTVAAPSVFIFPPSDEQKSGTASVCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 189

61 SKDSTYSLSTLTLSKADYKHKYACEVTHQGLSSPVTKSFNRGEC 107

190 SKDSTYSLSTLTLSKADYKHKYACEVTHQGLSSPVTKSFNRGEC 236

RESULT 12

Q6P5S8 HUMAN

ID Q6P5S8 HUMAN PRELIMINARY; PRT; 236 AA.

AC Q6P5S8;

DT 05-JUL-2004, integrated into UniProtKB/TrEMBL.

DT 05-JUL-2004, sequence version 15.

DT 07-FEB-2006, entry version 15.

DE Hypothetical protein.

OS Homo sapiens (Human).

OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;

OC Homo.

OC NCBI_TaxID=9606;

OX [1]

RN NUCLEOTIDE SEQUENCE.

RP TISSUE=Glandular pool- thyroid;

RC MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;

RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,

RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,

RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,

RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,

RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,

RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,

RA Brownstein M.J., Udell T.B., Toshiyuki S., Carninci P., Prange C.,

RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,

RA Bosak S.A., McSwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,

RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,

RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,

RA Fahey J., Helton E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,

RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bonifard G.G.,

RA Blakesley R.W., Touchman J.W., Green E.D., Dickinson M.C.,

RA Rodriguez A.C., Grimwood J., Schmutz J., Schmutz J., Myers R.M.,
 RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
 RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
 RT "Generation and initial analysis of more than 15,000 full-length human
 and mouse cDNA sequences.";
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).

RN [2]

RP NUCLEOTIDE SEQUENCE.

RC TISSUE=Glandular pool- thyroid;

RA Strausberg R.;

RL Submitted (NOV-2003) to the EMBL/GenBank/DBJ databases.

CC -----

CC Copyrighted by the Uniprot Consortium, see <http://www.uniprot.org/terms>

CC Distributed under the Creative Commons Attribution-NoDerivs License

CC -----

CC EMBL; BC062704; AAH62704.1; -; mRNA.

DR HSSP; P01837; 1KCU

DR SMR; Q6P5S8; 21-236.

DR InterPro; IPR003599; Ig.

DR InterPro; IPR007110; Ig-like.

DR InterPro; IPR003597; Ig-cl.

DR InterPro; IPR003006; Ig_MHC.

DR InterPro; IPR003596; IGV.

DR InterPro; IPR013106; V-set.

DR Pfam; PF07654; Cl-set; 1.

DR SMART; SM00409; IG; 1.

DR SMART; SM00407; IGcl; 1.

DR SMART; SM00406; IGV; 1.

DR PROSITE; PSS0835; IG LIKE; 2.

DR PROSITE; PS00290; IG_MHC; UNKNOWN_1.

DR PROSITE; PS00290; IG_MHC; UNKNOWN_1.

KW Hypothetical protein.

SQ SEQUENCE 236 AA; 25773 MW; 953E37BEB4FF5F27 CRC64;

Query Match 100.0%; Score 553; DB 2; Length 236;

Best Local Similarity 100.0%; Pred. No. 1e-46;

Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 RTVAAPSVFIFPPSDEQKSGTASVCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60

130 RTVAAPSVFIFPPSDEQKSGTASVCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 189

61 SKDSTYSLSTLTLSKADYKHKYACEVTHQGLSSPVTKSFNRGEC 107

190 SKDSTYSLSTLTLSKADYKHKYACEVTHQGLSSPVTKSFNRGEC 236

RESULT 13

Q6PIH4 HUMAN

ID Q6PIH4 HUMAN PRELIMINARY; PRT; 236 AA.

AC Q6PIH4;

DT 05-JUL-2004, integrated into UniProtKB/TrEMBL.

DT 05-JUL-2004, sequence version 1.

DT 07-FEB-2006, entry version 16.

DE Hypothetical protein.

OS Homo sapiens (Human).

OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;

OC Homo.

OC NCBI_TaxID=9606;

OX [1]

RN NUCLEOTIDE SEQUENCE.

RC MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;

RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,

RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,

RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,

RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,

RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,

RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,

RA Brownstein M.J., Udell T.B., Toshiyuki S., Carninci P., Prange C.,

RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,

RA Bosak S.A., McSwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,

RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,

RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettelman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakeley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.,
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Lung;
RG Strauberg R.;
RL Submitted (JUL-2002) to the EMBL/GenBank/DBJ databases.
CC -----
CC Copyrighted by the UniProt Consortium, see <http://www.uniprot.org/terms>
CC Distributed under the Creative Commons Attribution-NoDerivs License
CC -----
DR EMBL; BC034146; AAH34146.1; -; mRNA.
DR HSSP; P01607; IAR2.
DR SMR; O6PIH4; 23-236.
DR Ensembl; ENSG00000163245; Homo sapiens.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig cl.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; Cl-set; 1.
DR SMART; SM00409; IG; 1.
DR SMART; SM00407; IGcl; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG_LIKE; 2.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_1.
KW Hypothetical protein.
SQ SEQUENCE 236 AA; BE01A28CD06EE26 CRC64;

Query Match 100.0%; Score 553; DB 2; Length 236;
Best Local Similarity 100.0%; Pred. No. 1e-46;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 130 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 189

QY 61 SKDSTYSLSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 107
Db 190 SKDSTYSLSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 236

RESULT 14
ID Q6PIH7 HUMAN PRELIMINARY; PRT; 236 AA.
AC Q6PIH7;
DT 05-JUL-2004, integrated into UniProtKB/TrEMBL.
DT 05-JUL-2004, sequence version 1.
DT 07-FEB-2006, entry version 17.
DE IGKC protein.
GN Name=IGKC;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Lung;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.2426038999;
RA Strauberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,

RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Donald M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Udwin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettelman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakeley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.,
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Lung;
RG NIH MGC Project;
RL Submitted (JUL-2002) to the EMBL/GenBank/DBJ databases.
CC -----
CC Copyrighted by the UniProt Consortium, see <http://www.uniprot.org/terms>
CC Distributed under the Creative Commons Attribution-NoDerivs License
CC -----
DR EMBL; BC034141; AAH34141.1; -; mRNA.
DR HSSP; P01607; IAR2.
DR SMR; O6PIH7; 23-236.
DR Ensembl; ENSG00000163245; Homo sapiens.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig cl.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; Cl-set; 1.
DR SMART; SM00409; IG; 1.
DR SMART; SM00407; IGcl; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG_LIKE; 2.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_1.
SQ SEQUENCE 236 AA; 8BC561106861213F CRC64;

Query Match 100.0%; Score 553; DB 2; Length 236;
Best Local Similarity 100.0%; Pred. No. 1e-46;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 130 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 189

QY 61 SKDSTYSLSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 107
Db 190 SKDSTYSLSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 236

RESULT 15
ID Q6PIL8 HUMAN PRELIMINARY; PRT; 236 AA.
AC Q6PIL8;
DT 05-JUL-2004, integrated into UniProtKB/TrEMBL.
DT 05-JUL-2004, sequence version 1.
DT 07-FEB-2006, entry version 15.
DE Hypothetical protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Brain;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.2426038999;

RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner K.H., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.P., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Udén T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahy J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
RA Whitting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Brain;
RA Strausberg R.;
RL Submitted (JUN-2002) to the EMBL/GenBank/DBJ databases.
CC -----
CC Copyrighted by the UniProt Consortium, see <http://www.uniprot.org/terms>
CC Distributed under the Creative Commons Attribution-NoDerivs License
CC -----
DR EMBL; BC032451; AAH32451.1; -; mRNA.
DR HSSP; P01837; IKCU.
DR SNR; Q6PIL8; 21-236.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig cl.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR InterPro; IPR013106; V-set.
DR Pfam; PF07654; C1-set; 1.
DR SMART; SM00409; IG; 1.
DR SMART; SM00407; IGcl; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PSS0835; IG_LIKE; 2.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_1.
KW Hypothetical protein.
SQ SEQUENCE 236 AA; 25834 MW; 6647A9E77A3C0053 CRC64;

Query Match 100.0%; Score 553; DB 2; Length 236;
Best Local Similarity 100.0%; Pred. No. 1e-46;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVLNNFYPREAKVQWKVDNALQGNLSQESVTEQD 60
DB |||||
130 RTVAAPSVFIFPPSDEQLKSGTASVVLNNFYPREAKVQWKVDNALQGNLSQESVTEQD 189
|||

QY 61 SKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 107
DB |||||
190 SKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 236
|||

Search completed: June 10, 2006, 12:05:26
Job time : 90.042 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.9
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: June 10, 2006, 12:05:52 ; Search time 18.476 Seconds
(without alignments)
506.917 Million cell updates/sec

Title: US-10-733-563-112

Perfect score: 553

Sequence: 1 RTVAAPSVFIFFPSDEQLKLS.....EVTHOGLSSPVTKSFRNGEC 107

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 650591 seqs, 87530628 residues

Total number of hits satisfying chosen parameters: 650591

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued Patents:AA:*

1: /EMC_Celerra_SIDS3/ptodata/2/iaa/5 COMB.pdp:*
2: /EMC_Celerra_SIDS3/ptodata/2/iaa/6 COMB.pdp:*
3: /EMC_Celerra_SIDS3/ptodata/2/iaa/7 COMB.pdp:*
4: /EMC_Celerra_SIDS3/ptodata/2/iaa/H COMB.pdp:*
5: /EMC_Celerra_SIDS3/ptodata/2/iaa/PTUS COMB.pdp:*
6: /EMC_Celerra_SIDS3/ptodata/2/iaa/RE COMB.pdp:*
7: /EMC_Celerra_SIDS3/ptodata/2/iaa/backfiles1.pdp:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
1	553	100.0	107	1	US-08-422-101-8
2	553	100.0	107	1	US-08-422-091-8
3	553	100.0	107	1	US-08-422-092-8
4	553	100.0	107	1	US-08-788-800-5
5	553	100.0	107	2	US-08-422-093-8
6	553	100.0	107	2	US-08-422-112-8
7	553	100.0	107	2	US-09-301-593-20
8	553	100.0	107	2	US-09-628-568A-8
9	553	100.0	212	2	US-10-011-125A-5
10	553	100.0	213	2	US-08-630-820-6
11	553	100.0	213	2	US-08-397-411-12
12	553	100.0	213	2	US-09-273-453-6
13	553	100.0	213	2	US-09-996-288-209
14	553	100.0	213	2	US-09-996-288-211
15	553	100.0	213	2	US-09-996-288-213
16	553	100.0	213	2	US-09-996-288-215
17	553	100.0	213	2	US-09-996-288-217
18	553	100.0	213	2	US-09-996-288-219
19	553	100.0	213	2	US-09-996-288-221
20	553	100.0	213	2	US-09-996-288-223
21	553	100.0	213	2	US-09-996-288-225
22	553	100.0	213	2	US-09-996-288-227
23	553	100.0	213	2	US-09-996-288-229
24	553	100.0	213	2	US-09-996-288-231
25	553	100.0	213	2	US-09-996-288-233
26	553	100.0	213	2	US-09-996-288-235

27	553	100.0	213	2	US-09-996-288-237	Sequence 237, App
28	553	100.0	213	2	US-09-996-288-239	Sequence 239, App
29	553	100.0	213	2	US-09-996-288-241	Sequence 241, App
30	553	100.0	213	2	US-09-996-288-243	Sequence 243, App
31	553	100.0	213	2	US-09-996-288-245	Sequence 245, App
32	553	100.0	213	2	US-09-996-288-247	Sequence 247, App
33	553	100.0	213	2	US-09-996-288-251	Sequence 251, App
34	553	100.0	213	2	US-09-996-288-253	Sequence 253, App
35	553	100.0	213	2	US-09-996-288-255	Sequence 255, App
36	553	100.0	213	2	US-09-996-288-257	Sequence 257, App
37	553	100.0	213	2	US-09-996-265-209	Sequence 209, App
38	553	100.0	213	2	US-09-996-265-211	Sequence 211, App
39	553	100.0	213	2	US-09-996-265-213	Sequence 213, App
40	553	100.0	213	2	US-09-996-265-215	Sequence 215, App
41	553	100.0	213	2	US-09-996-265-217	Sequence 217, App
42	553	100.0	213	2	US-09-996-265-219	Sequence 219, App
43	553	100.0	213	2	US-09-996-265-221	Sequence 221, App
44	553	100.0	213	2	US-09-996-265-223	Sequence 223, App
45	553	100.0	213	2	US-09-996-265-225	Sequence 225, App

ALIGNMENTS

RESULT 1
US-08-422-101-8
; Sequence 8, Application US/08422101
; Patent No. 5739277
; GENERAL INFORMATION:
; APPLICANT: Leonard Presta
; APPLICANT: Brad Snedecor
; TITLE OF INVENTION: Altered Polypeptides with Increased
; TITLE OF INVENTION: Half-Life
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.
; STREET: 460 point San Bruno Blvd
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: patin (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/422,101
; FILING DATE: 14-APR-1995
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Lee, Wendy M.
; REGISTRATION NUMBER:
; REFERENCE/DOCKET NUMBER: 932-3
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415/225-1994
; TELEFAX: 415/952-9881
; TELEX: 910/371-7168
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 107 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; US-08-422-101-8

Query Match 100.0%; Score 553; DB 1; Length 107;
Best Local Similarity 100.0%; Pred. No. 6.3e-57;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIFFPSDEQLKSGTASVVLNNFPYBREAKVQWKVDNALQSGNSQESVTEQD 60

Db 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNFPYKQWKVDNALQSGNSQESVTEQD 60
QY 61 SKDSTYLSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 107
Db 61 SKDSTYLSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 107

RESULT 2

US-08-422-091-8
; Sequence 8, Application US/08422091
; Patent No. 5747035
; GENERAL INFORMATION:
; APPLICANT: Leonard Presta
; TITLE OF INVENTION: Altered Polypeptides with Increased
; TITLE OF INVENTION: Half-Life
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.
; STREET: 460 Point San Bruno Blvd
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: patin (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/422,091
; FILING DATE: 14-APR-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Lee, Wendy M.
; REGISTRATION NUMBER:
; REFERENCE/DOCKET NUMBER: 932-6
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415/225-1994
; TELEFAX: 415/952-9881
; TELEX: 910/371-7168
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 107 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
US-08-422-091-8

Query Match 100.0%; Score 553; DB 1; Length 107;
Best Local Similarity 100.0%; Pred. No. 6.3e-57;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNFPYKQWKVDNALQSGNSQESVTEQD 60
Db 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNFPYKQWKVDNALQSGNSQESVTEQD 60
QY 61 SKDSTYLSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 107
Db 61 SKDSTYLSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 107

RESULT 3

US-08-422-092-8
; Sequence 8, Application US/08422092
; Patent No. 5869046
; GENERAL INFORMATION:
; APPLICANT: Leonard Presta
; TITLE OF INVENTION: Altered Polypeptides with Increased

; TITLE OF INVENTION: Half-Life
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.
; STREET: 460 Point San Bruno Blvd
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: patin (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/422,092
; FILING DATE: 14-APR-1995
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Lee, Wendy M.
; REGISTRATION NUMBER:
; REFERENCE/DOCKET NUMBER: 932-4
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415/225-1994
; TELEFAX: 415/952-9881
; TELEX: 910/371-7168
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 107 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
US-08-422-092-8

Query Match 100.0%; Score 553; DB 1; Length 107;
Best Local Similarity 100.0%; Pred. No. 6.3e-57;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNFPYKQWKVDNALQSGNSQESVTEQD 60
Db 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNFPYKQWKVDNALQSGNSQESVTEQD 60
QY 61 SKDSTYLSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 107
Db 61 SKDSTYLSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 107

RESULT 4

US-08-788-800-5
; Sequence 5, Application US/08788800
; Patent No. 5914112
; GENERAL INFORMATION:
; APPLICANT: Bednar, Martin M.
; APPLICANT: Thomas, G. Roger
; APPLICANT: Gross, Cordell E.
; TITLE OF INVENTION: ANTI-CD18 ANTIBODIES IN STROKE
; NUMBER OF SEQUENCES: 15
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.
; STREET: 460 Point San Bruno Blvd
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: winPatin (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/788,800

```

Query Match      100.0%; Score 553; DB 2; Length 107;
Best Local Similarity 100.0%; Pred. No. 6.3e-57;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 RTVAAPSVFIFPPSDQLKSGTASVVCLLNNFYPRAKQVKVDNALQSGNSQESVTEQD 60
Db      1 RTVAAPSVFIFPPSDQLKSGTASVVCLLNNFYPRAKQVKVDNALQSGNSQESVTEQD 60

Qy      61 SKDSTVSLSTLTLSKADYEKKHYKVIACEVTHQGLSSPVTKSFNRGEC 107
Db      61 SKDSTVSLSTLTLSKADYEKKHYKVIACEVTHQGLSSPVTKSFNRGEC 107

RESULT 6
US-08-422-112-8
; Sequence 8, Application US/08422112
; Patent No. 6121022
; GENERAL INFORMATION:
; APPLICANT: Leonard Presta
; APPLICANT: Brad Snedecor
; TITLE OF INVENTION: Altered Polypeptides with Increased
; TITLE OF INVENTION: Half-Life
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.
; STREET: 460 Point San Bruno Blvd
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: patin (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/422,112
; FILING DATE: 14-APR-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Lee, Wendy M.
; REGISTRATION NUMBER:
; REFERENCE/DOCKET NUMBER: 932-1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415/225-1994
; TELEFAX: 415/952-9881
; TELEX: 910/371-7168
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 107 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
;
US-08-422-112-8

Query Match      100.0%; Score 553; DB 2; Length 107;
Best Local Similarity 100.0%; Pred. No. 6.3e-57;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 RTVAAPSVFIFPPSDQLKSGTASVVCLLNNFYPRAKQVKVDNALQSGNSQESVTEQD 60
Db      1 RTVAAPSVFIFPPSDQLKSGTASVVCLLNNFYPRAKQVKVDNALQSGNSQESVTEQD 60

Qy      61 SKDSTVSLSTLTLSKADYEKKHYKVIACEVTHQGLSSPVTKSFNRGEC 107
Db      61 SKDSTVSLSTLTLSKADYEKKHYKVIACEVTHQGLSSPVTKSFNRGEC 107

RESULT 7
US-09-301-593-20

```

```
; Sequence 20, Application US/09301593A
; Patent No. 6455677
; GENERAL INFORMATION:
; APPLICANT: Park, John E.
; APPLICANT: Garin-Chesa, Pilar
; APPLICANT: Bamberger, Uwe
; APPLICANT: Legier, Olivier
; APPLICANT: Saldanha, Jose W.
; APPLICANT: Rettig, Wolfgang J.
; TITLE OF INVENTION: FAP-specific Antibody with Improved Producibility
; FILE REFERENCE: 0652.1890001
; CURRENT APPLICATION NUMBER: US/09/301,593A
; CURRENT FILING DATE: 1999-04-29
; EARLIER APPLICATION NUMBER: EP 98107925.4
; EARLIER FILING DATE: 1998-04-30
; EARLIER APPLICATION NUMBER: US 60/086,049
; EARLIER FILING DATE: 1998-05-18
; NUMBER OF SEQ ID NOS: 108
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 20
; LENGTH: 107
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-301-593-20

Query Match      100.0%; Score 553; DB 2; Length 107;
Best Local Similarity 100.0%; Pred. No. 6.3e-57;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60

QY 61 SKDSTYSLSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 107
Db 61 SKDSTYSLSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 107

RESULT 8
US-09-628-568A-8
; Sequence 8, Application US/09628568A
; Patent No. 6998253
; GENERAL INFORMATION:
; APPLICANT: Presta, Leonard G.
; APPLICANT: Snedecox, Bradley R.
; TITLE OF INVENTION: ALTERED POLYPEPTIDES WITH INCREASED HALF-LIFE
; FILE REFERENCE: 11669.161USC1
; CURRENT APPLICATION NUMBER: US/09/628,568A
; CURRENT FILING DATE: 2000-07-31
; PRIOR APPLICATION NUMBER: US 08/422,112
; PRIOR FILING DATE: 1995-04-14
; NUMBER OF SEQ ID NOS: 31
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 8
; LENGTH: 107
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-628-568A-8

Query Match      100.0%; Score 553; DB 2; Length 107;
Best Local Similarity 100.0%; Pred. No. 6.3e-57;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60

QY 61 SKDSTYSLSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 107
Db 61 SKDSTYSLSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 107

RESULT 9
```

```
US-10-011-125A-5
; Sequence 5, Application US/10011125A
; Patent No. 6828121
; GENERAL INFORMATION:
; APPLICANT: Chen, Christina Yu-Ching
; TITLE OF INVENTION: BACTERIAL HOST STRAINS
; FILE REFERENCE: P1804R1
; CURRENT APPLICATION NUMBER: US/10/011,125A
; CURRENT FILING DATE: 2001-12-07
; PRIOR APPLICATION NUMBER: US 60/256,162
; PRIOR FILING DATE: 2000-12-14
; NUMBER OF SEQ ID NOS: 12
; SEQ ID NO 5
; LENGTH: 212
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Sequence is synthesized.
; Patent No. 6828121
US-10-011-125A-5

Query Match      100.0%; Score 553; DB 2; Length 212;
Best Local Similarity 100.0%; Pred. No. 1.6e-56;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 106 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 165

QY 61 SKDSTYSLSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 107
Db 166 SKDSTYSLSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 212

RESULT 10
US-08-630-820-6
; Sequence 6, Application US/08630820
; Patent No. 6008023
; GENERAL INFORMATION:
; APPLICANT: Oppen, Martin
; APPLICANT: Bosslet, Klaus
; APPLICANT: Czech, Joerg
; TITLE OF INVENTION: CYTOPLASMIC EXPRESSION OF ANTIBODIES.
; TITLE OF INVENTION: ANTIBODY FRAGMENTS AND ANTIBODY FRAGMENT FUSION MOLECULES
; TITLE OF INVENTION: IN E. COLI
; NUMBER OF SEQUENCES: 7
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Foley & Lardner
; STREET: 3000 K Street, N.W., Suite 500
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20007-5109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/630,820
; FILING DATE: 10-APR-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: DE 19513676.4
; FILING DATE: 11-APR-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: GRANADOS, Patricia D.
; REGISTRATION NUMBER: 33,683
; REFERENCE/DOCKET NUMBER: 18748/306
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202)672-5300
; TELEFAX: (202)672-5399
; TELEX: 904136
; INFORMATION FOR SEQ ID NO: 6:
```


; SEQUENCE CHARACTERISTICS:
; LENGTH: 213 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-630-820-6

Query Match 100.0%; Score 553; DB 2; Length 213;
Best Local Similarity 100.0%; Pred. No. 1.6e-56;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
|
Db 107 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166
|
Qy 61 SKDSTYLSSTLTLSKADYKHKYKVVACEVTHQGLSSPVTKSFNRGEC 107
|
Db 167 SKDSTYLSSTLTLSKADYKHKYKVVACEVTHQGLSSPVTKSFNRGEC 213
|

RESULT 11
US-08-397-411-12
; Sequence 12, Application US/08397411
; Patent No. 6129914
; GENERAL INFORMATION:
; APPLICANT: Weiner, George
; APPLICANT: Gingrich, Roger
; APPLICANT: Link, Brian
; APPLICANT: Tso, J. Yun
; TITLE OF INVENTION: Bispecific Antibody Effective to Treat
; TITLE OF INVENTION: B-Cell Lymphoma and Cell Line
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew
; STREET: One Market Plaza, Steuart Tower, Suite 2000
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/397,411
; FILING DATE: 01-MAR-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/859,583
; FILING DATE: 27-MAR-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Smith, William M.
; REGISTRATION NUMBER: 30,223
; REFERENCE/DOCKET NUMBER: 011823-004901
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-326-2400
; TELEFAX: 415-326-2422
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 213 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-397-411-12

Query Match 100.0%; Score 553; DB 2; Length 213;
Best Local Similarity 100.0%; Pred. No. 1.6e-56;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
|
Db 107 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166
|
Qy 61 SKDSTYLSSTLTLSKADYKHKYKVVACEVTHQGLSSPVTKSFNRGEC 107
|
Db 167 SKDSTYLSSTLTLSKADYKHKYKVVACEVTHQGLSSPVTKSFNRGEC 213
|

RESULT 12
US-09-273-453-6
; Sequence 6, Application US/09273453
; Patent No. 6602688
; GENERAL INFORMATION:
; APPLICANT: Oppen, Martin
; APPLICANT: Bosslet, Klaus
; APPLICANT: Czech, Joerg
; TITLE OF INVENTION: CYTOLASMIC EXPRESSION OF ANTIBODIES,
; ANTIBODY FRAGMENTS AND ANTIBODY FRAGMENT FUSION MOLECULES
; IN E. COLI
; NUMBER OF SEQUENCES: 7
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Foley & Lardner
; STREET: 3000 K Street, N.W., Suite 500
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20007-5109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/273,453
; FILING DATE: 22-MAR-1999
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/630,820
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: GRANADOS, Patricia D.
; REGISTRATION NUMBER: 33,683
; REFERENCE/DOCKET NUMBER: 18748/306
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202)672-5300
; TELEFAX: (202)672-5399
; TELEX: 904136
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 213 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 6:
US-09-273-453-6

Query Match 100.0%; Score 553; DB 2; Length 213;
Best Local Similarity 100.0%; Pred. No. 1.6e-56;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
|
Db 107 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166
|
Qy 61 SKDSTYLSSTLTLSKADYKHKYKVVACEVTHQGLSSPVTKSFNRGEC 107
|
Db 167 SKDSTYLSSTLTLSKADYKHKYKVVACEVTHQGLSSPVTKSFNRGEC 213
|

RESULT 13
US-09-996-288-209
; Sequence 209, Application US/09996288
; Patent No. 6818216
; GENERAL INFORMATION:
; APPLICANT: Young, James

```
; APPLICANT: Scott, Koenig
; APPLICANT: Leslie, Johnson
; TITLE OF INVENTION: Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxis
; FILE REFERENCE: 10271-047-999
; CURRENT APPLICATION NUMBER: US/09/996,288
; CURRENT FILING DATE: 2001-11-28
; NUMBER OF SEQ ID NOS: 259
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 209
; LENGTH: 213
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-996-288-209

Query Match      100.0%; Score 553; DB 2; Length 213;
Best Local Similarity 100.0%; Pred. No. 1.6e-56;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 RTVAAPSVFIFFPPSDQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
      |||
Db      107 RTVAAPSVFIFFPPSDQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166
      |||

QY      61 SKDSTYSLSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 107
      |||
Db      167 SKDSTYSLSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 213
      |||

RESULT 14
US-09-996-288-211
; Sequence 211, Application US/09996288
; Patent No. 6818216
; GENERAL INFORMATION:
; APPLICANT: Young, James
; APPLICANT: Scott, Koenig
; APPLICANT: Leslie, Johnson
; TITLE OF INVENTION: Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxis
; FILE REFERENCE: 10271-047-999
; CURRENT APPLICATION NUMBER: US/09/996,288
; CURRENT FILING DATE: 2001-11-28
; NUMBER OF SEQ ID NOS: 259
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 211
; LENGTH: 213
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-996-288-211

Query Match      100.0%; Score 553; DB 2; Length 213;
Best Local Similarity 100.0%; Pred. No. 1.6e-56;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 RTVAAPSVFIFFPPSDQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
      |||
Db      107 RTVAAPSVFIFFPPSDQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166
      |||

QY      61 SKDSTYSLSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 107
      |||
Db      167 SKDSTYSLSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 213
      |||

RESULT 15
US-09-996-288-213
; Sequence 213, Application US/09996288
; Patent No. 6818216
; GENERAL INFORMATION:
; APPLICANT: Young, James
; APPLICANT: Scott, Koenig
; APPLICANT: Leslie, Johnson
; TITLE OF INVENTION: Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxis
; FILE REFERENCE: 10271-047-999
```

```
; CURRENT APPLICATION NUMBER: US/09/996,288
; CURRENT FILING DATE: 2001-11-28
; NUMBER OF SEQ ID NOS: 259
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 213
; LENGTH: 213
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-996-288-213

Query Match      100.0%; Score 553; DB 2; Length 213;
Best Local Similarity 100.0%; Pred. No. 1.6e-56;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 RTVAAPSVFIFFPPSDQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
      |||
Db      107 RTVAAPSVFIFFPPSDQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166
      |||

QY      61 SKDSTYSLSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 107
      |||
Db      167 SKDSTYSLSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 213
      |||

Search completed: June 10, 2006, 12:08:43
Job time : 18.476 secs
```

GenCore version 5.1.9
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: June 12, 2006, 17:10:25 ; Search time 99.6545 Seconds

(without alignments)
497.358 Million cell updates/sec

Title: US-10-733-563-112

Perfect score: 553

Sequence: 1 RTVAAPSVFIPPSDEQLKS.....EVTHQGLSSPVTKSFNRGEC 107

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2097797 seqs, 463214858 residues

Total number of hits satisfying chosen parameters: 2097797

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 1000 summaries

Database : Published Applications AA Main:

- 1: /EMC_Celerra_SIDS3/ptodata/2/pubpaa/US07_PUBCOMB.pep.*
- 2: /EMC_Celerra_SIDS3/ptodata/2/pubpaa/US08_PUBCOMB.pep.*
- 3: /EMC_Celerra_SIDS3/ptodata/2/pubpaa/US09_PUBCOMB.pep.*
- 4: /EMC_Celerra_SIDS3/ptodata/2/pubpaa/US10A_PUBCOMB.pep.*
- 5: /EMC_Celerra_SIDS3/ptodata/2/pubpaa/US10B_PUBCOMB.pep.*
- 6: /EMC_Celerra_SIDS3/ptodata/2/pubpaa/US11_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	553	100.0	107	3	US-09-301-593-20
2	553	100.0	107	3	US-09-811-384-5
3	553	100.0	107	3	US-09-990-586-97
4	553	100.0	107	3	US-09-990-586-99
5	553	100.0	107	4	US-10-121-464-18
6	553	100.0	107	4	US-10-269-805-67
7	553	100.0	107	4	US-10-159-006-20
8	553	100.0	107	4	US-10-310-113-166
9	553	100.0	107	4	US-10-310-113-168
10	553	100.0	107	4	US-10-230-880-97
11	553	100.0	107	4	US-10-230-880-99
12	553	100.0	107	4	US-10-366-709-54
13	553	100.0	107	4	US-10-404-286-5
14	553	100.0	107	4	US-10-656-769-4
15	553	100.0	107	4	US-10-679-620-60
16	553	100.0	107	4	US-10-733-563-112
17	553	100.0	107	5	US-10-815-449-10
18	553	100.0	107	5	US-10-864-957-4
19	553	100.0	107	5	US-10-886-838-8
20	553	100.0	107	5	US-10-822-300-9
21	553	100.0	107	5	US-10-687-118-9
22	553	100.0	107	5	US-10-872-932A-41
23	553	100.0	107	5	US-10-891-658-8
24	553	100.0	107	5	US-10-937-596-29
25	553	100.0	107	5	US-10-893-576-44
26	553	100.0	107	5	US-10-810-881A-40
27	553	100.0	107	5	US-10-981-936-40

28	553	100.0	107	5	US-10-993-866-40	Sequence 40, Appl
29	553	100.0	107	5	US-10-988-207-21	Sequence 21, Appl
30	553	100.0	107	5	US-10-982-440-67	Sequence 67, Appl
31	553	100.0	107	5	US-10-935-005B-71	Sequence 71, Appl
32	553	100.0	107	6	US-11-001-980-4	Sequence 4, Appl
33	553	100.0	107	6	US-11-001-980-8	Sequence 8, Appl
34	553	100.0	107	6	US-11-132-143-60	Sequence 60, Appl
35	553	100.0	107	6	US-11-102-403-23	Sequence 23, Appl
36	553	100.0	107	6	US-11-025-712-5	Sequence 5, Appl
37	553	100.0	107	6	US-11-075-351-61	Sequence 61, Appl
38	553	100.0	107	6	US-11-061-821-40	Sequence 40, Appl
39	553	100.0	107	6	US-11-102-621-9	Sequence 9, Appl
40	553	100.0	107	6	US-11-122-622-97	Sequence 97, Appl
41	553	100.0	107	6	US-11-122-622-99	Sequence 99, Appl
42	553	100.0	107	6	US-11-218-813-134	Sequence 134, Appl
43	553	100.0	107	6	US-11-149-309-18	Sequence 18, Appl
44	553	100.0	109	4	US-10-272-899A-12	Sequence 12, Appl
45	553	100.0	109	4	US-10-733-563-116	Sequence 116, Appl
46	553	100.0	110	6	US-11-024-251-27	Sequence 27, Appl
47	553	100.0	134	4	US-10-272-899A-66	Sequence 66, Appl
48	553	100.0	212	4	US-10-011-125-5	Sequence 5, Appl
49	553	100.0	212	4	US-10-320-231A-77	Sequence 77, Appl
50	553	100.0	212	5	US-10-867-506-77	Sequence 77, Appl
51	553	100.0	213	3	US-09-796-848A-38	Sequence 38, Appl
52	553	100.0	213	3	US-09-796-848A-40	Sequence 40, Appl
53	553	100.0	213	3	US-09-796-848A-42	Sequence 42, Appl
54	553	100.0	213	3	US-09-796-848A-44	Sequence 44, Appl
55	553	100.0	213	3	US-09-796-848A-46	Sequence 46, Appl
56	553	100.0	213	3	US-09-796-848A-48	Sequence 48, Appl
57	553	100.0	213	3	US-09-796-848A-50	Sequence 50, Appl
58	553	100.0	213	3	US-09-796-848A-52	Sequence 52, Appl
59	553	100.0	213	3	US-09-796-848A-54	Sequence 54, Appl
60	553	100.0	213	3	US-09-996-288-209	Sequence 209, Appl
61	553	100.0	213	3	US-09-996-288-211	Sequence 211, Appl
62	553	100.0	213	3	US-09-996-288-213	Sequence 213, Appl
63	553	100.0	213	3	US-09-996-288-215	Sequence 215, Appl
64	553	100.0	213	3	US-09-996-288-217	Sequence 217, Appl
65	553	100.0	213	3	US-09-996-288-219	Sequence 219, Appl
66	553	100.0	213	3	US-09-996-288-221	Sequence 221, Appl
67	553	100.0	213	3	US-09-996-288-223	Sequence 223, Appl
68	553	100.0	213	3	US-09-996-288-225	Sequence 225, Appl
69	553	100.0	213	3	US-09-996-288-227	Sequence 227, Appl
70	553	100.0	213	3	US-09-996-288-229	Sequence 229, Appl
71	553	100.0	213	3	US-09-996-288-231	Sequence 231, Appl
72	553	100.0	213	3	US-09-996-288-233	Sequence 233, Appl
73	553	100.0	213	3	US-09-996-288-235	Sequence 235, Appl
74	553	100.0	213	3	US-09-996-288-237	Sequence 237, Appl
75	553	100.0	213	3	US-09-996-288-239	Sequence 239, Appl
76	553	100.0	213	3	US-09-996-288-241	Sequence 241, Appl
77	553	100.0	213	3	US-09-996-288-243	Sequence 243, Appl
78	553	100.0	213	3	US-09-996-288-245	Sequence 245, Appl
79	553	100.0	213	3	US-09-996-288-247	Sequence 247, Appl
80	553	100.0	213	3	US-09-996-288-251	Sequence 251, Appl
81	553	100.0	213	3	US-09-996-288-253	Sequence 253, Appl
82	553	100.0	213	3	US-09-996-288-255	Sequence 255, Appl
83	553	100.0	213	3	US-09-996-288-257	Sequence 257, Appl
84	553	100.0	213	3	US-09-996-265-209	Sequence 209, Appl
85	553	100.0	213	3	US-09-996-265-211	Sequence 211, Appl
86	553	100.0	213	3	US-09-996-265-213	Sequence 213, Appl
87	553	100.0	213	3	US-09-996-265-215	Sequence 215, Appl
88	553	100.0	213	3	US-09-996-265-217	Sequence 217, Appl
89	553	100.0	213	3	US-09-996-265-219	Sequence 219, Appl
90	553	100.0	213	3	US-09-996-265-221	Sequence 221, Appl
91	553	100.0	213	3	US-09-996-265-223	Sequence 223, Appl
92	553	100.0	213	3	US-09-996-265-225	Sequence 225, Appl
93	553	100.0	213	3	US-09-996-265-227	Sequence 227, Appl
94	553	100.0	213	3	US-09-996-265-229	Sequence 229, Appl
95	553	100.0	213	3	US-09-996-265-231	Sequence 231, Appl
96	553	100.0	213	3	US-09-996-265-233	Sequence 233, Appl
97	553	100.0	213	3	US-09-996-265-235	Sequence 235, Appl
98	553	100.0	213	3	US-09-996-265-237	Sequence 237, Appl
99	553	100.0	213	3	US-09-996-265-239	Sequence 239, Appl
100	553	100.0	213	3	US-09-996-265-241	Sequence 241, Appl

101	553	100.0	213	3	US-09-996-265-243	Sequence 243, App	174	553	100.0	213	5	US-10-962-285-223	Sequence 223, App
102	553	100.0	213	3	US-09-996-265-245	Sequence 245, App	175	553	100.0	213	5	US-10-962-285-225	Sequence 225, App
103	553	100.0	213	3	US-09-996-265-247	Sequence 247, App	176	553	100.0	213	5	US-10-962-285-227	Sequence 227, App
104	553	100.0	213	3	US-09-996-265-251	Sequence 251, App	177	553	100.0	213	5	US-10-962-285-229	Sequence 229, App
105	553	100.0	213	3	US-09-996-265-253	Sequence 253, App	178	553	100.0	213	5	US-10-962-285-231	Sequence 231, App
106	553	100.0	213	3	US-09-996-265-255	Sequence 255, App	179	553	100.0	213	5	US-10-962-285-233	Sequence 233, App
107	553	100.0	213	3	US-09-996-285-257	Sequence 257, App	180	553	100.0	213	5	US-10-962-285-235	Sequence 235, App
108	553	100.0	213	4	US-10-135-636-7	Sequence 7, Appli	181	553	100.0	213	5	US-10-962-285-237	Sequence 237, App
109	553	100.0	213	4	US-10-150-475A-4	Sequence 4, Appli	182	553	100.0	213	5	US-10-962-285-239	Sequence 239, App
110	553	100.0	213	4	US-10-150-475A-8	Sequence 8, Appli	183	553	100.0	213	5	US-10-962-285-241	Sequence 241, App
111	553	100.0	213	4	US-10-281-479A-46	Sequence 46, Appl	184	553	100.0	213	5	US-10-962-285-243	Sequence 243, App
112	553	100.0	213	4	US-10-281-479A-73	Sequence 73, Appl	185	553	100.0	213	5	US-10-962-285-245	Sequence 245, App
113	553	100.0	213	4	US-10-281-479A-74	Sequence 74, Appl	186	553	100.0	213	5	US-10-962-285-247	Sequence 247, App
114	553	100.0	213	4	US-10-281-479A-75	Sequence 75, Appl	187	553	100.0	213	5	US-10-962-285-251	Sequence 251, App
115	553	100.0	213	4	US-10-138-727A-42	Sequence 42, Appl	188	553	100.0	213	5	US-10-962-285-253	Sequence 253, App
116	553	100.0	213	4	US-10-138-727A-42	Sequence 42, Appl	189	553	100.0	213	5	US-10-962-285-255	Sequence 255, App
117	553	100.0	213	4	US-10-275-180A-46	Sequence 46, Appl	190	553	100.0	213	5	US-10-962-285-257	Sequence 257, App
118	553	100.0	213	4	US-10-275-180A-73	Sequence 73, Appl	191	553	100.0	213	5	US-10-880-028-49	Sequence 49, Appl
119	553	100.0	213	4	US-10-275-180A-74	Sequence 74, Appl	192	553	100.0	213	5	US-10-880-320-49	Sequence 49, Appl
120	553	100.0	213	4	US-10-275-180A-75	Sequence 75, Appl	193	553	100.0	213	5	US-10-916-758-18	Sequence 18, Appl
121	553	100.0	213	4	US-10-286-132A-46	Sequence 46, Appl	194	553	100.0	213	5	US-10-403-180-209	Sequence 209, App
122	553	100.0	213	4	US-10-286-132A-73	Sequence 73, Appl	195	553	100.0	213	5	US-10-403-180-211	Sequence 211, App
123	553	100.0	213	4	US-10-286-132A-74	Sequence 74, Appl	196	553	100.0	213	5	US-10-403-180-213	Sequence 213, App
124	553	100.0	213	4	US-10-286-132A-75	Sequence 75, Appl	197	553	100.0	213	5	US-10-403-180-215	Sequence 215, App
125	553	100.0	213	4	US-10-435-299-12	Sequence 12, Appl	198	553	100.0	213	5	US-10-403-180-217	Sequence 217, App
126	553	100.0	213	4	US-10-474-832-3	Sequence 3, Appli	199	553	100.0	213	5	US-10-403-180-219	Sequence 219, App
127	553	100.0	213	4	US-10-704-522-4	Sequence 4, Appli	200	553	100.0	213	5	US-10-403-180-221	Sequence 221, App
128	553	100.0	213	4	US-10-645-215-4	Sequence 4, Appli	201	553	100.0	213	5	US-10-403-180-223	Sequence 223, App
129	553	100.0	213	4	US-10-645-215-8	Sequence 8, Appli	202	553	100.0	213	5	US-10-403-180-225	Sequence 225, App
130	553	100.0	213	4	US-10-818-765-3	Sequence 3, Appli	203	553	100.0	213	5	US-10-403-180-227	Sequence 227, App
131	553	100.0	213	5	US-10-900-230-209	Sequence 209, App	204	553	100.0	213	5	US-10-403-180-229	Sequence 229, App
132	553	100.0	213	5	US-10-900-230-211	Sequence 211, App	205	553	100.0	213	5	US-10-403-180-231	Sequence 231, App
133	553	100.0	213	5	US-10-900-230-213	Sequence 213, App	206	553	100.0	213	5	US-10-403-180-233	Sequence 233, App
134	553	100.0	213	5	US-10-900-230-215	Sequence 215, App	207	553	100.0	213	5	US-10-403-180-235	Sequence 235, App
135	553	100.0	213	5	US-10-900-230-217	Sequence 217, App	208	553	100.0	213	5	US-10-403-180-237	Sequence 237, App
136	553	100.0	213	5	US-10-900-230-219	Sequence 219, App	209	553	100.0	213	5	US-10-403-180-239	Sequence 239, App
137	553	100.0	213	5	US-10-900-230-221	Sequence 221, App	210	553	100.0	213	5	US-10-403-180-241	Sequence 241, App
138	553	100.0	213	5	US-10-900-230-223	Sequence 223, App	211	553	100.0	213	5	US-10-403-180-243	Sequence 243, App
139	553	100.0	213	5	US-10-900-230-225	Sequence 225, App	212	553	100.0	213	5	US-10-403-180-245	Sequence 245, App
140	553	100.0	213	5	US-10-900-230-227	Sequence 227, App	213	553	100.0	213	5	US-10-403-180-247	Sequence 247, App
141	553	100.0	213	5	US-10-900-230-229	Sequence 229, App	214	553	100.0	213	5	US-10-403-180-251	Sequence 251, App
142	553	100.0	213	5	US-10-900-230-231	Sequence 231, App	215	553	100.0	213	5	US-10-403-180-253	Sequence 253, App
143	553	100.0	213	5	US-10-900-230-233	Sequence 233, App	216	553	100.0	213	5	US-10-403-180-255	Sequence 255, App
144	553	100.0	213	5	US-10-900-230-235	Sequence 235, App	217	553	100.0	213	5	US-10-403-180-257	Sequence 257, App
145	553	100.0	213	5	US-10-900-230-237	Sequence 237, App	218	553	100.0	213	6	US-11-021-874-15	Sequence 15, Appl
146	553	100.0	213	5	US-10-900-230-239	Sequence 239, App	219	553	100.0	213	6	US-11-021-874-18	Sequence 18, Appl
147	553	100.0	213	5	US-10-900-230-241	Sequence 241, App	220	553	100.0	213	6	US-11-021-874-19	Sequence 19, Appl
148	553	100.0	213	5	US-10-900-230-243	Sequence 243, App	221	553	100.0	213	6	US-11-021-874-21	Sequence 21, Appl
149	553	100.0	213	5	US-10-900-230-245	Sequence 245, App	222	553	100.0	213	6	US-11-005-677-3	Sequence 3, Appli
150	553	100.0	213	5	US-10-900-230-247	Sequence 247, App	223	553	100.0	213	6	US-11-006-136-3	Sequence 3, Appli
151	553	100.0	213	5	US-10-900-230-251	Sequence 251, App	224	553	100.0	213	6	US-11-136-538-8	Sequence 8, Appli
152	553	100.0	213	5	US-10-900-230-253	Sequence 253, App	225	553	100.0	213	6	US-11-136-538-9	Sequence 9, Appli
153	553	100.0	213	5	US-10-900-230-255	Sequence 255, App	226	553	100.0	213	6	US-11-172-320-4	Sequence 4, Appli
154	553	100.0	213	5	US-10-900-230-257	Sequence 257, App	227	553	100.0	213	6	US-11-172-320-8	Sequence 8, Appli
155	553	100.0	213	5	US-10-822-300-118	Sequence 118, App	228	553	100.0	213	6	US-11-174-186-42	Sequence 42, Appl
156	553	100.0	213	5	US-10-822-300-135	Sequence 135, App	229	553	100.0	213	6	US-11-120-338-13	Sequence 13, Appl
157	553	100.0	213	5	US-10-849-615-67	Sequence 67, Appl	230	553	100.0	213	6	US-11-120-338-16	Sequence 16, Appl
158	553	100.0	213	5	US-10-822-231-3	Sequence 3, Appli	231	553	100.0	213	6	US-11-173-969-4	Sequence 4, Appli
159	553	100.0	213	5	US-10-947-432-1	Sequence 1, Appli	232	553	100.0	213	6	US-11-173-969-8	Sequence 8, Appli
160	553	100.0	213	5	US-10-861-049-15	Sequence 15, Appl	233	553	100.0	213	6	US-11-102-621-118	Sequence 118, App
161	553	100.0	213	5	US-10-861-049-18	Sequence 18, Appl	234	553	100.0	213	6	US-11-102-621-135	Sequence 135, App
162	553	100.0	213	5	US-10-861-049-19	Sequence 19, Appl	235	553	100.0	213	6	US-11-107-028-31	Sequence 31, Appl
163	553	100.0	213	5	US-10-861-049-21	Sequence 21, Appl	236	553	100.0	213	6	US-11-107-028-44	Sequence 44, Appl
164	553	100.0	213	5	US-10-632-815-6	Sequence 6, Appli	237	553	100.0	213	6	US-11-156-505-34	Sequence 34, Appl
165	553	100.0	213	5	US-10-985-584-5	Sequence 5, Appli	238	553	100.0	213	6	US-11-106-820-24	Sequence 24, Appl
166	553	100.0	213	5	US-10-728-723-198	Sequence 198, App	239	553	100.0	213	6	US-11-106-820-29	Sequence 29, Appl
167	553	100.0	213	5	US-10-962-285-209	Sequence 209, App	240	553	100.0	213	6	US-11-106-820-44	Sequence 44, Appl
168	553	100.0	213	5	US-10-962-285-211	Sequence 211, App	241	553	100.0	213	6	US-11-143-077-13	Sequence 13, Appl
169	553	100.0	213	5	US-10-962-285-213	Sequence 213, App	242	553	100.0	213	6	US-11-143-077-16	Sequence 16, Appl
170	553	100.0	213	5	US-10-962-285-215	Sequence 215, App	243	553	100.0	213	6	US-11-124-620-6	Sequence 6, Appli
171	553	100.0	213	5	US-10-962-285-217	Sequence 217, App	244	553	100.0	213	6	US-11-143-386-13	Sequence 13, Appl
172	553	100.0	213	5	US-10-962-285-219	Sequence 219, App	245	553	100.0	213	6	US-11-143-386-16	Sequence 16, Appl
173	553	100.0	213	5	US-10-962-285-221	Sequence 221, App	246	553	100.0	213	6	US-11-187-364-13	Sequence 13, Appl

247	553	100.0	213	6	US-11-187-364-28	Sequence 28, Appl	320	553	100.0	214	6	US-11-010-797-4	Sequence 4, Appl
248	553	100.0	213	6	US-11-208-422-24	Sequence 24, Appl	321	553	100.0	214	6	US-11-085-368-19	Sequence 19, Appl
249	553	100.0	213	6	US-11-208-422-26	Sequence 26, Appl	322	553	100.0	214	6	US-11-085-368-91	Sequence 91, Appl
250	553	100.0	213	6	US-11-208-422-39	Sequence 39, Appl	323	553	100.0	214	6	US-11-025-712-11	Sequence 11, Appl
251	553	100.0	214	3	US-09-940-166A-2	Sequence 2, Appl	324	553	100.0	214	6	US-11-094-625-9	Sequence 9, Appl
252	553	100.0	214	3	US-09-811-384-11	Sequence 11, Appl	325	553	100.0	214	6	US-11-102-621-129	Sequence 129, Appl
253	553	100.0	214	3	US-09-949-559-128	Sequence 128, App	326	553	100.0	214	6	US-11-128-900-71	Sequence 71, Appl
254	553	100.0	214	3	US-09-996-288-249	Sequence 249, App	327	553	100.0	214	6	US-11-154-337-14	Sequence 14, Appl
255	553	100.0	214	3	US-09-875-221A-128	Sequence 128, App	328	553	100.0	214	6	US-11-154-337-16	Sequence 16, Appl
256	553	100.0	214	3	US-09-996-265-249	Sequence 249, App	329	553	100.0	214	6	US-11-154-337-16	Sequence 13, Appl
257	553	100.0	214	4	US-10-253-366-1	Sequence 1, Appl	330	553	100.0	214	6	US-11-182-908-13	Sequence 13, Appl
258	553	100.0	214	4	US-10-153-382-19	Sequence 19, Appl	331	553	100.0	214	6	US-11-182-908-15	Sequence 15, Appl
259	553	100.0	214	4	US-10-229-567-11	Sequence 11, Appl	332	553	100.0	214	6	US-11-005-728-163	Sequence 163, App
260	553	100.0	214	4	US-10-316-694-1	Sequence 1, Appl	333	553	100.0	214	6	US-11-049-536-700	Sequence 700, App
261	553	100.0	214	4	US-10-356-974-1	Sequence 1, Appl	334	553	100.0	214	6	US-11-183-205-55	Sequence 55, Appl
262	553	100.0	214	4	US-10-310-454-4	Sequence 4, Appl	335	553	100.0	214	6	US-11-199-739-700	Sequence 700, App
263	553	100.0	214	4	US-10-364-953-1	Sequence 1, Appl	336	553	100.0	214	6	US-11-199-739-724	Sequence 724, App
264	553	100.0	214	4	US-10-364-953-3	Sequence 3, Appl	337	553	100.0	214	6	US-11-208-422-15	Sequence 15, Appl
265	553	100.0	214	4	US-10-364-953-4	Sequence 4, Appl	338	553	100.0	214	6	US-11-208-422-19	Sequence 19, Appl
266	553	100.0	214	4	US-10-364-953-11	Sequence 11, Appl	339	553	100.0	215	3	US-09-972-656-100	Sequence 8, Appl
267	553	100.0	214	4	US-10-364-953-13	Sequence 13, Appl	340	553	100.0	215	3	US-09-791-153A-47	Sequence 100, App
268	553	100.0	214	4	US-10-423-299-1	Sequence 1, Appl	341	553	100.0	215	4	US-10-408-901-32	Sequence 47, Appl
269	553	100.0	214	4	US-10-423-299-3	Sequence 3, Appl	342	553	100.0	215	4	US-10-408-901-40	Sequence 32, Appl
270	553	100.0	214	4	US-10-408-901-36	Sequence 36, Appl	343	553	100.0	215	4	US-10-408-901-48	Sequence 40, Appl
271	553	100.0	214	4	US-10-408-901-44	Sequence 44, Appl	344	553	100.0	215	4	US-10-408-901-52	Sequence 48, Appl
272	553	100.0	214	4	US-10-411-037-55	Sequence 55, Appl	345	553	100.0	215	5	US-10-818-068-26	Sequence 52, Appl
273	553	100.0	214	4	US-10-435-299-5	Sequence 55, Appl	346	553	100.0	215	5	US-10-684-957-18	Sequence 26, Appl
274	553	100.0	214	4	US-10-404-286-11	Sequence 11, Appl	347	553	100.0	215	5	US-10-684-957-20	Sequence 18, Appl
275	553	100.0	214	4	US-10-411-026-55	Sequence 55, Appl	348	553	100.0	215	5	US-10-684-957-22	Sequence 20, Appl
276	553	100.0	214	4	US-10-410-962-55	Sequence 55, Appl	349	553	100.0	215	5	US-10-822-300-141	Sequence 22, Appl
277	553	100.0	214	4	US-10-411-049-55	Sequence 55, Appl	350	553	100.0	215	5	US-10-724-274-26	Sequence 141, App
278	553	100.0	214	4	US-10-659-825-1	Sequence 1, Appl	351	553	100.0	215	5	US-10-724-274-32	Sequence 26, Appl
279	553	100.0	214	4	US-10-467-546-3	Sequence 3, Appl	352	553	100.0	215	5	US-10-830-956-26	Sequence 32, Appl
280	553	100.0	214	4	US-10-379-392-170	Sequence 170, App	353	553	100.0	215	5	US-10-830-956-32	Sequence 32, Appl
281	553	100.0	214	4	US-10-379-392-175	Sequence 175, App	354	553	100.0	215	5	US-10-916-758-12	Sequence 32, Appl
282	553	100.0	214	4	US-10-410-930-55	Sequence 55, Appl	355	553	100.0	215	5	US-10-916-758-16	Sequence 12, Appl
283	553	100.0	214	4	US-10-410-997-55	Sequence 55, Appl	356	553	100.0	215	6	US-11-102-621-141	Sequence 16, Appl
284	553	100.0	214	4	US-10-411-012-55	Sequence 55, Appl	357	553	100.0	215	6	US-11-166-906-2	Sequence 141, App
285	553	100.0	214	4	US-10-287-994-55	Sequence 55, Appl	358	553	100.0	216	5	US-10-684-957-33	Sequence 2, Appl
286	553	100.0	214	4	US-10-762-967-2	Sequence 2, Appl	359	553	100.0	217	5	US-10-937-596-5	Sequence 5, Appl
287	553	100.0	214	4	US-10-410-913-55	Sequence 55, Appl	360	553	100.0	217	6	US-11-056-776-2	Sequence 2, Appl
288	553	100.0	214	4	US-10-813-483-3	Sequence 3, Appl	361	553	100.0	217	6	US-11-182-908-23	Sequence 23, Appl
289	553	100.0	214	5	US-10-635-908-15	Sequence 15, Appl	362	553	100.0	218	3	US-09-803-077-9	Sequence 9, Appl
290	553	100.0	214	5	US-10-635-908-17	Sequence 17, Appl	363	553	100.0	218	3	US-09-802-096-9	Sequence 9, Appl
291	553	100.0	214	5	US-10-612-497-71	Sequence 71, Appl	364	553	100.0	218	3	US-09-920-171-13	Sequence 13, Appl
292	553	100.0	214	5	US-10-776-649-71	Sequence 71, Appl	365	553	100.0	218	3	US-09-920-171-15	Sequence 15, Appl
293	553	100.0	214	5	US-10-835-641-24	Sequence 24, Appl	366	553	100.0	218	3	US-09-920-171-17	Sequence 17, Appl
294	553	100.0	214	5	US-10-900-230-249	Sequence 249, App	367	553	100.0	218	3	US-09-920-171-19	Sequence 19, Appl
295	553	100.0	214	5	US-10-822-300-129	Sequence 129, App	368	553	100.0	218	3	US-09-920-171-24	Sequence 24, Appl
296	553	100.0	214	5	US-10-410-980-55	Sequence 55, Appl	369	553	100.0	218	3	US-09-917-410-2	Sequence 2, Appl
297	553	100.0	214	5	US-10-877-532-1	Sequence 1, Appl	370	553	100.0	218	3	US-09-925-179-9	Sequence 9, Appl
298	553	100.0	214	5	US-10-728-420B-113	Sequence 113, App	371	553	100.0	218	3	US-09-925-179-67	Sequence 67, Appl
299	553	100.0	214	5	US-10-914-015-113	Sequence 113, App	372	553	100.0	218	3	US-09-792-938-1	Sequence 1, Appl
300	553	100.0	214	5	US-10-644-277-64	Sequence 64, Appl	373	553	100.0	218	4	US-10-171-452A-39	Sequence 39, Appl
301	553	100.0	214	5	US-10-949-683-1	Sequence 1, Appl	374	553	100.0	218	4	US-10-171-452A-57	Sequence 57, Appl
302	553	100.0	214	5	US-10-666-332-3	Sequence 3, Appl	375	553	100.0	218	4	US-10-113-996-13	Sequence 13, Appl
303	553	100.0	214	5	US-10-503-504-8	Sequence 8, Appl	376	553	100.0	218	4	US-10-113-996-15	Sequence 15, Appl
304	553	100.0	214	5	US-10-891-658-44	Sequence 44, Appl	377	553	100.0	218	4	US-10-113-996-17	Sequence 17, Appl
305	553	100.0	214	5	US-10-484-280-14	Sequence 14, Appl	378	553	100.0	218	4	US-10-113-996-19	Sequence 19, Appl
306	553	100.0	214	5	US-10-410-897-55	Sequence 55, Appl	379	553	100.0	218	4	US-10-113-996-24	Sequence 24, Appl
307	553	100.0	214	5	US-10-492-261-55	Sequence 55, Appl	380	553	100.0	218	4	US-10-292-869-1	Sequence 1, Appl
308	553	100.0	214	5	US-10-962-285-249	Sequence 249, App	381	553	100.0	218	4	US-10-353-708-37	Sequence 37, Appl
309	553	100.0	214	5	US-10-880-028-41	Sequence 41, Appl	382	553	100.0	218	4	US-10-353-708-59	Sequence 59, Appl
310	553	100.0	214	5	US-10-880-320-41	Sequence 41, Appl	383	553	100.0	218	4	US-10-378-567-3	Sequence 3, Appl
311	553	100.0	214	5	US-10-500-184-26	Sequence 26, Appl	384	553	100.0	218	4	US-10-449-566-98	Sequence 98, Appl
312	553	100.0	214	5	US-10-916-758-20	Sequence 20, Appl	385	553	100.0	218	4	US-10-449-566-102	Sequence 102, App
313	553	100.0	214	5	US-10-778-915-2	Sequence 2, Appl	386	553	100.0	218	4	US-10-449-566-119	Sequence 119, App
314	553	100.0	214	5	US-10-403-180-249	Sequence 249, App	387	553	100.0	218	4	US-10-318-397-21	Sequence 21, Appl
315	553	100.0	214	6	US-11-004-054-19	Sequence 19, Appl	388	553	100.0	218	4	US-10-317-747-21	Sequence 21, Appl
316	553	100.0	214	6	US-11-004-054-22	Sequence 22, Appl	389	553	100.0	218	4	US-10-731-984-4	Sequence 4, Appl
317	553	100.0	214	6	US-11-013-966-3	Sequence 3, Appl	390	553	100.0	218	4	US-10-731-984-28	Sequence 28, Appl
318	553	100.0	214	6	US-11-077-1717-2	Sequence 2, Appl	391	553	100.0	218	4	US-10-833-642-1	Sequence 1, Appl
319	553	100.0	214	6	US-11-084-729-1	Sequence 1, Appl	392	553	100.0	218	4	US-10-813-483-1	Sequence 1, Appl

393	553	100.0	218	4	US-10-813-483-2	Sequence 2, Appli	466	553	100.0	232	4	US-10-006-771A-6	Sequence 6, Appli
394	553	100.0	218	5	US-10-757-863-1	Sequence 1, Appli	467	553	100.0	232	4	US-10-377-109-4	Sequence 4, Appli
395	553	100.0	218	5	US-10-791-619-13	Sequence 13, Appli	468	553	100.0	232	5	US-10-877-363-3	Sequence 3, Appli
396	553	100.0	218	5	US-10-791-619-15	Sequence 15, Appli	469	553	100.0	232	5	US-10-922-651-3	Sequence 3, Appli
397	553	100.0	218	5	US-10-791-619-17	Sequence 17, Appli	470	553	100.0	232	5	US-10-861-049-3	Sequence 23, Appli
398	553	100.0	218	5	US-10-791-619-19	Sequence 19, Appli	471	553	100.0	232	5	US-10-985-584-23	Sequence 23, Appli
399	553	100.0	218	5	US-10-791-619-24	Sequence 24, Appli	472	553	100.0	232	6	US-11-021-874-3	Sequence 3, Appli
400	553	100.0	218	5	US-10-714-000-1	Sequence 1, Appli	473	553	100.0	232	6	US-11-106-820-23	Sequence 23, Appli
401	553	100.0	218	5	US-10-698-073-6	Sequence 6, Appli	474	553	100.0	232	6	US-11-190-364-21	Sequence 21, Appli
402	553	100.0	218	5	US-10-698-073-8	Sequence 8, Appli	475	553	100.0	232	6	US-11-147-780-21	Sequence 21, Appli
403	553	100.0	218	5	US-10-698-073-10	Sequence 10, Appli	476	553	100.0	233	4	US-10-153-382-11	Sequence 11, Appli
404	553	100.0	218	5	US-10-698-073-12	Sequence 12, Appli	477	553	100.0	233	4	US-10-071-485-69	Sequence 69, Appli
405	553	100.0	218	5	US-10-698-073-17	Sequence 17, Appli	478	553	100.0	233	4	US-10-404-724-68	Sequence 68, Appli
406	553	100.0	218	5	US-10-968-237-9	Sequence 9, Appli	479	553	100.0	233	4	US-10-377-121-16	Sequence 16, Appli
407	553	100.0	218	5	US-10-968-237-67	Sequence 67, Appli	480	553	100.0	233	4	US-10-377-121-20	Sequence 20, Appli
408	553	100.0	218	5	US-10-985-584-14	Sequence 14, Appli	481	553	100.0	233	4	US-10-656-769-40	Sequence 40, Appli
409	553	100.0	218	5	US-10-937-596-33	Sequence 33, Appli	482	553	100.0	233	4	US-10-663-244-150	Sequence 150, App
410	553	100.0	218	5	US-10-982-470-1	Sequence 1, Appli	483	553	100.0	233	4	US-10-663-244-151	Sequence 151, App
411	553	100.0	218	5	US-10-923-327-6	Sequence 6, Appli	484	553	100.0	233	4	US-10-660-128-9	Sequence 9, Appli
412	553	100.0	218	5	US-10-923-327-8	Sequence 8, Appli	485	553	100.0	233	5	US-10-612-497-15	Sequence 15, Appli
413	553	100.0	218	5	US-10-923-327-10	Sequence 10, Appli	486	553	100.0	233	5	US-10-612-497-67	Sequence 67, Appli
414	553	100.0	218	5	US-10-923-327-12	Sequence 12, Appli	487	553	100.0	233	5	US-10-776-649-15	Sequence 15, Appli
415	553	100.0	218	5	US-10-923-327-17	Sequence 17, Appli	488	553	100.0	233	5	US-10-776-649-67	Sequence 67, Appli
416	553	100.0	218	6	US-11-013-966-1	Sequence 1, Appli	489	553	100.0	233	5	US-10-835-641-25	Sequence 25, Appli
417	553	100.0	218	6	US-11-013-966-2	Sequence 2, Appli	490	553	100.0	233	5	US-10-769-144-6	Sequence 6, Appli
418	553	100.0	218	6	US-11-158-839-1	Sequence 1, Appli	491	553	100.0	233	5	US-10-985-581-69	Sequence 69, Appli
419	553	100.0	218	6	US-11-084-505-4	Sequence 4, Appli	492	553	100.0	233	5	US-10-903-191-6	Sequence 6, Appli
420	553	100.0	218	6	US-11-158-505-4	Sequence 4, Appli	493	553	100.0	233	6	US-11-085-368-11	Sequence 11, Appli
421	553	100.0	218	6	US-11-158-505-28	Sequence 28, Appli	494	553	100.0	233	6	US-11-085-368-47	Sequence 47, Appli
422	553	100.0	218	6	US-11-004-590-229	Sequence 229, App	495	553	100.0	233	6	US-11-031-485-16	Sequence 16, Appli
423	553	100.0	218	6	US-11-136-250-11	Sequence 11, Appli	496	553	100.0	233	6	US-11-031-485-54	Sequence 54, Appli
424	553	100.0	218	6	US-11-194-989-37	Sequence 37, Appli	497	553	100.0	233	6	US-11-128-900-15	Sequence 15, Appli
425	553	100.0	218	6	US-11-195-207-37	Sequence 37, Appli	498	553	100.0	233	6	US-11-128-900-67	Sequence 67, Appli
426	553	100.0	218	6	US-11-195-207-37	Sequence 37, Appli	499	553	100.0	233	6	US-11-182-908-17	Sequence 17, Appli
427	553	100.0	218	6	US-11-208-422-16	Sequence 16, Appli	500	553	100.0	233	6	US-11-182-908-17	Sequence 17, Appli
428	553	100.0	218	6	US-11-208-422-17	Sequence 17, Appli	501	553	100.0	234	3	US-11-218-813-130	Sequence 130, App
429	553	100.0	219	3	US-11-208-422-18	Sequence 18, Appli	502	553	100.0	234	3	US-09-740-002-24	Sequence 24, Appli
430	553	100.0	219	3	US-09-726-258-72	Sequence 72, Appli	503	553	100.0	234	3	US-09-800-729-150	Sequence 150, App
431	553	100.0	219	3	US-09-972-656-92	Sequence 92, Appli	504	553	100.0	234	3	US-09-848-832-4	Sequence 4, Appli
432	553	100.0	219	3	US-09-972-656-94	Sequence 94, Appli	505	553	100.0	234	3	US-09-833-245-2210	Sequence 2210, Ap
433	553	100.0	219	3	US-09-972-656-104	Sequence 104, App	506	553	100.0	234	4	US-10-153-382-15	Sequence 15, Appli
434	553	100.0	219	4	US-10-226-435A-11	Sequence 106, App	507	553	100.0	234	4	US-10-026-925-55	Sequence 55, Appli
435	553	100.0	219	4	US-10-487-322-11	Sequence 11, Appli	508	553	100.0	234	4	US-10-225-108A-4	Sequence 4, Appli
436	553	100.0	219	5	US-10-487-326-11	Sequence 11, Appli	509	553	100.0	234	4	US-10-292-088-24	Sequence 24, Appli
437	553	100.0	219	5	US-10-486-908-11	Sequence 11, Appli	510	553	100.0	234	4	US-10-292-088-48	Sequence 48, Appli
438	553	100.0	219	5	US-10-476-265-11	Sequence 11, Appli	511	553	100.0	234	4	US-10-292-088-72	Sequence 72, Appli
439	553	100.0	219	5	US-10-512-527-11	Sequence 11, Appli	512	553	100.0	234	4	US-10-292-088-88	Sequence 88, Appli
440	553	100.0	219	5	US-10-497-475-11	Sequence 11, Appli	513	553	100.0	234	4	US-10-461-148-2	Sequence 2, Appli
441	553	100.0	219	5	US-10-880-028-45	Sequence 45, Appli	514	553	100.0	234	4	US-10-325-698-24	Sequence 24, Appli
442	553	100.0	219	5	US-10-880-320-45	Sequence 45, Appli	515	553	100.0	234	4	US-10-684-109-85	Sequence 85, Appli
443	553	100.0	219	5	US-10-487-324A-11	Sequence 11, Appli	516	553	100.0	234	4	US-10-684-109-91	Sequence 91, Appli
444	553	100.0	219	6	US-11-080-587-8	Sequence 8, Appli	517	553	100.0	234	4	US-10-684-109-97	Sequence 97, Appli
445	553	100.0	219	6	US-11-224-623-11	Sequence 11, Appli	518	553	100.0	234	4	US-10-684-109-103	Sequence 103, App
446	553	100.0	219	6	US-11-194-989-12	Sequence 12, Appli	519	553	100.0	234	4	US-10-684-109-109	Sequence 109, App
447	553	100.0	219	6	US-11-195-207-12	Sequence 12, Appli	520	553	100.0	234	5	US-10-612-497-115	Sequence 115, App
448	553	100.0	219	6	US-11-155-843-177	Sequence 177, App	521	553	100.0	234	5	US-10-612-497-69	Sequence 17, Appli
449	553	100.0	219	6	US-11-259-232-72	Sequence 72, Appli	522	553	100.0	234	5	US-10-776-649-17	Sequence 17, Appli
450	553	100.0	220	3	US-09-301-593-17	Sequence 17, Appli	523	553	100.0	234	5	US-10-776-649-69	Sequence 69, Appli
451	553	100.0	220	3	US-09-917-410-5	Sequence 5, Appli	524	553	100.0	234	5	US-10-938-353-4	Sequence 4, Appli
452	553	100.0	220	3	US-09-995-693-1	Sequence 1, Appli	525	553	100.0	234	5	US-10-938-353-8	Sequence 8, Appli
453	553	100.0	220	4	US-10-233-408-1	Sequence 1, Appli	526	553	100.0	234	5	US-10-938-353-12	Sequence 12, Appli
454	553	100.0	220	4	US-10-159-006-17	Sequence 17, Appli	527	553	100.0	234	6	US-11-085-368-15	Sequence 15, Appli
455	553	100.0	220	4	US-10-737-208A-5	Sequence 5, Appli	528	553	100.0	234	6	US-11-085-368-55	Sequence 55, Appli
456	553	100.0	220	5	US-10-644-277-4	Sequence 4, Appli	529	553	100.0	234	6	US-11-128-900-17	Sequence 17, Appli
457	553	100.0	220	5	US-10-644-277-20	Sequence 20, Appli	530	553	100.0	234	6	US-11-128-900-69	Sequence 69, Appli
458	553	100.0	220	5	US-10-644-277-40	Sequence 40, Appli	531	553	100.0	234	6	US-11-041-095-25	Sequence 25, Appli
459	553	100.0	220	5	US-10-644-277-68	Sequence 68, Appli	532	553	100.0	234	6	US-11-264-096-2210	Sequence 2210, Ap
460	553	100.0	220	5	US-10-644-277-92	Sequence 92, Appli	533	553	100.0	235	3	US-09-800-729-152	Sequence 152, App
461	553	100.0	220	5	US-10-880-028-19	Sequence 19, Appli	534	553	100.0	235	3	US-09-910-059-17	Sequence 17, Appli
462	553	100.0	220	5	US-10-880-028-27	Sequence 27, Appli	535	553	100.0	235	3	US-09-910-059-52	Sequence 52, Appli
463	553	100.0	220	5	US-10-880-320-19	Sequence 19, Appli	536	553	100.0	235	3	US-09-910-059-97	Sequence 97, Appli
464	553	100.0	220	5	US-10-880-320-27	Sequence 27, Appli	537	553	100.0	235	3	US-09-910-059-99	Sequence 99, Appli
465	553	100.0	220	6	US-11-040-071-2	Sequence 2, Appli	538	553	100.0	235	3	US-09-833-245-2209	Sequence 2209, Ap

539	553	100.0	235	4	US-10-153-382-7	Sequence 7, Appli	612	553	100.0	236	6	US-11-144-248-52	Sequence 52, Appl
540	553	100.0	235	4	US-10-180-648-4	Sequence 4, Appli	613	553	100.0	236	6	US-11-144-222-47	Sequence 47, Appl
541	553	100.0	235	4	US-10-656-769-38	Sequence 38, Appl	614	553	100.0	236	6	US-11-144-222-48	Sequence 48, Appl
542	553	100.0	235	4	US-10-608-710-2	Sequence 2, Appli	615	553	100.0	236	6	US-11-144-222-51	Sequence 51, Appl
543	553	100.0	235	5	US-10-612-497-14	Sequence 14, Appl	616	553	100.0	236	6	US-11-144-222-52	Sequence 52, Appl
544	553	100.0	235	5	US-10-612-497-65	Sequence 65, Appl	617	553	100.0	236	6	US-11-086-289-4	Sequence 4, Appli
545	553	100.0	235	5	US-10-776-649-14	Sequence 14, Appl	618	553	100.0	236	6	US-11-086-289-8	Sequence 8, Appli
546	553	100.0	235	5	US-10-776-649-65	Sequence 65, Appl	619	553	100.0	236	6	US-11-086-289-20	Sequence 20, Appl
547	553	100.0	235	5	US-10-723-003-42	Sequence 42, Appl	620	553	100.0	236	6	US-11-106-820-19	Sequence 19, Appl
548	553	100.0	235	5	US-10-938-353-32	Sequence 32, Appl	621	553	100.0	236	6	US-11-182-343-47	Sequence 47, Appl
549	553	100.0	235	5	US-10-938-353-44	Sequence 44, Appl	622	553	100.0	236	6	US-11-182-343-48	Sequence 48, Appl
550	553	100.0	235	5	US-10-938-353-60	Sequence 60, Appl	623	553	100.0	236	6	US-11-182-343-51	Sequence 51, Appl
551	553	100.0	235	5	US-10-492-228-11	Sequence 11, Appl	624	553	100.0	236	6	US-11-182-343-52	Sequence 52, Appl
552	553	100.0	235	5	US-10-492-228-70	Sequence 70, Appl	625	553	100.0	236	6	US-11-190-364-17	Sequence 17, Appl
553	553	100.0	235	6	US-11-019-180-2	Sequence 2, Appli	626	553	100.0	236	6	US-11-147-780-17	Sequence 17, Appl
554	553	100.0	235	6	US-11-085-368-7	Sequence 7, Appli	627	553	100.0	236	6	US-11-264-096-237	Sequence 237, App
555	553	100.0	235	6	US-11-085-368-43	Sequence 43, Appl	628	553	100.0	237	3	US-09-056-160B-100	Sequence 100, App
556	553	100.0	235	6	US-11-004-639-42	Sequence 42, Appl	629	553	100.0	237	3	US-09-940-166A-6	Sequence 6, Appli
557	553	100.0	235	6	US-11-128-900-14	Sequence 14, Appl	630	553	100.0	237	4	US-10-194-975-109	Sequence 109, App
558	553	100.0	235	6	US-11-128-900-65	Sequence 65, Appl	631	553	100.0	237	4	US-10-020-786-8	Sequence 8, Appli
559	553	100.0	235	6	US-11-086-289-16	Sequence 16, Appl	632	553	100.0	237	4	US-10-020-786-10	Sequence 10, Appl
560	553	100.0	235	6	US-11-166-994-2	Sequence 2, Appli	633	553	100.0	237	4	US-10-227-694-1	Sequence 1, Appli
561	553	100.0	235	6	US-11-264-096-2209	Sequence 2209, Ap	634	553	100.0	237	4	US-10-227-694-4	Sequence 4, Appli
562	553	100.0	236	3	US-09-859-053-30	Sequence 30, Appl	635	553	100.0	237	4	US-10-234-671-100	Sequence 100, App
563	553	100.0	236	3	US-09-859-053-34	Sequence 34, Appl	636	553	100.0	237	4	US-10-409-938-25	Sequence 25, Appl
564	553	100.0	236	3	US-09-859-053-38	Sequence 38, Appl	637	553	100.0	237	4	US-10-663-244-146	Sequence 146, App
565	553	100.0	236	3	US-09-833-245-237	Sequence 237, App	638	553	100.0	237	4	US-10-663-244-152	Sequence 152, App
566	553	100.0	236	4	US-10-006-593-69	Sequence 69, Appl	639	553	100.0	237	4	US-10-663-244-153	Sequence 153, App
567	553	100.0	236	4	US-10-401-344-4	Sequence 4, Appli	640	553	100.0	237	4	US-10-763-967-6	Sequence 6, Appli
568	553	100.0	236	4	US-10-307-724-69	Sequence 69, Appl	641	553	100.0	237	5	US-10-754-212-2	Sequence 2, Appli
569	553	100.0	236	4	US-10-108-260A-4281	Sequence 4281, Ap	642	553	100.0	237	5	US-10-754-212-5	Sequence 5, Appli
570	553	100.0	236	4	US-10-038-591-47	Sequence 47, Appl	643	553	100.0	237	5	US-10-697-995-2	Sequence 2, Appli
571	553	100.0	236	4	US-10-038-591-48	Sequence 48, Appl	644	553	100.0	237	5	US-10-697-995-5	Sequence 5, Appli
572	553	100.0	236	4	US-10-038-591-51	Sequence 51, Appl	645	553	100.0	237	5	US-10-697-995-8	Sequence 8, Appli
573	553	100.0	236	4	US-10-038-591-52	Sequence 52, Appl	646	553	100.0	237	5	US-10-697-995-11	Sequence 11, Appl
574	553	100.0	236	4	US-10-800-250-30	Sequence 30, Appl	647	553	100.0	237	5	US-10-697-995-17	Sequence 17, Appl
575	553	100.0	236	4	US-10-800-250-34	Sequence 34, Appl	648	553	100.0	237	5	US-10-697-995-20	Sequence 20, Appl
576	553	100.0	236	4	US-10-800-250-38	Sequence 38, Appl	649	553	100.0	237	5	US-10-974-591-100	Sequence 100, App
577	553	100.0	236	4	US-10-625-105-30	Sequence 30, Appl	650	553	100.0	237	6	US-11-077-717-10	Sequence 10, Appl
578	553	100.0	236	4	US-10-625-105-34	Sequence 34, Appl	651	553	100.0	237	6	US-11-071-291-8	Sequence 8, Appli
579	553	100.0	236	4	US-10-625-105-38	Sequence 38, Appl	652	553	100.0	237	6	US-11-071-291-10	Sequence 10, Appl
580	553	100.0	236	4	US-10-775-444A-47	Sequence 47, Appl	653	553	100.0	237	6	US-11-054-669-109	Sequence 109, App
581	553	100.0	236	4	US-10-775-444A-48	Sequence 48, Appl	654	553	100.0	238	4	US-10-216-484-50	Sequence 50, Appl
582	553	100.0	236	4	US-10-775-444A-51	Sequence 51, Appl	655	553	100.0	238	4	US-10-216-484-52	Sequence 52, Appl
583	553	100.0	236	4	US-10-775-444A-52	Sequence 52, Appl	656	553	100.0	238	4	US-10-216-484-54	Sequence 54, Appl
584	553	100.0	236	5	US-10-858-186-20	Sequence 20, Appl	657	553	100.0	238	4	US-10-216-484-107	Sequence 107, App
585	553	100.0	236	5	US-10-737-290-69	Sequence 69, Appl	658	553	100.0	238	4	US-10-216-484-109	Sequence 109, App
586	553	100.0	236	5	US-10-723-003-56	Sequence 56, Appl	659	553	100.0	238	4	US-10-216-484-127	Sequence 127, App
587	553	100.0	236	5	US-10-910-901-4	Sequence 4, Appli	660	553	100.0	238	4	US-10-216-484-129	Sequence 129, App
588	553	100.0	236	5	US-10-910-901-8	Sequence 8, Appli	661	553	100.0	238	4	US-10-216-484-131	Sequence 131, App
589	553	100.0	236	5	US-10-910-901-12	Sequence 12, Appl	662	553	100.0	238	4	US-10-171-452A-38	Sequence 38, Appl
590	553	100.0	236	5	US-10-910-901-16	Sequence 16, Appl	663	553	100.0	238	4	US-10-171-452A-56	Sequence 56, Appl
591	553	100.0	236	5	US-10-938-353-16	Sequence 16, Appl	664	553	100.0	238	4	US-10-384-933-50	Sequence 50, Appl
592	553	100.0	236	5	US-10-938-353-20	Sequence 20, Appl	665	553	100.0	238	4	US-10-384-933-52	Sequence 52, Appl
593	553	100.0	236	5	US-10-938-353-28	Sequence 28, Appl	666	553	100.0	238	4	US-10-384-933-54	Sequence 54, Appl
594	553	100.0	236	5	US-10-938-353-36	Sequence 36, Appl	667	553	100.0	238	4	US-10-384-933-107	Sequence 107, App
595	553	100.0	236	5	US-10-938-353-48	Sequence 48, Appl	668	553	100.0	238	4	US-10-384-933-127	Sequence 127, App
596	553	100.0	236	5	US-10-938-353-52	Sequence 52, Appl	669	553	100.0	238	4	US-10-384-933-129	Sequence 129, App
597	553	100.0	236	5	US-10-938-353-55	Sequence 55, Appl	670	553	100.0	238	4	US-10-384-933-131	Sequence 131, App
598	553	100.0	236	5	US-10-917-073A-5	Sequence 5, Appli	671	553	100.0	238	4	US-10-353-708-38	Sequence 38, Appl
599	553	100.0	236	5	US-10-917-073A-6	Sequence 6, Appli	672	553	100.0	238	4	US-10-353-708-56	Sequence 56, Appl
600	553	100.0	236	5	US-10-961-567A-6	Sequence 6, Appli	673	553	100.0	238	4	US-10-663-244-144	Sequence 144, App
601	553	100.0	236	5	US-10-728-723-18	Sequence 18, Appl	674	553	100.0	238	4	US-10-663-244-145	Sequence 145, App
602	553	100.0	236	6	US-11-131-648-20	Sequence 20, Appl	675	553	100.0	238	4	US-10-663-244-147	Sequence 147, App
603	553	100.0	236	6	US-11-131-648-49	Sequence 49, Appl	676	553	100.0	238	4	US-10-663-244-148	Sequence 148, App
604	553	100.0	236	6	US-11-031-485-12	Sequence 12, Appl	677	553	100.0	238	4	US-10-663-244-149	Sequence 149, App
605	553	100.0	236	6	US-11-031-485-20	Sequence 20, Appl	678	553	100.0	238	4	US-10-467-253-14	Sequence 14, Appl
606	553	100.0	236	6	US-11-031-485-58	Sequence 58, Appl	679	553	100.0	238	4	US-10-731-984-3	Sequence 3, Appli
607	553	100.0	236	6	US-11-056-776-3	Sequence 3, Appli	680	553	100.0	238	4	US-10-731-984-27	Sequence 27, Appl
608	553	100.0	236	6	US-11-004-639-56	Sequence 56, Appl	681	553	100.0	238	5	US-10-937-046-10	Sequence 10, Appl
609	553	100.0	236	6	US-11-144-248-47	Sequence 47, Appl	682	553	100.0	238	5	US-10-937-046-10	Sequence 10, Appl
610	553	100.0	236	6	US-11-144-248-48	Sequence 48, Appl	683	553	100.0	238	5	US-10-497-475-19	Sequence 19, Appl
611	553	100.0	236	6	US-11-144-248-51	Sequence 51, Appl	684	553	100.0	238	5	US-10-943-640-2	Sequence 2, Appli

685	553	100.0	238	6	US-11-034-655-2	Sequence 2, Appl	758	553	100.0	239	6	US-11-031-485-36	Sequence 36, Appl
686	553	100.0	238	6	US-11-034-655-11	Sequence 11, Appl	759	553	100.0	239	6	US-11-031-485-44	Sequence 44, Appl
687	553	100.0	238	6	US-11-034-655-13	Sequence 13, Appl	760	553	100.0	239	6	US-11-031-485-66	Sequence 66, Appl
688	553	100.0	238	6	US-11-034-655-15	Sequence 15, Appl	761	553	100.0	239	6	US-11-031-485-68	Sequence 68, Appl
689	553	100.0	238	6	US-11-031-485-1	Sequence 1, Appl	762	553	100.0	239	6	US-11-004-439-14	Sequence 14, Appl
690	553	100.0	238	6	US-11-031-485-4	Sequence 4, Appl	763	553	100.0	239	6	US-11-139-439-6	Sequence 6, Appl
691	553	100.0	238	6	US-11-031-485-8	Sequence 8, Appl	764	553	100.0	239	6	US-11-086-289-12	Sequence 12, Appl
692	553	100.0	238	6	US-11-031-485-28	Sequence 28, Appl	765	553	100.0	239	6	US-11-041-095-19	Sequence 19, Appl
693	553	100.0	238	6	US-11-031-485-40	Sequence 40, Appl	766	553	100.0	239	6	US-11-177-648-10	Sequence 10, Appl
694	553	100.0	238	6	US-11-031-485-48	Sequence 48, Appl	767	553	100.0	239	6	US-11-271-590-4	Sequence 4, Appl
695	553	100.0	238	6	US-11-158-505-1	Sequence 1, Appl	768	553	100.0	240	3	US-09-301-593-28	Sequence 28, Appl
696	553	100.0	238	6	US-11-158-505-3	Sequence 3, Appl	769	553	100.0	240	3	US-09-301-593-36	Sequence 36, Appl
697	553	100.0	238	6	US-11-158-505-25	Sequence 25, Appl	770	553	100.0	240	3	US-09-799-514-8	Sequence 8, Appl
698	553	100.0	238	6	US-11-158-505-27	Sequence 27, Appl	771	553	100.0	240	3	US-10-159-006-28	Sequence 28, Appl
699	553	100.0	238	6	US-11-177-648-34	Sequence 34, Appl	772	553	100.0	240	4	US-10-153-006-36	Sequence 36, Appl
700	553	100.0	238	6	US-11-177-648-35	Sequence 35, Appl	773	553	100.0	240	4	US-10-630-406-8	Sequence 8, Appl
701	553	100.0	238	6	US-11-177-648-36	Sequence 36, Appl	774	553	100.0	240	5	US-10-938-353-24	Sequence 24, Appl
702	553	100.0	238	6	US-11-177-648-37	Sequence 37, Appl	775	553	100.0	240	5	US-10-805-177-139	Sequence 139, App
703	553	100.0	238	6	US-11-177-648-38	Sequence 38, Appl	776	553	100.0	240	6	US-11-073-453-8	Sequence 8, Appl
704	553	100.0	238	6	US-11-177-648-39	Sequence 39, Appl	777	553	100.0	241	5	US-10-723-003-22	Sequence 22, Appl
705	553	100.0	238	6	US-11-177-648-40	Sequence 40, Appl	778	553	100.0	241	6	US-11-031-485-24	Sequence 24, Appl
706	553	100.0	238	6	US-11-177-648-80	Sequence 80, Appl	779	553	100.0	241	6	US-11-031-485-62	Sequence 62, Appl
707	553	100.0	239	3	US-09-758-173-6	Sequence 6, Appl	780	553	100.0	241	6	US-11-004-639-22	Sequence 22, Appl
708	553	100.0	239	3	US-09-825-012-9	Sequence 9, Appl	781	553	100.0	241	6	US-11-106-820-15	Sequence 15, Appl
709	553	100.0	239	3	US-09-249-011A-22	Sequence 22, Appl	782	553	100.0	241	6	US-11-190-364-14	Sequence 14, Appl
710	553	100.0	239	3	US-09-948-429B-6	Sequence 6, Appl	783	553	100.0	241	6	US-11-147-780-14	Sequence 14, Appl
711	553	100.0	239	3	US-09-992-600A-8	Sequence 8, Appl	784	553	100.0	242	3	US-09-819-266-26	Sequence 26, Appl
712	553	100.0	239	3	US-09-924-304-8	Sequence 8, Appl	785	553	100.0	242	3	US-09-726-258-51	Sequence 51, Appl
713	553	100.0	239	3	US-09-992-095B-8	Sequence 8, Appl	786	553	100.0	242	3	US-09-726-258-62	Sequence 62, Appl
714	553	100.0	239	3	US-09-990-570-8	Sequence 8, Appl	787	553	100.0	242	3	US-09-726-258-62	Sequence 62, Appl
715	553	100.0	239	4	US-10-124-905-6	Sequence 6, Appl	788	553	100.0	242	6	US-11-259-232-51	Sequence 51, Appl
716	553	100.0	239	4	US-10-000-489-8	Sequence 8, Appl	789	553	100.0	242	6	US-11-259-232-56	Sequence 56, Appl
717	553	100.0	239	4	US-10-000-986-8	Sequence 8, Appl	790	553	100.0	242	6	US-11-259-232-62	Sequence 62, Appl
718	553	100.0	239	4	US-10-154-678-8	Sequence 8, Appl	791	553	100.0	245	3	US-09-797-941A-6	Sequence 6, Appl
719	553	100.0	239	4	US-10-124-807-6	Sequence 6, Appl	792	553	100.0	245	5	US-10-965-585-6	Sequence 6, Appl
720	553	100.0	239	4	US-10-291-532-6	Sequence 6, Appl	793	553	100.0	247	5	US-10-466-164-69	Sequence 69, Appl
721	553	100.0	239	4	US-10-404-724-6	Sequence 6, Appl	794	553	100.0	247	5	US-10-887-230-50	Sequence 50, Appl
722	553	100.0	239	4	US-10-404-724-10	Sequence 10, Appl	795	553	100.0	258	3	US-09-979-948C-4	Sequence 4, Appl
723	553	100.0	239	4	US-10-404-724-12	Sequence 12, Appl	796	553	100.0	258	3	US-09-979-948C-6	Sequence 6, Appl
724	553	100.0	239	4	US-10-404-724-39	Sequence 39, Appl	797	553	100.0	260	4	US-10-264-049-2296	Sequence 2296, Ap
725	553	100.0	239	4	US-10-404-724-41	Sequence 41, Appl	798	553	100.0	271	5	US-10-887-230-46	Sequence 46, Appl
726	553	100.0	239	4	US-10-404-724-43	Sequence 43, Appl	799	553	100.0	290	6	US-11-041-095-13	Sequence 13, Appl
727	553	100.0	239	4	US-10-404-724-45	Sequence 45, Appl	800	553	100.0	291	6	US-11-041-095-60	Sequence 60, Appl
728	553	100.0	239	4	US-10-404-724-47	Sequence 47, Appl	801	553	100.0	323	3	US-09-746-359A-60	Sequence 60, Appl
729	553	100.0	239	4	US-10-404-724-49	Sequence 49, Appl	802	553	100.0	323	3	US-09-951-268-41	Sequence 41, Appl
730	553	100.0	239	4	US-10-292-088-8	Sequence 8, Appl	803	553	100.0	323	3	US-09-745-752A-60	Sequence 60, Appl
731	553	100.0	239	4	US-10-292-088-16	Sequence 16, Appl	804	553	100.0	323	4	US-10-424-658-60	Sequence 60, Appl
732	553	100.0	239	4	US-10-292-088-32	Sequence 32, Appl	805	553	100.0	323	5	US-10-471-151-29	Sequence 29, Appl
733	553	100.0	239	4	US-10-292-088-40	Sequence 40, Appl	806	553	100.0	323	5	US-10-994-116-67	Sequence 67, Appl
734	553	100.0	239	4	US-10-292-088-56	Sequence 56, Appl	807	553	100.0	323	5	US-10-994-151-67	Sequence 67, Appl
735	553	100.0	239	4	US-10-292-088-102	Sequence 102, Appl	808	553	100.0	347	4	US-10-272-899A-108	Sequence 108, App
736	553	100.0	239	4	US-10-428-408A-28	Sequence 28, Appl	809	553	100.0	352	3	US-09-746-359A-21	Sequence 21, Appl
737	553	100.0	239	4	US-10-108-260A-4028	Sequence 4028, Ap	810	553	100.0	352	3	US-09-951-268-22	Sequence 22, Appl
738	553	100.0	239	4	US-10-428-894-28	Sequence 28, Appl	811	553	100.0	352	3	US-09-745-792A-21	Sequence 21, Appl
739	553	100.0	239	4	US-10-699-874-28	Sequence 28, Appl	812	553	100.0	352	4	US-10-424-658-21	Sequence 21, Appl
740	553	100.0	239	5	US-10-723-003-14	Sequence 14, Appl	813	553	100.0	352	4	US-10-471-151-28	Sequence 28, Appl
741	553	100.0	239	5	US-10-816-276-2	Sequence 2, Appl	814	553	100.0	352	5	US-10-994-116-66	Sequence 66, Appl
742	553	100.0	239	5	US-10-816-276-6	Sequence 6, Appl	815	553	100.0	352	5	US-10-994-151-66	Sequence 66, Appl
743	553	100.0	239	5	US-10-816-276-8	Sequence 8, Appl	816	553	100.0	366	6	US-11-075-351-88	Sequence 38, Appl
744	553	100.0	239	5	US-10-816-276-35	Sequence 35, Appl	817	553	100.0	367	6	US-10-291-265-899	Sequence 899, App
745	553	100.0	239	5	US-10-816-276-37	Sequence 37, Appl	818	553	100.0	367	6	US-11-000-463-899	Sequence 899, App
746	553	100.0	239	5	US-10-816-276-39	Sequence 39, Appl	819	553	100.0	374	6	US-11-075-351-42	Sequence 42, Appl
747	553	100.0	239	5	US-10-816-276-41	Sequence 41, Appl	820	553	100.0	384	4	US-10-291-265-804	Sequence 804, App
748	553	100.0	239	5	US-10-816-276-43	Sequence 43, Appl	821	553	100.0	384	4	US-10-291-265-805	Sequence 805, App
749	553	100.0	239	5	US-10-816-276-45	Sequence 45, Appl	822	553	100.0	384	4	US-10-291-265-806	Sequence 806, App
750	553	100.0	239	5	US-10-838-854-8	Sequence 8, Appl	823	553	100.0	384	4	US-10-291-265-807	Sequence 807, App
751	553	100.0	239	5	US-10-476-265-19	Sequence 19, Appl	824	553	100.0	384	6	US-11-000-463-804	Sequence 804, App
752	553	100.0	239	5	US-10-644-256-4	Sequence 4, Appl	825	553	100.0	384	6	US-11-000-463-805	Sequence 805, App
753	553	100.0	239	5	US-10-981-738-14	Sequence 14, Appl	826	553	100.0	384	6	US-11-000-463-806	Sequence 806, App
754	553	100.0	239	5	US-10-986-780-6	Sequence 6, Appl	827	553	100.0	384	6	US-11-000-463-807	Sequence 807, App
755	553	100.0	239	6	US-11-131-648-21	Sequence 21, Appl	828	553	100.0	392	4	US-10-272-899A-110	Sequence 110, App
756	553	100.0	239	6	US-11-131-648-51	Sequence 51, Appl	829	553	100.0	411	6	US-11-075-351-47	Sequence 47, Appl
757	553	100.0	239	6	US-11-031-485-32	Sequence 32, Appl	830	553	100.0	488	6	US-11-084-080-18	Sequence 18, Appl

831	553	100.0	491	4	US-10-011-125-2	Sequence 2, Appli	904	550	99.5	263	3	US-09-979-948C-1	Sequence 1, Appli
832	553	100.0	498	5	US-10-491-653-146	Sequence 146, App	905	550	99.5	363	4	US-10-291-265-335	Sequence 335, App
833	553	100.0	512	4	US-10-679-620-70	Sequence 70, Appl	906	550	99.5	363	6	US-11-000-463-335	Sequence 335, App
834	553	100.0	513	6	US-11-132-143-70	Sequence 20, Appl	907	549	99.3	215	3	US-09-791-153A-45	Sequence 45, Appl
835	553	100.0	514	4	US-10-182-975-2	Sequence 70, Appli	908	549	99.3	234	4	US-10-045-674-587	Sequence 587, App
836	553	100.0	517	4	US-10-679-620-68	Sequence 68, Appl	909	549	99.3	239	4	US-10-292-088-64	Sequence 64, Appl
837	553	100.0	517	6	US-11-132-143-68	Sequence 68, Appl	910	548	99.1	106	3	US-09-925-664-49	Sequence 49, Appl
838	553	100.0	519	6	US-10-679-620-66	Sequence 66, Appl	911	548	99.1	106	3	US-09-995-898A-17	Sequence 17, Appl
839	553	100.0	519	6	US-11-132-143-66	Sequence 66, Appl	912	548	99.1	106	3	US-09-892-949-40	Sequence 40, Appl
840	553	100.0	663	4	US-10-412-406-32	Sequence 32, Appl	913	548	99.1	106	3	US-09-925-192-49	Sequence 49, Appl
841	553	100.0	666	5	US-10-981-356A-25	Sequence 25, Appl	914	548	99.1	106	4	US-10-066-895-12	Sequence 12, Appl
842	553	100.0	666	5	US-10-981-356A-27	Sequence 27, Appl	915	548	99.1	106	4	US-10-408-901-4	Sequence 4, Appli
843	553	100.0	666	5	US-10-981-356A-28	Sequence 28, Appl	916	548	99.1	106	4	US-10-420-034A-17	Sequence 17, Appl
844	553	100.0	666	5	US-10-981-356A-29	Sequence 29, Appl	917	548	99.1	106	4	US-10-038-591-26	Sequence 26, Appl
845	553	100.0	666	5	US-10-981-356A-30	Sequence 30, Appl	918	548	99.1	106	4	US-10-773-531-40	Sequence 40, Appl
846	553	100.0	666	6	US-11-096-046-27	Sequence 27, Appl	919	548	99.1	106	4	US-10-775-444A-26	Sequence 26, Appl
847	553	100.0	667	5	US-10-764-428-7	Sequence 7, Appli	920	548	99.1	106	5	US-10-733-969A-63	Sequence 63, Appl
848	553	100.0	667	5	US-10-764-428-13	Sequence 13, Appl	921	548	99.1	106	5	US-10-887-954-12	Sequence 12, Appl
849	553	100.0	667	5	US-10-764-428-25	Sequence 25, Appl	922	548	99.1	106	5	US-10-706-689-4	Sequence 4, Appli
850	553	100.0	667	5	US-11-096-046-25	Sequence 25, Appl	923	548	99.1	106	5	US-10-988-360-4	Sequence 4, Appli
851	553	100.0	667	6	US-11-096-046-28	Sequence 28, Appl	924	548	99.1	106	5	US-10-901-736-58	Sequence 58, Appl
852	553	100.0	667	6	US-11-096-046-29	Sequence 29, Appl	925	548	99.1	106	5	US-10-983-555-40	Sequence 40, Appl
853	553	100.0	667	6	US-11-096-046-30	Sequence 30, Appl	926	548	99.1	106	6	US-11-013-537-3	Sequence 3, Appli
854	553	100.0	669	3	US-09-807-721-2	Sequence 2, Appli	927	548	99.1	106	6	US-11-013-537-25	Sequence 25, Appl
855	553	100.0	669	5	US-10-764-428-21	Sequence 21, Appl	928	548	99.1	106	6	US-11-090-846-46	Sequence 46, Appl
856	553	100.0	669	5	US-10-764-428-23	Sequence 23, Appl	929	548	99.1	106	6	US-11-090-846-46	Sequence 46, Appl
857	553	100.0	669	5	US-10-900-928-3	Sequence 3, Appli	930	548	99.1	106	6	US-11-090-846-46	Sequence 46, Appl
858	553	100.0	670	5	US-10-764-428-5	Sequence 5, Appli	931	548	99.1	106	6	US-11-144-248-26	Sequence 26, Appl
859	553	100.0	670	5	US-10-764-428-9	Sequence 9, Appli	932	548	99.1	106	6	US-11-024-251-29	Sequence 29, Appl
860	553	100.0	670	5	US-10-764-428-11	Sequence 11, Appl	933	548	99.1	106	6	US-11-163-141-17	Sequence 17, Appl
861	553	100.0	670	5	US-10-764-428-27	Sequence 27, Appl	934	548	99.1	106	6	US-11-144-222-26	Sequence 26, Appl
862	553	100.0	692	5	US-10-981-356A-26	Sequence 26, Appl	935	548	99.1	106	6	US-11-005-726-155	Sequence 155, App
863	553	100.0	695	6	US-11-096-046-26	Sequence 26, Appl	936	548	99.1	106	6	US-11-182-343-26	Sequence 26, Appl
864	553	100.0	713	4	US-10-679-620-64	Sequence 64, Appl	937	548	99.1	108	3	US-09-313-942-13	Sequence 13, Appl
865	553	100.0	713	6	US-11-132-143-64	Sequence 64, Appl	938	548	99.1	108	3	US-09-935-868-13	Sequence 13, Appl
866	553	100.0	715	4	US-10-679-620-62	Sequence 62, Appl	939	548	99.1	108	4	US-10-287-035-13	Sequence 13, Appl
867	553	100.0	715	6	US-11-132-143-62	Sequence 62, Appl	940	548	99.1	108	4	US-10-282-162-13	Sequence 13, Appl
868	553	100.0	738	6	US-10-418-836-19	Sequence 19, Appl	941	548	99.1	108	4	US-10-741-481-58	Sequence 58, Appl
869	553	100.0	738	6	US-11-007-886-19	Sequence 19, Appl	942	548	99.1	108	6	US-11-134-114-13	Sequence 13, Appl
870	553	100.0	739	4	US-10-418-836-26	Sequence 26, Appl	943	548	99.1	138	3	US-09-837-306-355	Sequence 355, App
871	553	100.0	739	4	US-10-418-836-27	Sequence 27, Appl	944	548	99.1	138	4	US-10-045-674-54	Sequence 524, App
872	553	100.0	739	6	US-11-007-886-26	Sequence 26, Appl	945	548	99.1	214	3	US-09-754-998-1	Sequence 1, Appli
873	553	100.0	739	6	US-11-007-886-27	Sequence 27, Appl	946	548	99.1	214	6	US-11-173-564-1	Sequence 1, Appli
874	553	100.0	740	4	US-10-418-836-28	Sequence 28, Appl	947	548	99.1	220	3	US-09-822-698A-24	Sequence 24, Appl
875	553	100.0	740	6	US-10-418-836-34	Sequence 34, Appl	948	548	99.1	235	4	US-10-016-986-153	Sequence 153, App
876	553	100.0	740	6	US-11-007-886-28	Sequence 28, Appl	949	548	99.1	235	4	US-10-410-907A-2	Sequence 2, Appli
877	553	100.0	740	6	US-11-007-886-34	Sequence 34, Appl	950	548	99.1	236	4	US-10-235-175-79	Sequence 79, Appl
878	553	100.0	741	4	US-10-418-836-30	Sequence 30, Appl	951	548	99.1	237	3	US-09-726-238-25	Sequence 25, Appl
879	553	100.0	741	6	US-11-007-886-30	Sequence 30, Appl	952	548	99.1	237	6	US-11-259-232-25	Sequence 25, Appl
880	553	100.0	742	4	US-10-418-836-29	Sequence 29, Appl	953	548	99.1	238	4	US-10-027-075-30	Sequence 30, Appl
881	553	100.0	742	6	US-11-007-886-29	Sequence 29, Appl	954	548	99.1	238	4	US-10-027-075-32	Sequence 32, Appl
882	553	100.0	743	4	US-10-418-836-9	Sequence 9, Appli	955	548	99.1	238	4	US-10-792-637-30	Sequence 30, Appl
883	553	100.0	743	4	US-10-418-836-31	Sequence 31, Appl	956	548	99.1	238	4	US-10-792-637-32	Sequence 32, Appl
884	553	100.0	743	4	US-10-418-836-35	Sequence 35, Appl	957	548	99.1	238	5	US-10-985-832-30	Sequence 30, Appl
885	553	100.0	743	6	US-11-007-886-9	Sequence 9, Appli	958	548	99.1	238	5	US-10-985-832-32	Sequence 32, Appl
886	553	100.0	743	6	US-11-007-886-31	Sequence 31, Appl	959	548	99.1	307	3	US-09-746-359A-58	Sequence 58, Appl
887	553	100.0	743	6	US-11-007-886-35	Sequence 35, Appl	960	548	99.1	307	3	US-09-951-268-42	Sequence 42, Appl
888	553	100.0	750	6	US-11-084-080-16	Sequence 16, Appl	961	548	99.1	307	3	US-09-745-792A-58	Sequence 58, Appl
889	553	100.0	750	6	US-11-084-080-20	Sequence 20, Appl	962	548	99.1	307	4	US-10-424-658-58	Sequence 58, Appl
890	553	100.0	750	6	US-11-084-080-22	Sequence 22, Appl	963	548	99.1	310	2	US-10-471-151-35	Sequence 35, Appli
891	553	100.0	750	6	US-11-084-080-24	Sequence 24, Appl	964	548	99.1	310	2	US-08-485-163-7	Sequence 7, Appli
892	553	100.0	751	6	US-11-084-080-26	Sequence 26, Appl	965	548	99.1	310	3	US-09-766-995-6	Sequence 6, Appli
893	553	100.0	751	6	US-11-084-080-28	Sequence 28, Appl	966	548	99.1	310	3	US-09-746-359A-57	Sequence 57, Appl
894	553	100.0	4852	4	US-10-412-406-33	Sequence 33, Appl	967	548	99.1	336	3	US-09-951-268-34	Sequence 34, Appl
895	550	99.5	135	4	US-10-408-765A-153	Sequence 153, App	968	548	99.1	336	3	US-09-745-792A-57	Sequence 57, Appl
896	550	99.5	214	5	US-10-484-790A-19	Sequence 19, Appl	969	548	99.1	336	4	US-10-424-658-57	Sequence 57, Appl
897	550	99.5	215	3	US-09-791-153A-49	Sequence 49, Appl	970	548	99.1	336	4	US-10-471-151-34	Sequence 34, Appl
898	550	99.5	223	3	US-09-837-306-305	Sequence 305, App	971	548	99.1	360	3	US-09-825-561A-18	Sequence 18, Appl
899	550	99.5	223	4	US-10-045-674-482	Sequence 482, App	972	548	99.1	360	5	US-10-872-087-18	Sequence 18, Appl
900	550	99.5	228	3	US-09-909-567B-50	Sequence 50, Appl	973	547	98.9	107	4	US-10-350-555-30	Sequence 30, Appl
901	550	99.5	232	6	US-11-013-537-23	Sequence 23, Appl	974	547	98.9	107	4	US-10-625-047-30	Sequence 30, Appl
902	550	99.5	239	4	US-10-292-088-80	Sequence 80, Appl	975	547	98.9	107	5	US-10-631-258-30	Sequence 30, Appl
903	550	99.5	241	4	US-10-221-945-1	Sequence 1, Appli	976	547	98.9	143	4	US-10-106-698-6554	Sequence 6554, Ap

```
977 547 98.9 206 4 US-10-264-049-4325 Sequence 4325, Ap
978 547 98.9 212 4 US-10-006-593-118 Sequence 118, App
979 547 98.9 212 4 US-10-307-724-118 Sequence 118, App
980 547 98.9 212 5 US-10-737-290-118 Sequence 118, App
981 547 98.9 214 5 US-10-745-775-117 Sequence 17, Appl
982 547 98.9 215 4 US-10-307-724-122 Sequence 122, App
983 547 98.9 215 4 US-10-698-041-6 Sequence 6, Appl
984 547 98.9 215 5 US-10-737-290-122 Sequence 122, App
985 547 98.9 217 4 US-10-251-215-39 Sequence 39, Appl
986 547 98.9 218 4 US-10-350-555-27 Sequence 27, Appl
987 547 98.9 218 4 US-10-350-555-28 Sequence 28, Appl
988 547 98.9 218 4 US-10-625-047-27 Sequence 27, Appl
989 547 98.9 218 4 US-10-625-047-28 Sequence 28, Appl
990 547 98.9 218 5 US-10-631-258-27 Sequence 27, Appl
991 547 98.9 218 5 US-10-631-258-28 Sequence 28, Appl
992 547 98.9 219 4 US-10-698-041-4 Sequence 4, Appl
993 547 98.9 239 5 US-10-737-290-142 Sequence 142, App
994 546 98.7 237 5 US-10-828-782A-16 Sequence 16, Appl
995 545 98.6 106 5 US-10-977-369-140 Sequence 140, App
996 545 98.6 216 5 US-10-916-758-22 Sequence 22, Appl
997 545 98.6 256 5 US-10-901-011-6 Sequence 6, Appl
998 544 98.4 211 3 US-09-974-449-36 Sequence 36, Appl
999 544 98.4 212 4 US-10-281-479A-72 Sequence 72, Appl
1000 544 98.4 212 4 US-10-275-180A-72 Sequence 72, Appl

ALIGNMENTS

RESULT 1
US-09-301-593-20
; Sequence 20, Application US/09301593A
; Publication No. US20020052480A1
; GENERAL INFORMATION:
; APPLICANT: Park, John E.
; APPLICANT: Garin-Chesa, Pilar
; APPLICANT: Bamberger, Uwe
; APPLICANT: Leger, Olivier
; APPLICANT: Saldanha, Jose W.
; APPLICANT: Rettig, Wolfgang J.
; TITLE OF INVENTION: FAP-specific Antibody with Improved Producibility
; FILE REFERENCE: 0652.1890001
; CURRENT APPLICATION NUMBER: US/09/301,593A
; CURRENT FILING DATE: 1999-04-29
; EARLIER APPLICATION NUMBER: EP 98107925.4
; EARLIER FILING DATE: 1998-04-30
; EARLIER APPLICATION NUMBER: US 60/086,049
; EARLIER FILING DATE: 1998-05-18
; NUMBER OF SEQ ID NOS: 108
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 20
; LENGTH: 107
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-301-593-20

Query Match 100.0%; Score 553; DB 3; Length 107;
Best Local Similarity 100.0%; Pred. No. 1.9e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60

QY 61 SKDSTYLSSTLTLSKADYKHKYKACVTHQGLSSPVTKSFNRGEC 107
Db 61 SKDSTYLSSTLTLSKADYKHKYKACVTHQGLSSPVTKSFNRGEC 107

RESULT 2
US-09-811-384-5
; Sequence 5, Application US/09811384
; Patent No. US20020081294A1

Query Match 100.0%; Score 553; DB 3; Length 107;
Best Local Similarity 100.0%; Pred. No. 1.9e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60

QY 61 SKDSTYLSSTLTLSKADYKHKYKACVTHQGLSSPVTKSFNRGEC 107
Db 61 SKDSTYLSSTLTLSKADYKHKYKACVTHQGLSSPVTKSFNRGEC 107

RESULT 3
US-09-990-586-97
; Sequence 97, Application US/09990586
; Publication No. US20030109680A1
; GENERAL INFORMATION:
; APPLICANT: JIAO, JIN-AN
; APPLICANT: WONG, HING C.
; TITLE OF INVENTION: ANTIBODIES FOR INHIBITING BLOOD COAGULATION AND METHODS
; FILE REFERENCE: 71758/46943-CIP2
; CURRENT APPLICATION NUMBER: US/09/990,586
; CURRENT FILING DATE: 2001-11-21
; PRIOR APPLICATION NUMBER: 09/293,854
; PRIOR FILING DATE: 1999-04-16
; NUMBER OF SEQ ID NOS: 102
; SOFTWARE: PatentIn Ver. 2.1
```

```
; GENERAL INFORMATION:
; APPLICANT: Bednar, Martin M.
; Thomas, G. Roger
; Gross, Cordell E.
; TITLE OF INVENTION: ANTI-CD18 ANTIBODIES IN STROKE
; NUMBER OF SEQUENCES: 15
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.
; STREET: 1 DNA Way
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WinPatIn (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/811,384
; FILING DATE: 20-Dec-2000
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/251652
; FILING DATE: 17-FEB-2000
; APPLICATION NUMBER: 08/788800
; FILING DATE: 22-JAN-1997
; APPLICATION NUMBER: 60/093038
; FILING DATE: 23-JAN-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Love, Richard B.
; REGISTRATION NUMBER: 34,659
; REFERENCE/DOCKET NUMBER: P1729C1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650/225-5530
; TELEFAX: 650/952-9881
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 107 amino acids
; TYPE: Amino Acid
; TOPOLOGY: Linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 5:
US-09-811-384-5

Query Match 100.0%; Score 553; DB 3; Length 107;
Best Local Similarity 100.0%; Pred. No. 1.9e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60

QY 61 SKDSTYLSSTLTLSKADYKHKYKACVTHQGLSSPVTKSFNRGEC 107
Db 61 SKDSTYLSSTLTLSKADYKHKYKACVTHQGLSSPVTKSFNRGEC 107

RESULT 3
US-09-990-586-97
; Sequence 97, Application US/09990586
; Publication No. US20030109680A1
; GENERAL INFORMATION:
; APPLICANT: JIAO, JIN-AN
; APPLICANT: WONG, HING C.
; TITLE OF INVENTION: ANTIBODIES FOR INHIBITING BLOOD COAGULATION AND METHODS
; FILE REFERENCE: 71758/46943-CIP2
; CURRENT APPLICATION NUMBER: US/09/990,586
; CURRENT FILING DATE: 2001-11-21
; PRIOR APPLICATION NUMBER: 09/293,854
; PRIOR FILING DATE: 1999-04-16
; NUMBER OF SEQ ID NOS: 102
; SOFTWARE: PatentIn Ver. 2.1
```

```
; SEQ ID NO 97
; LENGTH: 107
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-990-586-97

Query Match      100.0%; Score 553; DB 3; Length 107;
Best Local Similarity 100.0%; Pred. No. 1.9e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIPPPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 1 RTVAAPSVFIPPPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60

QY 61 SKDSTYSLSSTLTLSKADYEHKVKYACEVTHQGLSSPVTKSFNRGEC 107
Db 61 SKDSTYSLSSTLTLSKADYEHKVKYACEVTHQGLSSPVTKSFNRGEC 107

RESULT 4
US-09-990-586-99
; Sequence 99, Application US/09990586
; Publication No. US20030109680A1
; GENERAL INFORMATION:
; APPLICANT: JIAO, JIN-AN
; TITLE OF INVENTION: ANTIBODIES FOR INHIBITING BLOOD COAGULATION AND METHODS
; FILE REFERENCE: 71758/46943-CIP2
; CURRENT APPLICATION NUMBER: US/09/990,586
; CURRENT FILING DATE: 2001-11-21
; PRIOR APPLICATION NUMBER: 09/293,854
; PRIOR FILING DATE: 1999-04-16
; NUMBER OF SEQ ID NOS: 102
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 99
; LENGTH: 107
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-990-586-99

Query Match      100.0%; Score 553; DB 3; Length 107;
Best Local Similarity 100.0%; Pred. No. 1.9e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIPPPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 1 RTVAAPSVFIPPPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60

QY 61 SKDSTYSLSSTLTLSKADYEHKVKYACEVTHQGLSSPVTKSFNRGEC 107
Db 61 SKDSTYSLSSTLTLSKADYEHKVKYACEVTHQGLSSPVTKSFNRGEC 107

RESULT 5
US-10-121-464-18
; Sequence 18, Application US/10121464
; Publication No. US20030103968A1
; GENERAL INFORMATION:
; APPLICANT: Boehringer Ingelheim International GmbH
; APPLICANT: Boehringer Ingelheim Pharmaceuticals, Inc.
; TITLE OF INVENTION: Cancer treatment by using FAP-alpha specific antibodies
; FILE REFERENCE: 1-1203ff
; CURRENT APPLICATION NUMBER: US/10/121,464
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: US 60/283,868
; PRIOR FILING DATE: 2001-04-12
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 18
; LENGTH: 107
; TYPE: PRT
; ORGANISM: Artificial Sequence

; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Antibody
; OTHER INFORMATION: sequence
US-10-121-464-18

Query Match      100.0%; Score 553; DB 4; Length 107;
Best Local Similarity 100.0%; Pred. No. 1.9e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIPPPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 1 RTVAAPSVFIPPPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60

QY 61 SKDSTYSLSSTLTLSKADYEHKVKYACEVTHQGLSSPVTKSFNRGEC 107
Db 61 SKDSTYSLSSTLTLSKADYEHKVKYACEVTHQGLSSPVTKSFNRGEC 107

RESULT 6
US-10-269-805-67
; Sequence 67, Application US/10269805
; Publication No. US20030124129A1
; GENERAL INFORMATION:
; APPLICANT: OLINER, JONATHAN D.
; TITLE OF INVENTION: ANGIOPOIETIN-2 SPECIFIC BINDING AGENTS
; FILE REFERENCE: A-722
; CURRENT APPLICATION NUMBER: US/10/269,805
; CURRENT FILING DATE: 2002-10-10
; PRIOR APPLICATION NUMBER: US 60/328,604
; PRIOR FILING DATE: 2001-10-11
; NUMBER OF SEQ ID NOS: 76
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 67
; LENGTH: 107
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-269-805-67

Query Match      100.0%; Score 553; DB 4; Length 107;
Best Local Similarity 100.0%; Pred. No. 1.9e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIPPPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 1 RTVAAPSVFIPPPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60

QY 61 SKDSTYSLSSTLTLSKADYEHKVKYACEVTHQGLSSPVTKSFNRGEC 107
Db 61 SKDSTYSLSSTLTLSKADYEHKVKYACEVTHQGLSSPVTKSFNRGEC 107

RESULT 7
US-10-159-006-20
; Sequence 20, Application US/10159006
; Publication No. US20030143229A1
; GENERAL INFORMATION:
; APPLICANT: Park, John E.
; APPLICANT: Garin-Chesa, Pilar
; APPLICANT: Bamberger, Uwe
; APPLICANT: Leger, Olivier
; APPLICANT: Saldanha, Jose W.
; APPLICANT: Rettig, Wolfgang J.
; TITLE OF INVENTION: FAPA-specific Antibody with Improved Producibility
; FILE REFERENCE: 0652-1890002
; CURRENT APPLICATION NUMBER: US/10/159,006
; CURRENT FILING DATE: 2002-06-03
; PRIOR APPLICATION NUMBER: US 09/301,593
; PRIOR FILING DATE: 1999-04-29
; PRIOR APPLICATION NUMBER: EP 98107925.4
; PRIOR FILING DATE: 1998-04-30
; PRIOR APPLICATION NUMBER: US 60/086,049
; PRIOR FILING DATE: 1998-05-18
; NUMBER OF SEQ ID NOS: 108
```

```
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 20
; LENGTH: 107
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-159-006-20

Query Match          100.0%; Score 553; DB 4; Length 107;
Best Local Similarity 100.0%; Pred. No. 1.9e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQKVDNALQSGNSQESVTEQD 60
    |||||||
Db 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQKVDNALQSGNSQESVTEQD 60
    |||||||

Qy 61 SKDSTYSLSSLTLSKADYEHKVKYACEVTHQGLSSPVTKSFNRGEC 107
    |||||||
Db 61 SKDSTYSLSSLTLSKADYEHKVKYACEVTHQGLSSPVTKSFNRGEC 107
    |||||||

RESULT 8
US-10-310-113-166
; Sequence 166, Application US/10310113
; Publication No. US20030176664A1
; GENERAL INFORMATION:
; APPLICANT: JIAO, JIN-AN
; APPLICANT: WONG, HING C.
; APPLICANT: NIEVES, ESPERANZA LILIANA
; APPLICANT: MOSQUERA, LUIS A.
; TITLE OF INVENTION: USE OF ANTI-TISSUE FACTOR ANTIBODIES FOR TREATING
; FILE REFERENCE: 58122(71758)
; CURRENT APPLICATION NUMBER: US/10/310,113
; CURRENT FILING DATE: 2002-12-04
; PRIOR APPLICATION NUMBER: 09/990,586
; PRIOR FILING DATE: 2001-11-21
; PRIOR APPLICATION NUMBER: 60/343,306
; PRIOR FILING DATE: 2001-10-29
; PRIOR APPLICATION NUMBER: 09/293,854
; PRIOR FILING DATE: 1999-04-16
; PRIOR APPLICATION NUMBER: 08/814,806
; PRIOR FILING DATE: 1997-03-10
; NUMBER OF SEQ ID NOS: 169
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 166
; LENGTH: 107
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-310-113-166

Query Match          100.0%; Score 553; DB 4; Length 107;
Best Local Similarity 100.0%; Pred. No. 1.9e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQKVDNALQSGNSQESVTEQD 60
    |||||||
Db 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQKVDNALQSGNSQESVTEQD 60
    |||||||

Qy 61 SKDSTYSLSSLTLSKADYEHKVKYACEVTHQGLSSPVTKSFNRGEC 107
    |||||||
Db 61 SKDSTYSLSSLTLSKADYEHKVKYACEVTHQGLSSPVTKSFNRGEC 107
    |||||||

RESULT 9
US-10-310-113-168
; Sequence 168, Application US/10310113
; Publication No. US20030176664A1
; GENERAL INFORMATION:
; APPLICANT: JIAO, JIN-AN
; APPLICANT: WONG, HING C.
; APPLICANT: NIEVES, ESPERANZA LILIANA
; APPLICANT: MOSQUERA, LUIS A.
; TITLE OF INVENTION: USE OF ANTI-TISSUE FACTOR ANTIBODIES FOR TREATING
```

```
; TITLE OF INVENTION: THROMBOSES
; FILE REFERENCE: 58122(71758)
; CURRENT APPLICATION NUMBER: US/10/310,113
; CURRENT FILING DATE: 2002-12-04
; PRIOR APPLICATION NUMBER: 09/990,586
; PRIOR FILING DATE: 2001-11-21
; PRIOR APPLICATION NUMBER: 60/343,306
; PRIOR FILING DATE: 2001-10-29
; PRIOR APPLICATION NUMBER: 09/293,854
; PRIOR FILING DATE: 1999-04-16
; PRIOR APPLICATION NUMBER: 08/814,806
; PRIOR FILING DATE: 1997-03-10
; NUMBER OF SEQ ID NOS: 169
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 168
; LENGTH: 107
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-310-113-168

Query Match          100.0%; Score 553; DB 4; Length 107;
Best Local Similarity 100.0%; Pred. No. 1.9e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQKVDNALQSGNSQESVTEQD 60
    |||||||
Db 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQKVDNALQSGNSQESVTEQD 60
    |||||||

Qy 61 SKDSTYSLSSLTLSKADYEHKVKYACEVTHQGLSSPVTKSFNRGEC 107
    |||||||
Db 61 SKDSTYSLSSLTLSKADYEHKVKYACEVTHQGLSSPVTKSFNRGEC 107
    |||||||

RESULT 10
US-10-230-880-97
; Sequence 97, Application US/10230880
; Publication No. US20030190705A1
; GENERAL INFORMATION:
; APPLICANT: WONG, HING C.
; APPLICANT: STINSON, JEFFREY L.
; APPLICANT: MOSQUERA, LUIS A.
; TITLE OF INVENTION: METHOD OF HUMANIZING IMMUNE SYSTEM MOLECULES
; FILE REFERENCE: 71758/58066
; CURRENT APPLICATION NUMBER: US/10/230,880
; CURRENT FILING DATE: 2002-12-23
; PRIOR APPLICATION NUMBER: 09/990,586
; PRIOR FILING DATE: 2001-11-21
; PRIOR APPLICATION NUMBER: 60/343,306
; PRIOR FILING DATE: 2001-10-29
; PRIOR APPLICATION NUMBER: 09/293,854
; PRIOR FILING DATE: 1999-04-16
; NUMBER OF SEQ ID NOS: 174
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 97
; LENGTH: 107
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-230-880-97

Query Match          100.0%; Score 553; DB 4; Length 107;
Best Local Similarity 100.0%; Pred. No. 1.9e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQKVDNALQSGNSQESVTEQD 60
    |||||||
Db 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQKVDNALQSGNSQESVTEQD 60
    |||||||

Qy 61 SKDSTYSLSSLTLSKADYEHKVKYACEVTHQGLSSPVTKSFNRGEC 107
    |||||||
Db 61 SKDSTYSLSSLTLSKADYEHKVKYACEVTHQGLSSPVTKSFNRGEC 107
    |||||||

RESULT 11
```

```
US-10-230-880-99
; Sequence 99, Application US/10230880
; Publication No. US20030190705A1
; GENERAL INFORMATION:
; APPLICANT: WONG, HING C.
; APPLICANT: STINSON, JEFFREY L.
; APPLICANT: MOSQUERA, LUIS A.
; TITLE OF INVENTION: METHOD OF HUMANIZING IMMUNE SYSTEM MOLECULES
; FILE REFERENCE: 71758/58066
; CURRENT APPLICATION NUMBER: US/10/230,880
; CURRENT FILING DATE: 2002-12-23
; PRIOR APPLICATION NUMBER: 09/990,586
; PRIOR FILING DATE: 2001-11-21
; PRIOR APPLICATION NUMBER: 60/343,306
; PRIOR FILING DATE: 2001-10-29
; PRIOR APPLICATION NUMBER: 09/293,854
; PRIOR FILING DATE: 1999-04-16
; NUMBER OF SEQ ID NOS: 174
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 99
; LENGTH: 107
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-230-880-99

Query Match      100.0%; Score 553; DB 4; Length 107;
Best Local Similarity 100.0%; Pred. No. 1.9e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
DB 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
QY 61 SKDSTYLSSTLTLSKADYEHKHKVYACEVTHQGLSSPVTKSNRGE 107
DB 61 SKDSTYLSSTLTLSKADYEHKHKVYACEVTHQGLSSPVTKSNRGE 107

RESULT 12
US-10-366-709-54
; Sequence 54, Application US/10366709
; Publication No. US20030219433A1
; GENERAL INFORMATION:
; APPLICANT: HANSEN, HANS
; APPLICANT: QU, ZHENGXING
; APPLICANT: GOLDENBERG, DAVID M.
; TITLE OF INVENTION: ANTI-CD20 ANTIBODIES AND FUSION PROTEINS THEREOF AND
; FILE REFERENCE: 18733/115
; CURRENT APPLICATION NUMBER: US/10/366,709
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: 60/356,132
; PRIOR FILING DATE: 2002-02-14
; PRIOR APPLICATION NUMBER: 60/416,232
; PRIOR FILING DATE: 2002-10-07
; NUMBER OF SEQ ID NOS: 55
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 54
; LENGTH: 107
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-366-709-54

Query Match      100.0%; Score 553; DB 4; Length 107;
Best Local Similarity 100.0%; Pred. No. 1.9e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
DB 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
QY 61 SKDSTYLSSTLTLSKADYEHKHKVYACEVTHQGLSSPVTKSNRGE 107
DB 61 SKDSTYLSSTLTLSKADYEHKHKVYACEVTHQGLSSPVTKSNRGE 107

US-10-230-880-99
; Sequence 99, Application US/10230880
; Publication No. US20030190705A1
; GENERAL INFORMATION:
; APPLICANT: WONG, HING C.
; APPLICANT: STINSON, JEFFREY L.
; APPLICANT: MOSQUERA, LUIS A.
; TITLE OF INVENTION: METHOD OF HUMANIZING IMMUNE SYSTEM MOLECULES
; FILE REFERENCE: 71758/58066
; CURRENT APPLICATION NUMBER: US/10/230,880
; CURRENT FILING DATE: 2002-12-23
; PRIOR APPLICATION NUMBER: 09/990,586
; PRIOR FILING DATE: 2001-11-21
; PRIOR APPLICATION NUMBER: 60/343,306
; PRIOR FILING DATE: 2001-10-29
; PRIOR APPLICATION NUMBER: 09/293,854
; PRIOR FILING DATE: 1999-04-16
; NUMBER OF SEQ ID NOS: 174
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 99
; LENGTH: 107
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-230-880-99

Query Match      100.0%; Score 553; DB 4; Length 107;
Best Local Similarity 100.0%; Pred. No. 1.9e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
DB 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
QY 61 SKDSTYLSSTLTLSKADYEHKHKVYACEVTHQGLSSPVTKSNRGE 107
DB 61 SKDSTYLSSTLTLSKADYEHKHKVYACEVTHQGLSSPVTKSNRGE 107

US-10-404-286-5
; Sequence 5, Application US/10404286
; Publication No. US20040057951A1
; GENERAL INFORMATION:
; APPLICANT: Bednar, Martin M.
; APPLICANT: Thomas, G. Roger
; APPLICANT: Gross, Cordell E.
; TITLE OF INVENTION: ANTI-CD18 ANTIBODIES IN STROKE
; NUMBER OF SEQUENCES: 15
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.
; STREET: 1 DNA Way
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WinPatIn (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/404,286
; FILING DATE: 31-Mar-2006
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/811384
; FILING DATE: 20-DEC-2000
; APPLICATION NUMBER: 09/251652
; FILING DATE: 17-FEB-2000
; APPLICATION NUMBER: 08/788800
; FILING DATE: 22-JAN-1997
; APPLICATION NUMBER: 60/093038
; FILING DATE: 23-JAN-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Evans, David W.
; REGISTRATION NUMBER: NONE
; REFERENCE/DOCKET NUMBER: P1729C2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650/225-1739
; TELEFAX: 650/952-9881
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 107 amino acids
; TYPE: Amino Acid
; TOPOLOGY: Linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 5:
US-10-404-286-5

Query Match      100.0%; Score 553; DB 4; Length 107;
Best Local Similarity 100.0%; Pred. No. 1.9e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
DB 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
QY 61 SKDSTYLSSTLTLSKADYEHKHKVYACEVTHQGLSSPVTKSNRGE 107
DB 61 SKDSTYLSSTLTLSKADYEHKHKVYACEVTHQGLSSPVTKSNRGE 107

RESULT 14
US-10-656-769-4
; Sequence 4, Application US/10656769
; Publication No. US20040097712A1
; GENERAL INFORMATION:
; APPLICANT: Varnum, Brian
; APPLICANT: Witte, Alison
```

```
; APPLICANT: Vezina, Chris
; APPLICANT: Wong, Lu Min
; APPLICANT: Qian, Xueming
; TITLE OF INVENTION: Therapeutic Human Anti-IL-1R Monoclonal Antibody
; FILE REFERENCE: 01.1554
; CURRENT APPLICATION NUMBER: US/10/656,769
; PRIOR FILING DATE: 2003-09-05
; NUMBER OF SEQ ID NOS: 79
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4
; LENGTH: 107
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-656-769-4

Query Match      100.0%; Score 553; DB 4; Length 107;
Best Local Similarity 100.0%; Pred. No. 1.9e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60

Qy 61 SKDSTYSLSTLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 107
Db 61 SKDSTYSLSTLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 107

RESULT 15
US-10-679-620-60
; Sequence 60, Application US/10679620
; Publication No. US20040110930A1
; GENERAL INFORMATION:
; APPLICANT: Large Scale Biology
; APPLICANT: Reinf, Stephen J.
; APPLICANT: Edwards, Patricia C.
; TITLE OF INVENTION: MULTIMERIC PROTEIN ENGINEERING
; FILE REFERENCE: 34150-004A
; CURRENT APPLICATION NUMBER: US/10/679,620
; CURRENT FILING DATE: 2003-10-03
; PRIOR APPLICATION NUMBER: 60/415,940
; PRIOR FILING DATE: 2002-10-03
; NUMBER OF SEQ ID NOS: 122
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 60
; LENGTH: 107
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: huscFabmla6 , see Example 15
US-10-679-620-60

Query Match      100.0%; Score 553; DB 4; Length 107;
Best Local Similarity 100.0%; Pred. No. 1.9e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60

Qy 61 SKDSTYSLSTLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 107
Db 61 SKDSTYSLSTLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 107

RESULT 16
US-10-733-563-112
; Sequence 112, Application US/10733563
; Publication No. US20040151721A1
; GENERAL INFORMATION:
; APPLICANT: O'Keefe, Theresa
; APPLICANT: Ponath, Paul
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
```

```
; TITLE OF INVENTION: METHODS OF USE THEREOF
; FILE REFERENCE: 10448-213001
; CURRENT APPLICATION NUMBER: US/10/733,563
; CURRENT FILING DATE: 2003-12-10
; PRIOR APPLICATION NUMBER: US 10/272,899
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: US 60/392,364
; PRIOR FILING DATE: 2002-06-26
; PRIOR APPLICATION NUMBER: US 60/350,166
; PRIOR FILING DATE: 2001-10-19
; NUMBER OF SEQ ID NOS: 122
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 112
; LENGTH: 107
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: human C Kappa protein
US-10-733-563-112

Query Match      100.0%; Score 553; DB 4; Length 107;
Best Local Similarity 100.0%; Pred. No. 1.9e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60

Qy 61 SKDSTYSLSTLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 107
Db 61 SKDSTYSLSTLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 107

RESULT 17
US-10-815-449-10
; Sequence 10, Application US/10815449
; Publication No. US20040228859A1
; GENERAL INFORMATION:
; APPLICANT: GRAUS, Ivo
; APPLICANT: KOPETZKI, Erhard
; APPLICANT: KUENKELE, Klaus-Peter
; APPLICANT: MUNDIGL, Olaf
; APPLICANT: PARREN, Paul
; APPLICANT: REERS, Frank
; APPLICANT: SCHUMACHER, Ralf
; APPLICANT: Van de WINKEL, Jan
; APPLICANT: Vugt, Martine
; TITLE OF INVENTION: Antibodies against insulin-like growth factor I receptor and uses
; FILE REFERENCE: 21655 US2
; CURRENT APPLICATION NUMBER: US/10/815,449
; CURRENT FILING DATE: 2004-04-01
; PRIOR APPLICATION NUMBER: US 60/459,837
; PRIOR FILING DATE: 2003-04-02
; PRIOR APPLICATION NUMBER: US 60/463,003
; PRIOR FILING DATE: 2003-04-15
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10
; LENGTH: 107
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-815-449-10

Query Match      100.0%; Score 553; DB 5; Length 107;
Best Local Similarity 100.0%; Pred. No. 1.9e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60

Qy 61 SKDSTYSLSTLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 107
```


Db 61 SKDSTYLSSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 107
|||||

RESULT 18
US-10-684-957-4
; Sequence 4, Application US/10684957
; Publication No. US20050004953A1
; GENERAL INFORMATION:
; APPLICANT: Amgen, Inc.
; APPLICANT: Welcher, Andrew
; APPLICANT: Chute, Hilary
; APPLICANT: Li, Luke
; APPLICANT: Huang, Haichun
; TITLE OF INVENTION: Human anti-IFN-gamma Neutralizing Antibodies as Selective IFN-gam
; TITLE OF INVENTION: Pathway Inhibitors
; FILE REFERENCE: 01-1635-B
; CURRENT APPLICATION NUMBER: US/10/684,957
; CURRENT FILING DATE: 2003-10-14
; PRIOR APPLICATION NUMBER: US 60/419,057
; PRIOR FILING DATE: 2002-10-16
; PRIOR APPLICATION NUMBER: US 60/479,241
; PRIOR FILING DATE: 2003-06-17
; NUMBER OF SEQ ID NOS: 57
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4
; LENGTH: 107
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-684-957-4

Query Match 100.0%; Score 553; DB 5; Length 107;
Best Local Similarity 100.0%; Pred. No. 1.9e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
QY 61 SKDSTYLSSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 107
Db 61 SKDSTYLSSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 107

RESULT 19
US-10-886-838-8
; Sequence 8, Application US/10886838
; Publication No. US20050008642A1
; GENERAL INFORMATION:
; APPLICANT: Hoffmann-La Roche Inc.
; TITLE OF INVENTION: Antibodies against insulin-like growth factor I receptor and use
; TITLE OF INVENTION: thereof
; FILE REFERENCE: 21695
; CURRENT APPLICATION NUMBER: US/10/886,838
; CURRENT FILING DATE: 2004-07-08
; PRIOR APPLICATION NUMBER: EP 03015526
; PRIOR FILING DATE: 2003-07-10
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8
; LENGTH: 107
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-886-838-8

Query Match 100.0%; Score 553; DB 5; Length 107;
Best Local Similarity 100.0%; Pred. No. 1.9e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60

QY 61 SKDSTYLSSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 107
Db 61 SKDSTYLSSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 107

RESULT 20
US-10-822-300-9
; Sequence 9, Application US/10822300
; Publication No. US20050014934A1
; GENERAL INFORMATION:
; APPLICANT: Hinton, et al.
; TITLE OF INVENTION: ALTERATION OF FC γ n BINDING AFFINITIES OR SERUM HALF-LIVES OF
; TITLE OF INVENTION: ANTIBODIES BY MUTAGENESIS
; FILE REFERENCE: 05882.0039.CPUS01
; CURRENT APPLICATION NUMBER: US/10/822,300
; CURRENT FILING DATE: 2004-04-09
; NUMBER OF SEQ ID NOS: 146
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9
; LENGTH: 107
; TYPE: PRT
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Humanized antibody
US-10-822-300-9

Query Match 100.0%; Score 553; DB 5; Length 107;
Best Local Similarity 100.0%; Pred. No. 1.9e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
QY 61 SKDSTYLSSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 107
Db 61 SKDSTYLSSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 107

RESULT 21
US-10-687-118-9
; Sequence 9, Application US/10687118
; Publication No. US20050032114A1
; GENERAL INFORMATION:
; APPLICANT: Hinton, et al.
; TITLE OF INVENTION: ALTERATION OF FC γ n BINDING AFFINITIES OR SERUM HALF-LIVES OF
; TITLE OF INVENTION: ANTIBODIES BY MUTAGENESIS
; FILE REFERENCE: 05882.0039.NFUS04
; CURRENT APPLICATION NUMBER: US/10/687,118
; CURRENT FILING DATE: 2003-10-15
; NUMBER OF SEQ ID NOS: 112
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9
; LENGTH: 107
; TYPE: PRT
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Humanized antibody
US-10-687-118-9

Query Match 100.0%; Score 553; DB 5; Length 107;
Best Local Similarity 100.0%; Pred. No. 1.9e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
QY 61 SKDSTYLSSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 107
Db 61 SKDSTYLSSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 107

Qy	1	RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQMKVDNALQSGNSQESVTEQD	60
Db	1	RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQMKVDNALQSGNSQESVTEQD	60
Qy	61	SKDSTVYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	107
Db	61	SKDSTVYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	107

```

RESULT 26
US-10-810-881A-40
; Sequence 40, Application US/10810881A
; Publication No. US20050129695A1
; GENERAL INFORMATION:
; APPLICANT: Mercken, Marc; Benson, Jacqueline M.
; TITLE OF INVENTION: ANTI-AMYLOID ANTIBODIES, COMPOSITIONS, METHODS AND USES
; FILE REFERENCE: CEN5021 NP
; CURRENT APPLICATION NUMBER: US/10/810.881A
; CURRENT FILING DATE: 2004-03-26
; PRIOR APPLICATION NUMBER: US 60/458,474
; PRIOR FILING DATE: 2003-03-28
; PRIOR APPLICATION NUMBER: US 60/458,469
; PRIOR FILING DATE: 2003-03-28
; PRIOR APPLICATION NUMBER: US 60/458,509
; PRIOR FILING DATE: 2003-03-28
; PRIOR APPLICATION NUMBER: US 60/458,510
; PRIOR FILING DATE: 2003-03-28
; NUMBER OF SEQ ID NOS: 131
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 40
; LENGTH: 107
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: MISC FEATURE
; LOCATION: (1)..(107)
; OTHER INFORMATION: Light chain kappa constant region (Igkc)
US-10-810-881A-40

```

Query Match	100.0%;	Score 553;	DB 5;	Length 107;
Best Local Similarity	100.0%;	Pred. No. 1.9e-51;		
Matches 107;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;

Qy	1	RTVAASVFIFPPSDEQLKSGTASVCLLNFFYPREAKVQWKVDNALQSGNSQESVTEQD	60
Db	1	RTVAASVFIFPPSDEQLKSGTASVCLLNFFYPREAKVQWKVDNALQSGNSQESVTEQD	60
Qy	61	SKDSTVLSLTLLSKADYEKHKVYACEVTHOGLSSPVTKSFNRGEC	107
Db	61	SKDSTVLSLTLLSKADYEKHKVYACEVTHOGLSSPVTKSFNRGEC	107

```

RESULT 27
US-10-981-936-40
; Sequence 40, Application US/10981936
; Publication No. US20050232923A1
; GENERAL INFORMATION:
; APPLICANT: Li, Yan; Nakada, Marian T.; Das, Anuk
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR TREATING MCP-1 RELATED PATHOLOGIES
; FILE REFERENCE: CEN5041 NP
; CURRENT APPLICATION NUMBER: US/10/981,936
; CURRENT FILING DATE: 2004-11-05
; PRIOR APPLICATION NUMBER: US 60/517,370
; PRIOR FILING DATE: 2003/11/05
; NUMBER OF SEQ ID NOS: 42
; SOFTWARE: PatentIn Ver 3.3
; SEQ ID NO 40
; LENGTH: 107
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: MISC.FEATURE
; LOCATION: (1)..(107)

```

```
; FEATURE:
; OTHER INFORMATION: mab TGN1412 constant region light chain
US-10-988-207-21

Query Match      100.0%; Score 553; DB 5; Length 107;
Best Local Similarity 100.0%; Pred. No. 1.9e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
   |||||||
Db 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
   |||||||

QY 61 SKDSTYSLSTLTLSKADYEHKVKYACEVTHQGLSSPVTKSFNRGEC 107
   |||||||
Db 61 SKDSTYSLSTLTLSKADYEHKVKYACEVTHQGLSSPVTKSFNRGEC 107
   |||||||

RESULT 30
US-10-982-440-67
; Sequence 67, Application US/10982440
; Publication No. US20060018909A1
; GENERAL INFORMATION:
; APPLICANT: Oliner, John
; APPLICANT: Graham, Kevin
; TITLE OF INVENTION: Angiopoietin-2 Specific Binding Agents
; FILE REFERENCE: 04-881-A
; CURRENT APPLICATION NUMBER: US/10/982,440
; PRIOR FILING DATE: 2004-11-04
; PRIOR APPLICATION NUMBER: 60/620,161
; PRIOR FILING DATE: 2004-10-19
; NUMBER OF SEQ ID NOS: 215
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 67
; LENGTH: 107
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-982-440-67

Query Match      100.0%; Score 553; DB 5; Length 107;
Best Local Similarity 100.0%; Pred. No. 1.9e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
   |||||||
Db 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
   |||||||

QY 61 SKDSTYSLSTLTLSKADYEHKVKYACEVTHQGLSSPVTKSFNRGEC 107
   |||||||
Db 61 SKDSTYSLSTLTLSKADYEHKVKYACEVTHQGLSSPVTKSFNRGEC 107
   |||||||

RESULT 31
US-10-935-005B-71
; Sequence 71, Application US/10935005B
; Publication No. US20060051844A1
; GENERAL INFORMATION:
; APPLICANT: HEAVNER, George A.; KNIGHT, David; GHAYEB, John; SCALLON, Bernard;
; APPLICANT: NESSFOR, Thomas; HUANG, Chichang
; TITLE OF INVENTION: HUMAN EPO METETIC HINGE CORE MIMETIBODIES,
; FILE REFERENCE: CEN5039NP
; CURRENT APPLICATION NUMBER: US/10/935,005B
; CURRENT FILING DATE: 2004-09-03
; NUMBER OF SEQ ID NOS: 89
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 71
; LENGTH: 107
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: MISC_FEATURE
; LOCATION: (1)..(107)
; OTHER INFORMATION: Light chain kappa constant region (IgKc)
US-10-935-005B-71
```

```
Query Match      100.0%; Score 553; DB 5; Length 107;
Best Local Similarity 100.0%; Pred. No. 1.9e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
   |||||||
Db 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
   |||||||

QY 61 SKDSTYSLSTLTLSKADYEHKVKYACEVTHQGLSSPVTKSFNRGEC 107
   |||||||
Db 61 SKDSTYSLSTLTLSKADYEHKVKYACEVTHQGLSSPVTKSFNRGEC 107
   |||||||

RESULT 32
US-11-001-980-4
; Sequence 4, Application US/11001980
; Publication No. US20050136055A1
; GENERAL INFORMATION:
; APPLICANT: Gladue et al., Ronald P.
; TITLE OF INVENTION: CD40 ANTIBODY FORMULATION AND METHODS
; FILE REFERENCE: PC32065A
; CURRENT APPLICATION NUMBER: US/11/001,980
; CURRENT FILING DATE: 2004-12-02
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4
; LENGTH: 107
; TYPE: PRT
; ORGANISM: 3.1.1: Human
US-11-001-980-4

Query Match      100.0%; Score 553; DB 6; Length 107;
Best Local Similarity 100.0%; Pred. No. 1.9e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
   |||||||
Db 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
   |||||||

QY 61 SKDSTYSLSTLTLSKADYEHKVKYACEVTHQGLSSPVTKSFNRGEC 107
   |||||||
Db 61 SKDSTYSLSTLTLSKADYEHKVKYACEVTHQGLSSPVTKSFNRGEC 107
   |||||||

RESULT 33
US-11-001-980-8
; Sequence 8, Application US/11001980
; Publication No. US20050136055A1
; GENERAL INFORMATION:
; APPLICANT: Gladue et al., Ronald P.
; TITLE OF INVENTION: CD40 ANTIBODY FORMULATION AND METHODS
; FILE REFERENCE: PC32065A
; CURRENT APPLICATION NUMBER: US/11/001,980
; CURRENT FILING DATE: 2004-12-02
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8
; LENGTH: 107
; TYPE: PRT
; ORGANISM: 21.4.1: Human
US-11-001-980-8

Query Match      100.0%; Score 553; DB 6; Length 107;
Best Local Similarity 100.0%; Pred. No. 1.9e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
   |||||||
Db 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
   |||||||

QY 61 SKDSTYSLSTLTLSKADYEHKVKYACEVTHQGLSSPVTKSFNRGEC 107
   |||||||
Db 61 SKDSTYSLSTLTLSKADYEHKVKYACEVTHQGLSSPVTKSFNRGEC 107
   |||||||
```

Db 61 SKDSTYSLSTLTLSKADYEHKVVACEVTHQGLSSPVTKSFNRGEC 107

RESULT 34
US-11-132-143-60
; Sequence 60, Application US/11132143
; Publication No. US20050207977A1
; GENERAL INFORMATION:
; APPLICANT: Large Scale Biology
; APPLICANT: Reinl, Stephen J.
; APPLICANT: Edwards, Patricia C.
; TITLE OF INVENTION: MULTIMERIC PROTEIN ENGINEERING
; FILE REFERENCE: 34150-004A
; CURRENT APPLICATION NUMBER: US/11/132,143
; CURRENT FILING DATE: 2005-05-17
; PRIOR APPLICATION NUMBER: US/10/679,620
; PRIOR FILING DATE: 2003-10-03
; PRIOR APPLICATION NUMBER: 60/415,940
; PRIOR FILING DATE: 2002-10-03
; NUMBER OF SEQ ID NOS: 122
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 60
; LENGTH: 107
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: huscFabmiA6 , see Example 15
US-11-132-143-60

Query Match 100.0%; Score 553; DB 6; Length 107;
Best Local Similarity 100.0%; Pred. No. 1.9e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 RTVAAPSVFIPPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 1 RTVAAPSVFIPPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Qy 61 SKDSTYSLSTLTLSKADYEHKVVACEVTHQGLSSPVTKSFNRGEC 107
Db 61 SKDSTYSLSTLTLSKADYEHKVVACEVTHQGLSSPVTKSFNRGEC 107

RESULT 35
US-11-102-403-23
; Sequence 23, Application US/11102403
; Publication No. US20050226876A1
; GENERAL INFORMATION:
; APPLICANT: GRAUS, YVO
; APPLICANT: HIMBER, JACQUES
; APPLICANT: JANSSEN-MOLENAAR, MIRANDA
; APPLICANT: KLING, DOROTHEE
; APPLICANT: KOPETZKI, ERHARD
; APPLICANT: PAREN, PAUL
; APPLICANT: REBERS, FRANK
; APPLICANT: STEINER, BEAT
; APPLICANT: STERN, ANNE
; APPLICANT: STUBENRAUCH, KAY-GUNNAR
; APPLICANT: VAN DE WINKEL, JAN
; APPLICANT: VAN VUGT, MARTINE
; TITLE OF INVENTION: ANTI-P SELECTIN ANTIBODIES
; FILE REFERENCE: 22354
; CURRENT APPLICATION NUMBER: US/11/102,403
; CURRENT FILING DATE: 2005-04-08
; PRIOR APPLICATION NUMBER: EP 04008722.3
; PRIOR FILING DATE: 2004-04-13
; NUMBER OF SEQ ID NOS: 55
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 23
; LENGTH: 107
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-102-403-23

Query Match 100.0%; Score 553; DB 6; Length 107;
Best Local Similarity 100.0%; Pred. No. 1.9e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 RTVAAPSVFIPPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 1 RTVAAPSVFIPPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Qy 61 SKDSTYSLSTLTLSKADYEHKVVACEVTHQGLSSPVTKSFNRGEC 107
Db 61 SKDSTYSLSTLTLSKADYEHKVVACEVTHQGLSSPVTKSFNRGEC 107

RESULT 36
US-11-025-712-5
; Sequence 5, Application US/11025712
; Publication No. US20050255108A1
; GENERAL INFORMATION:
; APPLICANT: Bednar, Martin M.
; APPLICANT: Thomas, G. Roger
; APPLICANT: Gross, Cordell E.
; TITLE OF INVENTION: ANTI-CD18 ANTIBODIES IN STROKE
; NUMBER OF SEQUENCES: 15
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.
; STREET: 1 DNA Way
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WinPatIn (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/11/025,712
; FILING DATE: 28-Dec-2004
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/10/404,286
; FILING DATE: 31-Mar-2003
; APPLICATION NUMBER: 09/811384
; FILING DATE: 20-DEC-2000
; APPLICATION NUMBER: 09/251652
; FILING DATE: 17-FEB-2000
; APPLICATION NUMBER: 08/788800
; FILING DATE: 22-JAN-1997
; APPLICATION NUMBER: 60/093038
; FILING DATE: 23-JAN-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Evans, David W.
; REGISTRATION NUMBER: NONE
; REFERENCE/DOCKET NUMBER: P1729C2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650/225-1739
; TELEFAX: 650/952-9881
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 107 amino acids
; TYPE: Amino Acid
; TOPOLOGY: Linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 5:
US-11-025-712-5

Query Match 100.0%; Score 553; DB 6; Length 107;
Best Local Similarity 100.0%; Pred. No. 1.9e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 RTVAAPSVFIPPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 1 RTVAAPSVFIPPPSDEQLKSGTASVVCCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60

QY 61 SKDSTYSLSTLTLSKADYEHKVVACEVTHQGLSSPVTKSFNRGEC 107
|||||
DB 61 SKDSTYSLSTLTLSKADYEHKVVACEVTHQGLSSPVTKSFNRGEC 107
|||||

RESULT 37
US-11-075-351-61
; Sequence 61, Application US/11075351
; Publication No. US20050260716A1
; GENERAL INFORMATION:
; APPLICANT: Moore, Margaret D.
; APPLICANT: Fox, Brian A.
; TITLE OF INVENTION: DIMERIC FUSION PROTEINS AND MATERIALS
; TITLE OF INVENTION: AND METHODS FOR PRODUCING THEM
; FILE REFERENCE: 02-16
; CURRENT APPLICATION NUMBER: US/11/075,351
; CURRENT FILING DATE: 2005-03-08
; NUMBER OF SEQ ID NOS: 63
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 61
; LENGTH: 107
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-075-351-61

Query Match 100.0%; Score 553; DB 6; Length 107;
Best Local Similarity 100.0%; Pred. No. 1.9e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQMKVDNALQSGNSQESVTEQD 60
|||||
DB 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQMKVDNALQSGNSQESVTEQD 60
|||||

QY 61 SKDSTYSLSTLTLSKADYEHKVVACEVTHQGLSSPVTKSFNRGEC 107
|||||
DB 61 SKDSTYSLSTLTLSKADYEHKVVACEVTHQGLSSPVTKSFNRGEC 107
|||||

RESULT 38
US-11-061-821-40
; Sequence 40, Application US/11061821
; Publication No. US20050266005A1
; GENERAL INFORMATION:
; APPLICANT: Heavner, George; Li, Li; Oneil, Karyn
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR TREATING IL-13 RELATED PATHOLOGIES
; FILE REFERENCE: CEN5048 NP
; CURRENT APPLICATION NUMBER: US/11/061,821
; CURRENT FILING DATE: 2005-02-18
; PRIOR APPLICATION NUMBER: 60/548,648
; PRIOR FILING DATE: 2004-02-27
; NUMBER OF SEQ ID NOS: 42
; SOFTWARE: PatentIn Ver 3.3
; SEQ ID NO 40
; LENGTH: 107
; TYPE: PRT
; ORGANISM: Homo sapiens
; NAME/KEY: MISC FEATURE
; LOCATION: (1)..(107)
; OTHER INFORMATION: Light chain kappa constant region (IgKc)
US-11-061-821-40

Query Match 100.0%; Score 553; DB 6; Length 107;
Best Local Similarity 100.0%; Pred. No. 1.9e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQMKVDNALQSGNSQESVTEQD 60
|||||
DB 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQMKVDNALQSGNSQESVTEQD 60
|||||

QY 61 SKDSTYSLSTLTLSKADYEHKVVACEVTHQGLSSPVTKSFNRGEC 107
|||||

DB 61 SKDSTYSLSTLTLSKADYEHKVVACEVTHQGLSSPVTKSFNRGEC 107

RESULT 39
US-11-102-621-9
; Sequence 9, Application US/11102621
; Publication No. US20050276799A1
; GENERAL INFORMATION:
; APPLICANT: Protein Design Labs, Inc.
; APPLICANT: Hinton, Paul R.
; APPLICANT: Tsurushita, Naoya
; APPLICANT: Tso, J. Yun
; APPLICANT: Vasquez, Maximiliano
; TITLE OF INVENTION: ALTERATION OF FcRn BINDING AFFINITIES OR SERUM HALF-LIVES OF
; TITLE OF INVENTION: ANTIBODIES BY MUTAGENESIS
; FILE REFERENCE: 05882.0039.00PC03
; CURRENT APPLICATION NUMBER: US/11/102,621
; CURRENT FILING DATE: 2005-04-08
; PRIOR APPLICATION NUMBER: US 10/822,300
; PRIOR FILING DATE: 2004-04-09
; NUMBER OF SEQ ID NOS: 146
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9
; LENGTH: 107
; TYPE: PRT
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Humanized antibody
US-11-102-621-9

Query Match 100.0%; Score 553; DB 6; Length 107;
Best Local Similarity 100.0%; Pred. No. 1.9e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQMKVDNALQSGNSQESVTEQD 60
|||||
DB 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQMKVDNALQSGNSQESVTEQD 60
|||||

QY 61 SKDSTYSLSTLTLSKADYEHKVVACEVTHQGLSSPVTKSFNRGEC 107
|||||
DB 61 SKDSTYSLSTLTLSKADYEHKVVACEVTHQGLSSPVTKSFNRGEC 107
|||||

RESULT 40
US-11-122-622-97
; Sequence 97, Application US/11122622
; Publication No. US20060039901A1
; GENERAL INFORMATION:
; APPLICANT: JIAO, JIN-AN
; APPLICANT: WONG, HING C.
; TITLE OF INVENTION: ANTIBODIES FOR INHIBITING BLOOD COAGULATION AND METHODS
; TITLE OF INVENTION: OF USE THEREOF
; FILE REFERENCE: 71758/46943-CIP2
; CURRENT APPLICATION NUMBER: US/11/122,622
; CURRENT FILING DATE: 2005-05-05
; PRIOR APPLICATION NUMBER: US/09/990,586
; PRIOR FILING DATE: 2001-11-21
; PRIOR APPLICATION NUMBER: 09/293,854
; PRIOR FILING DATE: 1999-04-16
; NUMBER OF SEQ ID NOS: 102
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 97
; LENGTH: 107
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-122-622-97

Query Match 100.0%; Score 553; DB 6; Length 107;
Best Local Similarity 100.0%; Pred. No. 1.9e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQMKVDNALQSGNSQESVTEQD 60
|||||

```
Db 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
QY 61 SKDSTYLSSTLTLSKADYKHKYKACVTHQGLSSPVTKSFNRGEC 107
Db 61 SKDSTYLSSTLTLSKADYKHKYKACVTHQGLSSPVTKSFNRGEC 107

RESULT 41
US-11-122-622-99
; Sequence 99, Application US/11122622
; Publication No. US20060039901A1
; GENERAL INFORMATION:
; APPLICANT: JIAO, JIN-AN
; APPLICANT: WONG, HING C.
; TITLE OF INVENTION: ANTIBODIES FOR INHIBITING BLOOD COAGULATION AND METHODS
; FILE REFERENCE: 71758/46943-CIP2
; CURRENT APPLICATION NUMBER: US/11/122,622
; CURRENT FILING DATE: 2005-05-05
; PRIOR APPLICATION NUMBER: US/09/990,586
; PRIOR FILING DATE: 2001-11-21
; PRIOR APPLICATION NUMBER: 09/293,854
; PRIOR FILING DATE: 1999-04-16
; NUMBER OF SEQ ID NOS: 102
; SOFTWARE: Patent In Ver. 2.1
; SEQ ID NO 99
; LENGTH: 107
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-122-622-99

Query Match 100.0%; Score 553; DB 6; Length 107;
Best Local Similarity 100.0%; Pred. No. 1.9e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60

QY 61 SKDSTYLSSTLTLSKADYKHKYKACVTHQGLSSPVTKSFNRGEC 107
Db 61 SKDSTYLSSTLTLSKADYKHKYKACVTHQGLSSPVTKSFNRGEC 107

RESULT 42
US-11-218-813-134
; Sequence 134, Application US/11218813
; Publication No. US20060062793A1
; GENERAL INFORMATION:
; APPLICANT: Webb, Iain J.
; APPLICANT: Horvath, Christopher J.
; TITLE OF INVENTION: MODIFIED ANTIBODIES TO PROSTATE-SPECIFIC
; FILE REFERENCE: 10448-163005
; CURRENT APPLICATION NUMBER: US/11/218,813
; CURRENT FILING DATE: 2005-09-02
; PRIOR APPLICATION NUMBER: PCT/US2004/006543
; PRIOR FILING DATE: 2004-03-03
; NUMBER OF SEQ ID NOS: 144
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 134
; LENGTH: 107
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Light chain variable and constant region of deJ591.
US-11-218-813-134

Query Match 100.0%; Score 553; DB 6; Length 107;
Best Local Similarity 100.0%; Pred. No. 1.9e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
```

```
Db 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
QY 61 SKDSTYLSSTLTLSKADYKHKYKACVTHQGLSSPVTKSFNRGEC 107
Db 61 SKDSTYLSSTLTLSKADYKHKYKACVTHQGLSSPVTKSFNRGEC 107

RESULT 43
US-11-149-309-18
; Sequence 18, Application US/11149309
; Publication No. US20060063228A1
; GENERAL INFORMATION:
; APPLICANT: Kasaian, Marion T.
; APPLICANT: Tchistiakova, Lioudmila
; APPLICANT: Veldman, Geertuida M.
; APPLICANT: Marquette, Kimberly Ann
; APPLICANT: Tan, Xiang-Yang
; APPLICANT: Donaldson, Debra D.
; APPLICANT: Shane, Tania
; APPLICANT: Tam, Amy Szepui
; APPLICANT: Peyfant, Eric
; APPLICANT: Wood, Nancy L.
; APPLICANT: Fitz, Lori J.
; APPLICANT: Widom, Angela M.
; APPLICANT: Parris, Kevin D.
; APPLICANT: Goldman, Samuel J.
; TITLE OF INVENTION: Antibodies against Human Interleukin-13 and Uses Therefor
; FILE REFERENCE: 16158-048001 / AM101493
; CURRENT APPLICATION NUMBER: US/11/149,309
; CURRENT FILING DATE: 2005-06-09
; PRIOR APPLICATION NUMBER: US 60/578,473
; PRIOR FILING DATE: 2004-06-09
; PRIOR APPLICATION NUMBER: US 60/581,375
; PRIOR FILING DATE: 2004-06-22
; PRIOR APPLICATION NUMBER: US 60/578,736
; PRIOR FILING DATE: 2004-06-09
; NUMBER OF SEQ ID NOS: 37
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 18
; LENGTH: 107
; TYPE: PRT
; ORGANISM: Homo sapiens
; NAME/KEY: MISC FEATURE
; OTHER INFORMATION: The "r" in position #1 represents amino acid residue #112 when
; OTHER INFORMATION: the sequence follows residue #111 of, e.g., SEQ ID NOS:11 or 12.
US-11-149-309-18

Query Match 100.0%; Score 553; DB 6; Length 107;
Best Local Similarity 100.0%; Pred. No. 1.9e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60

QY 61 SKDSTYLSSTLTLSKADYKHKYKACVTHQGLSSPVTKSFNRGEC 107
Db 61 SKDSTYLSSTLTLSKADYKHKYKACVTHQGLSSPVTKSFNRGEC 107

RESULT 44
US-10-272-899A-12
; Sequence 12, Application US/10272899A
; Publication No. US20040033561A1
; GENERAL INFORMATION:
; APPLICANT: O'Keefe, Theresa L.
; APPLICANT: Healy, Judith Jacques
; APPLICANT: Newman, Walter
; APPLICANT: Ponath, Paul
; APPLICANT: Bruce Keyt
```



```
; TITLE OF INVENTION: IMMUNOGLOBULIN DNA CASSETTE MOLECULES.
; TITLE OF INVENTION: MONOBODY CONSTRUCTS, METHODS OF PRODUCTION, AND METHODS OF
; TITLE OF INVENTION: USE THEREFOR
; FILE REFERENCE: MPI01-244P2RM
; CURRENT APPLICATION NUMBER: US/10/272,899A
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/350,166
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: 60/392,364
; PRIOR FILING DATE: 2002-06-26
; NUMBER OF SEQ ID NOS: 110
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 12
; LENGTH: 109
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: human C Kappa protein
US-10-733-563-116

Query Match          100.0%; Score 553; DB 4; Length 109;
Best Local Similarity 100.0%; Pred. No. 1.9e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIPPPSDEQLKSGTASVVCCLNFFYPREAKVQWKVDNALQSGNSQESVTEQD 60
   |||||
Db 3 RTVAAPSVFIPPPSDEQLKSGTASVVCCLNFFYPREAKVQWKVDNALQSGNSQESVTEQD 62

QY 61 SKDSTYSLSTLTSLKADYEHKHYACEVTHQGLSSPVTKSFNRGEC 107
   |||||
Db 63 SKDSTYSLSTLTSLKADYEHKHYACEVTHQGLSSPVTKSFNRGEC 109

RESULT 45
US-10-733-563-116
; Sequence 116, Application US/10733563
; Publication No. US20040151721a1
; GENERAL INFORMATION:
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; TITLE OF INVENTION: METHODS OF USE THEREOF
; FILE REFERENCE: 10448-213001
; CURRENT APPLICATION NUMBER: US/10/733,563
; CURRENT FILING DATE: 2003-12-10
; PRIOR APPLICATION NUMBER: US 10/272,899
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: US 60/392,364
; PRIOR FILING DATE: 2002-06-26
; PRIOR APPLICATION NUMBER: US 60/350,166
; PRIOR FILING DATE: 2001-10-19
; NUMBER OF SEQ ID NOS: 122
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 116
; LENGTH: 109
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: human C Kappa protein
US-10-733-563-116

Query Match          100.0%; Score 553; DB 4; Length 109;
Best Local Similarity 100.0%; Pred. No. 1.9e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIPPPSDEQLKSGTASVVCCLNFFYPREAKVQWKVDNALQSGNSQESVTEQD 60
   |||||
Db 3 RTVAAPSVFIPPPSDEQLKSGTASVVCCLNFFYPREAKVQWKVDNALQSGNSQESVTEQD 62

QY 61 SKDSTYSLSTLTSLKADYEHKHYACEVTHQGLSSPVTKSFNRGEC 107
   |||||
Db 63 SKDSTYSLSTLTSLKADYEHKHYACEVTHQGLSSPVTKSFNRGEC 109
```

```
RESULT 46
US-11-024-251-27
; Sequence 27, Application US/11024251
; Publication No. US20050266425a1
; GENERAL INFORMATION:
; APPLICANT: Zauderer, Maurice
; APPLICANT: Paris, Mark
; TITLE OF INVENTION: Methods for Producing and Identifying Multispecific Antibodies
; FILE REFERENCE: 1843.0230001
; CURRENT APPLICATION NUMBER: US/11/024,251
; CURRENT FILING DATE: 2004-12-29
; PRIOR APPLICATION NUMBER: 60/533,241
; PRIOR FILING DATE: 2003-12-31
; NUMBER OF SEQ ID NOS: 129
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 27
; LENGTH: 110
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: clambda Constant Domain
US-11-024-251-27

Query Match          100.0%; Score 553; DB 6; Length 110;
Best Local Similarity 100.0%; Pred. No. 2e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIPPPSDEQLKSGTASVVCCLNFFYPREAKVQWKVDNALQSGNSQESVTEQD 60
   |||||
Db 4 RTVAAPSVFIPPPSDEQLKSGTASVVCCLNFFYPREAKVQWKVDNALQSGNSQESVTEQD 63

QY 61 SKDSTYSLSTLTSLKADYEHKHYACEVTHQGLSSPVTKSFNRGEC 107
   |||||
Db 64 SKDSTYSLSTLTSLKADYEHKHYACEVTHQGLSSPVTKSFNRGEC 110

RESULT 47
US-10-272-899A-66
; Sequence 66, Application US/10272899A
; Publication No. US20040033561a1
; GENERAL INFORMATION:
; APPLICANT: O'Keefe, Theresa L.
; APPLICANT: Healy, Judith Jacques
; APPLICANT: Newman, Walter
; APPLICANT: Ponath, Paul
; APPLICANT: Bruce Keyt
; TITLE OF INVENTION: IMMUNOGLOBULIN DNA CASSETTE MOLECULES,
; TITLE OF INVENTION: MONOBODY CONSTRUCTS, METHODS OF PRODUCTION, AND METHODS OF
; TITLE OF INVENTION: USE THEREFOR
; FILE REFERENCE: MPI01-244P2RM
; CURRENT APPLICATION NUMBER: US/10/272,899A
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/350,166
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: 60/392,364
; PRIOR FILING DATE: 2002-06-26
; NUMBER OF SEQ ID NOS: 110
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 66
; LENGTH: 134
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: immunoglobulin cassette protein sequence
; OTHER INFORMATION: Leader-HuCK_57
US-10-272-899A-66

Query Match          100.0%; Score 553; DB 4; Length 134;
Best Local Similarity 100.0%; Pred. No. 2.5e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIPPPSDEQLKSGTASVVCCLNFFYPREAKVQWKVDNALQSGNSQESVTEQD 60
```

Db 28 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEOD 87
Qy 61 SKDSTYSLSTLTLSKADYEHKVKYACVETHQGLSSPVTKSFNRGEC 107
Db 88 SKDSTYSLSTLTLSKADYEHKVKYACVETHQGLSSPVTKSFNRGEC 134

RESULT 48
US-10-011-125-5
; Sequence 5, Application US/10011125
; Publication No. US20020142388A1
; GENERAL INFORMATION:
; APPLICANT: Chen, Christina Yu-Ching
; TITLE OF INVENTION: BACTERIAL HOST STRAINS
; FILE REFERENCE: P1804R1
; CURRENT APPLICATION NUMBER: US/10/011,125
; CURRENT FILING DATE: 2001-12-07
; PRIOR APPLICATION NUMBER: US 60/256,162
; PRIOR FILING DATE: 2000-12-14
; NUMBER OF SEQ ID NOS: 10
; SEQ ID NO 5
; LENGTH: 212
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Sequence is synthesized.

Query Match 100.0%; Score 553; DB 4; Length 212;
Best Local Similarity 100.0%; Pred. No. 4.5e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEOD 60
Db 106 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEOD 165
Qy 61 SKDSTYSLSTLTLSKADYEHKVKYACVETHQGLSSPVTKSFNRGEC 107
Db 166 SKDSTYSLSTLTLSKADYEHKVKYACVETHQGLSSPVTKSFNRGEC 212

RESULT 49
US-10-320-231A-77
; Sequence 77, Application US/10320231A
; Publication No. US20030194405A1
; GENERAL INFORMATION:
; APPLICANT: Neben, Steven
; APPLICANT: Takeuchi, Toshihiko
; APPLICANT: Tomkinson, Adrian
; TITLE OF INVENTION: Antibody Inhibiting Stem Cell Factor Activity And Use For
; FILE REFERENCE: 7430*163
; CURRENT APPLICATION NUMBER: US/10/320,231A
; CURRENT FILING DATE: 2002-12-19
; PRIOR APPLICATION NUMBER: US 60/342,174
; PRIOR FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 85
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 77
; LENGTH: 212
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: synthetic sequence

Query Match 100.0%; Score 553; DB 4; Length 212;
Best Local Similarity 100.0%; Pred. No. 4.5e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEOD 60

Db 106 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEOD 165
Qy 61 SKDSTYSLSTLTLSKADYEHKVKYACVETHQGLSSPVTKSFNRGEC 107
Db 166 SKDSTYSLSTLTLSKADYEHKVKYACVETHQGLSSPVTKSFNRGEC 212

RESULT 50
US-10-867-506-77
; Sequence 77, Application US/10867506
; Publication No. US20050112698A1
; GENERAL INFORMATION:
; APPLICANT: Neben, Steven
; APPLICANT: Takeuchi, Toshihiko
; APPLICANT: Tomkinson, Adrian
; APPLICANT: Delaria, Kathy
; APPLICANT: Yan, Kelly
; APPLICANT: Wong, Teresa
; APPLICANT: Longphre, Malinda
; TITLE OF INVENTION: Antibody Inhibiting Stem Cell Factor Activity And Use For
; FILE REFERENCE: 11334*10
; CURRENT APPLICATION NUMBER: US/10/867,506
; CURRENT FILING DATE: 2004-06-14
; PRIOR APPLICATION NUMBER: US 10/320,231
; PRIOR FILING DATE: 2002-12-16
; PRIOR APPLICATION NUMBER: US 60/342,174
; PRIOR FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 101
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 77
; LENGTH: 212
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: synthetic sequence

Query Match 100.0%; Score 553; DB 5; Length 212;
Best Local Similarity 100.0%; Pred. No. 4.5e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEOD 60
Db 106 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEOD 165
Qy 61 SKDSTYSLSTLTLSKADYEHKVKYACVETHQGLSSPVTKSFNRGEC 107
Db 166 SKDSTYSLSTLTLSKADYEHKVKYACVETHQGLSSPVTKSFNRGEC 212

RESULT 51
US-09-796-848A-38
; Sequence 38, Application US/09796848A
; Patent No. US20020098189A1
; GENERAL INFORMATION:
; APPLICANT: Young, James F.
; APPLICANT: Johnson, Leslie S.
; APPLICANT: Huse, William D.
; APPLICANT: Wu, Herren
; APPLICANT: Watkins, Jeffrey D.
; TITLE OF INVENTION: High Potency Recombinant Antibodies and Methods of
; FILE REFERENCE: 469201-526
; CURRENT APPLICATION NUMBER: US/09/796,848A
; CURRENT FILING DATE: 2001-10-30
; PRIOR APPLICATION NUMBER: U.S. 60/186,252
; PRIOR FILING DATE: 2000-03-01
; NUMBER OF SEQ ID NOS: 59
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 38
; LENGTH: 213
; TYPE: PRT

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Light chain of
; OTHER INFORMATION: high potency antibody.
US-09-796-848A-38

Query Match          100.0%; Score 553; DB 3; Length 213;
Best Local Similarity 100.0%; Pred. No. 4.5e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RTVAAPSVFIPPPSDEQLKSGTASVVCCLNNFYFPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 107 RTVAAPSVFIPPPSDEQLKSGTASVVCCLNNFYFPREAKVQWKVDNALQSGNSQESVTEQD 166

Qy 61 SKDSTYSLSSLTLSKADYERKHVKYVACEVTHQGLSSPVTKSFNRGEC 107
Db 167 SKDSTYSLSSLTLSKADYERKHVKYVACEVTHQGLSSPVTKSFNRGEC 213

RESULT 52
US-09-796-848A-40
; Sequence 40, Application US/09796848A
; Patent No. US20020098189A1
; GENERAL INFORMATION:
; APPLICANT: Young, James F.
; APPLICANT: Johnson, Leslie S.
; APPLICANT: Huse, William D.
; APPLICANT: Wu, Herren
; APPLICANT: Watkins, Jeffry D.
; TITLE OF INVENTION: High Potency Recombinant Antibodies and Methods of
; FILE REFERENCE: 469201-526
; CURRENT APPLICATION NUMBER: US/09/796,848A
; CURRENT FILING DATE: 2001-10-30
; PRIOR APPLICATION NUMBER: U.S. 60/186,252
; PRIOR FILING DATE: 2000-03-01
; NUMBER OF SEQ ID NOS: 59
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 40
; LENGTH: 213
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Light chain of
; OTHER INFORMATION: high potency antibody.
US-09-796-848A-40

Query Match          100.0%; Score 553; DB 3; Length 213;
Best Local Similarity 100.0%; Pred. No. 4.5e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RTVAAPSVFIPPPSDEQLKSGTASVVCCLNNFYFPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 107 RTVAAPSVFIPPPSDEQLKSGTASVVCCLNNFYFPREAKVQWKVDNALQSGNSQESVTEQD 166

Qy 61 SKDSTYSLSSLTLSKADYERKHVKYVACEVTHQGLSSPVTKSFNRGEC 107
Db 167 SKDSTYSLSSLTLSKADYERKHVKYVACEVTHQGLSSPVTKSFNRGEC 213

RESULT 53
US-09-796-848A-42
; Sequence 42, Application US/09796848A
; Patent No. US20020098189A1
; GENERAL INFORMATION:
; APPLICANT: Young, James F.
; APPLICANT: Johnson, Leslie S.
; APPLICANT: Huse, William D.
; APPLICANT: Wu, Herren
; APPLICANT: Watkins, Jeffry D.
; TITLE OF INVENTION: High Potency Recombinant Antibodies and Methods of
; FILE REFERENCE: 469201-526
; CURRENT APPLICATION NUMBER: US/09/796,848A
; CURRENT FILING DATE: 2001-10-30
; PRIOR APPLICATION NUMBER: U.S. 60/186,252
; PRIOR FILING DATE: 2000-03-01
; NUMBER OF SEQ ID NOS: 59
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 42
; LENGTH: 213
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Light chain of
; OTHER INFORMATION: high potency antibody.
US-09-796-848A-42

Query Match          100.0%; Score 553; DB 3; Length 213;
Best Local Similarity 100.0%; Pred. No. 4.5e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RTVAAPSVFIPPPSDEQLKSGTASVVCCLNNFYFPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 107 RTVAAPSVFIPPPSDEQLKSGTASVVCCLNNFYFPREAKVQWKVDNALQSGNSQESVTEQD 166

Qy 61 SKDSTYSLSSLTLSKADYERKHVKYVACEVTHQGLSSPVTKSFNRGEC 107
Db 167 SKDSTYSLSSLTLSKADYERKHVKYVACEVTHQGLSSPVTKSFNRGEC 213
```

```
; CURRENT APPLICATION NUMBER: US/09/796,848A
; CURRENT FILING DATE: 2001-10-30
; PRIOR APPLICATION NUMBER: U.S. 60/186,252
; PRIOR FILING DATE: 2000-03-01
; NUMBER OF SEQ ID NOS: 59
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 42
; LENGTH: 213
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Light chain of
; OTHER INFORMATION: high potency antibody.
US-09-796-848A-42

Query Match          100.0%; Score 553; DB 3; Length 213;
Best Local Similarity 100.0%; Pred. No. 4.5e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RTVAAPSVFIPPPSDEQLKSGTASVVCCLNNFYFPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 107 RTVAAPSVFIPPPSDEQLKSGTASVVCCLNNFYFPREAKVQWKVDNALQSGNSQESVTEQD 166

Qy 61 SKDSTYSLSSLTLSKADYERKHVKYVACEVTHQGLSSPVTKSFNRGEC 107
Db 167 SKDSTYSLSSLTLSKADYERKHVKYVACEVTHQGLSSPVTKSFNRGEC 213

RESULT 54
US-09-796-848A-44
; Sequence 44, Application US/09796848A
; Patent No. US20020098189A1
; GENERAL INFORMATION:
; APPLICANT: Young, James F.
; APPLICANT: Johnson, Leslie S.
; APPLICANT: Huse, William D.
; APPLICANT: Wu, Herren
; APPLICANT: Watkins, Jeffry D.
; TITLE OF INVENTION: High Potency Recombinant Antibodies and Methods of
; FILE REFERENCE: 469201-526
; CURRENT APPLICATION NUMBER: US/09/796,848A
; CURRENT FILING DATE: 2001-10-30
; PRIOR APPLICATION NUMBER: U.S. 60/186,252
; PRIOR FILING DATE: 2000-03-01
; NUMBER OF SEQ ID NOS: 59
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 44
; LENGTH: 213
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Light chain of
; OTHER INFORMATION: high potency antibody.
US-09-796-848A-44

Query Match          100.0%; Score 553; DB 3; Length 213;
Best Local Similarity 100.0%; Pred. No. 4.5e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RTVAAPSVFIPPPSDEQLKSGTASVVCCLNNFYFPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 107 RTVAAPSVFIPPPSDEQLKSGTASVVCCLNNFYFPREAKVQWKVDNALQSGNSQESVTEQD 166

Qy 61 SKDSTYSLSSLTLSKADYERKHVKYVACEVTHQGLSSPVTKSFNRGEC 107
Db 167 SKDSTYSLSSLTLSKADYERKHVKYVACEVTHQGLSSPVTKSFNRGEC 213

RESULT 55
US-09-796-848A-46
; Sequence 46, Application US/09796848A
; Patent No. US20020098189A1
```

```

; GENERAL INFORMATION:
; APPLICANT: Young, James F.
; APPLICANT: Johnson, Leslie S.
; APPLICANT: Huse, William D.
; APPLICANT: Wu, Herren
; APPLICANT: Watkins, Jeffrey D.
; TITLE OF INVENTION: High Potency Recombinant Antibodies and Methods of
; FILE REFERENCE: 469201-526
; CURRENT APPLICATION NUMBER: US/09/796,848A
; CURRENT FILING DATE: 2001-10-30
; PRIOR APPLICATION NUMBER: U.S. 60/186,252
; PRIOR FILING DATE: 2000-03-01
; NUMBER OF SEQ ID NOS: 59
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 46
; LENGTH: 213
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Light chain of
; OTHER INFORMATION: high potency antibody.
US-09-796-848A-46

Query Match      100.0%; Score 553; DB 3; Length 213;
Best Local Similarity 100.0%; Pred. No. 4.5e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db      107 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166

Qy      61 SKDSTYSLSTLTLSKADYERKHVKYACEVTHQGLSSPVTKSNRGEC 107
Db      167 SKDSTYSLSTLTLSKADYERKHVKYACEVTHQGLSSPVTKSNRGEC 213

Query Match      100.0%; Score 553; DB 3; Length 213;
Best Local Similarity 100.0%; Pred. No. 4.5e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db      107 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166

Qy      61 SKDSTYSLSTLTLSKADYERKHVKYACEVTHQGLSSPVTKSNRGEC 107
Db      167 SKDSTYSLSTLTLSKADYERKHVKYACEVTHQGLSSPVTKSNRGEC 213

RESULT 56
US-09-796-848A-48
; Sequence 48, Application US/09796848A
; Patent No. US20020098189A1
; GENERAL INFORMATION:
; APPLICANT: Young, James F.
; APPLICANT: Johnson, Leslie S.
; APPLICANT: Huse, William D.
; APPLICANT: Wu, Herren
; APPLICANT: Watkins, Jeffrey D.
; TITLE OF INVENTION: High Potency Recombinant Antibodies and Methods of
; FILE REFERENCE: 469201-526
; CURRENT APPLICATION NUMBER: US/09/796,848A
; CURRENT FILING DATE: 2001-10-30
; PRIOR APPLICATION NUMBER: U.S. 60/186,252
; PRIOR FILING DATE: 2000-03-01
; NUMBER OF SEQ ID NOS: 59
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 48
; LENGTH: 213
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Light chain of
; OTHER INFORMATION: high potency antibody.
US-09-796-848A-48

Query Match      100.0%; Score 553; DB 3; Length 213;
Best Local Similarity 100.0%; Pred. No. 4.5e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db      107 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166
```

```

Qy      61 SKDSTYSLSTLTLSKADYERKHVKYACEVTHQGLSSPVTKSNRGEC 107
Db      167 SKDSTYSLSTLTLSKADYERKHVKYACEVTHQGLSSPVTKSNRGEC 213

RESULT 57
US-09-796-848A-50
; Sequence 50, Application US/09796848A
; Patent No. US20020098189A1
; GENERAL INFORMATION:
; APPLICANT: Young, James F.
; APPLICANT: Johnson, Leslie S.
; APPLICANT: Huse, William D.
; APPLICANT: Wu, Herren
; APPLICANT: Watkins, Jeffrey D.
; TITLE OF INVENTION: High Potency Recombinant Antibodies and Methods of
; FILE REFERENCE: 469201-526
; CURRENT APPLICATION NUMBER: US/09/796,848A
; CURRENT FILING DATE: 2001-10-30
; PRIOR APPLICATION NUMBER: U.S. 60/186,252
; PRIOR FILING DATE: 2000-03-01
; NUMBER OF SEQ ID NOS: 59
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 50
; LENGTH: 213
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Light chain of
; OTHER INFORMATION: high potency antibody.
US-09-796-848A-50

Query Match      100.0%; Score 553; DB 3; Length 213;
Best Local Similarity 100.0%; Pred. No. 4.5e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db      107 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166

Qy      61 SKDSTYSLSTLTLSKADYERKHVKYACEVTHQGLSSPVTKSNRGEC 107
Db      167 SKDSTYSLSTLTLSKADYERKHVKYACEVTHQGLSSPVTKSNRGEC 213

RESULT 58
US-09-796-848A-52
; Sequence 52, Application US/09796848A
; Patent No. US20020098189A1
; GENERAL INFORMATION:
; APPLICANT: Young, James F.
; APPLICANT: Johnson, Leslie S.
; APPLICANT: Huse, William D.
; APPLICANT: Wu, Herren
; APPLICANT: Watkins, Jeffrey D.
; TITLE OF INVENTION: High Potency Recombinant Antibodies and Methods of
; FILE REFERENCE: 469201-526
; CURRENT APPLICATION NUMBER: US/09/796,848A
; CURRENT FILING DATE: 2001-10-30
; PRIOR APPLICATION NUMBER: U.S. 60/186,252
; PRIOR FILING DATE: 2000-03-01
; NUMBER OF SEQ ID NOS: 59
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 52
; LENGTH: 213
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Light chain of
; OTHER INFORMATION: high potency antibody.
US-09-796-848A-52
```

```
Query Match      100.0%; Score 553; DB 3; Length 213;
Best Local Similarity 100.0%; Pred. No. 4.5e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
    |||||
Db 107 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166

QY 61 SKDSTYSLSTLTLSKADYEHKHYACVETHQGLSSPVTKSFNRGEC 107
    |||||
Db 167 SKDSTYSLSTLTLSKADYEHKHYACVETHQGLSSPVTKSFNRGEC 213

RESULT 59
US-09-796-848A-54
; Sequence 54, Application US/09796848A
; Patent No. US2002098189A1
; GENERAL INFORMATION:
; APPLICANT: Young, James F.
; APPLICANT: Johnson, Leslie S.
; APPLICANT: Huse, William D.
; APPLICANT: Wu, Herren
; APPLICANT: Watkins, Jeffry D.
; TITLE OF INVENTION: High Potency Recombinant Antibodies and Methods of
; TITLE OF INVENTION: Producing Them
; FILE REFERENCE: 469201-526
; CURRENT APPLICATION NUMBER: US/09/796,848A
; CURRENT FILING DATE: 2001-10-30
; PRIOR APPLICATION NUMBER: U.S. 60/186,252
; PRIOR FILING DATE: 2000-03-01
; NUMBER OF SEQ ID NOS: 59
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 54
; LENGTH: 213
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Light chain of
; OTHER INFORMATION: high potency antibody.
US-09-796-848A-54

Query Match      100.0%; Score 553; DB 3; Length 213;
Best Local Similarity 100.0%; Pred. No. 4.5e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
    |||||
Db 107 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166

QY 61 SKDSTYSLSTLTLSKADYEHKHYACVETHQGLSSPVTKSFNRGEC 107
    |||||
Db 167 SKDSTYSLSTLTLSKADYEHKHYACVETHQGLSSPVTKSFNRGEC 213

RESULT 60
US-09-996-288-209
; Sequence 209, Application US/09996288
; Patent No. US20020177126A1
; GENERAL INFORMATION:
; APPLICANT: Young, James
; APPLICANT: Scott, Koenig
; APPLICANT: Leslie, Johnson
; TITLE OF INVENTION: Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxi
; TITLE OF INVENTION: and Treatment
; FILE REFERENCE: 10271-047-999
; CURRENT APPLICATION NUMBER: US/09/996,288
; CURRENT FILING DATE: 2001-11-28
; NUMBER OF SEQ ID NOS: 259
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 209
; LENGTH: 213
; TYPE: PRT
```

```
; ORGANISM: Homo sapiens
US-09-996-288-209

Query Match      100.0%; Score 553; DB 3; Length 213;
Best Local Similarity 100.0%; Pred. No. 4.5e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
    |||||
Db 107 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166

QY 61 SKDSTYSLSTLTLSKADYEHKHYACVETHQGLSSPVTKSFNRGEC 107
    |||||
Db 167 SKDSTYSLSTLTLSKADYEHKHYACVETHQGLSSPVTKSFNRGEC 213

RESULT 61
US-09-996-288-211
; Sequence 211, Application US/09996288
; Patent No. US20020177126A1
; GENERAL INFORMATION:
; APPLICANT: Young, James
; APPLICANT: Scott, Koenig
; APPLICANT: Leslie, Johnson
; TITLE OF INVENTION: Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxi
; TITLE OF INVENTION: and Treatment
; FILE REFERENCE: 10271-047-999
; CURRENT APPLICATION NUMBER: US/09/996,288
; CURRENT FILING DATE: 2001-11-28
; NUMBER OF SEQ ID NOS: 259
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 211
; LENGTH: 213
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-996-288-211

Query Match      100.0%; Score 553; DB 3; Length 213;
Best Local Similarity 100.0%; Pred. No. 4.5e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
    |||||
Db 107 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166

QY 61 SKDSTYSLSTLTLSKADYEHKHYACVETHQGLSSPVTKSFNRGEC 107
    |||||
Db 167 SKDSTYSLSTLTLSKADYEHKHYACVETHQGLSSPVTKSFNRGEC 213

RESULT 62
US-09-996-288-213
; Sequence 213, Application US/09996288
; Patent No. US20020177126A1
; GENERAL INFORMATION:
; APPLICANT: Young, James
; APPLICANT: Scott, Koenig
; APPLICANT: Leslie, Johnson
; TITLE OF INVENTION: Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxi
; TITLE OF INVENTION: and Treatment
; FILE REFERENCE: 10271-047-999
; CURRENT APPLICATION NUMBER: US/09/996,288
; CURRENT FILING DATE: 2001-11-28
; NUMBER OF SEQ ID NOS: 259
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 213
; LENGTH: 213
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-996-288-213

Query Match      100.0%; Score 553; DB 3; Length 213;
Best Local Similarity 100.0%; Pred. No. 4.5e-51;
```

Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RTVAAPSYFIFPPSDEQLKSGTASWCLLNFFYPREAKVQWKVDNALQSGNSQBSVTEQ 60

Db 107 RTVAAPSYFIFPPSDEQLKSGTASWCLLNFFYPREAKVQWKVDNALQSGNSQBSVTEQ 166

[illegible]

```

RESULT 63
US-09-996-288-215
; Sequence 215, Application US/09996288
; Patent No. US20020177126A1
; GENERAL INFORMATION:
; APPLICANT: Young, James
; APPLICANT: Scott, Koenig
; APPLICANT: Lesliffe, Johnson
; TITLE OF INVENTION: Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxis
; TITLE OF INVENTION: and Treatment
; FILE REFERENCE: 10271-047-999
; CURRENT APPLICATION NUMBER: US/09/996, 288
; CURRENT FILING DATE: 2001-11-28
; NUMBER OF SEQ ID NOS: 259
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 215
; LENGTH: 213
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-996-288-215

```

Query Match	100.0%	Score 553;	DB 3;	Length 213;
Best Local Similarity	100.0%;	Pred. No. 4.5e-51;		
Matches	107;	Conservative	0;	Mismatches 0;
				Indels 0;
				Gaps 0;

Qy 1 RTVAAPSVFIFPPSDEQLKSGTASVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60

Dh 107 RTVAAPSVFIFPPSDEQLKSGTASVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 165

QY 61 SKDSTYSLSSTLTLSKADYEKKVACEVTHTQGLSSPTVKSFNRGEC 107
| | | | |
Db 167 SGNQMYETSGMTTISKLDNVEFVVVACEVTHTQGLSSPTVKSFNRGEC 213

```

RESULT 64
US-09-996-288-217
; Sequence 217, Application US/09996288
; Patent No. US20020177126A1
; GENERAL INFORMATION:
; APPLICANT: Young, James
; APPLICANT: Scott, Koenig
; APPLICANT: Leslie, Johnson
; TITLE OF INVENTION: Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxis
; TITLE OF INVENTION: and Treatment
; FILE REFERENCE: 10271-047-999
; CURRENT APPLICATION NUMBER: US/09/996,288
; CURRENT FILING DATE: 2001-11-28
; NUMBER OF SEQ ID NOS: 259
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 217
; LENGTH: 213
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-996-288-217

```

Query Match	100.0%;	Score 553;	DB 3;	Length 213;
Best Local Similarity	100.0%;	Pred. No. 4.5e-51;		
Mismatch 107	Conservative 0.	Mismatch 0		
				Indels 0.

QY 1 RTVAAPSVEIFPPSDEQLKSGTAVVCLINNFYPREAKVQWKVDNALSGNSQESVTEQD 60

QY 61 SKDSTYSLSTLTSKADYEKKVYACEVTHOGLSSPVTKSFNRGEC 107

Db 167 SKDSTYSLSTLTSKADYEKKVYACEVTHOGLSSPVTKSFNRGEC 213

```

RESULT 65
; Sequence 219, Application US/09996288
; Patent No. US2002017126A1
; GENERAL INFORMATION:
; APPLICANT: Young, James
; APPLICANT: Scott, Koenig
; APPLICANT: Leslie, Johnson
; TITLE OF INVENTION: Methods of Admin
; TITLE OF INVENTION: Methods of Treatment
; FILE REFERENCE: 10271-047-999
; CURRENT APPLICATION NUMBER: US/09/99
; CURRENT FILING DATE: 2001-11-28
; NUMBER OF SEQ ID NOS: 259
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 219
; LENGTH: 213
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-996-288-219

```

Query Match	100.0%;	Score 553;	DB 3;	Length 213;
Best Local Similarity	100.0%;	Pred. No. 4.5e-51;		
Matches 107;	Conservative	0;	Mismatches	0;
	Indels	0;	Gaps	0;

QY 1 RTVAAPSVFIFPPSDEQLKSGTASVCLINNFYREAKVQWKVDNALQSGNSQESVTEQD 60

dh 107 RTVAAPSVFIFPPSDEQLKSGTASVCLINNFYREAKVQWKVDNALQSGNSQESVTEQD 166

QY 61 SKDSTYSLSTLTLSKADYEKHKYACEVTHQGLSSPVTKSFNRGEC 107

```

RESULT 66
US-09-996-288-221
, Sequence 221, Application US/09996288
, Patent No. US2002017126A1
, GENERAL INFORMATION:
, APPLICANT: Young, James
, APPLICANT: Scott, James
, APPLICANT: Leslie, Johnson
, TITLE OF INVENTION: Methods of Admin
, TITLE OF INVENTION: and Treatment
, FILE REFERENCE: 10271-047-999
, CURRENT APPLICATION NUMBER: US/09/99
, CURRENT FILING DATE: 2001-11-28
, NUMBER OF SEQ ID NOS: 259
, SOFTWARE: PatentIn version 3.1
, SEQ ID NO 221
, LENGTH: 213
, TYPE: PRT
, ORGANISM: Homo sapiens
US-09-996-288-221

```

Query Match	100.0%;	Score 553;	DB 3;	Length 213;
Best Local Similarity	100.0%;	Pred. No. 4.5e-51;		
Matches 107;	Conservative	0;	Mismatches	0;
			Indels	0;
			Gaps	0;

Qy 1 RTVAAPSVFIFPPSDEQLKSGTASVCLINNFYREAKVQWKVDNALQSGNSQESVTEQD 60
 |||||
 Dk 107 RTVAAPDSVFIFPPSDEQIKSGTASVCLINNFYREAKVQWKVDNALQSGNSQESVTEQD 166
 |||||

QY 61 SKDSTYSLSSLTLSKADYEKKHYACEVTHQGLSSPVTKSFNRGEC 107

```
RESULT 67
US-09-996-288-223
; Sequence 223, Application US/09996288
; Patent No. US20020177126A1
; GENERAL INFORMATION:
; APPLICANT: Young, James
; APPLICANT: Scott, Koenig
; APPLICANT: Leslie, Johnson
; TITLE OF INVENTION: Methods of Adminstering/Dosing Anti-RSV Antibodies for Prophylaxi
; FILE REFERENCE: 10271-047-999
; CURRENT APPLICATION NUMBER: US/09/996,288
; CURRENT FILING DATE: 2001-11-28
; NUMBER OF SEQ ID NOS: 259
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 223
; LENGTH: 213
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-996-288-223

Query Match      100.0%; Score 553; DB 3; Length 213;
Best Local Similarity 100.0%; Pred. No. 4.5e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 107 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166

QY 61 SKDSTYSLSTLTLSKADYERKHVKYACEVTHQGLSSPVTKSFNRGEC 107
Db 167 SKDSTYSLSTLTLSKADYERKHVKYACEVTHQGLSSPVTKSFNRGEC 213

RESULT 68
US-09-996-288-225
; Sequence 225, Application US/09996288
; Patent No. US20020177126A1
; GENERAL INFORMATION:
; APPLICANT: Young, James
; APPLICANT: Scott, Koenig
; APPLICANT: Leslie, Johnson
; TITLE OF INVENTION: Methods of Adminstering/Dosing Anti-RSV Antibodies for Prophylaxi
; FILE REFERENCE: 10271-047-999
; CURRENT APPLICATION NUMBER: US/09/996,288
; CURRENT FILING DATE: 2001-11-28
; NUMBER OF SEQ ID NOS: 259
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 225
; LENGTH: 213
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-996-288-225

Query Match      100.0%; Score 553; DB 3; Length 213;
Best Local Similarity 100.0%; Pred. No. 4.5e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 107 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166

QY 61 SKDSTYSLSTLTLSKADYERKHVKYACEVTHQGLSSPVTKSFNRGEC 107
Db 167 SKDSTYSLSTLTLSKADYERKHVKYACEVTHQGLSSPVTKSFNRGEC 213

RESULT 69
US-09-996-288-227
; Sequence 227, Application US/09996288
; Patent No. US20020177126A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Young, James
; APPLICANT: Scott, Koenig
; APPLICANT: Leslie, Johnson
; TITLE OF INVENTION: Methods of Adminstering/Dosing Anti-RSV Antibodies for Prophylaxi
; FILE REFERENCE: 10271-047-999
; CURRENT APPLICATION NUMBER: US/09/996,288
; CURRENT FILING DATE: 2001-11-28
; NUMBER OF SEQ ID NOS: 259
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 227
; LENGTH: 213
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-996-288-227

Query Match      100.0%; Score 553; DB 3; Length 213;
Best Local Similarity 100.0%; Pred. No. 4.5e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 107 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166

QY 61 SKDSTYSLSTLTLSKADYERKHVKYACEVTHQGLSSPVTKSFNRGEC 107
Db 167 SKDSTYSLSTLTLSKADYERKHVKYACEVTHQGLSSPVTKSFNRGEC 213

RESULT 70
US-09-996-288-229
; Sequence 229, Application US/09996288
; Patent No. US20020177126A1
; GENERAL INFORMATION:
; APPLICANT: Young, James
; APPLICANT: Scott, Koenig
; APPLICANT: Leslie, Johnson
; TITLE OF INVENTION: Methods of Adminstering/Dosing Anti-RSV Antibodies for Prophylaxi
; FILE REFERENCE: 10271-047-999
; CURRENT APPLICATION NUMBER: US/09/996,288
; CURRENT FILING DATE: 2001-11-28
; NUMBER OF SEQ ID NOS: 259
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 229
; LENGTH: 213
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-996-288-229

Query Match      100.0%; Score 553; DB 3; Length 213;
Best Local Similarity 100.0%; Pred. No. 4.5e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 107 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166

QY 61 SKDSTYSLSTLTLSKADYERKHVKYACEVTHQGLSSPVTKSFNRGEC 107
Db 167 SKDSTYSLSTLTLSKADYERKHVKYACEVTHQGLSSPVTKSFNRGEC 213

RESULT 71
US-09-996-288-231
; Sequence 231, Application US/09996288
; Patent No. US20020177126A1
; GENERAL INFORMATION:
; APPLICANT: Young, James
; APPLICANT: Scott, Koenig
; APPLICANT: Leslie, Johnson
; TITLE OF INVENTION: Methods of Adminstering/Dosing Anti-RSV Antibodies for Prophylaxi
```



```

; TITLE OF INVENTION: and Treatment
; FILE REFERENCE: 10271-047-999
; CURRENT APPLICATION NUMBER: US/09/996,288
; CURRENT FILING DATE: 2001-11-28
; NUMBER OF SEQ ID NOS: 259
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 231
; LENGTH: 213
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-996-288-231

Query Match 100.0%; Score 553; DB 3; Length 213;
Best Local Similarity 100.0%; Pred. No. 4.5e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIFFPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 107 RTVAAPSVFIFFPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166

QY 61 SKDSTYSLSTLTLSKADYKHKYKVVACEVTHQGLSSPVTKSFNRGEC 107
Db 167 SKDSTYSLSTLTLSKADYKHKYKVVACEVTHQGLSSPVTKSFNRGEC 213

RESULT 72
US-09-996-288-233
; Sequence 233, Application US/09996288
; Patent No. US20020177126A1
; GENERAL INFORMATION:
; APPLICANT: Young, James
; APPLICANT: Scott, Koenig
; APPLICANT: Leslie, Johnson
; TITLE OF INVENTION: Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxis
; TITLE OF INVENTION: and Treatment
; FILE REFERENCE: 10271-047-999
; CURRENT APPLICATION NUMBER: US/09/996,288
; CURRENT FILING DATE: 2001-11-28
; NUMBER OF SEQ ID NOS: 259
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 233
; LENGTH: 213
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-996-288-233

Query Match 100.0%; Score 553; DB 3; Length 213;
Best Local Similarity 100.0%; Pred. No. 4.5e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIFFPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 107 RTVAAPSVFIFFPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166

QY 61 SKDSTYSLSTLTLSKADYKHKYKVVACEVTHQGLSSPVTKSFNRGEC 107
Db 167 SKDSTYSLSTLTLSKADYKHKYKVVACEVTHQGLSSPVTKSFNRGEC 213

RESULT 73
US-09-996-288-233
; Sequence 235, Application US/09996288
; Patent No. US20020177126A1
; GENERAL INFORMATION:
; APPLICANT: Young, James
; APPLICANT: Scott, Koenig
; APPLICANT: Leslie, Johnson
; TITLE OF INVENTION: Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxis
; TITLE OF INVENTION: and Treatment
; FILE REFERENCE: 10271-047-999
; CURRENT APPLICATION NUMBER: US/09/996,288
; CURRENT FILING DATE: 2001-11-28
; NUMBER OF SEQ ID NOS: 259
```

```

; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 235
; LENGTH: 213
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-996-288-235

Query Match 100.0%; Score 553; DB 3; Length 213;
Best Local Similarity 100.0%; Pred. No. 4.5e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIFFPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 107 RTVAAPSVFIFFPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166

QY 61 SKDSTYSLSTLTLSKADYKHKYKVVACEVTHQGLSSPVTKSFNRGEC 107
Db 167 SKDSTYSLSTLTLSKADYKHKYKVVACEVTHQGLSSPVTKSFNRGEC 213

RESULT 74
US-09-996-288-237
; Sequence 237, Application US/09996288
; Patent No. US20020177126A1
; GENERAL INFORMATION:
; APPLICANT: Young, James
; APPLICANT: Scott, Koenig
; APPLICANT: Leslie, Johnson
; TITLE OF INVENTION: Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxis
; TITLE OF INVENTION: and Treatment
; FILE REFERENCE: 10271-047-999
; CURRENT APPLICATION NUMBER: US/09/996,288
; CURRENT FILING DATE: 2001-11-28
; NUMBER OF SEQ ID NOS: 259
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 237
; LENGTH: 213
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-996-288-237

Query Match 100.0%; Score 553; DB 3; Length 213;
Best Local Similarity 100.0%; Pred. No. 4.5e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIFFPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 107 RTVAAPSVFIFFPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166

QY 61 SKDSTYSLSTLTLSKADYKHKYKVVACEVTHQGLSSPVTKSFNRGEC 107
Db 167 SKDSTYSLSTLTLSKADYKHKYKVVACEVTHQGLSSPVTKSFNRGEC 213

RESULT 75
US-09-996-288-239
; Sequence 239, Application US/09996288
; Patent No. US20020177126A1
; GENERAL INFORMATION:
; APPLICANT: Young, James
; APPLICANT: Scott, Koenig
; APPLICANT: Leslie, Johnson
; TITLE OF INVENTION: Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxis
; TITLE OF INVENTION: and Treatment
; FILE REFERENCE: 10271-047-999
; CURRENT APPLICATION NUMBER: US/09/996,288
; CURRENT FILING DATE: 2001-11-28
; NUMBER OF SEQ ID NOS: 259
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 239
; LENGTH: 213
; TYPE: PRT
; ORGANISM: Homo sapiens
```


Qy 61 SKDSTYSLSSTLTLSKADYEKHVYACEVTHOGLSSPVTKSFNRGEC 107
|||||
Db 167 SKDSTYSLSSTLTLSKADYEKHVYACEVTHOGLSSPVTKSFNRGEC 213

```

RESULT 80
US-09-996-288-251
/ Sequence 251, Application US/09996288
/ Patent No. US20020177126A1
/ GENERAL INFORMATION:
/ APPLICANT: Young, James
/ APPLICANT: Scott, Koenig
/ APPLICANT: Leslie, Johnson
/ TITLE OF INVENTION: Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxis
/ TITLE OF INVENTION: and Treatment
/ FILE REFERENCE: 10271-047-999
/ CURRENT APPLICATION NUMBER: US/09/996,288
/ CURRENT FILING DATE: 2001-11-28
/ NUMBER OF SEQ ID NOS: 259
/ SOFTWARE: PatentIn version 3.1
/ SEQ ID NO 251
/ LENGTH: 213
/ TYPE: PRT
/ ORGANISM: Homo sapiens
US-09-996-288-251

```

Query Match	100.0%	Score 53;	DB 3;	Length 213;
Best Local Similarity	100.0%	Pred. No. 4.5e-51;		
Matches 107;	Conservative	0;	Mismatches 0;	Indels 0;
Gaps 0				

Qy 1 RTVAAPSVIIFPPSDEQLKSGTASVYLNNFYPRKAVQWVKDVALQSGNSQESVTEQD 60
|||
Db 107 RTVAAPSVIIFPPSDEQLKSGTASVYLNNFYPRKAVQWVKDVALQSGNSQESVTEQD 166

QY 61 SKDSTYSLSSLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 107
 |||||
 Db 167 SKDSTYSLSSLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 213
 |||||

```

RESULT 81
US-09-996-288-253
; Sequence 253, Application US/09996288
; Patent No. US20020177126A1
; GENERAL INFORMATION:
; APPLICANT: Young, James
; APPLICANT: Scott, Koenig
; APPLICANT: Leslie, Johnson
; TITLE OF INVENTION: Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxis
; TITLE OF INVENTION: and Treatment
; FILE REFERENCE: 10271-047-999
; CURRENT APPLICATION NUMBER: US/09/996,288
; CURRENT FILING DATE: 2001-11-28
; NUMBER OF SEQ ID NOS: 259
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 253
; LENGTH: 213
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-996-288-253

```

Query Match	100.0%	Score 53;	DB 3;	Length 213;
Best Local Similarity	100.0%	Pred. No. 4.5e-51;		
Matches 107;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;

Qy

1 RTVAAPSVFI FPPDSEQLKSGTASTVCLNNFYPREAKVKVDNALQSGNSQESVTEQD 60
|||||

Dβ

107 RTVAAPSVFI FPPDSEQLKSGTASTVCLNNFYPREAKVKVDNALQSGNSQESVTEQD 166
|||||

QY 61 SKDSTYSLSTLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 107
|||
Db 167 SKDSTYSLSTLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 213

```

RESULT 82
US-09-996-288-255
; Sequence 255, Application US/09996288
; Patent No. US20020177126A1
; GENERAL INFORMATION:
; APPLICANT: Young, James
; APPLICANT: Scott, Koenig
; APPLICANT: Leslie, Johnson
; TITLE OF INVENTION: Methods of Administering/Dosing Anti-RSV Antibodies for
; TITLE OF INVENTION: and Treatment
; FILE REFERENCE: 10271-047-999
; CURRENT APPLICATION NUMBER: US/09/996,288
; CURRENT FILING DATE: 2001-11-28
; NUMBER OF SEQ ID NOS: 259
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 255
; LENGTH: 213
; TYPE: PR1
; ORGANISM: Homo sapiens
US-09-996-288-255

```

Query Match	100.0%	Score 553	DB 3	Length 213
Best Local Similarity	100.0%	Pred. No. 4.5e-51		
Matches 107	Conservative 0	Mismatches 0	Indels 0	Gaps 0

Qy	1	RTVAAPSVFIFPPSDEQLKSGTASVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD	60
Db	107	RTVAAPSVFIFPPSDEQLKSGTASVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD	166

Qy	61	SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFN	107
D _b	167	SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFN	213

RESULT 83
US-09-996-288-257
; Sequence 257, Application US/09996288
; Patent No.US20020177126A1

GENERAL INFORMATION.
APPLICANT: Young, James
APPLICANT: Scott, Koenig
APPLICANT: Leslie, Johnson

```

; TITLE OF INVENTION:  and Treatment
;
; FILE REFERENCE: 10271-047-999
;
; CURRENT APPLICATION NUMBER: US/09/996,288
;

```

```

; NUMBER OF SEQ ID NOS: 259
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 257

```

RESULT 84
US-09-936-265-209
; Sequence 209, Application US/09996265
; Publication No. US20030091584A1
; GENERAL INFORMATION:

```
; APPLICANT: Young, James
; APPLICANT: Scott, Koenig
; TITLE OF INVENTION: Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxis
; FILE REFERENCE: 10271-048-999
; CURRENT APPLICATION NUMBER: US/09/996,265
; NUMBER OF SEQ ID NOS: 259
; SOFTWARE: PatentIn version 3.1
; CURRENT FILING DATE: 2001-11-28
; NUMBER OF SEQ ID NOS: 259
; SEQ ID NO 209
; LENGTH: 213
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-996-265-209

Query Match          100.0%; Score 553; DB 3; Length 213;
Best Local Similarity 100.0%; Pred. No. 4.5e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 107 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166

QY 61 SKDSTYSLSSLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 107
Db 167 SKDSTYSLSSLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 213

RESULT 85
US-09-996-265-211
; Sequence 211, Application US/09996265
; Publication No. US20030091584A1
; GENERAL INFORMATION:
; APPLICANT: Young, James
; APPLICANT: Scott, Koenig
; APPLICANT: Leslie, Johnson
; TITLE OF INVENTION: Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxis
; FILE REFERENCE: 10271-048-999
; CURRENT APPLICATION NUMBER: US/09/996,265
; CURRENT FILING DATE: 2001-11-28
; NUMBER OF SEQ ID NOS: 259
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 211
; LENGTH: 213
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-996-265-211

Query Match          100.0%; Score 553; DB 3; Length 213;
Best Local Similarity 100.0%; Pred. No. 4.5e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 107 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166

QY 61 SKDSTYSLSSLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 107
Db 167 SKDSTYSLSSLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 213

RESULT 86
US-09-996-265-213
; Sequence 213, Application US/09996265
; Publication No. US20030091584A1
; GENERAL INFORMATION:
; APPLICANT: Young, James
; APPLICANT: Scott, Koenig
; APPLICANT: Leslie, Johnson
; TITLE OF INVENTION: Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxis
; FILE REFERENCE: 10271-048-999
; CURRENT APPLICATION NUMBER: US/09/996,265
; CURRENT FILING DATE: 2001-11-28
; NUMBER OF SEQ ID NOS: 259
; SOFTWARE: PatentIn version 3.1
```

```
; FILE REFERENCE: 10271-048-999
; CURRENT APPLICATION NUMBER: US/09/996,265
; CURRENT FILING DATE: 2001-11-28
; NUMBER OF SEQ ID NOS: 259
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 213
; LENGTH: 213
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-996-265-213

Query Match          100.0%; Score 553; DB 3; Length 213;
Best Local Similarity 100.0%; Pred. No. 4.5e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 107 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166

QY 61 SKDSTYSLSSLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 107
Db 167 SKDSTYSLSSLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 213

RESULT 87
US-09-996-265-215
; Sequence 215, Application US/09996265
; Publication No. US20030091584A1
; GENERAL INFORMATION:
; APPLICANT: Young, James
; APPLICANT: Scott, Koenig
; APPLICANT: Leslie, Johnson
; TITLE OF INVENTION: Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxis
; FILE REFERENCE: 10271-048-999
; CURRENT APPLICATION NUMBER: US/09/996,265
; CURRENT FILING DATE: 2001-11-28
; NUMBER OF SEQ ID NOS: 259
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 215
; LENGTH: 213
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-996-265-215

Query Match          100.0%; Score 553; DB 3; Length 213;
Best Local Similarity 100.0%; Pred. No. 4.5e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 107 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166

QY 61 SKDSTYSLSSLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 107
Db 167 SKDSTYSLSSLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 213

RESULT 88
US-09-996-265-217
; Sequence 217, Application US/09996265
; Publication No. US20030091584A1
; GENERAL INFORMATION:
; APPLICANT: Young, James
; APPLICANT: Scott, Koenig
; APPLICANT: Leslie, Johnson
; TITLE OF INVENTION: Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxis
; FILE REFERENCE: 10271-048-999
; CURRENT APPLICATION NUMBER: US/09/996,265
; CURRENT FILING DATE: 2001-11-28
; NUMBER OF SEQ ID NOS: 259
; SOFTWARE: PatentIn version 3.1
```

```

; SEQ ID NO 217
; LENGTH: 213
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-996-265-217

Query Match      100.0%; Score 553; DB 3; Length 213;
Best Local Similarity 100.0%; Pred. No. 4.5e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
DB 107 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166

QY 61 SKDSTYLSSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 107
DB 167 SKDSTYLSSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 213

RESULT 89
US-09-996-265-219
; Sequence 219, Application US/09996265
; Publication No. US20030091584A1
; GENERAL INFORMATION:
; APPLICANT: Young, James
; APPLICANT: Scott, Koenig
; APPLICANT: Leslie, Johnson
; TITLE OF INVENTION: Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxis
; FILE REFERENCE: 10271-048-999
; CURRENT APPLICATION NUMBER: US/09/996,265
; CURRENT FILING DATE: 2001-11-28
; NUMBER OF SEQ ID NOS: 259
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 219
; LENGTH: 213
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-996-265-219

Query Match      100.0%; Score 553; DB 3; Length 213;
Best Local Similarity 100.0%; Pred. No. 4.5e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
DB 107 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166

QY 61 SKDSTYLSSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 107
DB 167 SKDSTYLSSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 213

RESULT 90
US-09-996-265-221
; Sequence 221, Application US/09996265
; Publication No. US20030091584A1
; GENERAL INFORMATION:
; APPLICANT: Young, James
; APPLICANT: Scott, Koenig
; APPLICANT: Leslie, Johnson
; TITLE OF INVENTION: Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxis
; FILE REFERENCE: 10271-048-999
; CURRENT APPLICATION NUMBER: US/09/996,265
; CURRENT FILING DATE: 2001-11-28
; NUMBER OF SEQ ID NOS: 259
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 221
; LENGTH: 213
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-996-265-221
```

```

Query Match      100.0%; Score 553; DB 3; Length 213;
Best Local Similarity 100.0%; Pred. No. 4.5e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
DB 107 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166

QY 61 SKDSTYLSSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 107
DB 167 SKDSTYLSSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 213

RESULT 91
US-09-996-265-223
; Sequence 223, Application US/09996265
; Publication No. US20030091584A1
; GENERAL INFORMATION:
; APPLICANT: Young, James
; APPLICANT: Scott, Koenig
; APPLICANT: Leslie, Johnson
; TITLE OF INVENTION: Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxis
; FILE REFERENCE: 10271-048-999
; CURRENT APPLICATION NUMBER: US/09/996,265
; CURRENT FILING DATE: 2001-11-28
; NUMBER OF SEQ ID NOS: 259
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 223
; LENGTH: 213
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-996-265-223

Query Match      100.0%; Score 553; DB 3; Length 213;
Best Local Similarity 100.0%; Pred. No. 4.5e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
DB 107 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166

QY 61 SKDSTYLSSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 107
DB 167 SKDSTYLSSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 213

RESULT 92
US-09-996-265-225
; Sequence 225, Application US/09996265
; Publication No. US20030091584A1
; GENERAL INFORMATION:
; APPLICANT: Young, James
; APPLICANT: Scott, Koenig
; APPLICANT: Leslie, Johnson
; TITLE OF INVENTION: Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxis
; FILE REFERENCE: 10271-048-999
; CURRENT APPLICATION NUMBER: US/09/996,265
; CURRENT FILING DATE: 2001-11-28
; NUMBER OF SEQ ID NOS: 259
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 225
; LENGTH: 213
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-996-265-225

Query Match      100.0%; Score 553; DB 3; Length 213;
Best Local Similarity 100.0%; Pred. No. 4.5e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

Qy 1 RTVAAPSVFIPPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
|||||
Db 107 RIVAAPSVFIPPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166
|||||
Qy 61 SKDSTYSLSSLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 107
|||||
Db 167 SKDSTYSLSSLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 213
|||||
RESULT 93
US-09-996-265-227
; Sequence 227, Application US/09996265
; Publication No. US20030091584A1
; GENERAL INFORMATION:
; APPLICANT: Young, James
; APPLICANT: Scott, Koenig
; APPLICANT: Leslie, Johnson
; TITLE OF INVENTION: Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxi
; FILE REFERENCE: 10271-048-999
; CURRENT APPLICATION NUMBER: US/09/996,265
; CURRENT FILING DATE: 2001-11-28
; NUMBER OF SEQ ID NOS: 259
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 227
; LENGTH: 213
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-996-265-227
Query Match 100.0%; Score 553; DB 3; Length 213;
Best Local Similarity 100.0%; Pred. No. 4.5e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 RTVAAPSVFIPPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
|||||
Db 107 RTVAAPSVFIPPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166
|||||
Qy 61 SKDSTYSLSSLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 107
|||||
Db 167 SKDSTYSLSSLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 213
|||||
RESULT 94
US-09-996-265-229
; Sequence 229, Application US/09996265
; Publication No. US20030091584A1
; GENERAL INFORMATION:
; APPLICANT: Young, James
; APPLICANT: Scott, Koenig
; APPLICANT: Leslie, Johnson
; TITLE OF INVENTION: Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxi
; FILE REFERENCE: 10271-048-999
; CURRENT APPLICATION NUMBER: US/09/996,265
; CURRENT FILING DATE: 2001-11-28
; NUMBER OF SEQ ID NOS: 259
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 229
; LENGTH: 213
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-996-265-229
Query Match 100.0%; Score 553; DB 3; Length 213;
Best Local Similarity 100.0%; Pred. No. 4.5e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 RTVAAPSVFIPPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
|||||
Db 107 RTVAAPSVFIPPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166
|||||
Qy 61 SKDSTYSLSSLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 107
|||||

Db 167 SKDSTYSLSSLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 213
|||||
RESULT 95
US-09-996-265-231
; Sequence 231, Application US/09996265
; Publication No. US20030091584A1
; GENERAL INFORMATION:
; APPLICANT: Young, James
; APPLICANT: Scott, Koenig
; APPLICANT: Leslie, Johnson
; TITLE OF INVENTION: Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxi
; FILE REFERENCE: 10271-048-999
; CURRENT APPLICATION NUMBER: US/09/996,265
; CURRENT FILING DATE: 2001-11-28
; NUMBER OF SEQ ID NOS: 259
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 231
; LENGTH: 213
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-996-265-231
Query Match 100.0%; Score 553; DB 3; Length 213;
Best Local Similarity 100.0%; Pred. No. 4.5e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 RTVAAPSVFIPPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
|||||
Db 107 RTVAAPSVFIPPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166
|||||
Qy 61 SKDSTYSLSSLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 107
|||||
Db 167 SKDSTYSLSSLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 213
|||||
RESULT 96
US-09-996-265-233
; Sequence 233, Application US/09996265
; Publication No. US20030091584A1
; GENERAL INFORMATION:
; APPLICANT: Young, James
; APPLICANT: Scott, Koenig
; APPLICANT: Leslie, Johnson
; TITLE OF INVENTION: Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxi
; FILE REFERENCE: 10271-048-999
; CURRENT APPLICATION NUMBER: US/09/996,265
; CURRENT FILING DATE: 2001-11-28
; NUMBER OF SEQ ID NOS: 259
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 233
; LENGTH: 213
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-996-265-233
Query Match 100.0%; Score 553; DB 3; Length 213;
Best Local Similarity 100.0%; Pred. No. 4.5e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 RTVAAPSVFIPPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
|||||
Db 107 RTVAAPSVFIPPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166
|||||
Qy 61 SKDSTYSLSSLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 107
|||||
Db 167 SKDSTYSLSSLTLSKADYERKHVYACEVTHQGLSSPVTKSFNRGEC 213
|||||
RESULT 97

```
US-09-996-265-235
; Sequence 235, Application US/09996265
; Publication No. US20030091584A1
; GENERAL INFORMATION:
; APPLICANT: Young, James
; APPLICANT: Scott, Koenig
; APPLICANT: Leslie, Johnson
; TITLE OF INVENTION: Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxis
; FILE REFERENCE: 10271-048-999
; CURRENT APPLICATION NUMBER: US/09/996,265
; CURRENT FILING DATE: 2001-11-28
; NUMBER OF SEQ ID NOS: 259
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 235
; LENGTH: 213
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-996-265-235

Query Match      100.0%; Score 553; DB 3; Length 213;
Best Local Similarity 100.0%; Pred. No. 4.5e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIFFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 107 RTVAAPSVFIFFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166

QY 61 SKDSTYSLSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 107
Db 167 SKDSTYSLSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 213

RESULT 98
US-09-996-265-237
; Sequence 237, Application US/09996265
; Publication No. US20030091584A1
; GENERAL INFORMATION:
; APPLICANT: Young, James
; APPLICANT: Scott, Koenig
; APPLICANT: Leslie, Johnson
; TITLE OF INVENTION: Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxis
; FILE REFERENCE: 10271-048-999
; CURRENT APPLICATION NUMBER: US/09/996,265
; CURRENT FILING DATE: 2001-11-28
; NUMBER OF SEQ ID NOS: 259
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 237
; LENGTH: 213
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-996-265-237

Query Match      100.0%; Score 553; DB 3; Length 213;
Best Local Similarity 100.0%; Pred. No. 4.5e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIFFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 107 RTVAAPSVFIFFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166

QY 61 SKDSTYSLSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 107
Db 167 SKDSTYSLSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 213

RESULT 99
US-09-996-265-239
; Sequence 239, Application US/09996265
; Publication No. US20030091584A1
; GENERAL INFORMATION:
; APPLICANT: Young, James
```

```
; APPLICANT: Scott, Koenig
; APPLICANT: Leslie, Johnson
; TITLE OF INVENTION: Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxis
; FILE REFERENCE: 10271-048-999
; CURRENT APPLICATION NUMBER: US/09/996,265
; CURRENT FILING DATE: 2001-11-28
; NUMBER OF SEQ ID NOS: 259
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 239
; LENGTH: 213
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-996-265-239

Query Match      100.0%; Score 553; DB 3; Length 213;
Best Local Similarity 100.0%; Pred. No. 4.5e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIFFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 107 RTVAAPSVFIFFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166

QY 61 SKDSTYSLSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 107
Db 167 SKDSTYSLSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 213

RESULT 100
US-09-996-285-241
; Sequence 241, Application US/09996265
; Publication No. US20030091584A1
; GENERAL INFORMATION:
; APPLICANT: Young, James
; APPLICANT: Scott, Koenig
; APPLICANT: Leslie, Johnson
; TITLE OF INVENTION: Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxis
; FILE REFERENCE: 10271-048-999
; CURRENT APPLICATION NUMBER: US/09/996,265
; CURRENT FILING DATE: 2001-11-28
; NUMBER OF SEQ ID NOS: 259
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 241
; LENGTH: 213
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-996-285-241

Query Match      100.0%; Score 553; DB 3; Length 213;
Best Local Similarity 100.0%; Pred. No. 4.5e-51;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 RTVAAPSVFIFFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 107 RTVAAPSVFIFFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166

QY 61 SKDSTYSLSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 107
Db 167 SKDSTYSLSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC 213

Search completed: June 12, 2006, 17:30:48
Job time : 111.654 secs
```


THIS PAGE BLANK (USPTO)

GenCore version 5.1.9
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: June 10, 2006, 12:32:32 ; Search time 3.6952 Seconds
(without alignments)
366.103 Million cell updates/sec

Title: US-10-733-563-112
Perfect score: 553
Sequence: 1 RTVAAPSVFIPPPSDEQLK.....EVTHQGLSSPVTKSFNRGEC 107

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 64916 seqs, 12643201 residues

Total number of hits satisfying chosen parameters: 64916

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published Applications AA New:
1: /EMC_Celerra_SIDS3/ptodata/1/pubpaa/US09_NEW_PUB.pep.*
2: /EMC_Celerra_SIDS3/ptodata/1/pubpaa/US06_NEW_PUB.pep.*
3: /EMC_Celerra_SIDS3/ptodata/1/pubpaa/US07_NEW_PUB.pep.*
4: /EMC_Celerra_SIDS3/ptodata/1/pubpaa/US08_NEW_PUB.pep.*
5: /EMC_Celerra_SIDS3/ptodata/1/pubpaa/PCT_NEW_PUB.pep.*
6: /EMC_Celerra_SIDS3/ptodata/1/pubpaa/US10_NEW_PUB.pep.*
7: /EMC_Celerra_SIDS3/ptodata/1/pubpaa/US11_NEW_PUB.pep.*
8: /EMC_Celerra_SIDS3/ptodata/1/pubpaa/US60_NEW_PUB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	553	100.0	107	6	US-10-983-104-7
2	553	100.0	107	7	US-11-091-234A-40
3	553	100.0	107	7	US-11-219-563-134
4	553	100.0	107	7	US-11-291-140-43
5	553	100.0	213	7	US-11-254-182-63
6	553	100.0	213	7	US-11-254-182-64
7	553	100.0	213	7	US-11-106-762-3
8	553	100.0	213	7	US-11-106-762-24
9	553	100.0	213	7	US-11-106-762-33
10	553	100.0	213	7	US-11-106-762-35
11	553	100.0	213	7	US-11-106-762-38
12	553	100.0	213	7	US-11-238-281-13
13	553	100.0	213	7	US-11-238-281-28
14	553	100.0	213	7	US-11-238-281-30
15	553	100.0	213	7	US-11-263-230-209
16	553	100.0	213	7	US-11-263-230-211
17	553	100.0	213	7	US-11-263-230-213
18	553	100.0	213	7	US-11-263-230-215
19	553	100.0	213	7	US-11-263-230-217
20	553	100.0	213	7	US-11-263-230-219
21	553	100.0	213	7	US-11-263-230-221
22	553	100.0	213	7	US-11-263-230-223
23	553	100.0	213	7	US-11-263-230-225
24	553	100.0	213	7	US-11-263-230-227
25	553	100.0	213	7	US-11-263-230-229

ALIGNMENTS

RESULT 1

US-10-983-104-7 26 553 100.0 213 7 US-11-263-230-231 Sequence 231, App
; Sequence 7, Application US/10983104 27 553 100.0 213 7 US-11-263-230-233 Sequence 233, App
; Publication No. US20060099203A1 28 553 100.0 213 7 US-11-263-230-235 Sequence 235, App
; GENERAL INFORMATION: 29 553 100.0 213 7 US-11-263-230-237 Sequence 237, App
; APPLICANT: Pease, Larry 30 553 100.0 213 7 US-11-263-230-239 Sequence 239, App
; APPLICANT: Van Keulen, Virginia 31 553 100.0 213 7 US-11-263-230-241 Sequence 241, App
; TITLE OF INVENTION: B7-DC Binding Antibody 32 553 100.0 213 7 US-11-263-230-243 Sequence 243, App
; FILE REFERENCE: 07039-558001 33 553 100.0 213 7 US-11-263-230-245 Sequence 245, App
; CURRENT APPLICATION NUMBER: US/10/983,104 34 553 100.0 213 7 US-11-263-230-247 Sequence 247, App
; CURRENT FILING DATE: 2004-11-05 35 553 100.0 213 7 US-11-263-230-249 Sequence 249, App
; NUMBER OF SEQ ID NOS: 14 36 553 100.0 213 7 US-11-263-230-251 Sequence 251, App
; SOFTWARE: FastSeq for Windows Version 4.0 37 553 100.0 213 7 US-11-263-230-253 Sequence 253, App
; SEQ ID NO 7 38 553 100.0 213 7 US-11-263-230-255 Sequence 255, App
; LENGTH: 107 39 553 100.0 213 7 US-11-263-230-257 Sequence 257, App
; TYPE: PRT 40 553 100.0 213 7 US-11-263-230-306 Sequence 306, App
; ORGANISM: Homo sapiens 41 553 100.0 213 7 US-11-263-230-312 Sequence 312, App
; US-10-983-104-7 42 553 100.0 213 7 US-11-263-230-318 Sequence 318, App
43 553 100.0 213 7 US-11-263-230-324 Sequence 324, App
44 553 100.0 213 7 US-11-263-230-330 Sequence 330, App
45 553 100.0 213 7 US-11-263-230-333 Sequence 333, App

Query Match

Best Local Similarity 100.0%; Score 553; DB 6; Length 107;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RTVAAPSVFIPPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60

Db 1 RTVAAPSVFIPPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60

Qy 61 SKDSTYLSSTLTLSKADYEHKHYACVTHQGLSSPVTKSFNRGEC 107

Db 61 SKDSTYLSSTLTLSKADYEHKHYACVTHQGLSSPVTKSFNRGEC 107

RESULT 2

US-11-091-234A-40
; Sequence 40, Application US/11091234A
; Publication No. US2006008845A1
; GENERAL INFORMATION:
; APPLICANT: Lu, Jin
; TITLE OF INVENTION: METHOD AND APPARATUS FOR ANALYZING AND GENERATING
; FILE REFERENCE: CEN5052NP
; CURRENT APPLICATION NUMBER: US/11/091,234A
; CURRENT FILING DATE: 2005-03-28
; PRIOR APPLICATION NUMBER: 60/558,090
; PRIOR FILING DATE: 2004-03-31
; NUMBER OF SEQ ID NOS: 41
; SOFTWARE: PatentIn version 3.3

```

; SEQ ID NO 40
; LENGTH: 107
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: MISC FEATURE
; LOCATION: (1)..(107)
; OTHER INFORMATION: Light chain kappa constant region (IgKc)
US-11-091-234A-40

Query Match          100.0%; Score 553; DB 7; Length 107;
Best Local Similarity 100.0%; Pred. No. 3.3e-48;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60

Qy 61 SKDSTYSLSTLTLSKADYEHKHYACEVTHQGLSSPVTKSFNRGEC 107
Db 61 SKDSTYSLSTLTLSKADYEHKHYACEVTHQGLSSPVTKSFNRGEC 107

RESULT 3
US-11-219-563-134
; Sequence 134, Application US/11219563
; Publication No. US20060088539A1
; GENERAL INFORMATION:
; APPLICANT: Bander, Neil
; TITLE OF INVENTION: MODIFIED ANTIBODIES TO PROSTATE-SPECIFIC
; FILE REFERENCE: 13651.001 (BZL-001)
; CURRENT APPLICATION NUMBER: US/11/219,563
; CURRENT FILING DATE: 2005-09-02
; PRIOR APPLICATION NUMBER: PCT/US04/06586
; PRIOR FILING DATE: 2004-03-03
; PRIOR APPLICATION NUMBER: US 10/379,838
; PRIOR FILING DATE: 2003-03-03
; PRIOR APPLICATION NUMBER: 10/449,379
; PRIOR FILING DATE: 2003-05-30
; NUMBER OF SEQ ID NOS: 144
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 134
; LENGTH: 107
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Light chain variable and constant region of deJf591
US-11-219-563-134

Query Match          100.0%; Score 553; DB 7; Length 107;
Best Local Similarity 100.0%; Pred. No. 3.3e-48;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60

Qy 61 SKDSTYSLSTLTLSKADYEHKHYACEVTHQGLSSPVTKSFNRGEC 107
Db 61 SKDSTYSLSTLTLSKADYEHKHYACEVTHQGLSSPVTKSFNRGEC 107

RESULT 4
US-11-291-140-43
; Sequence 43, Application US/11291140
; Publication No. US20060115475A1
; GENERAL INFORMATION:
; APPLICANT: CARTON, JILL M.
; APPLICANT: CHEN, SHIZHONG
; APPLICANT: CUNNINGHAM, MARK
; APPLICANT: DAS, ANUK
; APPLICANT: DUFFY, KAREN

```

```

; APPLICANT: GILES-KOMAR, JILL M.
; APPLICANT: GOLETZ, THERESA J.
; APPLICANT: KNIGHT, DAVID
; APPLICANT: LAMB, ROBERTA
; APPLICANT: MBOW, M.LAMINE
; APPLICANT: PICHA, KRISTEN
; APPLICANT: RAGHUNATHAN, GOPALAN
; APPLICANT: SAN MATEO, LANI
; APPLICANT: SARISKY, ROBERT T.
; APPLICANT: STOWELL, NICOLE
; APPLICANT: STOJANOVIC-SUSULIC, VEDRANA
; APPLICANT: SWEET, RAYMOND
; APPLICANT: ZHAO, SHANRONG
; TITLE OF INVENTION: TOLL LIKE RECEPTOR 3 ANTAGONISTS,
; FILE REFERENCE: METHODS AND USES
; FILE REFERENCE: CEN5083 USA NP
; CURRENT APPLICATION NUMBER: US/11/291,140
; CURRENT FILING DATE: 2005-11-30
; PRIOR APPLICATION NUMBER: 60/631,815
; PRIOR FILING DATE: 2004-11-30
; PRIOR APPLICATION NUMBER: 60/636,399
; PRIOR FILING DATE: 2004-12-15
; PRIOR APPLICATION NUMBER: 60/641,877
; PRIOR FILING DATE: 2005-01-06
; PRIOR APPLICATION NUMBER: 60/713,195
; PRIOR FILING DATE: 2005-08-31
; PRIOR APPLICATION NUMBER: 60/727,610
; PRIOR FILING DATE: 2005-10-18
; NUMBER OF SEQ ID NOS: 63
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 43
; LENGTH: 107
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Human k constant region
US-11-291-140-43

Query Match          100.0%; Score 553; DB 7; Length 107;
Best Local Similarity 100.0%; Pred. No. 3.3e-48;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
Db 1 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60

Qy 61 SKDSTYSLSTLTLSKADYEHKHYACEVTHQGLSSPVTKSFNRGEC 107
Db 61 SKDSTYSLSTLTLSKADYEHKHYACEVTHQGLSSPVTKSFNRGEC 107

RESULT 5
US-11-254-182-63
; Sequence 63, Application US/11254182
; Publication No. US20060088523A1
; GENERAL INFORMATION:
; APPLICANT: ANDYA, JAMES
; APPLICANT: GWEE, SHIANG C.
; APPLICANT: LIU, JUN
; APPLICANT: SHEN, YE
; TITLE OF INVENTION: ANTIBODY FORMULATIONS
; FILE REFERENCE: P2104R1
; CURRENT APPLICATION NUMBER: US/11/254,182
; CURRENT FILING DATE: 2005-10-19
; PRIOR APPLICATION NUMBER: US 60/620,413
; PRIOR FILING DATE: 2004-10-20
; NUMBER OF SEQ ID NOS: 74
; SEQ ID NO 63
; LENGTH: 213
; TYPE: PRT
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Sequence is synthesized.

```

US-11-254-182-63

```
Query Match      100.0%; Score 553; DB 7; Length 213;
Best Local Similarity 100.0%; Pred. No. 7.8e-48;
Matches 107; Conservative 0; Mismatches 0; Indels
```

Qy	1	RTVAAPSVFIFPPSDEQLKSGTASVVCCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD	60
Db	107	RTVAAPSVFIFPPSDEQLKSGTASVVCCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD	166
Qy	61	SKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	107
Db	167	SKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	213

RESULT 6

US-11-254-182-64
; Sequence 64, Application US/11254182
: Publication No. US20060088523A1

```

/ ORGANISM: US-11-254-182-64
/
/ GENERAL INFORMATION:
/
/ APPLICANT: ANDYA, JAMES
/ APPLICANT: GWEE, SHIANG C.
/ APPLICANT: LIU, JY
/ APPLICANT: SHEN, JY
/
/ TITLE OF INVENTION: ANTIBODY FORMULATIONS
/
/ FILE REFERENCE: P2104r1
/ CURRENT APPLICATION NUMBER: US/11/254,182
/ CURRENT FILING DATE: 2005-10-19
/ PRIOR APPLICATION NUMBER: US 60/620,413
/ PRIOR FILING DATE: 2004-10-20
/ NUMBER OF SEQ ID NOS: 74
/
/ SEQ ID NO 64
/   LENGTH: 213
/   TYPE: PRT
/
/ ORGANISM: Artificial sequence
/
/ FEATURE:
/
/   OTHER INFORMATION: Sequence is synthesized
/ US-11-254-182-64

```

US-11-254-182-64

```
Query Match      100.0%; Score 553; DB 7; Length 213;
Best Local Similarity 100.0%; Pred. No. 7.8e-48;
Matches 107; Conservative 0; Mismatches 0; Indels
```

Qy	1	RTVAAPSVFIFPPSDEQLKSGTASVCLLNNFY	PREAKVQWKVDNALQSGNSQESVTEQ	60
Db	107	RTVAAPSVFIFPPSDEQLKSGTASVCLLNNFY	PREAKVQWKVDNALQSGNSQESVTEQ	166
Qy	61	SKDSTYLSLTLTLSKADYERKHVYACEVTHQGLSSPVT	KSFNRGEC	107
Db	167	SKDSTYLSLTLTLSKADYERKHVYACEVTHQGLSSPVT	KSFNRGEC	213

RESIT.T 7

US-11-106-762-3
; Sequence 3, Application US/11106762
: Publication No. US20060099662A1

```

; SEQUENCE INFORMATION:
; GENERAL INFORMATION:
; APPLICANT: CHUNTHARAPAI, ANVAN ET AL.
; TITLE OF INVENTION: ASSAY FOR ANTIBODIES
; FILE REFERENCE: P2075R1
; CURRENT APPLICATION NUMBER: US/11/106,762
; CURRENT FILING DATE: 2005-04-15
; PRIOR APPLICATION NUMBER: US 60/563,193
; PRIOR FILING DATE: 2004-04-16
; NUMBER OF SEQ ID NOS: 39
; SEQ ID NO 3
; LENGTH: 213
; TYPE: PRT
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Sequence is synthesized
US-11-106-762-3

```

US-11-106-762-3

```
Query Match      100.0%; Score 553; DB 7; Length 213;
Best Local Similarity 100.0%; Pred. No. 7.8e-48;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

Qy	1	RTVAARSVTFPPSPDQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQSSVTEQD	60
Db	107	RTVAARSVTFPPSDQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQSSVTEQD	166
Qy	61	SKDSTVSLSTLTLSKADYEKKHYACEVTHQGLSSPVTKSFNRGEC	107
Db	167	SKDSTVSLSTLTLSKADYEKKHYACEVTHQGLSSPVTKSFNRGEC	213

RESULT 8

US-11-106-762-24
; Sequence 24, Application US/11106762
; Publication No. US20060099662A1

```

; GENERAL INFORMATION:
; APPLICANT: CHUNTHARAPAI, ANAN ET AL.
; TITLE OF INVENTION: ASSAY FOR ANTIBODIES
; FILE REFERENCE: P2075R1
; CURRENT APPLICATION NUMBER: US/11/106,762
; CURRENT FILING DATE: 2005-04-15
; PRIOR APPLICATION NUMBER: US 60/563,193
; PRIOR FILING DATE: 2004-04-16
; NUMBER OF SEQ ID NOS: 39
; SEQ ID NO 24
; LENGTH: 213
; TYPE: PRT
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Sequence is synthesized
US-11-106-762-24

```

US-11-106-762-24

```
Query Match      100.0%; Score 553; DB 7; Length 213;
Best Local Similarity 100.0%; Pred. No. 7.8e-48;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

Qy	1	RTVAAPSVFIFPPSDEQLKSGTASVVCCLINFFYPREAKVQWKVDNALQSGNSQESVTEQD	60
Db	107	RTVAAPSVFIFPPSDEQLKSGTASVVCCLINFFYPREAKVQWKVDNALQSGNSQESVTEQD	166
Qy	61	SKDSTVSLSGSTLTLSKADYEKKHVKYACEVTHQGLSPVTKSFNRGEC	107
Db	167	SKDSTVSLSGSTLTLSKADYEKKHVKYACEVTHQGLSPVTKSFNRGEC	213

DECEMBER 9

RESULT 9
US-11-106-762-33
; Sequence 33, Application US/11106762
; Publication No. US20060099662A1

```

PUBLICATION NO. US20060099862A1
GENERAL INFORMATION:
APPLICANT: CHUNTHARAPAI, ANAN ET AL.
TITLE OF INVENTION: ASSAY FOR ANTIBODIES
FILE REFERENCE: P2075R1
CURRENT APPLICATION NUMBER: US/11/106,762
CURRENT FILING DATE: 2005-04-15
PRIOR APPLICATION NUMBER: US 60/563,193
PRIOR FILING DATE: 2004-04-16
NUMBER OF SEQ ID NOS: 39
SEQ ID NO 33
LENGTH: 213
TYPE: PRT
ORGANISM: Artificial sequence
FEATURES:
OTHER INFORMATION: Sequence is synthesized
US-11-106-762-33

```

US-11-106-762-33

```
Query Match      100.0%; Score 553; DB 7; Length 213;
Best Local Similarity 100.0%; Pred. No. 7.8e-48;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

1 RTVAAPSVFEPSPDEOLKSGTASVCLLNFFYPBREAKVOWKVDNALOSGNSOESVTEOD 60

```
|||||
Db 107 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166

Qy 61 SKDSTYSLSTLTLSKADYEHKVKYACEVTHQGLSSPVTKSFNRGEC 107
|||||
Db 167 SKDSTYSLSTLTLSKADYEHKVKYACEVTHQGLSSPVTKSFNRGEC 213

RESULT 10
US-11-106-762-35
; Sequence 35, Application US/11106762
; Publication No. US20060099662A1
; GENERAL INFORMATION:
; APPLICANT: CHUNTHARAPAI, ANAN ET AL.
; TITLE OF INVENTION: ASSAY FOR ANTIBODIES
; FILE REFERENCE: P2075R1
; CURRENT APPLICATION NUMBER: US/11/106,762
; PRIOR FILING DATE: 2005-04-15
; PRIOR APPLICATION NUMBER: US 60/563,193
; PRIOR FILING DATE: 2004-04-16
; NUMBER OF SEQ ID NOS: 39
; SEQ ID NO 35
; LENGTH: 213
; TYPE: PRT
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Sequence is synthesized
US-11-106-762-35

Query Match 100.0%; Score 553; DB 7; Length 213;
Best Local Similarity 100.0%; Pred. No. 7.8e-48;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
|||||
Db 107 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166

Qy 61 SKDSTYSLSTLTLSKADYEHKVKYACEVTHQGLSSPVTKSFNRGEC 107
|||||
Db 167 SKDSTYSLSTLTLSKADYEHKVKYACEVTHQGLSSPVTKSFNRGEC 213

RESULT 11
US-11-106-762-38
; Sequence 38, Application US/11106762
; Publication No. US20060099662A1
; GENERAL INFORMATION:
; APPLICANT: CHUNTHARAPAI, ANAN ET AL.
; TITLE OF INVENTION: ASSAY FOR ANTIBODIES
; FILE REFERENCE: P2075R1
; CURRENT APPLICATION NUMBER: US/11/106,762
; PRIOR FILING DATE: 2005-04-15
; PRIOR APPLICATION NUMBER: US 60/563,193
; PRIOR FILING DATE: 2004-04-16
; NUMBER OF SEQ ID NOS: 39
; SEQ ID NO 38
; LENGTH: 213
; TYPE: PRT
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Sequence is synthesized
US-11-106-762-38

Query Match 100.0%; Score 553; DB 7; Length 213;
Best Local Similarity 100.0%; Pred. No. 7.8e-48;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
|||||
Db 107 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166

Qy 61 SKDSTYSLSTLTLSKADYEHKVKYACEVTHQGLSSPVTKSFNRGEC 107
|||||
```

```
Db 167 SKDSTYSLSTLTLSKADYEHKVKYACEVTHQGLSSPVTKSFNRGEC 213

RESULT 12
US-11-238-281-13
; Sequence 13, Application US/11238281
; Publication No. US20060110387A1
; GENERAL INFORMATION:
; APPLICANT: Brunetta, Paul G.
; TITLE OF INVENTION: METHOD FOR TREATING VASCULITIS
; FILE REFERENCE: P2177R1
; CURRENT APPLICATION NUMBER: US/11/238,281
; CURRENT FILING DATE: 2005-09-28
; PRIOR APPLICATION NUMBER: US 60/616,104
; PRIOR FILING DATE: 2004-10-05
; NUMBER OF SEQ ID NOS: 43
; SEQ ID NO 13
; LENGTH: 213
; TYPE: PRT
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Sequence is synthesized
US-11-238-281-13

Query Match 100.0%; Score 553; DB 7; Length 213;
Best Local Similarity 100.0%; Pred. No. 7.8e-48;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
|||||
Db 107 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166

Qy 61 SKDSTYSLSTLTLSKADYEHKVKYACEVTHQGLSSPVTKSFNRGEC 107
|||||
Db 167 SKDSTYSLSTLTLSKADYEHKVKYACEVTHQGLSSPVTKSFNRGEC 213

RESULT 13
US-11-238-281-28
; Sequence 28, Application US/11238281
; Publication No. US20060110387A1
; GENERAL INFORMATION:
; APPLICANT: Brunetta, Paul G.
; TITLE OF INVENTION: METHOD FOR TREATING VASCULITIS
; FILE REFERENCE: P2177R1
; CURRENT APPLICATION NUMBER: US/11/238,281
; CURRENT FILING DATE: 2005-09-28
; PRIOR APPLICATION NUMBER: US 60/616,104
; PRIOR FILING DATE: 2004-10-05
; NUMBER OF SEQ ID NOS: 43
; SEQ ID NO 28
; LENGTH: 213
; TYPE: PRT
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Sequence is synthesized
US-11-238-281-28

Query Match 100.0%; Score 553; DB 7; Length 213;
Best Local Similarity 100.0%; Pred. No. 7.8e-48;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 60
|||||
Db 107 RTVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 166

Qy 61 SKDSTYSLSTLTLSKADYEHKVKYACEVTHQGLSSPVTKSFNRGEC 107
|||||
Db 167 SKDSTYSLSTLTLSKADYEHKVKYACEVTHQGLSSPVTKSFNRGEC 213

RESULT 14
US-11-238-281-30
```

```

Qy      1  RTVAAPSVFIIPPDDELQKSTASVCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD  60
      |||||
Db      107 RTVAAPSVFIIPPDDELQKSTASVCLNNFYPREAKVQWKVDNALQSGNSQESVTEQD  166

Qy      61  SKDSTYSLSSLTLLSKADYEKKHYACEVTHQGLSSPVTKSFNRGEC  107
      |||||
Db      167  SKDSTYSLSSLTLLSKADYEKKHYACEVTHQGLSSPVTKSFNRGEC  213

Search completed: June 10, 2006, 12:39:09
Job time : 4.6952 secs

```

Search completed: June 10, 2006, 12:39:09
Job time : 4.6952 secs

THIS PAGE BLANK (USPTO)